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It is our great pleasure to present this Supplement Issue on “Macedonian Pharmaceutical Bulletin” to the scientific and 
professional community. This supplement includes the short communications from the Sixth Congress of Pharmacy 
in Macedonia with International participation, as the largest gathering for the pharmacy profession held in the 
Republic of Macedonia. The main theme of the Congress was “Modern pharmacist - bridging science with practice”. 
A broad spectrum of topics within the pharmaceutical sciences and practice carefully selected for this special occasion in 
order to build up a highly interesting and comprehensive program were covered. The contributions submitted to the Congress 
included 6 plenary lectures, 84 section lectures, and more that 240 posters. This Congress, followed the excellent international 
tradition, was attended by close to 1000 domestic and foreign participants. We received 326 short paper submissions from 
more than 25 countries. These numbers show that our Congress is aiming for the highest scientific standards, and that it can 
be considered a well-established venue for researchers in the broad fields of Pharmaceutical sciences and practice.
We would like to thank all internationally prominent researchers for their contribution to reinforcing the overall quality 
of the Congress. They give the state of the art of the recent advances in the field of pharmacy research.
Sincere thanks to the hosts of the Sixth Congress of Pharmacy in Macedonia with International participation, Macedonian 
Pharmaceutical Association and Faculty of Pharmacy, Ss Cyril and Methodius University in Skopje for their vision and 
commitments.
We acknowledge the sponsoring companies: the platinium sponsor AD ALKALOID, Skopje, the golden sponsor PLIVA, 
the silver sponsor EUROFARM and the bronze sponsor SEPTIMA, for the permanent support to our efforts during the 
organization. 
We would also like to thank our members of the Scientific Committee for their volunteer time and dedication to the 
critical peer review process and in the organization of the program. We also wish to thank all the members of the Organizing 
Committee, whose work and commitment was invaluable.
On behalf of the Advisory and Scientific Committees, we would like to especially thank the authors, whose work was the 
essential part of the congress and contributed to a very successful event.  Besides the many academic staff  and professionals 
who contributed to the success of the Congress, we are grateful to the students who participated with oral presentations and 
posters. 
The pharmaceutical sciences continue to grow as dynamic scientific interdisciplinary fields. We believe that published 
short communications will be an excellent source of scientific material in the fast evolving fields in Pharmaceutical sciences 
and practice. 
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Short communication
The modern pharmacist: Is the future in the past?
Roberto Frontini
Centre for Patient Safety, University Hospital of Leipzig, Liebigstraße20, 04103 Leipzig, Germany
Background
The role of the pharmacist changed during the centu-
ries. In the 20th century most of the pharmacists accepted a 
role as provider of medicines and the education was miss-
ing any clinical aspect. But looking back to the 18th century 
in Italy we discover that the role of the pharmacist was dif-
ferent and similar to what should be the modern profession. 
In the statute of the Ospedale Maggiore della SS Annunzia-
ta di Savigliano (1762) was indeed stated: “The pharmacist 
must accompany the physician in all rounds...and more he 
will make daily additional rounds to judge the pain of the 
most worsening patients and their immediate needs..“.The 
pharmacist had an important clinical role and was a partner 
of the physician. Even more is part of the agreement be-
tween the Ospedale Maggiore della SS Trinità di Fossano 
and Gino Stefano Bertolo, speziale (pharmacist) (1741): 
“… he has to prepare the prescribed medicines... and bring 
them personally to the patients labelling every cup or de-
canter with the number of his or her bed and compassion-
ately and gently inviting to take them either immediately or 
at least at time of the mass in the cathedral...”. The con-
tract describes in fact the competencies of a modern phar-
macist. He or she is the expert in preparing medicines and 
understands the formulation as an important issue. But his 
or her commitment does not end in the preparation. He or 
she has to go to the patient and promote adherence and best 
use of the medicine while using strategies for the reduction 
of medication errors.The challenge to speak about the fu-
ture is not to re-invent the past.
The environment of the 18th century was indeed dif-
ferent to what we have nowadays and in this short article I 
would like to underline some of the challenges of a mod-
ern pharmacist both in the hospital as well as in the com-
munity setting. I think thatin the whole system the phar-
macist should be the healthcare professional in the care 
team who seeks to ensure that pharmacologically active in-
gredients achieve the best possible benefit for the individ-
ual patient. 
The competencies of a modern Pharmacist
The  pharmacist  needs  first  skills  and  competence  in 
the formulation of a medicine. This does not necessarily 
mean in the era of industrial production that the medicine 
is compounded in the pharmacy, but the properties of the 
formulation may influence the correct use and the adher-
ence as well. Only the pharmacist can understand this in 
deep. Sometime is also necessary to adapt medicine to the 
individual, especially in paediatric patients. Skills in com-
pounding are therefore of primary importance and also the 
modern pharmacist should not forget the roots of our pro-
fession as the only manufacturer of medicines.
A further taskfor a pharmacist is to seek the balance 
between expected effects and drug related problems. It is 
essential to underline that the best outcome for patients is 
only achievable in a multidisciplinary care team (Zuling et 
al., 2013) and the pharmacist as part of this team should be 
alert when advising patients. He or she needs social com-
petence in communication with the aim to understand any 
problem related to the medication and explain the appro-
priate use of drugs to the patient “..in terms he can under-
stand” (EAHP, 2014). This social competence is also nec-
essary in the team work. Physicians, nurses, pharmacists 
and other healthcare professionals have to abandon a hier-
archy driven relationship and accept each other as a partner 
in achieving the best for the patient. As well the patient has 
to be part of any decision and has to articulate the desired 
outcome. Especially in oncology those expectations should 
be respected and the goal for the care team is not necessar-
ily to prolonger life but to create quality of life. 
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The challenges of a modern Pharmacist
In the daily work the modern way of life and technol-
ogy challenge the modern pharmacist. The daily increas-
ing knowledge about drugs and their effect, complex med-
ications, personalised medicines,IT technology, the over-
whelming information through social media, the explosion 
of costs hampering healthcare systems, the globalisation of 
the supply chainare some examples. 
One example of personalised medicine may underline 
those challenges: Enthusiastic researchers believed that we 
are “on the leading edge of a true revolution in medicine” 
(Collins, 2010) but critical authors say that “they can also 
obscure more effective approaches to common complex 
disorders” (Juengst et al., 2012). What is true? We do not 
know yet as data are contradictory. But an interesting pa-
per on the adherence to the targeting INR in Warfarin med-
ication may show the dilemma (Kimmel et al., 2013). Kim-
mel et al. (2013) explored two different approaches to con-
trol Warfarin medication: the first based on the genomic of 
the patients, the second based on clinical interventions. In 
average no difference was found between the two groups 
bringing to the conclusion that “genotype-guided dosing of 
warfarin did not improve anticoagulation control”. Inter-
estingly in the subgroup of black patients the mean percent-
age of time in the therapeutic range was less in the geno-
type-guided group than in the clinically guided group. This 
example may underline that clinical interventions are still 
important even if our knowledge of genomics helps us to 
make better decisions. The modern pharmacist has to con-
sider this while advising patients. In another paper (Wright 
et al., 2013) Wright concluded that “Our ability to generate 
data now far outstrips our ability to interpret it”.
A second example of challenge for the modern phar-
macist is the information technology of today. No doubt 
that internet and social media have completely changed our 
sources of information. The modern patient is informed and 
internet  is after  the physician the first source of  informa-
tion according to a study by Marrie (2013). There is some 
differences between young and old people (Couper et al., 
2010) and persons with mental disease (e.g. depression) 
(Pohjanoksa-Mäntylä et al., 2011), the last using more and 
more the internet as an information source. But the qual-
ity of the internet information is not necessarily the best. 
Celebrities e.g. misuse their influence promoting products 
without scientific evidence (Hoffman and Tan, 2013) and 
for non-healthcare professionals is not easy to distinguish 
between spam and real scientific message. The challenge 
is for the modern pharmacist that patient sometime know 
more than the healthcare professional but they do not un-
derstand the background. The pharmacists as well as the 
physician must learn comprehensive, clear and for the pa-
tient understandable communication and educate him or 
her in the proper use of internet-information. This is no 
easy task as demonstrated by Watermeyerand Penn (2009). 
Healthcare professional’s education should therefore in-
clude communication training as an essential part for the 
transfer of scientific data to the patient.
Conclusion
In conclusion between a medicine with its active in-
gredient and the outcome of the patient there are a lot of 
barriers like e.g. drug formulation, patient attitude, social 
context, medication errors, patient’s genomic, biased infor-
mation. The pharmacist has to help patients in overcoming 
such barriers but this is only possible if he or she is part of 
a cure team working in collaborative way without hierar-
chy barriers.
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Short communication
Commitment to quality means commitment to change
Michael J. Rouse
Accreditation Council for Pharmacy Education, 135 South LaSalle Street, Suite 4100, Chicago, 
Illinois, 60603-4810, United States of America
* mrouse@acpe-accredit.org
Pharmacy practice and the education and training re-
quired to prepare pharmacists for practice have undergone 
dramatic change in the past several decades, and more 
change will come. Beyond ensuring that the right medi-
cine is delivered to the right patient in the right dose, there 
is now a greater focus on pharmacist-delivered patient-
centered care. The aims of such care are to ensure opti-
mal therapeutic outcomes and improved quality of life, re-
duce adverse reactions to medication and the risk of patient 
harm, improve access, and reduce the overall cost of health 
care delivery. For pharmacists, the focus has shifted from 
the medication itself to the correct and optimal use of the 
medication by the patient.
With advances in technology, medical and pharmaceu-
tical knowledge, medication use has a greater potential for 
good, but therapy is often more complex, and the risk of 
suboptimal outcomes or even patient harm through inap-
propriate selection and/or use of medication can be high. 
The need for a competent healthcare professional to advise 
on selection and manage the medication therapy is becom-
ing increasingly clear, both at the individual patient level 
as well as at a societal level.
The foundational knowledge needed by pharmacists 
in the biomedical and pharmaceutical sciences has not di-
minished but additional knowledge is now needed in so-
cial, behavioral, administrative, and clinical sciences. But 
it does not stop there; in order to effectively manage the 
medication use process of patients and populations, phar-
macists need to acquire new skills and develop the appro-
priate attitudes and values. Together, these reflect the com-
petency profile of a contemporary pharmacist, which has 
been described by the International Pharmaceutical Fed-
eration across four domains: pharmaceutical public health, 
pharmaceutical care, organization and management, and 
professional/personal (FIP, 2012). 
Schools of pharmacy have to undertake a major reform 
of their curriculum - both in terms of content and delivery 
– in order to prepare graduates with the needed competen-
cies, to be “fit for purpose” and able to deliver the servic-
es required to meet societal needs. In addition, models for 
continuing education and continuing professional develop-
ment have to change, because it is likely that the majority 
of pharmacists in practice today do not have all the compe-
tencies to deliver this model of care.
In addition to practice and education, a third sector 
plays a vital role when it comes to advancing the profes-
sion of pharmacy. This is the regulatory sector, which is 
by nature, however, more conservative due to its primary 
role to protect the public. For obvious reasons, profession-
al regulations cannot be changing constantly, but change is 
certainly needed in this sector. With the roles of pharma-
cists evolving and expanding, regulation of the profession 
has also had to change. In addition, regulation has had to 
change – or in some cases be introduced for the first time 
– for the pharmacy support workforce, members of which 
play a vital role in supporting pharmacists to free them 
up to deliver pharmaceutical care, or “medication thera-
py management” services as now referred to in some coun-
tries.
It is evident that for improvements and advancement 
to come in the profession of pharmacy, change is required, 
but change will not come without commitment – commit-
ment from practitioners, educators, regulators and all other 
key stakeholders who have a role to play. People can often 
recognize the change that they want to happen in their en-
vironment to improve their situation. It is, however, not al-
ways as easy for individuals to recognize and be commit-
ted to the change that must occur within themselves. We 
assume that all pharmacists want to succeed in their pro-
fessional careers. At the end of their career when they look 
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back, they want to believe that they have made a difference 
…. left some “footprints.” What are some of the factors 
that will determine whether or not pharmacists will, in fact, 
make a difference in the lives of patients, their professional 
colleagues, and others they meet and work with? What will 
determine if the “seeds” that pharmacists plant in the “field 
of pharmacy” will grow and produce a harvest?
Pharmacists work in different “fields” and likely have 
different ideas about what results they want to achieve … 
what impact they want to have personally and profession-
ally, but are there some principles and values that are com-
mon – and important - regardless of where pharmacists live 
and work, and what they do?
Today, pharmacists acquire expert knowledge and 
skills, firstly through their pre-service education and train-
ing, and after that through continuing education and con-
tinuing professional development activities. How does the 
profession ensure that pharmacists also develop the right 
attitudes and values to be ethical, professional and car-
ing pharmacists, and members of inter-professional teams, 
working together to achieve optimal medication therapy 
outcomes for patients? Can these attitudes and values be 
“taught” in a classroom? How else can they be cultivated?
Beyond having the right knowledge, skills, attitudes, 
and values, what else determines whether or not pharma-
cists will bring about the changes that are needed and have 
the desired impact; whether or not pharmacists make the 
difference in life that they aspire to make? That takes com-
mitment, and “Commitment to Change” is the bridge that 
spans the “chasm” between learning and behavior change, 
between good intentions and real impact (Wakefield et al., 
2003; Wakefield, 2004).
While some things must change in order to achieve im-
provement, certain values and attitudes must be preserved 
throughout the career of a pharmacist for him/her to be a 
successful professional, delivering quality care and oth-
er services. Important lessons learned and attitudes, val-
ues and habits that the author has found to be important 
in his pharmacy career include: have a desire to innovate; 
build the best team; learn to work with others who are not 
like you, take pride in what you do; keep searching for the 
things that are hard to find; keep climbing; draw on others’ 
experience; find a mentor; be a mentor; take some chanc-
es; build strong networks; know your strengths and don’t 
underestimate your contribution; find things to be passion-
ate about; don’t suffer from “paralysis by analysis” or al-
ways insist on perfection; there are no shortcuts to any 
place worth going; partner with people who share your vi-
sion; not all change leads to improvement… but all im-
provement requires change; and perhaps most importantly, 
sometimes “availability” is more important than “ability.”
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New psychoactive substances - analytical challenges and threats 
to the public health: European and Polish experience in the new 
drugs combating
Zbigniew Fijalek
Department of Bioanalysis and Drug Analysis, Faculty of Pharmacy,
 Warsaw Medical University, Banacha 1, 02-097 Warsaw, Poland
Introduction to the problem and European NPS 
market
In recent years, the UE has seen the emergence of new 
drugs that have similar effects to drugs that are interna-
tionally controlled. These drugs can be collectively called 
New Psychoactive Substances (NPS). The key features are 
that NPS are psychoactive i.e. ones that stimulate, or de-
press the central nervous system, or cause a state of depen-
dence; have a comparable level of potential harm to inter-
nationally controlled drugs; and are newly available, rath-
er than newly invented. These substances may be the ac-
tive pharmaceutical ingredients (APIs) used in authorised 
medicines (phenibut) or suspended/withdrawn medicines 
(sibutramine, DMAA) or potential medicines in the mak-
ing (remimazolam). Methcathinone was originally used as 
an antidepressant in the former Soviet Union in the 1930s, 
but very quickly it became a recreational drug. Pyrova-
lerone and amfepramone have been used as anorectics, but 
they are currently obsolete. Bupropion is used as antide-
pressant and as an aid for those who wish to quit tobacco 
smoking. But NPS goes beyond APIs, in fact most of them 
come originally from the scientific and patent literature as 
a result of Pharma and academic institutes’ research and 
development efforts. They have been designed to evade 
drug laws, are widely available and have the potential to 
pose serious risks to public health and safety and can even 
be fatal. The short‐term harms of NPS can include para-
noia, psychosis and seizures and their long‐term harms 
are often unknown. NPS a new class of psychoactive sub-
stances, known as ‘legal highs’, ‘herbal highs’, ‘designer 
drugs’ or ‘party pills’ has emerged on the drug use market. 
They are frequently advertised as ‘plant fertilizers/food’, 
‘air fresheners’, ‘herbal incenses’, ‘spice’, ‘bath salts’, ‘re-
search chemicals’ (in Poland commonly known as ‘dopal-
acze’ - literally translated as afterburners). 
Based on their chemical structures, designer drugs 
can be classified  into amphetamine  types, 2,5-dimethoxy 
amphetamines,  2,5-phenylamines,  β-keto  amphetamines 
(cathinones), phencyclidines, piperazines, pyrrolidinophe-
nones, fentanyls, piperidines, tryptamine derivatives and 
synthetic cannabinoids. Based on the spectrum of exert-
ed psychoactive effects, NPS can be classified into four ba-
sic categories: synthetic cannabinoids, stimulants, opioid-
like compounds, and hallucinogenic/dissociative (psycho-
dysleptic); however, they may have a combination of these 
effects due to their designed chemical structure.
From 2008 there has been a rapid increase in the num-
ber and range of new substances with greater ease of avail-
ability,  with  their  open  sale  in  offline  retail  outlets  and 
through the global marketplace of the internet (‘clearnet’ 
and ‘darkweb’). The Early Warning System (EWS) run by 
the European Monitoring Centre for Drugs and Drug Ad-
diction (EMCDDA) detected 86 novel NPS in 2013, 101 in 
2014 and 100 in 2015. 
Whilst generally there has been an increase in the 
number of novel NPS detected, it is important to note that 
the vast majority are permutations of groups of similar sub-
stances with similar effects (e.g. cathinones), or dissimilar 
substances that produce similar effects (e.g. synthetic can-
nabinoids), rather than new distinct types of drugs. Fur-
thermore, it is likely that many of the substances identified 
are not in widespread or even limited use. It may be that 
the market, to some extent, regulates itself with less effec-
tive or more harmful NPS only being seen for very short 
periods of time or in a limited number of countries (Dar-
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gan and Wood, 2013;  Zawilska and Andrzejczak, 2015; 
Zawilska, 2015).
Polish new drugs market
New psychoactive substances were present on the Pol-
ish drug scene before 2008. At the beginning, there were oc-
casional sale offers of psychoactive substances on the Pol-
ish Internet forums, which were in compliance with legal 
regulations at that time. In 2008, a website called ‘dopalac-
ze.com’ was launched. It offered a new quality approach in 
terms of professional and marketing strategy. The website 
products were advertised as safe alternatives to illicit psy-
choactive substances. One advertising slogan of ‘dopalac-
ze.com’ emphasised the harmless effects of its products: 
‘Life is too short to take unhealthy pills’. NPS were mar-
keted as collectibles not intended for human consumption. 
They were described as legal in the European Union, con-
trolled, regulated and safe. They were also marketed as the 
so-called ‘party drugs’. The shops also stocked herbal con-
coctions, known for centuries in various cultures and used 
for a number of purposes including rituals e.g. Salvia divi-
norum. It came as a big surprise to NPS users that herbal 
concoctions contained synthetic cannabinoids, which were 
to a large extent, if not wholly, responsible for the psycho-
active effects thereof. In mid-2008, following the opening 
of the first high street smart shop, trade in NPS entered the 
reality offline. As soon as by the end of 2008, 40 high street 
smart shops were operational in the centers of major Pol-
ish cities offering an increasingly wide range of psychoac-
tive products. While describing the beginnings of the le-
gal highs scene it is worth mentioning a first synthetic can-
nabinoid called JWH-180, which was identified in Poland 
by the Central Forensic Laboratory in February 2009. This 
substance gave rise to a massive supply of such-like sub-
stances on the Polish market. At the same time, other new 
psychoactive substances and products were arriving rapid-
ly including synthetic cannabinoids, mephedrone and later 
on a whole range of cathinone-type substances. New smart 
shops started springing up exponentially and soon, by the 
end of 2010, 1 400 smart shops were up and running across 
the country. After the closure of high street smart shops by 
sanitary inspection, NPS kept being sold online (Jablonski 
and Malczewski, 2014).
Unfortunately in next years, some shops have been re-
opened and the situation regarding increased hospitaliza-
tions in July 2015 was similar to that from 2010, so there-
fore, it became necessary to develop a new orthogonal ap-
proach  to  solve  the  problem of  identification of  the  new 
chemical structures appearing on the market by applying 
complementary techniques, i.e. LC-MS/MS-TOF, GS-MS/
MS, LC-CAD and NMR. In December 2010 analysis of 
NPS samples collected by the sanitary inspection found 
seven main chemical groups; the highest incidences being 
MDPV (23%), and 16% for JWH-081 and RCS-4. From 
2010 Polish National Medicines Institute have analyzed 
over 7000 various designer drugs and herbal highs prod-
ucts. About 160 psychoactive compounds were identified 
including: substituted cathinones, phenethylamines, syn-
thetic cannabinoids, phenylpiperazines, tryptamines, phar-
maceuticals and other. Poland still has one of the fastest 
growing market for new psychoactive substances in the EU 
with hundreds of hospitalizations resulting (approx. 1100 
in 2013, 2000 in 2014 and 7000 in 2015).
Conclusions
Designer drugs present an ongoing challenge to chem-
ists, toxicologists, and law enforcement agencies due to 
their dynamic and changing markets. To effectively com-
bat the problems associated with designer drugs, a collec-
tive effort needs to be in place from forensic scientists, 
health professionals, and law enforcement authorities. It is 
important to stay at the forefront of drug detection tech-
niques and strategies to allow speedy identification of new 
substances as they emerge. Metabolism and toxicity data 
need to be collected to facilitate diagnosis and treatment of 
designer drug intoxication. At the same time, drug sched-
uling authorities need to schedule these drugs promptly to 
enable laws to be applied to the production, distribution, 
and consumption of these illicit substances to safeguard so-
ciety.
The global nature of the NPS phenomenon also pres-
ents opportunities for enhanced international collabora-
tion, and the importance of data sharing within the Euro-
pean and international authorities. The Poland is currently 
an active participant in the European Early Warning Sys-
tem on NPS and this network has proved useful in the ear-
ly identification of emerging threats in this area. Sustained 
collaboration in the future would not only continue to al-
low the rapid exchange of information between countries 
but also the potential for mutual benefit through collabora-
tion in research initiatives or through the sharing of refer-
ence material and toxicological information.
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Background
Nanotechnology revolutionizes drug delivery by en-
abling achieving: i) targeted drug delivery; ii) transcyto-
sis of drugs across biological barriers; iii) delivery of drugs 
to intracellular targets and iv) visualization of sites of drug 
delivery (theranostics). High loadings and surface engi-
neering are important prerequisites for efficient drug nano-
carriers. 
Green “cage” nanocarriers
Will be presented a few examples of “cage” nanopar-
ticles composed of cyclodextrins (CDs) (Gref et al., 2006) 
or made of highly porous Metal-Organic Frameworks 
(MOFs) (Horcajada et al., 2010). “Cage”nanoparticles 
were produced by solvent-free green procedures such as 
microwave assisted hydrothermal synthesis. The nanopar-
ticles were fully characterized to determine their chemi-
cal composition, morphology, size distribution and specif-
ic surface. 
Drug substances were encapsulated in the “cages” 
of these nanoparticles, thus ensuring optimal interactions 
with the matrices, leading to high loadings and controlled 
release properties.  
Antibiotics, anticancer and antiviral drugs were load-
ed simply by soaking the nanoparticles in aqueous solu-
tions of the drugs, reaching in most cases efficiencies close 
to 100%. Remarkably, drugs with different physico-chem-
ical properties could be co-encapsulated in different inter-
connected cages inside the porous nanoparticles. Further-
more, to achieve stable, versatile coatings on highly porous 
MOF nanoparticles without altering their ability to entrap 
molecules of interest, the outer surface of the nanoparticles 
was functionalized with CDs in a biofriendly, non-cova-
lent manner (Agostoni et al. 2015). Versatile coatings were 
obtained in aqueous media, within a few minutes. Ligands 
could be coupled to the shell, to ensure specific interaction 
with cancer cells.The coatings were remarkably stable in 
cell culture media, despite their non-covalent nature. 
Conclusion
Drug  loaded,  surface  modified  “cage”  nanoparticles 
were prepared using only biofriendly solvent free proce-
dures. Each step of the fabrication procedure (systhesis, 
drug encapsulation, coating) was performed in aqueous 
medium, at room temperature, without the need of cou-
pling reagents nor protective surfactants. 
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We live in an era of ensuing prevalence rates of non-
communicable disease, which pose an increasing risk to 
the  financial  sustainability  of  health  systems worldwide. 
It has been suggested  that a paradigm shift is required if 
we are to properly deal with these challenges, transforming 
our healthcare system to one which can bridge the silos of 
care provision in a patient-centered approach, move from 
reactive therapeutic to proactive preventive care, and aban-
don our paternalistic narrative to a participatory and engag-
ing patient-physician relationship.
It has been realized in recent years that a key driving 
force and a pre-requisite for these changes is the availabil-
ity and intelligent integrated use of data and information 
technology. Israel has benchmarked high in global NCD 
mortality and complications measures. Over the last two 
decades. These clinical improvements were supported by 
wide early adoption of Electronic Health Records through-
out the country, all tiers of community care. 
Clalit is Israel’s largest healthcare organization which 
serves as insurer/payer and integrated care provider for 
over half of the Israeli population – over 4.3 million peo-
ple. Clalit has been leading innovative interventions using 
clinical data to drive people-centered targeted and effective 
care models, for NCD prevention and control.  In its strate-
gic plans, Clalit aims to perform a paradigm shift to prop-
erly deal with these challenges, transforming the health-
care system to one which can bridge the silos of care pro-
vision in a patient-centered approach, move from reactive 
therapeutic to proactive preventive care, and abandon our 
paternalistic narrative to a participatory and engaging pa-
tient-physician relationship (Balicer et al., 2015; Leventer-
Roberts et al., 2015; Feldman et al., 2014; Shadmi et al., 
2015).
We at Clalit believe that a key driving force and a pre-
requisite for these changes is the availability and intelligent 
integrated use of EHR-based clinical data, and have been 
practicing innovative utilization of this data for quite a few 
years with successful measurable outcomes. Many of the 
unique innovative interventions introduced by Clalit are 
data-driven, made possible by real-time data provided to 
physicians and nurses, in an actionable, decision-support-
ing format. Clalit has 100% (single software) Electronic 
Health Records coverage of ambulatory and hospital care, 
with an aggregated data warehouse that received feeds 
from both, on our 4.3 million members, for well over 1.5 
decades. This data included detailed and full demographic 
(i.e. place of birth of person and parents), diagnoses (both 
EMRs and Claims), measures (i.e. as BMI, blood pres-
sure), full laboratory test data, imaging data, patient report-
ed such as smoking status and willingness to quit smoking, 
cost (pricelist and real-life monthly cost per patient), both 
prescription and dispensing medication data, and admin-
istrative health services consumption data. These data are 
augmented in Clalit by the largest ongoing patient experi-
ences survey performed in Israel, ongoing all year long to a 
very large patient sample, and an increasing amount of data 
becoming available through Clalit’s patient portal and Per-
sonal Health Record (PHR). Quality of care, patient expe-
riences and financial benchmarks are all part of an online 
balanced scorecard system available to all managers at all 
levels of the organization. 
To turn this abundance of data into actionable insights, 
Clalit launched in 2010 its Research Institute, which now 
holds over 30 professionals of multidisciplinary qualifica-
tions – top notch clinicians, epidemiologists, biostatisti-
cians, IT experts, algorithm specialists and public health 
experts. The institute associates gained invaluable expe-
rience in mining and interpreting the organizational data-
base, and creating tools introduced into policy and medi-
cal practice. These tools allowed for implementing innova-
tive clinical interventions to tackle key health issues such 
as reducing healthcare disparities, preventing avoidable re-
admissions, tackling inadequate treatment adherence, as-
sessing the impact of multi-morbidity, improving control 
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of key chronic diseases, performing comparative effective-
ness real-life studies and using predictive modeling and ad-
vanced analytics to allow targeted care in high risk groups. 
The institute is augmented by its affiliates - leading clini-
cians from Clalit’s 8 districts and 14 public hospitals that 
initiate and perform advanced studies with the support of 
the institute. 
The Clalit Research Institute has focused in creating 
data-driven tools for enabling, supporting and assessing 
innovative clinical interventions to tackle key health and 
healthcare issues. These include including measuring and 
tackling inadequate treatment adherence, assessing and 
tackling the impact of NCDs and multi-morbidity, using 
predictive modeling and advanced analytics in the point 
of practice to allow targeted care in high risk groups, and 
comparative effectiveness real-life studies.
In the presentation at this conference we will review 
the driving forces and the need for such disruptive inno-
vations, and detail specific examples  that allowed for  re-
ducing healthcare disparities, preventing avoidable read-
missions, and improving control of key chronic diseases. 
Key conclusion can be drawn from of these case studies 
to be presented - that integrated data systems allow a wide 
potential for implementing innovations in care integration. 
Integrated data allows for innovative patient selection ap-
proach, in-depth program planning, real-time implementa-
tion support IT tools and real-time monitoring of interven-
tion outcomes thus allowing multi-level effective interven-
tion management.  
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Clinical pharmacy – development and standards
Over the past 5 decades the role of a pharmacist has 
significantly changed, from traditionally dispensing med-
ications, to performing clinical services or pharmaceuti-
cal care (ACCP - American College of Clinical Pharma-
cy, 2008). Although there is no international consensus on 
the definition of clinical pharmacy/pharmaceutical care, it 
is agreed that a clinical pharmacist, as a member of an in-
terdisciplinary health care team in direct patient care en-
vironments, contributes through comprehensive medica-
tion management to optimal drug therapy (ACCP, 2008; 
Frankin and Van Mil, 2005; Van Mil and Fernandez-Lli-
mos, 2013). The American College of Clinical Pharmacy 
has  recently  published  specific  requirements  for  clinical 
pharmacists practicing in the USA and around the world 
(ACCP, 2014).
Clinical pharmacy – specialty services, 
certification, job satisfaction
Clinical Pharmacy services are performed in various 
health care settings (e.g. community, ambulatory, hospital) 
and may differ for patient populations (e.g. pediatric, geri-
atric). Accordingly, clinical pharmacists may specialize to 
acquire the unique skills and expertise needed for specif-
ic patient groups. Specialization can be in different forms, 
e.g. on the job training, gradually transitioning into the spe-
cialty field, or via specific postgraduate training (Schom-
mer et al., 2008). Clinical Pharmacy specialists practice 
in many different areas (e.g. cardiology, psychopharmacy, 
oncology) (CPP - Certification Programs for Pharmacists, 
2012; Schommer et al., 2008). Advanced practice pharma-
cists provide clinical services in primary care clinics ad-
dressing common diseases (e.g. hypertension, hyperlipid-
emia, COPD) and may have prescribing privileges under 
collaborative practice arrangements with physicians (Mu-
rawski et al., 2011).
To demonstrate specialized clinical knowledge beyond 
licensing standards increasingly more clinical pharmacists 
seek national, state or organization certification or creden-
tialing,  in specific disease state management (e.g. antico-
agulation, diabetes, poison information specialist) (CPP, 
2012; Schommer et al., 2008). 
Survey results indicate that most clinical pharmacy 
specialists are extremely satisfied with their job and con-
sider direct patient care, interaction with others, autono-
my, practicing in a unique environment and applying their 
knowledge as very attractive aspects of their job. Howev-
er, long hours (average work time/week 50.6 h) and heavy 
workload are challenges, yet also welcomed as stimuli for 
professional growth and innovative services (Schommer et 
al., 2008).
Clinical pharmacy practice - newer trends 
Recent trends are clinical pharmacist involvement in 
ID subspecialties (i.e. HIV care, Hepatitis C disease, An-
tibiotic Stewardship programs) and in Transition of Care, 
and respective practice guidelines have been published 
(ASHP, 2010; Hume et al., 2012; Schafer et al., 2016; 
SIDP, 2010).
Pharmacist in HIV and hepatitis C management 
Management of HIV disease/AIDS and Hepatitis C 
provide excellent clinical pharmacy opportunities as both 
diseases are affecting millions of people, are predominant-
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ly chronic illnesses with major morbidity, known challeng-
es (e.g. poor medication adherence, numerous drug relat-
ed concerns) and new considerations (i.e. HIV in the aging 
population or pre-exposure prophylaxis, recent treatment 
options for hepatitis C, coinfections, high costs) (Schafer et 
al., 2016; Spooner, 2011). Pharmacist involvement in HIV/
Hep C testing, treatment selection and monitoring, man-
agement and prevention of drug-related problems, compli-
cations or opportunistic infections, and education will pro-
vide effective disease state management and optimal pa-
tient support.
Antimicrobial stewardship 
Antimicrobial Stewardship (AS) is another opportuni-
ty for clinical pharmacists (ASHP, 2010; Dellit et al., 2007; 
MacKenzie et al., 2007). Data show that unnecessary and 
inappropriate prescription of antibiotics exposes patients to 
serious adverse drug effects and superinfections (i.e. Clos-
tridium  difficile);  antibiotic misuse  is  a  critical  factor  in 
rising antibiotic resistance and poses a public health threat 
(CDC, 2013). Regarding improvement of antibiotic use 
and patient safety as a national priority (CDC, 2013a), and 
based on evidence that designated programs can optimize 
treatment of infections and reduce adverse effects (Dav-
ey et al., 2013; Ohl and Luther, 2011) the CDC in 2014 
recommended that all hospitals implement AS programs 
(CDC, 2014). Designated ID pharmacist leaders collabo-
rate with ID specialists in infection prevention and con-
trol by tracking/optimizing antibiotic prescribing and use, 
reporting outcomes, implementing policies (i.e. “antibiot-
ic time out”, IV to PO changes, dose adjustments) and ed-
ucating clinicians.  
Transition of care
Major medication errors can occur when patients 
are transferring between different care locations or lev-
els (e.g. admission to, transfer or discharge from hospi-
tal) resulting in significant adverse drug events, increased 
length of stay, high readmission rates and costs (Hume et 
al., 2012). Official organizations (e.g. US Joint Commis-
sion, ASHP/APhA) (ASHP-APhA, 2013; Joint Commis-
sion, 2012) have established national patient safety goals 
requiring accurate patient information in hospitals to pre-
vent readmission rates, and potential payment penalties by 
insurers (Kristeller, 2014). Transition of Care (TOC) phar-
macists plays an instrumental role in facilitating the pro-
cess of continuing/coordinating therapeutic care (ACCP, 
2008; ASHP-APhA, 2013; Hume et al., 2012). Obtaining 
patient medication histories, performing medication recon-
ciliation, inpatient education, patient discharge counseling 
and post-discharge follow-up are key activities of the TOC 
pharmacist. 
Clinical pharmacy practice - future trends 
It is envisioned that most future clinical pharmacists 
(and all clinical faculty) will have post-graduate training, 
will be board-certified specialists, and will be formally rec-
ognized and reimbursed as health care providers who en-
sure optimal drug therapy outcomes (Gubbins et al., 2014; 
Saseen et al. 2006).
Pharmacy faculty and pharmacists will work in in-
terdisciplinary patient-centered medical homes (PCMH), 
where an entire team delivers comprehensive and coordi-
nated health care (Smith et al., 2010; Zellmer, 2012) Phar-
macists will provide medication therapy management uti-
lizing health information technology and will engage in: 
handling, administering and monitoring of complex spe-
cialty drugs and of medications delivered in innovative 
dosage forms (e.g. nanoscale devices); digitally moni-
toring drug levels; and personalized medicine (Guglie-
mo, 2015). Pharmacy education will need to prepare fu-
ture clinical practitioners for these innovative and exciting 
professional practice opportunities (e.g. through interdisci-
plinary education).
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Background
Obesity is a major metabolic disorder leading to vari-
ous health risks and reduced life expectancy. Food intake, 
energy expenditure and body adiposity are homeostatical-
ly regulated, and malfunctions of this balance can cause 
increased fat storage and obesity (Farooqi and O’Rahilly, 
2005;Murphy and Bloom, 2006). Mammals have two 
types of adipose tissue (fat): brown and white, with oppos-
ing functions. Mammalian white fat is an important reg-
ulator of the whole body homeostasis that stores energy 
in form of triglycerides. The brown adipose tissue catab-
olises lipids to produce heat, function mediated by the tis-
sue-specific uncoupling protein 1 (Ucp1) abundantly pres-
ent in the brown fat mitochondria. The brown adipose tis-
sue differentiation can be induced by prolonged cold ex-
posure and beta-adrenergic stimulation which leads to ele-
vated intracellular cyclic AMP (Cannon  and Nedergaard, 
2004; Young et al., 1984). The classical brown fat is pres-
ent at distinct anatomical sites, including the interscapular, 
perirenal and axillary depots. Brown fat cells also emerge 
in subcutaneous white fat (known as “beige” cells) in re-
sponse to cold or exercise (Cousin et al., 1992; Guerra et 
al., 2001), a process referred to as fat “browning”. Promo-
tion of increased brown fat development increases ener-
gy expenditure and white fat loss, and leads to improved 
insulin sensitivity and glucose metabolism, without caus-
ing dysfunction in other tissues and is associated with a 
lean and healthy phenotype (Lowell et al., 1993), suggest-
ing the manipulation of the fat stores as an important ther-
apeutic objective.
Gut microbiota regulates metabolic homeostasis
Thegastrointestinal tract is the body’s largest endo-
crine organ that releases a number of regulatory peptide 
hormones  that  influence  many  physiological  processes 
(Badman and Flier, 2005). The intestinal microbiota co-
develops with  the host, and its composition is  influenced 
by several physiological changes (Koren et al., 2012; Rid-
aura et al., 2013). The colonization starts immediately af-
ter birth and is initially defined by the type of delivery and 
early feeding. A wide range of pathologies have been as-
sociated with alterations of the gut microbial composition 
(e.g.: asthma, arthritis, autism or obesity) (Sommer and 
Bäckhed, 2013). The intestinal microbiota can also influ-
ence the whole-body metabolism by affecting energy bal-
ance (Bäckhed et al., 2004; Koren et al., 20012; Ridaura et 
al., 2013; Turnbaugh et al., 2006). Transplantation of mi-
crobiota from obese human, or animal donors to germ free 
mice is sufficient to promote increased adiposity and insu-
lin resistance of the new host, suggesting that microbiota 
alone is sufficient to induce these metabolic changes. The 
mechanisms and the nature of the phenotypic and morpho-
logical alterations that regulate the energy homeostasis of 
the new host following microbiota transplantation remain 
poorly understood.
Our recent findings show that cold exposure leads to 
marked shift of the microbiota composition, referred to as 
cold microbiota (Chevalier et al., 2015). Transplantation 
of  the  cold microbiota  to  germ-free mice  is  sufficient  to 
increase insulin sensitivity of the host, and enable toler-
ance to cold partly by promoting the white fat browning, 
leading to increased energy expenditure and fat loss. Dur-
ing prolonged cold however, the body weight loss is at-
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tenuated, caused by adaptive mechanisms maximizing ca-
loric uptake and increasing intestinal, villi and microvil-
li lengths. This increased absorptive surface is transferable 
with the cold microbiota leading to altered intestinal gene 
expression promoting tissue remodelling and suppression 
of apoptosis - effect diminished by co-transplanting the 
most cold-downregulatedbacterial strain Akkermansiamu-
ciniphila during the cold microbiota transfer. Our results 
demonstrate the microbiota as a key factor orchestrating 
the overall energy homeostasis during increased demand 
((Chevalier et al., 2015). We recently also showed that the 
development of functional beige fat is promoted by micro-
biota depletion either by means of antibiotic treatment or 
in germ-free mice within the white adipose tissues (Suárez-
Zamorano et al., 2015). This leads to improved glucose tol-
erance, insulin sensitivity and decreased white fat and ad-
ipocyte size in lean mice and obese mice. Such metabolic 
improvements are mediated by eosinophil infiltration and 
enhanced type 2 cytokine signaling and M2 macrophage 
polarization in the white fat depots of microbiota-deplet-
ed animals. The metabolic phenotype and the browning of 
the subcutaneous white fat are impaired by suppression of 
the type 2 signaling and are reversed by recolonization of 
the antibiotic-treated, or the germ-free mice with microbes 
(Suárez-Zamorano et al., 2015). These results provide in-
sights into the microbiota-fat signaling axis and the beige 
fat development in health and metabolic disease. The re-
duced adiposity, and improved glucose tolerance and insu-
lin sensitivity of the microbiota depleted obese animalssug-
gestthat browning of the white fat depots by modulation of 
the microbiota composition could be a new approach for 
combatingobesity and the associated metabolic disorders. 
Conclusion
Microbiota transplantation was reported almost 50 
years ago, and has re-gained interest as a treatment option 
for several pathologies. In the context of the increased obe-
sity prevalence and energy unbalance, our studies show-
ing microbiota changes that promote fat browning, weight 
loss and increased energy dissipation, imply microbiota as 
a key player mediating the tight control of the energy ho-
meostasis with large therapeutic potential.
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Introduction
Currently, the world of computing is overwhelmed with 
huge numbers depicting the extraordinary performance 
of the current computers. This is especially true for the 
biggest supercomputers in the world, showing off their 
exa-FLOPS, aggregating peta-bytes of data, measuring 
and comparing each other on several top charts (Filiposka 
et al., 2016).  But is this their real power? If we compare 
the best of the best from only 23 years ago (at the time the 
first top500 (Top500) list was published), with the todays 
list leader, there is more than 400000 times increase in 
the peak performance capabilities. One can have all the 
exas and petas in the world, but the true power of todays 
supercomputers is in their applicability to solve real life 
problems. VI-SEEM (VI-SEEM) is one of the examples 
of trying to put the supercomputers to work on practical 
problems. It tries to facilitate regional interdisciplinary 
collaboration,  focusing  on  the  scientific  communities  of 
Life Sciences, Climatology and Digital Cultural Heritage. 
Through unification of the existing e-infrastructure into an 
integrated platform, it strives to better utilize synergies, 
for  an  improved  service  provision  within  a  unified 
Virtual Research Environment to be provided to scientific 
communities of high impact in the combined South East 
Europe and Eastern Mediterranean region.
The project
Building on the success of the previous regional 
projects and initiatives that helped bridge the digital divide 
by ensuring access to regional e-Infrastructures, VI-SEEM 
includes partners from 16 countries in the SEE and EM 
region, both from the resource providers’ and potential 
users’ communities. Bridging the two worlds would 
bring new value and improve research productivity and 
competitiveness on the pan-European level. 
The general project objective is to provide integrated 
e-Infrastructure platform for regional cross-border 
Scientific Communities in Climatology, Life Sciences, and 
Cultural Heritage for the SEEM region that will be user-
friendly and accessible to the fore mentioned communities. 
This goal will be achieved by linking compute, data, 
and visualization resources, as well as services, models, 
software and tools. This Virtual Research Environment 
- VRE will provide the scientists and researchers with 
the support in full lifecycle of collaborative research: 
accessing and sharing relevant research data, using it with 
provided codes and tools to carry out new experiments and 
simulations on large-scale e-Infrastructures, and producing 
new knowledge and data - which can be stored and shared in 
the same VRE. Through training, user support, application 
development and porting, the researchers will be able to 
truly utilize the power of the regional e-infrastructure, to 
try to solve realistic problems, including computer aided 
drug delivery, modelling of biomolecules, introduction 
of novel methodologies into drug development, regional 
genotype databases development are only a few of the 
possible applications. Our expectations are that this and 
similar projects will actually bridge the gap between the 
computing power and its real applications, for a healthier 
world and better living.
VI-SEEM for life sciences
Advances in computational infrastructure during the 
last decade have facilitated the development of biological 
data analysis for big data and computational biology 
as key research methodologies in both academia and 
industry. The use of computers in biology has enabled 
our better understanding of mechanistic aspects in 
health and disease and has accelerated the development 
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of novel therapeutics. In this project, the Life Sciences 
research community is chosen because of its central role 
in achieving a higher quality of life in the SEEM region. 
The aim of the VRE is to create and provide the necessary 
services over a capable infrastructure to facilitate research 
for understanding of disease mechanisms and appropriate 
mitigation methodologies in the SEE and EM populations. 
Project participants and related institutes will assist in data 
collection and analysis, run and optimizing computational 
codes and using the research results to understand the 
molecular basis of diseases associated with SEE and EM 
areas with projections to develop personalized therapies. 
The Life Sciences research community in the SEEM 
region  could  benefit  greatly  from  the  e-infrastructures  at 
hand. Large amounts of data need to be stored and be made 
available to researchers for processing in the compute 
centres of the region. Therefore, apart from storage 
resources, fast and reliable networking infrastructure is 
important for moving large datasets from data archives to 
the computing centres and also moving simulation results 
to the researchers’ facilities for further post processing and 
acquisition of results. In terms of compute infrastructure, 
the models and services to be used by the research groups 
require capacity and capability computing as well as the 
provision of computing resources for the installation of 
user facing services. For example, codes such as NAMD 
and NWCHEM scale up to hundreds or thousands of 
cores  and  can  benefit  from  scalable  HPC  clusters  or 
supercomputers such as the IBMs BlueGene. Molecular 
dynamics applications are also known to perform well on 
GPU systems, while also are being ported to new Intel’s 
Phi accelerator platform. On the other hand, parametric 
codes  for  human  genome  sequence  analysis  can  benefit 
greatly from the Grid or Cloud IaaS computing model. 
Finally, user-facing services can be also installed in the 
IaaS infrastructure that will be available in the project. 
It  is evident  that  the Life Sciences Scientific Community 
requires a variety of infrastructure resources all of which 
are going to be available in the VI-SEEM VRE.
Life science use cases
Some most important and most representative 
examples of using the regional e-Infrastructure for the 
needs of the Life Science VRE include:
•	 Modelling and Molecular Dynamics (MD) study of 
proteins, membrane proteins and biological model 
membranes. These three biomolecular entities are 
responsible for signal transduction and are important 
drug targets. Therefore, in order to design more 
efficient  drugs  and  drug  delivery  systems,  a  better 
understanding of the physicochemical interactions that 
govern biomembrane and protein interfaces is needed.
•	 Computational simulation of DNA and RNA to enable 
studying  the  influence  of  thermodynamic  properties 
of the DNA/DNA and RNA/DNA duplexes on the 
transcription and processing of RNA. Computational 
modelling of the structure, thermodynamics and 
kinetics of RNA, involved in cancer cell growth
•	 Computer-aided drug design. By using computational 
methods and the 3D structural information of the 
protein target, we are now able to investigate the 
detailed underlying molecular and atomic interactions 
involved in ligand: protein interactions and thus 
interpret experimental results in detail. 
•	 Image processing for biological applications includes 
experiments by spinning disk confocal microscopy of 
living cell, which generate images of dozens of GBs per 
experiment. The generated images require extensive 
image processing, such as registration, deconvolution, 
volume rendering, surface rendering, object detection, 
measurement of shape, size, and intensity of cell 
objects and automatic object movement tracking of 
the living cell in 3 dimensions and time.
•	 Analysis of Next Generation DNA sequencing data 
to identify disease mechanism pathways and provide 
patients with timely diagnosis, assessment of risk for 
developing the disease, targeted and efficient therapy, 
and give support for possible future reproduction 
planning.
•	 Synchrotron data analysis: SESAME is a 3rd 
generation synchrotron light source that produces 
very intense pulses of light/X-rays, with wave lengths 
and intensities that allow detailed studies of objects 
ranging in size from human cells, through viruses 
down to atoms, with a precision that is not possible 
by other means.
The list above is does not limit the possible usage of 
the resources, only provides some current and ongoing 
efforts in using the computational, networking and storage 
infrastructure to aid the Life Science research communities. 
The research into computer aided drug design will 
be given a strong focus during the project, both from the 
LS researchers, but also from the infrastructure support 
point of view.  Through advances in the drug delivery 
modelling, novel and hybrid methodologies (Markova et 
al., 2015) such as molecular dynamics, statistical physics, 
Monte Carlo etc. will be compared to the traditional 
methodologies, enabling better understanding of the 
processes at a very small scale. Through computer aided 
molecular design (Ng et al., 2015), the simulation results 
are  expected  to  significantly  reduce  the  clinical  trials  in 
anticancer drug research (Kim et al., 2013). 
Conclusion
Enabling access to e-Infrastructure through intuitive 
and  user  friendly  interfaces  could  bring  great  benefit  to 
the research communities in the SEE and EM regions. 
Through virtual collaborative environment, these 
communities can achieve research excellence on the pan-
European and global level. From the point of view of the 
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e-Infrastructures,  strong  justification  of  the  investments 
can be accomplished, demonstrated through real life 
results. Bridging possibilities of the high end computing 
infrastructures and the life science scientific communities 
will produce deeper knowledge of the human biology, 
better disease understanding, shorter development time of 
new and targeted drugs with less clinical trials. As in many 
other cases, the addition of these two will bring much more 
to the humanity than their simple sum. 
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Introduction
Non-adherence to prescribed medication is a perva-
sive phenomenon, pronounced more in chronic conditions. 
Non-adherence to prescribed medication is very common, 
with approximately half of the patients failing to adhere 
to the medication regimen. It a complex and multi-faceted 
phenomenon that involves factors associated with the med-
ication, patient, provider and health system, and thus can-
not be addressed with single effort interventions (Oster-
berg et al., 2015).
Poor adherence to medication regimens has been as-
sociated with poor medical outcomes over a range of diag-
noses, associated with avoidable admissions costs of $100 
Billion a year, in the US alone. Moreover, patient non-ad-
herence is a growing legal concern (Cutler, 2010). In one 
review, five percent of malpractice cases cite patient non-
compliance as a contributing factor, with over a third of 
these resulting in payment to the plaintiff.
The opportunity in integrated EMR-driven 
databases 
Integrated large clinical datasets offer a unique oppor-
tunity to assess the magnitude and impact of the non-adher-
ence phenomenon. In the case studies we will discuss, we 
used data from Clalit - Israel’s largest healthcare organiza-
tion which serves as insurer/payer and integrated care pro-
vider for over half of the Israeli population – over 4.3 mil-
lion people. Clalit holds abundance of real-time data pro-
vided to physicians and nurses, in an actionable, decision-
supporting format. Clalit has 100% (single software) Elec-
tronic Health Records coverage of ambulatory and hospi-
tal care, with an aggregated data warehouse that received 
feeds from both, on all its members, for well over 1.5 de-
cades. This data included detailed and full demographic, 
diagnoses (both EMRs and Claims), measures, full labora-
tory test data, imaging data, patient reported such as smok-
ing status and willingness to quit smoking, cost, both pre-
scription and dispensing medication data, and administra-
tive health services consumption data. 
The case of statins adherence 
Statins, as one of the most widely-prescribed medica-
tions with proven preventive efficacy, have a single indica-
tion and are given long term, and thus are a simple candi-
date drug to assess adherence patterns. In one study we de-
termined the proportion of patients prescribed statins who 
never fill a prescription, identified who they are, and com-
pared their LDL control to adherent and non-adherent pa-
tients. The methods included a retrospective examination 
among patients prescribed a statin in 2008 and followed 
through 2010 in Clalit. Statin adherence in patients over 
age 21 was tracked for 2 years utilizing a new, validated 
adherence measure based on both written and dispensed 
prescriptions. Adherence below 20% was considered non-
adherence. In this study, we found a total of 67,517 patients 
received 1,386,270 written prescriptions over the 3-year 
period. While a traditional adherence measure identified 
8000 patients as non-adherent, a prescription+dispensing 
adherence measure identified 19,000 patients as low ad-
herence patients. Thus, 1 in 6 patients prescribed statins 
would be overlooked using existing adherence methodolo-
gies. Changes in LDL levels of non-adherent patients were 
11.9-14.1 mg/dl, compared to 48.3 mg/dl, p<0.001 in ad-
herent patients. We thus concluded that non-adherence to 
statins was a very prevalent problem – more than we have 
previously assessed, as a large proportion of low-adher-
ence patients may have been overlooked unless full data 
(prescriptions and dispensing) was available for adherence 
assessment (Singer et al., 2015).
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The case of hypoglycemic drugs adherence 
In another study we assessed the attributable impact of 
adherence to oral glucose medications as a risk factor for 
poor glycemic control using Clalit’s electronic health re-
cords data.Adherence to diabetes medications over a two-
year period was calculated by prescription-based Med-
ication Possession Ratios for adults with diabetes diag-
nosed before January 1, 2010. Glycemic control was de-
termined by the HbA1c test closest to the last drug pre-
scription during 2010–2012. Poor control was defined as 
HbA1c>75 mmol/mol (9.0%). Medication adherence was 
categorized as “good” (>80%), “moderate” (50–80%), or 
“poor” (<50%). 
Among 228,846 diabetes patients treated by oral anti-
glycemic medication, 46.4% had good, 28.8% had moder-
ate, and 24.8% had poor adherence. Good adherence rates 
increased with increasing disease duration, while glycemic 
control became worse. We used logistic regression models 
to assess the role medication adherence plays in the asso-
ciation between disease duration, age, and poor glycemic 
control. There was a strong inverse association between ad-
herence level and poor control (OR = 2.50; CI = 2.43–2.58), 
and adherence was a significant mediator between age and 
poor control.While poor adherence does not mediate the 
poorer glycemic control seen in patients with longer-stand-
ing disease, it was a significant mediator of poor glycemic 
control among younger diabetes patients. A greater frac-
tion of poorly controlled younger patients (up to one third 
of them), compared to older patients, could be prevented if 
at least 80% adherence to their medications was achieved. 
Therefore, these results suggest that interventions to im-
prove adherence should focus on this younger sub-group 
(Feldman, 2014).
The case of anti-depressants
In another study we aimed to uncover the impact of 
adherence to anti-depressant medications (AD) treatment 
on all-cause mortality. We performed a four-year histori-
cal prospective cohort of a total of 251,746 patients aged 
above 40 years old who were prescribed AD at least once 
during 2008-2011. Patients were stratified into: non-adher-
ence (<20%), poor (20%-50%), moderate (50% - 80%), 
and good (>80%) adherence levels. Adherence was mea-
sured as a continuous variable representing possession ra-
tio (duration of claimed AD divided by duration of pre-
scribed AD). The association between adherence and Haz-
ard Ratio (HR) for mortality follow a quadratic model in 
which the lowest HR (0.66 [95% Confidence interval (CI): 
0.64 to 0.69]) is at a level of 60% adherence in respect to 
non-adherence, and leveled off as compared to higher ad-
herence. This shows again that adherence to AD is signifi-
cantly associated with a corresponding decrease in the risk 
of mortality, controlling for relevant covariates. Thus phy-
sicians from all disciplines should actively improve their 
patients’ adherence to AD since their persistent use is asso-
ciated with increased survival (Krivoy et al., 2016).
Summary
Our data from these multiple case study suggests 
that non-adherence is a frequent, impactful phenomenon, 
which exists across clinical domains and drives control 
challenges in chronic illness care. In the presentation at 
this conference we will also review the profound changes 
brought in the potential of information technology and dig-
ital health to allow innovative interventions that may ad-
dress low rates of medication adherence and the multiple 
inadequacies in current healthcare systems that drive it. We 
will discuss medication adherence tracking, using patient 
health records to engage patients, cost-related aspects of 
non-adherence and discuss what approaches have shown 
success and/or promise in addressing this high-impact uni-
versal health challenge. 
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Introduction
In this study, we examined the impact of Pharma Eco-
nomic Act (PEA), which was introduced in Hungary in 
2007. The motivation to analyze this particular legislative 
measure within a single mid-size country is in its compre-
hensiveness and in its unique approach toward marketing 
authorization holders (MAHs). Moreover, recent econom-
ic crisis is making such a »laboratory of cost-containment 
tools« attractive for authorities and payers not only among 
the Central and Eastern European (CEE) countries, but 
also among Western (e.g., EU-15) jurisdictions. Final rea-
son for the analysis is availability of detailed data on Hun-
garian prescription drug market, which are provided to the 
public by the authorities. 
While the National Health Insurance Fund (NHIF-
OEP) data provide strong evidence that the PEA resulted in 
cost-containment of the public expenditure for prescription 
drugs in Hungary,  cost-contaninment itself, however, may 
not lead to efficiencies either in the prescription drug mar-
ket, let alone in the overall healthcare market. As it is well 
known, cost-containment may stifle innovation, thereby re-
ducing the dynamic efficiency; on the other hand, price re-
ductions of off-patent drugs and their generic versions may 
be insufficent, allowing their prices to remain way above 
the marginal cost of production and thus promoting static 
inefficiencies.
Static efficiency
To assess static efficiency, we examined risperidone 
group (ATC5 group N05AX08). Risperidone group is a 
suitable proxy for genericized therapeutic group at the time 
of introduction of the PEA. 
Risperidone faced expiry of its intellectual property 
right (IPR) at the end of 2005, however, in this particular 
case, the branded firm was unable to follow the price de-
crease due to the fact that the IPR was still in power in EU-
15 jurisdictions and Hungarian price could thereby have a 
potential detrimental spill-over effect via international ref-
erence pricing. To prevent complete loss of revenue, the 
branded firm launched in 2006 its own authorized generic 
drug in cooperation with the local partner; in 2008, the lo-
cal partner launched its own generic, completely abandon-
ing marketing of the authorized generic. 
After the introduction of PEA, public expenditure 
per mg of risperidone decreased in 2008 from 162.7 HUF 
(€0.54) to 101 HUF (€0.33) for a branded drug and from 
155.2 HUF (€0.51) to 92.5 HUF (€0.3) for authorized ge-
neric drug. In 2008, public expenditure per mg of risper-
idone fell further to 37.1 HUF (€0.12) for authorized ge-
neric drug. The co-payment per mg increased sharply in 
2007 due to the PEA; having in mind that patients suffer-
ing from schizophrenia typically poorly adhere to the treat-
ment, such an increase could present potential adherence 
risk. However, since the average daily dose of risperidone 
is 4.7 mg, the monthly co-payment would be in total ap-
proximately 340 HUF (€1.1), unlikely a financial issue 
even for such a socially disadvantaged patient group. As 
we have observed earlier with atorvastatin, price of generic 
risperidone initially dropped rapidly (by 76% from 2006 to 
2008), but in 2009 and 2010 remained virtually unchanged. 
If we take cost of goods sold (COGS) at 10% of the mo-
nopoly price as the rough estimate of marginal cost of pro-
duction, for a typical branded small molecule launched in 
1990s then the potential for further price reduction does 
exist. Public expenditure with included 12%-rebate was in 
2010 for risperidone relatively modest – 871 million HUF 
(€2.8 million) – yet could still be reduced by about 60%.  
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Dynamic efficiency
To assess dynamic efficiency, we examined a line ex-
tension of oral risperidone, which was launched by the 
branded firm at the end of 2004. This incrementally modi-
fied product, however, reached way beyond the usual »ev-
ergreening strategies« of branded firms as the product pre-
sented the first long-acting atypical antipsychotic (admin-
istered once every 2 weeks) and thus addressed the issue of 
adherence of patients suffering from schizophrenia and as-
sociated higher hospitalization rates and costs. The brand-
ed firm entered in 2005 into price-volume agreement with 
NHIF-OEP, which was renewed in 2008. In spite of the 
controlled nature of growth, the long acting atypical an-
tipsychotic achieved in Hungary diffusion which was 
globally surpassed only by Spain; in April 2011, its mar-
ket share in the total antipsychotic market (N05A) was 
23.7% (vs 26.7% in Spain, 17.1% in France, 13.4% in It-
aly, 10.9% in Germany and 6.8% in the United Kingdom) 
(IMS, 2011). One of the former top ranking NHIF-OEP of-
ficials mentioned that in his opinion, »majority of patients 
should be treated by long-acting atypical antipsychotic« 
and thus corroborated the fact that Hungarian authorities 
did not oppose the novel technologies in spite of the over-
all framework of cost-containment.As with oral risperi-
done, co-payment surged in 2007 and the absolute amount 
has been with average monthly dose of 75 mg around 525 
HUF (€1.7), which is as with oral risperidone likely not ex-
cessive. In fact, OEP's own publication found no impact of 
co-payments on adherence of patients with schizophrenia; 
another former NHIF-OEP official claimed that in 2006 
»25% of schizophrenic patients were treated with two or 
more atypical antipsychotics, which was clearly a waste 
of resources«.   
Conclusions
NHIF-OEP managed to sharply decrease expenditure 
for risperidone by implementing the PEA in January 2007. 
The cost-containment policies did not exclude innovation: 
an example of a long acting atypical antipsychotic suggests 
that Hungarian prescription market under the PEA has en-
abled diffusion of new technologies, on at least per-capi-
ta basis comparable to those of G-5 countries. An obvious 
inefficiency is that the PEA was still financing excessive 
rents for off-patent drugs, which remain a global challenge 
for payers. The Hungarian off-patent market reinforces in 
particular the general notion that regulating generic prices 
may lead to price convergence and inefficiencies and that 
generic competition is not sufficiently fierce in regulated 
environment. Our study has some obvious limitations as 
we have examined a limited number of products and one 
might well find the product or a group of products which 
would deviate from our conclusions.
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Introduction
Parallel trade of pharmaceuticals in European Union 
(EU) started in the ‘70s as a process in which licensed phar-
maceutical distributor in any EU member state can, after 
obtaining proper authorization, import any drug from an-
other member state, so long as the drug that is being import-
ed is identical to the drug that is locally sourced, that is, it 
contains the same active ingredient and is produced by the 
same manufacturer (Kanavos et al., 2005). Since the middle 
‘90s the share of parallel trade grew up to 7-17%, especially 
in countries like Denmark, Sweden, United Kingdom, Ger-
many and the Netherlands. This process is based on the ex-
istence of heterogeneous price regulation systems among 
different countries in EU. Parallel trade of pharmaceuticals 
is legal within the EU based on the principle of free move-
ment of goods laid down in Article 28 of the EC Treaty to 
create a single market. However, it is subject to restrictions 
to protect industrial and commercial property and human 
life and health, according to Article 30 (Ginter et al., 2005). 
Representatives of the parallel trader’s consumers and pa-
tients while converging prices between different geographic 
markets and thereby harmonizing the markets for pharma-
ceutical products. Representatives of the pharmaceutical in-
dustry, on the other hand, claim that parallel trade (or “gray 
market trade”) is nothing more than free riding, or piggy-
backing, on pharmaceutical companies’ profits and thereby 
condemning innovation by reducing the ability and willing-
ness to invest in research and development (“R&D”), while 
at the same time distorting the supply chain of drugs in low-
price countries, which makes availability of certain drugs 
uncertain for patients (Nilsson, 2013).
In the previous year’s parallel trade originally was 
concentrated on the most important patented products, but 
now the situation is a different and this process has extend-
ed to a wider range of pharmaceutical products. The main 
problem generated within the parallel trade in CEE coun-
tries is a drug shortage. Namely these countries realize the 
greatest export of drugs resulting in hampering the access 
to drugs for the local patients. 
Republic of Macedonia (RM) as a associate member 
of the EU is not a part of parallel trade process. There is a 
similar process named parallel import of drugs. The paral-
lel import of medicines is legally defined and basically it is 
a modification of the procedure for parallel trade in med-
icines in the EU Member States. According to our law, PI 
is import of such medical products that has medical au-
thorization in the R.M under import license issued by the 
Drug agency from the referent countries, when the import-
er is not appointed by the MA holder (national decision). 
The term “Parallel” implies that the MP is imported via 
pathways that are different to the established one (desig-
nated by manufacturer or its original supplier), as competi-
tive channels that are active in the same time/parallely. The 
countries that are chosen as the reference for the registra-
tion of drugs are also chosen as the reference countries for 
parallel importation. Those countries are: EU Countries, 
USA, Japan, Switzerland, Canada. Russia and Turkey are 
added as two another counties to this list. This fact was rea-
son for development of two different and opposing views 
on the feasibility of introducing of the parallel importation 
of medicines in our country. On one side was the attitude 
of some experts and the representatives of the pharmaceu-
tical companies, first of all the innovative pharmaceutical 
companies, according to which this process will lead to the 
possibility for the emergence of the counterfeit drugs that 
will affect the quality of the medicines, the safety in their 
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use and will be the reason for the closure of the representa-
tive offices of these companies and the withdrawal of reg-
istration files for these drugs from our country. On the oth-
er side was the attitude of the managing persons from the 
Ministry of Health according to whom this process will 
lead to increased competition, lower drug prices and the 
proposed legislation and prevent the occurrence of drugs 
of dubious quality pharmaceutical market. 
The aim of this article is to present the effects of par-
allel trade/import in the pharmaceutical markets in CEE 
countries.
Methods
Traditional legal search methods were used for iden-
tification of impact of parallel trade/import on CEE coun-
tries. A literature search was carried out in the PubMed da-
tabases, ISPOR databases, Google Scholar and on official 
web sites of regulatory bodies from CEE countries. A fol-
lowing combination of key words has been used: paral-
lel trade and pharmaceuticals and Central East European 
Countries or medicines.
Results and discussion
The share of parallel imports in EU increased contin-
ually due to a growing focus on specialty drugs (oncology, 
hematology products, HIV- and CNS-therapeutics) and the 
capping of price differences at 15 euros per package worth 
100 euros or more. The annual turnover of more than 100 
parallel traders in 2015 was 5.5 billion in Europe. The par-
allel trade as a process has some negative effects for the 
CEE countries. The main is the problem of drug shortage 
in the countries with smaller prices of medicinal products. 
Medications imported on other markets come mainly from 
these countries. They are exported from those particular 
countries in large numbers, thus hampering the access to 
drugs for the local patients, causes delays in bringing prod-
ucts to market. For example, the parallel import market of 
medicinal products in Poland in 2005 was 0.01% of the 
pharmaceutical market with 40 licenses for this procedure, 
in 2009 was already 0.7% with 308 licenses, and only in 
the first three quarters by 2010 it reached nearly 1.1% (Re-
ligioniand Czerw, 2012). In Czech Republic the parallel 
export of medicines is around 185 Mil. € in 2015 (Skoupá, 
2016). The oncology drugs are accounted for about 30% of 
exports in values. In Slovakia, the problem is particularly 
acute. The medicines price regulation makes Slovakia an 
attractive destination to buy cheap medicines and export 
them abroad. Drug sales in Slovakia amount to about €1 
billion annually, with re-exports making up as much as 30 
percent of the revenue. In Greece in 2012 parallel exports 
accounted for around 500 million euros of the total value 
of the pharmaceutical market. During the economic crisis 
in 2014 the situation it became worst. Based on this situ-
ation the Greek government has announced a provisional 
ban on the parallel exporting of 34 innovative medicines as 
a emergency measure. Faced with this problem CEE coun-
tries from begging of 2013 have been started with intro-
ducing of new legal measures to monitor and restrict par-
allel exports. Slovakia’s parallel trade-restricting law has 
served as the model for a similar regulation introduced in 
Bulgaria, Romania and Estonia latter. 
In R. Macedonia in the previous 2 years period almost 
350 different drugs have obtained parallel import authori-
zation. The list includes drugs which are used in oncology, 
neurology, hematology daily practice, drugs for treatment 
of respiratory disease, interferons, insulins. List is getting 
wider and wider. These are drugs that mostly belong to the 
group of originator medicines and are intended for the hos-
pital usage. But, on the list you can also find generic drugs. 
In this period parallel importation of medicines in Mace-
donia led to a reduction in drug prices and to the savings in 
the health system, while the occurrence of counterfeit med-
icines and disorders in the quality of imported products are 
not recorded for now. Based on the data from Ministry of 
health, to date the total savings enabled through the parallel 
importation of drugs in RM is 14 million euros.
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Introduction
In the previous eight years the Law on Medicines 
and Medical Devices has been uniquely changed for 12 
times, either by a new law enactment or by amendments 
to the existing laws. The Agency of Medicines regulated 
the prices of 2700 registered drugs placed on the market 
in the R. of Macedonia on three levels: unique wholesale 
price, unique retail price and defined wholesale and retail 
mark-ups. In December 2011, after a series of attempts 
to perform regulatory pricing pressure on importers and 
manufacturers of drugs, the Agency has introduced a new 
Methodology (Official Gazette of RM No. 156/11, 2011). 
Core data on the price reductions of the registered drugs 
were provided by the Macedonian Agency of Medicines. 
Data are covering the period 2012-2015, during which 
8 revisions were made. For the workflow control of the 
computer model and in order to produce data analysis 
we have used the programming language Python v3.5. 
Microsoft Excel was used for additional statistical 
analysis. This study is the first comprehensive analysis of 
the result of the implementation of the new Methodology 
in Macedonia. 
Results
The introduction of the new Methodology and its 
implementation by the Agency for the period 2012-2015 
resulted in price decrease of 1386 drugs (including all 
available registered dosage forms) out of total 2178. In 
total 680 drugs were lowered by more than 10%. The major 
price reduction happened in 2014, followed by reductions 
in 2015, 2012 and 2013. Furthermore, the analysis of the 
average price changes of the drugs shows that after initial 
13% decrease of the prices in 2012, significant percentage 
of reductions was registered in 2013, followed by declining 
dynamics in 2014 and 2015. 
For objective research reasons we extended our 
analysis and grouped the pharmaceutical and dosage forms 
of the drugs. The results shows that since the introduction 
of the new Methodology until October 2015, a total of 
843 drugs with the same INN have reduced prices. Major 
decrease by generics has been registered in 2014, in total 
of 355 generic drugs, followed by 2015 with 307 drugs, 
2012 with 125 drugs and 56 in 2013. Our next focus was on 
averaging the percentages of price reduction of evaluated 
drugs. The results show that the major decrease of 23% 
was in 2013, followed by 18.4% decrease in 2014, 17.8% 
in 2012 and 10.8% in 2015. For more precise calculations 
we have used iterative calculation of the changes of the 
same generics year over year (YoY). By this same analysis, 
we have found that major price decrease were registered 
on glimepiride 88%, fluconazole 87%, ramipril 82%, 
bicalutamide 80%, torasemide 77% etc. 
Detailed analysis of the dynamics of price reduction of 
the drugs with the same INN shows that major reduction 
of the prices took place in 2014, when the price of 355 
drugs was lowered, with over 32 drugs lowered by 30% 
or more. Second biggest price reduction took place in 
2015 when 307 of the drugs have lowered price, but with 
lower dynamics of reductions compared to previous years. 
Moreover, the analysis clearly shows that in 2012, a total 
of 125 drugs with the same INN have lower prices with 
12 drugs lowered on average by 30% or more. Finally, the 
lowest number of reduced prices of drugs was in 2013 (56 
drugs in total), but with the highest average dynamic of 
reductions of 23% for the period 2012-2015. The average 
price change was the lowest in 2015 with reductions of 
only 10.8%, in 2012 with 17.74% and in 2014 with 18.4%. 
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Obviously the dynamics of the average price changes 
of the drugs with the same INN is slowing down YoY, 
considering the fact that in most of the cases the price 
reductions are affecting the same generic groups.  
Next segment we have focused on was the evaluation 
of the drugs by the ATC code. Since the introduction of the 
new Methodology, major price reduction was registered 
in the Group L with total of 180 drugs and average price 
decrease of 27%. Next was Group N with a total of 123 
generic drugs and an average price decrease of 19%. Group 
J with 119 drugs and average price reduction of 29% is 
“the leader” in terms of the relative number of generic 
drugs and the size of the price reductions. Finally, Group 
C where the price of total of 69 drugs was lowered in 
range between 77% and 10%. What is also noticeable is 
that the average price reduction in this ATC code group is 
27%. 2012 tendencies by ATC classification show that the 
prices of a total of 119 drugs were reduced with average 
size of 26%. Major price decrease in 2012 by number of 
generic drugs was registered in Group N and by percentage 
of reduction in the Groups A and L. In the following year 
the price of a total of 63 generic drugs by ATC code was 
reduced with highest average decrease of 28% with major 
number of drugs in the Groups J, C, A and Group N. 2014 
was the year of major changes concerning the number of 
a total of 276 generic drugs with reduced price by 27.7% 
as well as dynamics. Major developments are in Group L, 
with a decrease ranging from 51% to 24%. Second major 
changes were registered in Group M, reductions of 46% to 
22%, Group J with a changes ranging between 58% and 
10%, and Group N with a range of reductions between 
64% and 11%. In 2015 the price of a total of 197 generic 
drugs was reduced with major decrease in the Group J with 
51%, Group N with 46%, S with 44%, Group H with 35%, 
Group M with 32% and, Group N with 30% decrease. 
Finally we have analysed the ratios between the price 
reductions and the quantities sold by inserting on X axis 
average percentages of price reduction calculated by the 
use of iterative approach and on Y axis sales for 2015 given 
the year 2012 as basis with 100 points level. The result was 
a downward slope at rate -0.83x which confirms that the 
price reduction leads to declining sales of the generic drugs. 
It is noticeable that out of total 118 generic drugs with 
lowered prices for the period 2012-2015, in the year 2015 
a total of 31 generic drugs have zero sales. Furthermore, 50 
out of 118 in 2015 have higher sales than in 2012, but only 
19 have increased sale of over 10%. Remaining 31 generic 
drugs have increase of sale sizing below 10%.  Major part 
of the sales increase was registered for those generic drugs 
whose price was reduced by approximately 40%, but with 
the average size of sales stagnating in the range between 
100 and 120 level. Finally we have analyzed the price-
quantities changes for the period 2012-2015 by dividing 
the drugs with registered sale increase, and drugs with 
lowered sales after the prices were reduced. Contrary to 
the expectations, the group of drugs above level 100 has 
declining tendency of sale, which reflects the drop in the 
sales as consequence of continuous price reduction. In the 
second group, stagnation of the sales quantities is evident 
(y=0.1x). By excluding the zero sales drugs for the period 
2012-2015, we came to the conclusion that the price 
reductions of generic drugs have insignificantly increased 
the sales of the drugs, whereby most of the drugs are bellow 
or on the levels of 2012.
Conclusion
The introduction of the new Methodology in 2011 may 
look like a win-win solution in which the prices of number 
of drugs have been reduced, which is preferred policy 
target of the governments, and the patients have access 
to cheaper drugs. However, the price reductions of some 
generics did happen only on some registered dosage forms 
and for those the sale was dramatically reduced, or zero. 
The pharmaceutical companies have shifted the sale to the 
same generics but for different dosage forms, which at the 
end of the day creates similar profit ratio but it changes 
the composition of the portfolio offer for the drugs. The 
decrease of the prices has pushed down the level of sales 
of the drugs, which is a negative correlation and a clear 
signal that the supply side is negatively reacting to the 
price reduction. 
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The term “biologicals” most often refers to complex 
biopharmaceuticals with very specific chemical, physical 
and biological characteristic due to the nature of their active 
substance and manufacturing process, immunogenicity 
and a generally higher variability in their structure. In 
this heterogenic group of medicines there are different 
therapeutic proteins like insulin, filgrastim, growth 
hormone, erythropoietin, interferons and monoclonal 
antibodies. Often viewed as miracle drugs they offer 
hope, transforms patient’s lives and provide cures and 
treatments for many severe diseases including diabetes, 
blood conditions, neurological disorders, autoimmune 
disorders and cancer.  All that hope and promise that this 
treatments are offering comes with very high price that 
accounts for most of the biologicals. Data for global sales 
from 2014 are showing that approximately 80 billons US 
dollars are spend for this medicines. The predictions are 
that by 2017 global biological pharmaceutical market will 
amounts to about 220 billion dollars (Dolinar and Reilly, 
2013). This trend of biological spending and growth is 
putting big financial pressure on the health care budget. 
The high price of this drugs and the financial crisis that 
has required healthcare systems to make significant 
cost reductions and in the same time patent expirations 
on many of the biological blockbusters were the main 
factors that drive the interest towards biosimilar medical 
products (biosimilars). Biosimilars are relatively new 
but growing segment, offering less costly alternative 
and enhanced competition to existing biological market. 
There is a strong interest by healthcare stakeholders in 
measuring the biosimilar utilization and impact on the 
market entry. Regulatory issues, manufacturing, safety, 
pricing, and physician and patient acceptance have a big 
influence in the developing the biosimilar market. By 
definition biosimilars are biological medicine similar toor 
a version of another biological medicine that has already 
been authorized, with similar active substance and which 
can prove their similarity towards quality, safety and 
efficacy (European Medicines Agency, 2014). Biosimilars 
began to enter European Union (EU) markets in 2007 and 
increase competition among producers of biologicals. 
However, the generic approach of substitution is not 
applied in the case of biosimilars due to their specificity 
(Weise et al., 2014). In the last years biosimilars have e 
significant clinical, regulatory and economic impacts in the 
medical market. At this moment there are 20 biosimilars 
with marketing authorization in EU, in seven classes as 
following: 7 Filgrastims, 5 Epoetins, 2 Folitropin alpha, 
2 monoclonal antibodies, 1 insulin, 1 somatropin and 
1 etanercept. When it comes to the market uptake of 
biosimilars, in the Consensus paper from EU Comission 
from 2013 (Consensus Information Paper, 2013) it was 
clearly stated that the most important conditions for market 
uptake of biosimilar medicines are driven by factors in the 
commercial market place. Differences across EU member 
states in national healthcare systems, have big impact on 
the biosimilars uptake. Factors influencing the market 
uptake of biosimilars are local pricing and reimbursement 
regulation, procurement policies and terms, physician 
perception of biosimilar medicine and patient acceptance 
of biosimilar medicines. There are differences in uptake by 
country, reflecting variations in local healthcare systems. 
Biosimilar penetration of the accessible market is only 
relevant when there is significant price difference between 
the originator and biosimilar, and where treatment options 
are limited to the molecule for which biosimilars are 
available. If the therapy area also has products that have 
been launched more recently, are still patent protected 
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and which bring differential clinical benefit to patients 
or segments of patients who do not respond to other 
therapies, then payers and health systems should more 
usefully understand the role of biosimilars in the context of 
the total class of therapeutic options. There are important 
factors driving biosimilar market performance which play 
out differently across therapy areas and countries. These 
approaches in turn are often influenced by budgetary 
or financing measures imposed on healthcare payers 
and those with responsibility for managing the drug 
expenditure budget (Ruiz et al., 2013). Patients can also 
influence the shape of biologic markets and the uptake 
of biosimilars through their advocacy voice, typically 
through patient groups that represent the interests of those 
suffering from certain diseases. Current differences in 
the use of biosimilars and competition dynamics across 
European markets are not just explained by epidemiology 
and disease factors, but instead reflect local adoption of 
treatment practices and guidelines influenced by funding 
decisions and payer actions. These decisions are often 
made with a narrow focus on medicine costs rather than a 
broader view that considers the full cost of administering 
the medicine to patients. Relevant measures and use of 
real world evidence are needed to bring policy-makers 
the level of transparency and visibility they need to assess 
options, make decisions and monitor the results (Wang and 
Chow, 2012). With respect to the use of biosimilars, these 
measures may include the appropriate expansion of access 
to patients who will benefit from biologics, the evolution 
of medicine cost, as well as the evolution of overall patient 
treatment cost and health outcomes.
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Introduction
Although pharmacists’ role to secure quality healthcare 
and educate patients on disease prevention is by all means 
very important and presents their role in primary health 
care, the potential of pharmacists is not recognized by the 
healthcare authorities in Serbia, as is the case with many 
other countries (Chandra et al., 2003).
Related to dispensing medicines, pharmacists provide 
much more than merely detailed information on medicines 
(Chandra et al., 2003). Community pharmacist must be sure 
that the patient has received and understood in a proper 
manner all the information provided, in order to safely and 
effectively use the medicines and improve the treatment out-
come.
In addition to dispensing medicines, patient counsel-
ing presents one of the most important services rendered by 
community pharmacists (Puspitasari et al., 2009). The coun-
seling process includes time, empathy and understanding, 
an individual approach and open communication with pa-
tient (Puspitasari et al., 2009). 
By talking with the patients, pharmacists can identify 
the majority, as well as, solve minor health problems, ed-
ucate patients on self–medication, proper use of medicines 
and medical devices and where necessary direct the patient 
to the doctor.
The objective of this study was to determine in which 
degree patients/citizens trust in knowledge and expertise of 
pharmacists subject to their health status, age and education.
Materials and methods
For the needs of this study were used responses to ques-
tions from a questionnaire conducted in 26 chosen Farma-
nea pharmacies in Belgrade, Republic of Serbia, during 
the period from January 3rd to February 28th, 2014. The 
questionnaire was anonymous and consisted of 17 closed 
type questions. The patients filled out the questionnaires in 
the pharmacy either alone or in consultation with pharma-
cists. At the beginning of the questionnaire the patients were 
asked to state their health status, age and education level. 
The questions referred to reasons and frequency of pharma-
cy visits and counseling service satisfaction. For the needs 
of this survey four questions from questionnaire were cho-
sen and the influence of health status, age and education lev-
el of respondents was analyzed.
The chosen questions were to give answers to: (1) Most 
common reasons patients visit pharmacies, i.e. how many of 
them state counseling for minor ailments as major reason for 
visit to the pharmacy; (2) To what degree do the patients first 
consult the pharmacist when facing a minor health problem 
and (3) Do they subsequently consult the GP; (4) Which 
health professional do the patients consult on queries relat-
ed to proper use of medicines or medical devices. The ques-
tionnaires were processed by statistic program SPSSV19.
Results and discussion
A total of 3656 fully completed questionnaires were 
collected. This survey presents and discusses results ob-
tained by analyzing of responses to four questions from the 
questionnaire depending on the health status, age and edu-
cation level of respondents. 
To the question “Which is the most common reason 
for your visits to the pharmacy”  21.4% of the patients an-
swered that they visited the pharmacy because of health 
problem, 27.1% in order to obtain prescription medicine 
from pharmacy and 51.5% came to buy a specific product.
Related to health status structure of respondents, the 
analysis showed that healthy persons (23.4%), persons 
with minor ailments (24.5%) as well as those who didn`t 
check their health status (27.6%) were those who visited 
the pharmacy for reason of health problem in a percentage 
above the general average.
Patients who suffered from serious health problems and 
severe chronic illnesses in largest number of cases (60.8% 
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and 69.6%) visited the pharmacy in order to get their pre-
scription medicines. Analysis determined that persons who 
suffered from serious health problems and severe chronic 
illnesses where in 57% of cases over 65 years of age, hence 
the most common reason for their visits was as anticipated.
In view of patient age structure, oscillations to general 
average answers were most noticeable with persons young-
er than 30 and over 65 years of age. Patients younger than 
30 in 26.6% of cases visited the pharmacy for health prob-
lem reasons.
Patients over 65 stated obtaining of prescription med-
icine (59.2%) as the most common reason for visiting the 
pharmacy which was expected, hence these patients were 
the majority of those who suffered from serious health prob-
lems and severe chronic illnesses.
Related to respondent education level there were no 
significant oscillations in percentage of patients visiting the 
pharmacy for health problem reason.
To the question “Which health professional do you first 
consult when facing a minor health problem”, the majority 
of respondents, 65.3%, stated that they first consult the phar-
macist, while 34.7% stated that they first consult their doc-
tor/dentist.
Healthy persons (74.4%), persons with minor health 
problems (69.8%) and those who don`t check their health 
status (81.6%) first consult the pharmacist when facing a 
minor health problem.
Patients younger than 65 in a larger number of cases 
consulted a pharmacist when having a minor health prob-
lem. Patients over 65 years of age were in 67.3% of cases 
persons who suffered from serious health problems and se-
vere chronic illnesses, who because of possible deteriora-
tion of health status or comorbidity in 54.2% of cases con-
sulted their doctor when facing a minor health problem. Fur-
thermore these patients visit their doctors once per month to 
receive prescriptions for their regular therapy and use this 
opportunity for physician counseling (Nikolic et al., 2014).
The responses to the question “Do you visit your doctor 
after pharmacist counseling regarding the same health prob-
lem” were analyzed on the answers of those who said that 
they first consult the pharmacist when facing a minor health 
problem. Results have shown that 81% of them don`t con-
sult their doctor related to same health problem.
The patient health structure analysis determined that 
persons who suffered from serious health problems and se-
vere chronic illnesses in a lager degree, in relation to aver-
age question response, subsequently consulted their doctor. 
The stated patient group visits their doctor once monthly in 
order to get their regular monthly therapy prescription and 
uses these visits for counseling (Nikolic et al., 2014).
Patients younger than 45 do not consult the doctor after 
pharmacist counseling in 85.6% of cases, while in 31.7% of 
patients over 65 years of age subsequently consult their doc-
tor, which was expected bearing in mind their health status.
Results analysis to question “When you hear in a com-
mercial “please consult your doctor or pharmacist on indi-
cations, safety precautions and adverse reactions related to 
medicine or medical device”, who do you consult” showed 
that 61.6% of patients consulted the pharmacist, 15.5% the 
doctor and 22.9% of patients didn`t consult neither the doc-
tor nor pharmacist.
Responses from persons suffering from serious health 
problems and severe chronic differed from those of gener-
al average, hence they in 22.1% and 24.8% of cases respec-
tively consulted their doctor after watching the advertise-
ment. An interesting fact is that persons with serious health 
problems consulted the pharmacist in 64.4% of cases af-
ter watching the commercial. The category of patients who 
don`t check their health status especially stands out. They 
don`t consult any health professional after watching the 
commercial in 49.3% of cases.
Conclusion
The majority of the respondents recognize the impor-
tance of the counseling role of the pharmacist. Healthy 
persons, persons with minor health problems, persons who 
don`t check their health status and those younger than 65 
years of age visit the pharmacy for counseling on their 
health issues in over the average number of cases. Persons 
under 45 years of age don’t consult their GP after consult-
ing the pharmacist regarding the same health problem in a 
high percentage.
The majority of patients on indications, safety precau-
tions and adverse reactions consult their pharmacist after 
watching a commercial.
This study has shown that the role of pharmacist in 
primary healthcare is reflected in education on preven-
tion, solving of minor ailments and advising on therapy 
for patients who are younger, those who consider them-
selves healthy or are with minor ailments while for patients 
who are older, with serious or chronic illnesses the primary 
role of the pharmacist is in therapy dispensing, advising on 
proper use and monitoring of therapy outcome. This survey 
has shown that persons who don`t check their health status 
see the pharmacy as the place of their first choice. 
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Introduction
Information technologies are accepted as ubiquitous 
resources for social and professional information. In 
particular, Internet use has become important to most daily 
activities, from work and entertainment to education and 
participation in society. Also, statistics show that ¾ of all 
European citizens (EU-27) is using Internet, with Central 
and Nordic countries as the most active and Southern 
countries comparably less active (Seybert, 2012). Internet 
communication is preferred due to speed and ease in many 
services and activities (Komerik, 2005). With younger 
generations being the most intense users, students present 
an interesting group for studying Internet use and potential 
misuse. 
Social networks, online gambling, shopping, banking, 
watching TV series/movies, and education resources, are 
known to be the most popular reasons for using Internet 
among university students (Miller et al., 2010; Turkish 
Statistical Institute, 2012; Wang et al., 2011; Yılmaz, 2012). 
However, no comparative analysis on Internet use 
has been done so far on pharmaceutical students, which 
present a rather homogeneous group, with curricula that 
are equivalent or similar in most European countries 
(PHARMINE Consortium, 2011). Knowing some 
differences between Southern and Northern European 
countries, a comparitive analysis focusing on both 
differences and similarities between countries and regions 
seems worthwhile. The present study aims to describe 
Internet use by pharmacy undergraduates as well as 
to establish an initial comparison of this use amongst 
European countries. 
Materials and methods
This study is descriptive using a questionnaire-based 
survey. Pharmacy Schools from Northern, Central and 
Southern Europe participated. A total of 748 4th year 
university students from Estonia, Latvia, the Netherlands, 
Portugal and Turkey were invited to participate. 
Notably, included centers were: Ankara, Gazi, 
Hacettepe Universities; the University of Lisbon; the 
University of Groningen; the University of Tartu; and 
Universities of Riga Stradinš and Latvia. 
The questionnaire aimed to gather information 
regarding students’ socio-demographics, health status, and 
Internet use and potential misuse. The questionnaire was 
pre-tested in each partner country, assuring that no linguistic 
issues remained. The participants filled out a paper-based 
questionnaire in the presence of a local coordinator. 
Data gathering and structuring was completed for all 
countries in December 2012. SPSS v15.0 was used for data 
entry, merging and qualitative and quantitative analysis. 
Pearson Chi-Square, ANOVA and linear correlations, were 
applied using the significance level at 0.05.
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Results and discussion
Out of 748 graduate students, 654 students (87.4%) par-
ticipated in the study. The majority of the participants were 
from Turkey (44.5%) and Portugal (32.6%). In all countries, 
the majority of the students were females.
Students’ Internet use is presented in Table 1. Latvi-
an students used Internet at school in a significantly low-
er frequency (43.1%) than students from all other countries. 
For all countries, students used Internet more outside (e.g. 
at home) than inside the school, except in the Netherlands. 
Turkish students reported less frequent use of Internet at 
home than rest students in other countries (p<0.001). The 
frequency of Internet access via smart or cell phone was less 
than 19.0% in Latvia, presenting the lowest frequency of all 
countries investigated here (p<0.001) compared to all other 
studied countries.
The most often reported purposes for using Internet 
were communication, academic work, social networking, 
listening to music and watching movies. Dutch students 
used Internet for social networking and listening to music 
more frequently than the others and this difference was sta-
tistically significant (p=0.016 and p=0.002, respectively). 
Portuguese students used Internet for both watching mov-
ies and shopping less frequently than all the others (p=0.002 
and p<0.001, respectively). Internet use for chatting was 
more popular among the Estonian students than among oth-
er pharmacy students (p<0.001).
The results of this study provide valuable evidence on 
how Internet is being used by pharmacy students, recogniz-
ing its true potential and actual use in this group in higher 
education (Garrison and Kanuka, 2004). 
This study aimed to look at a coherent educational co-
hort (i.e. 4th year pharmacy students) between 5 countries: 
2 Mediterranean, 1 Central European and 2 Baltic nations. 
There was a good participation rate (near 90%). 
The pharmaceutical profession in Europe is predomi-
nantly a female occupation (FIP, 2012; Ruiz et al., 2006). 
And this predominance was also found in all the surveyed 
countries. 
Beyond the demographic apparent homogeneity, com-
puter and Internet use varied significantly between studied 
countries, with a lower overall use for the Turkish partic-
ipants. This lower use can be explained by relatively low 
computer penetration rates at home in Turkey among the 
5five countries (Turkish Statistical Institute, 2012). 
Internet use for communication and educational pur-
poses was found not to differ from country to country. This 
suggests a common electronic ground for studying pharma-
cy, although information sources may vary. More important-
ly, results confirmed the central role of computers and In-
ternet for communication and performing academic work. 
All countries presented high percentages for those activi-
ties, which have a clear implication on the development of 
teaching and learning. Educators should not neglect the pro-
gressive, but continuously, swift to online education, while 
keeping the right balance between media-based/distant and 
face-to-face teaching (Ruiz et al., 2006). 
Social networks have emerged as important tools for 
maintaining and improving social capital (Johnston et al., 
2013; Miller et al., 2010). Although statistically significant 
differences were found in this sample, high use of social net-
works was observed in all countries. This issue may take a 
lot time and interrupt academic working and success. Also 
social isolation may occur because of intense use of Inter-
net social networking. This can lead the teaching staff to re-
member their roles and responsibilities: the emergence of an 
“e-professionalism” concept, the legal and ethical implica-
tions of online postings in students’ educational decisions, 
how online personas may blend into professional life – all 
these factors increase educators’ role demands (Cain, 2008). 
Conclusion
According to the results, Internet and computer use 
amongst pharmacy students during their education seems 
to be equivalent amongst culturally diverse countries.
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Introduction
The enormous development of new medicines and 
their permanent introduction in the pharmaceutical market 
as well as permanent raising of medicines consumption on 
global level are very challenging and they are not so easy 
to face with. In particular it is not so easy for developing 
countries which have low health budgets and rationality 
in managing this budget is of strategic importance. Most 
countries are interested to enable access to medicines for 
their population but at the same time they must establish 
policies that will promote their rational use.
In Republic of Macedonia the improvement of rational 
use of medicines is a part of the Health strategy and the Na-
tional strategy for medicines. Considering the above men-
tioned findings and being aware that the trend of increas-
ing medicines consumption often caused by their irratio-
nal use may affect the public health, the last few years the 
health authorities in the country, including all stakehold-
ers and the medical experts, have conducted activities at all 
levels of health care in order to improve the rational use of 
medicines and public health as well. These activities were 
preceded by a situational analysis that detected and located 
the causes of irrational use of medicines, after which Ac-
tion plan at government level (AP, 2014) were approved. 
These activities included the educational, social and regu-
latory dimension of the issue. 
In this regard, the Agency of medicines and medical 
devices conducted inspections in community pharmacies 
throughout the country.
Objectives
The main purpose of this activity was to check whether 
the regime of medicines dispensing is in compliance with 
the legal provisions (LP, 2016) and according to the ap-
proved action plan to share educative materials regarding 
medicines use intended for patients.
Methods
In the first half of 2014 (from January to June) 880 
community pharmacies across the country were inspect-
ed. Target pharmacotherapeutic groups of medicines to be 
checked were: antibiotics, anxiolytics, sedatives and anti-
depressants. The inspection was repeated in the second half 
of 2014 and the results evaluated. 
Results and discussion
Inspection conducted in the first half of 2014 (from 
January to June) in 880 pharmacies state wide showed  that 
a significant amount of the medicines that belong to above 
mentioned therapeutic groups were being dispensed with-
out a prescription. These findings were very worrying. The 
highest consumption was marked in anxiolytics, more pre-
cisely medicines that belong to the group of benzodiaze-
pine derivates, followed by sedatives and antidepressants. 
At the third place were antibiotics (all medicines were for 
oral use).
The medicines that lead regarding antibiotic consump-
tion are combination of penicillins’ including beta lacta-
mase inhibitors more precisely the combination of amox-
icillin and clavulanic acid, followed by cephalosporin of 
first generation (cephalexin) than amoxicillin and cipro-
floxacin.
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What were the most often causes stated by the pharma-
cies for these worrying data?
The pressure from the patients who demanded to buy 
the medicine because:
- The elder cannot visit their doctors to take pre-
scriptions for medicines that they use continu-
ously (for example sedatives and anxiolytics)
- People that work, state that they cannot wait to 
take prescriptions from their doctors, because 
they know which antibiotic is going to be pre-
scribed to them ( most often amoxicillin + cla-
vulanic acid or cephalexin )
- Relatives and friends insisting to get the med-
icine because they have used it before and got 
better
During the checkups that have been conducted in the 
first half of 2014, for all pharmacies where medicines were 
dispensed without a prescription, a data-record has been 
written about the established findings and it was pointed 
out that every pharmacy should work in compliance with 
the regulatory demands. 
Educative brochures regarding rational use of medi-
cines in particular of antibiotics, sedatives and anxiolytics 
were prepared for patients so they can be informed through 
their community pharmacies. Considering the low level of 
health literacy in majority of patients, these brochures con-
tained very clear and simple messages regarding the risks 
they take by using medicines without medical advice.
During the second half of 2014 Agency of medicines 
repeated the checkups (from July to December). In most 
pharmacies it was not recorded at all dispensing of antibi-
otics, sedatives and anxiolytics without prescription. The 
comparative analyzes showed the following results: The 
dispensing of anxiolytics without prescription in particu-
lar dispensing of benzodiazepine derivates was decreased 
for approximately 93% to 95% for all strengths, dispens-
ing sedatives (zolpidem) was decreased for 95% and dis-
pensing of antidepressants (amitriptyline) was decreased 
for 99.5%. Dispensing without prescription of  antibiotics 
more precisely  combination of penicillin’s  including beta 
lacatamase inhibitors, (combination of amoxicillin and cla-
vulanic acid 875/125 mg) was decreased for 99% , amox-
icillin 500 mg - 97.5% while   dispensing cephalosporin’s 
of first generation (cephalexin 500mg) was decreased for 
95% which means that conducted comparative analyzes 
showed significant improvement in proper dispensing of 
prescription only  medicines.
Conclusion
The role of pharmacists is not only dispensing of med-
icines, the pharmacists are health professionals responsi-
ble for improving public health by giving appropriate in-
formation to their patients, in order to raise their aware-
ness on the safety risks of improper and irrational use of 
medicines, educating them and advising on what is best 
for their well being. The legal provisions must be respect-
ed and they are legally binding. The Agency of medicines 
is very confident that this kind of checkups in community 
pharmacies should be a continuous process until achieving 
full implementation of legal provisions. These regulatory 
and educational activities related to dispensing and rational 
use of medicines does not mean that the problem of irratio-
nal use of medicines is solved once and for all. But on the 
other hand, exactly these activities are crucial steps in the 
path of eradication of bad attitude related to medicines use.
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Introduction
Appropriate and objective information how to make 
right decision by choosing and using the medication is vi-
tally important (FIP, 2008). The times when health care 
professionals were expected to take decisions on treatment 
or new medication without explanation are gone (Coulter, 
1999). Nowadays patients access a variety of human, print 
and electronic sources. It is very important to get know the 
sources there they pick the information. Given that some 
of medicine information sources available for the patients 
could provide misinformation, it is important that patients 
and health care professionals discuss the medications ful-
ly before making decisions. The primary purpose of patient 
medicines information is to assist the patient and health 
professional in achieving safe and effective use of medi-
cines. This includes providing information that allows the 
patient to make an informed decision as to the appropriate 
selection and use of medicines. 
Information about medicines and treatment is avail-
able from healthcare professionals, mostly doctors and 
pharmacists. Other medicine information sources where 
patient seeks for information are Patient Information Leaf-
lets (PILs), various media sources, etc. Most patients ac-
cess information from sources that are convenient for them 
without considering if the information they get is enough 
confident. It is becoming increasingly important to better 
understand what places patients report as their sources of 
drug information (Hamrosi et al., 2014). The aim of the 
study was to determine the use and perceived reliability 
of different medication information sources among Lithua-
nian community pharmacy patients. 
Materials and methods
The 385 community pharmacy patients who visit-
ed pharmacy to obtain medications or came for consul-
tation in pharmacies in different Lithuanian regions were 
asked to participate in the study. A method of questionnaire 
was chosen. The questions about reliability and usability 
of different medication information sources were includ-
ed. 60.8% of participants lived in the city (or center of re-
gion), 23.6% of participants lived in town and 15.6% lived 
in village. 73% of respondents were women and 27% were 
men. The youngest participant in the survey had age of 18 
years and the oldest was 84 years. To evaluate results all 
respondents were categorized in three age groups: 18-40 
years old, 41-65 years old and 66-84 years old. The statis-
tical analysis was performed using SPSS (Statistical Pack-
age for Social Science) 17.0. Descriptive statistics were 
calculated to summarize the data. T test and chi-square test 
were used to analyze differences among groups. Results 
were considered statistically significant when the p value 
was less than 0.05.
Results and discussion
All participants were asked about reliability of med-
ical sources that they use and whether these sources are 
S1 PP 17
50
Maced. pharm. bull., 62 (suppl) 49 - 50 (2016)
Pharmacoeconomics / Social pharmacy / Drug information
Po
st
er
 p
re
se
nt
at
io
ns
reliable and confident. Doctor and pharmacist seemed to 
be most reliable sources among all age groups. Almost all 
respondents in all age groups (Reliability and usability of 
both medical information sources were evaluated more 
than 95% in each age group!) use these sources to receive 
medical information they require. According to results in 
the third place little less reliable medical source is phar-
macy technician. Mostly it’s being used and looks confi-
dent for respondents between 66-84 years old. 88.6% of 
these respondents reported this source as usable and reli-
able compared to 77.5% in 41-65 years and 81.2% in 18-40 
years groups. Patient information leaflet takes fourth place 
however is the first one among all written medical infor-
mation sources. Only 50% of respondents in age group be-
tween 66 years and 84 years claimed this source as reliable 
and 25.3% of respondents in same age group reported not 
using this source of information at all. 84.8% of respon-
dents in 18-40 years age group find this source reliable. 
Books, family and friends, commercials, magazines, tele-
vision and internet are less reliable sources to patients.  Al-
most half of all respondents answered they use internet as a 
source, but information is not reliable. Older patients (age 
group 66-84) do not use this source to search for medical 
information. Results of our survey shows that patients are 
tended to trust healthcare professionals and identifies them 
as their first choice to receive confident medical informa-
tion about treatment, taken medications, etc. More than 
95% of respondents in all age groups indicate that they use 
doctors and pharmacists as their sources of medical infor-
mation and that these sources are reliable. Both sources 
give accurate and constructive information targeted to pa-
tient, his condition and his needs in medical treatment. 
Survey revealed that among healthcare professionals 
pharmacy technicians are to be treated positively due to 
their interactions with patients. 88.6% of respondents in age 
group between 66-84 years reported this source as reliable. 
There are not many studies where importance of their role 
in consulting patients is investigated however we assume 
that this specialist plays an important role in providing 
patient with specific and needed medical information. 
Patient information leaflets were indicated as reliable 
sources. More than 80% of respondents in age groups of 
18-40 years and 41-65 years reported to use this source.
Conclusion
Community pharmacy patients reported general 
practitioner and pharmacist as most reliable and mostly 
usable sources. Patient information leaflet remains in line 
with other most usable medical information sources and 
is number one among all written medical information 
sources. It is necessary to better adopt patient information 
leaflet to older patients. As reliability of other written 
medical information sources is uncertain it is necessary to 
overview and to control this information. 
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Introduction
Antipsychotics are used to treat psychotic symptoms, 
agitation and diseases such as schizophrenia and mania 
(Freudenreich and Goff, 2010).
Nowadays antipsychotics may be classified in two 
groups, typical and atypical antipsychotics. Typical anti-
psychotics have been used since the 1950s, while atypical 
drugs are newer drugs approved for use between 1990 and 
2000. Atypical antipsychotics have certain superior thera-
peutic characteristics compared to typical drugs in terms of 
efficacy and side effect profile. However, certain clinical 
trials have failed to prove any superiority in effectiveness. 
This is because the newer atypical drugs have their own 
disadvantages, too (Schatzberg et al., 2011).
Atypical drugs are much more expensive than the old-
er typical drugs. Statistics in Albania have revealed that 
risperidone, an atypical antipsychotic, is among the top ten 
most expensive drugs (Kola, 2009).
Since their approval, there has been an increase of use 
of atypical antipsychotics as compared to typical antipsy-
chotic use (Verdoux et al., 2010). Meanwhile, in Albania 
there are few reports on antipsychotic use. This study’s ob-
jective is to characterize the use of antipsychotics in Al-
bania.
Materials and methods
Data from National Compulsory Health Care Insurance 
Fund were used for the study. The Compulsory Healthcare 
Insurance Fund (the Fund) is a government entity which 
provides healthcare to insured Albanian citizens and keeps 
records on medications purchased at community pharma-
cies by insured citizens (pharmacy claims data). Every citi-
zen who pays a monthly health care contribute to the Fund 
can purchase medications at a lower price. The total cost of 
a drug is partially reimbursed by the Fund (reimbursement 
cost) and partially paid by the patient (patient cost/price). 
Nationwide antipsychotic pharmacy claims data collected 
from the Fund from 2006 to 2012 were used for the study. 
In the obtained data, antipsychotics were defined by 
their ATC (Anatomical-Therapeutic-Chemical) code. ATC 
codes for antipsychotics were used to identify antipsychot-
ics in the pharmacy claims data. 
Quantities of antipsychotics were determined as de-
clared in the data, i.e., by their dosage forms, such as cap-
sules, tablets, flacons, ampoules, etc. The amount of typ-
ical, atypical and total antipsychotics was calculated for 
each year of data. 
For a more accurate estimation of utilization of anti-
psychotics, the number of defined daily doses (DDDs) was 
estimated for each antipsychotic medication. The defined 
daily dose is the average maintenance dose per day for a 
drug used for its main indication (World Health Organiza-
tion, 2003). DDDs were determined using the maintenance 
daily doses referred to in the British National Formulary. 
The number of DDDs per 100 000 inhabitants per day was 
calculated for each antipsychotic every year using the mil-
ligrams of antipsychotics utilized. Reimbursement costs in 
Albanian Lek (ALL) and the mean costs paid by the patient 
were also estimated. Data were analyzed with Microsoft 
Excel and SAS statistical software package, version 9.1.
Results and discussion
Typical antipsychotics covered by the Compulsory 
Healthcare Insurance Fund during 2006-2012 were Chor-
promazine, Fluphenazine, Haloperidol, Levomeproma-
zine. Atypical antipsychotics were Clozapine, Olanzapine, 
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Risperidone. Lithium is considered as a distinct drug cate-
gory in the antipsychotics group.
All antipsychotics were available in either one of the 
oral dosage forms such as capsules, tablets, or oral drops 
solutions. Fluphenazine and chlorpromazine also existed 
as solutions for injection of immediate release. Haloperi-
dol and fluphenazine were available also as long-acting so-
lutions for injection. 
The purchased antipsychotics totaled 3.36 million in 
2006 and increased to 4.78 million in 2012. This is a 42% 
an increase of total antipsychotic use. Of all antipsychot-
ics, the amount of purchased typical antipsychotics de-
clined gradually from 1.2 million in 2006 to 1 million dos-
age forms in 2012. The amount of atypical antipsychotics 
increased from 1.7 million in 2006 to 3.7 million in 2012 
(more than doubled). Atypical antipsychotics constituted 
60% and 78% of the total amount of purchased antipsy-
chotics in 2006 and 2012, respectively. Quantity of Lithi-
um more than doubled from 362 thousand in 2006 to 729 
thousand in 2008. 
Numbers of DDDs were estimated for each antipsy-
chotic. Among typical antipsychotics, haloperidol had the 
highest number of DDDs /day/ 100 000 inhabitants with 
40 DDDs in 2006 and rose to 58.8 DDDs in 2012. Chlor-
promazine came second behind haloperidol. Other typical 
antipsychotics use such as fluphenazine, levomepromazine 
and thioridazine also decreased during 2006-2012. Lithi-
um’s number of DDDs increased from 11.5 to 21.9 during 
the study period. 
Among atypical antipsychotics, olanzapine had the 
greatest increase in use, with a number of DDDs of 18.9 in 
2006 and 127 DDDs in 2012. Olanzapine in 2012 had the 
greatest number of DDDs than any other antipsychotic dur-
ing the entire 2006-2012 period. Clozapine was among the 
drugs with the highest number of DDDs during the study 
period with 32.3 DDDs in 2006 and 57.2 DDDs in 2012. 
The number of DDDs for risperidone increased also from 
28.7 to 46.9 during 2006 - 2012. Number of DDDs for Lith-
ium also doubled during the study period, from 11.5-21.9.
Total reimbursement costs for antipsychotics equaled 
252 million ALL in 2006 and 293 million in 2012 (lith-
ium not included). In 2006, the reimbursement costs in-
curred by atypical and typical antipsychotics were 230 mil-
lion ALL (91% of total reimbursement costs) and 22 mil-
lion ALL, respectively. In 2012, the reimbursement costs 
incurred by atypical and typical antipsychotics were 234 
million ALL (80% of the total reimbursement costs) and 
59 million ALL, respectively. The reimbursement costs for 
Lithium were 2.6 million ALL in 2006, and increased to 
7.9 million ALL in 2012, a threefold increase during 2006-
2012.
For the entire study period, the mean price per typical 
antipsychotic paid by the patient ranged from 87-105 ALL. 
This price was on average 5% - 9% of the total typical an-
tipsychotic cost. The mean price per atypical antipsychot-
ic paid by the patient ranged from 815 – 1385 ALL, which 
on average constituted 11-26% of the atypical antipsychot-
ic total cost during the study period. No distinct trend was 
noticed for patient costs. 
Conclusion
During 2006-2012 there was a 42% increase of total 
antipsychotic use. While the amount of typical antipsy-
chotics declined, the amount of atypical antipsychotics 
more than doubled from 2006 to 2012. Among typical anti-
psychotics, haloperidol had the highest number of DDDs /
day/ 100 000 inhabitants, which showed an increase during 
the study period. Among atypical antipsychotics, olanzap-
ine had the greatest increase in use; its number of DDDs 
during the study period increased seven-fold. Clozapine 
was among the atypical drugs with the highest number of 
DDDs. 
Total reimbursement costs increased from 2006 to 
2012. There was an increase in the costs of both typical and 
atypical antipsychotics. Atypical antipsychotics accounted 
for the majority of reimbursement costs for antipsychotics. 
Notable is the increase of 2.7 fold of typical antipsychot-
ics reimbursement costs, despite the fact that their use has 
not changed significantly over the same period. For the en-
tire study period, the mean price per atypical antipsychotic 
paid by the patient was 10 times higher than the mean price 
of typical antipsychotics.
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Introduction
Pharmacists and professional healthcare workers 
face new challenges on daily basis in various aspects in 
their line of work. 
Medication is the most frequent intervention 
within healthcare systems worldwide. Achieving the best 
possible outcome of medication for the quality of life of 
patients should be the primary aim of all health profession-
als involved in the medication chain, as well as careers and 
patients depending on their abilities and capacities. Phar-
maceutical care is a quality philosophy and working meth-
od for professionals within the medication chain. It is in-
dispensable for helping to improve the good and safe use 
of medicines, thus realizing the full potential of medicines 
available on the market to achieve the best possible out-
come in patients as observed (Cousins et al., 2012).
In the years that have passed since we opened our 
pharmacy in 2007, we managed to establish work policies 
while dealing with numerous problems. Even from the be-
ginning, the patients themselves were in the focus of our 
work due to the fact that it was our firm belief that being 
professional and honest with our patients will only bring 
positive feedback on the long run.
In a close collaboration with other professional 
healthcare personnel, especially the doctors, we created an 
important bond that has had only positive effects on our 
patients. Creating trust and a strong belief in our principles 
was one of the biggest benefits during the first couple of 
years. Of course, the trust is something we built very care-
fully and it is long-lasting, and it has to be maintained irre-
spective of everything.  
Throughout the years, as we grew, our main ob-
jective was focused on the well-being of the patients. We 
started with patients with diabetes, making them aware of 
the importance of eating properly and managing the thera-
py. We always reminded them how to use and take insulin, 
or when to take their tablets.
We continued with, perhaps, the most struggling 
patients – the ones with cancers. We tried to bring some 
light and positive thinking and, of course, help them with 
advice on how to improve their immune system and their 
overall health condition.     
The next group of patients with a great need of 
extra care was the patients with high blood pressure. We 
are well trained to organize and recognize any drug inter-
actions for this group of patients. Informing them which 
tablets to drink in the morning and which during the day 
was the first thing we did for them. Emphasizing the im-
portance of proper dieting and physical activity was the 
second thing we did, and instructing them how to proper-
ly measure their blood pressure was the third. At the end of 
the day, all of them were happy and pleased with the infor-
mation and the care they got in our pharmacy.
Materials and methods
The study was conducted by observation of the 
patient’s habits during the months of January to June ev-
ery year, starting from 2007 to 2014. As shown in another 
study (Nikolic et al., 2014) 29.09% of patients visit phar-
macy seeking advice for minor health problems and 83.5% 
of patients come to the pharmacy at least once per month. 
65% patients said that in case of minor ailments, they con-
sult pharmacist first. 
Having this in mind, we took in consideration the 
number of daily visits by our patients and the time need-
ed for them to be served and answered any questions. The 
objective was that one patient shouldn’t wait more than 5 
minutes inside the pharmacy.
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Next objective was the total revenue for every fiscal 
year and the differences between consecutive years in rise 
of the income parallel to the rise of the number of patients.
Results and discussion
For the first 6 months, we reached an average of 35-
40 visits by patients a day. Every patient was treated with 
great care and we started the implementation of the “Good 
Pharmaceutical Practice” from the first to the last patient. 
Very soon, patients started to recognize and appreciate our 
hard work and constant care. In the next 3 years we reached 
an average of 80-90 visits per day, in other words, we dou-
bled the frequency of patients visiting and buying different 
products in our pharmacy. 
In 2010 we needed more staff, so we hired our fist 
pharmaceutical technician. We spent two mounts in train-
ing with her so that she could reach out to the patients in 
the same manner we did. Having a third person working 
was a big relief for us because we could concentrate more 
on the patients and on the interaction - “pharmacist-pa-
tient”. On the long run this brought us more work, mean-
ing more patients. The quality of the service was improved, 
the waiting period was shortened much more and more pa-
tients were visiting our pharmacy. We finished 2010 with 
an increase in total revenue for 11.6% in comparison to 
2009. Compared to 2010, our total revenue in 2011 and 
2012 increased 12% and 23% respectively.
We continued with the same trend in 2013. By reach-
ing an average number of 140 visits per day we stayed in 
line with our goal to become one of the most appreciat-
ed and trusted pharmacies in our city. Working in pairs we 
maintained the waiting time under 4 minutes per patient. In 
2014 we averaged 165 visits per day, our goal was to main-
tain the core stability of our pharmacy and that has always 
been the patients.
Conclusion
Now, in 2016, having gained a lot of experience, we 
are ready for challenges. In the middle of this year we plan 
to create support groups. Those groups should be consisted 
of struggling patients with the same or similar health con-
ditions that make their life seem unbearable. The concept 
of support groups is fairly unknown in our city, or maybe 
even in our country, so we are hoping to bring again some 
new light in the difficult life of the high-risk patients. We 
plan to organize meetings with small groups of patients ev-
ery week. They can share within their own experiences and 
struggles within the group. By sharing important informa-
tion they can only help others. This concept, we believe, 
can have only positive impact in our patients’ lives. 
We strongly believe that interacting and evolving in 
some social aspects of people’s lives is the future of the 
modern pharmacist. The continued education and the con-
stant striving for positive changes are our guidelines for 
the future.
To conclude, providing a high-quality care for our pa-
tients and constantly improving their quality of life is a 
work policy that not only generates immensely satisfied 
patients, but also generates higher income, which is a result 
of the increasing number of patients seeking the best possi-
ble care, which we, as health workers, constantly provide. 
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Introduction
Industrial property rights, as is the case with other 
intellectual property rights, are generally defined in terms 
of exclusive entitlements granted to the holder of such 
rights. The exclusivity is granted, in most legal systems, 
upon a registration of the relevant industrial property right 
in an administrative procedure. By granting industrial 
property rights, competent authorities of the state offer 
certain monopoly which, construed in terms of different 
legal theories (Dabovic-Anastasovska and Pepeljugoski, 
2012), is limited. Legally speaking, the term of the 
exclusivity granted is limited and, after its expiry, the 
relevant industrial property right lapses and enters the so 
called public domain. Such is the case also with patents as 
industrial property rights. The term of protection is 20 years 
from the filling of the application for protection (Article 33 
of the Agreement on Trade-Related Aspects of Intellectual 
Property Rights (hereinafter: the TRIPS)). The Republic of 
Macedonia is a party to the TRIPS and this requirement is 
implemented by national legislation (Article 74(1) of the 
Industrial Property Law (hereinafter: the IPL)).
Materials and methods
The IPL recognizes the granting of patents for 
inventions of drugs, in terms of Article 27(1) of the TRIPS. 
When a patent for an invention of a drug is granted, its 
holder is authorized to undertake certain exclusive 
entitlements and to claim such exclusivity relating to third 
parties (Article 28 of the TRIPS and Article 89 of the IPL). 
On the other hand, said exclusivity is not absolute bearing in 
mind that applicable law may reserve certain entitlements 
only until the public interest becomes affected. Therefore, 
the exclusivity granted is limited by applicable law. In 
terms of Article 30 of the TRIPS, its Members may provide 
limited exceptions to the exclusive rights conferred by a 
patent, provided that such exceptions do not unreasonably 
conflict with a normal exploitation of the patent and do 
not unreasonably prejudice the legitimate interests of the 
patent owner, taking account of the legitimate interests 
of third parties. When patents for inventions of drugs are 
concerned, third parties interests are converged in terms of 
the interest of public health.
Article 91(2) of the IPL provides that the exclusive 
entitlements of the patent holder in terms of the IPL 
shall not relate to the undertaking activities for research 
and development of the subject matter of the protected 
invention, in particular: manufacture, use, offer for sale, 
export or import of the protected invention, including 
also the activities for obtaining approval for placing on 
the market of drugs for human and veterinary medicine or 
products for protection of plants. This is the case of the so 
called “Bolar clause”, introduced in terms of the TRIPS 
(Neethu, 2015), which allows for fast introduction of a 
generic drug after the patent term by permitting technical 
preparation for registration of the same drug from an 
alternative source before the patent has expired (Dukes, 
2006). Its brooder acceptance came after the 1984 Hatch-
Waxman Act (35 U.S. Code § 271(e) (1)) was adopted in 
the US following the decision in Roche Products v. Bolar 
Pharmaceutical 733 F.2d 858 (Fed. Cir. 1984) where the 
court held that Bolar’s acts (obtaining the active ingredient 
from a foreign manufacturer and beginning studies for 
filing an application for a generic drug before the Food 
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and Drug Administration) constitute an infringement 
of Roche’s patent (and not an exception in terms of an 
experimental use) which had not lapsed yet (Haracoglou, 
2008; Kretzschmar, 2014). In the EU, a similar exemption 
from a patent infringement exists in terms of Article 10(6) 
of Directive 2001/83/EC of the European Parliament and of 
the Council of 6 November 2001 on the Community code 
relating to medicinal products for human use, as amended 
in 2004 (Barnden, 2008; De Stasio and McClay, 2004), 
although its scope is under dispute (Cohen and Peirson, 
2013).
Results and discussion
The public health argument considers the “Bolar 
clause” in terms of the right of access to drugs (Van 
Puymbroeck, 2010). One should, on the other hand, bear 
in mind the scope of the “Bolar clause” and its scope and 
possible limitations are dependent on national law. For 
example, the Court of Justice of the European Union is 
yet to reach a decision in case C-661/13 Astellas Pharma 
Inc. v Polpharma SA Pharmaceutical Works on whether 
EU law considers the research exemptions also in terms of 
acts by which a third party for purely commercial reasons 
offers or supplies to a manufacturer of generic medicinal 
products a patent-protected active substance which that 
generic pharmaceutical undertaking has planned to use for 
conducting studies or trials for a marketing authorization 
under medicinal product law (Ostrowska and Minde, 2014; 
Straus, 2014). Also, in a dispute before the WTO it was 
previously found that one may undertake acts generally 
reserved for the patent holder in terms of obtaining 
approval for placing on the market of drugs but one cannot 
undertake activities of stockpiling patented goods during a 
certain period before the patent expires (Canada – Patent 
Protection of Pharmaceutical Products, WT/DS 114/R, 
March 17, 2000).
Conclusion
A “Bolar clause”-like exception to patent infringement, 
as regulated by the IPL, can therefore be deemed as generally 
consistent with the TRIPS. On the other hand, one may also 
find that the wording of Article 91(2) of the IPL is broader 
than EU law, while also taking into account the ambiguities 
of the latter. The IPL, in those terms, seems to be enacted 
in the spirit of the 1984 Hatch-Waxman Act as it expressly 
covers the acts of manufacture, offer for sale, export or 
import. Here one may even dispute the alignment with the 
TRIPS. Although this may prove to be inadequate when 
legal rules are concerned, the Macedonian pharmaceutical 
market will probably not be largely affected by it. Truth be 
told, the mainstream pharmaceutical sector will function 
notwithstanding the provisions of the IPL. In any case, 
intentionally or not, the wording of the “Bolar clause”-like 
exception of the IPL may be treated as an argument for 
the need of a clarified and more developed EU range rule, 
as the Republic of Macedonia is a candidate country for 
membership in the Union.
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Introduction
As from beginning of 2012 a legal frame for parallel 
trade (imports) of medicines was introduced in the Repub-
lic of Macedonia. Since this regulatory reform raised a lot 
of practical dilemmas our aim is to clarify some of them. 
Parallel imports are legitimate goods that are placed into 
circulation in one market and then imported into a second 
market without the authorization of the patent holder, but, 
at the same time, allow existence of competition for a drug 
which is still under patent protection (Religioni and Czerw, 
2012). They are neither generic versions of a brand name 
drug, nor are pirated copies that form part of the “black 
market” (Brougher, 2014). They have the same active in-
gredient, in the same amount and the same dosage form as 
the locally sourced drugs. 
The driving force for parallel trade is the price differ-
ence between the source (exporting) and the destination 
(importing) country. This kind of arbitrage has been for de-
cades legally practiced in the Europe Union (EU) under the 
common norms of the primary EU law, in particular Euro-
pean competition law on free movement of goods (Articles 
34, 101 and 102 of the Treaty on the Functioning of the Eu-
ropean Union - TFEU) and represent instrument for creat-
ing competition for any medicine during its patent life (Mi-
yase, 2011). 
Parallel trade in the European pharmaceutical sector is 
widespread. In its 2009 Final Report following its inqui-
ry into the pharmaceuticals sector, the European Commis-
sion (EC) noted that the turnover of parallel traders was be-
tween EUR 3.5 billion and EUR 5 billion in Europe, that 
is, between 2% and 3% of the overall market (EC report, 
2009). Drugs facing competition from parallel imports are 
found to have on average 17% to 21% lower prices than 
they would have had if they had never faced such competi-
tion (Granlund and Miyase, 2011). There is a vast body of 
case law regarding competition law issues in parallel trade 
of medicines: The Istituto Chemioterapico Italiano S.p.A. 
and Commercial Solvents Corporation v Commission of 
the EC; The Bayer AG v Commission of the EC; Glaxo-
SmithKline Services Unlimited v Commission of the EC; 
Syfait and others v GlaxoSmithKline; AstraZeneca v Com-
mission of the EC; Hoffmann-La Roche & Co. AG v Com-
mission of the EC; etc. (Jones and Sufrin, 2008).
Parallel imports, nevertheless, might differ from local-
ly-sourced drugs in color, taste or shape. Due to the dif-
ferences in country-specific labelling requirements or stan-
dard package sizes, parallel imports might thus be repack-
aged or relabeled. The ECJ has also issued decisions re-
lated to this issue: Bristol-Myers Squibb; Upjohn; Mer-
ck Case; Boehringer Ingelheim I and II Cases. Two recent 
cases on the repackaging of pharmaceutical goods by par-
allel importers reconsidered the exhaustion of rights prin-
ciple in the context of free movement of pharmaceuticals: 
the Welcome Foundation Ltd v Paranova Pharmazeutika 
Handels GmbHand Orifarm and Paranova v Merck Sharp 
and Dohme (Armengod and Baudenbacher, 2009). Parallel 
imports are inevitably related to the pharmaceutical indus-
try which itself is subject to rigorous patent system (Fol-
land et al., 2013). 
Although territorial by nature, patent law is faced with 
the challenge of protecting and managing patent rights 
worldwide. Those rights are governed by two main or-
ganizations: the World International Patent Organization 
(WIPO) and the World Trade Organization (WTO). One of 
the agreements that countries must ratify upon joining the 
WTO is the Agreement on Trade Related Aspects of Intel-
lectual Property Rights (TRIPS). Parallel imports are al-
lowed under Article 6 of the TRIPS Agreement (Brough-
er, 2014). The legality of parallel imports steams from the 
S1 PP 21
58
Maced. pharm. bull., 62 (suppl) 57 - 58 (2016)
Pharmacoeconomics / Social pharmacy / Drug information
Po
st
er
 p
re
se
nt
at
io
ns
territorial exhaustion of intellectual property rights (IPRs). 
Regional exhaustion applies in the EU, meaning that IPRs 
are exhausted upon first sale anywhere in the EU (Gran-
lund and Miyase, 2011). On EU level there is continuous 
struggle between different associations representing inter-
ests of various stakeholders.  
The European Association of Euro-Pharmaceuti-
cal Companies (EAEPC) as professional and representa-
tive voice of pharmaceutical parallel distribution in Eu-
rope should be mentioned first. Its position is that the de-
spite the specifics of the pharmaceutical market, parallel 
distribution of pharmaceuticals is a legitimate commer-
cial practice and consistent with the goals of the EU sin-
gle market (EAEPC, 2016). On the other hand, the Euro-
pean Alliance for Access to Safe Medicines (EAASM) rep-
resents the stance that the main academic and policy ar-
guments should not be only driven by the economics of 
parallel imports, but rather many other issues of equal im-
portance should be considered as well (EAASM, 2014). 
Hence, pharmaceutical companies should be permitted to 
implement practices responding to parallel trade as long 
as these measures are not contrary to the EU competition 
rules (Forrester and Dawes, 2008). For example, parallel 
imports may cause negative effects such as: drug shortage 
in the exporting countries; the drug quality may be dam-
aged due to the transportation, inappropriate storage or re-
packing; disruption of already established producer – ex-
clusive distributor relations on a particular market; cuts in 
research and development investments and negative ef-
fects in launching new medicines (Monti, 2007; Religio-
ni and Czerw, 2012); consumers might consider parallel 
imports to be imperfect substitutes for the locally-sourced 
drugs, increased risks relating to the entry of counterfeit 
medicines into the legitimate supply chain, etc. (Hawkins, 
2011). Thus, practices for gaining exclusivity extensions 
by pharmaceutical companies should be justified. Those 
practices are: non-patent exclusivities, combining two or 
more successful drugs into one tablet and marketing it as 
a new product, continuation application practice, strategic 
patenting, etc. (Brougher, 2014; Gupta et al., 2010). 
The case of the Republic of Macedonia
As mentioned before the concept of parallel imports in 
Macedonia was introduced in 2012 by amending the 2007 
Law on Drugs and Medical Devices. The parallel trade is 
not defined by the 2010 Law on Protection of Competi-
tion. However, Macedonian competition legislation is ful-
ly in line with the EU one, meaning that EU practices are 
fully effective in national context. Macedonia is member 
of WTO since April 2003. Up to December 2015, 186 ap-
provals have been issued for parallel imports by the Drug 
Agency in Macedonia. Turkey emerges as an exclusive ex-
porting country in all imports. Four drug wholesalers are 
engaged in parallel imports (MALMED, 2016).  However, 
there is still no significant official evaluation as regards the 
economic effects of these imports on the Macedonian phar-
maceutical market.
References
Armengod, H. and Baudenbacher, L.M., 2009. The repackag-
ing of pharmaceutical products and parallel trade in the EU. 
Regulatory Affairs Pharma 783–786.
Brougher, T. J., 2014. Intellectual property and health technolo-
gies balancing innovation and the public’s health. Springer 
Science Business Media New York, 175–202.
EC report, 2009. Available at http://ec.europa.eu/competition/
sectors/pharmaceuticals/inquiry (accessed on January 11th, 
2016)
EAEPC, 2014.  Available at http://www.eaepc.org (accessed on 
January 17th, 2016)
EAASM, 2016. Available at: http://www.eaasm.eu/eaasm-reports 
(accessed on January 19th, 2016)
Folland, S., Allen, C., Goodman, A.C., Miron S., 2013. The eco-
nomics of health and health care, Seventh Edition, Pearson 
Education, Inc. 347-349.
Forrester, I.S. and Dawes, A., 2008. Parallel Trade in Prescrip-
tion Medicines in the European Union: The Age of Reason? 
Published in: Yearbook of Antitrust and Regulatory Studies 
1, 9-31. 
Granlund, D. and Miyase, Y.K., 2011. EU Enlargement, Parallel 
Trade and Price Competition in Pharmaceuticals - What’s to 
Blame? Derogation or Perception? No 831, Umeå Universi-
ty, Department of Economics.
Gupta H., Suresh K., Saroj K. R., Gaud R. S., 2010. Patent pro-
tection strategies, J. Pharm. Bioall. Sci. 2(1), 2–7. 
Hawkins, L., 2011. WHO/HAI Project on Medicine Prices and 
Availability, Review Series on Pharmaceutical Pricing Pol-
icies and Interventions, Working Paper 4: Competition Pol-
icy. 
Jones, A. and Sufrin, B., 2008. EC Competition Law, third edi-
tion. Oxford University Press. 410, 486-487, 529-530, 581-
582, 607-608.
MALMED, 2016.  Available at https://lekovi.zdravstvo.gov.mk/ 
(accessed on January 21st, 2016)
Miyase, Y.K., 2011. Parallel Trade, Reference Pricing and Com-
petition in the Pharmaceutical Market: Theory and Evidence, 
Economics and Law University of Gothenburg, 199, Geson 
Hylte Tryck,4.
Monti, G., 2007. EC Competition Law, Cambridge University 
Press, 41.
Religioni, U. and Czerw, A., 2012.  Economic impact of paral-
lel trade on the selected pharmaceutical markets in the EU. 
Prog. Health. Sci. 2(2), 181-189. 
Poster presentations
Macedonian pharmaceutical bulletin, 62 (suppl) 59 - 60 (2016)
ISSN 1409 - 8695
UDC: 618.19-006.6-052
Short communication
Evaluation of reliability and validity of the European 
Organization for Research and Treatment of Cancer Quality of 
Life Questionnaire (EORTC QLQ-C30) questionnaire (Albanian 
version) among breast cancer patients from Kosovo 
Selveta Shuleta-Qehaja1*, Aleksandra Grozdanova2, Aleksandra Kapedanovska 
Nestorovska2, Zorica Serafimoska2, Ljubica Shuturkova2, Zoran Sterjev2
1Kosovo Medicines Agency, Rrethiispitalit (QKUK), 10000  Pristina, Kosovo; 2
2University “Ss Cyril and Methodius”, Faculty of Pharmacy, Majka Tereza 47, 1000 Skopje, Macedonia
* sshuleta@yahoo.com
Introduction
Breast cancer is the second most common cancer in the 
world and, by far, the most frequent cancer among wom-
en with an estimated 1.67 million new cancer cases diag-
nosed in 2012 (25% of all cancers) (Ferlayet al., 2015).The 
diagnosis and subsequent treatment of cancer is often as-
sociated with considerable psychological and social diffi-
culties for patients (Cankurtanet al., 2008). Quality of life 
(QoL) has become a part of the evaluation criteria for can-
cer therapy besides the classical biomedical criteria. It is 
the most frequently used outcome measures in oncology 
research (Lee et al., 2000). In Kosovo there is very little in-
formation available about the QoL of cancer patients.
The European Organization for Research and Treat-
ment of Cancer Quality of Life Questionnaire (EORTC 
QLQ-C30) is a questionnaire to assess the quality of life 
in cancer patients. The QLQ-C30 questionnaire has been 
used worldwide (Aaronson et al., 1993). The Albanian 
QLQ-C30 version has been translated by EORTC, and to 
our knowledge this is the first evaluation of the question-
naire. 
Materials and methods
A random sample of 62 breast cancer women patients, 
who were attending the Institute of Oncology of the UCCK 
were included in the study. The study period was between 
the end of February 2014 until the middle of May, 2014. 
The study was approved by ethics committee from Univer-
sity Clinical Centre of Kosovo (UCCK). Patients were in-
formed about the purpose of the study questionnaire and 
were voluntarily included in the study and gave the ver-
bal informed consent. The personal interview with patients 
was conducted by the clinician. Obtained results were ana-
lyzed with current published literature. 
Results and discussion
62 women with breast cancer were interviewed. The 
patients’ mean age was 50.0 (SD 10.9), with a range of 
32–80 years. Most of the patients were married (91.9%) 
and had completed primary or secondary education (71%), 
while 16.1 % had completed high school/university. Most of 
patients had undergone chemotherapy (96.8%) and 82.3% 
of patients had undergone surgical treatment-mastectomy. 
The disease stage of patients was as following: 11.3% 
stage 0-I, 30.6% stage II, 58.1% stage III-IV, while 29% 
had distant metastasis. 
Mean scores for the GH/QoL, physical, role, emotion-
al, cognitive and social functioning subscales were above 
33 suggesting there were no problems regarding their func-
tioning. Mean scores of symptom scales were less than 66 
for almost all symptom scale and/or items suggesting lack 
of severe symptomatology among patients with exception 
for financial difficulties with mean score of 92.47 indicat-
ing financial problems for women with breast cancer.  
Eight subscales achieved the acceptable standard of 
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reliability (≥ 0.70), exception was only the  cognitive scale 
which was 0.54. The highest score of internal consistency 
was 0.96 for GH/QoL. 
The convergent  validity testing showed that all cor-
relation coefficients between an item and its own subscale 
were  ≥ 0.40 with the exception of item 5 (self care) with 
(ρ = -0.22). In Table 3 are presented Spearman’s correla-
tion coefficients between each item and its own subscale. 
The correlation coefficients ranged from -0.22 to 0.98. 
Item 7 (hobbies/limited leisure activities) had strongest 
negative correlation with its corresponding role function-
ing subscale, as well as item 25 (memory difficulties) with 
its corresponding cognitive functioning subscale. Items 29 
(physical condition) and 30 (general QoL) had the stron-
gest positive correlation with their corresponding GH/QoL 
as well as item 14 (nausea) with its corresponding nausea 
and vomiting subscale. The results for item discriminant 
validity were satisfactory, with exception for item 5 (self 
care) which showed higher correlation with other subscales 
(role functioning, social functioning, GH/QoL), vomiting 
and pain than with its corresponding physical functioning. 
Generally the QLQ-C30 subscales showed moderate to 
strong correlation with each other. Exception was a strong 
relationship between fatigue with GH/QoL (ρ = 0.73), 
fatigue with physical functioning (ρ = 0.72) and between 
pain with fatigue (ρ = 0.70). 
Findings of known group comparisons according to 
the disease stage generally showed that patients with ad-
vanced stages of breast cancer (stages III-IV) had high-
er symptomatic scores than those in early stages. Howev-
er, none of these differences was statistically significant. 
In terms of education level, patients with high school/uni-
versity reported higher cognitive functioning compared to 
other subgroups (p = 0.03), other functional scales differ-
ences were not statistically significant. Interestingly, pa-
tients with secondary school showed better GH/QoL than 
patients with high school/university (p = 0.009).  
Conclusion
In this initial study the EORTC QLQ-C30 (version 3.0) 
in Albanian language for breast cancer women patients was 
found to be reliable and valid.  Although the sample size 
was small and in the study were included only women with 
breast cancer it is still important for its preliminary infor-
mation on validity and reliability of the EORTC QLQ-C30 
in Albanian language. Studies with larger number of pa-
tients, including male patients as well as other groups of 
cancer patients and test-retest reliability are recommended 
to assess the results of this initial study. 
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Introduction
The concept of Pharmaceutical Care (PC), perceived 
as a responsible pharmacist’s philosophy, aiming to sup-
ply the community with quality medicines and reliable ser-
vices, (EU, 2012), involves the provision of a complex set 
of pharmacist’s actions with patients and healthcare pro-
fessionals for the improved patient’s health condition (Ed-
mundsa and Calnan, 2001).
Additional services, competent activities provided by 
pharmacists, represents the basis of the PC (Puspitasari, 
2009), where one of the services is counseling, a cognitive 
ability of pharmacists to transfer valuable information and 
establish a rationale relationship with their patients. Coun-
seling, combined with other competences produces addi-
tional defined services, the Medication Therapy Manage-
ment (MTM) and Disease management, approaches that 
are managing the disease for achieving positive outcomes 
(McGivney, 2007). The significance of MTM lies in the 
ability of the pharmacist systematically to achieve the de-
sired therapeutic effects, starting from the therapy review, 
continuing with the patient’s personal record, based on a 
healthcare management plan (APhA and NACDS Founda-
tion, 2008). This is one way how the pharmacists could 
bring mutual collaboration on a desired level with other 
healthcare providers, as well. Counseling and MTM en-
ables the determination of the therapy regimes (Al Rah-
bi, 2013), and playing inevitable role in the health system. 
Particular important for the health system is the creation 
of an individualized management programs for elderly pa-
tients with chronic diseases, where community pharma-
cists are considered one of the best healthcare providers, 
especially for elderly patients with chronic diseases (Nash, 
2001).
Research studies have found that in patients, receiving 
the additional services for their health improvement gen-
erates satisfaction with the received attention (Tinelli, et 
al., 2007). One particular example of successful implemen-
tation of additional services is United Kingdom (Paudy-
al, et al., 2011), where pharmacists deliver The New Med-
icine Service, Medicine use review and Appliance Use Re-
views (Wells et al., 2013), with whom pharmacists treat 
minor ailments with non-prescription medicines, provide 
information, guidance and education on patients for self-
medication (Anderson, 2000).The significance of the PC 
is practically shown through the generated savings of 600 
million dollars for the compliance and additional 700 mil-
lion dollars for the improved prescribing (Etemad and Hay, 
2003), with only 40 dollars an hour, for what the PC con-
cept is remunerated.
The aim of this study is to evaluate the current prac-
tices of pharmacist in Macedonia, regarding the possibil-
ities of future representation of PC through the addition-
al services.
Materials and methods
Quantitative method was used for the data collec-
tion method, using anonymous structured closed ended 
33 questions questionnaire, divided in several groups. The 
sampling population was pharmacists working in pharma-
cies in Macedonia. The questionnaire was constructed and 
distributed through the web site platform Survey Monkey 
(Palo Alto, CA, United States). The interest in entering the 
survey occurred in total number of 85 participants, where 
from 67 completed the survey. Generated data was ana-
lyzed using the statistical program SPSS v. 20 (IBM Cor-
poration, Armonk, New York, US).
The demographic data showed that majority of sur-
veyed were females (83.6%), over 90% between 18-45 
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years old, with 80% of surveyed with professional expe-
rience below 10 years. Majority of participants were from 
Skopje and South West Macedonia, 53.7% and 34.3% re-
spectively.
Results and discussion
The survey showed that 90% of surveyed are famil-
iar with the PC, expressing at the same time the need to re-
define their community roles.Regarding the additional ser-
vices, 92.5% consider to have the competence to provide 
additional services, for what they have positive respond 
to patients request for additional services, equally in pa-
tients with acute and chronic diseases, out of which, 85% 
are asking additional advices. Respectively, 60% of sur-
veyed have the practice to follow up their patient’s med-
ical condition, thus in a way they are practicing addition-
al services, with 40% giving an example of a particular 
service they provide. Majority of those services are advic-
es for improved diet and healthy life style, better therapy 
management and counselling for possible medicine inter-
actions. Mostly, time spend for additional services is be-
tween 5-10 minutes, with only 36% of pharmacists devot-
ing below 5 minutes and in only 9% of cases, between 11-
15 minutes.The collaboration of pharmacist with doctors is 
at only 30%, but with a mood at 70% of surveyed, that in-
teraction to be improved. Almost all surveyed, 98%, have 
expressed that proper regulation and remuneration by the 
health system is important for the practical implementation 
of additional services.According to 55% of the surveyed, 
all stakeholders can benefit from PC, where pharmacies, 
could expect high level of loyalty from their patients and 
improved economic results.
Conclusion
The basis of PC, as a contemporary concept lies in the 
successful introduction of additional services, for what the 
pharmacist have the knowledge and capabilities to provide 
them to their patients. The research found, that majority of 
surveyed pharmacist are well known with the concept and 
its essence. Practically, for the patient’s interest, they al-
ready provide certain services, with which they are helping 
their patients in therapy management and improved medi-
cation results, for what pharmacist are being awarded with 
high degree of patient’s loyalty, which is essential for the 
functioning of the pharmacies. On the other hand, for the 
complete introduction of the PC, there is need for a state’s 
support, especially in the part of remuneration with which 
the pharmacies will be stimulated to deliver even more 
qualitative approach for their patients and made them eco-
nomically more stable and independent.
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Introduction
The Macedonian Law on Industrial Property (herein-
after: LIP) in general terms defines the patent as an indus-
trial property right by which inventions are protected (Ar-
ticle 3, par. 1, line 2) and does not restrict patenting phar-
maceuticals. In the period for which the patent is granted 
(20 years, with possibility for additional protection period 
of up to 5 years for pharmaceuticals) the patent holder en-
joys the exclusive rights to use the protected invention in 
production, marketing goods manufactured as per the pro-
tected invention and to dispose the patent. These rights in 
the same time mean that the patent holder enjoys the right 
to prohibit third parties to use the patent in production or 
in trade, including production, offering for sale, export, or 
import and storage of products for those purposes, without 
license (LIP, Article 89, par. 1 and 2, in line with Article 27 
of the Agreement on Trade Related Aspects of Intellectual 
Property Rights (hereinafter: TRIPS). 
By principle rule, the license is obtained by agreement 
between the patent holder and the third party (licensee) and 
the scope of the rights transferred to the licensee is mutu-
ally agreed by the parties (Dabovic - Anastasovska, 2009). 
Exception to this rule exists in the cases of the compulso-
ry license. 
Materials and methods
A compulsory license is an authorization granted by 
competent state body, in Macedonia the court, a third par-
ty to use the patented invention without the permission of 
the patent holder (Dabovic-Anastasovska and Pepeljugos-
ki, 2012). This research examines the national legal sys-
tem of compulsory licensing in reference to the one estab-
lished under the TRIPS and how are the main functions of 
the system enabled. 
Results and discussion
 The TRIPS does not limit the grounds for granting 
compulsory licenses; however it provides that countries can 
only use those grounds which are allowed by their national 
legislation. The conditions under which a compulsory 
license is granted are to be regulated in the national 
legislation in accordance with the TRIPS (Article 31). This 
possibility is seen as one of the TRIPS’ flexibilities (Van 
Zimmeren and Van Overwalle, 2011)
Countries, including Macedonia, have specified dif-
ferent grounds for issuing compulsory licenses (Article 97 
par. 1 and 2) and these include public health reasons. The 
LIP further details the compulsory license for the needs 
of public health, specifying in Article 102 par. 1, that the 
court (that is the curt with jurisdiction for settlement of dis-
putes in the field of industrial property, may grant compul-
sory patent license i.e. a supplementary protection certifi-
cate for the needs of production and sale of pharmaceutical 
products, where such a product is intended to be exported 
in the importing countries with problems in public health. 
The LIP, in this context, defines pharmaceutical product as 
any product in the pharmaceutical industry, including the 
medications for human use, which include any substance 
or mixture of substances designed for treatment or preven-
S1 PP 24
64
Maced. pharm. bull., 62 (suppl) 63 - 64 (2016)
Pharmacoeconomics / Social pharmacy / Drug information
Po
st
er
 p
re
se
nt
at
io
ns
tion of human diseases including any substance or mixture 
of substances which may be applied to people in terms of 
renewal, improvement, or adjustment to their physiologi-
cal functions by causing pharmaceutical, immunological, 
or metabolic effects or by giving the medical diagnosis, 
including active components and accessories to diagnose 
outside the alive human body (Article 102, par.3). 
When deciding upon issuing compulsory license, as 
per Article 102, par. 2 of LIP, the court is obliged to take 
into consideration the WTO General Council Decision 
of 30 August 2003 on the implementation of par. 6 of the 
Declaration on the TRIPS agreement and public health of 
14 November 2001 (hereinafter: Council Decision and 
Doha Declaration respectively). 
The Doha Declaration in par. 6 recognizes that WTO 
members with insufficient or no manufacturing capacities 
in the pharmaceutical sector could face difficulties in 
making effective use of compulsory licensing under the 
TRIPS Agreement, and instructs the Council for TRIPS 
to find an expeditious solution to this problem. Following 
this the General Council made a Decision, noting that, 
exceptional circumstances exist justifying waivers from 
the obligations set out in paragraphs (f) and (h) of Article 
31 of the TRIPS with respect to pharmaceutical products, 
establishes the system for granting compulsory licenses 
for pharmaceuticals. The use of this special compulsory 
license requires formal notification to the WTO. There are 
three types of notification: 1. importing member’s one-off 
general notification of intention to use the Par. 6 System 
(not required for least-developed country members); 2. 
importing member’s specific notification of the details 
of the needed pharmaceutical products and other details 
required under the Par. 6 System; and 3. exporting 
member’s notification of grant of a compulsory licence for 
export and conditions attached to it. The features of the 
system have been adequately transposed in LIP (Article 
103-115). The Council Decision will be replaced by the 
amendment to the TRIPS i.e. introduction of Article 31bis, 
when it is accepted by two thirds of the membership (the 
deadline is set to 31.12.2107; Macedonia accepted it on 
16.03.2016).
Conclusion
As noted by the General Council Chairperson’s 
statement inter alia the established system for compulsory 
license for pharmaceuticals should be used in good faith 
to protect public health and, without prejudice to par. 6 of 
the Decision, not be an instrument to pursue industrial or 
commercial policy objectives.  It is seen that compulsory 
license may also constitute an important tool to promote 
competition and increase the affordability of drugs, while 
ensuring that the patent owner obtains compensation for 
the use of the invention (Correa, 2000). It is also argued 
however, that the present system as such creates a series 
of obstacles preventing effective access to drugs (Gupta, 
2010). When assessing the functionality of the system one 
must take into consideration the opposing views and of 
the pharmaceutical companies (Reichman, 2009). It is to 
be noted that, as per available literature none of the SEE 
countries have granted compulsory licenses for the public 
health (Mešević, 2014). 
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Introduction
Adherence is exceptionally important for efficacy and 
safety of pharmacotherapy and has significant impact on 
clinical, economic and humanistic therapy outcomes. In-
adequate level of adherence is a widespread and everlast-
ing problem with possible immense and long-term conse-
quences affecting not only patient but also the health care 
system. For that reason the issue of adherence remains con-
siderable challenge for health care professionals in clinical 
practice. Community pharmacists, being most accessible 
to the public, are perfectly positioned to help patients un-
derstand the value of their medications, the importance of 
prescribed regimens and to underline the need for adher-
ence. A survey research has been conducted with an objec-
tive to examine attitudes of pharmacists about professional 
practice and work with patients in regard to reaching high 
level of adherence.
Materials and methods
The cross-sectional survey has been conducted in April 
and May 2014 during courses for pharmacists’ profession-
al education organized at the Faculty of Pharmacy, Uni-
versity of Belgrade. Validated questionnaire named Scale 
of general attitudes and beliefs of pharmacists regarding 
their work with patients was applied. (Jocić and Krajnović, 
2014). The questionnaires have been distributed to phar-
macists while they were registering for the course and they 
could submit them at a place specially intended for that 
purpose all the time while the lectures lasted. Participants 
completed questionnaires anonymously and all gave their 
informed consent for taking part in the survey. Statistical 
analysis has been performed with a software package IBM 
SPSS Statistics 21. Since it has been determined that distri-
butions of all numerical data deviate from the normal ones, 
statistically significant difference and correlation has been 
analyzed by adequate non-parametric methods of inferen-
tial statistics (Mann-Whitney test, Kruskal-Wallis ANO-
VA test, Spearman’s rank correlation). Threshold of statis-
tical significance has been set at the conventional level of 
p≤0.050 for all analyses. This study has been approved by 
the Ethics Committee for Clinical Trials of the Faculty of 
Pharmacy, University of Belgrade.
Results and discussion
A total of 483 questionnaires have been distributed 
while 447 have been returned. Nevertheless, 14 question-
naires have been excluded since they were partially or in-
adequately completed, thus the total sample of survey par-
ticipants in the research represents 433 pharmacists, the re-
sponse rate 89.64%. There were 312 survey participants 
(72.05%) who were employed in state owned community 
pharmacies and 121 participants (27.94%) employed in pri-
vately owned ones. The average age of survey participants 
was 34.7±9.8 years. Although there were predominantly 
females (374 or 86.37%), pharmacists in this research did 
not significantly differ regarding age (ZU=-1.19; p=.234), 
nor the work experience in pharmacies (ZU=-.86; p=.390). 
The total of 83.60% of survey participants deemed 
that patients were interested to be educated about medi-
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cines, medical devices or health products which they uti-
lize, while 76.75% of pharmacists claimed that they co-
operate with patients in regard to prescribed therapy. One 
of the pharmacists’ responsibilities and an important part 
of professional activities in a pharmacy is the provision 
of information and expert advice to public. In accordance 
with this, 87.43% of survey participants have stated that 
they always explain patients how to use certain medicine 
or medical device when dispensing them in a pharmacy, 
while 83.60% of them claimed to give information regard-
ing health maintenance and improvement on daily basis. 
Information, valuable pieces of advice and instructions 
which are given by pharmacists must be relevant, accurate, 
timely, objective and completely adapted to needs, specif-
ic characteristics and state of a particular patient. An ef-
fective patient education and counseling process optimizes 
the chance that patients will make informed decisions, use 
medications properly, and meet therapeutic goals. In the 
conducted survey, pharmacists employed in state owned 
and privately owned pharmacies have not demonstrated 
significant discrepancies in agreeing with the following 
statement “Patients understand my instructions as to use of 
medicines and medical devices” (ZU=-1.37; p=.171). Av-
erage survey participant in both groups has answered that 
he mainly agrees with this claim.
The majority of study participants have demonstrated 
a relatively high degree of agreement with claims from the 
questionnaire which relate to the importance of the role of 
pharmacists as members of a team of health profession-
als. Actually 94.70% of survey participants agreed with the 
claim “Patients rely on pharmacists more and more regard-
ing the use of medicines”. Statistically higher degree of 
agreement has been recorded (ZU=-7.91; p<.001) in the 
group of pharmacists employed in privately owned phar-
macies with the claim “Information which I give to pa-
tients are of high significance for the therapy outcomes” 
in comparison to their colleagues from state owned phar-
macies, although it should be stressed that average survey 
participant in both groups has responded that he complete-
ly agrees with this claim. 
Survey results indicate that pharmacists are aware that 
successful development of adequate interpersonal relation 
with patients highly depends on their professional commu-
nication skills. Inadequate verbal and/or non-verbal com-
munication, confusing messages, insecurity and lack of 
consistency all have a negative impact on the quality of 
pharmaceutical care and can significantly endanger the re-
alization of the desired degree of adherence. Therefore, it 
is important for pharmacists to realistically evaluate their 
communication skills and continuously improve them in 
the course of professional practice. Although most phar-
macists have shown a high degree of agreement with the 
claim “I think that my behavior during our interaction in-
fluences the patient motivation” by Spearman’s rank corre-
lation it has been determined that with higher age and lon-
ger work experience the degree of agreement with the stat-
ed claim decreases (ρ=-0.196; p<0.001). 
During pharmacist-patient interaction some disagree-
ments or differences in approaches to solving certain situ-
ations or problems are inevitable. Researchers have shown 
that there is a correlation between professionally negative 
characteristics of pharmacists (such as aggressiveness, in-
sensitiveness, tendency to conflicts) and low level of satis-
faction and adherence of the patient (Ranelli, 2000). Sur-
vey participants have on average responded that they com-
pletely disagree with the claim “I have conflicts with pa-
tients on daily basis”. Furthermore, pharmacists employed 
in state and privately owned pharmacies did not differ 
when agreeing with the claim “I think that I do not have 
much understanding for patients” (ZU= -.65; p=.513). Av-
erage survey participant in both groups has expressed com-
plete disagreement with this claim.
Conclusion
Due to specific competences and unique position of 
the most accessible health professionals pharmacists have 
an especially significant role in adherence optimization. 
They have a professional and ethical obligation to perform 
expert review of the overall patients’ therapy, give infor-
mation and council, identify potentially existing factors 
predisposing low adherence level, apply individually tai-
lored strategies for adherence enhancement and continu-
ally monitor patient cooperation and therapy outcomes. In 
order to empower them to successfully fulfill all those re-
sponsibilities it is necessary to insist on the development of 
adherence-related competences within the educational and 
programs of continual professional training, as well as to 
evolve consciousness about the significance of that aspect 
of the therapy management. It is necessary to pay special 
attention to improvement of communication skills and pro-
fessional virtues which could contribute to establishment 
of successful relations with patients based on cooperation, 
trust and mutual respect.
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Introduction
Many studies that have been conducted indicate the 
necessity of educating the youth on reproductive health. 
Promotion of youth reproductive health includes all mea-
sures, activities and efforts of the health service and the en-
tire community to protect, maintain and improve health. 
Health workers have a special place in preservation of re-
productive health. 
The aim is to highlight the importance of the role of 
pharmacists and other health workers in the education of 
young people about the importance of reproductive health. 
Based on these methods, opportunities for further develop-
ment and improvement of health literacy of young people 
about reproductive health have been analyzed.
Materials and methods
For analysis we used results of survey conducted on 
240 students of Pharmacy and Physiotherapy school dur-
ing school year of 2013/2014 and also surveys that were 
about knowledge and opinions of youth on reproductive 
health from project “Health education on reproductive 
health”.
Results and discussion
Young people, through teaching, acquire information 
and knowledge about reproductive health, as well as the 
awareness of active participation in decisions related to it. 
School has to achieve educational and behavioral goals on 
reproductive health, through the contents of the basic, nec-
essary and optional subjects. Young people learn to analyze 
information, and based on them develop critical thinking. 
The conducted study suggests that most students of first and 
fourth grade of secondary school of Pharmacy and Physio-
therapy have basic knowledge of reproductive health and 
use of emergency contraception (Vasić, 2015). The worst 
results were in matters related to the efficacy and mecha-
nism of action of emergency contraception. The synergy 
of the education and the health systems achieves preserva-
tion of reproductive health of youth. The role of the carrier 
of the activities related to the reproductive health of young 
people is assigned to counselors within the school health 
centers. Private health centers should be specially engaged 
in education of youth. Counseling centers perform medi-
cal and educational work with young people. The acquisi-
tion of knowledge, attitudes and skills of young people on 
reproductive health is carried out through group work, un-
der special programs. Through multiple levels, in a short 
period of time and by active learning, training on the top-
ics of risk behavior, lifestyles, is carried out. Preventive 
counseling activities can be conducted through brochures 
and manuals. Counseling centers for young people pro-
vide a sense of security, privacy and confidentiality. Con-
fidentiality gives a special sense of security. Health work-
ers should communicate with young people and create con-
fidence for the open discussion about problems (Rasević, 
2014). The most appropriate form of transfer and acquisi-
tion of knowledge represent a group work and active learn-
ing methods through the workshop proceedings. The rec-
ommendation of the World Health Organization from 2002 
“The Community is to promote the value of counseling, 
parents be encouraged to support the youth and adolescents 
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to be informed and involved in the activities of the institu-
tion”.
It is alarming that health workers have the least im-
pact on young people in the preservation of reproductive 
health. At a low level, there is a family, which should in-
fluence the formation of positive attitudes about sexuality. 
In the project “Health education on reproductive health” 
of 950 second grade students of secondary schools in Vo-
jvodina (10 high schools), average age of 16,9 years, the 
most common source of information about sex life is the 
media in 675 (71.0%) of students and peers-608 (64.0%) 
of students. Less common sources of information are par-
ents-152 (16.0%) of students, the school-85 (9.0%) of stu-
dents and health workers-38 (4.0%) of students (Ukropi-
na et al., 2014).
When it comes to students of the first and fourth grade 
of Pharmacy and Physiotherapy School, knowledge about 
emergency contraception is satisfying, although there is a 
small percentage of students who had not heard of it. For in-
formation about emergency contraception students of first 
and fourth grade have the least confidence in health profes-
sionals (doctors and pharmacists), and maximum in mag-
azines and friends. There are differences in the respons-
es of first and fourth grades in the awareness of the emer-
gency contraception tablets and the source of the informa-
tion. 15 first grade students (12.3%) haven’t heard about 
emergency contraception, while the number of informed 
students received information from various sources: 35 
students (28.8%) from the magazine, 39 students (32.6%) 
from a friend / relatives, 10 students (8.4%) from phar-
macists, 6 students (5.32%) from doctors and 15 students 
(12.6%) from other sources. The fourth graders showed 
better informed about emergency contraception. 8 students 
(6.9%) haven’t heard of it, and the other students had dif-
ferent sources of information: 50 students from magazines 
(41.5%), 41 students (33.8%) from a friend / relative, 9 stu-
dents (7.9%) pharmacists, 7 (5.6%) students from doctors, 
5 students (4.6%) from other sources (Vasić, 2015).
The results suggest that we should work on overcom-
ing prejudice and creating communication between stu-
dents and health workers. Students need to be provided 
with timely and accurate information about emergency 
contraception, and the best source for this is health work-
ers. Health workers are in similar position when it comes to 
sources of information about sex life in the project “Health 
education on reproductive health.” In this sensitive peri-
od of maturation young people should be given the correct 
message, so the responsibility of health workers is high. 
The results of research conducted in Pharmacies in Bel-
grade form May to June of 2014 on 60 people of repro-
ductive age (15-49) are similar. A total of 25% of respon-
dents have heard of emergency contraception: 21.3% from 
friends / relatives, 3.3% from doctors and 30 % from other 
sources (Milosavljević et al., 2014).
Conclusion
Test results related to reproductive health of young 
people show the need for further education of young peo-
ple in relation to reproductive health, better cooperation 
between young people and health workers and greater in-
volvement of the educational system in preserving the 
health of young people. Reproductive health of young peo-
ple is at risk because of lack of education on contraception 
and sexuality. It is alarming that health workers have the 
least impact on young people in the use of emergency con-
traception and preservation of reproductive health. Recog-
nized attitudes and gaps in knowledge of students about 
emergency contraception impose an obligation on health-
care professionals (doctors and pharmacists) in educating 
young people about emergency contraception with the aim 
of preserving and improving reproductive health. Pharma-
cists are the most accessible health care professionals in 
the primary health care level, and their role in the educa-
tion process of youth is very important.
It is necessary that health centers, pharmacies and ed-
ucational institutions in the municipalities organize pub-
lic discussions on reproductive health and its preservation. 
A permanent solution for information, education and pro-
motion of reproductive health and prevention of sexually 
transmitted diseases and HIV should be found. It is espe-
cially important that the socially disadvantaged and mar-
ginalized groups are informed as well. At the macro level, 
the reproductive health of young people should be part of 
the policy of the whole society in order to prosperity. Joint 
action of employees in education, health, local government 
units and families can preserve the health of young people.
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Using the drugs in compliance with the marketing li-
cense specifying the formulation, dosage and age-category, 
issued by a relevant authority is referred to as on-label use. 
However, the practice of off-label prescribing is very com-
mon. It implicates the use of the medication in a manner 
not listed in the approved prescribing guidelines with re-
spect to indications, age-category, dosage regimen or ad-
ministration route (Christopher, 1993). EMA, FDA. and 
other national regulatory authorities, as well as the ALIMS 
are responsible for ensuring the quality, safety and effec-
tiveness of the drug put on the market and its compliance 
with the approved guidelines. However, such authorities 
generally do not regulate the application of drug in every-
day practice. The doctors are entitled for freedom in pre-
scribing drugs. Such prescription-freedom must be in ac-
cordance with fundamental postulates of medicine – doc-
tor’s responsibility and care for patient’s wellbeing. The 
physicians must keep in mind their professional liabilities 
and responsibilities towards relevant national legislation 
and obey the medical ethical principles. In line with novel 
scientific accomplishments, the doctors should prescribe 
an off-label drug only if this off-label prescription is the 
safest and most effective therapeutic option for the patient 
(Beck, Azari, 1998). The aforementioned facts clearly indi-
cate that the off-label practice of drug prescribing is legal 
and very common in many countries worldwide. Based on 
the outlooks from the available international literature, it is 
evident that off-label prescribing is legitimate (Killick, 
Berghe, 2010). The question that inevitably arises is when 
is the off-label prescribing an appropriate approach? Re-
grettably, a universal answer does not exist. The physicians 
are entitled and responsible to estimate what could be con-
sidered the “appropriate” off-label application in each indi-
vidual case. Contrary to drug prescribing, which is regulat-
ed by somewhat more flexible regulations, promotion of 
drugs is strictly regulated by national laws. The European 
regulations governing the marketing of medicines do not 
offer a universal definition for “appropriate application of 
the off-label drugs”, yet defining the number of situations 
where off-label prescription is allowed: products currently 
undergoing clinical trial, exceptions from EU Directive 
and, off-label use under the individual decision of a treat-
ing physician while applying appropriate procedure to pro-
tect patients’ health (Sackett et al., 1996). In the majority of 
EU member countries, the patient’s right is to obtain infor-
mation about available alternative treatments to that pro-
posed by a treating physician, that is, available on-label 
therapies when a doctor suggested an off-label treatment 
option. Similar to the neighboring countries, the issue of 
off-label prescription of drugs in Serbia has not been ad-
dressed in relevant legislation. Although the off-label pre-
scription practice is evident from the data on everyday 
medical practice, the ALIMS has not yet publicly commu-
nicated any official data. Contrary to Great Britain where 
the registry of off-label drugs applied in pediatrics or neo-
natology is available, neither regulations pointing to the 
off-label drug prescription nor relevant registries of off-la-
bel medicines exist in our country. Moreover, promotion 
and advertising of off-label medication is not regulated, 
i.e., directly prohibited by any law or subordinate legisla-
tion except for the general prohibition on advertising and 
promotion of drugs other than OTCs. Advertising of a pre-
scription drug to professional community is allowed under 
conditions stipulated in the license, and in accordance with 
the previously approved summary of drug characteristics. 
One of the major reasons behind off-label prescribing by 
the physicians is the unavailability or lack of licensed, ef-
fective and safe therapeutic options for particular condi-
tions and diseases. Sometimes, off-label prescribing is the 
ultimate choice of the doctors, particularly after the ap-
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proved treatment options have failed. The lack of therapeu-
tic alternatives for specific patient populations, often re-
sults in off-label drug prescribing to unapproved patient 
population in spite of potential contraindications stated in 
the SmPC or PIL). Consequently, off-label prescription is 
often practiced in pediatric, geriatric and obstetric practice. 
Another common reason for prescribing medicines outside 
the limits of their original license is convincing evidence 
on their effectiveness and safe application in particular sit-
uations. Physicians’ decisions on off-label prescribing are 
often justified by the clinical and scientific facts relying on 
EBM The EBM concept represents “the conscientious, ex-
plicit, and judicious use of current best evidence in making 
decisions about the care of individual patients”, that is, “in-
tegrating individual clinical expertise with the best avail-
able external clinical evidence from systematic research” 
(Weynantset al., 2010). This very definition of EBM en-
courages some physicians in prescribing off-label drugs, 
provided that such application is appropriate in given cir-
cumstances. The doctor should decide about the best avail-
able therapeutic option for the patient while providing pa-
tient’s consent for its application. Off-label drug prescrip-
tion is highly prevalent in medical practice. Most frequent-
ly, the drugs are prescribed outside their licensed indica-
tions or to different age categories. The studies revealed 
that off-label prescribing is more common among special-
ists than in general practitioners. Psychiatric and malignant 
diseases are often associated with off-label prescribing, 
which is not surprising, having in mind, that unknown eti-
ology and factors influencing disease progression require 
highly complex approach to the treatment and selection of 
an effective therapeutic. Application of drugs outside their 
original license is evident in obstetrics, psychiatry as well 
as in the treatment of some infectious diseases. Off-label 
prescribing is common in pediatrics practice, which is due 
to the specific age of the patients. The most commonly pre-
scribed off-label drug categories include drugs used in the 
therapy of cardiovascular diseases, anticonvulsive drugs, 
antipsychotics, antidepressants and antiasthmatics. Nu-
merous studies conducted in various therapeutic fields, 
among different age groups and geographic regions indi-
cated that the newborns are the population that is most 
commonly treated with medications that are beyond the li-
cense for this particular age group. According to these 
studies, the percentage of children who received at least 
one off-label or unregistered drug  range between 36%-
92% at pediatric departments, 80%-97% at neonatology 
department and 11%-37% in primary health care. Off-label 
prescription is highly prevalent in oncology. According to 
available data, particular antineoplastics are more fre-
quently associated with unlicensed and off-label drug pre-
scriptions than with the licensed one. However, the draw-
backs of off-label prescription practice should not be ne-
glected. Potential problems associated with the off-label 
drug prescription include the following: adverse reactions 
associated with off-label drug prescription, increased re-
sponsibilities of health care providers in view of patient 
wellbeing, impossibility of compensating health care ex-
penses due to application of off-label drugs, promotion of 
off-label drugs by the manufacturers. Major drawback of 
the off-label drug application is an increased probability of 
adverse effects of the drug. It is attributed to the fact that 
safety and effectiveness of an off-label drug have not been 
confirmed. The, implementation of more precise legisla-
tion defining appropriate prescription and application of 
off-label drugs as well as stipulating the responsibilities of 
all parties participating in such therapeutic approach is 
highly demanded in our country. Creation and regular up-
date of a registry of off-label drugs applied in daily health-
care practice is of vital importance.
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Introduction
Pancreatic cancer is an aggressive disease which 
usually causes no symptoms in its early stages, making it 
difficult to diagnose. Initial symptoms may include severe 
pain in the back or stomach area, unexpected weight loss, 
jaundice, feeling sick, diarrhea, weight loss and loss of 
appetite, which can severely reduce a patient’s quality of 
life (QoL). As such, there are rarely more than a few months 
between diagnosis and death. In this context of limited 
survival, quality of life assumes great importance and it`s 
improvement must be the main treatment goal. Gemcitabine 
is a chemotherapy treatment that is toxic to cancer cells 
by stopping a part of the cancer cell replicating itself. It 
has been considered the standard treatment for locally 
advanced or metastatic adenocarcinoma of the pancreas, 
because it has a wider spectrum of antitumor activity due 
to its different cellular pharmacology and mechanism of 
action. Gemcitabine is metabolized intracellularly to two 
active metabolites, gemcitabine diphosphate (dFdCDP) 
and gemcitabine triphosphate (dFdCTP). The cytotoxic 
effects of gemcitabine are exerted through incorporation 
of dFdCTP into DNA with the assistance of dFdCDP, 
resulting in inhibition of DNA synthesis. The aim of this 
study is to assess the clinical effectiveness of gemcitabine 
on quality of life in patients through different stages of 
pancreatic cancer.
Materials and methods
Fifty pancreatic cancer patients, suffering from local, 
advanced or metastatic pancreatic adenocarcinoma, 
as histologically proven by the Oncological Institute 
of Kosovo, were recruited in a trial during the period, 
2014/2015. They were treated with gemcitabine of 1000 
mg/m2 once weekly for seven weeks, followed by one 
week of rest during the first cycle and subsequently 1000 
mg/m2 once weekly for three weeks followed by one week 
of rest until relapse or intolerable toxicity. The quality 
of life was measured by the Functional Assessment of 
Cancer Therapy-Hepatobiliary cancer (liver, bile duct and 
pancreas) (FACT-Hep) scale. The FACT-Hep contains 
specific subscales assessing physical well being (seven 
questions), social/family well being (seven questions), 
emotional well being (six questions), functional well being 
(seven questions), and additional concerns (18 questions) 
(FACT-Hep, 2007). The collected data were analyzed with 
STATA Version 11 program. Baseline characteristics were 
analyzed with t-tests for continuous data and Pearson’s 
χ2 was used for categorical variables. The focus of the 
analysis was to test whether significant differences existed 
between the age of patients, components of FACIT, surgery, 
radiotherapy, stage of cancer, quality of life, and clinical 
effect of the treatment. A P value of less than 0.05 shows 
the criterion for statistically significant results.
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Results and discussion
From 50 patients, 26 (52%) were newly diagnosed 
and 24 (48%) had prior treatment history. Median age is 
62 years (range 18–79 years), 28 males (56%), 22 females 
(44%).  A majority, 34 patients (68%) had stage IV dis-
ease at diagnosis, 10 patients (20%) had stage III, and 6 
patients (12%) had stage I-II at diagnosis. Only 8 patients 
(16%) underwent surgery, where 3 (6%) of them had whi
pple`spancreaticoduodenectomy, while 5 (10%) had gas-
troenterostomy. None of them went through radiation ther-
apy and all of them 50 (100%) were treated with chemo-
therapy –gemicitabine. Overall QOL, FACT-Hep, p-val-
ue shows significance of correlation between components 
of FACIT and stage of tumour. Physical well being shows 
significant p-value (p=0.0000). Social/family well-being 
shows significant p-value (p=0.003). Emotional well-be-
ing shows significant p-value (p=0.0001). Functional well 
being shows significant p-value (p=0.0000). Addition-
al well-being shows significant p-value (p=0.0000). All 
of these scales were significantly associated with surviv-
al, after inspecting the effects of stage at diagnosis. On av-
erage, about 50% of patients (25) with pancreatic cancer 
survived beyond 12 months. About 4% (2 patients) lived 
3-6 months, 6% (3 patients) 6-9 months, and 34% (17 pa-
tients) had a median of survival from 9-12 months. Two pa-
tients (4%) are still alive, which means they have survived 
over 18 months. Median survival time for the entire co-
hort was 10.3 months (range 1–24 months), p-value shows 
significance of correlation between survival rate and stage 
of tumour, respectively (p=0.0003). The best available evi-
dence relating to the use of gemcitabine as a first line ther-
apy has been shown to be well tolerated and to have a mild 
toxicity profile. Pancreatic cancer is the seventh most com-
mon cause of cancer death, according to Institute of Oncol-
ogy, Kosovo. Three-quarters of deaths are in people over 
60 years old. The findings in this study shows that the clin-
ical effect of gemcitabine on the QoL of patients with pan-
creatic cancer may improve it. This is in accordance with 
several other studies (Bourgade et al., 2013; Burris et al., 
1997; Halm et al., 2000; Kamar et al., 2003; Kuwahara et 
al., 2012) which shows beneficial effects of gemcitabine on 
overall QOL and psychological distress.
Conclusion
This study demonstrates that gemcitabine can improve 
quality of life in advanced pancreatic cancer patients. 
There is evidence of a very small survival possibility and 
an improvement in QoL. The QoL satisfaction of patients 
with pancreatic cancer measured by the FACIT-Hep, 
provides helpful information and they may have significant 
implications, as well as relief in getting clinical decisions.
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Introduction
Spontaneous reporting of adverse drug reactions 
(ADR) is one of the most effective ways to monitor the 
safety profile of a medicinal product during its post-au-
thorization life-cycle. Patients are direct participants in 
the spontaneous reporting system in Bulgaria since 2012 
(Lebanova et al., 2015). However the rate of ADRs report-
ed by patients to the competent authorities is still low. On 
the background of the significant under-reporting of ADRs 
through official channels, new medically orientated inter-
net forums have given voice to patients who share infor-
mation about their therapy, including experiences with ad-
verse events (Ginn et al., 2015 and Lardon et al., 2015). 
As a result some risks, which could be vital, are being dis-
cussed online. 
The effectiveness of several different gonadotro-
pin preparations, used for ovarian stimulation of wom-
en, undergoing therapy for assisted reproduction technol-
ogies (ART) has been widely discussed. Being focused on 
the comparative effectiveness studies of menotropins and 
FSH, derived by recombinant technologies, the issue of 
safety of these preparations is neglected and reduced only 
to the lack of ovarian hyper stimulation syndrome (OHSS) 
and multiple pregnancies, which are usually set as safety 
endpoints in clinical trials (Lebanova et al., 2015). How-
ever, as far as the safety monitoring of these medicines is 
concerned, there is still not enough and reliable post mar-
keting data for the safety profile of stimulation hormones. 
Objectives
To compare ADRs of recombinant medicines, used in 
ART, identified in consumer reviews from online forums 
and the corresponding data, mentioned in the Summary 
of Product Characteristics (SmPC) and the data, collected 
from the Bulgarian Drug Agency reporting system.  
Materials and methods
Both Google, social media and selected medical web-
based forums search was conducted using the follow-
ing key words in Bulgarian language: Adverse drug reac-
tion, side effects, assisted reproduction, in vitro fertiliza-
tion (IVF), ovarian stimulation. In addition a search for 
the INN and the trade names of medicines from the fo-
cus group was performed - Corfollitropin, Follitropinalfa, 
Follitropin beta, Urofollitropin, Menotropin, human meno-
pausal gonadotropine.  It was conducted a systematic re-
view of the SPCs of the medicines, approved by the BDA, 
current to the date of the consumers’ web posts. A leading 
aim of the current research was harvesting the information 
from user archives and posts to identify both expected (i.e., 
mentioned in the SPC) and unexpected ADRs. 
As most of the lexicon, used by forum participants, 
while sharing their experience with investigated medicines 
in the collected messages, does not correlate with the me-
dicinal terminology, some kind of “reference list” was cre-
ated for the purpose of this study to refer user content slang 
to the medical explanation of a clinical condition. 
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Results and discussion
The study identified 201 valid reports with resemblance 
to adverse events, among a sample of 1000 posts collected 
from 25 specialized forums, posted between November 
2013 and May 2015. In comparison, there are no adverse 
events reported to the BDA for the same period for the 
studied drugs. Forum discussions, used for extracting the 
consumer reviews are locked for changes and/or deletion 
by moderators. 
The analysis of the user generated content showed 
that the majority of reviews and comments, which possi-
bly could contain adverse event information are connect-
ed with the application of recombinant gonadotropins. The 
most often recombinant preparation, being detected in up-
loaded comments is Follitorpin beta (Puregon®) - 34% of 
all collected on-line posts, followed by Follitropinalfa (Go-
nal F®) - 25% of all the messages, concerning stimulation 
hormones and Corifollitropinalfa (Elonva®), which is less 
discussed and was found in only 13% of the investigated 
posts. The rest 28% of the analysed web content, obtained 
during the study, is connected with on-line discussions con-
cerning purified urinary gonadotropins and are not object to 
the current article. 
An important fact that should be noticed here is the de-
scriptive statistics mentioned above does not claim to re-
flect significantly the frequency of ADRs, observed in the 
real clinical practice. Current dissemination of user-related 
content can only result in conclusions about the frequency 
of on-line discussion of the mentioned recombinant stimu-
lating hormones, without pointing a tendency of prescrib-
ing or valid statements for benefit/risk ratio of these me-
dicinal products. What should be considered here are bias-
es like prescribing preferences of physicians at the time of 
the on line discussions, social-economic status of the pa-
tients, who are authors of the on-line comments, and the at-
titude of treated women to the Internet as source of medi-
cal information. 
The analysis of signals, detected in the user comments 
showed that social media based signals issued potential un-
expected adverse events for all of the investigated recombi-
nant medicinal products. Regarding Follitropinalfa, social 
media users electronically share descriptions of 4 condi-
tions that can be possibly associated with and following the 
administration of the product: weight gain, ovarian pain, 
frequent urination and emotional instability. None of this 
possible ADRs has been listed in the section 4.8. “Adverse 
Drug Reactions” of the SmPCs, where the following pos-
sible adverse events are categorized in accordance to their 
frequency: ovarian cysts, stomach ache and gastrointestinal 
disorders, ovarian torsion, thromboembolism, mild to se-
vere hypersensitivity, reactions, including anaphylactic re-
actions and shock. Comparison of the two lists showed that 
both internet signals and the SmPC provide information for 
two potential adverse reactions – headache and the OHSS 
syndrome. 
Consumers, who discuss electronically their experience 
with Follitropin beta cite 7 conditions, they suffered while 
using the medicine and can be read in the ADR section of 
the SmPC– local reactions at the site of injection, OHSS, 
headache, gastrointestinal disorders, pelvic pain, general-
ized hypersensitivity reaction, mood swings. In contrast, 
user-generated web signals offer 4 unexpected conditions, 
which can be possible adverse reactions: emotional insta-
bility, hot flashes, weight gain, and excessive hair growth. 
In support of the hypothesis that social media can be a 
valid source of reliable information about adverse reactions 
to recombinant gonadotropins, the current study found a 
significant parity between signals, provided on-line by us-
ers and the approved product characteristic. Both sources 
were found to offer reports for the following conditions, 
associated with the Corifollitropin administration: head-
ache, dizziness, nausea, back pain, OHSS, pelvic pain, pel-
vic discomfort, breast tenderness. All the collected user re-
views were checked for statements, corresponding with all 
the rest ADRs, mentioned in the SmPC: hot flushes, abdom-
inal distention, vomiting, diarrhea, constipation, spontane-
ous abortion, ovarian torsion, adnexa uteri pain, premature 
ovulation, breast pain, fatigue, injection site hematoma, 
pain at the injection site, irritability, increased level of Ala-
nine aminotransferase and Aspartate aminotransferase, pro-
cedural pain, but none of them were cited during the on-line 
discussions. Instead there were signals, detected which con-
tribute to the list of conditions, potentially connected with 
the product by describing palpitation, joint pain and fatigue 
and sleepiness, which might prove to be unexpected ADRs. 
Conclusion
The rate of reporting of ADRs by the official 
pharmacovigilance channels is still extremely low, 
especially for hormones, used for ovarian stimulation 
during fertility therapies. At the same time internet forums 
and chat rooms can be a source of valuable first-hand 
information for disorders, resulting from application of 
hormones mentioned above.
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Introduction
A major concern of public health worldwide is the 
emergence of antimicrobial resistance due to inappropriate 
use of antimicrobials and their impact on increasing mor-
bidity, mortality and costs (Herrera, 2013; Huttner et al., 
2013). To combat this phenomenon there is a consensus 
that coordinated action and measures are needed (Huttner 
et al., 2013, Maddocks, 2013). A simple, feasible way to 
provide information on antibiotic use on hospital level is 
conducting Point Prevalence Surveys (PPS). This survey 
is a part of a worldwide project on antibiotic surveillance 
called Global PPS, which will enable to make result com-
parisons between hospitals in Kosovo and abroad.
The aims of this survey were to monitor patterns of an-
tibiotic use in the hospital and to identify targets for quality 
improvement within the aim to optimize antimicrobial pre-
scribing for children and adults.
Materials and methods
The survey was implemented in June 2015. The sur-
vey included all inpatients (adults, children and neonates 
admitted on medical, surgical and intensive care units) at 8 
o’clock. Detailed data were collected only for patients who 
were being treated with antibiotic on the day of survey. 
These data included gender, age, weight (children and neo-
nates), antibiotic used (type, dose, dosage, route of admin-
istration), type of treatment (empiric, targeted), reason for 
treatment (community acquired infection CAI, hospital ac-
quired infection HAI, surgical or medical prophylaxis), use 
of treatment protocols, reason in notes. Surgical prophy-
laxis was encoded as single dose, 1 day or more than one 
day prophylactic prescribing. Since the audit of prophylax-
is was conducted for previous 24 hours, surgical depart-
ments were not audited on Monday. Data were collected 
from patient’s medical record, including treatment cards, 
laboratory results and other official medical documents. 
Daily hospitalizations and outpatients, defined as ambula-
tory care patients and emergency admissions on the day of 
the survey were excluded from the survey. Denominator 
data included all eligible inpatients on the day of survey. 
All the data were entered online using Global-PPS web 
based tool. After that data were validated and analyzed.
Results and discussion
On the day of the survey 1468 beds were available, 
with an occupancy rate of 63.56%. 
The total number of patients included in the survey 
was 933: 768 (82.31%) adults, 77 (8.26%) pediatric and 88 
(9.43%) neonatal patients. 
Overall, from the total number of hospitalized patients, 
325 (34.8%) patients received at least one antibiotic: adults 
32.3%, children 54.5% and neonates 39.8% of respective 
patients. 
Top 3 diagnoses for treatment, excluding prophy-
lactic treatment, NICU (Neonatal Intensive Care Unit) 
and NMW (Neonatal Medical Ward) patients, were Pneu 
(25.2%), Bron (15.4%) and TB (13.8%).
The majority of patients received parenteral antibiotics 
(89.2%). 26.3% of patients had multiple antibiotic diagno-
sis and 26.7% were identified as multiple antibiotic patients. 
95% of patients that received antibiotics were treated 
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empirically. 
The most prescribed group of antibiotics in UCCK 
were other beta-lactam antibiotics with 51.8% (ATC 
J01D), followed by aminoglycosides 15.1% (ATC J01G) 
and other antibiotics 14.4% (ATC J01X).
Overall 32 different types of antibiotics were pre-
scribed; cefazolin was the most prescribed one (21.9%), 
followed by ceftriaxone (16.0%) and gentamicin (7.8%). 
Analysis of quality indicators of antibiotic prescribing for 
adults and children in our survey showed that there were no 
treatment protocols and no stop/review dates documented. 
On the other hand, reason in notes was documented in most 
of antibiotic prescriptions. 
Community acquired infections (CAI) constituted 
85.3% of antibiotic prescriptions, whereas hospital ac-
quired infections (HAI), 14.7%. Prophylactic treatment 
was more pronounced in surgical prophylaxis 74.7%, in 
comparison with medical prophylaxis 25.3%. 
Our survey showed that in UCCK duration of prophy-
lactic treatment was more than 1 day in all cases.
Antibiotic use among children is considerably high-
er than 36.7% result from the ARPEC PPS study of 2012 
(Verspoten et al., 2016) and results from the Antibiotic Re-
sistance and Prescribing in European Children Point Prev-
alence Survey (ARPEC-PPS, 2011) conducted in Europe-
an (35.4; 95% CI: 33.6-37.2%) and non-European hospi-
tals (43.8%; 95%CI: 41.3-46.3%) (Versporten et al., 2013).
What stands out from our results is high percentage of 
antibiotics used for the treatment of tuberculosis (13.8%), 
which suggests high prevalence of tuberculosis in Koso-
vo and it is a concerning fact for our public health system. 
Parenteral antibiotic administration was significantly 
greater than European results from (ECDC, 2013; ESAC, 
2009) where parenteral prescription for adults and children 
was 70.6% (country range: 47.8-91.4%). 
Empiric prescription of antibiotics was unacceptably 
high. Reasons for this may be various, i.e. Clinical Mi-
crobiology Laboratory is a part of Public Health Institute 
and not within the hospital, and another contributing factor 
may be the lack of sufficient collaboration between clini-
cists and microbiologists. Antibiotic prescription based on 
susceptibility testing is considered as an important factor in 
raising the success rate of treatment as well as in shorten-
ing the time of hospital stay. 
In Europe prescribing patterns are characterized by 
very common use of the combination penicillins, mainly 
co-amoxiclav (11% of all antimicrobial agents) in 79.2% 
of 17 European Hospitals (2000 - 2005) (Zarb et al., 2011).
Our survey showed that cephalosporin’s were the most 
used group of antibiotics in UCCK, which is not in line 
with recommendations of WHO. High level of cefazolin 
prescription, an older 1st generation cephalosporin, devi-
ates from the recommendation on ceftriaxone use from the 
cephalosporin group. 
Results show quite high aminoglycoside prescription 
(15.1%). Actual recommendations on their prescription 
suggest to be as restrictive as possible and in strict thera-
peutic monitoring (Avent et al., 2011).
Overall, it is noted that antibiotic prescription patterns 
in UCCK are in contradiction with approved WHO rec-
ommendations, which recommend prescription of narrow 
spectrum antibiotics, targeted therapy and implementation 
of restrictive policies (WHO, 2011). 
Also, of great concern is the fact that medical and sur-
gical prophylactic use of antibiotics in UCCK is more than 
1 day in all recorded cases, which suggest the need for es-
tablishing proper prophylactic protocols. 
Conclusion
Antibiotic prescription in UCCK hospitalized patients 
deviates from rational prescribing standards. Data from 
this survey will be an important tool in identifying goals 
for quality improvement in UCCK and Kosovo and to sup-
port preparation of guidelines and protocols for prudent 
use of antibiotics.
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Introduction
Antimicrobial resistance is a major public health prob-
lem and continuing progress in the treatment of many in-
fections is threatened by the growing resistance of patho-
gens to antimicrobial agents (Versporten et al., 2016). Ju-
dicious use of antibiotics is essential to slow the emergence 
of antibiotic resistance in bacteria and extend the useful 
lifetime of effective antibiotics (Goossens, 2009). 
The importance of surveillance data with regard to an-
timicrobial use and resistance at local and national levels 
and the role of antibiotic stewardship is emphasized by 
the 2011 European Commission Action Plan against rising 
threats from antimicrobial resistance (COM, 2011).
A simple and feasible way to assess antibiotic con-
sumption is using a point prevalence survey (PPS).
Kosovo is a part of global efforts to combat irratio-
nal antibiotic use and accompanying bacterial resistance 
through the Global PPS program. As part of this nation-
al and global program, we conducted the survey in region-
al hospital Prizren.
The study aimed to describe antibiotic prescribing 
practices among hospitalized patients in regional hospital 
(RH) in Prizren, among adults, children and neonates and 
to identify targets for improvement of the quality of anti-
biotic prescribing. 
Materials and methods
The survey was implemented in June 2015. The sur-
vey included all inpatients from all wards admitted at 8 
o’clock. Detailed data were collected only for patients who 
were being treated with antibiotic on the day of survey. 
These data included gender, age, weight (children and ne-
onates), antibiotic used (type, dose, dosage, route of ad-
ministration), type of treatment (empiric, targeted), reason 
for treatment (community acquired infection CAI, hospi-
tal acquired infection HAI, surgical or medical prophy-
laxis), use of treatment protocols, reason in notes. Surgi-
cal prophylaxis was encoded as single dose, 1 day or more 
than one day prophylactic prescribing. Since the audit of 
prophylaxis was conducted for previous 24 hours, surgical 
departments were not audited on Monday. Data were col-
lected from official patient’s medical record. Daily hospi-
talizations and outpatients, defined as ambulatory care pa-
tients and emergency admissions on the day of the survey 
were excluded from the survey. Denominator data includ-
ed all eligible inpatients on the day of survey. All the data 
were entered online using Global-PPS web based tool, af-
ter what data were validated and analyzed.
Results and discussion
Total number of patients included in the survey was 
232. 47% of them received an antibiotic, 200 adults (43% 
treated with antibiotics), 18 children (83.3% treated with 
antibiotics) and 14 neonates (57.1% treated with antibiot-
ics). Two most frequent diagnoses for treatment with anti-
biotics were ENT (ear-nose-throat infections) and TB (tu-
berculosis) with 17.7% each. Parenteral antibiotic prescrip-
tion was 95.8% in total. Empiric prescribing was domi-
nant (91.3%) in comparison to targeted treatment.  Most 
prescribed groups of antibiotics in RH Prizren were oth-
er beta-lactams 57.1% (ATC J01D), followed by amino-
glycosides 18.3% (ATC J01G) and penicillins 15.9% (ATC 
S1 PP 31
78
Maced. pharm. bull., 62 (suppl) 77 - 78 (2016)
Pharmacoeconomics / Social pharmacy / Drug information
Po
st
er
 p
re
se
nt
at
io
ns
J01C). Top 3 AB prescribed were ceftriaxone 42.9%, gen-
tamicin 9.3% and ampicillin 8%. Investigation of quality 
indicators for antibiotic prescribing in adults and children 
in RH Prizren showed a consistent lack of treatment pro-
tocols and documentation of stop/review date of antibiot-
ic treatment. Reason for treatment was documented in al-
most all cases. Community acquired infections were the 
main reason for treatment (93.9%); health care infections 
(6.1%). 71.2% of prophylactic prescribing was for surgical 
prophylaxis, and 28.8% for medical prophylaxis. In terms 
of duration of prophylactic treatment, all patients were 
treated for more than one day. Regional hospital Prizren is 
a secondary type hospital and one of the largest in Kosovo. 
Antibiotic use in pediatric (83.3%), neonatal (57.1%) 
and in adult  (43%) patients is very high, when compared 
with numbers from ECDC report, according to which 35% 
of patients received at least one antibiotic (country range 
21.4%–54.7%) (ECDC, 2013), results from ARPEC PPS 
from 2012, according to which the mean antibiotic use in 
European children was 36.7% (Verspoten et. al, 2016) and 
results from (ARPEC-PPS, 2011) conducted in European 
(35.4; 95% CI: 33.6-37.2%) and non-European hospitals 
(43.8%; 95%CI: 41.3-46.3%) (Versporten et al.,2013). An-
tibiotic use in children hospitalized in RH Prizren is sig-
nificantly higher than in European hospitals, especially in 
medical wards (83.3% vs. 39.5%, according to ARPEC-
PPS 2012). What stands out in RH Prizren is the top place 
for tuberculosis treatment, alongside ear-nose-throat infec-
tions, which is quite concerning. 
When compared to European hospitals, RH Prizren has 
a very high percentage of parenteral antibiotic prescription 
(95.8%). Studies conducted in Europe show that paren-
teral prescription in adults and children is 70.6% (country 
range: 47.8-91.4%)  (ECDC, 2013; ESAC, 2009). 
Total empiric prescribing was very high resulting from 
different reasons common in Kosovo’s health system, such 
as low capacities of clinical microbiology laboratories, 
lack of collaboration between clinicians and microbiolo-
gists, scarce funding of laboratories etc. As prescription 
based on susceptibility testing is one of the cornerstones of 
prudent antibiotic use we recommend urgent measures to 
improve this anomaly.
Excessive use of ceftriaxone (42.9%) is an indicator 
of a irrational antibiotic prescription which needs to be ad-
dressed, due to impact on triggering bacterial resistance, 
particularly for ESBL strains (extended spectrum beta-lac-
tamase) (Skrlin et al., 2011). Results show high rate of ami-
noglycoside prescribing, which are the second most pre-
scribed group with 15.1%. Actual recommendations rec-
ommend that prescription of this group of antibiotics be as 
restrictive as possible and in strict therapeutic monitoring. 
Narrow spectrum antibiotics (benzylpenicillin, erythromy-
cin, azithromycin, clarithromycin), targeted treatment and 
implementation of restrictive policies on antibiotic pre-
scription, recommended by WHO, are not applied in RH 
Prizren. The lack of treatment protocols and documenta-
tion of stop/review date greatly impacts the quality of an-
tibiotic prescribing, so we recommend urgent measures to 
correct these quality indicators.
Conclusion
Antibiotic prescribing in RH Prizren is not accord-
ing to standards. Data gathered from this survey will help 
to identify targets to improve the quality of antibiotic pre-
scription within the hospital. 
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Introduction
Diabetes mellitus is a syndrome characterized by 
chronic hyperglycemia and disorder of the metabolism of 
carbohydrates, protein and fat associated with a relative or 
absolute lack of insulin secretion and insulin action. Diabe-
tes is one of the most common endocrine disorders, with a 
tendency of increased growth. It is a consequence of mod-
ern lifestyles and the increasing number of internal, genet-
ically conditioned and external etiological triggers. Diabe-
tes is not only medical but also economic and social prob-
lem (Brunton, 2008).
Diabetes mellitus - type 1 is a disease of the young 
people - children, adolescents and adults. Insulin is part of 
their daily treatment because without it the outcome is fa-
tal (Haycox, 2004; Heise et al., 2004).
Diabetes mellitus - type 2 covers 90% of all cases, 
90% of insulin therapy, while the rest use the pill therapy. 
Average daily dose of insulin is about 40 IE (International 
Units) (Alberti and Zimmet, 1998).
The optimal insulin therapy should induce physiolog-
ical insulin secretion. Insulin analogues have different ab-
sorption, distribution, metabolism and elimination in terms 
of human insulin. This enables the analogues to get approx-
imately closer to the human insulin (Nathan et al., 2009).
Insulin  that are required for  patients in the Munici-
pality of Stip are  obtained and issued by the hospital phar-
macy at PHI Clinical Hospital Stip. Until  2012  year they 
were obtained  under the Law on public procurement, 
through tenders organized by the hospital. Since 2012, in-
sulins strips to measure blood sugar, insulin needles, pens 
and kits are obtained through centralized procurement by 
the Ministry of Health.
The purpose of this paper is to realize the changes in 
the variety and number of consumed units of insulin PHI 
Clinical Hospital Stip given the type of mostly used insu-
lin per producer, strips to measure blood sugar, insulin nee-
dles, pens and whales in Stipdiabetes center in the period 
from 2011 to 2014.
Materials and methods
The research and evaluation of the spent insulin’s is 
based on the data of the consumption of insulin in the peri-
od from 2011 to 2014 received from the Hospital pharma-
cy in PHI Clinical Hospital Stip.
The data is arranged by type and origin of insulin prep-
arations, summed by year and made a comparison of con-
sumption and variety. The results are expressed in number 
of packages.
Descriptive method was used in data processing.
Results and discussion
According to data from the Diabetes Centre in Stip, in-
sulin’s consumption in 2011, 2012, 2013 and 2014 contin-
ues to grow. The hospital has purchased various types of in-
sulin, according to the events, and generics manufacturer.
Insulin consumption in 2011 was 34932 insulins units 
from different manufacturers with different types of action, 
with 16 trade names. Over the coming years, the consump-
tion increased. In 2012 was 36932 packages from 16 trade 
names, in 2013 increased to 41597 packages from 12 trade 
names, while in 2014 the consumption of  insulin reaches up 
to 46460 from 11 trade names . The highest consumption in 
all four years has insulin NovoMix “30” / Flexpen 3 ml / 300, 
which is a generic Insulin aspart, and belongs to a group of 
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insulin’s with average-long acting and it is combined with 
long-acting insulin’s. It’s consumption in 2011, 2012, 2013 
and 2014 was 9656, 13573, 18426 and 15950 respectively.
Since 2013, there was reduced range of insulins used 
under the trade name and manufacturer, as a result of the 
centralized supply of insulin from the Ministry of Health. 
This measure is taken because of the steady rise in con-
sumption of insulin, which is probably due to the increased 
number of patients with diabetes, early detection and time-
ly same passage of patients with insulin dependent diabetes 
treated with insulin. With centralized procurement there is 
provided lower range of branded insulin, low prices, total 
costs and reliability in the supply of sufficient quantities to 
meet the increased needs.
In the research there are processed the spending strips 
to measure blood sugar, needles and other accessories. In 
2012 and 2013, we issued a number of different types of 
strips to measure blood sugar depending on the type of the 
glucometar. While in 2014 was issued only one type of 
strips for measuring blood sugar and it is called Trueressult. 
In 2012 there are issued 63600 boxes of strips to measure 
blood sugar, while in 2013 consumption increased by 29% 
and amounted to 89650. In 2014 there are issued 115620 
strips to measure blood sugar levels from Trueressult and 
that consumption increased by 22%. The highest consump-
tion of strips to measure blood sugar levels in 2012 are from 
Roche Accucheck Nano 1/50 and it was 28250.
Consumption needle apparatus for measuring blood 
sugar in 2011 was 67711. In 2012 the use  of the needles 
increased by 16.8% and amounted to 81391, in 2013 in-
creased by 22.6% and amounted to 105178 needles. In 
2014 we have reduced the use of needles by about 10% 
and it amounts to 94639 needles.
The rising use of bands for measuring glucose in the 
blood and needle apparatus for measuring the sugar is part-
ly due to the growing number of diabetics, and it is a part 
of a program of measures introduced by the Government of 
the Republic of Macedonia by introducing centralized pro-
curement of insulin and stripes for measuring blood sugar.
Conclusion
Consumption of insulin in 2011, 2012, 2013 and 2014 
PHI Clinical Hospital Stip continues to grow. The highest 
consumption of fast-acting insulin, while the consumption 
of insulins intermediate - long action in the last two years 
completely replaced with insulins medium - long-acting 
combined with long-acting; 
Since 2013, decreased variety of insulins used un-
der the trade name and the manufacturer, which is a re-
sult of the centralized supply of insulin from the Minis-
try of Health
Increasing use of strips to measure blood sugar and 
needle apparatus for measuring glucose on blood level 
which is partly due to the growing number of diabetics, 
part of a program of measures introduced by the Govern-
ment of the Republic of Macedonia by introducing central-
ized procurement of insulin strips to measure blood sugar.
By tracking the consumption of insulin improves the 
basics for quality procurement and reliable supply of qual-
ity and reliable insulin.
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Introduction
Over the last decade, medication errors have become 
an issue of major concern in health care and a critical com-
ponent of quality management (Bonnabry et al., 2008). 
These types of failures may arise at any stage of the health 
care delivery process, and various policy documents have 
been published, stressing their frequency and impact. How-
ever, despite the growing interest indecreasing the rate of 
medication errors, a low level of awareness and knowledge 
has been noticed among health care professionals. There-
fore, this paper aims to provide a short review of the con-
cept of medication errors, with a special attention given to 
their definitions, types and causes, as well as to the cur-
rent regulatory requirements regarding their reporting and 
monitoring in the Republic of Serbia.
Material and methods
A comprehensive search of available electronic data-
bases Medline and Web of Science has been carried out 
from database inception to December 2014. A following 
combination of key words has been used: (medication er-
rors OR adverse drug events) AND (definitions OR taxon-
omy); (medication errors OR adverse drug events) AND 
(incidence OR frequency OR types OR causes OR classi-
fication). Additionally, applicable laws and regulations of 
the Republic of Serbia related to the issue of errors’ report-
ing and monitoring have been examined.
Results and discussion
Patient safety and medication errors represent a 
significant part of the quality of health care, as a wider 
concept. A 1999 landmark report “To err is human” brought 
this issue to the forefront for both professional and general 
public, stating that “At least 44,000 people, and perhaps as 
many as 98,000 people, die in hospitals each year as a result 
of medication error that could have been prevented” (Kohn 
et al., 1999). In addition to such morbidity and mortality 
rates, it was estimated that medication errors resulted in 
considerable health expenditures as well. 
Various definitions of medication errors have been 
identified, such as the one from the National Coordinating 
Council for Medication Errors Reporting and Prevention 
(NCCMERP), stating that this type of failures represents 
“any preventable event that may cause or lead to 
inappropriate medication use or patient harm while the 
medication is in the control of the health care professional, 
patient, or consumer” (NCCMERP, 1998). However, 
authors have identified heterogeneity of definitions and 
terminology in this area, which significantly hampers 
the synthesis of existing scientific knowledge and a 
comparison of the results. Therefore, it would be necessary 
to develop an international taxonomy, in order to facilitate 
errors’ reporting and the synthesis of data obtained. 
Medication errors may occur at any stage of the 
medication delivery process, such as prescribing, 
dispensing and administration. Prescribing errors include 
prescribing faults, a type of failure which results in an 
irrational, inappropriate or ineffective prescribing, and 
prescription errors, as omissions in filling the prescription 
that results in erroneous specifying one or more data. The 
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second type of potential failures are dispensing errors, 
which could be defined as any discrepancy between the 
medication order and delivery made by pharmacists in 
a hospital or community pharmacy setting. According 
to the study results, these errors occur at a rate of 51.5 
million out of 3 billion prescriptions filled annually in 
the United States i.e. 4 per day in a pharmacy filling 250 
prescriptions daily, respectively (Bootman et al., 2006), 
whereas the commonest types are dispensing the wrong 
medicine, strength, form or quantity, as well as improper 
labeling. Lastly, administration errors include failures 
made by nurses during administration of medicines to 
hospitalized patients, as well as errors made by patients 
during the use of medicines. This is mostly caused by a 
low level of adherence, health illiteracy, inadequate way 
of drug storage and accidental medication mix-ups caused 
by visually/audio similar names and/or packages. Elderly 
patients are considered to be particularly vulnerable, owing 
to the polypharmacy, physical disability and cognitive 
limitations.
Various critical system elements that may have an im-
pact on medication errors occurrence have been identified, 
such as incomplete collection and use of demographic and 
clinical patient data; insufficient health care professionals’ 
knowledge of medications; poor and ineffective commu-
nication among health care providers and the absence of 
collaborative practice; sound-alike/look-alike medications 
and/or their improper labeling; inadequate working envi-
ronment such as poor lighting, high noise levels, cluttered 
work space and work overload; inadequate and/or insuffi-
cient health professionals’training about interventions for 
the safety improvement; the lack of adequate education of 
patients regarding their own health status and treatment; 
and finally, the lack of supportive strategies for reporting, 
analysis and reduction of medication errors in health care 
facilities (Cohen, 2007).
Nowadays, the underreporting of medication errors 
has been recognized as a tremendously significant prob-
lem. In the Republic of Serbia, this aspect of risk manage-
ment has been regulated by the Rulebook on indicators of 
quality of health care (Official Gazette of RS, No 49/2010). 
All health care providers have been obliged to monitor and 
report defined indicators, including those related to the pa-
tient safety, such as the rate of adverse drug reactions re-
ported, the number of prescriptions with administrative 
and professional mistake (prescribing faults and prescrip-
tion errors), as well as the rate of dispensing the wrong 
drug. However, a significant trend of missing data regard-
ing the patient safety indicators has been noticed in annual 
reports on improving the quality of health care, due to in-
adequate reporting. Owning to this fact, the same conclu-
sion that our health care professionals do not realize the 
importance of failures’ monitoring and reporting has been 
drawn for several years, emphasizing the necessity of rais-
ing their awareness related to the significance of recording 
all failures incurred so as to prevent them from happening 
again. In addition, it is necessary to conduct research on 
the types and causes of medication errors, which has not 
yet been undertaken in Serbia. This may allow the proac-
tive detection of systemic weaknesses and implementation 
of appropriate risk-reduction strategies.
Conclusion
Raising awareness of the issue of medication errors 
has resulted in an increase in the number of studies on in-
cidence, types and causes of prescribing, dispensing and 
administration errors. However, the identified heterogene-
ity of operational definitions disables the synthesis of ex-
isting findings in this area. Furthermore, even though risk 
management phases, including monitoring and recording 
of medication errors, have been regulated in many coun-
tries, experience from Serbia indicates the necessity of fur-
ther health care providers’ education regarding these activ-
ities, since underreporting still remains one of the most sig-
nificant barriers for the prospective risk management and 
errors prevention.
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Introduction
Cardiovascular diseases (CVDs) are the foremost 
health problem in the world today and hold the lead in 
mortality causes. This is why the search and development 
of new effective pharmaceutical substances for the 
protection of cardiovascular system are among the priority 
directions of scientific research. A lot of drugs that are used 
for correction of cardiovascular system disturbances can 
be in certain manner placed among membrane-stabilizing 
substances that reduce the accumulation of free radicals and 
reactive oxygen species (ROS) in cells. Among the most 
attractive are original complex substances of germanium 
with organic bio ligands that are characterized by wide 
spectrum of pharmaceutical activity and low toxicity.
Aim
The goal of this work was to determine a potential car-
dioprotective activity of a new coordinational compound 
of germanium and nicotinic acid (МІГУ-1) that was syn-
thesized in laboratory of Department of General Chemis-
try and Polymers of Odessa I.I.Mechnikov National Uni-
versity under the supervision of professor Seifullina I. I. 
using a model of experimental chronic heart failure (Kre-
syun et al., 2004).
Materials and methods
Studies were conducted in adult male Wistar rats 
(weight: 180-220 g). The animals were maintained (in-
cluding euthanasia) pursuant to the European Convention 
for the Protection of Vertebrate Animals used for Exper-
imental and Other Scientific Purposes (2016/63/EU) The 
animals were fed a normal, balanced diet and had free ac-
cess to water in the animal house (vivarium) of the Bogo-
molets National Medical University (Kyiv City, Ukraine). 
Experimetal chronic heart failure (CHF) was induced by 
intramuscular injection of doxorubicin (DXR) (manufac-
tured by Kyivmedpreparat, OJSC, Ukraine 5 mg/kg once 
a week for 5 weeks. Investigated compound was admin-
istered intraperitoneally daily for 5 weeks. Control group 
consisted of animals that had solution of nicotinic acid 
(NA) (niacin, BP, crystal powder (substance), manufac-
tured by Aarti Drugs Ltd, India) administered to them in-
traperitoneally daily for 5 weeks, 10 mg/kg. Intact ani-
mals had physiological solution administered to them in-
traperitoneally daily for 5 weeks. After the end of exper-
iment the animals were decapitated under light ether an-
esthesia, followed by extirpation of a heart for biochemi-
cal analysis. Index of antioxidant protection system (APS) 
of a cell, products of peroxide oxidation of lipids (POL) 
and oxidative modification of proteins (OMP) of cardio-
cytes were measured using spectrophotonometry and fluo-
rescent methods (Nizhenkovska,2009. Kolesov et al.,1984, 
Chevari et al.,1985, Dubinina,1995). Amounts of protein in 
tissue were measured using Lowry method (Lowry et al., 
1951). Results were computed using the Student t-test or 
Mann-Whitney test for distribution-free quantitative sam-
pling (n=10) and estimated with p<0,05.
Results and discussion
DXR belongs to anticell antibiotics and is one of 
the most used drugs during chemotherapy of cancerous 
growth. On the other hand it is widely known that DXR is 
characterized by a several negative side effects, first of all 
– big cardiotoxicity (Klaunig et al., 2010).
S1 PP 34
84
Maced. pharm. bull., 62 (suppl) 83 - 84 (2016)
Pharmacoeconomics / Social pharmacy / Drug information
Po
st
er
 p
re
se
nt
at
io
ns
Oxidative stress is caused by an imbalance between 
excessive ROS formation and decrease in the body’s anti-
oxidant defense. ROS play a dual role in a variety of phys-
iologically normal and pathological conditions. In physi-
ological concentrations, ROS transmit signals of external 
and internal environment of the body through regulatory 
metabolic cascades, act as mediators and redox messen-
gers in various cellular processes and intracellular signal-
ling systems. At the same time, in certain pathological con-
ditions, excessive ROS accumulation promotes cell death 
through induction of oxidative damage to cellular macro-
molecules, such as lipids, proteins and DNA. Increased 
damage from ROS determines the cell fate through induc-
tion of cell cycle arrest and apoptosis. Normal tissues, bal-
ancing between synthesis and elimination of ROS, main-
tain intracellular redox homeostasis (Olson et al.,1981; 
Saleem et al., 2014).
As opposed to free-radical processes in the body, there 
is an antioxidant system consisting of a complex network 
of protective mechanisms for cells, tissues and organs that 
preserve and maintain body homeostasis. Balance between 
these two opposing components, in a state of physiologi-
cal optimum, keeps peroxidation at a certain low level, pre-
venting chain oxidative process, and describes the antiox-
idant status in the body. One of the ways to prevent oxida-
tive stress is antioxidant system activation, the components 
of which, in small concentrations, can inhibit the excessive 
free radical generation.
 In this work animals were observed to have an intense 
formation of ROS that leads to failure of exchange of lipids 
and proteins of cardiocytes in experimental animals under 
the chronic DXR intoxication. Administration of NA and 
МІГУ-1 led to decrease of toxic effect of DXR on heart 
tissue. It was proven that МІГУ-1 complex has more pro-
nounced antioxidant properties compared to NA.
Conclusions
Results of experiments prove expediency and efficien-
cy of МІГУ-1, member of a new class of chemical com-
pounds – coordination compound of germanium and nic-
otinic acid, in preventing problems that develop during 
chronic heart failure.
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Introduction
Clinical pharmacy as defined by European Society of 
Clinical Pharmacy is a branch specialized for health which 
includes all activities and services of clinical pharmacists 
to ensure development and growth of rational, proper and 
safe administration of drugs (ESCP, 2010).
Our country, Bosnia and Herzegovina, is a member of 
European Association of Hospital Pharmacists (EAHP), 
and we also have Hospital Pharmacy section. Needs for 
health care are growing, as well as the health departments` 
costs due to demographic changes, aging of population 
(number of people older than age of 65), needs for more 
and more resources because of other health services and 
polytherapy (use of multiple drugs in the therapy). Also, 
there are appearances of new diseases, growing number of 
diseases that require long-term and expensive treatments, 
arrival of modern medical procedures and expensive drugs 
with progress of technology. That is the reason why the 
Bosnia and Herzegovina government and the Ministry of 
health have decided to conducte reforms in health depart-
ment for reduction of the costs and system sustainability.
Nowadays, clinical pharmacists have more roles than 
it was in the past. Pharmacists as health care professionals 
are expected to be more included in process of prescrip-
tion, drug administration as well as tracking of efficiency 
and safety of therapy, which means an equal role of phar-
macists and physicians in order to achieve a better effect in 
patient treatment. 
One of the modern roles of pharmacist is conductance 
of rational pharmacotherapy in developed boundaries and 
pharmaceutical care, focused on direct relation of phar-
macist and the patient, meaning an individual approach to 
each patient, collecting data about drugs used by the pa-
tient from the disease history – therapy list, as well as by 
patinet direct contact. 
Individual approach to patient is foundation of rational 
pharmacotherapy for achieving optimal therapy effect with 
minimal side effects (Bačić Vrca at al., 2000). Patients` 
individual and constant medical status tracking (ex. drug 
concentration in body fluids) (Crnković and Bačić Vrca, 
2013), enable determination of eventual interactions and 
side effects. However, the certain role of hospital pharma-
cists has not been  into the  practice as much as it should be 
in Bosnia and Herzegovina hospitals and clinics. 
The purpose of this paper is to show the importance of 
clinical pharmacist in health care system, including phar-
macoeconomic aspects, patient safety and to establish the 
role of clinical pharmacist in hospital pharmacy in Bosnia 
and Herzegovina.
Materials and methods
Type of this research is of retrospective and descrip-
tive character. Official reports from Psychiatric hospital of 
Canton Sarajevo for period of three years (2013, 2014 and 
2015), that contain all relevant data about drug consump-
tion and financial reports were used. Those reports were 
analyzed and obtained results were compared.
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Results and discussion
Drugs in hospital pharmacy of Psychiatric hospital of 
Canton Sarajevo that have been dispensed from this de-
partment to other department in hospital is based on their 
needs.
Since 2015 we’ve have new procedures that leads to 
rationalizing pharmacotherapy. We have noted less drug 
consumption per patient, thus resulting with lower drug 
cost.
Pharmacoeconomy analysis, as it was previously men-
tioned was done for period of three years (2013, 2014 and 
2015) and it showed significant reduction in drug usage. 
Namely, analysis has shown that in 2013 in Psychiatric 
hospital in Canton of Sarajevo 91.285 BAM (Bosnia-Her-
zegovina Convertible Mark) were spent, or it was 41% of 
the budget. The same analysis for 2014 showed that 80.337 
BAM were spent or 37% of the budget, while in 2015 in 
Psychiatric hospital in Canton of Sarajevo 48.880 BAM 
were spent or 22% of the budget for analyzed period.
Comparison of traditional system of drug distribu-
tion with new established system distribution per patient 
where pharmacist can control the dosage, interval of dos-
age, clinically significant interaction of drugs etc., resulted 
with significantly lower usage of drugs expressed in daily 
defined doses (DDD)/100 thus indicating enhanced quali-
ty in drug distribution with new established system. Clini-
cal pharmacists helped to reduce polytherapy, medical mis-
takes and gives recommendations based on guidelines for 
engaging on untreated conditions or stoppage of unneeded 
therapy. The most common mistakes that might happen are 
drug administration in wrong time, missing out drug dos-
age and wrong dosage. 
Official Gazette of Sarajevo Canton in 2015 men-
tioned for the first time Decision on the positive, the hos-
pital and in-house compounded list of medicines in Sara-
jevo Canton, that contained drug distribution in hospital 
pharmacy and modern role of clinical pharmacist, which 
means that even cantonal government had accepted the im-
portance of clinical pharmacist in rationalization of phar-
macotherapy and reducing the costs for drugs (Official Ga-
zette of Sarajevo Canton 39/2015).
Conclusion
Clinical pharmacists as health care professionals 
have very important role in system of health care, with 
their knowledge and skills, thus improving the quality of 
health care by rationalization of pharmacotherapy leading 
to reduction of polypragmasy, reduced costs and improved 
quality of patient’s time in hospital.
As it can be seen from the results, new procedures im-
plemented in 2015, have brought positive results in re-
ducing costs for drugs in our hospital pharmacy for near-
ly 50%, thus pointing to the importance of clinical phar-
macists. 
We should pay attention that in current sitiation clin-
ical/hospital pharmacist in Bosnia and Herzegovina does 
not have the role that they should really have in order to 
work with physician and other health care professionals as 
a multidisciplinary team. So, the hospital management and 
Ministry of health should strengthen the importance of role 
of clinical pharmacist in hospital usage of drugs as well as 
that head of department of hospital pharmacy should be 
pharmacist who held specialist degree in clinical/hospital 
pharmacy. 
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Introduction
Health promotion has been described by the World 
Health Organization as a process of enabling people to in-
crease control over and improve their health (WHO, 2008). 
In primary care, community pharmacists are well accessi-
ble health care providers who could easily support health 
promotion initiatives at the individual, community and so-
cietal levels. A number of studies in UK, Australia and oth-
er countries give evidence that pharmacist interventions 
are willingly accepted by patients. Tobacco smoking is the 
main risk factor for several leading causes in death includ-
ing cancer and heart disease and also the leading cause of 
early death. Today, community pharmacies provide dif-
ferent extended services connected to health promotion 
and smoking cessation could be listed as one of these ser-
vices. It is important to emphasize that counselling about 
smoking cessation consists of different type of communi-
cation: identification of patient´s willingness to quit smok-
ing, evaluation of his/her health condition and providing 
information about nicotine replacement therapy. Earlier in-
ternational research has demonstrated that quality of smok-
ing cessation consultation given at community pharmacies 
could be improved by covering all above listed counsel-
ling aspects.
Materials and methods
Cross-sectional survey among community pharmacists 
and assistant pharmacists was undertaken in January till 
June 2015. The participants were recruited using universal 
sampling from six different districts of Lithuania. Ques-
tionnaires were distributed to randomly selected commu-
nity pharmacies and collected one week after the first visit. 
All pharmacists and assistant pharmacists who worked at 
the selected pharmacies were asked to fill in the question-
naire. The questionnaire consisted of 26 closed and open 
questions about health promotion and smoking cessation at 
community pharmacy and 12 questions about demograph-
ics of the respondents. The statistical analysis was per-
formed using Statistical package for Social Science (SPSS 
v. 17.0). Descriptive statistics were calculated to summa-
rize the data. T test and chi-square test were used to ana-
lyze differences among groups. Statistical significance was 
set at the level p<0.05.
Results and discussion
In total there were 450 questionnaires distributed 
and 352 returned as completed (response rate 78.2%). 
Majority of the respondents (97.2%) agreed that health 
promotion is very important to patients and half of them 
(53.4%) considered that community pharmacies could 
provide this type of services.  Although even 69.3 present 
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of pharmacy professionals think that smoking cessation 
information is available for the pharmacy patients in many 
various resources, but  only 31,9 percent of the respondents 
think that  patients who want to quit smoking can do it by 
themselves without any professional consultation and the 
only condition for stop smoking is a wish.  73.3 percent 
of all the respondents agrees that  community pharmacy 
is the place where comes patients with smoking cessation 
questions, but only 33.3 percent of the respondents 
strongly agreed with a statement that that “I am a qualified 
professional who can help people who want to stop 
smoking” (26.5 percent disagreed with this statement). 
Most of the pharmacist (85.3 percent) also disagreed with a 
statement that “It is nothing wrong to smoke few cigarettes 
per day”. Respondents have experienced interest towards 
smoking cessation consultation one to two times per day 
and mostly it took up to five minutes to communicate with 
patient. Despite on 79.8% of the respondents reported 
having professional experience on smoking cessation 
consultation, a number of barriers connected with 
pharmacist (professional competence and communication 
skills); management of pharmacy (payment for extended 
services, selection of nicotine replacement products, 
possibility for private consultation, lack of time for 
communication with patients) and governmental activities 
(dissemination of information on tobacco use risks and 
reimbursement of nicotine replacement therapy) were 
listed. More frequent information sources about smoking 
cessation for pharmacists were professional journals and 
books (76.1%), formal education (university/college) 
and internet (53.6%) and the information provided from 
industry of nicotine replacement therapies 4 (2.3%), the 
patient’s motivation (91.1%), pharmacist´s competence 
(78.6%) and duration of the consultation were named as the 
main factors for successful communication. Pharmacists 
who had longer working experience and previous status of 
smoking were more keen on providing smoking cessation 
consultation (p<0.05). Nicotine gum (94.4%) and nicotine 
patches (86.3%) were indicated to be the most effective 
medications for ceasing smoking. 
Conclusion
Community pharmacists in Lithuania have positive 
perception towards health promotion activities at 
community pharmacy. Most of the respondents declared 
existing professional knowledge for provision of this type 
of services. Smoking cessation counseling is everyday 
practice at community pharmacies in Lithuania. Improving 
pharmacists´ education in patient counseling and health 
promotion including smoking cessation would increase 
quality of extended community pharmacy services in the 
future. 
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Introduction
In order to provide medical assistance to children, 
physicians often have prescribed unauthorized medicinal 
products due to lack of suitable and authorized medicine 
for children (Cuzzolinet al., 2006). This attitude seems 
to lead to an increased rate of adverse drug reactions and 
medical errors (Auby, 2008). Moreover, tablets have been 
authorized for children below the age of 6 years, even 
though they may be not able to swallow tablets (Cohen et al., 
2009). It is very important to study at what rate authorized 
medicines are really adequate for use in children. 
The first objective of this study was to evaluate the 
number of medicines and active ingredients for pediatric 
population that are authorized and marketed in Albania, 
for five selected groups. The second objective was to 
evaluate the age-appropriateness of the selected medicines 
evaluated on two aspects: dose capability and suitability of 
the pharmaceutical form for use in children.
Materials and methods
From database of medicines of Albanian National 
Agency of Medicines and Medical Devices in Albania, till 
10 April 2015, was identifies authorized medicines. For 
this study were selected the following active ingredients: 
ACE Inhibitors: Captopril, Ramipril, Enalapril; Calcium 
antagonists: Nifedipine, Verapamil, Amlodipine; β– 
Blockers: Propranolol, Carvedilol, Atenolol. 
This database doesn’t allow extraction of marketed 
products and active ingredients classified based on age-
appropriateness. For this reason were the evaluated 
Summary of Product Characteristics (SmPC). From 
SmPCs that were used sources information document, 
were analyzed sections: pharmaceutical form, therapeutic 
indications, posology, route of administration, suitability 
of dosages and pharmaceutical forms for use in children. 
A special focus was dedicated to age-appropriateness 
of selected products. First investigated aspect was if 
recommended dose is prescribed to children based on 
classification of pediatric age: preterm newborn infants, 
term newborn infants, infants and toddlers, children and 
adolescents. Second investigated aspect was if approved 
pharmaceutical form, for selected products in this study, 
were suitable for use in children. For solid forms (such as 
tablets and capsules) were evaluated presence of score line 
and possibility of opening or not of contain of capsules and 
mixing of it with liquid.
Based on all prescribed methodology use for this 
study were collected these data: authorized indications; 
authorized age-group; pharmaceutical form; authorized 
dosage; presence of score line in tablets or film coated 
tablets; information on possibility for opening capsules 
contains.
Results and discussion
In total was studies 118 authorized medicinal products 
in Albania; 5 products containing Captopril, 18 products 
containing Ramipril, 17 products containing Enalapril, 
17 products containing Nifedipine, 9 products containing 
Verapamil, 19 products containing Amlodipine, 1 product 
containing Propranolol, 24 products containing Carvedilol 
and 8 products containing Atenolol. 
Evaluation of the SmPCs of products suggesting that 
only 3 active substances are authorized for use in children. 
Furthermore, all these products were for solid oral intake 
forms and all were tablets (n = 118, 100 %). Investigation 
of the SmPCs for age-appropriateness of these products 
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based on recommended dose and suitability of forms for 
use in children showed that all products are authorized in 
following pharmaceutical forms: 78.5 % tablets, 7.4 % 
coated tablets, 12.4 % modified-release film-coated tablets 
and 1.7 % film coated tablets. For any active ingredient 
weren’t found authorized liquid formulations, which are 
more appropriate for use in children. 
Evaluation of authorized solid (tablets, film coated 
tablets, capsules) pharmaceuticals forms for the presence 
score line, in other to archives smaller dosages shows these 
results: 40.7 % of medicinal products were without score 
line (n = 48), 53.4 % have score line in one side of the tab-
let (n = 63), 3.4 % have score line in both sides (n = 4) and 
for 2.5 % (n = 3) information wasn’t available in checked 
SmPCs.
Conclusion
This study shows lack of availability of pediatric 
medicines for selected products and shows that pediatric 
medicines may not be age-appropriate. Therefore, are 
needed more efforts to increase the number of drugs 
authorized for the pediatric groups. 
The development of medicines for use in children 
require that a specific active ingredient need to be available 
in different dosage forms and strengths. The dose capability 
was considered an important criteria. A medicine is either 
dose capable or it is not. However, the suitability of 
pharmaceutical forms is not as absolute. According to EU 
reflection paper tablets and capsules are only suitable from 
the age of 6 years. However, recent studies have shown 
that small tablets can be swallowed by young children. 
Also, some capsules can be opened and their content can 
be mixed with liquids, such as water. This make possible 
easy intake comparing with other solid forms.
Healthcare personnel’s should consider that by using 
formulation not appropriate for children may cause 
administration errors, lack of therapeutic compliance and 
unexpected side effects. In order to reduce the risk of any 
of below problems, they are encouraged to search between 
marketed products the most appropriate medicine for 
treating groups of pediatric population.
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Introduction
In recent years, the number of independently owned 
pharmacies has declined even as the total number of phar-
macies in Lithuania has increased. The studies indicate that 
current factors affecting public pharmacy are not condu-
cive to independent pharmacies development. Global trend 
is that that the traditional model of a pharmacist owning 
his/her own pharmacy is replaced by chains of communi-
ty pharmacies .With increasing corporate ownership, there 
is concern that this trend will adversely affect the profes-
sion’s ability to influence pharmacy practice and practice 
change. “Dual loyalty” of pharmacists (to the employ-
er and to the patient) is present in all sectors of pharma-
cy practice. The professional autonomy is defined as “the 
right and privilege granted by a governmental authority 
to a class of professionals, and to each licensed individ-
ual within that profession, to exercise independent, expert 
judgment within a legally defined scope of practice, to pro-
vide services in the best interests of the client. It is very im-
portant to pharmacy practice because of the change in the 
profession vision: the movement from a mainly medication 
compounding and supply to a patient-care function is ob-
served. A code of Ethics for Pharmacists regulates the pri-
ority of patient need and wellbeing, but corporate owner-
ship can force the pharmacist to the enhancement of supply 
side” (FIP, 2014). The risks associated with the decrease of 
health professional autonomy are poorly perceived by con-
sumers, policy makers, health insurance executives, hos-
pital and health care administrators, and many health-care 
practitioners. The aim of the study is to determine the char-
acteristics of non-chain community pharmacies and to ana-
lyze their owners’ attitude towards professional autonomy.
Materials and methods
The research was conducted from January to Decem-
ber, 2015. The research projects was divided into 2 stages. 
In first part the independent non - chain pharmacies were 
identified and classified, and then only the owners of inde-
pendent pharmacies who owned 4 or less pharmacies were 
asked to participate in the survey, using structured ques-
tionnaire. Questionnaire included the questions about at-
titudes towards professional autonomy and characteristics 
of their pharmacies. The evaluation of professional auton-
omy consisted of two parts: pharmacist’ professional au-
tonomy benefits (1) for society and (2) for the profession 
of pharmacy. In total there were 121 questionnaires distrib-
uted, out of which 102 were returned fully completed (re-
sponse rate 84.3%). The statistical analysis was conducted 
using SPSS (Statistical Package for Social Science) 17.0. 
Descriptive statistics such as frequencies, means and rang-
es were calculated to summarize the data. T test and chi-
square were used to analyze the differences among groups. 
Results were considered significant when the p value was 
less than 0.05.
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Results and discussion
81.4% of the respondents were women and 91. % of 
respondents had a Master’s degree in Pharmacy. In most 
cases, respondents indicated that they manage one pharma-
cy (71.6%). Over half of respondents (56.86%) do not offer 
additional services in their pharmacies (i.e. blood pressure 
measurement, the determination of glucose concentration 
in the blood, etc.). Evaluating their pharmacies respon-
dents provided the following answers – nearby treatment 
facility (55.89 %), is not far away from a direct competitor 
(58.82%), is not nearby intensive flow of people (85.29 %), 
is not a niche pharmacy (77.45%). Individual non-chain 
pharmacies owners claim highly qualified professionals 
work in their pharmacies (100%). Respondents strong-
ly agreed and agreed that pharmacists, whose profession-
al autonomy is unrestricted, (1) can meet the patients ex-
pectations better (94.12%), can apply professional knowl-
edge more competently (90.20%), can collaborate with 
other health care professionals more actively (87.25%), 
contribute to better health care system (92.16%) and (2) 
have greater public confidence (68.63%), avoid a conflict 
of interest when they recommend a product to patients 
(82.35%), ensure pharmacist profession cultural improve-
ment and maintenance of professional honor (92.16%). 
According to respondents, the main benefits of indepen-
dent pharmacy are motivated staff (39.31 %) and patient’s 
stability (28.32%). The main difficulties in the manage-
ment of an independent pharmacy are unequal discounts 
from wholesale (47.2%) and tax burden (25.6%). 43.14% 
of respondents hoped that they will be able to keep their 
pharmacies in the coming 5 years. This study highlights 
distinct ‘independent’ expression of professional identity 
and suggests the need to assess the value of independent 
community pharmacy as being different from but comple-
mentary to the service provided by multiples/large chains.
Conclusion
This study showed that all owners of independent 
community pharmacy work in their pharmacies as 
pharmacists or administration staff. Pharmacy owners 
perceive professional autonomy a high level.. They 
believe that it has great influence to their professional 
practice, enhance job satisfaction and bring added value 
to the patients. Despite all difficulties in the management 
and tough competition with non-chain pharmacies, the 
majority of independent community pharmacies owners 
value the professional autonomy and this encourages them 
to keep business.
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Introduction
Heart failure can be defined as an abnormality of car-
diac structure or function that results in the inability of the 
heart to deliver oxygen at a rate sufficient to meet the re-
quirements of metabolizing tissues, despite normal filling 
pressures (McMurray et al., 2012). Heart failure is a ma-
jor cause of morbidity and mortality. The aim of this study 
is to assess the impact of socio-demographic and lifestyle 
factors in patients diagnosed with heart failure as lifestyle 
interventions could have substantial power to improve pa-
tient’s health. The prevalence of heart failure is expected to 
increase by 25% by 2030 (Heidenreich et al., 2011). Heart 
failure is a life-threatening disease and it should be consid-
ered a global priority. There is little evidence about heart 
failure patients in Albania, hence the necessity of carrying 
out such a study.
Materials and methods
We surveyed 200 patients, who were hospitalized at the 
department of Internal Medicine in QSUT “Nënë Tereza”, 
Tirana during the period from January 2015 until June 2015. 
The methodology consisted of the use of both primary and 
secondary data. This study was mostly prospective, but it 
had some retrospective elements. We used Chi-squared test 
to find statistically significant correlations between socio-
demographic and lifestyle factors with heart failure. When 
p<0.05, the correlation was statistically significant, while 
when p<0.1, the correlation was considered marginally sig-
nificant.                                                                                                                                                             
Results and discussion
In total, 200 patients were included in this study, 160 
of them were diagnosed with heart failure. 117 (58.5%) of 
them answered the questionnaire during their stay in the 
hospital, while for the other 83 (41.5 %) patients, we ob-
tained their data from their clinical files. From 200 patients 
included in this study, females represented 52.5% and 
males represented 47.5%. Meanwhile, among patients di-
agnosed with heart failure, females and males represented 
equally 50%. This ratio is in accordance with other stud-
ies in the world, where the prevalence of heart failure in fe-
males and males is similar. This can be explained with the 
fact that females live longer than males, even though males 
have higher incidence than females (Mehta and Cowie, 
2006). The mean age of 200 patients was 66.9, while the 
mean age of patients diagnosed with heart failure was 70.1. 
81% patients lived in the city and 19% lived in the village. 
From 117 patients that were asked about their level of edu-
cation, 31.6% patients answered that they had finished pre-
elementary school or less, 23.1% patients had finished ele-
mentary school, 35% had finished high school and 10.3% 
had been graduated. Furthermore, 53.8% of the patients in-
terviewed indicated their income as low, 45.3% as average 
and 0.9% as high. 
Another question that was asked to patients was if they 
performed any physical activity; in regards to this ques-
tion, 41.9 % answered Yes and 58.1 % answered No. To the 
question if they kept a healthy diet, 44% answered Yes and 
56% answered No. Also, patients were asked if they smoke 
and the responses were as below:  7.7% were active users, 
36% used to smoke in the past, but they no longer did and 
56.3% had never smoked. With regards to the use of alco-
hol, 72.6% of the patients answered that they never used 
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it, 23.9% answered that they used it rarely and 3.4% an-
swered that they used it frequently. 
From the Chi-squared test was found a strong corre-
lation between age and heart failure (p=0.001). Heart fail-
ure becomes more common with increasing age. This re-
sult is consistent with  studies in North America and Eu-
rope, where few patients with heart failure are 50 years of 
age or under and more than 80% are 65 years of age or over 
(Bui et al, 2011) Another strong correlation was also found 
between physical activity and heart failure (p=0.001). Pa-
tients that did physical activity had lower risk to develop 
heart failure than patients who did not. This correlation has 
also been found from other studies in the world. Further-
more, physical activity is one of the elements where there 
can be intervention to prevent heart failure (Young et al., 
2014)
Our study didn’t find any correlation between income 
level, smoke, place where patients lived and heart failure 
(p-values, respectively: 0.262, 0.563 and 0.787). On the 
other hand, there was a correlation between the level of ed-
ucation and heart failure (p=0.041). Lastly, the results of 
this study indicated a marginally significant correlation be-
tween healthy diet, alcohol use and heart failure (p-values, 
respectively: 0.084 and 0.068).  
Conclusion
Based on our findings, it can be concluded that phys-
ical activity and healthy diet should be part of patient’s 
lives, because they have an important role in preventing 
heart failure. Health professionals should be the ones to 
promote a healthy lifestyle, which has a direct impact on 
the development of heart failure and the disease recidivism. 
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Waste represents an enormous loss of resources in the 
form of both materials and energy. The amount of waste 
produced can be seen as an indicator of how efficient we 
are as a society, particularly in relation to our use of nat-
ural resources and waste treatment operations. Historical-
ly, waste management systems were introduced to protect 
public health. 
In the 1970s and 1980s, waste management systems 
focused on controlling outlets to air, water and groundwa-
ter. In recent years, the focus has been increasingly on uti-
lizing waste as a resource. Even though several measures 
have been introduced to reduce waste quantity, waste vol-
umes still increase. Environmental pollution by pharma-
ceutical waste can become a hazardous waste if it is not 
disposed of in accordance with law and if you are irrespon-
sible and out of control delayed and thrown in the trash 
container, poured into drains or buried in the ground. Haz-
ardous waste at its origin, composition or concentration of 
hazardous substances can cause harm to the environment 
and human health. Considerable concern has been raised 
regarding potential effects on human health due to pres-
ence of pharmaceuticals from environmental to drinking 
water. Thus, drugs and their degradation products can pol-
lute underground waters or enter the food chain. Some 
studies show that several common drugs were present in 
the final effluent in concentrations high enough to poten-
tially affect ecosystems (UK Water Industry Research, 
2014). Expired household drugs often end up in waste-
waters or in municipal wastes. In accordance with the EU 
regulations, throwing away unused drugs has been forbid-
den since 1994 (European Union: European Council Di-
rective 94/67/EC, 1994). Yet, it was established that a third 
of all sold drugs in Germany, as well as around 25% of 
those sold in Austria is disposed of with other household 
waste or ends up in wastewaters (Greiner and Ronnefarhrt, 
2003). A survey showed that 17.7% of respondents dispose 
of the expired and surplus drugs by flushing them down 
the toilet. More than half the respondents of the USA-made 
study threw drugs into wastewater, while only 23% of the 
respondents had returned drugs to the pharmacist (Bound 
and Voulvoulis, 2005).
Research conducted in other countries has shown that 
unused drugs are mostly stored in households and that they 
are most often thrown into municipal waste or spilled into 
wastewater.  All of the previously mentioned facts are im-
portant from the aspects of estimate of ways in which drugs 
get into the environment. Due to the continuous release of 
active substances, their bioactive metabolites accumulate 
in the ground and sediments and have an unfavorable im-
pact on natural ecosystem (Tong et al., 2011).
In Serbia, particularly in Novi Sad, most of expired 
drugs citizens have returned to the special containers 
placed within the pharmacies of Public Pharmacy Institu-
tion of Novi Sad, Autonomous Province of Vojvodina.
At the Public Pharmacy Institution of Novi Sad, was 
established Pharmacy Waste transfer station in 2011. There 
were collected and classified drugs from 34 pharmacies 
that people dispose in containers placed in pharmacies. 
It can be seen that the percentage of deferred and unused 
medications is large. Boxes and blisters that make phar-
maceutical waste, indicating that some of the prescribed 
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drugs, because most of the drugs are from the list of pre-
scription, half- used and unopened. It would be a huge 
harm that drugs were not used and did not contribute to im-
proving therapeutic outcomes, were not collected as phar-
maceutical waste, and accidentally found exposed to the 
influence of atmospheric factors and reaches the soil or wa-
ter, which is an immense and immeasurable danger to the 
environment and for human health.
In addition to the organized collection and classifica-
tion, pharmacists at Public Pharmacy Institution of Novi 
Sad organized and proper storage of pharmaceutical waste 
for transport and destruction are is done by registered com-
panies. This waste with appropriate documentation is ex-
ported and destroyed in the neighboring countries that have 
organized incinerators such as Hungary and Poland.
IPA grants supported transport and destruction of ex-
pired drugs stored in Pharmacy Waste transfer station 2011 
to 2013. From 2013, more than 5 tones of expired drugs are 
stored in Pharmacy Waste transfer station and still waiting 
to be destroyed.
The Law on pharmaceutical waste in Serbia has not 
regulated who is responsible for payment of transport and 
destruction of pharmaceutical waste. Most of stored drugs 
in Pharmacy Waste transfer station in Public Pharmacy In-
stitution of Novi Sad are drugs for cardiovascular diseases 
(angiotensin converting enzyme inhibitors, diuretics, beta-
blockers, calcium channel Blockers), antipsychotics, anal-
gesics (diclofenak), antibiotics, drug for diabetes (metfor-
min, sulfonylureas, insulins), sleeping pills (barbiturates) 
and some antineoplastics.
The action performed by pharmacists within Public 
Pharmacy Institution of Novi Sad contributed to the dis-
posal of a part of pharmaceutical waste arising in the ter-
ritory of Novi Sad and its surroundings, but it is not suffi-
cient, since remained uncovered other possible “ produc-
ers “ of pharmaceutical waste such as hospitals, outpatients 
department, within the dental, medical centers, institutes, 
private pharmacies, veterinary clinics and others. It is nec-
essary a large-scale action that will lead to the organized 
collection of pharmaceutical waste from all sorts of “pro-
ducers” and then the waste must be classified and kept un-
til destruction.
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Introduction
More than 1 million Portuguese have diabetes and of 
these, about half don’t know to have the disease, which 
progresses silently until appear the first complications. 
Given the extent of this problem there is the need to 
find integrated approaches across society in an effort to 
prevent and identify individuals at risk.
There is a significant opportunity for a coordinated and 
synergistic action between pharmacies and primary care 
regarding the promotion of primary and secondary preven-
tion of diabetes.
Aim
This study aim was to assess the risk of diabetes type 2 
in the patients of the community pharmacy and subsequent 
personalized assistance, in particular the recommendation 
for the medical consultation of patients with high and very 
high risk of type 2 diabetes. Has also aimed sensitize the 
population to the problem of diabetes, inform and educate 
about the risk factors and promote ways to control them.
Materials and methods
For two weeks between, 14 to 28 November 2015 the 
pharmacy assessed the risk of type 2 diabetes of its pa-
tients. Promoting information and education about the dis-
ease, informed about the risk factors and strategies to con-
trol, advising also individually each patient to adopt the 
most appropriate measures, maintaining healthy lifestyles. 
Prompting the patient for the necessary monitoring, includ-
ing medical, in situations where there was a greater risk of 
diabetes.
Thus, all patients over 18 years old, who visited the 
pharmacy were invited to participate in the study.
It was made a qualitative interview to all patients in-
cluded in the study, and all data was collected in order to 
follow the design observational study.
Patients diagnosed with diabetes or taking medications 
for diabetes and pregnant women were excluded
We applied the questionnaire “Evaluation Sheet Dia-
betes Risk Type 2” of the Portuguese national program for 
diabetes, (adapted from the WHO International Diabetes 
Program, with the international score purpose, DGS 2008) 
to determine the risk of getting type 2 diabetes within 10 
years.
Questionnaire variables were: gender, age, weight and 
height, waist circumference, anti-hypertensives in taking, 
family history of diabetes, habits and lifestyles and history 
of high blood glucose levels.
The questionnaire consists of 8 Likert questions, al-
lowing immediate calculation of the score based on the 
responses. Since the scale determines the risk of having 
type 2 diabetes within 10 years. A score less than 7 points, 
was considered very low risk, the patient was only warned 
to keep styles and healthy life. A score between 7 and 11 
points, was considered low risk, although the risk is slight 
the patient was warned to continue maintaining healthy 
lifestyles. A score between 12 and 14 points, was consid-
ered moderate risk, the patient should adopt healthy life-
styles and review their risk factors. A score between 15 and 
20 points, was considered high risk, the patient should in 
the next doctor’s appointment tell the doctor about his risk 
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of diabetes. Finally a score higher than 20 points, was con-
sidered very high risk, the patient was informed that he 
must consult his doctor and inform it about his risk of di-
abetes.
In light of this evaluation, each of the assessed pa-
tients had specific information about his individual risk and 
about the needs and behaviors that should adopt regard-
ing the prevention of diabetes. In cases where the risk was 
highest was recommended seeking medical care.
The risk factors considered for diabetes were: age 
above 45 years old, overweight (BMI> 25 kgm2) or obese 
(BMI> 30Kgm2), waist circumference more than 94 cm for 
men or 80 cm in women , sedentary lifestyle (less than 30 
minutes a day of physical activity), family history of dia-
betes in first grade, hypertension or dyslipidemia, previ-
ous history of cardiovascular disease, blood glucose ab-
normalities in fasting and previous impaired glucose tol-
erance, prior gestational diabetes, and use of drugs predis-
posing to diabetes.
The data presented after performed the statistics anal-
ysis include descriptive information from the patients and 
the narratives of qualitative data.
Results and discussion
In these two weeks, we included 85 patients. The sam-
ple was mostly formed by women, 69.7%. There were 
26.7% patients younger than 45 years old, 27% had be-
tween 45 and 54 years old and 46.6% were over 55 years 
old. It was found that 51.1% had a BMI lower than 25kgm2, 
but 63.3% of women had a waist circumference exceeding 
88 cm and 34.6% of men exceeding 102 cm. As for physi-
cal activity 50% of men said to practice at least 30 minutes 
a day and only 41.6% of women did it. However 93.0% ate 
any vegetables or fruit every days. About 43% of the sam-
ple was taking anti hypertensives. As for family history of 
diabetes type 1 or type 2, 48.8% of subjects had no history 
and 48.8% did not report any episodes of high blood sug-
ar in any health examination. However we obtained 18.6% 
of patients with very low risk, 39.5% with low risk, 20.9% 
with moderate risk, 18.6% with high risk and 2.3% with 
very high risk.
 This assessment score has potential as a tool to iden-
tify a high risk group of DM2/pre-DM2 among communi-
ty pharmacy patients, especially, when used together with 
information from health care providers. There is evidence 
that intensive lifestyle and various pharmacotherapeutic 
interventions decrease the incidence of DM2 or even can 
delay the progression of DM2 among persons with predi-
abetes
 Therefore this population mainly formed by women 
with a sedentary lifestyle and overweight may gain if mod-
ify their lifestyles. Since they have non-modifiable fac-
tors such as age and gender, pharmacist can help in order 
to persuade the patient to lose weight and decrease of ab-
dominal circumference. With a non pharmacological inter-
vention this patients can improve their diabetes assessment 
and also the pharmacist may give a good help to obtain this 
objective. 
Conclusion
The participation of pharmacy, translated into a large 
number of patients at risk of diabetes evaluated in this ini-
tiative is a critical success factor for the demonstration of 
Pharmacy relevance in the development of new forms of 
collaboration recoverable by the health system. Besides the 
contribution of this initiative to combat diabetes, we are 
also making an important step in the development of dif-
ferentiating initiatives pharmacy as indispensable to a net-
work of modern health care, efficient and citizen-centered
There was a strong recommendation for medical con-
sultation of patients with high risk and very high of type 
2 diabetes and was intended to sensitize the population to 
the problem of diabetes. Information and education about 
the risk factors of diabetes is one way to avoid in the future 
more diabetic patients and to avoid the excessive waste of 
money with their treatment. Having a better understanding 
about the disease, the evaluation of the risk factors to pre-
vent the illness and also to control it, have certainly phar-
macoeconomical repercussion in the wastes of national 
health systems economy and mainly advantage for the pop-
ulation that use the pharmacy services and accepts the dai-
ly work of the pharmacists.   
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Introduction
Infections posed a serious threat to human life, kill-
ing millions of people until the discovery of antibiotics. 
The term antibiotics, which means ‘‘against life’’, is de-
rived from the fact that an antibacterial drug is extracted 
from living things and used to kill or attenuate bacteria. 
However, there is a tight correlation between longer dura-
tion and multiple courses of antibiotic uptake and higher 
rates of bacterial resistance.
In recent decades, the emergence and spread of bac-
terial resistance to antibiotics is an ongoing threat world-
wide, which presents a significant threat to public health 
globally in the 21st century. The increase of antibiotics re-
sistance will decrease their therapeutic effectiveness, in-
crease treatment failures and, as a result, lead to longer and 
more severe illness episodes with higher costs and mortal-
ity rates.
As more strains of bacteria become resistant to an ev-
er-larger number of antibiotics, our drug choices will be-
come increasingly limited and expensive and, in some cas-
es, nonexistent. If this trend continues unchecked, a wide 
range of modern medical procedures, from basic dental 
care to organ transplants, likely would be accompanied by 
a much greater risk of developing a difficult-to-treat or un-
treatable antibiotic infection. The safety of many modern 
medical procedures is dependent on the ability to treat bac-
terial infections that can arise as post treatment complica-
tions. 
The aim of this study is to measure the levels of knowl-
edge of the population about the effectiveness of antibiot-
ics and risks associated with their unnecessary use.
Materials and methods
A cross sectional survey using a validated question-
naire, conducted among the general public in Kosovo, 
during the months of October and November 2014. The 
English version of the questionnaire from Eurobarometer 
(2008) (Special Eurobarometer 407, Antimicrobial Resis-
tance, May – June 2013), was adapted and translated into 
Albanian. A random convenience sample of 392 people 
was included in this study. The questionnaire consisted of 
6 questions.
The respondents in the sample are mainly from Prishti-
na as the largest city, the capital of Kosovo that has a va-
riety of locations, people from the town or villages. The 
questionnaire application was made in different places like 
in some private pharmacy, family medical centers and lab-
oratories, people on the streets, in some Dental Clinics, 
Medical Private Clinics, Homes and the University. The 
data was digitally stored and analyzed using Microsoft Ex-
cel. Descriptive statistics were carried out by providing the 
number and percentage of each of the demographic vari-
ables as well as knowledge about the questions of antibi-
otics.
Results and discussion
From 392 patients, 194 were males (49.49%) and 198 
females (50.50%). Median age is 51 years (range 15 - 74 
years).
The subjects in the survey were asked to rank from 
their knowledge of antibiotics as low, middle or high. From 
392 respondents 184 (46.94%) said that they knowledge of 
antibiotics is middle, 149 (38.01%) said that they have low 
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knowledge of antibiotics and 59 (15.05%) said that they 
have high knowledge of antibiotics.
The study also has one declaration and asked the re-
spondents if they ‘agree’ ‘disagree’ or ‘don’t know’ that all 
of us have a responsibility towards the effectivity of anti-
biotics. 249 (63.52%) of the respondents agreed with this 
declaration, 86 (21.94%) said they did not know and 49 
(12.50%) did not agree with this declaration. A further 8 
(2.04%) respondents did not want to answer this question.
Respondents were asked if each of the following four 
statements about antibiotics (Antibiotics kill viruses; Anti-
biotics are effective against colds and flu; Unnecessary use 
of antibiotics makes them become ineffective; Taking an-
tibiotics often has side-effects, such as diarrhea) was ‘true’ 
‘false’ or ‘don’t know’.
Almost half of the respondents 176 (44.90%) said that 
it is true that antibiotics kill viruses, 116 (29.59%) said that 
it is false that antibiotics do not have effectiveness on viral 
infection and 100 (25.51%) responded they do not know if 
antibiotics kill viruses.
 A large majority 210 (53.57%) of those polled gave 
the correct answer that the overuse of antibiotics reduc-
es their effectiveness. Just 71 (18.11%) gave us the wrong 
answer that it is ‘false’ and 111 (28.32%) ‘do not know’ if 
that is true or not.
Antibiotics are effective against cold and flu which is 
‘false‘and the right answer to this question was obtained 
from only 116 (29.59%) of respondents. More than half of 
the respondents answered wrong by stating that is ‘True‘ 
that antibiotics are effective against the cold and flu 220 
(56.12%) whereas 56 (14.29%) others answered that they 
don’t know.
Respondents were asked whether taking antibiotics of-
ten has side effects such as diarrhea. 241 (61.48%) of the 
respondents gave the correct answer that antibiotics can 
produce side-effects. There is more uncertainty over this 
issue than the preceding ones: 130 (33.16%) of the respon-
dents were unable to give an answer to this question. A 
slightly smaller proportion 20 (5.10%) gave an incorrect 
answer. This is in accordance with several other studies 
(Awad and Aboud, 2015; Mouhieddine et al., 2014; Sirijo-
ti et al., 2014; Widayati et al., 2012;)
Conclusion
The finding in this study showed that the majority of 
the population had a moderate level of knowledge and 
attitudes in relation to antibiotics, by using them for wrong 
reasons and in the wrong way. We believe that this study 
may be useful in increasing people’s knowledge for the 
correct use of antibiotics and their awareness concerning 
the risks of inappropriate use of them, because of the 
developing resistance of antibiotics.  
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Introduction
One of the most significant health issues are the dis-
orders of mood because they have a significant effect on 
the quality of life of the patients, their families, their work-
ing and wider social surroundings.  According to the World 
Health Organization (WHO, 1992; WHO, 2001), mood 
disorders are the fourth cause of morbidity and mortality 
with a tendency to move to the second place by the 2020. 
The prediction that there is going to be an increase in the 
number of ill in the future comes from the facts that the 
factors of risk, like stress, are in constant rise, that the de-
mographic image (ageing of the population) is changing 
which has an effect on the rise of comorbidity of these ill-
nesses with the chronic illnesses of the elderly population 
and that the incidence of genetically predisposed depres-
sions increases etc. 
Patients with depression are often not in a state to cor-
rectly apply the prescribed pharmacological therapy which 
leads to cessation/disruption of therapy, inadequate treat-
ment of depression which as a consequence has frequent 
hospitalizations, incapability to work and are marginalised 
and stigmatised by the community. That is why a pharma-
cist through an interdisciplinary approach and appliance of 
pharmaceutical care can affect the proper selection of ther-
apy and can also make a follow up of the patient, counsel 
him/her about the side effects and interactions, and final-
ly improve the quality of life of the patient suffering from 
depression which is the final goal of including pharmacists 
and pharmaceutical care into a multidisciplinary team (Bi-
nakaj, 2015). Keeping track of compliance and concor-
dance in use of the medication for the nervous system is 
of special importance. The development of pharmaceuti-
cal studies, increase of pharmaceutical industry as well as 
the changes in healthcare systems and policies sets addi-
tional challenges which include continuous monitoring of 
the needs of patients as well as the trade and consumption 
of medications for the sake of rational medication admin-
istration. 
To define, describe and question the role of pharma-
cists in the treatment of patients suffering from depression, 
as well as measure the impact of pharmaceutical care on 
significant parameters in treatment of depression like the 
selection of appropriate therapy according to the guide-
lines, adherence of the patient, quality of life, work capa-
bility, anxiety, side-effects and interactions.
Materials and methods
The study is a randomised controlled clinical study in 
which a psychiatrist in General Hospital Tesanj will ran-
domise patients according to the methods of random se-
lection and the criteria of inclusion and exclusion defined 
in the protocol. The target population is adult patients 18 
to 75 years old who suffer from diagnosed depressive ep-
isodes (according to the criteria set up for the diagnosis) 
and who are treated in General Hospital Tesanj (Bosnia and 
Herzegovina). A pharmacist will set up monthly appoint-
ments for the patients and educate them about depression 
and medications with a special review of side-effects and 
interactions of medications. During this study the pharma-
cist and the doctor will have two meetings where they will 
analyze observations of the pharmacist and evaluate the 
impact of pharmaceutical care with the intervention group. 
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The standard group will only fill in the questionnaire about 
quality of life during their regular visit to the doctor at the 
beginning of the study, after three months and after six 
months of the study. The gathered data will be analyzed 
with the SPSS software for statistical analysis of data and 
it will include qualitative and quantitative elements.
Results and discussion
Forty eight patients were monitored in this research, 
11 men and 37 women, where we notice that the incidence 
of depression is more frequent in women, which is also vis-
ible in the research of WHO 2008.
During this research three tests were conducted using 
which we gathered information which showed us the sig-
nificance of a pharmacist in the treatment of patients suf-
fering from depression. Consideration of the anxiety test 
showed that the treatment with a team which includes a 
pharmacist compared to a team without a pharmacist 
shows progress in the treatment because there was a sig-
nificant decrease in irritability and anxiety. 56% of the pa-
tients had these symptoms during the first visit while this 
figure in the third visit was 4.3%. When considering the 
questions from the life quality test we didn’t get significant 
results which showed us progress in the patient’s depres-
sion treatment with the presence of a pharmacist in an in-
terdisciplinary team. Also, the patients’ life test showed us 
the contribution of the pharmacists in the treatment of pa-
tients with depression.
These results showed us that the pharmacist should be 
included in the interdisciplinary team which takes care of 
the treatment of patients with depression and by further ed-
ucating the pharmacist in the area of mental disorders, es-
pecially depression; even better results would be achieved. 
A research conducted in Belgium about the role of phar-
macists in the care of patients with depression showed that 
pharmacists are not sufficiently involved in the treatment 
of patients with depression as well as the insufficient edu-
cation of the pharmacists regarding mental disorders (Liek-
ens et al., 2012). Pharmacists are the most devoted health 
professionals – patients visit pharmacists seven times more 
than they visit doctors. These data show us that pharma-
cists through pharmaceutical care can make the fastest and 
the cheapest contribution to a good outcome of this multi-
disciplinary approach in the treatment of patients with de-
pression.
Conclusion
The high prevalence of depression and anxiety disor-
ders and the trend of growth of the affected demand a de-
tailed analysis of causes, treatment, cormobidity and in-
teractions, as well as keeping track of the consumption 
of medications for the rehabilitation of symptoms caused 
by these disorders which in the future could facilitate im-
provement of adherence, the effect of therapy and im-
provement in quality of life.
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Introduction
In Albania, neoplasm is the second leading cause of 
death following circulatory system diseases. Within neo-
plasms, breast cancer is the second most frequent cancer 
after lung cancer (INSTAT, 2016). Breast cancer treatment 
generally involves multiple approaches including surgery, 
radiation and/or chemotherapy. Adjuvant treatment is the 
administration of additional therapy after primary surgery 
to kill or inhibit micrometastasis (Tarifa et al., 2007). De-
pending on the model of risk reduction, adjuvant therapy 
has been estimated to be responsible for 35-72% reduction 
in mortality rate (Newton and Grethlein, 2015).
The adjuvant chemotherapy of breast cancer has 
changed several times since the first effective chemother-
apy regimen for breast cancer CMF, (cyclophosphamide; 
methotrexate; 5-fluorouracil) was developed (Bonadonna 
et al., 1976).
To date, there is no ‘gold standard’ regimen in adjuvant 
chemotherapy of breast cancer. The diversity of the disease 
depending on biomarkers, the proliferation process and di-
versity of trials, with different interpretations, has led to 
endless suppositions and discussion on the best treatment. 
However, there is general agreement that CMF-like regi-
mens are ‘better than nothing’, that anthracycline-contain-
ing regimens are better than CMF, and that the taxanes fur-
ther add to the benefit of anthracyclines (Peto, 2007).
The aim of this study was to evaluate the results of ad-
juvant chemotherapy, taxane-based regiment with anthra-
cycline- based regiment in woman with breast cancer in 
Albania.
Materials and methods
A case-series study was conducted at the University 
Hospital Center “Mother Teresa” in Tirana including 181 
women diagnosed with breast cancer and treated with ad-
juvant chemotherapy. Women included in this study had 
an age range 18-70 years, with stage I-III of breast cancer 
irrespective of nodal, hormonal, or HER2 status. Respec-
tively, 35 women were treated with taxane-based adjuvant 
chemotherapy regimen and 146 women were treated with 
anthracycline-based adjuvant chemotherapy regimen after 
primary surgery. The clinical diagnosis was based on biop-
sy findings. A 5-year follow-up of took place where the re-
lapse experience was recorded for all women included in 
this study. 
Results and discussion
Taxane–based regimen has become the most popular 
adjuvant therapy for breast cancer in the last decade (Jones 
et al., 2009). Overall, in our study there were 35 women 
treated with taxane-based regimen. In the group of wom-
en treated with taxane-based (paclitaxel or docetaxel) regi-
men as adjuvant chemotherapy, 8 (22.9%) of them experi-
enced relapse within four years compared with 27 (77.1%) 
women who did not manifest relapse after the fourth year 
of follow-up. The distribution of relapse time among wom-
en treated with 4AC-4T(paclitaxel or docetaxel) was as 
follows: there were 2 women (5.7%) who experienced 
a relapse within the first 12 months; 2 (5.7%) within 24 
months; 1 (2.9%) within 36 months; and 3 (8.6%) women 
within 48 months. Conversely, 27 (77.1%) did not manifest 
relapses after the fourth year of follow-up.         
Overall, in our study there were 142 women treated 
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with anthracycline-based regimen. In the group of  women 
treated with anthracycline-based regimen (CAF (N=142, 
or 97.3%) or AC-CMF (N=4, or 2.7%) of adjuvant 
chemotherapy, overall 34 (24.5%) of them experienced 
relapse within four years compared with 105 (75.5%) 
women who did not manifest relapses after the fourth year 
of follow-up.  On the whole, 6 (4.3%) women experienced 
a relapse within the first 12 months; 13 (9.4%) within 24 
months; 6 (4.3%) within 36 months; and 9 (6.5%) women 
within 48 months. On the other hand, 105 (75.5%) did not 
manifest relapses after the fourth year of follow-up.         
After 5 years of follow-up, there was an improvement 
in relapse-free survival between taxane-based regiment 
and anthracycline based regiment (77.1% vs 75.5%). Ben-
efits were observed irrespectively of nodal, hormonal or 
HER2 status.
The 2011 EBCTCG meta-analysis also included tax-
anes such as docetaxel and paclitaxel in its analysis of ad-
juvant therapy. Incorporation of taxanes into an anthracy-
cline containing regimen resulted at 8 years in the reduc-
tion of the risk of recurrence, risk of breast cancer mortali-
ty, and overall mortality. This benefit was present irrespec-
tive of age, nodal status, tumor size, tumor grade or estro-
gen receptor (ER) status (Peto et al., 2012). 
Our study obtained similar results, regardless of the 
small size sample. Hence, incorporation of taxanes such 
as docetaxel or paclitaxel into adjuvant chemotherapy reg-
imens led to a reduction in disease recurrence. This benefit 
was evident independent of age, nodal status, tumor size, 
tumor grade, estrogen receptor (ER) and HER2 status. 
Conclusion
After 5 years of follow-up, there was an improvement 
in relapse-free survival between taxane-based regimen 
and anthracycline-based regimen respectively 77.1% and 
75.5% in Albanian women diagnosed with breast cancer 
and treated with adjuvant chemotherapy.  Benefits were 
observed irrespectively of nodal, hormonal, or HER2 
status. These findings have important implications for 
practitioners and policy-makers in Albania and beyond. 
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Introduction
Colorectal cancer (CRC), with an estimated 447,000 
new cases and an estimated 215,000 deaths occurring in 
2012,  is the second most common cancer and also the sec-
ond most common cause of cancer death in Europe (Gra-
ham et al., 2014). The incidence of CRC is strongly re-
lated to age (83% of cases occurring in patients who are 
aged 60 years or older). The ageing population and glob-
al effect of “westernization” are additional factors driving 
a rapid increase in new CRC cases worldwide. As a conse-
quence, the already significant societal burden of CRC is 
likely to increase over time. Important economic compo-
nents of this burden include direct medical care costs, di-
rect nonmedical costs (such as patient time involved with 
receiving medical care), and productivity losses among pa-
tients and caregivers (Yabroff et al., 2013).
 The most important CRC prognostic factor is 
the disease stage at the time of diagnosis (from a 90% of 
5-year survival rate for cancers detected at the localized 
stage; 70% for regional; to 10% for people diagnosed for 
distant metastatic cancer).  Approximately 25% of newly 
diagnosed patients have already developed metastases; al-
most 50% of all CRC patients will form metastases over 
time as the disease progresses. Metastatic colorectal can-
cer (mCRC) is characterised by a high mortality rate. 
In the last decade, fluoropirimidine drugs (5-fluoro-
uracil-FU and leucovorin -LV) combined with oxaliplat-
in or irinotecan chemotherapy regimens (FOLFOX and 
FOLFIRI), were best available mCRC treatment. In re-
cent years, the significantly increased mCRC survival rates 
have resulted mainly from the introduction of monoclonal 
antibodies (mAbs) as additional first-line treatment to che-
motherapy or in subsequent treatment lines (Lange et al., 
2014). 
According to the European Society for Medical Oncol-
ogy (ESMO) clinical practice guidelines for mCRC, beva-
cizumab (mAb against the vascular endothelial growth fac-
tor -VEGF) and panitumumab and cetuximab (which bind 
the epidermal growth factor receptor - EGFR) in combina-
tion with chemotherapy can be considered as first line op-
tions for selected patients with mCRC. The ESMO recom-
mendations are based on the improved outcomes report-
ed for these biologics versus chemotherapy alone in clini-
cal trials (Van Cutsem et al., 2010). Despite the established 
therapeutic efficacy and safety, this new mAbs based che-
motherapy regimens have dramatically increased the cost 
of treatment.  
Pharmacoeconomic assessments are a part of the deci-
sion process not only during reimbursement setting, but in 
clinical practice as well. Estimates of the costs associated 
with cancer care are essential both for assessing burden of 
disease at the population level and for conducting econom-
ic evaluations of interventions to prevent, detect, or treat 
cancer. Comparisons of cancer costs between health sys-
tems and across countries can improve understanding of 
the economic consequences of different health-care poli-
cies and programs.
The aim of this analysis was to evaluate the cost-effec-
tiveness/ utility of bevacizumab plus FOLFOX   vs.  FOLF-
OX alone in 1st line treatment of patients with mCRC from 
the payer perspective in R. Macedonia
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Materials and methods
A Decision tree structure approach was selected to as-
sess the cost-effectiveness of Bevacizumab plus FOLFOX 
relative to FOLFOX in the first line treatment of patients 
with mCRC. The model uses a 2-week cycle length and a 
time horizon of 2 years post treatment initiation.  The en-
tire patient population was composed of a simulated co-
hort of 100 mCRC patients/treatment branch. The patients 
progressed through the decision tree based on the risk of 
early therapy discontinuations because of severe toxicity 
(ST), disease progression (DP) and cancer associated death 
(CAD) during active treatment. After completion of the first 
2 cycles of chemotherapy, patients without experienced ST 
from first-line therapy (FOLFOX ± bavacizumab) are con-
tinuing the treatment until DP. For patients with intolera-
ble toxicity, first-line therapy is discontinued and second-
line FOLFIRI is offered until DP. Upon progression, all pa-
tients receive best supportive care until death. The transi-
tion probabilities between the health states for bevacizumab 
plus FOLXOX and FOLFOX alone treatment were based on 
parametric survival curves estimated in a patient-level anal-
ysis of progression free survival (PFS) and overall surviv-
al (OS) from the NO16966 clinical trial (Saltz et al., 2008).
 Only direct costs (bevacizumab and FOLFOX che-
motherapy), were included in the analysis. Drug-acquisition 
costs were calculated utilizing official government and hos-
pital pharmacy publicly available data. All costs are report-
ed in 2016 Euros. The benefit and performance of medical 
treatments, measured as quality-adjusted life years (QALY) 
were extracted from the published data (Ramsey et al., 2000, 
2002).  The incremental cost per QALY gained was calcu-
lated as the difference in total costs divided by difference in 
QALY. All costs and outcomes (benefits) in the model were 
discounted using discount rate of 3.5% per annum. 
A sensitivity analyses on the estimates of costs, utili-
ties, and health state transitions were performed to evaluate 
the robustness of the model and address uncertainty of vari-
ables. In univariable sensitivity analyses, we varied the val-
ue of costs and utilities within ± 20% of their baseline values 
and examined the effect on the ICER. In probabilistic sen-
sitivity analyses (PSAs), we ran the model 1000 times, each 
time randomly varying all parameters simultaneously. We 
used uniform distribution for cost parameters and gaussian 
distribution for the efficacy parametars and discount factor. 
The analysis was conducted from the perspective of both the 
Macedonian public and private health care systems.
Results and discussion
Base case analyses 
The initial drug costs for bevacizumab +FOLFOX 
compared to FOLFOX were estimated at €2312.86 and 
€451.22, respectively, per 2-week cycle. In the primary 
analysis, the effectiveness and costs were compared in 
the first-line model for the FOLFOX and FOLFOX-plus-
bevacizumab groups. FOLFOX provided 1.31 QALYs  at 
a cost of  €1963.86. FOLFOX plus bevacizumab provided 
1.41 QALYs at a cost of €11021.899. The ICER for 
FOLFOX plus bevacizumab was €90580.374 per QALY.
Sensitivity analysis
According to the sensitivity analyses results, the 
base case model is robust to alternative parameters and 
assumptions. The parameters with the greatest influence 
on the ICERs were median OS and PFS for each regimen, 
drug cost of bevacizumab, and utility values for living 
with mCRC. The discount factor had a minor influence 
on the ICER in the first-line model. The PSA indicate 
that 82% of simulations performed showed bevacizumab 
plus FOLFOX to be more effective and more costly than 
FOLFOX chemotherapy alone.
Conclusion
Based on the model projections, the introduction of 
bevacizumab to the standard FOLFOX chemotherapy 
protocols for mCRC treatment resulted in longer survival 
and greater QALYs than FOLFOX alone at an incremental 
cost of € 90580.374 per quality adjusted life-year gained.
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Introduction
Over-the-counter (OTC) drugs are medicines that can 
be used safely and effectively by the general public with-
out a prescription. Available for sale directly to a consum-
er, they are one of the most important and easily accessible 
public health aids for the treatment of common conditions 
or symptomatic relief (Håkonsen, et al., 2016; Halvorsen et 
al., 2016). In the last 10 years, many medicines that were 
originally prescription only have now become available 
over the counter (OTC), either from pharmacies or oth-
er general retail outlets (Bond et al., 2003). However, cer-
tain cases of misuse or overuse of OTC drug products re-
sulting in adverse drug events have been recorded, lead-
ing to the conclusion that they may not be totally harmless. 
Although there are different means of providing the con-
sumers with drug information, the advertising, used by the 
pharmaceutical companies, is one of the best and power-
ful methods for information broadcasting and introducing 
these products to the consumers (Hanna et al., 2010 Major, 
et al., 2010). Thus, trying to make appropriate recommen-
dations and decisions regarding OTC medications can be 
tempting for the community pharmacists and daunting and 
confusing for patients (Cooper et al., 2013).
The aim of this study was to examine the advertising 
influence on pharmacist and consumers attitudes in selec-
tion of OTC medicines.
Materials and methods
The multicenter, observational cross-sectional study 
was conducted at 70 randomly selected community pharma-
cies in Skopje, R. Macedonia. Data were collected during 
one shift at each pharmacy. The instrument used for investi-
gating the research questions in this the study is a previous-
ly validated survey available in the literature (Potnis, 2012). 
Pharmacists were provided with a printed copy of survey.
 Variables measured in this study are the cumula-
tive scores for pharmacists’ perceptions of OTC drug ad-
vertising concerning their recommendations and consum-
er selection of over-the-counter drugs.  The questionnaire 
included 27 items divided into 2 sections. Section I of the 
questionnaire was comprised of seven questions measur-
ing the demographic variables (gender, years of practicing 
as a pharmacist, practice setting, location of the pharmacy, 
frequency of exposure on OTC drug advertisements, aver-
age weekly OTC prescription volume and medium of OTC 
drug advertisements) related to the pharmacists’ practice. 
Section II  was comprised of 20 questions (divided in 
4 subsections),  measuring pharmacists experience regard-
ing: 1) pharmacists’ beliefs about the effects of over-the-
counter drug advertising, 2) impact of OTC drug adver-
tising on pharmacists’ recommendations, 3) influence of 
OTC drug advertising on patients’ choice of the drug prod-
ucts, 4) Effect of over-the-counter drug advertising on pa-
tient pharmacist interactions. The subsection 1 and 2 con-
sisted of 4 questions, while sections 3 and 4 comprised of 
6 questions. All questions from section II were measured 
on a 5-point Likert scale (items rated from one to five; ‘1’ 
denoting ‘Strongly Agree’ and ‘5’ denoting ‘Strongly Dis-
agree’). 
With each item having a maximum possible score of 
five, the highest score for the beliefs measure, consisting 
of four or six questions, was 20 or 30, respectively.  Phar-
macists, whose cumulative score for the above items was 
found to be less than or equal to 10 or 15 were consid-
ered to believe that over-the-counter drug advertising has 
a great effect on the measured variable. The obtained data 
were descriptively analyzed.
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Results and discussion
All of the participants were females (100%) work-
ing in large chain pharmacies, previously defined as phar-
macies with more than or equal to 12 stores (61.1%). Ap-
proximately 33.3% of the pharmacist worked in small 
chain pharmacies (with 1-12 stores). Most of the phar-
macists were working in pharmacies located in urban re-
gions (81.5%) with most of them practicing for 1-10 years 
(70.6%). Approximately 59.3% of the surveyed pharma-
cists mentioned coming across over-the-counter drug ad-
vertisements/informations for 1- 5 times a week. Mar-
keting representatives, as reported by 45% of the partic-
ipants, were found to be the medium where the pharma-
cists gain most of the over-the-counter drug informations, 
followed by internet (33.3%). A large number of pharma-
cists (31.4%) were working at a pharmacy with a volume 
of prescriptions between 100-150 and more than 200 OTC 
drugs /week.
A majority of the surveyed pharmacists (61.5%) were 
found to have a cumulative score of 8 and thus believe that 
over-the-counter drug advertising has a great effect on pa-
tients. Approximately 77.7% of the pharmacists had a cu-
mulative score of 12 and agreed that over-the-counter drug 
advertising does not impact on pharmacists’ recommenda-
tions. A large number (81.4%) of pharmacists, based on a 
score of 14 agreed that the patients choice of the drug prod-
ucts was largely influenced by over-the-counter drug ad-
vertising. In all, 51.8% of the pharmacists, with a score 
of 12, were of the opinion that patient - pharmacist inter-
actions were increased as a result of the over-the-counter 
drug advertising.
Conclusion
These findings serve as a starting point for addition-
al research in the field of over-the-counter drug advertising 
in our country. Although pharmacists use marketing adver-
tisement as a means of information about over-the-coun-
ter drugs they strongly believe that their role is to offer 
patients the best care at the least possible cost and to en-
sure that the recommendations regarding OTC drug pro-
vides enough revenue to maximize its value to the patient. 
Considering that patients choice of the OTC drug 
products is greatly influenced by over-the-counter drug ad-
vertising in order to promote a rational usage of the OTC 
drug the advertisement has to contain all necessary patient 
information in a way that is clear and understandable and 
to encourage patients to carefully read the package leaflet 
or instructions. In view of the fact that in recent years, di-
rect-to-consumer advertising of OTC drugs has increased 
all advertisements must give a clear message that the ad-
vertised product is a medicinal product.
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Background
Parallel with the development of pharmaceutical sci-
ence and legal regulations (law on medicinal products and 
medical devices, law on health care), this area is gain-
ing greater recognition in national and international level. 
Pharmacy, unlike chemistry and biology is not just science, 
rather, it is a profession that encompasses a broad range 
of academic and professional disciplines that are based on 
science, business, sociology and law. Pharmaceutical law 
as a discipline of recent date, although its foundation and 
academic profiling is an area that legally has be present in 
order to develop different approached to problems, and to 
cooperate with pharmaceutical science and practice (Ap-
pelbe and Wingfild, 1997). The rules in pharmaceutical 
laws may be universally agreed and respected or may be 
controversial and applied only in part or only by some of 
those concerned, so this article seeks to provide an outline 
of the law that affects the pharmacy.
Pharmacy law
Interdisciplinary is a kind of cooperation where experts 
from various academic disciplines work in order to achieve 
common outcomes. The past decade has witnessed an un-
precedented interest and controversy surrounding in ethi-
cal and legal aspects of health, including pharmaceutical 
care. One reason for the establishment and development of 
such program as pharmaceutical law, is the conviction that 
traditionally established disciplines individually are unable 
to solve key problems. What is more there are many oth-
er areas of law and regulation affecting the industry, con-
cerning, for example the pricing of medicines, the conduct 
of clinical studies, the health protection and health care in-
surance (Dukes, 2006). In some fields it is hardly impos-
sible to maintain standards through regulation. So we can 
freely say that the manner and quality of the relationship on 
both sides (pharmacy and law) depends on boosting over-
all pharmaceutical activity and protection. This suggests 
that the pharmacy and law although at first glance are two 
mutually different areas, still they have numerous and im-
portant common ground. Considering that, interdisciplin-
ary approach of pharmaceutical law is very complex and 
requires knowledge of the lawyers in the pharmaceuticals-
but also demands from pharmaceutical professionals bet-
ter knowledge of the legal institutions whose application 
refers to them.
This pharmacy-law relationship puts the task of phar-
macists not only in the implementation of regulations re-
lated to pharmaceutical law, but also needs the right ap-
proach to shape legal institutions to regulate rights and ob-
ligations, which requires a very serious approach by legal 
experts. The pharmacists work reaches out to entire com-
munity. Pharmaceutical law in an objective sense consti-
tute a set of laws governing pharmaceutical activity, regu-
late the rights and obligations of health professionals and 
their relationship to the beneficiaries. It is especially im-
portant to emphasize that this discipline also called, “law 
for drugs” covers the legal definition and corresponding 
action to the pharmaceutical care of the individual in the 
health care system (Mujovik-Zornik, 2008). It covers parts 
of the regulation for legal issues relating to the manufac-
ture, trade and use of drugs in the context of health care. 
For this reason pharmaceutical law is broadly viewed as an 
integral part of health law or legislation. 
Pharmaceutical law as a discipline is recognizable 
recent, and appears separately in order to identify first of 
all regulatory aspects in the definition and implementation 
of health legislation. The need and the existence of these 
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two disciplines (medical and pharmaceutical law), on the 
one hand requires their integration and harmonization, and 
on the other hand allow consideration of legal problems 
from different aspects.For example, from the perspective of 
medical law separates the part of pharmaceutical regulation 
under which person (patient) consumed drugs comes into 
contact with them, but again portions over a health or 
medical procedures undertaken in connection therewith. 
This will also mean that aspects of pharmaceutical law, 
which relate to public or rather socially significant issues 
associated with the production of pharmaceuticals, 
intellectual property rights, and advertising may appear as 
second.
Unlike traditional branches of law, pharmaceutical law 
is not specifically codified but is defined by the field governed 
not uncommon liaison with ethical norms associated with 
this regulated profession, because it is a limited legal 
area, which refers to a profession and those who use its 
services. This arises and specificity of pharmaceutical law 
and its sources are simultaneously multiple of a different 
nature, legal and professional (intellectual property rights 
and norms associated with putting drugs on the market, 
quality and safety of medicines and other pharmaceutical 
products, health care insurance, competition, advertising, 
ethical codes, etc.).
Therefore, all legal norms and regulations of pharma-
ceutical law recognize and affect each other, because a de-
cision to bring a specific legal issue entails application of 
the regulation and other areas of law (Junod, 2006). This 
indicates that the rules of pharmaceutical law have their 
own specifics, but when it comes to legally relevant com-
plex cases, its use is public law and regulation, private 
and often even criminal character. Considering the consti-
tutionally guaranteed right to health as a universal value, 
(The Constitution of the World Health Organization-1946 
states that the “enjoyment of the highest attainable stan-
dard of health is one of the fundamental rights of every hu-
man being without distinction of race, religion, political 
belief, economic or social position “) pharmaceutical law 
as part of health activity has the same characteristics.
Although still in development in our country the 
national legislation related to these issues is in the process 
of harmonizing with the standards as in the other EU 
member states. Promotion of pharmaceutical law as a 
discipline and the ongoing debate on current issues of legal 
theory and practice is of great scientific and professional 
importance. Presence as a special study program at a 
growing number of faculties, slowly gaining status, along 
with medical law as a scientific discipline that is taught and 
continually exploring.
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Introduction
Importance of the pharmaceuticals is well acknowl-
edged and recognized for health and wellbeing of our so-
ciety but on the other hands they have become chemicals 
of concern to the public because of their potential to reach 
drinking-water. Recent study in Serbia showed the pres-
ence of pharmaceuticals in water samples collected from 
25 locations (in total 47 out of 81 investigated drugs were 
detected) (Petrović et al., 2014).
Although more research is needed to properly estimate 
the risk and the impact of measured concentrations of the 
pharmaceuticals on the environment and on human health, 
it is clear that more attention needs to be paid to this issue 
in coming years. This is especially because the production 
rate of pharmaceutical waste is constantly growing world-
wide as a consequence of increased use of pharmaceuticals 
(Smith, 2002).
Pharmaceutical waste management is complex chal-
lenge requiring compliance with of health and environmen-
tal regulations as well as involvement of all parties includ-
ed in providing and receiving of health service. To mini-
mize the risk of uncontrolled pharmaceutical waste dispos-
al preventive measures and systematic drug-take back pro-
grams are needed. However, equally important prerequi-
site for success of the whole process is enhanced commu-
nication to the public on proper pharmaceutical waste man-
agement. And for that purpose pharmacists can and should 
play key role. Focus of this work was to investigate to what 
extent raising of public awareness is needed and if there are 
any particular population groups (i.e. regarding education, 
age) that require additional attention.   
Materials and methods
This research has been conducted among citizens 
of Serbia. The study included 100people. People in the 
pharmacies in the cities of Novi Sad, Subotica, Ruma, 
Arandjelovac and Vlasotince and their country sides, were 
approached randomly and invited to participate. The anon-
ymous questionnaire consisted of 9 questions. Three ques-
tions were related to the socio-demographic characteristic 
of the population, and other six were related to medication 
storage and disposal. Participants could either complete the 
questionnaire themselves or have their responses marked 
by the investigators. Analysis was performed in Excel.
Results and discussion
Out of total sample size of 100 responders, 10% of re-
sponders were from municipality of Arandjelovac, 10% of 
responders were from Ruma, 9% of responders were from 
Subotica, 28% responders were from Vlasotince and 43% 
responders were from Novi Sad. The majority of the exam-
inees were from the cities (83%) and 17% from the coun-
try sides. Fifty-four percent (54%) of responders had high 
school degree and forty-one (41%) had university degree. 
Out of all respondents, 18% were students, 52% were em-
ployed and 28% were retired. 
More than 80% of responders said that they had kept 
the unused medicine at home.In the questionwhat do they 
do with unused medicine the examinees most often an-
swered “I keep it in a case I may needed it for later” (60%), 
“I give to other people if they need it” (16%), “I dispose it 
in the household ban” (19%) and about 5% answered “I re-
turn unused medicine to a pharmacist or a doctor”.
Also, the examinees were asked about their dispos-
al practice of primary packaging of medicines (prescrip-
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tion bottles, blister packs, etc.) and 89% of them did this 
in an environmentally inappropriate way. Answers indicat-
ed that primary packaging of medicine was disposed as a 
house hold waste. Only 7% of the examinees were recy-
cling and just 4% reported returning primary packaging to 
a pharmacy for disposal. This is in line with our previous 
study where some 87% out of 253 examinees answered to 
dispose primary packaging as household waste (Gigov et 
al., 2014).
Among the examinees who tried to return unused 
pharmaceuticals or primary packaging to a pharmacy, only 
36% had founded pharmacy that accepted unused pharma-
ceuticals, 45% of them were referred to other institution 
and in a case of 19% of responders the pharmacy could not 
accepted pharmaceutical waste.
Obtained results show that the lack of public aware-
ness of pharmaceutical waste management is unfortunate-
ly equally distributed throughout the population in Serbia. 
The majority of the examinees were not informed about 
proper pharmaceutical waste management. There are no 
differences between behavior of the responders related to 
the place where they were interviewed, neither to their ed-
ucation nor their employment/student status.
Conclusion
It is obvious that further education of the population 
is needed. Active involvement of the pharmacists is one of 
the most important steps. Pharmacists due to their educa-
tion and their position to daily communicate with the pa-
tients about the medicines can offer the most updated and 
relevant info about pharmaceutical waste management. 
Raising public awareness with central role of pharma-
cists on one hand and introducing a systematic approach in 
pharmaceutical waste management with preventive mea-
sures should decrease a risk of unwanted and potential haz-
ardous effect of pharmaceutical waste. This effort should 
be centrally promoted and supported by government and 
health sectors in Serbia that should enable a system for 
continuous education and regular update of the pharma-
cists with most recent regulations and trends in pharmaceu-
tical waste management. 
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Introduction
Diabetes is a complex, chronic illness requiring con-
tinuous medical care with multifactorial risk-reduction 
strategies beyond glycemic control. Ongoing patient self-
management education and support are critical to prevent 
acute complications and reduce the risk of long-term com-
plications. 
Hyperglycemia, or raised blood sugar, is a common 
effect of uncontrolled diabetes and over time leads to se-
rious damage to many of the body’s systems, especially 
heart, blood vessels, eyes, kidneys, and nerves. Type 1 di-
abetes is characterized by deficient insulin production and 
requires daily administration of insulin. Diabetes Type 2, 
results from the body’s ineffective use of insulin and com-
prises 90% of people with diabetes around the world, and 
is largely the result of excess body weight and physical in-
activity. Until recently, this type of diabetes was seen only 
in adults but it is now also occurring in children. Gesta-
tional diabetes is hyperglycemia with blood glucose values 
above normal but below those diagnostic of diabetes, oc-
curring during pregnancy. Impaired glucose tolerance and 
impaired fasting glycaemia are intermediate conditions in 
the transition between normality and diabetes. 
About 347 million people worldwide have diabetes 
and this number is projected to reach 552 million in 2030 
(Whiting et al. 2011). In 2014, 9% of adults (18 years and 
older) had diabetes. About 6% of Macedonian population 
has diabetes mellitus, either type 1 or 2. There is an emerg-
ing global epidemic of diabetes that can be traced back to 
rapid increases in overweight, including obesity and phys-
ical inactivity. In 2012 diabetes was the direct cause of 1.5 
million deaths. Majority of diabetes deaths (80%) occur in 
low- and middle-income countries. The overall risk of dy-
ing among people with diabetes is at least double the risk 
of their peers without diabetes (Roglic et al. 2005). Ear-
ly diagnosis can be accomplished through blood testing. 
Treatment of diabetes involves lowering blood glucose and 
the levels of other known risk factors that damage blood 
vessels. Nevertheless improvement in diabetes manage-
ment in the last years, 33–49% of patients still do not meet 
targets for glycemic, blood pressure, or cholesterol control, 
and only 14% meet targets for all three measures and non-
smoking status (Ali et al., 2013).
Patients with diabetes type 2, without cardio vascular 
disease (CVD) and mikroalbuminemija, are in the catego-
ry of patients with very high 10-year risk (13.4±11.4%) of 
fatal CVD as a result of inadequate glycemic control with 
a mean HbA1c 9.5±2.0% (recommendations for adequate 
glycemic control HbA1c < 6.5%) (Smokovski I., 2009). In 
parallel to healthcare system further development and im-
provement, successful diabetes care requires a systematic 
approach to supporting patients’ behavior change efforts, 
including: 1. Healthy lifestyle choices (physical activity, 
healthy eating, tobacco cessation, weight management, and 
effective coping), 2. Disease self-management (taking and 
managing medications and, when clinically appropriate, 
self-monitoring of glucose and blood pressure) and 3. Pre-
vention of diabetes complications (self-monitoring of foot 
health; active participation in screening for eye, foot, and 
renal complications; and immunizations). High-quality di-
abetes self-management education (DSME) in US has been 
shown to improve patient self-management, satisfaction, 
and glucose control (Powers, 2015). To date, perception for 
the importance of self-management in diabetes patients has 
not been evaluated in Republic of Macedonia (RM).
The aim of this paper is to assess the awareness and 
level of perception of the self-management importance as-
sociated with glycemic control achievement in patients 
from RM.
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Materials and methods
The study follows a descriptive design using a ques-
tionnaire-based survey. The questionnaire was created to 
assess perception for self-management in diabetes patients 
using the principles of Diabetes Self-Management Ques-
tionnaire developed at the Research Institute of the Dia-
betes Academy Mergentheim (Schmitt et al., 2013). First 
part of the questionnaire contains 6 demographic ques-
tions related to gender, age, urban or rural place of resi-
dence, education, history and type of diabetes. The second 
part contains 19 questions segmented in 4 subgroups relat-
ed to: Glucose Management, Dietary Control, Physical Ac-
tivity and Health-Care Use. The rating scale was designed 
as a four-point Likert scale, in a range 3-0 points, from the 
response options “applies to me very much” (3 points) to 
‘does not apply to me’ (0 points). 300 diabetes patients have 
been assessed with this questionnaire in 11 different towns 
in R. Macedonia: Skopje, Bitola, Strumica, Kumanovo, 
Kicevo, Tetovo, Prilep, Veles, Ohrid, Struga, and Stip. As-
sessment has been performed in direct contact of pharma-
cist with patient, with previously gained patient’s consent 
for participation. Statistical analysis was performed using 
SPSS 21.0.0. Group comparisons involved One-way Anal-
ysis of Variance, Student’s t-test and Pearson’s chi-squared 
test. In all analyses a P-value of < 0.05 (two-tailed test) was 
considered as criterion of statistical significance.
Results and discussion
300 diabetes patients were assessed, most at age 
>51years and older, 60% female and 40% male. Most of 
the patients come from urban environment with second-
ary education. 90% of the subjects have diabetes type 2 
and a history of disease > 5 years. Regarding to our find-
ings, diabetes patients from Republic of Macedonia most-
ly pay attention in regards to glucose management and reg-
ular treatment. In Dietary control questionnaire segment, 
most of the patients rated with 2 points (applies to me to a 
considerable degree). What is concerning is the low level 
of the perception for the need for physical activities and its 
impact on overall disease management.
Conclusion
The preliminary results suggest on concerning low 
level of perception for self-management in diabetes pa-
tients in R. Macedonia.
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Introduction
According to WHO, rational use of medicines is de-
fined as process that allows prescribing of the right drug for 
a right patient in the proper dose, duration of therapy, with 
the lowest cost for the patient and the community. World-
wide, more than 50% of all medicines are prescribed, is-
sued, or sold inappropriately. The most common reasons 
for the irrational drug use are: using too much medication 
per patient, improper use of antibiotics (inadequate intake 
for non-bacterial infection), use of the wrong medication 
for specific condition, drug use with questionable effec-
tiveness, using a drug with uncertain security status, exces-
sive use of parenteral formulations, where the use of oral 
formulations is more appropriate, inappropriate self-med-
ication. Irrational drug use represents a major generator of 
progressively increasing costs in all health systems. (Hol-
loway and Green, 2003).The aim of this study was to eval-
uate rational/irrational drug use at orthopedic department - 
Clinical HospitalStip.
Materials and methods
A retrospective evaluation for the period of 4 months 
concerning to consumption of analgesics (Tramadol and 
Ketoprofen), antibiotics (Ceftriaxon), unfractionated hep-
arin and low molecular weight heparins was done. Total 
number of patients was 348 in evaluated period January 
- April 2013. The Evaluation of the therapy used in the 
study was according to the guidelines for evidence-based 
medicine issued by the Ministry of Health of RM for the 
treatment of diseases that are diagnosed in the test popula-
tion.  For the diagnoses for which there is not recommend-
ed guidelines, the European and American Associations for 
the treatment of given diseases guidelines were used. In 
order to detect discrepancies in the rational drug use for 
each of the evaluated drugs, DDD expressed per 100 hos-
pital beds was calculated. The obtained data were statisti-
cally analyzed using SPSS.v.20 software licensed program.
Results and discussion
In Clinical hospital – Stip, annually expenditure for 
drugs is 500 000.00 euros and 7.1% belongs to the orthope-
dic department. From 348 hospitalized patients on this de-
partment in evaluated period, 218 patients (62.64%) were 
treated conservatively and 130 patients (37.36%) with sur-
gery intervention. The average age of evaluated patients 
was 57.14 ± 20.3 years and average time of hospitaliza-
tion per patient was 7.74 ± 10.4 days. In most of the hos-
pitalized patients diagnose was bone fracture and almost 
all patients received more than 4 drugs as parenteral thera-
py. The most commonly used analgesic for the pain control 
treatment was Amp. Ketoprofen. According to the obtained 
data in February, 51 out of 75 patients (68%) received Ke-
toprofen of which 19 (38.59%) more than 5 days. In Feb-
ruary 56.99 DDD/HHB Ketoprofen was used with extra 
costs of 27.35%. In March 66 patients (61%) received Ke-
toprofen of which 17 (25.76%) more than 5 days. In April 
41 patients (43.16%) received Ketoprofen of which 16 
(39.02%) received more than 5 days. The DDD/HHB for 
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Ketoprofen in April was 18.82. Ketoprofen was applied in 
almost all patients who were hospitalized at the orthopedic 
department at the Clinical Hospital Stip, much longer than 
recommendations of  5 days and parenteral form of the this 
drug was not replaced with an oral form.
The same situation is evident for the application of 
Tramadol. From total 160 inpatients for four months peri-
od who received Tramadol, 65 of them received more than 
4 days. In January, 41 patients (58.57%) received Trama-
dol of which 22 (53.66%) received Tramadol more than 
4 days. The DDD/HHB in January was 11.35. In Febru-
ary, 32 (42.67%) received Tramadol, 8 of which (25%) 
received more than 4 days. Relatively same situation we 
evaluated in March and April. 
Prophylaxis of deep vein thrombosis (DVT) is indi-
cated in patients who performed more surgical interven-
tion. Evidence-based medicine shows that the prevalence 
of asymptomatic DVT detected by routine venography af-
ter larger orthopedic intervention is lower in hospitals that 
implement prophylaxis 10 days compared to hospitals that 
carry out prophylaxis only 5 days. This observation sup-
ports the current recommendations of the American Col-
lege of Chest Physicians (ACCP) for a minimum 7-10 
days prophylaxis in patients who undergo surgery at or-
thopedics. In January, total of 16 (22.86%) hospitalized pa-
tients received thromboprophylaxis with low-molecular-
weight heparin (LMWH) and only 5 (31.25%) patients re-
ceived prophylaxis in accordance with the recommenda-
tions (≥7days). The associated DDD/HHB value for this 
month was 20.07. In February, 3 patients (4%) received 
LMWH and only 1 (33.33%) received more than 7 days 
and the DDD/HHB was 1.52. In March 5 patients (4.63%) 
received LMWH with highest extra cost of 68.46 %. In 
April, 14 patients (14.74%) patients received LMWH 5 of 
which (35.71%) received more than 7 days. Low-Dose Un-
fractionated Heparin (LDUH) is used at the department in 
accordance with recommendations for thromboprophylax-
is prevention and treatment of thrombosis for several de-
cades. In January, 22 patients (31.43%) received thrombo-
prophylaxis with LDUH of which 15 (68.18%) patients re-
ceived prophylaxis as it was recommended (≥7days). In 
January utilization was 35.48 DDD/HHB with extra cost 
of 33.26%. In February, 32 patients (42.67%) received 
LDUH of which 15 (46.87%) received more than 7 days. 
In March, from 108 patients, 39 (36.11%) received LDUH 
of which 17 (43.59%) more than 7 days and the DDD/HHB 
value was 39.99. In April 34 (35.79%) received LDUH of 
which 23 (67.65%) received more than 7 days and DDD/
HHB value was 34.95.
Regarding to the use of antibiotics for prophylaxis in 
orthopedic patients we found that ceftriaxone was mostly 
used antibiotic values for DDD/HHB from 26.24 to 42.74 
and in all evaluated period the period of using of this anti-
biotic was more than 2 days. 
Conclusion
Evaluation of the drug consumption at orthopedic de-
partment at Clinical Hospital Stip indicates irrational drug 
use in terms of all monitored indicators and recommen-
dations for rational use of medicines. proper dose, dura-
tion of therapy, with the lowest cost for the patient and the 
community
References
Holloway, K., Green, T., 2003. Drug and therapeutics committees 
- A Practical Guide. World Health Organization.
Poster presentations
Macedonian pharmaceutical bulletin, 62 (suppl) 117 - 118 (2016)
ISSN 1409 - 8695
UDC: 615.2-027.512:347.77.038
Short communication
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Biosimilar medicinal products (biosimilars) are de-
fined as highly similar versions of reference biological 
products, which in the same time are offering new oppor-
tunity for innovation in the pharmaceutical industry. The 
complexity of the manufacturing process of those drugs, 
the character of the active substance and the nature of 
their activity, demands a stringent regulatory framework 
for these medicines. Biosimilar medicines, according to 
the World Health Organization (which refers to them as 
“similar biotherapeutic products”), are products which are 
manufactured following the expiration of the patents or the 
data protection for the first major group of the originator’s 
biological products. There is a strong interest by health-
care stakeholders in measuring the biosimilar utilization 
and impact on the market entry. Regulatory issues, manu-
facturing, safety, pricing, and physician and patient accep-
tance have a big influence in the developing the biosimi-
lar market. With regulatory approval pathways encourag-
ing more competition among manufacturers of biologics, 
there follows the prospect of increased litigation and other 
threats to intellectual property rights. Biosimilar patent lit-
igation continues to evolve as biosimilars enter new glob-
al markets. The European Union (EU) was the one of the 
first highly regulated areas to develop a legal and regulato-
ry framework for the approval for highly similar versions 
of innovator biological products. Although formal approv-
al pathway for biosimilar began in the EU very early in 
2001 (European Medicines Agency, 2003), the European 
Commission (EC) first amended its market authorization 
forsimilar biological medicinal products in 2003 (Com-
mission Directive 2003/63/EC, 2003), and issued its first 
general biosimilar guidance in 2005 (European Medicines 
Agency, 2005). The European Medicines Agency’s (EMA) 
first approval under the new similar biological medicinal 
product pathway was in 2006 (Sandoz’s somatropin called 
Omnitrope®) and since then 20 biosimilars are approved 
in EMA (European Medicines Agency list of approved bi-
osimilars, 2016).While the EU’s legal system is complicat-
ed by the lack of a unified patent litigation system that re-
quires a multicountry patent litigation approach, the US’s 
biosimilar patent litigation has been complicated by bio-
similar applicants and the reference biological product ap-
plicants picking and choosing what portion of the default 
patent litigation exchange system to utilize. Despite the 
differences between the litigation strategies in the EU and 
the US, as biosimilar approvals become worldwide more 
globalized, and it will be increasingly important to appre-
ciate these differences and consideration to how biosimi-
lars patent litigation arguments and outcomes in one situa-
tion can benefit and be utilized in other situation, even if in 
different countries or legal systems. 
Still there are some limitation on the patent issue of bi-
osimilars like that the subject matter is not patentable, the 
invention was not explained clearly or completely enough 
or the subject matter extends beyond the content of the ap-
plication filed. From the other side, there are also different 
possible outcomes such as rejection of patent, the patent is 
maintained in amended form with a new published specifi-
cation, or the patent is revoked. Initial opposition decisions 
may be appealed within two months, and countries may 
have conflicting rules whether they stay or halt further le-
gal process, national patent infringement actions while an 
opposition and any associated appeal is pending. The me-
dian time for an appeal is close to three years, which is the 
same approximate median time for an opposition for pat-
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ents concerning pharmaceutical and biotechnology prod-
ucts (Patient Protection and Affordable Care Act, 2010).
Concurrently or following an opposition, biosimilars pat-
ent litigation may begin in member countries but still liti-
gation in each county requires detailed knowledge of that 
country’s national patent litigation procedures. 
Due to the differences in patent litigation rules and bi-
osimilars regulatory applications, there may be advantag-
es to bring an initial biosimilars patent litigation in the one 
primary biosimilar markets, the place of business or man-
ufacture of the biosimilar, or based on a received jurisdic-
tional favoring the action. Because each country has its 
own law system where patent holders may enforce their 
patents, there is the possibility for conflicting patent en-
forcement decisions in different countries, where biosimi-
lar manufacturers may pursue national patent litigations in 
member countries simultaneously or successively. There-
fore there appears to be limited patent litigation challeng-
es in the EU with a preference to patent issuance challeng-
es and some limited country patent challenges. There are 
many unresolved issues that will affect European patent 
challenges, especially for bridging biosimilar products on 
the EU market.
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Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are 
among the most commonly used medications in modern 
pharmacy. NSAIDs have anti-inflammatory, analgesic, an-
tipyretic or antireumatic action and differ in activity and 
severity of adverse effects. These drugs have more or less 
serious side effects affecting the most gastrointestinal tract. 
NSAIDs should not be prescribed to patients with gastric 
or duodenal ulcer, because their use may lead to bleeding 
and even to a lethal outcome. 
All NSAIDs can be structurally divided into several 
groups: derivatives of salicylic acid, p-aminophenol deriv-
atives, propionic acid derivatives, indole derivatives, phen-
ylacetic acid derivatives, oxicams, and fenamates naftilac-
etatne acid derivatives. NSAIDs are indicated in different 
treatments because of their anti-inflammatory, analgesic, 
antipyretic and antirheumatic effects. The NSAID anti-in-
flammatory action is due to inhibitory activity on prosta-
glandin G/H synthase (cyclooxygenase). This enzyme cat-
alyzes the transformation of arachidonic acid to prosta-
glandins and thromboxanes. There are two forms of this 
enzyme: COX-1 and COX-2. COX-1 enzyme is normal-
ly present in the body, whiles the inducible COX-2 enzyme 
(cytokines, fibroblasts, epithelial cells) occurs only in in-
flammatory conditions. Both enzymes have very similar 
structure (COX-1 consists of 599 amino acids, a COX-2 of 
604) (Varagić and Milošević, 1991).
The analgesic effect NSAIDs is achieved by reduc-
ing peripheral sensitization of polymodal nocireptor, while 
antipyretic effect is achieved by inhibition of prostaglan-
din E2. This prostaglandin is responsible for the activation 
of a special section in the hypothalamus, which regulates 
body temperature in the formation of an inflammatory con-
dition. General side effects of NSAIDs are associated di-
rectly or indirectly with the irritation of the digestive sys-
tem. NSAIDs have a twofold effect on the digestive sys-
tem: acid molecules directly irritate the lining of the stom-
ach, and the inhibition of cyclooxygenase-1 reduces the 
levels of protective prostaglandins.
Common side effects on the digestive system include, 
nausea, vomiting, dyspepsia, stomach ulcer/bleeding in the 
stomach, diarrhea. Higher doses treatment is associated 
with increased risk of ulceration. In efforts to reduce the 
adverse effects on the digestive system, it is recommend-
ed to use the lowest effective dose for the shortest possible 
period, which is not the case in practice (Walker and Ed-
wards, 1998).
Materials and methods
In this study, data were collected at the pharmacy, 
where we monitored quantity of prescription for NSAIDs, 
and the utilization of these drugs issued at the request of 
the patient (without a prescription). Evaluation lasted one 
month and twenty days, in which we monitored the amount 
of received recipes and amount of patients who take this 
medication without consulting doctor or pharmacist. Also 
we asked doctor how many patients come and ask for a 
prescription for NSAIDs and how they used them.
Results and discussion
On average 200 patients come in the pharmacy and 
130 out of them were looking for drugs that are used as 
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analgesics or antipyretics, whereas approximately 90 pa-
tients used some NSAIDs. Only 15 out of 90 patients have 
a prescription for the drug. Patients were not familiar with 
the problems that are linked to use of this type of medica-
tion. According to results obtained from doctors approx-
imately 85% of patients who use NSAIDs do not have a 
doctor’s prescription. Patients used these drugs mainly for 
treatment of pain, and they chose them because are easi-
ly available. 
Conclusion
NSAID medicines are of great importance and one of 
the most commonly used medicines in hospitals and out-
patient conditions. They are relatively safe drugs but their 
complications sometimes can be severe and fatal. Patients 
with current ulcer disease are more eligible for treatment 
with proton pump inhibitors in therapeutic dose, while pa-
tients without current ulcer with a history of previous ill-
ness of bleeding for treatment with dose of maintenance. 
The use of selective COX-2 inhibitors is justified for pa-
tients at risk for gastrointestinal complications with previ-
ous consultation with doctor or pharmacist.
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Background - ten years of QRM developments
Over the past ten years, since the finalisation of the 
ICH guideline titled Quality Risk Management, ICH Q9, 
there have been significant efforts by industry and regula-
tors to drive risk-based approaches forward.  This has in-
cluded initiatives by regulators to update the GMPs and 
other official guidance documents to incorporate increased 
provisions relating to risk and its management (Campbell 
et al., 2016; European Commission, 2010; O’Donnell et 
al., 2012). There have also been many industry-led pub-
lications, guides and technical reports, offering practical 
guidance for how to implement the concepts of QRM in 
the GMP environment (Calnan et al., 2013; Vesper et al., 
2006).
However, the question remains as to whether the man-
agement of risk in relation to the production of defective 
and sub-standard medicines has significantly improved in 
these last ten years, and whether, from a product quality 
perspective, medicines are any safer now than they were 
before the ICH Q9 guideline was introduced.  While there 
are many different areas one could study when consider-
ing the question of medicines safety, such as pharmaco-
vigilance, Marketing Authorisation withdrawals and drug 
shortages, to name but a few, the focus of this presenta-
tion is on GMP, and specifically on product quality con-
siderations.
Looking for the added value for patients
The presentation discusses how, while the aforemen-
tioned QRM initiatives had product quality and patient 
safety as their overall focus, many of the product quality 
and compliance issues occurring before 2005 are still with 
us, and the evidence indicates that certain types of prob-
lems are increasing (Waldron et al., 2015).  Some of these 
relate to:
• Serious quality defects and product recalls continuing 
to occur globally;
• Market Authorisation non-compliance issues some-
times resulting in the cessation of batch release;
• Product shortages as a result of serious GMP failures.
QRM and risk assessment inspection deficiencies
In relation to serious quality defect issues, the presen-
tation explores that various factors that may have led to 
the level of those issues seen in the last ten years - and 
how formal research projects are currently underway in 
Ireland and at the European Medicines Agency to better 
understand this area.  Of concern is the fact that most of 
these defective batches were manufactured using qualified 
equipment, trained staff, and validated manufacturing pro-
cesses, and this leads one to question what is happening. 
The paper considers:
• Whether the manufacturing and control processes cur-
rently in place have been properly risk assessed and de-
signed using QRM principles.  
• Whether qualification and validation activities were ac-
tually based on risk, as required by Annex 15 of the EU 
GMPs.  If so, why are defective batches of medicines 
still being produced, with the same kind of defects over 
and over – product contamination, mix-ups, labelling 
errors, etc.? 
• What areas need most attention in the QRM activities at 
manufacturing sites? 
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Improving QRM activities in the GMP 
environment
The presentation explains how, while GMP Inspec-
tors have noted an increasing use of risk assessment and 
QRM activities at sites since ICH Q9 was finalised in 2005, 
and while some good practices have been seen in these ar-
eas (Fischhoff et al., 1993; Kahneman et al., 1972), signif-
icant concerns remain.  These relate to the lack of good sci-
ence, robustness and rigour in many of risk assessment and 
QRM-related activities taking place currently.  The presen-
tation presents a series of brief real-life case study exam-
ples showing some of the inspectional deficiencies that the 
HPRA has cited in recent years in these areas, and it also 
presents a number of suggestions and ideas for how to im-
prove QRM activities in the GMP environment.  
Notes 
The views expressed in this paper are those of the 
author and do not necessarily represent the views of the 
HPRA. This presentation is based on a paper published in 
the Journal of Validation Technology in December 2015 
(O’Donnell, 2015).
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Over the last years the role and responsibilities of the 
Qualified Persons have been increasing considerably. As 
a key person in the company, the Qualified Person has to 
consider many issues and has to take up the challenges 
within its areas of responsibilities. The previous year 2015 
was an eventful year. Again there were new developments 
in the Good Manufacturing Practice environment as well 
as announcements of changes that preoccupied the phar-
maceutical industry. 2016 won’t be less exciting, also be-
cause now many of the new requirements must be imple-
mented:
•	 Excipients - Formalized Risk Assessment, EMA 
Guideline, “… on the formalized risk assessment 
for ascertaining the appropriate good manufac-
turing practice for excipients of medicinal prod-
ucts for human use”, In operation from 21. March 
2016 (EudraLex, 2015a; ICH, 2005).
•	 Qualified Person should be fully involved in the 
system, in the new concept of cleaning validation 
with Toxicological Evaluation - Shared Facili-
ties, EMA/CHMP/ CVMP/ SWP/169430/2012 / 
Guideline on setting health based exposure lim-
its for use in risk identification in the manufacture 
of different medicinal products in shared facili-
ties. Describes determination of Permitted Daily 
Exposure (PDE), on basis of all available phar-
macological and toxicological data (clinical and 
non clinical) (CE, 2001; EMA, 2012; EudraLex, 
2016).  
•	 EU-GMP Guideline Part I, Chapter 3 “Premis-
es and Equipment“, EU-GMP Guideline Part I, 
Chapter 5 “Production“, Prevention of Cross Con-
tamination Chapter 5.17 - 5.22 (EudraLex, 2010).
•	 Revision Annex 15 – news in Qualification & Val-
idation… includes elements of ICH Q8, ICH Q9 
and ICH Q10 and advancing technologies, such 
as PAT and references the new chapters 3 & 5, 
coming into operation 1 October 2015 (EudraL-
ex, 2010; EudraLex, 2015b).      
A comprehensively designed Pharmaceutical Quali-
ty System (PQS) incorporating Good Manufacturing Prac-
tice (GMP) and Quality Risk Management (QRM), imple-
mented, maintained and continuously improved, allows a 
consistent delivery of products with appropriate quality at-
tributes. The level of GMP, is regularly checked by com-
petent authorities, authorized with a GMP Certificate, and 
it is a basis for maintenance of Marketing Authorization 
(MA) and marketing of medicinal products within the EC/
EEA (CE, 2001; CE, 2003).       
The results of product and processes monitoring are 
taken into account during batch certification, having into 
consideration deviations or OOS, OOT or OOE (if any) by 
implementing QRM. (EudraLex, 2016; ICH, 2005).  
The Qualified Person is responsible for ensuring that 
each individual batch has been manufactured and checked 
in compliance with laws in force, in accordance with the 
requirements of the marketing authorisation (MA) and 
with Good Manufacturing Practice (GMP) (CE, 2001; Eu-
draLex, 2016).
When the batch is intended to be sold in the EU, in the 
new annex is clear on this: “Samples may either be tak-
en after arrival in the EU, or be taken at the manufactur-
ing site in the third country in accordance with a technical-
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ly justified approach which is documented within the com-
pany’s quality system. Any samples taken outside the EU 
should be shipped under equivalent transport conditions as 
the batch that they represent (EudraLex, 2016).
Marketing authorizations require a QP declaration 
(issued by the Qualified Person) to confirm that the ac-
tive substance (active pharmaceutical ingredient - API) 
has been manufactured in accordance with the EU-GMP 
Guide, Part II: Basic Requirements for Active Substanc-
es used as Starting Materials. The QP declaration template 
provides, in a format considered suitable for submission, a 
basis for demonstrating compliance of the active substance 
manufacture with GMP requirements, based on audit on 
site(s) and that the manufacturer has relevant knowledge 
of the supply chain (EMA, 2014).  
Relying on assessment by third parties, e.g. audits, 
should be in accordance with Chapter 7 of the GMP Guide 
in order to appropriately define, agree and control any out-
sourced activity. Special focus should be given to the ap-
proval of the audit reports (CE, 2003).   
A signed Quality or Technical Agreement(s) between 
all parties involved in the supply chain, have to be in place, 
including manufacturers of the starting materials, in bulk 
and finished products manufacturers, batch control test-
ing laboratories, importation and batch certification and 
release site(s), transportation and distribution. The entire 
supply chain of the active substance and medicinal product 
up to the stage of certification is documented and available 
for the QP. This should include the manufacturing sites of 
the starting materials and packaging materials for the me-
dicinal product and any other materials deemed critical 
through a risk assessment of the manufacturing process. 
The document should preferably be in the format of a com-
prehensive diagram, where each party, including subcon-
tractors of critical steps are included (CE, 2003, EudraL-
ex, 2016).     
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Introduction
The presence of impurities in pharmaceutical samples 
is a concern, not only because some contaminants are 
inherently toxic, but also because they may adversely affect 
drug stability and shelf-life, or may cause unwanted side-
effects. As a result, inorganic elemental impurities (As, 
Pb, Cd, Hg,…) must be monitored and controlled in raw 
materials, including: water, used for drug manufacturing; 
intermediates; active pharmaceutical ingredients (APIs); 
excipients and in the final dosage form. 
ICH, which includes the regulatory bodies from the 
US, Europe and Japan, as well as representatives from 
other countries and the pharmaceutical industry, has 
defined a Guideline for Elemental Impurities (Q3D) due 
to be implemented in December 2017 (Liba et al., 2011).
The new methods will introduce the use of closed vessel 
sample digestion and modern instrumental techniques 
(ICP-AES, ICP-MS) to ensure the accurate recovery and 
determination of individual analyte (McCurdy et al., 2004)
Material and methods
An Agilent 7800 ICP-MS with Octopole Reaction 
System (ORS4) fitted with a low-flow concentric quartz 
nebulizer was used for all measurements. The objective was 
to use the ICP-MS to determine a full range of elements. 
The ORS4 was operated in helium collision mode (He 
mode) only, which is effective at removing a wide range of 
plasma and matrix-based polyatomic species using kinetic 
energy discrimination (KED). Because He mode does 
not react with any analyte, and does not create any new 
interferences, elements that do not suffer from polyatomic 
interferences were also analyzed using He mode
Reagents and materials
HNO3 (BASF); ultrapure water (18.2 MΩ) produced 
by Milli-Q ultrapure water systems; 100 g/mL of multi 
element internal standard solution containing 6Li, Sc, Ge, 
Rh, In, Tb, Lu and Bi (Agilent Part # 5188-6525); multi-
element calibration standard STD-2A solution (Agilent 
Part # 8500-6940)
Results and discussion
In this study, we investigated the use of collision cell 
technology using helium gas to eliminate interferences 
generated by the plasma and the sample matrix. Typical 
matrix-derived polyatomic interference ions arising from 
the analysis of gelatin capsules include 40Ar12C+, 51V1H, 
35Cl16O1H and 40Ca12C, etc. on 52Cr and 40Ar13C, 
37Cl16O and doubly-charged 106Ru++ on 53Cr. The total 
dissolved solids (TDS) of the samples were less than 0.2% 
and any matrix effects were eliminated via the use of the 
internal standard calibration method.
Conclusion
Operating the Agilent 7700x with ORS3 in helium 
mode effectively removes polyatomic interferences via 
kinetic energy discrimination allowing the rapid, accurate, 
semi-quantitative screening of complex sample types, such 
as gelatin capsules. For each sample, semi-quantitative and 
full quantitative analysis can be performed simultaneously 
without the need to adjust the instrument.
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Introduction
Illicit production and trade of Cannabis affects many 
societies. This herb is mostly produced for domestic or re-
gional markets and its production in Europe is believed to 
be increasing in indoor settings, under the control of orga-
nized crime groups. Usually, the authorities are faced with 
the problem of a lack of information on where the canna-
bis was grown. This material is also widely consumed by 
the population in each country and therefore establishing 
of system for classifying the origin of this plant can be a 
challenge for the scientists and a great benefit for the po-
lice authorities. 
When drugs are concerned and especially for the fo-
rensic purposes, the most significant compounds in Canna-
bis samples are cannabinoids, terpenophenolic compounds 
unique to cannabis. For the forensic practice, the most im-
portant cannabinoids are: ∆9-tetrahydrocannabinol (∆9-
THC), cannabinol (CBN) and cannabidiol (CBD). The first 
compound, ∆9-THC is psychoactive component, while the 
other two mentioned cannabinoids are not. On the other, 
hand, transition metals are important for plant growth and 
they are distributed in different cells, in certain concen-
trations due to the established homeostasis. Hemp has the 
ability to tolerate and accumulate heavy metals. Bearing in 
mind the lack of literature on possible correlations between 
content of cannabinoids in Cannabis plants and metals in 
both Cannabis samples and soil where the plants were cul-
tivated, multivariate methods were applied aiming to assist 
in determination of origin of cannabis and its production. 
Materials and methods
Young plants of Cannabis sativa species had been 
seized by the Police authorities as material planted by the 
criminal groups on different locations in Serbia. The plants 
were grown illegally under controlled indoor conditions by 
applying certain levels of temperature, humidity and inten-
sity of light. The plants were randomly selected from the 
plantations in the early growing stage for the purpose of fo-
rensic analyses. The rhizosphere soil from the root zone at 
a depth of 5-10 cm was sampled. The plant samples were 
further separated into roots, stems and leaves. The roots 
parts were cleaned from traces of soil, washed with de-
ionised water and dried. The Cannabis leaves were dried 
and grounded to a powder. The mass of 33.3 mg of dried 
leaves material was dissolved in 5 mL of methanol, shak-
en in an ultrasonic bath for 30 min, and filtered. The fil-
trate was heated for 12 min at 150 °С in order to run decar-
boxylation of the cannabinoid acids into cannabinoids. The 
evaporated extracts were reconstituted with 2 mL of meth-
anol.  The resulting solution of 1 µL, for each sample was 
applied on the TLC plate together with the volume of 1 µL 
of the dissolved reference materials:  Δ9-THC, CBN and 
CBD in methanol in concentration of 0.05 mg/mL and 1 
µL of pure methanol. Mobile phase was n-hexane: diethyl 
ether in ratio 4 : 1. Visualization was conducted by the dis-
solved Azoic Diazo Component in 0.1 M sodium hydrox-
ide in water. 
In the second step, 20 mg of each sample were dis-
solved in 5 mL methanol, shaken in an ultrasonic bath for 
30 min, filtered and evaporated to dryness. The residue 
was reconstituted with 2 mL of methanol. 1 µL of the re-
sulting solution for each sample was injected into the GC-
FID system in order to analyse the content of cannabinoids. 
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For the purpose of elemental analysis, the sampled soils, 
roots, stems and leaves were subjected to microwave-as-
sisted acid digestion, according to a known procedure (Ra-
zic et al., 2006). 
The determination of the cannabinoids by thin lay-
er chromatography (TLC) with plates made of aluminium 
and covered with silica gel with fluorescence indicator of 
UV254, by conducting the semi quantitative analyses.
The determination of the cannabinoids was performed 
using an Agilent GC System, Model 7890A, fitted with 
a Flame Ionization Detector. The conditions were as fol-
lows: column HP-5 (30 m × 320 µm × 0.25 µm), injection 
temperature: 250 °C, splitless mode, oven program: initial 
temperature 150 °C for 0 min, heating rate 15 °C/min to 
300 °C and held for 5 min, nitrogen flow rate: 46 mL/min. 
The determination of the Cu, Zn, Mn, Fe, Ca and Mg 
was conducted on a Perkin-Elmer Model 5000 atomic ab-
sorption spectrophotometer, operated under optimized 
measurement (Razic et al., 2005).  The determination of 
the Cr was accomplished using a Perkin-Elmer Model 
5000 atomic absorption spectrophotometer with a graph-
ite furnace HGA 400 Automatic Burner Control (Razic et 
al., 2006).
Statistical analysis was performed using SPSS 11.0 
(SPSS Inc., Chicago, IL) and Minitab 13.20 (Minitab Inc., 
State College, PA), for Windows software packages. 
Results and discussion
Since the roots contain only trace amounts of these sub-
stances while the stems, branches and twigs have less than 
the leaf material, the cannabinoid content was measured 
only in the leaves. For the purpose of comparison of the can-
nabinoid content in the young plants and the mature one the 
semi quantitative method of the TLC was conducted and the 
difference in the cannabinoids content was detected. 
The cannabinoids content in the leaves of the exam-
ined cannabis plants was determined by external calibra-
tion. The values varied from 0.03 to 1.47 mg/mL for THC 
and from 0.11 to 1.12 mg/mL for CBN. The lowest lev-
els were from 0.003 to 0.06 mg/mL for CBN, what is rea-
sonable since the level of this cannabinoid, as degradation 
product of THC, increases with time during storage of can-
nabis plants. 
Quantification of metals was performed by external cal-
ibration. The accuracy of the methods was checked by anal-
ysis of a standard reference material, NIST SRM 1547 – 
Peach Leaves and NIST SRM 2711 - Montana II Soil, when 
satisfactory recoveries (90.06 - 115.35%) were obtained.
The objective of this study was to analyse the corre-
lations of seven metals and three main cannabinoids us-
ing multivariate methods of analysis. After preliminary 
tests (Ryan-Joiner and Grubbs tests) the concentration data 
were subjected to principal component analysis (PCA) 
in order to highlight any relations between the elements. 
Four principal components (PCs) appeared to account for 
89.42% of the variance of the data. These factors are re-
lated to the sources of the elements and cannabinoids in 
the studied samples. The first factor comprises Mn, THC 
and CBN with high loadings. A correlation like this indi-
cates that they arise from the same sources. Fe and Cr show 
significant positive loadings in the second factor and are 
negatively correlated with Zn and CBD with high nega-
tive loading. The third factor is dominantly loaded by Cu 
as an essential element; a constituent of co-enzymes im-
portant for a plant cycle. It is also correlated with Mg, with 
a high but negative loading. These correlations led to the 
consideration of the biosynthesis of cannabinoids and the 
involvement of metals as cofactors in the enzymatic cata-
lyzed synthesis cycles (De Meijer et al., 2002; Pate, 1994; 
Radosavljevic-Stevanovic et al., 2014; Sirikantaramas et 
al., 2005; Taura et al., 2007).
Conclusion
This work is conducted in order to determine whether 
the metals content in rhizosphere and cannabis can affect 
the levels of three important cannabinoids. The obtained 
results were subjected to chemometrics evaluation which 
gave an opportunity to get a better insight into role of met-
als in the biosynthesis of cannabinoids. Identified patterns 
could be helpful in tracking the origin of Cannabis plant 
and its product adding a value to the applied analytical and 
chemometrics methods in forensic sciences. 
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Background 
Falsification of active pharmaceutical ingredients 
(APIs) has been recognized as an important health issue 
since a series of health scares involving large numbers of 
casualties happened when altered APIs escaped detection 
in routine analytical testing (Dégardin et al., 2014). 
API falsification usually means discrepancy between 
the information for declared manufacturer and the actual 
manufacturer of the APIs used for manufacturing of fin-
ished dosage forms (FDF). Any form of tampering the con-
tent or information about the content might affect the qual-
ity of an API and therefore constitutes a direct threat to the 
health of patients. Since the reason for any falsification is 
fast and easy money, there is no general rule what APIs 
can be subjected to falsification. For any substance that can 
bring economic benefits to the manufacturer / distributor 
there is a potential risk to be falsified. 
The conventional analytical approach often fails to de-
tect falsification since the quality and quantity of the API 
is within the standards. Instead, methods that allow for dis-
tinguishing API samples and determining the source of 
APIs suspected for falsification are needed. Alternative ap-
proach must include broader analytical window using spe-
cific techniques to reveal some characteristic analytical in-
formation, such as impurity profile, spectral data, physico-
chemical constants, etc., thus creating an ‘API fingerprint’ 
database. APIs can be characterized, compared and clas-
sified based on features revealed from such ‘fingerprints’, 
using chemometric methods, like different pattern recog-
nition techniques (PRT) (Acevska et al., 2015; Petrusevs-
ki et al., 2015).
The aim of this research was to give an overview of 
analytical and chemometric methods used to differentiate 
the origin of the samples based on a ‘fingerprint’ database 
by the discriminatory matching of specific analytical fea-
tures of the specific API.
API fingerprinting 
API fingerprinting is the common name of a group 
of analytical applications for detection, identification and 
quantitative determination of related substances and oth-
er impurities. Impurity profiling (organic, inorganic im-
purities, residual solvents, enantiomeric purity), chemi-
cal characterization (polymorphism/solvatomorphism) and 
other contaminants (radioactivity) of the APIs requires ad-
vanced and robust fingerprint method. It usually comprise 
a set of several highly specific techniques, like: liquid and 
gas chromatography coupled with mass spectrometer (LC/
MS, GC/MS), differential scanning calorimetry (DSC), & 
differential termogravimetric analysis (TG/DTG), Furrier-
transformed infrared (FTIR), near infrared (NIR), Raman 
or nuclear magnetic resonance spectroscopy (NMR); in-
ductively coupled plasma combined with optical emission 
(ICP-OES) or mass spectrometry (ICP/MS), X-ray diffrac-
tion (XRD) etc. The characteristic and reproducible chemi-
cal features revealed during the API fingerprinting are used 
for discriminating between samples. This data highlights 
the API fingerprinting as core activity in modern drug anal-
ysis and tool for getting reliable results for combating API 
falsification. 
Pattern recognition of API fingerprints
Pattern recognition techniques that can be applied to 
API fingerprinting consist of two general areas; unsuper-
vised or supervised. From the characterization of the sam-
ples of known origin, predictive models can be built and 
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tested with new samples of unknown composition. By de-
termination of different origins of the APIs, their falsifica-
tion can be detected.
In unsupervised pattern recognition (hierarchical clus-
ter analysis (HCA), principal component analysis (PCA), 
generally viewed as exploratory data analysis methods, 
from which natural clusters in the data set can be identi-
fied, no knowledge concerning the origin of the samples is 
necessary. HCA gives no indication of the variables which 
contribute most to the classification of objects in the data 
set, unlike PCA, where the loadings indicate the variation 
contained within each variable. There may be a loss of in-
formation in the dendrogram generated by HCA, especial-
ly if clusters are not well resolved. However, HCA does 
present all the variation in the data set, in contrast to PCA 
where only a percentage of the variation is typically pre-
sented (Adams, 2004).
In supervised pattern recognition (classification and 
discriminant analysis (CDA), orthogonal partial least 
square regression (OPLS/O2PLS), soft independent mod-
eling of class analogy (SIMCA), etc.), the groupings of 
samples must be known to allow predictions to take place. 
These methods require prior knowledge of the sample ori-
gin to develop models, which are subsequently used to as-
sign unknown samples to a parent group. The OPLS-DA 
method is well suited for classification of data that have 
multi-collinear and noisy variables, which is common for 
many types of chemical data. Refined properties of the 
OPLS-DA methodology have illustrated how Y-orthogo-
nal variation can be useful not only for evaluation, but also 
for classification, thus rendering a PLS-DA/SIMCA hybrid 
discriminatory model (Bylesjo et al., 2006).
Validation of the classification method 
The outcome of the investigation on API falsification 
should be accurate and reliable. For sample authentica-
tion purposes, it is essential to ensure that their affiliation 
is properly defined (Gonzalez, 2007). In other words, de-
tection of false negatives (excluding sample that belongs 
to the class) and false positive (includes a sample that does 
not belong to the class) results must be enabled. Ultimate-
ly a method should be found for which there are no false 
negatives at the cost of several more false positives. For il-
lustration, obtaining a false positive result during the API 
fingerprinting, means further more detailed analytical test-
ing of the substance suspected to be falsified. But the risk 
of obtaining a false negative result must be completely re-
moved, as it is unacceptable to pass a falsified API to mar-
ket. 
Perspective 
There are several milestones (sampling, choice of an-
alytical and statistical methods, and dissemination of re-
sults) that need to be challenged. 
Sampling is mainly based on a goodwill of the manu-
facturers/MAHs; the regulatory frame need to be strength-
en for sampling can be possible on each step where tam-
pering of substance or information of its origin might oc-
cur (manufacturing site, distribution, brokers if any, FDF 
manufacturer, APIs used for preparations in pharmacies).
Number of samples is often insufficient for robust sta-
tistical evaluation of results; wider involvement of OMCLs 
and regulatory authorities (including customs and police) 
is expected for more efficient sampling process.
Manufacturer’s specification is not sufficient for API 
fingerprinting; an overall strategy against falsification in-
cluding wide analytical window in combination with PRT 
should be implemented by competent authorities. 
Dissemination of the results is sometimes burdened 
by intellectual or industrial property issues and therefore 
sometimes is only used by API manufacturer for protection 
from competition; in order for results to be used for better 
control of the APIs used for the medicines available on the 
market, proper agreement between industry and competent 
authorities should be in place. 
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Introduction
Orphan drug is a drug intended for treatment of rare 
(orphan) diseases. No single definition for an orphan 
disease exists worldwide, but it is generally a disease that 
affects a small portion of the population. Today, there are 
more than 6,000 to 7,000 known rare diseases, 80 percent 
of which have been identified as genetic in nature, with 
incidence of less than one in 2,000 people. Symptoms of 
some rare diseases may appear at birth or develop later in 
childhood or even during adult life. Other rare diseases 
are a result of infection (bacterial or viral), allergies or 
are caused by degenerative and proliferative conditions 
(Orphaned, 2012). Currently, the number of rare diseases 
for which there is no available treatment is estimated to 
be around 4,000 - 5,000 worldwide (Morin et al., 2013). 
The objective of this paper is to compare the regulation for 
orphan drugs defined by Food and Drug Agency (FDA) and 
European Medical Agency (EMA), in the United States and 
EU, respectively. These two regulatory agencies stimulate 
processes of a parallel application for orphan designation 
appropriate, when dealing with potential orphan drugs.
FDA regulations for orphan drugs
The first regulation for orphan drugs in USA was 
introduced in 1983. According to the FDA guidelines, 
orphan drug is a drug that is intended for treatment of 
disease or condition which affects less than 200,000 people 
in the USA or more than 200,000 in case when there is 
no reasonable expectation that the cost of developing and 
making available this drug in the USA will be recovered 
from it sales (Morin et al., 2013). Today, in USA there are 
three laws that apply to orphan drugs, as follows:
1. Orphan Drug Act (first regulation for orphan drugs) 
- legal act which aims to protect every orphan drug, 
produced and placed on the market in the USA by the 
pharmaceutical company, domestic or international. This 
regulation assumes that the drugs intended to treatment of 
rare diseases need patent protection, because basically this 
class of drugs is characterized by lower return of invested 
funds (Abramowicz, 2010).
2. Protection from generic competition - reference 
this legislation, when one drug is designated as “orphan” 
drug, FDA cannot give designation to a generic drug for 
the period of five to seven years. The main purpose of this 
legislation is to discourage the idea of development of non-
patented drugs. This legislation allows better protection 
from generic competitors than the Orphan Drug Act, 
and the same applies for drugs intended for treatment of 
diseases that affect more than 200,000 people but the costs 
of research and development will not be cover by their 
projected sales (Abramowicz, 2010).
3. Hatch-Waxman Act is regulation for stimulating 
the generic competition. Under this act, a generic drug 
company that challenges the pioneer drug with patent 
protecting receives 180 days exclusivity period, meaning 
that no other generic drug manufacturer can enter the 
market during that time. The main goal is to accelerate the 
generic competition. The authorized generic manufacturer 
can charge considerably above marginal cost, allowing it 
to earn a profit and providing it an incentive to challenge 
pioneer patents (Abramowicz, 2010).
According to the FDA regulation, orphan drugs 
have market exclusivity for period of five to seven years, 
shortened procedure of registration; the company owner 
of orphan designation receives a tax incentives, protocol 
assistance as well as exemption from payment of certain 
fees (Morin et al., 2013).
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EMA regulations for orphan drugs
The regulation for orphan drugs in EU legislation 
was first time adopted in 1999. According to EMA rules, 
orphan drug is designated drug which is intended for 
treatment of rare disease or condition which affects not 
more than 5 in 10,000 people in the EU. Most of these 
people suffer from diseases affecting less than 1 in 100,000 
people (EMA, 2015). At the European Union granting of 
orphan designation can be made only by the European 
Commission. The application is evaluated by the EMA’s 
Committee for Orphan Medicinal Products (COMP), 
which provides its opinion on whether or not the medicine 
qualifies as orphan medicines for the treatment, prevention 
or diagnosis of a rare disease. If the COMP issues a 
positive opinion, the European Commission may then 
grant the medicine orphan status (EMA, 2015). Rules for 
obtaining the orphan designation at EMA are defined by 
six regulations and two additional guidelines (EMA, Legal 
background).
 To qualify for orphan designation, a medicine must 
meet a number of criteria: it must be indicated for the 
treatment, prevention or diagnosis of a disease that is life-
threatening or chronically debilitating, the prevalence of 
the condition in the EU must not be more than 5 in 10,000 
or it must be unlikely that marketing of the medicine 
would generate sufficient returns to justify the investment 
needed for development or there is no satisfactory method 
of diagnosis, prevention or treatment of the condition 
concerned can be authorized or if such a method exists, 
the new medicine must be of significant benefit to those 
affected by the condition. Drugs that meet the EMA’s 
requirements for orphan designation received protocol 
assistance, access to centralized approval procedure for 
marketing authorization, a period of ten years market 
exclusivity in the EU with the possibility of additional 
two years market exclusivity for drugs that have valid and 
approved pediatric research plan (pediatric investigation 
plan). Additionally, all drugs with orphan designation by 
EMA received further compensate for micro, small and 
medium-sized companies, reduction of costs, grants and 
national compensate in the EU Member States (EMA, 
Activities after orphan designation).
Instead of conclusion
The comparative review of FDA / EMA regulations 
showed that FDA and EMA permit shortened registration 
procedure and both regulatory agencies allow exemption 
from payment of certain fees and provide protocol 
assistance. There are three main differences between 
FDA and EMA. The first difference is period of market 
exclusivity, noted that the period of market exclusivity in 
the USA could be from five to maximum seven years, apart 
from EU where market exclusivity for drugs with orphan 
designation is ten years, with additional two years for 
orphan drugs with valid and approved pediatric research 
plan. The second difference is in terms of tax incentives 
and exemptions, which are currently permitted in general 
in the all the USA countries by the FDA, as opposed to 
the EU, where EMA gives general tax incentives and 
exemptions, but each EU Member State has the possibility 
to provide additional national exemptions and incentives 
for some orphan drugs. And the third difference exists in 
terms of grants. In the USA they’re getting from the part 
of the FDA Orphan products grants program. Unlike the 
FDA, EMA does not offer any additional grants from 
its budget for research and development of new orphan 
drugs. However EMA makes funds available through 
the European Commission such as Horizon 2020, The 
EU Framework Programme for Research and Innovation 
E-Rare, a transnational project for research programmes 
on rare diseases International Rare Diseases Consortium 
(IRDIRC).
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Introduction
Development and validation of effective cleaning pro-
cedures are of а great importance to Quality Assurance Sys-
tem and these activities are described in the current GMP 
and FDA regulations.
In many cases, the same equipment may be used for 
manufacturing of different products. It is therefore essential 
to develop adequate cleaning procedures, in order to avoid 
cross contamination. Pharmaceutical products and active 
pharmaceutical ingredients (APIs) can be contaminated by 
other pharmaceutical products, by cleaning agents, micro-
organisms or by other material (i.e. airborne particles, dust, 
raw materials, products of degradation (EudraLex, 2014).
The cleaning validation is a very complex task, and the 
implementation requires a carefully elaborated plan. The 
Cleaning Validation Master Plan is a basic document ac-
cording to which the validation is performed. It presents 
an overview of the scope of the project, establishes essen-
tial requirements, such as acceptance criteria, sampling pro-
cedures, methods of analysis and is used as a planning and 
monitoring instrument (EudraLex, 2015). 
Establishing a cleaning validation program
Written cleaning procedures must be established for all 
equipment parts and surface which come into contact with 
the medicinal product. Responsible stuff has to be trained 
on the cleaning procedures. The critical parameters of the 
cleaning procedures can be determined by the risk-analy-
sis. The risk-analysis should evaluate the influence of the 
product, equipment and process specific parameters on the 
cleaning objective (Hiob and Gomez, 2011).
Important phase during effective planning of clean-
ing validation study is selection of the worst-case prod-
uct, manufactured in each equipment line. To assure effec-
tiveness under worst-case conditions, the worst case must 
be defined in more exact terms. The first thing to be deter-
mined is whether all the products made using the equip-
ment, can be cleaned according the same procedure, or sev-
eral cleaning procedures are required due to different prod-
uct properties. Within each group of products, for which 
an individual cleaning procedure is required, the product 
which is the most difficult to clean represents the worst 
case. If the cleaning procedure is designed in such a way 
that this product can be cleaned in a reliable manner, the ef-
fectiveness of the cleaning procedure is assured for all other 
products which are easier to clean and are in the same group 
as well (Haider and Asif,  2010a).
In the selection of worst-case product, the solubility of 
the ingredients, the tendency of the product towards crust 
formation and where relevant, residues left by colored in-
gredients should be reviewed as being critical factors to the 
success of the cleaning. The pharmacological characteris-
tics and toxicity data of drugs have a significant impact on 
the selection of worst-case product also. 
During the optimization phase the following informa-
tion must be defined: maximum hold time for uncleaned 
equipment and clean hold time.
Analytical testing and reporting phase
Dirty hold time is defined as the time between the end 
of manufacturing process of the product batch and the be-
ginning of the cleaning process. Clean hold time is the time 
between the completion of cleaning of the equipment and 
the initiation of the subsequent manufacturing operation, if 
in the production area the conditions are appropriate.
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Acceptance criteria must be defined before the valida-
tion begins. A limit is an actual numerical value and is one 
of the requirements of the acceptance criteria of a clean-
ing validation protocol.  Compliance with limits can be as-
sured by direct (swab test) or indirect sampling (rinse test). 
Sampling (by swab) should be performed from the criti-
cal areas of the production equipment. These critical areas 
of the production equipment are usually difficult to access 
during cleaning and/or are very difficult to see during the 
final checks. These areas, as well as dirty and clean hold 
times, should be included in the cleaning Standard Opera-
tional Procedures (FDA, 2011).   
Maximum Allowable Carryover (MACO) - maximum 
quantity of acceptable transferred residue from the active 
substance of the previous product is calculated by thera-
peutic dose criteria or by permitted daily exposure criteria.
The quantitative determination of residues of the sub-
stances, cleaning agent and microbiological contamination 
that should be carried out after sampling, will require val-
idated analytical methods with sufficient specificity and 
sensitivity to be able to detect the results at or below the 
established acceptance limits.
Validation of analytical methods are carried out on the 
parameters: Limit of Detection (LOD), Limit of Quantifi-
cation (LOQ), Specificity, Selectivity, Recovery, Precision, 
Range and Linearity (Borchert and Gomez, 2011a).   
Validation of the cleaning procedure should be per-
formed analytically after the approval of visual inspection 
(absence of stains or any materiel residue). 
Selecting a method to detect cleaning agent be per-
formed analytically after the approval of visual inspec-
tion (absence of stains or any materiel residue).overyraphy 
(HPLC), ion selective electrodes, flame photometry, deriv-
ative Ultraviolet (UV) spectroscopy, Thin Layer Chroma-
tography, enzymatic detection, and titration. 
It can also involve non-specific methods that detect the 
presence of a blend of ingredients such as: TOC, pH, and 
conductivity. The regulators prefer specific methods, but 
will accept non-specific methods with adequate rationales 
for their use. For investigations of failures or action levels, 
a specific method is usually preferable.
For the swab sampling method it is necessary to deter-
mine: the percent recovered with the swab extraction pro-
cedure; the effectiveness of the swab at recovering residues 
from equipment parts surface and the interference of swab 
materials in the analysis.
For the rinse sampling method it is necessary to deter-
mine: the percent recovered with the rinse solution extrac-
tion procedure; the effectiveness of the rinse solution at re-
covering residues from equipment parts surfaces and the 
interference of the rinse solution in the cleaning procedure 
and analysis; a correction for recovery efficiency in calcu-
lations for acceptable residue levels.
The percentage of recovery is important because it will be 
applied when evaluating the final concentration of residuals.
All equipment that comes in contact directly with raw ma-
terial -intermediate as well as final product - must be included, 
because of its potential to act as a possible source for microbi-
ological contamination. The microbial testing is performed on 
the selected surface of the equipment in order to determine the 
number of colony forming units (CFUs) present. 
Analysts from Quality Control Department will per-
form the analysis on the swab and/or rinse samples. The 
results are reported in Quality Assurance Department and 
the Quality Assurance Manager will give final approval to 
the reviewed results by signing the final Report (Haider 
and Asif, 2010b). 
Validated cleaning process must be subject to change 
control. Further, revalidation is necessary in order to main-
tain the validated status where a differentiation must be made 
between change-related and periodic revalidation. An effi-
cient change control procedure must ensure that the effect of 
changes on the cleaning validation is identified and that any 
necessary follow-up action is initiated. Checks must be car-
ried-out to verify whether revalidation is necessary follow-
ing changes to the cleaning procedure, production equipment 
and products. A suitable time interval must be determined 
for the periodic revalidation. Implementation may be stream-
lined by linking this to the change control procedure and by 
reducing the scope of the validation based on a review of 
data and documents (Borchert and Gomez, 2011b).
Conclusion
Cleaning procedures should be suitable for their in-
tended purpose. This should be confirmed by the success-
ful execution of a cleaning validation study. The clean-
ing validation must ensure that the quality of the product 
produced using specified equipment is not influenced by 
cross-contamination from the previous product, cleaning 
agent’s residues or microorganisms.
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Introduction
Most people nowadays suffer from problems with the 
gastrointestinal tract and indigestion. Gastroguard chew-
able tablets are a pharmaceutical solid dosage form from 
the group of antacids, which contains 680 mg calcium car-
bonate and 80 mg magnesium carbonate. Its effect is to 
act locally and neutralize the gastric acid in the stomach, 
not depending on the systemic absorption. Therefore it al-
leviates the symptoms caused by indigestion and releases 
the feeling of bloating. The carbonate salts react with the 
gastric acid in the stomach developing water and miner-
al salts as products (http://www.alkaloid.com.mk/vademe-
cum-step-2.nspx?LekTipId=150). 
Every pharmaceutical product must be subjected to 
chemical and microbiological analysis before the batch 
release. Those analyses are under the jurisdiction of the 
Quality Control department. In addition to the microbio-
logical analysis a working method for determination of the 
microbiological purity in this pharmaceutical solid form, 
which would be used in the routine, must be validated. For 
pharmaceutical solid forms the parameters that should be 
tested are Total Aerobic Microbial Count (TAMC), Total 
Yeasts and Molds Count (TYMC) and absence of Esche-
richia coli (Ph.Eur., 2013; USP, 2014).
The aim of this work is to validate the analytical meth-
od which would be used in the routine work for determina-
tion of the microbiological purity of Gastoguard chewable 
tablets as part of the quality control of the product before 
releasing of the batch. The method should be simple for 
manipulation and in compliance with the current Europe-
an Pharmacopeia. The validation of the method was made 
by the microbiological team of the Quality Control depart-
ment of Alkaloid AD.
Materials and method
Materials
During validation of the method standard laborato-
ry equipment was used: Laminar flow Class II, Incubators 
Gallencamp on 20-25 ºC; 30-35 ºC and 42-44 ºC, Bunsen 
burner, Vortex, glass pipetes, glass tubes intended for mi-
crobiological use. In addition to validate the method 10g of 
Gastoguard chewable tablets were weighted using Sartori-
us analytical scale. Buffered sodium chloride peptone wa-
ter pH 7 was utilized as medium for dissolving of the sam-
ple and for making the dilutions of the culture suspensions. 
Ready to use nutrient media from BioMérieux were used. 
90 mm Petri dishes from Trypcase Soy agar, Sabouraud 
Dextrose agar and Mac Conkey agar and 100 mL Trypcase 
Soy broth and 100 mL Mac Conkey broth of the liquid me-
dia were used for manipulation.
The test microorganisms that were part of this val-
idation were the standard microorganisms recommend-
ed by the current European Pharmacopeia for the meth-
od suitability test. Those are: Escherichia coli ATCC 8739, 
Pseudomonas aeruginosa ATCC 9027, Bacillus spizizenii 
ATCC 6633, Staphylococcus aureus ATCC 6538, Candida 
albicans ATCC 10231 and Aspergillus brasiliensis ATCC 
16404 (Ph.Eur., 2013).
Method
 For determination of the antimicrobial activity and 
validation of the test method challenge test with the above 
mentioned microorganisms were used and the microbio-
logical method of choice was the surface-spread method 
and direct inoculation in the liquid media for the test of ab-
sence of Escherichia coli. The number of all microorgan-
isms applied in the challenge tests was less than 100 cfu/
mL. Each application was made in duplicate and the tem-
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perature and the time of incubation depended of the type 
of the medium. Trypcase Soy agar was incubated for five 
days at temperature from 30-35 ˚C, Sabouraud Dextrose 
agar was incubated for seven days at temperature from 20-
25 ˚C, Trypcase Soy broth was incubated for 24h at tem-
perature from 30-35 ˚C, Mac Conkey broth was incubat-
ed for 24h at temperature from 42-44 ˚C and Mac Conkey 
agar was incubated for 24h at temperature from 30-35 ˚C.
After the incubation time the relation between the 
number of the each microorganism dissolved in buffered 
sodium chloride pepton water pH 7 and the number of the 
of the same microorganism in the presence of the product 
was calculated. When verifying the suitability of the plate-
count method, a mean of any of the test organisms not dif-
fering by a factor greater than 2 must be obtained (Clontz, 
2009; Ph.Eur., 2013; USP, 2014).
Results and discussion
The results from the determination of the antimicrobial 
activity of Gastoguard chewable tablets showed that it does 
not show antimicrobial effect against the used microorgan-
isms. In addition to this the working dilution of the product 
would be 1:10 dilution. 
The individual challenge test revealed the following 
results:
The number of cfu of the challenge microorganism in 
the test with P. aeruginosa was 93 cfu/mL and the average 
number of the microorganism in the presence of the prod-
uct was 89 cfu/mL. The acceptability factor in this test is 
1.04.
The number of cfu of the challenge microorganism in 
the test with B. spizizenii was 52 cfu/mL and the average 
number of the microorganism in the presence of the prod-
uct was 50 cfu/mL. The acceptability factor in this test is 
1.04.
The number of cfu of the challenge microorganism in 
the test with E. coli was 61cfu/mL and the average number 
of the microorganism in the presence of the product was 50 
cfu/mL. The acceptability factor in this test is 1.22.
The number of cfu of the challenge microorganism in 
the test with S. aureus was 26 cfu/mL and the average num-
ber of the microorganism in the presence of the product 
was 20 cfu/mL. The acceptability factor in this test is 1.30.
The number of cfu of the challenge microorganism in 
the test with C. albicans was 31cfu/mL and the average 
number of the microorganism in the presence of the prod-
uct was 37 cfu/mL. The acceptability factor in this test is 
0.84.
The number of cfu of the challenge microorganism in 
the test with A. brasiliensis was 22cfu/mL and the average 
number of the microorganism in the presence of the prod-
uct was 24 cfu/mL. The acceptability factor in this test is 
0.92. The acceptability factors for all the used microorgan-
isms were in the compatibility framework and they never 
exceed the value 2.
In the test for absence of E. coli, there was good visible 
growth in Trypcase Soy broth after 24h and in Mac Conkey 
broth the growth was followed by a change of color of the 
medium. There was also presence of red non-mucous colo-
nies on Mac Conkey agar after 24h.
The growth promotion test of the used media showed 
that they are adequate for routine microbiological analysis.
Conclusion 
Gastoguard chewable tablets do not have antimicrobi-
al activity against the used test microorganisms.
The method suitability test of the product revealed that 
the routine microbiological analysis should be performed 
with surface-spread method from 1:10 dilution for TAMC 
and TYMC and the method of direct inoculation in the test 
for absence of E. coli. The acceptability factors were in the 
frame provided by the current European Pharmacopeia and 
never exceeded the value 2.
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Introduction
Caffeine, 1,3,7- trimethylxanthine, is odorless, bit-
ter taste substance which can be naturally found in cof-
fee, cocoa, tea leaves, and is intentionally added in food 
products. It is considered to be one of the most commonly 
consumed drugs with more than 80 percent of the world’s 
population consuming caffeine daily. The Europeans are 
found to be the world’s largest consumers of caffeine in-
take of approximately 4.6 kg/person/year (Norton et al., 
2014). The presence of the pharmaceutical residues in the 
environment has become the subject of growing concern 
in the past decade. Due to the continuous input that leads 
to the long-term adverse effects on the aquatic and terres-
trial organisms, the special attention is being paid to their 
concentration levels in the aquatic environment. Caffeine 
can be found in traces in surface water. The main paths for 
caffeine to enter wastewater stream are either in urine or 
when caffeine-containing products are discharged through 
household pipelines or sewers. Determination of caffeine 
in surface water is an important task for environmental re-
searches and analysis because it is found to be a good in-
dicator for human sewage because of its relatively high 
concentrations in surface water and its unambiguous an-
thropogenic origin. Other important usage of caffeine is as 
an analgesic adjuvant in drug formulations for the treat-
ment of headache and pain related to postpartum, postop-
erative, and dental surgery and it is therapeutically applied 
for the treatment of migraine in combination with other 
drugs such as aspirin, paracetamol and tramadol. Caffeine 
is claimed to enhance the efficacy of these drugs (Madhu-
sudhan, 2013). The goals of this study were to develop and 
validate high-performance liquid chromatography (HPLC) 
method for caffeine determination in food, beverages, sur-
face water and drugs which is simple and easy to perform. 
This method could have a widespread application in food, 
environmental and pharmaceutical sciences.
Materials and methods
Samples for caffeine determination in food and bever-
ages were purchased at the Serbian market, samples of sur-
face water were collected in amber bottles from seven rep-
resentative locations of the Danube River on the territory 
of Novi Sad, Serbia, and tablets of analgoantipyretics con-
taining caffeine were purchased from pharmacies in the vi-
cinity of Novi Sad, Serbia. Caffeine from all samples was 
separated by solid-phase extraction and analyzed by HPLC. 
The chromatography was using two-solvent isocratic elu-
tion. The HPLC-diode array detection (DAD) model Agi-
lent HP 1100 system equipped with an autosampler (Wald-
bronn, Germany) was used. The analytical column was the 
Zorbax Eclipse XDB-C8 column (4.6 mm x 150 mm, i.d., 5 
µm particle size). Mobile phase was water-THF (0.1% THF 
in water adjusted to pH 8 with 0.1 M NaOH) - acetonitrile 
(90:10) with a flow rate of 0.8 mL/min. The HPLC mobile 
phase was prepared fresh daily and filtered through a 0.45 
µm nylon filter. Run time was 10 min, column temperature 
25 °C and analytes were detected at 273 nm.
Results and discussion
The linearity between caffeine concentrations and the 
response was tested for concentration levels ranging from 
(0.010-100) mg/L. High value of coefficient of correlation 
r=1 showed an excellent correlation between concentra-
tions and peak areas. Calculated limit of detection (LOD-
3.3*σ/S) and quantification (LOQ-10*σ/S) were 0.007 
mg/L and 0.012 mg/L, respectively. According to the re-
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covery values of (98.33-100.22)% the method showed ac-
ceptable accuracy. Repeatability of the method was test-
ed by analyzing three different concentrations of caffeine 
standards in six repetitions. The relative standard devia-
tions (RSD) ranged from 0.028% to 0.063% for retention 
time and from 0.015% to 0.65% for peak area showing ex-
cellent repeatability. There were no interferences in the 
HPLC results by impurities or matrix in tested samples, 
which indicate that developed method, had very good se-
lectivity.
The results of caffeine content in food and beverag-
es showed that it ranged 5.6-158 mg/100 g in food sam-
ples, 24.71-30.81 mg/100 ml in commercial tea samples, 
1328-3594 mg/100 g in coffees and 9.69-30.79 mg/100 ml 
in energy drinks. Also, obtained values in this study were 
consistent with the available manufacturer data. Analyz-
ing surface water samples for caffeine, significant concen-
trations were found at the sampling sites near the waste-
water discharges. Mean caffeine concentrations for sum-
mer, fall, winter and spring periods were 24.78 ng/L, 26.83 
ng/L, 24.61 ng/L, and 86.29 ng/L, respectively. The high-
est mean caffeine concentration was detected in samples 
collected in the spring period which is in an agreement 
with the literature (Fernandez et al., 2010). The caffeine 
content in combined non-narcotic analgoantipiretics varied 
from (96.48-100.74)% of the declared value. The require-
ments of the British Pharmacopoeia include (95-105)% of 
active drug content. According to obtained data it can be 
concluded that all brands did meet this specification in the 
HPLC assay method.
Conclusion
In this work a unique and simple to perform HPLC 
method was established for caffeine content determina-
tion in food, beverages, surface water and analgoantipiret-
ics. Obtained data for accuracy, repeatability, selectivity 
and robustness confirmed that the proposed method could 
be used for routine control of caffeine content in differ-
ent mixtures. The results of food and beverages analysis 
showed that caffeine content was consistent with the avail-
able manufacturer data and obtained data for combined 
commercial formulations of non-narcotic analgoantipiret-
ics of all brands did meet specification of the British Phar-
macopoeia for active drug content. Testing the surface wa-
ter samples for caffeine showed that significant concentra-
tions were found at the sampling sites near the wastewater 
discharges. The potential risk for chronic effects may occur 
in resident organisms in the long-term period so an appro-
priate treatment of wastewater would be essential in pre-
vention of the potential pollution.
References
Fernandez, C., Gonzales-Doncel, M., Pro, J.,Carbonell, 
G.,Tarazona, J.V., 2010. Occurrence of pharmaceutically 
active compounds in surface waters of the Henares–Jarama–
Tajo River system and a potential risk characterization. Sci. 
Total Environ. 408, 543–551.
Madhusudhan, S.K., 2013. Novel analgesic combination 
of tramadol, paracetamol, caffeine and taurine in the 
management of moderate to moderately severe acute low 
back pain. J. Orthrop. 10, 144-148.
Norton, T.R. Lazev, A.B., Sullivan, M.J., 2011.The „Buzz“ on 
caffeine: patterns of caffeine use in a convenience sample of 
college students. J. Caffeine Res.1, 35-40.
Poster presentations
Macedonian pharmaceutical bulletin, 62 (suppl) 141 - 142 (2016)
ISSN 1409 - 8695
UDC: 615.356:577.161.3]:543.544.5.068.7
Short communication
Determination of α-tocopheryl acetate in sunscreen lotion and 
cream by using the solid phase extraction and HPLC method
Milica Kostić* and Slavica Sunarić
Department of Pharmacy, Faculty of Medicine, University of Niš, Bulevar Zorana Đinđića 81, Niš, Serbia
* milicakosticnipsa@gmail.com; 
slavica.sunaric@medfak.ni.ac.rs
Introduction
The α-tocopheryl acetate (TA) is the esterified form 
of vitamin E. Vitamin E is a fat-soluble vitamin that ex-
ists in eight different forms, among them, α-tocopherol is 
the most active form in humans. Vitamin E is very popular 
cosmetic ingredient. It acts as antioxidant to protect cells 
against free radicals and reduces oxidative stress. Ultravio-
let light and environmental pollutants are known initiators 
of free radicals and skin damage. Topical antioxidants have 
the potential to diminish the reactive oxygen species gen-
erated from the UVA radiation. For that reason, there is an 
increasing interest in the incorporation of vitamins and an-
tioxidants in skin care products (Lupo, 2001).
The stability of the vitamin E in the cosmetic formu-
lations and when applied to the skin is low. When exposed 
to UV light, it forms α-tocopheroxyl radicals that consume 
other antioxidants for recycling. For better stability, vita-
min E is commonly used as a biologically non-active ester-
ified form, such as tocopheryl acetate (Shapiro and Saliou, 
2001). Vitamin E esters act as a pro-drug since they are hy-
drolyzed to the active vitamin E (α-tocopherol) upon pen-
etration into skin. However, there is conflicting evidence 
as to what extent this conversion actually takes place in 
the skin and many studies have shown that these substi-
tutes have very low biological activity. While numerous 
topical skin care products claim to contain ‘‘vitamin E’’, 
these products may actually contain very different concen-
trations and forms including active vitamin E, its several 
esters and many other derivatives (Thiele and Ekanayake-
Mudiyanselage, 2007).
The solid and emulsified cosmetic products must be 
carefully prepared for any of instrumental techniques 
which would be employed in the tocopherol analysis. 
The aim of this study was to develop an effective solid-
phase extraction procedure for the HPLC determination of 
α-tocopheryl acetate, which could be important for assess-
ment the content of this synthetic form of vitamin E in sun-
screen lotions and creams. 
Materials and methods
Materials
Methanol, ethanol and acetonitrile used in this work 
were of HPLC grade (J.T.Baker). α-tocopheryl acetate 
(TA) of analytical grade was obtained from Fluka (Fluka-
Analytical BioChemika). Stock solution of 1.03 mg/mL 
was prepared by dissolving the appropriate amounts of the 
α-tocopheryl acetate in absolute ethanol. Two sets of cali-
bration standards were prepared by diluting aliquots of the 
stock solution.
Cosmetic products
Commercial sunscreen products were purchased from 
a local cosmetic shop. Formulations under study were Pro-
ducer 1-Sun Lotion SPF 30 and Producer 2-Sunscreen 
cream SPF 50. According to the product label, both formu-
lations contained vitamin E only in the form of tocopheryl 
acetate and TA content was not exactly declared.
Sample preparation
A 0.5 g of the formulation was measured in 20 ml plas-
tic volumetric container and 0.5 mL of 0.5% ascorbic acid 
was added. The emulsion was dissolved by vortex-mixing 
with 5 mL of ethanol. After centrifugation for 10 min, a 3 
mL of the supernatant was pipetted and applied to the SPE 
column.
SPE conditions
Solid phase extraction was performed on Chromabond 
C18ec cartridges (1ml/100mg, Macherey–Nagel, GmbH, 
Düren, Germany), which was previously selected among 
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five cartridges with different sorbent type. Cartridges were 
conditioned with 1mL of deionized water, followed by 
1mL of methanol and 1mL of acetonitrile. After the sam-
ple was aspirated through the cartridge, analyte elution was 
made by 2 x 1 mL of methanol.
HPLC conditions
The Agilent Technologies 1200 Series apparatus with 
DAD and FL detection was used for the analysis. Sepa-
ration was performed on the Restek Ultra IBD C18 col-
umn (150 mm x 3 mm, 3 μm). UV detector was set at 220 
nm and 295 nm. Based on our previous work, 100% ace-
tonitrile was selected as the optimal mobile phase (Sunarić 
et al., 2012). The column temperature was maintained at 
40°C and the flow rate was kept at 0.45 ml/min.
Results and discussion
Tocopheryl acetate in extracted samples of the sun-
screen formulations was identified by comparing the re-
tention time of the observed chromatographic peak with 
that of the standard. Recovery of the solid-phase extrac-
tion method was calculated by comparison of the TA peak 
area for extracted and non-extracted standard TA solution 
on five different cartridges. The obtained recovery value 
was higher than 85% for Chromabond C18ec, therefore 
this cartridge was selected for further analysis. Addition-
ally, the cartridge selection was confirmed by extraction 
of the real samples supernatants obtained in sample prepa-
ration procedure for the examined cosmetics. Even in this 
case, the highest chromatographic peak area of TA was ob-
tained on Chromabond C18ec cartridge.  
The calibration curves for two concentration ranges, 
0.2 μg/mL - 2.0 μg/mL and 0.1 mg/mL - 1.0 mg/mL with 
the correlation coefficients > 0.998 were constructed and 
applied for the determination of TA in the injected samples. 
Final tocopheryl acetate content found in the examined 
formulations was as follows: (200±15) mg/100g (0.2%) 
in Producer 1-Sun Lotion SPF 30 and (490±20) mg/100g 
(0.49%) in Producer 2-sunscreen cream SPF 50. These re-
sults are in agreement with those given by other authors, 
that TA content is from 0.1% to 1% (Shapiro and Saliou, 
2001; Thiele and Ekanayake-Mudiyanselage, 2007). As 
was expected, much higher content of TA was found in the 
formulation with a higher SPF level.
Conclusion
Cosmetic formulations contain a high number of in-
gredients and the analysis often requires extensive pre-
treatments. A SPE method followed by HPLC determina-
tion has been developed for the analysis of tocopheryl ace-
tate in cosmetics. For the present experimental conditions, 
it can be concluded that the proposed extraction method 
was appropriate for the determination of TA in sunscreen 
lotion and cream. The extraction procedure was efficient, 
showing good accuracy and precision. Proposed analytical 
procedure for TA determination can be useful tool to know 
the amount of this synthetic form of vitamin E in cosmet-
ic products. 
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Introduction
Non-sterile drugs must satisfy the appropriate microbi-
ological purity criteria which are included in monographs 
in pharmacopoeias. Pharmacopoeial studies are prepared 
specifically to ensure that the medicinal product is thera-
peutically effective and safe for the patient.
Caffetin Cold is a combined medicinal product, con-
taining several active ingredients: paracetamol (500 mg), 
pseudoephedrine hydrochloride (30 mg), dextrometho-
rphan hydrobromide (15 mg) and ascorbic acid (60 mg). 
Paracetamol is a pain reliever and reduces body tempera-
ture. Pseudoephedrine hydrochloride decreases nasal con-
gestion, allowing nasal and respiratory passages to open 
up. Dextromethorphan hydrobromide suppress cough due 
to minor throat and bronchial irritation. Ascorbic acid (Vi-
tamin C) fortifies the immune system (www.alkaloid.com.
mk/vademecum-step-2.nspx?LekTipId=64). 
The importance of determination of microbiological 
purity of Active Pharmaceutical Ingredients (APIs) in solid 
forms comes from the fact that the final product must com-
ply with the criteria for microbiological purity.
Objective: Validation of analytical method for deter-
mination of microbiological purity of paracetamol, pseu-
doephedrine hydrochloride, dextromethorphan hydrobro-
mide and ascorbic acid in the composition of Caffetin cold 
tablets. This method further should be used for routine de-
termination of microbiological purity of APIs in Caffetin 
cold tablets. The method should be simple for manipula-
tion and in compliance with the current edition of Europe-
an Pharmacopoeia (Ph.Eur., 2013).
Materials and methods
Materials
Standard laboratory equipment was used. Buffered so-
dium chloride peptone solution pH 7.0 was used as medi-
um for dissolving of the sample and for making the dilu-
tions of the culture suspensions.
Ready to use nutrient media from BioMérieux® (69280 
Marcy-l’Etoile-France) 90 mm Petri dishes of Trypcase 
Soy agar and Sabouraud Dextrose agar were used.
Standard test microorganisms recommended by the 
current Ph.Eur. for the method suitability test: Escherichia 
Coli ATCC 8739, Pseudomonas aeruginosa ATCC 9027, 
Bacillus spizizenii ATCC 6633, Staphylococcus aureus 
ATCC 6538, Candida albicans ATCC 10231 and Aspergil-
lus brasiliensis ATCC 16404 were used for challenge test.
Methods
Surface-spread method and determination of antimi-
crobial activity of APIs in Caffetin cold tablets was used. 
The number of all test microorganisms applied in the chal-
lenge tests was less than 100 cfu/ml. Each application was 
made in duplicate and the temperature and time of incu-
bation depended of the type of the medium. Trypcase Soy 
agar was incubated for five days at a temperature from 30-
35 ˚C, Sabouraud Dextrose agar was incubated for 7 days 
at a temperature from 20-25 ˚C. After the incubation time, 
the relation between the number of the each test microor-
ganism dissolved in buffered sodium chloride pepton solu-
tion pH 7.0, and the number of that test microorganism in 
the presence of the product was calculated. 
When verifying the suitability of the plate-count meth-
S2 PP 63
144
Maced. pharm. bull., 62 (suppl) 143 - 144 (2016)
Pharmaceutical analysis / Quality assurance / Regulatory affairs
Po
st
er
 p
re
se
nt
at
io
ns
od, a mean of any of the test organisms not differing by 
a factor greater than 2 must be obtained (Clontz, 2009; 
Ph.Eur. 2013; USP, 2014).
Results and discussion  
Microbiological purity was determined with direct 
application on the nutrient medium with surface-spread 
method. 
Results for paracetamol (1:10) showed that acceptabil-
ity factor is 0.93 when Escherichia coli was used, 1.35 for 
Pseudomonas aeruginosa, 0.97 for Staphylococcus aure-
uss and 1.05 for Bacillus spizizenii. For Candida albicans 
the acceptability factor ranges from 0.93 to 1.07 and for 
Aspergillus brasiliensis from 1.06 to 1.13.
Paracetamol does not have antimicrobial activity on 
the used test micro-organisms. Acceptability factor ranged 
within the compatibility framework and it never exceeded 
the value of 2.
Results for pseudoephedrine hydrochloride (1:10) 
showed that there is no increase of colonies of Escherich-
ia coli. Acceptability factor when Pseudomonas aerugino-
sa was used is 29.33, for Staphylococcus aureus is 1.61, 
for Bacillus spizizenii is 6.00, for Candida albicans is 2.15 
and for Aspergillus brasiliensis ranges from 1.30 to 2.93.
Pseudoephedrine hydrochloride has an antimicrobial 
activity on the used test micro-organisms. 
Inactivation of antimicrobial activity of pseudoephed-
rine hydrochloride was done using the dilution of 1:100 in 
buffered sodium chloride peptone solution pH 7.0. 
Results for pseudoephedrine hydrochloride (1:100) 
showed that acceptability factor when Escherichia coli 
was used  is 1.00, for Pseudomonas aeruginosa is 1.20, 
for Staphylococcus aureus is 1.06, for Bacillus spizizenii 
is 1.20, for Candida albicans ranges between 0.96 to 1.00 
and for Aspergillus brasiliensis ranges from 0.92 to 1.00.
Acceptability factor ranged within the compatibility 
framework and it never exceeded the value of 2.
Results for dextromethorphan hydrobromide (1:10) 
showed that there is no increase of colonies of the test mi-
cro-organisms. Dextromethorphan hydrobromide has an 
antimicrobial activity on the used test micro-organisms.
Inactivation of antimicrobial activity of dextrometho-
rphan hydrobromide was done using the dilution of 1:100 
in buffered sodium chloride peptone solution pH 7.0. 
Results for dextromethorphan hydrobromide (1:100) 
showed that acceptability factor when Escherichia coli 
was used  is 1.23, for Pseudomonas aeruginosa is 1.44, 
for Staphylococcus aureus is 1.06, for Bacillus spizizenii 
is 1.28, for Candida albicans ranges between 1.03 to 1.12 
and for Aspergillus brasiliensis ranges from 0.90 to 0.93.
Acceptability factor ranged within the compatibility 
framework and it never exceeded the value 2.
Results for ascorbic acid (1:10) showed that there is no 
increase of colonies of Pseudomonas aeruginosa, Staphy-
lococcus aureus and Bacillus spizizenii. Acceptability fac-
tor when Escherichia coli was used is 7.00, for Candida al-
bicans ranges from 1.18 to 1.38 and for Aspergillus brasil-
iensis ranges from 0.94 to 1.21.
Ascorbic acid has an antimicrobial activity on the used 
bacterial test micro-organisms. Inactivation of antimicro-
bial activity of ascorbic acid was done using the dilution 
1:100 in buffered sodium chloride peptone solution pH 7.0. 
Results for ascorbic acid (1:100) showed that accept-
ability factor when Escherichia coli was used is 1.23, 
Pseudomonas aeruginosa is 0.79, Staphylococcus aureus 
is 0.79, Bacillus spizizeniiis 0.80, Candida albicans ranges 
from 1.05 to 1.70 and for Aspergillus spizenii ranges from 
0.89 to 1.00.
Acceptability factor ranged within the compatibility 
framework and never exceeded the value of 2.
Conclusions
Paracetamol does not have antimicrobial activi-
ty against used test micro-organisms. Direct application 
method with the dilution of 1:10 is suitable for further rou-
tine testing.
Pseudoephedrine hydrochloride, dextromethorphan 
hydrobromide and ascorbic acid in the dilution of 1:10 
have an antimicrobial activity against used test micro-or-
ganisms. Inactivation of antimicrobial activity was done 
using the dilution of 1:100 in buffered sodium chloride 
peptone solution. Direct application method from the dilu-
tion 1:100 was suitable for further routine testing.
Validation of analytical method showed that routine 
microbiological analysis could be done with the surface-
spread method. 
All results showed that the acceptability factor ranged 
within the compatibility framework and it never exceeded 
the value of 2.
The test micro-organisms and culture media were in 
compliance with current pharmacopoeial requirements.
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Introduction
The development of reliable LC-MS/MS bioanalyti-
cal method is a challenging process due to the large num-
ber of variables and pitfalls that can compromise the qual-
ity of the data. The reliability of the method is remarkably 
dependent upon the timely recognition of all factors that 
may generate erroneus resuts once the validated method 
is applied in practice. Therefore the scientific approach in 
course of LC-MS/MS bioanalytical method development 
should involve risk analysis. The risk analysis denotes as-
sessment of all critical steps (factors) that may affect the 
accuracy and ruggedness of the method. Matrix effect, me-
tabolite interference, stability of the analyte and the selec-
tion of an adequate regression model are identified as most 
common sources of method imprecision (Mulvana, 2010). 
Assessment of critical steps in bioanalytical 
method development
Matrix effect (ME) is directly related to the sample 
clean-up procedure, thus selecting the optimal extraction 
procedure plays a crucial role for ensuring data quality in 
LC-MS/MS bioanalysis (Chambers et al., 2007). Different 
types of extraction procedures, depending on the analyte, 
exhibit different extraction recoveries and ME. Therefore 
testing out various extraction procedures should become 
inevitable part of the contemporary bioanalytical meth-
od development. The implementation of Quality by de-
sign, as a new trend, enables shortening the time needed 
for the optimization of the sample preparation procedure. 
Until recently, the optimal extraction procedure was cho-
sen only upon the extraction recovery. However, consider-
ing the LC-MS/MS analysis, the cleanliness of the extract, 
expressed through ME, obtained with different extraction 
procedures gains paramount importance. The EMA vali-
dation guideline (ЕМА, 2011) recommends evaluation of 
the variability of the internal standard (IS)-normalized ME. 
However, it is more rational to assesses the degree of the 
absolute ME itself and not just the variability of the IS-nor-
malized ME. This derives from the fact that the IS-normal-
ized ME indicates that ME is consistent and not affected by 
the different lots of biological material. On the other hand, 
the absolute ME points out to the cleanliness of the ex-
tracts (Nakov et al., 2015). Hence, it becomes evident that 
the selection of the sample preparation procedure should 
be based on the absolute ME and the extraction recovery 
should be put in second place, especially when problems 
related to the sensitivity of the method are not expected. 
The quantitative acceptance criteria applied in bioan-
alytical validation guidelines (EMA, 2011; FDA, 2001) 
rely on data generated using quality control (QC) samples. 
However the QC samples do not contain phase I and II me-
tabolites of the analyte of interest and therefore may be un-
reliable model for real study samples. These metabolites 
are usually not stable and they can convert back to their 
parent drug in the mass spectrometer (in source back-con-
version) and/or during sample preparation (in vitro back-
conversion), jeopardizing the accuracy of the bioanalyti-
cal method (Wenkui et al., 2011). Therefore the assessment 
of the possibility of metabolite back-conversion prior the 
method validation becomes a crucial part of risk analysis. 
The first step includes assessment of the in source back-
conversion through the verification of the chromatographic 
separation between the analyte and its metabolite. This is 
especially important for high throughput LC-MS/MS anal-
ysis, where chromatographic separation between the ana-
lyte and the metabolite can be compromised, resulting in 
overestimated measurements. In case of this type of inter-
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ference, optimization/modification of the ion source pa-
rameters and/or the chromatographic conditions should be 
applied. The metabolite back-conversion could also occur 
during the different steps of the sample preparation pro-
cess, so second step involves investigation whether the 
proposed extraction procedure leads to metabolite back-
conversion. For that purpose the optimized extraction pro-
cedure should be applied on samples containing only the 
metabolite standard and the amount of analyte generated 
by metabolite back-conversion is then computed. In case 
of unavailability of metabolite standards, stability exper-
iments under different storage conditions using real sam-
ples could be applied as well (Jemal et al., 2010). 
The investigation of the sample stability in course of 
method development helps to avoid stability related prob-
lems that may latter appear during the validation and appli-
cation of the method. Although various sources may affect 
the sample stability, the focus within this paper is placed on 
chiral interconversion. All chiral compounds may undergo 
in vitro R/S conversion occurring at physiological pH and 
temperature or under extreme pH and elevated temperature 
(Briscoe and Hage, 2009). Therefore the assessment of the 
possibility of R/S interconversion during the overall ana-
lytical procedure should be an integral part for every enan-
tioselective method development, thus allowing quantifi-
cation of the extent of in vivo interconversion without bias.
The selection of an adequate regression model is the 
basis for accurate and reproducible quantification over the 
whole concentration range (Rozet et al., 2011). Most bio-
analytical methods usually have wide concentration range, 
so heteroscedasticity of the data may be expected. In the 
above instance weighted linear or quadratic regression 
models should be applied. The recommendation of the reg-
ulatory agencies (EMA, 2011; FDA 2001) is that the sim-
plest model that adequately describes data should be used 
and the selection of more complex model should be jus-
tified. Therefore the use of statistical approach based on 
non-parametric statistical tests (Nakov et al., 2014; Singto-
roj et al., 2006) during the selection of the regression mod-
el will provide justification of the choice of the adequate 
regression model, and will enable accurate quantification 
in whole calibration range.
Summary
The implementation of risk analysis during the LC-
MS/MS bioanalytical method development is longer last-
ing process compared to conventional method develop-
ment. However the timely perceiving and assessment of 
the critical steps generates highly reliable bioanalytical 
methods and lowers the possibility of late discovery of un-
expected problems than often lead to method re-optimiza-
tion and revalidation.
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Introduction
Forced degradation studies provide data to support 
identification of possible degradants; degradation path-
ways and intrinsic stability of the drug molecule and vali-
dation of stability indicating analytical procedures (Singh 
and Bakshi, 2002). Although most of the literature de-
fines the concept of forced degradation, they do not pro-
vide detailed information about a forced degradation strat-
egy (Klick et al., 2005) and the experimental conditions to 
conduct forced degradation are described in a general way 
(Singh and Bakshi, 2000) without description of the exact 
stress conditions to be applied. 
Generally, a trial and error approach is adopted to 
select the strength, temperature and time of exposure to 
achieve loss of active substance from 10–30% (ICH, 2003; 
Singh and Bakshi, 2000). Such approach involves consid-
erable cost, time consumption and scientific expertise and 
there is high incidence of random results. Therefore a need 
for more systematic approach is recognized (Dolan, 2002).
A contemporary approach in the field of forced degra-
dation is to evaluate correlation of degradation parameters 
by applying the concept of design of experiment (DoE). In 
turn, this can help studying the combination of conditions 
where optimal enrichment of degradation products is ob-
tained.  
The basic concept of factorial design is performing an 
experiment in which all the possible combinations of fac-
tors and levels are investigated (Lundstedt et al., 1988).
Literature review reveals the implementation of DoE 
and factorial design concepts for optimization of forced 
degradation conditions (Kurmi et al., 2014; Singh et al., 
2013; Sonawane and Gide., 2011), but no report exists on 
application of DoE for simvastatin (SIM) as model drug.
The aim of this study was to develop stability-indicat-
ing LC-MS method for quantification of SIM and its im-
purities, and also, an attempt was made to simplify forced 
degradation studies by adopting DoE concept.
Materials and methods
Simvastatin (SIM) samples with Certificate of Suit-
ability to the monographs of the European Pharmacopoia 
(CEP) were used. Simvastatin CRS and Simvastatin for 
peak identification were provided by the EDQM (Stras-
bourg, France). All reagents used were of analytical grade.
Experiments were made on Dionex UltiMate™ 3000 
(Thermo Scientific), interfaced with mass spectrometer 
with an electrosparay-ionization source, operated in neg-
ative mode. Mass parameters were optimized as follows: 
Ion source heater temperature was set at 350 °C; capillary 
temperature at 300 °C; capillary voltage was 10 V with 
collision energy 35 eV. The separation was performed on 
Poroshell 120 EC C18 (Agilent Technologies, USA), 50 x 
3.0 mm, 2.7 μm, using buffer (10 mM ammonium format, 
pH 4.0) and acetonitrile as a mobile phase in a gradient 
mode. The column temperature was 40 °C. Flow rate was 
0.5 mL/min. Injection volume was 5 μL. UV detection was 
performed at 238 nm. 
SIM was subjected to stress under acidic, alkaline, ox-
idative, thermal and photolytic conditions. Variables, cho-
sen from previously conducted initial experiments were: 
time of exposure, temperature and stressor strength. The 
forced degradation experiments set-up on the basis of 2n 
full factorial design were performed and the obtained re-
sults from LC-MS samples were analyzed by Design Ex-
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pert Software (Stat-Ease Inc., Minneapolis, MN, USA). 
Acid and alkali degradation was performed using 23 
factorial design (three variables considered at two levels: 
0.01M and 0.1M HCl/ NaOH heated at 25 °C and 60 °C 
for 60 and 120 min) was conducted to set up eight experi-
ments for each stressor. 
For oxidative degradation two variables were consid-
ered at two levels (the high level for H2O2 and time was 
30% and 24 h, and the low level was 3% and 2 h, respec-
tively), a 22 factorial design was conducted to set up four 
experiments. 
22 factorial designs was conducted to set up thermal 
degradation where the high level values were 105°C and 5 
h and the low level were 80 °C and 3 h, respectively. 
Photo degradation study was performed by exposing 
the drug powder, spread as a thin film in a covered petri 
plates and exposed to direct sunlight for 3, 5 and 12 h. Ad-
ditionally, control study in dark was run simultaneously. 
All stress studies were performed at an initial drug con-
centration of 1 mg/mL in amber color glassware in order to 
protect the solutions from light degradation.
Results and discussion
Under the proposed chromatographic conditions, sat-
isfactory separation (Rs >1.5) of SIM and all seven impu-
rities stated in the European pharmacopeia was achieved 
proving the stability-indicating power of the method. Ac-
cording to the results obtained from the degradation study 
SIM is susceptible to degradation under acid, alkali, oxi-
dative and photolytic conditions. The applied factorial de-
sign, determine significant factors responsible for degra-
dation and provides prediction of the optimal conditions.
The relationship between each factor and their interac-
tion were evaluated by creating Pareto chart. These analy-
sis indicated that under acidic condition, strength of HCl 
and temperature were most significant factors and for alka-
line condition, temperature and time of exposure. Further-
more, desirability plots were generated for acid and alka-
li conditions, providing prediction of conditions for opti-
mum degradation. 
It was suggested that for acidic stress, 10% degrada-
tion would be achieved by treating with 0.1 M HCl at 25 
°C for 60 min. When these conditions were adopted in 
practice, the resulting degradation was 10.78%. 
Also, for alkaline degradation 10% degradation would 
be achieved by using 0.1M NaOH heated for 10 min. at 
25 °C. The actual degradation, when these conditions were 
adopted in practice was 11.12%.
For oxidative degradation, it has been observed that 
18.75% degradation can be achieved with 30% H2O2 at 25 °C 
for 60 min. For photolytic conditions about 3.9% degradation 
has been obtained after exposure of UV light for 12h.
The desirability plots obtained from thermal degra-
dation study demonstrated that an increase in temperature 
from 80 °C to 105 °C favored the degradation significantly. 
The targeted drug degradation was obtained heating the so-
lution at 80 °C for 5 h.
Thus, factorial design approach was successfully used 
to achieve optimum degradation conditions for SIM and 
simple, specific, stability-indicating LC/MS method was 
developed.
Conclusion
This study highlights significant utility of DoE in op-
timization of forced degradation conditions. Using 2n full 
factorial design degradation conditions were optimized to 
obtain the targeted level of degradation. The use of DoE to 
identify theoretical values of variables for optimum deg-
radation was successful, because when these parameters 
were put in practice, the % degradation obtained matched 
the predicted degradation. This suggests that factorial de-
sign approach can replace the trial and error approach used 
to achieve optimum degradation in forced degradation 
studies.
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Introduction
Organic solvents are widely used in the manufacturing 
process of pharmaceutical products. Their application in 
the synthesis of active pharmaceutical ingredients (APIs) is 
of exceptional importance as the use of appropriate solvents 
may enhance the yield or determine characteristics such as 
crystal form, purity and solubility (Grodowska and Parcze-
wski, 2010). The European Pharmacopoeia (Ph.Eur., 2015) 
limits the amount of residual solvents (RS) in pharmaceuti-
cals, considering the ICH guideline for RS (Q3C). Beyond 
the influence on safety and quality of the active pharmaceu-
tical ingredients, the residual solvent profile indicates their 
manufacturing history. This core parameter for API finger-
printing allows for authentication and identification of the 
API origin (Poceva-Panovska et al., 2016).  
Methodology
The main technique employed in RS analysis is gas 
chromatography (GC) because of its suitability for anal-
ysis of volatile samples and substantial separating capa-
bility of capillary columns. European Pharmacopoeia (Ph.
Eur.) in the general chapter recommend GC coupled with 
headspace (HS) sampling system for qualitative and quan-
titative determinations of residual solvent. This technique 
is robust, convenient and readily automated and it is the 
method that is generally used for the control of residual 
solvents. As reported in 80% of the literature citations for 
GC procedures on RS testing, flame ionization detector 
(FID) is most commonly used for the detection of resolved 
compounds because of its low detection limits, wide lin-
ear dynamic range, robustness, ease of operation, and gen-
eral reliability and utility, especially for trace organic com-
pounds (Camarasu et al., 2006). 
However profiling of the RSs in practice using the GC-
FID method, usually require additional identification tool 
because of the co-elution and possible misinterpretation of 
the RS peaks. In order to confirm identifications and solve 
co-elutions Ph. Eur. proposes conformation analysis to be 
performed on a second chromatographic column coated 
with different stationary phase.
Another more convenient approach to solve possi-
ble misinterpretation of the RS peaks is the use of GC-
FID/MS, since the mass spectrometer adds an additional 
spectrometric dimension to the identification. Mass spec-
trometry also excels for determination of co-eluting peaks 
through use of extracted ion or SIM ion chromatograms, 
thereby eliminating the need of additional analysis on dif-
ferent columns (Poceva-Panovska et al., 2016).  
Sample preparation
Although pharmacopoeias propose their methods for 
control of residual solvents, practically and through the lit-
erature they are found to be disadvantageous due to their 
long equilibration and analysis time, relatively complex 
sample preparation and quantification problems. In order 
to solve these issues, different aspects of method develop-
ment and sample preparation have to be considered. Opti-
mized sample preparation conditions, including HS condi-
tions and dilution media, are crucial for the reliability of 
the residual profiling results.
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Internal standard
The proposed Ph. Eur. methodology for RS analysis 
does not utilize internal standard (IS) for quantification. 
The use of IS in RS analysis can be beneficial since it ac-
counts for routine variation in the response of the GC sys-
tem and can considerably improve the precision of quanti-
tative analysis. When choosing IS for HS-GC analysis, be-
side the chromatographic and physico-chemical character-
istics, it is mandatory to consider the stability and reactiv-
ity of the compound candidate for the IS. Many of the or-
ganic compounds have functionalities that may be reactive 
at elevated temperatures and different pH values during 
the equilibration time. IS decomposition or formation of a 
new product can lead to misinterpretation of the results and 
poor quality of the analysis (Poceva-Panovska et al. 2016). 
Optimization of headspace parametars
Vial equilibration temperature and time are major HS 
parameters that can be used to improve the transfer of vol-
atile analytes from the sample into the HS of the vial. 
The equilibration temperature has a profound effect on 
the sensitivity of the method because temperature has a di-
rect impact on the equilibrium concentration of the RS in 
the HS of the sample vial. However, effect of the temper-
ature is specific for the RS tested. The increase of the tem-
perature enhances the headspace sensitivity for the polar 
compounds with high partition coefficients (K) only, while 
the non-polar compounds with low K were practically not 
affected, since temperature affects the fraction of the ana-
lyte (RS) in the condense fraction only. 
Sufficient time is also crucial in order to achieve con-
stant state of equilibrium. Equilibration times should be 
set to optimal as they can considerably shortened overall 
method analysis time.
According to our recent study (Poceva Panovska et al., 
2016) the increase of equilibration temperature and equil-
ibration time generally resulted in better sensitivity, al-
though the effect of equilibration time was not as profound 
as temperature. For equilibration times longer than 20 min, 
no significant increase in the chromatographic responses of 
RS was observed. This observation has considerably short-
ened the overall time for RS analysis when compared to the 
official Ph.Eur. method.
Dilution media
Another approach to increase the sensitivity in the RS 
analysis is by selecting suitable dilution media as it has di-
rect influence on partition coefficient. Organic solvents used 
as dilution media (DMSO, DMF etc.) offer higher partition 
coefficient values for most of the RSs when compared with 
water and consequently lower the concentration of the RS in 
the gaseous (HS) phase. According to the Ph.Eur., the choice 
of sample preparation technique is dependent on sample sol-
ubility in the dilution solvent. For water soluble substances 
water is used and for water insoluble substances an alterna-
tive sample preparation is considered, using DMF as solvent. 
The use of single sample preparation for water soluble 
and water insoluble substances is highly practical and bene-
ficial. A mixture that includes DMSO, as a solvent with ex-
ceptional properties for organic and inorganic chemicals and 
low toxicity (class III), and water that is crucial for better 
sensitivity, in a suitable ratio usually offers satisfactory re-
sults as dilution media. Additionally the sensitivity of the 
analysis can be increased with the decrease of the percentage 
of organic dilution media (DMSO). A mixture of DMSO/wa-
ter in ratio 1:4 (V/V) can be used as a dilution media regard-
less of the sample solubility (Poceva-Panovska et al. 2016).
Chemometric approach in optimization of 
analytical methods
Development and optimization of methods for RS pro-
filing require a well-designed strategy for efficient data pro-
cessing in an economical and timesaving manner. For exact 
determination of the relationship between the sample prep-
aration conditions and the chromatographic response of the 
analytes, design of experiments (DoE) can be effectively em-
ployed since it enables the maximum utilization of data from 
previously planned experiments. Furthermore, by conducting 
the optimization of the method in very rational manner us-
ing DoE, a great deal of excessive and unproductive labora-
tory research work can be avoided. Response surface meth-
odology (RSM) can be used to optimize experimental values 
for important experimental factors (Lundstedt et al., 1998).
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Introduction
Health care-associated infections or nosocomial infec-
tions can be defined as those occurring within 48 hours of 
hospital admission, 3 days of discharge or 30 days of an 
operation. Hospital-acquired infection is an infection that 
is contracted from the environment or staff of a healthcare 
facility. It can be spread in the hospital environment, nurs-
ing home environment, rehabilitation facility, clinic or oth-
er clinical settings. Infection is spread to the susceptible pa-
tient in the clinical setting by a number of means (Inwereg-
bu et al., 2005; WHO, 2007). Nosocomial infections are 
huge problem all over the world. They are a major problem 
in health care facilities, resulting in extended durations of 
care, substantial morbidity and mortality, and excess costs. 
Effective hand hygiene of the health care workers remains 
the single most important and economical means of con-
trolling the nosocomial infections. Every health care work-
er is responsible for maintaining high personal standards 
of hygiene and hand cleanliness (WHO, 2007). The etiol-
ogy of nosocomial infections, the frequency of contami-
nated hands with the different nosocomial pathogens, and 
the role of health care workers’ hands suggest that spe-
cial attention should be paid on selection of hand hygiene 
preparations as well on the compliance to the hand disin-
fection protocols. From the times of I. P. Semelweiss, we 
know that clean hands are the most important single fac-
tor that can decrease the extent of the health-care associ-
ated infections. Handwashing frequently is called the sin-
gle most important and the cheapest measure to reduce the 
risks of transmitting skin microorganisms from one per-
son to another or from one site to another on the same pa-
tient (Borges et al., 2012). Since alcohol-based hand sani-
tizers combine high immediate antimicrobial efficacy with 
ease of use (Christiaens et al., 2006) they are the main dis-
infectants in our hospital as they are in almost every hos-
pital worldwide. The pharmacists from the hospital phar-
macy in our hospital are obviously members in the tender 
commission for selections of the disinfectants and the in-
evitable link in the supplying of disinfectants as well, so a 
complaint from the intensive care ward nurse, for inappro-
priate selection of the disinfectants was directly addressed 
to us. Considering that we decided to conduct microbiolog-
ical tests of antimicrobial efficacy of the two rapid alcohol-
based hand disinfectants used by caregivers in the hospital.
Materials and methods
We selected “fingerpad method”-appropriate samples 
collected from the subject’s fingers, as a suitable model for 
testing the in vivo efficacy of hand-washing agents (Ansa-
ri et al., 1989), for our purpose-to test microbiological ef-
ficacy of two rapid alcohol-based hand disinfectants. The 
examination consisted of two parts on the randomly select-
ed health care workers including nurses, physicians and 
subsidiary hospital staff. In the first part of the examina-
tion these seven clinical wards were included: Maxilo-fa-
cial surgery, Ophthalmology with ophthalmo-surgery, Ot-
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to-Rhino-Laringology, Gynecology and Obstetrics, An-
aesthesia Reanimation and Intensive Care, General sur-
gery and Orthopedy. The selection of the clinical wards 
was planed according to grade of risk for developing nos-
ocomial infection. One of the selected wards was the one 
that the complaint for the inappropriate selection and sup-
ply of disinfectants came. The observers and facilitators of 
the test procedures were three pharmacists and one nurse. 
Each pharmacist had different task in the examination with 
intention of minimizing the bias. Total number of included 
respondents (health care givers) was 54; 34 in the first part 
and 20 in the second part of the examination. 54 (Biomer-
ieux) COUNT-TACT AGAR for aerobic mesophyllic bac-
teria and 54 (Biomerieux) VRBG AGAR for Gram nega-
tive/enterobacteria determination were used, for each part 
of the examination proportionally to the respondents. Eco-
sal® Forte an ethanol/2-propanol based disinfectant and 
Ecosal® Ultra a 1-propanol, 2-propanol+benzalconium 
chloride disinfectant were used. Incubation, cultivation 
and determination of the bacterial growth were done in the 
Centre for public health at the Department for sanitary mi-
crobiology (accredited according to ISO 17025).
Results and discussion
Fingerpad/touch method with not disinfected hands 
showed abundant bacterial growth on both type of agar. 
There was only one VRBG AGAR for Gram negative/en-
terobacteria determination, from the undisinfected hands, 
without any bacterial growth, that represented 2.940% of 
total VRBG AGAR in the first part of examination. There 
were 9 cases (of total 34) of aerobic mesophyllic bacteri-
al growth on disinfected hands. That number represented 
26.471% of which, 2 plates were for Ecosal® Forte and 
7 plates for Ecosal® Ultra. Those were from the hands of 
subsidiary hospital workers that were not very familiar 
with the hand disinfection protocol and from staff not 
applied sufficient volume of disinfectant or/and didn›t let 
sufficient time (30 sec.) for antimicrobial action. Both, 
facilitators and observers of the examination, noticed and 
reported various irregularities in the hand disinfection 
protocol during first part of examination (Alkaloid-AD 
Skopje, 2014). Trend of recontamination of the hands of 
the health care workers included in the study, with touch-
ing other objects or part/s of the face, after the hand dis-
infection was reported. Those irregularities were decisive 
for performing the second examination part-repetition of 
the test on the clinical departments where microbial growth 
appeared after disinfection of the hands, on the same work-
ers as in the first part, but after a lesson of appropriate edu-
cation. In the first part of examination there was no case of 
Gram negative/entherobacteria growth. In the second part 
of the examination, i.e. the repeated tests with both dis-
infectants, there was no case of any bacterial growth, nor 
aerobic mesophylic or entherobacteria neither on Ecosal® 
Forte nor on Ecosal® Ultra. The presence of aerobic me-
sophyllic bacterial growth, in the first part of the examina-
tion, after the disinfection of the hands appeared from the 
air or from the weaknesses stated above.
Conclusion
This examination highlighted the importance of effi-
cient disinfection of health care workers’ hands. Absence 
of any bacterial growth on the repeated controls implied of 
efficient antimicrobial activity of both disinfectant. Select-
ed rapid hand disinfectants were effective. Non-adherence 
to the hand hygiene protocol was reason for bacteriological 
contaminated smears occurrence. That confirmed that the 
hand hygiene on the medical staff is a quality indicator for 
nosocomial infections prevention. In the Commission for 
prevention of nosocomial infection in our hospital, a phar-
macist should be incorporated for education of the medi-
cal and subsidiary staff for the importance of hand disin-
fectants selection and of the adherence to the hand hygiene 
protocols. That will contribute for reducing of the nosoco-
mial infections and improvement of the patients’ care, out-
comes and safety.
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Background
Sterile drugs and medical devices must be tested with 
the bacterial endotoxin test (BET) and must be shown to 
contain less than Endotoxin Limit. BET testing is a catego-
ry IV test as listed in United States Pharmacopeia <1225> 
and requires specificity testing. Procedure should be veri-
fied to establish its suitability for use, such as their accura-
cy and absence of interference when used for a new prod-
uct or raw material. In common with many other Quality 
Control (QC) tests, validation is a key element in preparing 
for testing and product release. 
Bacterial endotoxin test 
The three essentials for BET include endotoxin lim-
its for pharmaceutical and medical devices, procedures for 
validation in laboratory, and procedures for conducting 
routine testing. Different pharmacopoeias, LAL manufac-
turer’s documentation, and US Food and Drug Adminis-
tration (FDA) document are available to the user when un-
dertaking validation. Finished preparation release checks 
are still required according to United States Pharmacopeia 
(USP) Chapter <797> (USP, 2006). The QC laboratory fa-
cilitates these release checks by utilizing its staff’s thor-
ough understanding of the regulatory requirements and em-
ploying analytical techniques that ensure preparation safe-
ty. Even with this knowledge, challenges arise in microbi-
ological testing of some preparations. The key challeng-
es are the development of new and more sensitive meth-
ods and the interpretations of some results (Troja, 2010). 
On june 22, 2011, FDA withdrew the LAL test Guide-
line, which was issued in 1987 (Cooper, 2011). Elements 
of Guideline continued to impact current methods because 
they can be found in other references relied on by the in-
dustry. Following European, Japanese, and US Pharma-
copeia harmonization, the tests methods are identical and 
these tests are described in the Bacterial Endotoxins Test 
chapter in the USP (Chapter <85>) and in the equivalent 
chapters in the European pharmacopeia (Chapter 2.6.14) 
and the Japanese Pharmacopoeia (General Tests, No. 4.01). 
Endotoxin testing presents many challenges, yet trouble-
shooting is generally more effective because of the infor-
mation generated from each test (USP, 2006). It is critical 
that the user know the concentration of active substance, 
excipients, final pH and maximum human dose per hour, 
and whether the preparation contains a suspending agent 
such as carboxymethyl cellulose. The analyst must deter-
mine the conditions under which the product does not in-
terfere with BET. The dilution of product is the best choice 
to overcome inhibition or enhancement. This information 
is helpful in performing calculations to find the maximum 
valid concentration, and in determining the endotoxin lim-
it when not published. The maximum human dose is es-
pecially important in establishing an endotoxin limit for 
combination medicines such as multivitamins. On the ba-
sis of this information, the laboratory can test the prepara-
tion and obtain the accurate endotoxin data. By incorporat-
ing the patient’s body weight (EU/kg) into a suitable equa-
tion, the allowable endotoxin limit (EL) can be calculated 
for the preparation class (e.g., intrathecal, subcutaneous-
ly, or radiopharmaceuticals). The potency of an endotox-
in to cause pyrogenic reaction is variable according to dif-
ferent factors, such as the nature of the toxin, the weight 
of the subject and the maximum human dose. Therefore, 
the endotoxin concentrations are expressed as Endotoxin 
Units (EU) for result comparisons. The endotoxin limit for 
pharmaceuticals products is calculated using the formula: 
K/M, where K is the threshold human pyrogenic dose of 
endotoxin per kilogram (kg) of body weight per hour, and 
M is the maximum recommended human dose/kg of body 
weight that would be administered in a single one-hour pe-
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riod. The creation of the general endotoxin limit of 5 EU/
kg/hour enabled the industry to develop dose-related lim-
its for individual and classes of parenteral drugs and de-
vices. However the EL for intrathecal administration was 
assigned arbitrarily and was not science-based (Munson, 
2010). Williams (2007) has recently shown endotoxin tol-
erance or allowable limit by type of parenteral products. 
FDA proposed to the USP Micro committee an endotox-
in limit of 2.0 EU/dose/eye for intraocular administration, 
consistent with ISO 11979-9:2006 Ophthalmic Implants, 
Intraocular Lenses. An endotoxin limit for topical ophthal-
mic administration was not proposed. FDA suggests to ap-
plicants that EU for topical eye drops is 0.5 EU/ml, but 
BET interference is high because of additives. A major-
ity of the substances tested for endotoxin interfere with 
the LAL test to some degree (the obvious exception being 
water samples). An understanding of the chemistry of the 
test sample and its possible effects upon endotoxin and/or 
LAL, can aid in overcoming interference problems (Daw-
son, 2005). It is often possible to overcome interference by 
diluting the sample at which the endotoxin limit concen-
tration is still detectable or choosing ultrafiltration meth-
od. The greatest dilution at which the endotoxin limit can 
be detected is the maximum valid dilution (MVD). Dilu-
tion is always the technique of choice and should be at-
tempted first. The LAL Guideline described ways to devel-
op test parameters by use of the MVD and Minimum Val-
id Concentration (MVC) to prepare samples for endotox-
in testing, independent of the method. MVD and MVC are 
calculated as below: MVD= EL/λ ; MVC= λ/EL, where λ 
is sensitivity of lysate. MVD is used for products with EL 
in EU/mL. MVC is used for products with EL in EU/mg or 
some other unit. Once calculations of EL, MVD, MVC are 
done, the analyst can start the interference/validation test-
ing. The user should prepare several sample dilutions be-
tween undiluted and the MDV or MVC. The other steps 
of product validation are Control Standard Curve, Positive 
Product Control (PPC) and Positive and Negative Sample 
and Water Controls. The critical components are a test ma-
terial (diluted to an extent that was validated) and a posi-
tive control, which must be recovered within a prescribed 
range. Recovery of the PPC allows the analyst to have con-
fidence in test results. Several researchers have found that 
even the selection of lysate reagent source can contribute 
to variability in test results. Therefore, if any change in re-
agent source is made, the test must be re-validated.
Conclusions
After the determination of EL, MVD, and MVC, the 
analyst should undertake validation to confirm perfor-
mance and to assure reproducibility. Product validation 
steps include reagent and sample preparation, selection of 
sample preparation, and calculation of endotoxin value in 
product. Final choice to set up efficient BET testing meth-
od is up to the budget, application (water, raw material, in-
process sample or final products), material and volume to 
be tested, endotoxin limit and degree of compliance. 
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Introduction
A number of chemical preparations in recent years 
are used as disinfectants and antiseptics. Disinfectants are 
chemicals that act as microbicides or microbiostatics of ob-
jects and the environment. They are present on the market 
as finished industrial products obtained in different concen-
trations and forms depending of its purpose. In the compo-
sition of disinfectants enter a wide variety of active chem-
ical agents (biocides). According to their chemical compo-
sition they represent alcohols, aldehydes, anilides, bigua-
nides, diamines, halogen release agents, silver compounds, 
peroxides, phenols, bis-phenols, halophenols, quaterna-
ry ammonium compounds, volatile compounds for ster-
ilization. Biocide is a general term describing a chemical 
agent, usually with a broad spectrum of activity that inac-
tivates microorganisms. The biocide activity is within the 
antimicrobial activity, but depending on the circumstanc-
es may have “static” activity directed to agents that inhib-
it growth (bacteriostatic, fungistatic and sporostatic), and 
also “cidal” activity directed to agents that completely de-
stroy all microorganisms present (bactericidal, sporocidal, 
fungicidal). The antiseptics are chemicals that are safely 
used for disinfection of skin and mucous membrane con-
tact (McDonnell and Russell, 1999).
Intra-hospital or nosocomial infections are caused by 
organisms acquired during hospitalization of the patients 
and clinically manifest from 48 to 72 hours after their ad-
ministration (Rutala et al., 2008).
Mechanical cleaning before applying the disinfectant 
is essential. The mechanism of action of disinfectants is 
summarized in a number of papers published and avail-
able to the entire scientific community. For example, al-
cohols show quick action, and broad spectrum antimicro-
bial activity through denaturation of proteins, but do not 
act sporocidal. Aldehydes bind with amino groups of pro-
teins, RNA and DNA. Oxidizing agents such as peroxides 
and halogen elements oxidize the protein thiol groups, and 
surface active agents act mainly on the cytoplasmic mem-
brane of the bacterial cell. Phenols generally destroy the 
cell membrane (Block, 2001).
It is well known that the type and quantity of used dis-
infectant and the disinfection procedures is directly related 
to the effects of their use (Ducel et al., 2002).
The aim of this study was to review of the use of an-
tiseptics and disinfectants in general hospital in Gevgelija 
in Republic of Macedonia over five years period, to make 
analysis of the amount of antiseptics and disinfectants con-
sumed annually on each department in hospitals, to ana-
lyze of the total amount of consumed antiseptics and dis-
infectants in selected hospitals for five years and to com-
pare the results to the data obtained from the microbiolog-
ical evaluations conducted periodically in each department 
in selected hospitals for five years.
Materials and methods
The data were collected from the general hospital in 
Gevgelija over five years, form 2010 till 2014. The data 
from the annual reports for disinfectants and antiseptics 
(Bactosal, Ecosal 10%, Ecosal ultra, Dezintal, Betadine 
10%, Betadine 7,5%, Hydrogen peroxide 30%, Formalde-
hyde 33%, Ethanol concentrate, Gigazyme, Deconex 36 
Intensiv, Gigasept forte AF, Gigasept FF, Gigasept PAA, 
Deconex 54 Sporocide, Microzid AF liquid, Arcana alca 
combi, Plivasept, Arcana san, Arcana anti fat) used on the 
selected departments (gynecology, surgery, transfusion, 
treatment of infections, internal medicine etc.) were col-
lected. The results of microbiological testing conducted by 
the public health center in Gevgelija over five years were 
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collected and used. Routine testing period for microbiolog-
ical controls in hospitals was 15 days.
Results and discussion
The obtained data are getting an overview of the disin-
fectants and antiseptics used in the departments each year. 
It can be concluded that the highest consumption is in the 
operating room. The reason for this is that there are used 
all cleaning tools for disinfection of surfaces and instru-
ments and antiseptics. Reduction of use of disinfectants 
and antiseptics in surgery room would cause much higher 
risk for intra-hospital infections. The highest amount (227 
l) in the operating room is wasted in 2012. The lowest con-
sumed amount of antiseptics and disinfectants was in men-
tal health center and center for addicts. 
To determine the relationship between the amount 
of used antiseptics and disinfectants with the emergence 
of intra-hospital infections, in addition the data obtained 
by the microbiological analysis in public health center in 
Gevgelija were processed. In 2012 a total of 27 inspections 
were conducted, 156 swabs and sediments were taken, 147 
were sterile and 9 conditionally pathogenic. 
The reason for the reduced number of isolated patho-
gens was increased amount of antiseptics and disinfectants 
used during 2012. From children’s department and neona-
tology, all taken swabs were sterile. From surgical opera-
tion room, 2 pathogen samples were detected. In the rest of 
the surgical department, 2 pathogenic bacteria are isolated: 
Staphylococcus epidermidis, and Staphylococcus albus, 
but they have been isolated from patient beds and hands 
which is normal findings. Comparing to 2011 when they 
were isolated 6 conditionally pathogenic samples at the gy-
necology department; in 2012 the number of conditional-
ly pathogenic samples was reduced to 2. At dialysis, a to-
tal number of swabs taken was 16 and 3 of them were con-
ditionally pathogenic.
It is detected that the number of conditionally patho-
genic bacteria is reduced starting from 2012. The reduction 
of the quantity of disinfectant used is also noted from 2012. 
By appointment of Ministry of health in 2012 each hospi-
tal had been established the intra-hospital infection times. 
The results indicate a significant reduction of contamina-
tion with conditionally pathogenic bacteria when disinfec-
tion is conducted according to the standardized procedures 
controlled by the intra-hospital infection times.
Conclusion
In general the disinfectants and antiseptics are used 
optimally and correctly according to the needs of the hos-
pital investigated. The amount of disinfectants and antisep-
tics consumed comparing with the microbiological data in-
dicates their rational utilization starting from 2012. Use of 
disinfectants according to the standardized procedures es-
tablished by the intra-hospital infection time allows current 
daily care for patients and staff in the hospital investigated. 
The processed data from public health center confirm the 
above and point out the precautions to be taken when con-
ditionally pathogenic bacteria have been detected. 
It is pointed out the role of intra-hospital infection 
times in the hospitals as well as the role of hospital phar-
macists. We would like to suggest the implementation of 
disinfection process validation as standardization measure 
as well as more often routine microbiological controls in 
the hospitals.
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Introduction
Caffeine, an organic nitrogenous base is a naturally oc-
curring methylxanthine alkaloid, which is being increas-
ingly used in cosmetics due to its high biological activi-
ty and ability to penetrate the skin barrier. As for a cosmet-
ic purpose, caffeine is used as an active compound in an-
ti-cellulite products. Cellulite deposition is one of the most 
common problems associated with a large population male 
and female person throughout the world. Caffeine prevents 
an excessive accumulation of fats and promotes the lipol-
ysis process. It inhibits phosphodiesterases, which leads to 
lipogenesis reduction. Caffeine also stimulates the drain-
ing lymph systems in fatty tissue by removing accumu-
lated fat and toxins, which can improve the microcircu-
lation of blood vessels (Herman and Herman, 2013). The 
commercially available topical anti-cellulite formulations 
usually contain 1-2% of caffeine, although some products 
may contain up to 3% of caffeine (Hexsel and Soirefmann, 
2011). 
There are number of papers about caffeine determina-
tion in different food products, but limited works which 
describe caffeine determination in cosmetics (Injac et al., 
2008; Marchei et al., 2013). Cosmetics are complex for-
mulations and for their analysis different and lengthy sam-
ple treatments are required. Sample preparation and clean-
up are crucial, especially for the HPLC analysis, where the 
sample solutions are directly injected to HPLC column. 
Also, anti-cellulite gels and creams contain a wide variety 
of synthetic and natural (plant-derived) substances which 
may interfere with the caffeine determination. Solid phase 
extraction (SPE) is useful for sample preparation and clean-
up in the analysis of pharmaceutical creams. It is more rap-
id and efficient than liquid/liquid extraction, yields quanti-
tative extractions that are easy to perform without using of 
high volumes of toxic organic solvents. 
In this study, a solid phase-extraction method followed 
by HPLC with ultraviolet-diode array detection to deter-
mine of caffeine content in anti-cellulite gels was devel-
oped. 
Materials and methods
Caffeine (1,3,7-trimethylxanthine) of analytical grade 
was obtained from Sigma-Aldrich (Germany). The sol-
vent used, methanol, was of HPLC grade (J.T.Baker). For 
the sample preparation ethanol (95-96%, Ph.Eur.V, Zorka-
Pharma, Serbia) was used. Stock solution of caffeine con-
centration of 1.0 mg/mL was prepared in deionized water. 
This solution was stored for up to one week at 4 °C.Working 
solutions were prepared by diluting and mixing the stock 
with deionized water.
Cellulite reduction cosmetics were obtained from a 
local perfumery. Two products were analyzed: Producer 
1-Aqua Destock and Anticelulit gel-Producer 2. Both prod-
ucts contain caffeine in significant amount, and many syn-
thetic substances and plant extracts also. The exact content 
of caffeine was not declared.   
Solid-phase extraction Chromabond®HR-X cartridg-
es (100 mg, 1 mL volume, Macherey-Nagel, Germany) 
were selected as optimal for the clean-up and extraction of 
caffeine from anti-cellulite gels. SPE cartridges were con-
ditioned with 3 mL of methanol and 3 mL of deionized wa-
ter. One milliliter of the prepared sample was loaded on the 
cartridge at the flow rate of 1 mL/min. Desorption of caf-
feine was achieved with 4 x 1 mL of methanol. 
HPLC analyses were performed on the Agilent Tech-
nologies 1200 Series apparatus with DAD and FL detec-
tion. Separation was carried out on the Restek Ultra IBD 
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C18 column (150 mm x 3 mm, 3 μm) at 30 °C. The mobile 
phase consisted of a methanol-water solution (40:60, 
isocratic) at a flow rate of 0.4 mL/min. A 2 μL of the final 
eluate was injected in the HPLC column. UV detection at 
274 nm was used as the optimal wavelength for caffeine 
determination.
Sample preparation
 A 0.5 g of the gel was accurately weighed and dis-
solved in 10 mL of 95-96% ethanol. NH4OH was added to 
obtain pH 7-8. Insoluble excipients were separated by cen-
trifugation for 10 min. Then, 1 mL of the supernatant was 
loaded on the cartridge and SPE procedure was performed. 
Results and discussion
Optimization of SPE procedure included cartridge se-
lection, solvent selection and recovery evaluation. To eval-
uate the accuracy of the extraction method, recovery stud-
ies were carried out. A known amount of caffeine standard 
solution, at three different concentration levels was ex-
tracted on different cartridges and recovery was calculated 
as the ratio of the loaded and eluted caffeine. The percent-
age extraction recovery was found to be 82-90% for the 
Chromabond®HR-X cartridge, while for the other types of 
cartridges this value was significantly lower. After the pro-
cedure of gel preparation, the obtained supernatants were 
also loaded on different SPE cartridges. The highest chro-
matographic peak purity, peak area and concentration lev-
els of caffeine were also obtained for Chromabond®HR-X 
cartridge. For that reason, this type of cartridge was select-
ed for the extraction and clean-up of the examined anti-cel-
lulite gels.
The caffeine content in the examined samples was 
determined by using the calibration curve in the range of 
0.01-0.2 mg/mL. The caffeine concentration found in Pro-
ducer 1-Aqua Destock was 1.70 g/100 g (1.70%), while 
the value for Anticelulit gel-Producer 2 was 0.69 g/100 g 
(0.69%). The found content of caffeine in investigated cel-
lulite reduction cosmetics were in agreement with those re-
ported by other authors (Injac et al., 2008; Marchei et al., 
2013). and with the expected values.
Conclusion
The most effective and marketed products for cellulite 
reduction contain caffeine as the active ingredient, but its 
exact content in these products is not strictly declared.  The 
extraction step is necessary for the analysis of caffeine in 
anti-cellulite gels by chromatographic methods. Because of 
the fact that caffeine is contained in the complex cosmetic 
matrix, its extraction is difficult and depends on the nature 
of the sample. A purification of the cosmetics and extrac-
tion of the analyte can be achieved by using SPE technique.
The present results show the applicability of the pro-
posed SPE procedure for the caffeine extraction from anti-
cellulite gels and its HPLC determination, which could be 
used for the routine analysis of these commercial products. 
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Introduction
Bacterial endotoxins are contaminants from gram-neg-
ative bacteria and are the most common cause of pyroge-
nicity in pharmaceutical products. Any preparation admin-
istered parenterally should be sterile and comply with the 
test for bacterial endotoxins (BET) as described in the Ph. 
Eur. (Ph. Eur., 2014). Finished products often contain in-
gredients in addition to the active drug substance. Excipi-
ents serve as a solvents, solubilizing, suspending, thicken-
ing, and chelating agents; antioxidants, antimicrobial pre-
servatives, buffers, pH adjusting agents, bulking agents, 
and special additives (British Pharmacopoeia, 2014; 
CHMP, 2013; ICH, 2009; Ph Eur., 2014).
Benzyl alcohol is an aromatic alcohol with the formu-
la C
7
H8O. In the body, benzyl alcohol is metabolised into 
benzoic acid. It is used as an excipient for its preserva-
tive properties or as a solubilising agent. Benzyl alcohol is 
also used as an active ingredient in local antiseptics and lo-
cal anesthetic products. It is also present in medical prod-
ucts administered intravenously (anti-cancer drugs, hepa-
rins, cardiovascular drugs) and as a preservative in many 
topical preparations, such as antifungal and anti-inflamma-
tory products (Ph.Eur., 2014). However benzyl alcohol is 
mainly used as an excipient in medicinal products that are 
administered intramuscularly, such as antibiotics, anti-in-
flammatory or neuroleptic medicines where its anesthetic 
properties reduce pain at the injection site. 
Objective: Validation and quantifications of Bacterial 
endotoxins with Turbidimetric kinetic method, for benzyl 
alcohol.  
Materials and methods
Benzyl alcohol (Merck Certified; Merck KGaA, Darm-
stadt, Germany); Reagents for Kinetic turbidrimetric meth-
od: PYROGENT™- 5000, LAL Reagent Water, and Py-
rosperse™ Dispersing Agent, one of a group of metallo-
modified polyanionic dispersants which has proven useful 
as a sample modifying agent for certain types of products 
showing inhibition in the BET assay from Lonza (Lonza 
Group Ltd, Walkersville, MD21793), along with  Micro-
plate reader ELx808 from BIO-TEK® (BIO-TEK Instru-
ments, INC.,P.O.BOX998, Hghlsand Park, Winooski, Ver-
mont 05404 USA). The results were calculated and stored 
with WinKQCL 4.0.2 software™ (Lonza Group Ltd, Walk-
ersvilleThe Kinetic turbidrimetric method is based on mea-
suring the turbidity (optical density) of an LAL/sample 
mixture at regular interval troughout the test. The time re-
quired before the appearance of turbidity (Reaction time) is 
inversely proportional to the amount of endotoxin present. 
In accordance with the Ph. Eur. Commission at its 
149th Session, June 2014: Substances to be used in par-
enteral preparations must comply with the BET, whatever 
their origin, since:
- contamination by bacterial endotoxins can take place 
prior to or during the manufacturing process;
- bacterial endotoxins cannot easily be removed by the 
manufacturing process;
- bacterial endotoxins should be detected as early as 
possible in the manufacturing process.
It is to be noted that the ICH Guideline Q6B: Specifi-
cations: Test Procedures and Acceptance Criteria for Bio-
technological/Biological Products provides the following 
recommendation under section Drug Substance Specifi-
cation: “Pharmacopoeial tests (e.g., endotoxin detection) 
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should be performed on the drug substance, where appro-
priate”.
Benzyl alcohol, as an excipient in parenteral prepa-
rations, has strongly inhibitory effect on Bacterial endo-
toxins test (Kinetic Turbidimetric method) when diluted 
with LAL reagent water (LRW). It is necessary to over-
come the inhibition and for that purpose 2% solution of Py-
rosperse™ Dispersing Agent from Lonza was used in com-
bination with laboratory techniques: shake 30min, vortex 
30sec. and centrifuge 3min. (3000rpm/min), (British Phar-
macopoeia, 2014; EMA, 2013; FDA, 2012; Ph.Eur., 2014; 
Thomas et al., 1984)
Results and discussion
Validation was performed by beginning with screen-
ing (Inhibition / Enhancement) test. For that purpose PY-
ROGENT™- 5000, Lonza’s reagents were used; lysate 
sensitivity  λ = 0,01 EU/mL; maximum valid dilution 
(MVD) = ELC/λ = 2.5 / 0.01 = 250. Most products in-
terfere with the performance of the BET. The easiest way 
to overcome interference is to dilute the product in LRW. 
Dilutions used for preliminary, Inhibition / Enhancement 
test were as follows: 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128 
and the MVD 1:250. All dilutions were made with LRW 
(FDA, 2012; Ph.Eur., 2014; McCullough, 2011; Williams, 
2009). Benzyl alcohol shows strong inhibition includ-
ing MVD. To overcome the inhibition new dilutions were 
made. For the first dilution 1:10, as a solvent 2% solution 
of Pyrosperse™ Dispersing Agent, from Lonza was used, 
shaked for 30 min, vortexend for 30 sec and centrifuged 
3 min (3000 rpm/min). Tested dilutions: 1:50, 1:100 and 
1:200 were made from the aqueous part of the first dilu-
tion. Aqueous part was used for analysis. There was an in-
hibition only at 1:50 dilution, PPC recovery: not applicable 
(N/A). The inhibition was overcomed at 1:100 and 1:200 
dilution which gave PPC recovery 73% and 115% respec-
tively (Lonza Group Ltd, Walkersville; Ph.Eur., 2014). 
Upon received results the validation further was done 
on three consecutive batches of benzyl alcohol with di-
lution 1:200 (considering that recovery must be close to 
100%). The endotoxin concentration reported for the three 
consecutive batches was less than 2.00 EU/ml with PPC 
115%, 149% and 151% respectively. All three batches of 
the tested benzyl alcohol showed endotoxin recovery be-
tween 50 and 200%.
Conclusion
Validation of the Bacterial endotoxins test on Benzyl 
alcohol was successfully done. The inhibition was over-
come. Further, routine testing of Benzyl alcohol should be 
done with dilution 1:200 using Pyrosperse™ Dispersing 
Agent from Lonza, shaking for 30 min, vortexing for 30 
sec and centrifuge 3 min (3000 rpm/min) in accordance 
with the method developed.
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Introduction
Disorders that involve anxiety are the most common 
mental disturbances. Many of the anti-anxiety medicines 
also cause some sedation, so the same medicine is of-
ten functioning clinically as both, anxiolytic and hypnot-
ic agent. Benzodiazepines are the most widely used anx-
iolytic medicines. They have largely replaced barbiturates 
in the treatment of anxiety, because the benzodiazepines 
are safer and more effective. Anxiety is an unpleasant state 
of tension, apprehension, a fear that seems to arise from 
a sometimes unknown source. The physical symptoms of 
severe anxiety are similar to those of fear (such as tachy-
cardia, sweating, trembling, and palpitations) and involve 
sympathetic activation. Episodes of mild anxiety are com-
mon life experiences and do not warrant treatment. How-
ever, the symptoms of severe, chronic, debilitating anxi-
ety may be treated with antianxiety medicines (sometimes 
called anxiolytic or minor tranquilizers) and/or some form 
of behavioral or psychotherapy.
Bromazepam is a benzodiazepine (BZD) generally 
used for a number of medical reasons, it is an intermidi-
ate-acting tranquiliser (Ashton, 2005), prescribed for the 
treatment of moderate to severe anxiety and panic attacks 
for the short-term treatment of insomnia. It has been wide-
ly used in psychiatry disorders for four decades, with selec-
tive anxiolytic, anticonvulsant, myorelaxant and hypnotic 
actions. It acts on the central neural system as an inhibitor 
of the neurotransmitter gamma aminobutyric acid (GABA) 
(Nascimento et al., 2012).
Bromazepam is an active substance that belongs to 
class of 1,4-benzodiazepine and chemically corresponds 
to 7-bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzodi-
azepine-2-one, C14H10BrN3O (Ph.Eur., 2010). It is a con-
trolled psychotropic substance-B1 class according to the 
National Agency of Sanitary Vigilance in Brazil (ANVI-
SA), with the DCB identification numbers: 01366, DCI: 
2692 and CAS: 1812-20-2. The solid dosage form (tablet) 
is the widespread used and prescribed in clinical practice. 
The solid dosage form presents problems associated to the 
bioavailability (FDA, 2003).  The absorption of active sub-
stance from the solid dosage form for oral application de-
pends on the solubility and dissolution in physiologic liq-
uids and its permeability through the gastrointestinal tract, 
factors that influence directly its bioavailability and sub-
sequent pharmacological effects. The biotransformation 
from solid into absorbable form depends on its dissolution 
in organic liquids; therefore, dissolution tests became an 
essential parameter to determine the properties of biophar-
maceutical formulations in order to predict their quality. 
The quality of pharmaceutical formulations is important in 
financial and ethical terms because it is directly associat-
ed with the patient’s health. Thus, there is a real need for 
the development of dissolution tests able to predict in vivo 
physiological conditions.
Materials and methods
Dissolution test is a standardized method for measur-
ing the rate of active substance release from a dosage form 
(FDA, 1997).  The test was performed on ERWEKA DT 
700, apparatus 2 (paddle), using 0.1 M HCl as a dissolu-
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tion medium, in volume of 500 ml, at 37°C, with 75 rpm 
for 45 minutes.
The quantity of the dissolved bromazepam was deter-
mined using analytical method based on High Performance 
Liquid Chromatography (HPLC). Validation of the method 
was performed on Shimadzu Nexera HPLC system.
To optimize chromatographic parameters several mo-
bile phase compositions were tested in this method. A sat-
isfactory separation, good peak symmetry and optimal re-
tention time was obtained using mobile phase consisting 
of a mixture of methanol, acetonitrile and potassium di-
hydrogen phosphate buffer (11.33 g/l of KH2PO4, pH 7.0 
adjusted with KOH, 0.5 M) in ratio of 45:5:50 (v/v/v), at 
flow rate of 1.0 ml/min. A LiChrospher RP Select B col-
umn (125 × 4.0 mm, 5μm) was used as stationary phase 
with temperature of column oven, 50 °C. The elution was 
monitored at 239 nm.
Results and discussion
A simple reverse phase HPLC method for in vitro dis-
solution test was developed and validated for the determi-
nation of bromazepam and its release from pharmaceutical 
dosage form. Several high-performance liquid chromato-
graphic (HPLC) methods have also been reported for the 
determination of bromazepam and other BZDs (Sruthi et 
al., 2013).  Chromatogram showed a peak of bromazepam 
(BZP) at retention time of 3.50 ± 0.1 min. The most suit-
able mobile phase was selected on the basis of time re-
quired for the analysis and the sensitivity of the method. 
The method was validated according to ICH Q2 guideline 
with respect to specificity, linearity (with correlation coef-
ficient of 0.999), accuracy, precision, robustness, solution 
stability and filter paper compatibility. All results of the 
validation parameters were within the limits of ICH guide-
lines (ICH, 2005). The benefits of the proposed method in-
clude simple preparation of the solutions for the analysis 
and usage of readily available solvents. 
Conclusion
The proposed method is simple, rapid, accurate, pre-
cise and specific without interference of excipients. The 
short chromatographic run time allows the analysis of a 
large number of samples in short period of time. There-
fore, it is suitable for the routine analysis of bromazepam 
in pharmaceutical dosage forms and it could be used for 
the rapid and reliable determination of dissolved bromaze-
pam in tablet formulations. The present study was focused 
on minimizing method limitations and developing a simple 
and economic method for determination of dissolved bro-
mazepam from tablet dosage form.
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Introduction
The goal of antiepileptic drugs (AED) therapy for peo-
ple with epilepsy is seizure freedom without side effects (Va-
jda, 2007). In the last decade, several new AEDs have been 
licensed around the world (Krasowski, 2010). Considering 
the variable nature of epilepsy, patient’s pathophysiologi-
cal features, co-medications, AED therapy must be careful-
ly optimized for each patient by the aid of therapeutic mon-
itoring (TDM), concerning both therapeutic and toxicolog-
ical profiles. In many cases TDM facilitates drug treatment 
by increasing clinical effectiveness and safety while mini-
mizing adverse effects, as well as reducing treatment costs. 
The availability of a simple, validated and inexpensive ana-
lytical method for reliable measurements of drug concentra-
tions in biological fluids is pivotal for its successful utiliza-
tion in pharmacokinetic and bioequivalence studies, and for 
therapeutic drug monitoring in different clinical situations. 
Various analytical methods have been reported for measure-
ment of AEDs in biological fluids, including immunoassays 
and chromatographic methods (gas chromatography and 
high-performance liquid chromatography). Immunoanaly-
sis techniques are specifically designed to analyze a single 
drug but the chromatographic methods can allow for the si-
multaneous separation and quantitation of many compounds 
in a single run which is important when is need the simulta-
neously monitoring the AEDs in polytherapy, which is giv-
en very common to patients (Aldaz et al., 2011)
The aim of this study was to develop a sensitive and 
fast bioanalytical method for simultaneous determine the 
plasma concentration of recent old and new AEDs used 
in the current clinic practice: lamotrigine (LTG), leveti-
racetame (LEV), carbamazepine (CBZ), the active metab-
olite carbamazepine -10,11-epoxide (CBZ-EP) and valpro-
ic acid (VPA). 
Materials and methods
Chemicals and reagents
LTG, LEV, CBZ, CBZ-EP, VPA and nitrazepam (in-
ternal standard,IS), were purchased from Sigma Aldrich, 
USA. Methanol and acetonitrile, HPLC grade, were pur-
chased from Merck, Germany. Potassium dihydrogen 
phosphate and phosphoric acid for buffer preparation were 
analytical grade and were also obtained from Merck, Ger-
many. For all analyses HPLC grade water purified with a 
TKA_LAB Reinstwasser system (Niederelbert, Germany) 
was used. OASIS HLB cartridges (30 mg/1 ml) used for 
sample preparation were supplied by Waters, USA.
Human plasma sampling
Plasma was collected from healthy volunteers (drug-
free plasma for the method validation) and from the epilep-
tic patients undergoing chronic AEDs therapy. Blood sam-
ples were collected in the morning, just before the first dai-
ly drug administration, into heparinized tubes and centri-
fuged at 3000 rpm for 15 min. The supernatant plasma was 
transferred into test tubes and frozen at -20 °C until analy-
sis. The Ethics Committee at the Faculty of Pharmacy and 
the Faculty of Medicine, Ss. Cyril and Methodius Univer-
sity - Skopje, approved the research protocol for this study 
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and all volunteers signed the Study Informed Consent form. 
Chromatographic conditions
The assay was performed on Shimadzu LC-30 Nexera, 
using Zorbax Eclipse XDB C-18 (150 x 4.6 mm; 5 µm) col-
umn, using gradient elution with acetonitrile and phosphate 
buffer (pH 3.0), as a mobile phase. The analyses were run at 
a flow rate of 1 mL/min, volume of injection 50 µL, temper-
ature 25 ºC and UV detection was set at 210 nm. 
Experimental design (Fractional factorial 34) was used 
for the optimization of chromatographic conditions. The 
influence of four experimental factors (pH of buffer solu-
tion in the mobile phase, initial and final content of ace-
tonitrile in mobile phase during gradient elution and the 
gradient time) was investigated at three factor levels. All 
remaining factors such as the flow rate of mobile phase, 
wavelength of UV detection, temperature of the column 
and volume of injection were kept at constant level. The 
method was validated according to the EMA Guideline on 
validation of bioanalytical method (EMA, 2011). 
Preparation of standards and quality control standards
Stock solution of analytes (500 µg mL LTG, 500 µg/
mL LEV, 500 µg/mL CBZ, 500 µg/mL VPA, 200 µg/mL 
CBZ-EP) and the IS (500 µg/mL ) were prepared by dis-
solving appropriate amounts of each compound in metha-
nol. Working solutions were prepared daily from stock so-
lutions by dilution with purified water. Calibration stan-
dards were made by spiking the blank plasma aliquots with 
appropriate volume of working solutions of LTG, LEV, 
CBZ, VPA and CBZ-EP at 7 different concentrations con-
taining the IS at constant concentration 10 µg/ml. The re-
sulting plasma concentration ranges were: 1.0 - 25.0 µg/mL 
(LTG); 3.0 -70.0 µg/mL (LEV); 1.0 - 25.0 µg/mL (CBZ); 
0.5 -15.0 µg/mL (CBZ-EP); 25.0 - 250 µg/mL (VPA). Four 
levels of quality control (QC) samples were prepared at 
the concentration range of: 1.0; 5.0; 10.0; 20.0 µg/ml for 
LTG; 3.0; 7.5; 30.0; 60.0 µg/ml for LEV; 1.0; 5.0; 10.0; 
20.0 µg/ml for CBZ; 0.5; 2.5; 5.0; 10.0 µg/ml for CBZ-EP 
and 25.0; 100; 150; 200 µg/ml for VPA, in same way as de-
scribe above and stored at - 20 ºC until analysis.
Sample preparation 
The sample preparation step is an important compo-
nent of bioanalytical method i.e determination of plasma 
concentration of AEDs. To find the most efficient method, 
sample pre-tretment methodology was initially investigat-
ed by protein precipitation (PP) and than a solid- phase ex-
traction (SPE) using Oasis ® HLB cartridges.
Results and discussion
Under the proposed chromatographic conditions, no 
interfering peaks were observed in the retention times of 
analytes. Calibration curves were constructed by means of 
the least-squares method, obtained by plotting the analyte 
- IS peak area ratios versus the respective analyte concen-
trations. The correlation coefficients were 0.9989 for LTG, 
0.9979 for LEV, 0.9986 for CBZ, 0.9978 for CBZ-EP and 
0.9978 for VPA, respectively. The results for within-run 
and between-run accuracy and precision were within rec-
ommended limits. The pretreatment of plasma samples by 
protein precipitation, gave no profitable results because the 
processed samples were relatively unclean with low recov-
ery. Since SPE procedures are usually associated to high 
and reliable extraction of AEDs from human plasma, sev-
eral SPE conditions were tested, including washing steps 
and eluting solvents. The use of SPE procedure (loaded a 
200 µL of sample, washing with 1ml water and 1 ml 5% 
methanol and eluting with methanol) demonstrated to be 
the best option as it allowed a more effective elimination 
of interfering substances with good recoveries. The abso-
lute mean recoveries for determined AEDS and metabo-
lite ranged from 85.2% to 99.6% while mean recovery of 
IS was 98.9% for SPE. The stability studies analytes indi-
cate that stock solutions and plasma samples were stable 
under different storage conditions and that no stability re-
lated problems would be expected during the routine plas-
ma sample analysis.
The proposed method gives satisfactory results when 
was applied to plasma samples collected from epileptic pa-
tients simultaneously treated with carbamazepine and le-
vetiracetame; lamotrigine and valproate; or in combination 
levetiracetame, lamotrigine and carbamazepine. 
Conclusion
A simple, sensitive, precise and accurate HPLC meth-
od has been developed for simultaneous determination of 
LEV, LTG, CBZ, CBZ-EP and VPA in human plasma sam-
ples. Time of analysis and resolution were simultaneously 
optimized by applying Fractional factorial 34 design. To-
tal chromatographic analysis time per sample was approx-
imately 15 min. The proposed method can be applied suc-
cessfully in routine analysis for the estimation of therapeu-
tic concentration of LEV, LTG, CBZ, CBZ-EP and VPA in 
human plasma.
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Introduction
High-quality stability data is crucial to pharmaceutical 
industries around the world. These data form the basis 
for justifying specification limits (Huynh-Ba, 2008). The 
stability data, combined with the specification limits, are 
used for setting and/or extending product shelf life and for 
establishing product storage conditions. Stability studies 
are initiated annually and may be used to support product 
or process modifications (ICH, 2003). These studies are 
vital for ensuring the continuous quality of production 
batches. In order to identify potential issues and to ensure 
data quality, it is often advantageous to use objective and 
statistical methods for trend analysis of stability data. 
The presented paper describes trending of stability 
results for pharmaceutical product Caffetin Cold film 
coated tablets. This paper will provide an overview of one 
statistical approach for trending stability results. According 
to ICH Q1E guideline (ICH, 2003), evaluation of the 
stability data, after the assessment of the shelf life, should 
progress through the trends and variability of the long-term 
stability data (Yoshioka and Stella, 2000). The evaluation 
of stability data (not necessary statistical) is done in order 
to identify the trends and their impact on the stability of the 
product (Yoshioka and Stella, 2000).
Materials and methods
In order to evaluate stability data and find the pattern 
of data that indicates change over time, stability studies for 
Caffetin Cold film coated tablets were subjected to trend 
analysis. The trending analysis was performed to evaluate 
whether the data demonstrates increasing or decreasing 
trend (change of mean) for the stability indicating 
parameters over time or the data indicates no discernible 
change at all. In order to evaluate trends and variability 
of the long-term stability data, we evaluated three stability 
indicating parameters: assay, dissolution rate and related 
and degradation products. In order to assess the trend of the 
parameters Paracetamol assay, Paracetamol dissolution rate, 
Dextromethorphan assay, Dextromethorphan dissolution 
rate, Pseudoephedrine assay, Pseudoephedrine dissolution 
rate, Ascorbic acid assay, Ascorbic acid dissolution rate 
and related and degradation products, we collected all the 
stability data obtained for this parameters through the years 
and graphically presented them. The results are presented 
both as a table and as a graph.
Results and discussion
Caffetin Cold film coated tablets is a pharmaceutical 
product with long manufacturing history with the same 
manufacturing route, on the same manufacturing site and 
following described manufacturing procedure in Alkaloid 
AD, Skopje and with well-established stability. Ongoing 
stability studies in Alkaloid AD, Skopje are performed on 
one batch annually for long term stability testing, including 
the batches from years of 2010, 2011, 2012, 2013, 2014 
and 2015.
Evaluation was conducted using one common 
statistical graph (scatter plotting of the results) in order to 
compare the obtained results. The obtained results were 
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incorporated into respective trends. The suitable trends 
for all stability indicated parameters were defined from 
the collected stability data. The evaluation of stability data 
was conducted in non-statistical way in order to identify 
the trends.
Parameters such as Paracetamol assay, Paracetamol 
dissolution rate, Dextromethorphan dissolution rate, 
Pseudoephedrine dissolution rate and Ascorbic acid 
dissolution rate indicate no discernible change. All the 
results retain almost constant around the initial result value. 
Results for this investigated parameter remain within the 
shelf-life requirements.  
Parameters Dextromethorphan assay and Ascorbic acid 
assay indicate mild decreasing trend, but results remain 
within the limits for shelf life specification. Parameter 
Pseudoephedrine assay indicate a trend in which a single 
result within a batch is resulting in atypical trend compared 
to the other batches. This situation shows a single atypical 
result within a study that cannot yet form a trend and needs 
further investigation in the following frequencies of testing 
(in order to avoid false alarm). For all other collected 
data we find that they indicate mild decreasing trend, but 
results remain within the limits for shelf life specification. 
Parameters 4-aminophenol, unknown impurity and total 
impurities indicate no discernible change.
Parameter Paracetamol assay indicates no discernible 
change. All results retain almost constant around the initial 
result value. Results for investigated parameter Paracetamol 
assay remain within the shelf-life requirements. Parameter 
Paracetamol dissolution rate indicates no discernible 
change. All the results retain almost constant around the 
initial result value. Results for investigated parameter 
Paracetamol dissolution rate remain within the shelf-life 
requirements.  
Parameter Dextromethorphan assay indicates mild 
decreasing trend, but the results remain within the limits 
for shelf life specification. Parameter Dextromethorphan 
dissolution rate indicates no discernible change. All the 
results retain almost constant around the initial result value. 
Results for investigated parameter Dextromethorphan 
dissolution rate remain within the shelf-life requirements. 
Parameter Pseudoephedrine dissolution rate indicates 
no discernible change. All the results retain almost constant 
around the initial result value. Results for investigated 
parameter Pseudoephedrine dissolution rate remain within 
the shelf-life requirements. Parameter Pseudoephedrine 
assay indicate a trend in which a single result within a batch 
is resulting in atypical trend compared to the other batches. 
This situation shows a single atypical result within a study 
that cannot yet form a trend and needs further investigation 
in the following frequencies of testing (in order to avoid 
false alarm). For all other collected data we find that they 
indicate mild decreasing trend, but results remain within 
the limits for shelf life specification. 
Parameter Ascorbic acid assay indicates mild 
decreasing trend, but results remain within the limits for 
shelf life specification. Parameter Ascorbic acid dissolution 
rate indicate no discernible change. All the results retain 
almost constant around the initial result value. Results 
for investigated parameter Ascorbic acid dissolution rate 
remain within the shelf-life requirements. Parameters 
4-aminophenol, unknown impurity and total impurities 
indicate no discernible change.
Conclusion
From the presented results it could be observed 
that the parameters assay, dissolution rate and related 
and degradation products, considered as critical quality 
attributes, reveal very similar profile for all batches tested 
at the same conditions. The results of all batches follow 
a trend suggesting that there is no statistically significant 
difference in parameters trends.
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Introduction
Macedonia and Serbia fully follow EU regulation of 
medicines. Herbal medicines in Macedonia are regulated 
by the Law on Medicines and Medical Devices (2007) and 
the Regulation on the registration of traditional herbal me-
dicinal products from 2008. Serbia also follows EU legis-
lation. Laws on Medicines in Macedonia and Serbia are 
harmonized with the EU regulation of medicines.
Macedonia follows EU legislation for food supple-
ments. The products are regulated by the special require-
ments for safety of food supplements from 2012 (Official 
Gazzette of Republic of Serbia no. 45/10, 27/11; 50/12), 
and the Rulebook amending the Rulebook on special re-
quirements for food supplements from 2013 and 2015 (Of-
ficial Gazzette of Republic of Serbia, no. 41/13), and in 
compliance with the Croatian Rulebook on food supple-
ments in terms of their classification from 2013. Serbia also 
follows EU legislation, but has not implemented and do not 
follow the Regulation on nutrition and health claims, novel 
food regulation procedures and the law on using symbols 
on packaging and packaging waste. For food supplements, 
indications and properties that are not possessed should not 
be attributed (Dzeparoski, 2013; Kotler, 1989; Kotler and 
Keler, 2009). 
The main goal of this paper was to make comparative 
analysis of advertising and promotion of the product Sen-
tis by the company Bionika Pharmaceuticals in Macedonia 
and Serbia. The marketing campaigns, TV spots and inter-
net advertisement have been analyzed. The choice of the 
countries is based upon different product categorization in 
which Sentis is classified.
Materials and methods
Comparative method for analyzing the regulation, ad-
vertising and promotion of the food supplements and tradi-
tional herbal medicines was used.
Results and discussion
Case study
Sentis is a natural sedative in the form of soft gela-
tin capsules containing 200 mg of extract of valerian root 
(Valeriana Officinalis). In Macedonia Sentis is registered 
in 2012 as traditional herbal medicine (THM), while in 
Serbia is registered as a food supplement in 2013. Valeri-
an root has been used since ancient times before the exis-
tence of synthetic sedatives. The action is due to valeren-
ic acid; experimental pharmacological studies have shown 
that it reduces motility, causing hypnotic activity, offset-
ting the effect of caffeine and improves coordination. In 
both countries registered indications are temporary relieve 
of the symptoms of nervous tension, stress and insomnia. 
Benefits are unlike synthetic sedatives, it does not cause 
drowsiness and dependence (Bionika, 2013; PDR, 2007; 
WHO, 1999).
The differences regarding dosing and indications, re-
sulting from the different classification of the same prod-
uct are as follows:
- dosing registered as THM in Macedonia is 4 
x 200 mg, while as food supplement in Serbia 
maximum daily dose is decreased to 2 x 200 mg;
- -indications are the same in both countries, ex-
cept that in Macedonia additionally is registered 
the sedative effect. 
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These differences concern advertising and promotion-
al activities. 
In Macedonia and Serbia same package in green and 
stylized cubist design of flowers and brain with minimal-
istic look is used. The text on the package and the patient 
leaflets are different in accordance with the categoriza-
tion, in correlation with the specific regulation. For THM 
it is written clearly that it is medicine without prescription, 
with specific 6 line content structure of the patient leaflet 
and indications based on traditional use. For the food sup-
plement is clearly stated that the product is food supple-
ment and also ingredients, nutrition and energetic values 
must be printed on the package, whereas the leaflet and 
claims are not obligatory. In Serbia the food supplement 
Sentis is sold with leaflet which contains claims.
Internet is universal and powerful digital marketing 
tool in promotion of company products, including compa-
ny web-sites. The content of websites also varies in differ-
ent countries.
Promotional materials are with similar text content and 
same design in both countries, except the statement that it 
is THM or food supplement. The other difference for the 
THM is also that “the patient leaflet should be read, for 
more information you should consult your pharmacist or 
doctor“. The last is valid for all forms of advertisement. 
TV spot for Sentis as THM has been approved for ad-
vertising in electronic media to the general public by the 
Ministry of Health. The message which should remain in 
the subconscious of the audience is that when you use Sen-
tis the life will be without anxiety, stress, carefree, without 
worries and the consumer will continue on with life. TV 
spot for Sentis as food supplement in Serbia is from infor-
mative character. It is not necessary approval for advertis-
ing, because is based on generally accepted scientific data 
and they are comprehensible to the average consumer. In 
Serbia should be submitted for approval only health claims 
for reducing the risk of disease. The message which should 
remain in the subconscious of the audience is that it is a 
natural product for healthy people, which if used will help 
reduce certain symptoms. 
Except promoting the product, with both advertise-
ments is also promoted the new pharmaceutical company. 
TV advertising in Macedonia with a strong and distinctive 
message, along with the promotion activities, helped the 
company to achieve significant market share in this seg-
ment. Marketing of products by companies should be in 
accordance with the current country regulation for specif-
ic product category.
Conclusion
There are major differences in the marketing of THM/
OTC and food supplements. All promotional materials for 
THM to the general public are subject to approval by reg-
ulatory bodies, based on the approved summary of product 
characteristics and patient leaflet. The marketing of food 
supplements is more liberal in advertising and in Serbia is 
not subject to approval, if based on generally accepted sci-
entific data. Macedonia follows the EU Regulation on nu-
trition and health claims for food supplements. The results 
of the case study can also be used for preparation of mar-
keting materials for other products on other markets of in-
terest with similar regulation. 
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Introduction
Near InfraRed - Fourier transform infrared 
spectroscopy (FT-NIR) in recent years has gained much 
interest due to its simple maintenance and short measuring 
time. This technique differs from the conventional 
techniques such as HPLC and GC, because the essential 
component is the sampling interface. That allows for fast, 
non-destructive measurement of materials with little or no 
sample preparation. 
Near Infrared Spectroscopy (NIRS) is used for 
identification on every container that has been delivered. 
The principle is based on the comparison of the spectral 
data of the substance with the spectral data of several 
samples, which are present in a spectral reference library. 
These samples have positive chemical/physical and 
microbiological test analysis, tested in accordance with 
producer Certificate of Analysis and producer Drug Master 
File. Positive identification of these samples originally is 
confirmed with IR Spectrophotometry or other specific 
identification method. Besides others parameters, these 
analyses include testing of loss on drying, content of water, 
optical rotation, related substances and assay that may 
cause of variables in the NIR spectra. 
According to the “Guideline on the use of NIR 
spectroscopy by the pharmaceutical industry and the data 
requirements for new submission and variations” issued 
by the European Medicine Agency, when NIR procedures 
are used for qualitative analysis should be validated for 
a minimum specificity and robustness (EMA, 2009). For 
the specificity, independent set of samples is created of 
different batches, which are not included in the creating of 
the reference library. All of the samples should be approved 
correctly (pass). The reference library should be also 
challenged with relevant structural analogues, which should 
be rejected (fail). As for robustness, the effects of relevant 
variables should be understood, tested and documented. 
Some of the variables include: environmental temperature, 
humidity, different probe depth, different packaging 
material, changes in the instrumental method, for example 
the number of scans. Also instrumental variation can be 
consider, e.g. changing lamps or reflectance material.
Materials and methods
The NIRS analyses were performed on Thermo 
Antaris II FT-NIR Analyzer. It is dedicated FT-NIR 
analyzer designed specifically for use in the industrial 
environments of the pharmaceutical, food and beverages, 
chemical and polymer industries (Hirsch, 2008). Some 
of the characteristics of the instrument are: the detection 
is performed on high - sensitive, high - stable matched 
InGaAs; the light source is long - life, high intensity 
halogen NIR source; the interferometer is frictionless 
stable, long - life Michelson. The sampling method used 
is Fiber Optic. NIRS sampling by fiber optics allows 
rapid point-of-use QC for raw material identification. The 
Antaris II Fiber Optic module can be used with the SabIR 
hand - held diffuse reflectance probe which can analyze 
samples directly or indirectly through packaging materials. 
The spectral range of SabIR Probe is 12000 – 4000 cm-1. 
The probe shaft is made of stainless steel, and the window 
material of the shaft is made is made of high quality, 
chemical resistance sapphire according to the instrument 
specification (Antaris II FT-NIR Analyzer).
The method that is used in Alkaloid is with SabIR Fiber 
Optic module. The spectral range in which the collecting is 
performed is 10000 - 4000 cm-1. The number of scans in 
30, and the resolution is 8 cm-1.
In the first step of creating the reference library, NIR 
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spectrum of Ibuprofen Lysine Reference standard was 
collected. Due to lack of certified reference standard from 
pharmacopoeia, in – house standard sent from the suitable 
manufacturer was used. Further the library was continually 
updated with samples of commercial batches of Ibuprofen 
lysine received from the manufacturer.
The spectral reference library is composed of spectra 
collected with direct scanning of the substance and indirect 
scanning (through the polyethylene bag). In routine, 
indirect scanning is preferred, by reason of faster scanning 
and not requiring opening every package. 
The NIR method for identification of Ibuprofen lysine 
was validated in terms of Specificity and Robustness, 
according to the Guideline on the use of Near Infrared 
Spectroscopy (NIRS) by the pharmaceutical industry 
and the data requirement for the new submissions and 
variations, issued by the European Medicine Agency.
Results and discussion
Verification workflows are created for performance 
the following tests of specificity and robustness. These 
workflows are chosen for verification of the production 
workflow for Ibuprofen lysine.
Verification workflow for performing specificity
One verification workflow that contains independent 
set of three samples, which are batches not included in 
the reference library are included is created. The results 
for these samples are PASS. The other verification 
workflow has three different substances that have similar 
structure with Ibuprofen Lysine, and therefore is expected 
to have similar NIR spectrum. That is Ibuprofen, the 
difference is with the Lysine group; Ketoprofen, belongs 
to the same group of Nonsteroidal anti-inflammatory drug; 
Paracetamol, together with Ketoprofen, they have similar 
structure.  The result for Ibuprofen Lysine is PASS, and for 
the other three substances is FAIL.
Verification workflow for robustness
Robustness is performed for testing the effect of 
minor changes to normal operating conditions on the 
analysis (Tang, 2012). Verification workflows are created 
for performance these tests. The parameters for validation 
robustness of the method, which can affect the method 
in our operating environment, are the following: change 
in the number of scans (performed only with indirectly 
scanning), change in probe depth (performed with direct 
scanning) and change in thickness of the packaging 
material (performed with indirect scanning). The results 
for these three workflow are PASS, which brings the 
conclusion that certain changes in the method does not 
affect the test results.  
Conclusion
The obtained results confirm that the NIR method for 
identification of Ibuprofen lysine is verified and appropriate 
for it use. 
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Introduction
Residual solvents in pharmaceuticals are defined as 
organic volatile chemicals that are used or produced in 
the manufacture of drug substances or excipients, or in 
the preparation of drug products. The solvents are not 
completely removed by the manufacturing techniques 
and therefore it is required appropriate selection of the 
solvent for the synthesis. The solvent used can enhance 
the yield, or even determine some of the characteristic of 
the substances, such as crystal form, purity and solubility 
(CHMP, 2015). Considering that residual solvents do 
not provide any therapeutically benefits, they should be 
removed, to the extent possible, to meet ingredient and 
product specifications and good manufacturing practices. 
The residual solvents, based on their toxicity, are 
divided into three groups. The solvents that are known 
to cause unacceptable toxicities are class 1. In this group 
belongs: benzene, carbon tetrachloride; 1,2-dichlorethane; 
1,1 - dichlorethene and 1,1,1-trichlorethane. These 
solvents are proven human carcinogens and environmental 
hazardous. Considering the unacceptable toxicity, this class 
of solvents should be avoided during the manufacturing 
process, unless their use can be strongly justified in a risk-
benefit assessment. The Class 2 solvents are associated with 
less severe toxicity. Some of the solvents that belong to 
this group are: acetonitrile; chloroform; 1,2-dichlorethene; 
N,N-dimethylacetamide; N,N-dimethylformamide; 
1,4-dioxane; ethylene glycol; formamide; methanol; 
hexane; pyridine; toluene. The use of these solvents should 
be limited in order to protect the patients from potential 
adverse effects. 
Ideally, less toxic solvents should be used where is 
possible. Those are solvents that belong to Class 3. They 
are counted as less toxic and of lower risk to human health 
then Class 1 and Class 2 residual solvents.  The solvents 
in this class are not known as a human health hazard at 
level normally accepted in pharmaceuticals. However 
there are no long-term toxicity or carcinogenicity studies 
for many of the residual solvents in Class 3. Available data 
so far, indicate that they are less toxic in acute or short term 
studies and negative in genotoxicity studies. Some of the 
solvents that belong to this group are: acetic acid; acetone; 
1-butanol; 2-butanol; dimethyl sulfoxide; ethanol; ethyl 
acetate; ethyl ether; formic acid (USP, 2015).
Residual solvent that was used in the synthesis of 
sodium citrate is methanol. Since methanol belongs to class 
2 residual solvents, quantification should be performed. 
Materials and methods
The experiments were performed on Shimadzu 2010 
Plus GC instrument. The pressure was set to 9.8 Psi, 
column flow was 2.08 mL/min and total flow was 15.5 mL/
min. Helium was used as the carrier gas. Other gases that 
were used are Hydrogen and Air. The injection volume was 
1000 µL and the split was 1:5. The column used is DB-624, 
30 m x 0.32 mm, 1.8 µm (Agilent). Methanol standard was 
supplied from Merck Darmstad (Shimazdu, 2013).
The methanol standard solution was prepared in final 
concertation of 150 ppm. 1 mL of this solution was put 
in headspace vial of 20 mL and 5 mL water was added. 
The sample was prepared with weighting 50 mg of Sodium 
citrate in a headspace vial and 6 mL water was added. 6 mL 
in a headspace vial was used as blank.  
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Results and discussion
Several modifications of the general method for 
determining water soluble residual solvents Class 1 
and 2, were made (USP, 2015). The general method is: 
chromatography system, composed of gas chromatograph 
equipped with a flame-ionization detector, 0.32 mm x 30 m 
fused-silica column coated with a   1.8 µm layer of phase 
G43 (6% cyanopropylphenyl 94% dimethylpolysiloxane). 
The temperature of the column is maintained at 40 °C for 20 
minutes, then raised at a rate of 10 °C per minute to 240 °C, 
and maintained at 240 °C for 20 minutes. The headspace 
conditions are: incubation at 80 °C for 60 minutes and 
syringe temperature of 90 °C (USP, 2015).  
This method has undergone several modifications 
and adaptations during the verification process. The 
adaptation was made in the temperature program of 
the column. The peak of methanol was at ~2.2 min, and 
since the diluent was water, there are no other peaks than 
methanol; consequently it was not necessary to run the full 
temperature program. Therefore finally, the method was as 
follows: injector temperature 140 °C, detector temperature 
250 °C, temperature program for the column: 40 °C /
hold 20 min, then raised to 120 °C, at a rate of 30 °C per 
minute. In addition, adaptation in the headspace condition 
was made, precisely the incubation time was shorted to 30 
minutes, and because it has been proven that there are no 
extra peaks, other than methanol. 
Tests that were performed during the verification were: 
specificity, repeatability, accuracy, detection limit (LOD) 
and quantification limit (LOQ).
The specificity of the method was validated with 
demonstrating that there is no other peak from the diluent 
that interfere with the peak of methanol. 
The repeatability of the chromatographic system was 
determined with ten replicate injections of the standard and 
determining the Relative Standard Deviation (RSD). This 
RSD value for organic volatile solvents should be below 15. 
The accuracy of the method was determined by 
interaction studies for constant amount of sample, but 
varying concentration of methanol. The concentrations 
are: 50 ppm, 150 ppm, 300 ppm, 500 ppm, 2000 ppm and 
3500 ppm. On each concentration level, three samples 
were injected and calculations were made. The limits for 
the recovery are 80 - 120% or RSD below 15%. 
For determination of the LOQ and LOD, criteria 
of signal-to-noise (S/N) ratio of about 10:1 and 3:1, 
respectively was employed. In the first step S/N ratio was 
determined on the standard of 150 ppm and that standard 
is used as a stock solution. Consequently several dilutions 
were prepared and S/N ratio was determined. S/N ratio of 
about 10:1 was obtained at concentration of 10 µg/ml, and 
that concentration was taken as LOQ. S/N ratio of about 
3:1 was obtained at concentration of 3 µg/ml, and that 
concentration was taken as LOD.
Conclusion
The verified method was proven to be suitable for 
determination of residual solvent methanol in Sodium 
Citrate.
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Introduction
Endotoxins are high-molecular-weight complexes as-
sociated with the outer membrane of Gram-negative bac-
teria, and are the most significant pyrogen for the pharma-
ceutical industry. The importance of endotoxin contamina-
tion in sterile manufacturing becomes apparent when con-
fronted with four aspects of its existence: its ubiquity in 
nature, potent toxicity, stability or ability to retain after be-
ing subjected to extreme conditions and relative likelihood 
of its occurrence in pharmaceutical products. Any prepara-
tion administered parenterally should be sterile and com-
ply with the test for bacterial endotoxins, BET (Ph. Eur., 
2014).
Lactic acid is an organic compound with the formu-
la CH3CH(OH)CO2H. It is a white, water-soluble solid or 
clear liquid that is produced both naturally and synthetical-
ly. Lactic acid is chiral, consisting of two optical isomers. 
One is known as L-(+)-lactic acid or (S)-lactic acid and 
the other, its mirror image, is D-(-)-lactic acid or (R)-lac-
tic acid. In humans, L-lactate is constantly produced from 
pyruvate via the enzyme lactate dehydrogenase (LDH) in 
a process of fermentation during normal metabolism and 
exercise. In industry, lactic acid fermentation is performed 
by lactic acid bacteria, which convert simple carbohydrates 
such as glucose, sucrose, or galactose to lactic acid.
Lactic acid is used as an excipient in medicinal prod-
ucts that are for intravenous administration. In medicine, 
lactate is one of the main components of antibiotics and in-
fusion solutions. These intravenous fluids consist of sodi-
um and potassium cations along with lactate and chloride 
anions in solution with distilled water, generally in concen-
trations isotonic with human blood. 
Objective: Validation and quantification of BET (Bac-
terial endotoxins test) with Turbidimetric kinetic method 
for Lactic acid. 
Materials and methods
Materials
 (S)-Lactic acid; LAL reagent Water; Sodium Hydrox-
ide 0.1 N for pH adjustment of sample; reagents for Kinetic 
turbidimetric method; PYROGENT-5000™, LAL Reagent 
Water, disposable endotoxin-free glass dilution tubes; dis-
posable sterile microplates; automatic hand - held pipettes 
with sterile tips; timer; vortex mixer; Microplate read-
er Elx808cse from BIO-TEK® (BIO-TEK Instruments, 
INC.,P.O.BOX998, Highlsand Park, Winooski, Vermont 
05404 USA).
The results are calculated and stored with Win QCL 
4.0.2 software™ (Lonza® Walkersville, MD21793).
Methods
The Kinetic turbidimetric method is based on measur-
ing the turbidity (optical density) of LAL/sample mixture 
at regular interval troughout the test. The time required be-
fore the appearance of turbidity (reaction time) is inversely 
proportional to the amount of endotoxin present. 
In accordance with the Ph.Eur., 2014 and British phar-
macopoeia commission, 2014, substances to be used in 
parenteral preparations must comply with BET, whatever 
their origin, since:
- contamination by bacterial endotoxins can take 
place prior to or during the manufacturing pro-
cess;
- bacterial endotoxins cannot easily be removed 
by the manufacturing process;
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- bacterial endotoxins should be detected as ear-
ly as possible in the manufacturing process.
It is to be noted that the ICH Guideline Q6B: Specifi-
cations: Test Procedures and Acceptance Criteria for Bio-
technological/Biological Products provides the following 
recommendation under section 4.1 Drug Substance Speci-
fication: “Pharmacopoeial tests (e.g., endotoxin detection) 
should be performed on the drug substance, where appro-
priate”. 
Lactic acid, as an excipient in parenteral prepara-
tions, has strongly inhibitory effect on Bacterial endotox-
ins test (Kinetic Turbidimetric method) because of its pH 
value and it is necessary to overcome this problem. Prob-
lems with pH value are the most significant biochemical 
cause of LAL-test inhibition. When dealing with acid or 
base solutions, correction of pH should be made in opti-
mum rang 6-8. Lactic acid has pH value of 1.2 and the 
correction should be done by diluting in with 0.1N NaOH 
(Zink McCullough, 2011; Williams, 2009).  
Results and discussion
Validation was performed begining with screening (In-
hibition / Enhancement) test (FDA, 2012 ). The validation 
was performed on three batches. For that purpose Lonza® 
reagents were used; lysate sensitivity  λ = 0,01 EU/ml; 
MVD = ELCxPP/λ = 0.005x10/0.01 = 5. Dilutions used 
for preliminary, Inhibition/ Enhancement test were as fol-
lows: 1:2, 1:4 and the MVD (maximum valid dilution) = 
1:5 with LRW.
To overcome the inhibition of lactic acid, the first di-
lution was made with 0.1N NaOH from Lonza® and vor-
tex for 1 minute. Test solutions (at dilutions: 1:2, 1:4 and 
1:5) were obtained by diluting with LRW™ from Lonza®. 
Lactic acid is not inhibitory in 1:2 dilution (pH=6.85-6.92), 
showing PPC recovery 120%. Test solutions (at dilutions 
1:4 and 1:5, MVD) gave PPC recovery of 105% and 118% 
respectively. Upon received results the validation was done 
on three consecutive batches of lactic acid with dilution 
1:2 (considering that recovery must be close to 100%). The 
endotoxin concentration reported for the three consecutive 
batches is less than 0.00200 EU/mg with PPC 78%, 94% 
and 91% respectively. All three batches of the tested lac-
tic acid showed endotoxin recovery between 50 and 200%.
Conclusion 
Validation of the Bacterial endotoxins test on (S)-Lac-
tic acid was successfully done. The inhibition was over-
come. Routine testing of (S)-Lactic acid should be done 
with dilution 1:2 (conc. 5 mg/ml) using LRW from Lon-
za®. According to the results, the bacterial endotoxins test 
- Turbidimetric kinetic method for (S)-lactic acid was vali-
dated and can be used for routine testing.
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Introduction
The regulatory approval process of the new veterinary 
medicinal products is intricate and rigorous, since its pri-
mary purpose is to have a drug on the market that can guar-
antee quality, effectiveness and safety to both, animals and 
humans. This is part of the marketing authorization proce-
dures, strictly stipulated and regulated by law. Macedonian 
Law on Veterinarian medicinal products (2010) is harmo-
nized with the standards defined within the EU legislation. 
The main aim of this study is to present the current sit-
uation regarding the marketing authorization of veterinary 
medicinal products in Macedonia and to identify strengths 
and weaknesses in the process of registration.
Materials and methods
Research presented in the study was completed with-
in the period September-November 2015, through direct 
contact with the distributors of veterinary medicinal prod-
ucts from all over Macedonia. Main research method was a 
questionnaire composed of 20 questions with option of an-
swers. In order to reduce subjectivity the questionnaire of-
fered a binary model with yes, no and not familiar as pos-
sible answers. All questions in the questionnaire were con-
crete and specific, targeting issues related with registration 
and selection of veterinary medicinal product, distribution 
practice, pharmacovigilance etc. All answers were careful-
ly examined and the results of the research have indicated 
the current situation of the marketing authorization process 
of the veterinary medicinal products in the Macedonia. To 
all contacted companies anonymity in responding as well 
as data confidentiality was guaranteed.
Results and discussion
All new veterinary medicinal products need to be ap-
proved by the competent authority. After positive scientific 
evaluation of the submitted documentation, competent au-
thority issues marketing authorization that allows the vet-
erinary medicinal products to be placed on the market. Na-
tional procedure is a type of authorization for veterinary 
medicinal products in Macedonia. The applicants need to 
submit an application to the Food and Veterinary Agency as 
a competent authority. The registration process of the vet-
erinary medicinal products in Macedonia is governing by 
the Law on Veterinary Medicinal Products (2010), but its 
implementation is closely defined by the rulebooks, where 
it is clearly described troughs of the entire procedure. 
The report of this research contains qualitative infor-
mation of the structural indicators and perceptions which 
were subsequently used for obtaining the qualitative pa-
rameter with which reflect the present situation of knowl-
edge of registration process for veterinary medicinal prod-
ucts.
In the Republic of Macedonia there are 23 veterinary 
medicinal products wholesalers which are registered by the 
Food and Veterinary Agency, and authorized to distribute 
veterinary medicinal products. Only 16 of them are active 
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in the field. During the preparation of this study, in order to 
receive more accurate information, all of them were con-
tacted, but only 9 of them responded positively to our re-
quest.
The results of this research showed that veterinary me-
dicinal products wholesalers in some points are familiar 
with the process of marketing authorization and post-mar-
keting authorization and the Law on Veterinary medicinal 
products (2010), but there in certain areas of the epony-
mous Law are not familiarized. On the basis of their an-
swers, it can be concluded that most companies are famil-
iar with the basics of the process, such as, the procedure for 
marketing authorization for veterinary medicinal product 
and legal obligations, the existence of a register of veteri-
nary medicinal products, good distribution practice, good 
storage practice and procedure for withdrawal of veteri-
nary medicinal products. On the questions such as: infor-
mation of public interest, the existence of national refer-
ence laboratories, the existence of a national list of essen-
tial veterinary medicinal products, pharmacovigilance sys-
tem, some of respondents did not know the exact answer, 
indicating a poorly knowledge of the marketing authoriza-
tion and post-marketing authorization of veterinary medic-
inal product on these specific issues.
The results also show that the Good distribution prac-
tice and Good storage practice are implemented and that 
the cooperation between companies and Food and Veteri-
nary Agency is on satisfactory level. On the website of the 
Food and Veterinary Agency there are clearly set of infor-
mation of public interest for implementation of the mar-
keting authorization process for the interested parties, but 
some of them had trouble in their availability
This research indicated satisfactory level of the imple-
mentation of the law in practice, identified, as follows: the 
existence of publicly available written information about 
the procedure of marketing authorization of veterinary me-
dicinal products, formally established commission for re-
view of applications for registration, the existence of a for-
mal system for submitting complaints commission fea-
ture. There are some weaknesses in the process of market-
ing authorization, such as: an official national essential list 
for veterinary medicinal products is not amended by 2012, 
absence of timed deadline for providing official informa-
tion on the status of application for approval for marketing, 
absence of publicly available pharmacovigilance system, 
and additionally, not always satisfactory level of applica-
ble knowledge on the process and issues connected with 
the process by the veterinary medicinal products wholesal-
ers’ representatives. 
Conclusion
In this paper all aspect of the issue of marketing au-
thorization of veterinary medicinal products in Macedonia 
were studied and critically analyzed. On the basis of the 
collected data, the existing legislation, as well as, admin-
istrative procedures of marketing authorization and post-
marketing authorization of veterinary medicinal products 
can be revised and adjusted providing better efficiency and 
transparency. Furthermore, although the cooperation be-
tween the wholesalers and Agency of Food and Veterinary 
was found to be satisfactory, improvement of communica-
tion could be the added value.
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Introduction
The transfer of analytical procedures (TAP), also re-
ferred to as method transfer, is the documented process that 
qualifies a laboratory (the receiving unit, RU) to use an 
analytical test procedure for quality control, that is fully 
validated in another laboratory (the transferring unit, TU) 
(USP, 2012). Usually, the most common need for this pro-
cedure is transferring methods developed and validated in 
the research and development department to the quality 
control unit in the same or different site. In the last years, 
with widening the business strategies of the pharmaceuti-
cal companies, necessity for different types of transfer oc-
curs. Transfer activities are required between Quality con-
trol laboratories of the manufacturers and different batch 
release laboratories: laboratories of the contactor suppli-
ers, contract laboratories and European Union batch re-
lease testing sites.
The presented paper describes the process of Analyti-
cal method transfer for Cilostazol 100 mg tablets in which 
Alkaloid QC laboratory is involved as receiving laboratory. 
Materials and methods
Analytical method transfer protocol is created, re-
viewed and approved by both laboratories, prior to exper-
imental performing of the methods (Eudralex, 2014). Ac-
cording the protocol, assessing the sort of test and the ex-
perience of the receiving laboratory, the methods to be 
transferred have been determined: 
- The method for Dissolution - UV Spectropho-
tometry method;
- The method for Assay of cilostazol - gradient 
HPLC method with UV detection;
- The method for Identification of cilostazol - as-
sessed in Assay;
- The method for Related and degradation sub-
stances - gradient HPLC method with UV de-
tection
Methods for all the rest specification parameters: ap-
pearance, uniformity of mass, subdivision, water content, 
Uniformity of dosage units by mass variation don`t need 
to be transferred. Microbial examination method should be 
verified but it is not part of this protocol. 
One batch of Cilostazol tablets 100 mg was tested in 
both laboratories. 
Results and discussion
In the analytical procedure for dissolution test, follow-
ing system suitability acceptance criteria are set: no sig-
nificant blank absorbance is noticed, RSD% of 6 replicate 
measurements of cilostazol standard 1 should be ≤ 2.0%, 
cilostazol standard 2 recovery should be between 98.0 - 
102.0%. System suitability criteria are met in both labora-
tories. The analysis for dissolution was performed on six 
samples in the TU and on 12 samples in the RU involv-
ing different days, instruments and analysts. The results 
were compared at the specification time limit of 60 min-
utes. The obtained results for inter-laboratory repeatability: 
mean values of 96.33% and 91.81% are within the limits of 
not less than 85% (Q=80) in 60 minutes. Absolute differ-
ence between 6 samples per each laboratory is 1.80% and 
3.80% respectively, absolute difference between the labo-
ratories is 4.52%. All differences are below 5% which is set 
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as acceptance criteria (Medsafe, 2007; WHO, 2011). The 
obtained results for intra-laboratory repeatability (repro-
ducibility in RU): absolute difference between each anal-
ysis of 6 samples is 3.80% and 1.80% respectively, abso-
lute difference between 12 samples is 1.24%. All differenc-
es are below 5% which is set as acceptance criteria. The 
linearity of the method in the concentration range for cilo-
stazol from 20 % to 120 % of the theoretical sample solu-
tion concentration is proved in the RU. Acceptance crite-
ria for Linearity are accomplished: correlation coefficient 
≥ 0.999, Y-intercept confidence interval includes zero, re-
sidual plot presents no particular trend, RSD (%) of the re-
sponse factor ≤ 2.0%. 
In the analytical procedure for assay following system 
suitability acceptance criteria are set: no blank interference 
is noticed at the cilostazol elution time, RSD of the areas 
of cilostazol peak of 5 consecutive injections should be ≤ 
2.0%, symmetry factor (As) of cilostazol peak should be ≤ 
2.0, cilostazol standard 2 recovery should be between 98.0 
- 102.0%. System suitability criteria are met in both labo-
ratories. The analysis for assay was performed on six sam-
ple preparations in the TU and on 12 sample preparations 
in the RU involving different days, instruments and ana-
lysts. The obtained results for inter-laboratory repeatabili-
ty: mean values of 100.18% and 99.59% are within the lim-
its for cilostazol content of 95.0 - 105.0%. Absolute differ-
ence between 6 samples per each laboratory is 1.20% and 
0.80% respectively, absolute difference between the labo-
ratories is 1.50%. All differences are below 3% which is 
set as acceptance criteria (Medsafe, 2007; WHO, 2011). 
The obtained results for intra-laboratory repeatability (re-
producibility in RU): absolute difference between each 
analysis of 6 samples is 0.8% and 0.5% respectively, abso-
lute difference between 12 samples is 1.8%. All differenc-
es are below 3% which is set as acceptance criteria. Iden-
tification is confirmed by obtaining similar retention times 
for cilostazol in sample and standard solution. The lineari-
ty of the method in the concentration range between 80 % 
of the theoretical sample solution concentration to 120% 
is proved in the RU. Acceptance criteria for linearity are 
accomplished: correlation coefficient ≥ 0.999, Y-intercept 
confidence interval includes zero, residual plot presents no 
particular trend, RSD (%) of the response factor ≤ 2.0%. 
In the analytical procedure for Related substances fol-
lowing system suitability acceptance criteria are set: reso-
lution between peaks of impurity B and cilostazol > 1.5, 
no blank interference is noticed during the cilostazol elu-
tion time, RSD of the areas of Cilostazol peak of 5 consec-
utive injections ≤ 2.0%, Standard 2 recovery should be be-
tween 95.0 – 105.0%, As of Cilostazol peak should be ≤ 
2.0. System suitability criteria are met in both laboratories. 
Limit of quantification (QL) is determined and confirmed 
in the RU. 0.01% cilostazol standard solution gives S:N ra-
tio of 14 which is ≥ 10:1.  The obtained RSD at QL level is 
7.83% which is lower than the acceptance criteria ≤ 15.0% 
(ICH, 2005). The analysis for related substances was per-
formed on six sample preparations in the TU and on 12 
sample preparations in the RU involving different days, in-
struments and analysts. Acceptance criteria for inter and 
intra laboratory repeatability are set: the % impurity should 
comply with the release specification Impurity B ≤ 0.2%, 
unknown impurities ≤ 0.2%, total impurities ≤ 0.5%. Ob-
serving chromatographic profiles and results obtained by 
both laboratories, it can be concluded that they are qualita-
tively and quantitatively similar. The linearity of the meth-
od in the concentration range between QL and 0.20% is 
proved in the RU. Acceptance criteria for linearity are ac-
complished: correlation coefficient ≥ 0.999, Y-intercept 
confidence interval includes zero, residual plot presents no 
particular trend, %RSD of the response factor ≤ 10.0%. 
Conclusion
From the comparison of the obtained results from both 
laboratories it can be concluded that all results are meet-
ing the predetermined acceptance criteria limits. No devia-
tions from the protocol were observed. Analytical method 
transfer report is generated by the transferring laboratory, 
reviewed and approved by both laboratories. The success-
fulness of the transfer is confirmed. The analytical trans-
fer report qualifies Alkaloid QC laboratory to use the Ci-
lostazol 100 mg tablets finished product methods of anal-
ysis, ensuring that the receiving laboratory has the proce-
dure, knowledge and ability to perform it. 
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Introduction
Pharmaceutical counterfeiting is an expanding threat 
to worldwide public health. It crosses geographic boundar-
ies and impacts patients suffering from a variety of diseas-
es. It is a crime that generates large profits for the counter-
feiters even as it steals one of medicine’s most important 
ingredients: trust. According to the World Health Organi-
zation (WHO), a counterfeit medicine is one that is delib-
erately and fraudulently mislabeled with respect to identi-
ty and/or source. Counterfeiting can apply to both branded 
and generic medicines and counterfeits may include prod-
ucts that are fraudulently packaged or mislabeled with re-
spect to identity and/or source;  contain no active ingre-
dient, incorrect quantities or an undeclared active ingre-
dient; contaminated with other materials; past their expi-
ry date; contain no or incorrect patient information leaf-
lets (WHO, 2010). The most counterfeit medicines are can-
cer medicines, cholesterol lowering medicines, antibiotics, 
hypertension medicines, hormones, steroids and copies of 
many commonly used pain killers and antihistamines. In 
developing countries, counterfeit medicines are drugs for 
the treatment of life-threatening conditions such as malar-
ia, tuberculosis and HIV/AIDS.
Counterfeit medicines - reason and consequences 
There are several reasons for counterfeiting. One of 
the main reasons is profit, because manufacturing of coun-
terfeit medicines is very low cost and doesn’t meet quali-
ty and safety standards. Inadequate legislation, regulations 
and enforcement results in supply systems vulnerable to 
counterfeit products and extremely low capacity to uncov-
er and punish counterfeiters. The costs of legitimate med-
icines, both original and generic, may be too high for pa-
tients, and is one of the reasons why patients buy cheaper 
medicine with dubious quality. 
The consequences of counterfeit medicines could be 
divided into three groups: consequences for the public and 
patients’ health, consequences for pharmaceutical compa-
ny and consequences for the country. Consequences for 
the public and patients health are life-threatening effects, 
does not provide effective treatment, needs prolonged hos-
pitalization, cause direct damage or toxic effects. Counter-
feit medicines cause direct financial losses for the compa-
ny and loss of reputation and trust of patients. The conse-
quences for the country include evading payment of taxes 
and customs duties and higher costs in the health system.
Activities of the pharmaceutical industry against 
counterfeiting of drugs 
Pharmaceutical industry is one link of the chain that 
is fully committed in combating counterfeiting medicines 
and takes actions to protect their products. There are two 
main forms of product security and those are traceabili-
ty and authentication. Traceability means ability to track 
drugs cheaply, securely, and efficiently across the globe, 
from manufacturer to patient, thus improving the safety of 
medicines. Tracking technologies allows pharmaceutical 
products to be tracked and monitored as they move from 
the manufacturer to the patient. The synonym for tracking 
technologies is ” Track and Trace”, and it incorporates se-
rialization and pedigree. This technology implies an abili-
ty of the system to know where a product went (track) and 
where it came from (trace). Serialization is simply a pro-
cess of assigning a unique number to a unit of production 
such that it can be identified later. Pedigree is process of re-
cording most or all of the product history.
There are various authentication technologies that can 
be used at different levels of packaging and in different 
circumstances. Most security-printing deterrents can be 
grouped into three categories: overt, covert, and forensic. 
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Overt features are easy to detect by sight, touch or smell. 
Examples of overt security-printing deterrents include col-
or-shifting inks, alignments that are difficult to replicate, 
microprinting, optically variable microstructures (also 
known as holograms) and visible watermark. Covert fea-
tures can be detected by machines but are not visible to 
the naked eye. Examples of covert security-printing de-
terrents include invisible inks (such as those visible only 
when exposed to ultraviolet light), magnetic printing, en-
crypted codes, hidden overprints, micro-displacement of 
glyphs and metal fibers. Forensic features require laborato-
ry testing in order to be detected. Examples of forensic se-
curity printing deterrents include various embedded chem-
ical compositions known as chemical taggants that are de-
signed to uniquely identify an object (Davison, 2011) 
Combining track-and-trace with secure printing dra-
matically improves protection against counterfeiting and 
increases efficiencies in product recalls and other supply 
chain challenges.
Global activities in combating counterfeit 
There are three strategies that are applied globally in 
order to combat counterfeiting of medicines
• Providing tools, international norms, standards and 
guidelines to assist that medicines circulating in nation-
al and international commerce are safe, efficacious and of 
good quality
• Providing support to non EU and EU Member States 
to build national regulatory capacity 
• Developing global activities to combat counterfeit 
medicines, in collaboration with all relevant stakeholders
In 2006, World Health Organization established Inter-
national Medical Products Anti Counterfeiting Taskforce 
(IMPACT) and the main conceptual approach is a volun-
tary coalition of partners, with the purpose of coordinat-
ing international activities aimed at combating counter-
feit medical products. IMPACT partners reflect the fact 
that combating counterfeiting of medical products can-
not be successfully achieved by the health sector alone 
but requires a coordinated effort and effective collabora-
tion among health sector, enforcement, border control, jus-
tice (all at different administrative levels), as well as health 
professionals, manufacturers, importers, distributors, me-
dia, and patients/consumers. IMPACT outputs include rec-
ommendations, policy advice and training materials that 
reflect consensus reached among IMPACT partners (IM-
PACT, 2010).
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Introduction
The process of evaluation of the efficacy of a given 
pharmacological treatment, in general, is performed in 
two subsequent steps: 1) monitoring numerous pre-defined 
clinical and laboratory parameters which provide informa-
tion on treatment benefits and 2) analysis and interpreta-
tion of the obtained results. In order to get thorough under-
standing of the studied problem, the data obtained in step 
2 are studied using chemometric algorithms for multivar-
iate data analysis. Compared to the traditional univariate 
approach, the application of chemometric algorithms pro-
vides comprehensive overview of the studied data and re-
sults in greater statistical power even when there is small 
number of observations or missing data points (Helmy et 
al., 2012).
The treatment of periodontal disease consists of scal-
ing and root planning followed by local application of an-
tiseptics or antibiotics such as chlorhexidine (CHX) and 
doxycycline (DOX). The efficacy of the treatment is mon-
itored using the following parameters: clinical indices 
(index of gingival inflammation (GI), periodontal pock-
et depth (PD) and clinical attachment loss (CAL)) or de-
termination ofactivity/concentration of inflammatory bio-
markers in gingival crevicular fluid (GCF) such as en-
zymes: alkaline phosphatase (ALP), lactate dehydroge-
nase (LDH), aspartate aminotransferase (AST) or cyto-
kines: interleukin-1β (IL-1β) and tumor necrosis factor –α 
(TNF-α) (Aimmeti et al., 2012). However, the data analy-
sis of the results obtained from monitoring treatment effi-
cacy parameters is commonly performed using the tradi-
tional approach (Tu et al., 2009). 
The aim of our study was to perform comparative eval-
uation of the efficacy of local periodontal treatment with 
DOX and local periodontal treatment with CHX using che-
mometric algorithm for multivariate data analysis, orthog-
onal projection to latent structures - discriminant analysis 
(OPLS-DA). 
Materials and methods
The subjects enrolled in the study were divided in two 
groups: a group of 25 patients (DOX group) treated local-
ly with 10% DOX gel (controlled-release gel formulation) 
and a group of 34 patients (CHX group) treated locally 
with 1% CHX gel (conventional-release gel formulation). 
DOX group was treated with 115 mg gel containing 10 mg 
of DOX and the GCF samples were taken 7 days after the 
local treatment. The CHX group was administered 330 mg 
gel containing 2 mg CHX and GCF samples were taken 
30 min after gel application. GCF samples were collected 
from quadrants consisting of five periodontal pockets, be-
fore and after the local treatment. In brief, paper strips were 
placed in the selected periodontal pockets until mild resis-
tance was felt and left in place for 30 s. 
The study protocol was approved by the Ethics Com-
mittee at the Faculty of Dentistry, Skopje.
For determination of biomarker activity/concentra-
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tion in GCF, five paper strips were placed in 500 μL PBS 
(phosphate buffer saline, pH=7.4) and the tube was cen-
trifuged for 5 min at 4000 rpm (4 ˚C). The resulting so-
lutions were divided in two aliquots of 250 μL. The ali-
quot for determination of enzyme activity was assayed im-
mediately after collection whereas the aliquot for determi-
nation of cytokine concentration was added proteinase in-
hibitor cocktail and kept at – 80 ˚C until analysis. ALP, 
LDH and AST activity in GCF samples was determined 
using appropriate kits in accordance with the Internation-
al Federation of Clinical Chemistry (IFCC) recommenda-
tions. The concentration of IL-1β and TNF-α in GCF sam-
ples was determined according to manufacturer’s instruc-
tions, using commercial ELISA kits. The clinical indices 
PD and CAL were measured in mm, while the index of gin-
gival inflammation was scored with values 1-3 (1-healthy 
tissue, 2-moderate inflammation, 3-severe inflammation). 
The OPLS-DA algorithm was applied using SIMCA 13.0.3 
software (Umetrics, Umea, Sweden). The comparisons of 
significantly different variables between the DOX group 
and the CHX group, identified by the OPLS-DA model, 
were confirmed using non-parametric Mann-Whitney U 
test in the SPSS 17 software. P < 0.05 was considered sta-
tistically significant.
Results and discussion
OPLS-DA is a supervised chemometric algorithm 
widely applied to investigate different treatment effects. 
The properties of the OPLS-DA provide comprehensive 
description on the discrimination between classes of sam-
ples, especially in cases where subtle differences among 
classes are present. This algorithm separates the system-
atic variation in the matrix X (inflammatory biomarkers 
and clinical indices for the DOX and the CHX group, in 
our case) in two parts, one linearly related (variation of 
interest) to the matrix Y (the classification variables) and 
one orthogonally related (so-called orthogonal variation or 
structured noise) to the matrix Y. The partitioning of the X-
data improves the interpretation of the model.
In the score plot of the developed OPLS-DA model, 
the samples from both treatment groups were divided in 
two different clusters, indicating that DOX and CHX show 
different effect on the examined variables. To confirm 
model validity, the method of cross-validation was used. 
The results from the cross-validation were R2X (cum) = 
0.527, R2Y (cum) = 0.507 and Q2X (cum) = 0.530, indi-
cating a good model.
Based on the VIP statistics from the cross-validated 
OPLS – DA model, statistically significant variables re-
sponsible for separation between both treatment groups 
were extracted. VIP ranks the overall contribution of each 
variable to the generation of the model. According to the 
criterion for the VIP statistics, a VIP value > 0.8 was used 
as a threshold value for determining importance of vari-
ables. The variables most strongly influencing the discrim-
ination between the DOX treatment group and the CHX 
treatment group were periodontal pocket depth, AST activ-
ity and concentration of the cytokines IL-1β and TNF-α in 
GCF. The discriminatory variables identified by the OPLS-
DA model were additionally confirmed at a univariate lev-
el by the non-parametric Mann Whitney U test (P<0.05) 
which revealed that the DOX treatment markedly de-
creased periodontal pocket depth, AST activity and con-
centration of the cytokines IL-1β and TNF-α in GCF com-
pared to the CHX treatment. The different effects are due 
to the different mechanism of action of DOX and CHX. 
DOX possesses anti-inflammatory properties, thus is de-
creasing the inflammatory response presented by the pro-
inflammatory cytokines IL-1β and TNF-α. This molecule 
also stabilizes cell membranes, which decreases the activi-
ty of intracytoplasmic enzymes, such as AST. 
Conclusion
The comparative evaluation of the efficacy of the local 
periodontal treatment with DOX and the local periodon-
tal treatment with CHX using the OPLS-DA algorithm re-
vealed differences in the therapeutic effects of both treat-
ments, at the same time providing insights into their mech-
anisms of action. The results from this study suggest that 
the OPLS-DA algorithm is a valuable tool for comparative 
evaluation of treatment efficacy. 
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Introduction
Doxycycline (DOX), a second generation tetracycline 
antibiotic, is widely used in the treatment of periodonti-
tis. DOX accumulates in gingival fibroblasts and is further 
distributed in gingival crevicular fluid (GCF), a valuable 
matrix for monitoring concentration of drugs used in peri-
odontal treatment (Lavda et al., 2004). Since GCF is ex-
creted in low volumes, determination of drug’s concentra-
tion must be performed using sensitive methods. Applica-
tion of HPLC-UV methods for DOX determination in bi-
ological samples results in inadequate sensitivity. On the 
other hand, HPLC methods with fluorescent (FLD) detec-
tion provide the required sensitivity and are less affected 
by interference from other components from the sample 
matrix (Denic et al., 2013; Lu et al., 2004).     
The aim of our study was to develop, optimize and val-
idate RP-HPLC-FLD method for determination of DOX in 
GCF and saliva. 
Materials and methods
Referent standards of DOX, tetracycline (internal stan-
dard, IS) and oxytetracycline were supplied by Sigma-Al-
drich (Germany). Solvents (methanol and water) were of 
HPLC grade and reagents (CH3COONa, EDTA disodium 
salt and CaCl2) were of analytical grade. Whatmann 3MM 
chromatography paper strips, 2 x 5 mm (Whatman Lab 
sales Ltd., UK) were used for GCF collection.
Calibration standards for determination of DOX in 
GCF were prepared using serum instead of GCF, in the fol-
lowing concentrations: 20, 50, 100, 150, 200, 400, 500 and 
1000 ng/mL. For determination of DOX in saliva samples, 
the concentrations of the calibration standards prepared in 
saliva were 20, 50, 100, 150, 200, 400, and 500 ng/mL. For 
both GCF and saliva samples, the concentration of the IS 
was 1 μg/mL. Methanol: water mixture (50:50, V/V) was 
used as an extracting solvent.
60 patients with chronic periodontitis were assigned in 
two groups (group I and II). Group I (n=30) received con-
ventional short-term orally administered regimen (100 mg 
DOX, once a day for 21 days). Group II (n=30) received 
sub antimicrobial dose doxycycline (SDD) regimen (20 
mg DOX, twice daily for 2 months). GCF samples were 
collected from 10 periodontal pockets (pocket depth: 3-5 
mm) for 30 s, by insertion of the paper strips in the pock-
et and unstimulated saliva samples were collected in sterile 
containers (- 20 ˚C until analysis). GCF and saliva samples 
were collected 7, 15 and 21 days after beginning of thera-
py (group I) and 15, 30 and 60 days after beginning of ther-
apy in patients from group II. The study protocol was ap-
proved by the Ethics Committee at the Faculty of Dentist-
ry, Skopje. 
Before analysis, 50 μL IS working standard solution 
and methanol: water mixture (50:50, V/V) as an extract-
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ing solvent was added to each GCF sample up to volume 
of 500 μL. They were vortex for 30 s and then centrifuged 
at 1000 rpm for 5 min. For saliva samples, 100 μL of IS 
working standard solution was added to a 500 μL sample. 
The extraction solvent (methanol: water mixture (50:50, 
V/V) was added up to volume of 1000 μL. Saliva samples 
were vortex-mixed for 30 s and then centrifuged 5 min at 
4000 rpm. 
The HPLC analysis was conducted on Agilent 1200 
RR series. The chromatographic separation was performed 
on a Purospher STAR RP 18e column (250 x 4.6 mm, 5 
μm) at 30 ˚C. The mobile phase consisted of methanol 
and buffer solution (a mixture of 15 mM CaCl2, 25 mM 
CH3COONa and 25 mM Na2EDTA, pH=8.1), 50:50, V/V. 
The flow rate was 0.8 mL/min. DOX and IS were record-
ed at 380 nm as excitation (λex) and 532 nm as emission 
wavelength (λem). 100 μL were injected on the column. 
The total runtime for the analysis was 10 min. 
Results and discussion
During preliminary investigations, mobile phase com-
position, λex and λem, flow rate and the volume of injec-
tion were optimized. An IS was selected as well. 
Several mobile phases containing methanol and buf-
fer solution were investigated where the organic phase was 
varied from 20-50% (organic phase/buffer, V/V). The best 
result was obtained using mobile phase containing 50% 
methanol and 50% buffer solution (V/V). Mobile phase 
flow rate was investigated in the range from 0.6-1 mL/min 
and the final flow rate was set at 0.8 mL/min. The injection 
volume was tested and it was found that 100 μL was opti-
mal for further analysis. DOX fluorescence intensity was 
estimated using the following λex: 375 nm, 380 nm, 385 
nm and λem: 512 nm, 520 nm and 532 nm. The optimal 
value for the λex and λem were 380 nm and 532 nm, re-
spectively. Two compounds were tested as an IS, tetracy-
cline and oxytetracyline. Under the optimized conditions, 
oxytetracycline resulted in poorer peak symmetry and elut-
ed early, so tetracycline was selected instead. After the en-
tire optimization procedure the retention times for DOX 
and IS were 5.1 min and 6.5 min, respectively. Method 
validation was performed according to EMA Guideline on 
bioanalytical method validation (EMA, 2011). 
Selectivity of the method was evaluated by compari-
son of blank GCF and saliva samples and spiked samples 
of GCF and saliva containing DOX and IS. No interfering 
peaks were found at the retention times of DOX and the IS 
in both samples, thus method selectivity was confirmed. 
For GCF samples, linearity was observed within range 
20-1000 ng/mL (R2=0.9979). The within- run accuracy and 
precision ranged from 96.29-112.93% with a coefficient of 
variation (CV) within the range 2.60-4.66%. The between 
–day accuracy and precision was within the range from 
98.29-104.23 with a CV from 2.32 – 7.05%. The mean ex-
traction recovery (94.6-98.77%) confirmed an efficient ex-
traction procedure.    
For saliva samples, linearity ranged from 20-500 ng/
mL (R2=0.9965). The with-in run accuracy and precision 
ranged from 95.30-109.2% with a coefficient of varia-
tion (CV) within the range 0.81-4.26%. The between -day 
accuracy and precision was within the range from 99.00 
-109.26% with a CV of 2.11 - 8.34%. The mean extraction 
recovery of DOX from saliva samples (96.13-98.5%) con-
firmed an efficient extraction procedure. Stability testing 
showed that GCF and saliva samples are stable after three 
freeze-thaw cycles, after 12 hours in the autosampler, 24 
hours at room temperature and one month at – 20 ˚C.   
The validated method was applied for determination 
of DOX concentrations in GCF and saliva samples from 
periodontitis patients. DOX concentrations in GCF sam-
ples for group I on day 7, 15 and 21 reached 2.24 ±0.32 μg/
mL, 1.68 ± 0.19 μg/mL and 1.39 ± 0.17 μg/mL, respective-
ly. The DOX concentration in saliva samples for the select-
ed time points were  0.19 ± 0.03 μg/mL, 0.07 ± 0.01 μg/mL 
and 0.04 ± 0.01 μg/mL. 
For group II, DOX concentrations in GCF samples on 
day 15, 30 and 60 were 1.72 ± 0.29 μg/mL, 1.67 ± 0.33 μg/
mL and 1.38 ± 0.12 μg/mL, respectively. For saliva sam-
ples, DOX concentrations on day 15, 30 and 60 were 0.71 ± 
0.10 μg/mL, 0.88 ± 0.22 μg/mL and 0.31± 0.07 μg/mL, re-
spectively. As it can be seen from the results, the determined 
DOX concentrations in GCF are much higher compared to 
those in saliva which is consistent with the fact that gingival 
fibroblasts act as reservoirs of this drug (Lavda et al., 2004).
Conclusion
The data presented in this study indicate that the pro-
posed method used for determination of DOX in GCF and 
saliva samples showed satisfactory selectivity, linearity, 
accuracy and precision. The method is therefore suitable 
and applicable for the analysis of DOX in GCF and saliva 
samples in patients undergoing conventional or SDD peri-
odontal therapy.  
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Introduction
The concentration of indapamide for the needs of phar-
macokinetic and bioequivalent studies should be deter-
mined in whole blood. Given the complexity of the blood 
as an extraction medium, matrix effect (ME) is the most 
critical aspect in the method development. For these rea-
sons, particular attention should be paid during the opti-
mization of the extraction procedure. There are several re-
ported LLE procedures for extraction of indapamide us-
ing HPLC-UV or MS detection (Hang et al., 2006; Tang et 
al., 2005; Zendelovska et al., 2003). However they did not 
meet the expectations concerning the modern bioanalytical 
challenges towards sample preparation. In our previous-
ly published research, automated SPE-LC-MS/MS meth-
od for determination of indapamide in blood was devel-
oped (Nakov et al., 2013). Given the automation of the ex-
traction procedure, the method resulted in low matrix ef-
fect and great performance consistency. Taking into con-
sidering that this type of equipment is not very disseminat-
ed across the laboratories, optimization of low matrix LLE 
was acceded.  
The effectiveness of the LLE procedure in remov-
ing ME depends on the choice of a suitable organic sol-
vent, because various organic solvents can remove differ-
ent classes of phospholipids. Since the phospholipids are 
the main class of endogenous components responsible for 
the ME, monitoring of the specific phospholipids mass 
transitions was used as a tool for targeted optimization of 
the LLE procedure for indapamide extraction from human 
whole blood. 
Materials and methods
The blood samples (0.5 mL) were spiked with 50 μL 
zolpidem tartarate (internal standards, IS) working solu-
tion of 300 ng/mL, 1 mL 5% ZnSO4 and 1 mL 100 mM 
KH2PO4 (pH 6.8). The samples were vortex-mixed for 2 
min and 1 mL organic solvent was added. The extraction 
was performed by vortex-mixing for 10 min. The samples 
were centrifuged at 4000 rpm for 15 min, the upper or-
ganic layer was transferred to another tube and evaporated 
in vacuum centrifuge for 60 min. The dried residues were 
dissolved in 1 mL methanol and 10 µL were injected into 
the LC-MS/MS system. The experiments were performed 
on Shimadzu LCMS 8030 triple quadrupole mass spec-
trometer in positive ESI mode, using Kinetex C18 (100 
x 2.1mm, 1.7µm particle size) chromatographic column. 
Mobile phase was consisted of a mixture of 2 mM ammo-
nium acetate (added 0.5 mL formic acid in 1L buffer) and 
acetonitrile in ratio 10:90. Analyses were conducted at a 
flow rate of 0.2 mL/min. Positive precursor ion scan m/z 
184 was used for phospholipids monitoring. Indapamide 
and IS were quantified in selected reaction monitoring 
(SRM) using the transition of m/z 366.1→132.15 and m/z 
309.0→236.10, respectively.  
Results and discussion
The procedure of monitoring specific mass transitions 
of phospholipids (precursor ions scan of m/z 184) provides 
information about all precursor ions that fragment to tri-
methylammonium-ethyl phosphate ion (m/z 184), allow-
ing detection of all phosphatidylcholine phospholipids, ly-
sophospholipids and sphingomyelins. This procedure was 
used for identification of the class of phospholipids pres-
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ent in blood extracts and selection of an appropriate ex-
traction solvent for LLE of indapamide. Two nonpolar (di-
ethyl ether; mixture of n-hexane and dichloromethane) and 
two polar (5% MTBE in NH4OH and MTBE) extraction 
solvents were evaluated for elimination of ME and extrac-
tion recovery during the optimization of the LLE proce-
dure. Post-extraction experiments were conducted to de-
termine the degree of ME. The absolute ME was assessed 
from the responses obtained from blood extract containing 
indapamide added after the LLE and same concentration 
of indapamide added to neat solution. The post-extraction 
experiments showed that the nonpolar solvents gave high 
ME (30%). Intense peaks in the region from 1.5 - 4 min 
were found in the total ion chromatogram (TIC) of pre-
cursor ions scan of m/z 184. Several precursor ions (m/z 
496, m/z 520 and m/z 512) were detected in both blood 
extracts using nonpolar extraction solvents. These precur-
sor ions indicated the presence of lysophospholipids. Ly-
sophospholipids belong to the class of early-eluting phos-
pholipids and given the short retention time of indapamide 
(1.55 min), it was evident that this class of phospholipids 
was responsible for the ME. 
The literature data showed that polar organic solvent 
are more effective in lysophospholipids removal (Cham-
bers et al., 2007). Therefore, the subsequent experiments 
towards LLE optimization were conducted using more po-
lar extraction solvents (alkaline MTBE and MTBE). The 
TIC of precursor ions scan of m/z 184 obtained from blood 
extract after LLE with alkaline MTBE, also showed pres-
ents of lysophospholipids. The absolute ME was reduced 
from 30% to 63.6%. However, if we consider the ME 
(91%) obtained using the automated SPE procedure (Na-
kov et al., 2013); the obtained result was still unsatisfac-
tory. In addition, the extraction recovery was low (around 
62%). The use of MTBE resulted in significant removal 
of lysophospholipids, which was confirmed with the phos-
pholipids monitoring. The phospholipids signals obtained 
during the precursor ions scan of m/z 184 were with low 
intensity, which coincided with the post-extraction experi-
ments. The ME obtained using MTBE as extraction solvent 
was 90.4%, suggesting that removal of the ME from com-
plex biological material such as whole blood was achieved. 
The recovery of indapamide was found to be around 77% 
and the coefficient of variation of the LLE procedure was 
around 5%, thus confirming the acceptable repeatability.
Conclusion
In this research, it was found that MTBE is effective 
solvent for lysophospholipids removal from human blood, 
thus leading to elimination of ME during the LLE of indap-
amide. The monitoring of specific mass transitions of phos-
pholipids, as well as the post-extraction experiments, con-
firmed that the optimized LLE yields clean extract same as 
the automated SPE, thus it could be used for extraction of 
indapamide from human blood during the pharmacokinet-
ic and bioequivalent studies.
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Introduction
Lately, the Shelf Life Extension Program (SLEP) for 
extending the shelf life of the pharmaceutical products has 
been gaining more actualization and application, particu-
larly in the pharmaceutical industry (Lyon et al., 2000).
Data used for the statistical evaluation are collect-
ed from the examined parameters indicating the impact of 
the storage conditions on the quality, safety and efficacy of 
the product defined in the shelf life specification during the 
monitoring of the long-term stability of a final pharmaceu-
tical product (Yoshioka and Stella, 2000). After comple-
tion of the stability studies the results are evaluated in ac-
cordance with the regulation (ICH, 2003a).
The goal of this paper was to explore the possibility of 
shelf life extension based on statistical evaluation of stabil-
ity data of ongoing stability studies for final pharmaceuti-
cal product, Lisinopril tablets of 10mg, that contain active 
substances from different manufacturers, both with Euro-
pean quality certification (EDQM, 2015).
Materials and methods
The investigated batches of final pharmaceutical product, 
Lisinopril tablets 10 mg, with incorporated active substanc-
es from two different manufacturers, were examined over fol-
lowing stability indicating parameters: content of active sub-
stance, release of the active substance, related and degrada-
tion products and organoleptic characteristics (Diana, 2008).
Samples used in studies of stability are kept in stabili-
ty chambers, with strictly defined and controlled monitor-
ing of temperature and relative humidity (ΔC ± 2 °C, ΔRH 
± 5%) with the software system Sympati (ICH, 2003a). 
F-test method and analysis of variance (ANOVA) 
have been applied to the obtained analytical data in order to 
determine whether there are statistically significant differenc-
es between the batches in which the active substance is built 
from different manufacturers, or whether the quality of the 
active substance from various manufacturers affects the qual-
ity of the final product and the variation of the tested param-
eters (O’Brien, 1979). The interdependence between the re-
sults obtained with the long-term stability tests to 36 months 
is determined by using regression analysis. Regression anal-
ysis of the dependence of the tested parameters from the time 
of examination is performed by logarithmic regression, as a 
kind of curve that best corresponds to the nature of the re-
sults. Non-linear, i.e. logarithmic regression more suitably 
reflects the actual connection between the examination time 
and tested parameters, i.e. the content and release of the ac-
tive substance. Based on the equation, the desired shelf life is 
provided and it is compared with the experimentally obtained 
value of the parameters tested for 48 months.
Results and discussion
Evaluation of the results of stability study within the pre-
scribed period of use
The calculated F-value is 1.89 for the content of the 
active substance, i.e. 1.68 for the release of the active sub-
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stance, which is a value lower than the tabular F-value = 
19.0 on 2 degrees of freedom and statistical confidence of 
99.0%, which means that there is no statistically signifi-
cant difference between the variability of the content of the 
active substance and the release of the active substance in 
the tested batches of different manufacturers of the active 
substance.
According the Analysis of the variance, F-test value (p 
= 0.968 > 0.05 and p = 0.847 > 0.05), it can be conclud-
ed that among the average values of the content and re-
lease of the active substance in Lisinopril tablets 10 mg of 
both manufacturers there is no statistically significant dif-
ference.
Evaluation of the results of extended stability studies
The results obtained by determining the content of the 
active substance during long-term stability tests are incor-
porated in the logarithmic regression curve, from which 
extrapolating theoretical values for the content of the ac-
tive substance are derived for the new proposed shelf life 
of 48 months. The same examined samples of batches of 
Lisinopril 10 mg tablets are left in the room for stabili-
ty under the same conditions for another 12 months, in to-
tal 48 months.
By extrapolating the logarithmic regression curve the-
oretical values for the content of the active substance in 
Lisinopril tablets 10 mg are obtained after 48 months, with 
an interval of reliability at a statistical confidence of 95% 
and compared with the experimental values obtained. All 
experimental values were in the range of extrapolated val-
ues.
By extrapolating of the logarithmic regression curve, 
theoretical values for release of the active substance in 
Lisinopril tablets 10 mg after 48 months are obtained, with 
interval of confidence at a statistical confidence of 95% 
and compared with experimental values obtained. All ex-
perimental values were in the range of extrapolated values. 
In the study for the stability of tested Lisinopril tab-
lets 10 mg, the parameter “related content and degradation 
products” was monitored as well as the organoleptic char-
acteristics of the same batches on which content and re-
lease the active component of both manufacturers was de-
termined. Most of the obtained values for impurities were 
below limit of quantification, defined in the validation of 
analytical methods. These parameters were processed us-
ing risk analysis. Risk assessment of Lisinopril tablets 10 
mg was performed by using Failure Mode Effects Analysis 
(FMEA) method to identify and assess the risk of extend-
ing the shelf life and introducing an active substance from 
a new manufacturer.
Conclusion
In line with the pre set goals of this paper, the influ-
ence of the choice of the active substance on the stability of 
Lisinopril 10 mg tablets is defined through monitoring the 
stability with defined testing up to 36 months, with possi-
bility of extending the shelf life up to 48 months, in order 
to extend the period of use.
The results of the determination of the content and re-
lease of the active substance during the stability tests up 
to 48 months, indicate that none of the tested batches of 
Lisinopril tablets 10 mg exceeds the limit of the permitted 
deviation of the content of the active substance of 94% i.e. 
the limit of tolerance of the parameter of release does not 
affect the stability and quality of products and allows ex-
tension of the active substance of 85%. It can be conclud-
ed that the expiry date can be extender for an additional 
12 months, without risk of occurrence of endangering the 
health of the patient, if using the active substance of the 
two manufacturers.
Monitoring and statistical evaluation of the results 
from the stability studies of the final pharmaceutical prod-
uct has proved as useful approach for extending the shelf 
life of products with proven life cycle stability and possi-
bility for incorporation of active substances from different 
manufacturers. This concept can be applied to any prod-
uct of interest and established need for extension of the 
shelf life.
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Introduction
“Cleaning validation is a process to ensure that equip-
ment cleaning procedures are removing residues to prede-
termined levels of acceptability” (FDA, 1993).
In many cases the same equipment is used for man-
ufacturing of different pharmaceutical products (ICH, 
2000b). Well defined cleaning procedure must be used to 
avoid any contamination of a subsequent product with res-
idues of a previous product, cleaning agents and microbi-
al contaminants.
A new EU GMP requires that limits for the maximum 
acceptable carry over (MACO) of product i.e. API’s res-
idues should be based on toxicological evaluation, PDE 
(permitted daily exposure) concept (EMA, 2014).
There is a difference between the acceptance criteri-
on usually used so far (1/1000 dose and 10 ppm), in ac-
cordance with FDA’s guidelines and the determination the 
MACO by the PDE concept. For residues where toxico-
logical data is available, the MACO calculation should be 
based on the no observed effect level (NOEL). NOEL is 
the amount of drug in mg that does not have any effect on 
the human health and is calculated by using LD50 of the 
drug. The principle of MACO calculation is that the cal-
culated acceptable carry-over from the previous product, 
based upon the PDE, is transferred into the next manufac-
turing product (APIC, 2014; ECA, 2007). 
For the control of a cleaning procedure, a method suit-
able for determination of the clarithromycin residues dur-
ing the process of cleaning validation is needed.
In this research a sensitive analytical method based on 
high performance liquid chromatography was adapted and 
validated to determine residues of clarithromycin in swab 
samples.
Materials and methods
Varian HPLC System was used, equipped with Vari-
an Prostar 240 pump, Varian 325 LC detector and Galax-
ie1.9.301.220 software for data handling. The experiments 
were carried out by HPLC using Discovery C18, (125 x 4,6 
mm i.d., 5μm) column. The HPLC system was operated at 
isocratic mode using mobile phase composed of buffer so-
lution (30mM phosphate buffer pH 3.8 - 4.0) and methanol 
in ratio 35:65 (%). The temperature was 45°C, UV detec-
tion was at 200 nm and injection volume 100 μL.
The swabbing procedure was optimized in order to ob-
tain a suitable recovery of clarithromycin from stainless 
steel surfaces. Using the head of AlphaTM Swab Texwipe 
previously rinsed with methanol, the predefined 25 cm2 
surface area was wiped first in a horizontal and secondly in 
a vertical way, starting from the outside towards the centre.
Results and discussion
The HPLC method was appropriately adapted and 
validated according to ICH guidelines (ICH, 2000a). The 
method was validated through determining these valida-
tion characteristics: selectivity, linearity, precision, accura-
cy, quantification limit and detection limit. Predetermined 
maximal levels of acceptability for clarithromycin residues 
were 21 ppm in samples and 17.3 μg/cm2 per surface area 
(LeBlanc, 2000). Achieved values for LOD of 0.59 µg/mL 
(ppm) and for LOQ of 1.9 µg/mL, indicate that the pro-
posed HPLC method is enough sensitive for determining 
the established product residual limits.  Linearity was stud-
ied in the concentration range 1 - 40 ppm, and the corre-
lation coefficient (r2) = 0.9998 obtained for the regression 
line demonstrates the excellent relationship between peak 
area and the concentration of clarithromycin. The selectiv-
ity was studied by comparing a blank solution and an clar-
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ithromycin test solution, which was prepared by wiping a 
stainless steel plate 5x5cm² spiked with 10 μg/cm2  of clar-
ithromycin according to optimized swabbing technique. 
The blank solution was prepared in the same way by wip-
ing a clean plate. No sources of interference of the swab 
material were observed at the retention time of the analyte. 
As sensitive sampling methods require development 
and must be applicable to each specific piece of equipment 
used, swab recovery was determined using spiking studies 
incorporating coupons of equipment surfaces. The swab-
bing procedure was optimized in order to obtain a suitable 
recovery of clarithromycin from stainless steel plates. The 
obtained ”swab recovery” factor of 87.81% confirmed the 
appropriateness of the cleaning method, that recovery  was 
taken  into account in the results of cleaning validation.
Conclusion
HPLC method was developed and validated in order 
to determine residual amounts of clarithromycin after the 
cleaning procedure. The chromatographic technique was 
demonstrated to be sensitive, linear, accurate and precise 
in the concentration range studied. Direct sampling meth-
od was optimized to obtain effective and reliable recov-
eries. The detection limit for proposed liquid chromatog-
raphy analytical method was sufficiently sensitive to de-
tect the established acceptable level of the residues of clar-
ithromycin.
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Introduction
Hydrochlorothiazide is thiazide diuretic whose phar-
macological effects are based on inhibition of the sodium 
and chloride reabsorption and enhancement of potassium 
secretion. Cilazapril is angiotensin-converting enzyme in-
hibitor. Hydrochlorothiazide and cilazapril are antihyper-
tensive drugs which can be used as monotherapy or in fixed 
combinations (Skolnik et al., 2000; Sweetman, 2009). 
Forced degradation studies are complementary part of 
drug development strategy being undertaken for identifica-
tion of degradation products, to elucidate the degradation 
pathway and intrinsic stability of the drug. Investigation 
of degradation products formed under stress conditions is 
useful in development and validation of stability-indicat-
ing procedures and it is also necessary due to changes in 
toxicity, bioavailability or therapeutic effects of the dos-
age form (Alsante et al., 2007; ICH Q1A (R2), 2003; Kur-
mi et al., 2014). 
To date, no information on stability of cilazapril and 
hydrochlorothiazide in therapeutic combination was found 
in the literature. Therefore, stability-indicating method was 
developed. In order to confirm its applicability in routine 
quality control of cilazapril and hydrochlorothiazide dos-
age forms, robustness and other validation parameters of 
the established method have been investigated.
Materials and methods
Satisfactorily chromatographic separation was 
achieved on Kinetex C18 (2.6 µm, 50 mm x 2.1 mm) col-
umn (Phenomenex Inc., Torrance, USA) with column tem-
perature set to 25 °C with the mobile phase consisting of 
acetonitrile and buffer solution (20 mM ammonium for-
mate, pH adjusted to 8.5 with formic acid) and pumped at 
400 μL/min flow rate in following gradient elution mode: 
initial composition was acetonitrile : buffer solution (5:95, 
v/v) and final composition was acetonitrile : buffer solution 
(35:65, v/v). Time of the gradient elution mode was 15.38 
minutes. The detection was performed using PDA detec-
tor at 215 nm, 250 nm and 270 nm. Cilazapril and hydro-
chlorothiazide solutions were subjected to acidic (1.0 M 
HCl), basic (1.0 M NaOH), thermal (70 °C) and oxidative 
(15-30% H2O2) degradation and appropriate stress solu-
tions were used during method development and meth-
od selectivity investigation. Standard stock solutions of 
cilazapril and hydrochlorothiazide were prepared in con-
centrations of 1000 µg/mL and standard stock solutions of 
cilazaprilat and hydrochlorothiazide impurity B were pre-
pared in concentrations 200 µg/mL, separately by dissolv-
ing standard substances in the mixture of acetonitrile-water 
(50:50, v/v). For method validation purposes, further dilu-
tions of standard stock solutions were done with the mix-
ture of acetonitrile and 20 mM ammonium formate buf-
fer solution pH = 8.5 (20:80, v/v) in order to attain con-
centrations in the following ranges: 50.00-150.00 µg/mL 
for cilazapril, 125.00-375.00 µg/mL for hydrochlorothia-
zide, 0.50-1.50 µg/mL for cilazaprilat and 0.25-3.75 µg/
mL for hydrochlorothiazide impurity B. Cilazil HCT® tab-
lets (Pliva, Zagreb, Hrvatska) containing 5 mg of cilaza-
pril monohydrate and 12.5 mg of hydrochlorothiazide were 
purchased and used for validation.
Results and discussion
Forced degradation studies on cilazapril and hydro-
chlorothiazide active substances were conducted prior to 
method development in accordance with the ICH regulato-
ry guidelines (ICH Q1A (R2), 2003). Cilazapril appeared 
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to be unstable towards acid and base hydrolysis which re-
sulted in formation of cilazaprilat. Hydrochlorothiazide de-
graded after acid, base and thermal hydrolysis and formed 
degradation product was hydrochlorothiazide impurity B. 
Both degradation products were already reported in offici-
nal monographs of cilazapril and hydrochlorothiazide (Ph.
Eur., 2011) as their related organic impurities. After oxida-
tive degradation of both active substances, unknown prod-
ucts arisen. 
The stability-indicating UHPLC-UV-MS method was 
developed. The experimental conditions that enabled sep-
aration of cilazapril, hydrochlorothiazide and all of their 
degradation products were previously described. Method 
validation was carried out in accordance to ICH and FDA 
guidelines (Guidance for industry: Bioanalytical method 
validation, 2001; ICH Q2(R1), 2005).The selectivity of the 
method was confirmed by chromatographic screening for 
interfering substances. No interfering peaks were present 
in the chromatogram of dosage form sample at the reten-
tion times of cilazapril, hydrochlorothiazide, cilazaprilat, 
hydrochlorothiazide impurity B and unknown degradation 
products that were recorded in the chromatograms of stress 
samples. 
The method robustness was considered during the 
method development and optimization procedure. Initial 
percentage of acetonitrile in mobile phase, final percentage 
of acetonitrile in mobile phase, time of gradient elution and 
column temperature were defined as critical variables. In-
vestigated responses were retention factors of degradation 
products of cilazapril and hydrochlorothiazide denoted as 
k283.6 and k429.9, respectively, as the first and the last elut-
ing substances. Initial percentage of acetonitrile in mobile 
phase and column temperature demonstrated more signif-
icant influence on observed responses while the influenc-
es of final percentage of acetonitrile in mobile phase and 
time of gradient elution was less significant. Small chang-
es in value variables did not jeopardize responses of inves-
tigated substances. 
The concentration range for testing of the lineari-
ty of the method was: 50.00-150.00 µg/mL for cilazapril, 
125.00-375.00 µg/mL for hydrochlorothiazide, 0.50-1.50 
µg/mL for cilazaprilat and 0.25-3.75 µg/mL for hydrochlo-
rothiazide impurity B. The calculated calibration equa-
tions were y=29.7081x+18.9990, y=83.4604x+2180.4154, 
y=7.0676x-2.2344 and y=6.3525x+0.1990 for cilazapril, 
hydrochlorothiazide, cilazaprilat and hydrochlorothiazide 
impurity B, respectively. The correlation coefficients were 
0.9999, 0.9998, 0.9977 and 0.9959 for cilazapril, hydro-
chlorothiazide, cilazaprilat, hydrochlorothiazide impurity 
B, respectively and they indicated that the relationship be-
tween peak area and the concentration was linear over in-
vestigated concentration range. 
Experimentally determined value of limit of quantifi-
cation for cilazaprilat and hydrochlorothiazide impurity B 
were 0.5 µg/mL and 0.25 µg/mL, respectively. 
The precision of the method was considered as intra-
assay and it was performed in six repetitive measurements 
where concentration levels were: 100 µg/mL for cilaza-
pril, 250 µg/mL for hydrochlorothiazide, 1.0 µg/mL for 
cilazaprilat and 2.5 µg/mL for hydrochlorothiazide impu-
rity B. Results were expressed as relative standard devia-
tion values which were 0.35%, 0.25%, 4.61% and 3.23% 
for cilazapril, hydrochlorothiazide, cilazaprilat and hydro-
chlorothiazide impurity B, respectively.
Conclusion
Stability profile of cilazapril and hydrochlorothiazide 
was established and stability-indicating method was devel-
oped. The method showed good robustness and met all val-
idation criteria.
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Introduction
Moxifloxacin is a fourth-generation synthetic fluo-
roquinolone antibacterial agent. It is monohydrochloride 
salt of 1-cyclopropyl-7-[(S,S)-2,8-diazabicyclo[4.3.0]
non-8-yl]-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3 quino-
line carboxylic acid (RxList, 2016). The analytical meth-
ods for its determination in pharmaceutical dosage forms 
are not so numerous and can be categorized generally into 
two groups: nonseparative UV-Vis spectroscopic methods, 
zero order (Dhumal et al., 2011; Sahu et al., 2011) or de-
rivative (Dhumal et al., 2011) and separative, dominantly 
chromatographic methods (Abdelaziz et al., 2012; Dewani 
et al., 2011; Singh et al., 2014). These cited HPLC meth-
ods for quantification of moxifloxacin, found during liter-
ature search, show some unwanted features like skewed or 
asymmetric peaks and excessive retention achieved with 
250 mm long columns. 
Above presented facts prompted us to develop HPLC 
method for fast, simple, accurate, reproducible and rugged 
quantification of moxifloxacin in solid pharmaceutical dos-
age forms.
Materials and methods
The chemicals were Ph.Eur. grade. Potassium dihydro-
gen phosphate, ammonium dihydrogen phosphate, dipro-
pylamine and 85% phosphoric acid were purchased from 
Sigma - Aldrich, USA, whereas methanol was purchased 
from Merck KGaA, Darmstadt, Germany. The demineral-
ized water was Stilman produced and had conductivity less 
than 1 µS. Moxifloxacin working standard and Moxiflox-
acin film-coated tablets 400 mg were purchased from Re-
plek Farm, Skopje, Macedonia. 
The experiments were performed on three HPLC sys-
tems: Varian Prostar with DAD 330 detector controlled with 
Varian Star software version 6.21, UPLC Dionex with four-
channel UV-Vis detector controlled with Chromeleon ver-
sion 6.8 and UPLC Shimadzu Nexera with dual-channel 
UV-Vis detector controlled with Lab Solutions version 5.54.
Following HPLC columns were tested: 
- RP Select B 125 mm x 4 mm, 5 µm (Merck Darm-
stadt, Germany);
- Discovery C8 150 mm x 4.6 mm, 5 µm (Supelco 
Bellefonte, USA);
- Discovery C18 100 mm x 4.6 mm, 5 µm (Supelco 
Bellefonte, USA);
- Discovery C18 125 mm x 4.6 mm, 5 µm (Supelco 
Bellefonte, USA).
The test and standard solutions were prepared by dis-
solving suitable amount of the active substance or pow-
dered film-coated tablets in methanol or water to obtain 
concentrations in the range of 0.1 - 0.5 mg/mL.
Results and discussion
The characteristic UV-absorption spectrum of moxi-
floxacin with maximum at 293 nm permits use of almost 
all commonly used buffers in chromatography. Consider-
ing moxifloxacin pKa values (pKa1=6.25 and pKa2=9.29) 
(Lanqlois et al., 2005) and its well documented solubility 
in more polar solvents, phosphate buffers with pH value 3 
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in combination with methanol as mobile phase were used. 
Two different phosphate buffers, 25-30 mM NH4H-
2PO4 and KH2PO4 with pH=3 were tested. Slight insignifi-
cant advantage was given to ammonium dihydrogen phos-
phate compared to potassium dihydrogen phosphate, when 
peak symmetries were compared. The mobile phases were 
tested without and with added dipropylamine as a peak 
symmetry corrector by suppressing the ion-exchange inter-
action of residual silanol groups with protonated N-atoms 
in analyte molecule. The addition of 0.2% v/v dipropyl-
amine in 25 mM ammonium  dihydrogen phosphate at pH 
3 improved the peak symmetry from 1.47 to 1.25. 
Fluoroquinolones with their characteristic molecule 
structure are well known to chromatographists as prob-
lematic with yielding tailing peaks on the chromatograms, 
usually corrected with use of high percentage of amines in 
mobile phase composition, up to 1 - 2% v/v. This prompt-
ed our investigation, to choose chromatographic column 
which has high quality end-capped silica particles with 
lowest content of residual metal cations.
Toward aiming the goal, two C8-octylsilane columns 
and two C18-octadecylsilane columns from the same man-
ufacturer but with different dimensions were tested. 
The comparison of the chromatograms obtained with 
C8 and C18 columns from identical vendors showed that 
no significant preferences could be noticed. Both C8 and 
C18 can create perfect peak of moxifloxacin which can be 
fine adjusted with retention needed. It was clearly seen that 
lowering the percentage of methanol from 55% v/v to 40% 
v/v increases the peak retention and symmetry. Slight pref-
erence from the peak symmetry and less organic consump-
tion point of view in our experiments showed C8 filled col-
umns, that yielded moxifloxacin peak with t5% = 1.15. 
This fact generally does not prefer C8 over C18 columns, 
since peak symmetry could be sacrificed in aim to improve 
resolution, which is more important in chromatographic 
separations. Depending on the sample constituents com-
plexity and target system suitability demands of the chro-
matographic method, C8 and C18 could be successfully in-
terchanged and optimized for all demands. 
C8 reversed phase column has stronger hydrophobic 
interactions than Phenyl-RP columns but weaker than C18. 
The HPLC method for related compounds of moxifloxacin, 
described in Ph.Eur.8 (2014) uses Phenyl-bonded RP col-
umn with TBAH cationic ion pair reagent in mobile phase, 
and it shows relatively close elution of related compounds 
with moxifloxicin. This is expected to be improved with 
use of more retentive C18 column.
The use of chromatographic columns having particles 
with wide pores also showed to be advantage in our in-
vestigations. Discovery C8 columns have pores with about 
180 nm diameter, whereas RP Select B columns have 60 
nm pores diameter, and generate wide skewed and distort-
ed peak of moxifloxacin. 
Discovery columns are better end-capped and more 
base-deactivated, which was shown to be advantage dur-
ing our method development. 
Finally, the proposed chromatographic conditions for 
the optimized method for quantification of moxifloxacin 
are: mobile phase composed of 25 mM NH4H2PO4 pH=3 
and methanol (65% : 35%, v/v), with flow rate 1.1 ml/min, 
HPLC column Discovery C8 150 mm x 4.6 mm with 5 µm 
particles, thermostated at 35 °C, detection wavelength at 
293 nm and injection volume of 5 µl. Moxifloxacin peak 
elutes for less than 5 minutes with symmetry expressed as 
AsUSP ~1.2.
Conclusion
The proposed method is fast, simple cost-effective, re-
producible and rugged, intended for high-throughput rou-
tine assay analysis of moxifloxacin in solid pharmaceutical 
dosage forms. It can be further optimized and improved, 
using columns with different properties, better retention 
and selectivity, or changed ratio of mobile phase constit-
uent, in order to achieve better retention of moxifloxacin 
peak and better resolution from its degradation products in 
order to make it suitable for use during stability testing of 
the pharmaceutical formulations. 
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Introduction
Norfloxacin is a first generation synthetic fluoroqui-
nolone, a broad spectrum antibacterial agent, approved 
for treatment of urinary tract infections, sexually trans-
mitted diseases and prostatitits. Its IUPAC name is 1-eth-
yl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quino-
linecarboxylic acid (RxList, 2016). Majority of fluoroqui-
nolone molecules, especially norfloxacin, are well known 
as problematic in terms of peak shape appearing on the 
chromatograms. They are often obtained as highly asym-
metric, tailing peaks with calculated values of symmetry 
factor of about 2 or even greater. This fact complicates and 
compromises method accuracy based on the difficulties in 
determination of peak end on baseline. These problems 
are frequently solved with use of expensive high quality 
HPLC columns with double and triple end-capped bond-
ed reversed phase silica matrixes and extensive base-deac-
tivation of metal cations from silica particles. British Phar-
macopoeial monograph (BP, 2013) for norfloxacin active 
pharmaceutical ingredient assay determination prescribes 
use of C16 column with gradient elution with water acidi-
fied to pH ~2 and acetonitrile at high column temperature 
of 60 °C and for norfloxacin tablets acidic isocratic elu-
tion with 0.1% v/v o-H3PO4 and acetonitrile with previous 
washing of column with different buffer, for 8 hours.
Many different methods are published (Bera et al., 
2014; Chierentin and Salgado, 2013; Oliveira et al., 2009; 
Singh et al., 2013) for norfloxacin determination in phar-
maceutical dosage form. All of them conflict with the men-
tioned problem of peak symmetry of norfloxacin and this 
problem is differently eliminated with use of amines, gra-
dient elutions, high column temperatures, expensive high 
quality columns employment etc.
The aim of our study was to develop fast, simple ac-
curate and robust HPLC method for determination of nor-
floxacin in pharmaceutical dosage forms, yielding chro-
matographic peak of norfloxacin with satisfying symme-
try, without using gradient elution, high column tempera-
tures and expensive high quality columns.
Materials and methods
Ammonium dihydrogen phosphate (NH4H2PO4), 
85% phosphoric acid and potassium hexafluorophos-
phate (KPF6) were purchased from Sigma - Aldrich, USA, 
whereas methanol, acetonitrile and 70 % perchloric acid 
(HClO4) were purchased from Merck KGaA, Darmstadt, 
Germany. All the chemicals used were Ph.Eur. grade. The 
demineralized water was Stilman produced and had con-
ductivity less than 1 µS.
Common HPLC system was used, Varian Pro Star sys-
tem with autosampler 410, Varian 325 dual-channel and 
Varian 335 photodiode-array detector, with ternary high 
pressure mixing pump, controlled by Galaxy software ver-
sion 1.91.
Following two chromatographic columns were tested: 
RP Select B 75 mm x 4 mm, 5 µm and RP Select B 125 
mm x 4 mm, 5 µm, both products of Merck Darmstadt, 
Germany.
Norfloxacin working standard and Norfloxacin film-
coated tablets 400 mg were purchased from Replek Farm, 
Skopje, Macedonia.
Test and standard solutions were prepared by dissolv-
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ing suitable content of the active substance or powdered 
film-coated tablets in solvent composed of 5% v/v aceto-
nitrile and 95% v/v 0.1% v/v H3PO4, to concentration of 
0.4 mg/ml.
Results and discussion
During development of appropriate chromatograph-
ic method for quantification of norfloxacin with improved 
peak symmetry, we intended to investigate influence of 
participation of chaotropic salts in mobile phase constitu-
tion. 
For this investigation we decided to use lower quality 
reversed HPLC column, RP Select B with two dimensions 
75 mm x 4mm and 125 mm x 4 mm, with 5 µm particles, 
manufactured by Merck Darmstadt, Germany. These col-
umns have a matrix which is single end-capped and partial-
ly base-deactivated silica particles with small, 60 nm wide 
pores. With these characteristics RP Select B is not appro-
priate choice for column in chromatographic method for 
norfloxacin determination, but use of this column should 
better manifest the influence of appropriate mobile phase 
on peak symmetry.
We performed two tests of same column matrix of RP 
Select B with different dimensions:
1. Using RP Select B 75 mm x 4 mm with 5 µm par-
ticles, mobile phase flow rate of 1.1 ml/min, chromato-
graphic column temperature of 32 °C, injection volume of 
5 µl, UV detection at 277 nm, and mobile phase consisted 
of 30% v/v methanol and 70% v/v mixture of 0.13% w/v 
NH4H2PO4, 0.2% w/v KPF6 and 0.1% v/v HClO4 with pH 
value 2.39. 
The chromatogram obtained under these conditions 
showed norfloxacin peak with retention time ~2.9 minutes, 
height ~570 mAU and symmetry expressed as AsUSP ~1.25.
2. Using RP Select B 125 mm x 4 mm with 5 µm par-
ticles, mobile phase flow rate of 1.0 ml/min chromato-
graphic column temperature of 30 °C, injection volume of 
5 µl, UV detection at 277 nm, and mobile phase consisted 
of 35% v/v methanol and 65% v/v mixture of 0.13% w/v 
NH4H2PO4, 0.2% w/v KPF6 and 0.1% v/v HClO4 with pH 
value 2.39.
The chromatogram obtained under these conditions 
showed norfloxacin peak with retention time ~3.75 min-
utes, height ~560 mAU and symmetry expressed as AsUSP 
~ 1.2.
With these results, the peak symmetry and retention 
correction features of potent chaotropes like KPF6 was 
confirmed as beneficial. In our case, peak retention was not 
a primary problem. The main problem was the peak sym-
metry. According to theory and publication of Kazakievic 
and Lobrutto (2007), the beneficial features of the chaotrop 
KPF6 are more significant with use of acetonitrile instead 
of methanol. But in our case, use of KPF6 chaotrop showed 
much better peak symmetry correction benefit, than ex-
tended peak retention. Other important thing to mention is 
that use of 0.1% v/v HClO4 contributes to peak symmetry 
too, since the ClO4- anions are also chaotropic, but in less-
er extent than PF6- anions.
Further improvements of peak symmetry and reten-
tion can be achieved with increase of content of chaotropic 
agent KPF6, but it is not necessary to extent run time for 
insignificant increase of peak symmetry. Better peak sym-
metry can be achieved with use of more expensive, new, 
high end-capped and well base-deactivated columns. Use 
of wider particle pore column is preferential when com-
pared with 60 nm pores of RP Select B column.
Conclusion
New approach in creating fast, simple, accurate and 
robust RP-HPLC method was developed, which is very 
useful in high-throughput analysis per day, in pharmaceu-
tical quality control routine analysis of norfloxacin phar-
maceutical dosage forms. Method can be further adjusted 
and adapted for other intents of analysis, bioequivalence 
testing, pharmacodynamic, forensic analysis and similar.
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Introduction
In process of stability testing of a drug product it is 
very important to perform forced degradation studies. It is 
necessary to perform these studies in process of develop-
ment the stability indicating method which can be applied 
latter for the analysis of samples generated from accelerat-
ed and long term stability studies in proposed shelf life to 
ensure that all possible degradation products that may oc-
cur in proposed shelf life in normal conditions of storage 
can be separated, detected and quantified (Djurdjevic et al., 
2009; Singh  et al., 2014; Sultana et al., 2011).
Moxifloxacin is a fourth-generation antibiotic drug of 
the fluoroquinolone familly, with higher activity against 
Gram-positive pathogens including Streptococcus pneu-
monie, than the other drugs from fluoroquinolone family 
(Dewania et al., 2011; Lalitha Devi and Chandrasekhar, 
2009).
The objective of the present study was to report the sta-
bility of moxifloxacin in tablet formulations available on 
the local market, based on the information obtained from 
forced degradation studies, to develop and validate new 
stability-indicating HPLC method for quantitative analy-
sis of moxifloxacin and its related substances in pharma-
ceutical dosage form tablet and to develop LC-MS method 
for the characterization of new degradation products in ac-
cordance with the information obtained from forced degra-
dation studies. 
Materials and methods
Three different tablet formulations (Formulation A: 
MOXI film tablets 400 mg-ZADA Pharmaceuticals, For-
mulation B: AVELOX film tablets 400 mg-Bayer, Formu-
lation C: CENOMAR film tablets 400 mg-Hemofarm), 
purchased from the local market were tested. European 
Pharmacopoeia Reference Standards Moxifloxacin hy-
drochloride CRS and Moxifloxacin for peak identification 
CRS were used. Analytically pure moxifloxacin was ob-
tained from Nosch Laboratories Limited, India. All chemi-
cals and reagents used were of HPLC-grade purity.
A High Performance Liquid Chromatographic system 
(Thermo Surveyor HPLC) equipped with Finnigan Sur-
veyor LC quaternary pump, Finnigan Surveyor Autosam-
pler plus, Finnigan Surveyor PDA plus detector in isocrat-
ic mode was used for the analysis.
Experimental design was used to optimize experimen-
tal conditions. The method was optimized by analysis of 
the samples generated during the forced degradation stud-
ies. Experimental factors, independent variables, were se-
lected as inputs and as dependent variables were study res-
olution between typical peaks and retention factor of moxi-
floxacin because latest eluted. 
To assess the impact of some experimental factors on 
the responses of the system it was applied central compos-
ite design. The optimal chromatographic conditions were 
selected by calculating Desirability function.
After optimizing the experimental conditions the sep-
aration was conducted on a ZORBAX-SB Phenyl column 
(250x4.6 mm, 5 μm particle size) with mobile phase com-
posed of methanol:buffer (0.5 g/L tetrabutylammonium 
hydrogen sulphate, 1.0 g/L monobasic potassium dihydro-
gen phosphate and 3.4 g/L phosphoric acid in water) in ra-
tio 71:29, v/v; pumped at 1.5 ml/min flow rate. The column 
temperature was set at 50 °C and the detection at 293 nm 
using Diode Array Detector. 
LC-MS method was developed for characterization 
of degradation products using HYPERSIL GOLD PFP 
150x4.6 mm, 5 μm column with mobile phase composed 
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of ammonium formate (20mM): acetonitril pH=4; (70:30, 
v/v ) pumped at 1 ml/min flow rate. The column tempera-
ture was set at 25 °C and the detection at 295 nm using Di-
ode Array Detector. 
The medicine was subjected to acid (4 mol/l HCl, 
70 °C for 6 days) and base (4 mol/l NaOH, 50 °C for 6 
days) hydrolysis, oxidative decomposition (3% H2O2), 
thermal and photolytic stress. 
Forced degradation studies were conducted on the ac-
tive substance, placebo mixture and binary mixtures of 
moxifloxacin with the excipients from the tablet formula-
tions, in the same stress conditions, to determine the origin 
of the formed degradation products.
Results and discussion
New LC-MS compatible stability-indicating HPLC 
method for moxifloxacin was developed. Significant deg-
radation was caused by acidic and basic conditions. The 
results were comparable in all tested tablet formulations. 
In the samples without stress impurities were not detected.
Under basic conditions  (4 mol/l NaOH, 50 °C for 6 
days) two degradation products have been detected (RRT 
0.5 min. and 0.6 min.) in all three tested tablet formulations. 
Under acidic conditions (4 mol/l HCl, 70 °C for 6 
days) one degradation product (RRT 0.8 min.) was detect-
ed with significant area in all three tablet formulations. In 
formulation B it one additional degradation product on 
RRT 1.3 min. was detected, while in formulation C two ad-
ditional degradation products (RRT 0.4 min. and 1.3 min.) 
were detected.
It was found that the degradation products formed in 
the presence of base are result of the interaction between 
moxifloxacin and excipients in the tablet formulation: lac-
tose and cellulose, while the degradation products caused 
by acidic conditions are performed as a result of degrada-
tion of the active substance moxifloxacin. 
Composition of formulation A and B included cellu-
lose and lactose, while formulation C had only cellulose 
in its composition. All degradation products were identi-
fied as unknown.
Conclusion
An isocratic stability-indicating RP-HPLC method for 
quantification of moxifloxacin and its related substances 
in moxifloxacin tablets was optimized and validated. LC-
MS method was found to be suitable for separation of deg-
radation products formed under stress conditions. In all of 
the three tested tablet formulations unknown degradation 
products were found, which need to be identified.
The developed LC-MS method can be used for fu-
ture research which objective will be the identification of 
formed degradation products.
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Introduction
Diazepam (DZP) (7-chloro-1, 3-dihydro-1-methyl-
5-phenyl-2H-1, 4-benzodiazepin-2-one) is a benzodiaz-
epine (BZD) generally used as hypnotic, anxiolytic and 
muscle relaxant. DZP is also routinely prescribed as the 
standard first-line treatment for acute convulsions and pro-
longed status epilepticus (Martindale, 2009). Several meth-
ods for the analysis of BZDs have been reported. A num-
ber of chromatographic methods such as: thin-layer chro-
matography (TLC) (Hancu et al., 2011), gas chromatog-
raphy and gas chromatographic–mass spectrometry (GC–
MS) (Kudi et al., 1988) have been used in the analysis of 
DZP and other 1,4-benzodiazopines. Several high-perfor-
mance liquid chromatographic (HPLC) methods have also 
been reported for the determination of diazepam and oth-
er BZDs (Magalhães et al., 2012; Moros et al., 2007). Ben-
zyl alcohol (BA) is used as an antimicrobial preservative 
in pharmaceutical and cosmetic products and its concen-
tration should not exceed limit values for each formulation 
type because it could produce fatal toxic effects, allergies 
and various other effects on the nervous system (Martin-
dale, 2009). Benzyl alcohol is quantitatively estimated in 
raw material and pharmaceutical preparations by gas chro-
matography, derivative spectrophotometry, HPLC, am-
perometric enzyme electrode, polarography des and cap-
illary electrokinetic chromatography (Khade et al., 2014; 
Sen, 2011). To the best of our knowledge no analytical 
method is available for the simultaneous determination of 
DZP and BA in pharmaceutical preparations. Therefore, it 
was considered necessary to develop a HPLC method for 
the quantification of these compounds in pharmaceutical 
dosage forms. We wish to describe a simple, rapid, eco-
nomical and accurate method of analysis using reversed-
phase HPLC to simultaneously determine DZP  and BA in 
microclismes.
Materials and methods
The chromatographic analysis was performed using 
DionexUltiMate 3000 UHPLC focused. The HPLC grade 
acetonitrile was developed using ReproSil-Pur 120 C4, 150 
x 4,6 mm, 3,0 µm  chromatographic column with mobile 
phase containing a mixture of 0.1% (v/v) orthophosphoric 
acid in water and acetonitrile in the ratio of 70:30 v/v, re-
spectively. Isocratic method was used with runtime of 10 
minute. The flow rate of the mobile phase was 1.5 mL/
min. The column temperature was maintained at 35°C and 
the eluted compounds were monitored at the wavelength 
of 254 nm. The injection volume was 20 μL. A standards 
stock solution of DZP and BA were prepared in metha-
nol with a concentration of 2 mg/mL and 0.015 mL/mL. 
Working standard solutions were prepared from  stock so-
lutions by further dilution with water. The sample solution 
was prepared by dissolving 0.5 mL solution of microclisme 
in a 50 mL volumetric flask (US bath for 7 min) and dilut-
ing with water to volume. The sample solution was filtered 
through a 0.45 µm PTFE membrane filter.
Results and discussion
The proposed method was validated as per ICH guide-
line (ICH, 2003). The following validation characteristics 
were addressed:  suitability, specificity, precision,  lineari-
ty,  accuracy, and robustness.
System suitability was checked for the conformance 
of suitability and reproducibility of chromatographic sys-
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tem for analysis. The system suitability was evaluated on 
the basis of USP capacity factor, tailing factor and theo-
retical plates of DZ and BA and relative standard devia-
tion (RSD) of six injections of standard solution. Sys-
tem suitability was determined before sample analysis. 
The acceptance criteria were % RSD should not be more 
than 2.0%, USP tailing factor should less than 2.0 and the-
oretical plate should be more than 3000 for DZ and BA 
peak from standard solutions. All critical parameters test-
ed met the acceptance criteria [kDZ’=5.35  kBA’=1.14, 
AsDZP=1.4 and AsBA=1.1, NDZP=4800 and NBA=4253, 
RSDDZP=0.001  and  RSDBA=0.0017). Specificity study 
to establish the interference of placebo was conducted. 
Study was performed on Placebo (Placebo contains excipi-
ents without DZP and BA). Chromatogram of placebo had 
shown no peaks at the retention time of DZP and BA, indi-
cating that the excipients used in the formulation do not in-
terferewith the estimation of DZP and BA. The precision of 
the method was verified by repeatability and intermediate 
precision at three concentration levels (DZP: 0.017 mg/mL 
to 0.023 mg/mL and BA: 0.118 µL/mL to 0.162 µL/mL). 
The intermediate precision of the method was also evaluat-
ed using different analyst and different instrument and per-
forming the analysis on different days. The RSD (%) of re-
sult for DZP and BA was calculated. The % RSD for the 
result of DZP in was within 0.65% and in intermediate pre-
cision study was within 0.28%, The % RSD for the result 
of BA in was within 0.63% and in intermediate precision 
study was within 0.29%, which confirms the good preci-
sion of the method. Linearity test solutions were prepared 
by diluting the stock solutions to the required concentra-
tions by covering the range from 0.014 to 0.026 mg/mL of 
DZP and 0.098 to 0.182 µL/mL of BA. Calibration curves 
were plotted between the responses of peak versus ana-
lyte concentrations. The correlation coefficient obtained 
was greater than 0.999 (for DZP is 0.9995 and for BA is 
0.9992). The above result shows that an excellent correla-
tion existed between peak area and concentration of DZP 
and BA. Accuracy of the method was evaluated in triplicate 
using three concentrations levels (80%, 100% and 120%) 
and confirmed by calculated recovery values. The percent-
age recoveries for DZP and BA were calculated and varied 
from 98.76 to 101.50 for DZP and from 98.15 to 101.96 for 
BA. To determine the robustness of the developed method, 
experimental conditions were deliberately altered and sys-
tem suitability (SST) parameters for DZP and BA standard 
were recorded. The variables evaluated during the robust-
ness testing were: composition of the mobile phase, col-
umn temperature and flow rate. The obtained results have 
shown that the method is robust for experimental variation 
of composition of the mobile phase and column tempera-
ture, but it is not robust for the change of the flow rate. Re-
covery value lies in the proper range of from 95% to 105%, 
ie. RSD does not deviate by more than ± 5% (RSD=0.64% 
for diazepam, RSD=0.49% of benzyl alcohol). 
Conclusion
A simple and efficient reverse-phase HPLC meth-
od was developed and validated for quantitative analy-
sis of DZP and BA inmicroclisme as pharmaceutical dos-
age forms. The method found to be precise, accurate, lin-
ear, robust and rugged during validation. The method could 
be used for routine analysis of production samples and to 
check the stability of the DZ and BA.
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Introduction
Developing GC-MS methods for chemical character-
ization of pharmaceutical packaging materials presents 
significant challenge, since the sheer number of additives 
and their degradation products that can be found in packag-
ing materials and subsequently separated and detected with 
this technique is enormous (Jenke, 2009). These methods 
need to be capable of simultaneous separation and detec-
tion of aliphatic fatty acids, alcohols, amides and their de-
rivatives, compounds that are traditionally difficult to sep-
arate and detect, due to the large similarity in structure and 
their physico-chemical properties.
The aim of this paper was to develop a GC method for 
chemical characterization of semi-volatile additives and 
their degradation products in packaging materials for phar-
maceutical use.
The GC method was developed using a commercial-
ly available system suitability mixture (Grob Test Mix), 
containing 11 compounds that belong to different chemi-
cal groups of compounds, which was suitable for the in-
tended approach to develop a method that will be simulta-
neously capable of separation of different groups of pack-
aging additives.
Materials and methods
Development was made using Grob DA 280 Column 
Test Mix (Restek Corp., Bellefonte, USA). The mixture is 
composed of 11 compounds (n-Decane (C10), Methyl dec-
anoate (C10:0), n-Undecane (C11), Methyl undecanoate 
(C11:0), Methyl dodecanoate (C12:0), L(+)-2,3-Butanedi-
ol, 2,6-Dimethylaniline, 2,6-Dimethylphenol, 2-Ethylhex-
anoic acid, Nonanal and 1-Octanol), dissolved in methy-
lene chloride (DCM). 
All experiments were performed on Shimadzu GC-
2010 Plus gas chromatograph and Agilent 7890B gas chro-
matograph equipped with Agilent 5977A single quadru-
pole mass spectrometer. MS identification of the detected 
compounds was performed by AMDIS spectral deconvo-
lution and comparison of spectra with NIST library, using 
MassHunter software. For those compounds where library 
match was low, attempts to establish compound’s identity 
were made via mechanistic fragment predictions of avail-
able spectral data, using MassFrontier v7.0 software.
Results and discussion
The development of the chromatographic conditions 
started using a non-polar GC WCOT chromatographic col-
umn (Agilent DB-5 ms; 30m x 0.25 mm x 0.25 μm), with 
helium as carrier gas at 2 ml/min (constant velocity, which 
has the advantage over constant pressure mode toward the 
end of the run, where increase in temperature would other-
wise drastically reduce the flow, leading to prolonged run-
time and reduced sensitivity because of decrease of col-
umn efficiency). The following temperature gradient con-
ditions were chosen for initial separation of the Grob Test 
Mix: 40 °С (hold 2 minutes), 10 °С/min to 330 °С (hold 10 
minutes), injector temperature was set at 250 °С and injec-
tion volume of 1 µL with split ratio of 1:10. Evaluation of 
the chromatograms quickly revealed that the method con-
ditions aren’t capable of separating the mixture, with mul-
tiple co-elutions observed.
In order to achieve specificity of the method, optimi-
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zation of the conditions by variation of the carrier gas flow 
and temperature gradient was attempted. Besides the im-
provement in the separation of the components, is was 
found to be impossible to separate two critical pairs of 
compounds (n-undecane and n-nonanal; 2,6-dimethylphe-
nol and 2-ethylhexanoic acid), even with extreme gradi-
ent changes.
A change in the stationary phase chemistry was the 
next logical step, therefore the Agilent DB-5 column was 
replaced with a non-polar Rxi-1 column (Rxi-1 MS 30m x 
0.25mm x 0.25μm, Restek Corp., Bellefonte, USA), with 
the idea to promote different interactions between the sta-
tionary phase and the components from the critical pairs. 
The change in column chemistry proved to be successful, 
and minor changes to the temperature gradient conditions 
yielded complete baseline separation of all components 
from the Grob DA 280 Column Test Mix. The final chro-
matographic conditions were defined as: flow: 2 ml/min 
(constant flow); temperature gradient: 60 °С (hold 2 min-
utes), 10 °С/min to 80 °С (hold 2 minutes), 3 °С/min to 100 
°С, 25 °С/min to 310 °С (hold 10 minutes); injection vol-
ume: 1 µL; split ratio: 1:5. The injector temperature was in-
creased to 310 °С to obtain faster evaporation of the sam-
ple, better sensitivity and reduced peak width.
Besides the components from Grob DA 280 Column 
Test Mix, stearic acid and erucamide (cis-13 docosen-
amide) were chromatographically evaluated, and proved to 
be completely separated from the rest of the components 
from the Grob DA 280 Column Test Mix. These two com-
pounds were evaluated not only because they are frequent-
ly used additives in the packaging materials, but also be-
cause they are candidate molecules for derivatization in 
gas chromatography.
Detection of the separated components was simulta-
neously performed with FID and MS detector using post-
column splitter valve, in accordance with PQRI’s recom-
mendations (PQRI Leachables and Extractables Working 
Group 2006) to reduce the chances of missing an extracted 
compound, due to detector type specificities.
Low-density polyethylene (LDPE) and polypropylene 
(PP) plastics were evaluated by generating a number of ex-
tracts in water buffers, methanol and hexane and analyzed 
using the proposed method. Both detectors showed equiv-
alent responses (as a number of detected compounds), us-
ing their default parameters, with the methanol and hexane 
extracts showing highest numbers of detected components 
of all extracts.
Conclusion
Gas chromatography is extremely important technique 
for analysis of extractables and leachables, due to the fact 
that it enables efficient separation and detection of an enor-
mous number of organic compounds commonly encoun-
tered in packaging materials. Coupling gas chromatogra-
phy with MS detection further enhances its capabilities to-
ward identification of the detected compounds, giving a 
clearer picture of the additives profile of the tested mate-
rial.
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Introduction
Pregabalin is described chemically as (S)-
3-(aminomethyl)-5-methylhexanoic acid and is also known 
as β-isobutyl-γ-aminobutyric acid (beta-isobutyl-GABA). It 
is pharmacologically similar to gabapentin. Pregabalin is ap-
proved for the management of neuropathic pain associated 
with diabetic peripheral neuropathy and postherpetic neural-
gia and for adjunctive treatment of partial onset seizures. 
This drug has a specific chemical structure, without 
presence of any specific UV-chromophore, like, for exam-
ple, cyclic structure with double bonds, absorptive group 
or bond in the molecule, which complicates its detection 
with UV absorbing detectors. 
Patil et al. (2015) have developed spectrophotometric 
method for determination of Pregabalin, based on conden-
sation reaction of Pregabalin with p-dimethylaminobenz-
aldehyde in an acidic medium, leading to formation of a 
complex that shows maximum absorbtion at 395.80 nm.  
There are also many HPLC methods with UV detec-
tion. Some of them require precolumn chemical derivatiza-
tion of Pregabalin, using 1-fluoro-2,4-dinitrobenzene as 
derivatiozation agent (Ahmadkhaniha et al., 2014). How-
ever, their application for routine pharmaceutical quali-
ty control of drug products is difficult and inappropriate. 
Among the other common HPLC/UV methods developed 
for this aim, the following deficiencies can be met: low ca-
pacity peak (Kasawar and Farooqui, 2010), inappropriate 
UV absorbing mobile phase components having lowUV-
cut off, such as ammonium acetate buffer (Balaji et al., 
2014), highly asymmetric peaks (Ashu et al., 2011; Kanna-
pan et al., 2010) and even not-acceptable declared sensitiv-
ity (Saeed et al., 2014).
The aim of this work was to overcome above men-
tioned obstacles, and to develop HPLC method for Prega-
balin determination in solid pharmaceutical dosage forms, 
for routine analysis, in quality control laboratories, in phar-
maceutical industry. 
Materials and methods
All the chemicals used were Ph.Eur grade. Acetoni-
trile and sodium hydroxide were products of Merck KGaA, 
Darmstadt, Germany, whereas potassium dihydrogen phos-
phate and 37% hydrochloric acid was purchased from Sig-
ma  Aldrich, USA. The demineralized water was Stilman 
produced and had conductivity less than 1 µS. Pregabalin 
capsules and Pregabalin working standard were purchased 
from Replek Farm, Skopje, Macedonia.
Analyzes were conducted on HPLC system Varian 
Prostar with ternary high pressure mixing pump, autosam-
pler 410 with column oven and DAD 330 detector con-
trolled by Varian Star software version 6.21 and UPLC sys-
tem Shimadzu Nexera with low pressure mixing quaterna-
ry pump, autosampler, column oven, controller and dual-
channel UV-Vis detector, controlled by Lab Solutions soft-
ware version 5.54. 
Following HPLC columns were used: 
- Hypersil C18 ODS 100 mm x 4 mm, 3 µm 
(Thermo scientific, USA); 
- RP Select B 75 mm x 4 mm, 5 µm (Merck 
Darmstadt, Germany);
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- Purospher C18e STAR 125 mm x 4 mm, 5 µm 
(Merck Darmstadt, Germany);
- Discovery C18 125 mm x 4,6 mm, 5 µm (Su-
pelco Bellefonte, USA).
The final proposed chromatographic conditions are: 
Discovery C18 chromatographic column, mobile phase 
consisted of 7% v/v acetonitrile and 93% v/v of 25 mM 
KH2PO4 (pH 7.0) with flow rate 1.0 mL/min, column tem-
perature 30 οC and 20 µL injection volume.
Test solution was prepared by dissolving 1 capsule in 
500 mL volumetric flack and diluted with 0.1 M hydro-
chloric acid to volume.
Results and discussion
The choice of HPLC column had strong impact on Pre-
gabalin peak height, shape and capacity. Therefore, during 
method development four different HPLC columns were 
tested: 3 µm particle column Hypersil C18 ODS, RP Select 
B with 5 µm, Purospher C18e STAR with 5 µm and Dis-
covery C18 with 5 µm particles. Best results were achieved 
using Discovery C18 column matrix, which was somewhat 
expected from particles having 180 nm wide pores, well 
base deactivated (metal cations purified) and end-capped 
of free silanol groups of silica chromatographic matrix. Pu-
rospher columns have highest purity (lowest quantity of 
metal cations) chromatographic matrix but the wide pore 
particles of Discovery yield higher and narrower peak of 
Pregabaline, which makes this column more appropriate 
for achieving good sensitivity of the method.
Increasing the injection volume was another way to im-
prove sensitivity, accompanied by creation of deeper base-
line disturbances even when highly UV transparent mo-
bile phase composition was used. Similarity between sam-
ple solvent and mobile phase improved the chromatogram 
appearance, since the presence of water in sample always 
generates deep negative peaks when working at very low 
UV wavelength signal. It is essential to dissolve the sam-
ple in mobile phase in aim to avoid negative peaks on the 
whole picture of chromatogram.  Additionally, the method 
sensitivity could be decreased if the sample is additionally 
diluted with water or mobile phase. 
The use of UV-DAD detector enabled comparison of the 
increase of method sensitivity by lowering monitoring wave-
length from 215 nm up to 200 nm. It was found out that sig-
nal monitoring wavelength at 210 nm was adequate for most 
types of pharmaceutical analysis of Pregabalin in solid phar-
maceuticals, i.e. for assay and dissolution determination. 
Pregabalin molecule has two pKa values, 4.2 and 10.6, 
corresponding to the carboxylic acid and the amine groups, 
respectively. Mobile phase buffer with pH = 7.0 was tested 
and yielded satisfying chromatohraphic peaks of the analyte 
with retention time ~ 2 - 5 minutes depending on the HPLC 
column characteristics and length and the exact ratio of the 
inorganic and organic part in the mobile phase composition. 
The optimal chromatographic conditions were ob-
tained using Discovery C18 chromatographic column, mo-
bile phase consisted of 7% v/v acetonitrile and 93% v/v 
of 25 mM KH2PO4 (pH 7.0), and 20 µL injection volume. 
Conclusion
The method was found to be simple, fast and cost-ef-
fective, thus suitable for high-throughput routine determi-
nation of Pregabalin in solid dosage forms in pharmaceuti-
cal quality control laboratories. The method could be fur-
ther improved if needed for higher sensitivity and higher 
throughput of analysis per day. 
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Introduction
Vitamin B12, or Cyanocobalamin is a part of the group 
of B-complex vitamins. Its chemical name is 5,6-dimeth-
yl-benzimidazoyl cyanocobamide. It belongs to a group of 
cobalt-containing compounds, known as corrinoids (Eiten-
miller et al., 2007; Hurst, 2002; NCBI). 
Vitamin B12 (cobalamin) functions as a coenzyme. It 
is involved in the red blood cells formation and nervous 
system functioning, in DNA synthesis and regulation, and 
also in fatty acid metabolism and amino acid metabolism. 
Vitamin B12 is synthesized only by bacteria and it is pres-
ent only in food bacterially fermented or obtained from an-
imals that has this cobalamin from their gastrointestinal 
microflora (Institute of Medicine (US) Standing Commit-
tee, 1998). 
Microbiological method is one of the oldest methods 
for measuring the concentration of Vitamin B12. Although 
this technique has developed through time, still it has sev-
eral drawbacks such as: relatively low specificity, low pre-
cision, it is time consuming and requires very well trained 
technicians. 
Several authors have developed different HPLC meth-
ods for determination of Cyanocobalamin, alone, or in com-
bination with other vitamins and/or active substances (Chen 
et al., 2010; Perveen et al., 2009; Radhika et al., 2012).
Cyanocobalamin is the commercial form of Vitamin 
B12 and specifications are found in the Codex for usage as 
food, and in the USP and BP for pharmaceutical use. The 
official Pharmacopoeia monographs for Vitamin B12 pre-
scribe UV-spectrophotometric assay determination, as an 
analytical procedure for quantification of our analyte of in-
terest, at 361 nm.
The aim of our work is to propose two different meth-
ods for routine analysis of the active compound whether it 
is consisted in dietary supplement or pharmaceutical dos-
age form, as an alternative to each other in quality control 
laboratories in pharmaceutical/chemical industry.
Materials and methods
All used chemicals were of Ph.Eur. quality and the 
demineralized water was Stilman produced and had con-
ductivity less than 1 µS. Pottasium phosphate monobasic 
(KH2PO4) and 85% phosphoric acid were purchased from 
Sigma - Aldrich, USA, whereas acetonitrile was purchased 
from Merck KGaA, Darmstadt, Germany. Cyanocobala-
min working standard, the pharmaceutical dosage forms 
and dietary supplements were purchased from Replek 
Farm, Skopje, Macedonia.
Spectrophotometric method includes “VARIAN Car-
ry Win 50” UV-VIS-spectrophotometer, 1-cm quartz cell 
at wavelength range 190 - 750 nm, with resolution 0.5 nm 
and scan rate of 300 nm/min. 
The HPLC determination was performed on Vari-
an Pro Star HPLC system, with autosampler 410, Varian 
325 dual-channel and Varian 335 photodiode-array detec-
tor, with ternary high pressure mixing pump, controlled by 
Galaxy software version 1.91. 
The test and standard solutions for both proposed 
methods were prepared by dissolving suitable amount of 
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the active substance or powdered film-coated tablets in de-
mineralized water, as solvent, to concentration of 0.02 mg/
ml for spectrophotometric determination and 0.1 mg/ml for 
HPLC determination.
Results and discussion
Cyanocobalamin is the most stable form of vitamin 
B12. It has optimum stability at pH range 4.0 - 4.5, and 
therefore the extraction is usually carried out in this range. 
Severe alkaline and acid conditions, ultraviolet (UV) or 
strong visible light, and oxidizing agents inactivate the vi-
tamin (Eitenmiller et al., 2007; Hurst, 2002). 
Cyanocobalamin is water-soluble vitamin, therefore 
water is a good extraction solvent. In UV and visible spec-
trophotometry, aqueous solutions of Cyanocobalamin ex-
hibit maximums in UV and visible region at 278 nm, 361 
nm, and 550 nm. The spectrophotometric method we pro-
pose prescribes signal measurement at wavelength of 550 
nm of aqueous solutions with concentration ~0.02 mg/ml. 
Spectrophotometric method for determination of Cyanoco-
balamin has low cost and acceptable specificity in compar-
ison with radio ligand assay. However, it is not suitable for 
complex samples, where the sensitivity is relatively low, so 
it is not used routinely for determination of Cyanocobala-
min in combined pharmaceutical products.
According to available literature, Vitamin B12 is a 
weak base that stays approximately neutral at pH from 
about 5 to 10. The pKa values reported are 3.3 and 9.3 
(Trang, 2013). Since it is preferred to avoid use of mo-
bile phase with pH in proximity of the pKa values of an-
alytes, if possible up to at least ± 1 pH unit, we chose to 
use mobile phase containing buffer with pH ~2.5 and or-
ganic constituent (acetonitrile) in variable amount, in or-
der to achieve optimal retention of the analyte. The opti-
mized chromatographic method uses mobile phase consist-
ed of 13% v/v acetonitrile and 87% v/v (20 mM KH2PO4, 
buffer adjusted to pH = 2.5 with 85% phosphoric acid). 
The tests are performed on a LiChropher RP Select B chro-
matographic column (125 x 4 mm with 5 µm particles), 
with UV detection at 550 nm. Volume of injection used is 
50 µl, with mobile phase flow rate of 1.5 ml/min.
Cyanocobalamin peak elutes with retention time ~5 
minutes, with symmetry expressed as AsUSP ~0.9. 
Almost the same results were obtained when the two 
developed methods were used in analysis of tablets con-
taining Cyanocobalamin. The absolute difference between 
values for Cyanocobalamin assay obtained using the pro-
posed UV-spectrophotometric and HPLC method was in-
significant (far lower than 2%), which indicates that both 
can be used in quality control laboratories for Cyanocobal-
amin determination.
Conclusion
The two developed methods are suitable for routine 
analysis of the active compound Cyanocobalamin in di-
etary supplements or pharmaceutical dosage forms, and 
can be used as an alternative to each other in quality con-
trol laboratories in pharmaceutical/chemical industry.
Both methods are simple, fast, cost-effective, sensi-
tive, accurate, reproducible and rugged. We suggest use of 
the spectrophotometric method as a routine for industri-
al application and analysis of Vitamin B12 in more simple 
matrixes. The chromatographic method is more selective 
and can be used either in routine analyses or in more com-
plex analyses and can be further optimized for purpose of 
analysis of various multivitamin dosage forms.
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Introduction
The objective of this study was to develop a new drug 
product formulation with amino acid as active substance. 
The direct detection by ultraviolet absorbance of amino ac-
ids is possible only at low wavelengths, where sensitivi-
ty is poor and interference in background absorption is po-
tentially high (Petritis et al., 1999). There are two report-
ed spectrophotometric methods with UV detection at 210 
nm of this active substance in pharmaceutical preparation 
(Onal and Sagirli, 2009). Several derivatization methods 
have been proposed, by using derivatizing reagents such 
as potassium iodide for spectrophotometric detection (Gu-
jral et al., 2009), fluorescamine, 2,4-nitrofluorobenzen and 
2,3,5,6-tetrachloro-1,4-benzoquinon (Shaalan, 2010) for 
spectrofluorometric detection. The HPLC methods with 
precolumn (Vermeij and Edelbroek, 2004) and post col-
umn derivatization of this active substance with o-phthal-
dialdehyde (Douou et al., 2010) and derivatization with 
fluorescamine (Martinc et al., 2010) were also reported. 
All these methods with derivatization and fluorescence de-
tection cannot be applied for determination of related and 
degradation products, because the main degradation prod-
uct produced by cyclization between amino and carbox-
ylic acid group has lactam ring in the structure, which is 
a strong chromophore group. The ultraviolet absorption 
method is suitable for its detection (Dee-Noor et al., 2009).
To establish degradation pathways of the active sub-
stance, its stability in a combination with excipients in fi-
nal formulation mixture and detection of interactions be-
tween the drug and excipients, all in order to develop the 
most stable drug product, forced degradation study was 
performed by applying different stress conditions (Baerts-
chi et al., 2005).
Materials and methods
Testing formulation I was consisted of amino acid as 
active substance and excipients in a ratio of 1:3 (% w/w), 
respectively, with filler 1, which was excipient without car-
bonyl group in the chemical structure.
Testing formulation II was consisted of the same filler 
1, but active substance and excipients were in a ratio of 3:1 
(% w/w), respectively. 
Testing formulation III was consisted of amino acid as 
active substance and excipients in a ratio of 1:3 (% w/w), 
respectively, but with filler 2, which is reducing sugar with 
carbonyl group in the chemical structure.
The following forced degradation study was applied:
a) Thermal degradation: the samples were kept in dry-
ing oven at 80 °C for 20 days;
b) Thermal/humidity degradation: the opened and cap-
sulated samples sprayed in thin layer on Petri of 1:3 (% 
w/w),ept in pharmaceutical stability chamber at 40 °C and 
75% RH for 90 days;
c) Photo degradation: the samples were kept in photo 
stability chamber under maximum radiation of the xenon 
lamp (765Wh/m2) for 35 hours;
d) Acid hydrolysis: the samples were treated with 
0.5M hydrochloric acid at 50 °C for 2 hours; 
e) Base hydrolysis: the samples were treated with 
0.5M sodium hydroxide at 50 °C for 2 hours;
f) Oxidative degradation: the samples were treated 
with 1% (v/v) hydrogen peroxide at room temperature for 
1 hour.
All samples, control and treated, were analyzed by the 
in-house developed HPLC method for determination of re-
lated and degradation products in the drug product.
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Results and discussion
Considering all of the reported data for the Maillard 
reaction between carbonyl group from reducing sugar and 
amino group (Qiu et al., 2005) the main goal was to find 
the adequate filler in the development of the drug prod-
uct formulation containing amino acid as active substance. 
The first differences caused by the type of excipient used 
as filler and the second differences caused by the content 
of excipients in the formulation, have been fully identified 
and understood. 
The active substance was unstable under elevated tem-
perature, acid and base hydrolysis. No degradation of ex-
cipients was found under all applied stress conditions. It 
has been observed different modes of degradation accord-
ing to the type of formulation mixture. Under thermal deg-
radation the main degradation product, lactam, was formed 
in the same amounts, regardless of the type of filler and the 
content of the excipients in the formulation. Further, in for-
mulation III one unspecified impurity with RRT 2.37 was 
slightly increased, which is the product of the Maillard re-
action between amino acid and reducing sugar used as fill-
er 2. Under thermal and humidity degradation, many dif-
ferences between the formulations were observed because 
the samples were treated in two different ways: as opened 
capsule masses sprayed in thin layer on Petri’s dishes and 
as capsulated samples. Two degradation pathways, cycliza-
tion to lactam and the interaction between amino and car-
bonyl group were enhanced due to several factors for in-
stance, the higher content of the excipients in terms of the 
active component, the hygroscopic characteristics of an an-
other filler, filler 3, used in amount of 33% w/w and the 
capsule shell, especially in the formulation I and III.
As was expected, the acid hydrolysis causes the reac-
tion of cyclization of amino acid to lactam (Dee-Noor et 
al., 2009), where the most susceptible formulations in our 
study were formulation I and III. 
After the base hydrolysis, lactam was increased in 
greater, but in the same amounts in all samples. Besides 
lactam, formulation I and III with the higher content of 
the excipients were shown as much unstable, degraded 
to a few unspecified impurities, where total impurities of 
10.56% and 12.01%, respectively, were obtained.  The ef-
fect of photo degradation was insignificant. Under oxida-
tion, the content of the active substance in all samples was 
not decreased. All samples treated with mild oxidative con-
ditions, 1% H2O2, room temperature for 1 hour, degrad-
ed to several products with higher ultraviolet absorption 
than active substance, due to the new formed chromophore 
groups in the structure. 
Conclusion
In this study, it has been shown that the amino acid as 
active substance in the presence of reducing sugar used as 
filler in the drug product formulation undergoes a Maillard 
reaction over time, especially enhanced by increased tem-
perature and humidity. In order to produce the most stable 
formulation during the manufacturing process and during 
the proposed shelf-life of the drug product, the proposed 
filler without carbonyl group in the chemical structure was 
proved as a suitable excipient, avoiding the drug-excipi-
ent interaction, and further, lower content of excipients in 
terms of the active component in the drug product formu-
lation, has been suggested.
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Background 
“An Official Medicines Control Laboratory (OMCL) 
is a public institution, which performs laboratory testing of 
medicinal products on behalf of National Competent Au-
thority (NCA) and in fulfilment of other national obliga-
tions, independently from the manufacturer or Marketing 
Authorisation Holders (MAH). Testing is carried out in the 
interest of official market surveillance of medicinal prod-
ucts in relation to the safety of human patient and/or ani-
mals, prior to and/or after marketing of the respective med-
icines and is demonstrated to be free from conflicts of in-
terest” (Directive 2001/83/EC, Directive 2001/82/EC, PA/
PH/OMCL (07) 89 14R, 2015).
The role of the OMCLs is focussed on the independent 
quality control of medicines and it includes a number of 
different pre and post-marketing surveillance programmes. 
These extend to the sampling and testing of branded and ge-
neric medicines, unlicensed (unauthorized) medicines, ille-
gal medicines (counterfeits / medicines with falsified label-
ling), vaccines, blood and plasma-derived medicinal prod-
ucts, and active substances. OMCL surveillance work also 
includes examinations of product packaging and labelling. 
It supports the evaluation of the quality part of MA files, as 
well as pharmacovigilance assessments, quality defect in-
vestigations, and GMP inspections. In the framework of 
the European Pharmacopoeia, the work of OMCLs plays a 
vital part, in relation for example to monograph develop-
ment activities, etc. Beside medicines, a number of OM-
CLs also perform laboratory testing on cosmetics, medi-
cal devices, diagnostics, food, feed (premixes) for veteri-
nary use, and other “borderline products” (PA/PH/OMCL 
(07) 89 14R, 2015).
Public and stakeholder awareness of the 
importance of OMCL work
The public and animal health benefits of having a well-
established and resourced system of quality control sur-
veillance of medicines placed on the market are numerous 
- such work helps to independently assure the quality of 
the medicines on the market, and it results in regulatory ac-
tions when sub-standard or illegal medicines are found in 
the market. However, the benefits of this work are not al-
ways apparent to the various stakeholders, especially in re-
lation to the routine surveillance day-to-day testing work 
that is carried out. This lack of awareness can lead to ques-
tions among stakeholders about the usefulness of the work 
of OMCLs, and about the level of resources and funding 
that OMCLs require.  
Furthermore, it may not be evident to the public how 
a reduction in the funding of an OMCL (or the downsizing 
of an OMCL) may affect public and animal health protec-
tion (PA/PH/OMCL (14) 123 R, 2015).
Therefore, a common need for raising the national 
and wider awareness of the benefits of the OMCL and the 
GEON was acknowledged.
Public relation efforts
Recently, GEON began renewed efforts to strength-
en its stakeholder-interaction strategies and its communi-
cation activities so as to more effectively disseminate in-
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formation on the benefits of having a strong OMCL Net-
work in place for the independent surveillance of the qual-
ity of medicines.
Despite some earlier successes of GEON public rela-
tion (PR) efforts towards the general public as well as in 
the relation with supranational bodies (PA/PH/OMCL (14) 
123 R, 2015), it was envisaged that a new communications 
strategy is required for the GEON.  There are various el-
ements to this work, including the need to identify what 
key messages about OMCLs and the GEON need to be 
made and to what stakeholders. While the general public if 
of course a very important stakeholder, it is unclear at the 
present time exactly what PR activities should be directed 
towards the general public. It may be more beneficial to fo-
cus communication strategies on those stakeholders direct-
ly involved in regulatory, legal and funding activities.
Best communication practices
If a country is dedicated to strengthening Quality Man-
agement (QM) & Quality Control (QC) systems, then each 
measure for developing the capacity of the national OM-
CLs within national strategic programmes should be con-
sidered. As the OMCLs are usually part of bigger organiza-
tions, special efforts should be made to address the stake-
holders that provide the OMCL directly with resources. 
This can be done by means of presenting data under-
pinning the performance of OMCLs e.g. by highlight-
ing particularities and/or added values. Each success sto-
ry should be released to the public, so higher awareness 
amongst the concerned stakeholders is achieved.
Each opportunity for joint national, bilateral and inter-
national projects that facilitate recognition of the impor-
tance of OMCLs and involvement in critical issues of the 
health care system should be utilized.
Social network platforms should be populated with in-
formation on regular OMCL activities and lessons learned 
on health hazardous issues, especially those affecting pa-
tients directly (i.e. in case when medicine, medical devices 
or ‘food supplements’ are purchased from untrusted sourc-
es, such as internet or teleshops).
The best communication practices from each individu-
al OMCL could help developing a common ‘tool kit’ on in-
ternational level, which could in revert help OMCLs to bet-
ter reposition themselves within their national competent 
authorities for the benefits of all. In this context the Euro-
pean Directorate for the Quality of Medicines & Health-
Care (EDQM), under the auspice of Council of Europe, 
has a central role in the process of strengthening the role 
of OMCLs and its Network, as it compiles the best com-
munication practices from the GEON, and identifies key 
points to elaborate European wide strategy. Target partners 
in this respect would be: Co-ordination Group for Mutu-
al Recognition and Decentralised procedures - Human and 
veterinary (CMDh and CMDv) within Head of the Medi-
cine Agencies (HMAs), Committee for Medicinal Products 
for Human and Veterinary Use (CHMP and CMVP) within 
European Medicine agency (EMA),etc.
Perspective
The authors wish to highlight the importance of the 
work done by OMCLs within the national and international 
health systems, but also to point out that the role of OMCL 
is very often underestimated which as a consequence might 
result in negative impact on the global patient safety in par-
ticular regarding the combat against substandard and falsi-
fied medicines. Additionally, the authors acknowledge that 
other types of laboratories with comparable scope of activ-
ities are experiencing similar pressure with respect to cost/
resource cuttings. The aim of this paper is to motivate each 
OMCL and other quality control laboratories to consider 
activities which could help raising public awareness, and 
in particular the awareness of stakeholders which decide 
about and provide resources to these laboratories. The im-
portance of investments to develop OMCL capacities in or-
der to meet new analytical challenges against substandard 
and falsified medicines must become part of national strat-
egies, as it would pronounce a benefit for the health system 
in a cost/effective way.
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Introduction
The process of dissolution is of fundamental impor-
tance for the bioavailability and therapeutic efficacy of 
drug products. The process of drug release in an aque-
ous body fluid includes different physical phenomena as 
wetting of the particle’s surface, breakdown of solid state 
bonds, solvation, diffusion as well as convection in the sur-
rounding bulk fluid. Drug release rate from modified re-
lease drug products can be controlled by diffusion, deg-
radation, swelling followed by diffusion and dissolution. 
Different mathematical models may be used as an instru-
mental tool for understanding the drug release form dif-
ferent drug delivery systems (Siepmann and Siepmann, 
2013). Some of the models were used to explore and ex-
plain the release mechanisms of prolonged-release drug 
product.
Materials and methods
Dissolution tests of prolonged-release tablets with 
BCS Class I have been performed, using basket appara-
tus at 100 rpm, in 500 mL phosphate buffer with pH 6.8 at 
37±0.5 °C for 24 hours. Dissolution profiles were obtained 
by sampling 10 mL at 8 time points (1, 2, 4, 6, 8, 10, 12, 24 
hours). Quantification of the dissolved drug is performed 
with HPLC method with UV detection at 242 nm, mobile 
phase is solution of sodium edetate and acetic acid, meth-
anol and acetonitrile (60:20:20 v/v/v), pump flow 2.0 mL/
min, column temperature 40 °C and injection volume 100 
μL. Mathematical modeling of the dissolution data was 
performed with DDSolver (Zhang et al., 2010). Three for-
mulations with different rate-controlling excipients were 
evaluated. A number of mathematical models have been 
assessed for evaluation of drug release data: zero order, 
first-order, Higuchi, Korsmeyer-Peppas, Hixon-Crowell, 
Hopfenberg, Peppas-Sahlin, Weibull and Gompertz.
Results and discussion
The average values (in percentage) of the dissolu-
tion profile of formulation 1 are: 7.78, 14.69, 26.87, 38.02, 
48.22, 56.82, 64.87 and 97.71, formulation 2: 4.55, 8.71, 
17.5, 27.88, 38.23, 50.64, 60.69 and 93.9 and formulation 
3: 4.36, 8.84, 18.46, 26.94, 35.55, 45.12, 54.38 and 88.85.
Concerning the model selection criteria, DDSolver 
provides a number of statistical criteria for evaluating the 
goodness of fit of a model, among which the most popular 
are adjusted coefficient of determination (R2
adjusted
), Akaike 
Information Criterion (AIC), and Model Selection Criteri-
on (MSC) (Zhang et al., 2010).
The Adjusted Coefficient of Determination is an ad-
justment for the Coefficient of Determination that takes 
into account the number of variables in a data set.
AIC is a measure of the relative quality of statistical 
models for a given set of data. Given a collection of models 
for the data, AIC estimates the quality of each model, rel-
ative to each of the other models. When comparing mod-
els with different numbers of parameters, the model with a 
lower AIC value can be considered to be the better model.
MSC is a modified reciprocal form of the AIC and is 
independent of the scaling of the data points. When com-
paring different models, the most appropriate model will 
be that with the largest MSC.
Zero order kinetics describes the systems where the 
drug release rate is independent of its concentration and 
can be used to describe the dissolution of several types of 
modified release dosage forms and dissolution from dos-
age forms that do not disaggregate and release the drug 
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slowly (assuming that area does not change and no equi-
librium conditions are obtained) (Costa and Sousa Lobo, 
2001). R2
adjusted
 is 0.91-0.98, AIC 46.85-61.05 and MSC 
1.95-3.40.
Dosage forms that follow first order dissolution pro-
file, such as those containing water-soluble drugs in porous 
matrices, release the drug in a way that is proportional to 
the amount of drug remaining in its interior, in such way, 
that the amount of drug released by unit of time diminish-
es (Costa and Sousa Lobo, 2001). R2
adjusted
 is 0.96-0.98, AIC 
45.29-53.53 and MSC 2.82-3.70.
Higuchi describes drug release as a diffusion process 
based in the Fick’s law, square root time dependent and 
can describe drug dissolution from several types of mod-
ified release dosage forms, such as some transdermal sys-
tems and matrix tablets with water soluble drugs (Costa 
and Sousa Lobo, 2001). R2
adjusted
 is 0.87-0.94, AIC 56.84-
63.97 and MSC 1.66-2.41.
Korsmeyer-Peppas is exponential equation often used 
to describe the drug release from polymeric systems, when 
the release mechanism is not well known or when more 
than one type of release phenomena could be involved 
(Costa and Sousa Lobo, 2001). The n-value from the Kors-
meyer-Peppas model indicates (0.70-0.85) anomalous dif-
fusion or nonfickian diffusion which refers to combination 
of both diffusion and erosion controlled rate release (Pep-
pas 1985). R2
adjusted
 is 0.98-0.99, AIC 35.76-46.04 and MSC 
3.65-4.63.
Hixon-Crowell model describes the release from sys-
tems with a change in surface area and diameter of parti-
cles or tablets. When this model is used, it is assumed that 
the release rate is limited by the drug particles dissolution 
rate and not by the diffusion that might occur through the 
polymeric matrix (Costa and Sousa Lobo, 2001). R2
adjusted
 is 
0.98-1.00, AIC 28.81-46.03 and MSC 3.66-5.53.
The release of drugs from surface-eroding devices with 
several geometries was analyzed by Hopfenberg who de-
veloped a general mathematical equation describing drug 
release from slabs, spheres and infinite cylinders display-
ing heterogeneous erosion (Costa and Sousa Lobo, 2001). 
R2
adjusted
 is 0.99-1.00, AIC 19.69-37.60 and MSC 4.59-6.54.
Peppas-Sahlin model (Zhang et al., 2010) demon-
strates the following goodness of fit: R2
adjusted
 0.99-1.00, 
AIC 26.09-42.81 and MSC 4.01-5.83.
Weibull model demonstrates the following goodness 
of fit: R2
adjusted
 around 1.00, AIC -8.91 to 21.67 and MSC 
6.36-9.72. This is an empiric model, not deducted from any 
kinetic fundament, therefore, could only describe, but does 
not adequately characterize, the dissolution kinetic proper-
ties of the drug. This model is useful for characterization 
of release profiles of matrix type drug delivery (Costa and 
Sousa Lobo, 2001).
The Gompertz model (Costa and Sousa Lobo, 2001) 
is suitable for characterization of release profiles of drugs 
having good solubility and intermediate release rates. R2ad-
justed
 is 0.99-1.00, AIC 16.83-37.30 and MSC 4.63-6.86.
Conclusion
Mathematical models are generally designed to devel-
op new drug delivery systems based on the release charac-
teristics, to predict the effect of design parameters on the 
resulting drug release rate, to optimize the release kinetics, 
to elucidate the underlying mass transport mechanisms, to 
accurately predict the drug release profile and improve the 
overall therapeutic efficacy and safety of these drugs.
The mathematical models with better goodness of fit 
are Weibull, Gompertz, Hopfenberg, Peppas-Sahlin, Hix-
on-Crowell and Korsmeyer-Peppas and they characterize 
the dissolution kinetic and help to better understand the 
underlying drug release mechanisms. Also the amount of 
drug release percent by each mechanism at each time can 
be also calculated.
The drug release profiles from all formulations can be 
best expressed by Weibull’s equation, as the plots showed 
highest goodness of fit. This is an empiric model that can 
describe the dissolution kinetic properties.
The results from the mathematical modeling indicate 
that more than one type of release phenomena is involved. 
Hopfenberg model indicates that erosion is one of the re-
lease mechanisms. Korsmeyer-Peppas model indicates that 
there is combination of both diffusion and erosion con-
trolled rate release. Hixon-Crowell model includes disso-
lution as one of the release mechanisms. When the pro-
longed-release tablets come in contact with the dissolution 
medium, they take up water and swell, forming a gel lay-
er around the matrix and simultaneously erosion occurs.
References
Costa, P., Sousa Lobo, J.M., 2001. Modeling and comparison of 
dissolution profiles, Eur. J. Pharm. Sci. 13, 123–133.
Peppas, N.A., 1985. Analysis of Fickian and non-Fickian drug 
release from polymers. Pharm. Acta. Helv. 60, 110–111.
Siepmann, J., Siepmann, F., 2013. Mathematical modeling of 
drug dissolution. Int. J. Pharm. 453, 12- 24.
Zhang, Y. Huo, M., Zhou, J., Zou, A., Li, W., Yao, C., Xie, S., 
2010. DDSolver: An Add-In Program for Modeling and 
Comparison of Drug Dissolution Profiles. The AAPS Journal 
12(3), 263-271.
Poster presentations
Macedonian pharmaceutical bulletin, 62 (suppl) 213 - 214 (2016)
ISSN 1409 - 8695
UDC: 615.277.074:543.544.5.068.7
Short communication
Validation of RP-HPLC method for determination  
of exemestane and its impurities  
in pharmaceutical dosage forms
Branka Ivković*, Aleksandra Jonić, Jelena Žunić, Sote Vladimirov,  
Milkica Crevar Sakač, Zorica Vujić
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade,  
Vojvode Stepe 450, Belgrade, Serbia
* blucic@pharmacy.bg.ac.rs
Introduction
The nonsteroidal aromatase inhibitors are competi-
tive inhibitors that bind to the enzyme active site by co-
ordinating the iron atom present in the heme group of the 
P450 protein. Exemestane is 6-methylenandrosta-1,4-di-
ene-3,17-dione a newer steroidal aromatase inhibitor. It is 
an enzyme activated irreversible inhibitor of aromatase. It 
is orally available and highly selective for aromatase. Its 
structure reflects only minor structural modifications to the 
natural substrate, androstenedione. Plasma estrogen levels 
are reduced by 85% to 95% within 2 to 3 days, and ef-
fects last 4 to 5 days. Exemestane does not inhibit any of 
the major cytochromes P450 and has essentially no interac-
tion with steroid receptors, with only a very weak affinity 
for the AR. The 17-hydroxyexemestane reduction product, 
however, has much higher affinity for the AR than the par-
ent (still several fold less than DHT, 0.28% for parent vs. 
30% for metabolite). The clinical significance of the affini-
ty is likely minimal because of the low levels of the metab-
olite produced (Pagani et al., 2014).
Literature survey reports that Exemestane can be de-
termined by different analytical techniques such as HPTLC 
(Mane et al., 2010), UV-spectrophotometry (Angala-
parameswari et al., 2012), GC-MS (de Albuquerque Cav-
alcanti et al., 2011), LC-MS (Allievi et al., 1995), HPLC 
(Konda et al., 2011; Ksycinska et al., 2011) and UPLC 
(Reddy et al., 2011)  in pharmaceutical dosage forms. In 
these described methods C18 (modified silica gel with a 
hydrocarbon chain of 18 carbon atoms) stationary phas-
es were used. In our work C12 stationary phase was used. 
Using C12 stationary phase we have developed a method 
for the quantification of exemestan and its impurities in the 
tablets. The developed method was validated as per ICH 
guidelines with respect to specificity, linearity, LOD, LOQ, 
accuracy, precision and robustness.
Materials and methods
The experiments were performed on the chromato-
graphic system Agilent HP1200 with DAD detector. The 
analytical columns used in this study were in examining of 
chromatographic conditions were used: reference standards 
exemestane, impurities B and C, the chromatographic col-
umn Synergi 4µm MAX-RP 80A 150 x 4.60 mm (C12). 
The optimum conditions for separation and determination 
of exemestane and its impurities were achieved with the 
mobile phase: water /acetonitrile in the ratio 50/50 (v/v), at 
a flow rate of 1.2 mL / min and the column temperature was 
maintained at 30 °C. Stocks of standard solutions were pre-
pared in the methanol and storage in the fridge. To evalu-
ate the linearity of the developed method, five solutions of 
exemestan and its impurities were prepared in the concen-
tration range from the 50 μg/mL to 150 μg/mL, 0.49 μg/mL 
to 49 μg/mL and 0.54 μg/mL to 54 μg/mL for exemestan, 
imp. B and imp. C. The accuracy of the method was con-
firmed by preparing three series of solutions containing ap-
propriate placebo, exemestan and impurities in three levels: 
low level 80%, medium level 100% and high level 120%. 
To prove the precision of the method, three different solu-
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tions of exemestan and impurities were prepared. The val-
ues for LOD and LOQ were obtained by calculating the sig-
nal / noise ratio. Sample solution was prepared in the mo-
bile phase in the final concentration 75 μg/mL.
Results and discussion
The proposed method was validated as per ICH guide-
line. The system suitability was evaluated on the basis of res-
olution between exemestan and impurities (Rs >1.5). In the 
specificity study chromatograms of placebo had shown no 
peaks at the retention time of exemestan and impurities. The 
precision of method was verified by repeatability and inter-
mediate precision at three concentrations levels (1-3 μg/mL 
for impurities B and C, 80-120 μg/mL for exemestan). The 
RSD (%) of results for exemestan and impurities were calcu-
lated (RSD for exemestan is 0.06% to 1.41%, for impurity B 
0.41% to 1.41% and impurity C 0.56% to 1.52% RSD < 2%). 
The intermediate precision of the method was also evaluated 
using different analyst and different instrument and perform-
ing the analysis on different days (RSD < 3% for both im-
purities and exemestan). The LOD and LOQ for impurities 
were determined at a signal-to-noise ratio of 3:1 and 10:1, 
respectively, by injecting a series of diluted solutions with 
known concentrations (LOD is 0,049 μg/mL and LOQ 0,12 
μg/mL for both impurities). The method was linear over the 
range of concentrations: for impurities B 0.49 μg /ml to 4.90 
μg /ml (r =0.999), impurity C of 0.54 μg /ml to 5.40 μg / ml 
(r = 0.999) and for exemestane 50.90 μg /mL to 152.70 μg /
mL (r =0.999) In the based on the obtained results, the iden-
tification and quantification of impurities in the investigated 
exemestane tablets examined the impurities C is present in 
quantities of less than 0.10%, while the amount of B < LOQ. 
On the basis of validated methods to determine the content of 
exemestane in the exemestane tablets of 95.68%.
Conclusion
It can be concluded that the defined RP-HPLC method 
is rapid and efficient for purity testing of exemestane in the 
raw material and pharmaceuticals dosage forms. 
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Introduction
The rate and extent in which the amount of drug sub-
stance dissolves over a period of time is called dissolution. 
Dissolution testing has emerged in the pharmaceutical field 
as a very important tool to characterize drug product per-
formance. Dissolution test is required to study the drug re-
lease from the dosage form and its in vivo performance. 
Dissolution test is used to assess the lot to lot quality of 
drug product. Before selecting the proper dissolution me-
dium should be determined physical and chemical charac-
teristics of the active substance (Ph. Eur., 2015). Dissolu-
tion test procedures can be a challenging process, on mul-
tiple fronts. The aim of the study was to develop a dissolu-
tion test for the quality control for new generic immediate-
release drug product with one active substance. Sink con-
ditions, drug solubility in different dissolution media, dif-
ferent filter type, different volume of the dissolution medi-
um and different apparatus were tested. 
Materials and methods
The dissolution procedure has several distinct compo-
nents. These components include a dissolution medium, an 
apparatus, the study design (including acceptance criteria) 
and the mode of assay. All of these components must be 
properly chosen and developed to provide a method that 
is reproducible for within laboratory day-to-day operation 
and robust enough to enable transfer to another laboratory.
Selection of dissolution medium 
When selecting the dissolution medium, physical and 
chemical data for the drug substance and drug product 
need to be considered, e.g. the solubility and solution state 
stability of the drug as a function of pH value. The solubil-
ity of the active substance is pH dependent and the increase 
of pH would enhance its solubility and consequently the 
dissolution rate, particularly at pH > pKa of the compound.
Sink conditions have been determined by in house 
method. Generally, when developing dissolution method, 
one of the goals is to obtain sink conditions. According to 
the European Pharmacopoeia (Ph. Eur., 2015), “sink con-
ditions” normally occur in a volume of dissolution medium 
that is at least 3 to 10 times the saturation volume, there-
fore sink conditions are maintained throughout the dura-
tion of the test film-coated tablets in the specified medium, 
phosphate buffer at pH 7.2. The dissolution media temper-
ature is fixed i. e. 37.0 (±0.5) °C (Ph. Eur., 2015). 
Media deaeration is usually required, and can be ac-
complished by heating the medium or (more commonly) 
filtering the medium or placing it under vacuum for short 
period of time. Bubbles can cause particles to cling to the 
apparatus and vessel walls. On the other hand, bubbles on 
the dosage units may increase buoyancy, leading to an in-
crease in the dissolution rate, or may decrease the avail-
able surface area, leading to a decrease in the dissolution 
rate (USP, 2015). 
Selection of dissolution apparatus/ agitation 
The choice of apparatus is based on the dosage form 
performance in the in vitro test system. For solid oral dos-
age forms, Apparatus 1 and Apparatus 2 are used most fre-
quently. For immediate-release and capsule (both soft gel 
and hard gel) formulation , USP-I i.e. basket apparatus  at 
100 rpm or USP-II i.e. paddle apparatus  at 50 or 75 rpm 
are recommended. Coning in dosage form can be reduced 
by increasing the paddle speed, thus reducing the artifact 
and improving the data (USP, 2015).
Apparatus II (paddle) rotating at 75 rpm was selected 
as most appropriate. Different paddle speeds (50 rpm and 
75 rpm) and different Apparatus (Apparatus 1 and Appara-
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tus 2) were tested. On 50 rpm conning was noticed which 
leads to incomplete release of active ingredient from tab-
lets and higher variability in dissolution rates. 
Results and discussion
Dissolution is evaluated by measuring rate release pro-
file or the amount dissolved over time. For immediate-re-
lease dosage forms, dissolution time from 30 min to 60 min 
is recommended (British Pharmacopoeia, 2015). In our ex-
perimental case multiple time points were performed for 
establishing the dissolution time. Observations are espe-
cially useful during method development and optimiza-
tion. USP chapter <1092>contains additional information 
on observations (USP, 2015). 
Sampling probe can affect the hydrodynamics of the 
system and so that can change the dissolution rate. Regard-
ing the position of sampling, the probe should be sampled 
at approximately half the distance from the basket or pad-
dle to the dissolution medium and not closer than 1 cm 
to the side of the flask. Adsorption of the active substance 
onto filter needs to be evaluated. Filter material must be 
saturated with the active substance by repeated passage to 
avoid losses that might go undetected during the test sam-
pling. Accumulation of the particulate matter on the sur-
face may cause significant error in the dissolution testing. 
Sample solutions were prepared in proposed dissolu-
tion medium. The sample solutions were prepared using 
film-coated tablets into 900 mL dissolution medium at 37.0 
± 0.5 °C and with at 75 rpm for 45 minutes.  Different al-
iquots (0.3 and 6 mL) were filtered using different filter 
types (0.45-µm), diluted suitably and analyzed spectropho-
tometrically. A filter type is found to be acceptable for use 
if the results of the filtered portions are within 98-102% of 
the original concentrations of the unfiltered standard solu-
tion and the centrifuged sample solution. 
Acceptance criteria must also be considered during 
test development. Acceptance criteria are derived in the 
form of “Q-factors” a minimum amount dissolved at a giv-
en time as a percentage of the labeled content (ICH, 1999). 
Assaying the results
There are two common ways of analyzing dissolution 
test samples, spectrophotometric (UV) determinations and 
HPLC. The selection of the optimal wavelength for analy-
sis was based on the wavelength of maximum absorption 
in the UV spectrum of the active substance. Cells with path 
lengths ranging from 0.02 to 1 cm were used. 
Optimization of Dissolution Test
The dissolution experiments were conducted in a six-
station bath dissolution apparatus by subjecting six imme-
diate-release  tablets to 900 mL of proposed dissolution 
medium, paddle dissolution apparatus, and stirring speeds 
of  75 rpm. The temperature was maintained at 37 ±0.5 °C. 
Aliquots of 10 mL were withdrawn manually at 5, 10, 15, 
20, 30, and 45 min, and replaced by the same volume of 
the medium heated at 37 ±0.5 °C. The sample was filtered 
using regenerated cellulose (RC), 0.45-µm filter and ana-
lyzed spectrophotometrically at 221 nm. Acceptance crite-
ria for not less than 85% (Q+5%) of the labeled content for 
45 min was set.
Discriminatory properties of the dissolution method
Finally, the dissolution test procedure should be dis-
criminating enough to be capable of distinguishing signif-
icant changes in a composition or manufacturing process 
that might be expected to affect in vivo performance. In 
general, a properly designed dissolution test should result 
in reproducible data.
The proposed dissolution methodology has shown to 
be suitable for quality control of tablets manufactured us-
ing the commercial process and is capable of discriminat-
ing changes in the critical manufacturing process steps and 
formulation composition. To elucidate the discriminatory 
power of the dissolution method, a formulation contain-
ing different quantity of the active ingredient than the fi-
nal tested product, was analyzed using the proposed disso-
lution method and the dissolution profiles of both formula-
tions were compared. 
Conclusion
The obtained results indicate that pH 7.2 as a dissolu-
tion medium of choice, together with the selected dissolu-
tion method parameters, are reflective of the product char-
acteristics and are able to distinguish differences in formu-
lation of the product.
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Introduction
During extraction and synthesis of pholcodine mono-
hydrate, organic solvents are used. For that purpose a HS-
GC-FID method for determination of ethanol, methanol, 
toluene and benzene in pholcodine monohydrate has been 
developed and validated. Even though benzene is not used 
during any of the manufacturing stages, it is a regulato-
ry requirement to monitor for its eventual presence in the 
product, since benzene is a known degradation product of 
toluene. Furthermore, benzene is the most toxic among 
these solvents (Class 1) and it is recommended to be avoid-
ed in the production of drug substances, in accordance to 
ICH Q3C (R5) (ICH, 2011). Methanol and toluene show 
severe toxicity (Class 2), hence their usage should be limit-
ed, and ethanol is the least toxic of them (Class 3) (Ph.Eur., 
2014). As residual solvents are highly volatile compounds, 
HS-GC-FID is the most convenient technique for their de-
termination and quantitation (Ph.Eur., 2014). 
This study describes the development and validation 
of method for routine analysis of four residual solvents 
(ethanol, methanol, toluene and benzene) in pholcodine 
monohydrate drug substance.
Materials and methods
Ethanol, methanol, N,N-dimethylsulfoxide (DMSO) 
and N,N-dimethylformamide (DMF) - GC grade were ob-
tained from Merck Millipore (Darmstadt, Germany), tolu-
ene and benzene-from Sigma Aldrich (Sent Louis, USA) 
and pholcodine monohydrate API was obtained from Al-
kaloid AD Skopje, Macedonia. 
The method was developed, optimized and validated 
on a Shimadzu 2010 Plus gas chromatograph, equipped 
with FID detector and PAL AOC-5000 autosampler for 
headspace and liquid samples (Shimadzu Corporation, 
Kyoto, Japan), with helium as a carrier gas in the split 
mode. The separation of the components was performed 
using Agilent DB-624 (30 m x 0.53 mm x 3 µm) WCOT 
capillary column.
Results and discussion
A standard stock solution in N,N-Dimethylformamide 
containing the investigated residual solvents in API phol-
codine monohydrate was prepared in such a way that the 
final concentrations of the solvents were approximately 
2500 ppm for ethanol, 1500 ppm for methanol, 440 ppm 
for toluene and 1 ppm for benzene (concentration level 
100%). The sample solution was prepared by weighing ap-
proximately 500 mg of pholcodine monohydrate in a 20 ml 
headspace vial, followed by addition of 1 mL N,N-Dimeth-
ylformamide as diluent.
Chromatographic method development started with ini-
tial gradient conditions: 0 to 10 minutes isocratic segment 
at 45 °C, then linear temperature gradient of 10 °C/min to 
220 °C and finally and isocratic segment at 220 °C for 2.5 
minutes, for total chromatographic runtime of 30 minutes. 
These conditions provided complete separation of the four 
tested solvents and the diluent, with adequate column per-
formance and good peak shape for all analytes, howev-
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er with unnecessarily long run time. Judging by this con-
clusion, chromatographic conditions was performed by in-
creasing the initial column temperature to 50 °C, shortening 
the initial isocratic segment to 3 minutes and selecting more 
aggressive temperature gradient of 20 °C/min.
The method was validated within the ICH guidelines. 
Parameters included in the validation procedure were: 
specificity, linearity and range, accuracy, repeatability and 
intermediate precision, limit of detection, limit of quantita-
tion and robustness. 
In order to determine the specificity of the optimized 
method, a blank solution (DMF), sample solution and in-
dividual standard solutions of the investigated residual sol-
vents, as well as their mixture, were injected onto the GC 
column. DB-624 column (30 m length x 0.53 mm i.d. x 3 
µm film thickness) provided sufficient baseline separation 
of all residual solvents, including the diluent, fulfilling the 
criterion for the resolution between ethanol and methanol 
peaks being not less than 4. The retention time for residual 
solvents individually and in spiked standard solution was 
determined. There was no co-elution between the observ-
able peaks.
Linearity evaluation was prepared by quantitative di-
lutions of the stock solutions of ethanol, methanol and tol-
uene in order to obtain solutions in the range from quantifi-
cation limit to 150% of working concentration (Lokhannde 
et al., 2012). The average value for the area under the peak 
obtained from the three injections for each solvent was 
plotted against the corresponding concentration in ppm, 
hence calibration curves were obtained. The correlation 
coefficients were above 0.990. 
The accuracy of the analytical method was confirmed 
by evaluation of the recovery. The recovery test was car-
ried out at three concentration levels: 50%, 100% and 
150% of the limits for each residual solvent. The percent-
age recovery ranges was from 82.12% to 104.41%.
Repeatability of the system as a validation parame-
ter was evaluated on the basis of the results for the rela-
tive standard deviation from six successive injections. The 
RSD for at least of six injections was not more than 15% 
according to Ph.Eur. (Jahnavi and Saravanan, 2012). 
To evaluate the intermediate precision, six sample so-
lutions were prepared individually using single batch of 
pholcodine monohydrate drug substance as per test meth-
od, and were applied in two consecutive days according to 
the same procedure. The difference between the results ob-
tained in two different days was less than 20%, so accep-
tance criteria was fulfilled and the method was confirmed 
being precise.
The limit of detection and limit of quantification were 
found to be specific for each solvent.
Robustness was tested by introducing small variations 
in the method parameters: carrier gas flow (± 0.1 ml/min), 
injector temperature (± 5 °C) and detector temperature 
(± 5 °C). For each set of variation, six replicate injections 
of the standard solution with concentration level of 100% 
were performed. The obtained results for all variations in-
dicated that studied variations of GC-HS conditions will 
not cause any significant changes in system suitability and 
the method robustness was confirmed.
Conclusion
During the validation procedure, carried out accord-
ing to ICH guidelines, highly selective HS-GC-FID meth-
od was developed and validated for the identification and 
quantification of residual solvents present in pholcodine 
monohydrate API through an understanding of the synthet-
ic process, nature of solvents and nature of stationary phas-
es of columns. The residual solvents, ethanol, methanol, 
toluene and benzene were determined and quantified. The 
developed method was found to be: specific, accurate, pre-
cise and robust as per ICH guidelines, hence can be used 
for routine quality control of residual solvents in pholco-
dine monohydrate API. 
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Introduction
Ibuprofen is a nonsteroidal anti-inflammatory drug 
(NSAID) used to reduce fever and treat mild to moderate 
pain or inflammation caused by minor injury, menstrual 
cramps, toothache, back pain, arthritis or headache. There 
is a great interest to develop non-oral dosage forms of ibu-
profen to reduce its common side effects which are related 
to gastric disorders. Using topical gel means that the total 
amount of ibuprofen in the body remains low; this in turn 
means reducing the mentioned side effects.
In general excipients are known to facilitate the ad-
ministration and release of active component as well as to 
protect and stabilize formulation from the environment. 
However, excipients can also give rise to inadvertent or 
unintended effects such as increased degradations of the 
drug. Knowledge of the chemistry of the active substance 
and excipients can often minimize formulation surprises 
(Bharate et al., 2010). Assessment of possible interactions 
(incompatibility) between the active substance (i.e. ibupro-
fen) and different excipients along with the evaluation of 
thermal stability are crucial parts of a normal study prior to 
the formulation of a medicine (Lira et al., 2007).
Excipients used for formulating gel for topical use 
often consist of gelling agents (cellulose derivates; car-
bomers; poloxamers), solvents in which the active ingredi-
ent is dispersed or solubilized (water, alchohol), pH stabi-
lizers which neutralize polymers as a means of gel forma-
tion (organic amines, NaOH), penetration enhancers and 
cooling agents (menthol).
The aim of this study was to evaluate binary/terna-
ry mixtures prepared between ibuprofen and some of the 
most used excipients for gel topical formulations and pre-
dict possible interactions by evaluating the related and deg-
radation products of ibuprofen using HPLC stability indi-
cating method, when exposed to different stress conditions 
for a predetermined period of time. 
Materials and methods
Materials
Active pharmaceutical ingredient (API) ibuprofen 
used for preparation of the mixtures was of pharmaco-
poeial quality (with Certificate of Suitability to the mono-
graphs of the European Pharmacopoeia, CEP). European 
Pharmacopoeia Chemical Reference standard ibuprofen 
impurity BCRS was used. Excipients used for preparation 
of the binary/ternary mixtures are all pharmacopeial grade. 
All other chemicals used in this study were obtained com-
mercially as HPLC or analytical grade reagents.
Preparation of binary and ternary mixtures 
Binary and ternary mixtures were prepared by mix-
ing equal masses of ibuprofen and the excipient (1:1 and 
1:1:1), except Propylene glycol (1:2). Diisopropylamine 
was pre-hated at temperature of 40-45 °C. Due to aggre-
gate form of the excipients, some mixtures were liquids, 
solid state and slurry mixtures.
One of the approaches to investigate drug-excipient in-
teraction is using drug and excipients under thermal meth-
ods of analyses (Patel et al., 2015). All binary/ternary mix-
tures and pure API, were stored under stress conditions, ex-
amining the effect of temperature and humidity at different 
conditions (25 °C/60% RH and 40 °C/75% RH) for 14 days.
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Methods
Evaluation of related and degradation products of ibu-
profen in binary/ternary mixtures, was performed using 
validated HPLC method. The equipment consisted of Agi-
lent 1260 binary pump, 1260 diode array detector, and de-
tection wavelength on 214 nm. Samples were analyzed on 
Zorbax Extend C18 column (150 mm x 4.6 mm column ID, 
5µm particle size). The mobile phase consisted a mixture 
of 1ml o-H3PO4 85% in 2L water and acetonitrile (64:36, 
v/v) and run through HPLC system at a flow rate of 2 ml/
min at room temperature.
Results and discussion
The HPLC method used in this study was selective 
since no other peaks due to excipients appear on the reten-
tion time of ibuprofen. The limit of detection and quanti-
fication were found to be 0.12 µg /ml and 0.40 µg/ml, re-
spectively. 
Related substances present as impurities in ibuprofen 
can originate from the synthesis and from degradation. Ac-
cording to Ph. Eur. (04/2008:0721) specified impurities in 
ibuprofen API are ibuprofen impurity A, impurity J and 
impurity N. All other impurities are limited as other/un-
specified impurities. 
The results obtained from the HPLC analyses revealed 
that pure drug ibuprofen and the mixtures with Carbopol 
940 and levomenthol, were stable during 14 days under 
both storage conditions since no significant change in the 
degradation profile were noted. There were no other peaks 
related to degradation products of drug or excipients.  
Binary mixture of ibuprofen and propylene glycol re-
vealed significant increase of unknown impurities (RRT 
1.57; RRT 1.67; RRT 1.74) at 40 °C/75% RH. This may 
be expected having in mind the chemical properties of pro-
pylene glycol as oxidative reagent which is easily degrad-
ed under presence of high temperature, acidic or basic con-
taminants and the extreme mass ratio (1:2) between ibu-
profen and propylene glycol.  
Regarding the corresponding binary mixtures, the ter-
nary mixture, composed of ibuprofen, diisopropylamine 
and Carbopol 940 shows different degradation profile. 
While 25 °C/60% RH for 14 days did not reveal signifi-
cant change in the degradation profile, 40 °C/75% RH re-
vealed rise of unknown impurities (RRT 0.11 and RRT 
0.12) which are not noted as degradation products in the 
binary mixtures. As for RRT 0.38 which occurs in signifi-
cant amount in the binary mixture with diisopropylamine 
(40 °C/75% RH), in the ternary mixture it is reduced for 
60% on 40 °C/75% RH, and not detected on 25 °C/60% 
RH, for the same period of time. 
It is well known that the chemical compatibility of an 
API in a binary mixture may differ from that of a multi-
component prototype formulation. Although the degrada-
tion is evident at elevated temperature or at unrealistical-
ly high concentration ratio of excipient to API, they may 
not be seen at ambient (real) temperature or at excipient to 
API ratio for the duration of the product shelf-life (Bharate 
et al., 2010). However such information can be very help-
ful in analyzing any instability issues with commercial for-
mulations or during the development of new formulations. 
Conclusion
Traditionally, excipients have been regarded as inert. 
In this study, excipients which were commonly used for gel 
topical formulation of ibuprofen were evaluated for inter-
actions possibility by estimating the degradation profile of 
ibuprofen in the mixtures under stress conditions.
No significant change of known impurities was ob-
served during 14 days stress conditions in all samples.  Bi-
nary mixtures with organic amines (triethanolamine and 
diisopropylamine) and propylene glycol, reveled signifi-
cant increase of unknown impurities on accelerated condi-
tions of 40 °C/75% RH. However the behavior of ternary 
mixture, composed of ibuprofen, Carbopol 940 and DIPA 
is completely different then the binary mixtures (mild ris-
ing of unknown impurities which are not noted in the bina-
ry samples and extreme reducing of the significantly raised 
unknown impurities).
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Introduction
Analytical method development can be a time-con-
suming process that can last a long time. Methods are com-
monly developed using the traditional approach called 
“one-factor-at-a-time” (OFAT) which is carried out by se-
lecting one instrument parameter to study while holding all 
other parameters constant. The best performing level of the 
study parameter is identified by visual inspection of the tri-
al chromatograms. The parameter is then constant at this 
level, and a new instrument parameter is selected for the 
next trial. The OFAT process is repeated parameter by pa-
rameter until an adequately performing instrument method 
is obtained (Krull et al., 2008). This type of development 
may create an adequate method but provides a limited un-
derstanding of method capabilities and method robustness.
Another, systematic screening approach that evaluates 
a number of stationary phases, pH ranges and organic mod-
ifiers provides a more thorough approach to method devel-
opment. A Quality by Design (QbD) approach to method 
development uses statistical design of experiments (DoE) 
to develop a robust method ‘design space’. The design 
space defines the experimental region in which changes to 
method parameters will not significantly affect the results 
(ICH, 2009; Lukulay et al., 2009). This approach builds-in 
robustness to the method as the method is being developed. 
A better understanding of the overall method capabilities 
and limitations in development ensures a greater chance 
of successful method validation, transfer and routine use 
(Heyden, 2006). Method development using software af-
fords considerable time savings for the analyst and the use 
of quality by design can produce a significantly more ro-
bust and quality submission to regulatory authorities.
In this study, a quality by design approach using meth-
od development software for determination of assay of 
drug products is presented. 
Materials and methods
The study was carried out on an Agilent 1290 infini-
ty system equipped with a 6-position column manager and 
solvent selection valve to allow for automated exploration 
of a wide range of conditions. Fusion AE Method Develop-
ment software was used in conjunction with Chemstation 
to facilitate a more comprehensive QbD approach meth-
od development. For the first phase of initial screening 6 
different columns were used: Sun fire C8, 150 x 4.6 mm, 
5 µm; Halo Phenyl-Hexyl 150 x 4.6 mm, 5 µm; Zorbax 
Eclipse XDB C18 150 x 4.6 mm, 3.5 µm; Zorbax SB AQ 
150 x 4.6 mm, 3.5 µm; X Select CSH Fluoro-Phenyl 150 
x 4.6 mm, 3.5 µm and X Select HSS C18 100 x 4.6 mm, 
3.5 µm. Organic modifiers acetonitrile and methanol were 
varied from 5 to 30 percent. The buffer solution which in-
cluded a 5 mM sodium dihydrogen phosphate monohy-
drate and a 10 mM 1-pentasulphonic acid sodium salt  was 
varied in pH range from 3.0-8.0. The column temperature 
(25 °C), flow rate (1 mL/min), injection volume (20 µL) 
and wavelength (233 nm) were maintained constant. The 
samples were prepared by spiking placebo, active sub-
stance and all known impurities of the active substance in 
a concentration of 1.0 percent of the concentration of the 
active substance. The samples were diluted with the buffer 
solution with pH value depending on the pH value of the 
mobile phase of the experiments in order to avoid eventual 
peak distortion or other chromatography problems caused 
by differences in sample solvent and mobile phase. 
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Results and discussion
After defining the variables of interest and the region 
of variation, an experimental design was generated within 
Fusion AE. A partial factorial statistical design was select-
ed by the software to obtain the maximum amount of infor-
mation with the least number of experimental runs (Hey-
den and Dejaegher, 2007). The experimental design was 
then transmitted to Chemstation software where all meth-
ods were automatically generated and ready to run. After 
the end of all the experiments the chromatograms were in-
tegrated and the results were imported back into Fusion AE 
which was used to model the data and to generate an initial 
method for subsequent optimization. The critical quality 
attributes (CQA), like retention time (3-8 min), Max Peak-
Resolution (>1.5) and USP peak tailing (0.9-2.0) were es-
tablished and the software carried out some possible solu-
tions.
The contour plots of the modeled data show the un-
shaded (white) region as the acceptable region where all 
the critical quality attributes (CQA) are within the above 
designated criteria. By choosing the contour plot for each 
column, the type of organic modifier and changing the fac-
tors on each axis, the software gives predictions how the 
critical attributes are changing as a function of the factors 
on x and y axis. With the usage of the point prediction tool 
the most optimal method conditions which were located 
in the unshaded region of the contour plot were selected. 
These conditions were then exported to chromatography 
data system and additional experiments were performed. 
The best chromatography and the “widest” unshaded re-
gion was obtained with column Sun Fire C8 150 x 4.6mm 
with particle size of 5 µm with acetonitrile as organic mod-
ifier. The optimal percent of the organic modifier was 5 
percent and the pH value of the buffer was 3.0. 
The DoE contour plot helped to determine the settings 
for the next phase of the development of the method when 
the concentration of buffer solution was tested. For this 
purpose a 20 mM sodium dihydrogen phosphate monohy-
drate and a 5 mM 1-pentasulphonic acid sodium salt buffer 
with pH value of 3.0 was used and analyzed with the above 
specified chromatographic conditions. It can be seen that 
with a higher concentration of sodium dihydrogen phos-
phate monohydrate and lower concentration of 1-penta-
sulphonic acid sodium salt a better resolution between the 
peak of the active substance and the nearby eluting impu-
rity is observed. 
Conclusion
Chromatographic analytical method development nor-
mally begins with selection of the analytical column, the 
pH of the mobile phase and the organic solvent type. When 
using the OFAT approach in the initial phase of develop-
ment, there is a possibility that this approach will provide 
limited coverage of the design space and there will be no 
understanding about the interaction effects between the in-
strument parameters. On the other hand a quality by de-
sign approach employs a statistically designed experiment 
to address the design space comprehensively and enables 
all important variable effects to be understood.
The initial column-solvent screening experiment car-
ried out by using the quality by design approach and soft-
ware capabilities can identify the correct analytical col-
umn, pH, and organic solvent type to use in the next phase 
of method development. The chromatographic conditions 
for the determination of the assay of drug substance set in 
this phase of the method development were: column Sun 
Fire C8 150 x 4.6 mm with particle size of 5 µm; mobile 
phase (buffer 20 mM sodium dihydrogen phosphate mono-
hydrate and a 5 mM 1-pentasulphonic acid sodium salt 
buffer with pH value of 3.0  with acetonitrile in ratio of 
95 : 5 percent); flow rate (1.0 mL/min); column tempera-
ture (T=25 °C), injection volume (20 µL) and wavelength 
(λ=233 nm). 
The automated method development approach using 
Fusion AE software provides a better performing and more 
robust method in less time compared to manual method de-
velopment. 
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Introduction
The test for bacterial endotoxins is used to detect or 
quantify endotoxins originating from gram-negative bac-
teria using amebocyte lysate from horseshoe crab (Limu-
lus polyphemus or Tachypleustridentatus). There are three 
techniques for this test: the gel-clot technique, which is 
based on gel formation; the turbidimetric technique, based 
on the development of turbidity after cleavage of an endog-
enous substrate; and the chromogenic technique, based on 
the development of color after cleavage of a synthetic pep-
tide-chromogen complex (Ph.Eur., 2014).
Material and methods
The testing was performed in accordance with Ph.Eur 
8.0/2.6.14 by using Method A. Gel-Clot method: limit test 
and Method B. Gel-Clot method: quantitative test where 
permissible endotoxin limit concentration (ELC) in phar-
maceutical preparation containing somatropine is < 5IU/
mg. The maximum valid dilution (MVD) is 1:400. One In-
ternational Unit (IU) of endotoxin is equal to one Endotox-
in Unit (EU). 
The following  reagents, equipment and inventory were 
used in the test: Limulus amebocyte lysate (LAL), Reagent, 
λ = 0,125 EU/ml from Charles River Endosafe, USA; En-
dotoxin control standard, E.coli 055:B5 from Charles Riv-
er Endosafe, USA; LAL water from Charles River Endo-
safe, USA; Thermoblock for incubation (37 ± 1 °C) from 
Lab-Line Instruments, USA; Vortex mixer from Barnstead, 
USA; Micropipettor from 5-50 ml; 50-200 ml and 200-1000 
ml from Socorex, Switzerland; sterile and apyrogen exten-
sions for multipipettors from Socorex, Switzerland; ster-
ile and apyrogen glass test tubes from Charles River Endo-
safe, USA; sterile and apyrogen glass test tubes for dilution 
from Charles River Endosafe, USA and universal indicator 
paper pH 0-14 from Sigma-Aldrich.
Method A
Diluting used for preparation testing, which is not 
higher than MVD is 1:300.
The following test solutions were prepared:
Solution A: Diluted test solution being diluted less 
than MVD (1:300).
Solution B: Calibration curve of the endotoxin control 
standard (CSE) and diluted test solution (1:300) - concen-
trations equivalent to 2λ, λ, λ/2 and λ/4 (test for interfer-
ing factors).
Solution C: Calibration curve of the control endotoxin 
standard (CSE) and LAL water-concentrations equivalent 
to 2λ, λ, λ/2 and λ/4 (Confirmation test for the declared ly-
sate sensitivity).
Solution D: LAL water as a negative control.
Procedure: Preparation tested on MVD (1: 400) – so-
lutions 1, 2, 3 and 4.
The test is valid if the following condition is met:
The both replicates in the solutions 2 and 3 of the pro-
cedure are positive, while being negative in the solution 4. 
The tested preparation meets the test if there is a nega-
tive result for both replicates in solution 1. If a positive re-
sult is obtained on both replicates of solution 1diluted on 
MVD, it does not meet the test. If a positive result is ob-
tained on both replicates of solution 1 diluted to dilution 
less than the MVD, the test will be repeated with dilution 
which does not exceed the MVD or at the level of MVD.
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Method B
Dilutions for preparation testing, and which are not 
higher than MVD 1:1; 1:2; 1:4; 1:8; 1:10; 1:100; 1:200 and 
1:400.
The following test solutions were prepared:
Solution A: Test solution diluted lower than MVD (test 
for interfering factors).
Solution B: Undiluted test solution containing CSE at 
the concentration of 2λ (Positive Product Control).
Solution C: Calibration curve of the endotoxin control 
standard (CSE) and LAL water - concentrations equivalent 
to 2λ, λ, λ/2 and λ/4 (Confirmation test for the declared ly-
sate sensitivity).
Solution D: LAL water as a negative control.
The test is valid if the following three conditions are 
met:
1. The both replicates of solution D (negative control) 
are negative.
2. The both replicates of solution B (positive product 
control) are positive.
3. Geometric mean of the final points in solution C is 
in the range of 2λ to λ/2.
Results and discussion
Method A
The obtained test results in Solution A are satisfactory 
i.e. the preparation does not contain detectable endotoxins. 
In Solution B with the dilution of 1:300 the interference 
factors exceeded, while the obtained result 0.2102 EU / ml 
is within the permissible limits of 2 λ to λ/2 (0.25 EU / ml 
to 0.0625 EU / ml). The declared lysate sensitivity in solu-
tion C is confirmed and the obtained result 0.2102 EU/ml 
is within the limits of 2 λ to λ/2 (0.25 EU/ml to 0.0625EU/
ml). The obtained negative results in Solution D satisfy the 
test. In the mentioned procedure, both replicates in solution 
2 (Positive Product Control) and solution 3 (Positive Water 
Control) are positive, while the both replicates in solution 
1 (Negative Product Control) and solution 4 (Negative Wa-
ter Control) are negative.
Method A 
The obtained result 0.003525 EU/ml i.e. 0.0003525 
EU/mg (allowed < 5IU/mg) in Solution A meets the quali-
ty specifications and the preparation does not interfere with 
the test. The obtained results of the both replicates in so-
lution B (Positive Product Control)  are positive and the 
results satisfy the test. Declared lysate sensitivity in solu-
tion C was confirmed and the obtained result 0.0884 EU/
ml is within the limits of 2 λ to λ/2 (0.25 EU/ml to 0.0625 
EU/ml). The obtained results of the both replicates in so-
lution D (Negative Water Control) are negative and the re-
sults satisfy the test.
Conclusion
The obtained value of the lysate sensitivity determined 
by Method A.Gel-Clot method: the limit and test method 
B.Gel-Cloth method:quantitative test is within the limits 
of 2λ to λ/2.
The advantage of Method B compared to Method A 
is the option it has to determine concentration of endotox-
in on unknown sample (a sample with unknown composi-
tion declaredand endotoxin limit concentration not listed).
Using the Method A, with dilution of 1:300, the inter-
ference factors exceeded and the preparation meets the test 
i.e. neither false positive nor false negative results were ob-
tained.
Using the Method B, with dilutions of 1:200, the fac-
tors of interference started exceeding, while complete-
ly exceeded at dilution 1:400, which leads to a conclusion 
that Method B confirms the results of Method A since the 
dilution of 1:300 in Method A with exceeded interference 
factors in the range between 1:200 and 1:400.
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As technological innovations advanced so did the 
medical devices that became part of surgery (so called in-
vasive surgery) from the mid 19th century onward.  There 
are many medical devices that are used in diverse surgical 
procedures on a daily basis (medical equipment and instru-
ments). Medical devices covers a wide spectrum of differ-
ent technological devices starting from simple depressors 
to complex, highly-technical and computerized devices. 
They play a crucial role in healthcare, whether in small, ru-
ral healthcare facilities or in expert medical diagnostic and 
treatment centers (Radisic, 2008). An additional proof of 
their necessity and significance is the fact that many gov-
ernments across the world provide more than one billion 
Euros for medical purposes (WHO, 2003). 
The purpose of this paper is to address the necessity of 
legal regulation of the types of liabilities of the entities in-
volved for damage caused by using the medical devices in 
the R. Macedonia.
The technological advance of the modern medical de-
vices is one of the most important elements of an efficient 
healthcare system. However, specific medical devices can 
be hazardous to the health of the medical staff or patients. 
There are numerous risks such as: improper alignment of 
the medical device, improper and inadequate usage of it, 
inadequate maintenance, and inadequate supervision be-
fore and after usage, breaking down of the medical device 
as well as the existence of dysfunctional medical devic-
es. The medical devices that are most harmful for the pa-
tients’ inner and outer body are the ones with specific us-
age, features, positioning and way of usage. (Tupanchevs-
ki et al., 2012)  
Having in mind the increased usage of different medi-
cal devices that are harmful to the patients’ overall health, 
the liability of the inflicted harm is also a big legal prob-
lem. Furthermore, this represents a complex social and le-
gal problem, not just because it hasn’t been regulated by 
specific legal norms, but because it has been expanding 
rapidly as well.
The liability for the damage caused by the use of med-
ical devices in most legal systems as it is the case with Re-
public of Macedonia is not separately regulated. On the 
contrary, the liability is regulated by several laws of differ-
ent legal disciplines. Namely the types of liability for the 
caused damage from using of medical devices can be the 
following: a) disciplinary liability (for which the most se-
vere sanction includes the health worker’s loss of licence), 
b) civil liability (that results in liability for compensation 
due to individual error which leads to a violation of pa-
tient’s rights) c) misdemeanor  liability (which usually en-
tail a fine for inflicting minor injuries) and d) criminal lia-
bility (in cases where besides individual interests, it is nec-
essary to ensure the protection of the wider social inter-
est). However, despite this classification, the abovemen-
tioned forms are mutually intertwined and complementa-
ry to some extent, which means, whenever possible, it is 
necessary to avoid multiple punishments (Davitkovski et 
al., 2009). 
The health workers are not solely responsible for the 
damage caused by using different types of medical devic-
es. The manufacturer or the importer, the health institution 
and the people in charge of the health institution, should 
also take legal liability.
Civil liability is determined and accomplished by gen-
eral legal rules liable for any caused damage. Above all, 
these are rules  for personal liability, which is based on the 
guilt of the health worker and the liability rules of the le-
gal entity (healthcare facility) for any damage caused by 
the employee to a third party. This liability arises as a con-
sequence of violating contractual or legal duties of health 
professionals related to medical devices, and qualifies as a 
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medical error. Nevertheless, the rules of objective liability 
(liability regardless of fault) are no exception in terms of 
rules of personal liability, but have a special scope of ap-
plication that is defined by general terms such as: danger-
ous object and dangerous activity. The rules of liability for 
dangerous objects or dangerous activities have their field 
of application, and in that context can be used in all cir-
cumstances under which the damage is caused by the use 
of medical devices that have been labeled as dangerous ob-
jects. Therefore, apart from health workers, the manufac-
turer of the medical device and the holder of the dangerous 
object are also deemed as liable for the damage (Radisic, 
2008). The compensation for the harm caused by medical 
devices is established in the Law on Obligations (Assem-
bly of the Republic of Macedonia, 2001).
Criminal liability of health professionals, legal entities 
and responsible persons in the legal entity is established in 
the Criminal Code, in the chapter – criminal violations of 
people’s overall health are provided the following crimes: 
Unscrupulous treatment of the ill (Article 207), as well as 
manufacturing and using of harmful devices for treatment 
(Article 212), (Assembly of the Republic of Macedonia, 
1996).
Misdemeanor liability of the entities is established 
in Chapter VI Penalty Sanctions Law on Medicines and 
Medical Devices (Assembly of the Republic of Macedo-
nia, 2007). Disciplinary liability of health workers stems 
from the codes of professional ethical duties and rights of 
health care workers, who make the respective chambers, 
and whose obligation for the Chambers derives from Arti-
cle 250, Paragraph 3 of the Law on Health Protection (As-
sembly of the Republic of Macedonia, 2012).
The liability for the damage that may be caused by the 
use of medical devices is governed by several laws. The 
manufacturer or the importer of medical devices, the re-
sponsible person in the legal person, public health officials 
and the health facility are deemed liable criminally, civilly, 
and disciplinary for the inflicted damage.
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Introduction
Regulatory authorities FDA and ICH are encourag-
ing and promoting implementation of Quality by Design 
(QbD) principles in the pharmaceutical industry environ-
ment (ICH, 2008; ICH, 2009; Reid et al., 2013; Sangshet-
ti et al., 2014). It is a current trend among pharmaceutical 
industry that a method development process is done by im-
plementing an Analytical Quality by Design (AQbD), as 
a part of risk management, pharmaceutical development, 
and pharmaceutical quality system. The application of 
QbD concept to analytical method is justifiable, because of 
many variables that significantly affect the method results 
(Peraman et al., 2015).
There is no single QbD approach to chromatographic 
method development. A systematic approach that is broad-
ly-applicable includes the following steps: establishing the 
critical quality attributes (CQAs), creating an experimental 
design that includes screening and optimization, defining 
an operational design space and defining a control strategy 
(McBrien, 2010; Salman and Vinayak, 2014). 
Quality is guaranteed with robustness and reproduc-
ibility of the method that with this approach is built in 
method development stage. Submission is based on prod-
uct knowledge and assured by analytical target profile 
(ATP). Method flexibility, meaning allowed movement 
within method operable design region (MODR) and con-
tinuous improvement that can be done without prior reg-
ulatory approval, are one of the benefits that come along 
with this approach. 
Materials and methods
QbD approach for development of a high pressure re-
versed phase liquid chromatography (HPLC) method for 
determination of impurities in a drug product that contains 
two active ingredients and five known impurities was per-
formed. Several common critical parameters in HPLC - gra-
dient time, pH of the aqueous eluent, type of organic modi-
fier, temperature and stationary phase were evaluated with-
in the quality by design framework by the means of comput-
er modelling software Fusion AE. Agilent 1290 Infinity auto-
mated method development system equipped with a column 
and solvent selection valves was used. As for initial chemis-
try screening of our experiment setup, four different column 
chemistries were tested: Zorbax SB-CN, Zorbax Eclipse 
XDB-Phenyl, Zorbax Eclipse XDB-CN, and Zorbax Eclipse 
Plus Phenyl-Hexyl, to maximize selectivity. Five different 
pH levels of 50 mM ammonium formate buffer in a pH range 
of 3.5-5.5 were tested and two organic modifiers, acetoni-
trile and methanol. Column temperature was varied in the in-
terval 20-50 °C. Gradient time was set variable, from 28 to 
30 minutes. As constant variables were set flow rate (0.7 ml/
min), injection volume (20µl), initial and final hold time (2 
and 10 minutes, respectively), initial and final hold percent 
organic (25 and 100 percent, respectivelly). 
An experimental design was converted in redy to run 
sequence with 62 chromatografic runs, along with columns 
equlibratin stages. We run the experiment and analyze the 
data. The experimental results were import back to Fusion 
AE and processed to generate an initial method for sub-
sequent optimization. We set a specific goal for each re-
sponse along with lower and upper acceptability limits for 
the solution search as follows: number of peaks - target 7, 
number of peaks that have USP resolution ≥ 1.50, target 6 
and number of peaks that have USP Tailing ≤ 2.0, target 7. 
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Results and discussion
As stage one of our experiment based on QbD princi-
ples, analytical target profile was defined. The goal of this 
analytical method development process was getting a ro-
bust method for determination and quantification of relat-
ed compounds of our drug product. The criteria for the suc-
cessful separation (defined critical quality attribute) is tree 
fold: detection of all peak of interest, maximum critical 
resolution and USP tailing factor.
The software carried out a number of solution search-
es equal to the number of runs in the experiment design, 
with the specific goal settings of the experiment run as the 
starting point. The software then ranked the result of each 
search in terms of relative goodness (closeness to meeting 
or exceeding all goals). It then displayed the best overall 
answers in decreasing rank (LC Method Development Tu-
torial, Fusion QbD Quality by Design Software, S-Matrix 
Corporation, 2014, Version 9.7). All parameters were stud-
ied in combination, thus defining a multi-dimensional de-
sign space. Fusion AE enable visualization of the effect of 
each factor on the separation. This visualization of the de-
sign space was found very helpful in thorough understand-
ing on the impact of each variable on method performanc-
es (Monks et al., 2011). By changing the factors on each 
axis, the design space was explored in detail. Column Zor-
bax SB-CN and acetonitrile were found to be optimal, as 
the acceptable performance region for these variables was 
found to be the broadest. The initial method was further 
optimized in experiment where secondary effectors such as 
column temperature, initial gradient slope and strong sol-
vent percent and flow rate were varied. After processing 
the results, the final optimized method was generated. 
Conclusion
HPLC analytical procedure for related and degrada-
tion products in new pharmaceutical product was devel-
oped, using the AQbD approach. Column Zorbax SB-CN, 
50 mM ammonium formate buffer pH 4.5 as weak and ace-
tonitrile as strong solvent in a gradient time of 28 minutes 
and column temperature of 20 °C were established as in-
put variables that fulfil the goals set at the very beginning, 
thus defining a well-known and understandable multi-di-
mensional method operable design region. 
This kind of approach to analytical method develop-
ment gave us better understanding of method variables, 
since they were studied in combination. Given the large 
amount of chromatographic information contained in gen-
erated models, these offer a sound foundation for method 
troubleshooting and to justify continuous future improve-
ment.
An automated method development using Fusion AE 
software take less time compared to manual method de-
velopment, but also requires a huge understanding in se-
lection of input variables and output response. QbD means 
the right analysis at the right time, based on science and 
risk assessment. This way of understanding and practic-
ing the AQbD  is current area of focus and needs to be im-
plemented.
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Introduction
Moxifloxacin is a fourth generation fluoroquinolone an-
tibacterial agent, active against Gram-negative and some 
Gram-positive bacteria, developed primarily for the treat-
ment of community acquired pneumonia and upper respi-
ratory tract infections (Balfour and Wiseman, 1999). Var-
ious procedures have been developed for the synthesis of 
the drug during which different process-related impuri-
ties are formed. Isolation and structural identification has 
been achieved for many of the synthesis-related impurities 
(Bayer, 2000; Kumar et al., 2004, Petersen, 2006). A num-
ber of methods have been developed for the determination 
of moxifloxacin hydrochloride and its related substances, 
based on reverse-phase high performance liquid chromatog-
raphy (HPLC) (Dewani et al., 2011; Djurdjevic et al., 2009; 
Singh et al., 2014). Ultra high performance liquid chroma-
tography (UPLC) is a relatively new technique which of-
fers several advantages over conventional high performance 
liquid chromatography (HPLC), especially substantially de-
creased time of analysis and reduced solvent consumption 
while retaining chromatographic efficiency, resolution and 
sensitivity (Swartz, 2005). The aim of our study was to de-
velop and optimize an UPLC method for determination of 
moxifloxacin hydrochloride and its related impurities.
Materials and methods
Moxifloxacin hydrochloride and its five impurities: (1) 
8-hydroxy quinolonic acid, (2) 8-methoxy quinolonic acid, 
(3) ethyl quinolonic ester, (4) 8-hydroxy moxifloxacin and 
(5) N-methyl piperazine were used for this study. Stock so-
lutions were prepared in methanol at the concentration lev-
el of 1 mg/ml for moxifloxacin and 0.1 mg/ml for each of 
the selected impurities. The resolution solution of moxi-
floxacin and its related impurities was prepared by diluting 
the stock solutions in mobile phase A, to the final concen-
tration of 0.4 μg/ml for each compound. 
The chromatographic analysis was conducted on Shi-
madzu Nexera UPLC system equipped with PDA detector. 
The separation was performed on an Acquity UPLC BEH 
C18, 50 x 2.1 mm, 1.7 μm chromatographic column, using 
gradient elution of mobile phase  B (%): 0-2 min: 19%; 2-6 
min: from 19% to 67%; 6-8 min: from 67% to 27%; 8-8.1: 
from 27% to 19%; 8.1-9 min: 19%. Mobile phase A was a 
mixture of aqueous phase pH=2.2 (containing 0.16 mol/L 
phosphoric acid and 1 ml/L trifluoroacetic acid, adjusted to 
pH 2.2 with triethylamine) and methanol (85:15 v/v). Mo-
bile phase B consisted of a mixture of methanol and water 
(80:20 v/v). The column temperature was maintained at 50 
˚C and the flow rate was 0.3 ml/min. Injection volume was 
5 μL and the total run time for analysis was 9 min. Moxi-
floxacin and its impurities were recorded at 296 nm.
Results and discussion
Optimization of the method started by varying the 
composition and the pH of the mobile phase, using isocratic 
and gradient elution. Two aqueous mobile phases were ex-
amined, one containing potassium dihydrogen phosphate, 
and the other containing phosphoric acid, at three pH values 
(2.2; 5.5; 6.0), maintaing the column temperature at 25 ˚C. 
The studied compounds were partially separated by isocrat-
ic elution, therefore to achieve full separation, gradient elu-
tion was used. The best separation and peak symmetry were 
observed with the aqueous phase containing phosphoric 
S2 PP 106
230
Maced. pharm. bull., 62 (suppl) 229 - 230 (2016)
Pharmaceutical analysis / Quality assurance / Regulatory affairs
Po
st
er
 p
re
se
nt
at
io
ns
acid at pH=2.2, therefore it was selected for further analy-
sis. Under these conditions, 8-methoxyquinolonic acid and 
ethylquinolonic ester impurities were not resolved at all. In 
order to achieve their separation, column temperature was 
gradually increased. Satisfactory resolution was achieved 
at 50 ˚C. In order to obtain adequate sensitivity the injec-
tion volume was also varied. Optimal results were obtained 
using injection volume of 5 μL. According to the litera-
ture data, the wavelength was optimized in the range from 
290-296 nm (Djurdjevic et al., 2009). The wavelength of 
maximum absorption was selected according to the record-
ed UV spectrum of the moxifloxacin hydrochloride, which 
was 296 nm. Different diluents for preparation of the reso-
lution solution were tested as well. The best peak shape of 
the studied compounds was observed using mobile phase A 
as diluent. The final step in the optimization process was the 
selection of the best conditions for gradient elution. There-
fore, the ratio of mobile phase B, the flow rate and the gra-
dient steps were optimized. Best peak shape and resolu-
tion with optimal run time was acquired using gradient elu-
tion of mobile phase B (%): 0-2 min: 19%; 2-6 min: from 
19% to 67%; 6-8 min: from 67% to 27%; 8-8.1: from 27% 
to 19%; 8.1-9 min: 19%. Using the finally optimized chro-
matographic conditions a critical resolution between 8-me-
thoxy quinolonic acid and ethyl quinolonic ester of 1,8 was 
obtained. All the peaks of the studied compounds have a 
good symmetrical shape, with maximum tailing factor of 
1.3 for the peak of 8-hydroxy moxifloxacin. The number 
of theoretical plates (tp) shows suitable column efficiency, 
with a minimum NTP of 1770 tp/column for the peak of N-
methyl piperazine. The obtained values for signal to noise 
(minimal value of 11.9 for the peak of 8-hydroxy moxi-
floxacin) confirmed the sensitivity of the method. All of the 
aforementioned parameters indicate on a satisfactory per-
formance of the chromatographic system.
Conclusion
An UPLC method for quantitative determination of 
moxifloxacin hydrochloride and its related impurities was 
developed and optimized. The method is simple and sen-
sitive and the studied impurities were separated with ex-
cellent resolution in only 9 minutes. The results from our 
study indicate that, after proper validation, the proposed 
method could be used for routine analysis of moxifloxacin 
hydrochloride and its related substances as an active ingre-
dient and in pharmaceutical dosage forms as well.
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Introduction
Fluoroquinolone as active compound belongs to a 
class of synthetic antimicrobial agents. Fluoroquinolones 
absorb radiation energy in the ultraviolet range. A loss of 
antibacterial activity was observed after UV exposure, as 
a result of changed colour, decreased assay and increased 
degradation products, suggesting photodegradation of the 
active substance. Regarding to this, selection of an appro-
priate packaging to protect the drug product from light and 
a storage advice is necessary to be established.
The photodegradation itself has not yet been docu-
mented, as well as no information has been so far provided 
on the nature of the photoproducts. For some fluoroquino-
lones, however, metabolites have been identified with re-
duced antibacterial activity (Eva-Maria et al., 1993).
In order to demonstrate that appropriate light expo-
sure does not lead to unacceptable changes in dosage form, 
photostability testing was performed on the drug solution, 
as part of formal stability study ICH guideline Q1A (R2) 
(Blessy et al., 2014). 
Materials and methods
Photo stability study was conducted according to ICH 
guideline Q1B ”Photo stability Testing of New Drug Sub-
stances and Products”- Option 1. Testing was performed 
on one batch of Alkaloid’s drug product, solution packed 
in glass colorless ampoules as primary packaging and 
cardboard boxes as secondary packaging, using following 
methods:
Determination of colour of solution: Ph.Eur 2.2.2 
method and visual method
Determination of assay and related and degradation 
compounds of the drug product: validated in-house HPLC 
methods.
The formulation was examined at confirmatory stor-
age conditions: exposure time in the visible range is 7.1 
hours, which corresponds to an illumination of 1.2 million 
lux hours and in the UV range 2.9 hours, which corresponds 
to an integrated near ultraviolet energy of 200 Wh/m2.
In first phase of photostabilty study, samples and pla-
cebo, were exposed outside the immediate pack, placed in 
a quartz Erlenmeyer’s with stoppers, alongside with pro-
tected sample and placebo (solutions placed in amber glass 
volumetric flasks) used as a dark control to evaluate the 
contribution of thermally induced change.
In the second phase, the samples and placebo were ex-
posed in primary packaging to the same conditions.
In the last, third phase, the samples and placebo were 
exposedin the secondary packaging as intended for mar-
keting, also to the same conditions.
After treatment, samples were examined for any changes 
in physical properties: i). colour of solution with visual meth-
od; ii). determination of assay with HPLC method and iii). 
determination of degradation products with HPLC method.
Results and discussion
In this study, photo stability of the drug product and 
degradation pathways of the active substance was fully de-
terminate and understood. 
After the exposure for 2.9 hours to an integrated near 
ultraviolet energy of 200 Wh/m2, the assay of the active 
component was slightly decreased in both samples, the sam-
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ples outside of primary packing and samples in the prima-
ry packaging. The decrease in the assay was followed with 
changed levels of impurity amount significantly for the 
specified impurity C, susceptible to light degradation (Hani 
et al., 2015; Mohammad and Zaynab, 2014; Ummeet al., 
2013) which has increased to 0.43 and 0.47%, respectively.
All samples have shown change in colour, compared 
with Ph.Eur. Reference standard solution GY4, used for 
determination of the colour.
After the exposure for 7.1 hours to an illumination of 
1.2 million lux hours in the visible range, the obtained re-
sults from the opened samples and samples in the primary 
packaging were very similar. The assay of the active com-
ponent was decreased to 97.82% and 97.50% respective to 
the increased amount of the specified impurity in the lev-
el above the qualification threshold, 0.76% and 0.74%, re-
spectively. Also, both samples have shown change in the 
colour of the drug product.
No changes were noticed in the amount of the un-
known impurities in all treated samples at end of exposure. 
Alongside with the drug product, placebo solution was 
also stressed in order to exclude those impurities that are 
not degradation products, which was found stable during 
the photo stability study.
In the dark control samples and samples in the second-
ary packaging, no changes have been observed at the end 
of exposure period.
Data review of the tests on the exposed drug product 
outside the immediate packaging as well as in the primary 
packaging suggest that the drug product is sensitive to light 
and should be kept in the secondary packaging. The sec-
ondary packaging, cardboard box, provides sufficient pro-
tection, where the physical properties, assay and impurity 
levels are comparable to the untreated samples.
Conclusion
From the results for colour, assay and related and deg-
radation products, obtained from conducted photo stabil-
ity study on the drug product, it has been concluded that 
the drug product, containing fluoroquinolone, is suscepti-
ble to photo degradation and loss of antibacterial activity. 
No photo degradation was observed at the third phase of 
performed study, confirming that product should be kept 
in its original package in order to be protected from light.
With regard to data presented, the SmPC and label-
ling sections for the drug product should be amended with 
a storage advice: ‘Store in the original package to protect 
from light’.
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Introduction
Aripiprazole is an atypical antipsychotic drug, recently 
approved for the treatment of acute manic and mixed epi-
sodes associated with bipolar disorder and as an additional 
treatment of depression (Thakkar et al., 2011). It acts pri-
marily as partial agonist of D2 receptors. It is also a partial 
agonist of the 5-HT1A receptors, and like other atypical 
antipsychotics displays an antagonist profile binding to the 
5-HT2A receptors. Aripiprazole has moderate affinity for 
histamine and alpha adrenergic receptors, and no apprecia-
ble affinity for cholinergic muscarinic receptors 1-2 (Ra-
vindra et al., 2014). Chemically, it is 7-[4-[4-(2, 3-dichlo-
rophenyl) piperazin-1-yl] butoxy]-3, 4-dihydro-1H-quino-
lin-2-one. 
Organic impurities can arise during the manufactur-
ing process or storage of a drug substance, and include 
starting materials, intermediates and degradation products 
(ICH, 2006). In this study, retention behavior of aripipra-
zole and its five impurities was investigated. The follow-
ing impurities were analyzed: hydroxy quinoline impuri-
ty (Impurity A): 7-hydroxy-3,4-dihydro quinolin-2 (1H)-
one; piperazine impurity (Impurity B): 1-(2,3-dichloro-
phenyl)piperazine hydrochloride; diquinoline impurity 
(Impurity C): 7,7’-(butylenedioxy)di-3,4-dihydroquino-
lin-2(1H)-one; chlorobutoxyquinoline impurity (Impuri-
ty D): 7-(4-chlorobutoxy)-3,4-dihydroquinolin-2(1H)-one 
and N-oxide impurity (Impurity E): N-oxide-7-[4-{4-(2,3-
dichlorophenil)-1-piperazinyl}butoxy]-3,4-dihydroquino-
lin-2(1H)-one. 
β-Cyclodextrins (β-CDs) are macrocyclic oligosaccha-
rides composed of seven α-D-glucopyranose units joined 
in a cone-shaped structure (Chen et al., 2004). They exhib-
it a hydrophobic cavity delimited by two rims, a wide and a 
narrow one, composed of secondary and primary hydroxyl 
groups (Fifere et al., 2012). This structure enables β-CDs 
to generate inclusion complexes with a wide variety of hy-
drophobic organic compounds in aqueous solutions. In an-
alytical chemistry β-CDs could be used as mobile phase 
additives, in order to reduce the amount of organic solvents 
and introduce the concepts of green chemistry.
The aim of the present study was to investigate the re-
tention behavior of aripiprazole and its five impurities us-
ing High-performance liquid chromatography (HPLC) 
method and applying the concepts of green analytical 
chemistry. The influence of β-CD on retention behavior of 
aripiprazole and its five impurities was examined, in order 
to shorten retention times with smaller percentage of ace-
tonitrile, as an organic modifier.
Materials and methods
All experiments were carried out on Thermo Scientif-
ic, Dionex Ultra 3000 equipped with PDA detector. Chro-
matographic separation was performed at non-polar C18 
analytical column Chromolith RP-18e column (100 mm × 
4.6 mm, macropore size 2 µm, mesopore size 13 nm) at 
temperature varying from 25 °C to 40 °C. Injection volume 
was 5 μL. Mobile phase was prepared by dissolving an ap-
propriate amount of β-CD in water to achieve 10 mM and 
15 mM β-CD solutions. The pH was adjusted using formic 
acid. The mobile phase was degassed in ultrasonic bath and 
filtered through membrane filter prior to use. The flow rate 
was 1 mL/min. The detection was performed at 235, 254 
and 285 nm using PDA detector. 
Stock solution of aripiprazole was prepared by dis-
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solving 500 μg of standard substance in 1 mL of HPLC wa-
ter. Working solution was prepared from appropriate vol-
ume of stock solution and mixture of β-CD and acetonitrile 
(80 : 20, v/v). The same procedures were used for prepar-
ing stock and working solutions of the impurities, but the 
concentration of stock solutions was 100 μg/mL. All the re-
agents used were of analytical grade except water and ace-
tonitrile which were of HPLC grade.
Results and discussion
Investigation of retention behavior of aripiprazole and 
its five impurities was done by varying the pH value of the 
mobile phase in the range from 2 to 4, the β-CD concen-
tration from 10 mM to 15 mM, column temperature from 
25 °C to 40 °C and acetonitrile as an organic modifier from 
25% to 30%. Under the chosen acidic conditions, aripira-
zole was in cationic form, as well as its impurity B and 
impurity E. Impurity A was in molecular form, but its re-
tention time was short, which could be explained by the 
polarity of a molecule (logP = 1.28). Impurities C and D 
were in molecular forms, which probably caused longer 
retention times. Percentage of acetonitrile was the factor 
with the most significant impact on retention times of an-
alyzed compounds. Although aripiprazole is a lipophilic 
compound (logP = 4.79), its satisfactory elution time was 
achieved with 25% of acetonitrile. The same amount of 
acetonitrile was used for impurities, which were also most-
ly lipophilic. LogP values of impurities B, C, D and E are 
2.79, 2.95, 2.52 and 4.18, respectively. 
It was recognized from the recent literature reports 
that reducing the consumption of organic solvents intro-
duces an environment-friendly approach to drug analysis 
(Cielecka-Piontek et al., 2013). The mobile phase consist-
ing of β-CD could play an important role in reducing the 
amount of acetonitrile. Taking into consideration the struc-
ture of β-CD, there was a possibility for building inclusion 
complexes with aripiprazole or its impurities, which could 
shorten the time of analysis. The higher column tempera-
ture also shortens the retention times of all the analyzed 
compounds. The change in β-CD concentration from 10 
mM to 15 mM did not have a significant influence on the 
retention times. Based on all described facts it was decid-
ed to work with 15 mM β-CD. Also, it was decided that 
the percentage of acetonitrile could be 30% and the col-
umn temperature should be set at 40 °C. Retention time 
of aripiprazole under these circumstances was 5.343 min, 
impurity A 1.717 min, impurity B 2.067 min, impurity C 
10.917 min, impurity D 10.773 min and impurity E 5.940 
min. From the obtained UV spectra the most appropriate 
wavelength for monitoring the compounds was decided to 
be 254 nm. Finally, although aripiprazole and its five im-
purities differ in structure and polarity, using HPLC meth-
od with β-CD solution as mobile phase additive, they could 
be separated in single analytical run.
Conclusion
The present study shows that β-CD has an important 
influence on retention behavior of aripiprazole and its five 
impurities. Reducing the amount of organic solvents by 
using β-CD solutions as mobile phases is a great advan-
tage and step forward to limit the exposure to toxic agents, 
without decreasing the sensitivity and resolution of deter-
mination. Under these circumstances the proposed HPLC 
method could be successfully used for separation of aripip-
razole and its five impurities. Besides, another advantage 
of proposed method is the compliance with the novel trend 
in analytical method development according to which it is 
recommended to use methods suitable for adopting the en-
vironment-friendly approach to pharmaceutical analysis.
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Introduction
Alcohol Induced Dose Dumping (ADD) is a term that 
describes the unintended, rapid release in a short period of 
time of the entire amount or a significant fraction of the 
drug contained in a prolonged-release dosage form. De-
pending on the therapeutic indication, the therapeutic in-
dex and other characteristics of the drug, dose dumping can 
pose a significant risk to patients, either because of safe-
ty issues or diminished efficacy or both. Generally dose 
dumping is observed as a result of an impairment of the 
release-rate-controlling mechanism. Some prolonged-re-
lease oral dosage forms contain drugs and excipients that 
exhibit higher solubility in ethanol solutions compared to 
water solutions. Such products can be expected to exhibit 
a more rapid drug dissolution and release rate in the pres-
ence of ethanol. Therefore, when a prolong-release prod-
uct is consumed with alcohol, the prolong-release mecha-
nism could be adversely affected, which could lead to dose 
dumping.
Where appropriate, based on the risk of dose dumping 
when a prolonged-release drug product is consumed with 
alcohol, the prolonged-release drug products labeling in-
cludes warnings against the consumption of alcohol while 
taking the drug product. Even with significant warnings in 
the labeling, the consequences of concomitant alcohol use 
need to be considered for certain drug products because 
alcohol use may still be likely and such alcohol use may 
lead to dose dumping, which could result in serious ad-
verse events especially for certain narrow therapeutic in-
dex drugs.
Mitigating the risks of alcohol-induced dose dumping 
is an issue that puts great demands on formulators, regula-
tory agencies and the industry at large. Over the last few 
years, the pharmaceutical industry has become increasing-
ly concerned with the topic of alcohol-induced dose dump-
ing, which can lead to dangerous or even potentially lethal 
side effects. The goal of the regulatory approach should 
be to minimize the risk of alcohol-induced dose dumping 
from prolonged-release dosage forms, irrespective of any 
warnings on product labeling and instructions by health 
care providers (Meyer et al.,2005). To address the prob-
lem, regulatory guidelines have been implemented, result-
ing in the need for new formulation approaches.
Guidelines in Europe and the United States 
In the European Union, all prolonged-released formu-
lations must be evaluated for alcohol-induced dose dump-
ing risk. Effects of alcohol for generic oral formulations, 
in vitro studies of the release in alcohol solutions should 
be performed. Where accelerated active substance release 
is seen in vitro either at high or low alcohol concentrations 
over a short period of time or at lower alcohol concentra-
tions over a longer period of time, the product should be re-
formulated. If the alcohol effect cannot be avoided and it is 
present also in the reference product, the applicant should 
justify / demonstrate that it lacks of clinical relevance or 
discuss the possible clinical relevance in comparison to the 
reference product. EMA guidelines show a path for deci-
sion-making for formulators (Friebe et al., 2005). 
Differences are present in US and EU regulations. Ac-
cording to EMA guideline the prolonged-released product 
must undergo in vitro testing in the presence of 20% al-
cohol concentration (EMA, 2014). On the other hand, the 
United States’ Federal Drug Administration (FDA, 2015), 
requires in vitro testing in concentrations up to 40% alco-
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hol for a list of defined generic formulations (Friebe et al., 
2005). 
Nevertheless, the applicant should discuss the signif-
icance of any out of specification results, particularly at 
the early time points, together with consideration of the 
risks of dose dumping and accelerated release. Appropriate 
warnings in the summary of product characteristics should 
be proposed and justified (EMA, 2015).
With respect to increasing globalization of pharmaceu-
ticals, harmonization of the regulatory guidelines for in vi-
tro ADD resistance testing is highly desirable. It should be 
based on a common understanding of the physiological im-
pacts of alcohol consumption and realistic exposure times.
Materials and methods
Comparative dissolution tests of prolonged-release 
tablets containing BCS Class I active substance in three 
different media have been performed: buffer pH 6.8 (solu-
tion of sodium hydroxide and potassium dihydrogen phos-
phate in water R) also proposed for routine testing, buffer 
pH 4.5 (solution of sodium acetate R and acetic acid in wa-
ter R) and medium pH 1.2 (solution of hydrochloric acid 
and sodium chloride in water R), each of them with and 
without 20% ethanol. The level of alcohol in the medium 
mimics level that can be reached in the fluids of the gastro-
intestinal tract following alcohol consumption.
Dissolution tests have been performed, using basket 
apparatus (Apparatus I) at 100 rpm, in 500 ml aforemen-
tioned media at 37±0.5 °C for a total period of 24 hours. 
Dissolution profiles were obtained with sampling at 8 time 
points on 12 individual units. 
The dissolution rate of the prolonged-release drug 
product has been determined using in-house validated 
HPLC method. 
Results and discussion
In vitro dissolution studies with alcohol have been per-
formed to evaluate whether ethanol ingestion may modify 
the release characteristics of the drug product.
To demonstrate in vitro similarity of the dissolution 
profiles performed in media with and without ethanol, ƒ2 
statistic method was employed.
The results of the performed comparative dissolution 
tests of prolonged-release tablets in the dissolution medi-
um proposed for routine testing, but with alcohol, are with-
in the specification limits.
Furthermore the ƒ2 statistic method indicates similar-
ity between the dissolution profile in the presence of al-
cohol and the dissolution profile of the same batch in the 
same media in absence of alcohol, for all three dissolution 
media. 
Conclusion
The conducted in vitro dissolution studies demonstrate 
that there is no potential risk of alcohol-induce dose dump-
ing for the tested prolonged-release drug product.
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Introduction
Computers are widely used during development and 
manufacturing of drugs and medical devices. Proper function-
ing and performance of software and computer systems play 
a major role in obtaining consistency, reliability and accuracy 
of data. Therefore, computer system validation (CSV) should 
be part of any good development and manufacturing practice. 
It is also requested by EU and FDA regulations and guidelines 
through the overall requirement that “equipment must be suit-
able for its intended use”.
Specific requirements for computers can be found in sec-
tion 211.68 of the US cGMP regulations (USC, 2008). 
• Automatic, mechanical, or electronic equipment or 
other types of equipment, including computers, or 
related systems that will perform a function satis-
factorily, may be used in the manufacture, process-
ing, packing, and holding of a drug product. If such 
equipment is so used, it shall be routinely calibrat-
ed, inspected, or checked according to a written pro-
gram designed to assure proper performance. Writ-
ten records of those calibration checks and inspec-
tions shall be maintained.
• Appropriate controls shall be exercised over comput-
er or related systems to assure that changes in master 
production and control records or other records are 
instituted only by authorized personnel.
• Input to and output from the computer or related 
system of formulas or other records or data shall be 
checked for accuracy.
• The degree and frequency of input/output verifica-
tion shall be based on the complexity and reliability 
of the computer or related system.
• A backup file of data entered into the computer or re-
lated system shall be maintained except where cer-
tain data, such as calculations performed in connec-
tion with laboratory analysis, are eliminated by com-
puterization or other automated processes. In such 
instances a written record of the program shall be 
maintained along with appropriate validation data.
• Hard copy or alternative systems, such as duplicates, 
tapes, or microfilm, shall be designed to assure that 
backup data are exact and complete and that it is se-
cure from alteration, inadvertent erasures, or loss 
shall be maintained.
Specific requirements for computers and electronic re-
cords and signatures are also defined in FDA’s regulations 
21 CFR Part 11 on electronic Records and Signatures (USC, 
1997).
The Good Automated Manufacturing Practices Forum 
(GAMP) has developed guidelines for computer validation. 
All these guidelines and publications follow a couple of prin-
ciples:
• Validation of computer systems is not a onetime 
event. It starts with the definition of the product or 
project and setting user requirement specifications 
and cover the vendor selection process, installation, 
initial operation, going use, and change control and 
system retirement.
• All publications refer to some kind of life cycle mod-
el with a formal change control procedure being an 
important part of the whole process. 
• There are no detailed instructions on what should be 
tested. All guidelines refer to risk assessment for the 
extent of validation.
Validation of computer systems is not a once off event. 
Annex 11 of the European GMP directive is very clear about 
this: Validation should be considered as part of the complete 
life cycle of a computer system. This cycle includes the stag-
es of planning, specification, programming, testing, commis-
sioning, documentation, operation, monitoring and modify-
ing” (EC, 2010).
Scope 
The scope of this work is to present the validation of ERP 
SAP computer system used in Alkaloid AD Skopje known as 
AlkaSAP system.
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Background
AlkaSAP system was implemented in Alkaloid AD Sko-
pje in 2007. Within AlkaSAP there are several ‘modules’, 
each of which contains transactions in order to perform nec-
essary tasks to complete business processes. Several of these 
tasks and processes are considered critical or have regulatory 
implications to Alkaloid. 
The SAP implemented modules in Alkaloid AD Skopje 
in 2007 were: 
1.  Sales & Distribution (SD)
2.  Production Planning (PP)
3.  Quality Management (QM)
4.  Materials Management (MM)
5.  Financial Accounting (FI)
6.  Controlling (CO)
During 2014 additional SAP module concerning human 
capital management (HCM) was implemented. 
Validation of the AlkaSAP
Validation of the AlkaSAP system was made in accor-
dance with GAMP 4. All validation activities were defined 
in Validation Master Plan (VMP). The validation programme 
was divided into phases according to the validation life cy-
cle. Each phase was divided into tasks and for every task there 
were actions, responsibilities and associated procedures. 
Specification / Design Phase
During this phase the following documents were created:
Validation Master Plan (VMP); User Requirement Spec-
ification (URS); Functional Specification (FS); Risk Assess-
ment (RsA); Hardware Design Specification (HDS); Software 
Design Specification (SDS); Code Review (CR);
Testing phase
Both hardware and software elements were tested as part 
of the AlkaSAP implementation.
Hardware Acceptance Testing
Hardware Acceptance Testing (including Infrastructure) 
was conducted successfully on all servers.
Document reference: CSV VMP AlkaSAP HATS
Software Acceptance Testing
All bespoke and functional application software identi-
fied in the Functional Specification or Software Design Speci-
fication was tested against the Software Acceptance test Spec-
ification.
Document Reference:  CSV VMP AlkaSAP SATS
Software Performance Test Specification
All software identified in the Functional Specification or 
Software Design Specification was given a risk priority and 
was tested against the Software Performance Test Specifica-
tion:
Document Reference: CSV VMP AlkaSAP SPTS
In accordance with risk priority given in the Risk Assess-
ment tests were executed as Detailed Functional Tests; User 
Acceptance Tests; Business Scenarios
Validation Report
The Validation Report has been issued as a phased report 
for the purpose of ‘go-live’ for the AlkaSAP and summarizes 
the validation programme activities.
Document Reference:  CSV VMR AlkaSAP
Ongoing Operation and Evaluation
In order to control and maintain the validation status of 
the AlkaSAP system, the following procedures are established 
and written:
Policies and Procedures for Security and Access to serv-
ers
Policies and Procedures for Back Up, Restore and Ar-
chive
Procedures for Training and Operating of the system
Periodic review
Periodic Reviews of the System is covered by Alkaloid 
Guideline ensuring SOPs, validation documentation and re-
cords are audited on a regular basis to evaluate the effective-
ness of controlling procedures.
Summary
Alkaloid AD Skopje started ‘go-live’ with the validated 
AlkaSAP computer system. The validation test results were of 
sufficient detail and quality to establish that this computer sys-
tem does what it purports to do. 
AlkaSAP still remains status of “validated system” which 
can be proved with regular periodic review of the system.
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Introduction
Cannabis sativa L. is a medicinal plant, known and 
used for a long time. There are 400 – 500 compounds 
that have been identified in its extracts, and among them 
approximately 70 are C21 terpenophenols, members of 
a group known as cannabinoids, specific for this plant 
(ElSohly and Slade, 2005; Fischedick, et al., 2009; Turn-
er, et al., 1980). The constituent of Cannabis sativa L., Δ9-
tetrahydrocannabinol (∆9THC), is the primary psychoac-
tive cannabinoid. Given that the main pharmacological 
and psychoactive effects have been attributed to this com-
pound, the most of the studies have been focused on its ef-
fects (Costa, 2007). The effects of Cannabis sativa L. are 
not solely due to ∆9THC because cannabidiol (CBD) was 
found to cause pharmacological effects (Russo and Guy, 
2006). It was shown that CBD and other cannabinoids 
achieve synergy with ∆9THC causing potentiation of ben-
efits, antagonism of adverse effects, summation, pharma-
cokinetic advantages, and metabolism (Russo and Guy, 
2006). 
Many countries became more liberal towards medici-
nal use of Cannabis sativa L. (Baker et al., 2003). Recent-
ly there has been an increasing interest in development of 
cannabinoids and Cannabis sativa L. preparations as legiti-
mate medicines for a variety of medical applications. Some 
of them include, but are not limited to, multiple sclerosis, 
chronic pain, glaucoma, asthma and cardiovascular condi-
tions, and as an antiemetic (Williamson and Evans, 2000). 
Cannabidoids are very potent compounds and their control 
in Cannabis sativa L. preparations is very important, espe-
cially because their potential users are patients which al-
ready have serious health problems. 
The aim of this study was to apply our in-house HPLC/
DAD method on the Cannabis sativa L. preparations pres-
ent in the European market and to control their quality.
Materials and methods
The samples of Cannabis sativa L. preparations were 
purchased from the European market, produced by Endoca 
(Pharmaceutical Company, Denmark). The standard sub-
stances were obtained from Lipomed AG (Switzerland). 
The samples of standard substances were: ∆9-THC (3-pen-
tyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)
pyran-1-ol), delivered as 1 mL ampule solution (5 mg/ mL 
prepared in ethanol, with purity 98.52%, m/m) and CBD 
((-)-trans-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinol) as 
the solid substance (99.73%, m/m). The solvents used dur-
ing the analysis were with HPLC grade. 
For the chromatographic analysis Agilent Technolo-
gies HPLC system 1200 series (Germany) was used. The 
analysis was performed on HPLC-column: Purospher® 
Star RP18e (150 mm x 4.6 mm ID, 5 µm) from Merck 
KGaA (Germany) using mobile phase composed of ace-
tonitrile and water in gradient mode with acetonitrile from 
50%, V/V, to 80%, V/V, at flow rate 1.5 mL/min, tempera-
ture 30 °C, detection at 220 nm, injection 10 µL, in 31 min 
run time. 
The working solutions of standard substance CBD 
were prepared in methanol in two concentration ranges: 
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95.48 µg/mL – 286.43 µg/mL and 103.13 µg/mL – 309.40 
µg/mL. The ∆9THC working solutions were prepared in 
methanol in concentration range: 9.81 µg/mL – 19.63 µg/
mL. 
The sample solutions were prepared by liquid/liquid 
extraction technique using a mixture of methanol and chlo-
roform (9:1). When the layers were clearly separated, the 
sample from the methanolic layer was applied in HPLC/
DAD system. 
Results and discussion
Five different Cannabis sativa L. preparations pur-
chased from the European market were analyzed. All were 
prepared from hemp oil with various amounts of CBD as 
active compound and naturally contains ∆9-THC, as an im-
purity. According to the certificates the amount of CBD 
was: 3%; 5%; 10 %; 15% and 30%, m/m, and expected im-
purity as ∆9THC was limited at maximum of 0.20%, m/m.
For preparation of the samples we used the recom-
mended United Nations Office on Drugs and Crime meth-
od (UNODC Manual, 2009). For identification and quan-
tification of cannabinoids we used our in-house chromato-
graphic gradient method which we have proposed for hemp 
seed oil analysis (Shishovska et al., 2014) because of the 
similarity of samples in origin and form. 
In the analyzed samples of hemp oil preparations can-
nabidiol and ∆9THC were identified and quantified. Iden-
tifications were done by comparing of the retention times 
and UV spectra of standard compounds with retention 
times of peaks at the chromatograms of samples and their 
UV spectra. The retention times of CBD and ∆9THC peaks 
were 15.9 min and 21.0 min, respectively.
For the quantification, data obtained from the chro-
matograms were calculated using the method of the cal-
ibration curve (constructed as concentration, c (µg/ml), 
versus peak area, A (mAU)). The analyzed working solu-
tions of the active compound CBD and the trace compound 
∆9THC showed high linearity in the working ranges. The 
estimated coefficient of the linearity for CBD working so-
lutions at concentration range: 95.48 µg/mL – 286.43 µg/
mL was 1.000 (A = 23688 c + 16.188); while for the CBD 
working solutions at concentration range: 103.13 µg/mL – 
309.40 µg/mL it was 0.9998 (A = 39613 c + 31.129), and 
for the working solutions of standard substance ∆9THC 
at concentration range: 9.81 µg/mL – 19.63 µg/mL it was 
0.9997 (A = 25269 c - 7.0738).
It was found that content of cannabidiol in analyzed 
samples is from 109.7% to 125.4%, m/m of the declared 
values. The assays of ∆9THC traces at the samples vary 
according the concentration of the active compound. As 
quantities of CBD at samples were lower (3 – 5%), the as-
say of ∆9THC is under the allowed maximum limit (0.02% 
– 0.14%), but at samples with higher concentrations of 
CBD (10 – 30%) the ∆9THC traces are above the allowed 
maximum limit (0.45% – 1.14%).
Conclusion
The satisfactory chromatographic data proved that our 
in-house gradient HPLC/DAD method can be successful-
ly used for determination of the active substance CBD and 
traces of ∆9THC in Cannabis sativa L. preparations. The 
results obtained for the analyzed samples of Cannabis sati-
va L. preparations showed higher amounts of CBD than de-
clared value in the certificate (differences range from 9.7% 
m/m to 25.4%, m/m). In two samples, the amount of ∆9THC 
found was under allowed maximum limit of 0.20%, while 
in three samples the amount was above that value. Not all 
of the samples tested have composition as declared in the 
certificate, although they all origin from a European manu-
facturer and are present in the European market.
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Introduction
Nitrofurantoin (N-(5-nitro-2-furfurylidene)-1-amino-
hydantoin) is antimicrobial compound, used extensively as 
a prophylactic for urinary tract infections in humans and 
animals (Maaland and Guardabassi, 2011). It is reported 
that the modes of action underlying DNA damage or cyto-
toxicity induced by nitrofurantoin in rodent liver and lungs 
may involve ROS generation by reduction to nitro radi-
cal anion (Suntres and Shek, 1992). A recent study showed 
that the drug exhibits carcinogenicity in the kidneys of 
male rats and the structure of the nitro furan plays a key 
role in the induced genotoxicity (Kijima et al., 2015).
Most nitroaromatic drugs, containing nitroquinone, ni-
troimidazole or nitrofuran moiety, are considered to ex-
ert their toxic effect by nitro reduction (Boelsterli  et al., 
2006). One-electron reduction of  the nitro group catalyzed 
by nitro-reductase gives rise to nitro anion  radical, the 
chemical instability of which promotes production of var-
ious ROS such as superoxide anion and hydroxyl radical 
via its electron-donating ability (Wang et al., 2008).
Despite these drawbacks, new nitrofuran derivatives 
are still being developed as antimicrobial agents (Zorzi et 
al., 2014). Therefore, improved knowledge on the struc-
ture and reactivity of nitrofurantoin radical anion could 
help reduce the toxicity of the new nitrofuran antimicro-
bial agents.
This reports motivated us to generate electrochemi-
cally the nitro radical anion of nitrofurantoin and study its 
chemical structure by spectroscopic IR methods and DFT 
computations. The radical anion was electrochemically 
generated and the spectral and structural changes arising 
from the conversion were described based on IR spectra 
and DFT calculations. The structural variations, electron 
charge distribution over molecular fragments and IR fre-
quency shifting were discussed. 
Materials and methods
The electrochemical generation of the radical anion 
of nitrofurantoin was carried out in a special CaF2 cell, 
provided with platinum electrodes build in the polyethyl-
ene spacer. 4.5 V were applied to the cathode in the solu-
tion cell containing 0.1 mol/l nitrofurantoin and equimo-
lar amount of tetraethylammonium bromide in DMSO-d6. 
Electrochemical generation of the radical anion was con-
tinued for a period of 75 min and then the polarity of the 
electrolysis cell was reversed in order to regenerate the 
parent compound. The process of nitrofurantoin reduc-
tion and regeneration was monitored by recording IR spec-
tra in 10 min intervals. The IR spectra were measured on 
a Brucker Tensor 27 FT spectrometer at a resolution of 2 
cm-1 and 64 scans. 
All theoretical calculations were performed using the 
Gaussian 09 package of programs. Geometry and vibra-
tional frequencies of species studied were performed by 
analytical gradient technique without any symmetry con-
straint. All the results were obtained using the density func-
tional theory (DFT), employing the B3LYP (Becke’s three-
parameter non-local exchange correlation) method in con-
junction with 6-311+G(2df,p) basis set. In order to account 
for the ifluence of the medium, we used the Integral Equa-
tion Formalism Polarizable Continuum Model (IEF-PCM) 
on the same level of theory with inclusion of DMSO.
Results and discussion
The initial IR spectrum of nitrofurantion in DMSO-
d6 solution, containing tetraethylammonium bromide as 
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electrolyte salt, showed that the asymmetric and symmet-
ric stretching vibrations of the nitro group are observed at 
1521 and 1350 cm-1. The stretching vibration of the N-C 
bond linking the nitro group to the furan ring is found at 
rather high wavenumber - 1211 cm-1, respectively. A few 
minutes after applying the current, the solution in cathode 
space became brown, and the bands of the anion radical 
of nitrofurantoin appeared in the IR spectrum. More pro-
longed electrolysis (75 min) caused strong increase of the 
bands of the anion radical, while the bands of the neutral 
compound vanished. Reversal in the polarity of the elec-
trolysis cell resulted in gradual decrease of the IR bands 
of the radical anion and reappearance of the neutral mole-
cule absorptions. After 75 min of reversed electrolysis the 
initial spectrum of the parent compound was completely 
restored without the presence of any additional IR bands. 
This fact unambiguously demonstrates that the observed 
spectral changes are due to the reduction of nitrofurantoin 
to radical anion and not to other chemical transformations.
The conversion of nitrofurantoin into radical anion 
is related to strong frequency decreases in the assymetric 
N-O stretching: Δνas(NO2) = 220 cm
-1, strong frequency 
decreases in the symetric N-O stretching: Δνs(NO2) = 209 
cm-1 and strong frequency increase in C-NO2 stretching: 
Δν(C-NO2) = 273 cm-1. Based on the calculated spin den-
sity, the odd electron is localized mainly on the nitro group 
(c.a. 70%) and in smaller extends – on the furan ring (c.a. 
30%). The radical anion formation leads to simultaneous 
shortening of the C-N bond and lengthening of the N-O 
bonds.
Conclusion
The observed frequency shifts arising from the con-
version of nitrofurantoin into radical anion are larger than 
those found with the conversion of dinitrobenzenes and cy-
anobenzonitriles. It is evidence that larger structural vari-
ations in the nitrofuran moiety occur upon conversion into 
radical anion than in case of dinitrobenzenes and nitroben-
zonitriles. The localization of the spin density over the ni-
tro group is a sign for high reactivity of the formed nitro-
furantoin radical anion and strong ability to initiate pro-
duction of various ROS via electron donation. The impor-
tance of aminohydantoin moiety for the stability and reac-
tivity of the nitrofurantoin radical anion has to be elucidat-
ed by studying other nitrofuran derivatives with modified 
side chains.
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Introduction
Inflammatory bowel disease is an idiopathic disease 
caused by a dysregulated immune response to host intes-
tinal microflora, with a high incidence in younger adults. 
Generally, its treatment is based on immunosuppressive 
drugs. Azathioprine is thiopurine metabolite with immuno-
suppressive and cytotoxic effects, which is used in the treat-
ment of inflammatory bowel disease and childhood acute 
lymphoblastic leukemia. Unfortunately, about one third of 
patients under azathioprine therapy, have need for modify-
ing or terminating the treatment because of adverse effects 
or low therapeutic outcome. As a prodrug of 6- mercapto-
purine (6-MP), azathioprine acts through the formation of 
thioguanine and methylthioinosine nucleotides, which are 
capable of incorporating in DNA strains like “false” bases 
(Dervieux and Boulieu, 1998). Hence the immunosuppres-
sive effect, target cells of azathioprine main metabolites - 
6-thioguanine nucleotide (6-TGN) and 6-methylmercapto-
purine (6-MMP) are the “fast-growing” cells, mainly lym-
phocytes, though the bone marrow and the hepatic cells are 
not excluded. Consequently, the risk-benefit ratio of azathi-
oprine therapy is dose-dependent and here lies the crucial 
need for therapeutic drug monitoring (TDM) (Vikingsson, 
2012). On the other hand, intra- and inter-individual varia-
tions seem to reflect individual differences in 6-MP absorp-
tion and metabolism, resulting in different bioavailability 
and distribution of the active metabolites in patients receiv-
ing similar doses. The purpose of this study is to establish 
a specific, sensitive HPLC method for simultaneous deter-
mination of 6-TGN and 6-MMP found in erythrocytes af-
ter azathioprine administration. 
Materials and methods
Chemicals and reagents. 6-MMP, 6-TGN and dithio-
threitol (DTT- derivatization agent) were purchased form 
Sigma-Aldrich Inc., St. Louis, USA. Methanol, phosphate 
buffer (pH 3,5), perchloric acid, hydrochloric acid, all 
HPLC grade, were obtained from Merck, Darmstadt, Ger-
many. For all analysis, HPLC grade water was used. Zorb-
ax Eclipse XDB C18 column, 150 x 4.5mm, 5 μm was sup-
plied by Agilent Technologies. 
Erythrocyte samples. Blood samples were collected 
from healthy volunteers (used for method validation) and 
from patients under azathioprine therapy (used like testing 
samples). Erythrocytes were extracted by centrifugation at 
4 °С. Further on, the eppendorf tubes were normalized on 
4х109 erythrocytes, and frozen at -80 °С until the analysis.
Preparation of standard solutions. Stock solution of the 
analytes (5 μg/ml 6-TGN and 40 μg/ml 6-ММР) were pre-
pared by dissolving each compound in 0,1 M HCl. Work-
ing solutions were prepared in 6 different concentrations 
(concentration range between 0,04 μg/ml to 2,50 μg/ml for 
6-TGN and 0,25 μg/ml to 20 μg/ml for 6-ММР) from stock 
solutions by dilution with 0,1 M  HCl. Calibration stan-
dards were made by spiking the blank erythrocytes with 
appropriate volume of working solutions of 6-TGN and 
6-MMP at six different concentration. Samples for qual-
ity control (QC) were prepared in 4 different concentra-
tions that cover the range of the calibration curve (LLOQ, 
low QC, medium QC, high QC appropriate for 6-TGN and 
6-MMP). 
Sample preparation. Sample solutions were made by 
adding DTT in each eppendorf tube which contains 500 μl 
of erythrocytes from patients under azathioprine therapy. 
In each eppendorf tube 50 μl 70% Perchloric acid (acid hy-
drolysis and deproteinization agent) was added and centri-
fuged at 3000 rpm, for 15 minutes at 4 °C. After centrifu-
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gation thiopurine nucleotides are obtained. Acid superna-
tants were collected and heated at 100 °C for 45 minutes in 
order to release thiopurine bases after hydrolysis. 
Chromatographic conditions. The separation was car-
ried out with Agilent 1100 HPLC system on Zorbax Eclipse 
XDB C18, 150 x 4.5mm, 5μm column using gradient elu-
tion with methanol and phosphate buffer (pH 3,5) in ratio 
5:95 (V/V) with linear gradient to 15:85 (V/V) for a period 
of 12 minutes and flow rate of 1,2 ml/min. The temperature 
was set at 25 °C with UV detection at 341 nm for 6-TGN 
and 304 nm for 6-MMP. Method was validated following 
the recommendations for validation of bioanalytical meth-
ods of EMA guideline (Guideline on validation of bioana-
lytical methods, European Medicines Agency, 2011). 
Results and discussion
The recovery values of the extraction procedure were 
higher than 84% for both metabolites, 6-TGN and 6-MMP. 
Under the proposed chromatographic conditions, no inter-
fering peaks were observed in the retention time of analyt-
es. The correlation coefficient from calibration curves for 
linearity of the method was 0.9996 for 6-TGN and 0.9989 
for 6-MMP, respectively. The results for accuracy (±15% 
of the nominal values for the QC samples and ± 20% of 
the nominal value for the LLOQ) and precision (the val-
ue for coefficient of variation should not exceed 15% for 
QC samples and 20% for LLOQ) were within recommend-
ed limits. Stability studies indicated that no stability relat-
ed problems would be expected during the routine erythro-
cytes sample analysis. Samples of erythrocytes spiked with 
6-TGN and 6-MMP are stable after 12 hours in the autos-
ampler, 24 hours at room temperature and can be stored 
for up to six months at temperature of -80 °C. The inter-
pretation of the measured 6-TGN and 6-MMP levels, re-
spectively is following – subtherapeutic (< 235 pmol/8*108 
erythrocytes), therapeutic (235-400 pmol/8*108 erythro-
cytes) and high levels correlated to myelotoxicity (> 400 
pmol/8*108 erythrocytes); below 5700 pmol/8*108 eryth-
rocytes and more than 5700 pmol/8*108 erythrocytes – 
associated with hepatotoxicity (Vikingsson et al., 2013). 
Measured metabolite levels correlated to the clinical re-
sponse from azathioprine therapy.
Conclusion 
A simple, sensitive, precise and accurate HPLC meth-
od has been developed and validated for simultaneous de-
termination of 6-TGN and 6-MMP in erythrocytes. Its main 
pros are: chromatographic run time less than 10 minutes 
(3.67 minutes for 6-TGN and 7.60 minutes for 6-MMP), 
facilitated pre-analytical procedure, rapid and specific de-
termination of 6-MMP and 6-TGN intra-erythrocyte con-
centrations. The proposed method was successfully applied 
to erythrocytes samples obtained from 33 patients with in-
flammatory bowel disease under azathioprine therapy. The 
method results are in agreement with those obtained with 
other available methods, demonstrating its applicability for 
monitoring the azathioprine treatment.
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Introduction
Lipid-derived autacoids play important roles in the in-
flammatory response and are a major focus of research into 
new anti-inflammatory drugs. These compounds include 
the eicosanoids such as prostaglandins, prostacyclin, leu-
kotrienes, and thromboxane and the modified phospholip-
ids such as platelet activating factor (PAF). Eicosanoids are 
synthesized from 20-carbon polyunsaturated fatty arachi-
donic acid, found in many cells, including activated leu-
kocytes, mast cells, and platelets and therefore are widely 
distributed. Many inflammatory mediators (TNF-α, brady-
kinin) stimulate eicosanoid production either by direct ac-
tivation of PLA2, or indirectly by increasing intracellular 
Ca2+ concentrations, which in turn activate the enzyme. Ar-
achidonic acid can be converted to these products by three 
different pathways: cyclooxygenase, leading to the forma-
tion of prostanoids (prostaglandins and thromboxanes), li-
pooxygenase, where leukotrienes and certain mono-, di- 
and tri-hydroxy acids are synthesized, and epoxygenase 
pathway, which includes cytochrome P-450 and epoxides 
as final products. Accordingly, cyclooxygenases, lipooxy-
genases and epoxygenases are enzymes involved in these 
pathways (Smith, 1989). Cyclooxygenase (COX), impli-
cated in cyclooxygenase pathway, exists in two forms, 
named COX-1 and COX-2. COX-1 is expressed constitu-
tively in different tissues, blood monocytes and platelets, 
and transforms arachidonic acid to prostanoids, which are 
involved in normal cellular homeostasis. In contrast, COX-
2 may be induced by a series of pro-inflammatory stimuli 
and its role in the progress of inflammation, fever and pain 
has been known (Hawkey, 1999). Furthermore, three types 
of lipoxygenases, termed 5-, 12- and 15-lipoxygenase are 
engaged in lipoxygenase pathway. Some compounds, like 
12(S)-hydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoic acid 
(12-HETE), a product of 12-lipoxygenase (12-LOX), has 
influence on the regulation of platelet aggregation, but is 
also found to be involved in the progression of several hu-
man diseases like various cancers (Nie and Honn, 2002) 
psoriasis (Müller, 1994) and rheumatoid arthritis (Liagre 
et al., 1997). Aforementioned enzymes can be found in dif-
ferent cell types. Thus, in human platelets, COX-1 and 12-
LOX are the initial enzymes responsible for arachidonic 
acid metabolism leading to the formation of thromboxane 
B2 (TXB2), prostaglandin E2 (PGE2), 12-HHT (12(S)-hy-
droxy-(5Z,8E,10E)-heptadecatrienoic acid) and 12-HETE. 
In vitro technique for evaluation of anti-
inflamatory activities of natural products and 
plants extracts
Since our research is focused on biological activity of 
plant extracts, we aimed to evaluate and optimize an in vi-
tro assay for anti-inflammatory activity, that can be easi-
ly used to determine COX-1 and 12-LOX inhibitory po-
tential of plant extracts or natural products, using LC–MS/
MS technique for quantification of metabolites and human 
platelets as a source of enzymes. 
We used human platelets as the cell system for testing 
anti-inflammatory activity of numerous plant extracts and 
secondary metabolites. Inflammation is induced by cal-
cymicin (calcium ionophore A23187) with subsequent ad-
dition of Ca2+. Detailed procedure is described in our previ-
ous report (Beara et al., 2010; Lesjak et al., 2013). Consid-
ering quantification of formed products, our research was 
focused on LC–MS/MS technique in order to attain high 
sensitive and specific method with short analysis time. 
Furthermore, tandem mass spectrometry provides far bet-
ter sensitivity and selectivity than traditional UV detectors 
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and does not depend on presence of chromophores.  The 
method is optimized in order to get best performance for 
detection of PGE2, TXB2, 12-HHT (COX-1 pathway) and 
12-HETE (12-LOX pathway) products, using PGB2 as in-
ternal standard.  The method performances were confirmed 
by measuring several parameters (Beara et al., 2010). 
The advantage and efficiency of this method was fur-
ther confirmed through numerous subsequent studies on 
biological activity of natural plant products (Beara et al., 
2012a, 2012b, 2014; Lesjak et al., 2011; Lesjak et al., 
2013; Nadjpal et al., 2016, Simin et al., 2013). Further-
more this method provides valuable information about the 
metabolism of arachidonic acid under inflammation. And 
finally, it should be noted that one of the important advan-
tage of applied experiment is avoidance of undesirable in 
vivo tests on experimental animals.  
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Introduction
Metals are chemicals of natural origin and in use for a 
long time. All environmental media have naturally occur-
ring mixtures of metals, and metals often are introduced 
into the environment as mixtures. Some of them are es-
sential for maintaining proper health of humans, animals, 
plants, and microorganisms.
Metals and inorganic requiring different approach-
es for Environmental Hazard and Exposure assessments, 
compared to “typical organic contaminants”. Several prop-
erties and aspects of metals – their natural occurrence, es-
sentiality, bioavailability, homeostatic control mechanisms 
and acclimatization to diverse natural environments, - re-
quire specific recognition in the context of an environmen-
tal risk assessment. The basic concept of ENV-Hazard and 
Risk Assessment of metals consist of four stages:
−	  Classification & ranking (acute/ chronic aquatic tox-
icity, transformation /dissolution, particle sizes, rank-
ing systems, etc…);
−	 Effects assessment (soil, sediment, water, data selec-
tion, data handling, effects analysis, uncertainty man-
agement, etc… sec. Poisoning...);
−	 Exposure assessment (data selection, data handling, 
local scenario, regional scenario, waste scenario, 
etc… ) and
−	 Risk characterization (soil sediment water sec. Poi-
soning, local scenario, regional scenario, waste sce-
nario, etc…) (USEPA, 2007).
This paper will be short introduction to challenges and 
key concepts specific to metals environmental assessment, 
through specific parts on bioavailability, effects assess-
ment, and bioaccumulation.
Bioavailability
Bioavailability should be taken into account for hazard 
and risk assessment of metal compounds in order to focus 
on interspecies sensitivity. A tired approach can be used, 
ensuring that first tier assessments use effects data where 
bioavailability is maximized (MERAG, 2007). Knowl-
edge of the chemistry of a compound will normally guide 
the need for the development of bioavailability correction 
models. Biotic Ligand Models (BLMs) can be used to esti-
mate bioavailability, taking into account competition from 
other ions and binding of metals with natural organic mat-
ter. Many countries have developed frameworks for tak-
ing into account metal specificities in environmental risk 
assessment.
Bioavailability models have a specific applicability 
domain and have to cover soil/water parameters and back-
ground relevant for the region where they are applied; in 
addition it may be needed to do checks with species spe-
cific for that region. Further research is recommended to 
investigate to which extent commonalities between Biotic 
Ligand Models (BLMs) for species from different trophic 
levels apply amongst different metals. Further discussion 
is needed for developing a decision scheme as to the con-
ditions for implementing BLMs in risk assessment.
Effects assessment
Hazard identification of metals and metal compounds 
is related to the toxicity of the soluble metal ions. The tox-
icity of the metal ions and the release of these ions from 
the metal-containing substances are therefore used as a ba-
sis for read-across.
Effects assessments of metals could follow the follow-
ing strategy: Data compilation & read-across
−	 Data screening for relevancy and quality
−	 Database development
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−	 Data normalization (i.e. Bioavailability correction) 
Data aggregation
−	 Species Sensitivity Distribution (SSD) construction 
and HCX derivation if relevant PNEC derivation (in-
cluding uncertainty assessment).
−	 Metal-specific criteria for quality and relevancy of ef-
fects data to be used in the assessment should be de-
veloped, taking into account criteria already developed 
for chemicals effect data in general (MERAG,2007).
Bioaccumulation and bioconcentration
For some metals, background can be significant (rela-
tive to the PEC or PNEC) and should be integrated in the 
risk assessment. At the level of PEC/PNEC: the total bio-
availability approach and the added risk approach could be 
considered; Background should be measured in unpollut-
ed environments.
Available data for BCFs and other Accumulation Fac-
tors for metals indicate that they are inversely related to 
water (and sediment, and soil) concentrations. Therefore 
the use of a single value for assessing risks from secondary 
poisoning has to be considered.
Measures of tissue concentrations along the food chain 
provide a useful way to assess secondary poisoning.
Further discussion is needed as to how to improve 
comparisons/interpretations of BCFs and BAFs for metals 
to regulatory threshold values.
For the assessment of secondary poisoning, a tiered 
approach should be used, taking into account: dietary com-
position for consumer organisms, high BCF values could 
be used as a trigger to perform more detailed assessments, 
relevant food chains should drive the selection of BAFs 
and oral PNEC values, bioavailability of the metal in the 
food or incidentally ingested soil/sediment and the water 
concentration used in BCF or BAF experiments should 
preferably be in the same range as the PEC.
Conclusion
Presented key guiding principles is based on the 
unique attributes of metals. Metal speciation affects met-
al behavior in environmental media. PH and redox poten-
tial affect speciation. Kd values – a coefficient for mobili-
ty in soils limited use of single values. Aging of metals in 
media reduces bioavailability. Metal sorption behavior af-
fects bioavailability.
The aim of this paper is describe how metals-specific 
attributes and principles may be applied in the context of 
existing risk assessment guidance and in existing human 
health and ecological risk assessment practices.
References
MERAG fact sheets: 03,07,08, 2007. In: MERAG: Metals 
Environmental Risk Assessment Guidance; Published: 
January 2007 by ICMM, London, UK. The International 
Council on Mining and Metals. ISBN: 978-0-9553591-2-5.
MERAG fact sheets 05, 06, 2007. In: MERAG: Metals 
Environmental Risk Assessment Guidance; Published: 
January 2007 by ICMM, London, UK. The International 
Council on Mining and Metals. ISBN: 978-0-9553591-2-5. 
United States Environmental Protection Agency (USEPA), 
2007. Framework for metal risk assessment. EPA 120/
R-07/001, Washington, D.C. [http://www.epa.gov/osa/
metalsframework/].
O
ral presentations
Macedonian pharmaceutical bulletin, 62 (suppl) 251 - 252 (2016)
ISSN 1409 - 8695
UDC: 615.322:634.23:[616.61-099-02:632.95
Short communication
Dimethoate-induced renal toxicity in rats and the protective/
ameliorative effects of Laurocerasus officinalis Roem.  
(cherry laurel) fruit extract
Ayşe Eken1*, Burcu Ünlü-Endirlik1, Elçin Özger1, Ayşe Baldemir2, Arzu Hanım Yay3
1Erciyes University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, 
Merkez Kampüsü Melikgazi, Kayseri, Turkey
2Erciyes University, Faculty of Pharmacy, Department of Pharmaceutical Botany,  
Merkez Kampüsü Melikgazi, Kayseri, Turkey
3Erciyes University, Faculty of Medicine, Department of Basic Sciences,  
Merkez Kampüsü Melikgazi, Kayseri, Turkey
* eken.ayse@gmail.com
Introduction
Dimethoate is one of the most important organophos-
phate insecticides in agriculture (Sharma et al., 2005). The 
toxicity of dimethoate results in deleterious effects caus-
ing oxidative stress on many organs and systems in human 
and animals particularly the kidney, liver, testes, brain, ner-
vous, and reproductive system (Abou-Baker et al., 2014). 
The cellular antioxidant defense is reinforced by the pres-
ence of dietary antioxidants. Accordingly, there has been 
recently growing interest in the role and usage of natural 
antioxidants as a strategy to prevent oxidative damage in 
various health problems (Saafi et al., 2011).
Laurocerasus officinalis Roem. is known as “cher-
ry laurel” in English. L. officinalis is grown as a native 
fruit crop locally called “taflan, lazkirazı, karayemiş”on 
the coasts of the Black Sea region of Turkey (Erdogan-
Orhan and Küpeli-Akkol, 2011). The fruits and seeds of 
the L. officinalis are widely utilized as herbal medicine in 
Turkey for the treatment of stomach ulcers, digestive sys-
tem problems, bronchitis (seeds), eczemas, hemorrhoids, 
anti-diabetic (seeds), analgesic on local pain, and as a di-
uretic (fruits) (Ayaz  et al., 1998; Elmastas et al., 2013; 
Küpeli-Akkol et al., 2012; Şenaylı et al., 2012; Yaylacı-
Karahalil and Şahin, 2011). By in vitro models  a neuropro-
tective effect of the fruits of L. officinalis was found (Er-
dogan-Orhan and Küpeli-Akkol, 2011). In vivo experimen-
tal study determined the anti-inflammatory effects of L. of-
ficinalis leaves (Küpeli-Akkol, 2012). L. officinalis fruit is 
rich in phenolics and a good source of natural antioxidant 
protecting humans from several diseases caused by oxida-
tive stress (Yaylacı-Karahalil and Şahin, 2011). 
The aim of the study was to determine the nephrotoxic 
effects of dimethoate on biochemical indicators of kidney 
function tests, oxidative stress parameters, and histological 
examination in rats and the protective/ameliorative effects 
of L. officinalis fruit extract. 
Materials and methods
60 male Wistar albino rats were divided into six ex-
perimental groups of 10 rats each and were treated daily 
by oral gavage for 60 days. Group I (control group) re-
ceived only saline (0.9% NaCl); Group II was treated with 
dimethoate; Group III was given fruit extract; Group IV 
was treated with fruit extract and dimethoate; Group V was 
treated with vitamin C and dimethoate; Group VI was ad-
ministrated only dimethoate for the first month. During the 
second month, the rats were treated with dimethoate and 
fruit extract. Dimethoate, L. officinalis fruit extract, and 
vitamin C were applied at 7, 4, and 100 mg/kg/day dos-
es, respectively. At the end of the 60 days, rats were an-
aesthetized by ketamine and xylazine. Blood samples were 
taken from hearts to the sterile tubes and centrifugated at 
3500 rpm for 20 min to separate serum. The serum sam-
ples were stored at -80 °C until analysis of blood urea ni-
trogen (BUN) andcreatine. The kidneys were removed im-
mediately and washed with sodium phosphate buffer (pH 
7.4). They are divided into two sections. One section was 
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placed in formaldehyde solution for routine histopatholog-
ic examination by light microscopy. The other half of kid-
ney tissue section was homogenized in ten volumes of ice-
cold 140 mMKCl and Tris-HCl buffer (50 mM, pH 7.6) us-
ing a homogenizer for 2 min at 13.000 rpm. The levels of 
malondialdehyde (MDA) for lipid peroxidation index were 
determined in the tissue homogenates by using spectropho-
tometer. The homogenates were then centrifuged at 5000 g 
for 60 min to remove debris. Clear supernatant was used 
for superoxide dismutase (SOD), catalase (CAT), and glu-
tathione peroxidase (GPx) enzyme activity assays. 
Results and discussion
In comparison to the control group, a statistically 
significant increase was observed in the serum levels of 
blood urea nitrogen (BUN) and creatine in dimethote treat-
ed group (p<0.05). However, administration of L. offici-
nalis to dimethoate treated groups (group IV and VI) pro-
vided a markedly reduction in levels of BUN and creatine 
(p<0.05). Moreover, vitamin C treated rats to dimethoate 
treated group showed  decreased BUN and creatine lev-
els (p<0.05).
Treatment with dimethoate caused an increase in the 
kidney tissue levels of MDA as compared with the control 
group (p<0.05). However, treatment with L. officinalis to 
dimethoate treated groups (group IV and VI) provided a re-
duction in MDA levels compared to the dimethoate treated 
group (p<0.05). The antioxidant enzymes activities of SOD 
and GPx in the group of only dimethote treated rats were 
significantly lower than those in the control group. Howev-
er, L. officinalis treatment resulted in a significant increase 
of SOD and GPx activities (p<0.05). The activity of CAT 
enzyme was markedly decreased in dimethoate treated rats 
and elevated in L. officinalis treated rats as compared to 
control rats, but this effect was not statistically significant.
The kidneys of the control group showed normal kid-
ney parenchym. With light microscopic examinations, his-
topathological changes such as mononuclear cell infiltra-
tion, glomerular atrophy, congestion and necrosis in the 
kidney tissues were observed in the dimethoate treated 
group as compared with control group. Administration of 
L. officinalis apparently reduced kidney tissue damage. On 
the other hand, there were not any differences in histologic 
appearance of kidneys between the control and L. officina-
lis treated group. Also, the kidney morphology in vitamin 
C treated group was similar to that of the control group.
The antioxidants may play a major role in the preven-
tion of diseases related to oxidative stress. Therefore, there 
is an increasing interest in the research of antioxidant com-
pounds such as phenolics present in the plants (Erdogan-
Orhan and Küpeli-Akkol, 2011). These phenolics provide 
protection against toxic radicals due to their radical scav-
enger activities and have therapeutically beneficial effects 
on human health (Yaylacı-Karahaliland Şahin, 2011). It 
was found that L. officinalis fruit extract has strong radi-
cal scavenging activity and antioxidant effects  (Erdogan-
Orhan and Küpeli-Akkol, 2011; Kolaylı et al., 2003). 
Conclusion
In conclusion, dimethoate exposure indicated the dis-
ruption of nephrotic architecture in kidney section as com-
pared to control group. We observed that L. officinalis fruit 
extract pre- and post- administration to dimethoate treated 
rats significantly reduced kidney injury by preventing oxi-
dative damage. Therefore, L. officinalis fruit may be useful 
for the prevention of oxidative stress-induced kidney injury.
This research was financially supported by Research 
Fund of the Erciyes University Scientific Research Project 
Unit (Project number: TCD-2013-4127).
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Introduction
The demand for functional foods that promote health 
beyond basic nutrition increases along with the increased 
consumer awareness for the influence of diet on their 
health. In respect to probiotic foods both the viability of 
the probiotic within foods and bioavailability within the 
host has to be studied (Figueroa-González et al., 2011), 
while at least maintaining the quality of conventional prod-
uct used as a carrier. Microencapsulation may offer good 
protection of probiotic viability loss during manufacture, 
product storage and after ingestion of probiotics, especial-
ly during exposure to unfavorable GI conditions (Sánchez 
et al., 2012).
The aim of the study was to obtain a functional prod-
uct ayran with therapeutic level of viable and metabolic ac-
tive cells of L. casei 01 (a minimum of 107 log CFU per 
mL ayran). Quality of the prepared probiotic and synbiotic 
samples was examined as well as their therapeutic benefits 
in animal model with chemically induced colitis.
Materials and methods
Ayran samples were prepared by fortifying commer-
cially available product (Ayran, Zdravje, Macedonia) with 
non-encapsulated probiotic L. casei 01 (Chr. Hansen, Den-
mark) and/or prebiotic oligofructose-enriched inulin (Syn-
ergy 1, Orafti-Rue L. Maréchal, Belgium) and encapsulat-
ed synbiotic. Synbiotic microparticles were produced when 
an overnight activated culture in MRS broth (37 °C, 24 h) 
with a cell load ca. 11-12 log CFU/mL in a mixture with 
4% w/w alginate (Protanal LF 10/60 LS, fG 35-45%, FMC 
BioPolymer, IMCD, UK) and prebiotic (1.5% w/w) was 
infused to the spray-dryer (Büchi Mini Spray Dryer B-290, 
SW). Spray-drying was performed at inlet and outlet tem-
perature of 120 °C and 58±3 °C, respectively, flow rate 6 
ml/min, nozzle diameter 0.7 mm, aspirator pressure 90% 
and atomizer pressure 600 Nlh-1. Polyelectrolyte com-
plexation/cross-linking of the dried powders was done un-
der continuous stirring for at least 3 h with 0.5% w/w chi-
tosan (Chitine, France) and 5% w/w CaCl2 (Merck, Ger-
many) dissolved in 1% v/v acetic acid. The hardened mi-
croparticles were freeze-dried (-50 °C, 0.070 mbar, 24 h) 
(FreeZone Freeze Dry System, Labconco, USA) (Petres-
ka Ivanovska et al., 2014). Analyses of the quality of ayran 
samples include determination of protein, fat and carbohy-
drate content of the ayran by Bradford, Gerber and phenol-
sulphuric acid methods, respectively, while the total solids 
were determined using gravimetric method. Titration acid-
ity (lactic acid,%) and pH measurements were also eval-
uated. AAS and HPLC was applied to quantify minerals 
and organic acid production, respectively. Then, to female 
Wistar rats (n=6, 180-250 g, 10-14 weeks old), function-
al ayran samples (8.5-8.9 log CFU/mL of the food prod-
uct) were administered orally, once and twice daily. Plain 
ayran and drinking water were given to positive controls. 
Two weeks after starting the experiment, the rats were fast-
ed overnight and those from the positive controls and treat-
ed groups were rendered colitic. Colitis was induced intra-
rectally at 8 cm proximal to the anus using TNBS (trinitro-
benzenesulfonic acid) dissolved in 50% ethanol at a dose 
10 and 30 mg/kg. After 6 days of continued treatment the 
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rats were sacrificed. Negative controls treated with 0.9% 
NaCl were also included in the protocol. The anti-inflam-
matory effects of functional ayran samples were evaluated 
in respect to the clinical activity/total damage score (quan-
tified by loss on weight, consistency of feces and rectal 
bleeding), macroscopic and histopathological changes, co-
lon weight/colon length and colon weight/body weight ra-
tios, and myeloperoxidase (MPO) activity.
Results and discussion
At the day of preparation, probiotic counts of 9.43, 9.7 
and 9.58 log CFU/mL were determined in ayran enriched 
with non-encapsulated probiotic and synbiotic, and encap-
sulated synbiotic, respectively. Viability loss during the 
shelf-life of the product was significant with viable level 
above the therapeutic minimum in ayran containing encap-
sulated synbiotic of 8.22 log CFU/mL. Total solids in the 
ayran samples fortified with probiotic, synbiotic and synbi-
otic microparticles were moderately increased due to add-
ed dry matters with no negative effect on the texture or sen-
sory properties of the product. Significant differences of 
acidity and pH values were not detected between the sam-
ples, which showed no excess of acidity when probiotic 
was added. The content of proteins and fats in ayran sam-
ples was in accordance with the required levels (2.8 and 1 
g per 100 mL of product, respectively) during the shelf-life 
of 15 days at 4 °C. Analyses of carbohydrates have shown 
increased content in samples containing non-encapsulated 
and encapsulated synbiotic due to the carbohydrate nature 
of the prebiotic, with the latter to be more significant. No 
significant difference for sodium content in prepared sam-
ples were observed compared to the plain ayran, while po-
tassium and calcium content differed significantly among 
the samples with decreasing trend probably due to the abil-
ity of probiotic bacteria to use these minerals as nutrient 
sources. Exception was observed with the increased calci-
um content in the sample containing synbiotic microparti-
cles which were prepared using calcium as a cross-linking 
agent. Increased metabolic activity of the probiotic was ob-
served in ayran containing encapsulated synbiotic due to 
the higher production of lactic and acetic acid up to 81.83 
mmol/L and 79.93 mmol/L, respectively. Low quantity of 
propionic acid (12.15-15.03 mmol/L) was determined in 
functional ayran samples only, but no butyric acid was de-
tected.
In rats with induced colitis using 10 mg/kg TNBS, 
most significant reduction of parameters of inflammation 
was found in group treated by ayran containing encapsu-
lated synbiotic. Microscopic assessment have shown ul-
cerations on mucosa and sub-mucosa, accompanied by ex-
tensive inflammatory infiltrate and congested blood ves-
sels, in groups receiving plain ayran or drinking water. In 
the groups treated with ayran containing non-encapsulat-
ed probiotic/synbiotic visible segments of ulcerations and 
subepithelial polymorph nuclear infiltration were found, 
while higher integrity of mucosal architecture of colon tis-
sue was seen in group treated with ayran enriched by en-
capsulated synbiotic. Hence, when colitis was induced us-
ing 30 mg/kg TNBS, sample containing encapsulated syn-
biotic was administered. The lowest value of MPO activi-
ty was observed when ayran with microparticulated synbi-
otic was given twice daily, but parameters of inflammation 
were not significantly different between groups adminis-
tered once and twice daily. Dilated blood vessels in submu-
cosal layer as well dilated intestinal glands were observed 
in the rats treated by ayran with microencapsulated synbi-
otic, regardless of the frequency of administration. These 
findings indicate that a single administration of ayran en-
riched by microencapsulated formulation successfully pro-
tect the viability of the probiotic through the upper GIT 
and ensure prolonged residence time of viable cells in the 
lower intestinum with no necessity to increase the frequen-
cy of usage.
Conclusion
Functional samples with maintained quality of the 
product ayran within its shelf-life were developed, while 
the ayran containing synbiotic microparticles has the ad-
vantage of increased probiotic viability and better profile 
of the bacterial metabolism end products known to main-
tain morphologic and functional integrity of colonic epi-
thelium. Ayran enriched by microencapsulated synbiotic 
administered once a day provided efficient anti-inflamma-
tory activity due to adhesive properties of the microparti-
cles and their favorable interaction with the ayran as me-
dium, thus showing potential to be used as adjuvant ther-
apy in IBD.
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Introduction
Food supplements in European Union (EU) are initial-
ly regulated by Directive 2002/46/EC (2002), according to 
which, a range of nutrients and other ingredients may be 
present in food supplements, including: vitamins, minerals, 
amino acids, essential fatty acids, fiber and various plants 
and herbal extracts. In 2006, EU adopted the new Regula-
tion on nutrition and health claims made on food – Regula-
tion 1924/2006, which applies to nutrition and health claims 
made in commercial communication, labeling, presentation 
or advertising on foods. Health claims are defined as ‘any 
claim that states, suggests or implies that a relationship ex-
ists between a food category, a food or one of its constituents 
and health” (Reg. 1924/2006), currently the list of permitted 
health claims made on food in EU, is established by Com-
mission Regulation (EU) No 432/2012 (Reg.432/2012).
Meanwhile, defined by the congress of Dietary Sup-
plement Health and Education Act (DSHEA, 1994), sim-
ilarly with the Directive 2002/46/EC (2002), a “dietary 
supplement” is a product containing a “dietary ingredi-
ent” intended to supplement the diet. According to FDA 
– DSHEA (1994) these products are not subject to pre-
market safety evaluations, allowing for products labeling 
claims as long as it does not diagnose, prevent, treat or cure 
a specific disease.
Amino acids
Amino acids are big part of cells, muscle and tissue, 
this way carrying out a big role in many body functions, 
cells structure, transport and storage of nutritious. Ami-
no acids have been object of many scientific studies and 
there are many ongoing studies, consequently research 
over years claim for the possibility of useful of amino acids 
against osteoporosis, diabetes, heart trouble, metabolic dis-
orders, erectile dysfunction, menopausal complaints etc.
This paper presents a literature review of health claims 
on the current state of the health claims of amino acids as 
dietary ingredient of dietary supplements in general, focus-
ing in amino acids, such as: Arginine (conditionally essen-
tial amino acid in humans); Glutamine (non-essential and 
conditionally essential in humans); Lysine (an essential 
amino acid in humans).
Arginine is the precursor of nitric oxide, an endoge-
nous messenger molecule involved in a variety of endo-
thelium-mediated physic ological effects in the vascular 
system. Generally speaking, is involved in many metabol-
ic processes and many studies so far argue for its impor-
tance in heart disease and high blood pressure, improve-
ment of circulation, strengthening of immune system and 
a positive influence on male libido. Arginine supplementa-
tion is considered safe, but people with renal failure or he-
patic disease may be unable to appropriately metabolize 
and excrete supplemental arginine, this way they should be 
monitored. According to Scientific opinion of EFSA Pan-
el on Dietetic Products, Nutrition and Allergies (NDA) for 
Health Claims of L-arginine (EFSA FEEDAP Panel, 2015) 
the claimed effects “erection”, “supporting spermatogene-
sis”, effect “vascular system”, “normal blood pressure” are 
considered of a beneficial physiological effect and L-argi-
nine itself is considered to be sufficiently characterized but 
there is no cause-effect relationship established apart from 
the role of arginine contributing to protein synthesis.
Glutamine is the most abundant free amino acid in 
human blood. Glutamine is important as a constituent of 
proteins, means of nitrogen transport between tissues, im-
portant in acid base regulation, gluconeogenesis, as a pre-
cursor of nucleotide bases and the antioxidant glutathi-
one. Also glutamine is considered important in prolifera-
tion of lymphocytes and other rapidly dividing cell, includ-
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ing the gut mucosa and bone marrow stem cells. Many re-
searchers suggest that glutamine may provide benefit for 
surgery, trauma, help support digestive system health af-
ter periods of physical stress, wound healing, helps sup-
port immune system health after periods of physical stress, 
helps to assist in muscle cell repair after exercise, cancer 
and bone marrow transplantation and it`s administration is 
well tolerated. Meanwhile, according to Scientific opin-
ion of EFSA - NDA for Health Claims of glutamine such 
as “immune health” and “intestinal health” are considered 
of a beneficial physiological effect (EFSA FEEDAP Pan-
el, 2015) and health claim referees to faster restoration of 
glycogen stores in skeletal muscle after strenuous exercise, 
“increasing cell swelling, volumization”, “muscle protein 
metabolism” and “improves muscles metabolism” (EFSA 
FEEDAP Panel, 2015) are considered of a beneficial phys-
iological effect but based on scientific data the Panel con-
cludes the relationship of cause and efficacy of the above 
claimed effects has not been established.
Lysine is converted to acetyl CoA, a critical compo-
nent in carbohydrate metabolism and the production of en-
ergy. Lysine is precursor of the carnitine, which is transport-
ing long-chain fatty acids into the mitochondria for energy 
production. According to studies, supplemental L-lysine has 
putative anti-herpes simplex virus activity, also because ly-
sine seems to have an antagonist effect with arginine, which 
is required for the replication of HSV. However, according 
to Scientific opinion of EFSA (EFSA FEEDAP Panel, 2015) 
for Health Claim of L-lysine maintenance of bone is con-
sidered of a beneficial physiological effect and other health 
claims such as “immune defense against herpes virus”, 
“maintenance of normal blood LDL-cholesterol concentra-
tions”, “increase in appetite leading to an increase in energy 
intake”, “contribution to normal protein synthesis” might be 
of a beneficial physiological effect but no cause and effect 
relationship has not been established. Studies have shown 
that L-lysine can contribute to a positive Ca balance, sug-
gesting a potential use of L-lysine supplements for preven-
tive and therapeutic intervention in osteoporosis.
Conclusion
Generally speaking, food supplements can be benefi-
cial to the health of consumers, but based on a general re-
view any health claim of food should be scientifically jus-
tified toward protection of people from any bed interpreta-
tion and information.
But still, a part of all the studies and researches, ami-
no acids still don`t take their credit yet and are not properly 
recognized in medical sciences in Europe, since the health 
claims of food containing amino acids are still considered 
to be not established in terms of cause and effect relation-
ship. Therefore, analyzing all the publications in this di-
rection, the faster this process goes, the greater will be the 
chances for health benefits amongst population in relation 
to amino acids uses.
As it is well said by the Millward: “Few issues in nutri-
tional science have aroused such long-standing and deep-
seated controversies as protein and amino acid require-
ments?” (Millward et al., 1997).
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Introduction
Antibody conjugates are therapeutics that function 
through mediating alterations in antigen or receptor func-
tion, modulating the immune system (for example, changing 
Fc function and T cell activation) or delivering of a specif-
ic drug conjugated to antibody that targets a specific antigen 
(Scott et al., 2012; Weiner et al., 2010). Four main classes 
using antibodies are investigated to target cytotoxic agents 
to cancer cells: antibody-protein toxin conjugates, antibody-
chelated radionuclide conjugates, antibody–small-molecule 
drug conjugates, and antibody-enzyme conjugates (admin-
istered together with small-molecule prodrugs) (Teicher and 
Chari, 2011). Only antibody-radionuclide conjugates and 
antibody-drug conjugates have reached the regulatory ap-
proval stage. Radio immunotherapy, exploits the specifici-
ty of an antibody to deliver a radionuclide, and affords some 
potential benefits over conventional radiotherapy. Antibody-
radionuclide conjugates have been successfully developed 
for the treatment of non-Hodgkin’s lymphoma (NHL), re-
sulting in the approval of 131I-tositumomab (Bexxar) and 
90Y-ibritumomab tiuxetan (Zevalin), which are CD20-tar-
geted agents (Maloney et al., 2010). Important steps that are 
necessary to transform monoclonal antibodies (mAbs) in 
drugs for human use must be followed to achieve success in 
treatment of cancer patients with antibodies. Furthermore, 
dealing with the challenges in the process of target selection 
and selection of conjugate elements including the design of 
antibody formulation is also imperative. 
Development and evaluation of antibody 
conjugates
The successful development of candidate antibodies 
involves complex evaluations, concerning cancer biology 
and the properties of antibodies in vivo. Essential preclin-
ical characterization includes identification of the physical 
and chemical properties of the antibody; detailed analysis 
of antigen expression using normal and malignant tissues; 
study of the immune effector functions and signaling path-
way effects of the antibody; toxicity assessment; analysis 
of in vivo antibody localization and distribution in tumor 
systems; and observation of the in vivo therapeutic activity 
of the antibody, alone or conjugated with radioactive iso-
topes or other drugs.
In case of NHLs, the biodistribution studies of a radio-
conjugate in the tumor tissue and an assessment of whole-
body toxicity and dosimetry were essential in preclinical 
trials leading to approval of CD20 specific radioimmuno-
conjugates tositumomab and ibritumomab for treatment by 
US Food and Drug Administration (FDA) (de Bono and 
Ashworth, 2010). Rituximab also has considerable suc-
cess in treatment of patients with CD20 positive NHL and 
chronic lymphocytic leukemia. Radioimmunotherapy with 
rituximab labeled with suitable radioisotopes, is new op-
portunity after promising preliminary results where pre-
clinical data demonstrated improved tumor response (Scott 
et al., 2012). 
Toxicity studies
One of the most essential steps in the evaluation of a 
potential diagnostic/therapeutic antibody is determination 
of the toxicity of an antibody (often radiolabelled) and the 
ratio of antibody uptake in the tumor versus normal tissues. 
This information is essential for the rational design of an-
tibody conjugates therapy, where uptake of antibodies by 
normal tissues is crucial for predicting toxicity on one side, 
but also is crucial for defining dose regimen where optimal 
tumor concentration of the antibodies will be achieved on 
the other. 
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Normal and tumor tissue distribution can be quanti-
fied and evaluated by toxicity studies in animal models, 
where kinetics, distribution and induced effects in mice/
rats or other nonrodent species, with or without implanted 
tumor are followed.  These studies include administration 
of selected doses of radiolabelled mAbs and monitoring of 
tumor growth or survival of animals over time (Reilly et 
al., 2006). A control group of animals receives only the sol-
vent of the formulation or non-specific radiolabelled mAbs 
of the same class. Generalized and gastrointestinal toxici-
ty is followed by the weight monitoring (significant weight 
loss > 10-20%), while bone marrow toxicity is assessed by 
hematology analyses including leukocyte (WBC), erythro-
cyte (RBC), and platelet counts as well as hematocrit (Hct) 
and hemoglobin (Hb) concentrations. Biochemistry anal-
yses included serum alanine aminotransferase (ALT) for 
liver toxicity and creatinine (Cr) levels for renal toxicity. 
In addition, samples from different tissues (liver, kidneys, 
etc) are obtained for hystopatological examination by light 
or electron microscopy. Potential radiotherapeutic agent 
should demonstrate specific anti-tumor effects targeted 
only tumor tissue with only minimal to moderate toxici-
ty to normal tissues. 
Conclusions
Varied and newly designed antibody conjugates are 
currently directed toward various tumor targets in clinical 
trials, and more are nearing clinical trial. Before reaching 
any possibility for patient’s treatment, successfully passed 
preclinical phase is essential. The future development of 
antibody conjugates as therapeutics in cancer treatment is 
dependent on data from laboratory studies, on applying in-
novative approaches to target and antibody selection and 
on appropriate development strategies, leading at the end, 
to clinical benefit in cancer patients.
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Introduction
Animal models are used intensively in scientific stud-
ies regarding cancer, immune or autoimmune diseases as a 
relevant resource for gathering data concerning the appari-
tion, the development and the progression of these diseas-
es. In the field of environmental toxicology, the animals, 
also, play important roles in establishing the degree of tox-
icity of the potential toxic agents. 
In the scientific research the mice are preferred as ani-
mal models. The strain of mice is chosen by respecting dif-
ferent conditions, such as: the type of experiment that will 
be performed, the susceptibility of the mice to develop the 
pathology or the signs specifics to the model desired, the 
mouse genetics, the lifespan and other factors experiment-
related.
The Cosorb process is known as the process used for 
the recovery of carbon monoxide (CO) from gas mixtures. 
This method requires an equimolar amount of CuCl and 
AlCl3 that will be added to an excess of toluene and the re-
sult will be the formation of a CuAlCl4-toluene complex 
that is capable to fix CO (Foster, 2007). 
The objective of this study was to evaluate the pro-in-
flammatory effect of the organic phase resulted during the 
Cosorb process by the means of ear-inflammation mouse 
model using 3 different strains of mice: Balb/c, SKH-1 and 
C57BL/6J mice. 
Materials and methods
For this experiment there were used male Balb/c, 
SKH-1 and C57BL/6J mice weighing between 23-35g, 
purchased from Charles River Labs, Budapest, Hungary 
and housed in standard conditions in the Animal house Fa-
cility from our University.
The organic phase composition consists of the follow-
ing aromatic volatile compounds: toluene (84.46%), xy-
lems (5.3%) and benzene (0.1%). The ear-inflammation 
mouse model protocol proposed in this study was per-
formed as described in the literature (Dkhil et al., 2010; 
Iyadomi et al, 2000) with several modifications. In brief, 
different volumes of the organic phase (20, 40 and 80 µl) 
were applied using a micro-pipette on the skin of the front 
and back of the right ear and the left ear was untreated in 
order to be used as control. The ear swelling was monitored 
for 24h post-application and at different time points: 2h, 4h, 
8h and 24h were taken photos and the mice were weighed. 
At every time point mentioned, the mice were sacrificed 
under anesthesia and the both ears were cut off, sized and 
weighed. The increase in ear’s weight determined by the 
organic phase application which represents the intensity of 
ear edema was calculated by subtracting the weight of the 
treated ear from that of the left ear, untreated, used as con-
trol (Dkhil et al., 2010; Wang et al., 2011).
Samples from control and treated ears of mice were 
collected and fixed in formalin solution for histopathologi-
cal analysis. The samples will be stained with hematoxylin 
and eosin and analyzed. 
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Results and discussion
The aim of our study was to evaluate the pro-inflam-
matory effects of the compounds found in the organic 
phase: toluene, xylene and benzene as a mixture of organic 
solvents by using animal models of ear inflammation. We 
decided to use three different strains of mice (Balb/c, SKH-
1 and C57Bl/6J mice) to verify if the species variability in-
fluences the effects of these compounds at skin level.
Our data indicated the presence of erythema, swelling 
and edema, first signs being observable earlier than 2 hours 
post-application of the organic phase in all three strains of 
mice. The weights of the right ears treated with the organ-
ic phase solution were bigger as compared to the left ears 
untreated used as controls, a marker of ear edema intensity. 
The capacity of inducing ear edema was dose dependent, 
the intensity of the effects being higher at the highest vol-
umes added.   
In a previous study, we showed that topical applica-
tion of organic and inorganic phases induced modifications 
in the physiological cutaneous parameters (hydration, tran-
sepidermal waterloss and erythema) in a hairless SKH-1 
mouse model (Coricovac et al., 2015; Simu et al., 2016). 
The use of xylene as an inducer of ear edema mouse 
model was associated with acute inflammation character-
ized by severe vasodilation, edematous changes at skin 
level and infiltration of inflammatory cells (Igbe et al., 
2010). Another signs of xylene toxicity at skin level after 
topical application were: increased vascular permeability, 
swelling within the dermis and proliferation of keratino-
cytes (Dkhil et al., 2010). Iyadomi and coworkers showed 
that application of toluene to the ear skin of Balb/c mice 
induced ear swelling and skin irritancy in a dose depen-
dent manner (Iyadomi et al., 2000). Similar results were 
observed in our study, too.
Toluene is an aromatic organic solvent known as an 
environmental toxicant. Inhalation of toluene was associat-
ed with airway inflammation and neurotrophin production 
in hippocampus of mice. Benzene and xylene induce irri-
tation of the airway and dizziness in humans. Volatile or-
ganic compounds as toluene, benzene and xylene were de-
scribed as substances able to determine inflammatory re-
sponses at pulmonary level, but also to modulate neurolog-
ical responses in brain (Wang et al., 2012).
According to the literature, Balb/c mice are suscepti-
ble to develop tumors, like mammary and colon cancer, 
to infection diseases and as animal models for ear edema 
studies by the dermal application of different inflammatory 
agents (Chen et al., 2005; Iyadomi et al., 2000).
SKH-1 hairless mice are a strain used very often in 
studies concerning the development of skin cancers and, 
in pathologies involving skin changes, due to the fact that 
the lack of hair offers a better observation of the changes 
that occur.
Conclusion
Our preliminary data indicate that the application of 
the organic solvents mixture induced ear inflammation in 
all three strains of mice used in the study. The information 
obtained in the present study is valuable, especially from 
the point of toxicity that might develop by the workers in 
the industry of CO recovery and, in addition, this mixture 
could be used as an agent for animal model of ear edema 
in order to test the anti-inflammatory effects of different 
compounds.
Acknowledgment
This research was supported by the PN-II-PT-PC-
CA-2013-4-0612 grant, nr. 110/2014 (REMACAT).
References
Dkil, M.A., Abdel-Baki, A.S., Al-Quirashi, S.,Al-Khalifa, M., 
2010. Anti-inflammatory activity of the venom from samsum 
ants Pachycondyla sennaarensis. Afr. J. Pharm. Pharmacol. 
4(3), 115-118.
Iyadomi, M., Ichiba, M., Zhang, J., Enoki, M., Tomokuni, K., 
2000. Evaluation of skin irritants caused by organic solvents 
by means of the mouse ear thickness measurement method. 
J. Occup. Health 42, 44–46.
Wang, Y.F., Shao, S.H., Xu, P., Yang, Q., Qian, L.S., 2011. 
Catechin-enriched green tea extract as a safe and effective 
agent for antimicrobial and anti-inflammatory treatment. Afr. 
J. Pharm. Pharmacol. 5(12), 1452-1461.
Foster P.J., 2007. Thesis - Continuous co separation by liquid 
absorption in aqueous cuprous chloride (CuCl) and 
magnesium chloride (MgCl2) solution. Department of 
Chemical Engineering Brigham Young University.
Igbe, I., Ching, F.P., Eromon A., 2010. Anti-inflammatory activity 
of aqueous fruit pulp extract of Hunteria umbellata k. schum 
in acute and chronic inflammation. Acta Pol. Pharm. Drug 
Res. 67(1), 81-85.
Wang, F., Li, C., Liu, W., Jin, Y., 2012. Effect of exposure to 
volatile organic compounds (VOCs) on airway inflammatory 
response in mice. J. Toxicol. Sci. 137(4), 739-748.
Coricovac, D., Dehelean, C., Pînzaru, I., Ionescu, D., Soica, 
C., Simu, G., 2015. Toxicological evaluation of the effects 
induced by the organic phase obtained via Cosorb process on 
skin physiological parameters Toxicol. Lett.  238(2S), S264.
Simu, G.M., Coricovac, D., Cseh, L., Soica, C., Borcan, F., 
Ionescu, D., Andoni, M., Dragos, D., Dehelean C., 2016. 
Assessment of skin injuries induced by organic and inorganic 
phases of the Cosorb process by means of non-invasives 
techniques. Rev. Chim. (Bucharest) 62(2), 291-296.
Chen, X., Oppenhelm, J.J, Howard, O.M.Z., 2005. BALB/c mice 
have more CD4CD25 T regulatory cells and show greater 
susceptibility to suppression of their CD4CD25– responder 
T cells than C57BL/6 mice. J. Leukoc. Biol. 78, 114–121.
O
ral presentations
Macedonian pharmaceutical bulletin, 62 (suppl) 261 - 262 (2016)
ISSN 1409 - 8695
UDC: 615.322.015.3
Short communication
Antioxidant versus toxic capacity of selected herbal products
Blagica Jovanova*, Marija Hiljadnikova-Bajro, Tatjana Kadifkova Panovska
Institute of Applied Biochemistry, Department of Toxicology, Faculty of Pharmacy, 
Ss. Cyril and Methodius University, Majka Tereza 47, 1000 Skopje, Republic of Macedonia
* blagicajovanova@hotmail.com
ROS and antioxidant defense 
In the past 20 years numerous achievements were 
made in the area of testing the cellular damage caused by 
the excessive production of free radicals. Reactive oxygen 
species (ROS) are strongly related with the onset of dis-
eases such as cancers, atherosclerosis, neurodegenerative 
diseases, infections, chronic inflammatory diseases, diabe-
tes, autoimmune diseases, hypertension, idiopathic pulmo-
nary fibrosis, chronic obstructive pulmonary disease and 
asthma.
ROS are produced from molecular oxygen as a result 
of the normal cellular metabolism in living organisms or 
as a result of environmental factors. The three major types 
of ROS that are of physiological significance are superox-
ide anion, hydroxyl radical and hydrogen peroxide. They 
are essential for the physiological signaling pathways and 
other cell processes. However, these highly reactive mol-
ecules, if present at high concentrations, damage the cell 
structures (such as lipids, proteins, nucleic acids) and al-
ter their functions. The disbalance between the oxidant and 
antioxidant effects inside a viable cell in favor of the oxi-
dants is described with the term “oxidative stress”. Oxida-
tive stress occurs when the balance between antioxidants 
and ROS is disrupted because of either depletion of anti-
oxidants or accumulation of ROS. Consequently, high con-
centrations of ROS result in a higher degree of oxidative 
stress leading to many pathological conditions.
Aerobic organisms have integrated antioxidant sys-
tems that are usually effective in blocking the harmful ef-
fects of ROS. If present in small quantities, antioxidants 
are powerful agents that can prevent or reduce the oxida-
tive destruction of biomolecules. Generally, antioxidants 
can be divided in two categories: enzymatic and nonen-
zymatic. The major enzymatic antioxidants are superoxide 
dismutase, catalase, glutathione peroxidase, thioredoxin, 
peroxiredoxin, glutathione transferase. Nonenzymatic an-
tioxidants include vitamins C and E, β-carotene, uric acid, 
and glutathione. However, in pathological conditions, the 
antioxidant systems can be overwhelmed, causing disbal-
ance of ROS/antioxidant index. Consequently, additional 
source of antioxidants is essential, to enhance the metabo-
lism against the excess of free radicals.
Natural sources of antioxidants
Beside the many benefits of the plant utilization for 
different reasons, herbs have been identified as sources of 
various phytochemicals, many of which cause antioxidant 
effects. For a very long time, herbs were the only medici-
nal therapy that people used in the treatment of various dis-
eases. Although synthetic drugs were developed in the 19th 
century and replaced herbal therapy in many fields of treat-
ment, herbs are still found in 40% of prescription drugs. 
Additionally, herbs are also used in the cosmetics industry, 
food industry and chemical industry. 
Herbs and spices are reliable sources of potential bio-
active compounds in human diet. Research indicates that 
these bioactive components may act alone or in combina-
tion with other bioactive moieties to reduce disease risk 
through their antimicrobial, anti-inflammatory, antirheu-
matic, hepatoprotective, antimutagenic, and anticancer ac-
tivities. They are rich in phytochemicals that are natural 
antioxidants, of which phenolic diterpenes, flavonoids, fla-
vanols, alkaloids, tannins and phenolic acids are the most 
prominent. Compared to other food products, herbs and 
spices used in diet are shown to manifest highest antiox-
idant capacity. Additionally, the antioxidant capacity has 
shown to be concentration dependent, to a degree where 
the naturally occurring phytochemicals with antioxida-
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tive properties are not manifesting their prooxidative ef-
fects. These results are of great importance in many re-
search areas especially for the possibility of isolation of 
single compounds and their utilization in medicinal pur-
poses (Charles, 2013).
In many research papers it is pointed out that the in-
take of herbs is a significant contributor to the antioxidant 
intake in general. Dragland et al. (2003) declare a 1000-
fold difference among antioxidant concentrations of vari-
ous herbs, indicating the enormous diversity of their phyto-
chemical composition. Furthermore, they recommend the 
use of herbs as a better source of dietary antioxidants than 
many other foods including fruits, berries, cereals and veg-
etables.
Quantification of the antioxidant capacity 
Many commercially available herbs are regularly used 
as teas, extracts, infuses, decocts or aromatic herbs for taste 
improvement of food. Therefore, their antioxidant prop-
erties are already affecting the population that consumes 
them. The quantification of their antioxidant potential is 
very important, in order to evaluate their impact on the re-
dox processes in the organisms. Various methods are used 
to investigate the antioxidant properties of plant samples. 
In general, antioxidant assays are classified as in vitro and 
in vivo methods, with a highlight on the first group of tests 
since they are relatively straightforward to perform and 
most of them are fast and inexpensive, compared to in vivo 
methods. Among the in vitro methods, the most common-
ly used are DPPH (1,1-diphenyl-2-picrylhydrazyl) method, 
FRAP (Ferric Reducing Antioxidant Power) assay, TRAP 
(Total radical-trapping antioxidant parameter) method, 
TEAC (Trolox equivalent antioxidant capacity) method, 
NRD and SRD (Nonsite Specific and Site Specific Hydrox-
yl Radical-mediated 2-deoxy-D-ribose Degradation) meth-
ods, TBA (Thiobarbituric acid) method, H2O2 (Hydrogen 
Peroxide Scavenging) assay, etc. Additionally, Folin – Ci-
ocalteu method for the determination of total phenols and 
AlCl3 method for the determination of flavonoids in plant 
samples are most commonly used assays along with the 
previously mentioned antioxidant assays, since many stud-
ies showed the positive correlation between antioxidant ca-
pacity of plant extracts and their total phenolic content. 
Cytotoxicity testing 
On the other hand, many herbs that possess antioxi-
dant properties can also manifest toxic effects under cer-
tain conditions. According to Paracelsus’ maxim: “Dosis 
sola facit venenum” (The dose makes a substance poison-
ous), any substance could be defined as a toxic substance 
if administered in high doses. An excellent in vivo prelim-
inary model for the discovery of potential toxic agents is 
the Brine Shrimp Lethality Assay (BSLA). This is a conve-
nient, fast and technically feasible method for the determi-
nation of LC50 of herbal extracts (Meyer et al., 1982). The 
method determines the percentage of dead Artemia salina 
nauplii after their exposure to the tested plant extract. Us-
ing probit regression analysis (Finney, 1952), the LC50 val-
ues are calculated and expressed for each herbal extract, 
which are later compared to the LC50 values of confirmed 
toxic substances (such as potassium dichromate, emetine 
hydrochloride etc). The classification of the examined 
plant extracts is achieved according to the obtained LC50 
using different classification scales, of which the Meyer’s 
scale (Meyer et al., 1982) and the Clarkson’s scale (Clark-
son et al., 2004) are most commonly used.
Plant extracts as cytotoxic agents
Many herbs which have proven toxic potential in cer-
tain doses, are promising cytotoxic agents. Their wide 
range of properties (antioxidant, antimicrobial, hepatopro-
tective, anticancer) makes them promising candidates for a 
formulation of chemo protective agents. This means a new 
opportunity for the clinical practice for the treatment of nu-
merous diseases, either in a way of preventing their onset 
or reducing the extent of their progression. However, not 
all toxic substances possess cytotoxic properties. The pre-
condition for a cytotoxic effect is the selectivity towards 
the tumorigenic cells of the substance itself. Therefore, po-
tential cytotoxic agents are the compounds which specifi-
cally act on cancer cells, leaving out viable cells as intact. 
Although BSLA cannot estimatethe cell selectivity of the 
potential toxic herbs, it is still an excellent predictive tool 
that preliminary filters the potential candidates for a more 
detailed cytotoxicity research. 
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Introduction
Lifestyle of our population with the advent of science 
and new technologies adversely changes, reduces physi-
cal activity and develops negative eating habits. Shift from 
malnutrition and infectious diseases to chronic diseases 
(cardio metabolic diseases, cancer, diabetes mellitus) is 
typical for current epidemiological situation (Riečanský, 
2009). Obesity leads to a worse quality of life and short-
er life expectancy. Mortality of cardio metabolic diseas-
es is 2.5 times higher than the average in European coun-
tries. This current epidemiological situation in overweight 
and obesity is alarming. Compulsory school physical ed-
ucation is the only place for physical activity for a lot of 
children. And the number of these children is increasing. 
The research is based on project “Respect for Health”. We 
analysed the relationship between participation in com-
pulsory PE and cardio metabolic risk factors (blood pres-
sure, weight and body mass index). The project “Respect 
For Health” is monitoring the situation in the cardiovascu-
lar health of secondary school students. Assessment of car-
diovascular risk factors and physical activity (compulsory 
physical education (PE) and extra-curriculum sport activi-
ties) in secondary school children is followed by education 
in effective lifestyle measures.
Materials and methods
Target group in evaluating the relationship of partic-
ipation in compulsory school physical education and risk 
factors for cardio metabolic diseases consisted of 760 stu-
dents of which 295 boys and 465 girls. In respect of par-
ticipation in extra-curricular sports activity and selected 
risk factors consisted of audience of 211 pupils, 119 boys 
and 92 girls from 55 secondary schools in Bratislava re-
gion aged 15-18. Data were collected by 2 types of ques-
tionnaire (questionnaire of parent and questionnaire of stu-
dent). We measured anthropometric parameters (neckline, 
chestline and hipline), blood pressure and tested physical 
ability by Ruffier test.
Project: “Respect for Health” monitoring the situation 
in the cardiovascular health of secondary school students. 
The project was initiated by Bratislava Region in collabo-
ration with the Regional Public Health Institute in Bratisla-
va. The main idea of the project is based on the recogni-
tion that risk factors for cardiovascular diseases can oc-
cur at a young age. Elimination of a risk is possible thanks 
to prevention and change of eating habits. The project was 
implemented by the Regional Institute of Public Health in 
Bratislava with Public Health students of Slovak Medical 
University.
Results and discussion
For evaluation of the relationship of participation in 
compulsory school physical education and risk factors for 
cardio metabolic disease, we found out that students who 
regularly attend compulsory PE are more physically profi-
cient than those who avoid it according to the Ruffier in-
dex. Students who spend more hours per a day at the com-
puter during the week are physically less proficient than 
those who spend fewer hours at the computer during the 
week, according to the Ruffier index. All these relations 
were statistically significant (p <0.05). We found out that 
smoking students avoid compulsory PE twice as much as 
non-smokers. The current problem is smoking in young 
children and the number of smokers in young age are mul-
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tiple (Cvopová et al., 2011). The number of smoking girls 
is 1.2 times higher than the number of smoking boys. This 
is really a good example of how one negative habit picks 
on another and they multiply. For other indicators, a statis-
tically significant difference was not confirmed, but more 
favourable results in blood pressure, weight and body mass 
index (BMI) were shown for regularly participating stu-
dents at the compulsory PE. In respect of participation in 
extra-curricular sports activity and selected risk factors, we 
confirmed that the active Ruffiers´ test of sport active chil-
dren testified better shape of these students (p = 0.048). We 
also demonstrated a statistically significant relationship be-
tween regular supply of food and BMI values (p = 0016). 
Extra -curricular sports activity leads to better fit children. 
Regular diet directly affects BMI. Because of physical ac-
tivity they feel their life filled with experiences and activ-
ities.
Conclusion
Lack of physical activity is one of the major risk fac-
tors of cardio metabolic diseases, with significant impact 
on years of disability adjusted life (DALYs) in the Europe-
an region (WHO, 2006). Compulsory physical education 
and in the same way extra-curricular sports activities of 
secondary school children have a positive impact on car-
diovascular risk factors. The results of our thesis confirmed 
the positive impact of compulsory PE for the child’s body, 
and therefore the importance of taking measures for the de-
velopment of physical activity in schools, in the family and 
beyond. Negative habits (avoid the PE and smoking) of 
lifestyle in young people often multiply. Qualified profes-
sional teachers of PE and as well as parents play a key role 
in creation of positive attitude towards physical activities 
in children.“The movement is life” and in case of cardio-
vascular prevention this true are multiple (Farský, 2010). 
Parents should be an example for their children in a choice 
of extra – curricular sport activity. They should support 
children in sport activity with enthusiasm (Račková, 2011)
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Introduction
As known by almost everyone in many EU countries’ 
agenda food and health are in the first place especially in 
the last decade. The rationale for this trend is there is an in-
crease both for obesity and for nutrition related disorders 
those cause diabetes and cardiovascular diseases (Gallus et 
al., 2015; van Vliet-Ostaptchou et al., 2014; WHO, 2009). 
Thus tailoring the nutrition system in parallel to the com-
munity’s need, it’s being reliable; effective and flexible are 
becoming more and more important each day.
Awareness rising on healthy eating has not led to sig-
nificant changes in patterns of food purchase and consump-
tion so far.
Bringing together industry, science, and the civil soci-
ety in a meaningful exchange is essential to success in ad-
dressing this pivotal challenge.
Materials and methods
As a first step all the food related and patient related 
organizations belonging to governmental, non-governmen-
tal and business sector were tried to be determined. In the 
second phase the ones those will be enrolled to the Europe-
an Awareness Scenario Workshops (EASWs) were select-
ed randomly.
European Scenario Workshop, also known by the ac-
ronym EASW, is a qualitative research method which has 
been born in Denmark with purpose to find an agreement 
between the different group of actors at local level with the 
aim of reaching a consensual definition of city sustainable. 
It promotes discussion and participation. An EASW serves 
to foster democratic participation in decisions related to the 
improvement of living conditions in communities.
EASW methodology is particularly suited to:
•	 encourage dialogue and participation of the 
various components of society;
•	 creating a balanced relationship between envi-
ronment, technology and society;
•	 enable a sustainable development while re-
specting the needs and aspirations of members 
of a local community (http://toolbox.climate-
protection.eu/list-of-all-methodologies/ ).
According to its application, the EASW method could 
be a tool for:
•	 information and learning,
•	 understanding and participation in the decision 
making process, common planning for the fu-
ture
•	 identifying responsibilities and priorities or 
just any combination of the above.
An EASW is built on three main activities:
a.the development of scenarios
b.stakeholder mapping 
c.EASW workshop for the development of visions and 
ideas 
The workshop typically lasts two days and goes 
through three phases: critical analysis phase, visionary 
phase and implementation phase (http://www.cipast..org/
cipast.php?section=1012). 
Results and discussion
In the capital of Turkey we conducted three EASWs 
(one in 2012 October and two in 2013 June and Septem-
ber). Totally 47 representatives from non-governmental, 
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governmental and business sector participated in our Sce-
nario workshops.
In those EASWs the following were discussed:
a.How research management and policy should be on 
food and health?
b.In this sense should every kind of research be fund-
ed?
c.Which type of research should be supported? : Basic 
or practical research aiming contemporary issues?
d.How research politics will be determined and shaped 
on innovative food production? 
Under these topics the following were found in terms 
of  “Nutrition and Innovative Approaches on Food Produc-
tion” for Turkey among NGO, business sector and govern-
ment sector participants respectively:
Change in living conditions (global warming, popu-
lation growth, GMO, etc.) is a significant factor. Civil so-
ciety opinion is ignored while doing research on innova-
tive food production. Resources are being used ineffective-
ly while doing food research. There is a lack of informa-
tion on healthy nutrition among the society. Scientific re-
search outcomes are not reflected to the policies. As the in-
equalities become deeper, hunger; obesity; and social prob-
lems become more. The media directs the individuals in a 
wrong way. Use of agricultural land(s) for different aim(s) 
is a big problem. There is a lack of inspection in food sec-
tor. Healthy food options are expensive. Although the Con-
sumer Protection Act exists there is a violation of consum-
er rights.
Resources are being wasted unwisely in researches. 
In order to make “healthy nutrition as a never ending pro-
cess”, independent authorities (i.e. EFSA) should be estab-
lished. There exist unfair competitions (both internal and 
external). There is very easily licensing process/easy cer-
tification process on food production. Lots of misleading 
information are observed Consumers are unconscious in 
many ways. There is a deterioration of the food because of 
the long distances, etc. Unconsciousness exists in the steps 
of healthy food production.
Institutions’ working together is a must. On the oth-
er hand bureaucracy is huge. Scientific data are not avail-
able or accessible. Furthermore the ones those are accessi-
ble lacks quality. There is a slow process in research and 
publication. Lack of national database is a big problem. 
Lack of National Policies for Sustainable Agriculture is an-
other issue.
Conclusion
In the light of the conducted EASWs we concluded 
that the projects should be handled according to the nation-
al policies other than governmental policies. An indepen-
dent institution is a must which will make healthy nutrition 
researches. This institution should also raise awareness 
among the community and make risk assessment. Innova-
tion studies based on reliable and scientific data should be 
conducted. Three should be continuous dialogue/trialogue 
between/among NPO, government/public and academia/
research institutions.
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Introduction
Ionizing radiation (IR) has been found to produce del-
eterious effects on the biological systems. IR is known to 
induce mutations and cell transformations, predominant-
ly by causing single-strand and double-strand DNA break-
age, thereby leading to chromosome instability and carci-
nogenesis (Hayata, 2005). Genetic instability can be ana-
lyzed by using cytogenetic parameters such as sister chro-
matid exchange (SCE), and micronuclei (MN). It is known 
that cytogenetic damage accumulates in humans with age, 
due to the prolonged exposure to oxidative damage, chemi-
cals as well as occupational, therapeutic or accidental radi-
ation (Ramsey et al., 1995). However, studies on genotox-
ic effects of low dose occupational exposure is limited and 
with contradicting results. 
IR is known to induce oxidative stress through gen-
eration of reactive oxygen species (ROS) resulting in ox-
idative damage to biomolecules such as deoxyribonucle-
ic acid (DNA), proteins, and lipids (Chi et al., 2005). Aer-
obic organisms possess antioxidant defense systems that 
deal with free radicals produced as a consequence of aero-
bic respiration and substrate oxidation. Cells maintain their 
vital functions against oxidative stress status with the help 
of an antioxidant defense system that includes three major 
classes of antioxidant enzymes: the superoxide dismutase 
(SOD), catalase (CAT), and glutathione peroxidase (GPx) 
(Sies, 1997). It has been hypothesized that chronic low-
dose IR leads to oxidative stress but there are few studies to 
clarify oxidative stress status in radiology workers (Male-
kirad et al., 2005). 
The aim of this study was to evaluate the genotoxic ef-
fects and oxidative stress status of occupational radiation 
exposure in radiology unit staff. 
Materials and methods
The study population of 40 hospital workers occupa-
tionally exposed to IR was comprised of 12 physicians and 
28 technicians in the units of radiology at the Gulhane Mil-
itary Medical Academy in Ankara, Turkey. Radiology unit 
personnel were healthy volunteers occupationally exposed 
to IR working 5 h/day in the hospital for a period of one 
to 30 years. The control group consisted of 30 individu-
als (10 physicians and 20 administrative staff) working in 
the same hospital who had never been occupationally ex-
posed to IR or chemicals. None of the study group partici-
pants had reported unusual alcohol consumption. Vegetari-
ans and those who used vitamin supplements, antioxidants 
or any therapeutic drugs were excluded. No one had under-
taken any medical radiological examination or any carci-
nogenic agent in the 6 months before blood sampling. 
The occupational exposure group were routinely mon-
itored by personal exposure measurements devices (film 
badges), every 40 days. The radiation dose was estimat-
ed from the official personal dosimeters based on thermo-
luminiscent dosimeters. This dose range represents only 
the dose from a single month exposure and was measured 
within 6 months prior to enrolment in the study.
Genotoxic effects were determined by using the cyto-
kinesis-blocked micronucleus (CB-MN) and SCE tests in 
peripheral blood lymphocytes. Oxidative stress status was 
assessed by measuring the antioxidant enzyme activities of 
copper-zinc superoxide dismutase (CuZn-SOD), selenium 
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dependent glutathione peroxidase (Se-GPx), CAT and the 
malondialdehyde (MDA) levels as lipid peroxidation in-
dex in erythrocytes. 
All statistical analyses were performed using the soft-
ware SPSS 13.0 for Windows statistical package. Groups 
were compared with the Student t-test. The results were 
expressed as mean value ± standard deviation (SD). Val-
ues of p<0.05 and p<0.001 were considered to be statisti-
cally significant. 
Results and discussion
The mean exposure dose of the radiological staff was 
0.32±0.69 mSv ranging from 0.10 to 3.86 mSvper month 
according to their individual dosimeters. None of them had 
recorded doses above the permitted levels of 20 mSv.
It was found that the mean frequency of MN was sig-
nificantly increased in radiation-exposed group compared 
to control group (p<0.05). This finding is in agreement 
with other studies (Maluf et al,2001; Zakeri and Assaei, 
2004; Angelini et al., 2005). The mean frequency of SCE 
did not show any significant difference in the exposed in-
dividuals in comparison to the controls (p>0.05). However, 
Engin et al. (2005) and Mrdjanovic et al. (2005) revealed 
that the frequency of SCE was significantly increased in all 
radiation-exposed individuals compared with controls. The 
enzymes activities of CuZn-SOD and Se-GPx observed for 
the exposed group were very significantly higher than in 
the control group (p<0.001). 
Oxidative stress causes various types of damage fol-
lowed by cell death or an activation of the repair systems. 
Antioxidant enzymes are considered as a very important 
component of cell defense mechanisms which protect or-
ganisms from the detrimental action of ROS damaging 
DNA and other biomolecules (Dimova et al. 2008). The 
enzyme activity of CAT and MDA levels in the exposed 
group were found significantly lower than in the control 
group (p<0.05, p<0.001, respectively). Our findings may 
be explained in terms of chronic low-dose radiation in-
duced radiation hormesis. Low-dose radiation has been re-
ported to induce hormesis, which is a beneficial stimulant 
effect of chronic low-dose radiation and radiation-adap-
tive response (Prasad et al. 2004). However, its molecu-
lar mechanism or signaling pathway is not yet known and 
needs to be clarified (Miura et al. 2002). Additional studies 
will provide essential information; in particular, larger and 
well-designed studies may be helpful. 
Conclusion
We observed that low dose chronic occupational ex-
posure to ionizing radiation causes an increase of MN fre-
quency in chromosomes, even though the absorbed dos-
es were below the permissible limits. Although the small 
sample size prevents a definitive conclusion on the oxi-
dative stress induced by occupational low dose IR expo-
sure, nevertheless, our experimental evidences highlight 
the stimulant effect of the low dose IR on oxidative stress 
related parameters in hospital staff and enhanced resistance 
to oxidative stress. 
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Introduction
Dietary supplements are defined as products intended 
to supplement the diet. They may contain a variety of in-
gredients including vitamins, minerals, amino acids, herbs 
or other botanicals, or other dietary substances “for use by 
man to supplement the diet by increasing the total dietary 
intake”. Dietary supplements are in the form of capsules, 
tablets, pills, and other similar pharmaceutical forms (Di-
etary Supplement Health and Education Act, 1994).
Medical evidence has suggested that dietary supple-
mentation can be beneficial for a group of people, who do 
not have a balanced diet. In such cases, after nutritional 
deficiency has been detected, the increase in the intake of 
such nutrients is recommended, either by means of food or 
supplements (Gardiner et al., 2004).
Age range that constitutes youth is important in many 
aspects. Physical growth and mental development of young 
population in adolescence will affect future physical and 
psychological chances as adults. The use of dietary supple-
ments among adolescents seems to be influenced by their 
beliefs and attitudes that dietary supplements work. The 
media has contributed to stimulate the use of dietary sup-
plements by spreading, for instance, the myth of the ide-
al body. 
Consumption of supplements in European countries 
ranged between 17.9% and 60% of the population (Flynn 
et al., 2009, Tetens et al., 2011).
During adolescence, a period when self-assurance is 
being developed, many adolescents do anything they can 
to meet that goal. Dietary supplements are sold in drug-
stores or gyms as over-the-counter products without advice 
from a pharmacist.
Based on the issues mentioned above, the objective of 
this study was to determine the frequency of dietary sup-
plements consumption, types of supplements being con-
sumed and reasons for consumption among high medical 
school students.
Materials and methods
The survey was conducted using an anonymous ques-
tionnaire. The total of 238 students of medical high school, 
of which 162 were girls and 76 boys, were surveyed. The 
questionnaire includes gender and grade, as well as ques-
tions concerning types and quantities of dietary supple-
ments respondents use. The survey was conducted in April 
2015. The methods of descriptive statistics were used in 
processing and analysing data, and then the differences of 
the obtained values were assessed via the chi-square test. 
In all analyses, differences were interpreted as statistically 
significant if the p-value is less than 0.05, and statistically 
significant if the p-value is less than 0.01.
Results and discussion
Of the total number of respondents 67.2% had used di-
etary supplements. Overall, 79% of participants were fe-
male. To determine the differences between gender with 
respect to dietary supplements consumption, chi-square 
test was used. Based on this test, it can be concluded that 
there is a statistically significant difference between the 
groups analysed (p = 0.00012, χ² = 20,626). No significant 
association was observed between supplement use and age. 
Of the total number of users of dietary supplements, 
64.78% mostly bought in pharmacies, while others were 
purchased in supermarkets. Information on these medi-
cines 38.8% search on the Internet, 26.12% of pharmacists, 
and 11.94% of the doctors. The most commonly used di-
etary supplements are vitamin C, then multi-vitamins and 
minerals (66.26%). Most of the respondents pleaded not 
regularly read the declaration of the purchased products 
(72.4%), while 73.88% thought that there was insufficient 
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information on indications and side effects
The most commonly cited reasons for usage are to 
maintain or improve health (68%), to increase energy 
(25%), to build muscle or increase weight (28%), to de-
crease body fat or weight loss (11%). Gender differences 
in types of dietary supplements are apparent. Males were 
more likely to consume supplements to build muscle (p = 
0.006), and females were more likely to consume supple-
ments to increase weight (p = 0.002). 
The most common forms of dietary supplements being 
used are multivitamin, or individual vitamin/mineral prep-
arations (particularly vitamin C). This finding is consistent 
with the data reported from other study (Kang et al., 2016; 
Moreno et al., 2014). This supplement, as the main report-
ed supplement used among interns, indicates that they may 
be concerned about their nutritional adequacy in general. 
Thus, they selected a type of supplement providing a vari-
ety of nutrients. 
Some studies shows the most commonly cited reasons 
for usage are to maintain or improve health, to increase en-
ergy, to build muscle or increase weight, to decrease body 
fat or weight loss, to increase athletic ability, to help heal 
injury or illness, or because of an inadequate diet (Bailey 
et al., 2013; Dwyer et al., 2013; Kang et al., 2016) what is 
similar with findings in this study.
Dietary supplement use in adolescents remains a con-
troversial strategy to improve nutrient intakes because, 
even though their use is associated with lower preva-
lence of inadequate intakes, it is also associated with an in-
creased risk of excessive intakes.
As the dietary supplement industry is now a multi-bil-
lion dollar industry, there is growing pressure, and a subse-
quent need for research to establish the efficacy and safe-
ty of these products particularly for adolescent users. The 
psychological and educational components of such use 
cannot be ignored as they play an equally important role in 
the health and safety of adolescents.
Conclusion
It is clear from the results of the current study that di-
etary supplementation is popular among adolescents.
There is need of further scientific research involving 
adolescents with the purpose of assessing the beneficial 
effects and safety of long-term dietary supplements use. 
More screening tests should be conducted on the consump-
tion of dietary supplements among adolescents. Toxicity 
surveillance should be improved, and regulations of di-
etary supplements market should be based on appropriate 
research. Nutritional education of adolescent is highly im-
portant, especially among future medical workers. 
Finally, regulations on this topic could assist the activi-
ty of health professionals and improve the education of the 
general population about the safe and effective use of di-
etary supplements.
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Introduction
Renal failure (acute and chronic) is described as a de-
crease in glomerular filtration rate (GFR). It is a condition 
in which the kidneys are unable to adequately filter tox-
ins and waste products from the blood. The cause of acute 
renal failure (ARF) is divided into sources of renal injury 
such as pre-renal, intrinsic and post-renal. In ARF there is 
an increase of blood urine nitrogen (BUN) and serum cre-
atinine, and decrease urine production. It is characterized 
by abrupt decline in renal filtration function (Haller, 2000).
In chronic renal failure (CRF) the amount of creati-
nine is higher and glomerular filtration rate is lower. CRF 
is a progressive loss in kidney function over a period of 
time. In the early stages, there may be no symptoms but it 
gets worse gradually. The adverse outcome of CRF is kid-
ney failure, cardiovascular disease (CVD), and premature 
death (Park, 2012).
Chronic and acute renal failure can be primary distin-
guished by different characteristics - cause and duration. 
CRF is a lifelong problem and it tends to get worse over 
months or years. Presence of disease in last few months, 
normochromic anemia, growth failure, and a history of 
nephritic or nephritic syndrome, high blood pressure, di-
abetes mellitus, kidney stone, glomerulonephritis and in-
fection make chronic renal failure more likely to happen 
(Saucier, 2010). Acute renal failure has a sudden onset and 
can occur as a complication of medical conditions, surgery, 
or trauma. 
Healthy kidneys produce a hormone - erythropoietin 
(EPO). The kidney cells that produce EPO are sensitive 
to low oxygen levels in the blood that passes through the 
kidney. EPO prompts the bone marrow to make red blood 
cells (Radtke, 1979). Red cell production due to the EPO 
deficiency is too low in CRF and causes development of 
anemia in this situation. Anemia is also seen in patients 
with acute renal failure, but the exact relationship between 
them remains unclear. In addition to anemia, platelet count 
also seems to be affected by renal disorder. The exact pat-
tern of platelet count in patients with renal failure is contro-
versial, but several studies revealed the decrease in platelet 
count in renal failure (Gafter, 1987; Prasad, 2012).
The aim of this paper is to evaluate the effect of acute 
and chronic renal failure on severity of anemia and plate-
let count.
Materials and methods
This case-control study was conducted on 92 patients 
with acute renal failure and 50 patients with chronic renal 
failure, and two groups of 95 and 75 individuals as con-
trols. At first, all patients with proven renal failure were 
included in the study. Then, patients were divided in two 
groups of acute (<3 month) and chronic (>3month) based 
on disease duration. In order to eliminate the influences 
of sex and age when the observation group and the con-
trolled group are compared, each of the two groups was se-
lected according to the same sex and similar age. Initially, 
two separate blood samples were taken from each patient, 
2 ml uncoagulated sample harvest for biochemical assay, 
and EDTA anti coagulated whole blood sample for com-
plete blood cell count. To determine the levels of BUN and 
creatinine, the serums were used, and then complete blood 
counts were done with EDTA anti coagulated samples. 
Statistical independent T- test was used to evaluate the 
significance of the differences between the two groups. 
P<0.05 was considered as a significant change.
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Results and discussion
In groups of patients with acute (53% male, 47% fe-
male) and chronic (65% male, 35% female) renal failure, 
mean age was 56±15 and 58±11.5 years, respectively. In 
controlled groups of acute (49% male, 51% female) and 
chronic (73% male, 27% female) renal failure, mean age 
was 61±12 and 63±11 years, respectively.
The average levels of BUN in patients with acute renal 
failure were 31.7±7.4 mmol/L, which is above the normal 
value, compared to the control group (6.4±2.1 mmol/L). 
The average of creatinine in patients with acute renal fail-
ure is also above the normal value (256.3±79.5 mmol/L) 
compared to the controlled groups (88.4±35.3 mmol/L).
The observation of the group of chronic patients also 
shows that BUN and creatinine are high (29.9±8.9 mmol/L 
and 740.8±180.4 mmol/L) compared to normal ranges 
of the controlled group (5.3±2.4 mmol/L and 88.4±12.3 
mmol/L).
The levels of Hb, HCT, MCHC and RBC counts were 
significantly lower in the patient group in comparison to 
healthy, non-renal affected people (P < 0.05), and anemia 
was substantial in patients with acute renal failure.
The study has also revealed that acute renal failure 
did not cause significant thrombocytopenia, and even the 
platelet count in these patients were slightly higher in com-
parison to the controlled group.
In patients with chronic renal failure, RBC count, he-
moglobin, hematocrit level, MCHC, and platelet count are 
significantly lower than the controlled group (P < 0.05), but 
MCH and MCV levels are not significantly different be-
tween these two groups (P > 0.05).
Conclusion
In acute renal failure the ability of the kidney to elim-
inate waste products, regulate acid-base balance, and man-
age water homeostasis is rapidly declined. When this im-
pairment is prolonged and has entered the chronic phase, 
the EPO secretion by this organ is decreasing. Low EPO 
level causes decrease of HCT, MCV, RBC and platelet 
counts. Therefore, the hematological changes in the blood 
count can be an early diagnostic marker for kidney failure. 
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Introduction
The Cosorb process is a solvent extraction process 
which provides a low cost opportunity to a selective and 
almost complete recovery of high purity carbon monoxide. 
During the process, cuprous aluminium chloride (CuAlCl4) 
in an aromatic solvent (by instance toluene) is used in order 
to form a chemical complex with carbon monoxide, which 
is further recovered by more than 96%. So, one could con-
sider this process as a reliable source of carbon monoxide 
in the case of downstream manufacture of chemicals and 
pharmaceuticals. However, some down sides of this pro-
cess are associated to the partially poisoning of the copper 
catalyst, and to some environmental risks mostly related to 
the disposal of the used catalyst, to the recovery of copper 
and aluminium, as well as to the impact on human health of 
the different phases resulted from the process (Chadeesi-
ngh, 2011). In this respect, toxicological studies of the 
different phases resulting from the Cosorb process could 
bring valuable information related to their potential impact 
onto human and environmental safety.  
In this work, an in vivo study of the adverse effects of 
two phases (organic and inorganic) resulting from the Co-
sorb process on skin hydration and barrier level was car-
ried-on. For this aim, murine model (C57BL/6N and SKH-
1 hairless mice) was used, and the evaluation of the ob-
tained results was performed by means of Corneometry 
and Tewametry.
Materials and methods
The reagents used in this study were of analytical grade 
and were provided by Merck and Sigma–Aldrich. The in-
organic phase was evaluated by High-Resolution Contin-
uum Source Atomic Absorption Spectrometer ContrAA 
700. It was found that the main metals present in this phase 
are copper and aluminium, while zinc, chrome and iron 
are in traces. The analyze of the organic phase by means 
of gas chromatography/mass spectroscopy (Hewlett Pack-
ard Gas Chromatograph HP 6890 associated with a Mass 
Spectrometer HP 5973) showed that the main compounds 
are toluene (84.46%) and some of its oxidation products 
(10.1%) (Simu et al., 2016). 
The in vivo study was performed on 4 months old 
C57BL/6N and SKH1 male mice (Charles River Labora-
tories, Budapest, Hungary), according to the 2010/63/EU 
Directive (Coricovac et a., 2015; Simu et al., 2016). Mice 
were fed ad libitum and kept under standard conditions: 
12-hours light/dark cycle, constant temperature of 22.5 ± 2 
°C, and 55 ± 5% humidity. Each type of mice (C57BL/6N 
and SKH1) were divided in 4 groups (5 mice/ group) as 
follows: the control group (1) - no interventions; group 2 
in which the mice were treated once, topically, with 200µl 
of inorganic phase (on the dorsal side); group 3 in which 
the mice were treated once a day, 5 times/week with 100µl 
of inorganic phase, and group 4 in which the mice were 
treated once a day, 5 times/week with 100µl of organic 
phase. The animals were daily observed both at skin’s 
level, and from behavior changes point of view. The eval-
uation of the skin’s response to the inorganic and the or-
ganic phase’s effect was performed by Corneometry and 
Tewametry. The physiological skin parameters, e.g. the 
hydration level of the skin surface and the transepidermal 
S3 PP 127
274
Maced. pharm. bull., 62 (suppl) 273 - 274 (2016)
Clinical biochemistry / Toxicology / Food and nutrition
Po
st
er
 p
re
se
nt
at
io
ns
water loss (TEWL) were measured with the Multiprobe 
Adapter System (MPA5) from Courage-Khazaka Electron-
ics (Germany), equipped with Tewameter®TM300 and 
Corneometer®CM 825 probes.
Results and discussion
Mice are widely used as mammalian model organism 
in numerous studies related to subjects within the biomed-
ical field in order to obtain answers and new insights onto 
the human health and welfare, in examining skin-related 
gene functions, as well as in modeling skin diseases. This 
is due to the fact that murine skin presents a great number 
of similarities with human skin.
In this work, SKH-1 and C57BL/6N mice were used. 
SKH-1 mice are a variety of unpigmented and immuno-
competent mice which are characterized by a more perme-
able skin than the human one. Their skin is less permeable 
to benzo[a]pyrene than the skin of haired mice. Moreover, 
a prolonged in vitro hydration of their skin can generate a 
consistent increase in permeability, particularly to polar or 
ionized solutes. The C57BL/6N mice were used in order to 
emphasize the differences between pigmented skin model 
and the SKH-1’s ones.
Corneometry is a non-invasive technique which is able 
to estimate the hydration level of the skin surface (mainly 
at the stratum corneum level). The measurements associ-
ated to this technique offer valuable information onto the 
modifications of the dielectric constant, due to skin surface 
hydration changing. So, this method presents a great deal 
of interest in dermatological and cosmetic applications, but 
also in formulation, claim support and efficacy testing of 
moisturizers. Corneometry is of great importance in objec-
tive clinical diagnosis, as well as for monitoring therapies. 
The obtained results from the Corneometric study 
showed a significant decrease of the skin’s hydration level 
in both types of mice, as well as for both studied aggressors 
(inorganic and organic phases). This decrease was noticed 
after the first 24 hours after application of the test solution, 
in both animal models. The decrease of this parameter may 
be associated to some toxicity signs, or may indicate the 
apparition of different injuries at skin level. It is important 
to note that in the case of the mice topically treated with the 
inorganic phase, some skin colour changes were noticed. 
Nowadays, Tewametry is used for many purposes, in-
cluding dermatology (for objective clinical diagnosis) and 
occupational medicine, for monitoring and detecting skin 
damages, as well as in the testing of cosmetic products 
and pharmaceuticals. Through this technique, the TEWL 
parameter is assessed. This parameter brings information 
onto the skin’s intrinsic properties, especially as its water 
barrier function. The measurements evaluate the density 
gradient of the water evaporation from the skin indirectly, 
by means of temperature and relative humidity. Great val-
ues of this parameter indicate that the water barrier func-
tion of the skin become inefficient, or even some stratum 
corneous deteriorations. It was found that increased TEWL 
values can be associated with different skin diseases, but 
could be also induced by different chemical compounds. 
The evolution of the TEWL parameter was studied 
both for the inorganic phase solution and the organic one. 
The obtained results indicate a significant decrease of this 
parameter in both cases. In the case of both animal mod-
els, it was noticed that the organic phase induced cutane-
ous damages after only 2 weeks after exposition (2 weeks). 
However, the progress of lesions was slightly decreased 
when medical treatment was applied at this stage.
Conclusion
Modifications of skin surface hydration level, and of 
the TEWL parameter were induced by the topical applica-
tion of inorganic and organic phase solutions resulted from 
the Cosorb process. 
These results were more obvious in the case of the 
SKH1 mice model, and could be associated with the first 
signs of a short-term pathology at the skin’s level.
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Introduction
Breast milk is considered as an ideal source of nutri-
tion and immunological support for infants. The World 
Health Organization (WHO) strongly supports breastfeed-
ing for newborns from birth until 6 months postpartum as a 
global public health recommendation. Sometimes mothers 
are unable to make enough milk for the infant feeding and 
in such a case, milk-based infant formulas might be used 
as supplement to breast milk or may also be used as substi-
tute if breastfeeding is impossible. Human milk provides 
the normative standard for infant nutrition with its unique 
composition that differs from infant formulas, although nu-
trient composition of infant formulas is generally based to 
have similar functional properties as breast milk. 
Infant formula is a product based on milk of cows or 
other animals and/or other ingredients which have been 
proven to be suitable for infant feeding. Nowadays, a wide 
variety of infant formulas are available, so its nutritional 
safety and adequacy should be scientifically demonstrated 
to support normal growth and development of infants, es-
pecially during the first 6 month of age. 
Infant formula is not officially a pharmaceutical prod-
uct, though in many cases the manufacturers are pharma-
ceutical companies. Regulatory bodies around the world 
agree that continual nutrient analysis is crucial in infant 
formulas quality control. The nutritional composition of 
all infant formulas must fulfill the global standards recom-
mended by the European Society for Paediatric Gastroen-
terology, Hepatology and Nutrition’s (ESPGHAN) interna-
tional expert group that was commissioned by The Codex 
Alimentarius Commission. These documents contain data 
about minimum and maximum values of nutrient contents 
in infant formulas with the goal to provide safe and nu-
tritionally adequate infant formula products that meet the 
nutritional requirements of healthy babies during the first 
months of life until the introduction of appropriate comple-
mentary feeding (Owens et al., 2012).
Thiamine (vitamin B1) and riboflavin (vitamin B2) are 
nutritional components present in both breast milk and in-
fant formulas which support normal infant growth. Thia-
mine pyrophosphate as biologically active form of vitamin 
B1, is a cofactor for a number of key enzymes in Krebs cy-
cle and in pentose phosphate pathway. Riboflavin is a pre-
cursor of the flavin coenzymes, flavin adenine dinucleo-
tide (FAD) and flavin mononucleotide (FMN), which par-
ticipate in oxidation–reduction reactions in many meta-
bolic pathways. As FAD is part of the respiratory chain, 
riboflavin is central to energy production. Both vitamins 
are essential for development of infant tissues, function of 
muscles, heart, nervous system and mental activity. Also 
they are involved in carbohydrates, lipid and protein me-
tabolism, red blood cell formation, respiration, antibody 
production and normal infant growth (Lalić et al., 2014; 
Sunarić et al., 2012). The levels of these vitamins in infant 
formulas are very important for term infants during the first 
6 months of life, and especially for pre-term or low birth 
weight infants.
The aim of this work was to determine thiamine and ri-
boflavin content in some infant formulas available in Ser-
bian pharmacies, as well as to define the level to which 
these infant formulas comply with the ESPGHAN recom-
mendations and with Recommended Dietary Intake (RDI) 
for infants.
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Materials and methods
Ten most commonly used standard infant formulas 
were purchased from a local pharmacy. All analyzed brands 
were initial milk-based formulas designed for infant con-
sumption during the first 6 months of life. Powdered sam-
ples were dissolved and prepared following manufactur-
er’s instructions, in order to attain vitamins concentrations 
as given on the label.
Samples preparation procedures and vitamins content 
analysis were done according to our previously published 
methods with minor modifications (Lalić et al., 2014; 
Sunarić et al., 2012). 
The percentage of compliance has been calculated 
with the mean minimum and maximum levels of vitamins 
according to ESPGHAN recommendations using the for-
mula: Composition in 100 ml infant formula/ ESPGHAN 
mean value by 100 ml × 100.
Results and discussion
Vitamins contents in analyzed samples were expressed 
as micrograms (μg) per 100 ml of prepared milk, as given 
on the label. The concentrations of thiamine and ribofla-
vin in herein examined infant formulas were in the range 
of 57.5-91.3 μg/100 ml and 106.7-224.8 μg/100 ml, re-
spectively. Also, values obtained for thiamine and ribofla-
vin content in all samples accounted for over 88.5% of the 
values declared on the product label, with good precision 
(RSD < 1.8%, n = 5).
The amounts of both vitamins in all analyzed samples 
exceeded the minimum requirements according to ESP-
GHAN recommendations (48 μg/100 ml for thiamine and 
180 μg/100 ml for riboflavin). The percentage of compli-
ance was in the range of 39.9-63.4% for vitamin B1 and 
19.8-41.6% for vitamin B2, respectively. These results 
were within the acceptable limits found in most of the lit-
erature and very similar compared to the data in other stud-
ies conducted according to ESPGHAN recommendations.
Recommended Dietary Intake for infants (0-6 months 
old) are 200 μg/day for thiamine and 300 μg/day for ribo-
flavin. Thus, assuming that the advised daily intake of 500 
ml of prepared infant formula is optimal for 0- to 6-month 
infants, all analyzed samples supply much higher lev-
els than the values established by the RDI for B1 (143.7-
228.2%) and B2 (177.8-374.6%).
Conclusion
In this work, thiamine and riboflavin content in differ-
ent infant formulas available in Serbian pharmacies was 
determined. Levels of both vitamins in all samples were 
consistent with the values declared on the products label. 
Results of this study revealed that analyzed infant formu-
las comply with the nutritional needs of infants with regard 
to vitamins B1 and B2. Their content in all samples ex-
ceeds the RDI values, so there is an excess of these nutri-
ents supplementation. Moreover, the satisfactory compli-
ance with ESPGHAN recommendations was observed so 
analyzed milk-based formulas might be used as adequate 
breast milk supplements or substitutes.
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Introduction
Intensive use of pesticides has resulted in their 
residuals being detected in all environmental segments 
and therefore raising concern about their monitoring 
throughout the world. The determination of pesticides in 
fruits and vegetables has always been an important issue 
in ensuring the quality of the products, given the fact 
that residues of pesticides in raw food could affect the 
consummator (Abbassy et al., 2014). 
Neonicotinoid insecticides, which have a high affinity 
for insect nicotinic acetylcholine receptors (Matsuda et al., 
2001) are widely used to protect against a broad range of 
pests, including aphids, whitefly, thrips and mealy bugs. 
Their physicochemical properties make them useful for 
a wide range of application techniques, including seed 
treatment, soil drench, and foliar and stem application 
(Tomlin, 2009). Because some pesticides can be applied 
to crops up to the day before harvest, the residual pesticide 
concentrations in crops immediately after harvest may 
be relatively high. Among the neonicotinoid pesticides 
commercially available, imidacloprid and acetamiprid are 
of common use in our region. 
This study focuses on the residuals of acetamiprid 
on green peppers (Capsicum annum L.) one of the most 
important vegetable crops in our country. Various methods 
for neonicotinoid insecticide residue analysis have 
been reported, demonstrating that acetamiprid could be 
analyzed by both gas and liquid chromatography (Mateu-
Sanchez et al., 2003; Navalon et al., 1997; Obana et al., 
2002). According to the recommendation issued by Food 
and Agriculture Organization of the United Nations 
(FAO)/WHO the Maximum Residual Levels (MLR) for 
acetamiprid in vegetables should not exceed 0.2 mg/kg. 
Materials and methods
The study was conducted in a ventilated and 
temperature regulated greenhouse. The surface involved 
approximately 250 m2 and was divided in three main 
sections consisting of 30 plants each: S1 – untreated plants; 
S2 – plants treated with the minimal dose of acetamiprid 
(Mospilan®) 0,02%; and S3 - treated with the maximal 
dose of acetamiprid (Mospilan®) 0,04%. Considering that 
the Pre Harvest Interval (PHI) for acetamiprid is 7 days, 
the residual levels have been measured up to 9 days after 
spraying with two different concentrations of Mospilan®. 
Sampling was conducted in compliance with the guidelines 
published by the Codex Alimentarius Commission (CCPR, 
2009).
Approximately 300 g of vegetables were chopped into 
small pieces and blended in a homogenization apparatus so 
that a fine paste is formed. A portion of 5 g was accurately 
weighted and mixed with 10 g of hard-powdered synthetic 
magnesium-silica gel (Florisil®) in a mortar. Cleanup was 
carried out using a chromatographic column. The column 
(40 cm x 20 mm) was carefully prepared placing at the end 
glass wool and a thin layer of anhydrous sodium sulphate 
(Kadenezki et al., 1992). The column was then packed by 
transferring the mixture prepared in the mortar using a 
funnel.  Extract was eluted with 50 ml of ethyl acetate and 
acetone mixture and elute was evaporated to dryness on 
rotary evaporator and reconstituted in 1ml hexane. 
The cleaned extracts were analyzed on a Shimadzu gas 
chromatograph (GC) equipped with capillary column using 
an electron capture detector (ECD) (Chandra et al., 2010). 
Analysis of acetamiprid was carried out in a 30 m length, 
0.32 mm internal diameter and 0.25 µm film thickness 
coated DB-5 column. Helium was used as the carrier 
gas at 1 ml min-1 flow. The injector was set at constant 
temperature of 260 °C and the detector temperature was 
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300 °C. The initial oven temperature was set at 170°C (1 
min isothermal) then the temperature increased with a ramp 
of 10 °C/ min till 280 °C and subsequently isothermal for 
15 minutes. The injection volume was 1µl. All the solvent 
used were HPLC grade.
Results and discussion
The compound of interest was identified by comparing 
its retention time with respect to technical grade reference 
standard. The elution time for acetamiprid under the chosen 
chromatographic conditions was 7.29 min. The quantitative 
determination was carried out with the help of a calibration 
curve drawn from chromatographic experiments with 
standard solutions.  The limit of quantification (LoQ) was 
measured by the signal to noise ratio and was 0.01 μg/ml 
(ppm). 
The method was validated. Linear calibration curve 
was found between peak areas and analyte concentration in 
the whole range of the study. The linear regression (y = a + 
bx) parameters for method calibration were taken and the 
regression coefficients (R2) was near 0.998, which allows the 
quantification of this compound by the method of external 
standardization. Accuracy and precision were calculated 
based on repeated injections (n=5) and the RSD was 0.51%. 
Recovery studies were performed to examine the efficacy 
of extraction and clean up. Untreated peppers were spiked 
with known concentration of the pure insecticide standard 
solution and extraction and cleanup were performed as 
described earlier. The recovery was 93%.   
Monitoring the degradation of acetamiprid, revealed 
that the samples treated with  the lowest dose of acetamiprid 
(0.02%) reached the MRL within seven days, whereas the 
samples treated with the highest dose (0.04%), could not 
reach the recommended MRL values for the same period 
of time. 
Conclusion
Vegetable growers have been using neonicotinoid 
pesticides frequently to have a higher and insect free yield. 
Unfortunately, overdoses of systemic pesticides sprayed on 
to the plant, fail to dissipate and do not reach the required 
MRL that are advisable by the WHO directives, constituting 
potential health risks to consumers. The pesticides residues 
can be decreased only if the recommended dose is applied 
by the vegetable. In conclusion, a further investigation 
upon PHI of acetamiprid should be conducted and the data 
would be of great benefit to cultivators in our region.  
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Introduction
Toluene (methyl-benzene) is a colorless liquid, with 
high vapor pressure and an aromatic odor, mostly used in 
paint fabrication as a solvent, fuel industry and in chemical 
synthesis. Toluene also naturally occurs in the crude oil an 
in the tolu tree (Agency for Toxic Substances and Disease 
Registry - ATSDR, 2015). The main oxidation derivatives 
of toluene include benzaldehyde, benzoic acid, cresols or 
methyl-phenols, methyl-catechols and methyl-resorcinols. 
However, among these compounds, cresols are known to 
be more toxic then the others upon exposure. Cresols or 
methyl phenols are oxidation products of toluene, consist-
ing of 3 isomers: o-cresol, m-cresol and p-cresol. Two of 
the compounds are colorless solids with low melting points 
(o-cresol and p-cresol), whereas the third one is a colorless 
thick liquid (Pubchem open chemistry database, https://
pubchem.ncbi.nlm.nih.gov/). 
Exposure to these substances often occurs by inhala-
tion of contaminated air or accidental ingestion.
Toluene induced toxicity
The main pharmacological effect, correlated with tol-
uene intoxication in humans and animals, via inhalation, 
is the depression of the central nervous system (CNS) 
(Faust, 1994).  After the uptake into the blood stream, tol-
uene crosses the blood brain barrier. In the brain, the sol-
vent interacts with CNS neurotransmitters, especially 
γ-aminobutyric acid and to a lesser degree, with glycine 
and dopamine, inducing symptoms like: euphoria, hallu-
cinations, delusions, tinnitus, dizziness, confusion, head-
ache, vertigo, seizures, ataxia, stupor, and coma (McKe-
own, 2015). Toluene also influences locomotor activity in 
rats, as shown by Apawu et al. by modulating dopamine 
levels across the striatum. The study showed that acute and 
chronic exposure to toluene increased locomotor activity 
in rats and although dopamine levels in the striatum were 
increased, dopamine uptake was not affected (Apawu et 
al., 2015).
Other toluene exposure induced effects include cardio-
toxicity, hepatotoxicity, nephrotoxicity and skeletal muscle 
damage and reproduction system impairment.
Symptoms related to the cardiovascular system in tol-
uene exposure include blood pressure and heart rate fluc-
tuations. Toluene exposed rats exhibited apoptosis in heart 
tissues mediated by increased caspase-3 activity (Tas et al., 
2013). 
Toluene is metabolized in the liver to benzoic and hip-
puric acid. The metabolism produces free oxygen radicals 
which cause liver damage through oxidative stress. A study 
by Tas et al. showed that rats exposed to toluene suffer se-
vere liver damage exhibiting: increased levels of amino-
transferase and malonylaldehyde (parameter for oxidative 
damage), balloon degeneration and fibrosis in the liver tis-
sue (Tas et al., 2011). Liver cell apoptosis is also present, 
mediated by increased activity of Bax and caspase-3 en-
zymes (Ayan et al., 2012). 
Toluene exposure affects the renal system, serum ion 
concentrations and locomotor activity. Patients exposed to 
toluene showed distal tubular renal acidosis type 1, hypo-
kalemic acidosis, increased serum alkaline phosphatase, 
muscle paralysis and proteinuria due to rhabdomyolysis 
(Camara-Lemmaroy et al., 2015). Meydan et al. showed 
that rats exposed to toluene exhibited renal tissue damage. 
Shrinkage in the glomerular tufts, differentiation in the 
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capsule, and increase in the connective tissue in the inter-
stitial area all occurred. Also increased levels of serum cre-
atinine, catalase and superoxide dismutase were observed 
(Meydan et al., 2013).
Another study by Nakai et al., reported that toluene in-
duces male reproductive dysfunctions in rats. The results 
suggested that toluene induced reproductive toxicity by di-
rect oxidative damage of the spermatozoa was related to 
the formation of 8-oxo-7,8-dihydro-2’-dezoxyguanosine in 
the male rat testicles, which is a biological marker for DNA 
oxidative damage (Nakai et al., 2002).
Cresol induced toxicity
Toxic effects of cresols due to inhalation can affect re-
spiratory functions, and produce mucosal irritation. Sys-
temic effects on humans due to inhalation are not report-
ed but there are several studies that report cardiotoxicity, 
hepatotoxicity, renal toxicity, neurotoxicity in animals ex-
posed to cresol aerosols (Agency for Toxic Substances and 
Disease Registry - ATSDR, 2008). Ingestion of cresols is 
more severe and can cause death in humans.
The most studies regarding cresol toxicity are centered 
on p-cresol (4-methylphenol). 
P-cresol induces hepatotoxicity in rats. The mecha-
nism proposed for hepatotoxicity induction involves bio-
transformation of p-cresol to a reactive quinone methide 
intermediate which covalently binds to cellular macromol-
ecules and elicits cytotoxicity (Thompson et al., 1996).  
P-cresol is also a protein-bound uremic toxin (toxins 
which accumulate in the serum in chronic renal failure pa-
tients treated with standard dialysis) (De Smet et al., 2003). 
A study by Tanaka et al. focused on the effects of p-cresol 
on 3T3-L1 cells. The results showed that p-cresol inhibit-
ed cell proliferation, adipogenesis, glucose uptake and in-
duced apoptosis in these cells (Tanaka et al., 2014). Anoth-
er effect of p-cresol is the increase in the reactive oxygen 
species production, cell cycle proliferation arrest and apop-
tosis stimulation, as stated by Chang et al. The study car-
ried on U937 cell lines also revealed an induced delayed 
effect on endothelial cell migration which can be translated 
in an increase in the time needed for wound closure (Chang 
et al., 2014).
Conclusion
Toluene and cresols are widely used in various indus-
tries. Exposure to these compounds may lead to intoxica-
tion. It is best that exposure is avoided taking in account 
that intoxication with toluene and cresols could be very 
dangerous since it can affect significant number of organs 
like the brain, heart, lungs, liver, kidneys, muscles and re-
productive glands.
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Introduction
Colostrum is a pre-milk fluid secreted by mammals 
within the first few days after giving birth. Colostrum is 
a rich natural source of more than 90 essential nutrients: 
immune and growth factors, vitamins, minerals and ami-
no acids. Bovine colostrum is milk produced during first 
few days after calving and its chemical composition is very 
similar to that found from humans. It contains high con-
centrations of immunoglobulins, cytokines, growth fac-
tors, lactoperoxidase, lactoferrin, transferrin, lysozyme, 
proline-rich polypeptides, lactalbumins and other proteins 
which play an important role for immunity and act as im-
munomodulators. Vitamins A, B1, B2, B6, B12, C, D, E, 
folic and pantothenic acid and minerals: calcium, magne-
sium, chromium, iron, zinc are also components of bovine 
colostrum (McGrath et al., 2016). 
Vitamin E is a lipid soluble vitamin responsible for a 
variety of functions in the body. The main biological func-
tion of vitamin E is as an antioxidant which protects the 
polyunsaturated fatty acids of cell membranes from free-
radical damage. Natural vitamin E includes two main 
groups of compounds: tocopherols (α, β, γ and δ) and to-
cotrienols (α, β, γ and δ). Alpha-tocopherol is the most ac-
tive, whereas the activity of the other tocopherols is 70–
95% less.
Colostrum is a natural food that has been used in tra-
ditional medicine for hundreds of years. It has many bene-
fits for resistance, strength and vitality of human body. This 
natural product is widely considered to help slow the aging 
process and assist with healing the body. Aging and disease 
are the result of losing the natural immune and growth fac-
tors. It is considered helpful in alleviating the symptoms 
of influenza and the effects of some types of allergies and 
auto-immune diseases. It helps balance blood sugar levels 
and increase mental alertness and assists with weight loss. 
Since colostrum is an important and rich source of immune 
and growth factors, it is recommended regular intake, at 
all ages (Donovan and Odle, 1994). Pharmaceutical colos-
trums are based on bovine sources and they are safe and 
effective health supplements. They are produced as pow-
der or capsules as dietary products for oral intake. Vitamin 
E is an important component of colostrum. The esterified 
form of vitamin E (tocopherol acetate) is commonly used 
in commercial pharmaceutical health supplements because 
of better stability in the products.
For the vitamin E determination purification of the 
sample is necessary in order to perform HPLC analysis, be-
cause of colostrum is very complex sample and cannot be 
directly injected into the HPLC column. The objective of 
this study was to evaluate both α-tocopherol and tocopher-
ol acetate content in commercial pharmaceutical colostrum 
product by using previously developed solid phase extrac-
tion (SPE) and HPLC method. 
Materials and methods
Standards of α-tocopherol and tocopherol acetate (TA) 
of analytical grade were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). All solvents were analytical grade 
(JT Baker, Deventer, Netherlands). Chromabond C18 ec 
cartridges, used for purification of samples, were pur-
chased from Macherey-Nagel, Düren, Germany. 
Concentrations of α-tocopherol and tocopherol acetate 
in analyzed samples were determined by calibration curve 
method. The range of the calibration curve was 0.01-0.5 
μg/mL for α-tocopherol and 0.2-2.0 μg/mL for tocopher-
ol acetate. The stock standard solutions of α-tocopherol (1 
mg/mL) and tocopherol acetate (1 mg/mL) were prepared 
by dissolving standards in absolute ethanol. The working 
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calibration solutions were freshly prepared for each run by 
diluting the stock standard with absolute ethanol.
Commercial pharmaceutical colostrum was obtained 
from local pharmacy. One of the bovine colostrum prod-
ucts, available on the Serbian market is Ekolostrum®. This 
product was made from the fresh bovine colostrum ob-
tained in the first 16 hours after calving. Ekolostrum® cap-
sule contains 480 mg high-quality 100% natural bovine co-
lostrum powder with no additives and flavouring. The con-
tent of any form of vitamin E was not exactly declared.
Sample preparation: 500 mg of powder sample from 
the capsule was weighted and dissolved in 50 mL of deion-
ized water. After complete dissolving, 1 mL of the sample 
was treated with 0.5 mL of 0.5% ascorbic acid and 5 mL of 
absolute ethanol. The mixture was vortexed vigorously for 
1 min and centrifuged at 4000 rpm for 10 min at 20 °C. Fi-
nally, supernatant was purified with solid phase extraction. 
Based on our previously extraction recovery evalua-
tion, Chromabond C18 ec column was selected among five 
different types of cartridges. Chromabond C18 ec was pre-
conditioned by passing through 1 mL of deonized water, 
followed by 1 mL of methanol and 1 mL of acetonitrile. 
Then, 3 mL of supernatant was slowly passed through the 
cartridge at a flow rate of 1 mL/min and the analyte was 
eluted with 2 x 1 mL of methanol. 
HPLC determination was achieved at 40 °C using 
RESTEK Ultra IBD column (3µm, 150x3mm) with the mo-
bile phase consisted of 100% acetonitrile and fluorescence 
detection (λex=295 nm, λem=330 nm) for α-tocopherol 
and UV detection at 220 nm for tocopherol acetate. The 
flow rate was kept at 0.45 mL/min.
Results and discussion
The analyzed samples of commercial colostrum sup-
plement had average α-tocopherol and tocopherol ace-
tate concentration of (0.2±0.01) mg/100 g and (6.5±0.3) 
mg/100 g, respectively. The content of α-tocopherol in the 
examined pharmaceutical colostrum was similar to that for 
the fresh bovine colostrum found by Kehoe et al. (2007), 
who reported that the concentration of α-tocopherol is in 
ranges from 0.06 to 1.04 mg/100 g, with a mean value of 
0.29 mg/100 g. On the other hand, the found value was 
lower than for human colostrum (1.28 mg/100 g) reported 
in our previous work.
The high content of the synthetic form of vitamin E 
(tocopherol acetate) was found in the examined sample. 
Tocopherol acetate is not naturally present neither in bo-
vine nor in human colostrum. TA is added to many pharma-
ceutical and dietary products for the fortification and en-
richment, but it needs to be hydrolyzed in gut to free to-
copherol which exerts its activity in vivo. Also, the differ-
ent vitamin E stereoisomers obtained by hydrolysis of TA 
have different biopotencies.
Conclusion
This work showed that the SPE method was success-
fully applied for the preparation of colostrum samples for 
HPLC simultaneous determination of α-tocopherol and to-
copherol acetate, which is important for the quality control 
for this type of pharmaceutical products. Examined bovine 
colostrum product contains appropriate amounts of vita-
min E, therefore it can be considered as important nutri-
tional source of vitamin E and good supplement for all gen-
erations.
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Introduction
Researches with micronutrients are getting more and 
more important in science and also in practice. In this view 
zinc, chromium, copper and selenium are having a special 
role in preventing micro- and macro vascular diabetic com-
plications, as integral components of antioxidant enzymes 
and also as cofactor of enzymes and hormones involved in 
the metabolism of glucose and lipid. Results of numerous 
studies also suggested that, because of hyperzincuria and 
low zinc absorption, diabetic patients are more susceptible 
to zinc deficiency compared to healthy persons. 
On the other side, it`s known that zinc, as divalent cat-
ion, compete with cadmium, copper, lead, iron and calci-
um for similar binding site. The physiological effects of 
zinc and several other cations such as copper and calci-
um are due to alteration in the permeability of the cellu-
lar membrane or modulation of the activity of membrane-
bound enzymes. It has been reported that zinc may sup-
press calcium effect by displacement of calcium ions from 
its cell binding sites, thus altering the membrane calcium 
pump resulting in a reduction in free intracellular calcium 
(Pathak et al., 2011). Copper deficiency might be a contrib-
utor to the glucose intolerance in diabetic patients.
There are also reports of altered metabolisms of other 
micronutrients such as copper (Cu) and iron (Fe) in diabe-
tes. Moreover, previous investigation reported that Zn de-
ficiency increases the absorption of intestinal Cu and that 
Cu significantly inhibits the influx of Zn across the intesti-
nal brush border membrane (Condomina et al., 2002). It`s 
only unknown whether Zn supplementation can normalize 
the Cu/Zn ratio. Iron is capable of generating reactive ox-
ygen species and contributes to diabetic nephropathy. Ex-
cess Fe has been implicated in the pathogenesis of diabetes 
and its complications.
In view of these facts, the aim of our study was to eval-
uate the effects of three different single doses of zinc glu-
conate on serum copper, iron and calcium levels in exper-
imentally induced diabetic rabbit and type 2 diabetic pa-
tients.
Materials and methods
The experimentally study was conducted on twenty-
four New Zealand rabbits, weighing 2 to 3.5 kg. Experi-
mental diabetes was induced in rabbits by intravenous in-
jection of alloxan (80 mg/kg BW). Two weeks after ap-
plication of alloxan, animals were subjected to 16h fast-
ing, which was determined by the concentration of glucose 
in the blood. The test includes only 14 rabbits with fast-
ing glucose between 9.99 and 14.98 mmol/L, which corre-
sponds to the degree of damage of the pancreas in patients 
with insulin-independent diabetes mellitus. Three weeks 
after induced experimental diabetes, rabbits were treated 
orally appropriate doses of zinc gluconate determinate by 
Clarc formula: first dose 5.5 mg, after the washout period 
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(10 t1/2) - second dose 9.2 mg, after the washout period 
(10 t1/2) - third dose 18.4 mg. Blood samples were taken 
at certain time intervals: before and 24h after the first, sec-
ond and third dose of zinc gluconate. 
The human study was conducted on a group of 12 pa-
tients with type 2 diabetes mellitus and a control group of 
12 healthy subjects. All participants did not take nutritional 
supplements and any drugs that are known to interfere with 
metabolism of studied metals during the period of study 
and at least 2 week before sampling. Blood samples were 
drawn after an overnight fasting in both groups, before and 
24 hour after administration of zinc gluconate in three dif-
ferent single doses (15, 25 and 50 mg) with washout peri-
od (10 t1/2) between treatments.
All the material used for zinc collection, separation 
and storage was plastic and metal free. Serum samples 
were frozen and stored at -20 ºC until the time of measure-
ment.  Determination of concentrations essential minerals 
(Zn, Cu, Fe and Ca) was performed by colorimetric meth-
od (Randox and Roche Diagnostics assays). 
Each value is expressed as the mean±SD. Differenc-
es between groups were examined using the unpaired 
Student`s t-test, differences in the group were examined 
using the paired Student`s t-test and to asses possible rela-
tionship between different variables, Pearson`s correlation 
coefficient (r) was used. 
The study protocol was approved by Ethical Commit-
tee of the University of Pristina Faculty of Medicine, in 
Kosovska Mitrovica (Serbia). All subjects gave written, in-
formed consent. The animals were handled in accordance 
with the European Community guidelines (86/609/ EEC).  
Results
Different single doses of zinc gluconate did not cause 
any significant change on copper, iron and calcium levels 
in serum of healthy rabbits. However, in diabetic rabbits 
the calcium concentration in serum was significantly de-
creased 24h after zinc gluconate administration in doses 
of 9.2 and 16.4 mg, compared with the baseline value (0h) 
marked before the treatments (p=0.041; p=0.039).
Also, different single doses of zinc gluconate did not 
cause any significant change on copper, iron and calcium 
levels in serum of healthy subjects. In patients with type 2 
diabetes mellitus were found significant decreased the se-
rum calcium concentration 24h after zinc gluconate admin-
istration in dose of 50 mg compared with the baseline val-
ue (0h) marked before the treatment (p=0.038). The Cu/
Zn ratio were significantly reduced in diabetic patients 24h 
after zinc gluconate administration in doses of 25 and 50 
mg compared with baseline values (0h) marked before the 
treatment (p=0.033; p=0.026). 
Conclusions
Based on obtained results it can be observed that ad-
ministration of zinc gluconate in single higher doses 
showed reduction of serum calcium level in type 2 diabe-
tes mellitus. Considering that zinc, as divalent cation, com-
pete with calcium for similar binding site, this could to be 
due to antagonistic effect of zinc on calcium. 
Also, the administration of zinc gluconate in single 
higher doses decreased the Cu/Zn ratio only in type 2 dia-
betic patients. These results are very significant consider-
ing that previous studies reported that an impaired Cu/Zn 
ratio in serum from diabetics could be an important factor 
in the development of micro- and macro-vascular compli-
cations in type 2 diabetes mellitus.
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Introduction
Probiotics are widely used as functional ingredients 
because they beneficially affect the host by improving its 
intestinal microbial balance. Accepted dose of live probi-
otic bacteria is required to be between 106-108 CFU per 
mL or g of the food product at the time of consumption 
(Vasiljevic and Shah, 2008). As probiotic viability is con-
sidered essential for their health benefits, viability of pro-
biotic bacteria in foods throughout their storage is a con-
stant challenge for the food industry. Dairy foods are the 
most frequently used as probiotic carriers and well accept-
ed by the consumers, while development of non-dairy ma-
trices has been encouraged due to the increasing demand 
for new probiotic products. Food matrix was found to play 
an important role in the beneficial health effects of probi-
otics on the host (Do Espírito Santo et al., 2011). Incorpo-
ration of microencapsulated probiotics is a potential strate-
gy for manufacture of both dairy and non-dairy products at 
the same time improving the functional value of the prod-
uct and ensuring protection of living cells from unfavor-
able conditions.
The aim of the present study was to examine the sur-
vival and metabolic activity of probiotic strain Lactobacil-
lus casei 01 both in dairy product (ayran) and non-dairy 
matrix (carrot juice) during storage for two weeks at 4 °C.
Materials and methods
The cell suspension of probiotic Lactobacillus casei 
01 (Chr. Hansen, Denmark) was divided into two parts: 
one part was used for microencapsulation and another was 
used as free cells for direct adding in carrot juice prepared 
by extraction of washed and peeled carrots and commer-
cially available ayran (Ayran, Zdravje Radovo, Macedo-
nia). Carrot juice samples after pasteurization at 80 °C for 
20 min was fermented using a cell concentration of 7.4±0.1 
log CFU/mL according to the recommendations for min-
imum counts of approximately 7.0 log CFU per g or mL 
of probiotic food to exert beneficial effects (Vasiljevic and 
Shah, 2008). Prebiotics fructooligosaccharides (FOS) with 
DP > 10 (Sigma-Aldrich, USA) and oligofructose-enriched 
inulin (Synergy 1) which is the mixture of oligofructose 
(DP 2-8) and long-chain inulin fraction (DP 10-60) (Orafti-
Rue L. Maréchal, Belgium) were added to carrot juice and 
ayran samples containing non-encapsulated cells, respec-
tively, at the same time with the probiotic cells. An opti-
mal formulation of microparticles containing FOS or Syn-
ergy 1 as prebiotic with high cell viability of L. casei 01 
(11.28-11.38 log CFU/g) was prepared using 4% w/w algi-
nate, 0.5% w/w chitosan and 5% w/w CaCl2 (Petreska Iva-
novska et al., 2014). An aqueous dispersion of alginate (LF 
10/60 LS, fG 35-45% Protanal, FMC Biopolymer, IMCD, 
UK), prebiotic at a level of 1.5 w/w and L. casei 01 with a 
cell load ca. 12 log CFU/mL was submitted to spray-drying 
(nozzle diameter 0.7 mm, aspirator pressure 90%, flow rate 
6 mL/min, inlet and outlet temperature, 120 °C and 60 °C; 
Büchi Mini Spray Dryer B-290, SW) followed by subse-
quent cross-linking and coating in solution of CaCl2 (Mer-
ck, Germany) and chitosan (Chitine, France) in 1% v/v 
acetic acid. The microparticles formed were cured at least 
3 h, separated and freeze-dried (-50 °C, 0.070 mbar, 24 h, 
FreeZone Freeze Dry System, Labconco, USA). Synbiot-
ic microparticles were added to the carrot juice and ayran, 
respectively, on the same day of preparation. All samples 
were packed into sterile flasks and stored at 4 °C. The via-
bility of L. casei 01 was determined on MRS agar (Merck, 
Germany) after 72 h of incubation at 37 °C using a plate-
count method. For enumeration of bacteria, 1 mL of the 
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sample was mixed with 9.0 mL of peptone water, vortexed 
for 15 s and serially diluted with peptone water. In the sam-
ples containing microparticles enumeration was done after 
removing the particles by filtration, washing with sterile 
saline solution and liquefying with phosphate buffer (pH 
6.9). The pH values of synbiotic samples were also exam-
ined (pH meter PB 11 Sartorius, Germany). The production 
of lactic and acetic acid was measured using HPLC (Agile-
nt Technologies 1200, USA) by loading supernatants of the 
pretreated samples with 0.5 M H2SO4 on a reverse phase 
column (250 mm x 4.6 mm, 5 μm, Discovery HS C 18, Su-
pelco Park, USA) set at 40 °C and eluted with 0.005 M 
H2SO4 at a flow rate of 1 mL/min with detection wave-
length of 210 nm.
Results and discussion
Encapsulated L. casei 01 added to ayran either carrot 
juice survived significantly better compared to non-encap-
sulated cells upon cold storage due to the ability of chito-
san-coated alginate particles to preserve cell viability. Rel-
atively high viable cell counts in carrot juice and ayran at 
the end of storage were observed, 9.11 and 8.22 log CFU/
mL, respectively. The viability of free and encapsulated L. 
casei 01 in ayran samples was reduced for 3.38 and 1.21 
log CFU/mL, respectively, while the corresponding cell vi-
ability loss in carrot juices was 1.49 and 0.44 log CFU/mL. 
Results have shown that both non-encapsulated and encap-
sulated L. casei 01 survived better in carrot juice compared 
to ayran. This finding may be the result of characteristics 
of probiotic strain or substrate as well as the oxygen con-
tent in the product. Acidity of the carrot juice as substrate 
was determined to be lower than ayran acidity (pH 6.25 
vs. 4.55, respectively). The mild acidity of carrot juice de-
clined to 4.23 and 5.44 after fermentation with free and en-
capsulated L. casei 01, respectively, while pH values mea-
sured in ayran samples enriched with free and encapsulat-
ed L. casei 01 were 4.54 and 4.58, respectively. The reduc-
tion of pH values was similar in both carrot juice or ayran 
samples during the storage, but ayran contains 0.4% salt 
which may contribute to further reduction of the cell via-
bility. Probiotic culture L. casei 01 produced higher quan-
tity of lactic acid in ayran samples compared to carrot juice 
samples due to the presence of lactose in dairy products. 
In ayran samples containing non-encapsulated and encap-
sulated synbiotic, the concentration of lactic acid tend to 
increase during storage from initial values of 51.32 and 
56.94 mmoL/L to 59.14 and 72.36 mmoL/L, respective-
ly. Production of acetic acid was lower, but with similar in-
creasing trend to those of lactic acid. As the result of sac-
charolytic activity of the probiotic culture able to ferment 
sugars present in the carrot juice, production of lactic and 
acetic acid was observed. Initially measured concentra-
tion of 30.53 mmoL/L lactic acid remained constant during 
the storage of the carrot juice containing non-encapsulat-
ed synbiotic, while initial concentration of 18.43 mmoL/L 
lactic acid of the sample with encapsulated synbiotic in-
creased to 31.53 mmoL/L at the end of storage. In the car-
rot juice samples both containing non-encapsulated or en-
capsulated synbiotic, the concentration of acetic acid was 
significantly lower compared to corresponding ayran sam-
ples and tend to decrease during the storage period. How-
ever, in both dairy either non-dairy product, the metabolic 
activity of L. casei 01 was better retained in samples with 
encapsulated synbiotic as lactic acid is the main product of 
lactobacilli metabolism.
Conclusion
Survival rate of the encapsulated L. casei 01 incor-
porated in carrot juice as well in ayran was found to be 
above the therapeutic level with retained metabolic cell 
activity during the investigation period. The results have 
shown higher probiotic viability in carrot juice compared 
to ayran, albeit dairy products are naturally connected with 
lactic acid bacteria. Further, synbiotic carrot juice may be 
offered to lactose intolerant individuals and to those suffer-
ing from cardiovascular diseases. Additional studies to in-
vestigate the influence of the food matrix in preserving cell 
viability under gastrointestinal conditions as well the abil-
ity of the matrix to deliver viable cells to the lower intes-
tine are required.
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Introduction
During the last couple of decades, the interest among 
the nutritionists and food industry for production of low 
alcohol and alcohol free wines has been increased. It has 
been reported that the consumption of low alcohol wines 
had a very positive effect on the consumer’s health. Thus, 
Karatzi (Karatzi et al., 2004), showed that the consump-
tion of 250 mL per day of alcohol free wine has improved 
the condition of the cardio-vascular system in patients with 
a progressive coronary disease. There are, also, literature 
data witnessing the benefit of alcohol free wine consump-
tion and its connection with lowering the high blood pres-
sure (Chiva-Blanch et al., 2012). 
In order to produce low or alcohol free wines, food in-
dustry applies several pre-fermentative, during and post-
fermentative procedures. Post-fermentative techniques are 
usually physical like pervaporation or utilization of spin-
ning cone column, but all of these processes have draw-
backs such are specific and expensive equipment and 
changes in aromatic composition (Heux et al., 2006).
Unlike post-fermentative, pre-fermentative enzymatic 
methods for lowering the alcohol level in wines are fast-
er, high specific methods that minimize loss or alteration 
of sensory qualities and off-flavor development (Schmid-
ke et al., 2012). 
In this paper the effect of glucose concentration in the 
minimal model must on the enzymatic activity of sever-
al different commercial glucose oxidase preparations was 
examined. The first one was the commercial bakery addi-
tive Alphamalt Gloxy 5080 (glucooxidase and low catalase 
activity). The second one was pure glucooxidase from the 
mould Aspergillus niger and the third preparation was cou-
pled mould glucooxidase and a beef liver catalase. The glu-
cose concentration of 10 g/L and 100 g/L were used as sug-
ar concentrations in the minimal model must. The effect of 
the enzyme activity on the final pH of the reaction media 
was also studied.
Materials and methods
Enzymatic preparations: Alphamalt Gloxy 5080 
(Muhlenchemie, Germany) was a commercial enzyme 
preparation obtained from Aspergillus niger strain. This 
was a food grade bakery additive with activity of 10500 
units per gram (U/g) and low catalase activity. 
The pure glucose oxidase (EC 1.1.3.4) was in its ly-
ophilized form and was also derived from Aspergillus ni-
ger (Merck, Germany). This preparation was with much 
lower activity than the previous one. The activity of the ly-
ophilized glucose oxidase was 8 U/mg. 
The liquid catalase (Merck, Germany) was obtained 
from beef liver and had an activity of 1300000 U/mL. 
Media: A medium with high glucose concentration of 
100 g/L was prepared. This high concentration was chosen 
to be of the same order of magnitude as the one measured 
in the real must. For comparison, the medium with low-
er concentration of glucose of 10 g/L was also used.  The 
minimal model must, besides glucose, was also containing 
4.0 g/L tartaric acid, 1.5 g/L malic acid and 0.5 g/L citric 
acid. The pH of the medium was adjusted to pH 3.5 using 
sodium hydroxide (10 M NaOH) to be similar as the pH of 
the real must.
Glucose oxidase reaction: All the three preparation 
used were diluted in the medium to give a certain concen-
tration of the enzyme preparation. The reactions were car-
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ried on an orbital shaker (Ceromat R, B. Brown Biotech In-
ternational) with agitation rate of 150 rpm (oxygen disso-
lution) in 100 mL Erlenmeyer flasks containing 50 mL of 
medium. The reaction temperature was kept 30 °C.
Determination of glucose concentration: D-glucose 
was measured using DNS method for determination of 
reduced sugars (Miller, 1959). The absorbance was mea-
sured on a spectrophotometer Cary 50 Scan (Varian) at 540 
nm wave length.
Determination of pH value: The pH value of the media 
was determined by utilization of Sartorius Basic pH Meter 
PB-11. The pH value was determined at the beginning (ini-
tial pH value) and at the end of the enzymatic reaction (fi-
nal pH value).
Results and discussion
Enzymatic reaction in the minimal model must with 10 g/L 
glucose
The effect of the lower concentration of glucose, 10 
g/L, on the enzymatic activity was evaluated by utilizing 
three different glucose oxidase preparations in the medi-
um simulating a must (minimal model must). Those were 
Alphamalt Gloxy 5080, pure glucose oxidase and the third 
one was a combination of glucose oxidase and catalase. 
The most active of all the three was the commercial Alpha-
malt Gloxy 5080 preparation, showing even 71.12% con-
version at the 24th hour of the reaction. Unlike the Alpha-
malt Gloxy 5080, the other two glucose oxidase prepara-
tions showed negligible activity towards the glucose sub-
strate used in the concentration of 10 g/L. It was, thus, ob-
vious, that not even the presence of catalase could increase 
the activity of the pure glucose oxidase, in this, not favor-
able conditions for the enzyme activity (pH 3.5).
Enzymatic reaction in the minimal model must with 100 g/L
In the second experiment, ten times higher concentra-
tion of glucose was used, as it was actually necessary to 
simulate the concentration of glucose present in the real 
must (approx. 100 g/L glucose+100 g/L fructose). None of 
the three enzymatic preparations used was active enough 
at this high concentration of glucose. However, the Alpha-
malt Gloxy 5080 showed certain activity. Namely, during 
the reaction period of 120 hours it converted only 7.37% of 
the substrate. It can be assumed that for the conversion of 
glucose into gluconic acid in media with high glucose con-
centration, at these unfavorable conditions for glucose ox-
idase activity, the acidic environment, high concentrations 
of enzyme preparation, preferably Alphamalt Gloxy 5080, 
should be used.  
The pH value of the media and its difference between 
the initial and the final value (after the reaction), is also a 
good indirect indicator of the enzymatic activity. Thus, the 
very logical results were obtained when the pH value of the 
medium containing 100 g/L was used as a minimal model 
must. Only a very slight difference in the pH value (from 
3.55 to 3.50) was measured in the medium with coupled 
glucose oxidase/ catalase enzymatic system used as a cata-
lyst. It was interesting that the Alphamalt Gloxy 5080 has 
changed the pH value of the medium from 3.50 to pH 3.00, 
and it was the most active enzymatic preparation among 
the three examined.
Conclusion
The effect of glucose concentration on the enzyme ac-
tivity was evaluated by utilization of three different enzy-
matic preparations. It was found out that the commercial 
bakery additive Alphamalt Gloxy 5080 was the most suit-
able enzymatic preparation for glucose oxidation, at as low 
pH of the medium as pH 3.5, although even this enzymatic 
preparation was not very active at the higher glucose con-
centration (100 g/L). This paper is only a part of the com-
plex research process for development of a sophisticated 
method for pre-fermentative lowering of the sugar concen-
tration in the must, with a final aim- production of low al-
cohol wine. 
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Introduction
Humans can be exposed to heavy metals through var-
ious ways, including consumption of contaminated food. 
Although heavy metals are usually present in foods at very 
low levels, long-term exposure can have negative health 
impacts. According to the Macedonian regulations for gen-
eral requirements for food safety, determination of cadmi-
um (Cd) and lead (Pb) are obligatory. It can enter food ei-
ther through environmental processes or through contami-
nation in processing and/or packaging. Therefore, it is very 
important to measure levels of Cd and Pb in a variety of 
food matrices. A major challenge in the analysis of food 
samples is the extremely low analyte levels versus the very 
high matrix levels. The most commonly used technique for 
the determination of Pb and Cd is a graphite furnace atom-
ic absorption spectroscopy (GFAAS) after microwave di-
gestion (Kenneth, 2014; Belc et al., 2014).
This article will present the use of GFAAS for the de-
termination of Pb and Cd in a variety food samples.
Materials and methods
Chemicals
All solutions were prepared in polypropylene volu-
metric flasks using ultra pure deionized water. All the plas-
tic and glassware were cleaned by soaking in dilute HNO3 
(1+9), were rinsed with distilled water and air dried before 
use. All reagents used (nitric acid 65%, hydrochloric acid 
30%, hydrogen peroxide 30%) were of Suprapure quality 
(Merck, Darmstadt, Germany).  
Lead and cadmium stock solutions, 1000 mg/L (Mer-
ck, Darmstadt, Germany) are commercially available. 
Cadmium and lead working solutions were prepared fresh 
daily by dilution of the cadmium and lead stock solutions 
with 0.5% (v/v) nitric acid.
Mixtures of palladium [(Pd(NO3)2] and magnesium ni-
trate [Mg(NO3)2x6H2O] in deionized water was used for 
Cd analysis. Ammonia phosphate [NH4H2PO4] and magne-
sium nitrate [Mg(NO3)2x6H2O] was used for Pb analysis. 
Matrix modifiers were added automatically to each blank 
and samples. 
Samples
Different samples were bought from local markets and/
or were brought to our laboratory by border health inspec-
tors: 160  cereal samples  and their products (113 wheat, 40 
wheat flour, 4 barley; 3 oat flakes); 13  piper samples; 5 on-
ion samples, 3 garlic samples; 2 cabbage samples; 2 beet-
root samples; 4 mushrooms samples and 7 potato samples.
Sample preparation
The samples were dried at 105 ˚C for 24 h. Dried 
samples were homogenized using an agate pestle and 
stored in pre cleaned polyethylene bottles until analysis.
Microwave digestion system Multiwave 3000 Anton 
Paar equipped with quartz vessels Q80, was used for sam-
ple preparation. The samples were rapidly digested in a mi-
crowave oven. Samples of 300 mg each were accurately 
weighed into the digestion vessels, followed by the addi-
tion of  nitric acid  (65%), and/or hydrochloric acid (30%) 
and/or hydrogen peroxide (30%),  all suprapure quality. A 
blank digest was carried out in the same way. Than ves-
sels were placed into the rotor and heated in the microwave 
oven, according to the temperature program recommended 
by the manufacturer. The rotor was removed from the mi-
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crowave oven and allowed to cool to room temperature. 
The vessels were carefully opened in a fume cupboard and 
the inner walls rinsed with ultra pure deionized water. The 
final volume of each sample was made up to 20 mL with. 
All sample solutions were clear.
GF AAS conditions  
All samples were analyzed using a GFAAS. The wave-
length and GFAAS instrument parameters for the determi-
nation of lead and cadmium are according to the MKC EN 
14083:2010. A Perkin Elmer A Analyst 600 was used for 
heavy metals analyses, equipped with THGA Graphite 
Furnace and  Zeeman background correction, AS-800 Au-
tosampler. Winlab 32 software for the acquisition and pro-
cessing of data was used.
Methods 
Calibrations were performed using external standards. 
The limits of detection (LOD) were calculated as triplicate, 
and the limits of quantification (LOQ) were calculated as 
six times the standard deviation of repeated measurement 
of a blank solution. 
The accuracy of the method was tested by lead and 
cadmium reference materials with certified known lead 
and cadmium content and expressed through z-scores re-
sults (-2 ≤ z ≤ 2).  Recovery checks were carried out us-
ing spikes.
Repeatability was estimated for lead and cadmium, 
based on standard deviation and relative standard devia-
tion, using the data from the QC sample analyses.
Results and discussion
Three working standard solutions were used for the 
linearity testing. Lead was calibrated at 10 µg/l, 20 µg/l 
and 30 µg/l, resulting in a calibration correlation coeffi-
cient (R2) of > 0.999. Cadmium was calibrated at 1 µg/l, 2 
µg/l and 3 µg/l, resulting in a calibration correlation coef-
ficient (R2) of > 0.999.   
The limits of detection (LOD) were 0.2 µg/l for Pb and 
0.1 µg/l for Cd. The limits of quantification (LOQ) were 
0.5 µg/l for Pb and 0.3 µg/l for Cd.  The values obtained 
matched closely with the certified values (z- score for Cd 
was 0.1 and for Pb - 0.3). The obtained results were satis-
factory, showing levels of Pb and Cd close to the allowed 
levels of concentration. The recoveries of the trace metals 
were in the range from 95% for Cd and 103% for Pb.  The 
standard deviations were less than 5%.
Lead content of almost all cereal samples is bellow 0.2 
mg/kg limit according to national regulation (Official Ga-
zette of Republic of Macedonia, 102/2013), except for the 
six samples where the concentration of lead was 0.574 mg/
kg, 0.820 mg/kg, 0.901 mg/kg, 0.721 mg/kg, 0.255 mg/kg 
and 0.385 mg/kg. These concentrations exceed the maxi-
mum allowed concentration. Cadmium content of all ce-
real samples is bellow 0.2 mg/kg according to the nation-
al regulations. 
Lead and cadmium content of all vegetables samples 
(onion, garlic, beetroot, and potato) is bellow 0.1 mg/kg 
(maximum permitted limits by national regulation).  
Lead content of piper samples is bellow 0.1 mg/kg and 
for cabbage and mushrooms is bellow 0.3 mg/kg, (maxi-
mum permitted limits by national regulation).  Cadmium 
content is bellow 0.05 mg/kg for piper and 0.2 mg/kg for 
cabbage and mushrooms.
Conclusion
The proposed method for trace heavy metal determi-
nation in food samples showed satisfactory value for re-
covery, detection limits and standard deviation. Therefore, 
it can be recommended as suitable procedure for routine 
analysis of heavy metals in variety food matrices.
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Introduction
Aflatoxins are toxic secondary metabolites produced 
mostly by Aspergillus flavus and Aspergillus parasiticus. 
Among them, aflatoxin B1 exhibits the highest toxicity and 
carcinogenetic and it can be found in many commodities 
(groundnuts, nuts, cereals and their products, dried fruits, 
herbs) (Soleimany et al., 2012). The International Agen-
cy for Research on Cancer (IARC) classified naturally oc-
curring aflatoxin B1 as carcinogenic to humans - Group 1. 
Total aflatoxin content in food is regulated by legis-
lation worldwide - Commission Regulation 466/2001, 
2174/2003 and 1881/2006.  Our country has adopted the 
EU regulations since December 2005 - 118/2005. 
Different analytical methods are used for aflatoxins 
analysis. The HPLC methods for mycotoxin analysis have 
gained more attention due to their efficiency and high sen-
sitivity, especially when fluorescence detection is used 
since it provides high selectivity, low LOQ and accurate 
analysis. Since only the aflatoxins B2 and G2 show natu-
ral fluorescence, B1 and G1 must be derivatized prior to de-
tection. This can be done photo chemically using irradia-
tion with UV light at 254 nm. The aflatoxins B1 and G1 are 
thus hydroxylated, leading to stable and measureable fluo-
rescence (Ibáñez –Vea et al., 2011; Ren et al., 2007). Very 
important aspect concerning mycotoxin analysis is sample 
preparation and clean-up procedure.  Application of immu-
noaffinity column (IAC) provides clean extracts due to the 
specificity of the antibody, applicability to complex matri-
ces, good precision, accuracy and sensitivity of analytical 
methods (Scott et al., 1997).  
The aim of this article was determination of B1 affla-
toxin and total aflatoxins in some foodstuffs collected from 
local supermarkets, using immunoaffinity column clean-
up procedure and liquid chromatography with fluorescence 
detection.
Materials and methods
Chemicals
HPLC grade reagents (methanol, acetonitril, water) 
and chemicals were purchased from Merck (Darmstadt, 
Germany).  For clean-up purification immunoaffinity col-
umns Afla-OtaCLEAN LCTech, Germany was used. Afla-
toxins mix from Supelco, with concentrations of B1 1.026 
µg/ml, B2 0.311 µg/ml, G1 1.046 µg/ml and G2 0.322 µg/ml 
were used as standards.
Samples
Many different commodities, cereal samples and their 
products (94), nuts (17), dried fruits (55), spices (33) and 
sunflowers seeds (12) were brought to our laboratory by 
border health inspectors or food operators during 2015 
year.
The samples were kept in their original packages in 
dark, dry and cool place before analyzed.
Sample preparation
The extraction and purification of aflatoxins was per-
formed according to LCTech sample extraction and clean-
up procedure. According to the matrix, the appropriate 
method was selected. For non fatty matrices e.g. wheat and 
maize, 20 g of sample was extracted with 100 ml metha-
nol: water (8:2 V/V) in a blender jar at a high speed for five 
minutes. For fatty matrices (nuts, paprika, and chilli) as 
well as for spices (black pepper, coriander, cumin, ginger), 
20 g of tested samples with addition of 2 g NaCl, was ex-
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tracted with 100 ml methanol: water (8:2 V/V) and 50 ml 
of n-hexane. The mixture was filtered through a fluted fil-
ter paper or centrifuged. The purified extract (14 ml) was 
added to an 86 ml PBS buffer (pH 7.2) and filtered again 
through 0.2 µm microfiber filter paper. 50 ml of the sec-
ond filtrate (for spices maximum 14 ml) was quantitative-
ly passed through the immunoaffinity column. The column 
was washed with 10 ml of water. Then, eluted with at 2 ml 
of methanol and measured directly by HPLC (ISO 16050, 
2012).
HPLC conditions 
HPLC analysis was performed with Agilent Technol-
ogies 1260 Series chromatographic system equipped with 
vacuum degasser G4225A, Binary Pump G1312B, Auto 
sampler G1329E, Column Compartment G1316C. Fluores-
cence Detector G1321B and UVE System for Photochem-
ical derivatization LC Tech The UVE™ (LCTech, Germa-
ny).  Post-column photochemical derivatization was used 
to increase the sensitivity of detection of Aflatoxins B1 and 
G1. Aflatoxins were separated on ZORBAX Eclipse plus 
C18 Column 4.6 x 100 mm, 3.5 µm at room temperature. The 
mobile phase was a mixture of water:acetonitril:methanol 
(63:11:26, V/V/V).  The flow rate was 1 ml/min and the in-
jection volume was 10 µl. The detection was carried out at 
and data were acquired using Agilent life Sciences Open-
LAB CDS ChemStation software.
Methods
The limit of detection (LOD) was 3:1, calculated as 
S/N. The limit of quantification (LOQ) was 10: 1, S/N. Re-
covery, as a part of method performance evaluation, was 
determined according to the method of standard addition. 
Repeatability was estimated for B1 and B2, based on stan-
dard deviation and relative standard deviation, using the 
data from the QC sample analyses.
Results and discussion
Three-point calibration curves were linear in the pro-
posed concentration range for all four aflatoxins and they 
had satisfactory coefficient of correlation (R2) in the range 
of 0.9991- 0.9996.
Limits of detection were in the range 3 - 8 µg/kg for 
all four aflatoxins and limits of quantification were in the 
range of 9 – 23 µg/kg.
The following fortified concentration levels were ap-
plied: for B1 (5.0 µg/kg), for B2 (1.5 µg/kg), for G1 (5.0 
µg/kg), for G2 (1.5 µg/kg), using an aflatoxin-free Trilo-
gy reference material. For B1 the recovery was 93.93%, for 
B2 92.14%, for G1 100.96% and for G2 the recovery was 
78.87%. 
Repeatability was 0.16% for B1 and 3.7% for B2.
Laboratory for toxicological chemistry at PHI Cen-
ter for Public Health Kumanovo took part in FAPAS Food 
Chemistry proficiency Test 04238 Aflatoxins B and G in 
Maize. Proficiency testing aims to provide an independent 
assessment of the competence of participating laboratories 
and is an essential element of laboratory quality assurance. 
The performance of the laboratory is shown with z-scores 
results (-2 ≤ z ≤ 2).  Z- scores  results for B1 was  - 0.8, for 
B2 -1.1, for G1 -0.5, for G2  -1.5 and 0.9 for total aflatoxins. 
They were statistical satisfactory.
Most of the cereals, nuts and dried fruits samples are 
below LOD. Two samples of red pepper powder had 1.486 
ng/g and 1.612 ng/g total aflatoxins, respectively, which 
was below the permitted MRL of 10.0 ng/g. Four samples 
of sunflowers seeds had 28.7 ng/g, 19.4 ng/g/ 22.6 ng/g and 
8.3 ng/g total aflatoxins, respectively.  The values exceed-
ing the maximum permissible limits of 4 ng/g set by na-
tional regulative.
Conclusion
Liquid chromatography linked to fluorescence detec-
tion (HPLC/FD) and system for photochemical derivatiza-
tion is suitable for routine analysis of aflatoxins in many 
commodities. Limits of quantification, precision, and re-
covery were satisfactory allowing it to be used also as a 
method for aflatoxins confirmatory analysis.  
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Introduction
Biochemical reactions in the body generate reactive 
oxygen species, which can damage important bio-mol-
ecules, leading to several disease conditions (Bhatt and 
Negi, 2012). Antioxidants are compounds which have the 
ability to trap the free radicals. In recent years, the interest 
in finding naturally occurring antioxidants has increased 
considerably for use in foods or medicinal materials to re-
place synthetic antioxidants, which are being restricted due 
to their carcinogenicity (Zheng and Wang, 2001). Majority 
of the antioxidants from plants are secondary metabolites 
like phenolic and flavonoids that have been reported to be 
potent free radical scavengers (Baba and Malik, 2014). 
Resistance to available antibiotics is increasing at a 
very alarming stage globally. The antibacterial activity of 
plants is continuously attracting global attention. Plants, 
as the source of medicine, have been playing an impor-
tant role in the health services around the world (Subedi et 
al., 2012). All crude extracts from plants represent a valu-
able source of antioxidant and antibacterial agents, as well 
(Hossain et al., 2014). 
Recently, there have been great efforts to find safe and 
potent natural antioxidants and antibacterial agents from 
various plant sources. Therefore, the aim of the present 
study was to evaluate the in vitro antioxidant and antibac-
terial activity of ethanol extracts of leaves of Betula pendu-
la L., Tusilago farfara L., Plantago major L., Urtica dioi-
ca L., Rosmarinus  officinalis L. and Melissa officinalis L.
Materials and methods
Dried leaves of Betula pendula L., Tusilago farfara L., 
Plantago major L., Urtica dioica L., Rosmarinus officina-
lis L. and Melissa officinalis L. were purchased from the 
botanical departments of Macedonian manufacturers.
The crude extracts were prepared by extraction of 
grounded dried leaves of plants with ethanol. The total 
phenolic content was quantified by Folin-Ciocalteu meth-
od and was expressed as Gallic acid equivalents (GAE), 
milligram’s per 1 gram of dry weight. The total flavonoids 
content was quantified by Aluminum chloride method, 
which was expressed as milligrams of quercetin equiva-
lents (QE) per gram of dry extracts.  In vitro antioxidant ac-
tivity was carried out by DPPH assay and expressed as IC50 
(Gyamfi et al., 1999). The antibacterial activity was car-
ried out by well diffusion method. This activity was quali-
tatively assessed by presence or absence of inhibition zone 
(Perez et al., 1999).
Results and discussion
The total phenolic content was ranged as fol-
lowed: Melissa officinalis L.(181.98±0.6016 GAE mg/
g)>Rosmarinus officinalis L. (179.03±0.4171 GAE mg/
g)>Tusilago farfara L.(169.59±0.5840 GAE mg/g)>Betula 
pendula L. (169.12±0.0834 GAE mg/g)>Plantago ma-
jor L. (128.9±0.8343 GAE mg/g)>Urtica dioica L. 
(70.71±0.6516 GAE mg/g). The total flavonoid con-
tent was 154.52±2.5534 QE mg/g, 115.13±0.1178 QE 
mg/g,142.3±5.0675 QE mg/g, 58.47±0.6123 QE mg/g, 
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75.97±0.4249 QE mg/g and 25.63±1.0606 QE mg/g, re-
spectively. Ranking based on the antioxidant activity 
was: Melissa officinalis L. (2.6 µg/ml)>Rosmarinus offi-
cinalis L. (78.58 µg/ml)>Tusilago farfara L. (140.9 µg/
ml)>Betula pendula L. (244.45 µg/ml)>Plantago major L. 
(295.9 µg/ml)>Urtica dioica L. (458.7 µg/ml).
Sensitivity of test strains, in decreasing order, was as 
follows: Pseudomonas aeruginosa ATCC 9027>Entero-
coccus faecalis ATCC 19433>Escherichia coli   ATCC 
25922 >Escherichia coli   ATCC 8739 >Klebsiella pneu-
moniae  ATCC 700603>Staphylococcus aureus  ATCC 
25923.
Melissa officinalis L. showed the highest total pheno-
lic and flavonoids content and the strongest DPPH radical 
scavenging activity, followed by Rosmarinus officinalis L. 
and Tusilago farfara L. It  is known that phenolic com-
pounds in plant extracts contribute significantly to their an-
tioxidant potential because of their unique structure (Bhatt 
and Negi, 2012). Betula pendula L. showed moderate anti-
oxidant properties beside the high phenolic content. Plan-
tago major L. showed moderate antioxidant properties. 
Urtica dioica L. showed the lowest total phenolic and fla-
vonoids content and the weakest DPPH radical scaveng-
ing activity.
According to the results of antimicrobial screening, 
Rosmarinus officinalis L. showed strong antibacterial ac-
tivity against all six bacterial stains. Tusilago farfara L., 
showed strong antibacterial activity towards the investigat-
ed bacteria except the weak antibacterial activity against 
Escherichia coli   ATCC 8739 and Klebsiella pneumoniae 
ATCC 700603. Betula pendula L. has been shown to pos-
sess the strongest antimicrobial activities against Entero-
coccus faecalis ATCC 19433 and Pseudomonus aerugino-
sa ATCC 9027. Plantago major L. and Urtica dioica L. ex-
hibited strong antimicrobial activity towards Pseudomonas 
aeruginosa ATCC 9027, weak activity against Escherichia 
coli ATCC 8739 and Klebsiella pneumonia ATCC 700603. 
Melissa officinalis L. shows moderate antibacterial activi-
ty against gram (+) bacteria and very weak or no activity 
against gram (-) bacteria.
Conclusion
The results indicated that all of the plant extracts test-
ed in this study could be considered promising antioxidant 
sources and great potential as antibacterial compounds 
against gram-positive and gram-negative bacteria.
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Introduction
During the intensive research in past decades, the sci-
entific community and regulatory agencies also, focused 
their interest on measuring contaminant levels in tissues 
and environmental samples and on understanding the 
mechanisms of toxicity of different and pervasive contam-
inants. Among them, metals were always in focus because 
of possible detrimental and long lasting effects on living 
organisms (Gjorgieva et al., 2011; Stafilov et al., 2010). 
DNA damage and genotoxic stress are important param-
eters that are followed in a case of chemicals exposition 
as an indication of carcinogenicity (Aydin et al., 2015; 
Kekec et al., 2010; Villatoro-Pulido et al., 2013). Plants are 
unique systems in their ability to serve as in situ monitors 
for environmental genotoxins. Molecular assays related to 
DNA-based techniques, like Random Amplified Polymor-
phic DNA (RAPD), are very sensitive method of screening 
for nucleotide sequence polymorphisms that are random-
ly distributed throughout the investigated genome (Gjor-
gieva et al., 2012). 
The current study was designed to assess the effects of 
long term, high metal exposition (cadmium, lead, copper, 
nickel and zinc) on DNA damage. 
Materials and methods
Four different plants [Taraxacum officinale (Astera-
ceae), Matricaria recutita L. (Asteraceae), Robinia pseu-
doacacia L. (Fabaceae), and Urtica dioica (Urticaceae)] 
were chosen as model systems for genotoxicity assessment 
in a case of metal stressors. Plant samples were collected 
from two different areas, metal polluted (area around city 
of Veles, known for its lead and zinc industrial activity in 
the nearest past) and referent area (without metal exposi-
tion, Plačkovica Mountain). Element analysis (analyzed by 
Inductively Coupled Plasma – Atomic Emission Spectrom-
eter (ICP-AES)), DNA extraction (frozen plant samples 
were used for DNA isolation by using REDExtract-N-Amp 
Plant PCR Kit (Sigma-Aldrich)) and RAPD-PCR analysis 
were performed with samples included in this study. Am-
plifications were performed in a DNA thermo cycler ac-
cording to protocol of Enan, 2006. Seven different primers 
(with 60-70% GC content) were used. Sequences (5’→3’) 
from Primer 1 to 7 were: Primer 1 - GGTGCGGGAA; 
Primer 2 – GTTTCGCTCC; Primer 3 – GTAGACCCGT; 
Primer 4 – AAGAGCCCGT; Primer 5 – AACGCGCAAC; 
Primer 6 – CCCGTCAGCA; Primer 7 - GGCACTGAGG. 
All amplifications were repeated twice in order to confirm 
the reproducible amplification of scored fragments. Only 
reproducible and clear bands were scored for the construc-
tion of the data matrix.
Results and discussion
RAPD technique was used to quantify DNA sequence 
changes. Agarose-gel electrophoresis of extracted DNA 
from all samples, revealed total of 37 bands with different 
molecular weights ranging from 1250 to 5000 bp. It gener-
ated distinctive polymorphism value of 72.97% (27 bands) 
total in four plant species investigated. Polymorphism in 
the RAPD profiles is scored as the presence or absence 
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of DNA bands in comparison to the control. The numer-
ical analysis based on the banding pattern obtained from 
the samples exposed to metals was compared with that of 
the control sample via hierarchical cluster analysis. RAPD 
profiles generated by samples exposed to metals were dif-
ferent from those obtained using control DNA. Samples 
which were close to the pollution source (high metal-expo-
sition area) showed considerable polymorphism. The diag-
nostic analysis (considering band intensity differences or 
the disappearance and/or appearance of RAPD bands) and 
the phenetic numerical analysis are important parameters 
in the RAPD method (Bhaduri and Fulekar, 2015; Gjor-
gieva et al., 2012; Zhiyi and Haowen, 2004). Amplifica-
tion with primer 1 and primer 2 yielded not enough signif-
icant polymorphism, so we find that this primer sequenc-
es are not suitable for fingerprinting genome of this four 
plant species. When amplification is performed with prim-
er 3 and 5, the highest number of new bands is obtained 
(9 and 8 bands, respectively), with exception of primer 5 
for T. officinale, where probably there is no suitable se-
quence in the genome of this plant for annealing of above 
mentioned primer. The dendrogram constructed using NT-
SYSpc programme (Rohlf, 1994) is statistical presenta-
tion of the obtained date and showed that there is group-
ing in separate clusters of the same plant species collect-
ed from two different areas, according to modifications in 
the RAPD “fingerprints” following metal exposure. In ac-
cordance with literature data that considered concentration 
of 40 mg L-1 of lead and 30 mg L-1 of cadmium (Aydin 
et al., 2013; Aydin et al., 2015) as the point of maximum 
appearance and disappearance of new bands in RAPD as-
say, we assume that high metal content in all samples from 
Veles area, determined in present study, was directly in-
volved in DNA damage detected which can lead to initia-
tion of mutations.
Conclusion
RAPD assay is a valuable tool to evaluate the effects 
of toxicants on organisms under optimized conditions and 
for genotoxicity studies. RAPD markers can be used as di-
agnostic markers. In this regard, induction of DNA band 
changes with one kind of a stressor (found in areas with 
metal pollution) might provide evidence of its genotoxic 
potential. 
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Background
Despite the public awareness and technological ad-
vancement in early cancer detection as well as the discov-
ery of many novel therapeutic treatments, cancer takes 
away many lives worldwide each year. The limited ther-
apeutic effects of the traditional treatments and their nu-
merous side effects which compromise patients’ compli-
ance, urge the need for development of new medicinal an-
ticancer agents. Therefore, numerous new research studies 
have been directed towards development of more specific 
targeted therapy.
The most common reason for mortality among cancer 
patients is the tumor progression and formation of metasta-
sis within organs distant to the location of the primary tu-
mor. The purpose of this paper is to review the most rele-
vant biomolecular factors that enable the metastatic pro-
cess, and their potential for employment as targets for fu-
ture development of new therapeutic anticancer agents. 
Angiogenesis
The access to the host’s vascular system and the de-
velopment of a blood network around and within the tu-
mor, a process known as angiogenesis, is of crucial impor-
tance for tumor’s supply with oxygen and nutritional sub-
stances and subsequent increase of the tumor mass, inva-
sion and cancer dissemination. A lot of experimental and 
clinical data evidence that tumors can’t grow beyond a di-
ameter of 2-3 mm until the blood network is created, i.e. 
they can’t progress until they acquire angiogenic ability. 
Hence, it has been proposed that the inhibition of angio-
genesis could suppress the tumor’s growth and its targeting 
has an important clinical validity for development of new 
approaches for cancer treatment.
The vascular endothelial growth factor (VEGF) 
and its receptor vascular endothelial growth factor 
receptor(VEGFR) have major roles in the process of an-
giogenesis and they can often be overexpressed in tumor-
ous cells. Having in regard the role of VEGF as a potent 
angiogenic factor, many therapeutic strategies that target 
the angiogenesis via inhibition of VEGF signal pathway 
have been developed. These therapeutic strategies include 
use of: small molecule tyrosine kinase inhibitors of VEGF 
receptors, neutralizing monoclonal antibodies against 
VEGF or its receptor, soluble VEGF receptors which act 
as VEGF traps and ribozymes which specifically target 
VEGF mRNA (Cardones and Banez, 2006).
Other important biochemical mediators are the fibro-
blast growth factors (FGFs), which belong to the family of 
heparin binding proteins. The fibroblast growth factors and 
their receptors participate in the proliferation and migra-
tion of endothelial cells, production of proteases and an-
giogenesis. Recent studies show that FGFs synergize with 
VEGF during neovascularization and that FGFs could be 
involved in the mechanism for resistance towards anti-
VEGF agents. Therefore, the new plausible therapeutic ap-
proaches are focused either on the combined or the con-
secutive inhibition of these two crucial angiogenetic signal 
pathways (Lieu et al., 2011).
Angiopoietins are growth factors that also participate 
in the formation of blood vessels in several tumor types. 
Angiopoietin-1 and -2 are the best characterized cyto-
kines which accomplish their biological function by bind-
ing to the Tie-2 receptor. Angiopoietin-1 enables survival 
of endothelial cells, formation and stabilization of the vas-
cular network. On the other hand, the positive regulation 
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of angiopoietin-2 disrupts the interaction between angio-
poietin-1 with its receptor leading to destabilization of the 
blood vessels and subsequent enabling of VEGF-inducted 
angiogenesis. Because of this, the targeting of angiopoet-
in-2 has a promising potential for cancer treatment. A nov-
el therapeutic strategy involves development of agents that 
target the angiopoietin/Tie-2 signaling pathway. The first 
such agent which has reached advanced stages of clinical 
trials is AMG-386. AMG-386 is an anti-angiopoietin pepti-
body which inhibits the interaction between the ligands an-
giopoietin-1 and angiopoietin-2 with Tie-2 receptor (Neal 
and Wakelee, 2010).
Cell detachment and extracellular matrix 
degradation
Apart from its relation to the angiogenesis, the acquisi-
tion of metastatic potential is also related to the detachment 
of the malignant cell from the primary tumor and degrada-
tion of proteins which comprise the surrounding extracel-
lular matrix (ECM). The loss of cell-cell adhesion capacity 
enables the malignant cells to dissociate from the primary 
tumor, while the changes in the cell-matrix interaction en-
able the cells to invade the surrounding stroma and dissem-
inate. The most important adhesive molecules which have 
been considered as potential therapeutic anticancer targets 
are E-cadherin and integrin. 
E-cadherin is type-1 transmembrane protein that me-
diates the cell-cell interaction. The reduced expression of 
E-cadherin is associated with an increase of the metastatic 
potential. One of the possible approaches for reduction of 
the invasive capacity of cancer cells implies enhancement 
of the inter-cell adhesive capacity through overexpression 
of E-cadherin.
The integrins are surface receptors which mediate the 
cell-ECM interaction. The integrin’s role in the metasta-
sis of malignant cells, their localization on the cell’s sur-
face and sensitivity to a pharmacological blockade, makes 
them attractive for pharmacological targeting. Small mol-
ecule integrin antagonists, including the αvβ3 and αvβ5 
inhibitor Cilengitide, have shown encouraging activity in 
controlling cell proliferation and metastasis. Beside from 
the small molecule antagonists, monoclonal antibodies 
against integrins, such as CNTO95, etaracizumab (MEDI-
522), and volociximab are being subjected to clinical trials 
(Xiangming, 2015).
ECM is composed of a thick network of proteins such 
as collagen and fibronectin. It must be invaded by the inva-
sive cancer to enable itself space for migration. The most 
important proteolytic enzymes are the matrix metallopro-
teinases (MMPs) which belong to the group of zinc-depen-
dent endopeptidases. These enzymes have an important 
role in tumor invasion, metastasis, and angiogenesis and 
are considered the major mediators of changes in the new 
microenvironment at the time of progression of the can-
cer. As such, they are an attractive target for its treatment.
The Epithelial-mesenchymal transition pathway is a 
dynamic process that enables the polarized epithelial cells 
to lose the epithelial differentiation and acquire mesenchy-
mal phenotype via numerous biochemical and morpho-
logical changes. Thus, they gain higher migratory ability 
and Felicity’s group suggests the Epithelial-mesenchymal 
transition pathway as promising target for development of 
therapeutic agents for prevention of tumor dissemination 
and metastasis (Felicity et al., 2014).
Conclusion
Understanding the biomolecular mechanisms under-
lying the process of malignant progression and identifica-
tion of the factors involved in this process should enable 
new therapeutic agents that would target the key molecu-
lar pathways of cancer growth and dissemination to be de-
veloped in future. In that way, selective action, higher effi-
ciency and minimization of side effects of anticancer drugs 
would be accomplished.
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Introduction
The term cancer is broadly used to describe over a hun-
dred malignant diseases in the human population. The inci-
dence and prevalence of cancer are constantly increasing. 
It is presumed that by 2030 the annual number of newly di-
agnosed cases will reach 23 600 000 which is an increase 
of 68% compared to the reported cases in 2012 (Bray et 
al., 2012). This fact points out the expansive tendency of 
cancer worldwide and emphasizes the need for dedicating 
higher attention both to prevention and treatment of this 
disease. 
The traditional methods for cancer treatment have lim-
ited efficiency and high toxicity, exerting inevitable ag-
gressiveness towards healthy tissues. Hence, medical prac-
titioners and scientists are faced with the need for consider-
ing the options of targeted action of the therapeutic agents 
and for focusing further research efforts on their develop-
ment. The targeted therapy would be directed towards nor-
malization of what is changed or cessation of some of the 
active cascades that initiate tumor development. There are 
already established molecular targets which can contribute 
to the inhibition of tumor’s growth and restoration of nor-
mal functions. The aim of this study is to review current-
ly available data on the biomolecular processes involved 
in the early steps of cancer initiation and the possibility of 
their use as therapeutic targets in order to achieve maximal 
efficacy and minimal toxicity of the anticancer treatments.
Cyclin and cyclin dependent kinases
Cyclin and cyclin dependent kinases (CK/CDK) are 
responsible for the normal function and control over the 
cell cycle. They are check-up points which control the pos-
sible irregularities during the cell cycle. It is known that, 
in certain tumors, the levels of CK/CDK are constitutive-
ly increased, continuously encouraging the cell cycle and 
the creation of new cells. As such, CK/CDK are serious 
target candidates towards which new therapeutic agents 
can be directed in order to reduce their expression and nor-
malize the cell division. Studies have been done on cyclin 
E which is important for controlling the cell cycle in G1 
phase and its activation is important for postponing the ma-
lignant processes. It is believed that the new medicaments 
should act at the level of inhibiting distinct phases of the 
cell cycle. Recently, several preclinical and phase I/II clin-
ical studies have been conducted using a novel, reversible 
CDK4/6 inhibitor named Palbociclib. It was shown that 
Palbociclib has the role of CDK4/6 as a potential target 
in estrogen receptor-positive (ER+) breast cancers (Finn et 
al., 2016).
Oncogenes and tumor suppressor genes
The activation of oncogenes and inactivation of tumor 
suppressive genes have an important role in the process of 
malignant cell transformation. One of the cancer treatment 
modalities has the opposite goal. The suppression of the 
RAS-pathway is a significant target regarding the mech-
anism of oncogene inactivation. This can be achieved by 
several mechanisms. One of them is disabling the bind-
ing of the Epidermal Growth Factor (EGF) to its receptor 
(EGFR), so that the dimerization of the intercellular part of 
the receptor, which associates with the adapter protein Son 
of Sevenless (SoS) and the receptor of the growth-binding 
protein 2 (Grb-2), is prevented. It is very important to at-
tain this blockade, as the SoS-Grb-2 complex directly ac-
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tivates the RAS-oncogene. RAS-induces intracellular cas-
cade of kinases for promotion of proliferation. On the other 
hand, with activation of the RAS-oncogene, an activation 
of RAF-oncogene happens, which encourages RAF-Mito-
gen-activated protein kinases and direct signals are sent to 
the core for starting cell division. The function of the RAS-
oncogene is related to the proliferation, genetic expression, 
differentiation, emphasizing the cell survival and apopto-
sis.  Because of the fact that RAF-MEK-ERK cascade is 
very complex and it is difficult to find RAF and MEK in-
hibitors or inhibitors for RAS genes, the new strategies for 
inhibition of the RAS-oncogene are directed towards mu-
tations of RNA and RAS-oncogene (Baines et al., 2011).
A significant representative of the group of tyrosine 
kinases is the BCR-ABL oncogene. This oncogene is re-
lated to the Philadelphia chromosome-positive leukemia. 
The kinase activity of BCR-ABL is the primary factor for 
stimulation of myeloid cells proliferation. As such, BCR-
ABL oncogene is considered as a potential target, during 
treatment of chronically myeloid leukemia, for Imatinib, 
which inhibits both the ABL and BCR-ABL tyrosine kinas-
es. However it was discovered that in some patients, white 
blood cells become resistant to Imatinib. One  newer ap-
proach presents  BMS-354825  developed by Bristol-My-
ers Squibb, that binds to the active form of ABL and over-
comes 14 of 15 Imatinib-resistant mutants (Scholar et al., 
2005)
When it comes to the tumor suppressive genes, a meth-
od should be developed for their activation in order to de-
lay cell’s growth and proliferation and to re-establish the 
processes of DNA reparation and apoptosis. The most 
studied gene is p53 which is also most frequently inacti-
vated in cancer processes. Research directed towards new 
targets should take into consideration the suppression, the 
possible induction of p53 in normal, healthy cells, as well 
as the fact that increased levels of MDM2 are expected. 
The increased levels of MDM2 arise from the activation of 
p53 with its potential target and are expected to cause sup-
pression of p53 as negative regulator (Wang et al., 2010).
Apoptosis
Apoptosis is a genetically controlled form of cell death 
with a huge importance for physiological tissue remodel-
ing during embryogenesis and maintaining homeostasis 
later in cell’s life. The process of apoptosis is regulated via 
extrinsic and intrinsic pathways. The extrinsic pathways 
are activated through cell surface receptors such as the tu-
mor-necrosis factor receptor (TNFR), death  receptors and 
the CD95/FAS/APO1 receptor. The intrinsic pathways are 
activated through intracellular stimuli caused by cytotoxic 
medicaments, hypoxia, DNA damage. These paths are es-
pecially interesting for investigation as potential targets for 
anti-cancer agents. One of the possible targets are Smac 
peptidomimetics which act as mimetic agents but the poor 
pharmacokinetic properties prevents their clinical applica-
tion (Elsayed et al., 2015).
Conclusion
The above mentioned pathways involved in initia-
tion and development of malignant neoplasm, as well as 
those which are to be identified in future, will have a sig-
nificant contribution in the development of a suitable ther-
apy for this disease, by specifically and selectively target-
ing malignant cells and aberrant signaling pathways with-
out harming the physiologically healthy cell processes. 
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Introduction
The infection with the bacterium Helicobacter pylo-
ri (H. pylori) is one of the major causative factors for the 
development of gastric cancer. The presence of H. pylori 
bacteria in the human gastrointestinal tract is determined 
by different invasive and noninvasive diagnostic methods. 
The invasive  strategies are based on endoscopy which can 
be complemented by histology, urease test or tissue cul-
ture to detect bacteria. Non-invasive tests include: anti-
body tests (using serum, saliva or whole blood samples) 
which do not directly detect the presence of H. pylori but 
rather the presence of an immune response to H. pylo-
ri in the form of antibodies. These antibodies may persist 
even after successful eradication. The antigen tests are per-
formed on stool, saliva or urine samples, current interest 
focuses mainly on the stool antigen test for the detection of 
H. pylori antigens by an enzyme immunoassay technique. 
One of the recent advances regarding methodological ap-
proaches for diagnosis and monitoring of patients with sus-
pected gastric infection with  H. pylori is the urease test 
also termed urea breath test. 
The aim of this paper is to provide an up-to-date com-
prehensive review on the urea breath test as a noninva-
sive method, its application and expansive usage for ear-
ly detection of infections caused by the H. pylori bacteria, 
as well as prevention of other progressive illnesses by en-
abling prompt eradication of the infection.
Studies on the urea breath test
The urea breath test is an accurate, practical and read-
ily available test which becomes known as a golden stan-
dard when compared to other tests for identification and 
quantification of H. pylori. Being both specific and sensi-
tive, the urea breath test is based on testing the expired air 
samples collected before and after ingestion of urea con-
taining specifically labeled carbon. H. pylori bacteria pro-
duce an enzyme called urease that converts urea into car-
bon dioxide and ammonia. The carbon dioxide is excreted 
with the expired air from the lungs and the amount of the 
labeled carbon dioxide can be measured in the expired air 
sample, in order to determine the presence of the active H. 
pylori infection in the stomach and the level of the infec-
tion. In order to postpone stomach draining during the ex-
amination, a citric acid solution is consumed prior to the 
test. The lemon acid induces imminent relaxation of the 
gastric fundus as well as inhibition of the antral motility 
through biliary reflux. It has been reported that best results 
can be obtained with expired air samples collected within 
10-15 minutes after the urea is consumed (Berger, 2002). 
The collected samples of expired air can be easily stored 
for a couple of days at different temperatures.
A substantial number of research projects have studied 
the influence of several factors on the sensitivity and accu-
racy of the test. The first studies were focused on the label-
ing of the urea used in the breath test.Generally, two meth-
ods are being used for labeling the urea-carbon, the first 
one uses a steady and heavy isotope 13C while the other one 
uses radioactive isotope 14C (Berger, 2002). It is also possi-
ble to label the urea with both 13C and14C but this approach 
has relative strengths and flows. The radioactive 14C urea 
breath test can be performed only in hospitals that have nu-
clear wards and for some patients a few attempts might 
be needed in order to produce sufficient amounts of CO2 
to change the color of the solution. On the contrary, 13C 
urea breath test can be used in non-nuclear laboratory set-
tings and the samples can be sent for mass spectrometry 
analysis elsewhere which is a great advantage in compari-
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son with the radioactive 14C urea breath test. Furthermore, 
the small amount of expired air which is needed for analy-
sis,  makes13C urea breath test ideal for usage (Desroches, 
2001).  Even though the dose of 14C used in the urease test 
is very low, it is contraindicated for application in preg-
nant women and small children.On the contrary, 13C – urea 
breath test can be used for the above mentioned groups of 
patients and is especially useful for testing the pediatric 
population (Jones et al., 2005).
The hydrolysis of the 13C – labeled urea by H. pylori 
urease in the stomach produces13C02 which is then trans-
ported to the lungs, whereby 13C in the expired air is re-
vealed by the usage of special equipment. Currently sever-
al types of equipment are suggested for evaluation of the 
13C expired in air samples: Mass Spectrometry – Isotope 
Relationship (MSIR), non – dispersive isotope – selective 
IR spectroscopy (NDIRS) and laser analyzer equipment 
(LAE) (Parente et al., 2001).
The influence of the amount of consumed urea on the 
accuracy of the urea breath tests has been extensively stud-
ied and debated. The oldest tests were performed with 
350 mg of urea, later the dose was decreased to 125 mg 
or 100mg and all tests turned out to be successful.Recent-
ly, it was  suggested that 75 mg of urea might be sufficient 
for obtaining reliable results, but  later on, it has been con-
firmed that an urea dose as low as 50 mg can be used for 
obtaining more precise urea breath test results.
Urease – producing oropharyngeal bacteria can cause 
falsely positive results of the urea breath test. This problem 
has been solved by encapsulating the urea for its oral ad-
ministration. Considering the advantages, the development 
of a capsular formulation with 13C urea is an outstanding 
progress and the most appreciated system for labeled urea 
delivery. A 50 mg capsule with 13C urea for detection of H. 
pylori in expired air manifests high sensitivity and distinc-
tiveness in clinical conditions (Mattar et al., 2014). 
Several types of drug treatments are associated with 
falsely-negative results when using urea breath test. There-
fore, antibiotics, bismuth concoctions and proton pump in-
hibitors should not be taken within one month prior to the 
urea breath testing. Also, according to some studies H2– 
antagonists cause falsely-negative results if administered 
in high doses. This should be taken into consideration, es-
pecially because patients are frequently treated with H2– 
antagonists before urea breath test is performed.
Conclusions
The UBT is based on the simple principle that a solu-
tion of isotopically labelled urea is rapidly hydrolyzed by 
the abundantly expressed urease of H. pylori. The UBT is 
a non-invasive, simple and safe test, providing excellent 
accuracy both for the initial diagnosis of H. pylori infec-
tion, confirmation of its eradication after treatment and pa-
tients’ follow-up. 
Although definitive standardization of the protocol for 
UBT isn’t currently available, several recommendations 
could be suggested. It seems prudent to perform UBT in 
fasting conditions until new data definitively clarify this 
issue. Citric acid should be used as a test meal, amounts 
of 75 mg or even 50 mg of urea seem to be sufficient to 
perform highly accurate UBT. The test can be carried out 
by different types of equipment, such as IRMS, NDIRS or 
LAE with recommendation to collect and test two breath 
samples, one collected before and another collected 10–
30 min after urea ingestion. Further studies should be per-
formed to justify the cost-benefit ratio for routine applica-
tion of this method in the biochemical laboratories.
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Introduction
Ochratoxin A (OTA) is the most common mycotox-
in that can affect human health. The International Agen-
cy for Research on cancer (IARC) classifies it as possi-
bly carcinogenic to humans (group 2B). This mycotoxin is 
produced by toxigenic Aspergillus and Penicillium species 
(Pfohl-Leszkowicz et al., 2007). OTA has been extensive-
ly documented as a contaminant of a wide variety of foods 
including cereals, green coffee, spices, nuts, dried fruits, 
beer, wine, grapes, and grape juice (Bellí et al., 2005). The 
target organ of OTA is the kidney. However, it has a wide 
range of other toxic effects, including hepatotoxicity, im-
munotoxicity, teratogenicity and neuorotoxicity (Pfohl-
Leszkowicz et al., 2007; Sava et al., 2006). 
Many countries and international organizations have 
regulated the OTA content in several commodities. The 
European Commission (EC) has enforced the limits of 
OTA in cereals and cereal products with the following lev-
els: 5.0 ng/g for raw cereals grains, 3.0 ng/g for cereals and 
cereal products intended for human consumption, 0.5 ng/g 
for baby food and cereal- based food intended for young 
children.  For the dried vine fruits, soluble coffee and some 
dried fruits, the EC has set a maximal permissible limit for 
Ochratoxin A at 10.0 ng/g. Liquid chromatography linked 
to fluorescence detection (HPLC/FD) was extensively used 
for OTA confirmatory analysis (Ghali et al., 2009). 
The aim of this article was to determine concentration 
of OTA in some foodstuffs collected from supermarkets by 
liquid chromatography.
Materials and methods
Chemicals 
HPLC grade reagents (methanol, acetonitril, glacial 
acetic acid) and chemicals were purchased from Merck 
(Darmstadt, Germany). For clean-up purification immuno-
affinity columns Ochraprep (R-Biopharm Rhone, Glasgow, 
Scotland), were used. Ochratoxin A Trylogy, with concen-
trations of 10.0 µg/ml in methanol was used as a standard.
Commercially available Ochratoxin A, with concen-
trations of 10.0 µg/ml in methanol, was used as a stock 
solution.  Ochratoxin A spiking solution contains 2.5 µg/
ml Ochratoxin A and Ochratoxin A standard solution (0.25 
µg/ml Ochratoxin A).  Ochratoxin A working solutions, in 
concentration ranging from 2.0 ng/ml to 10.0 ng/ml, were 
prepared by serial dilution of the standard solution.
Samples
During 2015 year, 57 dried fruits samples including 
raisins (8), figs (8), dates (5), apricots (5), plumes (10), 
cranberries (3), cherries (3), pineapples (3), strawberries 
(2), goji (1), and papaya (1) were randomly collected from 
local supermarkets. Samples were stored in plastic bags at 
-200C until the analysis.
Sample preparation
To ensure homogeneity before analysis, laboratory 
samples are normally slurred with water in the ratio of five 
parts fruit to four parts water, and test materials in this form 
were used.  
A test portion, 45 g of fruit slurry, is extracted with a 
mixture of 50 ml methanol and 5 ml phosphoric acid solu-
tion 0.1 mol/L. The extract is filtered, diluted with phos-
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phate buffered saline, and applied into an immunoaffini-
ty column containing antibodies specific for Ochratoxin A. 
The Ochratoxin A is isolated, purified and concentrated on 
the column and then released with elution solvent. Ochra-
toxin A is quantified by reverse-phase high performance 
liquid chromatography (HPLC) with fluorescence detec-
tion (MKC EN 15829:2011). 
HPLC conditions
HPLC analysis was performed with Agilent Technol-
ogies 1260 Series chromatographic system equipped with 
vacuum degasser G4225A, Binary Pump G1312B, Auto 
sampler G1329E, Column Compartment G1316C and Flu-
orescence Detector G1321B.  Ochratoxin A was separated 
on ZORBAX Eclipse Plus C18 Column 4.6 x 100 mm, 3.5 
µm at room temperature. The mobile phase was a mixture 
of water:acetonitril:glacial acetic acid (99:99:2, V/V/V). 
The flow rate was 1 ml/min and the injection volume was 
10 µl. Total running time was four minutes. The detection 
was carried out at   and   Data were acquired using Agile-
nt life Sciences Open LAB CDS ChemStation software.
Results and discussion
The described analytical methods effectively separated 
the Ochratoxin A of all analyzed products.  It was observed 
that under these optimized chromatographic conditions, 
Ochratotoxin A eluted in less than 5 minutes. The retention 
time was 3.131 minutes. The calibration curve was set in 
the range from 2.0 to 10.0 ng/ml using four-point calibra-
tion curve. The regression equation was y=0.02198191x 
+0.0013271 with R2 - 0.99988. The accuracy was 4.7%. 
The limit of quantification was 1 ng/g. The mean recovery 
for Ochratoxin A was 86.4%. 
Laboratory for toxicological chemistry at PHI Cen-
ter for Public Health Kumanovo took part in FAPAS Food 
Chemistry proficiency Test 17150 Ochratoxin A in dried 
Vine Fruit. Proficiency testing aims to provide an indepen-
dent assessment of the competence of participating labora-
tories and it is an essential element of laboratory quality as-
surance. The performance of the laboratory is shown with 
z-scores results (-2 ≤ z ≤ 2).  The result for z-score was at 
satisfactory level of 1.8.
Ochratoxin A was found in two of all analyzed prod-
ucts. Two samples of raisins contain 2.01 ng/g and 1.89 
ng/g, respectively. None of the samples exceeded maxi-
mum permissible limits of 10 ng/g set by national regula-
tive (Official Journal of the R Macedonia No.102/2013).
Conclusion
The described method is suitable for routine analy-
sis of Ochratoxin A in dried fruits. Limits of quantifica-
tion, precision, and recovery were satisfactory. The benefit 
from short time analysis is not only in the increased sam-
ple throughput, but also in dramatically decreased solvent 
consumption. Therefore, the liquid chromatography linked 
to fluorescence detection (HPLC/FD) was extensively used 
for OTA confirmatory analysis. 
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Introduction
Herbal medicine has been used since ancient times for 
prevention and treatment of numerous diseases. Different 
cultures utilize numerous plant species which are usually 
characteristic for the geographical region where they are 
natively growing. The repeated use of herbal preparations 
for various purposes is commonly based on the positive ex-
perience and the beneficial outcome of their usage as part 
of traditional medicine of the population.
According to the World Health Organization statistics, 
80% of the population relies on traditional herbal medicine 
as a primary healthcare system. Furthermore, more than 
50% of the population in developed countries such as Ger-
many (90%), France (75%) and Canada (70%) has at least 
once in their lifetime relied on herbal products as a pri-
mary treatment. Beside the common practice of tradition-
al herbal medicine, commercially available herbal products 
are also widely used in the treatment of cardiovascular dis-
eases, allergies, asthma, arthritis and many other diseas-
es. On the other hand, the increasing usage of herbal prod-
ucts is becoming major concern of health regulatory bodies 
and the general public, mainly because of the high avail-
ability of the herbal products on the market (Ekor, 2014). 
Moreover, a great portion of these products are classified 
as food or dietary supplements in some countries, making 
them easily accessible for the general public. The common 
perception of herbal products being generally safe regard-
less of the administered dose is often misleading. There-
fore, toxicity evaluation of commercially available herbal 
products is mandatory, considering the possibility of using 
their toxic potential in cytotoxicity studies.
Materials and methods
Plant samples of 9 different species were tested for 
their toxic potential: 2 samples of bark (Rhamnus fran-
gula and Quercus pedunculata), and 7 samples of whole 
herbal parts (Capsella bursa-pastoris, Epilobium parviflo-
rum, Hypericum perforatum, Polygonum aviculare, Teu-
crium chamaedrys, Viscum album and Galega officinalis).
These samples are commercially available as one-com-
ponent herbal teas and are commonly used for the treat-
ment of various pathological conditions. The tested plant 
samples were prepared as methanol extracts, lyophilized, 
freeze dried and later reconstituted with DMSO (dimeth-
yl sulfoxide). 
For the evaluation of potential toxicity among the 
selected herbal teas, the Brine Shrimp Lethality Assay 
(BSLA) was the most suitable method. BSLA is based on 
counting dead Artemia salina nauplii after their exposure 
to plant extracts in a certain time frame. The most relevant 
time period for the determination of LC50 is after 24 hours. 
After this period, dead nauplii were counted and the mor-
tality of Artemia salina was calculated and expressed for 
each concentration of tested plant extract. The obtained re-
sults for the mortality of the brine shrimps were further an-
alyzed with regression analysis and LC50 values were ob-
tained by application of probit regression analysis. 
Results and discussion
According to the obtained LC50 values for the tested 
methanol extracts, the toxicological bioactivity is decreas-
ing in the following order: Polygonum aviculare > Teu-
crium chamaedrys > Capsella bursa-pastoris > Epilobi-
um parviflorum > Galega officinalis > Rhamnus frangu-
la > Quercus pedunculata > Hypericum perforatum > Vis-
cum album.
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Out of the tested plant samples, highest toxic potential 
manifested Polygonum aviculare (LC50 185 µg/mL) and 
the lowest toxic potential was obtained for Viscum album 
(LC50 590 µg/mL). The classification of the samples was 
done according to 2 scales: Meyer’s scale and Clarkson’s 
scale (Meyer at al., 1982; Clarkson et al., 2004). Meyer’s 
scale classifies plant samples as toxic (LC50< 1000 µg/mL) 
and non-toxic (LC50> 1000 µg/mL). Clarkson’s scale clas-
sifies plant samples in several subcategories: plant samples 
with high (0 - 100 µg/mL), medium (100 – 500 µg/mL), 
low (500 – 1000 µg/mL) and no toxic potential (>1000 µg/
mL). All tested samples were classified as toxic accord-
ing to both scales, since the obtained LC50 values for each 
sample is below 1000 µg/mL. However, the tested plant 
extracts manifested a different level of toxicity. In accor-
dance with the Clarkson’s scale, Viscum album was clas-
sified as a plant sample with low toxic potential, while the 
rest were classified as plant samples with medium toxic 
potential. The obtained results for the toxic potential of 
the selected herbs are in accordance with the literature re-
sults. Thus, the anticancer effects of Polygonum aviculare 
were investigated against MCF-7 cells (human breast can-
cer cell line). It has been shown that the methanol extract of 
Polygonum aviculare induced cytotoxicity in MCF-7 cell 
line, which confirmed the cytotoxic (anticancer) potential 
of this plant species (Habibi Roudkenar et al, 2011). Fur-
thermore, the cytotoxic potential of the methanol extract of 
Teucrium chamaedrys against HCT-116 cells (human co-
lon carcinoma cells) was evaluated. The obtained results 
have shown that Teucrium chamaedrys exhibited a signif-
icant cytotoxic activity against the HCT-116 cells after 24 
hour exposure (Stankovic et al., 2011).
Conclusion
All tested herbal teas manifested medium toxic poten-
tial, except for Viscum album which manifested low toxic 
potential according to Clarkson’s scale of toxicity, but the 
mechanism and origin of this activity need to be further ex-
amined and clarified. The Brine Shrimp Lethality Assay is 
a reliable preliminary tool to evaluate the toxic potential 
of plant samples. This is also supported by the good cor-
relation between BSLA and other in vivo toxicity models. 
Therefore, the Brine Shrimp Lethality Assay is a conve-
nient approach for a pre-selection of promising toxic plant 
samples that could further be examined for their cytotoxic 
potential in a more detailed research. 
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Introduction
Studies of the cancer metabolism attract a growing sci-
entific interest and targeting the metabolism should be one 
of the first choices of treatment. The aim of this study is 
to summarize the current extensive knowledge of the met-
abolic aberrations in cancer and propose plausible mole-
cules and pathways that could be targeted for specific treat-
ment of this disease.
Key concepts and clinical potential of the 
Warburg effect
The important discovery that highlighted the area of 
cancer metabolism is the Warburg effect, an  anti-physio-
logical way for energy generation used by the cancer cells 
for their proliferation. This effect explains the alteration of 
the normal process of oxidative phosphorylation follow-
ing the process of glycolysis and excessive lactate produc-
tion despite adequate oxygenation of the tissue, provid-
ing an acidic environment that encourages the prolifera-
tion and tumor invasion. Several studies have contribut-
ed to the discovery of key biochemical pathways and their 
regulators, which can shed light on the field of cancer me-
tabolism and can serve as new targets for cancer therapy 
(Semenza, 2011). 
One of the main metabolic features of all cancer cells 
is an increased utilization of glucose that offers several ad-
vantages: the survival in an environment with unstable ox-
ygen concentration which is otherwise fatal to normal cells 
referring predominantly  to the oxidative phosphorylation 
as a source of adenosine triphosphate (ATP), secondly the 
production of lactate as an end product of aerobic glycol-
ysis makes acidic environment, which favors invasion of 
cancer and also suppresses the activity of anti-cancer im-
mune effectors. Additionally, cancer cells utilize glycolyt-
ic intermediates for anabolic reactions necessary for rapid 
proliferation, and, finally, the production of pyruvate and 
nicotinamide adenine dinucleotide phosphate (NADPH), 
the two main products of glycolysis and the pentose phos-
phate cycle, are used by the cancer cells in order to deal 
with oxidative stress. Pyruvate catches hyperoxides while 
NADPH participates in the glutathione peroxidase medi-
ated destruction of hydrogen peroxide (Singleterry et al., 
2014). 
The essential role of glycolysis as a necessary process 
for cell proliferation is based on the fact that this process 
provides compounds with hydrocarbon skeleton, which are 
required for the biosynthesis of various biomolecules such 
as nucleic, amino and fatty acids. In spite of the fact that 
the process of oxidative phosphorylation provides greater 
amounts of ATP, the process of glycolysis is a much faster 
process of energy supply, and therefore is a more appropri-
ate process to meet the large energy needs of cancer cells 
during active division. There are various types of deviation 
regarding the process of oxidative phosphorylation and ac-
tivation of glycolysis used by cancer cells. One of them is 
activation of the enzyme phosphofructokinase, a key en-
zyme for the process of glycolysis, by reduced produc-
tion of ATP. Another approach implies changing the pH of 
the environment by reactive oxygen radicals and hydrogen 
peroxide. These radicals are known to cause intracellular 
alkalization which can activate the enzyme and thereby in-
duce the process of glycolysis. Additionally, hydrogen per-
oxide can also activate HIF 1 and the oncogenic RAS, SRC 
and MYC that are involved in the expression of enzymes 
and transporters participating in the process of glycolysis. 
Another major catabolic way that links the glucose 
metabolism to nucleotide biosynthesis and production 
of NADPH is the pentose-phosphate cycle. This process 
is necessary for the antioxidative surveillance and reduc-
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tive biosynthesis. It is controlled by the enzyme glucose-
6-phosphate- dehydrogenase (G6PD), which activity is 
mediated by several signals and it serves as a sensor for the 
cellular NADP+ level. 
As glycolysis has a crucial role in the development of 
cancer, the Warburg effect can be used for therapeutic tar-
geting of cancer metabolism. One approach is inhibition of 
the glycolytic enzymes involved in certain limiting steps of 
glycolysis, such as hexokinase 2 which ionizes the molecule 
of glucose and as such is retained inside the cell. A mole-
cule that affects this enzyme is 2 deoxyglucose, a competi-
tive inhibitor that cooperates with glucose for the active site 
of hexokinase 2, whereby with phosphorylation, this com-
pound can’t be further metabolized and accumulated inside 
the cell. The activity of the enzyme phosphofructokinase is 
also a potential target. The fact that this enzyme is very sen-
sitive to small changes in pH and its action is induced by 
high pH values, the inactivation of the Na/H+ pump NHE1 
which excretes H+ ions from the cell, may lead to decreased 
intracellular pH, decreased activity of phosphofructokinase 
and inhibition of the process of glycolysis, endangering the 
survival of cancer cells. Molecules that inhibit the activi-
ty of the Na/H+ pump NHE1 are amiloride and 5,5-dimeti-
lamiloride. Lactate dehydrogenase is another enzyme that 
contributes for the Warburg effect which may serve as a tar-
get for aerobic glycolysis in the heart.
Another approach for reducing the glycolysis level in 
cancer cells is by inhibiting the synthesis of glucose trans-
porters and glycolytic enzymes. HIF1 is a transcription fac-
tor that controls the activity and its inhibition is assessed in 
multiple studies. As a result, several Food and Drug Ad-
ministration approved anticancer drugs such as topotecan, 
imatinib, celecoxib and ibuprofen have proven to inhibit 
the activity of this factor. The role of G6PD as an oncogene 
makes this enzyme a potential therapeutic target. Hense, 
the combination of oxythiamine and dehydroepiandros-
terone, has an additive inhibitory effect over cancer cells. 
This indicates that the combinatory targeting of the pentose 
phosphate cycle and other metabolic pathways may be an 
effective approach to selective suppression of cell growth.
Targeting the glutamine metabolism
The dependability of the cancer cells survival on the 
aerobic glycolysis solely has been discredited by research 
showing that glutamine metabolism is also essential for 
certain types of cancer. Recent studies demonstrate the vi-
tal need for this amino acid, its buffering effect against ox-
idative stress, the role of a mediator in intracellular sig-
naling, and as a quality control of macromolecules and or-
ganelles (Shanware et al., 2011). Crucial enzymes involved 
in the glutamine metabolism such as isocitrate dehydroge-
nase, are found to be mutated in certain types of cancer, 
such as gliomas and acute myeloid leukemia, hense target-
ing this enzyme may be an alternative  anti-cancer thera-
py. Other two important enzymes that control the gluta-
mine metabolism are glutamate dehydrogenase and gluta-
mate aminotransferase. Glutamate dehydrogenase can be 
inhibited by a component of the green tea named epigal-
locatechin-3-gallate, while the aminotransferase can be in-
hibited by aminooxyacetate.
There are various other potential factors that play an 
important role in maintaining the high glycolytic pheno-
type of the cancerous tissue that can be used as potential 
targets such as: oxidative stress which causes apoptosis in 
cancer cells, transporters that facilitate the entry of glu-
cose, the facilitated lactate efflux and the active transport 
of protons in the tumor microenvironment.
Conclusion
The growing awareness of the difficulty for therapeu-
tic targeting signal transduction in tumors, and the side ef-
fects that accompany this approach, shift the therapeutic 
strategies towards targeting the aberrant tumor metabo-
lism. Further research and discoveries in the field of cancer 
metabolism may lead to a better understanding of the dis-
ease and enable development of efficient anti-cancer drugs.
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Introduction
Pinus species is a diverse and widely distributed group 
of plants that are harvested and used in folk medicine for 
thousands of years. They grow natively in Macedonia form-
ing pure and mixed stands in subalpine forests (Kałucka et 
al., 2013). The common used parts of the plant are root, 
stem, bark, branch, resin, tar, leaf, pollen, cone, seed, nee-
dles (Kızılarslan and Sevg, 2013). They are used as antisep-
tics, tonics, expectorants, analgesics, and especially in the 
treatment of respiratory (common cold, asthma, bronchitis) 
and urinary system disorders, skin diseases (wounds) and 
digestive system diseases. The bark and resin obtained from 
the Pinus trees are the primarily used parts of the plant, 
mainly because of the antimicrobial and antiseptic proper-
ties. Additionally, diverse benefits have been claimed for 
pine needles as well, such as antibacterial, cholesterol low-
ering, antioxidant and antitumorial effects.
In this research, needles and bark of selected Pinus 
species were tested for their toxicological bioactivity, as 
a starting point for the selection of promising toxic agents 
that could be further investigated in more detailed studies 
of cytotoxicity.
Materials and methods
Needles and bark of Pinus peuce, Pinus sylvestris, 
Pinus nigra and Pinus mugo were collected at five different 
localities in the Republic of Macedonia: Pelister, Kozhuf, 
Karadzica, Berovo, Nidze. The plant material was harvest-
ed in the year of 2008, 2009 and 2010. The collected plant 
materials weredried at room temperature for two weeks, 
and then milled to fine powder. A stock solution from each 
sample was prepared as a methanol extract, followed by 
lyophilization and freeze drying. The final extracts were 
prepared by reconstitution of the lyophilized powders with 
DMSO (dimethylsulfoxide). The toxicity of each plant 
extract was tested using the Brine Shrimp Lethality As-
say (BSLA) (Meyer et al., 1982). The toxic potential was 
determined by counting the number of dead Artemiasali-
nanauplii after 24 hours exposure to the tested plant ex-
tracts. Furthermore, based on the calculated percentage of 
mortality of the brine shrimps, LC50 values were calculated 
using probit regression analysis (Finney, 1952). According 
to the obtained LC50values, the tested plant samples were 
classified using two scales of toxicity: Meyer’s scale and 
Clarkson’s scale (Clarkson et al., 2004; Meyer et al., 1982). 
Results and discussion
The obtained LC50values represent the toxic poten-
tial of eachPinus species selected for toxicity testing in 
this research. According to the obtained data, every sam-
ple of needles was classified as toxic according to Mey-
er’s scale and Clarkson’s scale of toxicity. Pinuspeuce nee-
dles collected from the locality of Pelister have the lowest 
LC50 value (LC5083 mg/mL). According to this result, it is 
classified as a sample with high toxic potential (0-100 mg/
mL) using the Clarkson’s scale of toxicity. The toxic bioac-
tivityof the needles declines in the following order: Pinus 
peuce (Pelister)>Pinus mugo (Karadzica)>Pinus sylvestris 
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(Kozhuf)>Pinus nigra (Kozhuf). 
Among the tested samples of bark, the highest tox-
ic potential was detected for Pinus peuce collected from 
Nidze(LC50135 mg/mL) and was classified as a sam-
ple with medium toxic potential (100-500 mg/mL) using 
Clarkson’s scale.The results vary among the samplesand 
an important factor appears to be the locality of their ori-
gin: the samples of bark collected from the locality of Ni-
dze (Pinus peuce and Pinus sylvestris) manifested great-
er toxicity compared to the same species collected from 
the localities of Berovo and Pelister. The toxic bioactivi-
ty of the tested bark samples declines in the following or-
der: Pinus peuce (Nidze) >Pinus sylvestris (Nidze) >Pinus 
sylvestris (Berovo) >Pinus peuce (Pelister) >Pinus nigra 
(Berovo).
However, the prominent toxicity detected for the test-
ed samples is probably a result of certain bioactive com-
pounds with toxic characteristics that are naturally found 
in the selected Pinus species, since the samples were col-
lected from localities which are characterized with a clean 
and healthy environment for plant growth. According to 
literature data, α-pinene is the dominant compound in most 
Pinus species. Additionally, this compound is a confirmed 
toxic agent (Leite et al., 2009), which suggests the origin 
of the toxic potential for the tested plant samples in this re-
search.
Conclusion
All tested Pinus needles and bark were classified as 
samples with a toxic potential according toMeyer’s scale 
and Clarkson’s scale. Moreover, Clarkson’s scale classi-
fied the examined samples in subcategories, according to 
which most of the tested extracts were samples with me-
dium toxic potential. This gives a future perspective for 
further analysis of their cytotoxic potential and determi-
nation of the components responsible for the toxic effects 
they manifest. Although BSLA cannot determine the com-
pounds responsible for a toxic effect, it is still a useful tool 
for the selection of potential cytotoxic candidates based on 
the extent of toxicity they manifest against Artemia sali-
na nauplii. 
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Introduction
The primary molecular mechanism of action of the 
organophosphorus (OP) pesticides is inhibition of acetyl-
cholinesterase (AChE) producing excessive acetylcho-
line (ACh) accumulation and overstimulation of choliner-
gic neurons. The organophosphates (OPs) or their active 
metabolites are electrophilic compounds with moderate 
to high potency for phosphorylating the serine hydroxyl 
group located in the active site of AChE. The reactivity of 
OP compounds varies depending upon the chemical struc-
ture. OPs may also interact (inhibit) with other serine es-
terases: neurotoxic esterase (NTE), butyrylcholinesterase 
(BuChE), carboxylesterases (CarbE), phosphorylphospha-
tases (A-esterases), fatty acid amide hydrolase (FAAH), 
arylformamidase (AFMID), acylpeptide hydrolase (APH) 
(Casida and Quistad, 2004). 
Materials and methods
In order to explore cholinergic and non-cholinergic 
targets of OPs, literature review was undertaken. 
Results and discussion
The half-life of recovery of inhibited brain AChE is 
about 1 week (approximately 5% per day) in experimen-
tal animals and is believed to be the same in man. BuChE 
activity takes approximately 4-6 weeks to return to pre-
exposure levels whereas erythrocyte AChE requires 5-7 
weeks. BuChE is generally more sensitive than AChE to 
OP esters. Some OPs (tri-o-cresyl phosphate, mipafox, lep-
tophos) considered to be extremely potent to inhibit NTE 
producing organophosphate-induced delayed polyneurop-
athy that is associated with inhibition of at least 70% of the 
activity sometimes followed by irreversible transformation 
to its non-reactivatable form.
The endocannabinoid arachidonyl ethanolamide 
(anandamide) and the endogenous sleep-inducing agent 
oleamide are hydrolyzed by FAAH. Anandamide also 
binds to the CB1 receptor in brain that is the target for 
marijuana and its principal psychoactive ingredient Δ9-
tetrahydrocannabinol. Particularly potent inhibitors of 
FAAH in vivo in mice are chlorpyrifos and tribufos.
 The OPs may create a nicotinic acid deficiency by 
blocking its biosynthetic pathway. Tryptophan is the met-
abolic precursor for N-formyl-L-kynurenine, L-kynuren-
ine, nicotinic acid, NAD(H), and NADP(H) in mammals. 
AFMID (formerly known as kynurenine formamidase), the 
second enzyme in this pathway, is very sensitive in birds 
and mammals especially to OPs with nitrogen-containing 
hetero cyclic or aliphatic leaving groups (diazinon, diazox-
on, monocrotophos). 
APH hydrolyses the N-terminal acetylated amino acid 
residue on peptides, thereby removing one form of pro-
tection from proteolysis. It also hydrolyses oxidized pro-
teins in human erythrocytes with a possible physiological 
function of removing oxidatively damaged components in 
cells. APH activity has been potently inhibited by chlorpy-
rifosmethyl oxon, dichlorvos and diisopropyl fluorophos-
phates with resultant IC50 values of 18.3, 118.7 and 22.5 
nM, respectively. Malathion and malaoxon inhibit lysyl 
oxidase (LyO) (IC50 = 1-9 nM) as well as proline hydrox-
ylase (IC50= 50-58 nM) in homogenates of Xenopus em-
bryos, suggesting that they alter posttranslational modifi-
cation of collagen with resultant morphological defects in 
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connective tissue.
Additionally, OPs may have a direct action on musca-
rinic and nicotinic receptors, binding to (with high/low af-
finity) and modulating the function of these receptors (as 
indicated by clinical effects). Specific binding of an OP 
compound to muscarinic receptors does not necessarily 
produce predictable effect (some OPs bind to muscarinic 
receptors and activate them, while others may bind to and 
inhibit the action of muscarinic receptors). OPs may bind 
to allosteric sites on nicotinic receptors stimulating recep-
tor desensitization. The OP concentrations required to act 
directly on nicotinic receptors are much higher than those 
on muscarinic receptors, suggested that muscarinic recep-
tors are more important as secondary targets in OP action. 
Cannabinoid system is also sensitive to OPs and their me-
tabolites. Chlorpyrifos oxon is a potent in vitro inhibitor of 
cannabinoid CB1 receptor binding (IC50 = 14 nM) but is ef-
fective in vivo only at near lethal levels. Combination of 
possible interactions will produce resultant toxic effect(s) 
for the certain OP. The spectrum of effects is modulated by 
various toxicokinetic factors. 
Exposure to OPs can induce four different clinical syn-
dromes: 1. acute cholinergic crisis as a result of AChE inhi-
bition (in CNS and PNS), 2. intermediate syndrome whose 
underlying mechanism(s) is still unclear(excessive stim-
ulation of cholinergic receptors etc.), 3. organophosphate 
induced delayed neuropathy (OPIDN) that has been ex-
plained by the inhibition of NTE, and 4. chronic organo-
phosphate induced neuropsychiatric disorder (COPIND) 
due to long-term low-level exposure (LTLL) (Antonijević 
and Stojiljković, 2007). Chronic exposure to OP substanc-
es is a controversial area of toxicology: a number of au-
thors propose that prolonged exposure at low levels of or-
ganophosphates can produce adverse effects in man and in 
animals, while others have reported no such effects. Sever-
al studies have reported long-term, persistent, chronic neu-
rotoxicity symptoms in individuals as a result of acute ex-
posure to high doses that cause acute cholinergic toxici-
ty, or from long-term low-level, subclinical doses of these 
chemicals with or without previous history of acute epi-
sode. Available data on neurotoxicity showed/suggest-
ed that: animals treated chronically with OPs exhibit re-
duced sensitivity (adaptive responses), probably due to 
down-regulation of ACh receptors and reduced synthesis 
of ACh, so that the presynaptic release is restricted; sub-
lethal or subclinical doses of OPs  can produce apoptotic 
neuronal cell death and involve oxidative stress due to an 
increase of the excitatory neurotransmitter, glutamate and 
subsequent increase in intracellular calcium; genetic sus-
ceptibility (genetic variation in paraoxonase) could be re-
lated to OPs neurotoxicity; inhibition of brain CarbE, the 
activity of which appears to be unrelated to the liver and 
plasma type, and/or even other non-target enzymes such as 
carboxyamidase, whose endogenous function is unknown 
although it has been suggested that it has a role in xenobi-
otic metabolism, may play a role in explaining the mech-
anism of cognitive dysfunction; behavioral changes could 
be induced by the effects of OP compounds on neuropep-
tide metabolism due to inhibition of acylpeptide hydrolase, 
the enzyme which is responsible for the removal of N-acet-
ylated amino acids from the N-terminus of short peptides.
Several low dose studies as well as some epidemio-
logical studies did not identify any link between neurolog-
ical disorder and erythrocyte and/or plasma cholinesterase 
activity. The mechanisms of OPs – induced chronic neu-
rotoxicity have yet to be established. An important conse-
quence of this is that non-cholinergic mechanism can be 
expected to show different structure-activity relationship 
to those established for conventional end points such as 
acute toxicity (Vučinić at al., 2014).  
Conclusion
In conclusion, based on the available data, their qual-
ity and quantity, and the fact that inhibition of AChE is 
both the most specific and one of the most sensitive mecha-
nism of OPs action, it seems that inhibition of AChE is still 
the most reliable parameter to predict absolute and relative 
potency with regard to long-term low-level exposure and 
neurodevelopmental toxicity produced by OPs.
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Introduction
Acute myocardial infarction (AMI) is a life-threaten-
ing condition which diagnosis must be established right 
away and to be currently treated. Early identification and 
confirmation of acute myocardial infarction is quite impor-
tant for the patient care and making the right decisions. The 
acute myocardial infarction belongs within the spectrum of 
acute coronary syndromes, including unstable angina pec-
toris, acute myocardial infarction without elevation of ST-
segment (NSTEMI) and acute myocardial infarction with 
elevation of ST-segment (STEMI). Acute myocardial in-
farction is a major cause of morbidity and mortality world-
wide (Atman et al., 2000).
Angina pectoris is the medical term for chest pain 
or discomfort caused when the heart muscle doesn’t get 
enough oxygen-rich blood. But, angina is not a disease. It 
is a symptom of an underlying heart problem, usually coro-
nary heart disease (CHD). There are many types of angina, 
including stable and unstable angina. In fact, unstable angi-
na is a pre-infarction syndrome (Braunwald, 1990).
Diagnosis on an electrocardiogram (ECG) is not an ab-
solute criterion, particularly in the case of small infarctions. 
Cardiac markers are used in the diagnosis and risk stratifi-
cation of patients with chest pain and suspected acute cor-
onary syndrome (ACS) (Higgins et al., 1999). The mea-
surement of cardiac markers in the blood is the basis of 
the diagnosis of acute myocardial infarction for more than 
50 years. The release of biomarkers in the bloodstream in 
higher than normal amounts, suggests a pathological pro-
cess. Thus, the detection of elevated concentrations of car-
diac biomarkers in the blood is a sign of cardiac injury that 
may be due to toxic effects or hemodynamic stress. Tradi-
tional cardiac markers (CK-NAC, LDH) have many dis-
advantages: they secrete into the circulation very late (12 
hours after necrosis of the heart muscle), thus preventing 
the early diagnosis. To overcome this situation, for detec-
tion of cardiac necrosis, there are introduced new biochem-
ical markers from the circulation, CK-MB and troponin 
(Rajappa and Sharma, 2005).
CK-MB rise twice higher than normal after 6 hours 
of the infarction, to reach its maximum after 24-48 hours, 
when its concentration decreases, therefore it can’t be di-
agnosed cardiac necrosis quickly. Troponin I appears in the 
serum relatively early after the infarction (approximately 
4 hours), reaches its maximum 12-48 hours after necro-
sis, and remains in the circulation up to 14 days later. The 
cardiac troponins, in particular, have become the cardiac 
markers of choice for patients with acute coronary syn-
drome (Thygesen et al., 2010).
The aim of the study was to evaluate the clinical value 
of cardiac Troponin I over CK-MB as essential marker in 
early assessing myocardial cell damage.
Materials and methods
Blood samples (serum and heparinized plasma) were 
taken from 38 patients (29 males and 9 females) with com-
plain on chest pain at the Special Hospital for Surgical Dis-
eases “Filip Vtori” Skopje. According to their age, the pa-
tients were divided into 3 groups (from 31-50; 51-70 and 
over 70 years old) in order to prove which will be the most 
risk group in regards of cardiovascular diseases.
Daily measurements of Troponin I and CK-MB levels 
were made in all patients with no history of coronary heart 
disease. Regardless the values, the measurements were re-
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peated every 4 hours in order to conceive the trend line of 
the markers. Also, on the receipt day of the patients, the 
ECG tests were made, respectively.
Determination of these markers was made with Im-
munoassay System –Advia Centaur XP by of chemilumi-
nometric immunoassay method. Minimum concentration 
limit (“cut off” value) for Troponin I is 0.78 ng/ml and the 
referent values for CK-MB are from 0-15 ng/ml. There-
fore, any increase of the concentration of these markers, 
indicates the condition of acute myocardial infarction. If 
there is no increasing above the baseline value of Tropo-
nin I and if ECG tests are normal, it’s a question of angi-
na pectoris.
Results and discussion
In regards of age group, the obtained results indicated 
that the risk group in terms of cardiovascular diseases (in 
this case AMI) is the group from 51-70 years (29 patients).
As expected, serum Troponin I levels increased in 30 
from all 38 patients (79%). Thus, these increased concen-
trations of cardiac troponin (cTnI) which deviate from nor-
mal values, indicate of acute myocardial infarction. There-
fore, 20 patients of them (67%) had elevation of ST-seg-
ment (STEMI) on ECG test which can confirm the diagno-
sis. There were no signs of myocardial infarction on ECG 
test (NSTEMI) on the rest 10 patients (33%), only the con-
centration of Troponin I was elevated. In this case, Tropo-
nin I is the leading biochemical parameter which affirms 
that these patients had AMI, which is very important.
CK-MB was elevated only in 9 of the 38 patients and 
according to literature data (that this marker stays elevat-
ed in the blood up to 72 hours), it appears in blood after 
6-9 hours after the onset of chest pain, unlike the Tropo-
nin which was already increased. Just to confirm the low-
er sensitivity of CK-MB compared with Troponin I, when 
the second tests were made (after next 4 hours), only on 5 
patients the concentration of CK-MB started to elevate. On 
the other side, the elevated CK-MB levels on those 9 pa-
tients, appeared to be decreasing next day (the concentra-
tions were in the referent values), unlike Troponin I which 
concentration was still over the “cut off” value.
In the rest 8 patients (21%) the ECG findings were nor-
mal and the results for Troponin were in the referent val-
ues, which indicate that these patients were with angina 
pectoris. If their symptoms become worse over time, test 
for Troponin must be ordered, because it can lead to a heart 
attack.
Conclusion
Cardiac Troponin I appears to be diagnostically superi-
or to CK-MB due to its high sensitivity (appears very early 
after infarction) and specificity.
Therefore, Troponin I is considered as “gold standard” 
in the early detection of myocardial infarction and is nec-
essary in setting the correct diagnosis. Thus, the use of test 
for Troponin enables early noninvasive diagnosis of acute 
myocardial infarction.
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Introduction
The routine screening in the Laboratory of Forensic 
Toxicology encompasses assays for determination of psy-
choactive substances, commonly used drugs and presence 
of ethanol. The positive finding on opiates does not always 
imply the presence of heroin (HER) and/or its metabo-
lites because various drug formulations contain an opiate 
as an active substance. The detection of HER and its main 
metabolite 6-monoacetylmorphine (6-MAM) as a gener-
al marker of HER use, poses some analytical challenges, 
mainly due to their short half-lives (Goldberger et al.,1994; 
Paterson and Cordero, 2006; Rook et al., 2006). The scope 
of this study includes 3 forensic cases with positive find-
ings on opiates, where the presence of HER and 6-MAM 
could not be detected, but some additional markers of HER 
use were identified.
Materials and methods
The analyses which are subject of this study were con-
ducted by routine screening for the presence of psychoac-
tive substances, using fluorescence polarization immuno-
assay and/or biochip array technology for urine and blood 
samples, respectively. The positive results were confirmed 
by gas chromatography-mass spectrometry (GC-MS), af-
ter previous sample preparation using ion exchange solid 
phase extraction (SPE) columns. In the case of urine sam-
ples, acid hydrolysis was performed prior to SPE, in order 
to determine free opioid alkaloids. 
Results
Case 1: The routine screening of the postmortem urine 
samples did not show positive results for the presence of 
psychoactive substances. However, further analyses us-
ing GC-MS were conducted due to the information on the 
presence of a syringe and an unknown powdered substance 
near the body of the deceased. The GC-MS analysis of the 
serum revealed the presence of the following substances: 
caffeine, morphine (MOR), acetaminophen and traces of 
noscapine, papaverine and hydrocodone. In the unknown 
powder sample and the syringe, acetaminophen, caffeine, 
codeine (COD), 6-MAM, papaverine, MOR and noscap-
ine were detected.
Case 2:  Positive results on the presence of opi-
ates and methadone in postmortem blood and urine sam-
ples were obtained during the routine screening. Further 
GC-MS analyses of the biological samples were conduct-
ed and the following substances were identified in the se-
rum: nicotine, cotinine, caffeine, theophylline, theobro-
mine, paracetamol, methadone and its metabolite 2-ethyl-
idene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), met-
amizol, MOR, meconine and traces of COD. The same 
substances were identified in the urine sample, along with 
noscapine, hydrocotarnine and desmethylpapaverine.
Case 3: Screening of postmortem urine samples 
showed positive finding on opiates, whereas postmortem 
blood screening showed presence of opiates, methadone, 
benzodiazepines and cannabinoids. The GC-MS analy-
sis confirmed the presence of caffeine, nicotine, tramad-
ol, methadone and meconin in serum. The same substances 
were detected in the urine sample, along with COD, MOR, 
papaverine, hydrocotarnine and paracetamol.
S3 PP 148
316
Maced. pharm. bull., 62 (suppl) 315 - 316 (2016)
Clinical biochemistry / Toxicology / Food and nutrition
Po
st
er
 p
re
se
nt
at
io
ns
Discussion
HER is quite unstable in aqueous medium and is rap-
idly converted to 6-MAM due to spontaneous hydrolysis 
(Knight et al., 2014; Rook et al., 2006). This can be no-
ticed in the results of the first case presented, where only 
6-MAM was detected in the extracts from the syringe and 
the unknown powdered substance. The same hydrolysis 
occurs in the serum, resulting in the deacetylation of HER 
to 6-MAM, which is further metabolized to MOR (Rook 
et al., 2006). Different data on the half-lives of HER and 
6-MAM have been reported in the literature. It is thought 
that HER can be detected in blood 10-40 min after intrave-
nous administration, while 6-MAM 1-3 h, reaching max-
imum plasma concentration immediately after injection 
(Rook et al., 2006). In our cases, larger number of opi-
oid alkaloids and their metabolites were identified in urine 
rather than in blood. Several studies conducted using post-
mortem biological samples suggest that the most suitable 
medium for detection of 6-MAM is the cerebrospinal flu-
id (CSF), while others consider the vitreous humor to be 
the sample with the greatest number of positive findings 
on 6-MAM compared to other fluids and tissue samples 
from the same forensic cases, with CSF having the sec-
ond greatest number of positive results (Goldberger et al., 
1994;  Pragst et al., 1999; Wyman and Bultman, 2004). 
6-MAM was not detected in any available biological sam-
ple from the three forensic cases, thus further analysis is 
needed to determine the origin of the opiates. Even though 
MOR is an end product of HER metabolism, it can also be 
a metabolite of COD, which is an active substance in some 
formulations. Some studies have compared MOR/COD 
concentration ratio, suggesting that MOR/COD concentra-
tion ratio >1 indicates HER use (Bogusz et al., 2001; Ceder 
and Jones, 2001; Konstantinova et al., 2012).  Other stud-
ies suggest the use of acetylcodeine (AC), a by-product of 
HER synthesis, as a marker of illicit HER use. AC is con-
sidered as the only definite marker of illicit HER use, along 
with 6-MAM, but its short half-life aggravates its useful-
ness in forensic applications (Bogusz et al., 2001; Gold-
berger et al., 1994; Musshoff et al., 2010). This is also con-
firmed by the results of our study, where AC was not de-
tected in any death case. Though some authors propose the 
presence of papaverine, especially its metabolites as a re-
liable marker of HER use, several studies have shown that 
papaverine metabolites can be detected in urine after the 
consumption of poppy seeds (Musshoff et al., 2010; Pa-
terson and Cordero, 2006). COD and noscapine (and its 
metabolites meconin and cotarnine) are also considered as 
markers of HER use (Bogusz et al., 2001; Paterson and 
Cordero, 2006). However, they can also be detected in bio-
logical samples after food consumption as papaverine (Bo-
gusz et al., 2001; Musshoff et al., 2010;  Paterson and Cor-
dero, 2006). In our cases, almost all opium alkaloids were 
identified, but 6-MAM was not detected. Pharmaceutically 
prepared HER is not available as a treatment option in Re-
public of Macedonia, therefore it can be concluded that the 
deceased had used illicit HER. 
Conclusion
The absence of 6-MAM in postmortem biological 
samples is not an indicator of HER non-use. When inter-
preting the results for the opiate presence due to the use of 
HER or different opioids, the results of numerous research-
es can be utilized, such as MOR/COD ratio as the most rel-
evant marker or the presence of AC as a definite marker 
of HER use. The determination of other opioid alkaloids 
such as papaverine, noscapine and its metabolites, togeth-
er with additional forensic evidences can be useful in au-
topsy cases.
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Introduction
Opioid dependence is a complex socio-medical state 
and a serious problem for the society, linked with a high 
morbidity and mortality rate (WHO, 2004). Even though 
several pharmacological agents are available, in the Re-
public of Macedonia, the maintenance therapy includes 
methadone (METH) and buprenorphine, with METH be-
ing the first agent used in the opioid substitution treatment 
(OST) and it still remains the main prescribed medication 
(EMCDDA, 2013). There are indications that alongside 
with the general decrease in drug seizures between 2009 
and 2012 in Republic of Macedonia, there was some short-
age in supply, encouraging users to replace heroin with 
other substances such as METH, benzodiazepines (BZDs) 
and tramadol (EMCDDA, 2013). Despite the prescription 
of BZDs for therapeutic purposes, the prevalence of their 
misuse among OST patients is reported to be high in oth-
er countries and is related to severe consequences such as 
non-fatal and fatal overdoses (EMCDDA, 2015).
The aim of this report is to assess the number and nature 
of drug-related deaths (DRDs) in the Republic of Macedo-
nia over the period 2011-2015, with the emphasis on death 
cases involving positive findings for METH and BZDs.
Materials and methods
All toxicological analyses from autopsies performed 
at the Institute of Forensic Medicine in Skopje during a 
5-year-period were reviewed. Postmortem toxicological 
analysis of blood and urine samples was conducted using 
biochip array technology and fluorescence polarization im-
munoassay, respectively. Whenever possible, the positive 
results from the screening were confirmed by gas chro-
matography-mass spectrometry (GC-MS), after previous 
sample preparation by ion-exchange solid-phase extrac-
tion (SPE). Acid hydrolysis was performed prior to SPE 
for the urine samples showing positive results for BZDs 
tested with screening methods. The concentration of etha-
nol in the samples was determined by headspace gas chro-
matography-flame ionization detection.
Results and discussion
The postmortem toxicological analyses were per-
formed on a total of 1251 cases in the 5 year period be-
ing reviewed. A total of 89 cases showed positive results 
for drugs of abuse, whereas combined use of psychoactive 
substances was noticed in 57 cases (64.05% of all DRDs). 
Concomitant use of METH and BZDs was implicated in 
39 DRDs over the time period studied (43.82% of the to-
tal DRDs), with the highest number of fatalities involving 
their combined use in 2013 (14 cases). The percentage of 
METH and BZDs DRDs gradually increases starting from 
2011, with the highest peak seen in 2012 and 2013 (50% 
of all DRDs). After that, the percentage declines in 2014, 
reaching the same level as in 2011. A rise in the trend of 
DRDs is seen again in 2015. No information on the possi-
ble involvement of deceased in OST was available. In all 
cases analyzed by GC-MS diazepam was the only BZD 
identified. The presence of ethanol was detected in only 
9 cases of all studied DRDs.  Other substances (cannabi-
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noids, cocaine, tricyclic antidepressants and opiates) were 
detected in addition to the combination of METH and 
BZDs in 16 cases.
The number of deaths in which METH is either the 
cause of death or a positive toxicological finding has sig-
nificantly increased (Mijatović at al., 2014). In some stud-
ies it has been reported that alcohol and BZDs are most 
commonly detected concomitants together with METH 
(Laberke and Bartsch, 2010; Mijatović at al., 2014). None-
theless, regarding alcohol presence, this was not confirmed 
in this report where ethanol was detected in only 9 cases of 
all DRDs. Concomitant use of METH and BZDs was im-
plicated in 43.82% of the total DRDs, with diazepam being 
the only BZD identified in all analyzed cases by GC-MS, 
similar to other studies (Iwersen-Bergmann at al., 2014; 
Mijatović at al. 2014).  Furthermore, this correlates with 
the data from EMCDDA stating that BZDs with a more 
rapid onset of action (diazepam, alprazolam) appear to be 
more frequently used by opioid users than those with a 
slower onset (EMCDDA, 2015). Much of the BZDs mis-
use consists of self-medication for treatment of psychiat-
ric and mood disorders, alleviation of withdrawal symp-
toms and increase of the rewarding and reinforcing effects 
of the opioids (Eiroa-Orosa at al., 2010; EMCDDA, 2015).
The potential for significant morbidity and mortality 
with METH, either alone or in combination with BZDs, is 
widely reported (Lee at al., 2014). METH’s inhibitory ef-
fect on the brain’s respiratory center can lead to respirato-
ry depression, hypoventilation and pulmonary edema (Ber-
nard, 2013). It is suggested that µ-opioid agonists suppress 
respiration by acting on the respiratory centers in the brain-
stem, decreasing the ventilatory response to CO2 (Pattin-
son, 2008). In this way, the inspiration is prolonged, while 
changes in tidal volume can be observed at higher opioid 
doses (Lalley, 2003) The concurrent use of opioids with 
BZDs and other central nervous system depressants is con-
sidered to be an important element in the mechanism of 
death (Bernard, 2013). Some authors suggest that BZDs 
compete with METH for µ-opioid receptors, resulting in 
higher concentrations of METH in acute intoxications with 
METH and BZDs, while in chronic abuse situations, BZDs 
inhibit hepatic enzymes that metabolize METH, also lead-
ing to increased METH concentrations (Mikolaenko at al., 
2002). Moreover, it had been postulated that BZDs may 
also have effects on signal transduction and second mes-
senger systems involved with µ-opioid receptor regulation 
(Poisnel at al., 2009). Other possibly fatal METH-relat-
ed effects in the body, such as pulmonary oedema and ar-
rhythmias secondary to QT-interval prolongation must be 
also borne in mind (Bernard, 2013). 
The high frequency of positive findings on METH 
and BZDs in postmortem analysis of DRDs implies possi-
ble METH diversion and widespread availability of BZDs 
among METH users. 
Conclusion
It is complicated to establish the role of BZDs in DRDs 
and their misuse has been shown to contribute to morbidi-
ty and mortality rate among METH users. Much still needs 
to be done regarding the monitoring of METH and educat-
ing the patients involved in OST about the risks associated 
with multiple drug use.
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Introduction
According to World Health Organization, the suicide 
death rate per population of 100000 in the Republic of 
Macedonia is 5.42 suicides (WHO, 2014). The most com-
mon suicide methods in our country are hanging, intoxica-
tion with corrosive substances and gunshot wounds. Rarest 
way of suicide is intoxication with drugs especially with 
barbiturates. We have only two cases of intoxication with 
barbiturates in the last five years. 
Materials and methods
Case hystory: Female, twenty-five years was found 
dead lying on the bed in a hotel room, where she stayed. 
During the external examination of the body on the crime 
scene we found complete development of rigor mortis. On 
the bedside table, were found a box of Diazepam, gel tube 
of Lidocaine, a plastic bag with white powder contents and 
two suicide letters (one designated for the mother, and one 
for the police). The suicide letters for the police contained 
the whole process of the suicide, with mentioning of the 
drug types used. In the letter was described Pentobarbital 
used because causes coma and respiratory depression, Li-
docaine used for decrease the unpleasant bitter taste and 
Metoclopramide used to prevent vomiting. 
Postmortem blood and urine samples were collected 
for toxicological investigation. Toxicological qualitative 
analysis of blood using gas chromatography mass spec-
trometry (GC-MS) was performed. Determination of eth-
anol was performed using headspace gas chromatography. 
Quantification of urine samples was performed with fluo-
rescence polarization immunoassay (FPIA, AxSym system 
analyser– Abbott, USA). 
Results
Autopsy findings
Postmortem lividity was developed, distributed on the 
dorsal portion of the body and disappeared on blunt pres-
sure. Medico-legal autopsy revealed no external changes. 
No findings of natural disease were observed. During the 
internal examination, we observed non-specific signs of 
asphyxia. The brain was slightly oedematous. The lungs 
were congested and oedematous, with subserous petechi-
al hemorrhages.
Toxicology findings 
GC-MS toxicological analysis confirmed the presence 
of Pentobarbital, Diazepam, Lidocain-M-(desethyl) and 
Metoclopramide. No ethanol was detected in the samples. 
FPIA results from the urine samples indicated a level of pen-
tobarbital (more than 2000 ng/ml) and 498 ng/ml of diaze-
pam. According to urine cut–off levels for reporting posi-
tive blood level or limit of quantitation (CLR,2016), both 
urine pentobarbital and diazepam are over the cut off. No 
other drugs were found in the blood and urine of the victim.
Psychoautopsy
The suicide letter to her mother contained the reason 
of the suicide explaining the lack of reason and motivation 
for life and fatigue, mentioning unsuccessful treatment at 
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physiatrist. In the letter to her mother she stated that she 
was tired from being depressed all the time and that she 
had had nothing to live for, because she had no intention 
to work, get married or have a child. She had one previ-
ous suicide attempt with barbiturates and benzodiazepines. 
Discussion 
Suicide is an act or an instance of taking one’s own life 
voluntarily and intentionally. Suicide is a behavior that dif-
fers from one person to another and from one time to an-
other and has different motivations and anticipated gains. 
There are differences in the suicide method used in dif-
ferent countries. Three methods – hanging, pesticide poi-
soning and firearm are dominated. Jumping from a height 
and other methods of poisoning (i.e. mainly poisoning by 
drugs) occasionally appears as important alternative meth-
ods. The suicide method with poisoning is more popular 
in women than in men. In general, underlying suicide pat-
terns tell us more about the availability and acceptability 
of suicide methods than about other disparities (Ajdacic-
Gross et al., 2008). Factors that affect the risk of suicide 
include genetic vulnerability and psychiatric, psychologi-
cal, familial, social, and cultural factors. The effects of me-
dia are also important; the spread of information about sui-
cide methods affects the choices that people make when at-
tempting to kill themselves. In this case during forensics 
analyses and psychoautopsy of the suicide letters we con-
cluded depressed mood, lack of interest in pleasure, fillings 
of worthlessness, guilt, suicide statements and attempts all 
point out to major depressive disorder. Detailed description 
of suicide, the information of drug effects used direct on 
preparation process and internet investigation, which sug-
gest awareness of the consequences.
The suicide letter mentioned alleged ingestion of Pen-
tobarbital, Diazepam, Lidocaine and Reglan. The toxicol-
ogy department of our institute confirmed the presence of 
these compounds in the blood and urine of the victim. Pen-
tobarbital is a short-acting barbiturate that acts like a non-
selective central nervous system depressant, and is primar-
ily used as sedative hypnotic, as an anticonvulsant in sub 
hypnotic doses, medically induced coma and euthanasia in 
veterinary medicine (Charney et al., 2006; Greenblatt et 
al., 1979). In cases of intoxications, suppression of the cen-
tral nervous system, hypotension, hypothermia, coordina-
tion disorders, respiratory failure and coma are the major 
clinical symptoms (Fell et al., 1968). Diazepam is a de-
rivative of benzodiazepine that is widely prescribed as an 
antianxiety agent. Diazepam is sometimes used with other 
medications to treat seizures. When barbiturates are com-
bined with other central nervous system (CNS) depres-
sants, such as alcohol, opiates, or benzodiazepines, over-
dose is even more dangerous due to additive depressant 
effects on the CNS and respiratory system (Mactier et 
al., 2014). The clinical effects of barbiturates and benzo-
diazepines are similar and result as sequelae to hyperpo-
larizing the neuron, there are subtle differences in terms 
of receptor binding. Barbiturates increase the duration of 
Cl ion channel opening at the gamma-aminobutyric acid 
(GABA) receptor, which, in turn, increases the efficacy of 
GABA. Benzodiazepines, on the other hand, increase the 
frequency of Cl ion channel openings at the GABA recep-
tor, which, in turn, increases the potency of GABA (Shar-
ma and Hoffman, 2011). 
Conclusion
Suicides with intoxication with these types of drugs are 
rare because of the unavailability of drugs, because they are 
prescription drugs, or are intended for clinical practice only. 
This case, suggest on detailed planned and determination to 
end her life. The combination of Pentobarbital, Diazepam, 
antiemetic drugs and the content of the suicide letter stat-
ing when, and how she will die, suggest that the victim was 
familiar with drug effects and knew where to get them. We 
should point that among all classical forensic methods, we 
include psychoautopsy as a good method which helps us to 
finalize all investigation and make scientific based conclu-
sions for motivation and way of taking her own life. 
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Introduction
For centuries, juniper berries and leaves extracts and 
their essential oils have been used in the folk medicine due 
to their therapeutic properties, such as antimicrobial, an-
ti-inflammatory, diuretic, hypoglycemic, hypotensive and 
analgesic effect. Due to the exclusive aroma, juniper cones 
are utilized in the food industry as a spice and in the pro-
duction of alcoholic beverages as flavor. Today, there is an 
increased interest in the identification of natural and safe 
sources of antioxidants, in order to replace synthetic anti-
oxidants such as butylated hydroxyanisole (BHA), butylat-
ed hydroxytoluene (BHT) and tertiary-butyl hydroquinone 
(TBHQ) which have a limited use due to their toxicity and 
carcinogenicity.
The purpose of this study is to determine total phenols, 
total flavonoids and the antioxidant activity of ethanol ex-
tracts from berries of Juniperus excelsa, Juniperus commu-
nis and Juniperus foetidissima from different localities of 
the R. of Macedonia.
Materials and methods
The plant samples were collected in late autumn in 
2011 and 2012. The berries (4 samples) of J. communis 
(JC) were collected from Skopje (sk), Velestovo (ve), Kice-
vo (ki), and Resen (re), the berries (2 samples) of J. excel-
sa (JE) from Dojran (do) and Velestovo (ve) and the berries 
(2 samples) of J. foetidissima from Valandovo (va) and Ve-
lestovo (ve). Botanical identification was made at the Insti-
tute of Pharmacognosy, Faculty of Pharmacy - Skopje. The 
plant material was properly dried, stored in paper bags and 
kept in dark and cool place until testing.
The plant material (0.5 g) was milled to a fine powder 
and extracted with 70% ethanol. The extraction procedure 
for sample preparation was performed with 10 mL of 70% 
ethanol for 30 min in the ultrasonic bath. After filtration of 
the extracts, the volume was adjusted to 10 mL. 
Estimation of the total phenolic content (TPC) was 
done using Folin-Ciocalteu reagent according to the Sin-
gleton’s method with minor modifications.
The total flavonoid content (TFC) was estimated using 
the aluminium chloride colorimetric method described by 
Talari (Talari, 2012).
The antioxidant activity was determined using three 
methods: DPPH (1,1-diphenyl-2-picrylhydrazyl) method, 
FRAP (Ferric Reducing Antioxidant Power) method and 
H2O2 (Hydrogen peroxide) method.
The ability of the tested extracts to reduce the DPPH 
radical was determined from the color bleaching of the 
purple ethanol solution of DPPH. The antioxidant activi-
ty of the extracts is expressed as IC50 (mg/mL), indicating 
the concentration that is required to cause 50% reduction 
of the DPPH radical. The FRAP activity of the extracts was 
determined according to the procedure described by Oyai-
zu. The scavenging capacity of the extracts for hydrogen 
peroxide was determined according to the method of Ruch 
with minor modifications. 
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Results and discussion
The content of total phenolic compounds in all in-
vestigated samples vary from 41.32±0.20 mg GAE/g dw 
to 96.83±0.41mg GAE/g dw in the samples JF(va) and 
JE(ve), respectively. The total flavonoid content in the 
plant samples was in the range from 14.03±1.20 mg QE/g 
dw to 34.01±3.87 mg QE/g dw in the samples of JF(va) 
and JC(ki), respectively.
All the extracts showed antioxidant activity using the 
DPPH method. The DPPH radical scavenging activity of 
the samples increased with an increase in extract concen-
tration. The ability of the corresponding extract for reduc-
tion of DPPH free radicals expressed as IC50 values was 
obtained in the range from 0.006 mg/mL for the sample 
JF(ve) to 0.713 mg/mL for the sample JC(ki). The obtained 
reducing ability against DPPH radical was compared to the 
IC50 values for Quercetin and BHA (1.0 µg/mL and 6.0 
µg/mL, respectively). All tested samples manifested good 
scavenging potential for H2O2. The lowest inhibitory activ-
ity against H2O2 was found in JE(do):17.68%, 16.29% and 
15.24% for the extract concentrations 25, 10, and 5 mg/
mL, respectively, while the highest inhibitory activity was 
found in JF(va): 52.73%; 49.47% and 44.2%, for the corre-
sponding extract concentrations.
The ferric reducing antioxidant potential was deter-
mined by evaluating the capacity of the extract to reduce 
Fe3+ to Fe2+. Very similar to the DPPH test, the reducing 
antioxidant potential of every extract showed a positive 
correlation with their concentrations. The JF(ve) sample 
showed the strongest reduction of iron 51.08%, 25.19%, 
and 16.33% for the corresponding concentrations of the 
extract (0.71; 0.28 and 0.14 mg/mL), while the weak-
est activity is detected in the JC(re) sample with 18.85%, 
11.13% and 6.88% for the corresponding extract concen-
trations. The activity of extract was compared to the reduc-
ing capacity of two standard substances - ascorbic acid and 
quercetin in concentrations of 0.007 mg/mL, with 27.71% 
and 21.37% FRAP capacity, respectively.
The berries of the Macedonian wild grown J. commu-
nis, J. excelsa and J. foetidissima are a rich source of poly-
phenolic compounds. These results are corresponding to 
those obtained by other authors (Miceli et al., 2009, Elmas-
tas M., 2006). Additionally, the obtained values for the an-
tioxidant potential of the tested samples are also in accor-
dance with the results found in numerous research papers 
in the field of interest, suggesting that the selected plant 
samples are a rich source of phenolic and flavonoid com-
ponents, and a potential source of antioxidant compounds 
(Stassi et al., 1998).
Conclusion
According to the obtained results for total phenols, fla-
vonoids and the antioxidant potential of the selected plant 
samples, it may be concluded that the ethanol extracts of 
berries of J. communis, J. excelsa and J. foetidissima rep-
resent potential sources of natural antioxidants. Although a 
positive correlation was obtained between the total phenol 
content and the antioxidant activity, further studies are re-
quired to clarify which of the components are responsible 
for the antioxidant properties. In addition, screening with 
in vitro assays has little meaning if there is no clear evi-
dence of the effectiveness of the extracts in vivo. There-
fore, it is suggested that further studies are to be performed 
in order to evaluate the in vivo effects of these extracts.
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Introduction
Many analytes of interest in the clinical laboratory 
can vary over an individual’s lifetime, simply because of 
natural biological factors involved in the aging process. 
These variations may occur rapidly at critical points in the 
life cycle, such as during the neonatal period, childhood, 
puberty, menopause, or old age. Biological variation has 
an important effect on the interpretation of all laboratory 
investigations, including triglycerides and cholesterol 
(Fraser, 2001).
Biological variation, i.e., the normal day-to-day 
variation of cholesterol is within the range of 3-5%. 
Many studies have also documented a seasonal variation. 
Although there is a discordance between the studies, 
cholesterol levels tend to be higher in winter and lower 
during the summer months independent of the country of 
origin, ethnicity, age, sex, and baseline lipids. The seasonal 
variation has been reported to be as high as 12% (Deeg, 
2006).   
Triglycerides are the main constituent of body fat in 
humans and animals, as well as vegetable fat. They are also 
present in the blood to enable the bidirectional transfer of 
adipose fat and blood glucose from the liver, and are a 
major component of human skin oils.
Cholesterol is a sterol (or modified steroid), a lipid 
molecule that is biosynthesized by all animal cells because 
it is an essential structural component of all cell membranes 
required to maintain both membrane structural integrity 
and fluidity. It enables animal cells to dispense with a cell 
wall to protect membrane integrity and cell viability.
Cholesterol and triglycerides, like many other essential 
components of the body, attract clinical attention when 
present in abnormal concentrations. For the diagnosis of 
different lipoprotein disorders, one can usually rely on 
simple plasma values of total cholesterol and triglycerides. 
Obtained lipid values will be interpreted in relation to age 
and gender according to reference values (Mula-Abed et 
al, 2008). 
Methods
Analysis of serum total cholesterol and triglycerides 
is usually performed on blood specimens collected by the 
standard procedure. Fasting venous blood was collected 
at 8-10 am following an overnight fast, from apparently 
healthy participants (men and women, aged 15-67 years). 
The specimens were collected in 1-year period. Serum 
TG and total cholesterol were measured by enzymatic 
methods using kits from Biosystems (Spain) and 
biochemistry analyzer Mindray BS-200. Cholesterol was 
assayed by the cholesterol esterase/cholesterol oxidase/4-
aminophenazone/phenol method and the triglycerides 
by glycerol phosphate oxidase/peroxidase method 
(Biosystems, 2012)
Standard statistical methods were used or the analysis 
of data. The mean and SD were calculated for each 
parameter of serum triglycerides and cholesterol from each 
participant. The data was inspected for any outlier (defined 
as values outside ± 3 SD from the mean). There was no 
outlier and all results were within the mean value ± 2 SD. 
Results
The study was conducted with cholesterol samples 
from 210 apparently healthy participants with mean of 
5.22±1.85 (Coefficient of variation (CV) 17.73%) and 
triglycerides samples from 204 participants with mean of 
1.56±1.54 (CV 49.46%). These results were divided for 
observation in groups by age and gender. 
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There are 10 groups with number of participants: 
Group 1: 15-29 years male, Group 2: 15-29 years female, 
Group 3: 30-39 years male, Group 4: 30-39 years female, 
Group 5: 40-49 years male, Group 6: 40-49 years female, 
Group 7: 50-59 years male, Group 8: 50-59 years female, 
Group 9: 60+ years male and Group 10: 60+ years female. 
From these groups 5 groups were made for observation by 
gender. The obtained results from the participants were 
compared with the reference values provided by the used 
kits manufacturer (Biosystems, 2012).
The results from cholesterol measurements follows:
Group 1, N=26, x=5.11±1.76 (CV 17.19%); Group 
2, N=21, x=4.87±1.6 (CV 16.46%); Group 3, N=23, 
x=5.37±1.84 (CV 17.2%); Group 4, N=21, x=5.00±1.76 
(CV 17.67%); Group 5, N=20, x=5.58±1.92 (CV 17.24%); 
Group 6, N=20, x=5.25±1.06 (CV 20.19%); Group 7, N=21, 
x=5.27±2.16 (CV 20.5%); Group 8, N=20, x=5.57±1.12 
(CV 10.1%); Group 9, N=21, x=5.15±2.22 (CV 21.53%); 
Group 10, N=17, x=4.99±1.5 (CV 14.97%).
The results from triglycerides measurements follows:
Group 1, N=24, x=1.57±1,7 (CV 54.12%); Group 
2, N=22, x=1.16±1.0 (CV 43.37%); Group 3, N=22, 
x=1.94±1.06 (CV 27.53%); Group 4, N=21, x=1.20±1.7 
(CV 70.71%); Group 5, N=17, x=1.96±1.58 (CV 40.64%); 
Group 6, N=18, x=1.40±1.8 (CV 64.65%); Group 7, N=20, 
x=1.72±1.86 (CV 54.13%); Group 8, N=21, x=1.73±1.26 
(CV 36.36%); Group 9, N=20, x=1.33±1.08 (CV 40.38%); 
Group 10, N=19, x=1.66±1.48 (CV 44.39%).
Discussion
Biological variation has an important effect on the in-
terpretation of different laboratory investigations, includ-
ing triglycerides and cholesterol. There is also a growing 
interest in evaluating the cut-off limits for the desirable 
thresholds of serum cholesterol and triglycerides accord-
ing to different recommendations and clinical trials, with a 
trend is towards lowering these limits.
The inter-individual variations for cholesterol are 
17.73% and for triglycerides are 49.46%. The study by 
Ford (1989) had reported an inter-individual variation 
17.3% for cholesterol, which is in agreement with the val-
ues observed in our study. The range of variability in serum 
lipid profile between individuals in this study for cholester-
ol is 4.3-6.14 mmol/L, but according to the kit documenta-
tion cholesterol level should be lower than 5.2 mmol/L and 
for triglycerides this range is between 0.79-2.33 mmol/L 
(lower than 1.7 mmol/L declared in the kit documentation).
Conclusion
From the data for cholesterol, with the usage of t-test, 
we can conclude that there are no significant differences 
in the results between different age groups and gender, but 
there is a significance in results for triglycerides (p<0,05) 
between participants with age of 15-49 in both male and 
female groups. The study should be widened with imple-
menting analytical variation and intra-individual data.
Extensive medical research has identified hyperlipid-
emia as a major risk factor for heart disease with an estab-
lished clinical correlation between hyperlipidemia and the 
incidence of Coronary Heart Disease (CHD). The impor-
tance of this study is detection of sudden changes in lipid 
values that may indicate a change in diet, medications, or 
onset of a new disease state.
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Introduction
Many analytes in biochemistry laboratories may vary 
during the life of an individual, simply because there is a 
factor involved in its aging process. Also gender in various 
analytes can play an important role. In our study we made 
a comparison between different age groups, gender and 
reference range for creatinine and urea in serum (Cvitkovic 
and Mesic,1999).
Creatinine is a chemical waste molecule that is 
produced when muscles use creatine, another naturally 
occurring product in the body, to create energy. About 
2% of creatine is converted to creatinine each day. Most 
of the waste creatinine is expelled from the body in the 
urine (Hosten, 1990). The creatinine level measured for 
an individual should be relatively constant over time and 
should be within a “normal” range. The creatinine level 
is one of the main indicators of kidney function. If the 
creatinine level is elevated, the patient should be further 
evaluated for other signs of kidney disease and renal 
problems. Normal creatinine level ranges will depend on 
age, gender and other health factors (Taylor, 1989).
Blood urea nitrogen, known by the simple initials 
BUN is the measurement of urea nitrogen levels in the 
blood. Urea nitrogen is naturally produced by the liver 
as a waste product of digested protein. After production, 
urea is transported to the kidneys where it is excreted from 
the blood stream. The BUN test is therefore conducted to 
determine how much urea nitrogen is still present in the 
blood, and this test mainly determines if the kidneys renal 
functions are working as they should. There are many 
factors that could bring about high or low levels of BUN.
BUN and creatinine tests are often used together to 
determine the ratio of blood urea nitrogen to creatinine. 
The BUN to creatinine ratio ultimately helps the physician 
to find the cause of the poor kidney function and the causes 
may vary from dehydration to malnutrition or kidney 
failure.
Methods
Analysis of serum creatinine and urea was performed 
on blood specimens collected by the standard procedure. 
Fasting venous blood was collected at 8-10 am following 
an overnight fast, from apparently healthy participants 
(men and women, aged 15-65 years). The specimens were 
collected in a period of one year. Serum creatinine and urea 
were measured by enzymatic methods using kits and from 
Biosystems (Spain) and the biochemistry analyzer Mindray 
BS-200. Creatinine was assayed by picrate in alkaline 
medium forming colored complex, Jaffé method (Fabiny 
and Ertingshausen, 1971) and urea by urease/glutamate 
dehydrogenase method (Gutmann  and Bergmeyer, 1974).
Standard statistical methods were used or the analysis of 
data. The mean and SD were calculated for each parameter 
of serum creatinine and urea from each participant. The 
data were inspected for any outlier (defined as values 
outside ± 3 SD from the mean). There was no outlier and 
all results were within the mean ± 2 SD.
Results
The study was conducted with creatinine samples 
from 220 apparently healthy participants with mean value 
of 74.19±23.22 (coefficient of variation (CV) 15.64%) and 
urea samples from 217 participants with mean of 4,88±1,31 
(CV 26,94%). These samples results were divided for 
observation in groups by age and gender. 
There are 10 groups with number of participants: Group 
1 – 15-29 years male, Group 2 – 15-29 years female, Group 
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3 – 30-39 years male, Group 4 – 30-39 years female, Group 
5 – 40-49 years male, Group 6 – 40-49 years female, Group 
7 – 50-59 years male, Group 8 – 50-59 years female, Group 
9 – 60-65 years male and Group 10 – 60-65 years female. 
From these groups 5 groups were made for observation by 
gender. The obtained results from the participants were 
compared with the reference values provided by the used 
kits manufacturer (Biosystems, 2014).
The results from creatinine measurements were as 
follows:
Group 1, N=24, x=79.63±9.67 (CV 12.14%); Group 
2, N=22, x=64.457±9.85 (CV 15.28%); Group 3, N=24 
x=80.42±8.3 (CV 10.32%); Group 4, N=23, x=65.10±7.26 
(CV 11.15%); Group 5, N=22, x=80.23±9.09 (CV 
11.33%); Group 6, N=21, x=63.28±6.75 (CV 10.67%); 
Group 7, N=24, x=81.37±10.68 (CV 13.12%); Group 
8, N=21, x=68.28±6.02 (CV 8.81%); Group 9, N=21, 
x=83.28±10.832 (CV 13.0%); Group 10, N=18, 
x=72.78±9.81 (CV 13.48%).
The results from urea measurements were as follows:
Group 1, N=24, x=4.56±0.88 (CV 19.3%); Group 
2, N=22, x=3.8±1.16 (CV 30.53%); Group 3, N=24, 
x=5.364±1.21 (CV 22.57%); Group 4, N=21, x=3.91±1.33 
(CV 34.01%); Group 5, N=22, x=5.3±1.16 (CV 21.89%); 
Group 6, N=20, x=3.97±0.74 (CV 18.64%); Group 7, N=23, 
x=5.35±1.39 (CV 25.98%); Group 8, N=23, x=5.19±1.49 
(CV 28.71%); Group 9, N=20, x=5.59±1.58 (CV 28.26%); 
Group 10, N=18, x=5.56±1.29(CV 23.20%).
Discussion
Blood and urine analytes concentrations vary due 
to age factors from infancy to old age. From infancy 
to puberty, serum creatinine concentration uniformly 
increases, depending on the skeletal muscle development.
In the elderly, the kidney concentrating ability is 
decreased, which results in reduced creatinine clearance. 
This is due to a decreased urinary creatinine excretion as 
a result of reduced lean body mass rather than to renal 
dysfunction. Plasma urea concentration and urinary protein 
excretion increase with age. 
In addition to differences in gender specific hormones, 
differences also exist in hematology and clinical chemistry 
parameters. Plasma concentrations of amino acids, 
urea, uric acid and creatinine are higher in males than in 
females. Clinical chemistry analytes are greatly influenced 
by diet and drinking. A high-protein diet increases plasma 
urea, serum cholesterol, and phosphate concentrations. In 
contrast, starvation, fasting and malnutrition also induce 
clinically significant changes in analytes concentrations. 
Long-term starvation entails decreased concentrations of 
blood protein, cholesterol, triglycerides, apolipoproteins, 
and urea. On the other hand, the concentrations of creatinine 
and uric acid increase. Urinary excretion of ammonia and 
creatinine is increased, whereas the excretion of urea, 
calcium and phosphate is reduced. Due to the decreased 
skeletal mass, serum concentrations of urea and creatinine 
as well as creatinine clearance are reduced. Hemolysis can 
cause an interference factor for the analysis of creatinine. 
Also, bilirubin can cause false positive results in creatinine 
determination.
Conclusion
From this data for creatinine, with the usage of the 
t-test, we can conclude that there are significant differences 
in results between different age groups and gender, but 
there is no significance in results for urea for participants 
with age of 50-65 in both male and female groups.
The inter-individual variations for creatinine are 
15,64% and for urea are 26,94%. The range of variability 
in serum creatinine between individuals in this study is 
between 61,57-100,4 µmol/L for male participants and 
50,9-82,66 µmol/L for female, but according to the kit 
documentation creatinine levels should be 62-106 µmol/L 
for male and 44-80 µmol/L for female. For urea this range 
is between 2,08-7,64 mmol/L (2,6-6,5 mmol/L by the kit 
documentation).
It is of great importance that physicians be aware 
of these factors, because the final interpretation of the 
analyses and decisions on therapeutic procedures based 
on this interpretation actually lead to the physician’s final 
judgment. In this process, the laboratory should act as a 
reliable and consistent collaborator.
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Introduction
Opiates are one of the most frequently analyzed psy-
choactive substances due to their high abuse potential. 
Worldwide urine screening tests use for preliminary re-
sults of opiate abuse for employees in the workplace, ath-
letes in doping control and etc. (Lachenmeier et al., 2010; 
Lum and Mushlin, 2004). However, existing problem in 
interpreting the results of opiate urine analysis arises be-
cause immunoassays screening tests have high sensitivity 
but lower specificity because of cross-reactivity with sub-
stances other than the drugs in question (Lum and Mush-
lin, 2004). Therefore, it is well known that positive opi-
ate results may be obtained during drugs of abuse screen-
ing related to certain drugs and food intake (EFSA, 2011; 
Jankovičová et al., 2009; Lachenmeier et al., 2010; Lum 
and Mushlin, 2004). 
Seeds of the opium poppy plant are legally sold and 
widely consumed as food. Morphine and codeine are nat-
urally occurring substituent of the poppy plant, Papa-
ver somniferum. The opiate content of poppy seeds var-
ies greatly and is dependent on the seed origin and meth-
od processing (EFSA, 2011; Samano et al., 2015). Due to 
contamination during harvesting, the seeds can contain 
morphine and other opiate alkaloids (Lachenmeier et al., 
2010). Literature data and our previous case study indi-
cate that consummation of both, raw poppy seeds and bak-
ing mixtures, induce positive immunoassay test for opiates 
(Đukić-Ćosić et al. 2014; Jankovičová et al., 2009; Sama-
no et al., 2015; Smith et al., 2014). However, the time pe-
riod during which it is possible to obtain false positive opi-
ates results is not yet sufficiently understood.
The purpose of this case study was to determine time 
period of presence of opiates in urine after the consump-
tion of product which contain poppy seed using immuno-
assay test and liquid chromatography-mass spectrometry 
(LC/MS) technique. 
Materials and methods
Female participant age between 20 and 25 years with-
out previous known history of substance abuse provided 
written informed consent to participate in this case study. 
Participant consumed a piece of strudel with poppy seeds 
from a local bakery in the morning on the first day and 
collected ad libitum each urine sample during next three 
days. Urine samples (n=8) were collected 5, 12, 24, 30, 
36, 48, 60 and 72 hours after strudel ingestion. Specimens 
were analyzed with the Opiates Test Card (MP Biomed-
icals, LLC, California) immunoassay at 300 ng/mL cut-
offs, and all positive samples were quantified for morphine 
and codeine by LC/MS. Urine specimen was prepared us-
ing liquid/liquid extraction of opiate by mixture of chloro-
form and isopropanol (9 : 1; v/v). Extracts were analyzed 
by LC/MS technique: separation column Waters Spheri-
sorb 5 μm, ODS2, 4.6 x 100 mm; mobile phase: ammo-
nium acetate:acetonitrile (80 : 20; v/v), mobile phase flow 
rate 0.3 mL/min; mass detection range: 100-400 m/z.
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Results and discussion
The screening immunoassay test for opiates (cutoff 
300 ng/mL) was positive for all investigated urine samples. 
These results in accordance with previous studies that pop-
py-seed food products, such as poppy-seed strudels, may 
cause a true-positive immunoassay screening test for opi-
ates due to the presence of low, but still detectible, levels of 
opium alkaloids (Lum and Mushlin, 2004). The morphine 
content in poppy seeds from around the world is variable 
(0.1-294 mg/g), and exposure concentrations depend on 
poppy seed origin, harvesting procedure and the method 
of poppy seed foodstuffs preparation (Samano et al., 2015; 
Thevis et al., 2003). Significant reductions in opiate con-
tent have been documented after food preparative process-
es, with decreased drug concentration shown after wash-
ing, soaking, grinding and baking (Lachenmeier et al., 
2010; Samano et al., 2015). To minimize the number of 
positive opiate tests resulting from poppy seed consump-
tion, cutoff concentration for morphine and codeine raised 
from 300 to 2,000 ng/mL (Lachenmeier et al., 2010; Sa-
mano et al., 2015). However, only screening immunoassay 
test for opiates with lower cutoff  (300 ng/mL) are avail-
able in our country. 
In all investigated urine samples, morphine and co-
deine concentrations were determined by LC/MS. The 
following values were obtained for morphine: 0.25, 0.06, 
0.05, 0.04, 0.02, 0.02, 0.01 and 0.01 mg/L, and codeine 
0.07, 0.09, 0.06, 0.02, 0.009, 0.008, 0.001, 0.001 mg/L, re-
spectively. The highest measured concentration of mor-
phine and codeine was obtained at 5 and 12 hours, respec-
tively. This is in agreement with literature data that peak 
concentrations of morphine and codeine appeared 4-12 
hours after consumption of poppy seed (Lachenmeier et 
al., 2010). However, for interpreting urine opiate results 
need to know that measured concentrations of morphine 
and codeine after the consumption of products which con-
tain poppy seed are noticeably lower then concentrations 
of opiates which can be measured in urine of opiate abus-
ers. Furthermore, presence of heroin metabolite 6-mono-
acetylmorphine can be detected in urine of opiate abusers 
using LC/MS or GC/MS techniques (Lachenmeier et al., 
2010; Samano et al., 2015). 
In contrast to results of this case, the most studies with 
intake of poppy seeds, raw and cakes, shows that urine 
samples were negative by 20 hours after consumption 
(Jankovičová et al., 2009; Lachenmeier et al., 2010; Smith 
et al., 2014). Present data show that, even 72 hours after the 
oral intake of strudel containing poppy seeds, the urinary 
level of opiate alkaloids can be detectible. Namely, approx-
imate detection time of opiates of abuse in urine is up to 
three days and these data demonstrated that opiates can 
be detected in urine after consumption poppy seed stru-
del during the same time period as in users of psychoactive 
substances. Thevis et al. (2003) also demonstrated positive 
opiate urine at 48 h after consumption a typical poppy seed 
cake with high morphine content (151.6 mg/kg). The con-
sumption of poppy seed products in those out-of-competi-
tion time spaces might be considered as non problematic, 
but the long length of stay of opiates in urine samples can 
lead to positive doping results in competition tests up to 
three days after oral intake of cakes with poppy seeds (The-
vis et al., 2003; Lachenmeier et al., 2010). 
Conclusion
The results of the present case study support previous 
findings and confirm that opiates can be detected in urine 
after consumption popular poppy seed strudel. However, 
these data indicates that time period of presence of opiates 
in urine can be prolonged after consumption of this prod-
uct. This finding should be taken into account in routine 
testing of employees in the workplace, members of the mil-
itary, students in schools, as well as athletes. 
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Introduction
Cabbage (Brassica oleracea var. Capitata) is a vegeta-
ble crop, economically important in Republic of Macedo-
nia. In nutrition, it is used in fresh or processed state.
Dobrićević et al. (2006), have determined the chem-
ical composition of 100 g of cabbage, where the amount 
of vitamin C ranges from 20 to 100 mg/100 g, dry mat-
ter content from 5% to 9%, fiber 1.0% to 1.7%. Accord-
ing to Rumeza et al. (2006), the water content in cabbage 
was 92%, protein 1.6%, fat 0.2%, carbohydrates 4.8%, ash 
0.6%, Ca 52 mg/100g and P 44 mg/100g. The energy val-
ue is 24 kcal/100 g. Vitamin C which is contained in the 
cabbage has antioxidant effect, it protects the human body 
from stress, and it is a cofactor in several vital enzymat-
ic reactions (Cauniietal, 2010). According to Gjorgjev et 
al. (2008), the content of Ca and P in cabbage is in pro-
portion that contributes to a better use of these micronu-
trients for growth and development of the organism. There 
are also the following elements: K, Na and Cl, and the 
trace elements: Cu, Zn, Co and Mn (Lambaša, 2006). Cab-
bage contains a significant amount of aromatic substanc-
es and organic acids, which give the typical taste and smell 
(Gjorgjev et al., 2008). Fresh cabbage has healing proper-
ties when treating stomach ulcer, protects mucous mem-
branes, strengthens the immune system against many dis-
eases, increases hemoglobin in the blood and cures anemia, 
affect the normalization of blood pressure, cures rheuma-
tism, reduces the risk of colon hose etc (Vlahović, 1999).
During the drying process on appropriate temperature, 
free water evaporates which preserves the stability of the 
product from microbiological and chemical aspect. The 
content of water in the dried vegetables ranges from 8 to 
12%. At the same time, it the concentration of sugars and 
other ingredients is increased (Katalinić, 2006). During the 
drying process it is important to apply appropriate temper-
ature, otherwise it will adversely affect the texture and the 
color (Karakashova, 2003).
Hussein (2012), determined the chemical composition 
of the dry cabbage: water content 7.25%, proteins 14.34%, 
fat 0.97%, fiber 21.64%, ash 5.82%, carbohydrates 71.62% 
and phenolic components 81.58 mg/100 g.
Materials and methods
The research in both hybrid cabbage, transam (white 
cabbage) and maestro (red cabbage), in fresh and dried 
samples showed: total dry matter content, soluble dry mat-
ter, total acids, reducing sugars, ash, calcium, phosphorus, 
vitamin C, chlorophyll and anthocyanins.
In the analysis were used the following methods: total 
dry matter with drying chamber at T 105 °C to a constant 
mass; soluble dry matter by refractometer at 20 °C; vitamin 
C by Tillmans method with 2,6-dichlorophenolindophenol; 
total organic acid with 0.1 M solution of NaOH; reduc-
ing sugars by Luff-Schoorl method; total mineral matter 
(ash) in Muffle furnaces on 550 ºC; calcium and phospho-
rus were studied by the ICC ENISO14082:2003 method. 
Quantification of chlorophyll and anthocyanins was per-
formed by using a spectrophotometer, for chlorophyll at 
a wavelength 662 and 644 nm, and for anthocyanins at a 
wavelength of 700 and 420 nm.
The obtained results were statistically processed, using 
a special computer program (SPSS for Windows, Sum of 
squares procedure, Model III). 
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Results and discussion
The tested hybrids transam and maestro have Dutch 
origin, they have high dry matter content and are suitable 
raw material for the manufacturing industry.
Determination of total dry matter content is an impor-
tant parameter according to which are determined the qual-
ity features of tested hybrids in fresh state, as well as in 
dried products. It was determined that the average content 
of the total dry matter content of the hybrid maestro was 
7.50% in fresh and 86.85% in the dried samples, while hy-
brid transam had a value of 8.45% in fresh and 88.4% in 
the dried samples. The average content of reducing sug-
ars in hybrid transam was 4.40% in fresh and 39.75% in 
the dried samples and in the fresh head of cabbage of hy-
brid maestro is3.6%, while in the dried samples is 33.95%.
The total acids in fresh head of cabbage of the hybrid 
transam are 0.19% and for hybrid maestro are 0.21%, while 
for the dried samples they are 1.63% for hybrid maestro, to 
1.76% for the hybrid transam. The tests for vitamin C in 
hybrid maestro in fresh head of cabbage determined aver-
age content of 80.95 mg/100 g and 31.69 mg/100 g in the 
dried samples, the hybrid transam in fresh head of cabbage 
is 19.50 mg/100 g and 17.7 mg/100 g in the dried samples.
The average ash content in both fresh tested hybrids was 
0.53% for the maestro and 0.63% for transam, while for the 
dried samples were determined values of 5.70% for the mae-
stro and for the hybrid transam the value of ash was 6.20%. 
By analyzing the average calcium Ca content in tested fresh 
hybrids determined were the following values: 80.95 mg/100 
g in hybrid maestro and 45.15 mg/100 g in hybrid transam. 
Unlike in the fresh, in the dried samples the Ca is more com-
mon in the hybrid transam 41.11mg/100 g than in the hybrid 
maestro 36.26 mg/100 g. The average content of P for both 
tested hybrids in fresh head of cabbage was 0.53 mg/100 g 
for maestro and 0.63 mg/100 g for transam. In the dried sam-
ples were determined values of P 23.6 mg/100 g in hybrid 
transam and 21.2 mg/100 g in hybrid maestro.
By analysis of variance and LSD test at the level of 
0.05 and 0.01, it has been determined a statistically signif-
icant difference in values for all tested parameters between 
both hybrids for both the fresh and the dried samples.
In the hybrid transam in fresh state it has not been 
quantified the presence of chlorophyll. In the dried samples 
of the hybrid transam was found a greater concentration 
of chlorophyll b (0.24 mg/cm3) compared to chlorophyll a 
(0.20 mg/cm3). The presence of anthocyanins is found only 
in hybrid maestro. In the fresh head of cabbage was found 
more anthocyanins content, 7.14% and 1.5% polymeric 
dyes, compared to the dried cabbage, where the content of 
anthocyanins was 26.04% and 1.0% polymeric dyes. Their 
representation in dried cabbage compared with fresh cab-
bage, point to possible degradation changes of the antho-
cyanins colored matters which occur in the drying process 
of red cabbage.
Conclusion
Based on the analysis it can be concluded that the test-
ed hybrids are characterized by good technological and 
nutritional properties. Better nutrition values are featured 
in dried samples of the hybrid transam than of the hybrid 
maestro. In the hybrid maestro, the value of vitamin C is 
statistically significantly higher than the hybrid transam. 
Dry samples of the hybrid transam contain a larger amount 
of chlorophyll b than chlorophyll a, and of the hybrid mae-
stro contain larger amounts of anthocyanins and polymeric 
dyes compared with fresh red cabbage. Dried cabbage has 
a high nutritional and biological value, and the obtained 
dried product is greatly appreciated and interesting for the 
European and world markets.
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Introduction
In Anatolia, wine production has a long way back in 
history. In fact, Anatolia is believed to be the birthplace 
of vineyards and winemaking. The earliest records regard-
ing Anatolian wine production dates back to the Neolith-
ic age (Ozdemir, 2015). Currently, Turkey ranks fourth in 
the world in terms of area devoted to viticulture and fifth 
regarding the harvested grape tonnage (Peri et al., 2015). 
Grapes of local varieties such as Kalecik karasi, Bogaz-
kere, Okuzgozu, and Papazkarasi are the popular native 
Turkish cultivars of Vitis vinifera L. and they are used along 
with those of French origin for wine production in Turkey. 
The color of its fruits is black with gray bloom (Bozan et 
al., 2008; Peri et al., 2015). On the other hand, the interest 
on fruit wines, which are produced from fruits other than 
grapes, has also been recently increasing. A fruit wine can 
be considered as a biotechnological product of yeast fer-
mentation of natural sugars present in the fruit juice. Gen-
erally, the process for
fruit wine production resembles that of grape wines. 
Consequently, a non-grape fruit wine is a mixture com-
posed of fruit juice, alcohol, and a wide range of biomole-
cules that may already be present in the fruit or be biosyn-
thesized during the fermentation process (Amidžić Klarić 
et al., 2015; Kalkan Yildirim, 2006). Individuals are ad-
vised to boost their intake of dietary antioxidants, since 
they play a major role in increasing the body’s antioxidant 
potential and to provide protection against the harmful ef-
fects of oxidative stress (Willcox et al.,  2004). Recent ep-
idemiological data have clearly indicated that regular con-
sumption of wine in moderate amounts may have positive 
effects on health care. This health-promoting effect is gen-
erally attributed to their rich phenolic content and antiox-
idant effect (Naissides et al., 2006). The antioxidant po-
tential of wine is closely related to its phenols content, 
which may be affected by a number of factors, including 
grape variety, fermentation processes, vinification tech-
niques, ageing, and geographical and environmental fac-
tors (soil type and climate). In this study, selected Anato-
lian red wines and fruit wines were assayed for their poly-
phenols contents. 
Materials and methods
Standard materials of gallic acid (1), chlorogenic acid 
(2), epigallocatechin (3), caffeic acid (4), vanillin (5), p-
coumaric acid (6), rutin (7) and quercetin (8) were pur-
chased from Sigma-Aldrich Chemical Company (St. Lou-
is, MO, USA). Ortho-phosphoric acid (85%) solution, eth-
anol (HPLC gradient grade) and methanol (HPLC gradient 
grade) were from Merck (Darmstadt, Germany). 
Ultrapure water for preparation of mobile phase (18.2 
MΩ.cm at 25 °C) was obtained by using Millipore Sim-
plicity UV apparatus (Millipore , Molsheim, France).
The eıght analytes stock solutions were prepared by 
dissolving weighed amount of the standard substance in 
ethanol at 1mg/mL concentration value. All stock solutions 
were stored in a refrigerator at 4 °C. Combined working 
solutions of mixed analytes at the concentrations of 5, 10, 
20, 50, 100 µg/ml were obtained by dilution of appropri-
ate volume of stock solutions in volumetric flasks. Calibra-
tion curves were plotted, in triplicate, by analysing these 
standard solutions prepared freshly. Concentration values 
of the quality control samples (QC) were 7.5, 30 and 80 
µg/ml. Chromatographic experiments were performed by 
using Agilent 1260 HPLC system consisting of a quaterna-
ry pump model G1311B, an auto injector model G1329B, 
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a thermostated column compartment model G1316A and 
a diode array detector (DAD) model G4212B. The chro-
matograms was monitored and integrated by using Agile-
nt ChemStation software. Chromatographic separations of 
analytes was achieved on an Agilent Zorbax Eclipse XDB- 
C18 column (4.6 mm x 150 mm, 3.5 µm particle size) and 
the column was thermostated at 25±1 °C during analysis. 
DAD signals for every analyte were selected acoording to 
their spectrums obtained from Agilent ChemStation Soft-
ware. Appropriate wavelenghts were selected as: 214 nm 
for gallic acid, chlorogenic acid and quercetin, 306 nm for 
vanillin, p-coumaric acid and rutin, 333 nm for chlorogenic 
acid and caffeic acid. Gradient elution system was used to 
separate all analytes. For this purpose two different mobile 
phase were used; Mobile phase A was 10mM phosphor-
ic acid solution and mobile phase B was methanol using a 
flow rate of 1ml/min. The optimised gradient programme 
was as follows: 0–15 min (0-60% B), 15–20 min (60–80% 
B), 20.0–22 min (80-100% B), 22–27 min (100–0% B) and 
27–32 min (0% B). Samples were injected into the system 
as 10 µl. Both fruit wines and grape wine of Papazkarasi 
type cultivar were purchased from local producers in Tur-
key. After removal of alcohol by using a rotatory evapora-
tor, the residual part of each wine was lyophilized. The ly-
ophilized extracts were dissolved in water at proper con-
centrations prior the experimentation.
Results and discussion
To achieve the best separation different mobile phas-
es were investigated like buffers, organic solvents and dif-
ferent concentrations and different mixtures of these solu-
tions. 10 mM phosphoric acid solution was used as mobile 
phase A and methanol was used mobile phase B for fur-
ther experiments. On the other hand, other chromatograph-
ic conditions like flow rate, injection volume and tempera-
ture were investigated. At the end of experiments optimum 
parameters were determined as 1 ml/min for flow rate, 10 
µL for injection volume and 25°C for temperature provid-
ing the best separation of eight phenolic compounds. In the 
light of this information system suitability test results were 
investigated before validation studies. Six replicate analy-
sis of this standard mixture was performed. Different con-
centration values of each phenolic compounds were inves-
tigated to determine dynamic range for the method devel-
oped. For this purpose standard solutions of each analyte 
as a mixture were prepared daily by diluting from stock 
solution of compounds. Chromatograms obtained for each 
standard mixture were recorded and investigated to deter-
mine calibration parameters of the method. Accuracy stud-
ies for the method developed was performed by three re-
petitive analyzing samples of known concentration at three 
different level as low, medium and high level in dynam-
ic range. For this purpose standard mixtures of each com-
pund at three different concentration values were prepared 
by diluting stock solution and concentration values were as 
7.5, 30 and 80 µg/mL. Precision of the method was investi-
gated bythe way of RSD values obtained from three repeti-
tive analysis of known amount of standards at three differ-
ent level. These RSD values for inra-day studies were low-
er than 1% value that the method very precise in intra-day 
studies. The specifity of the method was demonstrated by 
using spiked wine extract samples. For this purpose each 
standard solution was spiked to same wine extract and ana-
lyzed. It was observed that materials being in wine extract 
samples do not present overlapping peaks with eight phe-
nolic compounds.The method developed and optimized 
was applied for analysis of eight different phenolic com-
pound in different wine extract samples.
Conclusion
The method developed was sensitive, accurate and 
sensitive for analysis of these phenolic constituents in dif-
ferent wine samples.
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Background
The use of nanocarriers for drug delivery represents 
nowadays a promising approach to overcome a series of 
pharmacological shortcomings of drugs, like low target 
specificity, rapid clearance, poor pharmacokinetics, severe 
side effects, and multidrug resistance phenomena. 
Cyclodextrin-based nanoassemblies as drug 
carriers
Supramolecular cyclodextrin-based nanoassemblies 
mediated by host-guest interactions have gained increased 
popularity because of their “green” and simple preparation 
procedure, as well as their versatility in terms of inclusion 
of active molecules (Gref et al., 2012). Here we show that 
original nanoparticlesof around 100 nm are spontaneously 
prepared in water, by a lock and key mechanism involving 
formation of inclusion complexes between CDs on one wa-
ter-soluble polymer and hydrophobic side chains on anoth-
er one (Anand  et al., 2012; Battistini et al., 2008; Daoud-
Mahammed et al., 2009; Fraix et al., 2013; Othman et al., 
2011). Whatever the mixing conditions, nanoparticles 
with narrow size distributions arespontaneously formed 
upon the contact of two polymeric aqueous solutions. Ad-
vantageously, the production of the nanoparticles can be 
scaled-up using a microfluidic device. In situ size measure-
ments helped understanding the mechanisms involved in 
nanoparticle self-assembly. Individual nanoparticle track-
ing analysis enabled to establish that despite the non-co-
valent nature of the nanoassemblies, they were remarkably 
stable, even upon extreme dilution (few ng/mL). Contrast 
agents bearing adamantly moieties were incorporated into 
the nanoassemblies, showing high relaxivities (Battistini et 
al., 2008). Spectroscopic and photophysical studies helped 
understanding the interactions involved in the nanoassem-
blies loaded or not with drugs (Anand et al., 2012). Final-
ly, another set of examples shows the utility of the nano-
assemblies for bimodal anticancer phototherapy (Fraix et 
al., 2013).
Conclusion
This study paves the way towards the “green” scal-
able formation of supramolecular assemblies with poten-
tial uses in cosmetics and drug delivery.
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Introduction
The lecture is intended to provide an overview of the 
use of geomaterials in medical and health care applica-
tions, including their use as active pharmaceutical ingre-
dients and  classical excipients together with new appli-
cations in drug and gene delivery, tissue engineering, as 
well as prospective used in future therapeutics and diag-
nostics trends. Both natural geomaterials and their deriva-
tives are attracting growing attention in a variety of fields 
and in particular as biomaterials. Pharmaceutical technolo-
gy is not an exception and geo-source excipients are com-
peting well with the synthetic materials.
Pharmaceutical uses of geomaterials: from 
conventional to innovative
For thousands of years, humans have been using avail-
able substances to achieve specific functions, including 
their use in contact with living tissues, organisms or mi-
cro-organisms. Like most of the materials used by humans, 
geomaterials are widely mentioned in the literature, and 
occasionally exploited clinically, as such, as devices or as 
part of devices to treat trauma and diseases. These classi-
cal used of geomaterials in health care applications will be 
revised.
In recent decades, research in biomaterials and their 
use in healthcare have increased all over the world. Ap-
plications of biomaterials in human healthcare include the 
development of new medical devices and prostheses, tis-
sue engineering, bone regeneration, implants and surgi-
cal tools, diagnostic techniques, bioadhesives, artificial or-
gans and drug delivery (Larsson et al., 2007). Biomateri-
als for medical applications must be biocompatible, and ei-
ther bioresorbable or biodurable. Nanotechnologies and in-
organic–organic hybrid technologies are currently two of 
the most active approaches to achieve these requirements. 
Many organic–inorganic hybrid materials and nanotech-
nology based targeted drug delivery systems imply the use 
of geomaterials. 
Arrangement, structure and properties of 
pharmaceutically interesting geomaterials
Some geomaterials, and significantly carbonates (and 
carbon structures), phosphates and silicates (special clays 
and zeolites) induce no adverse effect in contact with a liv-
ing organism (biocompatibility) and their presence may be 
beneficial (bioactivity) or without any significant health ef-
fect (bio-inert) but with biodurable properties. The specif-
ic function that a geomaterial have in any formulation de-
pends on its composition, structure and properties, includ-
ing both physical properties (particle size and shape, spe-
cific surface area, texture,…) and chemical features (sur-
face chemistry, charge,…).
Calcium phosphate and calcium carbonate are natural 
nanosized geomaterials than can be used in drug delivery 
and tissue engineering. Calcium phosphate nanoparticles 
can be tailored to be biocompatible and show high adsorp-
tion capacities to be used in controlled and targeted drug 
release.
It must be also remarked all the possibilities in med-
icine of graphitic forms deriving from graphene as fuller-
enes, carbon nanotubes and graphite. The possibilities of 
these carbon materials in health care products are a new 
frontier of pharmaceutics (Hong et al., 2015; Pan et al., 
2012; Sánchez et al., 2012).
S4 OP 158
338
Maced. pharm. bull., 62 (suppl) 337 - 338 (2016)
Pharmaceutical technology and biotechnology / Cosmetology / Biopharmacy
O
ra
l p
re
se
nt
at
io
ns
Calcium carbonate appears as three different anhy-
drous crystalline polymorphs: calcite, aragonite, and vat-
erite. Under standard conditions for temperature and pres-
sure, calcite is the stable phase, while aragonite and vater-
ite are the metastable forms that readily transform into the 
stable phase. Vaterite and other polymorphic forms of car-
bonate are receiving great attention as nanocarriers in drug 
delivery.
Silicates, including some tectosilicates, as zeolites 
(Cerri et al., 2016), but mainly phyllosilicates (clay min-
erals) have also featured in pharmaceutics due to their ad-
sorptive and ion exchange properties (Aguzzi et al., 2007). 
These minerals appear abundantly at the surface of the 
Earth as natural nanoscale particles with layered structures 
and interlayer spaces, which have potential to play a sig-
nificant role as biomaterials. Structurally, the layers, with 
thickness around one nanometre, consist in most cases of 
one or two tetrahedral silicate sheets and one octahedral 
metal oxide/hydroxide sheet. Many clay minerals form 
sheet-like particles or platelets, for example, kaolinite (a 
1:1-type clay mineral) formed by one tetrahedral sheet and 
one octahedral sheet, or talc, vermiculite, montmorillonite 
or saponite and others (2:1-type clay minerals), which are 
composed of an octahedral sheet sandwiched between two 
tetrahedral silicate sheets. Chemically, clay minerals are 
hydrous aluminium or magnesium phyllosilicates, usually 
with variable amounts of iron, magnesium, alkali metals, 
alkaline earths, and other cations present either in the in-
terlayer space or in the lattice framework by isomorphous 
substitution. Uses of clay minerals in healthcare include 
traditional applications but also, as a result of the nano-
metre-scale layering, interlayer spacing and strong electro-
static interactions, the possibility of developing functional 
materials for such advanced technologies as nanotechnol-
ogy and, in particular, biomaterials. Clay minerals and ze-
olites have been proposed as carriers of drugs, genes and 
proteins (López-Galindo and Viseras, 2004). The investi-
gation of geomaterials–drug interaction and release mech-
anisms is an essential contribution for the formulation of 
geomaterial-based drug delivery systems. The possibilities 
of such systems depend on the amount of drug retained by 
the geomaterial as well as on the release kinetics and the 
total amount released in regard of the therapeutic regime.
Some polymorphic forms of silicates resulted in struc-
tures with particular interest. As for example, natural min-
eral nanotubes comprise hollow tubular minerals with na-
noscale diameters.
Modification, functionalization and polymer 
conjugation of geomaterials.
Sometimes, properties of natural geomaterials cannot 
achieve the desired objectives, requiring their modification 
or functionalization as well as the incorporation into poly-
meric matrices to obtain nanocomposites with improved 
properties compared to the individual components (Viseras 
et al., 2008). All these improvements are notably prompt-
ing the availability of optimized and well characterized 
geomaterial-derivatives, suitable for a wide range of bio-
medical applications.
Concluding remarks
The therapeutic advantages of geomaterials in the de-
sign and development of technologically advanced drug 
products make this field of investigation a high-priority de-
velopment area in which the development of new applica-
tions will require the close collaboration of pharmaceutical 
technologist with geologist, and chemists.
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Background
The objective of our new facility of the University In-
stitute of Positron-Emission Tomography  are the produc-
tion of PET radiopharmaceuticals for clinical service of 
in-house patients, commercial distribution of PET radio-
pharmaceuticals and precursors and development of new 
PET radiopharmaceuticals for diagnostic and therapeutical 
purpose. The factors foremost in the planning and design 
phases were the current regulatory climate for PET radio-
pharmaceutical production, radiation safety issues, and ef-
fective production flow. A medium-energy cyclotron (16.5 
MeV) was installed in a bunker with the high-proton ener-
gy to offer a higher product radioactivity. This new state-
of-the-art Positron Emission Tomography (PET) Institute 
and with included research capabilities is dedicated to pro-
viding the highest quality of nuclear imaging research.
Positron emission tomography in the last decade is one 
of the most promising methods of detecting oncological, 
cardiological, neurological diseases and enters slowly in 
the other fields showing hopeful results. The introduction 
of the new radiopharmaceutical for diagnosis and therapy 
in the clinical practice including the clinical trials are pos-
sible only with the appropriate production site according 
all cGMP requirements. 
The new University Institute for Positron Emission To-
mography is in the final official establishment as a unique 
facility in the country and in the Balkan Region. The new 
facility is result of the Government investment and joint 
project with International Atomic Energy Agency (IAEA).
Methodology 
Establishing a PET institution is a large scale process 
that requires careful planning, inputs from multiple stake-
holders, the support and approval of the authorities, secure 
funding, and a detailed implementation strategy. The need 
for a carefully planned strategy is even more essential in 
the conditions prevailing in a developing country, where 
the introduction of PET may be impeded by a scarcity of fi-
nancial resources and, in many cases, an inadequate under-
standing of the potential roles and contributions PET imag-
ing can play in a health care system.
Our new institution integrates Department for Produc-
tion of Radiopharmaceuticals and Department of Molecu-
lar Imaging. They are connected in one unique system of 
Radiation protection, QA, BMS, Informatics and technical 
and administrative support of the network from the unified 
Health Care System in the country (IAEA, No.1, 2009).
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Results 
The facility include cyclotron (GE, PET trace 860) for 
production of ultra-short-lived isotopes (F-18, C-11, N-13 
and optional for solid targets that is planned already during 
the construction). Adjacent to the cyclotron is an area that 
houses the support equipment and a large dedicated work-
shop to support machine maintenance and target develop-
ment. The Radiopharmacy production site contains two 
clean room with controlled-air environment class 10,000 
(M5.5) and access via an interlocking entry change area. 
One completely dedicated for FDG production and sec-
ond for the production of other F18, C-11, N-13, Ga-68 ra-
diopharmaceuticals and Cu-64. The third production labo-
ratory is dedicated for small scale production of diagnos-
tic and therapeutical radiopharmaceuticals for clinical tri-
als and investigation (White S, 2016). A fully shielded hot 
cells (class 100 [M3.5]) is located in all clean rooms. The 
PET radiopharmaceuticals are delivered via shielded tub-
ing between the synthesizers and hot cells. Inside the hot 
cells, there is an automated device for dispensing the PET 
radiopharmaceuticals into either a bulk-activity vial or a 
unit-dose syringe (IAEA 2008). The dispensed PET radio-
pharmaceutical then passes through a hatch to a dedicat-
ed area where it is packaged for in-house use or commer-
cial distribution. Unit doses for in-house patients are trans-
ported via elevator to the PET imaging area away. There is 
extensive radiation area monitoring throughout the facili-
ty that continuously measures radiation levels (IAEA No.1, 
No.58, 2009).
The integrated parts are two QC laboratories well 
equipped and one research laboratory for preclinical inves-
tigation including toxicological studies of new radiophar-
maceuticals and imaging of small animal models.
The Department of Molecular Imaging is located in 
the second floor with two PET/CT cameras dedicated for 
clinical investigation and advanced biomedical imaging in 
human using extensive suite of state-of-the-art internally 
produced radiopharmaceuticals as imaging tools (IAEA 
2010, Calabria and Schillaci, 2016).
This institution will be the full partner to the physi-
cians not only in the country, but also in the region.
PET in that condition may serve as a magnet for re-
cruitment in many areas and promote national and inter-
national interdisciplinary cooperation, to provide universi-
ty educational opportunities for master, doctoral and post-
doctoral studies, specialties in Nuclear Medicine, Radio-
pharmacy and Medical Physics with distinctive strength in 
education and research and an entrepreneurial dimension.
Conclusion
The University Institute for Positron Emission Tomog-
raphy in Skopje will move a nationally and international-
ly recognized unit with true integration of research and ser-
vice to the high level. The heath care for patients will be 
improved in many aspects and will help keeping the PET 
at the forefront of imaging procedures. Our Institute will 
serve as a model for future and more widespread clinical 
use of PET radiopharmaceuticals and provide proficiencies 
how PET technology may facilitate research and develop-
ment opportunities.
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Introduction
Mini-tablets (d≤3mm or 5 mm) are emerging as prom-
ising type of drug delivery platoform suitable in the pro-
duction of both single- or multiple-unit systems. Mini-tab-
lets proved to be suitable dosage forms for targeted pa-
tient groups such as pediatrics, geriatrics and hospitalized 
patients since they may offer ease in swallowing (alone or 
mixed with soft food) and flexible dosing regarding age/
weight/condition. When formulated as multiple unit sys-
tems, mini-tablets offer broad GIT distribution, less signifi-
cant ‘’all or nothing’’ effect and combining different release 
kinetics/compounds in one system (Aleksovski et al., 2015).
Hot-melt extrusion (HME) using circular dies and sub-
sequent extrudate cut is emerging as promising technolo-
gy in the production of mini-matrices aimed to deliver API 
by modified fashion. HME is solvent free process based on 
mixing, kneading, melting and transporting powdered ma-
terials through a pre-heated barrel equipped with one or two 
rotating screws up to an end plate die which determines fi-
nal size and shape of the extrudate (Repka et al., 2012).
The aim of this research was to develop and evaluate 
mini-matrices based on either glyceryl behenate (GB) or 
glyceryl palmitostearate (GPS) for extended drug release 
of highly soluble model drug metoprolol tartrate. Mini-ma-
trices were produced by two different techniques: hot-melt 
extrusion (mini-extrudates, EX) and compression of mini-
tablets from untreated powder mixtures (direct compressed 
mini-tablets, DCMT) or granules obtained by milling ex-
trudates (granule based mini-tablets, GMT).
Materials and methods
The following materials were used: metopro-
lol tartrate (MPT, EsteveQuimica) (20-40%), glyceryl 
behenate(GB, Compritol 888 ATO, Gattefosse) or glycer-
yl palmitostearate(GPS, Precirol ATO 5, Gattefosse) (80-
60%), colloidal Si dioxide (0.5% in extrudates and tablets) 
and magnesium stearate (1% in tablets). The last two were 
replacing suitable amount of the glyceride.
Production methods: HME was performedon a co-ro-
tating twin screw extruder with pre-heated barrel segments 
(entry to die T°C, GB EX -77/75/75/75/72/66 and GPS 
EX - 57/57/57/55/53/50). Obtained strains (d=3mm) were 
manually cut into mini-extrudates of 3 or 5 mm height. 
Mini-tablets (30 mg, d = 4mm) were produced on a single 
punch tablet press by compressing untreated powder mix-
tures (DCMT) or milled extrudates (GMT) 3kN compres-
sion force. When investigating influence of granule size on 
drug release, GMT samples were prepared by granules in 
the range of 0.150 mm ≤ d ≤ 0.250 mm (GMT S) or gran-
ules ranging 0.500 mm ≤ d ≤ 0.750 mm (GMT L).
Evaluation methods: Drug release studies (USP I) were 
carried out in H2O, 0.1 M HCl, phosphate buffer pH 6.8, 
FESSIF with addition of pancreatin and CaCl2 and blank 
FESSIF (without pancreatin, CaCl2, lechitin, and Na tauro-
cholate). Calculation of similarity factor f2 was performed. 
Solid state studies were performed using DSC and X-ray 
diffracttometry. Drug- glyceride interactions were evaluat-
ed by ATR-FTIR, while drug distribution by Raman map-
ping. Matrix porosity was determined by microcomputed 
tomography (μCT). Stability testing was performed at room 
and accelerated conditions in vapor protective bags.
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Results and discussion
HME and granule compression proved to be robust and 
reliable techniques when producing mini-matrices for ex-
tended drug release in all drug to glyceride ratios. Direct 
compression was seen as unsuitable technique due to poor 
flow properties of powders. Drug release from both fresh-
ly produced GB and GPS EX, GMT and DCMT was affect-
ed by the MPT loading.Increasing the loading (from 20% 
up to 40%) led into faster drug delivery, supposedly  due to 
increase in system’s hydrophilicity and formation of more 
open pore structure and thus more rapid MPT leaching in 
the medium. Formulations produced by melting technology 
(EX and GMT) provided increased embedment of the drug 
in the hydrophobic carrier and thus provided slower extend-
ed release pattern compared to formulations made by direct 
compression (DCMT). EX and GMT formulations based on 
20% MPT were chosen for further studies due to most suit-
able prolonged drug release outcome over 24 hours. DCMT 
was not selected as further platform due to abovementioned 
problems with poor flow properties and the low extent of 
drug release retardation. When comparing the delivery of 
20% MPT form either GB or GPS units, GBEX  and GB 
GMT matrices gave similar delivery patterns between them-
selves (square root of time pattern, f2=72) while in case of 
GPS EX and GPS GMT release outcomes were versatile 
with EX sample showing specific sigmoidal release fash-
ion and GMT square root of time release profile (f2=28). 
The sigmoidal outcome could be related to the appearance 
of ‘’wall depletion’’ effect, where due to shearing appear-
ance at the inner surface of the extruder MPT is emerging 
towards the extrudateinterior leaving very thin layer con-
taining mainly glyceride which behaves as a diffusion bar-
rier and thus limits drug release just from the cut sides of 
the matrix surface. During dissolution GPS EX cracks (af-
ter 8 h) which provides faster delivery rate and thus appear-
ance of sigmoidal release pattern.  GB EX and GB GMT 
showed higher porosity and thus faster drug release com-
pared to the same units based on GPS. Porosity of GB EX is 
probably high enough to overcome the ‘’wall depletion’’ ef-
fect. GB EX has more porous and less dense surface appear-
ance compared to GPS EX. Milling the EX breaks the thin 
glyceride layer and thus disable its action as diffusion barri-
er and results in faster release profile of GPS GMT sample. 
Solid state properties (thermal and diffractional) of fresh-
ly produced matrices were slightly different than the ones 
of physical mixtures and also pointed partial solubilisation 
of MPT in the molten glyceride. Raman mapping and ATR-
FTIR measurements indicated uniform drug distribution 
through either GB or GPS matrices and no significant inter-
actions between the drug and used glycerides, respectively. 
Increasing the size of the EX from 3mm to 5mm in both GB 
and GPS samples led into decreased delivery rate due to in-
creased diffusion route and decreased specific surface area 
of the units. Increasing the size of the granules in GB GMT 
led to faster release pattern of GB GMT L compared to GB 
GMT S due to higher porosity and larger pores of first ones 
compared to last ones. GPS GMT showed in general low-
er porosity compared to GB GMT and thus probably bet-
ter compactibility of GPS granulate, which minimized the 
impact of the particle size on the drug delivery profile. GB 
units were insignificantly affected by the pH of the dissolu-
tion medium and presence of biorelevant compounds while 
GPS samples demonstrated faster delivery rate in phosphate 
buffer pH 6.8 compared to 0.1 M HCl and in FESSIF com-
pared to blank FESSIF. Glycerides having higher acid num-
ber (GPS ≤ 6mg KOH/g vs GB ≤ 4mg KOH/g) and shorter 
fatty acid chains (GPS: C16 and C18 vs GB: C22) tend to ex-
hibit increased ionization at phosphate buffer pH (decreas-
ing hydrophobicity) and are more prone to lypolisis respec-
tively, therefore giving slightly faster drug release outcome. 
Storing of GB units and GPS units at increased temperature 
for two months provoked changes in glyceride’s solid state 
properties (GB – thermal changes: increased enthalpy and 
melting point maximum; GPS –thermal changes: increased 
enthalpy and peak maximum and change in the peak appear-
ance; x-ray pattern changes), which was related to the alter-
ations seen in the unit’s drug release outcome after storage. 
GB units gave slower drug release probably due to bloom-
ing effect, while GPS units gave faster release probably due 
to increase in unit’s porosity after storage. Storing units at 
room conditions affected only GPS samples,leading to fast-
er drug release compared to freshly prepared units.Drug re-
lease changes were again connected to changes in the sol-
id state properties of the glyceride. After thermal process-
ing glycerides appear in a layered forms with lower crystal-
linityand are with time and other factors (increased temper-
ature) transformed to a more stable state. Glycerides com-
posed of longer fatty acid chains such as GB tend to change 
their crystalline form slower and at more extreme environ-
ment conditions, while glycerides based on shorter fatty 
acid chains such as GPS are prone to faster crystal altera-
tions already at less extreme conditions.
Conclusion
Obtained results outline GB as more reliable matrix for-
mer for developing extended release mini-matrices com-
pared to GPS. HME appeared as robust and reproducible 
process for mini-matrix production. However, understand-
ing of material features and, HME equipment, process opti-
mization and coupling with suitable down-stream processing 
are prerequisites for successful introduction of this technique 
as a viable alternative to the compression of mini-tablets.
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Introduction
Chronotherapy refers to a treatment method in which 
in vivo drug availability is timed to match rhythms of dis-
ease in order to optimize therapeutic outcomes and mini-
mize side effects (Sajan et al, 2009). The pulsatile drug de-
livery system is intended to deliver a rapid drug release af-
ter a predetermined lag time (Kalantzi et al., 2009). Sim-
ple and inexpensive production methods, such as compres-
sion-coating of tablets, might be effective for these formu-
lations to gain widespread use. Compression-coated tablets 
are composed of an inner core (immediate release tablet) 
which is embedded in an outer coating shell containing ei-
ther a hydrophilic, hydrophobic or a mixture of both poly-
mers, that dissolves or disintegrates slowly to produce the 
lag time. The outer layer surrounds the inner core, there-
fore selection of the outer layer materials has a significant 
impact on the performance of the tablet, including the me-
chanical strength, drug release characteristics, and tablet 
stability (Lin and Kawashima, 2012).
The possibility of formulating compression-coat-
ed tablets of verapamil hydrochloride was examined us-
ing polyethylene oxide (PEO) as polymer in the outer lay-
er. The influence of different types and concentrations of 
polyethylene oxides (PEOs) on the drug release rate was 
investigated. Verapamil hydrochloride was selected as the 
model drug since the symptoms of hypertension are more 
prevalent during the early hours of the morning and devel-
opment of chronotherapeutic formulation could be useful 
to fulfill the needs of drug delivery at the required time.
Materials and Methods
Materials
Different grades of polyethylene oxide polymers – 
Polyox® WSR 1105 (Mr ~ 0.9 x 106) and Polyox® WSR 
301 (Mr ~ 7 x 106) were kindly provided by the manufac-
turer (Dow Chemical Company, USA). Verapamil Hydro-
chloride (Ph. Eur. 8.0), direct compression excipient based 
on coprocessed lactose and polyvinylpyrrolidone (Ludi-
press®, BASF AG, Germany), and anhydrous colloidal sil-
icon dioxide (AEROSIL® 200 Pharma, EVONIK Indus-
tries AG, Germany) were used for the tablets preparation.
Methods
Preparation of tablet cores and compression-coated tablets
The inner cores of the compression-coated tablets were 
prepared by direct compression on an eccentric tableting 
machine (Korsch EK-0, Germany) using 9 mm concave 
punches. Tableting blend consisted of verapamil hydro-
chloride (30% w/w), anhydrous colloidal silicon dioxide 
(1% w/w) and Ludipress® as a diluent.
Compression-coated tablets consisted of the core tab-
let and the PEO polymer (Polyox® WSR 1105 or Polyox® 
WSR 301) as the outer coating agent.  F 1 and F 2 batches 
were prepared using Polyox® WSR 1105 with core: poly-
mer at the following ratios 1:1 and 1:2, respectively. Batch-
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es P 1 and P 2 were prepared using Polyox® WSR 301 with 
core: polymer at the same ratios 1:1 and 1:2, respectively. 
Firstly, half of the amount of the polymer (outer layer) was 
placed in the die to make a powder bed. Then, the core tab-
let was carefully placed in the centre of the die and the re-
maining half of the polymer was filled into the die. The 
contents were then compressed using the eccentric tablet-
ing machine (Korsch EK-0, Germany) to form a flat-faced 
tablet with a diameter of 12 mm.
In vitro drug release studies 
The prepared core and compression coated tablets 
were subjected to in-vitro drug release studies in suitable 
dissolution media to assess their ability to provide the de-
sired release. The in-vitro drug release study of the core 
tablets was performed in the rotating paddle apparatus (Er-
weka DT600, Germany). The dissolution medium was 900 
mL of phosphate buffer (pH=6.8) maintained at tempera-
ture 37 ± 0.5 °C, and the rotating paddle speed was 50 rpm. 
The in-vitro drug release study of the compression coated 
tablets was performed in the reciprocating cylinder appara-
tus (VanKel’s Bio-Dis, USA). The dissolution medium was 
250 mL of 0.1 N HCl for the first 2 h followed by 6.8 pH 
phosphate buffer for the remaining period. Temperature of 
the medium was maintained at 37 ± 0.5 °C, and the dpm 
rate was set at 10 dpm.
In all experiments, an aliquot of 5 mL sample was 
withdrawn at the predetermined time intervals and re-
placed with an equal volume of drug-free dissolution fluid 
in order to maintain the sink conditions. The samples were 
filtered and analyzed spectrophotometrically at 273 nm by 
using UV/VIS spectrophotometer Evolution 300 (Thermo 
Fisher Scientific, Cambridge, UK). The amounts released 
were expressed as a percentage of the drug content.
Results and discussion
The prepared core tablets showed immediate release 
with more than 80% of the drug released in less than 15 
minutes. With compressed-coated tablets, different re-
lease patterns were obtained using either different polymer 
type or polymer concentration. It was observed that the lag 
time increased as the concentration of the PEO in the out-
er coat increased. For instance, formulation F 1 had a lag 
time of 2 hrs before burst release. On the other hand, F 2 
had lag time of 4 hrs. For batches P 1 and P 2, the results 
indicated that that the burst release of the drug occurred at 
3 and 6 hrs, respectively. This also confirms that the lag 
time increased as the concentration of the PEO in the out-
er coat increased, but this increase were different with dif-
ferent types of polymers. An increased molecular weight 
leads to increase in polymer chain length and greater de-
gree of chain entanglement, therefore stronger gel layers 
are formed in contact with water (Colorcon, 2009). Stron-
ger gel layer with the greater viscosity decreases drug dif-
fusion rate and water diffusion within the core tablet which 
consequently delays the drug release. Lower molecular 
weight PEOs form weaker gel layer, which is more sus-
ceptible to erosion. There is no general rule for selection of 
the appropriate polymer concentration that should be op-
timized taking into account the formulation composition, 
polymer molecular weight and drug solubility.
Conclusion
In the present investigation, compression-coated tab-
lets with Polyox® WSR 1105 and Polyox® WSR 301 in 
outer layer showed delayed-release, and drug release from 
formulated tablets showed the dependence on both poly-
mer concentration and its molecular weight. Further op-
timization of the Polyox® WSR 1105 and Polyox® WSR 
301 coated tablets could produce the desired predeter-
mined lag time.
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Introduction
The selection of the crystalline phases in a form of mo-
lecular co-crystals has become scientific challenge at the 
early stage of drug development of pharmaceutical formu-
lations and in the late stage of synthesis and isolation of 
active pharmaceutical ingredients (APIs) in desirable de-
fined crystalline forms. Optimal crystal form of API inter-
actively interrelates and impacts its aqueous solubility and 
dissolution rate that are benchmark for drug delivery and 
absorption determining the extent of its bioavailability and 
pharmacokinetics profile. Determining the crystal struc-
ture and revealing the crystal packing forces and geometry 
of the API has impact its physicochemical properties. This 
approach is the criteria for assessment of the performance 
of the API. The range of crystal forms in which molecular 
co-crystals of APIs may exist is advantageous comparing 
to their polymorphs, salts, solvates and hydrates due to the 
vast number of potential co-formers which extend the lim-
ited counterions for salt formation implying the existence 
of more complex intermolecular interactions based on dif-
ferent H-bonding patterns with API that lead to conforma-
tional changes and flexibility for crystal packing in process 
of co-crystallization.
Co-crystallization became well known bottom-up ap-
proach starting from intermolecular interactions among 
either selected neutral, ionic or zwitterionic molecules to 
design and control the properties of the multicomponent 
crystals (Braga, 2004). In the scope of interest for drug de-
sign and formulation, Good et al. (2009) and Cheney et al. 
(2011) emphasized that the main advantage for designing 
pharmaceutical co-crystals  (PCCs) is, through their mod-
ulating  properties, to improve the performance of the na-
tive APIs such are: biopharmaceutical profile (solubili-
ty and dissolution rate), thermodynamical stability (phase 
transition of polymorphs, solvate/ hydrate formation, de-
composition) or bulk powder processability (flowability, 
compressibility, particle size and shape control). Childs et 
al. (2007) has pointed out the necessity co-crystals (CCs) 
semantically to be classify based on accomplishments in 
research of supramolecular chemistry. This approach en-
lightens the complex reality of multi-component systems 
and the wide scope associated between salts and co-crys-
tals, and their differences based on the location of the trans-
ferred proton within the salt - co-crystal continuum. 
Biguanide drugs are well known and wide used oral 
antidiabetic drugs for oral therapy of diabetes type-2 that 
directly improve insulin action. Recent studies in the re-
search work carried out by Vujic et al. (2015) has point-
ed out that biguanides in combination with targeted in-
hibitors in order to obtain synergy in reduction cell via-
bility, inhibited tumor growth in the mutated neuroblasto-
ma rat sarcoma oncogene (NRAS) protein from melano-
ma cells. Hence, it is expected that combination of bigu-
anides which affect activation of the AMP-activated pro-
tein kinases (AMPK) and the regulation of energy metabo-
lism with outcome to cell’s energy sparing, in combination 
with other anti-cancer drug-models would influence direct 
blocking cell’s signaling and hinder the resistance.
Materials and methods
Co-crystallization screening reveals protocol was un-
dertaken in order to grown single crystalline phases of 
PCCs composed of drug model metformin (MET), selected 
from biguanides class of drugs and coformers that belong 
to different pharmacotherapy and functional group class-
es, respectively.
Co-crystallization screening was carried out on apply-
ing slow-rate solvent evaporation method for growing sin-
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gle crystalline phases at room temperature with quality ab-
solute structure to be determined. An equimolar quantity 
of MET and co-crystal partner was dissolved in the min-
imum quantity of ethanol and left for slow evaporation at 
room temperature. Colorless crystals were observed after 
a few days.  
For four MET PCC models, the methods of prepara-
tion reproducible batches were optimized. The quality of 
batches was controlled by Powder x-ray diffractometer 
comparing the obtained experimental diffractograms with 
the same one that was theoretically generated from the sin-
gle crystal for each of four PCC models.
Single-crystal diffraction data were collected on a 
Nonius Kappa diffractometer equipped with a CCD de-
tector with graphite-monochromatized MoKα radiation (λ 
= 0.71069 Å). Intensities were corrected for Lorentz and 
polarization effects. The structures were solved by direct 
methods with the SIR97 suite of programs and refinement 
were performed on F2 by full-matrix least-squares meth-
ods with all non-hydrogen atoms anisotropic.
Flow-cytometry was applied for measuring viability of 
the two PCC models.
Results and discussion
Vujic et al. (2015) has carried out research for both 
pro-cancer and anti-cancer effects of  biguanides on cancer 
cells, indicating existence of association of the antidiabetic 
therapy and reduced risk of cancer in diabetic patients. Be-
cause biguanide represents the π-conjugated system, MET 
can exist in three resonance-stabilized forms, i.e. as neutral 
molecule (MET), monoprotonated (MET+) or diprotonat-
ed (MET2+) cation, with dissociation constants in water in 
range from pKa1 ≈ 12.00 to pKa2 ≈ 2.00.
A search of the biguanide fragments in the structur-
al literature, both in the CCDC (Cambridge Crystallogra-
phy Database Center) database and in patents, shows that 
in crystals MET exists as   monoprotonated (MET+) or de-
protonated (MET2+) but never in its neutral form MET. 
We have undertaken a systematic study of the crystal 
chemistry of MET with the aim of understanding its prop-
erties in the solid state and finding relationships with its 
biopharmaceutical profile. We have determined the struc-
tures of the 29 MET PCCs. Four of this MET PCC mod-
els are “drug-drug” type of co-crystals.  The ligand used 
for co-crystallyzation was from the following classes: inor-
ganic acids (nitric, phosphoric and carbonic acid); organic 
NH-type acids (saccharine and acesulfame); organic OH-
type acids (squaric and picric acid); monocarboxylic ac-
ids (fumaric, acetic, trifluoroacetic, trichloroacetic, dichlo-
roacetic, monochloroacetic, glycolic, salicylic, diclofenac) 
and dicarboxylic acids (oxalic, malonic, maleic, fumaric, 
succinic, adipic acid). 
Conclusion
In the paper are presented structure analyses for “drug-
drug” type of PCCs where both API and CF exhibit phar-
macological effect. This approach of designing “drug-
drug” type of PCC aligned to the strategy for drug repo-
sitioning, the idea for use of a drug for treating diseases 
other than the drug-specified. This concept was prompt-
ed in 2012 through the Discovering New Uses for Exist-
ing Molecules program, initiated by US’s National Insti-
tute of Health (NIH).
The case study underlines the crystal growth and 
the method of preparation for “drug-drug” type of PCCs 
wherein two different APIs cocrystallized in single crystal 
cell, and that represent new paradigm for approaching in 
development of “fixed-doses” or “combo” pharmaceutical 
formulations. Preliminary results of the Structure-Activi-
ty Relationship study on the co-crystals composed of MET 
with dichloroacetic acid indicate dual and complementary 
anti-cancer activities of the two selected drug models for 
co-crystallization. 
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Introduction
This paper addresses current topics related to CD-20 
depleting agent rituximab, which has been widely used as 
a targeted therapy in the fields of oncology and rheumatol-
ogy. Apart from its structure and function, relevant issues 
regarding the analytical methodologies applied for the as-
sessment of the quality of this complex drug will be high-
lighted as well. 
Rituximab is the first approved targeted biologic ther-
apy for the treatment of haematological malignancies and 
it took very short time from its first description until the 
approval and clinical application. In USA it was approved 
in 1997, whereas in EU in 1998. Approved clinical indi-
cations of rituximab include non-Hodgkin’s lymphoma, 
chronic lymphocytic leukaemia, rheumatoid arthritis and 
granulomatosis with polyangiitis and microscopic polyan-
giitis (European Medicines Agency-EMA, 2016). Since the 
patents on MabThera and Rituxan expire in 2016 in USA 
and have already expired (2013) in EU, there are some bio-
similars of rituximab in the late stages of clinical trials de-
veloped by companies worldwide, whereas ‘non-origina-
tor biologicals’ of rituximab are approved in some South 
American and Asia countries (GaBI, 2016). Pharmaceuti-
cal formulation (Rituxan or Mabthera) is administered in-
travenously and supplied at a rituximab concentration of 
10 mg/ml in either 10 ml or 50 ml single-use vials.
Structure – activity relationship 
Rituximab is genetically engineered chimeric mono-
clonal antibody (mAb) that is produced in mammalian cell 
culture using Chinese hamster ovary cells. This IgG1an-
tibody contains murine light and heavy chain variable re-
gions, and human gamma 1 heavy chain and kappa light 
chain constant regions. During the chimerization pro-
cess, murine variable domain of heavy and light chain was 
cloned into the human IgG1 immunoglobulin framework. 
In the chimerised version only variable domains have mu-
rine origin (around 30%). The rest of molecule is human 
(around 70%). Rituximab binds specifically to the antigen 
CD20, which is found on the surface of normal and malig-
nant B-lymphocytes (Reff et al., 1994), which in addition 
play a role in the pathogenesis of rheumatoid arthritis. The 
Fab domain of rituximab binds to the CD20 antigen on B 
lymphocytes, and the Fc domain recruits immune effector 
functions to mediate B-cell lysis through complement-de-
pendent cytotoxicity (CDC), antibody-dependent cell me-
diated cytotoxicity (ADCC) and apoptosis. 
As all biological drugs, rituximab has very complex na-
ture, it contains 1328 amino acids with theoretical Mw of 
non- glycosylated form 144.54 kDa. It contains two identi-
cal heavy and two identical light chains linked via disulfide 
bridges. Each heavy chain contains 451 amino acids (49.2 
kDa) and pI 8.67, whereas each light chain contains 213 ami-
no acids (23.06.kDa) and pI 8.26. The apparent Mw of ritux-
imab is higher than 144.54 kDa, due to the presence of N-
linked oligosaccharides attached in the N-glycosilation site at 
conserved asparagines N-301. Variable regions of both chains 
comprise complementarity determining regions (CDR1-3), 
being responsible for antigen recognition and binding. On the 
other hand, human Fc γ1 (IgG1) fragment is responsible for 
ADCC and CDC. Heavy chains are linked via two interchain 
disulfide bonds at the flexible hinge region, while heavy and 
light chains are linked with a disulfide bridge. 
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Structural characterization 
As all biopharmaceuticals, especially mAbs, rituximab 
is extremely complex and heterogeneous drug. The main 
source of the antibody heterogeneity results from differenc-
es in protein glycosylation which is one of the most common 
post-translational modifications of proteins produced in eu-
karyotic cells although, primary structure variations, deami-
nation, deamidation, lysine truncation, methionine oxidation, 
sulfation and phosphorilation can create additional IgG vari-
ants. The characterization and stability study of rituximab 
are extensive and require a battery of orthogonal techniques 
as amino acid analysis, amino-terminal sequence analysis, 
peptide mapping, and analysis of oligosaccharides, ion-ex-
change chromatography (IEC), cIEF, SDS-PAGE, and circu-
lar dichroism (CD), UV spectroscopy, size exclusion chro-
matography (SEC), cellular mediated cytotoxicity (CMC). 
The oligosaccharide structure was investigated by CZE 
and MALDI-TOF after isolation from HPAEC-PAD (Eu-
ropean Medicines Agency-EMA, 2016). Two-dimension-
al gel electrophoresis (2-DE) complemented with MALDI 
TOF MS analysis was used for the characterization of iden-
tity, purity and structural integrity of rituximab. Experimen-
tal data revealed typical migration behavior of mAbs, result-
ing in poorly resolved spots with different isoelectric points 
and very small differences in Mw. Heavy chains migrated at 
about 50 kDa and light chains at about 23 kDa. After tryp-
tic digestion of 2-DE separated proteins, peptide mass fin-
gerprinting analysis was also used for the identification of 
rituximab heavy and light chains (Nebija et al., 2011). Gly-
cosylation of IgG is critical for effector functions including 
complement fixation, Fc receptor binding on macrophages 
and ADCC. In addition clearance of IgG-antigen complexes 
from circulation is influenced by IgG glycosylation. It was 
shown that predominantly N-linked oligosaccharides pres-
ent in rituximab belong to asialo, neutral complex biannte-
nary oligosaccharide type different terminal galactose resi-
dues, whereas terminal sialylated oligosaccharides are pres-
ent only in minor amounts (Kamoda et al., 2004).
Manufacturer of pharmaceutical product MabThera® 
as primary assay for characterization and lot release of N-
linked glycans on glycoprotein drugs employed CE-LIF. 
A method for direct characterization of glycans using CE-
LIF/MS has been reported, as well. Apart from major gly-
can components this method allowed accurate identifica-
tion of minor glycans such are asialo- and afucosylated spe-
cies. Since the fucosilation affects biological activity and 
sialylation affects the pharmacokinetics of glycoprotein 
drugs, the identification of these species is of particular sig-
nificance for the characterization of rmAbs. Charged vari-
ants of rmAbs can be studied with different methods such 
as IEC, IEF, CZE. A simple and rapid method for determi-
nation of relative amounts of rituximab glycoforms differ-
ing in terminal galactose was reported. Most abundant ions 
corresponding to the glycoforms found on the rituximab 
heavy chain were monitored by mass selective detection in 
the selected-ion monitoring mode (Nebija et al., 2011).
Lot release testing of the pharmaceutical product 
Rituxan included physicochemical and biological meth-
ods, such as SDS-PAGE, peptide mapping, fragment IEC-
HPLC, SECHPLC, glycan content, cIEF, CDC, UV-VIS. 
Validated human CDC assay was used for the determina-
tion of potency. Galactose content on the heavy chain oli-
gosaccharide was found to be critical parameter for biologi-
cal activity, therefore another release test for glycan content 
was developed (CE-LIF). cIEF was used to positively iden-
tify rituximab from other recombinant mAbs made by the 
manufacturer (US FDA CDER, 2016; Zhang et al., 2016).
Conclusion
As a conclusion, since rituximab belongs to rmAbs, 
class of drugs obtained by rDNA technology, biological 
processes are involved in its production. Therefore it dem-
onstrates high degree of inherent heterogeneity and com-
plexity and the combination of different techniques should 
be used for the extensive characterization of its quality attri-
butes, including identity, structural integrity, purity and sta-
bility. This is of primary importance for the safety and effi-
cacy of this class of drugs. In this regard, it was shown that 
gel electrophoresis and peptide mass fingerprinting analy-
sis may represent an important strategy for the assessment 
of the quality of rituximab and other biopharmaceuticals.  
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Introduction
In the UK, the National Institute of Clinical Excellence 
(NICE) clinical guidance on atopic eczema management 
in children from birth to the age of 12 years establishes 
emollient therapy as the treatment modality that should un-
derpin all else (NICE quick reference guide, 2007). The 
guidance recommends continuing emollient therapy even 
when the skin appears healthy. Healthcare profession-
als are advised to offer children with atopic eczema a re-
gime of ‘complete’ emollient therapy involving a choice of 
non perfumed emollients to use every day, both as leave 
on moisturisers and as soap substitutes for routine wash-
ing and bathing.
Emollient formulations suitable for such use typically 
contain both oily occlusive substances, such as petrolatum, 
paraffin or mineral oil, which form a water impermeable 
film over the skin to decrease evaporation of physiologi-
cal water from beneath, and humectant substances, such 
as glycerol and urea, which attract water to the skin (Cork, 
2007; Loden, 2003; Rawlings et al., 2004; Watkins, 2008). 
In order to encourage treatment concordance, however, it 
is also crucially important that these products are formulat-
ed in such a way that their physical characteristics render 
them appealing for patients to use over large surface areas 
and for long periods (Cork et al., 2003).
Ideally, emollients should exert their skin softening 
and moisturising effects within the upper layers of the 
skin. Thick, greasy ointments undoubtedly exhibit good 
emollient characteristics, but are not very popular with pa-
tients because they are not well absorbed into the skin and 
leave an oily residue which can feel uncomfortable and 
has a tendency to soil clothing and bed linen (Cork, 2007; 
Sidbury and Poorsattar, 2006). More popular emollients 
are formulated as oil-in-water creams or lotions to make 
them ‘feel’ lightweight and to encourage better absorption 
into the skin (Ersser et al., 2007). However, these dosage 
forms are less effective than ointments owing to their low-
er oil content, resulting in reduced occlusive capabilities 
(Clark, 2004) Moreover, cream and lotion formulations ex-
hibit poor substantivity and have a tendency to be easily 
rubbed off onto clothing, so they necessitate more frequent 
re-application than would be practicable for many patients. 
Emollient gels are alternative pharmaceutical presentations 
for atopic eczema sufferers and usually contain high con-
centrations of oily ingredients in semi-solid aqueous sys-
tems. To achieve maximum benefit, some of these gels, just 
like other emollients, need to be applied regularly and fre-
quently.
Performance evaluation methods for emollients and 
moisturisers are mainly focused on sensory aspects, skin 
visual appearance, perceived efficacy, and measurements 
of skin barrier hydration and integrity (Rawlings et al., 
2004). However, few studies have involved patients di-
rectly comparing the effectiveness of different emollients 
by using them concurrently or under conditions mimick-
ing normal therapeutic use (Clark, 2004; Simpson, 2006). 
Consequently, the aim of this study was therefore to 
compare the effects on skin hydration of two emollients 
prescribed in the UK, DELP gel and ZB cream, and us-
ing a dosage regimen consistent with most patients’ prac-
tical circumstances which limits their use of emollients to 
twice daily only. 
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Materials and methods
This was a single centre, randomised, double blind, 
concurrent bi-lateral (within-patient) comparison in 18 fe-
males with atopic eczema and dry skin of similar severity 
on their lower legs. Following 7 days’ run-in with no use 
of emollients or moisturisers on the lower legs, DELP gel 
and ZB cream were each applied to one lower leg twice 
daily (approximately at 9am and 9pm) for 4 days and on 
the morning only on day 5.  Washing of the lower legs was 
permitted only during the evening on days 2 and 4.  The 
efficacy of both products was assessed by hydration mea-
surements using a Corneometer CM825 probe (Courage-
Khazaka electronic). The measurements were made on 
days 1 to 5 at approximately 9am immediately prior to the 
first daily application (the measurement on day 1 being 
baseline), and around 1pm and 5pm. The primary efficacy 
variable was the area under the curve (AUC) of the change 
from baseline corneometer readings over the 5 days. 
Results and discussion
The two emollients showed very different effects on 
skin hydration. The AUC for DELP gel significantly out-
performed ZB cream. For DELP gel, the skin hydration ef-
fect was substantial, long lasting and cumulative, with the 
readings each day generally increasing over the treatment 
period.  Even the morning readings on days 3 and 5, fol-
lowing washing the previous evening, were significantly 
better than baseline. In contrast, for ZB cream, skin hy-
dration was not significantly different from baseline at any 
time point.
Conclusion
This study, performed by subjects with atopic ecze-
ma and dry skin using a dosage regimen simulating nor-
mal/practical use, has demonstrated very significant per-
formance differences between two marketed emollients. 
Whereas DELP gel achieved substantial, long lasting and 
cumulative skin hydration, ZB cream achieved no measur-
able improvement compared to before treatment. Health-
care professionals should be aware of this when prescrib-
ing these products. 
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Introduction
Usually known as Periorbital Hyperpigmentation 
(POH), this deficiency seems to have in literature many 
other denominations, such as: Idiopatic Cutaneous Hyper-
chromia in the Orbital Region, Infraorbital dark circles, 
Cutaneous idiopatic hypercromia of the orbital region  or 
Periorbital melanosis. The lack of a unique denomination 
should not be a serious problem, but behind these incon-
sistencies are usually some different approaches concern-
ing the ethiopathogeny, as well as the targeted pathogenic 
treatment by default. 
The literature data originating from European authors, 
as well as some articles of North Americans ones include 
the periorbital hypercolorations into the chronologic ag-
ing process, with implications resulted from vascular and 
sanguine deficiencies. In other words, it is considered that 
this deficiency is not necessarily originating from a genet-
ic anomaly. This point of view is due to the fact that most 
of the subjects from this geographic area are of pale or fair 
skin phototype (I, II or II phototypes). According to Suppa 
et al. (2011) the determinants of periorbital pigmentations 
and of the skin ageing processes are: UV exposure, smok-
ing, vascular problems. Lupo et al. (2011) consider the in-
trinsic aging role in the periorbital hyperpigmentations pa-
thogeny and suggest a new topical treatment based on hu-
man growth factors, cytokines, caffeine and glycyrrhetin-
ic acid.
On the other hand, literature data attributed to Asian 
or South American authors indicate that the primary cause 
of periorbital hypercolorations pathogeny should be rath-
er melanic, constitutional, and they refer to as subocular 
melanosis. This is probably due to the dark skin phototype 
(IV, V and VI phototypes), specific in these geographic ar-
eas. Some authors point-out the post-inflammatory pig-
mentations’ role onto color intensification of this pathoge-
ny, while in other situations it is exclusively assigned to the 
melanic cause of this process (Kanika and Kassir, 2013). In 
the same time, in the case of subjects with dark skin pho-
totype, it was stipulated that the main causes of periorbit-
al hyperpigmentation could be melanic, without excluding 
the aging specific endogeneous processes as aggravating 
factors. 
Corroborating these different approaches, one could 
consider that the main determinants of periorbital hyper-
pigmentations, for any skin phototype could be: the genet-
ic melanic pigmentation, the post-inflammatory hyperpig-
mentation, a tegument periorbital atrophy due to chrono-
aging, the venous congestion, hemoglobin and oxygenated 
hemoglobin accumulations, hemosiderine deposit, as well 
as some other anatomic causes. 
Materials and methods
The chemicals used in this study were of high puri-
ty grade. Acetyl tetrapeptide-5 (trade name EYESERYL®) 
was obtained as a gift from Lipotec S.A. (Isaac Peral, 17 
Pol. Ind. Camí Ral; E-08850 Gavà Barcelona, SPAIN) as 
0.1% aqueous solution. An o/w microemulsion was used 
as vehicle for the transport of acetyl tetrapeptide-5 through 
the skin. The main ingredients of the microemulsion were: 
deionised water, glycerol, liquid paraffin, vaseline, jellify-
ing and lubricant mineral agents, emulsifying agent (Mon-
tanov L), preservative agents, and acetyl tetrapeptide-5. 
The rheological properties of the microemulsion were as-
sessed using the Rheometer RC1 (Rheotec), and two type 
of probes: CC8 and C25-1. 
The study was carried-on on 2 test groups of healthy 
women volunteers aged of 22 to 64 years. The first group 
applied on both (right and left) eyes hemispheres the o/w 
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emulsion containing 0.1% peptidic complex, twice dai-
ly, during 60 days. The second group (control) applied the 
cosmetic emulsion containing 0.1% acetyl tetrapeptide-5 
only on the right eye suborbital area, while the left eye was 
treated with the simple cosmetic formulation. The effects 
of the cosmetic emulsion were evaluated every 15 days, 
both by clinical and instrumental methods. The instrumen-
tal evaluation was performed by Mexametry, using the MX 
18 Mexameter (Courage-Khazaka), which is able to mea-
sure two components, mainly responsible for the color of 
the skin: melanin and haemoglobin (erythema). 
The aim of the present work was to study in vivo the 
efficiency of the acetyl tetrapeptide-5 in the treatment of 
periorbital hyperpigmentations and eye puffiness, using 
mexametry as one of the most recent non-invasive meth-
od of evaluation of the coloration’s intensity of the sub-or-
bital area.
Results and discussion
In our study, the melanin parameter was excluded due 
to the fact that acetyl tetrapeptide-5 is not considered as 
a melanic depigmentant, lacking any tyrosine inhibitor in 
this composition. Considering that periorbital hyperpig-
mentations are dependent by individual metabolism, the 
relevant parameter used as a measure of suborbital color-
ation was the erythem one.
In the case of the control group, a significant reduction 
of the erythem values was obtained for the right eye, while 
for the left eye, the reduction of the erythem corresponding 
values was quite slight, or (in some cases) none, even at the 
end of the eight weeks of treatment. In the case of the study 
group which applied the o/w cosmetic emulsion containg 
the peptidic complex on both eyes hemispheres, significant 
reduction of the erythem values was recorded, in some cas-
es even after 15 days of treatment. For this group, 25% of 
the volunteers showed a slight reduction, 30% a fairly good 
reduction, and 40% a good one.
Conclusion
In conclusion, mexametry was successfully used as in-
strumental non-invasive method for the investigation of 
periorbital hyperpigmentations as consequence of a spe-
cific cosmeceutic treatment. The obtained results showed 
that the cosmetic formulation containing different amounts 
of acetyl tetrapeptide-5 was well tolerated at the tegument 
level and visible results were obtained, even after only 
15 days of treatment. Moreover, 95 % of the volunteers 
showed a significant reduction of the periorbital hyperpig-
mentations and eye puffiness after the treatment with the 
cosmetic preparation containing acetyl tetrapeptide-5.   
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Introduction
Liposomes are phospholipid-based vesicular carri-
ers that still attract great attention of formulators. Howev-
er, the selection of an appropriate carrier for liposomes re-
mains one of the most important issues. Although, gels are 
still considered as the most suitable bases for liposomes 
(Kulkarni, 2005), they are usually not appropriate, neither 
for the long-term care nor for all skin types. Therefore, 
emulsion systems are believed to be more convenient car-
riers. On the other hand, formulation of an emulsion with 
liposomes entails another problem: selection of suitable 
emulsifier(s) necessary for system stabilization, consider-
ing the fact that emulsifier may interfere with the mechan-
ical stability of vesicles and may enhance propensity for 
fusion or lead to their solubilization (Kulkarni, 2005). An 
interesting and highly promising group of novel emulsifi-
ers which could be used for development of emulsion car-
riers for liposomes are alkyl polyglucosides (APGs). Due 
to their favorable toxicological and dermatological proper-
ties they are considered as environment- and skin-friendly 
(Lukic et al., 2013). 
Therefore, our aim was to investigated whether a nov-
el APG emulsifier, hydroxystearyl alcohol & hydroxystea-
ryl glucoside, could be considered as an appropriate stabi-
lizer for emulsions containing liposomes. To accomplish 
this, a model emulsion carrier with liposomes was formu-
lated and characterized first. Additionally, the in vivo irri-
tation potential of the developed formulation was assessed, 
as a certain aspect of safety of the used emulsifier.
Materials and methods
Hydroxystearyl alcohol & hydroxystearyl glucoside 
was used for samples’ preparation with ARSC-liposomes-
stem cells of alpine rose leaves in liposomes as an active.
Two oil-in-water (o/w) creams (placebo Fp and active 
cream F1a containing 0.4% (w/w) of ARSC-liposomes) 
were developed and characterized by means of: polariza-
tion microscopy, rheology, differential scanning calorime-
try and thermogravimetric analysis as described (Lukic et 
al., 2013). Afterwards, an in vivo study with investigated 
creams and commercially available cream containing the 
same active was conducted. Skin hydration (EC), transepi-
dermal water loss (TEWL), and erythema index (EI) were 
measured in accordance with the Declaration of Helsinki 
and relevant guidelines on 16 healthy volunteers.
Results and discussion
Micrographs taken after 7 days revealed randomly dis-
tributed distorted Maltese crosses and birefringence at the 
oil droplets border (“onion rings”) within both samples (Fp 
and F1a), indicating lyotropic interaction of lamellar type 
(Lukic et al., 2013) and remained relatively unaltered after 
30 days. However, obtained micrographs showed the no-
ticeable difference in the colloidal structure between the 
placebo Fp and the active cream F1a. Considering that li-
posomes are also visible under polarization microscopy, it 
seems that liposome-similar structures could be observed 
near the lamellar phase gel network i.e. close to the “on-
ion rings” in the continual aqueous phase. Intact vesicles 
were apparently immobilized within the network of lamel-
lar phase of the system and as such are mechanically stabi-
lized, hence their interaction and fusion are limited.
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Continual rheology has shown that both samples ex-
hibited “shear-thinning” (pseudoplastic) flow behavior 
with pronounced thixotropy. The obtained flow curves and 
calculated hysteresis area values showed that the addition 
of the 0.4% (w/w) of ARSC-liposomes has led to a slight 
increase in viscosity and thickening of the placebo cream, 
but rheological behavior of both creams stayed rather sim-
ilar. Oscillation frequency sweep test has shown preva-
lence of the elastic over the viscous component as the one 
of the general characteristics of lamellar phase (Lukic et 
al., 2013) for both samples. Active sample (F1a) had high-
er elastic-storage modulus (G’) and viscous-loss modulus 
(G’’) compared to the placebo (Fp) which is in accordance 
with the result of continual rheological measurements. In-
crements in all the assessed rheological parameters upon 
the addition of ARSC-liposomes, could be due to lamellar 
phase promotion by the cosmetic active and the change in 
orientation of the lamellae under shear stress or due to the 
presence of intact liposomes themselves.
Thermal behavior of the investigated samples (Fp, 
F1a) was similar in terms of the shape of the obtained pro-
files with one marked peak. The addition of the liposome-
encapsulated active (sample F1a) induces a subtle shift 
of the curve towards higher peak temperature values. Al-
though such results may imply the promotion of the lamel-
lar phase (Lukic et al., 2013), considering the polarization 
micrographs and the rheology results, it is more likely that 
the detected thermal behavior is due to ARSC-liposomes 
themselves.
Regarding TGA results, upon the addition of the ac-
tive, amounts of the lost water decreased in the first tem-
perature range (25-50 °C, corresponds to the free water in 
the system) and increased in the third temperature range 
(70-110 °C, corresponds to interlamellar water) (Lukic et 
al., 2013). After the addition of ARSC-liposomes there 
was no change in the percentage of lost water in the sec-
ond temperature range (50-70 °C, corresponds to the wa-
ter bonded within the lipophilic gel phase). Based on all 
results, we assume that vesicles packed near the lamellar 
crystalline phase around the oil droplets and their inherent 
water-binding capacity jointly led to the observed transport 
of the water within the system. 
In order to assess the in vivo irritation potential of 
samples (Fp, F1a and Fc) and the investigated emulsifier, 
EI was monitored. Additionally, the potential skin barrier 
impairment was assessed via TEWL and EC. After the 24-
hour occlusion, EI was not significantly changed compared 
to the baseline values for any tested cream. TEWL was sig-
nificantly decreased for the creams Fp and F1a compared to 
the baseline. Considering that TEWL was not significantly 
changed for the commercial cream Fc (the same active, but 
different carrier), it could be speculated that these results 
can be attributed to the carrier itself (system with the liquid 
crystalline structure) and the used emulsifier. Assumption 
is in accordance with the reported results concerning skin 
mildness of this type of emulsifiers (Lukic et al., 2013). 
Regarding EC, it was significantly increased compared to 
the baseline values in all the treated sites, apart from the 
placebo sample Fp where merely a trend of increase was 
observed. Since there was no significant change in the EC 
for the untreated control under occlusion, the obtained re-
sults cannot be attributed to the occlusion. The absence of 
erythema and/or any impairment of the skin barrier func-
tion in a 24-h occlusion study may preliminarily imply a 
satisfying safety profile of the creams and the used APG 
emulsifier.
Conclusion
The study confirmed that a novel alkyl polyglucoside 
emulsifier, hydroxystearyl alcohol & hydroxystearyl glu-
coside, could be classified as liposome-friendly. It was 
shown that in the system stabilized with lamellar phas-
es, liposomes are apparently immobilized within its net-
work and as such are mechanically stabilized. Addition-
ally, due to the lack of skin irritation and skin barrier im-
pairment during the application on healthy skin, it could 
be said that the investigated emulsifier is skin-friendly and 
may be safely applied as stabilizer for cosmetic or prospec-
tive pharmaceutical emulsion carrier for liposomes.
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Introduction
Sunscreen products are cosmetics according to Coun-
cil Directive 76/768/EC (CD 76/768/EC, 1976). The ef-
ficacy and moreover the safety of sunscreen products, as 
well as the basis upon which they are claimed are part 
of extensive research because of the importance over the 
general human health. For the regulation of the sunscreen 
products referral to the EC 1223/2009 of the European Par-
liament (EC1223/2009, 2009) and to the Recommendation 
EC 2006/647 (2006) on the efficacy and claims of sun-
screen products was done. 
Based on this legislation it is necessary to validate the 
photo protection separately in the range of UVA and UVB, 
with in vitro and in vivo methods, with preference for the 
latter. The UVA range (320 - 400 nm) in vivo tests have 
been replaced with the in vitro tests, because of the con-
sideration of the good correlation found, harmonized and 
standardized in the ISO 24443 (2012). For the UVB range 
(290 - 320 nm) the use of the method in vivo is still a ne-
cessity, standardized by Standard ISO 24444 (2010), due to 
problems related to lack of correlation between the in vitro 
and in vivo data. The Sun Protection Factor (SPF) contin-
ues to be widely used for describing the real performance 
of the product as well as its safety, and it is sometimes mis-
understood, as the unique indicator for the efficacy and 
safety. Besides the numerical value of the SPF other prop-
erties and factors have to be taken into account by the con-
sumers. During the last decade the sunscreen formulations 
are enriched with many other ingredients such as boosters, 
antioxidants, immune-modulators. Also into many already 
marketed products for skin care and make up sunscreen fil-
ters are added. 
Accordingly, it is more appropriate to describe perfor-
mance as a whole formula protection factor: Formulation 
Efficiency Factor (FEF) calculated as SPF/actives % x 100 
(O’Lenick and Lott, 2011). FEF as a new parameter in the 
sunscreen research relates the amount of active sunscreens 
in a formulation to the overall SPF of the finished prod-
uct. A formulation chemist can quickly and accurately ap-
ply the method to access the efficiency of a certain formu-
lation. Sunscreens can be classified into three major cate-
gories based on the formulation active ingredients: organ-
ic, inorganic/organic and inorganic. In this complex pat-
tern and to properly address our work toward the develop-
ment of safe and effective solar products, we investigated 
the factors that influence the in vitro SPF determination. 
Having increasing problems in the determination of in vi-
tro SPF values predictive of the in vivo assessment. With 
this work, we intended to evaluate, at first repeatability of 
the measure and, secondly, the accuracy of the same. 
Test variables of the in vitro SPF determination, such 
as substrate surface temperature, substrate choice and pres-
sure of sunscreen spreading have been examined (Miksa et 
al., 2013).
The purpose of this study was to investigate the impact 
of the type of product, way of application and method used 
to determine in vitro SPF.
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Materials and methods
Sun Protection Factor (SPF) measurement and in vivo 
correlation
SPF in vitro assessment was carried out on 80 random 
commercially available products, beside the 3 standard 
products prepared by us as reference formulating SPF from 
low and medium to high. Two different protocols for in 
vitro determination were used: the Diffey-Robson method 
(method A) and the ISO-24443 (method B), using tape and 
PMMA plates respectively with two different pressured ap-
plied (100 and 200 g) for spreadability. In vivo tests of se-
lected products were also obtained for comparison using a 
solar simulator SPF Ultraviolet Solar Simulator 600-150 
W/300 W Multiport that provides ultraviolet radiation in 
the region between 290 and 400 nm from 6 independent 
outputs. The results were collected on 10 volunteers male 
and female, belonging to the phototype I, II and III, aged 
between 20 and 35 years.
Different PMMA’s and surgical tape Transpore TM, 
quantity of product, spectrophotometers (JascoV530PC 
and Shimadzu UV-2600) and method of application (man-
ual and mechanical) were examined. For the ISO-24443 
(method B), the tested product was applied to a new 
PMMA plate of 5 cm x 5 cm area, and 5 µm of roughness 
(Schonberg GmbH). The application rate of 0.0128 g/cm2 
± 0.0003 g was controlled by mass. The application dose 
was determined by measuring the plates before and after 
the spreading operation. The application of the product has 
been realized according to the ISO 24443 (2012) guidelines 
by spotting, with a pipette, the product on several points 
all over the plate surface and then distributed by a finger-
tip, pre-conditioned with the testing sample, for 30 second, 
with light circular movements; the plate is then positioned 
on a scale where the spreading phase is carry out perform-
ing a pattern of movements in horizontal in vertical direc-
tion, checking the pressure applied in all the moments. For 
all the products the spreading pressure is first of 100 g and 
in a second analyze of 200 g. Before the measure the sam-
ple lies for a minimum of 30 minutes in a dark place. The 
spectrophotometer used in this method is a Shimadzu UV 
2600 provided of integrating sphere ISR 2600 60 mm, and 
coupled with a SPF determination software: for each sam-
ple the transmittance is measured from 290 to 400 nm. Ev-
ery product has been measured 3 times, i.e. three different 
product applications on three different plates. Each sample 
has been tested in six different areas at least; therefore the 
results presented come from an average of 15 set of data.
Results and discussion
The in vivo test is only a recommendation (EC 
2006/647, 2006) and in fact many companies, limited by 
the cost of the in vivo procedure, are often relying on sole-
ly the results from the in vitro or even on simulations from 
calculating software, based on the concentration of filters 
used. In our investigation, the limited reliability of in vitro 
method was confirmed on complex formulation. The cal-
culated SPF data indicate that the spreading method devel-
oped in our laboratory is reproducible for all the product 
test e with Cov% values less than 5%. Most accurate re-
sults were obtained with the B method that, in terms of in-
ternal repeatability and of acceptance parameters, provid-
ed some correspondence with values obtained in vivo, in 
particular using PMMA plates standardized as the rough-
ness, pressure, amount of product and way of application. 
In conclusion, our method B gave statistically sound re-
sults and the better correlation between the in vitro and in 
vivo data, these data although preliminary, encourages us 
to further extend the study to a larger number of samples in 
order to better understand if any affordable method can be 
drawn on the basis of these premises.
Conclusion
Our study indicates that the variability of response is 
largely related with the standardization and thus harmoni-
zation of the procedure between different labs and thus we 
suggest joint cooperative efforts toward a possible ISO def-
inition of an SPF-Vitro protocol.
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Introduction
Emollients are therapeutic moisturisers that are usual-
ly available as leave-on formulations of various types i.e. 
creams, ointments, lotions and gels (Ersser et al., 2007). 
These products are used for the treatment of dry skin con-
ditions such as eczema and psoriasis (Voegeli, 2011). Due 
to the wide range of products available on the market it can 
be difficult to recommend the most effective and appro-
priate emollients for the patient. As such, prescribers tend 
to recommend leave-on topical emollient products based 
primarily on patient preference and cost (Moncrieff et al., 
2013). However, to achieve maximum benefit the emol-
lient product must be both clinically effective as well as 
cosmetically appealing (Dederen et al., 2013). It is also 
recognised that emollient preparations are not the same 
even if claimed to be equivalent to other products, hence 
prescribers are encouraged to avoid false economy in their 
prescribing practices (Moncrieff et al., 2013). It is there-
fore critical for manufacturers to develop innovative prod-
ucts with optimised clinical performance and appealing 
sensory characteristics (Herman, 2007). To achieve this, 
application of simple and cost-effective analytical meth-
odologies/approaches that can screen and compare such 
characteristics would be advantageous (Inoue et al., 2013; 
Stojiljković et al., 2013).
Emollient gels are considered one of the most cosmet-
ically acceptable leave-on topical formulations, because 
of their high water content and non-greasy feel (Ersser et 
al., 2007).  These emollient formulations are oil-in-water 
(O/W) dispersions emulsified using, in general, carbomer 
gelling agents. The gelling agent(s) act as a physical stabi-
lizer of the dispersed oil droplets, preventing phase separa-
tion. The effectiveness of these formulations when applied 
to the skin, however, relies on the ability of the gel ma-
trix to deconstruct, enabling the separation of the oil phase 
from the aqueous phase. This has the impact of allowing 
the oils (emollients) to spread easily and form a uniform 
occlusive barrier over the skin surface, whilst prolonging 
emollient retention on the skin by rendering the oily ingre-
dients resistant to re-emulsification (removal) upon subse-
quent contact with water (Ersser et al., 2007). The break-
down of the carbomer gel matrix is influenced by the shear 
applied, but driven by the interaction of the formulation 
with salts on the skin (Noveon, 2002). The interaction of 
the emollient gel formulations with salts is therefore an im-
portant consideration when occlusive performance of the 
product is of concern. 
The purpose of this investigation was to assess the 
physical structure changes under the influence of salts and 
compare two marketed emollient gel products, namely 
Doublebase Gel (DBG) and Zerodouble Gel (ZDG) mar-
keted in the UK.
Materials and methods
Visual appearance
Commercial samples of DBG and ZDG were dis-
pensed into a container measuring 13 mm diameter by 1 
mm deep and leveled using a glass slide. The samples were 
then allowed to stand at room temperature for 48 hours to 
allow evaporation of water. 
Behaviour under the influence of salts
Nearly 10% w/w salt (NaCl) to gel was prepared by 
sprinkling 2.0 ± 0.1 g of NaCl onto 20 ± 0.4 g of each for-
mulation and gently mixed by folding the sample on itself 
ten times using a spatula. They were then left to stand for 
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30 minutes. Untreated control samples for each formula-
tion were folded in the same manner without added salt so-
lution.
Microscopy
Approximately 20 mg of each treated and control sam-
ple was mixed with Nile Red fluorescent dye. The sam-
ples were then placed on microscopic slides and pressed 
with cover slips for 5 seconds. After 1h, the samples were 
viewed under a Laser microscope (Nikon eclipse 90i) x 60 
magnification. 
Results and discussion
Considerable differences were observed between the 
surface characteristics and consistencies of the two formu-
lations prior to salt treatment.  DBG was found to have 
a smoother and a more homogeneous textural appearance 
when compared to ZDG. These differences were found to 
be even more evident on drying under ambient conditions. 
These differences in appearance could result from the man-
ufacturing processes and the composition and quality of 
the ingredients used.
Carbomers are sensitive to the presence of salts. The 
addition of small amounts of salt can be used to thicken 
the emulsion. The thickening of the polymer is brought 
about by repulsion of like charges on the polymer back-
bone, causing the polymer to swell. Most carbomer grades 
have a tolerance limit of 0.1% salt (Noveon, 2002).  In the 
presence of a higher concentration of salt, this repulsion is 
reduced, resulting in the collapse of the extended polymer 
chain and reduced viscosity. This behaviour of the poly-
mer, in the presence of salt, is important for the delivery 
of the emollients during the application of these skincare 
products i.e. the salts on the skin are expected to break 
down the polymer, making the formulation spread more 
easily while releasing the emollient.
The behaviour of the two gel formulations after com-
ing into contact with salt (NaCl) were found to be differ-
ent. The DBG formulation seems to largely break down 
into a liquid (decreased viscosity). The ZDG formulation, 
on the other hand, does not break down and instead appears 
to curdle and become firmer (increased viscosity). This im-
plies that the polymers used in the manufacturing of the 
products are not similar. Furthermore, this difference in be-
haviour demonstrates why the DBG formulation might be 
expected to spread more easily when applied to the skin.
Microscopic examination also revealed differences be-
tween the emulsions, both as original untreated formula-
tions and following salt exposure. For DBG, the structural 
network stabilizing the oil droplets breaks down complete-
ly, releasing the oil droplets from the emulsion. In contrast, 
for ZDG, microscopic examination suggests that the emul-
sion structure does not break down to the same extent and 
manner as DBG. 
Conclusion
Presented work has shown that simple visual inspec-
tion of the physical structures of two emollient gels be-
fore and after interaction with salts can reveal important 
differences between two products that may have implica-
tions for their effectiveness and patient acceptability. The 
two emollient gel formulations studied have quite different 
visual appearances and behave very differently in circum-
stances mimicking contact with salts on the skin. In con-
trast to ZDG, DBG is a homogeneous gel that completely 
breaks down in the presence of salts, releasing the oil drop-
lets from the emulsion. This has very important implica-
tions in relation to clinical performance and patient pref-
erence, where the ease with which the oily ingredients can 
be spread, irreversibly delivering a uniform and occlusive 
barrier over the skin, are crucial. These results therefore 
point to qualitative differences between the formulations 
and very likely reflect important differences between their 
respective manufacturing methods and ingredients. 
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Introduction
Topical leave-on emollient gel formulations are one of 
the most cosmetically acceptable therapeutic moisturisers, 
because of their non-greasy feel (Ersser et al., 2007). These 
oil-in-water (O/W) dispersions use carbomer as both the 
gelling and emulsifying agent. Whilst the carbomer acts to 
physically stabilise the dispersed oil droplets and thus pre-
vent phase separation, its ability to deconstruct once ap-
plied to the skin is an important indicator of the effective-
ness of these formulations. Deconstruction/breakdown of 
the gel matrix, due to contact with salts in the skin, results 
in phase separation of the oil from the aqueous phase, al-
lowing the emollients (oils) to spread easily and form a 
uniform occlusive barrier over the skin surface. This also 
has the impact of prolonging the emollient retention on the 
skin by rendering the oily ingredients resistant to re-emul-
sification (Ersser et al., 2007). 
When applied, the ability of the gel formulation to 
spread easily and leave a uniform occlusive layer of emol-
lients on the skin is reliant on the textural properties i.e. 
firmness/stiffness of the gel matrix. These textural prop-
erties also have an important impact on the cosmetic ac-
ceptability of the formulation, such as the stickiness of the 
gel, which may influence the patient’s willingness to gen-
erously apply the product, and therefore obtain the maxi-
mum benefits. 
Interaction with salts causes the carbomer gel matrix to 
break down and it is therefore expected to have an impor-
tant influence on the textural properties (Noveon, 2002). 
Characterizing the textural properties before and after in-
teraction with salts could be an important indicator for the 
performance of the product during application. 
The purpose of this investigation was to compare the 
textural properties of two marketed emollient gel prod-
ucts, namely Doublebase Gel (DBG) and Zerodouble Gel 
(ZDG) marketed in the UK, before and after interaction 
with salt (NaCl).
Materials and methods
Firmness/stiffness and Stickiness by Texture Analysis (TA)
50 g of commercial samples of DBG and ZDG were 
weighed into a beaker and subjected to compression using 
35 mm diameter cylindrical probe (Stable Microsystems 
TA-HD plus) to measure firmness/stiffness and stickiness.
The force was measured as the probe compressed the 
sample by 15 mm distance after an initial trigger force (0.5 
N) at a rate of 0.5 mm/sec.
When 15 mm target distance was reached the probe 
moved back to its starting position at 10 mm/sec recording 
the force required to separate the probe from the sample. 
This force is an indicator of stickiness. Samples were ana-
lysed in triplicates.
Spreadability by TA
1.1 ± 0.1 g of samples were compressed between two 
glass plates using predetermined forces, namely 1, 5, 20, 
40 and 50 N. At each force the area of spread was marked 
out and calculated.
Different samples were used for the measurements of 
speadability at each force applied.
Behaviour under the influence of salts
Nearly 10% w/w salt (NaCl) to the gel were prepared 
by sprinkling 2.0 ± 0.1 g of NaCl onto 20 ± 0.4 g of each 
formulation and gently mixed by folding the sample on it-
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self ten times using a spatula. Firmness/stiffness, stickiness 
and spreadability of these samples were determined in the 
same manner as pre-treated samples.
Results and discussion
Firmness and stickiness of moisturisers are impor-
tant sensory characteristics for consumers (Herman, 2007). 
Furthermore, firmness of the formulations contributes to 
the ability of the material to spread. These properties of the 
products were investigated using texture analysis, which 
allows for the determination of the force required to com-
press the formulation (a measure of firmness) and the force 
required to separate the probe from the sample (a measure 
of stickiness).
Considerable differences were observed between the 
two untreated formulations in terms of firmness and stick-
iness. ZDG appears to form a significantly firmer (3.6 ± 
0.1 N) and more sticky (3.7 ± 0.2 N) polymeric structure 
in comparison to DBG formulation (2.6 and 2.5 N for firm-
ness and stickiness respectively). 
Upon treatment with salts, the DBG polymeric struc-
ture readily breaks down, resulting in extensive loss of 
firmness. In contrast, significant firmness of the ZDG 
structure was maintained after exposure to salts. The stick-
iness of the products could not be differentiated after salt 
treatment.
Important differences in spreadability were observed 
between the two emollient gels under applied force. The 
DBG formulation spread more easily than ZDG. For ex-
ample at 20 N of applied force, the untreated DBG formu-
lation spread over an area of 24.6 ± 0.1 mm2, whereas the 
ZDG formulation spread over an area of 16.2 ± 0.1 mm2. 
The capability of DBG to spread was greatly increased 
when exposed to salts and demonstrates a 27 % increase in 
area of spread. Interestingly, no such effect was observed 
for ZDG as no substantial difference was observed be-
tween the ZDG samples prior to and after being exposed to 
salts (15.4 mm2 area of spread obtained).
Conclusion
The presented work shows that these two emulsified 
gel formulations have different textural characteristics, 
with DBG being a less firm and less sticky gel that spreads 
more easily in comparison to ZDG. These two gels also be-
have very differently in circumstances mimicking contact 
with salts on the skin.  In contrast to ZDG, the DBG poly-
meric structure readily breaks down when exposed to salts, 
resulting in extensive loss of firmness and increased ability 
to spread. The study data highlights important qualitative 
differences between emollient gel products, which may 
have resulted from differences in their respective manufac-
turing methods and ingredients. This may in turn, have im-
portant implications for clinical performance and patient 
preference. Furthermore, this type of study points out the 
need for more comprehensive analysis of products as pa-
tient and prescriber perceptions may lead them to select 
products that sometimes may not be as beneficial as they 
believe. Development of new methodologies for the as-
sessment of emollient gel products is therefore necessary 
to fully assess the potential performance of such products. 
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Introduction
The present study investigated the transcellular and 
placental permeation of cefuroxime, an antibiotic used in 
cesarean sections, in pregnant women with diabetes and 
hypertension. Previous studies have shown that infections 
after cesarean section could be decreased using preop-
eratively an antimicrobial agent (Chelmow et al., 2001). 
However in order to achieve therapeutic concentrations in 
both maternal and fetal serum and amniotic fluid, antibiot-
ic have to pass placental barrier. It is proven that a single 
dose of intravenously administered antibiotic is as effec-
tive as multiple doses given perioperatively (Lamont et al., 
2011). Accordingly, single doses of cefuroxime have been 
widely used for antimicrobial prophylaxis during cesare-
an delivery. Previous studies have shown that cefuroxime 
concentrations in amniotic fluid and in umbilical cord plas-
ma are sufficient to combat most microorganisms. Howev-
er, diseases such are hypertension and diabetes could alter 
placental transferto the extent that the prophylactic effect is 
lacking in both the mother and fetus. Therefore, the aim of 
this study was to determine the effects of diabetes and hy-
pertension on the transplacental permeation of cefuroxime.
Materials and methods
Fifty-three women scheduled for cesarean section were 
divided into three groups: healthy women (n = 18), wom-
en with arterial hypertension (n = 21), and women with 
gestational diabetes (n = 14). All women received 1.5 g, 
intravenously cefuroxime. Study was conducted in accor-
dance with international ethical guidelines (CIOMS) and 
the study protocol was approved by Ethics Committee of 
the Gynecology and Obstetric Clinic of Clinical Centre of 
Vojvodina (no. 100-08/9). Informed consent was obtained 
from each woman before enrolment in the study. The study 
was designed as an open-label study. Each intravenous in-
jection of cefuroxime was completed in less than 1 min. 
Sampling points were chosen in order not to disturb reg-
ular cesarean section procedures in the clinic. Blood sam-
ples were collected from mothers after administration of 
cefuroxime before delivery (t1), at the time of delivery (t2), 
and after delivery (t3). At delivery, umbilical venous and 
arterial samples were obtained from a section of umbili-
cal cord (cross-clamped at delivery). Estimated gestation-
al age at birth, weight, length and 1and 5 min Apgar scores 
were recorded. Concentration of cefuroxime was measured 
using a modification of an HPLC method described previ-
ously (Szlagowska et al., 2010). Pharmacokinetic parame-
ters were calculated for each woman using plasma cefurox-
ime concentration data with WinNonLin version 4.1 (SCI 
software, Pharsight Corporation, Gary, NC, USA). The ef-
fects of diabetes and hypertension on cefuroxime placen-
tal-permeation were assessed by the fetomaternal plasma 
concentration ratios (Cv/Cm) and umbilical cord venous 
blood (Ca/Cv). Results were compared using ANOVA test 
(p˂0.05).
Results and discussion
Neonates born to women in the hypertensive group 
had significantly lower body surface area (BSA), weight, 
5-min Apgar score, and gestational age than neonates born 
to women in the control group. Neonate characteristics in 
the diabetic group did not differ significantly compared 
with either the hypertensive or control groups.
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Tthe Ca/Cv ratio in all three groups was near 1, with 
no significant differences among the control, hypertensive, 
and diabetic groups (1.01±0.16, 1.06±0.23, and 0.95±0.34, 
respectively). This correlates with the physicochemical 
characteristics of cefuroxime, which is a very hydrophil-
ic weak acid (Log Poctanol/water 0.4) and is almost com-
pletely dissociated at blood pH (7.4) (Holt et al., 1993). 
Thus, the slightly acidic pH of neonatal compared with ma-
ternal blood would not lead to the accumulation of cefurox-
ime in neonates. In the present study, neither hypertension 
nor diabetes had any significant effect on cefuroxime accu-
mulation in neonates. The Cv/Cm ratios were significantly 
lower in the diabetic compared with the control and hyper-
tensive groups (0.36±0.13 vs 0.71±0.46 and 0.59±0.40, re-
spectively). However, there were no significant differenc-
es between the control and hypertension group and because 
gestational age was significantly lower in the hypertensive 
than control group, the findings confirms those of a pre-
vious study that reported that gestational age had no ef-
fect on cefuroxime crossing the placental barrier (Holt et 
al., 1993). Pharmacokinetic parameters, such as drug plas-
ma concentrations at zero time (C0), mean resident time 
(MRT0–t3) and areas under the time-concentration curves 
to infinity (AUCinf) were not significantly different among 
the three groups. The elimination half-life (t½) was signifi-
cantly shorter in the hypertensive than control and diabetic 
groups because the constant of elimination (λz) was higher 
in the former group compared with the latter groups. Ap-
parent volume of distribution and clearance were signifi-
cantly lower in the diabetic group compared with the con-
trol and hypertensive groups. Lower transplacental transfer 
in the diabetic group compared with the hypertensive and 
control groups could be also due to lower volume of distri-
bution and clearance.
Conclusion
Hypertension had no significant effect on the perme-
ation of cefuroxime nor on its pharmacokinetics. Diabetes 
led to decreased placental transfer of cefuroxime, as well 
as volume of distribution and clearance, but did not affect 
other pharmacokinetic parameters. Prophylactic concen-
trations of cefuroxime were reached in all groups, but the 
dosing time of cefuroxime should not be less than 30 min 
or greater than 2 h prior to delivery.
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Introduction
Due to the widespread rise in early detection of high-
risk pregnant women in need of cesareans, its use is rapid-
ly increasing worldwide (e.g. uncontrolled diabetes, hyper-
tension and pre-eclampsia). Diazepam is lipophilic drug 
that is weak base and it is used in the treatment of maternal 
eclampsia and as a premedication in cesarean section de-
liveries. Diazepam readily crosses the blood–brain barri-
er and the placenta by passive diffusion. It is also excreted 
into breast milk and studies showed that diazepam reaches 
equilibrium in the feto-maternal systemic circulation 10-
15 minutes after intravenous administration (Bakke et al., 
1992). Also, some diseases such as diabetes and hyperten-
sion have been associated to impaired placental composi-
tion and functions. Previous studies carried out in our lab-
oratories have demonstrated impaired drug permeation in 
diabetic animals. The development and progression of di-
abetes have been associated with disturbed drug absorp-
tion due to dysfunctional protein expression and function-
ality, impaired transcellular transport and intercellular traf-
ficking as well as altered gut physiology (Al-Salami et al., 
2009). The aim of this study was to investigate the influ-
ence of diabetes and hypertension on the placental perme-
ation of diazepam.
Materials and methods
Pregnant women were recruited from the Gynecology 
and Obstetric Clinic in Vojvodina, Serbia. Pregnant wom-
en scheduled for cesarean section, those who were diag-
nosed with gestational or arterial hypertension as well as 
those who were diagnosed gestational diabetes were in-
cluded in this study. The study protocol was approved by 
Ethic Committee of the Gynecology and Obstetistric clinic 
in Vojvodina (N°00-08/9) and informed consents were ob-
tained from each participant before inclusion in the study. 
A total 75 pregnant women were divided into three groups: 
group 1 (healthy control, n=31), group 2 (diabetic, n=14) 
and group 3 (hypertensive, n=30). Two sets of diazepam 
plasma samples were collected and measured (after the ad-
ministration single dose of 5 mg/day intramuscularly), be-
fore (t1), during (t2) and after delivery (t3). The first set of 
blood samples was taken from the mother (maternal ve-
nous). The second set of samples was taken from the fetus 
(fetal umbilical veins and arteries). Diazepam concentra-
tions in plasma were measured by modified HPLC meth-
od previously described (Rouini et al., 2008). Pharmacoki-
netic parameters were calculated using non compartmen-
tal analyses using with WinNonLin version 4.1 (SCI soft-
ware, Pharsight Corporation, Gary, NC, USA). Values of 
AUCs after delivery were taken as a measure of diazepam 
elimination from blood. In order to assess the effect of dia-
betes and hypertension on diazepam placental-permeation, 
the ratios of fetal to maternal blood concentrations were 
determined. Also umbilical cord arterial to umbilical cord 
venous concentration ratio was determined as a measure of 
diazepam uptake, distribution and/or metabolism in neo-
nates. Data were analyzed by ANOVA test and differences 
were considered statistically significant if p≤0.05.
Results and discussion
All neonates were similar in length, weight and body 
surface area values. Also, there were no statistically signif-
icant differences neither in height, weight nor body surface 
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area of the women between three investigated groups. The 
diabetic and hypertensive groups have 2-fold increase in 
the fetal umbilical-venous concentrations, compared to the 
maternal venous concentrations. Feto: maternal plasma-
concentrations ratios were higher in diabetic (2.01±1.01) 
and hypertensive (2.26±1.23) groups compared with con-
trol (1.30±0.48) while, there was no difference in ratios 
between the diabetic and hypertensive groups. Umbili-
cal-cord arterial: venous ratios (within each group) were 
similar among all groups (control: 0.97±0.32; hyperten-
sive: 1.08±0.60 and diabetics1.02±0.77) and there were no 
statistically significant differences. There were statistical-
ly significant higher AUCs values before delivery in con-
trol and hypertension group compared to diabetes group. 
Meaning that transfer of diazepam in diabetic group was 
higher even though exposure was lower probably due to 
increased permeability of placenta in diabetic women. Val-
ues of AUCs after delivery were statistically higher in con-
trol group compared to hypertension and diabetes group, 
but there were no statistical differences between hyperten-
sion and diabetes group. These results implies that elimina-
tion of diazepam from central compartment is higher in hy-
pertension and diabetes group and that is likely that there 
were more unbound diazepam in the blood in these groups, 
since total clearance of diazepam is directly proportional to 
free diazepam fraction (Riss et al., 2008).
Conclusion
On line with our previous findings which demonstrate 
disturbed transcellular trafficking of lipophilic drugs in di-
abetes, this study shows significant increase in diazepam 
placental-permeation in diabetic and hypertensive preg-
nant women suggesting poor transcellular control of drug 
permeation and flux, and bigger exposure of the fetus to 
drug-placental transport.
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Introduction
Simvastatin is poorly water-soluble drug which belongs 
to class II (low solubility, high permeability) according to 
Biopharmaceutical Classification System (BCS) (Kuentz, 
2012). One of the strategies to improve its dissolution 
rate includes development of self-microemulsifying drug 
delivery systems (SMEDDS). SMEDDS are isotropic 
mixtures of oil, surfactant, cosurfactant, and a drug, 
that under dilution in vivo can spontaneously form 
microemulsions with droplet size less than 50 nm (Gursoy 
and Benita, 2004; Hauss, 2007). 
The aim of this study was to formulate and characterize 
self-microemulsifying drug delivery systems of simvastatin 
with increased dissolution rate of simvastatin.
Materials and methods
Materials
Simvastatin (Ph. Eur. grade) was obtained from 
Hemofarm a.d. (Serbia). Caprylocaproyl macrogol-8 
glycerides (Labrasol®), propylene glycol monocaprylate 
(Capryol™ PGMC) and oleoyl macrogol-6 glycerides 
(Labrafil® M1944CS) were obtained from Gattefossé 
(France). Polysorbate 80 was obtained from Sigma Aldrich 
Chemie GmbH (Germany). 
Methods
Formulation and preparation of SMEDDS
Surfactant phase of Labrasol® as surfactant and Poly-
sorbate 80 as cosurfactant were mixed at fixed weight ratio 
3:1. Oil (Capryol™ PGMC or Labrafil® M1944CS) was 
then added to surfactant phase at varios ratios (from 9:1 
to 1:9) and mixed on magnetic stirrer. After preparation, 
all samples were titrated with highly purified water drop 
by drop. Two single-phase, transparent systems are consid-
ered to be microemulsions and selected for further inves-
tigations. Both samples contained 67.5% Labrasol, 22.5% 
Polisorbat 80 and 10% oil (Capryol™ PGMC-sample F1 
or Labrafil® M1944CS-sample F2). Simvastatin (5% w/w) 
was dissolved in these selected SMEDDS by constant mix-
ing on magnetic stirrer at 50-60 °C until a clear solution 
was obtained (samples F1s and F2s).
SMEDDS characterization
Droplet size determination
Both, unloaded and simvastatin-loaded SMEDDS 
were diluted with highly purified water (1:10). The aver-
age droplet size (Z-ave) and polydispersity index (PDI) of 
unloaded and simvastatin-loaded systems were determined 
immediately after dilution by photon correlation spectros-
copy (NanoZS90, Malvern Instruments, UK) at wave-
length of 633 nm and a scattering angle of 90 °. The results 
were the mean and standard deviation (S.D.) of three con-
secutive measurements for each sample.
In vitro dissolution studies
For in vitro dissolution studies liquid SMEDDS with 
20 mg of simvastatin were filled into hard gelatin capsules 
(size 0), and compared to commercially available tablet 
containing the same dose of simvastatin. 
The dissolution test was carried out using rotating pad-
dle apparatus (Erweka DT70, Germany). The dissolution 
medium consisted of phosphate buffer pH 7.0, the volume 
S4 PP 172
366
Maced. pharm. bull., 62 (suppl) 365 - 366 (2016)
Pharmaceutical technology and biotechnology / Cosmetology / Biopharmacy
Po
st
er
 p
re
se
nt
at
io
ns
was 900 ml, and the temperature of the dissolution medi-
um was maintained at 37 °C with a rotating speed of 75 
rpm. At fixed time intervals (5, 10, 15, 30, 45 and, 60 min), 
10 ml samples were withdrawn from the dissolution medi-
um and replaced by 10 ml of fresh phosphate buffer. Sink 
conditions were maintained at all times. All samples were 
filtered using membrane filter (0.45 μm MF-Millipore® 
membrane filter, Millipore Corporation, USA) and simvas-
tatin concentration was determined spectrophotometrical-
ly at 239 nm (Evolution 300, Termo Fisher Scientific, Eng-
land). The dissolution experiments were carried out in trip-
licate, and data were expressed as mean value ± S.D.
Results and discussion
Droplet size analysis
The average droplet size (nm) of samples F1, F1s, 
F2 and F2s were 18.58±0.04, 46.41±0.17, 11.68±0.12 
and 17.45±0.04, respectively. It could be concluded that 
upon high water dilution both unloaded and drug-loaded 
SMEDDS are capable to form microemulsions, because 
the average droplet size is less than 50 nm (Gursoy and 
Benita, 2004; Hauss, 2007). Slightly higher droplet size of 
F1s, compared to unloaded F1, might be due to the inter-
ference of the drug with self-emulsification process (Gur-
soy and Benita, 2004).
Polydispersity index represents the uniformity of 
droplet size within the formulation and for selected sam-
ples F1, F1s, F2 and F2s were 0.155±0.005, 0.286±0.001, 
0.137±0.016 and 0.168±0.005, respectively. Lower value 
of PDI in sample F2s indicated better uniformity of drop-
let size, in comparison to formulation F1s. Both unloaded 
and SIM-loaded SMEDDS have shown monomodal drop-
let size distribution.
In vitro dissolution study
Comparative in vitro dissolution profiles of 
simvastatin from SMEDDS filled in hard gelatin capsules 
and commercial (immediate release) tablet showed that 
simvastatin was completely released from both SMEDDS 
within first 5 minutes. The release rate of simvastatin 
from SMEDDS was significantly faster compared with 
commercially available tablet (approximately 14.57% after 
1 hour), which might be due to the surfactants present in 
formulations.  Karim et al. (2015) showed that the droplet 
size of the microemulsion could determine the rate and 
extent of simvastatin release, since the in vitro drug release 
was faster from formulations with smaller droplet size. 
However, in this study there was no significant difference 
in simvastatin release between two selected SMEDDS.
Conclusion
Self-microemulsifying drug delivery systems 
(SMEDDS) containing simvastatin were formulated and 
evaluated. Upon appropriate water dilution SMEDDS 
formed microemulsions with droplet size less than 50 nm. 
Although F2s had smaller droplet size and narrower drop-
let size distribution, in vitro dissolution study revealed that 
simvastatin was completely released from both SMEDDS 
(F1s and F2s) in 5 minutes. These results indicated that de-
velopment of SMEDDS could effectively enhance in vi-
tro dissolution rate of simvastatin compared to commercial 
tablet and can be used as possible alternative.
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Introduction
In the last decades, the struggle for efficient targeted 
drug therapy and diagnostics paved the road to clinical use 
of nanomedicines. However, the research and understand-
ing of the interactions among the engineered nanomateri-
als and the biological environment, to date, presents quite 
a challenge. It is becoming clear that, when placed into a 
biological environment, nanoparticles initiate a cascade of 
interactions with the biomacromolecules resulting in the 
formation of the ‘protein corona’ (a layer(s) of proteins 
adsorbed on the nanoparticles surface) (Monopoli et al., 
2011). These interactions can alter the secondary structure 
of the adsorbed proteins promoting instability and/or expo-
sure of new epitopes at the protein surface, thus giving rise 
to unexpected biological responses (Calzolai et al., 2010). 
Undoubtedly, the protein corona modifies the nanoparticles 
interface and thus affects their biological fate and overall 
performance. Therefore the characterization of the interac-
tions at the nano-bio interface will greatly influence the un-
derstanding and capability for prediction of the nanoparti-
cles in vivo behavior. The aim of this work is to investigate 
the effects of the surface properties of different polymer-
ic nanoparticles upon their interaction with a model pro-
tein (bovine serum albumin - BSA) in a binary nanoparti-
cle – BSA system.
Materials and methods
Materials
PLGA-PEO-PLGA (Mw 148KDa and Mw 22KDa) 
was purchased from Akina Inc (USA). Lutrol F127 - 
Poly(ethylenoxide)-block-poly(propyleneoxide)-block-
poly(ethyleneoxide) was kindly donated by BASF (Germa-
ny) and BSA was purchased from Sigma Aldrich (USA). 
Bradford Protein assay dye reagent was obtained from Bio-
Rad (USA). All other reagents and chemicals used were of 
analytical grade.
Methods
Nanoparticles preparation procedure
Nanoparticle formulations were prepared from PLGA-
PEO-PLGA (Mw 70,000:8,000:70,000Da) – NP1 and 
PLGA-PEO-PLGA (Mw 6,000:10,000:6,000Da) – NP2, 
using the nanoprecipitation method, as described previous-
ly (Dimchevska et al., 2015).
Quantification of bovine serum albumin adsorption
All samples were diluted to concentration of 2mg/ml 
and subsequently 1ml from each formulation was mixed 
with 1ml of 2mg/mL BSA solution in phosphate buffer (pH 
7.4). The NP dispersions with BSA were incubated for 1h 
at 37°C in a water bath with horizontal shaking at 100 min-
1. After the incubation, the samples were concentrated to 
1mL using ultrafiltration tubes with pore size of 1000 kDa, 
and washed with phosphate buffer pH 7.4. Blank (BSA 
free) and control sample (without nanoparticles) were also 
used in the experiment. The amount of adsorbed BSA was 
indirectly quantified using the Bradford protein assay. 
Spectroscopic characterization of nanoparticle-bovine se-
rum albumin interactions
The samples were prepared as described above with 
additional freeze drying cycle (-40 °C, 0.055 mBar, FreeZ-
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one 2.5 L, Labconco, USA) in order to remove the water. 
FTIR spectra of the samples were carried out using FT-
IR spectrometer (660, Varian, USA). To calculate the rel-
ative proportions of the different secondary structures of 
albumin, the spectral region of the Amide I (1700-1600 
cm-1) was analyzed with appropriate software for spec-
tral analysis (Grams32, Thermo, USA). Using Gauss-Lo-
rentz transformation, six distinctive peaks of the second-
ary protein structures were analyzed (β-sheets in spectral 
regions 1696-1690 cm-1, 1642-1624 cm-1 and 1618-1613 
cm-1; β-turns in the spectral region 1685-1675 cm-1; α-helix 
in the region 1658-1654 cm-1; random coils in the region 
1648-1640 cm-1). To avoid any influence of the vibration of 
the polymer chains in the region of Amide I, the spectra of 
empty nanoparticles were previously subtracted from the 
spectra of the samples with adsorbed albumin.
Results and Discussion
The results from the quantitative BSA adsorption stud-
ies revealed that 24.6±1.9 and 13.1±0.9% of BSA were ad-
sorbed on the surface of NP1 and NP2, respectively. 
The FTIR spectra of freeze dried BSA revealed broad 
band at 3287 cm-1 that originates from N-H bending vibra-
tions (Amide A). The C-H bending of aliphatic chains can be 
noted on 2960 cm-1, 2933 cm-1 and 2875 cm-1. Strong C-O 
stretching vibration (Amide I) that originates from the am-
ide bond in the peptide chain appears at 1645 cm-1 while the 
Amide II band (mainly N-H bending vibrations) is on 1516 
cm-1. Several bands that represent mainly combinations of 
C-N stretching and N-H bending can be noticed in the region 
from 1400 cm-1 to 1200 cm-1. Distinctive blue shift of Am-
ide I (1654 cm-1) in the spectra of NP1-BSA complex can be 
noticed, relative to the FTIR spectrum of BSA. Such shift of 
Amide I could be attributed to possible secondary structure 
changes of BSA that are initiated as a result of the interaction 
with the surface of the nanoparticles. Also, significant de-
crease in the C-O antisymmetrical stretching vibrations from 
the PLGA blocks was noticed, indicating to possible growth 
of hydrophobicity in the microenvironment of surface ex-
posed carbonyl groups. The FTIR spectrum of NP2-BSA 
complex reveals blue shift of Amide I and II relative to the 
bands on BSA spectrum. Additionally, there is a slight de-
crease of the intensity of the carbonyl C-O vibrations band at 
1756cm-1 and a red shift of the antisymmetrical C-O stretch-
ing vibrations on the PEO chains (1087 and 955cm-1) relative 
to the respective bands in the spectrum of NP2. The curve fit-
ting on Amide I in the previously mentioned FTIR spectra 
revealed that the secondary structure of the BSA molecule 
contains 35% α-helix, 32.5% β-sheets, 12% β-turns (short 4 
amino acid segments that form antiparallel loops) and 20% 
of random coils. Having in mind that the spectrum was tak-
en from freeze-dried sample of BSA, one can assume that the 
portion of α-helix will be reduced on the expense of the in-
crease of β-sheets and random coils in the secondary struc-
ture. The NP1-BSA and NP2-BSA demonstrated presence 
of 77.63% and 34.39% of α-helix, 11.51% and 31.76% of 
β-sheets, 10.8% and 17.74% of β-turns, 0.05% and 16.11% 
of random coils in the BSA molecule, respectively. 
Considering the above results one can assume that the 
behavior of BSA towards NP1 and NP2 is different, main-
ly because of the differences in the density and PEO chain 
length of the nanoparticle hydrophilic corona. The PLGA/
PEO ratio in NP1 and NP2 is 17.5:1 and 1.2:1, respectively. 
Having this in mind, it can be presumed that the PEO chain 
length and surface density can affect the accessibility of the 
hydrophobic nanoparticle core towards nonspecific interac-
tions with BSA. The hydrophilic corona of NP2 is larger 
and more rigid and as such will be an effective steric barrier 
in the interaction of BSA with the hydrophobic PLGA core. 
The loss of α-helix in the secondary structure of BSA in the 
native BSA sample and NP2-BSA complex can be attributed 
to the freeze-drying stress of the BSA molecule that initiates 
hydrogen bonding redistribution in the secondary structure 
of the protein. The partially adsorbed BSA molecule won’t 
be able to protect its intramolecular hydrogen bonds during 
the freeze drying process that will initiate the conversion 
of α-helix to random coils and β-sheets. On the other hand, 
the structure of the BSA that is adsorbed on the NP1 sur-
face could be associated with its’ native structure. The pres-
ervation of the native structure during freeze drying is an-
other indication of the hydrophobic nature of the NP1-BSA 
interactions resulting in significant contribution towards the 
maintenance of the BSA original hydrogen bonds.
Conclusion
The results unambiguously point to the effect of the 
hydrophilic outer nanoparticle layer as a steric barrier for 
nanoparticle-BSA interactions. The formulations with low 
hydrophilic coverage expose the hydrophobic core and en-
able strong hydrophobic binding with the proteins pres-
ent in the corona. Such strong binding could result in ap-
pearance of different new protein epitopes on the nano-bio 
interface and significantly alter the biological fate of the 
nanoparticles.
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Introduction
There are a lot of records in the literature regarding 
the utility of linseed oil on the skin. Concerning to this, 
it is worth to mention here the experimentally confirmed 
effects, such as increased skin hydration after introducing 
in the diet linum usitatissimum oil (De Spirt et al., 2009). 
The linoleic and alpha-linolenic essential fatty acids are in-
volved in restoring the cutaneous barrier, important in skin 
ceramides synthesis. Other authors have noted the favor-
able effect of the linum usitatissimum oil on wound heal-
ing, on an animal model (De Souza Franco et al., 2012). 
There are also experimental evidences regarding the ben-
efits on skin excoriations. Additionally, the anti-inflamma-
tory and even antibacterial effect leads some authors to cite 
flax oil as showing a positive effect on treating ringworm.
On the other hand, theoretically, under the effect of 
lignans, (secoisolariciresinol diglucoside - SDG - the most 
abundant flax lignan) with estrogen-mimetic action, the oil 
of this species should have effects similar to other phytoes-
trogens. This is the premise of our experimental study. 
The study aims to: (1) evaluate fatty acids in Linum 
usitatissimum oil, in order to be, at least, protective and nu-
tritive for human skin, in topical application, (2) evidenc-
ing the sebum-reducing capacity of linum oil, (3) observa-
tion of a possible improvement of skin texture (a result of 
skin hydration), for the cases of seborrhea sicca (dry seb-
orrhea).
Materials and methods
Linseed oil was obtained from the seeds of the Alexin 
cultivar grown in the Didactic Station Timisoara of Banat’s 
University of Agricultural Sciences and Veterinary Med-
icine Timisoara in 2014. The cutaneous study benefited 
from the enrollment for testing of 24 healthy female volun-
teers, aged between 18 and 46, having oily and seborrhe-
ic skin and the sebaceous glands were measured in terms 
of numbers and dimensions, by using the apparatus Pro-
derm Analyser (NU SKIN, Provo, UT, USA). The evalua-
tion of the cutaneous evolution was performed in the Der-
matopharmacy and Cosmetology laboratory (University 
of Medicine and Pharmacy Timisoara). The criteria for in-
cluding the volunteers in the study were: (1) Written con-
sent of the volunteers after they understood the test proce-
dure, (2) Diagnostic of seborrhea or normal oily skin, based 
on clinical criteria, (3) Lack of any pathological complica-
tions (eg. acne, seborrheic scaling dermatitis) situations in 
which the oil is potentially harmful (obstructive, comedo-
genic, or irritating) (4) Elimination of intolerance, after a 
preliminary test of the oil at a topical skin application. The 
assessments with Proderm Analyzer were recorded after 7 
days of therapy, at the times: 7, 14, 21 and 28 days respec-
tively. For each volunteer, at each time point, were counted 
the colored points per skin field explored (number of over-
sized sebaceous glands per cm2) and the average was cal-
culated for each time unit, separately for seboreea oleossa 
and for seboreea sicca.   
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Results and discussion
Linseed oil is characterized by a high content of linole-
ic acid (0.313 mg / ml) and linolenic acid (0.214 mg / ml). 
The results are consistent with literature data mentioning a 
high concentration of linoleic acid in oil from linseed seeds 
cultivated in Romania but also in other countries. The daily 
use of linseed oil also produced an improvement in the ap-
pearance of the skin, reducing the appearance of scaly skin 
to complete fade-out. There are no obvious differences be-
tween the evolution of the seborrhea oleossa and the sicca 
during the test for the linum oil treated group, meaning that 
this oil has efficiency in both types of disorders.
The most significant decrease of sebaceous glands 
number was registrered starting with the 14th day after the 
first treatment. The 14 days also represent the turnover of 
the sebocyte. In other words, after two weeks there are oth-
er new sebocytes holding secretory activity under another 
hormonal stimulation, modified in the meantime. As a mat-
ter of fact, the sebocyte is a cell with a prompt response to 
other pharmaceutical treatments as well, for example af-
ter the treatment with topical retinoids the sebaceous se-
cretion decreases dramatically, sometimes after only 7-10 
days. The problem with retinoids, however, is their adver-
sity to the epidermis, dryness and the erythema generated. 
Conclusion
In conclusion, linseed oil is one of the oldest natural 
remedies for skin nutrition. Recent studies show its ben-
efits in scarring, in surgical wound healing optimization, 
in skin hydration and also in the domain of cutaneous ag-
ing prevention.
This study brings again linum usitatissimum oil in the 
foreground, this time for its sebum-reducing effect. This 
property is a confirmation of the hypothesis launched by 
the Lucas Meyer dermocosmetic laboratories, a property 
attributed to the lignans in flax seeds, known for their es-
trogen-mimetic and implicitly anti-androgenic attributes, 
which means exactly an intervention on the hormonal 
mechanism of seborrhea. Our study opens a new prospect 
to lignans determinations, in different sort of linseeds, for 
a natural alternative in sebum-regulation field.   
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Introduction
In the last years, there is a growing trend of utilization 
of natural cosmetics, that is related to the frequent occur-
rence of allergies and skin irritations caused by synthetic 
ingredients commonly included in the formulation of these 
products (Glampedaki and Dutschk, 2014). Antioxidants, 
especially the ones naturally derived from plants, have 
been recognized as excellent source of bioactive compo-
nents with beneficial effects on skin, especially to prevent 
premature skin aging and wrinkling. There is an increasing 
research interest in polyphenolic compounds which have 
proven to possess antioxidant activity, and have shown 
promising effects applied as cosmetic active ingredients 
(Braunlich et al., 2013).
Materials and methods
Therefore, our group developed an anti-age cosmet-
ic line consisting of day (D) and night (N) cream, both 
based on natural materials. Namely, in the stated creams 
(D and N) black chokeberry and hibiscus propylene gly-
col extracts (produced at Institute for Medicinal Plant Re-
search) and hyaluronic acid (low weight, Amedeo Brasca, 
Italy), were incorporated as active ingredients in the appro-
priate hydrophilic (D-V, yielding cream D) and hydropho-
bic (N-V, yielding cream N) vehicles, in which synthet-
ic excipients were replaced with the ones of natural ori-
gin. Chokeberry is one of the richest sources of natural an-
tioxidants among fruits and vegetables, because of its bio-
active components such as anthocyanins, flavonols, procy-
anidins, and phenolic acids (Kulling and Rawel, 2008; Ru-
gina et al., 2012; Sueiro et al., 2006). Beside chokebery ex-
tract, D and N creams contained hibiscus extract, abundant 
in vitamin C that stimulates synthesis of collagen, a pro-
tein responsible for skin tone and elasticity (Aburjai and 
Natsheh, 2003). Hyaluronic acid, natural component of the 
skin located in the extracellular matrix, recovers lost skin 
moisture and gives the visual effect of skin lifting (Scott 
and Banga, 2015). Avocado oil, grape seed oil and shea 
butter (all from Comcen, Serbia) included in both creams, 
effectively feed and revitalize the skin due to the complex 
of active ingredients they contain, especially high content 
of fatty acids. Creams contain components of natural wet-
ting factors of skin (complex of hexylene glycol, fructose, 
glucose, sucrose, urea, dextrin, alanine, glutamic acid, as-
partic acid, hexyl nicotinate) and elastin (both from Che-
misches Laboratorium Dr Kurt Richter GmbH, Germany). 
Elastin as a protein, is responsible for skin tone, gives it 
back skin moisturize, elasticity and freshness. Both creams 
contain a complex of UV filters (ethyl hexyl methoxy-
cinnamate, butyl methoxydibenzoylmethane, ethyl hexyl 
salycilate, Coning PPI, Serbia) that protect the skin from 
harmful sun rays.
Safety profile/irritation potential of the developed cos-
metic products (active creams-D and N, as well as their 
matching vehicles-D-V and N-V, respectively), was eval-
uated using noninvasive measurements of the appropriate 
biophysical parameters of the skin in a 24-h in vivo study 
under occlusion.
Thirty one healthy female volunteers (mean age 
46.09), which participated in the study, were thoroughly 
informed about the possible treatment effects and the pro-
tocol of the examination prior to signing written consents, 
in accordance with the Helsinki Declaration. The study 
was approved by the Ethical Committee of the Institute 
for Medicinal Plant Research “Dr. Josif Pančić”, Belgrade, 
Serbia (Decision No 01-9337-13). The following param-
S4 PP 175
372
Maced. pharm. bull., 62 (suppl) 371 - 372 (2016)
Pharmaceutical technology and biotechnology / Cosmetology / Biopharmacy
Po
st
er
 p
re
se
nt
at
io
ns
eters were evaluated: electrical capacitance (EC) (quanti-
fying the stratum corneum hydration), transepidermal wa-
ter loss (TEWL), as a measure of skin barrier function and 
erythema index (EI), as a measure of skin colour, using 
Multi Probe Adapter MPA®9 (Courage & Khazaka Elec-
tronic GmbH, Germany). All measurements were conduct-
ed on flexor aspects of forearms at square application sites 
of 9 cm2, leaving a site per each arm for untreated control 
under occlusion (UCO) and without occlusion (UC). The 
volunteers were instructed not to use dermopharmaceutical 
and/or cosmetic products on the tested areas as well as to 
spend at least 30 minutes in a room in which the measure-
ments were conducted in order to adapt to the temperature 
and relative humidity. After initial measurements, 0.016 g/
cm2 of the investigated samples were applied, covered with 
silicone film and fixed with hypoallergenic adhesive tapes. 
Two hours upon removal of the 24-h occlusion, all param-
eters were reassessed (Jakšić et al., 2012; Tasić-Kostov et 
al., 2011).
Results and discussion
The investigated samples showed overall satisfying 
preliminary safety profiles (low in vivo irritation poten-
tial). Namely, two hours after occlusion removal, all the 
investigated samples led to the significant upsurge of EC 
compared to the baselines and controls, revealing skin hy-
dration potential probably related to appropriate vehicles 
themselves (D-V and N-V), bearing in mind lack of signif-
icant differences after treatment with these samples com-
pared to the matching active creams (D and N, respective-
ly). There was no significant change in EI, which was even 
decreased for all the tested creams, indicating well-toler-
ated skin formulations. Also, there was no significant in-
crease of TEWL for the investigated samples compared to 
the baseline values, nor UCO. Significant growth of this 
parameter was detected after repeated measurement for the 
sample N compared to UC, but this increase cannot be at-
tributed to the treatment with this sample itself, while the 
same difference between test-spots N and UC was also not-
ed in the initial measurement.
Conclusion
In conclusion, preliminary safety profile of the inves-
tigated creams based on ingredients of natural origin can 
be considered satisfactory. Tested samples did not cause 
the change in the measured biophysical parameters-TEWL 
and EI, while they even increased EC i.e. stratum corneum 
hydration, a feature considered preferable in the cosmetic 
products intended for the treatment of aged skin. 
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Introduction
Intravenous (IV) fluid therapy is a commonly used in 
hospitalcare practice as one of the essential element in pa-
tient care. Over the years IV fluids in different forms have 
been specially designed  and developed according to the 
physiological demands of various patient’s medical condi-
tions. Understanding these IV fluids that are administered 
to the patient is important because each has a differentim-
pact on the body and particular indications for use. There-
fore, the choice of IV fluid should be based upon the hydra-
tion status of the patient and metabolic disorders associated 
with the patient’s condition. . 
Ringer’s solution for infusion is chemically prepared 
an isotonic crystalloid that contains sodium chloride, po-
tassium chloride, and calcium chloridein sterile water. The 
dosage of Ringer’s solution is dependent upon the age, 
weight, clinical conditions of the patient, and concomitant 
therapy.
This solution is indicated to replace extracellular fluid 
losses, to restore the sodium, potassium, calcium and chlo-
ride balances and, as well as for treatment of isotonic de-
hydration condition In practice, there are different recipes 
for Ringer’s solution composition depending on its intended 
use. For example, lactated Ringer’s solution is a hypotonic 
solution that the best approximate extra cellular fluid. It may 
be infused safely in large quantities in patients with condi-
tions such as hypovolemia with metabolic acidosis, shock 
syndromes and burns. It is well known that lactate is metab-
olized in the liver, and to a lesser degree inthe kidney while, 
acetate is metabolized mainly in the muscles and lesser in tis-
sues such as kidneys and heart, so it’s a good alternative in 
patients with impaired lactate clearance such as in advanced 
liver disease (Santoro et al., 2007; Zander, 2004). In general, 
there are three independent acid-base variables that need to 
be determined when studyingthe acid-base properties of IV 
fluids such as: the partial CO2 tension, the total concentration 
of nonvolatile weak acid (AToT), and the strong ion differ-
ence (SID) (Kellum, 2002, 2005). Metabolic acidosis and al-
kalosis are respectively caused by raising and lowering AToT 
while holding SID constant. Metabolic acidosis and alkalosis 
are respectively caused by lowering and raising plasma SID 
while clamping AToT. Fluid infusion causes acid-base ef-
fects by forcing extracellular SID and A ToT toward the SID 
and A ToT of the administered fluid (Morgan, 2005). The 
SID of isotonic saline being 0, the infusion of large quanti-
ties (as in correction of hypovolaemia, acute normovolaemic 
haemodilution, and cardiopulmonary bypass ) will dilute the 
normal SID of plasma and decrease pH. Using the Stewart 
equation, a balanced solution with a physiological SID of 40 
mEq/Lwould induce a metabolic alkalosis  (Chappel, 2008; 
Morgan, 2005). In order to avoid this inducti; n, balanced so-
lutions using organic anions such as lactate, acetate etc. in-
creases the SID and also decreases the osmolarity of the so-
lution (Bertrand, 2010; Chappel, 2008). Morgan has calcu-
lated that a balanced solution should have a SID of 24 mEq/L 
(Bertrand, 2010; Morgan, 2005). 
In the field of surgery and intensive care, hyperchlore-
mic acidosis is well-known problem in patients receiving 
large amount of standard electrolytes. A series of studie-
shas emphasized the disadvantageous effects of hyperchlo-
remic acidosis on various organ systems, for example, he-
modynamics, NO-production, renal blood circulation, uri-
nary output or hemostasis.
Having in mind that there is a lack of Ringer’s lactate 
and Ringer’s acetate solution on the drug market in our 
country, the aim of presented work was to formulate these 
IV solutions, and to evaluate theirquality and stability. Pre-
pared solutions, were used in our Hospital in the Depart-
ment of Anesthesiology.
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Material and methods 
The minimum conditions required for the small scale 
production and quality assurance of Ringer’s   lactate and 
acetate   solutions   were  established by elaboration of the 
required Pharmacopoeias monographs (Ph.Eur.8th; USP 
39). The IV fluids were prepared in laminar flow cabinet 
(LFC), using an aseptic technique along with sterile filtra-
tion and filled in the sterile containers. Solutionswerester-
ilized by autoclaving. The final solutionswerethen submit-
ted to quality control, 
Results and discussion 
Prepared IV fluids had good quality in respect to phys-
ical properties, physico-chemical parameters and microbi-
ological quality according to Ph.Eur. 8. It was also con-
firmed that IV fluids were stable for a year in the condi-
tions of the second (II) climatic zone. Each of these IV so-
lutions had a different profile in terms of impact on acid-
base status, electrolyte levels, coagulation, inflammation, 
renal, and liver function. The choice of the best solution for 
patient resides in a complete understanding of the expect-
ed response of each solution and the patient ‘s risk factors. 
In the preliminary comparison study, Ringer’s lactate 
as well as acetate- based IV solution, proved to be suitable 
for fluid replacement during surgery. Hemodynamic stabil-
ity remained unaffected by both of the solutions. Concern-
ing consistency of acid base parameters none of the solu-
tions seemed to be inferior. 
Conclusions
It has been revealed that prepared formulation of Ring-
er’s lactate and Ringer’s acetate solutions can be success-
fully used for fluid replacement.
References
Kellum, J.A., 2002. Saline-induced hyperchloremic metabolic 
acidosis. Crit. Care Med. 30(1), 259-261.
Kellum, J.A., 2005. Clinical review: Reunification of acid-base 
physiology. Crit. Care 9(5), 500-507.
Morgan, J.T., 2005. The meaning of acid–base abnormalities in the 
intensive care unit: Part III – effects of fluid administration. 
Crit. Care 9(2), 204–211.   
Santoro, A., Guarnieri, F., Ferramosca, E., Grandi,  F., 2007. 
Acetate –free biofiltration. Contrib. Nephrol.158, 138–152.
Ph.Eur 8th, Infusions 8. 4-4692
USP 39, Pharmaceutical compounding – sterile Preparations, 
<797>
Zander R., 2004. Fluid Management. Second expanded edition.
Poster presentations
Macedonian pharmaceutical bulletin, 62 (suppl) 375 - 376 (2016)
ISSN 1409 - 8695
UDC: 615.033.1
Short communication
Distribution coefficient of gliclazide as in vitro prediction model 
of blood brain barrier penetration
Mladena Lalić-Popović, Svetlana Goločorbin-Kon, Maja Đanić*, Nataša Milošević, 
Velibor Vasović, Boris Milijašević, Momir Mikov
Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21000 Novi Sad, Serbia
* majadjanic@gmail.com
Introduction
Development of effective in vitro model for predic-
tion of blood brain barrier (BBB) penetration of drugs is 
nowadays widely researched. BBB is selective barrier that 
eclipsed the brain and isolates it from the circulating blood. 
It represents a major barrier for drug permeation, especial-
ly of those molecules that are highly hydrophilic, ionisa-
ble, contain more than 10 hydrophilic moieties, low logP 
value and molecular mass bigger than 400 Da. Distribu-
tion of drug in system octanol/water is in correlation with 
its lipophilicity and its optimal value ranges between 2.5 
and 5 (Pardridge, 1998). Most of newly developed drugs 
have poor permeability. Thus novel pharmaceutical formu-
lations are developed containing drug permeators. Drug 
transfer across BBB could be facilitated using permeator 
enhancers (e.g. bile acids). Value logP in system octanol/
water is dependent on drug solvent interaction (i.e. hydro-
gen bonding), and because of this it is a poor predictor for 
BBB penetration, since this barrier is highly hydrophobic. 
Better system is cyclohexane/water since cyclohexane has 
no possibility for hydrogen bonding. If permeator that is 
most suitable could be predicted in vitro in preformulation 
investigations, it could decrease formulation development 
costs. Thus the aim of this study was to investigate glicla-
zide distribution in systems n-octanol/water and cyclohex-
ane/water as in vitro prediction models for in vivo BBB 
penetration. Also the aim was to determine whether men-
tioned in vitro models could predict the influence of per-
meators such is dexycholic acid (DCA) on gliclazide trans-
fer across BBB.
Materials and methods
Distribution coefficient (logD) was determined us-
ing a “flask shake“ method. In glass tubes 1 ml of organic 
solvent (cyclohexane or octanol) was mixed with 5 ml of 
aqueous phase. Partition profile was determined over phys-
iological pH range (pH 1.2 HCl solution, pH 4.5 acetate 
buffer, pH 6.8 and 7.4 phosphate buffer and pH 7 distilled 
water) for 5 combinations of n-octanol or cyclohexane with 
aqueous gliclazide solution (10 µg/ml) of different pH and 
with or without the addition of DCA (0.5 mM) into n-octa-
nol or cyclohexane phase. The analyses were done in tripli-
cate for each pair of organic solvent/water. Concentrations 
of gliclazide were determined using modified high perfor-
mance liquid chromatography method (Mikov, 2008). Val-
ues of logD at pH 7.4 were compared with literature date 
of gliclazide BBB penetration and influence of DCA on its 
penetration (Lalic Popovic, 2012).
Results and discussion
Gliclazide is a small lipophilic molecule which is ex-
pected to readily cross biological barriers. However it 
has poor BBB penetration, and since it shows antioxidant 
properties on brain cells its penetration into central ner-
vous system is of interest (Sandoval, 2009). Though some 
drugs do cross BBB, there is a great number of drugs like 
gliclazide for which BBB is impermeable. In this investi-
gation a higher partition into organic layer was found in 
system n-octanol/water than cyclohexane/water. Profiles 
of distribution after 1 and 24 h were different which leads 
to a conclusion that 24 h is needed time for a partition to 
be finished in system cyclohexane/water. There were no 
observed differences in logD values after 1 or after 24 h 
between systems with and without DCA in n-octanol (pH 
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6.8; 7 and 7.4), but minor differences were noticed in low-
er pH values (i.e. pH 1.2 and pH 4.5). Also DCA signifi-
cantly increased partition of gliclazide in system cyclohex-
ane/water but not in system n-octanol/water. Value of logD 
at pH 7.4 without DCA in organic layer in system n-octa-
nol/water was 0.34±0.05 and in system cyclohexane/wa-
ter was -0.74±0.11. According to logD value in cyclohex-
ane/water, gliclazide have poor BBB, which is in correla-
tion with in vivo data (logBBB 0.23±0.02 healthy animals 
and 0.85±0.03 diabetic animals) (Lalic Popovic, 2012). 
Value of logD at pH 7.4 with DCA in organic layer in sys-
tem n-octanol/water was 0.54±0.07 and in system cyclo-
hexane/water was 0.18±0.01. Both systems showed in-
creased transfer of gliclazide when DCA was present in or-
ganic layer. This is also in correlation with in vivo investi-
gation where animals were pretreated with DCA (logBBB 
0.96±0.03 healthy animals and 1.35±0.14 diabetic animals) 
(Lalic Popovic, 2012).  Thus partition of gliclazide in sys-
tem cyclohexane/water better correlates with in vivo data 
where penetration of gliclazide was increased with DCA 
pretreatement, but in diabetic animals, penetration was in-
creased in group with and without DCA pretreatement and 
investigated in vitro systems could not this predict.
Conclusion
Increased logD value in organic layer when DCA is 
present indicates existence of physicochemical interactions 
of DCA and gliclazide. Investigated system cyclohexane/
water predicted poor gliclazide BBB penetration and the 
influence of DCA on gliclazide penetration but system n-
octanol/water failed to do so. However investigated sys-
tems could not predict differences in penetration between 
diabetic and healthy animals. Further investigations are 
necessary to determine value of system cyclohexane/water 
in prediction of BBB transfer.
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Introduction
The main function of packaging is to ensure protec-
tion of the pharmaceutical product, its safety and proper 
use, information on the identity, instruction of use and stor-
age at any time point before expiration date of the drug 
product. The pharmaceutical dosage product and its con-
tainer closure system act together to serve as an integral 
unit. The primary packaging comes into direct contact with 
the product and it is the most significant component in the 
pharmaceutical product packaging. It serves the two main 
functions of protecting the product from outside influences 
that would otherwise render it useless while allowing the 
manufacturer of the product to package it using practices 
that typically involve automated form-fill-seal equipment. 
As innovations continue and new films enter the market, a 
thorough understanding of how regulatory, package perfor-
mance and film attributes fit together should help ease the 
selection process and, hopefully, provide some framework 
to avoid potential problems throughout the life of the phar-
maceutical product.
CGMP requirements for packaging materials for par-
enteral, inhalation and liquid products are wider than for 
solid oral dosage forms (FDA, 1999).
Objective
Correct selection of contact packaging has a signifi-
cant impact on safety and efficiency. The goal is to choose 
the appropriate contact material for blister packaging. Prin-
ciples and contribution to simplification and proper choice 
of packaging material are: out of the vast number of pack-
aging materials to choose a range of materials that can be 
used for packaging a certain product, materials that meet 
quality requirements and are tested by the manufacturer, 
from reliable suppliers of high quality and favorable price, 
to fully comply with the equipment and resources for pack-
aging at the factory. An analysis of the characteristics of 
materials for blister packaging was made.
Critical factors in choosing the right blister 
packaging film
For choosing the right blister packaging film it is nec-
essary to have great knowledge of drug characteristics, 
physical and chemical properties, microbiological quality, 
technical considerations of blister films, dimensional sta-
bility of the webs, ability for thermoforming and cooling of 
formed film, variation in thickness, compatibility of form-
ing film and lidding foil.
Films for blister packaging
The base in blisters produced by thermoforming pro-
cess is a polymer plastic film. The blisters are formed un-
der increased temperature. PVC film used for blister pack-
aging represents a rigid film due to the absence of soften-
ers and plasticizers, which provides structural rigidity and 
physical protection of the pharmaceutical dosage form. It 
is transparent, rigid material with a greattermoform abil-
ity, easy to color and low cost. The main disadvantage is 
low barrier properties, high water vapor and gases perme-
ability. PVDC has a significant role in blister packaging 
as lamination or coating of PVC. PVDC provides excel-
lent barrier to gases and water vapor, unlike other poly-
mers that provide either one or other protection. Perme-
ability to gases does not depend on the relative humidity, 
so it can be used for packaging in various environmental 
conditions. The properties of the copolymer depend on the 
content of the VDC, greater amount of VDC result in better 
barrier properties, the smaller the amount of VDC the flex-
ibility improves. The amount and type of co-monomer, as 
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well as additives and manufacturing technology affect the 
properties of PVDC. The weight of PVDC coatings ranges 
from 40, 60, 90 and 120 g/m2. PVDC coatings have been 
used with duplex (PVDC/PVC) and triplex (PVDC/PE/
PVC) structure being the most common ones used (Bauer, 
2009). Aclar® has the lowest water vapor permeability of 
all the films used for blister packaging. It has good barri-
er properties to gases, but this material is not used often in 
applications where impermeability to gases is primary de-
mand. Aclar®UltRx (CTFE homopolymer) has the highest 
moisture barrier of any clear thermoplastic film. It process-
es within the same range as other thermoforming films on 
conventional blister packaging equipment. PET has a high-
er permeability to water vapor compared to PVC. PVDC 
- coated PET has a similar permeability to water vapor as 
PVDC. PS has very good thermoforming properties, but 
has high permeability to water vapor. PP has good barri-
er properties to water vapor (similar to PVDC). The prob-
lem is thermoforming. The temperature required for ther-
moforming PP and the further cooling process must be pre-
cisely controlled. There may be distortion of blisters in sec-
ondary packaging due to the thickness of PP film. Another 
disadvantage is the thermal instability and the possibility 
of collection of the film after performing the process. The 
process of blister packaging on a standard blister machine 
with a PP is difficult to perform and is much slower unlike 
PVC. COC (Cyclic Olefin Copolymer) in multilayer com-
binations with PP, PE or PETG has very good barrier prop-
erties. Cyclic olefins have good thermoforming properties 
even for deep blister cavities. COC is used in combina-
tion with semicrystal PE or PP polymers to improve ther-
moform properties. The films are produced with co-extru-
sion or lamination. COC does not contain halogen in mo-
lecular structure comprising only from carbon and hydro-
gen. COC is used for packaging which requires deep blis-
ter cavities (Pilchik, 2000).
Blisters produced by cold forming are formed mechan-
ically without the use of temperature and have high barrier 
properties. OPA/aluminum/PVC/ALU has excellent barri-
er properties for oxygen and is also impermeable to water 
vapor and therefore, it is the first choice of packaging ma-
terial. Its cost per square meter can withstand comparison 
with PVDC. However, cold forming takes up more pack-
aging material for the same number of tablets or capsules 
of the same size, unlike PVDC.
Multilayer films can be laminated, co-extruded, or a 
combination of the two. In laminated films, all film layers 
are extruded separately and are bonded together by a ther-
moset adhesive. In co-extruded films, the film is manufac-
tured in a single-step operation in which the film layers are 
bonded together by a tacky thermoplastic polymer. These 
two manufacturing techniques can be combined. Flexible 
materials are used for the layers of the laminates, such as 
aluminum foils and films of polymer materials of varying 
thickness. With the right choice of a layer, a laminate with 
best suited properties for the packaging of a product at a 
low price could be obtained. Foil for the inner layer usu-
ally has good barrier properties, the lowest permeability to 
gases and water vapor. The inner layer should not have in-
teraction with the product. The possibility of shaping and 
closing is provided by inner layer that should be termoseal-
able (PE, PVC, PS, PVDC) (Stagnaro, 2011).
Conclusion
The categorization of the polymer film is made accord-
ing to their barrier properties: WVTR (water vapor trans-
mission rate) and permeability to gases. PVC has a signifi-
cantly higher permeability to water vapor from all types of 
PVC/PVDC and all types Aclar®. PVC/PVDC and Aclar® 
are closely comparable values for WVTR, depending on 
the thickness of the impermeable layer in the polymer film. 
Gas permeability, especially O2 and CO2 is important 
when the product inside the packaging material is sensi-
tive to oxidation. PVC and all types of Aclar® have signif-
icantly higher oxygen permeability of all types PVDC film. 
OPA/aluminum/PVC/ALU has excellent barrier properties 
for oxygen and is also impermeable to water vapor.
Identifying the most suitable blister packaging mate-
rial is complex. It requires very good understanding of the 
film properties in relation to application/ machine parame-
ters for getting an optimal packaging performance.
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Introduction
Clean rooms and associated controlled environments 
provide control of airborne particulate contamination to 
levels appropriate for accomplishing contamination-sensi-
tive activities. Production of sterile pharmaceutical prod-
ucts is regulated in a separate Annex 1 in European Guide-
line for Good Manufacturing Practice (EU GGMP, 2008) 
and contains instructions for minimizing the risk of con-
tamination of these specific products with particles, mi-
crobes and pyrogens.
Presented study represent a critical review of some 
tests in guidance document for pharmaceutical industry, 
used in the process of qualification and monitoring of clean 
rooms for the manufacture of sterile medicinal products. 
Qualification of clean rooms 
Qualification of clean rooms in pharmaceutical indus-
try is comprised of different tests like air supply, air veloc-
ity, air changes, flow pattern, filter integrity, pressure test, 
particle count, temperature, microbial count, relative hu-
midity, noise level and vibration test.
The purpose of air supply capacity test is to demon-
strate that the air system is balanced and capable of deliv-
ering sufficient air volumes as per design to maintained re-
quired air change in the defined area. The air capacity is 
demonstrated by following the procedure of measuring air 
flow in supply and returned duct and air volume to meet the 
design required.
The purpose of air velocity/uniformity test is to pres-
ent the capability of the air system for delivering sufficient 
air volumes to maintain a minimum cross section veloci-
ty under HEPA terminal filter modules. The measuring is 
performed by calibrated anemometer at numerous sites in 
order to provide one measurement for each 0.37 m2 filter 
area. For Laminar Flow sections air flows uniformity has 
to be 0.45 m/sec ± 20%. 
Testing of air flow pattern is performed in order to 
check the interference due to turbulence eddies in unidi-
rectional airflow area, like sampling and dispensing booth 
and under laminar airflow in microbiological area (Kit-
ain, 2010) Visualizing the air patterns at numerous points 
in room is performed by Titanium Tetra chloride sticks. In 
several cases the test is done by operating the HVAC sys-
tem of the sterile area and releasing smoke into unidirec-
tional air stream at selected sites. There is no minimum 
GMP requirement for air changes per hour. Air flow into 
and out of a space should be based on providing the re-
quired cooling, heating, relative humidity, pressurization, 
particulate control, ventilation. These factors generally re-
sult in air change rates between 4 and 20. There is also no 
numerical requirement for relative pressurization in clean-
room. The velocity and direction of airflow between spac-
es should be adequate to reduce counter flow of airborne 
particulates or vapour contaminants for spaces where air-
borne cross contamination is a concern (EU GGMP, 2008).
All HEPA filters installed in the facility are tested for 
filter integrity test by using PAO (Poly-alpha-olefin) aero-
sol into supply duct to the HEPA filter. Sampling of stream 
challenge is done with photometer and the instrument is set 
for this challenge. Cross contamination can originate from 
both the internal and external facility environment. In all 
air handling systems, the filtration should be evaluated for 
adequate arrestance of outdoor particulates. Any suitable 
particle counter instrument can be used for the measure-
ments, with no effect of the measurement principle used. 
During the operation an air flow rate should be 0.03 m3/
min. Measurement should be done at minimum 10 differ-
ent representative room locations for one minute at each 
location at 1 meter height from the floor. It must cover the 
central location of personal traffic during normal produc-
tion process (WHO, 2011). Measurements should obtain 
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information about concentration of two different ranges of 
particles: particles with size ≥ 0.5 µm as well as particles 
with size ≥ 5 µm (5 µm particles for ISO 5 class has been 
excluded from the limit value table), at each location (DIN 
EN ISO 14644-1, 2015; DIN EN ISO 14644 - 2, 2015).
Room temperature variation often can be a critical pa-
rameter in production processes. Most products, materials 
and processes can handle a wide range in temperature. The 
width of this range decreases as the exposure time increas-
es. Existing HVAC system had designed for 24 ± 2 °C to 
all critical area in manufacturing, warehouse and Quality 
Control department. Sometimes, for some products, in-
processing temperature requirement shall be maintained 
18 °C ± 2 °C. Relative humidity may affect exposed 
product or materials that are sensitive to air moisture. 
Relative humidity generally has effect on aqueous product. 
Liquid product can lose moisture to a low humidity room 
over an extended period. HVAC system in sterile area is 
designed to maintain the required humidity. Relative hu-
midity is checked by using calibrated humidity meter from 
different locations (DIN EN ISO 14644-1, 2015; DIN EN 
ISO 14644 2, 2015).
Microbial monitoring of manufacturing clean rooms 
should include compressed gases, surfaces, room and en-
closure air and any other materials and equipment that 
may produce a risk of contamination. Monitoring of the 
air should be performed on meter cubic air (active or pas-
sive sampling) by using special instruments or settle plates 
which are opened for 4 hours and after that incubated. Sur-
face sampling is conducted by using swab or contact plat, 
collecting the microbiological contamination from approx-
imately 25 cm2 surface from numerous defined locations. 
Taking samples for microbiological monitoring of the area 
should be performed for a period of one year routine pro-
duction in accordance with the sampling plan. Noise level 
may be present in the facility due to operation of variety of 
equipment, during processes etc. Requirements when per-
sonnel noise exposure exceed an eight hours time weighed 
average sound level of 85 dBa. HVAC system has designed 
not to generate more than 70 dBa noises in critical area 
during its normal operation (Kitain, 2010).
Conclusion
Clean environments should be certified as described 
in ISO 14644 series in order to meet their design classifi-
cation requirements. The design, construction, and opera-
tion involved in clean rooms and advanced aseptic clean 
rooms operations vary greatly, so it is difficult to general-
ize requirements for parameters such as filter integrity, air 
velocity, air patterns, air changes, and pressure differen-
tial. In particularly critical applications such as aseptic pro-
cessing, a structured approach to physical risk assessment 
might be appropriate.
Situations where some of the parameters are out of 
range with values defined by guidelines of pharmaceutical 
products manufacturing undoubtedly are reason for devia-
tion. After researching the presumable causes, the goal is 
finding solution for solving the problem, its future preven-
tion and reseting the qualified conditions of the cleanroom. 
Clean-room operators, particularly those engaged in 
aseptic processing, must strive to maintain suitable envi-
ronmental quality and must work toward continuous qual-
ity improvement of personnel operations and environmen-
tal control. In general, fewer personnel involved in aseptic 
processing and monitoring, along with reduction in inter-
ventions, reduces risk from contamination.
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Introduction
Consumption of probiotic products has been linked to 
improvement of a variety of health conditions such as hy-
percholesterolemia, hypertension, inflammation and lac-
tose intolerance and reducing health risks, including aller-
gy and even some forms of cancer. However, for probi-
otics health benefit to be exerted, it is estimated that they 
should be administered in a therapeutic minimum of 10-6 
to 10-7 CFU live probiotic cells per g final product (FAO/
WHO, 2006). Providing and maintaining at least this num-
ber of viable cells is a great challenge due to their sensi-
tivity to the harsh processing and GI conditions prior tak-
ing their place of action in the low intestine and delivering 
the claimed health benefits. For incorporation of probiotics 
into food or pharmaceutical products, the microencapsula-
tion offers protection to the fine particles produced during 
freeze- or spray-drying of probiotic concentrates. Among 
the many techniques for microencapsulation, spray-dry-
ing is one of the most challenging because of the low cost, 
industrial application, stability and throughput in cellular 
integrity while drying when optimized correctly. Howev-
er, the spray-drying process parameters might have nega-
tive impact on the outcome of viable cells. In addition, the 
choice of carrier material and its interaction with the bac-
teria have importance on protection efficacy and affect the 
probiotic delivery. In search for novel probiotic microen-
capsulated formulation that will combine favorable prop-
erties of alginate (ALG) and polymer that will provide 
controlled and targeted release of viable probiotic cells in 
the lower intestine, we have encapsulated the probiotic L. 
casei 01 in ALG and soy protein isolate (SPI) matrix by 
spray-drying. The aim of this study was to evaluate the ef-
fect of the critical formulation and process variables on vi-
ability of the probiotic after spray-drying.
Materials and methods
FD-DVS/Lactobacillus casei 01 was supplied from 
Chr. Hansen (Copenhagen, Denmark), SPI from Soja-
protein AD (Becej (Serbia), whereas ALG (10/60 LS, fG 
35%–45%) was kindly donated from Protanal FMC Bio-
polymers (Ayrshire, UK). CaCl2, de Man, Rogosa, Sharpe 
agar and broth as well as peptone water were purchased 
from MerckKGaA (Darmstadt, Germany).  
Aqueous mixture of ALG and SPI was inoculated with 
bacterial suspension (cell load ca. 12.5 log10 CFU/g), acti-
vated as previously described (Petreska Ivanovska et al., 
2014; Smilkov et al., 2014). The resulting mixture was in-
fused into a spray-dryer nozzle unit of Büchi Mini Spray 
Dryer B-290 (Büchi Laboratorius-Technik AG, Switzer-
land) and continuously sprayed at following conditions: 
S4 PP 180
382
Maced. pharm. bull., 62 (suppl) 381 - 382 (2016)
Pharmaceutical technology and biotechnology / Cosmetology / Biopharmacy
Po
st
er
 p
re
se
nt
at
io
ns
nozzle diameter 0.7 mm, aspirator pressure 90%, atomiz-
er pressure 600 Nl h-1, flow rate 5 mL/min. SPI-ALG mic-
roparticles (MPs) with encapsulated L. casei that were fur-
ther subjected to additional cross-linking by CaCl2 were 
prepared by consequent introduction of the MPs obtained 
by spray-drying into aqueous solution of CaCl2, followed 
by continuous stirring at room temperature (1 h). MPs thus 
obtained were removed from the solution of CaCl2 by cen-
trifugation (1000 rpm, 5 min), washed three times with 
sterile water, frozen at -20 °C and freeze-dried at 0.070 
mbar and -50 °C for 24 h (Freeze-Dryer, Labconco, USA). 
Critical material attributes (concentration of ALG, SPI and 
CaCl2) and process parameters (inlet temperature, IT) were 
previously identified varying one parameter at time, while 
the influence of critical variables on viability of the probiot-
ic after preparation was evaluated using face centered CC-
RSM design (Design-Expert® V8, Stat-Ease, Inc., USA). 
The total of 30 experiments were designed and carried out, 
with the following actual levels of studied variables: ALG 
(A, 1 and 4%w/v), SPI (B, 1 and 4%w/v), CaCl2 (C, 0 and 
5%w/v) and IT (D, 90 °C and 150 °C). Viability of the en-
capsulated L. casei 01 in SPI-ALG MPs was assessed after 
dissolution of 1 g MPs in 9 g PBS (1 mol/L, pH 8.0), using 
the plate-count method as previously described (Petreska 
Ivanovska et al., 2014; Smilkov et al., 2014).
Results and discussion
Viability of L. casei 01 in designed formulations after 
preparation was in range of 8.67-13.09 log10 CFU/g or ex-
pressed in % related to initial L. casei 01 cell count from 
68.38 to 99.61%. Influence of examined variables upon 
this response in terms of coded factors was described by 
reduced cubic model with the following equation:
Viability(after preparation) (%)  = + 86.78 + 0.95 x A - 
2.36 x B + 1.78 x C - 3.29 x D + 1.76 x A x C + 3.72 x A2 
- 6.84 x A2 x C
From the equation one can clearly see that the viabil-
ity after preparation positively correlated with the factors 
A, C, AC and A2 and inversely with B, D, and A2C. With 
increase in ALG and CaCl2 concentration, the viability of 
the probiotic increased, while oppositely was observed 
with increase in concentration of SPI, suggesting compe-
tition between the probiotic and SPI for the same bonding 
sites in ALG molecules. According to the literature data 
(Rajam et al., 2012), modification of the compactly folded 
protein molecules from their native form allows SPI-ALG 
interactions via hydrophobic and electrostatic interactions 
and hydrogen bonding as well. At the same time, a trend to 
segregation of SPI and ALG into separated microdomains 
can occur, which has also been confirmed when whey pro-
tein as complexation agent was used (Smilkov et al., 2014). 
One way ANOVA indicated that variable D is significant 
model term, meaning that increase in the IT significantly 
decreases probiotic viability after preparation. The loss of 
probiotics during thermal processing is the main disadvan-
tage of MPs production by spray drying and it is related to 
cellular injuries (e.g. denaturation of DNA and RNA, dam-
age of ribosomes, dehydration of cytoplasmic membrane, 
lipid peroxidation and rupture of cell membrane) due to 
water removal resulting from the combined effect of heat 
and mechanical stress (Soukoulis et al., 2013). Thus, pro-
tection from the IT of the spray-dryer, as a critical point in 
this method of microencapsulation, is required. In addition, 
the probiotic bacteria must be alive at the time of consump-
tion of the product and also capable of reaching the large 
intestine in quantities that are sufficient to facilitate coloni-
zation and proliferation. Therefore, probiotic loaded MPs 
should be customized in respect to their physicochemi-
cal and biological/biopharmaceutical properties as well to 
make them suitable for incorporation into food or pharma-
ceutical product as well as for administration in healthy in-
dividuals and/or individuals with specific disease.
Conclusion
L. casei 01 loaded SPI-ALG MPs were prepared using 
spray-drying method, with viability of the probiotic after 
preparation significantly exceeding the minimal therapeu-
tic value. Process and formulation parameters should be 
further optimized to obtain probiotic MPs with both, high 
viability after preparation and in simulated GI conditions. 
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Introduction
Curcumin is the active principle of the spice turmer-
ic, produced by the rhizome of Curcuma longa (Zingib-
eraceae), which is widely used in traditional eastern medi-
cine as a hepatoprotective, anti-infectious and anti-inflam-
matory remedy (Shehzad et al., 2010). A compelling body 
of recent evidence has shown that curcumin is endowed 
by pleiotropic antineoplastic effects, due to modulation 
of NFkB and other cell signaling pathways, implicated in 
cell survival, apoptosis and angiogenesis (Shehzad et al., 
2010). Regretfully, the enormous therapeutic potential of 
curcumin can`t be exploited in clinical practice, due to its 
extremely unfavorable physicochemical and pharmacoki-
netic characteristics, and also due to the instability in sys-
temic circulation (Singh and Khar, 2006). The contribu-
tion is focused on newly-synthetized octopus-shaped mac-
romolecules, consisting of hydrophobic calix[4]arene core 
and four arms of hydrophilic poly(ethylene oxide) chains 
as platform for delivery of curcumin.
Materials and methods
Two methods for preparation of inclusion complexes 
were used:
Heating method described by (Loftsson et al., 2005) 
with slight modifications. Briefly, to aqueous solutions 
of increasing concentrations of CX[4]PEG polyoxyeth-
ylatedtertbuthylcalix[4]arene ) (2 mg/ml – 12 mg/ml) a 
constant amount of curcumin (1 mg/ml) that exceeded its 
aqueous solubility (11 ng/ml) was added. The vials were 
closed and heated at 50 °C for two hours. After that, the 
samples were left at room temperature for 24 h. Then the 
samples were subjected to centrifugation at 5000 rpm for 
10 minutes. The clear transparent supernatants containing 
the inclusion complexes were collected and the amount 
of the curcumin was analyzed using a validated UV/VIS 
spectrophotometric method at 427 nm.
Solvent evaporation method: series of samples contain-
ing a fixed concentration of curcumin (1 mg/ml) and in-
creasing concentrations of CX[4]PEG (2-12 mg/ml) were 
prepared in absolute ethanol, and evaporated to dryness us-
ing a Buchi rotation-type vacuum evaporator (R-215, Sig-
ma-Aldrich). The concentrations of CX[4]PEG were cho-
sen on the basis of its critical micelar concentration (CMC) 
of 7.7 mg/ml (or 0.24 µmol/ml) (Momekova et al., 2012). 
Thereafter the dried CX[4]PEG/curcumin containing films 
were hydrated with deionizaed water and were left for 2 h at 
50 °C and then in dark at room temperature for 24 h. Then 
the samples were centrifuged for 10 minutes at 5000 rpm. 
The transparent yellow supernatants containing the cur-
cumin-CX[4]PEG complexes were analyzed for curcum-
in content using a validated UV/VIS spectrophotometric 
method. Phase-solubility profiles were obtained by plotting 
the solubility of drug versus the excipient concentration.
Characterization of the CX[4]PEG-curcumin 
complexation
UV/VIS spectroscopy 
The UV/VIS spectra of curcumin (in absolute ethanol 
and 10% ethanol solution) and its CX[4]PEG complex (in 
deionized water) were recorded on JASCO V570 UV-Vis-
NIR spectrophotometer equipped with thermostatic cell 
holder (Huber MPC-K6 thermostat with precision 1 °C). 
Fourier transform infrared (FT-IR) spectroscopy analysis
Samples of pure curcumin, pure CX[4]PEG, their phys-
ical mixture, and a lyophilized complex were characterized 
by an IRAffinity-1 Shimadzu FT-IR spectrophotometer. The 
scanning range was between 4000 and 400 cm-1.
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Dynamic light scattering (DLS) analysis
The size, size distribution patterns and zeta-poten-
tial of curcumin loaded supramolecular CX[4]PEG aggre-
gates were investigated by ZetaSizer NanoZS (Malvern In-
struments), equipped with a 633 nm laser. The parameters 
were evaluated from the measurements at the scattering an-
gle of 175 ° at 25 °C. 
In vitro curcumin release
The in vitro curcumin release from supramolecular 
BEC-X aggregates was evaluated by regular membrane di-
alysis at 37 °C against phosphate buffered saline (PBS). 1 
ml of tested formulations was placed in dialysis membrane 
tubing (MWCO 10,000). The dialysis bag was then placed 
in a temperature controlled vessel, containing 100 ml of 
PBS (pH 7). At various time intervals aliquots were tak-
en from the released medium and assayed for curcumin by 
UV–VIS spectroscopy.
Results and Discussion
Phase solubility studies
The phase solubility studies of curcumin with BEC-X 
were performed using the procedure utilized for the evalu-
ation of cyclodextrin inclusion complexes by Higuchi and 
Connors (Higuchi and Connors, 1965). Due to their am-
phiphilic nature, polyoxyethylated calyx(4)arenes (CX[4]
PEG) can self-associate in water by forming well-defined 
spherical nanoparticles. At concentration below the CMC, 
CX[4]PEG drastically increased curcumin solubility by 
formation of inclusion complexes with high stability con-
stant (Kc). A significantly higher solubility enhancement of 
curcumin was observed at concentration exceeding the crit-
ical micellar concentration, attributed with additional solu-
bilization of curcumin into the hydrophobic domains of the 
supramolecular aggregates by non-covalent interactions.
UV/VIS characterization
In order to characterize the spectral behavior of cur-
cumin and its inclusion complex, absorption spectra of 
pure curcumin in absolute ethanol and 10% ethanol are 
compared with the absorption spectrum of the inclusion 
complex in water. The characteristic absorption peak of 
curcumin at 427 nm is identical in the three media under 
investigation, which demonstrates that the inclusion com-
plex is formed by non-covalent hydrophobic interactions. 
An interesting finding is the appearance of a shoulder at 
361 nm in the spectrum of pure curcumin dissolved in 10% 
ethanol which cannot be seen in spectra of curcumin in ab-
solute ethanol and in the inclusion complex of curcumin 
in water. The shoulder can be attributed to the shifting of 
the tautomeric equilibrium from keto–enol to diketo-form. 
FT-IR analysis 
FT-IR spectroscopy is a useful tool for characteriza-
tion of inclusion complexes. Characteristic combination of 
a sharp peak at 3508 cm-1 and a broad peak at 3293 cm-1 in 
the curcumin spectrum implies the presence of aromatic OH 
group stretching vibrations (Kolev et al., 2005) and the inten-
sive sharp peaks at 1626 cm-1 and 1601 cm-1 corresponding 
to mixed C=O and C=C vibrations and symmetric aromat-
ic ring (C=C) stretching vibrations, respectively, did not in-
terfere with the vibrations in BEC-X spectra and can be used 
as marks for description of curcumin in inclusion complex.
DLS analysis
Physicochemical characteristics of the nanoparticles 
(size, size distribution and zeta potential were evaluated by 
DLS and the results revealed particles of app.180 nm with 
monomodal distribution (PDI below 0.2) and zeta potential 
of – 20 mV suitable for systemic application.
In vitro curcumin release
The in vitro curcumin release profiles from supramo-
lecular CX[4]PEG aggregates were studied under simulat-
ed physiological conditions for different incubation peri-
ods from 2, 4, 6, 8, 10 and 24 hours. The results showed 
initial burst release of curcumin, followed by slower drug 
release. 
Conclusion
Thus on the grounds of the excellent in vitro bio-
compatibility profile and the favorable physicochemical 
and drug loading characteristics of the tested liposomal 
nanoparticles, and their ability to retain the intrinsic phar-
macological properties of encapsulated drug they could be 
considered promising drug delivery platforms for lipophil-
ic curcumin.
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Introduction
Coadministration of alcohol beverages with extend-
ed-release (ER) oral dosage forms may lead to more rapid 
drug release and altered systemic exposure. Therefore, re-
cent trends in the development of ER dosage forms high-
light the importance of the investigation of potential al-
cohol-induced dose dumping (ADD) (Anand et al., 2011; 
Lennernäs, 2009). FDA and EMA guidances include gen-
eral recommendations regarding the assessment of ADD, 
stating that suitable in vitro dissolution tests should be car-
ried out to identify the risk of ADD, and differentiate be-
tween rugged and vulnerable formulations (EMA, 2014; 
FDA, 2016). In addition, the International Pharmaceuti-
cal Excipients Council Europe (IPEC) working group on 
ADD has summarized relevant scientific and regulatory in-
formation to help pharmaceutical companies to better han-
dle ADD issues. It has been recognized that increased sol-
ubility of drugs or excipients in the presence of ethanol, 
and/or formulation factors (e.g. impaired ability to retard 
drug release), in conjunction with changes in physiological 
conditions after alcohol intake (e.g. delayed gastric emp-
tying) are the key factors affecting the kinetics of drug re-
lease from ER oral formulations. Knowledge about these 
factors can help to identify and develop ADD-resistant for-
mulations.
The purpose of this study was: (i) to evaluate different 
dissolution test setups to in vitro assess the effect of ethanol 
on dose dumping from ER tablets, and (ii) to evaluate the 
potential of the combined in vitro-in silico approach for the 
prediction of drug absorption profiles after concomitant al-
cohol intake, using commercially available diclofenac so-
dium ER tablets as model formulations.
Materials and methods
Diclofenac sodium solubility was tested in various me-
dia (0.1 M HCl pH 1.1 and USP buffers pH 6.8 and pH 
7.4 without/with addition of 40% ethanol). Drug dissolu-
tion from the investigated hydroxypropyl methylcellulose 
(HPMC)-based tablets (ER1 - Diklofen® 100 mg diclof-
enac sodium ER tablets, Galenika a.d., ER2 - Diklofenak 
100 mg diclofenac sodium ER tablets, Hemofarm a.d.) was 
tested under different experimental conditions: (i) in pad-
dle apparatus at 50 rpm, using single medium pH 7.5 (USP 
Test 1 for diclofenac sodium ER tablets) without/with ad-
dition of 5% or 40% ethanol, and (ii) in basket apparatus 
at 100 rpm, using media change method (pH 1.1 without/
with addition of 5% or 40% ethanol for 2 h, pH 6.8 for 2 
h, pH 7.4 for 20 h). The later setup was designed to simu-
late changes in physiological conditions as the drug trav-
els along the gastrointestinal tract, and to approximate con-
ditions in the stomach, since ethanol is mostly absorbed 
through the gastric mucosa. The obtained dissolution data, 
incorporated in drug-specific absorption model (Simcyp® 
Population-Based Simulator, v. 14.1; Certara™, USA), 
were used for in silico simulations of drug plasma concen-
tration-time profiles. Drug physicochemical and pharma-
cokinetic properties, used as inputs for absorption model-
ling, were obtained from available literature sources or in 
silico estimated.
Results and discussion
The solubility study results indicated that solubility-
limited drug dissolution from the investigated tablets can 
be expected only in medium pH 1.1 without ethanol. In 
other words, due to increased drug solubility in the pres-
ence of 40% ethanol, concomitant intake of strong alcohol 
beverages might induce dose dumping from diclofenac so-
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dium ER tablets even at low pH in the stomach. 
Dissolution data revealed that 5% ethanol in medium 
pH 7.5 had no significant effect on drug release rate from 
the investigated tablets (similar dissolution profiles). In ad-
dition, drug release profiles from the two products were 
similar in medium pH 7.5 with 0% and 5% ethanol. The 
addition of 40% ethanol in medium pH 7.5 affected drug 
release rate from ER2 formulation, resulting in approxi-
mately 4 times shorter mean dissolution time in compari-
son to the drug release profile in simple buffer. On the oth-
er hand, diclofenac sodium release under “media change” 
conditions was not affected by the exposure to either 5% 
or 40% ethanol in acidic medium (less than 10% of drug 
dissolved in 2 h; similar dissolution profiles). Considering 
these results, the observed difference in alcohol-resistance 
of the investigated products in medium 7.5 with 40% eth-
anol is not expected to have significant effect on drug re-
lease profiles in vivo. 
The simulated pharmacokinetic parameters, based on 
the selected input data set, including drug dissolution rate 
under “media change” conditions without ethanol (Cmax 
0.50/0.55 µg/ml and AUC 4.12/3.91 µg/ml h for ER1 and 
ER2 tablets, respectively), were in agreement with the 
reported data from clinical studies (Altman et al, 2015). 
These results indicate that the employed in vitro dissolu-
tion test conditions for diclofenac sodium ER tablets could 
be considered biorelevant. As expected based on dissolu-
tion data, the presence of ethanol in acidic medium had 
no effect on drug absorption profiles (the simulated phar-
macokinetic parameters were Cmax 0.41-0.58 µg/ml, and 
AUC 3.97-4.16 µg/ml h). Simulation based on the hypo-
thetical dissolution scenario, illustrating the “worst case”, 
demonstrated that 100% diclofenac sodium release from 
100 mg ER tablets in the stomach would alter the rate and 
extent of drug absorption (Cmax 2.56 µg/ml, tmax 2.16 
h, AUC 6.43 µg/ml h), and consequently, the formulation 
would lose its modified release characteristics. But even 
this scenario would not pose safety issues for the patients, 
since the simulated plasma concentration profile is in the 
therapeutic range (Altman et al, 2015).
Conclusion
The presented case demonstrate that in vitro disso-
lution testing using the proposed “media change” exper-
imental setup could be indicative of drug in vivo behav-
iour in the presence of ethanol. In addition, the combined 
in vitro-in silico approach may provide insight into the ef-
fect of ADD on drug clinical performance, and therefore, 
can serve as an alternative to clinical studies for ADD risk 
assessment. This approach should be encouraged, and ap-
plied to other ER oral drug products.
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Introduction
Antirheumatic and analgesics drugs are the most com-
monly used drugs to treat diseases of the musculoskele-
tal system and to alleviate all sorts of pain that are caused 
from different origins. Their systemic use causes long se-
ries of side effects, so combination therapies of drugs with 
systemic and local action or only medicinal products in-
tended for topical use wherever possible, especially in 
physical therapy, would be treatment of choice.
Various formulations of dosage forms, by composition 
and consistency, allow different therapeutic approach, suit-
able for achieving the desired therapeutic effect and for be-
ing capable to adapt to the physiotherapist treatment. 
According to the regulations of the pharmacopoeia or 
to other regulations, the galenic drugs are made in small 
batches in a galenic laboratory, which are intended to be 
administrated directly to a pharmacy or a health institution. 
According to the health requirements, the preparation 
of pharmaceutical dosage forms in a galenic laboratory, 
mainly aims to provide a dosage form, which is designed 
as an opportunity for changes in the composition and con-
sistency of the product.  Therefore, it can be provided a 
product with a modified properties, compared with a fin-
ished and fixed composition of the medicinal and an aux-
iliary substances, or with the already existing traditional 
products, which have the same composition of active com-
ponents, satisfying the needs of the healthcare profession-
als who work with them and also allowing a simultaneous 
comfort and a therapeutic effect for the patients. 
The usage of this drug, immediately after the prepa-
ration, reduces the need for adding more funds to stabilize 
and to ensure longer shelf life. 
Obtaining the quality of this drug product, that satis-
fies the standards and maintains or enhances the therapeu-
tic properties, requires appropriate conditions for a prep-
aration and knowledge of all the components properties, 
technological process and requirements for the finished 
product as well. 
The usage of the traditional liquid, a  pharmaceutical 
product known as “Russian water”, which contains:  alco-
hol, menthol, procaine hydrochloride and  benzocaine, is 
well received and accepted by the patients and the phys-
iotherapists, but it also has some negative sides, such as, 
short effect, it is easily volatile, it acts surface and cannot 
be recommended as a massage supplement.  On the other 
hand, gels are a dosage forms for external use that can be 
applied easily, to tie up to the skin and to enable the drug 
to heal the affected area,it can realize deep action, such as 
the ability to quickly penetrate multi-layers on the skin, to 
be easily rinsed from the site of application and general-
ly does not irritate the skin, which is largely satisfying for 
our requirements.  
The aim of this study was to formulate and prepare gel 
formulation from the pharmaceutical composition named 
“Russian water”, with the ingredients: menthol, benzo-
caine, procaine HCl, which is easy and pleasant to apply 
on the painful area, also effective to reduce the pain and the 
inflammation. Formulation challenge was slight solubility 
of some of the components, getting a stable product with a 
proper consistency, ensuring the release of the active ingre-
dients, their affection on the skin and a prolonged action.
Materials and methods
In the formulation and preparation the following ac-
tive substances were used: menthol (Alkaloid), benzocaine 
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(Sigma Aldrich), procaine HCl (Sigma Aldrich), at the rec-
ommended doses and ingredients, carbopol 940 (Sigma Al-
drich), glycerol, (Alkaloid), triethylene tetramine (Sigma 
Aldrich) and aqua distillate.
Gel with menthol, benzocaine and procaine HClwas 
prepared in the galenic laboratory in Ohrid -General Hos-
pital.Used ingredients and a compounding procedure de-
scribed in a rational manner are:
menthol 4.0, benzocaine  2.0, procaine HCl 2.0, base 
gel ad 200.0. Basic gel was made with the following 
proscription:Carbopol 940 2.0, glicerolum 7.5, triethylene 
tetramine 2.5, aqua destilata 190.0.
In the step 1, preparation of base gel, Carbopol 940 
and aqua distillate 50 mL were left to bulge. Then glycer-
olumwas gradually added and mixed to achieve good ho-
mogenization. After that, triethylene tetraamin was add-
ed and mixed again until thick gel was obtained.In the 
step 2, preparation of healing gel, the menthol was grind-
ed through a sieve, and it was measured in the prescribed 
amount. It was mixed with the same amount of prepared 
basic gel to complete uniformity of the mixture. The ben-
zocaine was grinded, sieved and measured at the prescribed 
amount and mixed with equal quantity of earlier prepared 
gel with menthol.
The prescribed amount of procaine hydrochloride was 
measured and dissolved in distilled water 10mL. Then, the 
solution was gradually added to the gel with menthol and 
benzocaine, whileconstantly stirred.The remaining amount 
of distilled water was added, gradually and with constant 
stirring, to the homogeneous gel to obtain a homogeneous 
product.
Results and discussion
The obtained gel is a homogeneous product with milk 
appearance. The high degree of pulverization of the com-
ponents should improve solubility and ensure uniform dis-
tribution of insoluble components in the mixture. The pro-
cess of mixing equal amounts of the basic mixture and pul-
verized substance also provides uniform distribution of the 
components, and the high density of the base gel reduces 
the possibility of their sedimentation (Allen, 2002; Jova-
novic and Sekulovic, 1987; Racev and Lambov, 2005; Si-
mov et al., 2001; Winfeld and Richards, 1998). Menthol is 
practically insoluble in water and because of its sole dis-
tribution in the preparationit was pulverized and a special 
way for its incorporation into the system was applied.Ben-
zocaine is poorly soluble in water and an appropriate pul-
verization and mixing improved solubility and its uniform 
distribution in the product.The procedure of mixing and 
gradual addition of a small amount concentrated procaine 
hydrochloride solution reduces the possibility of decom-
position of the gel structure under the influence of the po-
tential ionic solution (Jackson and Lowey, 2010; Simov et 
al., 2001). 
The obtained gel is packaged in plastic recipients of 
200 mL, closed with a suitable stopper and signed with red 
signature marked “For external use.”It is used topically by 
applying to the affected area and/or with good rubbing in 
physical therapy.The product has a short shelf life and is 
prepared immediately before use, and to ensure the qual-
ity of the product it is recommended to be kept at a room 
temperature in well-closed recipients.During application it 
gives pleasant cooling sensation and pain relief and easi-
ly rinse out with water. It is not toxic and does not cause 
skin irritation.
The product can be prepared in galenic laboratory, and 
easy application and efficiency makes it acceptable to pa-
tients (Jackson and Lowey, 2010). It has been retained at 
the administration site longer than the expected, and has 
longer actions regarding to the liquid alcohol solution, 
which is with the same components. 
Conclusion
The results of the treatment of patients according the 
investigation of the staff that operated and the practical pa-
tients show that this gel is with a prolonged analgesic ac-
tivity compared to the liquid preparation, with an easy and 
safe application, a pleasant cooling sensation and a pain re-
lief, also an easy flushing and with an increased satisfac-
tion of therapists and patients.
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Introduction
Antibodies, proteins and other biotechnological prod-
ucts are often challenging in terms of their in-solution sta-
bility. Various physical and chemical changes occur dur-
ing their in-solution storage, leading to shorter shelf-life. 
Freeze drying is often proposed as a method of choice, 
since removal of water has been reported to greatly re-
duce the rate of degradation, both in physical and chemi-
cal terms. Still, during freeze-drying antibodies and other 
protein pharmaceuticals can experience in-process chang-
es that may reduce their physicochemical biological and/or 
pharmacological properties. In this context, many attempts 
have been made to reduce these changes, both in optimi-
zation of the freeze-drying process and in optimization of 
solution formulation, adding various buffers, cryoprotec-
tants, etc. 
The presented experience was in freeze-drying of 
monoclonal antibody – rituximab, conjugated with three 
types of bifunctional chelating agents, p-SCN-Bn-DOTA, 
p-SCN-Bn-DTPA, and 1B4M-DTPA, and evaluation of 
possible changes in post-freeze-drying phase. In order to 
assess possible defragmentation of the antibody, protein in-
tegrity test was performed, using SDS-PAGE electrophore-
sis and the analysis of several structural elements of FT-IR 
and Raman spectra pre- and post- freeze-drying process, 
provided an insight in possible changes in the structure. 
Materials and methods
Commercially available rituximab (Mabthera®) 
was conjugated with three bifunctional chelating agents, 
p-SCN-Bn-DOTA, p-SCN-Bn-DTPA, and 1B4M-DTPA 
(Macrocyclics Inc. USA). The conjugates were synthesized, 
purified, adjusted to concentration of 1 mg/mL and freeze 
dried, using Labconco Free Zone Stoppering Tray Dry-
er (USA), as previously described (Smilkov et al., 2014). 
The protein integrity was assessed using SDS-PAGE that 
was performed in about 5 µL of reconstituted samples and 
1 mg/mL purified, commercial rituximab (Mabthera®). 
Samples were mixed with sample buffer and boiled 5 min 
at 95 °C. Approximately 5 µL of each preparation was 
applied in 12% bisacrylamide under reducing conditions. 
Visualization of the bands was enabled using Coomassie 
Brilliant Blue R-250 (Sigma, USA). For comparison, low 
molecular weight marker (Amersham GE Healthcare, UK) 
was used. 
For determining protein structure, FT-IR spectros-
copy was conducted on PARAGON 1000 (Perkin Elmer, 
USA) spectrophotometer in the spectral range 2000–500 
cm–1. Attenuated Total Reflectance (ATR) spectra were ac-
quired at a resolution of 4 cm–1. The obtained data was 
processed with Grams_32 software (Thermo Scientific). 
Raman spectra (2000–400 cm–1) were recorded on a mi-
cro-Raman multichannel spectrometer Horiba JobinYvon 
LabRam 300 Infinity, using He:Ne laser. The spectral reso-
lution was set to 4 cm–1. The acquisition time and the accu-
mulation number were set to 10 s and 10 scans, respective-
ly (Gjorgieva Ackova et al., 2015).
Results and discussion
Using SDS-PAGE electrophoresis it is possible to de-
termine the purity and, therefore possible defragmentation. 
The electrophoresis in reducing conditions resulted in two 
distinct Mw species which migrated in two bands in all 
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three rituximab conjugates. The upper band corresponded 
to ~50 kDa and the lower band to ~25 kDa. This migra-
tion pattern is characteristic of IgG antibodies that have 
two identical subunits, each composed of two polypeptide 
chains: two heavy and two light chains, linked via four di-
sulfide bonds. Under the action of the reducing agent DTT, 
the antibody is separated to heavy and light chains, with 
molecular weight corresponding to the two formed bands 
(Maleki et al., 2013; Nebija et al., 2011). The lyophiliza-
tion protocol used did not affect structure properties and 
caused no post-lyophilization modification, as shown in 
the reducing SDS-PAGE lane patterns, compared to com-
mercially available rituximab sample. 
Spectroscopy studies can reveal information to wit-
ness preserved secondary structure upon freeze-drying, a 
mandatory prerequisite for immunoconjugates. Protein de-
naturation upon lyophilization is usually monitored by IR 
spectroscopy (Murphy et al., 2012), although Raman spec-
troscopy can also be applied (Wen, 2007). 
The IR spectra of all three rituximab conjugates re-
vealed higher percentage of β-sheet conformation (antipar-
allel and parallel) in the structure (strong band in the region 
between 1612 and 1640 cm-1, followed by a weaker band 
around 1685 cm–1), followed by α-helices (bands at 1655 
or 1656 cm–1), as obtained in the band frequencies for am-
ide I, II and III bands which are used as diagnostic bands. 
We observed that the freeze-dried rituximab conjugates re-
gain their native conformation upon rehydration (revers-
ible unfolding). 
Thermally-induced aggregation processes of the ma-
jority of proteins can also be studied by FT-IR and Raman 
spectroscopy. Strong absorption bands below 1620 cm–1 
can be correlated with aggregation, usually associated with 
the formation of new strong beta-sheet structures (Schüle 
et al., 2007). With the lowest frequency band detected at 
1620 cm–1 (in all samples analyzed), we concluded no ob-
vious aggregation in all three freeze-dried antibody con-
jugates. 
Conclusion
Among the many techniques available for evaluation 
of the structure and stability of freeze-dried antibody con-
jugates, SDS-PAGE electrophoresis, FT-IR and Raman 
spectroscopy can be employed in assessing structural prop-
erties as well as in determination of stability of these poten-
tial drug candidates. 
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Introduction
The drug delivery with a specified rate in the body for 
a certain period of time has become an important tool for 
improving therapeutic index (Patel et al., 2009). Reducing 
toxicity to the health cells and potential drug degradation 
is important for achieving an effective treatment (Chan-
da et al., 2011; Kaur and Kakkar, 2010). Liposomes are 
considered to be excellent models of cell membranes, as 
well as for stabilizing the pharmaceutical active substanc-
es (Chanda et al., 2011; Kaur and Kakkar, 2010). Phospho-
lipids and cholesterol assembled in one or more lipid bi-
layers with an aqueous core are the main components in 
the microscopic spherical liposome vesicles (Chanda et al., 
2011). The specific characteristics of the liposomes such as 
non-toxicity, flexibility, targetability to specific cells or tis-
sues, and biodegradation make them drug carriers, reduc-
ing drug toxicity through encapsulation (Kaur and Kakkar, 
2010; Patel et al., 2009). The importance of their utilization 
is due to the ability to encapsulate hydrophobic, hydrophil-
ic, and amphiphilic active pharmaceutical substances (Gó-
mez-Henz and Fernández-Romero, 2006; Sahasrabuddhe 
et al., 2012). Generally, liposome formulations are classi-
fied based on their structural characteristics, substances in 
their composition, size and lamellarity, method of prepara-
tion, and their application (Kaur and Kakkar, 2010; Sahas-
rabuddhe et al., 2012). 
Ketoconazole (cis-1-acetyl-4-[4-[[2-(2,4-
dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxo-
lan-4-yl]methoxy]phenyl]piperazine) is a chiral lipophilic 
imidazole antimycotic drug administered mainly as a race-
mic mixture (50:50) of enantiomers in the cis configura-
tion. The decomposition of the drug could be easily caused 
through acidic, chemical, photolytic, and oxidative con-
ditions. Commercially available ketoconazole pharma-
ceutical dosage forms such as topical cream, antidandruff 
shampoo, ointments, and tablets possess anti-inflammato-
ry and some antibacterial activities (Patel et al., 2009; Sa-
hasrabuddhe et al., 2012). Potential nephrotoxicity, hepato-
toxicity, and decomposition of ketoconazole require prep-
aration of new safety formulations (Patel et al., 2009). In 
the ketoconazole liposome preparation, a thin-film hydra-
tion (Patel et al., 2009) and an injection method using ei-
ther chloroform (Sahasrabuddhe et al., 2012) or dichloro-
methane (Patel et al., 2009) were described. The potential 
adverse effects of alkyl halide solvents (WHO, 2004) em-
phasize the aim of this work for introducing less toxic sol-
vent such as methanol in ketoconazole liposome prepara-
tion through injection method. 
Materials and methods
Standard ketoconazole was received as a gift from 
Pharmaceutical Company Replek Farm DOOEL–Sko-
pje, Republic of Macedonia. Analytical grade methanol, 
HPLC grade methanol and water were supplied from Mer-
ck (Germany). Cholesterol was supplied from Calbiochem 
(Japan) and L-α-phosphatidylcholine (egg yolk) was from 
Sigma (Germany). Potassium hydrogen phosphate and po-
tassium dihydrogen phosphate were supplied from Alka-
loid AD (Republic of Macedonia). An analytical balance 
Mettler Toledo (Switzerland) was used for the sample 
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weighing with 0.1 mg accuracy. A magnetic stirrer (type 
MM–530 Tehnika Železniki, Slovenia), a rotary evapo-
rator (Devarot Elektromedicina, Slovenia), and a centri-
fuge (MRC, Pharmachem, Republic of Macedonia) were 
used in the ketoconazole vesicle preparation. An Agilent 
Technologies 1200 high-pressure liquid chromatograph-
ic (HPLC) system (USA) equipped with a diode array de-
tector (G1315D), a binary pump (G1312A), a degasser 
(G1379B), a thermostatted column (TCC G1316A), and 
an autosampler (ALS G1329A) were used for the encap-
sulation efficiency determination of ketoconazole in lipo-
some formulations. The chromatographic separation was 
achieved on a column LiChrospher®100 C-18 (150 mm 
length x 4.6 mm i.d., 5 µm particle size) with a mixture of 
methanol and water (90:10 v/v) mobile phase adjusted to 
pH 8.90 with a phosphate buffer. The absorbance was re-
corded at 296 nm. The morphology of ketoconazole lipo-
somes was determined with an optical microscope Konus, 
(type M–100–FL, Italy), equipped with a digital camera 
(Sony, Cyber–shot W, type DSCW830V.CE3) and a lens 
ZEISS Vario–Tessar 8x (China).   
Ketoconazole, L-α-phosphatidylcholine, and choles-
terol in the weight ratio of 3.3:1:3.3 w/w/w were trans-
ferred with 5 mL methanol in a 100 mL round-bottom 
flask. Following the homogenization process on the mag-
netic stirrer at 1000 min-1, methanol was evaporated in the 
rotary evaporator at 55 °C and 80 min-1 (10 min). The lip-
id mixture was added to a portion of 5 mL distilled water 
(80 °C). The ketoconazole liposome mixture was left over-
night in order to mature at 4 °C. The separation of the li-
posome and free amount of ketoconazole was done in the 
centrifuge at 5000 min-1 for 10 min.
Results and discussion
In the preparation of ketoconazole liposomes through 
injection method, the solubility of ketoconazole was con-
sidered as a criterion of choosing less toxic methanol in-
stead of chloroform (Sahasrabuddhe et al., 2012). The 
large unilamellar ketoconazole liposome vesicles were 
prepared using the injection method with methanol. The 
determined encapsulation efficiency of the ketoconazole li-
posome formulations in methanol of 45% was smaller in 
comparison to the encapsulation efficiency of the ketocon-
azole in chloroform (71%) obtained by Sahasrabuddhe et 
al., 2012. The smaller encapsulation efficiency was justi-
fied with harmless preparation conditions of ketoconazole 
liposome formation with methanol. The encapsulation effi-
ciency and morphological appearance were followed with 
evaluated stability of ketoconazole liposome formulations 
at 4 °C and 25 °C, during a month. After the first week 
and one month of the liposome preparation, during stabil-
ity test at 4 °C, the encapsulation efficiency was 43% and 
40%, respectively. At 25 °C, the encapsulation efficiency 
was decreased to 40% after the first week of the prepa-
ration, while after one month, the determined encapsula-
tion efficiency was 45% less than the initial value. The uni-
formed liposome appearance with a tendency of aggrega-
tion at higher temperature (25 °C) during one month sta-
bility test was confirmed using microscopic analysis. The 
drug leakage increases at higher temperature as a result of 
higher lipid fluidity (Patel et al., 2009).
Conclusion
The injection method using methanol could be applied 
in the ketoconazole liposome preparation. Process and for-
mulation parameters should be further optimized to obtain 
vesicles with higher encapsulation efficiency, improving 
stability after preparation, as well as in simulated condi-
tions, and sterilizing the obtained liposomes. 
References
Chanda, H., Das, P., Chakrabortym R., Ghosh, A., 2011. 
Development and evaluation of liposomes of fluconazole. J. 
Pharm. Biomed. Sci. 5, 1–9. 
Gómez-Henz, A., Fernández-Romerom, J.M., 2006. Analytical 
methods for the control of liposomal delivery systems. 
Trends Anal. Chem. 25, 167–178.
Kaur I.P., Kakkar S., 2010. Topical delivery of antifungal agents. 
Expert Opin. Drug Deliv. 7, 1303–1327. 
Patel, R.P., Patel, H., Baria, A.H., 2009. Formulation and 
evaluation of liposomes of ketoconazole. IJDDT 1, 16–23. 
Sahasrabuddhe, S.H., Bajpai, N., Bais S., Ganesan, S., 2012. 
Ketoconazole: liposomal drug delivery system–a boon for 
cosmetic industry. IJAPS 3, 109–116. 
WHO, Library Cataloguing-in-Publication Data, 2004. 
Chloroform. Concise international chemical assessment 
document, 58, Wissenchaftliche Verlagsgesellschaft mbH, 
Stuttgart, Germany.
Poster presentations
Macedonian pharmaceutical bulletin, 62 (suppl) 393 - 394 (2016)
ISSN 1409 - 8695
UDC: 615.272.4.015
Short communication
In vitro model for the analysis of 12-monoketocholate impact on 
simvastatin physico-chemical behavior in octanol/buffer system
Maja Đanić*, Nebojša Pavlović, Mladena Lalić Popović, Bojan Stanimirov,  
Svetlana Goločorbin Kon, Karmen Stankov, Momir Mikov
Faculty of Medicine, University of Novi Sad, Serbia, Hajduk Veljkova 3, 21000 Novi Sad, Serbia
* majadjanic@gmail.com
Introduction
The octanol-water distribution coefficient represents a 
physico-chemical property of a compound, being a valu-
able parameter in the understanding of its biological be-
havior. It has been widely used in numerous quantitative 
structure-activity relationship (QSAR) models for predict-
ing the pharmaceutical properties of molecules (Hughes, 
2008). Determination of distribution coefficient is com-
monly used to predict the drug transport through biological 
membranes and to test the effect of drug promoters on drug 
distribution (fanić, 2016). Bile salts are known for their 
function as modifiers of drug penetration across the bio-
logical membranes (Stojančević, 2013). The effect of bile 
salts on drug penetration appears to be complex and it de-
pends on the physico-chemical properties of the drug and 
on interactions of the bile salt with the physiological en-
vironment. Taking into account that simvastatin (SV) is a 
highly lipophilic compound with extremely low water-sol-
ubility and bioavailability (<5%), many efforts have been 
made to increase the aqueous solubility of the drug conse-
quently leading to the increase of its bioavailability. Ac-
cordingly, the aim of this study was to estimate the influ-
ence of semysinthetic bile salt, sodium 12-monoketocho-
late (MKC), on the distribution coefficient of simvastatin 
and to suggest molecular mechanisms responsible for this 
effect.
Material and methods
Distribution coefficients (logD) of SV with or with-
out MKC were determined using a “flask-shake“ meth-
od at pH 5 and pH 7.4, resembling gastrointestinal envi-
ronment. The aqueous media used for these pH conditions 
were 0.1 M sodium acetate and 0.035 M sodium phosphate 
buffer, respectively, while octanol was used as organic sol-
vent. Experiments were performed according to the pro-
cedure described by Serajuddin et al. (1991). Concentra-
tions of SV were determined by high performance liquid 
chromatography method according to method described by 
Carlucci et al. (1991). The detection was performed at 238 
nm.  In order to analyze theoretically complexation of SV 
with MKC, semi-empirical PM3 method implemented in 
MOPAC software package in the Chem3D Ultra 7.0.0 pro-
gram has been applied. It was also used for computation 
of physico-chemical properties of observed compounds 
to give a better interpretation of obtained in vitro results. 
Data were analyzed using OriginPro Software (OriginLab 
Corporation, MA, USA).
Results and discussion
As a highly lipophilic molecule and weak acid, in more 
acidic environment, SV is expected to be more in its neu-
tral form that can more easily penetrate biological barriers 
which explains higher values of distribution coefficient at 
lower pH (4.70±0.01 at pH5 vs. 4.59±0.06 at pH7.4). The 
experimental logD values of SV were in good agreement 
with the calculated logD values reported by Serajuddin et 
al. (1991). Upon addition of MKC, the distribution coeffi-
cient of simvastatin significantly decreased at both select-
ed pH (4.60±0.02 at pH 5, and 4.41±0.05 at pH 7.4). This 
means that the concentration of SV, i.e. the solubility of 
simvastatin, in buffer layer is increased in the presence of 
bile salts. Value logD in system octanol/buffer is dependent 
on drug solvent interaction. Chemical structure of bile ac-
ids is different from ordinary aliphatic surfactants, due to 
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the presence of a large, rigid, and planar hydrophobic moi-
ety of a steroid nucleus carrying 2–4 hydroxyl groups and 
an ionic head of a carboxyl group, which provide the mol-
ecule a planar polarity with hydrophilic and hydrophobic 
domains (Mikov, 2006).The increase in SV solubility cor-
relates with known high hydrophobicity of SV for which 
strong hydrophobic interactions with the lipophilic steroid 
nucleus of bile salt are to be expected and are confirmed 
in analyzed complex SV-MKC. Significantly higher val-
ues of Conolly Accesible Area (SAS), Conolly Molecular 
Area (MS), and Conolly Solvent Excluded Volume (SEV) 
of SV-MKC complex than SV alone additionally support 
experimentally obtained results. MKC has similar struc-
ture to cholic acid, differing only in a keto group at the 
position 12 instead of hydroxyl group. It has been shown 
that replacing of hydroxyl with keto group in MKC result-
ing in decreased membrane toxicity without compromising 
ability to enhance membrane permeability (Lalic-Popovic, 
2013; Stojančević, 2013), which makes it as a good candi-
date for the novel drug formulations. 
Conclusion
Our data indicate that the addition of MKC into the 
octanol/buffer system decreases the values of SV distribu-
tion coefficient. This may be the result of the formation of 
hydrophilic complexes increasing the solubility of SV that 
could consequently lead to the increase of its bioavailabil-
ity. Results of this study could contribute to the develop-
ment of new formulations with improved pharmacokinetic 
properties and enhanced bioavailability of SV.
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Introduction
The pepper (Capsicum annuum L.) which belongs to 
the genus Capsicum is a widely cultivated and distribut-
ed vegetable crop (Huq and Arshad, 2010). It is consist-
ed of carbohydrates, proteins, carboxylic acids, miner-
als, vitamins, and other biologically active compounds. 
The green, yellow, orange, and red pepper colour is de-
pendent on a carotenoid pigment profile. Capsaicin as the 
main capsaicinoid compound determined the pungency in 
the red hot pepper (Kumar et al., 2011). Although the pep-
per is produced seasonally, it is consumed throughout the 
year in either various specialties or spices and oleoresin 
extracts (Huq and Arshad, 2010; Kumar et al., 2011). The 
pepper is not only popular spice, but it could also be used 
in plant based insecticide formulations (Huq and Arshad, 
2010). The Capsicum annuum L. could be differed from 
shape, pungency level, colour, and content of biochemi-
cal compound. The colour could be evaluated from sur-
face and extractable colour aspects (Malacara, 2011). The 
red colour intensity is considered as the main quality attri-
bute of the red pepper and oleoresins, since it influences 
on both consumer acceptance and commercial value. The 
surface colour is dependent on pepper species and condi-
tions during growing, storage, and processing (Belovič et 
al., 2014). Many factors affect pepper colour loss such as 
photolytic and thermal conditions, as well as the oxidative 
degradation of carotenoid pigments (Belovič et al., 2014). 
Several different methods for the pepper colour evaluation, 
based on the surface colour measurement and profiling of 
the carotenoids are reported in the literature (Belovič et 
al., 2014). Surface colour measuring is the method for de-
scribing colour changes closest to sensory visual percep-
tion (Malacara, 2011). In this work the influence of the par-
ticle size at extraction of pericarp, placenta, seed, and stalk 
of red hot pepper of Macedonian origin was studied by the 
determination of the extract yield and surface CIE Lab co-
lour values.  
Materials and methods
The red hot pepper (Capsicum annuum L., spp. mi-
crocarpum longum conoides, convar. Horgoshka) was 
grown in the locality Markova Cheshma, Prilep, Republic 
of Macedonia. Dried fruits of the red hot pepper were cut 
manually longitudinally with a knife. Pericarp was separat-
ed from the seed, placenta, and stalk. Analytical grade pe-
troleum ether (40–60 °C) was supplied from Merck (Ger-
many). An analytical balance Mettler Toledo (Switzerland) 
was used for the sample weighing with 0.1 mg accuracy. 
The samples were ground using a Retsch ZM1 mill (Ger-
many). The extraction of the red hot pepper (10 g ± 0.1 
mg) was carried out with Soxhlet procedure using petro-
leum ether (40–60 °C). After 420 min extraction, the sol-
vent was removed at 40 °C, 200 mPa using a rotary evap-
orator (Devarot Elektromedicina, Slovenia). The steps of 
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drying, cooling, and weighing were repeated until the dif-
ference between two consecutive weights was smaller than 
2 mg. The yield of the extract was calculated based on the 
dry matter weight of the red hot pepper sample used. The 
extraction procedure was performed in duplicate under the 
same operating conditions. Visual colour of the samples 
investigated was evaluated measuring the CIE Lab coor-
dinates L* (lightness–darkness), a* (red−green), b* (yel-
low−blue), chroma (C), and Hue (h°) using Dr. LANGE 
spectra colorimeter (Chelmsford, UK). Colour difference 
(ΔE) was calculated from a*, b*, and L* parameters, using 
Hunter-Scotfield’s equation (Ergüneş and Tarhan, 2006). 
Results and discussion
At extraction with petroleum ether (40–60 °C), 6.42% 
extract yield was obtained from pericarp with 0.25 mm 
particle size. Increasing the pericarp particle size from 
0.5 to 1 mm, the extract quantity decreased, from 4.60 to 
2.68%, respectively. The extract yield from red hot pep-
per placenta with 0.5 mm particle size was 7.05%. The dif-
ference in the extract quantity obtained from the placenta 
with 0.5 mm and 1.0 mm particle size was 1.49%. At seed 
extraction, the highest quantity of the extract was obtained 
in comparison to pericarp, placenta, and stalk. The highest 
extract yield of 22.32% was determined at seed extraction 
with 0.5 mm particle size. The obtained stalk extract quan-
tity was the lowest, 3.70, 2.98, and 1.98% with particles 
size of 0.25, 0.5, and 1.0 mm, respectively. The empirical 
models tested showed a good agreement between experi-
mental and calculated data for the extract yield (R2> 0.90). 
The values of colour parameters varied between the sam-
ples of pericarp, placenta, seed, and stalk of red hot pepper. 
According to the L* values, seed samples were character-
ized by the brightest (72.28), while pericarp samples by the 
darkest colour (54.26). The determined values of the co-
lour parameter L* for placenta and seed were close to each 
other (65.59). High values of redness, a* (32.11) and satu-
ration, C (41.94) were measured for the pericarp samples. 
The estimated value of a*/b* ratio in seed was the low-
est. Hue (h°) values were linear correlated (R2 = 0.9793) 
with the values for the ratio of red (a*) and yellow colour 
(b*). The values of the L*, a*, b*, and C decreased with 
increasing the sample particle size (p< 0.05). The sample 
with 0.25 mm particle size was whiter, vivid, and deep red 
in colour than samples with particle size of 0.5 mm and 1.0 
mm. The highest colour difference before and after extrac-
tion with petroleum ether (40–60 °C) was determined for 
the pericarp with 0.25 mm particle size (ΔЕ = 27.12). In-
creasing the particle size from 0.5 to 1.0 mm, ΔЕ for peri-
carp was decreased from 22.72 to 14.78. The influence of 
the particle size during extraction of placenta is insignifi-
cant. For placenta with 0.5 mm and 1.0 mm particle size, 
estimated ΔE values were 19.28 and 18.67, respectively. 
The lowest ΔE values were determined during stalk extrac-
tion. The values of colour parameters for obtained extracts 
from pericarp, placenta, seed, and stalk at extraction with 
petroleum ether (40–60 °C) correlated with the determined 
colour values of the samples before and after extraction. 
The colour of red pepper is controlled by carotenoids. Cap-
santhin, capsorubin, and xanthophylls are responsible for 
the red, while β-carotene and zeaxanthin for the yellow-
orange colour. The red colour of different spices of pep-
per is mainly due to the biosynthesis of keto-carotenoids 
such as capsanthin and capsorubin (Ergüneş and Tarhan, 
2006). The published data for the surface colour were relat-
ed to the pericarp as an edible part of the pepper fruits. The 
differences in the pepper varieties, the maturity degree of 
the pepper, as well as the influence of drying and process-
ing conditions were studied using characteristics of the sur-
face colour (Belovič et al., 2014; Zaki et al., 2013). Results 
for the visual colour samples of pericarp are in agreement 
with those reported in the literature (Belovič et al., 2014; 
Ergüneş and Tarhan, 2006; Zaki et al., 2013).
Conclusion
The extraction of pericarp, placenta, seed, and stalk of 
red hot pepper was carried out with petroleum ether (40–60 
°C). The bigger particle size enabled to obtain less extract 
yield. The highest quantities were extracted from seed, 
while the lowest quantities from stalk. The colour differ-
ences increased with decreasing the particle size. The high-
est colour differences were estimated at extraction of peri-
carp.    
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Introduction
Essential oils are aromatic, volatile, natural oily liq-
uids obtained from plants, mainly leaves and flowers, as 
well as from fruits, seeds, roots, and stems. The most com-
mon known essential oils are those from lemongrass, oreg-
ano, peppermint, rosemary, thyme, cinnamon, and clove. 
A variety of volatile compounds such as terpenoids, phe-
nol-derived aromatic and aliphatic compounds were deter-
mined in the essential oil composition. The essential oils 
are recognized for their medicinal value such as analge-
sic, sedative, anti-inflammatory, spasmolytic, and locally 
anaesthetic remedies. As a powerful natural products with 
bactericidal, virucidal, fungicidal, antiparasitical, and in-
secticidal properties, the essential oils take a significant 
place in cosmetic, pharmaceutical and food industry, as 
well as in agriculture (Hüsnü Can Başer and Buchbauer, 
2010). Concerning the complex chemical composition, the 
essential oils could be easily decomposed. Oxidative and 
photolytic conditions resulted in a quality loss and reduc-
ing of the biological activity (Bilia et al., 2014). In order 
to protect and to use in drug delivery systems, nanoencap-
sulation of the essential oils was proposed due to their ca-
pability of improving the solubility, stability, and effica-
cy of essential oil-based formulation. Nanoemulsion is dis-
persion of two immiscible liquids with droplet size ranging 
from 20 to 200 nm (Solè and Solans, 2013). Low and high 
energy methods are used in the development of nanoemul-
sion formulation. The high energy method required the me-
chanical energy such as an ultrasonic procedure and a high 
pressure homogenization. On the other hand, surfactants as 
emulsifiers either in aqueous phase titration or in sponta-
neous emulsification low energy method are used (Schuh 
et al., 2014).
The objective of this study was to develop stable nano-
emulsions of wild oregano essential oil using low energy 
emulsification methods.
Materials and methods
Surfactants: Tween 80 (polyoxyethylene sorbitan mo-
nooleate, Sigma–Aldrich, Germany), Tween 20 (polyoxy-
ethylene sorbitan monolaurate, Merck, Germany), and 
Span 80 (sorbitan monooleate, Fluka, Germany) were 
used. Propylene glycol (PG) was supplied from Aldrich 
(Germany). Wild oregano essential oil (Origanum minu-
tiflorum) produced in Turkey was purchased from Inter 
Connection Group DOOEL (Republic of Macedonia). Mil-
liQ PURElab Classic system (ELGA, USA) supplied ultra-
pure water.. An analytical balance Mettler Toledo (Switzer-
land) was used for the sample weighing with 0.1 mg accu-
racy. A magnetic stirrer (type MM–530 Tehnika Železniki, 
Slovenia) and a vortex (EV–102 Tehnika Železniki, Slove-
nia) were used in the preparation of the wild oregano na-
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noemulsion formulations. Pseudo ternary phase diagrams 
consisting of wild oregano essential oil, mix of surfactans 
Tween 20, Tween 80 and Span 80 (Smix), and water were 
constructed using aqueous titration method (Shaaban and 
Edris, 2015). In glass vials, the wild oregano essential oil 
was mixed with Smix in weight ratios from 1:9 w/w to 
9:1 w/w and was titrated with calculated amount of aque-
ous phase (water or water and PG in the ratio 1:1 w/w). 
After 24 h the samples were monitored, visually inspect-
ed for transparency and followability and water was add-
ed. The phases were identified as transparent/translucent 
emulsion, transparent gel, turbid gel or turbid/milky emul-
sion. The visually evaluated mixtures and nanoemulsion 
phase were marked on the phase diagram. The droplet size, 
polydispersity index (PDI), and ζ-potential were measured 
with Zetasizer Nano ZS (Malvern Instruments Ltd, United 
Kingdom) 24 h after the emulsion preparation.
Spontaneous emulsification in three step process 
method was employed (Schuh et al., 2014). In the first step 
organic and aqueous phase were prepared. The homoge-
neous organic phase contained oregano essential oil, lipo-
philic surfactant Span 80, and ethanol as water miscible 
solvent, while aqueous phase was composed of water and 
hydrophilic surfactants, Tween 20 or Tween 80. In the sec-
ond step organic phase was injected into the aqueous phase 
by stirring on the magnetic stirrer for 30 min at 750 min-
1to reach phase system equilibrium. In the third step, etha-
nol was evaporated on a BUCHI rotary evaporator system 
type R-114 and vacuum controller B-721 (Switzerland) at 
40 °C, 250 bar, 1 h. The influence of the surfactant mix-
ture (Tween 80 and Span 80 or Tween 20 and Span 80) and 
the surfactant to oil ratio on the droplet size, polydispersity 
index (PDI), ζ-potential, the particle size distribution, and 
average particle diameter were determined 24 h after the 
emulsion preparation.
Results and discussion
In the phase diagrams constructed using the oil, Tween 
80, and a surfactant mixture of Tween 80 and Span 80 in 
the ratio of 2:1 w/w and 1:1 w/w, the effective surface of 
formed nanoemulsion was smaller. The maximum amount 
of water incorporated in the system was 23%. As a result 
of the small amount of water, as well as the high nanoemul-
sion density, the preparation of water based nanoemulsion 
was disabled. Substituting Tween 80 with Tween 20 and 
changing water with a mixture of water and PG in the ra-
tio of 1:1 w/w, nanoemulsion surface increased. When the 
oil and the Smix in the ratio of 1:9 w/w were used, the 
formed nanoemulsion could be fully diluted with water 
without the formation of turbid-white emulsion. The av-
erage droplet size measured 24 h after preparation was 44 
nm, while PDI was 0.349. Transparent emulsion was not 
formed when mixture of Tween and Span 80 in the ratio 
1:2 w/w was used.
The droplet size of the nanoemulsion prepared using 
the spontaneous method influenced by the surfactant mix-
ture (Tween 80 and Span 80 or Tween 20 and Span 80) and 
the ratio of the mixed surfactants and oil (the weight ratio 
of Smix:oil was 0.5, 1 and 1.5 w/w). The droplets with 160 
nm particle size, 0.097 PDI, and -26 mV ζ-potential was 
obtained using a mixture of Tween 20 and Span 80 mixed 
with the oil in ratio of 0.5. Using the surfactant mixture of 
Tween 80 and Span 80 in the proportion of 0.5 with the oil, 
the droplets with 180 nm particle size, 0.134 PDI, and -20 
mV ζ-potential were obtained. Increasing the Six to oil ra-
tio at 1 and 1.5, nanoemulsions with bigger droplets were 
obtained. The average droplet size of Tween 20 or Span 
80 mixture oil in the proportion of 1.5 was 361 nm, while 
PDI was 0.071 and a low ζ-potential value was recorded 
(-2.69 mV).   
Conclusion
The low energy methods, aqueous titration and spon-
taneous emulsification method can be used in order to pro-
duce fine droplet nanoemulsions of wild oregano essential 
oil. Aqueous titration method requires high concentration 
of surfactants at low oil concentration. Spontaneous emul-
sification method can only be applied when low oil con-
centration, less than 1%, is used. In order to improve the 
emulsification efficiency of the essential oil with high con-
centration of carvacrol as a biological active compound 
and to increase the stability of the nanoemulsions prepa-
ration using aqueous titration and spontaneous emulsifica-
tion method, the process and working parameters should 
be optimized. 
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Introduction
Every product and every process has an associated 
risk. Every enterprise should have a methodology for iden-
tifying and evaluating the risks it faces and it should have 
a process for generating intervention plans to reduce the 
risks to an acceptable level. This process is generally re-
ferred to as a Quality Risk Management (QRM). QRM is 
a systematic process for the assessment, control, commu-
nication and review of risks to the quality of the medicinal 
product across the product lifecycle. Early in development, 
the purpose of the QRM process may be to acquire suffi-
cient product and process knowledge to assess risks asso-
ciated with formulation development of the finished phar-
maceutical product according to the quality target product 
profile. As development progresses, in addition to support-
ing that development, the purpose of the QRM process is 
to determine and manage risks to bioavailability, safety, ef-
ficiency and product quality.
Risk assessment is a systematic process of organizing 
information to support a risk decision to be made within a 
risk management process. It consists of the identification 
of hazards and the analysis and evaluation of risks associ-
ated with exposure to those hazards. 
Packaging represents a critical manufacturing op-
eration requiring strong Good Manufacturing Practices 
(GMPs) and quality oversight to ensure sustained and ro-
bust compliance. Historically, inadequate packaging prac-
tices have been a meaningful ongoing contributor to prod-
uct recall actions industry-wide. A strong understanding of 
the compliance risks associated with product packaging 
is a necessary and important component of a good quali-
ty system. The goal of risk assessment is to further enhance 
the quality assurance of existing packaging operations and 
practices (Guidance for industry “Q9 Quality Risk Manag-
ment”, 2006) (Quality Risk Management Q9, 2005).
Risk assessment
The aim of risk assessment in blister packaging is to 
identify, analyse and evaluate risks during blister packag-
ing process validation and the manufacturing processes.
Risk identification is a systemic use of information to 
identify potential sources of harm referring to the risk or 
problem. Information can include historical data, theoret-
ical analysis, and the concerns of stakeholders. Risk iden-
tification addresses the “What might go wrong?” question 
and provides the basis for further steps in the quality risk 
management process (Reddy et al., 2014). 
Risk analysis is the estimation of the risk associated 
with the identified hazards. It is the qualitative or quantita-
tive process of linking the likelihood of occurrence and se-
verity of harms (detectability) is also a factor in the estima-
tion of risk (Reddy et al., 2014). 
A team is assembled to collect relevant data about the 
packaging line. All operations involved with the line func-
tion (equipment, procedures, etc.) and all corresponding 
potential failures are listed. For each potential failure, the 
team works to understand its potential impact on packaging 
operations and then respectively to assign a severity cate-
gory. Following severity classification, the team is review-
ing all dominant causes relevant to the defined potential 
failure and then assigning a frequency category. For each 
potential failure, all safeguards (e.g. detection capabilities) 
are reviewed and a detection capability is assigned. For Se-
verity Frequency and Detection determination, all relevant 
data is  taken into consideration, to include maintenance 
and operation logs, batch records, deviation investigations, 
customer complaint records, etc. (Reich et al., 2011). The 
determined parameters and operations are: the environ-
mental conditions during the process of primary packag-
ing, issuing packaging material, issuing bulk product, blis-
ter forming, filling tablets into blisters, testing tablet pres-
ence in the blister, text printing on the aluminum lidding 
foil, blister sealing, embossing batch number and expiry 
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date on the blisters, the blister perforation, the blister cut-
ting, insertion of proper number of blisters, leaflets fold-
ing, pharma code reading on the boxes, pharma code read-
ing on the leaflet, embossing batch number and expiry date 
on the boxes, leaflet presence, weight check, determination 
of yield. For all parameters and operations potential risks 
are defined, consequences (severity of consequences, prob-
ability of occurrence, the possibility of detection). The as-
sessment effort requires that potential product defects from 
any given packaging operation is defined and graded for 
severity, frequency and on the ability of the operation and/
or an operator to detect the defect (Internal procedure: List 
of evidence for identification of risk, 2009)
Risk evaluation compares the identified and analyzed 
risk against given risk criteria. The output of a risk assess-
ment is estimated as quantitative description of a range of 
risk. A numerical probability is used. Defect detection is 
categorized and graded on a 1-to-4 scale to reflect a detec-
tion capability of “none” (unable to detect) to “always” de-
tect. 
For each potential failure, all precautions are reviewed 
and a detection capability is assigned.  For determinations 
of severity, frequency and detection, all relevant data is 
taken into consideration, including maintenance and oper-
ation logs, batch (Internal procedure: List of evidence for 
identification of risk, 2009).
Conclusion
The risk of blister packaging process is reduced to an 
acceptable level. According to the results of the risk as-
sessment on blister packaging on the IMA C80/A81 blis-
ter packaging line, we can conclude that the blister pack-
aging process is with low risk and the process is capable to 
perform effectively and gives reproducible products with 
quality that matches with the regulatory specifications and 
quality attributes.
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Introduction
Dementia is characterized by persons` significant cog-
nitive decline and interference with everyday life indepen-
dency. There are several types of dementia, but Alzheim-
er’s disease (AD) is most common form. AD a neurode-
generative disease is characterized by decline in memory, 
language, problem-solving and other cognitive skills that 
affects a person’s ability to perform everyday activities 
(Alzheimer’s, 2015). 
Currently there are only 5 drugs approved for AD 
treatment and all are targeted towards metabolic disor-
ders associated with the disease. Four of them, tacrine, do-
nepezil (DON), rivastigmine (RIV) and galantamine (ap-
proved in 1993, 1996, 1998 and 2001, respectively) are in 
group of acetylcholinesterase inhibitors (AChEi) and one, 
memantine (MEM), approved in 2003, is N-methyl-D-as-
partate (NMDA) receptor antagonist (Cummings et al., 
2014).  Although AD drugs are frequently used for more 
than 20 years there are evidences about controversies re-
lated to their efficacy and clinical significance (Lanctôt et 
al., 2009). 
The aim of the current study was to analyze safety 
and efficacy of dosage forms of AD most commonly used 
drugs with focus on meta-analysis as well as to identify 
trends in AD treatment. 
Current therapeutic options
Oral solution, hard capsules and transdermal patches 
with RIV, for treatment of mild to moderate dementia asso-
ciated with AD and Parkinson’s disease are present on the 
market.  Latest Cohran`s collaboration review is address-
ing RIV clinical efficacy/safety in treatment longer than 
12 weeks (any dose and administration route) in patients 
with AD dementia compared to placebo as well as compar-
ison of RIV patches and capsules given at the manufactur-
er’s recommended dose (Birks and Grimley Evans, 2015). 
Results from the study indicated that RIV use is associat-
ed with some benefits on some outcomes (cognitive func-
tion, activities of daily living and clinician rated global im-
pression) and no differences in behavioural symptoms and 
quality of life of carers compared to placebo. No difference 
compared to placebo for withdrawals before the end of the 
treatment and at least one adverse effect was identified for 
RIV lower dose (1-4 mg/day), while for higher dose (6-12 
mg/day) results favoured placebo. Fewer side effects re-
lated to nausea, vomiting, dizziness, effect on decreased 
appetite and asthenia for 9.5 mg/day patches compared to 
capsules were identified (Birks and Grimley Evans, 2015). 
DON for the treatment of mild to moderate AD is ap-
proved in form of film coated and dispersible tablets.  Ef-
fects of DON (any dose) in mild, moderate or severe de-
mentia in AD treatments longer than 1 day compared to 
placebo were assessed by Birks and Harvey (2006).  Re-
sults were similar as for RIV (Birks and Grimley Evans, 
2015) with the exception of positive findings for DON ef-
fect on behaviour. Dose of 5mg/day DON was found to be 
more cost-effective as 10 mg/day dose was associated with 
more adverse effects and only marginally higher effects.
Comparison of safety and efficacy of AChEi for AD 
was done by Birks (2006). Four studies were identified, 
but only one (DON vs RIV) met criteria for inclusion in 
meta-analysis. No differences in efficacy were observed, 
but DON was associated with less adverse effects, particu-
larly nausea, vomiting, anorexia, weight loss, event of fall 
and hypertension. However, conducted meta-analysis sug-
gested that their tolerability might be match if RIV is care-
fully and gradually titrated for more than 3 months (Birks, 
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2006).
MEM is marketed in form of film-coated tablets for 
treatment of moderate to severe AD dementia. McShane et 
al. (2006) meta-analysis was related to efficacy and safe-
ty of MEM (any dose and any route of administration) for 
people with AD, vascular and mixed dementia. Clinically 
significant reduction of deterioration in patients with mod-
erate to severe AD dementia was determined when MEM 
in dose of 20 mg/day for at least 28 weeks was compared to 
placebo. In general, MEM was well tolerated with low in-
cidence of adverse effects (McShane et al., 2006).  
Latest FDA approved drug for treatment of AD de-
mentia (in 2014) is Namzaric (memantine hydrochloride 
extended-release + donepezil hydrochloride). 
Trends in Alzheimer’s disease drug development 
Having in mind that we are facing with lack of effi-
cacious therapeutic options for prevention and treatment 
of dementia and specifically for AD and associated behav-
ioral and physiological symptoms there is extensive sci-
entific research in this field. For ex. search on Scopus da-
tabase (www.scopus.com.scopeesprx.elsevier.com) per-
formed on 1.11.2015 using key words “Alzheimer’s dis-
ease” resulted with 105860 items. Annual analysis pointed 
to the growing scientific interest for AD research as num-
ber of published items continuously increased during the 
years. First 2 published articles related to AD were found 
to be in 1912 year and the number was relatively low till 
1988 (less than 800 per year). Further on, AD research rap-
idly grew with more than 4000 published scientific papers 
in 2005, thus reaching its maximum in 2014 with >8000 
published scientific items (at the time of search for 2015 
there were 6417, and 60 for 2016 year). Also, search on 
www.clinicaltrials.gov.mk carried out on 27.10.2015 re-
sulted with total of 1769 AD clinical trials allocated to all 
continents around the globe. At the time of search 541 clin-
ical trials were with status OPEN, mainly in USA, Europe, 
China and Japan - 231, 175, 67 and 41 respectively. In Eu-
rope most of the studies (56.6%) were located in France, 
followed by United Kingdom (18.3%) and Spain (17.1%). 
Nearly 30% of active trials were related to drug substanc-
es not yet approved for AD. Beside high number of clini-
cal trials we have to be held in reserve as for a period of 
10 years (2002-2012) 244 AD drugs were in clinical trials, 
but only one, MEM in 2003, was approved (0.4% succeed 
rate) (Alzheimer’s, 2015).  It is a fact that development 
of new drugs for treatment of AD is difficult and compli-
cated due to the high costs, relatively long time needed to 
observe disease progression in AD and blood-brain bar-
rier.  Problems associated with blood-brain barrier might 
be surmounted by innovative therapeutic systems (ITS) 
for drug targeting and controlled release (liposomes, mi-
celles, nanoparticles etc). Namely, utilizing their unique 
physico-chemical and biopharmaceutical properties drug 
targeted and controlled release dosage form with modi-
fied/improved pharmacokinetics/dynamics might be de-
veloped.  Conducted search on Scopus database (accessed 
on 13.08.2015) retrieved 666 scientific papers (SP) related 
to micelles, liposomes, solidlipid nanoparticles, nanostruc-
tured lipid carriers and nanoparticles as ITS and/or RIV 
(197 SP), tacrine (124 SP), MEM (189 SP) and DON (156 
SP) as drug substances.  However in detail analysis of re-
trieved items revealed that only 15 (2.25%) were original 
research papers, and others were reviews. A vast majority 
of the original research papers (86.7%) were related to RIV 
and only 6.7% were related to DON and MEM, each. Li-
posomes and micelles as carriers for RIV were studied in 
26.7% and 6.7% of the research papers, respectively. On 
the other hand most of the conducted research (66.7%) was 
related to nanoparticles, where’s 80% were focused on RIV 
and 10% on DON and MEM, each. All of them were char-
acterized in terms of particle size, drug content/ encapsu-
lation efficiency, zeta potential and in vitro dissolution and 
majority (66.7%) conducted in vivo animal studies. All ob-
tained results in the reviewed studies pointed to ITS poten-
tial use for AD efficacious treatment.
Based on the retrieved data it can be concluded that 
although ITS for different conditions are already in use 
for more than 20 years (1989 FDA approved Diprivan® 
- surfactant-based nanoformulation of anestetic Propofol) 
exploration of their potentials for AD treatment is still in 
its begging’s.
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Introduction
In the recent years, mutual interactions between 
nanoparticles and various biomolecules have been increas-
ingly studied, in view of the well-known fact that they 
have major impact on nanoparticle overall performance. 
After intravenous administration blood is the first biolog-
ical environment nanoparticles are exposed to, compris-
ing a pool of several thousand proteins in different con-
centrations (Monopoli et al., 2011). Plasma proteins tend 
to adsorb on the naoparticle surface forming so-called pro-
tein corona, which governs the nano-bio interactions and 
determines nanoparticles fate following their administra-
tion. Modified biological identity of nanoparticles will af-
fect the physiological response including their circulation 
time, agglomeration, transport, accumulation, internaliza-
tion and toxicity.
Nanoparticle characteristics (size, shape, surface 
charge, surface functional groups and hydrophilicity/hy-
drophobicity), the nature of physiological environment 
(blood, intestinal fluid, cytoplasm) and the exposure time 
play a key role in the process of protein corona formation 
(Masoud et al., 2013). The rate of adsorption/desorption 
of different proteins, competitive binding, steric stabiliza-
tion induced by adsorbed polymers and surfactants as well 
as the protein composition of body fluids lead to dynamic 
changes of the protein corona. 
In the initial phase, usually the most abundant plasma 
proteins, such as albumin, are adsorbed at the surface of in-
travenously administered nanoparticles. In time, albumin 
can be replaced by proteins with higher binding affinity 
towards NP surface, since the protein corona composition 
continuously exchange (Vroman effect). It is worth men-
tioning that there is a possibility for structural and func-
tional changes of proteins that interact with the nanopar-
ticle surface, which could lead to activation of molecu-
lar mechanisms resulting in certain pathogenesis (Nel et 
al., 2009). Therefore, a detailed protein corona character-
ization is crucial for biocompatibility assessment of the 
nanoparticulate drug delivery system.
For this purpose, in this study we conducted compara-
tive protein corona composition analysis of three different 
polymeric nanoparticles at several time intervals.
Materials and methods
Poly(lactic-co-glycolic acid)-b-Poly(ethylene glycol)-
b-Poly(lactic-co-glycolic acid) (PLGA-PEG-PLGA) with 
two different molecular weights (Mw~148000Da and 
Mw~22000Da) and Poly(DL-lactide-co-caprolactone) 
(P(DLLACL copolymer, LA:CL 10:90, Mw 77799 Da) 
were purchased from AkinaInc, USA. Acrylamide-biacryl-
amide 37.5:1, 30% solution, Electrophoresis running buf-
fer, Laemmli buffer and Comassie brilliant blue were ob-
tained from Bio-Rad, USA. Tris (hydroxymethyl) amino-
methane (TRIS) base, Sodium dodecyl sulphate and Amo-
niumpersulphate were acquired from Sigma Aldrich, USA, 
while N,N,N’,N’-Tetramethylethylenediamine (TEMED) 
was purchased from MerckMilipore, Germany. All other 
chemicals were of analytical grade and were used as re-
ceived.
Nanoparticle preparation
Three types of nanoparticles (NP1, NP2 and NP3) were 
prepared by nanoprecipitation method as described before 
(Dimchevska et al., 2015; Koliqi et al., 2016). Following 
copolymers were used for this purpose: PLGA-PEO-PLGA 
(Mw~148000Da), PLGA-PEO-PLGA (Mw~22000Da) 
and P(DLLACL), respectively.
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Protein corona evaluation
Semi-quantitative protein corona evaluation was per-
formed using SDS-PAGE – sodium dodecyl sulphate poly-
acrylamide gel electrophoresis. 4% stacking gel and 10% 
resolving gel were used to estimate the protein corona com-
position of nanoparticles. At first, all NPs (1mg/mL) were 
incubated with 50% of human plasma at 37 °C for three dif-
ferent time periods (30min, 1h and 4h) in a water bath at 
stirring rate of 100 oscillations/min (Haake, Denmark). Af-
ter the incubation, nanoparticles were pelleted by centrifu-
gation (18000xg, 30 min at 4 °C) and the plasma was dis-
carded. The samples were washed twice with 1.5 mL PBS 
and the supernatant was removed. 25 µL of Laemmli sam-
ple buffer containing 5% β-mercaptoethanol was then add-
ed to each sample.  Samples were vortexed for 30s and heat-
ed at 95 °C for 5min in order to provide desorption and de-
naturation of adsorbed proteins. NPs were allowed to cool 
down at RT and then 5µL of each sample were loaded into 
the stacking gel placed on a vertical system (Mini Protean 
Cell, BioRad, USA). Gels were run for 60-90 min at 110 
mV. After the protein separation the gels were removed, im-
mersed in a 0.1% Coomassie blue solution and left to stand 
for 16h. The next day, each gel was washed with destaining 
solution (40% methanol, 10% glacial acetic acid and 50% 
deionized water) in four cycles. Pictures were acquired on 
white background using VersaDoc, Bio-Rad, USA. Densi-
tometric analysis of proteins was performed using Quantity 
One 1-D Analysis Software, Bio-Rad, USA.
Results and discussion
Time-resolved protein evaluation confirmed the dy-
namic character of protein corona for all types of investi-
gated nanoparticles. The results revealed a presence of an 
intense band around 66 kDa at each time point for all types 
of NPs, which corresponds to the molecular weight of al-
bumin. Since albumin is the most abundant plasma protein 
with modular structural organization, high molecular flex-
ibility and variety of binding sites on its surface, mutual 
non-specific interactions with the NPs were promoted, es-
pecially in the early time points of the experiment.
Further, we have noticed that different binding pat-
terns for different NPs over time were displayed, probably 
due to their specific surface properties. Also, various com-
position of protein corona for each type of NPs was ob-
served at the later time periods (1h and 4h) which corre-
spond to protein corona dynamic nature and concomitant 
association/dissociation of diverse protein molecules dur-
ing time. The results for longer incubation periods have 
shown that albumin was progressively replaced by other 
proteins with higher affinity and increased binding spec-
ificity to the NP surfaces, regardless of their plasma con-
centration. Proteins with molecular weights of 43 kDa, 41 
kDa, 32 kDa and 25 kDa have gradually replaced the ini-
tially adsorbed albumin (66 kDa) as well as proteins with 
Mw of 55 kDa and 50 kDa at the surface of NP1 and NP2. 
Additionally, one characteristic band at 8 0kDa was ob-
served at the later time points for NP2 which could not be 
observed for NP1. Protein corona composition of NP3 for-
mulation was significantly different compared to NP1 and 
NP2, probably due to the higher hydrophobicity of the NP 
core. Specific proteins adsorbed onto the NP3 surface were 
those with Mw of 28 kDa, 36 kDa, 46 kDa, including one 
high molecular weight protein (Mw 185 kDa). 
Our results correspond to the literature data for protein 
adsorption upon polymer NP surfaces. Namely, in the ear-
ly time points of the experiment, albumin and fibrinogen 
were dominant components of the NP protein corona. Lat-
er on, significant differences appeared among the adsorbed 
imunoglobulins upon the surfaces of various NPs and ad-
ditionally apolipoproteins came to be a significant portion 
of the total protein quantity.
Conclusion
Displacement of proteins over time was confirmed for 
all evaluated types of NPs. It was shown that abundant pro-
teins such as albumin and fibrinogen may initially occupy 
the NP surface and get subsequently replaced by other pro-
teins having higher binding affinity like apolipoproteins.
Different protein binding patterns lead to altered bio-
logical identity of NPs that will affect their in vivo behav-
ior including their biodistribution, cell internalization, tox-
icity and efficacy.
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Introduction
Prolonged-release oral dosage forms offer more advantag-
es over a conventional dosage form of the same drug like sus-
tained blood levels and better patients compliance, smaller dos-
age unit or higher dosage per unit and economical to manufac-
ture (Hanna et al., 1987). The active agent can now be delivered 
and made bioavailable in a sustained and well-controlled man-
ner up to a desired period of time. The matrix system is com-
monly used for manufacturing prolonged-release dosage forms. 
Bio-functional polymers have pharmaceutical interest in recent 
years and are widely used for formulation of modified release 
dosage forms (Meidan and Khan, 2007). Cellulose ethers are 
commonly employed as the hydrophilic, swellable and erodible 
matrix polymers for orally administered types of prolonged-re-
lease systems (Ferrero Rodriguez et al., 2000). As water insol-
uble excipients, ethylcellulose polymers (Ethocel) can effec-
tively control the release of an active ingredient by modifying 
the size and length of diffusion path. By varying the type and 
amount of the insoluble excipient ratio and the particle size, a 
wide variety of release rate patterns can be achieved.
The aim of the present study was to develop prolonged-
release matrix tablets for water-soluble drug using hydroxy-
propylmethylcellulose (Methocel) and Ethocel in order to re-
duce dosing frequency, to lesser the side effects and to im-
prove patient compliance.
Materials and methods
Materials
Water-soluble compound (API) was used as a model drug 
(solubility 10.2 mg/ml, pKa 10.26 and 9.12, Mw 473.49 g/
mol, BCS Class III). The other excipients were: Methocel 
K100M (Colorcon, EU), Ethocel 7cPs FP (Colorcon, EU), 
Kollidon K90 (BASF, Germany), Avicel PH 112 (FMC Bio-
polymer, USA), Aerosil 200 (Evonik, Germany) and Magne-
sium stearate (Mg S) (Carsco GE, Italy). All the other chemi-
cals used were of analytical grade.
Preparation of matrix tablets by wet granulation technique
The tablets were prepared by wet granulation technique. 
The API and other excipients were accurately weighed and 
mixed in laboratory mixer granulator (Diosna Dierks & 
Söhne GmbH, Germany). The mass ratio of API:Methocel 
K100M:Avicel112:Mg S was 7.56:29.04: 25.72:14.52:1 for 
sample 1 and API:MethocelK100M:Ethocel:Avicel 112:Mg S 
= 7.56:14.52: 14.52:29.04:1 for sample 2, respectively.
Kollidon K90 (5% sol. in alcohol 99%) was used as gran-
ulation fluid. The wet mass was passed through #6 mesh and 
granules were oven dried until a moisture content of 1-3% 
was achieved. Dried granules were further passed through 
#230 mesh. The granules were lubricated and compressed into 
round shaped (7.0 mm) tablets using 4-station rotary compres-
sion machine (Korsch XL 100, Korsch AG, Germany) with 
compression forces 3.8 kN and  8.3 kN (sample 1a,1b and 2, 
accordingly). 
Each tablet contained 15 mg of API in 150 mg tablet core 
weight. The tablets were evaluated for appearance, diameter, 
thickness and hardness. 
Characterization of the final blends 
Bulk density was determined by the following formula: 
Bulk density =Ws/Vs; where Ws is sample weight and Vs is the 
sample volume (Ph. Eur. 8.7).
Tape density is the indirect measurement of flow, mixing 
and tableting properties of powder. Tapped density was deter-
mined by Ph. Eur. 8.7 method: tablet blend was filled in 100 ml 
graduated cylinder of tap density tester which was operated for 
fixed number of taps until the powder bed volume has reached 
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a minimum, thus was calculated by formula: Tapped density = 
Weight of mixture/volume of mixture after 100 tapings.
Compressibility index of the final blends was determined 
by Carr’s compressibility (%) = Df - Do/Df; where Df is the 
bulk density and Do is the tapped density (Ph. Eur. 8.7).
Hausner’s ratio or index of flowability was calculated by 
the formula: Hausner’s ratio=V1/V2; where V1 is the volume 
before taping and V2 is the volume after taping (Ph. Eur. 8.7).
Angle of repose was determined using funnel method. 
Tablet blend were poured from funnel, that can be raised ver-
tically until a maximum cone height h was obtained diameter 
heap D, was measured (Ph. Eur. 8.7). The angle of repose was 
measured using Granulate flow tester (Erweka GmbH, Ger-
many).
Loss on drying is the loss of mass expressed as per cent 
m/m (Ph. Eur. 8.7). It was measured by drying the substance 
to constant mass using Moisture Analyzer (Mettler Toledo Ex-
cellence HS 153, US). 
Physical characterization of the prepared tablets
10 tablets were used to study the weight variation us-
ing electronic balance (Sartorius Secura 224-1CU, Sartorius 
AG,Germany). 
The diameter, thickness and tablet hardness was deter-
mined for ten tablets using ErwekaTablet Hardness Tester 
Type TBH 425 TD (Erweka GmbH, Germany).
In vitro drug release studies
Dissolution testing was conducted in 900 ml of phosphate 
buffer pH 6.8 (USP apparatus I, basket, speed 100 rpm) at 
37±0.5 °C. A 5 ml of the dissolution medium was withdrawn 
at regular tome intervals (after 2, 4, 10 and 12 h). The vol-
ume of dissolution medium was adjusted by replacing each 5 
ml aliquot withdrawn with 5 ml of fresh dissolution medium. 
Quantity of released API was determined by previously vali-
dated HPLC method.
Results and discussion
The bulk density of sample 1 and sample 2 were 0.272 
and 0.360 g/ml respectively, while tapped density values were 
0.331 and 0.439 g/ml. Compressibility index of sample 1 and 
sample 2 were 18 and 19%, while Hausner’s ratio values were 
1.22 and 1.21 correspondingly, which is an indication of fair 
flow properties. 
Angle of repose of the final blends was 41.2° for sample 1 
and 40.3° for sample 2. LOD was found to be 2.40% for sam-
ple1 and 2.55% for sample2 indicating that both of the final 
blends had moisture content up to acceptable limit which was 
good for compression to make uniform matrices. 
All tablets were smooth and elegant in appearance. Tablet 
weight variations for both samples prepared in this study were 
found to be less than 1%. Sample 1a had diameter of 7.00 
mm; thickness 4.23 mm and hardness 5.01 kP (at compression 
force 3.8 kN). Sample 1b had diameter of 6.97 mm; thick-
ness 3.37 mm and hardness 14.29 kP (at compression force 
8.2 kN). Sample 2 had diameter of 6.97 mm; thickness 3.32 
mm and hardness 12.12 kP (at compression force 8.2 kN).
Polymers belonging to hydrophilic matrix systems, when 
exposed to an aqueous medium, do not disintegrate, but im-
mediately after hydration form a highly viscous gelatinous 
surface barrier which control the liquid penetration into the 
center of the matrix system as well as drug release from the 
dosage form (Talukder et al., 1996). 
Sample 1a released 57.63, 71.96 and 100.78% after 2, 4 
and 10 h, respectively. In the same investigated period, sample 
1b released 50.44, 69.88 and 100.55%, indicating that there is 
no significant difference in the drug release from the Methocel 
matrices compresses at different compression forces. It can be 
implied that the porosity and/or tortuosity of the prepared tab-
lets after their hydration were not affected by an increase in 
tablet hardness from 3.8 kN and 8.2 kN. Obtained results in 
this work were in accordance with the literature data (Ravi et 
al., 2008).
Sample 2 released the 30.75, 50.78, 77.49 and 89.13% 
after 2, 4, 10 and 12 h, indicating that the fine Ethocel parti-
cles contributed to retard the drug release from the matrices. 
The reduction in release rates with addition of Ethocel was 
perhaps due to slow hydration of the matrix, based upon the 
hydrophobic character of Ethocel. The insoluble particles of 
Ethocel were probably acting as barrier to drug release in the 
gel layer of Methocel.
Conclusion
Based on these results it can be concluded that the com-
bination of Methocel and Ethocel could be a successful solu-
tion in modifying the release of water-soluble drug form ma-
trix system tablets. 
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Introduction
Statistical process control (SPC) provides a statistical 
approach for evaluating the process of production and for 
improving the quality of the process through better under-
standing. SPC is a process orientated data driven method 
to improve processes to deliver day after day results that 
have added value for the customer. In particular this meth-
od will help tocontinuously improve processes and reduce 
variability, describe and control the stability of process-
es, monitor and prove excellence of processes, alert before 
any batch is violating specifications, and document process 
understanding for regulatory agencies (Sven, 2016).
When SPC is effectively implemented within a com-
pany, benefits can be derived through a reduced cost of 
manufacture, improved quality, fewer troubleshooting cri-
ses, and improved relationships with customers (Thomas 
et al., 2006).
In this paper the application of SPC in the process 
of packaging of tablets in the pharmaceutical industry is 
shown. As a key process indicator (KPI) for the process of 
packaging the yield of the final product is observed. As a 
critical quality attribute an assay of tablets in the final prod-
uct is observed. For SPC studies, individual values - Con-
trol Charts and Moving Ranges-control charts were con-
structed and Process capability indexes were calculated in 
order to verify if the process is under control.
Materials and methods
Materials used were as follows: Amlodipin Alkaloid 
tablets 5 mg (Alkaloid A.D., Skopje, Macedonia), PVC 
foil 250 μm x 118 mm (Lamp East d.o.o., Serbia), alu-
minum foil Amlodipin Alkaloid tablets 5 mg (Lamp East 
d.o.o., Serbia), leaflet Amlodipin tablets 5 mg and 10 mg 
(Zapisd.o.o., Serbia), Carton boxes Amlodipin Alkaloid 
tablets 5 mg x30 (Grafolikd.o.o., Serbia). 
Equipment used was: blister packaging machine IMA 
TR100LT (IMA S.p.a. Italy), data printing line Videojet 
1210 + Etipack Clear (Videojet Technologies Itc, USA, 
Etipack, S.p.a., Italy), HPLC Thermo Scientific DIONEX 
UltiMate 3000 (Thermo Fisher Scientific Inc., USA) STA-
TISTICA 8, StatSoft Inc., USA. 
Data for the yield of the blister packaging process were 
obtained as a ratio of produced number of packages of final 
product Amlodipin Alkaloid tablets 5 mg x 30 and planned 
number of packages of each batch, expressed as a percentage.
The content of amlodipine in Amlodipin Alkaloid tab-
lets 5 mg was analyzed according to the Ph. EUR. 8 mono-
graph for Amlodipine besylate with HPLC method (EP 
2.2.29).
Control charts were generated by STATISTICA soft-
ware, after the following steps were performed:
- The data for yield and content of Amlodipine 
were obtained for all batches of Amlodipin Al-
kaloid tablets 5 mg x30 that were manufactured 
in 2015;
- The overall mean and average were calculated;
- Moving ranges were calculated;
- Process standard deviations for the process and 
moving ranges were calculated;
- Control limits for individual values (UCL and 
LCL) and moving ranges (UCLMR) were cal-
culated (Bakker et al., 2008).
Process capability indexes can be used as a tool that 
will show how often the process fits into the specification 
limits. There are two most common used process capabili-
ty indexes: Cp and Cpk.
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The Cp-value is the relation of the range of the specifi-
cation to the range of the process and it doesn’t show if the 
process is within the specification limits. 
The Cpk-value is the relation of the range of the spec-
ification to the mean value to the range of the process. If 
the value is below 1.0 there are values outside specifica-
tion. If the value is exactly 0 half of the values are outside 
specification. All process should have Cpk>1.33 to be sure 
that the process is stable and always in the desired specifi-
cation limits.
For the purpose of the study Cpk indexes for the yield 
of the packaging process and for the content of amlodipine 
in the finished product Amlodipin Alkaloid tablets 5 mg x 
30 were calculated.
Results and discussion
The new approach of the pharmaceutical industry was 
developed after the Food and Drugs Administration (FDA) 
announced initiative in August 2002, Pharmaceutical Cur-
rent Good Manufacturing Practices (cGMPs) for the 21st 
Century.  The modern approach of the pharmaceutical in-
dustry has a basis in good process and product understand-
ing. Quality should be built in each phase of the product 
lifecycle.
As a result of this approach the use of different tools 
that will help to gain better knowledge for the process is in-
creased in the last 15 years. These tools can be used in all 
stages of the lifecycle of the drug product. During the man-
ufacturing of the drug products the most common tools that 
might help in the understanding of the process are: quali-
ty risk management, corrective and preventive action, pro-
cess capability studies, Six Sigma and control charts.
Individual values control charts and moving ranges 
control charts should be always evaluated together in order 
to have a complete picture of the process. After the con-
trol charts were generated it was concluded that all of the 
Western Electric statistical rules were satisfied (Bonnie et 
al., 1956): 
1. One point outside of the control limits (3 σ);
2. Two points out of 3 are more than 2 σ from the cen-
tre line;
3. Four points out of 5 are more than 1 σ from the cen-
tre line;
4. Eight points on one side of the center line
for both control charts: yield and assay of amlodipine 
in the finished product Amlodipin Alkaloid tablets 5 mg x 
30. It was shown on data obtained from 83 produced batch-
es during 2015, that the process of packaging of Amlodipin 
Alkaloid tablets 30 x 5 mg is under statistical control and 
there is no special cause variability. Also the Cpk indexes 
values showed that the process is always capable to give 
high yield and the active substance content is always with-
in specified limits.
The values for the yield and assay of amlodipine in the 
finished product Amlodipin Alkaloid tablets 5 mg x 30, ob-
tained from the last 30 batches were used to calculate the 
control limits for continual process verification. The pack-
aging process of all batches that have been produced from 
01.2016 onwards will be followed by control charts with 
the new established control limits.
Conclusion
In the pharmaceutical industry SPC can be used for 
better understanding of the process, to analyze existing re-
sults for Annual Product Review and as a tool for continu-
ous process verification. Different kind of data can be an-
alyzed as per example: in-process control data (tablet’s 
weight, tablet’s height), quality control data (dissolution, 
content of active substance, and content of impurities) and 
process performance data (yield). 
It can be said that individual value-control charts, 
moving ranges-control charts and process capability in-
dexes are very simple but valuable tools for process under-
standing and for following the quality of the product con-
tinuously.
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Introduction
DC (direct compressible) granules nowadays are one 
of the most popular and most preferable pharmaceutical 
forms to formulators and as well as to companies because 
of their easy handling, less time consuming and cost effec-
tiveness aspects.
Granules are manufactured through a complex multi-
stage processes which takes relatively long times under 
which the starting materials change their physical charac-
teristics a number of times before they take place in final 
dosage form.
Ascorbic acid is a chemical substance that is best 
known by its antioxidant activity and free radical scaveng-
ing (Heber, 2007). Ascorbic acid is susceptible to oxidative 
degradation and, therefore, it requires significant physico-
chemical and stability considerations in its formulations 
(Odeniyi and Jaiyeoba, 2007).
The purpose of this study was to investigate the vari-
ability in the physical stability properties of ascorbic acid 
95% granules induced by wet granulation process of ascor-
bic acid in order to produce ascorbic acid 95% granules 
used as product which will take place in further processing 
of conventional tablets.
Materials and methods
Different batches from ascorbic acid 95% granules 
containing ascorbic acid (95.0% w/w) and hydroxypropyl 
methylcellulose (HPMC) type 2910 (50 mPas) (5.0% w/w) 
were prepared by wet granulation technique. Based on be-
fore gained experience and literature reference data, con-
centration of purified water used as granulation aid, pro-
cess parameters of drying process and sieves/screen size 
for dry granulate were varied, in order to evaluate the role 
and check which of this variables is/are most important 
from the aspect of colour stability of ascorbic acid 95% 
granules. All manufactured batches from ascorbic acid 
95% granulate were stored in stability testing chambers 
with defined conditions for temperature (40 ˚C) and hu-
midity (75% RH) in open Petri dishes for 15 days and were 
analysed on zero, fifth and fifteenth day. Physical charac-
terization of granules was conducted using a range of ex-
perimental methods.
All excipients used in the present study are approved 
for use in the pharmaceutical industry. Ascorbic acid 95% 
granules were produced by using ascorbic acid (DSM), hy-
droxypropyl methylcellulose type 2910 – HPMC E 5 LV 
(Methocel, Colorcon, UK). 
All methods were performed according to Good Man-
ufacturing Practices (GMP.) 
Process parameters: mixing time, mixing speed and 
chopper speed of the high shear mixer granulator (Dios-
na 4L, Diosna, Germany) used during wet granulation pro-
cess were same for all laboratory trials. Mixing of pre-
blend of ascorbic acid (475.0 g) and HPMC E 5 LV (50 
g) - mixing time: 3 min, mixing speed: 250 rpm, chopper 
speed: 1000 rpm. Wet granulation phase was separated in 
two phases granulation I/II (granulation time: 3 min /6 min, 
granulation speed: 150 rpm/200 rpm, chopper speed: 1000 
rpm/1000 rpm).
Concentration of water purified used as granulation aid 
during process of wet granulation was varied in different 
batches as 3.0% w/w, 3.5% w/w and 4.0% w/w.
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Drying process of granules were made in fluid bed dri-
er (Huttling, Germany), by varying of drying parameter in 
different batches as inlet air temperature 60 °C, 40 °C and 
30 °C. As end point determination for drying phase was 
used loss on drying (LOD) of granules to be maximum 
0.5%. In accordance with the varied drying parameters for 
inlet air temperature, drying time varied from 7 min to 35 
min for the drying process. Variations on drying process 
parameters were made on ascorbic acid 95% granules pro-
duced with 4.0% w/w water purified as granulation aid, be-
cause based on before gained experience, 4.0% w/w water 
purified is determined as optimal concentration of granula-
tion aid for obtaining good granulate with acceptable qual-
ity parameters.
Prepared dry granules from all batches were separate 
in two equal parts and were passed through laboratory sieve 
equipment (QuadroComil, Quadro, Canada) under differ-
ent sieve size. First part of granules were sieved through 
sieve with pore size 0.813 mm and the other part from the 
sieve with pore size 0.610 mm in order to obtained gran-
ules with different particle size distribution (PSD).
All manufactured batches of ascorbic acid 95% gran-
ules with all variables described above were placed sepa-
rately in open Petri dish in stability chambers with defined 
conditions for temperature (40 °C) and humidity (75% RH) 
and were stored for fifteen days.
Physical and chemical characterization of granules 
were analysed on zero, fifth and fifteenth day by various 
experimental methods: Fourier Transform Infrared spec-
troscopy (FTIR, Varian 660, Australia), Differential Scan-
ning Calorimetry (DSC, Netzsch 204F1 Phoenix, Germa-
ny), appearance, colour– organoleptic examination, bulk 
density and tapped density (Erweka SVM 102, Erweka, 
Germany), flow characteristics, angle of repose (°) (Erwe-
ka granulate flow tester GTB, Erweka, Germany), loss on 
drying (Mettler Toledo HG 63, Mettler Toledo, Switzer-
land) and optical microscopy (Morphologi G3S, Malvern, 
UK).
Results and discussion
From the results obtained in this study it can be eas-
ily seen that it is most challenging scientific task  to sep-
arate just one parameter as responsible for physical (co-
lour) stability issue of ascorbic acid 95% granules. From 
the produced batches with different variables it is more 
than obvious that humidity (concentration of granulation 
aid 4.0% water purified) and time spent under high humid-
ity (concentration of granulation aid 4.0% water purified 
and dried with 30 °C inlet air temperature which take about 
37 min for drying process) are the most responsible factor 
for changing the colour of ascorbic acid 95% granules and 
also PSD of the granules plays huge role in colour stabil-
ity because it was noticed that granules with bigger gran-
ules (their fraction with bigger granule) change their colour 
more drastically than the granules with smaller fraction. 
It is important to note that even we have made physical 
characterization by using range of experimental techniques 
with none of them except organoleptic and visual examina-
tion, changes can’t be detected. On the other side by visu-
al examination it can be easily seen that there is big colour 
difference among the granules. 
Conclusion
Results present in this study indicates that production 
of ascorbic acid 95% granules due to the nature of active 
substance is very complex process and as most important 
factors which affect physical stability of granulate, humid-
ity and temperature can be pointed.
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Introduction
Periodontal disease is simply defined as bacterially in-
duced chronic infectious-inflammatory disease that affects 
the tissues that support and anchor the teeth. It is a disease 
very difficult to treat, with very little change in the treat-
ment over the last several decades. So, even though with 
limited efficacy, mechanical plaque biofilm disruption is 
still at the mainstream of periodontal therapy with the ad-
dition of several treatment modalities (systemic antibiot-
ics, topical antimicrobials, laser therapy etc.) but only as 
adjunct to scaling and root planning. However, optimism 
for discovery of the treatments with improved efficacy is 
restored due to continuous research efforts especially dur-
ing the last two decades, and revised as well as upgrad-
ed understanding of the ethyology, pathogenesis and com-
plexity of this disease. Unquestionably, understanding of 
the complex microbial community, its virulence and the 
impact upon the host cells response as well as the impor-
tance of the host inflammatory-immune response to intra-
oral plaque for the disease development and progression 
creates new perspectives in management of periodontitis. 
Basically, novel research data clarified that the disease out-
come depends upon the host response towards the complex 
dysbiotic oral microbial community (Yucel, 2015). Addi-
tionally, it may be modified by genetic and different en-
vironmental factors. Consequently, host modulation ther-
apies are being proposed (Deshmukl et al., 2011) in order 
to tackle excessive host inflammatory reaction and target-
ing of various aspects of the inflammation pathways (lev-
els of enzymes, cytokines, prostanoids, as well modulation 
of osteoclast). Host modulating agents include non-steroi-
dal anti-inflammatory drugs (NSAIDS), sub antimicrobi-
al dose doxycycline as well as topical doxycycline, sys-
temic bisphosphonates, host modulating agents antagoniz-
ing pro-inflammatory cytokines, selective inhibitors of ni-
tric oxide synthase, inhibitors targeting the signaling path-
ways like c-Jun N-terminal kinases (JNK) inhibitor; Extra-
cellular-Signal-Regulated Kinases (ERK) inhibitor; NFκB 
inhibitor; JK3 inhibitor etc.Tetracycline apart from its an-
timicrobial property, when used in sub-antimicrobial doses 
works as anti-inflammatory agent and has capability of in-
hibiting the activities of neutrophils, osteoclasts, MMP 8, 
thereby inhibiting tissue and bone destruction. However, 
systemic therapy and conventional polymer implants with 
Doxycycline hyclate could not supply sufficient concentra-
tion of the active substance at the site of action for a pro-
longed period of time in order to provide efficient therapy. 
Smart bioadhesive micro and nano drug delivery systems 
with controlled release of the active substance will great-
ly contribute to improved therapeutic efficacy, considering 
their ability to interact with the permeable junctional epi-
thelium as well as elements of inflammation like macro-
phages, dendritic cells etc, at the same time allocating high 
concentration of Doxycycline in the vicinity and/or at the 
site of the inflammation.
Therefore, the main objective of this study is develop-
ment and evaluation of mucoadhesive controlled release 
chitosan microspheres for local treatment of periodontal 
disease, with a size span from 1-10 μm, loaded with Dox-
ycycline hyclate.
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Materials and methods
Materials
Doxycycline hyclate was obtained form Kunshau 
Chemical, China, chitosan with degree of deacetylation 
75-85%, sodium tripolyphosphate (TPP), sodium citrate, 
2-methyl-2-propanol and calcium citrate were purchased 
from Sigma Aldrich, Germany and tetrabutilammponium 
hydrogen sulphate was purshased from Merck Millipore, 
Germany.
Methods
Microparticles were produced by spray drying meth-
od (Buchi Mini Spray dryer B-290, Switzerland) with 
these conditions: inlet temperature 175 ˚C, aspiration 70%, 
pump flow 2% and air flow of 600 Nl/h. The colloidal so-
lutions were prepared by ionotropic gelation method, with 
gradual addition of the cross-linking agent solutions (10 
ml) to the solutions of polymers (1% chitosan sol.) and ac-
tive ingredient (50 mg) (magnetic stirrer Variomag, Multi-
point HP 15, Germany). Particle size and the swelling in-
dex were determined with laser difractometry (Mastersiz-
er 2000, Malvern Instr., Ltd, UK) using cell Hydro 2000S, 
(Malvern Instr., Ltd, UK). The swelling degree was mea-
sured in diluted 1:2 phosphate buffer pH 7.0 (USP) with 
similar ionic strength of saliva. Drug release rate was fol-
lowed in a suspension of microparticles in diluted 1:2 phos-
phate buffer pH 7.0 (USP), placed in closed tubes in hori-
zontal shaker at 37 °C, (Unitronic OR, Selecta, Barcelona, 
Spain). The concentration of released doxycycline hyclate 
in different time intervals as well as drug content and effi-
cacy of encapsulation were determined using HPLC meth-
od, column Phenomenex® 250-4.6 mm, PolymerX 5μm 
RP-1 100A (Phenomenex, Torrance, CA, USA), mobile 
phase of 2-methyl-2-propanol, buffer pH 8.0 R (Ph.Eur.), 
tetrabutilammponium hydrogen sulphate, and diluted solu-
tions of sodium hydroxide and sodium edetate.
Results and discussion
Doxycycline loaded microparticles were prepared by 
TPP ionic cross-linking combined with spray drying meth-
od. Since the cross-linking of chitosan depends on the 
availability of the cationic sites and the negatively charged 
TPP species, the crosslinking process was carried out at pH 
4.5, where chitosan as a polycation (pKa 6.3) will present 
–NH+3 sites and mostly phosphoric ions from TPP will be 
generated (Desai & Park, 2004). Different concentrations 
of the TPP cross-linking solutions (formulation A - 0.1% 
TPP; B - 0.5%; C - 0.75%; D - 1%) were used in order to 
evaluate their influence upon the physico-chemical prop-
erties of the chitosan microparticles like, particle size and 
particle size distribution, yield, efficacy of incorporation, 
drug content and dissolution rate. 
The results pointed that at higher TPP concentration 
larger particles were produced with a presence of aggre-
gates after the spray drying process. Mean particle sizes 
were 5.0 μm; 3.3 μm; 7.5 μm and 50 μm for series A, B, C 
and D, respectively. Span factor gradually increased with 
increasing concentrations of TPP solution, confirming the 
aggregation in series prepared using 0.75% (span = 2.9) 
and 1% (span = 4.8) TPP cross-linking solution. Yield and 
efficacy of encapsulation were slightly increased for mi-
croparticles prepared using 0.75% and 1% TPP. The dis-
solution studies showed that although dissolution rate de-
creased with increasing TPP concentrations, the rate reduc-
tion was not significant and it may have resulted from the 
particle size difference and the differences in the surface 
area exposed to the dissolution medium (formulation B - 
Dissolution results at T 1h, 3h, 5h were 40%, 60% and 90 
cum.% compared to formulation C Dissolution rate results 
of 35, 50 and 80 cum.% at T 1h, 3h, 5h, respectively).
Conclusion
The present study investigated the influence of differ-
ent concentration of the cross-linking agent on the physico-
chemical properties of the spray dried chitosan micropar-
ticles. It was found that the TPP concentration influenced 
the particle size, particle size distribution, yield, drug load-
ing and efficacy of encapsulation, swelling index as well 
as the dissolution rate of Doxycyline hyclate. Also, higher 
concentration of TPP resulted in production of larger parti-
cles with very broad particle size distribution and substan-
tial formation of aggregates with increasing concentrations 
of the cross-linker.
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Introduction
It may seem obvious to state that a new product should 
be adequately defined before anyserious product develop-
ment is undertaken. In many cases, the value of the design 
phase is often underestimated in the rush to start develop-
ment and get products to the market quickly.
This can result in much wasted time and valuable re-
sources. Since tablets and capsules account for approx-
imately 70% of pharmaceutical preparations, an inves-
tigation into the solid-state properties of candidate drugs 
is an important task to be undertaken during preformula-
tion (Wells, 1988). Generally speaking, when dealing with 
high strength solid dosage forms, this formulation will be 
more susceptible to any drug substance variability. Howev-
er, other studies are also important since, for example, the 
same chemical compound can have different crystal struc-
tures (polymorphs), external shapes (habits), and hence 
different flow and compression properties.
Preformulation is the initial phase in the development 
of pharmaceutical products. Suitable preformulation will 
inevitably result in obtaining simple and elegant formula-
tion and successful dosage form from a commercial aspect.
The performance of a solid dosage form is dependent 
on the physicochemical properties of the active ingredient 
and the excipients.
Preformulation is a critical phase in drug development 
where the physicochemical profiling of the active pharma-
ceutical ingredients (APIs) and excipients are determined 
and prototype formulations are made. 
Selection of stable polymorph and solid-state compat-
ibility studies of the compounds proposed for development 
of new pharmaceutical formulations are essential in the ini-
tial stage of formulation in order to identify possible in-
compatibilities that may affect the stability of the finished 
product (Gibson, 2004). 
A wide variety of methodologies that exist make it 
possible for the preformulation scientist to effectively 
study whatever needs.
The aim of this study was to choose the most stabile 
polymorph as well as to investigate possible solid-state in-
teractions between API of BCS class II and excipients pro-
posed for development of film-coated tablets, based on the 
changes in the infrared spectra of the both polymorphs and 
induced changes in the infrared spectra of the stressed bi-
nary mixtures compared to the infrared spectra of initial bi-
nary mixture, as consequence of possible solid-state chem-
ical reaction. Additionally, differential scanning calorim-
etry (DSC) and thermogravimetric analysis (TGA) were 
used to distinguish between the pseudopolymorphs of the 
studied API. 
Materials and methods
Materials used are: anhydrous pseudopolymorph of 
BCS class II active compound, monohydrate pseudopoly-
morph of BCS class II active compound, mannitol, dical-
cium phosphate, povidone, hydroxypropyl cellulose, low-
substituted, sodium stearyl fumarate, cellulose, microcrys-
talline, partially pre-gelatinazed maize starch and sodium 
lauryl sulfate.
Fourier Transform Infrared (FTIR) spectroscopy has 
proved to be suitable technique for these trials. The FT-
IR spectra were recorded using ATR method, in the 4000–
550 cm-1 region, on Varian 660 FT-IR spectrometer (Vari-
an, Australia) (resolution 4 cm-1, 16 scans per spectrum). 
Attenuated total reflectance (ATR) spectra were obtained 
by MIRAcleZnSe ATR module (PIKE technologies) with 
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low pressure micrometer clamp.
FT-IR spectra of the binary mixtures were recorded 
initially and then the same samples were placed in the sta-
bility chambers under various conditions (40 °C/75% RH, 
25 °C/60% RH).
Weighed samples of 2-3 mg of the studied API (mono-
hydrate and anhydrous form) were scanned in aluminum 
pans with a perforated lid at speed of 10 K/min from room 
temperature to 260 °C. All of the samples were analyzed 
in dry nitrogen atmosphere using a Netzsch DSC 204F1 
Phoenix instrument (Netzsch, Germany). The TGA curves 
were recorded in the 25–400 °C range, on a Netzsch TG 
209 F1 Iris analyzer (Netzsch, Germany) using aluminum 
oxide pans.   
Results and discussion
Results showed spontaneous transition of API from 
anhydrous to monohydrate form. Significant difference 
between these pseudopolymorphs was shown in data ob-
tained by Differential Scanning Calorimetry and Thermo-
gravimetric analysis. In the TG curves of monohydrate and 
anhydrous forms losses of mass of 5.11% and 1.27%, re-
spectively was observed which is in accordance with the-
oretical value for monohydrate and anhydrous form. The 
melting endothermic peak at around 253 °C (with decom-
position) in the both DSC curves, and continuous evapo-
ration of water in the DSC curve of the monohydrate form 
was observed. These observations are in good agreement 
with the studied pseudopolymorphic forms. Stability of the 
molecule of the monohydratepseudopolymorph was the 
main reason this polymorph to be chosen as more suitable 
for the development of film-coated tablet formulation.
Careful inspection of the obtained spectra of the pure 
API (fresh and stressed) and fresh and stressed binary mix-
tures, leads to conclusion that no changes in the position 
and shape of bands in regards to the spectrum of the ini-
tial sample are observable. This confirms that the applied 
stress conditions do not affect the overall appearance of 
the FT-IR spectra of the API. Therefore, the characteris-
tic vibrational bands from API as well, can be used as rel-
evant spectroscopic markers in order to assess the solid-
state stability between APIs in the presence of the stud-
ied excipients. Based on the comparison of the FT-IR spec-
tra of the initial and stressed binary mixtures it can be con-
cluded that after exposure on accelerated temperature and 
humidity levels during the screening period, there is no sig-
nificant change in the FT-IR spectra of the binary mixtures 
of API and described excipients in comparison to the cor-
responding FT-IR spectra of the freshly prepared samples. 
Minor spectral changes, in the binary mixture with po-
vidone stored at higher temperature/moisture levels were 
observed at 1660 cm-1 probably due to the higher presence 
of moisture and hygroscopic nature of the excipients. For 
this purpose binary mixture with povidone in formulation 
ratio was prepared and tested by the same procedure as pre-
viously described. In this binary mixture there were no sig-
nificant changes in the FT-IR spectra.
Conclusion
Results showed spontaneous transition of API from 
anhydrous to monohydrate form. Stability of the molecule 
of the monohydrate pseudopolymorph was the main reason 
this polymorph to be chosen as more suitable for the devel-
opment of film-coated tablet formulation.
The dedicated FT-IR spectroscopy of the binary mix-
tures between API and the proposed excipients clear-
ly demonstrated the solid-state compatibility of the API 
and the described excipients. The conclusion was derived 
based on the absence of significant changes in the FT-IR 
spectra of the stressed binary mixtures in comparison with 
the corresponding data obtained from the freshly prepared 
binary mixtures and the starting materials. 
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Introduction
Highly dose water soluble active pharmaceutical in-
gredient (API) with analgesic effect was formulated as an 
immediate-release film-coated tablet. This formulation is 
indicated for treatment of mild to moderate pain and to ex-
press the analgesic effect faster.
It is important to note that the film is not functional, 
and the presented data are related to the tablet core.The 
purpose of our study was to examine the influence of some 
formulation factors, such as particle size of the API, disin-
tegrant type and concentration (Bolhuiset al., 1994), mass 
of tablet core and concentration of starch (starch 1500/ par-
tially pre-gelatinized Maize starch) (Cunningham, 1999) 
on the dissolution profile of the API.
Materials and methods
API, Prosolv HD 90(Silicified microcrystalline cel-
lulose) was supplied from JRS Pharma Rosenberg, Ger-
many, Starch 1500 (partially pre-gelatinized Maize starch) 
was supplied from Colorcon, Indianapolis USA, Kollidon 
VA 64 (Copovidone) was supplied from  BASF, Ludwig-
shaften, Germany, Primojel (Sodium starch glycolate) was 
supplied from DFE Pharma, Goch, Germany, L-Hydroxy-
propyl cellulose LH-11 was supplied from Shin-Etsu, To-
kyo, Japan, Ac-Di-Sol (Croscarmellose sodium) was sup-
plied from FMC Bio Polymer, Wallingstown, Little Island, 
Cork , Ireland,  Aerosil 200 (Silica, colloidal anhydrous) 
was supplied from Evonik Industries , Rheinfelden, Ger-
many, Kolliphor SLS Fine (Sodium Lauryl Sulphate) was 
supplied from BASF, Ludwigshaften, Germany, Magne-
sium stearate was supplied from FACI SpA, Carasco, Italy 
and Talc from Merck, Darmstadt.
API used in the experimental trials is character-
ized with high water solubility and has molecular weight 
352.48. 
Formulations with different disintegrants, partially 
pre-gelatinized Maize starch (Starch 1500) concentration, 
different tablet core mass and API’s particle size were pre-
pared: 
- Formulation I: API is not sieved, has not Starch 
1500/ partially pre-gelatinized Maize starch, with 
mass of tablet core 875 mg and 5% pro tablet 
(Rowe et al., 2013) of L-hydroxypropyl cellulose.
- Formulation II: API is not sieved, with 5% pro 
tablet Starch 1500/ partially pre-gelatinized Maize 
starch, mass of tablet core 875 mg and 5% pro tab-
let of L-hydroxypropyl cellulose.
- Formulation III: API is not sieved, with 10.83 
% Starch 1500/ partially pre-gelatinized Maize 
starch, mass of tablet core 875 mg and 5% pro tab-
let of L-hydroxypropyl cellulose.
- Formulation IV: API is not sieved,  has not Starch 
1500/ partially pre-gelatinized Maize starch, mass 
of tablet core 875 mg and 10% pro tablet of L-hy-
droxypropyl cellulose.
- Formulation V: API is sieved through 610 µm 
sieve, with 11.83 % pro tablet Starch 1500/par-
tially pre-gelatinized Maize starch, mass of tablet 
core 875 mg and 5% pro tablet of L-hydroxypro-
pyl cellulose.
- Formulation VI: API is sieved through 610 µm 
sieve, with 6.33 % pro tablet Starch 1500/partially 
pre-gelatinized Maize starch, mass of tablet core 
875 mg, 5% pro tablet of L-hydroxypropyl cellu-
lose and 5% pro tablet Ac_Di-Sol/croscarmellose 
sodium.
- Formulation VII: API is sieved through 610 µm 
sieve, with 5.67 % pro tablet Starch 1500, mass of 
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tablet core 860 mg and 4% pro tablet of Primojel/
sodium starch glycolate.
- Formulation VIII: API is sieved through 610 µm 
sieve, with 10.42 % pro tablet Starch 1500/ par-
tially pre-gelatinized Maize starch, mass of tablet 
core 865 mg and 5% pro tablet of Primojel/sodi-
um starch glycolate.
- Formulation IX: API is sieved through 315 µm 
sieve, with 5.67 % pro tablet Starch 1500/par-
tially pre-gelatinized Maize starch, mass of tablet 
core 860 mg and 4% pro tablet of Primojel/sodi-
um starch glycolate.
- Formulation X: API is sieved through 315 µm 
sieve, with 10.42 % pro tablet Starch 1500/par-
tially pre-gelatinized Maize starch, mass of tablet 
core 865 mg and 5% pro tablet of Primojel/sodi-
um starch glycolate.
- Formulation XI: API is sieved through 610 µm 
sieve, with 8.00 % pro tablet Starch 1500/sodium 
starch glycolate, mass of tablet core 880 mg and 
4% pro tablet of Primojel/sodium starch glycolate.
- Formulation XII: API is sieved through 610 µm 
sieve, with 8.00 % pro tablet Starch 1500/partially 
pre-gelatinized Maize starch, mass of tablet core 
865 mg and 5% pro tablet of L-hydroxypropyl cel-
lulose.
- Formulation XIII: API is sieved through 610 µm 
sieve, with 8.00 % pro tablet Starch 1500/partially 
pre-gelatinized Maize starch, mass of tablet core 
880 mg, 3% pro tablet of L-hydroxypropyl cellu-
lose and 3% pro tablet of Primojel/sodium starch 
glycolate.
Dissolution profile is being conducted on the experi-
mental trials.
The dissolution method conditions were: apparatus II 
(paddle apparatus) at speed of 75 rpm, dissolution medium 
(900 ml ± 1% phosphate buffer pH 7.2 ± 0.05), 10 ml sam-
ple volume, dissolution medium temperature 37 ± 0.5 ◦C. 
Samples were collected at six time points: 5, 10, 15, 20, 30 
and 45 minutes. 
For determination of dissolution rate of active sub-
stance UV absorptionspectrophotometric method was 
used.The content of dissolved API was calculated by mea-
suring the UV absorptions of the test and standard solution 
at detection of 221 nm.
Results and discussion
Based on the results from the extensive dissolution 
evaluation on the experimental trials one may conclude 
that the most influential factor among the following: dis-
integrant type, tablet average mass and API particle size 
is the disintegrant type. Namely, the dissolution profile 
is most highly affected when pre-gelatinized starch is in-
corporated into the formulation in comparison to sodium 
starch glycolate and crosscarmelose sodium. This results 
point to conclusion that dissolution of the highly dosage 
highly water-soluble API is rather fastened by the parti-
tioning of the dissolution media between the pre-gelati-
nized starch and the API than with the use of a classical su-
per-disintegrants. The high percent of the API in the for-
mulation support this assumption having in mind that the 
mechanism of the super-disintegrants is hindered by this 
high percent of the API (85w/w% of the API in tablet for-
mulation).
As per the second factor, increase of the average mass 
of the tablet with other excipients (fillers) did not cause any 
increase on the dissolution of the API due to the fact that 
this slight percent of mass increase was not enough to mod-
ify and support the mechanism of disintegration related to 
super-desintegrants.
The third factor, particle size of the API (achieved by 
sizing with different sieve size) was also found to be not 
influential as the disintegrant type probably due to the API 
is characterized with high water solubility and penetration 
of the dissolution media is not hindered by different parti-
cle size of the API.
Conclusion
The presented study shows that optimized concentra-
tion of Starch 1500/ partially pre-geletanized Maize starch 
and the combination of two selected disintegrants (L-HPC 
and Primojel/sodium starch glycolate), as well as sizing 
step of the active pharmaceutical ingredient have influ-
ence on the dissolution rate of the highly dose water sol-
uble API.
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Introduction
Monoclonal antibodies are new type of targeted anti-
cancer therapy, which achieve specificity, selectivity and 
localization in tumor cells. There are many naked antibod-
ies and immunoconjugates commercially approved for dif-
ferent types of cancer (Mehren et al., 2003). In order to im-
prove specificity and selectivity of cytotoxic drugs and tox-
ins, monoclonal antibodies are used for formulation of im-
munoconjugates. Many efforts are done to develop stable 
immunoconjugates of trastuzumab with various drugs, tox-
ins and radioisotopes to improve the general conditions of 
the patients (Sharkey and Goldenberg, 2006). The aim of 
this paper is to focus on current achievements in the for-
mulation of radioimmunoconjugates of HER2-targeting 
trastuzumab.
Trastuzumab is a humanized IgG1 monoclonal anti-
body active against HER2 positive breast cancer. It orig-
inates from murine antibody 4D5 that is potent inhibitor 
of HER2 positive cancer cells. Subsequently, it was cho-
sen for further clinical development in order to reduce the 
probability of generation of HAMA (human anti-murine 
antibody) (Harries and Smith, 2002). Carter et al. (1992) 
cloned hypervariable regions from 4D5 in plasmids which 
encode formation of constant regions from human IgG1 
antibody and generated a vector that encode formation of 
chimeric antibody which is additionally humanized. The 
new humanized 4D5 has higher affinity for the HER2/neu 
antigen and reduced immunogenicity. Trastuzumab is act-
ing by binding to the IV subdomain of the HER2 receptor 
and Fc region of the antibody support ADCC (antibody-de-
pendent cellular cytotoxicity) (Gennari et al., 2004). 
Radioimmunoconjugates for imaging and 
therapy
Because of the easy detection, radioimmunoconju-
gates can be used for body imaging at a molecular level 
using sensitive imager like γ camera, computed tomogra-
phy and positron emission tomography (PET) (Goldenberg, 
1997). Significant radiopharmaceuticals based on pep-
tide and antibody for diagnostic and therapeutic purpose 
use different radioisotopes (99mTc/188Re, 67Ga, 177Lu, 
90Y, 131I) (Kassis, 2008). In order to obtain successful la-
beling, previously  conjugaton with a bifuntional chela-
tors (DOTA - 1,4,7,10-tetraazacyclododecane-1,4,7,10-tet-
raacetic acid; DTPA - diethylenetriaminepentaacetic acid; 
TCMC - (1,4,7,10-tetra-(2-carbamoyl methyl)-cyclodo-
decane; HYNIC - succinimidyl-6-hydrazino-nicotinamide; 
1B4M-DTPA - 2-(4-isothiocyanatobenzyl)-6-methyl-dieth-
ylene-triaminepentaacetic acid) is required. These chelators 
allow binding to the antibody on the one side, and coordi-
native binding of radioisotopes on the other side (Kang et 
al., 2012). 
Immunoconjugates of trastuzumab for PET 
imaging
In recent years there have been significant achieve-
ments in development of stable immunoconjugates of 
trastuzumab for PET imaging of HER2 positive lesions 
(Hooge et al., 2004). Chen et al. (2008) used 99mTc in or-
der to create a stable conjugate, 99mTc-NYCIN-trastu-
zumab, useful for identification of HER2 positive metas-
tasis. Tamura et al. (2010) have shown the possibility of 
identification of HER2 positive lesions in patients with pri-
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mary metastatic breast cancer with 64Ga-DOTA-trastu-
zumab. Three years later, Alitezapour et al. (2013) were 
able to formulate similar conjugate with another gam-
ma emitter 67Ga-DOTA-trastuzumab for the same pur-
pose. Investigations of Palm et al. (2003) for pharmaco-
kinetics of trastuzumab labeled with pure β emitters 86Y 
and 90Y in mice with ovarian cancershown a selective up-
take of the conjugate by the tumor cells and minimal lo-
calization in healthy organs. In vitro and in vivo investiga-
tions in mice with breast tumor show that 177Lu-DOTA-
trastuzumab can be new promising drug in treatment of hu-
man breast cancer (Rasaneh et al., 2012). Tan et al. (2012) 
have shown that 212Pb-TCMC-trastuzumab has a signifi-
cant therapeutic effect in HER2/neu positive prostate can-
cer. Borchardt et al. (2003) have tested therapeutic effects 
of alpha emitters 227Th-DOTA-p-benzyl-trastuzumab and 
225Ac-trastuzumab in mice with HER2 positive breast and 
ovarian cancer. Studies have shown rapid internalization 
and cytotoxicity in cancer cells which leads to a extend sur-
vival and low toxicity.
Our examinations will be focused on synthesis and 
evaluation of the immunoconjugates of trastuzumab with 
bifunctional chelators (DOTA, DTPA and 1B4M-DTPA) 
with already used method for freeze dried kit formula-
tion of rituximab-conjugates. The most stable immunocon-
jugate will be labeled with gamma emitter Ga-68 for fur-
ther in vitro characterization and in vivo biodistribution. 
The simplicity of Ga-68 labeling will increase the access 
of radioimmunoconjugates in hospitals for PET imaging of 
HER2 positive metastasis. 
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Background
This article describes trends in Radiopharmacy in the 
developing countries and the current status of Radiophar-
macy Practice in Eastern Africa.
The main goal of our presentation is to show and to 
stress the importance of existing problems related to the 
missing of the exact information on the number, status and 
size of Radiopharmacy units in African countries as the re-
gional status as well as for the human resources, education, 
suitable training and local demand for the Radiopharmacy 
and Nuclear Medicine services is not documented (Don-
di, 2006).
The Radiopharmacy Practice by the definition requires 
well-defined and controlled conditions to avoid any risk 
contamination with microbes, pyrogens and particulate 
matter as well as cross contamination with other radiophar-
maceuticals, together with established radiation protection.
Implementation of the Good Radiopharmaceuti-
cal Practices in all levels in the Radiopharmacy should 
be planned, introduced by the planned priority and strict-
ly monitored and reordered in the production, prepara-
tion, testing and in the packaging areas for all final prod-
uct ready for use.
The practice of nuclear medicine using established ra-
diopharmaceuticals, mostly from the first generation has 
clinical applications in virtually all systems of the body, 
for example, the skeletal, cardiac, endocrine, oncologic, 
gastrointestinal and renal systems. The commoner nucle-
ar medicine procedures in African developing countries are 
the bone scan, thyroid scan and the renal scan respective-
ly.Almost all radiopharmaceuticals are parenterally admin-
istered and requires techniques and procedures that guar-
antee sterility of the product done according to the clear-
ly defined protocol and and established and controlled con-
ditions.  
The critical moment for the realization of all these 
necessities is to have suitably staff, enough educated and 
trained to provide the implementation and development in 
the right direction.
Radiopharmacy professionals should have an adequate 
training in all aspects of the sterile production, quality con-
trol, GMP, GLP, radiation safety and radiochemistry to en-
sure the competent handling of the radioactive materials 
(IAEA NUMDAB, 2009).
Methodology
The practice of radiopharmacy combines the exper-
tise of pharmaceutical preparation and the skills needed 
to handle radioactive substances. Diagnostic radiopharma-
ceuticals do not normally have any pharmacologicale ffect 
and their administration is not associated with major clin-
ical side effects. Their clinical use, however, is associated 
with a risk deriving from radiation exposure and possible 
contamination during radiopharmaceutical formulation by 
chemical, biological and microbiological impurities.
Accordingly, principles of Good Practices should be 
planned in all levels, by priority and strictly observed in 
the production, preparation, testing and the packaging of 
the final product ready for use. The main powerful key for 
implementing Good Radiopharmaceutical Practice is qual-
ified and trained personnel. Trained and competent staffs 
are essential for achieving high standards and growth in 
Radiopharmacy. In African Countries there is an acute 
shortage and in some countries an absence of nationally 
registered pharmacists with radiopharmacy experience. 
Most nuclear medicine facilities operate their radiophar-
macies with the support of technologists not trained in ra-
diopharmacy practices. For that reason the basic quali-
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ty systems in the Radiopharmacy laboratory could be im-
proved significantly with the better training. 
This competency-based training is the first step to pro-
vide the essentials of a trainingprogramme for all radio-
pharmacy practitioners that addresses the following re-
quirements:
- Standardization of training for staff members 
that operate in hospital radiopharmacy prac-
tice;
- To improve performance and management of 
the radiopharmacy service;
- To encourage good radiopharmacy practices 
for the preparation and quality assurance;
- To establish a quality management system 
which encourages continuous update of core 
competencies in hot laboratory staff.
- Encourages continuous update of core compe-
tencies in hot laboratory staff.
Results
One of the key bottlenecks for Nuclear Medicine is 
a human resources shortfall, especially radiopharmacists. 
There is an acute shortage and in many countries absenc-
es of pharmacists with radiopharmacy experience. Most of 
Nuclear Medicine facilities operate at IAEA operational 
level 1 and 2’ mainly with support of technologists. There 
is a global need for effective implementation of the ‘oper-
ational guidance on hospital radiopharmacy-a safe and ef-
fective approach’ under which there is a strong recommen-
dation to strengthen skills, competencies and professional 
qualifications of all staff involved in clinical radiopharma-
cy practice. They should be empowered to address the poor 
state of Radiopharmaceutical laboratories in many coun-
tries and be more aware of cost of radiopharmaceuticals. 
For safety of patient they should be aware of proper 
registration of radiopharmaceuticals and quality assess-
ment required locally. At the time when there are difficul-
ties with supply and relative high cost of routine radiophar-
maceuticals, trained staffin Radiopharmaceutical laborato-
ries could make the difference to Nuclear Medicine (IAEA 
NUMDAB, 2009).
The trained radiopharmacist should have a:
1. working knowledge of the radiopharmaceuti-
cal terms, abbreviations, and symbols commonly 
used in prescribing, compounding and dispensing 
radiopharmaceuticals
2. working knowledge of the procedures and tech-
niques relating to aseptic compounding and par-
enteral admixture operations.
3. working knowledge of the procedures and opera-
tions relating to the reconstitution, packaging and 
labeling of radiopharmaceuticals
4. the ability to perform the usual functions associat-
ed with a specific radiopharmacy.
5. the ability to perform the manipulative and record 
keeping functions associated with the compound-
ing and dispensing of radiopharmaceuticals
6. manipulative and record keeping function sassoci-
ated with quality control testing of radiopharma-
ceuticals
7. working knowledge of drug dosage by imaging-
procedure, routes of administration, dosage forms, 
and be able to distinguish
8. the ability to perform the essential functions relat-
ing to drugpurchasing and inventory control
9. appropriate knowledge and understanding of the 
specific nuclearpharmacy site with emphasis on 
the technician duties and responsibilities, includ-
ing standards of ethics governing pharmacy prac-
tice therapeutic from diagnostic radiopharmaceu-
tical utilization
10. ability to perform them a thematical calculations 
required for the usual dosage determinations and 
solution preparations in the compounding and dis-
pensing of radiopharmaceuticals.
11. Demonstrate appropriate working knowledge 
of any additionaltraining or safety requirements 
mandated by the pharmacy or by any local, state, 
or federal agency by successful completion of any 
required program (DAT on-line, 2011).
Conclusion
This paper present our idea how to create suitable 
training and network of all professionals and state author-
ities for establishing and develop education for Good Ra-
diopharmacy Practice, qualified personnel and appropriate 
regulation according to the local and international parame-
ters that will be step forward to have advanced health care 
system and confidence of the patients.
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Introduction
Fourier transform infrared spectroscopy (FT-IR) was 
applied as suitable screening analytical method to assess 
the compatibility screening of CaCO3 and MgCO3 with 
several excipients aimed for development of solid-dosage 
formulation. 
The solid-state compatibility testing of the active phar-
maceutical ingredients (APIs) CaCO3 and MgCO3 and the 
selected excipients was performed by Fourier Transform 
Infrared (FT-IR) spectroscopy. The compatibility was stud-
ied by comparison of the FT-IR spectra of the pure samples 
(APIs and excipients) and freshly prepared binary mixture 
with the FT-IR spectra of the corresponding stressed binary 
mixtures. The appearance of new bands in the FT-IR spec-
trum, non-typical for the APIs or excipients, can be consid-
ered as most significant sign of possible solid-state inter-
action and formation of new molecular species. Changes 
due the water/moisture intake, resulting in band broaden-
ing or changes in the band resolution and intensities in the 
FT-IR spectra, can be considered normal, because the sam-
ples were exposed directly to the external influence, with-
out any protection or packaging.
The aim of this experiment was to investigate possible 
solid state interaction between APIs and the described ex-
cipients, based on the induced changes in the infrared spec-
tra of the binary mixtures exposed at different external con-
ditions, compared to the infrared spectra of the pure com-
pounds and the freshly prepared mixtures. The obtained re-
sults afforded deeper insight into the solid-state stability of 
the studied binary mixture.
Materials and methods
During development of the CaCO3 and MgCO3 tablets 
several excipients were evaluated for compatibility with 
the active ingredients as a screening for potential choice 
for tablet formulation. APIs: Calcium carbonate (CaCO3, 
purchased from Solvay Osterreich GmbH, Austria) and 
Magnesium carbonate heavy (MgCO3, purchased from 
Dr.PaulLohmann, Germany); Excipients: Silica, colloidal 
anhydrous (purchased from Evonik Resource Efficiency 
GmbH, Germany); partially pre-gelatinized maize starch 
(purchased from Colorcon, USA); copovidone (purchased 
from BASF (BTC Europe GmbH), Germany); xylitol (pur-
chased from Roquette, France); low-substituted hydroxy-
propylcellulose (purchased from ShinEtsu, Japan); spear-
mint flavor SD (purchased from Symrise AG, Germany); 
menthol L flavourspraydried (purchased from Symrise AG, 
Germany); talc (purchased from Merck, Germany) and Mg 
stearate (purchased from FACI SpA, Italy).
Binary mixtures were prepared by dry mixing of equal 
amounts of APIs and each excipient in 1:1 ratio (w/w). This 
ratio is different than the ratio used in the formulation, but 
according to the literature (Cunha-Filho et al., 2007), the 
equal masses afford bigger possibility for solid-state in-
teraction among the constituents of the mixture. Pure 
APIs, excipients, and corresponding binary mixtures were 
stressed by 30 days exposure in stability testing chambers, 
at open Petri dishes, at temperatures of 40 ºC and 25 ºC, 
with a relative humidity (RH) of 75% and 60%, respec-
tively. 
FT-IR spectra of pure APIs and excipients, freshly pre-
pared binary mixture and stressed binary mixtures after 30 
days were recorded and evaluated.
The FT-IR spectra were recorded using ATR method, 
in the 4000–550 cm-1 region, on Varian 660 FT-IR spec-
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trometer (Varian, Australia) (resolution 4 cm−1, 16 scans 
per spectrum). Attenuated total reflectance (ATR) spectra 
were obtained by MIRAcleZnSe ATR module (PIKE tech-
nologies) with low pressure micrometer clamp.
Results and discussion
Based on the comparison of the FT-IR spectra of pure 
CaCO3 and pure MgCO3, with fresh prepared binary mix-
tures and corresponding excipients, it can be concluded 
that in all cases the most prominent vibrational bands of the 
APIs can be identified in the initial prepared binary mix-
tures. Although, generally being obscured and overlapped 
by strong bands of the APIs, few stronger bands originat-
ing from the present excipient can be identified in some of 
the binary mixture. No additional bands, of unknown ori-
gin, were observed. 
In regards of the FT-IR spectra of the starting bina-
ry mixture and the FT-IR spectra of the same mixture af-
ter exposure for 30 days at 25 ºC/60% RH and 40 ºC/75% 
RH, it can be concluded that no significant spectral chang-
es were observed, except in binary mixtures between stud-
ied APIs with xylitol and copovidone. In the FT-IR spec-
tra of these binary mixture exposed at stressed conditions 
some spectral changes were observed according to higher 
moisture. Having in mind that both of excipients are hygro-
scopic at high moisture (Raymond et al., 2009), pure xy-
litol and copovidone were exposed 30 days at 40 ºC/75% 
RH. Based on the obtained FT-IR spectra, it can be con-
cluded that spectral changes observed in the FT-IR spec-
tra of the stressed binary mixtures are results from the ab-
sorbed moisture from xylitol and copovidone, which can 
be confirmed by their FT-IR spectra.
Conclusion
The closer inspection of the FT-IR spectra of the ob-
tained binary mixtures of CaCO3 and MgCO3 with the pro-
posed excipients, clearly demonstrated that there are no 
significant spectral changes induced in the FT-IR spectra 
during the screening period at all testing conditions. The 
preformulation studies have shown that in the FT-IR spec-
tra in the binary mixtures between: CaCO3 with xylitol 
and CaCO3 with copovidone; and MgCO3 with xylitol and 
MgCO3 with copovidone; exposed at stressed conditions, 
some spectral changes were observed due to moisture up-
take by the excipient with hygroscopic properties. 
These findings were confirmed by comparison of 
the spectral changes observed in the FT-IR spectra of the 
stressed binary mixtures and the individually stressed xyli-
tol and copovidone. 
The compatibility studies as a part of preformula-
tion screening of the excipients aimed for development of 
CaCO3 and MgCO3 solid dosage form were beneficial and 
give useful directions for development of a stable and ef-
fective formulation.
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Introduction
Tablets as solid preparations can range from relative-
ly simple immediate release formulations to complex mod-
ified release drug dosage forms. The desired drug release 
properties could be adjusted by proper selection of excip-
ients used in the formulation as well as by technological 
process and process conditions selected.
Numerous unit processes are involved in making tab-
lets, including blending, granulating, drying, compaction 
and coating. Various factors deriving from these processes 
can affect content uniformity, drug release rate and/or sta-
bility of tablets.
The fluid-bed method of wet granulation is well 
known in the pharmaceutical and other industries as a one-
step, enclosed operation. Because several ingredients can 
be mixed, granulated, and dried in the same vessel, the 
technique reduces material handling and shortens process 
times compared with other wet granulation techniques. 
In addition to granulation for tableting, the fluid-bed top-
spray method produces highly dispersible granules with 
a characteristic porous structure that enhances wettabili-
ty and improves many of the powder properties for tablet 
compression. Granules of high quality can be obtained by 
understanding and controlling the critical process parame-
ters by timely measurements (Parikh, 1997).
The aim of this study was to develop immediate re-
lease tablets with water insoluble drug (API), using fluid- 
bed granulation technique.
Materials and methods
Materials 
API from BCS Class II/IV (particle size D50 less than 
20µm, freely soluble in dichloromethane, sparingly solu-
ble in toluene, insoluble in methanol and water) as model 
drug substance was used. Other excipients used in the for-
mulation were: lactose monohydrate, microcrystalline cel-
lulose, starch maize, hydroxypropylcellulose, croscarmel-
lose sodium, magnesium stearate and iron oxide. All chem-
ical used in this present study are approved for use in phar-
maceutical industry.
Preparation of the granules
Three different formulations of granules were pre-
pared using fluid-bed granulation process (Hüttlin GmbH, 
Hohe-Flum-Strasse 42, Schopfheim, top spray configu-
ration, Germany). Water solution of hydroxypropylcellu-
lose was used as granulation vehicle. Fluid-bed granula-
tion was performed under the following working condi-
tions: air volume 15 m3/h; inlet temperature 66 °С; atom-
izing pressure 0.5-1 bar; mycroclimate 0.3-0.8 bar; filter 
pressure 0.8-1 bar; filter cleaning period 2 sec.; filter blow 
time 0.2 sec. After finishing the atomization of the binder 
solution, the granules were dried for a variable period of 
time in the same apparatus at 66 °C inlet temperature and 
air volume 15 m3/h.
For preparation of sample 1, API was granulated to-
gether with lactose monohydrate, while starch maize, mi-
crocrystalline cellulose and iron oxide were added extra-
granularly. For sample 2, API was granulated together with 
all excipients used in the formulation (lactose monohy-
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drate, starch maize, microcrystalline cellulose and iron ox-
ide). For sample 3, API was granulated together with lac-
tose, part of croscarmelose sodium and starch maize, while 
microcrystalline cellulose, iron oxide and the other part of 
croscarmelose sodium were added extragranulary.
All prepared samples were finally mixed with magne-
sium stearate (5 min.; Drum blender, Erweka PM5, Ger-
many) and compressed by a rotary tablet press (KorschXL 
100 Pro, Korsch AG, Germany), using round shaped 6 mm 
punches.
Determination of granules and tablets characteristics
Final blends were evaluated for loss on drying and flow 
properties. Loss on drying (LOD) was analyzed in Sartori-
us Infrared dryer MA 35 (Germany). Granulate in quanti-
ty of 1 g was dried to constant mass. The loss of mass was 
presented as percent m/m (Ph. Eur 8.7). 
Flowability of granulates was determined according to 
Ph. Eur 8.7 with Granulate flow tester (Erweka type GTB, 
Erweka, Germany). Nearly 50 g of granulate was poured 
from funnel and the time required to empty the funnel was 
measured. 
Determination of disintegration time and dissolution 
test of the compressed tablets was performed according to 
the official methods from the European Pharmacopoeia. 
For that purpose 6 tablets were placed in baskets of appa-
ratus for disintegration (Erweka type ZT302, Erweka, Ger-
many). Time required for disintegration was measured au-
tomatically. 
Dissolution testing was conducted in 900 ml of disso-
lution medium hydrochloric acid buffer pH 1.2 (USP 38 
NF 33) at 37 ± 0.5 °C using Apparatus II paddle (Varian 
VK, USA). Apparatus was adjusted to a speed of 60 rpm. 
Aliquots were taken at regular time intervals (after 5, 10, 
15, 20, 30 and 45 min) and replaced with an equal volume 
of pre-warmed hydrochloric acid buffer. Withdrawn ali-
quots were analysed for drug content using previously val-
idated HPLC method (Hitachi HPLC system, Japan), col-
umn 150 mm x 4.6 mm, 5µm, at 25 °C and flow rate of 
1.5 ml/min. Quantification of API was detected by UV at 
250 nm.
Results and discussion
LOD as a parameter is extremely important for the pro-
cess of fluid-bed granulation and drying. Obtained results 
indicated that sample 2 has the lowest loss of mass (3.1%) 
in comparison with samples 1 and 3 (3.25 and 3.74%, re-
spectively) probably due to the presence of microcrystal-
line cellulose into the granule matrix. Even though micro-
crystalline cellulose allows rapid addition of the granulat-
ing fluid, the water does not become bound inside, but rath-
er it is easily given up during drying process. This proper-
ty aids in preventing case hardening and uniform moisture 
content in granules (FMC Pharma, 2000). 
Results obtained for the flow properties of the final 
blends indicated that the flowability was excellent for all 
prepared samples (10, 8.7 and 10.8 sec for sample 1, 2 and 
3, respectively). 
The macroscopic appearance of the tablets was satis-
fying. All prepared tablets were smooth and elegant and 
no mottling was observed. Uniform appearance of the tab-
lets was probably due to presence of microcrystalline cel-
lulose, which enables equal migration of added dyes (FMC 
Pharma, 2000). 
The results of disintegration time show that all pre-
pared samples have disintegration time less than 15 min-
utes (1.38, 2.35 and 1.21 min for sample 1, 2 and 3, re-
spectively). 
Sample 1 did not meet acceptance criteria for immedi-
ate release tablet dosage forms (80.22% were dissolved for 
30 minutes). On the other hand, sample 2 and 3 were char-
acterized by > 85% dissolved API at the time interval of 30 
min (90.06% and 91.82%, respectively). Obtained results 
pointed to the rationality of microcrystalline cellulose in-
tragranular incorporation (sample 2) as well as addition of 
croscarmellose sodium (sample 3) equally between the in-
tra and extra granulation. 
Conclusion
In the present work efforts have been made to develop 
immediate release tablets with water insoluble API using 
fluid-bed granulation as a promising approach to enhance 
the drug release profile. The results showed that the release 
of the drug was depended on type of excipient used in the 
formulation. Formulation containing 2% croscarmellose 
sodium showed minimum disintegration time and better 
drug release profile as compare to other formulations.
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Introduction
Pharmaceutical semisolid preparations may be de-
fined as topical products intended for application on the 
skinor accessible mucous membranes to provide local-
ized and sometimes systemic effects at the site of applica-
tion. However, most of the semisolid preparations are ap-
plied to the skin for topical relief in dermatologic condi-
tions (Swarbrick et al., 1990). Several categories of semi-
solid preparations for cutaneous application may bedistin-
guished: ointments, creams, gels and pastes. These topical 
formulations are composed of drug in asuitable semisolid 
base which is either hydrophobic or hydrophilic in charac-
ter (Allen et al., 2011).
Depending on the physicochemical properties, desired 
site of action and formulation strategies for the drug de-
livery incorporation into semisolids can show their activ-
ity on the surface layers of tissues or via penetration into 
deeper layers to reach the site of action or through system-
ic delivery. Nonetheless if the drug is to act locally or sys-
temically, it must first penetrate the stratum corneum (Raw 
et al., 2013).
To treat a number of painful conditions affecting the 
joints and muscles, such as backache, rheumatic and mus-
cular pain, sprains, strains and sports injuries, an active in-
gredient that belongs to a group of non-steroid anti-inflam-
matory drug (NSAID) was used. During formulation de-
velopment, in order to obtain a stable, transparent, homo-
geneous hydro-alcoholic gel for topical use with satisfacto-
ry rheological properties, several gelling agents were test-
ed such as hydroxyethyl cellulose, sodium carboxymethyl-
cellulose, poloxamer and carbomers.
The aim of this research work wasto show the influ-
ence of different types of polymers as gelling agents on 
physical properties of gel, like grittiness, viscosity and 
spreadability which are important for achieving therapeu-
tic efficiency.
Materials and methods
Materials
NSAID (BCS class II), Poloxamertype 407, Carbomer, 
grade 940,C10-30 alkyl acrylate crosspolymer,ethanol 
96%, diisopropanolamine, sodium hydroxide, propylene 
glycol, levomenthol.
Equipment
Laboratory mixer homogenizer (IMA Stephan UMC 
5,Germany), magnetic stirrer (IKA Ret control/t, Germa-
ny), viscometer (Brookfield model DV2T with T- bar spin-
dle, USA), pH meter (Seven Compact Mettler Toledo, 
Germany),Morphologi-G3S, (Malvern instruments, UK).
Preparation of gels
Method of preparation of samples iskept to be same. 
Processing steps include hydration of the polymer with 
mixing until complete hydration is obtained. Next is the 
gel forming step,where with appropriate gel forming agent 
clear gelwasachieved. Separately, process of dissolving of 
active ingredient, levomentholand propylene glycol into 
ethanol 96% is performed.This solution is added to gel 
base and homogenized.
Sample S1 contains cross-linked polyacrylate polymer 
as a gelling agent and diisopropanolamineas a pH balanc-
er. Organic amines are commonly used to neutralize poly-
mers as agents for gel formation. In sample S2, C10-30 al-
kyl acrylate crosspolymer, polymer of the same group, but 
with different physical characteristics was used. The sam-
ple S3 was prepared with Poloxamer as a gelling agent. So-
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dium hydroxide solution as a pH balancer is used in the op-
timal amount to obtain a transparent gel.
Propylene glycol and ethanol (96 %) were includ-
ed in formulation as co-solvent and solvent for the ac-
tive ingredient. As a medium for hydration and swelling of 
polymer,water purified was used. Levomenthol in the for-
mulation was chosen as a cooling agent and skin penetra-
tion enhancer.
Physical properties of the prepared formulation
The produced gels were evaluated for grittiness, vis-
cosity and spreadability as physical tests.
Grittiness (texture)
The samples were evaluated microscopically for the 
presence of any appreciable particulate matter, seen un-
der light microscope. Proper quantity from the samples 
was applied directly to the glass for viewing under a mi-
croscope with a thickness that is appropriate for the lens.
The gel should fulfil the requirement of absence of par-
ticular matter and from grittiness as desired for any topi-
cal preparation.
This test was performed on three selected samples 
with differentpolymers on Morphologi-G3S Malvern in-
struments, UK.
Viscosity
Rheological properties such as viscosity of semisolid 
dosage forms can influence their drug delivery. The vis-
cosity of the formulations was performed using Brookfield 
viscometer DV2T model with T – Bar spindle, Brookfield. 
The test was developed according to European Pharmaco-
poeia test 2.2.10 (Ph. Eur. current version).
For the measurement approximately 50 g of gel were 
filled in a 100 ml beaker and the T-bar spindlewas lowered 
perpendicular in the centre taking care that the spindle does 
not touch bottom of the beaker. The viscosity was read as 
a single point measurement after 60 s, rotating with 5 rpm 
at room temperature. 
Spreadability test
The spreadability is a test of the gel easiness of appli-
cation. The spreadability of the samples was determined 
according to in-house test and is referenced according to 
Rao et al.(2010)  by measuring 1 g gel between horizon-
tal plates (20 x 20 cm2), after 1 minute. The standardized 
weight tied on the upper glass was 125 g. The results were 
calculated according to a formula.
The spreadability (S) can be calculated using formula:
Where: 
     S –spreadability(g.cm/sec)
     m - weighttied to upper glass slide (g)
     l - lengthmove on the glass slide (cm)
     t –timetaken (sec)
Results and discussion
For this purpose three different hydro-alcoholic gels-
were prepared for testing certainphysical properties.
Grittiness (texture)
All samples have a homogeneous appearance without 
particulate matter.That is an expected result for this kind of 
topical formulations.
Viscosity
The results from measurements are 54 000, 41 600 
and 700 000 cP for the samples S1, S2 and S3 respectively.
Viscosity results were influenced by the gelling properties 
andmolecular weight of thepolymers.
Spreadability test
Average result from ten measurementsof the samples 
S1, S2 and S3 were 10.04 g.cm/sec, 10.96 g.cm/secand 
5.67 g.cm/sec, respectively. Results are in accordance with 
the viscosity values, similar between S1 and S2, S3 being 
least spreadable.
Conclusion
All examined samples for the physical parameter grit-
tiness gave satisfactory results.From the presented results 
it can be concluded that gel sample with Poloxamer is the 
most viscous and it has weaker spreadability properties 
compared to the samples with cross-linked polyacrylate-
polymer and C10-30 alkyl acrylate crosspolymer. Samples 
S1 and S2 have optimal viscosity values, provide good 
spreadability properties and are easy to apply on the affect-
ed skin area.
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Introduction
Oral liquid pharmaceutical dosage forms are designed 
to provide maximum therapeutic response in a targeted 
population, especially for children and people with diffi-
culty in swallowing tablets and capsules, and to produce 
rapid therapeutic effects. Suspensions as dispersed sys-
tems are composed of two or more phases, where the solid 
phase, usually the drug substance, is distributed throughout 
the polymeric matrix (Cox, 2008).
Oral suspension described in this study is composed 
of active substance which belongs to BCS class II, and is 
nonsteroidal anti - inflammatory agent with very intensive 
burning taste, as is literally described as “burning mouth 
effect”. Taste masking effect is very difficult to achieve, 
but is inevitable step which must be satisfied during de-
velopment of successful formulation of such oral suspen-
sion. Different approaches are reported in the literature to 
achieve successful taste masking of bitter or unpleasant 
taste of drug, as follows: addition of flavoring and sweeten-
ing agents, taste suppressants and enhancers, viscosity en-
hancer, pH modifier, microencapsulation, coating with in-
ert material, ion-exchange, inclusion complexation, granu-
lation, adsorption, prodrug approach, by using liposomes, 
by effervescent agent etc. (Baig et al., 2014; Bhalerao et 
al., 2013; Suthar et al., 2010).
During formulation development several combination 
of polymers and ion exchange resins in different ratio are 
being used. Polymers used for achieving the desired vis-
cosity range were xanthan gum, carboxymethylcellulose 
sodium, microcrystalline cellulose and carboxymethylcel-
lulose sodium complex, maize starch, lambda carrageenan 
gum, and cross linked polyacrylic polymer. 
Materials and methods
For preparation of the oral suspension, the following 
materials were used: xanthan gum, carboxymethylcellu-
lose sodium, microcrystalline cellulose/ carboxymethyl-
cellulose sodium , maize starch, lambda carrageenan gum, 
polacrillin potassium, cross linked polyacrylic polymer, 
surfactants, flavor, pH regulatory agents, sweeteners and 
purified water. 
All the experimental trials were prepared in sever-
al continued steps including polymers hydration, swelling 
and incorporation of the active substance, using appropri-
ate equipment: table balance (Sartorius CP 4202 S, Mettler 
PM 200, Germany), stirrer (IKA UltraTurrax T-50 basic, 
Germany), magnetic stirrer (Heidolph MR Hei-Tec, Ger-
many), viscometer (Brookfield model RV with standard 
spindle set, Germany), pH meter (Seven Compact Mettler 
Toledo, electrode Inlab® Solids Pro, Germany). 
Seven different formulations were prepared. Combi-
nations of different percentage of xanthan gum, and the 
same percentage of carboxymethylcellulose sodium and 
microcrystalline cellulose/ carboxymethylcellulose sodi-
um, were included into 3 experimental trials (F1, F2 and 
F3). In the fourth formulation (F4), maize starch was in-
corporated instead of carboxymethylcellulose sodium, and 
the fifth formula (F5) included lambda carrageenan gum 
instead of carboxymethylcellulose sodium. 
Method of preparation of the above mentioned trials 
consists of several processes which include preparation of 
polymer medium with hydration and swelling process un-
der continuously stirring, and after that incorporation of 
the active substance into polymeric matrix. Additional in-
active ingredients which enhance the organoleptic proper-
ties and consistency of the suspension were added, such as 
sweetening agents, flavors, pH modifiers and surfactants. 
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Into the last two formulations (F6 and F7) ion-ex-
change resins were included. They were prepared with 
complexation process between the ion-exchange resins and 
the active substance.
Viscosity measurements were done of all of the pre-
pared experimental trials using laboratory viscometer 
(Brookfield DV2T RV with standard spindle set, Germa-
ny).
The experimental conditions (600 ml beaker, filled 
with 350 ml suspension, viscosity measured after 60 sec-
onds at 50 rpm of spindle rotation) are kept the same for all 
of the performed trials which means that the obtained re-
sults are comparable with each other.
The palatability study for the prepared experimental 
trials was performed by panel method. The study protocol 
was explained and written. Also, the consent was obtained 
from the volunteers. For this purpose, 10 human volunteers 
were selected. About 5 ml of the suspension was placed on 
tongue and taste evaluated after 15 seconds, using a nu-
merical scale. The numerical scale consists of values as 0 = 
excellent, 1 = good, 2 = slightly burning mouth effect, 3 = 
burning mouth effect, 4 = intensive burning mouth effect, 
which were determined by the formulator.
Also, measurement of the sedimentation volume of all 
of the experimental trials in the study was done. Sedimen-
tation volume (F) is a ratio of the final or ultimate volume 
of sediment (Vu) to the original volume of sediment (Vo) 
before settling. It can be calculated by following equation:
F = V u / Vo
where, 
Vu = final or ultimate volume of sediment
Vo = original volume of suspension before settling
Results and discussion
In the formulations with ion – exchange resins, inter-
action between the reactive functional group of the poly-
acrylic polymer and ionisable active substance mole-
cule occurs, until active substance - polymer complex is 
formed. The reaction is performed under determined pH 
and temperature values. The complex is insoluble in water 
and it has no taste, so the bitter taste of the active substance 
entrapped into the complex is masked. 
When such complex enters the gastro intestinal fluid, 
the bond between the active substance and polymer dif-
fuses and the molecule of the active substance is released 
throughout a decomplexation process. The process of re-
leasing the active substance is performed very quickly and 
completely into gastro intestinal fluid so it does not affect 
the absorption and bioavailability of the active substance. 
(Bilandi et al., 2014; Sampath Kumar et al., 2012).
Different values for the viscosity measurement of all 
of the experimental trials were obtained, which logically 
were in correlation with the used percentage of the selected 
polymer. Values from viscosity measurement for the for-
mulations F1, F2 and F3 were 1046 cP, 1234 cP and 1748 
cP, as follows. For the trials F4, F5, F6 and F7 were ob-
tained the following values 1040 cP, 1730 cP, 738 cP and 
1916 cP, respectively.
The sedimentation volume can have values ranging 
from less than 1 to equal or rarely, more than 1. The ulti-
mate height of the solid phase after settling depends on the 
concentration of solid and the particle size. To obtain an ac-
ceptable suspension the value of F should be at least 0.9. In 
the presented study there is no sedimentation after 14 days 
for all of the seven trials.
Conclusion
From the performed experimental trials it can be con-
cluded that increasing the viscosity of the prepared oral 
suspension with combination of different percentage of 
xanthan gum, and the same percentage of carboxymeth-
ylcellulose sodium and microcrystalline cellulose/car-
boxymethylcellulose sodium, results into satisfactory taste 
masking effect which is more intensively achieved in com-
parison with the rest of the experimental trials. The com-
plexation process does not give a satisfactory taste mask-
ing effect, although these formulations were optimistic and 
promising. 
The combination of the three polymeric matrices in 
the optimized concentration, which results into satisfacto-
ry viscosity of the suspension containing nonsteroidal anti 
- inflammatory active substance, was chosen as a favorite 
formulation and a candidate to work with in the future tri-
als.
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Introduction
Pharmaceutical/cosmetic industry trends are focused 
toward development of innovative formulations character-
ized by controlled release of active ingredient (AI) in or-
der to enhance effectiveness and to reduce AI related side/
adverse effects. 
Microsponges (MSPs) incorporated into well known 
dosage forms represent new generation of highly effective 
formulations. MSPs efficacy is related to particle size and 
size distribution, porosity, pore size, surface area, AI en-
capsulation efficiency (EE) and release rate. MSPs` char-
acteristics (physico-chemical, biopharmaceutical) influ-
encing their efficacy might be tailored using certain prep-
aration technique, as well as formulation and process pa-
rameters. Effect of formulation variables upon MSPs` EE 
is going to be presented in this review. Quasi-emulsion sol-
vent diffusion technique was most commonly used meth-
od for MSPs preparation, while drug to polymer ratio and 
composition of internal and outer (external) phase were 
identified as significant formulation variables that influ-
enced EE.
Influence of drug to polymer ratio
EE of Ethyl cellulose (EC) or Eudragit RS100 
(ERS100) based MSPs loaded with fluconazole (Abdel-
malak and El-Menshave, 2012), was in a range of ∼15 to 
90% depending from the variables studied. Results from 
their study pointed that increased polymer quantity result-
ed with higher EE (∼45% vs 55% for 1:1 and 1:2 drug to 
polymer ratio (DPr), respectively). According to authors 
the findings might be related to the fact that higher polymer 
amount would result with increased viscosity of internal 
organic phase (IOP), thus reducing drug molecule diffu-
sion into the external phase (EP) or simply higher amount 
of polymer encapsulated more drug molecules. 
Contrary, studies related to ERS100 MSPs loaded with 
diclofenac diethylamine (DPr 1:1 to 1:6) (Osmani et al., 
2015a) or domperidone (DPr 1:1 to 1:5) (Osmani et al., 
2015b) showed opposite trend. Determined diclofenac di-
ethylamine EE values ranged ∼10% for DPr 1:6 to 48% 
for DPr 1:1 (Osmani et al., 2015a), while domperidone 
EE were ∼73% (DPr 1:5) to 92% (DPr 1:1). Similar were 
the findings for benzoil peroxide EC MSPs (Jelvehgari et 
al., 2006) prepared with DPr of 1:1 to 13:1 characterized 
by EE of 70-98%, whereas probably higher drug quantity 
would result with increased EE as more drug molecules per 
polymer unit are available.
Studies of Çomoğlu at al. (2003), Orlu et al. (2006) 
and (D’souza and More, 2008) related to EE of ERS100 
MSPs loaded with ketoprofen (DPr 1:1 to 11:1, EE ∼92-
96%), flurbiprofen (DPr 3:1 to 5:1, EE ∼96-97%) and fluo-
cinolone acetonide (DPr 1:1 to 13:1, EE ∼87-94%) accord-
ingly, indicated that EE was not much affected by DPr. 
Studies of Arya and Pathak (2014) and Srivastava et al. 
(2012) associated to ERS100/EC and ERS100 MSPs load-
ed with curcumin and meloxicam, respectively, were con-
ducted using experimental design studies. EE were ∼80-
93% for curcumin ERS100/EC MSPs and ∼71-99% for 
meloxicam ERS100 MSPs. Derived correlations between 
EE and studied variables - EC amount (300-900mg) in the 
IOP and Polyvinil alcochol (PVA) (0.5-1.5% w/v) in the EP 
(Arya and Pathak, 2014) and volume of organic media - di-
chloromethane (DCM)(5-7 ml) and ERS100 content (400-
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1200 mg) in DCM (Srivastava et al., 2012) pointed to the 
positive influence of polymer quantity, although later noti-
fied that wasn`t statisticaly significant as it was expected. 
However, influence of interactions` factors upon EE was 
also identified. Similar findings were observed in the study 
of Gupta et al. (2015) where 5-fluorouracil ERS100 MSPs 
were prepared using different polymer quantity (400-1200 
mg) and IOP volumes (6-8 ml) consisted of ethanol:DCM 
mixture (7:3) (EE ∼36-61%) as well as in the study of 
Pawar at al. (2015) related to oxybenzone EC MSPs pre-
pared with DPr 1:1 to 1:3 and DCM - 3-5 ml (EE ∼90-
99%).
Influence of organic phase  
Influence of solvent type (ethanol, methylen chloride) 
upon MSPs` EE was investigated by Abdelmalak and El-
Menshave (2012) where determined EE indicated that eth-
anol was solvent of choice most likely due to the higher 
boiling point and hence lower evaporation rate thus de-
creasing the diffusion rate into the EP.  Orlu et al. (2006) 
used 3, 5 and 10 ml ethanol for MSPs preparation, but 
however MSPs could be prepared only with 3 ml ethanol 
as IOP. When volume of DCM was increased from 5 to 15 
ml in the study of Jelvehgari et al. (2006) a decrease of EE 
was observed (∼87 to 67%), most likely due to the lower-
ing of drug concentration. 
Higher EE values in increase of IOP volume were de-
termined by Gupta et al. (2015) and Pawar et al. (2015) 
probably due to the better drug solubility, but however in-
verse correlation for interaction term of polymer amount 
and IOP volume was observed. Alike were the results of 
Srivastava et al. (2012) where additionally quadratic func-
tions of investigated variables` influence upon EE were de-
termined. Inverse dependency of EE to (IOP)2 might be 
linked to the formation of more porous MSPs thus facili-
tating drug partitioning into the EP. 
Influence of surfactant concentration in the outer 
water phase
Curcumin EE of ERS100/EC MSPs (Arya and Pathak, 
2014) showed positive correlation with the interaction 
of EC and PVA, while negative correlation was estab-
lished with the influence of quadratic terms (EC2*PVA, 
EC2*PVA2). Influence of PVA on the EE was also deter-
mined in the study of Jelvehgari et al. (2006) where ob-
tained results pointed that benzoil peroxide EE was higher 
at lower PVA concentration (EE of 93.26% at 0.047% PVA 
and 77.87% at 0.187% PVA). Similar results were report-
ed by Abdelmalak and El-Menshave (2012) where flucon-
azole EE was inversely dependent from PVA concentration 
(EE ∼40% at 0.75% PVA to > 70% at 0.5% PVA).  These 
observations were explained by probable formation of al-
ternative hydrophobic regions dissolving some drug por-
tions thus resulting with decreased EE.
Opposite findings were determined when PVA solu-
tion in a concentration of 0.03 to 0.07% was used as EP 
for preparation of domperidone ERS100 MPSs (Osmani 
et al., 2015b) and hence EE was ∼76 to 90%, respective-
ly.  The difference with the previous studies might be re-
lated to the low PVA concentration used. Similar were the 
findings for diclofenac diethylamine ERS100 MPSs (Os-
mani et al., 2015a) prepared with sodium alginate solution 
(0.03 to 0.07%) as EP which were characterized by slight 
increase of EE (∼85 to 93%), consequently.
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Introduction
Suspensions are two-phase systems having solid, sub-
stantially water insoluble active agent particles dispersed 
throughout liquid medium. They represent thermodynam-
ically unstable disperse system, so it is necessary to add 
suspending agent which reduces the rate of settling and 
permits easy redispersion of any settled particulate matter, 
both by protective colloidal action and by increasing the 
consistency of the suspending medium. Gums and other 
polymers are frequently employed in pharmaceutical sus-
pensions as viscosity building, thickening, stabilizing and 
suspending agents. They are used to delay or prevent sed-
imentation by affecting the rheological characteristics of 
suspensions. Viscosity building agents increase the viscos-
ity of an aqueous mixture without substantially modifying 
its other properties, such as taste. They provide body and 
improve stability of added ingredients (Moreton, 2010). 
The aim of the study is optimization of viscosity build-
ing agent, xanthan gum in combination with hydroxyethyl 
cellulose in order to achieve stable oral suspension. In or-
der to evaluate the optimal concentration of the viscosity 
building agent, formulations with different concentration 
of xanthan gum were made. Appearance and homogeneity 
of suspension, viscosity, sedimentation volume and disso-
lution were evaluated.
Materials and methods
Materials 
Active pharmaceutical ingredient, sparingly soluble 
in water, para-aminophenol derivative that exhibits anal-
gesic and antipyretic activity with bitter taste was used. 
Solvents, co-solvent, stabilising agent, sweetening agent, 
buffering agent and preservative were used. Xanthan gum 
(Jungbunzlauer, Austria) and hydroxyethyl cellulose (Ash-
land, France) were used as viscosity building agents. Fla-
vour and taste masking agent were used to mask the bitter 
taste of the active ingredient. All excipients are approved 
for use in pharmaceutical industry.
Methods
Suspensions were produced by a common process for 
preparation of oral suspension by method of mixing with-
out heating, dispersing of active ingredient and homoge-
nization. Each of the laboratory trials was prepared under 
the same condition and with the same method. Suspensions 
were prepared with different concentration of xanthan gum 
0.15%; 0.17%; 0.20%; 0.25% and 0.35%. The concentra-
tion of hydroxyethyl cellulose was kept constant in all five 
laboratory trials. Visual inspection for appearance and ho-
mogeneity of suspension, viscosity, sedimentation volume 
and dissolution was evaluated as critical parameters. 
Homogeneity of the prepared suspensions was evalu-
ated using optical microscopy (Morphologi-G3S, Malvern 
instruments, UK). Viscosity of the suspensions was mea-
sured with rotating viscometer (Brookfield, USA, with RV 
spindle No. 3; temperature 20ºC). Sedimentation volume is 
defined as the ratio of the final, equilibrium volume of the 
sediment to the total volume before settling (F = Vu /V0 
x100; Vu – volume of sediment in ml; V0 – total volume of 
suspension in ml). The values for F range from 0 to 1. Val-
ues of F = 1 indicate that no sediment is apparent and that 
the suspension is stable and flocculated (Mohammad et al., 
2010).  Sedimentation volume was observed and calculat-
ed for a period of 30 days, in the following intervals: 60 
minutes; 180 minutes; 24 hours; 7 days and 30 days. Con-
tent of dissolved active component was determinate with 
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HPLC method. Dissolution testing was conducted in 900 
ml + 1% phosphate buffer pH 6.8+ 0.05 using USP appara-
tus II (paddle), set at rotation speed of 50 rpm and temper-
ature of the medium of 37 ± 0.5ºC.
Results and discussion
Homogeneity of the prepared suspensions was evalu-
ated microscopically and differences due to different con-
centration of viscosity building agent were not observed. 
Suspensions with concentration of xanthan gum in range 
from 0.15%; 0.17%; 0.20; 0.25% to 0.35% were measured 
and results from 562 cP; 687cP; 752 cP; 1005 cP to 1233 
cP, respectively for each concentration, were obtained. The 
increase of the concentration of xanthan gum resulted with 
an increase of viscosity of the suspensions, which was eas-
ily visually noticed and after that confirmed by measure-
ment with a rotating viscometer. The suspension with vis-
cosity above 1000 cP showed bad pourability which can 
directly influences the proper dosing of the oral suspen-
sion (Zatzx and Knapp, 1984). The suspensions were ob-
served during a period of 30 days and sedimentation ef-
fect was not observed. Sedimentation volumes for all eval-
uated concentrations were 1, indicating that xanthan gum 
used in a range from 0.15% to 0.35% is capable of forming 
and maintaining a stable suspension for this period. The 
increase in viscosity avoids the particle aggregation and 
helps particles to remain in a flocculated state (Tempio and 
Zatz, 1980). Dissolution testing was performed on the pre-
pared suspension and the following results were obtained 
98.22%, 95.15%, 92.22%, 89.42% and 67.95% for each 
concentration respectively, for the time point of 30 min-
utes and 99.52%, 98.21%, 97.36%, 91.50% and 81.65%, 
for the time point of 45 minutes. The percent of dissolved 
active component decrease by increasing the concentration 
of xanthan gum, or viscosity of the suspensions. Obtained 
results from dissolution of the suspensions were higher for 
the time point of 45 minutes in comparison with the results 
for 30 minutes. From the results can be noticed that due 
to its polysaccharide nature the viscosity building agent 
has the ability to decrease the dissolution rate of the ac-
tive component when added in higher concentration (Ver-
hoeven et al., 2006). As the viscosity of the dispersion me-
dium increases, the terminal settling velocity decreases 
thus the dispersed phase settle at a slower rate and remain 
dispersed for longer time yielding higher stability of the 
suspension. On the other hand as the viscosity of the sus-
pension increases, it’s pourability decreases and the incon-
venience to the patients for dosing increases. Also the in-
crease of the viscosity resulted in decrease of the dissolu-
tion rate of the active component, directly influencing the 
bioavailability of the drug.
Conclusion
With concentration optimization of viscosity build-
ing agent xanthan gum, viscosity of the suspension can be 
maintained within optimum range to yield a homogenous, 
stable suspension appropriate for oral delivery of the drug. 
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Introduction
Pharmaceutical excipients are substances other than 
the active pharmaceutical ingredient(API), which are in-
tentionally included in a drug delivery system. They are 
inert substances by definition but in many cases represent 
high proportion of the finished dosage form and their qual-
ity significantly influences the effectiveness or safety of the 
drug. Excipients support the processing of the finished dos-
age form during its manufacture; they protect, support or 
enhance stability, bioavailability or patient acceptability; 
help in product identification, or enhance other attribute of 
the general product quality attributes. 
Despite their critical role in the pharmaceutical formu-
lation, there are no specific GMP regulations obligatory for 
their manufacturers. On the other hand, there are a huge 
number of applications of these materials which makes the 
development of appropriate guidelines very demanding. 
Currently, in the pharmaceutical industry there is a gener-
al expectation that excipients are manufactured to recog-
nised GMP principles (The Joint IPEC – PQG Good Man-
ufacturing Practices Guide for Pharmaceutical Excipients, 
2006).
The major problem for Marketing Authorization 
Holders(MAHs) is that the excipient manufacturers pro-
duce ingredients that are not only intended for use in phar-
maceuticals but also in food, cosmetics, or as chemicals. 
The quantitative requirement for excipients in pharmaceu-
tical products is often insignificant compared to their use in 
other applications; however, the quality of the ingredients 
for use in medicinal products could be essential to the safe-
ty, quality and efficacy of the finished drug product (IPEC 
Federation Position Paper on EU Risk Assessment Guide-
lines for Excipients 2015C/ 95/02).
Most important global organizations which instruct 
and facilitate implementation of excipient quality stan-
dards are EDQM (European Directorate for Quality of 
Medicines and Healthcare) and the IPEC (International 
Pharmaceutical Excipients Council). 
EDQM position
At the moment it is the Eudralex Vol. 4, Part 2 guide-
line, which refers to the quality system of API manufactur-
ers and is sufficient and even higher standard for the excip-
ient manufacturers.
According to this guideline excipients and excipient 
manufacturers should be controlled based on the results of 
a formalised quality risk assessment (EudraLex, Volume 4 
Good manufacturing practice (GMP) Guidelines, Part 1, 
Chapter 5: Production). The MAHs are required to have a 
documented risk assessment/management system for ap-
propriate GMPs for excipients, available on site for review 
by EU GMP inspectors.
According to The Guideline of 19 March 2015 on the 
formalised risk assessment for ascertaining the appropri-
ate good manufacturing practice for excipients of medici-
nal products for human use, the risk assessment principle 
consists of three parts:
1. Determine the appropriate GMP level that the excip-
ient manufacturer needs to achieve; 
2. Determine the current GMP level that the excipient 
manufacturer has; 
3. GAP analysis between these two GMP levels and 
proposing actions.
The following specific areas of potential risks should 
be considered, understood and assessed when reviewing 
the excipient manufacturers’ GMP level: risk aspects relat-
ed to excipient quality and safety, and risk aspects related 
to excipient function in the drug product.
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Once the appropriate GMP for the excipient and the 
risk profile of the excipient manufacturer have been de-
fined, the EU guidelines specify that ongoing risk review 
should be performed.
IPEC’s position 
The newest and customized guideline for excipient 
manufacturers that covers topics from the EU GMP guide-
lines and ISO 9001 chapters is The Joint IPEC – PQG Good 
Manufacturing Practices Guide for Pharmaceutical Excipi-
ents, 2006, which represents good base for implementation 
of the highest GMP for the excipient manufacturers.
The major concern is that the risk assessment process 
by different MAHs could eventually classify one manufac-
turer into different categories of risk (high, medium, low) 
depending on the different approaches and intended use. 
This could lead to different quality requirements by differ-
ent companies for the same excipient. It would be impos-
sible to comply with these different requirements in one 
quality system unless the highest level of GMP was to be 
implemented. IPEC is concerned that there is not enough 
time to complete risk assessments for all excipients by the 
March 21, 2016 deadline, and that incomplete assessments 
may jeopardize the availability of high–quality excipients 
that have been in use for many years. 
IPEC will share their views with the EDQM on the 
challenges to comply with the current timeline and request 
more realistic goals and timelines (IPEC Federation Posi-
tion Paper on EU Risk Assessment Guidelines for Excipi-
ents 2015/C 95/02).
IPEC views third−party auditing and certification 
schemes, such as EXCiPACT, and national standards, such 
as NSF/IPEC/ANSI 363−2014, as playing an essential role 
to achieve compliance with new requirements for the qual-
ification of excipients and their suppliers. Without addi-
tional information about GMP and GDP compliance of the 
excipient manufacturers through independent third−party 
audits, it will be nearly impossible for MAHs on their own 
to gather all the necessary data required (Quality Risk As-
sessment for Excipients: An Industry Perspective, 2015).
Regulatory authority’s position 
Even though the groundwork for standardization is es-
tablished, there is a concern from the regulatory author-
ities: Ewan Norton of the UK Medicines and Healthcare 
products Regulatory Agency (MHRA) gave an inspector’s 
view of the new EU requirements on risk−assessment of 
excipients, expressing concern that despite a 12−month 
introduction period some pharma companies may not be 
ready to meet the deadline of 21 March, 2016. 
A survey carried out at an MHRA conference last year 
revealed that a considerable number of pharma industry 
had either not started the risk assessment process or were 
unaware of the upcoming requirements. Norton suggest-
ed that inspectors would be inclined to serve companies 
with a deficiency in their report if they were not compliant 
with the requirements (Excipients insight January/Febru-
ary 2016, IPEC e−newsletter, 2016).
Pharmaceutical industry position 
EFPIA (European Federation of Pharmaceutical In-
dustries and Associations) supports the new legislation but 
is concerned that its implementation may lead to an abun-
dance of regulatory guidance. EFPIA recommends that in-
stead of formalized risk assessment the process should be 
integrated into existing supplier qualification management 
programmes. They recommend that it is not necessary to 
develop additional GMP guidelines for excipients since the 
risk management principle is already embedded in Part III 
EU GMP: Quality Risk Management (ICH Q9). 
They propose more effective legislation without un-
necessary regulatory burden on manufacturers and suppli-
ers to ensure continuous supply of quality excipients and 
finished drug products (EFPIA TDOC Position Paper).
Conclusion
In the literature, depending on the standpoint there are 
an abundant number of guidelines, papers and articles that 
explain the general recommendations for risk assessment 
principle, but lack those describing hands−on application. 
There are a limited number of case studies of the pharma-
ceutical companies applying those guidelines and showing 
significance of those guidelines and practices.
It is recommended that the literature invests more in 
the area of application and significance of guidelines and 
practices. New case studies should be done to prove the 
success of such practices in risk assessment of excipients.
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Introduction
Three crucial characteristics of medicinal product are 
its safety, effectiveness and quality required for its intend-
ed use. In order to obtain and retain those characteristics, 
special consideration must be paid to proper storage of me-
dicinal product. Good Manufacturing Practice (GMP) re-
quires that raw materials, packaging materials, interme-
diates, bulk and finished product are stored under appro-
priate conditions. This also means that a maximum hold-
ing period for intermediates and bulk products before their 
further processing should be established. In order to avoid 
any misunderstanding, it is important to define terms “in-
termediates” and “bulk products” The term “Intermediate” 
is partly processed product that must undergo further man-
ufacturing steps before it becomes a bulk product. “Bulk 
product” refers to any pharmaceutical product that has 
completed all processing stages up to, but not including, fi-
nal packaging (Eudralex, 2010).
Hold-time studies guidance
Until 2015, relevant guidelines (CPMP/QWP/122/02, 
2003; ICH Q1A(R2), 2003; Eudralex, 2014; FDA 
Q1A(R2), 2003) thoroughly described the requirements 
for stability testing of finished drug product. The only 
statement in guidelines with regard to pharmaceutical bulk 
products or intermediates is that they have to be stored “in 
a suitable way”.
In 2015, World Health Organization (WHO) released 
a final version of “General guidance on hold-time studies” 
as a part of WHO Technical Report Series No. 992 (WHO, 
2015). Although this guidance describes the principles of 
establishing criteria for performing hold-time studies on 
coated tablets, those principles can be applied to other non-
sterile dosage forms. 
Recommendations for conducting hold-time studies
Hold time is a period of time during which materials 
can be stored under defined conditions and will retain their 
quality within the specified limits. This implies that hold 
times should be established for the materials at different 
phases of manufacturing, so one can be sure that holding 
didn’t compromise the quality of the finished product.
Hold times should be established based on scientific 
data. It is recommended that the test is to be performed 
on one batch prior to registration of the product. All tests 
should be performed using validated stability-indicating 
methods. Storage conditions of samples are required to be 
the same as for the quarantine area or manufacture stage 
(WHO, 2015). Apart from that, sample should be stored in 
a simulated package mimicking the packaging of the bulk 
product (Huynh-Ba, 2009; WHO, 2015). This means that 
containers should be made of the same material and us-
ing same closure system as the system in the manufactur-
ing stage. If there is a risk of substance’s degradation as a 
result of oxidation processes, headspace in the containers 
should also be tested. It is necessary to determine the ratio 
of headspace to contents in the containers, so degradation 
of substance is unlikely to occur (WHO, 2015).  
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Data to support holding times could be collected dur-
ing drug development, on a pilot or validation batches. 
If the product is already on the market, guidance (WHO, 
2015) leaves a possibility to perform retrospective hold-
time studies. Collected data should be processed statisti-
cally in order to note trends or to establish limits. Study 
should be performed through a period defined in the guid-
ance, and not beyond that. It isn’t necessary to prolong 
study until the lowest limit of quality is achieved. This ap-
proach is based on a “most probable” as opposed to “worst 
case” approach. For example, 90 days are enough time to 
keep core tablets as intermediates in the coated tablet man-
ufacturing, to study hold-time stability (WHO, 2015). 
General guidance on hold-time studies (WHO, 2015) 
provides examples of stages, tests and study times that may 
be performed for a coated tablet. Coated tablet have been 
chosen as an example, since tablets are the most widely 
used dosage form. Apart from that, manufacture of tablets 
and, especially, coated tablets can be a complex process, 
including a variety of manufacturing stages (Armstrong, 
2007). Each stage can, in some way, influence the quality 
of the final product.
Once hold time is established, intermediates and bulk 
products should not be stored beyond this period.
Conclusion
Hold-time study plays an important role in the manu-
facturing of drug products in the GMP environment. The 
maximum hold time for intermediates and bulk pharma-
ceuticals should be established in order to continue their 
processing or start the packaging of the drug products be-
fore their quality becomes compromised. 
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Introduction
Lorazepam has anxiolytic, sedative, hypnotic, and an-
ticonvulsant as well as muscle relaxant properties. It is a 
highly lipophilic compound whose partition coefficient is 
2.36 when measured at 20 °C. Lorazepam, as an amphiphil-
ic substance, has two pKa values (1.3 and 11.5) determined 
spectrophotometrically in aqueous buffers. It is main-
ly used in different dosage forms as an active substance. 
The injectable solution comes in 1 mL ampoules contain-
ing 2 or 4 mg lorazepam. As derivative of 1,4-benzodiaz-
epines, has certain limitations in pharmaceutical technol-
ogy due to its poor solubility in water. The aqueous solu-
bility of lorazepam, particle size 8.9 μm, is 0.0485 mg/mL 
(Hadžiabdić and Hadžović, 2005-2006). Often, in a certain 
volume of water, an adequate concentration of the drug can-
not be achieved during formulation of a liquid dosage form 
due to the low solubility of the drug (Jinal et al., 2012). 
This study investigated the use of the traditional sol-
ubilization approaches to increase the solubility of loraz-
epam. Our aim was to investigate the solubility of loraz-
epam in phosphate buffer solutions, in water/cosolvents 
mixtures (cosolvents: ethanol, propylene glycol, polyeth-
ylene glycol 200 and 400) (Corrigan and Healy, 2007; 
Vemula et al., 2010), and in water/surfactants mixtures 
[surfactants: Tween 80, Tween 20, Brij 35, sodium cho-
late, sodium deoxycholate, sodium taurocholate] (Corri-
gan and Healy, 2007; Rangel-Yagui et al., 2005) as well 
as its solubility in water/cyclodextrins mixtures [cyclo-
dextrins: α-cyclodextrin (α-CD), β-cyclodextrin (β-CD), 
2-hydroxypropyl-β-cyclodextrin (2-HP-βCD)] (Loftsson 
and Brewster, 2010; Sathesh Babu et al., 2008). The main 
objective was to find the most suitable method for provid-
ing good solubility of lorazepam and thus its formulation 
in a liquid dosage form.
Materials and methods
Materials
Used chemicals were obtained from: Lorazepam (LZ, 
Sigma-Aldrich, Germany); Acidum sulfuricum 95-97% 
and Methanolum (Kemika, Croatia); Acidum hydrochlo-
ricum 37%, Disodium hydrogen phosphate and Potassi-
um dihydrogen phosphate (Alkaloid, Macedonia); Acidum 
phosphoricum 85% (Fluka, Chemika, Switzerland); eth-
anol 96%, Polyethylene glycol 200, Polyethylene gly-
col 400 and Propylene glycol (Sigma-Aldrich, Germany); 
Tween 20, Tween 80 and Brij 35 (Merck, Germany); So-
dium cholate, Sodium deoxycholate, Sodium taurocho-
late, α-CD, β-CD and 2-HP-βCD (Fluka, Chemika, Swit-
zerland). 
Solubility studies
The solubility of LZ was estimated by the solubility 
method of Higuchi and Connors (1965). Solubility mea-
surements and the determination of saturation concentra-
tions were carried out by adding excess amounts of loraze-
pam to phosphate buffer solutions (pH 2.0-8.0), water/co-
solvent mixtures (concentrations 1-60% w/w), water/sur-
factants mixtures (concentrations 1-20% w/w, for anion-
ic surfactants and 1-35% w/w, for non-ionic surfactants). 
Concentrations of cyclodextrins were selected based on 
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their solubility in water. Testing of LZ solubility with the 
addition of α-CD in aqueous solutions was carried out by 
its addition in concentrations up to 14%. The testing of LZ 
solubility was carried out in concentrations up to 1.8% of 
aqueous solutions of β-CD. The testing of LZ solubility 
with the addition of 2-HP-β-CD in aqueous solutions was 
carried out by its addition in concentrations up to 40%. The 
concentrations of dissolved LZ in tested solutions were de-
termined using a Shimadzu UV-1601, UV VIS spectropho-
tometer (Shimadzu, Japan).
Results and discussion
It was found that LZ solubility was decreased with an 
increasing pH. When the pH value is lower, the percent-
age of protonation of lorazepam is higher. Protonation at 
low pH occurs at the nitrogen atom in position 4. Deprot-
onation occurs at a high pH with the loss of the hydrogen 
atom from the 3-hydroxyl group (Barrett et al., 1973).
To prepare the aqueous solution of LZ (2 mg/mL), it is 
necessary to have more than 50% (w/w) of propylene gly-
col, or more than 40% (w/w) of polyethylene glycol 400, 
polyethylene glycol 200 or ethanol. To completely dissolve 
4 mg/mL LZ in water more than 50% (w/w) of polyeth-
ylene glycol 400 or polyethylene glycol 200 or less than 
50% (w/w) of ethanol is needed. It is evident that LZ mole-
cules preferably solubilize in a nonpolar environment rath-
er than polar (aqueous) surroundings. The concentration of 
the solvents that enable this drug to be solubilized in water 
is far higher than that allowed for daily intake. 
Increase of surfactants concentration in water leads to 
LZ solubility enhancement linearly. The best solubility was 
achieved with sodium taurocholate, of all the tested bile 
salts, while the best LZ solubility in water was achieved 
with Brij 35, of all the tested non-ionic surfactants (Alkha-
mis et al., 2003; Rangel-Yagui et al., 2005). 
To dissolve 2 mg/mL of LZ in water, more than 15% 
of sodium cholate, more than 5% of sodium deoxycholate, 
or less than 10% of sodium taurocholate concentrations are 
needed. To make a LZ concentration in liquid form of 2 mg 
LZ/mL of water, more than 5% of Tween 80, more than 7% 
of Tween 20, or less than 3% Brij 35 is needed. To dissolve 
4 mg/mL of LZ in water, more than 20% of sodium cho-
late, ~15% of sodium deoxycholate or less than 15% of so-
dium taurocholate is needed. To dissolve 4 mg of LZ/mL 
of water, 20% of Tween 80, more than 15% of Tween 20 or 
less than 7% Brij 35 should be used. The surfactants with 
higher HLB values were better solubilizers. 
The increase of LZ solubility in aqueous solutions of 
chosen cyclodextrins, compared to its solubility in water. 
The solubility of LZ is increased 6.5-fold at 14% of α-CD, 
4.38-fold at 1.8% β-CD, and 170.1-fold at 40% of 2-HP-
β-CD. The changes in the solubility of LZ resulting from 
the addition of various concentrations of α-CD, β-CD and 
2-HP-β-CD were used to plot phase solubility diagrams 
and to evaluate the stoichiometry and stability constant of 
the resultant complex. The phase solubility diagrams ob-
tained are linear and show characteristics of AL-type of 
solubility curve. This is attributed to the formation of a sol-
uble complex. The apparent stability constants (K1:1) were 
estimated from the straight line of the phase solubility dia-
grams according to equation of Higuchi and Connors (Hi-
guchi and Connors, 1965; Mosher and Thompson, 2007). 
In this case, the K1:1 values obtained followed the order 
2-HP-β-CD > β-CD > α-CD, reflecting the greater affinity 
of modified cyclodextrin for LZ compared with their par-
ent α-CD and β-CD. 
Conclusion
Based on the results, the changes in the pH value of the 
media do not lead to a greater solubility of lorazepam. Of 
the cosolvents used, the greatest increase in solubility of 
lorazepam in water was achieved with ethanol. Of the bile 
salts used, sodium taurocholate showed the best solubili-
zation ability, while Brij 35 was the best of the non-ionic 
surfactants. The solubility of lorazepam with the cyclodex-
trin derivative, 2-hydroxypropyl-β-cyclodextrin was bet-
ter than natural cyclodextrins. Surfactants have the high-
est ability of solubilization of lorazepam in water. Thus, 
the study generates an array of data for solubilization of 
lorazepam using various pharmaceutically accepted tech-
niques which could be useful while formulating liquid dos-
age forms of lorazepam.
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Introduction
Colon drug targeting is valuable approach for the treat-
ment of serious GIT diseases like ulcerative colitis, Chron’s 
disease, colon carcinomas and infections; considering that 
high local concentration at the site of action can be achieved, 
and systemic exposure to the active substance as well as se-
rious side effects can be avoided (Chourasia and Jain, 2003). 
Different studies point to the connection of the inflamma-
tion and tumorigenesis and the presence of  immunoinflam-
matory mediators and inflammation in virtually all steps 
of colon cancer development, including initiation, promo-
tion, progression, and metastasis. Therefore, the design con-
cept of increased localization of micro and/or nanoparticles 
at the site of inflammation/cancer due to enhanced permea-
bility and retention in the tissue damaged by inflammation/
cancer may also be favourable for colon cancer targeting. 
Additionally, prolonged intimate contact with the epitheli-
al membranes at the site of action, which may be enhanced 
by incorporation of bioadhesive polymers into the carriers 
is crucial for improvement of specific interaction with mu-
cin and cell surfaces as well as for improved localization 
of the drug delivery systems at the site of action. Whence, 
the aim of this study was to design 5-fluorouracil loaded or-
ganomodified silica microparticles as systems for controlled 
and site specific colon delivery as well as to investigate the 
influence of the concentration of the silane coupling agent 
3-aminopropyltriethoxysilane  (APTES) upon the micropar-
ticle properties.
Materials and methods
Materials 
Silica microparticles were prepared using the follow-
ing reagents: tetraethoxysilane (TEOS; Sigma, Germany), 
3-aminopropyltriethoxysilane (APTES; Sigma, Germany), 
ethanol 96% (v/v) (Merck, Germany), acetic acid (Merck, 
Germany), 5-Fluorouracil (5-FU; EBEWE Pharma, Aus-
tria), and deionised water. All other used chemicals and re-
agents were of analytical grade.
Preparation of silica microparticles
Silica microparticles were prepared from tetraethoxysi-
lane (samples MP1) and tetraethoxysilane co-hydrolyzed 
with 3-aminopropyltriethoxysilane by combining sol-gel 
technology with spray-drying. TEOS-based silica micropar-
ticles (MP1) were synthesized by sol-gel method at room 
temperature using a one-step acid-catalized hydrolysis. Sil-
ica sol was prepared by hydrolysis and polycondensation of 
TEOS with deionised water, ethanol and acetic acid as a cat-
alyst. The molar ratio of the silica sol was TEOS: water : 
ethanol : acetic acid = 0.01 : 1.39 : 0.43 : 0.009. Hydrolised 
silica sol was spray dried with a mini spray dryer (B-290, 
Büchi Labortechik AG, Switzerland). 5-FU was added after 
completed hydrolysis and incorporated in microparticles in 
network synthesis phase at concentration 12 wt%. For par-
tial substitution of  TEOS,  2.5 mol% (MP2) and 5 mol% 
(MP3) organomodified alkoxide was used. 5-FU was dis-
solved in the hydrolised sol before spray drying at concen-
tration of 12 wt%.
Characterization of silica microparticles
Prepared silica microparticles were characterized in 
a terms of mean particle size and particle size distribution 
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(Mastersizer 2000, Malvern Instruments Ltd., UK), surface 
morphology (SEM; Jeol-SEM6400, Japan) and drug load-
ing efficiency (HPLC Agilent 1200 with UV detector).
Ex vivo mucoadhesion studies was performed and the 
percent of mucoadhesion was determined with modified 
everted sac method (Santos et al., 1999). 
In vitro drug release studies
The dissolution test from prepared silica microparticles 
were carried out in closed glass tubes at 37 °C and 50 hori-
zontal strikes/min (horizontal shaker; Shaker Unitronik OR, 
Selecta. Spain). To compare the drug release under differ-
ent pH conditions, 50 mg of the microparticles  mixed with 
10 ml buffer solution with pH 1.2 and 10 ml buffer solution 
with pH 7.4. At appropriate intervals, 2 ml of samples were 
withdrawn, filtered through 0.45 μm membrane filter, and 
assayed by HPLC method.
In order to investigate the possible drug release mecha-
nisms, data obtained from in vitro drug release studies were 
analyzed using different kinetic models (Higuchi equation, 
the traditional power law and modified power law) (Viitala 
et al., 2007). Determined n value  indicated most probable 
drug release mechanisam, while goodness of fit was evalu-
ated using the r (correlation coefficient) values.
Results and discussion
Prepared particles were spherical with smooth sur-
faces and unimodal narrow size distribution. Median vol-
ume diameter of microparticles was 1.3876 μm (SPAN fac-
tor 1.745), 2.1405 μm (SPAN factor 1.133) and 3.3763 μm 
(SPAN factor 1.713) for MP1, MP2 and MP3, respectively. 
The content of 5-fluorouracil was 89.5 mg (MP1), 145.71 
mg (MP2) and 160.78 mg 5-FU/g microparticles (MP3). 
The experimental results suggest that addition of precursor 
3-aminopropyltriethoxysilane  in the silica sol influenced 
the inner structure of the matrix, resulting with increased 
porosity and hydrophilicity of the network, resulting in in-
creased average paricle size and drug loading efficiency.
The results from the in vitro drug release studies of 
TEOS based microparticles showed that the silica matrices 
are capable for controlled release of 5-FU during prolonged 
time periods. However, the dissolution rate was proportional 
to 5-FU loading, most probably because of possible strong 
5-FU – silica interactions that could initiate formation of 
matrix microdeformations during the sol-gel process, result-
ing in overall increase of matrix porosity (Djurdjic et al., 
2011). pH dependent drug release was noticed from TEOS 
based particles with lower percent of 5-FU (2 and 6wt%) 
(Djurdjic et al., 2010, 2011), but pH dependency was lost 
when higher percent of 5-FU (12 wt%) was incorporated in 
the processed silica sol during production of the micropar-
ticles, most probably because of increased matrix porosity. 
The drug release data showed the best fit to modified pow-
er law equation; r2  were 0.967 and 0.963 at pH 1.2 and pH 
7.4, respectively for sample MP1. Values n  for sample MP1 
(0.07 and 0.09 at pH 1.2 and pH 7.4, respectively) point to 
drug diffusion through very porous matrix without capacity 
for control of the  release during time. 
Organically modified microparticles showed increased 
burst and increased drug release rate compared to TEOS 
based microparticles. Burst release varied accordingly to the 
percent of APTES. For formulations with highest percent of 
APTES and drug loading, the total ammount of incorporated 
5-FU was released within few hours. The drug release data 
of organically modified microparticles show the best fit to 
modified power law model and r2  were 0.859 and 0.955 (at 
pH 1.2 and pH 7.4, respectively) for MP2. Values n  for sam-
ple MP2 (0.16 and 0.13 at pH 1.2 and pH 7.4, respectively) 
indicating to drug diffusion through highly porous system. 
Formulations with high percent of APTES were unable to 
control the 5-FU release in time. 
The presence of -amino groups at the surface of AP-
TES particles affected the intensity of interaction with cell 
membranes and lead to increased muco/bioadhesive poten-
tial relative to the unmodified TEOS particles (Djurdjic et 
al., 2011). Percent of mucoadhesion for organically modi-
fied microparticles increased with increased proportion of 
APTES (55.7% of mucoadhesion for MP3).
Conclusion
The addition of precursor APTES modifies the mor-
phology of silica microparticles, resulting in increased par-
ticle size, drug loading efficiency, muco/bioadhesive poten-
tial and 5-FU release rate compared to TEOS based parti-
cles. Mucoadhesive potential, burst release and dissolution 
rate for organically modified particles varied accordingly to 
the percent of APTES.
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Introduction
Periodontal disease is chronic inflammatory disorder, 
believed to be generally caused by pathogenic microorgan-
isms colonising the toot surface, amongst which the most 
popular are Actonobacilius actinomyycetem comitans, 
Bacteroides forsitus, Porphyromonas gingivalis, etc.,  be-
ing ~75% GRAM- anaerobic type. This disease affect the 
structural organs supporting the teeth, causing gingiva de-
tachment from the tooth and periodontal pockets forma-
tion as an ideal ecological niche for the bacteria prolifera-
tion. Doxycycline (DOXY) is a wide spectrum antibacte-
rial, bacteriostatic drug, effective against the aerob-/anaer-
obic type of GRAM+ and GRAM- bacteria as well as pro-
tozoa. It is a member of the tetracycline group, which is 
frequently used in dental treatments due to matrix metal-
lo-proteinase- inhibitory effect and strong activity against 
periodontal pathogens (Tamimi et al., 2008). DOXY is al-
most completely absorbed in duodenum with a bioavail-
ability of more than 80% with an average of 95%, and half-
life of absorption is 0.85±0.41h.
Various drug delivery systems have been trailed in 
periodontitis treatments, such as fibres, gels, injectable 
systems, micro-spheres/particles, strips, compacts, films, 
and nanoparticles (NPs) (Raheja et al., 2013). Use of the 
later was found advantageous over the others due to their 
size allowing penetration in extra- and intracellular areas, 
such as gingival fluid, bacterial cells, from the gingival sul-
cus to the underlying connective tissue and to periodon-
tal pocket areas below the gum line, being otherwise hard-
ly accessible by different systems (Segundo-Pinon et al., 
2000). Variety of materials have been proposed for drug-
NPs  processing; the important biomimetic merits of par-
ent biopolymer (the biocompatibility and presence of mul-
tiple functional moieties) makes the gelatin (GEL) NPs ef-
fective delivery vehicles to be applicable for diverse thera-
peutics (Khan and Schneider 2013). 
By this respect, presented study examines the applica-
bility of nanoprecipitation as preferable methodology for 
DOXY-enriched GNPs processing. The variations range of 
processing factors, being selected within primary, trial-er-
ror experiments (i.e. the pH of GEL solution, DOXY con-
centration and EDC/NHS concentration) were established 
with utilization of ˝one factor each time˝ experimental ap-
proach. The limiting factor in all cases was drug/biopoly-
mer precipitation. The influence of processing and formu-
lation factors upon the particle size, drug content and en-
capsulation efficiency were estimate for processed formu-
lation using MODDE software- generated experimental 
design. Chemical modification (crosslinking degree) and 
(in vitro) dissolution behaviour of selected DOXY-GNP 
formulation will be also discussed in this paper.
Materials and methods
Materials. GEL type B from bovine skin Bloom 225 
(Sigma Aldrich, Germany), Doxycicline hyclate (DOXI) 
(Tocris, UK), Lutrol F-127 was kindly donated by BASF, 
Germany. 1-ethyl-3-(-3-dimethylaminopropyl) carbodi-
imide hydrochloride (EDC) and N-hydroxysuccinimide 
(NHS) were purchased from Sigma Aldrich, Germany. All 
other chemicals were of analytical grade and were used as 
received, without additional purification.
GNPs preparation. 0.5% w/v GEL/H2O solutions 
were prepared at 50°C under moderate stirring for 1h. The 
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two separate solutions were prepared in parallel, and sub-
sequently adjusted to pH 7.5 and pH 9.5. 1mL of select-
ed solution was added dropwise to 10mL of 7% w/v Plu-
ronic F-127 solution in 96% EtOH, latter being vigorous-
ly stirred onto magnetic stirred with 700rpm. Addition-
al 10mL EtOH were added afterwards, just prior addi-
tion of different concentrations of cross linkers (20-25% 
w/w, relative to gelatin), being dissolved in 1.250 mL de-
ionised water just prior experiments. One set of samples 
were removed from the magnetic stirred, while the other 
half were subjected to mild stirring for 24h. In parallel with 
DOXY-free HNPs, the DOXY-loaded one slight modifica-
tion of above procedure, by simple mixing of pre- prepared 
DOXY and GEL solutions in quantities described within 
experimental design.
Characterization. Scanning Electron Microscopy /
SEM/ imaging and Differential Light Scattering /DLS/ 
analysis were performed to evaluate particle size, PDI 
and aggregation behaviour in different physiological me-
dia and particle morphology. Drug content (%), encapsu-
lation efficiency (%) and drug release (%) were quantified 
by optimised HPLC method (according to European Phar-
macopoeia 5.0). Uv-Vis Spectroscopy (using tri nitro-ben-
zene-sulfonic acid /TNBS/ reagent) and Attenuated Total 
Reflectance - Fourier Transform Infrared Spectroscopy /
ATR-FTIR/ method were used to identify the crosslinking 
efficiency. Dissolution test was performed in relevant (sa-
liva-like) conditions (phosphate buffer pH 7.4, 37°C, hor-
izontal mixing) using cellulose ester- based Float a Lyser 
device (MWCO 100kDa) (at particular time point samples 
were withdrawn and analysed by HPLC means and Uv-de-
tection /254nm/ of DOXY component).
Results and discussion
Physiologically stable drug-free, as well as DOXY-
enriched GNPs were successfully processed by optimised 
nanoprecipitation method, where EDC/NHS chemis-
try was introduced in final processing phase. This chem-
ical stabilization results in up to 70% crosslinking degree, 
identified by means of NH2 group’s reduction. Due to the 
presence of suitable chemical moieties and their respec-
tive pKa values, we assume that cross-linking occur not 
only between GEL molecules, but also between GEL and 
DOXY, and potentially, between the GEL and the Pluron-
ic F-127.  DOXI chemical ˝arrestment˝ was found to af-
fect its dissolution profile, which, for particular formula-
tion was estimate to 35% in 24 h period. Moreover, we 
observe significant effect of processing conditions, i.e. 
the mixing of DOXY-GNPs dispersions after nanoprecip-
itation influence on their aggregation behaviour, giving a 
clue for more complex interactions within examined, mul-
ticomponent system.
Resulting DOXY- integrated GNPs where visualised 
mainly as individual, spherically shaped NPs in 150-240 
nm size range, while, relatively high encapsulation effi-
ciency (up to ~40%) and drug content (25%) were identi-
fied for selected factors combination.
Conclusion
DOXY-enriched GNPs may be further applied as sin-
gle formulation or included in other delivery system (e.g. 
Guided Tissue/Bone Regeneration /GTR, GBR/ mem-
brane) and used in periodontal disease treatment. Nanopre-
cipitation methodology can be further explored in process-
ing of GNPs as carriers of different types of drugs, thus 
serving as a processing platform for facile, yet controlled 
engineering of drug delivery carriers.
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Introduction
The University Institute for Positron Emission Tomog-
raphy of the Republic of Macedonia is the first center in 
our country with opportunity for production of PET radio-
pharmaceuticals, which are prepared as sterile solutions for 
parenteral use. In the first line of production are includ-
ed the most used radiopharmaceuticals for PET imaging, 
such as: [18F] FDG; Na18F; [13N] NH3; [11C] Choline 
and 68Ga labelled somatostatin analogs.
Pharmacological approach of the PET radiopharma-
ceutical drugs – first line of production of The University 
Institute for PET of Republic of Macedonia
[18F] FDG
[18F] FDG is the most widely used PET radiopharma-
ceutical in clinical practice, especially in oncology, neu-
rology and cardiology, providing functional information 
based on tissue metabolism. This radiopharmaceutical is 
a structural analogue of 2-deoxy-D-glucose labelled with 
positron-emitting isotope 189F in the position 2 of the glu-
cose core structure. Widespread use of [18F] FDG is based 
on the principle of ‘metabolic trapping’ in the cancer cells.
After intravenous administration, [18F] FDG through 
the bloodstream is distributed into cells with the same 
mechanism as plasma glucose. It is actively transported 
into the cell mediated by a group of structurally related 
glucose transport proteins (GLUT). Tumor cells have an 
overexpression of GLUT compared to a normal cell, and 
therefore the uptake of [18F] FDG is increased. When the 
[18F] FDG is transported in the cells, it is phosphorylat-
ed in [18F] FDG-6-phosphate under the catalytic action of 
hexokinase and it remains metabolically trapped intracel-
lularly, because [18F] FDG-6-phosphate is not a substrate 
for glucose-6-phosphate isomerase, the enzyme that me-
tabolizes glucose (Scott et al., 2012).
The accumulation of [18F] FDG in the malignant cells 
generally is proportional to the metabolic activity of the 
cancer cells, which enables their detection by the PET 
scanner. [18F] FDG is non-specific cancer radiopharma-
ceutical. Increased accumulation of [18F] FDG occurs in 
processes such as inflammation, infection, especially sar-
coidosis, tuberculosis, fungal infections, and pneumonia 
(Jacobson et al., 2012).
Normally increased accumulation of [18F] FDG is ob-
served in the brain because the glucose is the main ener-
gy source for the brain. Also very important is the concen-
tration of glucose in the blood of the patient and it should 
be evaluated prior to administration of [18F] FDG. The in-
creased concentration of blood glucose causes elevated 
levels of insulin, which increases biodistribution of [18F] 
FDG in muscle and adipose tissue (Lindholm et al., 1993).
[18F] Na18F
[18F] Na18F PET/CT is diagnostic tool for imaging 
benign and malignant bone diseases. Fluoride ions are in-
corporated into the bone matrix at the bone surface pref-
erably in sites of newly mineralizing bone, such as during 
growth, infection, malignancy (primary or secondary), af-
ter trauma or during inflammation. 
The initial [18F] Na18F distribution represents blood 
flow that varies among different bones. Almost all deliv-
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ered [18F] Na18F is retained by bone after a single pass of 
blood. The uptake of fluoride ions is better in osteoblastic 
processes, while purely osteolytic processes have a low-
er uptake or even no uptake at all. [18F] Na18F is rapid-
ly cleared from plasma and excreted by the kidneys. The 
target organ is bone, but approximately 20% is excreted 
through the kidney in the urine in the first 1-2 hours (Cz-
ernin et al., 2010).
[13N] NH3
The main clinical application of [13N] NH3 radiophar-
maceutical is assessment of myocardial perfusion in pa-
tients with suspected or known coronary heart disease.
Following intravenous injection, [13N] NH3 rapidly 
clears from the circulation. It is taken up mainly by the 
myocardium, brain, liver, kidneys, and skeletal muscle. 
[13N] NH3 is extracted from the capillaries through the 
ammonia transporter. The accumulation in tissue is in pro-
portion to blood perfusion of the tissue.
In the cells, it is converted to glutamine and can diffuse 
out of the cell or be metabolized to glutamate and retained 
within the cell. [13N] NH3 undergoes a five-enzyme step 
metabolism in the liver to yield [13N] Urea, the main cir-
culating metabolite, which is eliminated from the body by 
the urinary excretion (Adeva et al., 2012).
[11C] Choline  
[11C] Choline is radiopharmaceutical for oncological 
PET imaging of tumors which overexpress choline kinase. 
Result of overexpression of choline kinase is increased lev-
el of phosphorylcholine by accumulation of free choline 
for cell membrane synthesis. [11C] Choline is accumulated 
preferentially within prostate cancer tissue, for that reason 
the most important application of this radiopharmaceutical 
in clinical practice is in visualization of this type of tumor. 
[18F] FDG is not first choice in visualization of the tumors 
in pelvis area, because of the low uptake, related to low-
er expression of glucose transport proteins and to the huge 
[18F] FDG urinary excretion (Lodi et al., 2012).
The maximal tumoral[11C] Choline uptake is related 
to primary tumor stage (Reske et al., 2006).After intrave-
nous administration, the peak of uptake is reached by five 
minutes and the activity is retained over the subsequent 30 
minute scanning period. The distribution of [11C] Choline 
is mainly to the pancreas, kidneys, liver, spleen and colon. 
The major metabolite detected in blood is [11C] Betaine 
(Roivainen et al., 2000).
68Ga labelled somatostatin analogs: [68Ga] 
DOTATOC, [68Ga] DOTANOC and [68Ga] 
DOTATАТЕ
The use of [68Ga] DOTATOC, [68Ga] DOTANOC 
and [68Ga] DOTATАТЕ radiopharmaceuticals for visual-
ization of neuroendocrine tumors is based on high affinity 
of the biological ligand to somatostatin receptors (SSTR). 
Natural somatostatin has low metabolic stability, therefore 
synthetic analogues with high affinity for SSTR and resis-
tant to enzymatic degradation are developed. (Velykian, 
2014).
[68Ga] DOTA SST analogues show a rapid localiza-
tion of the target site, fast blood and renal clearance. Ra-
dioactive metabolites are not detected in serum or urine af-
ter 4 hours. The maximum accumulation of activity in the 
tumor is reached 70 ± 20 min after injection. Excretion is 
almost entirely by the kidneys.
Conclusion
The mapping of the radiopharmaceutical distribution 
in vivo provides images of functional morphology of or-
gans in a non-invasive manner and plays an important role 
in the diagnosis of many common diseases associated with 
the malfunctioning of organs in the body as well as in the 
detection of certain type of cancers (IAEA, 2006).
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Definition of a cosmetic
The human need for improvement of the physical 
appearance is in constant increase year after year. This 
is revealed by various types of tests and ongoing market 
research. Hence, the production, the application and the 
consumption of products for personal hygiene as well as 
cosmetic products for care, protection and enhancement of 
the beauty are becoming more and more popular among 
large number of consumers.  
A cosmetic product is classically defined as any 
preparation that is applied to the skin, eyes, mouth, hair or 
nails for the purpose of cleansing, appearance enhancement, 
protection and/or for pleasant smell. Unlike drugs, which 
are used for treatment or prevention of a disease in the body, 
cosmetics are not considered to change or affect the body’s 
structure or functions. However, the distinction between 
drugs and cosmetics is sometimes not well defined. In spite 
of the considerable safety of and the high skin tolerance 
for the cosmetic products, adverse effects still occur from 
their use, which might be a result from the use of an 
inappropriately chosen product. Most often these adverse 
effects are of small or medium intensity and appear usually 
on the skin (Evaluation of the Cosmetics and Explosives 
Directives, 2007; Regulation (EC) N0 1223/2009). The 
research subject of this work is cosmetovigilance, which 
refers to a series of defined actions that have the purpose 
of revealing, estimating, monitoring, recording and 
preventing the potential undesirable reactions that appear 
as a consequence of the application of a cosmetic product. 
The concept of cosmetovigilance is recently added 
to the European Regulation for cosmetic products.  It is 
a form for objective monitoring of the unwanted effects 
of the cosmetic products, which are of public health 
interest. In contrast to the monitoring carried out by the 
industry, the aim of which is the safety of its own market 
for commercial purposes, cosmetovigilance has strictly 
medical aim (Vigan and Castelain, 2014).
The European regulation
The European resolution (ResAP (2006)1) from 2006 
laid the foundations of the cosmetovigilance system which is 
based on the reports from the recorded cases. The European 
Regulation (EU) 1223/2009 for cosmetic products, which 
was officially introduced on 11 July 2013, requires from 
all manufacturers to appoint a responsible person who 
would constantly monitor and record the implementation 
of the cosmetovigilance for the products available on the 
market. From 2013 onwards, the new European regulation 
demands that the serious undesirable effects which are 
reported to the competent authority to be also delivered to 
the competent authority of the other member states as well 
as to the responsible person for a certain cosmetic product 
in the company. The regulation for cosmetic products 
primarily addresses the safety of the products that are 
used by large populations of healthy consumers. However, 
the efficacy and the safety of cosmetic products are not 
reviewed or approved by national competent authorities 
before they are sold to the public. The identification and 
the analysis of the adverse effects related to cosmetic 
products is a process that is still to a large extent industry-
driven. It is a manufacturers’ responsibility to determine 
that the product and its ingredients are safe before they 
are put on the market. Moreover, manufacturers have the 
responsibility of collecting the reports for all the recorded 
adverse effects. Although manufacturers do their best 
to ensure safety of their products, it should be taken into 
consideration that a potential conflict of interests is always 
present (Moretti and Velo, 2008).
The aim of this work is to present the implementation 
of the cosmetovigilance system in the countries in Europe 
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and how it is employed in practice. Also this work would 
attempt to resolve two major problems: evaluation of the 
causes and the types of reports. At the same time it would 
present data gathered from conducted studies the aim of 
which was to estimate the appearance of adverse effects 
from the use of a cosmetic product, utilizing different 
methods for their detection, monitoring and prevention, as 
well as establishing a standard cosmetovigilance system.
Causality assessment
The definition of causality assessment is slightly 
different for French Health Products Safety Agency 
(AFSSAPS) and European Cosmetic, Toiletry and 
Perfumery association (Colipa). For AFSSAPS, causality 
“assesses the cause and effect relationship between a 
cosmetic product and a specific clinical and/or paraclinical 
manifestation” (2010). Causality must be established for 
each product individually. For Colipa “Causality assessment 
is particularly useful when the same product is involved 
in the occurrence of several cases of undesirable effects, 
when it makes it possible to determine the extent of a link 
of cause and effect between the cosmetic product and the 
undesirable effects observed and then to take these effects 
into account in the subsequent drawing-up of corrective 
measures such as investigations, recommendations on 
the proper use of the product, or regulations at national or 
European level (restrictions on use, warnings on packaging 
labels, limited concentration or prohibition) (Zweers et al., 
2012).
Several methods have been published. They are based 
on the analysis of evolving chronological and semiological 
elements. The results of relevant tests or of re-challenge 
tests can alter causality, for instance as regards contact 
allergy; appropriate patch testing provides a certain degree 
of causality. The AFSSAPS method is based on 6 criteria, 
divided into two groups, which are used to calculate a 
chronological score and a semiological score. The level of 
causality is determined using a decision table in which the 
scores are combined. The method has five levels of causality 
assessment: very likely, likely, not clearly attributable, 
unlikely and excluded. The causality assessment method 
by Colipa is based on three major criteria: symptomatology, 
chronology and results of specific tests. This method 
offers 3 levels of causality on the basis of a decision 
tree in which these criteria are combined: questionable, 
likely and very likely. Another method uses a flow chart 
as soon as the case has been reported, following a PLM 
(product lifecycle management) call approach. It is also 
based on chronological and semiological criteria and all 
the notifications can be analysed using 6 levels: irrelevant, 
not enough information, unlikely, possible, probable and 
certain. (The SCCPS notes of guidance for the testing of 
cosmetic ingredients and their safety evaluation, 2006).
The cosmetovigilance system is the right means of 
obtaining information on the safety of cosmetic products 
and their ingredients. It can be used by the competent 
authorities in Europe, which would confirm that the new 
directives ensure a high level of safety. Cosmetovigilance 
makes it possible to exclude and control potentially 
hazardous ingredients which are included in the product 
content, and thus develops the costumers’ trust and 
reassures them about the safety of the products available 
on the market.
References
Evaluation of the Cosmetics and Explosives Directives, Final 
Report (Cosmetics), 2007. Retrieved from
http://www.pedz.unimannheim.de/daten/edzh/gdb/07/study_dg_
entr_legislation_cosmetics.pdf (last accessed 15th February 
2016)
Moretti, U., Velo, G., 2008. Cosmetovigilance: The Beautiful 
risk. Verona: University of Verona-Clinical Pharmacology 
Unit Sautebin, L. Understanding the Adverse Effects of 
Cosmetics. Drug Safety 31, 433-436.
Regulation (EC) N0 1223/2009 of the European parliament 
and of the council of 30 November 2009 on cosmetic 
products: Directive 93/35/EEC amending directive 76/768/
EEC. Official Journal of the European Union, Retrieved 
from http://eur-lex.europa.eu (last accessed 3th February 
2016).
The SCCPS notes of guidance for the testing of cosmetic 
ingredients and their safety evaluation, 2006. Scientific 
Committee on Consumer Products (SCCP), 6th revision. 
Vigan, M, Castelain, F., 2014. Cosmetovigilance: definition, 
regulation and use “in practice”. Eur.  J. Dermatol. 24, 643-
649.
Zweers, P.G.M.A., Gilmour, N.J., Hepburn, P.A., Gerritsen, 
R.F., Van Puijenbroek, E.P., 2012. Causality methods 
in cosmetovigilance: comparison of Colipa and PLM 
versus global introspection. Regulatory Toxicology and 
Pharmacology 63, 409-417.
Poster presentations
Macedonian pharmaceutical bulletin, 62 (suppl) 447 - 448 (2016)
ISSN 1409 - 8695
UDC: 615.2:658.86/.87
Short communication
Good Distribution Practice for medicinal products  
Fjola Hadjihamza1*, Eleonora Pandova2, Violeta Bozinova1
1Medika Internacional DOO, St. 1732 No 4 Lamela V 1/1-5 Skopje, Macedonia
2Malmed, Agency of medicines and medical devices “St. Cyril and Methodius” No. 54, 1000 Skopje, Macedonia
* f.haxhihamza@live.com
Good distribution practice (GDP), as part of quality as-
surance system, for medicinal products for human use   in-
cludes myriad requirements for purchase, receiving, stor-
age and export of drugs intended for human consumption. 
GDP regulates the division and movement of pharmaceuti-
cal products from the premises of the manufacturer of me-
dicinal products, or another central point, to the end user 
thereof, or to an intermediate point by means of various 
transport methods, via various storage and/or health estab-
lishments.
The wholesale distribution of medicinal products is an 
important activity in integrated supply chain management. 
Today’s distribution network for medicinal products is in-
creasingly complex and involves a lot of people from dif-
ferent professional profiles. 
The GDP Guidelines establish appropriate tools to as-
sist wholesale distributors in conducting their activities 
and to prevent falsified medicines from entering the le-
gal supply chain. Compliance with these Guidelines will 
ensure control of the distribution chain and consequently 
maintain the quality and the integrity of medicinal prod-
ucts (GGDP, 2103).
The GDP Guidelines are intended to be applicable to 
all persons and outlets involved in any aspect of the stor-
age and distribution of medicines from the premises of the 
manufacturer of the product to the person dispensing or 
providing medicines directly to a patient or his/her agent. 
This includes all parties involved in trade and distribution 
of medicines, including the manufacturers of bulk, finished 
products, wholesalers, as well as others such as suppliers, 
distributors, Government institutions, international pro-
curement organization, logistic providers, traders, trans-
port companies and forwarding agents and their employees 
as well as health workers. The main parts of GDP are: 1) 
Organization and management; 2) Quality management; 3) 
Personnel; 4) Equipment and premises; 5) Documentation; 
6) Operations; 7) Outsourced activities; 8) Self inspections 
and 9) Transportation. In fact, the parts mentioned above 
form the GDP network. They interfere between each oth-
er forming a complex system in order to provide quality 
assurance that ensures that the quality of pharmaceutical 
products is maintained through adequate control through-
out the numerous activities which occur during the distri-
bution process. Every part of the GDP system is important 
to maintain the quality of the distribution chain. Regarding 
Organization and management, an adequate organizational 
structure for each entity in the chain of distribution should 
be defined with the aid of an organizational chart. The aim 
of this organizational chart is to have a clear view of the 
duties and responsibilities of each person involved in the 
process (GGDP, 2103; WHO, GDP, 2005).
Every individual involved in the process of distribu-
tion should have a written job description and at every lev-
el of the supply chain, employees should be fully informed 
and trained in their duties and responsibilities.
Training should be based on written standard operat-
ing procedures (SOPs). Personnel should receive initial 
and continuing training relevant to their tasks, and be as-
sessed as applicable, in accordance with a written training 
program.
The system for managing quality should encompass 
the organisational structure, procedures, processes and re-
sources, as well as activities necessary to ensure confidence 
that the product delivered maintains its quality and integri-
ty and remains within the legal supply chain during storage 
and/or transportation. The quality system should be ful-
ly documented and its effectiveness monitored. All qual-
ity-system-related activities should be defined and docu-
mented. A quality manual or equivalent documentation ap-
proach should be established. A responsible person should 
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be appointed by the management, who should have clear-
ly specified authority and responsibility for ensuring that a 
quality system is implemented and maintained.
This responsible person is designated by the whole-
sale distributor and should meet the qualifications and all 
conditions provided for by the legislation of the Member 
State concerned. A degree in pharmacy is desirable. The re-
sponsible person should have appropriate competence and 
experience as well as knowledge of and training in GDP 
(GGDP, 2103; GGDPBP, 2012).
Besides the responsible person there should be an ade-
quate number of competent personnel involved in all stag-
es of the wholesale distribution activities of medicinal 
products. The number of personnel required will depend 
on the volume and scope of activities. 
Wholesale distributors must have suitable and ade-
quate premises, installations and equipment, so as to en-
sure proper storage and distribution of medicinal products. 
In particular, the premises should be clean, dry and main-
tained within acceptable temperature limits.
Different medicines require different storage condi-
tions. There are medicines that should be stored following 
the cold chain regime and medicines that should be stored on 
room temperature, 2-8 °C and 15 -25 °C respectively (Com-
mission Directive 2003/94/EC, 2003; WHO, GDP, 2005).
Equipment and processes should be respectively quali-
fied and/or validated before commencing use and after any 
significant changes, e.g. repair or maintenance.
There are a lot of SOPs (standard operative proce-
dures) that determine every step of the processes that are 
conducted during the reception, storage and dispatch of the 
medicines.
All actions taken by wholesale distributors should en-
sure that the identity of the medicinal product is not lost 
and that the wholesale distribution of medicinal products 
is performed according to the information on the outer 
packaging. The wholesale distributor should use all means 
available to minimise the risk of falsified medicinal prod-
ucts entering the legal supply chain.
Also in compliance with the GDP standard qualifica-
tion of the supplier and costumers must be done.
Regarding the situations that can occur after the pa-
tient has received the medicines, there must also be a SOP 
on how to handle a complaint from the costumer as well 
as a SOP for medicines that are returned for some reason.
In order to provide a continuous quality management 
system, self-inspections must be conducted in an impartial 
and detailed way by designated competent company per-
sonnel. Audits by independent external experts may also 
be useful but may not be used as a substitute for self-in-
spection.
The transportation of the medicines is a very impor-
tant part of the distribution process, that is why the person-
nel in charge of transportation must be trained how to op-
erate with the medicines that should be distributed and the 
vehicles involved in the process must be suitably calibrat-
ed and mapped as well.
Considering all the facts mentioned above a con-
clusion can be made that the Good Distribution Practice 
(GDP) system is a very important tool in order to provide 
a better medicine quality regarding distribution factors and 
an improved health care system as well, which will con-
tribute for a higher safety of the patients (Commission Di-
rective 2003/94/EC, 2003; GGDP, 2103).
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Introduction
The correct botanical identification of plant raw ma-
terials is a basic requirement to guarantee safety and effi-
cacy of phytomedicines. The principal identification strat-
egies are based on macro- and microscopic analysis, com-
plemented by phytochemical methods. The methods are 
defined in national and supranational pharmacopoeias. Be-
sides these methods, identification by DNA sequences is 
in fast development and supplements classical methods in 
difficult matrices like e.g. powdered roots or even extracts 
(Novak et al., 2007). 
The DNA-sequence as tool to identify species
The sequence of the nucleotides in the DNA (‘DNA 
sequence’) is unique for each individual. However, re-
lated individuals share their DNA sequence to a big ex-
tent and the closer the relationship the higher the degree 
of sequence consensus. With a well-defined set of refer-
ence samples, mutations in short DNA pieces can be iden-
tified that are variable between taxa (e.g. species) but sta-
ble within the taxon. Based on these informative muta-
tions, unknown samples can be assigned to a specific tax-
on (Kress et al., 2005). Right now, it is not possible to eval-
uate and compare the whole genome of each sample with 
each other in cheap and fast routine analysis. Therefore, 
routine methods are developed based on small informative 
sequence parts, which are mostly in the size range of a few 
hundred base pairs.
Since molecular biology has very wide application 
area from biology to medicine and forensics the develop-
ment of new technologies is very fast. Therefore, also pos-
sible molecular biological methods for identifying medic-
inal plants and biological contaminations in plant material 
are numerous as exemplarily listed below: 
•	 Hybridization-based methods (examples: dynam-
ic allele-specific hybridization, molecular bea-
cons, single nucleotide polymorphism (SNP) mi-
croarrays)
•	 Enzyme-based methods (examples: restriction 
fragment length polymorphism (RFLP), PCR-
based methods (e.g. amplification refractory mu-
tation system (ARMS))
•	 Post-PCR methods based on physical properties 
of the DNA (examples: Single strand conforma-
tion polymorphism, denaturing HPLC, high-reso-
lution melting of the entire amplicon (HRM), use 
of DNA mismatch-binding proteins, SNPlex)
This presentation will focus on a few methodological 
examples, namely DNA sequencing, ARMS and HRM. 
‘Classical’ DNA sequencing (Sanger sequencing)
The ‘classical’ DNA sequencing delivers complete 
sequence information of short DNA pieces (amplicons). 
Comparing a sample sequence with the reference sequenc-
es (e.g. with phylogenetic methods), the sample can be 
identified (Kress et al., 2005). However, the classical as-
sessment by DNA sequencing is still time-consuming and 
relatively expensive, a fact that can be overcome by oth-
er DNA-based methods better suitable for routine analysis. 
Amplification-Refractory Mutation System (ARMS)
One method is the ARMS in which alternative PCR 
primers are developed in a way to bind only to the infor-
mative mutation (Little, 2001). Therefore, a PCR-product 
is only obtained if the primer fits to the desired mutation. 
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In gel electrophoresis following PCR, the presence or ab-
sence of the PCR product can be detected. This method 
was used to identify Valeriana officinalis increasing rou-
tine efficiency by combining several PCR reactions in one 
tube (Ruzicka et al., 2016).
High-Resolution-Melting-Analysis (HRMA)
Another method is HRMA. The principle of this meth-
od is the separation of the two DNA-strands (‘melting’ of 
the DNA) by slowly increasing the temperature at high-
ly constant rates (‘high-resolution’). The ‘melting’ can be 
measured by the decreasing intensity of a fluorescence dye 
intercalating the DNA resulting in a melting curve that is 
specific for a DNA sequence (Ruzicka et al., 2016). The el-
egance of this method besides its reliability in measure-
ment is that the fluorescence measurement takes place im-
mediately after PCR in the same machine and in the same 
tube as the PCR reaction. Sample manipulation is therefore 
limited to a minimum, which makes this method especially 
attractive for routine analysis (Schmiderer et al., 2010, Ru-
zicka et al., 2016). Another aspect of medicinal plant qual-
ity control is adulteration. HRM can be also used to de-
tect adulterations in complex mixtures (Mader et al., 2011, 
Schmiderer et al., 2015).
Conclusion
In the last years, many different methods to identi-
fy medicinal plants using different technology were de-
veloped and their stability and efficiency proofed. There-
fore, the way is open to consider them for their inclusion in 
pharmacopoeias as official testing methods in order to sup-
plement classical identification methods in difficult species 
or matrices.
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Introduction
The Austrian Drug Screening Institute (ADSI) is a 
research enterprise owned by the University of Innsbruck 
that offers screening services for pharmaceutical companies 
and academic institutions. The focus of the ADSI is on the 
hit-to-lead development, toxicology and “mode of action” 
studies in vitro. Focused libraries of natural or synthetic 
compounds are tested using an innovative high-content 
screening (HCS) approach that allows for the reliable 
identification of bioactive compounds or natural products. 
Development of screening models
The main goal is on the development and uses of in 
vitro assays where cultivated cells have similarly to the 
patient’s tissue in vivo. These in vivo-like in vitro models 
are used for the high-content screening of focused libraries 
of natural or synthetic compounds. Automated microscopy, 
multiplexing readouts, metabolomics and proteomics 
allow the detection of molecules of interest, their changes 
during incubation with active substances and give a hint on 
the “mode of action” of particular substance in biological 
pathways. 
Primary cell co-culture systems in vitro
The use of human primary cell based culture systems 
provides for more predictable and clinically relevant results 
that facilitate new insights into the biology and cellular 
processes in the presence of tested compounds. Primary 
cells have much more delicate growth requirements and 
are often more sensitive to toxic agents than long-term 
cell lines. Synthetic and natural compounds are typically 
screened for toxicity with high-throughput assays that 
utilize tumor cell lines and simple endpoints like cell 
death or inhibition of cell proliferation. Although these 
methods have allowed the screening of huge numbers of 
compounds, many of the lead compounds screened by 
such practices have experienced late drug failure due to 
unacceptable toxicity in the clinic. In our hands, functional 
assays using primary cells from particular tissues deliver 
more predictive data on efficacy and actual toxic effects 
on the given tissues and organs than assays using cultured 
tumor cell lines. Toxicity tests developed in the ADSI 
enable early detection of potential side effects before 
the lead compounds reach pre-clinical tests in animal 
models. Following cell culture systems using human 
primary cells are available: mesenchymal stem cells 
(MSC), MSC derived adipocytes, MSC derived skeletal 
muscle myotubes, primary hepatocytes, monocytes and 
macrophages. 
Laboratory automation
Robotics and automation are applied in an appropriate 
manner to achieve maximal information gain from a single 
experiment. Continuous monitoring with state-of-the art 
analytical and optical methods enables measurement of 
multiple cellular parameters modified by test substances 
including cell communication and transmission of signals. 
3D cell culture 
The pharma and biotech industry recognizes the 
importance of moving from 2D cell culture towards 3D 
tissue culture platforms to increase the in vivo relevance 
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of in vitro-based assays for drug discovery. Synthetic 
hydrogels constitute the first choice to cultivate cells in a 3D 
environment when high levels of versatility, reproducibility 
and biological relevance are requested. Thanks to the 
possibility to engineer desired physical and biochemical 
properties, these hydrogels are capable of supporting the 
growth and differentiation of a wide range of cell types 
and tissue models in 3D. The Automated Screening Assay 
Platform was developed in order to automate cellular and 
tissue culture assays for 3D-cell-assay analyses in a time-
resolved manner. 24/7 automation is achieved using robotic 
plate handling system, enabling users to schedule multiple 
runs of up to 40 cell culture plates in 96-well format. 
Metabolomics, secretomics and proteomics
The analytical division focuses on the identification 
of compounds and pathways causing or mediating the 
biological activity in the cellular test systems. Advanced 
liquid chromatography separation techniques coupled to 
mass spectrometry provide the basis for analyses of test 
substances by means of metabolomics and proteomics 
approaches. Separation of samples is performed using 
analytical and preparative UPLC-systems either directly 
hyphenated to detection systems, sample spotters (MALDI-
analysis) or fraction collectors. Mass spectrometry is used 
for the detection of small molecules by means of untargeted 
metabolomics in supernatants of cell co cultures, as well as 
in context of secretomics (proteins in cell supernatants) and 
or proteomics (proteins in cell lysates). Data mining and 
detailed analysis of acquired data facilitate the identification 
of compounds and pathways causing or mediating the 
biological activity in the cellular test systems. 
Biostatistics & bioinformatics 
All described biological and analytical methods 
produce huge amounts of raw data that have to be 
analysed properly. Acquired raw data from all systems 
are stored in the databank for further analyses. Biological 
and analytical data are processed using sophisticated 
biostatistics & bioinformatics tools and are then combined 
into comprehensive data sets providing reliable basis for 
the selection of drug candidates for later stages of drug 
development. 
Extraction & fractionation
 ADSI developed an expertise in the systematic variation 
of extraction procedures that allows for the development 
of pharmacologically active substance mixtures, such 
as plant extracts, that are optimized for their content of 
pharmacologically active ingredients. The fractionation 
of the samples using chromatographic techniques allows 
the rapid isolation of molecules of interest and the 
elucidation without dilation of their chemical structure. 
Special extraction procedures and chemical analytics allow 
optimization of the pharmacologically active substance 
mixtures in plant extracts. Further tailor-made assays and 
analyses are under development according to the demands 
of customers.
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Introduction
Mass spectrometry profiling is used to determine the 
changes occurring in a biological system in response to dif-
ferent conditions in order to better understand aberrations 
in the biochemical pathways involved (Rojo et al., 2012). 
The same methodology can be applied to the understand-
ing of the biochemistry of plants that show medicinal prop-
erties (Avula et al., 2014). When the investigation focuss-
es upon the small molecule level, then different methods, 
mass spectrometry platforms and analytical conditions are 
required due to the various chemical properties of the com-
pounds of interest, leading to numerous data files for each 
biological replicate. More recently, the application of hy-
phenated techniques such as ion mobility have led to bet-
ter separation of complex biological samples while the ad-
ditional dimension has added another level of complexity 
to the data generated (May et al., 2015). Once the identi-
ty of metabolites of interest has been determined, a critical 
requirement for the understanding of the biochemistry is 
the ability to map results directly to biochemical pathways 
(Bhat et al., 2014).  In this presentation, an overview of the 
analytical and software requirements will be discussed to-
gether with the application of biochemical pathway anal-
ysis in the interpretation of complex data sets, which can 
lead to a better understanding of the biology of medicinal 
plants.
Material and methods
Compounds were extracted through maceration of 
plant material in 50% (v/v) methanol:water. Samples were 
then filtered to remove the plant material and the extract-
ed compounds separated directly into a 6550 quadrupole 
time of flight mass spectrometer using a 1290 ultra-high 
performance liquid chromatography system (Agilent Tech-
nologies). The compounds were ionized by both electro-
spray (ESI) and atmospheric pressure chemical ionization 
(APCI) and spectra acquired in both positive and negative 
ionization mode. An Eclipse Plus C18 column (2.1 mm x 
150 mm; 1.8 um) was used for the separation with a lin-
ear gradient of 0.1% formic acid in water against 0.1% for-
mic acid in acetonitrile starting from 2% to 98% over 20 
minutes at a flow rate of 250 μL/min. The resulting data 
was initially extracted using MassHunter ProFinder using 
batch recursive feature extraction and comparative analy-
sis then performed using MassProfiler Professional. Sig-
nificant, reproducible changes detected were identified us-
ing the METLIN PCDL. The results were then visualized 
by mapping onto biochemical pathways using MassHunt-
er Pathway Analysis.
Results and discussion
A comprehensive approach to LC/MS analysis using 
ESI and APCI ionization and both positive and negative ac-
quisition together with cross-platform investigations, such 
as GC/MS, significantly increased coverage of the metab-
olome. The addition of ion mobility separation further in-
creased coverage through an orthogonal separation method 
based upon collision cross section of each compound. How-
ever, this approach also produced a high volume of data and 
complexity to the investigation. Initial recursive batch ex-
traction of the data files allowed significant data reduction 
while also improving the quality of the data that was then 
used for biological profiling. The extracted features were 
initially aligned and normalized followed by hierarchical 
clustering to check the reproducibility of biological repli-
cates. Significant and reproducible differences between test 
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groups were determined by analysis of variance, principal 
component analysis and fold-change filtering. The result-
ing features were identified and annotated onto biochemical 
pathways to aid visualization. This was facilitated by the 
METLIN database of metabolites (Scripps Institute) local-
ly installed on the instrument computer, which also allowed 
smaller subset databases to be generated based on the me-
tabolites involved in biochemical pathways of interest. This 
provided an advantage in allowing such subset databases to 
be used for targeted data extraction of the metabolites in-
volved in the pathways. These metabolites belonged to en-
ergy, fatty acid, amino acid, nucleotide, and secondary met-
abolic pathways. Multi-omic correlation analysis between 
genomic and metabolomics technologies allowed the iden-
tification of co-regulated entities, such as genes and me-
tabolites involved with amino acid, carbohydrate and fatty 
acid metabolism. Such a multi-omic approach provided ad-
ditional evidence of important pathways and increased un-
derstanding of specific pathways in the production of com-
pounds of medicinal relevance.
Conclusion
LC/MS provides a reproducible, accurate method of 
analyzing complex samples to determine the compounds 
present. The challenge is in the interpretation of the high 
volume of complex data generated. Recursive batch ex-
traction, biological profiling and pathway analysis allowed 
the data generated to be converted to knowledge in the 
form of identified metabolites, but more importantly, that 
knowledge could then be utilized to provide understanding 
of the important underlying biochemical pathways through 
pathway analysis.
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Introduction
Cannabis or hemp (fam. Cannabinaceae) has three 
main types:  C. sativa, C. indica, and C. ruderalis. It is a 
matter of divided opinion whether the genus consists of 
one or more species. Cannabis  plants  contain  at  least  489 
distinct compounds distributed among 18 different chem-
ical classes  including  cannabinoids,  nitrogenous com-
pounds,  amino  acids,  proteins,  enzymes,  glycoproteins, 
hydrocarbons,  simple  alcohols,  aldehydes,  ketones  and 
acids,  fatty  acids,  simple  esters  and  lactones,  steroids, 
terpenes,  non-cannabinoid  phenols,  flavonoids,  vitamins, 
and pigments  (Hillig and Mahlberg, 2004).
Nowadays, the pharmacologically active substance in 
cannabis - cannabinoids, comprises more than 70 differ-
ent phytocannabinoids, with potentially significant appli-
cations in medicine and pharmacy. The principal cannabi-
noids appear to be delta-9-tetrahydrocannabinol (i.e. ∆9-
THC, THC), cannabinol (CBN), and cannabidiol (CBD). 
Other cannabinoids found in cannabis are cannabigerol 
(CBG), cannabichromene (CBC), tetrahydrocannabivarin 
(THCV) and many others.
Therapeutic properties of cannabis have been known 
since ancient times and have been a source of fiber, food, 
oil, medicine, and inebriant substances. There are signif-
icant health benefits associated with the consumption of 
seeds and its derivatives, due to its well-balanced fatty acid 
spectrum and high value proteins. The therapeutic appli-
cations of cannabis and its derivatives have been studied 
by various world bodies, including the Scientific Commit-
tee of the House of Lords in Great Britain (1998), the Insti-
tute of Medicine in the United States (1999) and the Senate 
Special Committee on Illegal Drugs in Canada (Abramov-
ici, 2013). In order to assess the current knowledge on the 
therapeutic potential of cannabinoids, a meta-analysis has 
been performed through Medline and PubMed up to July 1, 
2005. Seventy-two controlled studies evaluating the ther-
apeutic effects of cannabinoids were identified. Research 
studies have clearly shown that cannabinoids are highly ef-
ficient, primarily in the treatment of nausea and vomiting 
and the management of chronic pain. For patients who suf-
fer from severe, chronic diseases, such as cancer and AIDS, 
cannabis has been shown to relieve several symptoms at 
the same time in more efficient way than some registered 
medicines. Besides, there is a great potential of cannabi-
noids to be applied for the treatment of many other path-
ological conditions, such as multiple sclerosis, Alzheim-
er’s disease, spinal cord injuries, Tourette’s syndrome, ep-
ilepsy, hypertension, glaucoma, although it is necessary to 
complete the last phases of clinical trials in order to regis-
ter these compounds as drugs, and to assure safe therapy 
for these diseases (Ben Amar, 2006).
Cannabis is a well-known drug and a controlled sub-
stance, which possession and use are illegal in most coun-
tries of the world. Nowadays, the use of cannabis and its le-
galization for medical use has become a worldwide trend. 
Laws and attitudes toward cannabis are changing these 
days. Legalization of cannabis use for medical purposes is 
a hot topic at the global level and in most countries there 
have been initiatives to amend the existing laws in order 
to make drugs based on natural ingredients of cannabis, 
as well as other related products, synthetically produced, 
available to patients (Sarmento et al., 2015).
Therefore, due to the increased global necessity of re-
search on the cannabis and for the sake of reinforcing the 
ability of the R. Macedonia to respond to the challenges 
arising from this issue, we have started a study for chem-
ical characterization of various cannabis products, mainly 
cannabis oil, as well as plant material from indigenous and 
foreign origin.
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Materials and methods
Dry overgorund parts, leaves and buds, from wild 
growing Cannabis sativa L., Cannabinaceae (tentative 
identification) were collected in central east part of R. 
Macedonia (RM), during two vegetative seasons, in 2014 
and 2015. Additionally, coarsely grounded dry leaves and 
buds of Cannabis indica L., Cannabinaceae (tentative 
identification) obtained by donation from patient for scien-
tific-research purposes were used. 
Cannabis oil (CO): various samples were obtained by 
donations from patients for scientific-research purposes.
0.1 g dry plant material or oil were dissolved in 10 mL 
n-Hexane and placed in ultrasonic bath for 15 min. After-
word were filtrated through disposable Econofilter 25/0.45 
μm RC pore size and injected in the GC system.
Standard substance solutions were made by dissolv-
ing standards of THC and CBD into methanol in following 
concentrations: 0.05 mg/mL and 0.02 mg/mL, respectively.
Samples were analysed with an Agilent 7890А Gas 
Chromatography system with FID detector and Agilent 
5975C mass spectrometer. HP-5ms capillary column (30 m 
x 0.25 mm, 0.25 μm) was used. Adams’ analytical method 
was used prolonged for 10 min at the end (Adams, 2007). 
The components were identified by comparing the mass 
spectra of components present in the samples with refer-
ence spectra obtained from NIST, Wiley and Adams’ mass 
spectra libraries. Quantification of the THC and CBD was 
done according corresponding standard substances.
Results and discussion
In the analyzed samples (CO and dry plant) the follow-
ing six cannabinoids were identified: THCV, CBD, CBC, 
THC, CBG, CBN and delta-6-tetrahydrocannabinol (Δ6-
THC). Five terpenoids compounds (α-pinene, camphene, 
limonene, trans-E-caryophyllene and germacrene B) were 
also detected with percentage share 1-6%. THC and CBD 
were predominant cannabinoids in all analyzed samples. 
Two types of samples can be distinguished: type 1-high in 
THC (73-95%) and low in CBD (0-16%) and type 2- low 
in THC (2-4%) and high in CBD (48-84%). 
The analysis of the wild growing cannabis from RM, 
revealed low THC (3.02-4.13%), followed by CBC (4.48-
6.88%) and high CBD content (72.30-73.73%), thus can be 
classified as type 2. On the contrary, C. indica plant sam-
ple was classified as type 1, appearing to be high in THC 
(86.38%) and low in CBD (0.71%). The relative abun-
dance of these and other cannabinoids can vary depending 
on a number of factors such as the Cannabis strain, the soil 
and climate conditions or the cultivation techniques. The 
content of THC in the indigenous cannabis was (0.159-
0.587%) and 19.23% in C. indica. Quite the opposite the 
CBD content varied from 3.11-7.22% in the wild growing 
cannabis and 0.122% in the C. indica plant sample. From 
an average of 2 151 samples collected in Europe between 
2006 and 2008, the average concentration of THC found 
was 0.075% (Sarmento et al., 2015). The analysis showed 
that most of the CO belongs to type 1 and the content of 
THC and CBD is very close to the distinguished percent-
age share.
Recently, changes of the Law for narcotic substances 
in RM were made concerning legalization of cannabis for 
medicinal and scientific purposes, in a way of cultivation, 
production of cannabis medical preparations as well as im-
port of pharmaceuticals and cosmetics, containing canna-
bis or cannabinoids.
Conclusion
Due to the legal constraints on the possession and use 
of cannabis, relatively little research on the medicinal qual-
ities of this plant has been conducted. Recently, due to the 
changes of the Law for narcotic substances in RM, an op-
portunity, for starting a scientific-research work on this 
plant and related products, has appeared. Preliminary re-
sults of the study for chemical characterization of various 
cannabis products, CO and cannabis plant material from 
indigenous and foreign origin are reported.
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Introduction
According to the International Narcotics Control 
Board of UN (Technical report 2015: estimated world 
requirements for 2016 and statistics for 2014), in the 
preceding decades, the demand for natural poppy alkaloids 
(morphine, codeine, thebaine and oripavine) is continually 
growing, which consequently implies on the necessity for 
advanced production. Opium poppy (Papaver somniferum 
L.) is a valuable source of therapeutic agents and has great 
historical and socio-economic importance for Republic 
of Macedonia. The excessive and continuously growing 
need for natural alkaloids from opium poppy was the main 
reason to launch a project for reviving the growth and 
utilization of opium poppy in Republic of Macedonia.
One of the goals of this project is to increase the 
ultimate yield of opium poppy alkaloids. The production 
of opium poppy in Macedonia is mainly based on local 
landraces and one commercial cultivar. The need to 
improve existing germplasm became apparent in the 
recent years. Consequently, the renewal and upgrade 
of the poppy breeding program was necessary. The 
first step was to establish a germplasm collection out of 
which promising lines could be selected. The genotypes 
in the starting collection should be grouped according to 
their characteristics. Therefore, analyses of the genetic 
diversity among poppy landraces and breeding lines 
from Macedonia and introduced poppy genotypes based 
on various morphological traits and determination of the 
extent of genetic diversity for proper utilization in the 
breeding program were performed (Ivanovska et al., 2012; 
Jankulovska et al., 2012, 2013; Stefkov et al., 2012). The 
overview of the advancements in the newly established 
opium poppy breeding program is presented.
Materials and methods
The field experiments were performed every year 
(2010-2015) near Skopje in R. Macedonia. Each year, 
number of genotypes decreased as a result of positive 
selection. During the vegetation different growth stages 
were observed, as well as the morphology of the genotypes. 
The agro-morphological characterization and assessment 
of the genetic diversity of opium poppy genotypes was 
based on 11 quantitative and 10 qualitative traits. Agro-
morphological traits were described according to UPOV 
descriptor (1999). The GC/FID/MS and the HPLC/DAD 
analysis were performed on poppy straw methanolic 
extracts, obtained by optimized ultrasonic agitation, for 
determination of the content of six alkaloids: morphine, 
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codeine, thebaine, oripavine, papaverine and noscapine 
(Acevska et al., 2012a, 2012b). 
Principal component (PCA) and cluster analyses (CA) 
were applied for variation evaluation of the most important 
quantitative characters. Positive selection of genotypes with 
desirable traits was continuously conducted (Ivanovska et 
al., 2012; Jankulovska et al., 2012, 2013; Stefkov et al., 
2012). 
Results and discussion
The pattern of morphological and productive variation 
between all accessions was evaluated through the 
qualitative (shape of capsule base, capsule ribbing, shape 
of capsule, capsule dehiscence, shape of stigmatic disc, 
surface of lobes, shape of lobes apex, seed color, petal color, 
petal base color) and quantitative (plant height, number 
of capsules per plant, number of stigma lobes, diameter 
of stigmatic disc, diameter of capsule, length of capsule, 
weight of main capsule, weight of seed of main capsule, 
seed yield per plant, capsule yield per plant, total yield per 
plant) characters. The analyzed opium poppy collection 
expressed broad variability for all investigated traits. 
Principal component (PCA) and cluster analyses (CA) 
served as effective tools for identification of genotypes 
with a combination of positive characteristics. The most 
variable traits were seed yield per plant and number of 
capsules per plant. 
Extraction procedure (liquid extraction using methanol 
as an extraction solvent, under reflux and ultrasonic 
agitation) followed by HPLC/DAD were developed and 
optimized for fast screening and in same time accurate 
assessment of the content of six alkaloids in the poppy 
straw samples using design of experiments (DoE). 
Chemical characterisation of the samples revealed high 
variability in the alkaloid content between the analyzed 
genotypes e.g.: morphine (0.07-1.65%); codeine (0.01-
0.66%); thebaine (0.05-0.17%); oripavine (0.001-0.07%); 
papaverine (0.007-0.62%); noscapine (0.005-0.63%).
The starting germplasm collection represented a good 
basis for successful selection of promising opium poppy 
lines with a combination of high seed and capsule yield as 
well as high alkaloid content.
Conclusion
The characterization of opium poppy germplasm 
revealed high variability among the evaluated genotypes 
considering agromorphological traits and alkaloid content. 
Genotypes which expressed high seed and capsule yield 
per plant and high morphine content were successfully 
identified. These genotypes will be considered for variety 
registration and production in R. Macedonia.
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Introduction
In the public’s mind, the word “dietary fat” has be-
come synonymous with obesity and heart disease. Conse-
quently, as nuts are typically high in fat, they are tradition-
ally avoided in an attempt to low blood cholesterol and the 
risk of coronary heart disease (CHD). However, there is 
increasing evidence that diets that include nuts may elic-
it cardio protective effects (Ryan et al., 2006). Different 
heath studies reported that women who consumed nuts five 
or more times a week have a 35% lower risk of total CHD 
compared with women who rarely eat nuts (Hu et al., 1998) 
and strongly support the link between consumption of nuts 
and the reduced risk of heart disease (Albert et al., 2002; 
Fraser et al., 1992). Additionally, several clinical studies 
have evaluated the effect of diets high in nuts on blood 
lipids level. In a randomized controlled study, Sabate et 
al. (1993) reported that men on nut diet had a 12% and 
16% decrease in total and in low density lipoprotein (LDL) 
cholesterol levels, respectively, compared to normal diet. 
Furthermore, the beneficial effects of nut consumption ob-
served in epidemiological and clinical studies underscore 
the importance of distinguishing different types of fat and 
have long established that the type of fat, but not the total 
amount of fat, predicts serum cholesterol levels. Although, 
nuts are high in fat, the predominant types are “healthy or 
good fats” such as mono and polyunsaturated fatty acids 
which lower the LDL cholesterol and hence the CHD risk 
(Hu et al., 2001).
In many cultures, pine nuts are traditionally used as in-
gredients in sauces, pastries or in desserts and are added to 
savory foods. The main species consumed in Europe are 
Pinus pinea, Pinus koraiensis, Pinus sybirica and Pinus 
gerardiana (Destaillats et al., 2011). Nowadays, very little 
is known about the consumption of pine nuts from Mace-
donian species probably due to the lack of data related to 
their chemical composition as well as fatty acids profile. 
Thus, the aim of the present study was to determine to-
tal oil content and fatty acid composition of these conifers 
nuts in order to obtain any information that will help to dis-
close their possible usage.
Materials and methods
Plant materials (pine nuts) of two pine species (Pinus 
peuce and Pinus nigra) were collected from two localities 
in R. Macedonia (Pelister and Berovo, respectively). Be-
fore oil extraction, plant material was dried and properly 
homogenized.
A known weight of sample (30 g) was extracted in a 
Soxhlet apparatus using petroleum ether as a solvent for 36 
hours. After isolation, the samples were evaporated to re-
move residual traces of petroleum ether (Trajkovic et al., 
1983). 
Fatty acid methyl esters (FAME) were prepared from 
extracted oil with potassium hydroxide in methanol ac-
cording to method described by Trajkovic et al. (1983) 
and were analyzed on Agilent 7890А Gas Chromatogra-
phy system equipped with FID detector and Agilent 5975C 
Mass Quadrupole detector. For that purpose, HP-5ms cap-
illary column (30 m x 0.25 mm, film thickness 0.25 μm) 
was used. Operating conditions were as follows: oven tem-
perature at 60 °C (2 min), 10 °C/min to 200 °C (2 min) and 
5 °C/min to 240 °C (7 min); helium as carrier gas at a flow 
rate of 1 ml/min; injector temperature 250 °C and that of 
the FID detector 250 °C. One μl of each sample was inject-
ed at split ratio 1:1. 
The mass spectrometry conditions were: ionization 
voltage 70 eV, ion source temperature 230 °C, transfer line 
temperature 280 °C and mass range from 50 - 500 Da. The 
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MS was operated in scan mode.
Identification of FAME was made by comparison of 
their retention times and mass spectral data with those ob-
tained from standards and from Nist, Wiley and Adams 
mass spectra libraries. The percentage ratio of FAME was 
computed by the normalization method of the GC/FID 
peak areas without any correction factors.
Results and discussion
The content of total oil isolated from pine nuts of 
Macedonian species yielded from 32.61% to 38.56% in 
nuts of Pinus nigra and Pinus peuce, respectively.
Data analysis of the chemical composition of exam-
ined oil samples revealed three different classes of fatty ac-
ids: saturated, monounsaturated and polyunsaturated fatty 
acids. The last one was dominant fraction in both species 
(65.25% in nuts of Pinus peuce and 58.65% in nuts of Pinus 
nigra), while the fraction of saturated and monounsaturat-
ed fatty acids were present in smaller amount (7.15% and 
26.10% in Pinus peuce and 14.70% and 25.56% in Pinus 
nigra, respectively). 
Total of 21 fatty acids were identified in the investigat-
ed oil samples isolated from Pinus peuce nuts which rep-
resented 97.79% of total oil. The most abundant fatty acids 
were linoleic acid (61.95%) which is classified as polyun-
saturated ω-6 fatty acid and oleic acid (24.98%) known as 
monounsaturated ω-9 fatty acid. Palmitic acid (3.51%) was 
dominant in the class of saturated fatty acids. Similarly 28 
fatty acids were identified in the oil samples isolated from 
nuts of Pinus nigra which represented 98.60% of total oil. 
Predominant fatty acids were the same linoleic (54.81%), 
oleic (22.80%) and palmitic acid (9.07%).
In terms of data concerning the chemical composi-
tion of oil isolated from pine nuts, only one study could be 
found regarding chemical composition of fatty oil isolated 
from black pine or Pinus nigra but still there is no avail-
able published data about the composition of oil obtained 
from nuts of Pinus peuce or Macedonian pine. According 
Bagci and Karaagacli (2004), the oil isolated from nuts of 
black pine from Turkey contains linoleic (47.10%), oleic 
(17.80%) and palmitic acid (4.70%) as major constituents 
what correlates to our findings.
Conclusion
Summarizing the obtained results, it is evident that 
pine nuts collected from Macedonian species are rich in 
oil that contain significant amount of unsaturated ω-6 as 
well as ω-9 fatty acids thus could be considered as their 
potential source. Moreover further investigations of chem-
ical composition should be made in order to provide more 
data for their possible medicinal, pharmaceutical or com-
mercial utilization.
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Introduction
Biogenic amines (BA) are basic nitrogenous com-
pounds formed mainly by decarboxylation of amino ac-
ids or by amination and transamination of aldehydes and 
ketones which in low concentration are part of metabolic 
and physiological processes of animals, plants and micro-
organisms. They are organic bases with aliphatic (putres-
cine (Put), cadaverine (Cad), spermine (Spm), spermidine 
(Spd)), aromatic (tyramine (Tyr), phenylethylamine (Phe)) 
or heterocyclic (histamine (His), tryptamine (Trp)) struc-
tures, can be classified as monoamines (Phe and Tyr), di-
amines (His, Cad, Put) or such as volatile (Phe) and non-
volatile (His, Cad, Put, Tyr, Spm, agmatine (Agm), Trp) 
biogenic amines. The main factors for formation of bio-
genic amines in foods or fermented foods are following: 
the availability of free amino acids, the existence of de-
carboxylase positive microorganisms and the presence of 
suitable pre-conditions that allow bacterial growth. Pres-
ent in higher concentration in foods, poses health risk for 
sensitive peoples and are cause for a number of adverse ef-
fects on human health such as rash, edema, headache, ur-
ticaria, rhinitis, respiratory and digestive problems (Lade-
ro et al., 2010). Some pharmacological effects of biogen-
ic amines which have appropriate precursors are: liberates 
adrenaline and noradrenaline, stimulates both sensory and 
motor neurons, controls gastric acid secretion (histamine); 
increases the cardiac output, causes lacrimation and saliva-
tion, increases respiration (tyramine); hypotension, depre-
ciation of the wine aroma, potentiate the toxicity of other 
amines (putrescine and cadaverine); releases noradrenaline 
from the sympathetic nervous system, increases the blood 
pressure, causes migraine (phenylethylamine) etc. (EFSA, 
2011; Shalabi, 1996). 
During wine production biogenic amines are already 
present in must obtained from sunny or rotten grape, be-
cause from vineyard it is not possible to get grape which 
will be free of biogenic amines (Gloria et al., 1998). Addi-
tionally the biogenic amines are accumulated during fer-
mentation, from yeast (alcoholic fermentation) or bacteria 
(malolactic fermentation) or from other naturally present 
microorganisms. According to that, the wines where the 
amino acids are present are ideal environment for produc-
tion of biogenic amines. The negative influence of biogen-
ic amines on human health is the reason why the world 
with high velocity works on detection and determination 
the level of biogenic amines in different foods and wines. 
Although, different methods such as high performance 
liquid chromatography (HPLC), gas chromatography (GC) 
and capillary electrophoresis (CE) are usually used for sep-
aration and detection of biogenic amines in foods, ferment-
ed foods and wines, the aim of this study is to develop and 
optimise the HPTLC method for qualitative and quantita-
tive analysis of five biogenic amines in few red and white 
wines as an alternative method with several advantages. 
Materials and methods
Samples and chemicals: A total 12 wine samples (six 
red wines and six white wines) were collected from differ-
ent winery and different aging period for determination of 
five biogenic amines. All chemicals and reagents were ana-
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lytical grade. The hydrochloride forms of biogenic amines 
were used as standards and purchased from Sigma, Merck 
and VWR from Germany. Stock solution of His, Cad, Put, 
Phe and Tyr dissolved in 10% EtOH was prepared (500 
ppm) and then for determination of calibration curve were 
prepared standard biogenic amines solutions: 0.1 mg/L; 
0.5 mg/L; 1 mg/L; 5 mg/L; 10 mg/L; 15 mg/L in which 1.6 
diaminohexan was added as internal standard. 
Preparation of wine samples for HPTLC analysis: liq-
uid-liquid extraction of biogenic amines from wines was 
made by following procedure: 5 mL of wine sample was 
mixed with 1 mL 5 M NaOH and 2 mL 5 M Na2CO3. Af-
ter that were added successively three times butanol (6 Ml 
+ 3 mL + 3 ml), and upper butanol layer was segregate and 
mixed 4 min. with 5 mL 0.1 M HCl. Separated lower layer 
was derivatised as followed: 200 μL sample was mixed in 
plastic tubes (2 mL) with 400 μL Dansyl chloride (50 mg/ 
10 mL acetone) and 200 μL NaHCO3 (1.5 g/ 10 mL H2O). 
Derivatisation was conducted at 60 °C on dark place for 60 
min. and after that in sample was added 500 μL toluene. 
The above layer was separated and put in vials for automat-
ic ATS4 application of the sample on the HPTLC plate. For 
elution of biogenic amines was used 10 mL mobile phase: 
Toluene:Chloroform:Trietylamine (10:6:5 by volume) and 
0.5% Tween 80. Saturation time was 40 min. at room tem-
perature, on dark, avoiding air movements. Overall elution 
time was 20 min. 
Instrumentation and conditions: HPTLC plates pre-
coated with silica gel 60F254 (20 cm x 10 cm) from Merck 
(Germany) were used as the stationary phase. The samples 
were sprayed on the HPTLC plate (spray-on technique) 
with the help of a sample applicator AUTOMATIC TLC 
SAMPLER 4 (ATS4, CAMAG). The chromatogram was 
developed in horizontal developing chamber (CAMAG). 
Detection of components from developed HPTLC plates 
was made with fluorescence Vilber Lourmat detector. Ob-
tained chromatograms were analyzed by software packag-
es Infinity 15.01 and Tina.
Results and discussion
Biogenic amines are of increasing interest to the wine 
industry due to proposed regulatory issues. Although 
HPTLC technique is relatively simple, it is difficult to 
make directly separations of biogenic amines from com-
plex wine matrix. For effectively separation of biogenic 
amines and solve the problem with effect of wine matrix 
into qualitative and quantitative routine analysis two deri-
vatisation agents FMOC-CL (9-fluoroenylmethyl chloro-
formate) and DAN-CL (dansyl chloride) were investigat-
ed.  After derivatisations and liquid-liquid extraction, bio-
genic amines in wine samples were simultaneously anal-
ysed by using CAMAG ATS 4 automatic sampler on pre-
coated silica gel 60 F254 plate and Vilber Louromat fluo-
rescent detector. After analysis of obtained results was con-
cludes that second development derivatisation and modifi-
cated liquid-liquid extraction protocol allowed effectively 
HPTLC separations and identification of biogenic amines 
in complex wine (red and white) matrix in concentration 
from 0.1 to 15 μg/mL. Results of analysis shown that all 
red wine samples had higher level of  biogenic amines than 
white wines. The validated method displayed excellent se-
lectivity, sensitivity, linearity, precision, accuracy and ro-
bustness.
Conclusion
According to the known literature data, analysis of bio-
genic amines by HPTLC method in wines has been used 
for the first time in Republic of Macedonia. The optimised 
HPTLC method compared with HPLC is less expensive 
for routine analyses of wines and enables reducing the use 
of organic solvents for derivatisation and for mobile phase, 
and provides an opportunity for determination of biogen-
ic amines without higher interference with the compounds 
from the complex red or white wine matrix. 
In conclusion, the proposed HPTLC method is suitable 
for application in analysis of biogenic amines in differ-
ent wines and could be considered as an alternative meth-
od and an important tool in routine analysis of biogenic 
amines in wine.  
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Introduction
An expanding tendency of global scale is the commit-
ment of food processors and consumers to reduce the use 
of synthetic chemicals in food preservation. Recently, there 
has been a considerable interest in extracts and essential oils 
from common culinary herbs, spices and aromatic plants 
with established antimicrobial and antioxidant potency. 
Among all, some representatives of the Lamiaceae 
family (oregano, marjoram, savory, sage, rosemary, thyme, 
basil ect.), possessing high polyphenols content and vol-
atile compounds, are often used to prevent different meet 
products from food born microorganisms or to stabilize fat 
and fat-containing foods. 
The direct addition of spices to food is the most com-
mon technological method, in order to improve its taste, 
smell and organoleptic effect, to increase the freshness of 
products and at least to preserve the products in a proper 
way (Kostic-Nikolic, 2013). However, these days numer-
ous efforts have been made to find alternative solutions to 
the aim of avoiding undesirable inactivation, and adultera-
tion of the smell and taste. Spraying, dipping, and coating 
treatment of food with active natural principles are current-
ly applied to product prior to packaging as valid options 
(Ahmed and Ismail, 2010). 
Therefore the aim of this study was to assess the us-
age of some Lamiaceae spices and its respective prepara-
tions and formulations as natural preservatives in treatment 
of processed meat products, as well as developing novel 
technological formulation (active packing) to maintain the 
food quality and to prolong their shelf-life.
Materials and methods
Dry leaves of Salvia officinalis and Rosmarinus offici-
nalis were purchased from Herbal Pharmacy-Alkaloid AD, 
Skopje. 
Dry leaves, essential oils (EO) and dry extracts (wa-
ter, alcoholic) were prepared according to the methods list-
ed in the monographs in the European pharmacopoeia or 
in the Cvetkovikj et al. (2013) paper, and added in differ-
ent meet products (minced meat, kebabs, and sausages) as 
preserving agents. 
The different plant preparations were chemically char-
acterized by Agilent HPLC-DAD and HPLC–DAD–ESI-
MSn to examine the polyphenols and for the volatile com-
pounds characterization Agilent GC-FID-MS system was 
used. 
Chitosan/sodium-triphosphate/pectin microparticles 
containing extract from sage were prepared using spray 
drying technique (Büchi B-290, Flawil, Switzerland).
Microbial strains: Staphylococcus aureus ATCC 
25923, Staphylococcus epidermidis ATCC 12228, Clos-
tridium sporogenes ATCC 19404, Escherichia coli ATCC 
25992, Klebsiella pneumoniae ATCC 700603 and clinical 
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isolates from patients (Listeria monocytogenes, Salmonel-
la enteritidis) were used. 
Disc diffusion (the zone of inhibition was determined, 
expressed in mm) and disk dilution (the minimal inhibi-
tory concentration-MIC was determinate) methods were 
used in order to investigate the antimicrobial activity of 
the preparations. 
To assess the antioxidant potential of the plant prepa-
rations and formulation, β-carotene linoleic acid assay was 
performed according to Wettasinghe and Shahidi (1996), 
with small modifications, while the thiobarbituric acid 
(TBA) test for secondary products of lipid oxidation sug-
gested by Tarladgis et al. (1960), and modified by Shahidi 
et al. (1987) was used.
Results and discussion
With HPLC–DAD–ESI-MSn qualitative analysis of 
the extracts were performed and 27 different compounds 
were detected. The identified compounds were classified 
in four groups: nine hydroxycinnamic acid derivates, 10 
flavone glycosides of luteolin and apigenin, two flavanone 
glycosides of hispidulin and six phenolic diterpenes, deri-
vates of carnosol. Rosmarinic acid was predominant com-
pound, present with more than 40% in the analysed sam-
ples. On the other hand, the ratio of the flavanone glyco-
sides and the phenolic diterpenes was almost equal.
The EO yield was 1.65% and complies with the min-
imal requirements of the European Pharmacopoeia. With 
GC/FID/MS in total 32 constituents were detected. The 
identified compounds were classified in three groups: ox-
ygenated monoterpenes (68.76%), followed by the mono-
terpenes fraction (12.91%) and oxygenated sesquiterpenes 
(7.36%). The sesquiterepene fraction and the diterepenes 
were detected in amounts < 3.00%. As principal EO con-
stituents were considered: camphor, 1,8-cineole, cis-thu-
jone, trans-thujone, camphene and viridiforol. The chem-
ical composition of the EO did not comply with the ISO 
9909 and GDC standards.
The gas chromatographic analysis of the dry extract 
revealed four different classes of terpenes compounds (ox-
ygenated monoterpenes, diterpens, oxygenated sesqutere-
penes and sesquterepenes). When compared to the EO it is 
evident that in the methanolic extracts the highly volatile 
monoterepenes were not detected. 
The activity of the preserving additives (dry minced 
leaves, dry extracts, essential oil and microparticles load-
ed with extract) – was evaluated by the growth inhibition 
and MIC for food borne microorganisms (four Gram-posi-
tive and three Gram-negative bacteria). Generally all addi-
tives showed better activity towards Gram-positive bacte-
ria that is in accordance with the literature. The most potent 
antimicrobial activity posses the EO, with lowest MIC (mg/
mL) determinate towards five microorganisms (S. aureus, S. 
epidermidis, L. monocytogenes, E. coli and K. pneumonia) 
that can be attributed to the presence of oxygenated mono-
terpenes (60% of EO), which is in correlation with the on-
line available data (Pierozan et al., 2009). The microparti-
cles showed antimicrobial activity alike EO. 
On the other hand, the extract incorporated into mic-
roparticles (1 mg/mL), showed strong antioxidant activi-
ty thus inhibiting 90% of the oxidation of the linoleic acid 
compared to the extracts that can be probably attributed 
to the synergistic action between the dry extract and the 
formulation properties of the designed carrier system. Ad-
ditionally, performing the TBA test, this formulation pos-
sesses the potential to protect the product from lipid ox-
idation, and to provide longer shelf-life storage with low 
TBA number (0.2029) compared with the other investigat-
ed preparations (Valesco and Williams, 2011).
Conclusion
Different preparations of dry plant leaves from sage 
and rosemary, showed antimicrobial and antioxidant 
activity that have potential to be used as natural 
preservatives for processed meat products. Additionally, 
novel technological approach was investigated in order to 
diminish the adulteration of the taste, smell and color on 
the meat as most common side effect of adding of natural 
additives. The obtained results suggest that the dry extract 
incorporated into microparticles can be considered as 
promising technological solution in preserving food.
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Introduction
Kosovo retains a great biological diversity, current-
ly around 1 800 plant species known to make up the flo-
ra of Kosovo, and these are deposited at the Herbarium 
of the Faculty of Mathematical and Natural Science of the 
University of Prishtina. However, the actual total flora of 
Kosovo is estimated to comprise more than 2 500 plant 
species (Krasniqi, 1998), which accounts for about 30% of 
the entire Balkan flora and 16% of the European flora, al-
though Kosovo covers only 2.3% of the Balkan land area 
(Mustafa, 1998). The diversity of aromatic plants in Koso-
vo isn’t fully known, as up to now no detailed studies were 
carried in this regard. It is estimated that in Kosovo are 
present more than 100 aromatic plant species which can 
serve as a source of essential oils.
Materials and methods
This review focuses on the phytochemical composi-
tion of essential oils obtained from wild population of aro-
matic plats in Kosovo and on their biological activity (an-
timicrobial and antioxidant activity). For that, previously 
published papers related to the chemical composition of 
the essential oil originated from Kosovo and their biologi-
cal activities were used to produce this review.  
Results and discussion
Several researches on chemical composition and/or 
their biological activity of the essential oil originated from 
Kosovo were carried by different working groups. The in-
vestigated species  belong to different family as follow: 
Cupressaceae (Juniperus communis L., J. communis subsp. 
alpina (Suter) Čelak and J. oxycedrus L.), Pinaceae (Ab-
ies alba Mill., A. borisii-regis Mattf., Pinus mugo Turra, P. 
peuce Griseb., P. heldreichii H. Christ, P. sylvestris L. and 
P. nigra J. F. Arnold, Picea abies (L.) H. Krasr.), Lamiace-
ae (Betonica officinalis L., Hyssopus officinalis L., Micro-
meria albanica (Griceb. ex K. Mal) Silić), Origanum vul-
gare L., Satureja montana L., Stachys sylvatica L., Thymus 
jankae Čelak., Th. pulegioides L. subsp. montanus, Th. to-
sevii Velen., Th. longicaulis Presl.), Hypericaceae (Hyper-
icum perforatum L.), Anacardiaceae (Pistacia terebinthus 
L.), Asteraceae (Achillea alexandri-regis Bornm. & Rud-
sky, A. chrysocoma Friv., A.millefolium L., A. holosericea 
Sm., A. lingulata Waldst. & Kit., Artemisia absinthium L., 
A. vulgaris L., A. alba Turra., Tanacetum larcatum (Gris.) 
Kanitz.). Betulaceae (Betula pendula Roth), Tiliaceae (Til-
ia cordata Mill.).  
Except chemical screening of the essential oil, in the 
plant species J. communis, J. oxycedrus, Pinus mugo, P. 
peuce, B. officinalis, S. sylvatica, S. montana, H. perfora-
tum, P. terebinthus the chemical variability of the essential 
oil among different population were analysed too (Hajdari 
et al. 2012a; 2012b; 2014a; 2014b; 2015). Essential oil ob-
tained from the following species: J. communis, P. mugo P. 
peuce, P. heldreichii, P. sylvestris, P. nigra, T.s longicaulis, 
M. albanica and P. terebinthus were tested for their antimi-
crobial, while essential oil obtained from P. mugo P. peu-
ce, P. heldreichii, P. sylvestris, P. nigra were tested for their 
antioxidant activity too. In scientific aspect the most inter-
esting analysed taxa for their essential oils are M. albanica 
and A. alexandri-regis, which are local endemic of Koso-
vo and are characterized with limited population size. Oth-
er threatens aromatic plant species are A. alba, P. peuce, S. 
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scardica and T. cordata, because of their uses as biological 
resource (listed in the IUCN Red List).
Conclusion
The group of aromatic plant species in Kosovo rep-
resents important natural resources in term of economi-
cal aspects, in other hand aromatic plants represent anoth-
er group of plants that are particularly threatened by over-
exploitation. 
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Homeopathy uses medicines made of plants, animals 
or minerals. During preparation these remedies are 
repeatedly diluted and vigorously shaken at each stage 
of dilution. Their final potency is described in decimal 
(D) or centesimal (C) scale of dilution. There are low, 
medium and high potencies within each scale, while all D 
potencies are weaker then C potencies. Though, opinions 
on categorization of potencies may differ, potencies up to 
six are generally considered low potencies (6D or 6C). 
Classical homeopathic treatment involves taking a 
history of the case and a detailed examination. It differs 
from conventional treatment since it uses principle 
of treating the whole patient rather than individual 
symptoms. Improvement is seen as bothering symptoms 
are diminished or absent and patient reports more energy, 
better sleep and mood. Benefits of using homeopathic 
remedies are multiple: they are not teratogen, non-toxic 
and do not produce side effects, in acute cases they act 
faster than conventional drugs, they may be effective in the 
cases where conventional medicine has nothing to offer, 
their shelf-life is very long and possible unlimited, they 
are well tolerated by patients of all ages, their application 
is not invasive in conditions where swallowing is difficult 
(e.g. vomiting, coma, epilepsy) and they have very low 
cost (Vithoulkas, 2008).
There are two main approaches in use of homeopathic 
remedies – the use of single remedy made in single 
potency and only of one substance (classical homeopathic 
remedies) and the use of several substances in different 
potencies combined together in such a way to cover specific 
disturbing symptoms (complex homeopathic remedies). In 
both situations the use of homeopathic remedies may or 
may not be associated with the use of conventional, mostly 
chemical drugs. This paper discusses specificity of these 
approaches within Serbian settings.  
In classical homeopathy whole patient is treated by 
taking in account his mental (e.g. disposition, attitude 
etc.), general (e.g. tolerance to coldness, heat, damp, 
wind etc.) and particular or peculiar symptoms (worse 
from movement, better by hard pressure, throbbing pain, 
pulsating pain, etc.). This information helps determine one 
homeopathic remedy that is prescribed in one potency, in a 
posology that is adjusted to the individual patient’s health 
state. This remedy may be so compatible with constitution 
of the patient that outcome is amelioration or complete 
disappearing of the troubling symptoms, while at the same 
time patient feels better on a general level. That is the main 
aim for patients that choose homeopathy– either because 
the conventional medicine has failed to help them or they 
prefer it as the gentlest way of healing during acute or 
chronic ailments.
Complex homeopathy, on the other hand, tries to 
bridge classical homeopathy and conventional medicine 
offering partial benefits of both. A complex homeopathic 
remedy, made of  several different substances, all in 
low potencies and combined with the aim that each is 
targeting different symptoms, can be used independently 
of a homeopathic consultation – either by advice of 
a conventional doctor, a pharmacist or as a part of self-
medication. Complex homeopathic remedy of different 
content may be commercialized under a brand name and 
can undergo research that proves its efficacy (Thinesse-
Mallwitz et al., 2015). A complex remedy cannot offer 
constitutional healing to the patient, but one of its benefits 
is that it attempts to achieve clinical efficacy in cases 
when a classical homeopathic consultation is not available 
(Malapane et al., 2014). Still, many classical homeopaths 
never prescribe complex homeopathic remedies. Their 
negative attitude is based on the premise that use of 
complex homeopathic medicine compromises effects of 
classical prescribing and spoils the case.
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Homeopathic remedies, either classical or complex, 
can be used in conjunction with conventional medicine, 
although their action may be less effective in that case due 
to the difference in the mechanism of action. Homeopathic 
medicine acts on body’s auto regulatory mechanisms. If 
these have already been influenced by powerful drugs, the 
action of homeopathic remedy may be impaired. However, 
in the case of the maintenance therapy for deficiency 
diseases (e.g. insulin, thyroxine, etc.) conventional 
medicine must not be discontinued during the homeopathic 
treatment. A homeopathy is an effective additional form of 
therapy, but in a multi-medicated patient it should be used 
with high doctor’s prudence and experience.
There are several specificities in homeopathy in 
Serbia. One-component remedies for classical homeopathy 
are not imported and readily available in pharmacies since 
they are not registered. Patients self supply themselves 
in a difficult manner - mostly from abroad (Cupara et al., 
2013). Moreover, legislation and education of homeopaths 
are roughly regulated and there are practical inadequacies. 
Many homeopaths due to the above mentioned problems 
have small volume of consultations on annual level, 
which consequently lead to less experienced practice. 
There is a lack of competent structural information about 
practitioners and patients have obstacles in choosing and 
reaching a homeopath. The additional difficulty is the self-
medication that patients practice, which is also a driving 
force for unjustified use of many conventional drugs, even 
in a case when a proper pharmacist’s advice is given. 
In this specific situation, in which patient cannot easily 
reach a competent homeopath of his choice or cannot easily 
obtain the prescribed remedy, together with tendency for 
unjustified self medication by conventional drugs and 
slow, but steadily growing number of patients that require 
alternative to conventional drug, a complex homeopathic 
remedy seems to be a possible choice that harms the least.
References
Cupara, S.M., Djordjevic, V., Jakovljevic, M.B., 2013. Current 
legal status and research on complementary and alternative 
medicine in Serbia. J. Altern. Med. Res. 5, 195-198.
Malapane, E., Solomon, E.M., Pellow, J., 2014. Efficacy of a 
homeopathic complex on acute viral tonsillitis. J. Altern. 
Complement. Med. 20, 868-873.
Thinesse-Mallwitz, M., Maydannik, V., Keller, T., Klement, 
P., 2015. A homeopathic combination preparation in the 
treatment of feverish upper respiratory tract infections: 
An international randomized controlled trial. Forsch. 
Komplementmed. 22, 163- 170. 
Vithoulkas, G., 2008. Homeopathy – Medicine for the 
new Millennium, International Academy of Classical 
Homeopathy, Alonissos. 
Poster presentations
Macedonian pharmaceutical bulletin, 62 (suppl) 471 - 472 (2016)
ISSN 1409 - 8695
UDC: 633.888:615.212.7
Short communication
Is cannabis addictive?
Svetlana Golocorbin-Kon1*, Nebojša Pavlovic1, Maja Đanić2, Mladena Lalic-Popovic1, 
Slobodan Gigov3, Nikola Jojic3, Momir Mikov2
1 Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, Novi Sad, Serbia
2 Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, 
Hajduk Veljkova 3, Novi Sad, Serbia 
3 Faculty of  Pharmacy, University Business Academy in Novi Sad, Trg Mladenaca 5, Novi Sad, Serbia
* magistrakon@orcon.net.nz
Cannabis is a tall plant with a stiff upright stem, 
divided serrated leaves, and glandular hairs. Cannabis has 
an extremely long history of use. Although cannabis is 
indigenous to Central and South Asia, it spread all over the 
world very early in human history. While humans in Taiwan 
were growing hemp as early as 8 000 BCE, the historical 
use of cannabis as a physical and psychological medicine 
began over 5 000 years ago. Therapeutic properties of 
cannabis have been known since ancient times, although 
the application has been limited mainly due to narcotic 
characteristics of this plant. Cannabis is also known as 
marijuana and numerous other street names such as ganja, 
pot, astro turf, grass, hemp, dagga, kiff, weed, hash, purple, 
etc. Hashish is related form of the drug made from the 
resins of the Indian hemp plant. Also called chocolate, shit 
or hash, it is on average six times stronger than marijuana 
(Mikuriya, 1969).
Nowadays, the pharmacologically active substanc-
es in cannabis - cannabinoids, are very interesting group 
of compounds with potentially significant applications 
in medicine and pharmacy. Research studies have clear-
ly shown that cannabinoids are highly efficient, primarily 
in the treatment of nausea and vomiting and the manage-
ment of chronic pain. For patients who suffer from severe, 
chronic diseases, such as cancer and AIDS, cannabis has 
been shown to relieve several symptoms at the same time, 
in more efficient way than some registered medicines. Be-
sides, there is a great potential of cannabinoids to be ap-
plied for the treatment of many other pathological condi-
tions, such as multiple sclerosis, Alzheimer’s disease, epi-
lepsy, hypertension, glaucoma, although it is necessary to 
complete the last phases of clinical trials in order to reg-
ister these compounds as drugs, i.e. in order to assure the 
safe therapy for these diseases (Grotenhermen and Russo, 
2002). Although tetrahydrocannabinol (THC) proved to be 
very efficient in the treatment of numerous diseases, new 
drugs have been intensively developing that tend to possess 
improved selectivity, better pharmacokinetic properties, 
and favorable relationship between desired pharmacolog-
ical effect and side effects. Laws and attitudes toward can-
nabis are changing these days. Legalization of cannabis use 
for medical purposes is a hot topic at the global level and in 
most countries there have been initiatives to amend the ex-
isting laws in order to make drugs based on natural ingredi-
ents of cannabis, as well as other related products, synthet-
ically produced, available to patients, that would certainly, 
based on the results of investigations, contribute to a better 
quality of patients’ lives (Clark et al., 2004). On the other 
hands, there is a question: “Is cannabis addictive?” What 
would be a proper answer? Cannabis, like other analgesics, 
can cause dependence and addiction. Over time, the per-
sistent overstimulation of the endocannabinoid system can 
cause changes in the brain that result in addiction. This is 
much more likely in people who start using cannabis (mar-
ijuana) when young and who are heavy users. An estimated 
9% of people who use cannabis become dependent on the 
drug. Teenage users have a 17% risk of becoming addicted, 
and 25-50% of regular, daily, users become addicted. Short 
term effects of cannabis are both pleasant and unpleasant 
and short term cannabis effects are not the same for ev-
eryone. Short term cannabis effects vary depending on the 
person’s size, experience with the drug, the amount of drug 
consumed and individual physiology. Desirable short term 
effects of cannabis are generally characterized as “high”. 
Pleasant short term cannabis effects include: euphoria, in-
toxication, relaxation, detachment, decreased anxiety and 
S5 PP 224
472
Maced. pharm. bull., 62 (suppl) 471 - 472 (2016)
Medicinal and aromatic plants
Po
st
er
 p
re
se
nt
at
io
ns
alertness, altered perception of time and space, intensified 
experiences, laughter, talkativeness. However, while those 
short term effects of cannabis are pleasant, short term ef-
fects of cannabis also include: depression, anxiety, panic, 
paranoia, amnesia, confusion, delusions, hallucinations, 
psychosis, mania, short term memory impairment, sudden 
increase in heart rate, at risk for heart complications, diz-
ziness, lack of coordination and muscle strength, lethargy, 
decreased concentration, slurred speech. It is also known 
that mental illness and cannabis use are linked, particularly 
to schizophrenia, but at this time it’s not clear whether can-
nabis causes, exacerbates or is simply a predictor of men-
tal illness. Even the short term effects of cannabis can in-
clude an increase in the severity of existing mental illness-
es. Long term effects of cannabis tend to be more negative 
than the short term effects. This is primarily because toler-
ance builds to the drug’s effects and the user takes great-
er doses of cannabis, increasing the short and long term ef-
fects of cannabis as well as its potential for abuse. Once 
tolerance to the drug is achieved, one of the long term ef-
fects of cannabis becomes cannabis withdrawal after us-
ing it and during periods of abstinence (http //www.drug-
freeworld.org/drugfacts/marijuana/short-and-long-term-
effects.html). The withdrawal syndrome begins on the sec-
ond day of stopping and may persist for two weeks. Dis-
continuation symptoms include anxiety, irritability, insom-
nia, stomach pain and decreased appetite. Sleep problems 
can potentially persist beyond that time frame. Cannabis is 
an illicit drug that has the potential to lead to abuse and ad-
diction. Despite the commonly held belief that herbal can-
nabis is harmless, its use is not without adverse effects and 
undesirable outcomes. The full extent of long-term health 
risks of chronic cannabis use is currently unknown. It is 
also important to note that “synthetic cannabis” is not ac-
tually cannabis (http://www.addictions.com/marijuana/). 
There are many research projects that are examining the 
medical benefits of individual cannabinoid chemicals de-
rived from or related to those in the marijuana plant, not 
the plant itself, although a few use unprocessed plant mate-
rial. Individual cannabinoid chemicals may be isolated and 
purified from the marijuana plant or synthesized in the lab-
oratory, or they may be naturally occurring (endogenous) 
cannabinoids found in the body and modified using other, 
non-cannabinoid chemicals (Boyd, 2013).
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Introduction
Common bean (Phaseolus vulgaris L.) is a legume 
crop native to Central America and Mexico. As huge di-
versity of bean varieties and landraces are cultivated at 
the Balkan countries, this region is considered as second-
ary centre of origin. Cooked bean’s seed is traditional dish 
in Macedonia and although the white seeded varieties are 
more popular, farmers also preserve landraces varied in 
shape, size, color and pattern of seeds. This valuable diver-
sity is passed through generations for more than two centu-
ries (Ivanovska et al., 2013; Maras et al., 2009).
Lately, the trend of balanced diet essential for healthy 
life is increasing and the consumption of many agricultur-
al crops is recommended. In this sense, bean is considered 
as healthy food due to its nutritional and health benefits 
(Mesina, 2014). Its main nutritional component is starch, 
predominantly consisted of amylose and amylopectin. The 
specific ratio of these two polysaccharides along with the 
slow digestion of amylose raises blood sugar more gradu-
ally and keeps it lower, compared to other types of starch. 
Thus, bean ranks very low according to the glycemic in-
dex and is beneficial particularly for diabetics (Barrett and 
Udani, 2011; Hutchins et al., 2012). Beans are one of the 
richest sources of plant proteins, out of which widely stud-
ied are phaseolin, lectins and protease inhibitors. In partic-
ular, they are among the only plant foods that provide sig-
nificant amounts of the indispensable amino acid lysine. It 
also contains insoluble fibers alpha-galactosides that cause 
flatulence in some individuals and substantial quantity of 
resistant starch which may be used in weight control. Both 
substances are fermented in the colon by beneficial bac-
teria, stimulating their growth and function as prebiotics. 
Beside, as a result of the fermentation short-chain fatty ac-
ids are formed, such as butyrate, acetate and propionate 
that may reduce the risk of colon cancer (Havenaar, 2011). 
Beans are also rich in various vitamins and minerals, like 
molybdenum, vitamin B9, iron, copper, manganese, potas-
sium, vitamin K1 and phosphorus. Other positive bioac-
tive compounds of beans are the antioxidants isoflavones, 
known as phytoestrogens (Konar et al., 2012) and antho-
cyanins found in the colored seed coat (Lin et al., 2008). 
Bean also contains negative compounds such as phytic 
acid (found in all edible seeds) which reduces the absorp-
tion of minerals and can be eliminated by soaking and fer-
menting the beans, and a toxic lectin phytohaemagglutinin 
which is eliminated with cooking (Queiroz et al., 2002).
Beside its nutritional value, several studies have linked 
bean consumption with reducing the LDL cholesterol and 
systolic blood pressure, as well as the risk of overweight 
and obesity (Papanikolaou and Fulgoni, 2008), metabolic 
syndrome and ischemic heart disease (Mesina, 2014). As 
starch blockers are completely inactivated when seeds are 
boiled at 100 ºC for 10 min., they are extracted from raw 
white kidney beans and sold like a weight loss supplement 
(Grube et al., 2014).
Having all this in mind the aim of this study was to 
explore the existing bean diversity in Macedonia starting 
with creation of a landrace germplasm collection. Further 
on, they will be tested for different plant characteristics in-
cluding their nutritive value. The final goal of this initiative 
is to promote bean consumption in everyday diet and to ex-
plore the potential of different landraces as raw material for 
production of supplements.
Materials and methods
In order to assess the existing bean diversity in Mace-
donia, a collection mission was initiated in 2015 by the re-
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searchers of the Department of Genetics and Plant Breed-
ing, Faculty of Agricultural Sciences and Food in Skopje. 
Seed samples of landraces and relevant information were 
collected in 237 villages from 58 municipalities and pre-
served at the Faculty’s Gene bank. Considering that the ac-
tivities are continuous, until now a total number of 1025 
samples are collected. They will be analyzed in a field ex-
periment to eliminate duplicates and to characterize and 
evaluate the landraces.
Results and discussion
The collected 1025 samples belong to three types of 
beans. Two types are common bean belonging to the spe-
cies Phasolus vulgaris L.: ssp. nanus or bush bean (BB) 
and ssp. volubilis or pole bean (PB). The third one is runner 
bean (RB) belonging to the species Phaseolus coccineus L. 
Regarding to the type, distribution of samples is 590 BB, 
395 PB and 40 RB, indicating that the last type is facing 
extinction. The analysis based on seed color only, showed 
that white seeded beans share 46.9% of the collection with 
310 samples of BB, 155 of PB and 16 of RB. Further di-
vision for the white seeded beans only has been done ac-
cording to the seed shape on 4 general categories: kidney, 
round, oval and compressed. Highest amount (123) of PB 
samples was with compressed shape (like the famous local 
landrace Tetovski grav). Within the BB collection, three 
types of samples are almost equally distributed: oval (120), 
kidney (101) and round (79). Out of the 177 samples of 
mono-colored seeds, landraces with brown seeds prevail 
(30; 25), followed by cream (19; 30) and green (2; 35) 
of PB and BB, respectively. Other colors were much less 
present with 21 black, 10 dark red, 3 dark lilac and 2 dark 
green-blue seeded samples. 
A category bicolored seed (26 samples in total) refers 
to seeds with oval or round shape that have one half white 
and one half colored seed. In this category, the colored half 
has various colors and often an additional pattern.
The rest of the collected samples (341) belong to the 
colored seeds with pattern. Many different combinations of 
size, shape, color and pattern type (speckles, stripes etc.) 
are registered. Most distributed are cream seeds with dark 
red or brown speckles, as well as brown seeds with dark 
brown or black stripes or speckles. If additional categories 
are added in the analysis in total, like size and shape of the 
seeds, color and type of the pattern, as well as vegetative 
characteristics of the plants, it is obvious that diversity of 
landraces is huge. 
Conclusion
From the preliminary analysis of the bean collection 
based on the seed color only with several parameters it may 
be predicted that more than 300 different landraces are col-
lected. Thus, the collection presents a valuable gene pool 
which will be further analyzed for all traits according to 
bean descriptors. Landraces with colored seeds will be par-
ticularly promoted for their nutritional and medicinal val-
ue.
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Introduction
Adenocarcinomas are the cancer of intestinal gland 
cells and the representative of more than 95% of colon and 
rectal cancers. “Adeno” is the prefix for gland and the intes-
tinal gland cells that line the inside of the colon and/or rec-
tum, where the adenocarcinomas typically start. A reduction 
in the incidence of colorectal cancer is possible although the 
screening techniques are imperfect (CTCA, 2016).
Flavonoids exert their anticarcinogenic effects by 
modulation of cellular proliferation, differentiation, apop-
tosis, angiogenesis and metastasis. Flavonoids are proved 
to be highly effective scavengers of most types of oxidiz-
ing molecules, including singlet oxygen and various free 
radicals, which are possibly involved in DNA damage and 
tumor promotion (Sandhar et al., 2011). Apoptosis is an 
important way to maintain cellular homeostasis between 
cell division and cell death. So, one of the useful strategies 
for anticancer drug development is the induction of apop-
tosis in cancer cells (Kwon et al., 2006).
It has been reported by pharmacological trials that 
some members of the genus Centaurea possess antiinflam-
matory, antimicrobial, antipyretic, cytotoxic, and immuno-
logical activities (Zengin et al., 2010). The present study 
was carried out to evaluate the apoptotic and antioxidant 
effects and to determine the possible mechanisms of cell 
death elicited by the extracts of Centaurea depressa on hu-
man colorectal adenocarcinoma cell line Caco-2.
Materials and methods
Plant material and extract preparation
C. depressa was harvested from field in Gölbaşı, An-
kara, Turkey. The identification of plant materials was con-
firmed by plant taxonomist, Prof. Dr. Zeki AYTAC, at the 
Department of Biology, Gazi University, Ankara, Turkey. 
A voucher specimen was deposited at the Herbarium of 
Gazi University, Ankara, Turkey. The aboveground tis-
sues were shade dried, powdered and 30 g samples were 
separately extracted with either methanol or water, using 
Soxhlet apparatus for 6 h and the extracts were filtered and 
concentrated in rotary evaporator. 
Cell lines and culture medium
Caco-2 cell lines obtained from ATCC were cultured 
in DMEM with 20% fetal bovine serum, 1% L-glutamine 
and 1% penicillin/streptomycin. The cells were incubated 
at 37 ˚C with 5% CO2 (Hadjiakhoondi et al., 2013). The 
cells were planted in microtiter plates at an initial density 
of 1 x 104 cells/well. After optimum confluence cells were 
exposed to CME or CWE (500 µg/mL) as determined to be 
the effective dose in former antiproliferation experiments 
for 48 h. Untreated cells were considered as controls.
Determination of the total antioxidant capacity
Cayman’s antioxidant assay was used to determine 
the total antioxidant capacity. The assay relies on the abil-
ity of antioxidants in the sample to inhibit the oxidation of 
ABTS (2,2’-Azino-di(3-ethylbenzothiazoline-sulphonate) 
to ABTS●+ by metmyoglobin. The capacity of the antiox-
idants in the sample to prevent ABTS oxidation is com-
pared with that of Trolox, a water-soluble tocopherol ana-
logue, and is quantified as millimolar Trolox equivalents. 
The ABTS produced by the cells after the extract treatment 
were measured according to the kit’s protocol.
Determination of superoxide dismutase (SOD) activity
Cayman’s superoxide dismutase assay kit was used. 
The kit utilizes a tetrazolium salt for detection of superox-
ide radicals generated by xanthine oxidase and hypoxan-
S5 PP 226
476
Maced. pharm. bull., 62 (suppl) 475 - 476 (2016)
Medicinal and aromatic plants
Po
st
er
 p
re
se
nt
at
io
ns
thine. One unit of SOD is defined as the amount of en-
zyme needed to exhibit 50% dismutation of the superox-
ide radical. The measurements were achieved according to 
the kit’s protocol.
Cell death detection assay
Apoptosis was determined by a Cell Death Detection 
ELISAPLUS assay. This kit is based on a photometric en-
zyme immunoassay and is used to detect DNA fragmen-
tation; mono- and oligonucleosomes released into the cy-
toplasm by biotinylated anti-histone- and peroxidase-cou-
pled anti-DNA antibodies, following the manufacturer’s 
protocol. The enrichment factor (total amount of apopto-
sis) was calculated by dividing the absorbance of the sam-
ple (A405) by the absorbance of the controls without treat-
ment (A490) which was equal to 1.
Detection of apoptosis associated morphological 
changes with Hoechst 33342.
Apoptotic effects of plant extracts were evaluated with 
Hoechst 33342 staining assay determining the morpholog-
ical alterations in the cells. Propidiumiodide (PI) is used to 
detect the necrotic cells. Cells were imaged with fluores-
cence microscope (Türk et al., 2011). Apoptotic index was 
defined as the percentage (%) of apoptotic cells and cal-
culated with the formula; number of apoptotic cells / total 
number of cells x 100 (Jackisch et al., 2000).
Statistics
Results are expressed as means ± Standard deviation 
(SD). Data were analyzed by one-way analysis of variance 
(ANOVA), and means were compared using the Tukey’s 
test, with P<0.05 considered as statistically significant. All 
experiments were independently repeated at least three 
times, with triplicate samples for each treatment.
Results and discussion
In our former experiments investigating the antipro-
liferation activity of the C. depressa methanol (CME) and 
water extracts (CWE) in varying concentrations (100, 250 
and 500 µg/mL), the results exhibited a dose dependent 
trend and both methanol and water extracts showed a sig-
nificant antiproliferative activity on Caco-2 cells with 500 
µg/mL concentration (63%, 69% cell death, respective-
ly). So this study was carried out to evaluate the apoptotic 
and antioxidant effects of the extracts and to determine the 
possible mechanisms of cell death elicited by the extracts 
of C. depressa (500 µg/mL) on Caco-2 cell line. Activi-
ties of total antioxidant enzymes were analysed using Cay-
mans’s kit, however no detectable change were observed 
as compared with the control cells (0.31±0.02 mM Trolox) 
(p<0.5). Similar results were also found in the SOD activi-
ty (0.8±0.03 U/mL) (p<0.5) and SOD activity also did not 
vary according to the extract type.
Apoptotic effect of CME and CWE (500 µg/mL) on 
the Caco-2 cells were determined by cell death detection 
after 48 hours incubation. Apoptotic effect of the CME and 
CWE are higher as compared to the control group with the 
enrichment factor of 1.69-fold and 1.98-fold respectively 
and the CWE has higher apoptotic effect than CME.
Hoechst 33342 staining revealed the morphological 
changes including cell shrinkage and nuclear condensa-
tion occurred with C. depressa; producing a more brighter 
blue light in apoptotic cells compared to normal cells that 
showed normal nuclear morphology. Dead cells had violet-
red fluorescence and showed no signs of chromatin con-
densation and apoptotic bodies. PI dye cannot cross cell 
membrane of dead cells, as opposed to apoptotic cells. The 
extracts may have inhibited cell growth via inducing apop-
tosis. Therefore apoptotic index was defined as the percent-
age (%) of apoptotic cells stained with Hoechst 33342 dye 
and the results indicate that CME and CWE exhibited sig-
nificant high apoptotic index following 48 hours treatment 
in favor of CWE (47% and 60% respectively).
Conclusion
C. depressa exhibited considerable apoptotic effects 
on Caco-2 cancer cell lines. Studies investigating the bio-
active ingredients of these herbal extracts would pave the 
way for mechanistic and translational studies in efforts to 
design novel anticancer drugs to be used alone or concom-
itant with other therapies to prevent progression of tumors 
and/or to treat them.
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Introduction
Cannabis or hemp (Cannabis sativa L. Fam. Cannabi-
naceae) is very popular nowadays because of its medical 
use. The plant Cannabis sativa L. is a source of a number of 
drug products. Marijuana represents the dried top parts of 
female hemp plant in flower. The main ingredient in hash-
ish is the resin secreted by the glandular hairs found all 
over the plant but mainly around flowers. In addition, the 
cannabis plant can be used as a source hemp fibers, as well 
as hemp seeds and fatty oil (Kovacevic, 2000). Throughout 
human history cannabis has been used for many purposes 
such as recreation, therapy, art, religion, food, medicine, 
as a textile. This plant was also used for treating insomnia, 
healing and also as painkiller. Each culture and subculture 
from prehistory up to now use this plant because it causes 
selective changes in consciousness of its consumers strict-
ly dosing what is beyond reality, and also for medical rea-
sons. Today, cannabis is forbidden in many countries be-
cause of its narcotic and negative influence to the nerve 
system. In some cultures cannabis is a protected mark, oth-
er cultures are its big admirers and third do not know or do 
not look on that way about cannabis (Tyler et al., 1988). 
Canada is first country in the world that has offers med-
ical marijuana to its patients since 2003. Therefore, there 
is an increased necessity of research on the history of can-
nabis for the sake of reinforcing the ability of pharmacists 
and physicians to respond to the challenges arising in the 
provision of professional services in order to facilitate hu-
man life. 
Chronology from the past to the present 
History of cannabis
Cannabis is one of the oldest psychoactive plants 
known to humanity. It grows as weed and cultivated plant 
all over the world in a variety of climates and soils. Histor-
ical records and archaeological materials date from 6000 
BC pointing out the use of cannabis seeds for food in Chi-
na. In 4000 BC textiles made of cannabis are used in Chi-
na. Remains have been found of cannabis fibers from this 
period and a century later. First recorded use of cannabis 
as a medicine was in 2727 BC in Chinese pharmacopoeia. 
In 1500 BC cannabis is cultivated in China for food and fi-
ber. Scythians cultivated cannabis and use it to weave fine 
hemp cloth. According to Herodotus they introduced can-
nabis into Europe (Tucakov, 1948). Bhang, composed from 
dried cannabis leaves, seeds and stems is mentioned in the 
Hindu sacred text Atharva veda as “Sacred Grass”, one of 
the five sacred plants of India. It is used medicinally and 
ritually as an offering to Shiva. Scythian tribes leave canna-
bis seeds as offerings in royal tombs. This closely matches 
the Herodotus reports on both ritual and recreation use of 
cannabis by the Scythians. The psychotropic properties of 
cannabis are mentioned in the newly compiled herbal Pent 
Ts’ao Ching which is attributed to an emperor Shen Nung. 
He recommended it against malaria, constipation, rheu-
matic pains, and absence of the spirit, female problems and 
a mixture of cannabis, resin and wine as an analgesic dur-
ing surgery (Booth, 2003). Cannabis as psychoactive plant 
is respected from Buddhists. In an old testament is men-
tioned as a sacred plant in holy anointing oil prepared from 
myrrh, laurel, cinnamon and “kaneh bosm“- identified by 
linguists as cannabis (Teodorova et al., 2005). Dioscorides 
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in 70 AD mentions the use of cannabis as a Roman medi-
cament while Galen in 170 AD alludes to the psycho activ-
ity of cannabis seed confections. The Jewish Talmud men-
tions the euphoria properties of cannabis. Ancient Greeks 
and Romans were also familiar with cannabis, while in the 
Middle East, use spread throughout the Islamic empire to 
North Africa. In the early 12th century hashish smoking is 
very popular throughout the Middle East. Cannabis is in-
troduced in Egypt during the reign of the Ayyubid dynas-
ty in 12th century. Arab traders bring cannabis to the Mo-
zambique coast of Africa in 13th century. Marco Polo dur-
ing his journeys from 1254-1324 gives reports that Assas-
sins are using hashish (Mez-Mangold, 1971). In 1545 can-
nabis spread to the western hemisphere where Spaniards 
imported it to Chile for its use as fiber. In North America 
cannabis, in the form of hemp, was grown on many plan-
tations for use as rope, clothing and paper. In the late 17th 
century hashish becomes a major trade item between Cen-
tral Asia and South Asia. Napoleon discovers that much of 
the Egyptians habitually used hashish. His soldiers in their 
returning to France bring the tradition with them in 1798 
year (Tucakov, 1948).
Medicinal properties of cannabis
Medicinal use of marijuana arrived in Europe from 
the East during the 18th century. It was brought to Eu-
rope much later, but it was not less popular. It reaches the 
high society very soon. In Paris, a club was open where 
many famous people, even Balzac, enjoyed marijuana. The 
first comprehensive description of the medical use of In-
dian hemp in Europe was written in 1830 by the German 
pharmacist Friedrich Ludwig Nees von Esenbeck. Until 
that point in time, use of marijuana for medical purpos-
es had remained at a low level. Thanks mainly to the work 
of W.B.O’Shaugnessy in 1839 marijuana become recog-
nized within European – school medicine. He used various 
hemp compounds in his investigations, partly with great 
success, against rheumatism, rabies, cholera, tetanus, con-
vulsions and delirium tremens. In America in 1840 medici-
nal preparations with cannabis base are available in Persian 
pharmacies. Hashish’s eater’s club is established in Paris 
in 1843 and after 1850 hashish appears in Greece (Booth, 
2003). Cannabis begins to prohibit for nonmedical use in 
the US during 1915-1927. The prestigious US Institute of 
Medicine published its report Medical Use of Marijuana in 
1999 (Weiner, 1990). Recent studies reviewed by Park et 
al. 2004 that marijuana, THC and other exogenous canna-
binoids exert potent effects on the endocannabinoid sys-
tem in both the gonads and during pregnancy (Frankhaus-
er, 2008). 
Conclusion
Cannabis preparations have been used as remedies for 
thousands of years and the active ingredients of the plant 
can be put to use in a multitude of medical conditions. Can-
nabis has been used throughout history in many different 
cultures to change mood, perception and consciousness. Its 
effects range from increasing creativity to provoking mys-
tical experiences, to heightening the capacity to feel sense 
and share. The reports established the evidence base sup-
port for the further examination of cannabis products for 
medical use. 
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Introduction
Juniperus communis subsp. alpina (Suter) Čelak (Cu-
pressaceae) grows mainly in the high-mountain regions of 
the in the Dinarides, northern Scardo-Pindic mountain sys-
tem, Rhodopes and the Balkan mountains (Filipowicz et 
al., 2006; Lakusic and Lakusic, 2011). Juniper cones have 
long been used in medicine, food and the cosmetic indus-
try. In the traditional medicine, preparations of juniper 
cones are used as folk remedy mostly against rheumatic 
complaints (Mustafa et al., 2012). In addition to the man-
ifold and diverse chemical composition of secondary me-
tabolites found in Juniper cone oil, it also has different bi-
ological activities, including hypoglycemic, carminative, 
antioxidant, antiseptic, and antibacterial activity (Hajdari 
et al., 2015). Chemical composition of essential oils of J. 
nana has been reported by several authors (Filipowicz et 
al., 2006; Proenca da-Cunhaa and Roquea, 1989). 
Previously we studied the composition of essential oils 
in two Juniperus species J. communis and J. oxycedrus re-
spectively growing wild in Kosovo (Hajdari et al., 2015). 
On the other hand, to the best of our knowledge, there are 
no published studies that address the composition of es-
sential oils obtained from J. nana, therefore the principal 
aim of this study was to investigate the chemical composi-
tion of the essential oils obtained from ripe cones, branch-
es and leaves of this plant harvested from wild population 
in Kosovo. 
Materials and methods
Plant materials (ripe cones) of Juniperus nana were 
collected in wild populations in locality Hajle, Bjeshket e 
Nemuna, Kosovo (Latitude, 42° 45’ 12’’ N; Longitude, 20° 
07’ 59’’ E; Altitude, 2029 m). Voucher specimens of each 
population were deposited with the Herbarium of the De-
partment of Biology, University of Prishtina. For the es-
sential oil extraction the plant material was air-dried in the 
shade at room temperature, prior to processing and chemi-
cal analysis. The ripe cones were chopped up in small piec-
es, and the essential oils were obtained by hydrodistilla-
tion using a Clevenger apparatus for 3 hours. The sam-
ples were stored in the dark at -18 °C in a freezer until 
further analysis. The yield of essential oil is expressed 
as the volume percentage of the dry mass of the air-dried 
plant material. GC/FID analyses were performed using an 
Agilent 7890A GC system equipped with an FID detector 
(Agilent Technologies). The separation was conducted on 
a HP-5MS column (30 m × 0.25 mm with a 0.25 μm film 
thickness). Helium was used as the carrier gas with an ini-
tial flow rate of 0.6 ml/min and then at a constant pressure 
of 50.0 psi. The front inlet was maintained at 250 °C in a 
split ratio of 50:1. The GC oven temperature was increased 
from 60 °C to 260 °C at a rate of 5 °C/min, and the FID 
was operated at 250 °C with an air flow of 350 mL/min 
and a hydrogen flow of 35 mL/min. The injection volume 
was 1.0 μL.
GC/MS analyses were performed using an Agile-
nt 7890A GC system coupled to a 5975C MSD (Agile-
nt Technologies). The ionisation energy was 70 eV with a 
mass range of 40 - 400 m/z. The separation was conduct-
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ed using the same column and temperature program as for 
the analytical GC.
The identification of each of the components of the es-
sential oil was performed by comparing their Kovat’s re-
tention indices with those from the literature. The Kovat’s 
index was calculated based on a linear interpolation of the 
retention times of a homologous series of n-alkanes (C9-
C28) under the same operating conditions. The components 
were also identified by comparing the mass spectra of each 
constituent with those stored in the NIST 08.L and WI-
LEY MS 9th databases and with mass spectra from the lit-
erature. Furthermore, some of the main peaks were iden-
tified by comparing the retention times and mass spectra 
with those of authentic constituents. The percentage com-
position of the oils was computed using the normalization 
method from the GC peak areas, calculated as the mean of 
three samples, without correction factors. 
Results and discussion
In total 75 constituents were identifies in the essential 
oils obtained from the juniper cones, leaves and branch-
es. Principal constituents were monoterpenes: α-pinene 
(24.7-36.7%); sabinene (8.2-22.9%); myrcene (4.3-
1.6%); D-limonene (2.4-4.4%); β-pinene (1.6-2.4%); ter-
pinolene (1.0-1.9%). Concentration of oxygenated mono-
terpene, terpinene-4-ol was 1.4-7.5%. Monoterpenes 
were followed by sesquiterpenes: germacrene D (2.0-
7.9%); α-caryophyllene (0.4-2.1%); bicyclogermacrene 
(0.3-2.2%); β-caryophyllene (0.1-1.9%); zonarene (0.5-
3.1%); δ-cadinene (0.7-3.9%); germacrene B (0.2-1.1%); 
β-elemene (0.3-1.9%), whereas concentration of the oxy-
genated sesquiterpene, 1-epi-α-cadinol, ranged from 0.7-
4.1%. In regard to the percentages of essential oil constit-
uents in different drug organs, experimental data revealed 
that monoterpenes were the most abundant constituents 
in berries, whereas the highest concentration of sesquiter-
penes and oxygenated sesquiterpenes was in branches. Re-
sults are in the accordance with previously published data 
where α-pinene and sabinene were principal components of 
J. nana (Filipowicz et al., 2006). In Portugese sample, the 
major hydrocarbon components of the oil were α-pinene 
(20.0%), δ-cadinene (10.4%), limonene (8.7%), and myr-
cene (8.5%) (Proenca da-Cunhaa and Roquea, 1989). 
Conclusion
The study of chemical composition essential oils ob-
tained from berries, branches and leaves of J. nana grow-
ing wild in the Bjeshket e Nemuna region in Kosovo repre-
sents a contribution in the field of the essential oil constit-
uents of the genus Juniperus. The main essential oil com-
ponents were a-pinene, followed by sabinene, myrcene and 
germacrene D. 
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Introduction
The interest in a natural and healthy lifestyle has moved 
the functional food under the spotlight. Functional food pro-
vides the health advantages because of their physiologically 
active substances (Maskovicet al., 2015). Phenolics and fla-
vonoids isolated from plants are one of the groups of func-
tional ingredient which can enhance health, increase psychi-
cal and mental well-being and scavenge free radicals (Men-
rad, 2003). It is known that family Lamiaceae, where sweet 
basil (Ocimum basilicum, L.) belongs to, has a strong anti-
oxidant activity because of great amount of phenolic and fla-
vonoid components. Phenolic antioxidants prevent free rad-
icals from the substrate by donating hydrogen atoms or elec-
trons (Kaurinovic et al., 2011). Sweet basil is widely used 
plant which could be used in the form of teas, essential oils, 
liquid extracts, and as a spice and has an important appli-
cation in the food, pharmaceutical and cosmetic industries. 
It is mostly used in a treatment of inflammatory diseases, 
headaches, constipation, respiratory infections, flu, cough, 
insomnia and also as sedative and anticonvulsant. It is es-
timated that about 60% of the total population of the world 
uses herbs and natural products and basil is recognized as 
important drug in their nutrition (Harvey, 2000). 
Materials and methods
Different extracts were obtained by various types of 
extraction: maceration with ethanol (30%, v/v) and dis-
tilled water (30 minutes and 24 hours), infusion (10 min-
utes), microwave (4 minutes) and ultrasound extraction 
(10 minutes). The amount of total phenolic compounds in 
the extracts was determined colorimetrically with the Fo-
lin–Ciocalteu (FC) reagent (Božin et al., 2008). The absor-
bance of the resulting solution was measured at 760 nm 
on a UV/Vis spectrophotometer. The concentration of to-
tal phenolic compounds was expressed as mg of gallic acid 
equivalents (GAE) per g of dried extract (DE), using a stan-
dard curve of gallic acid. Measurement of total flavonoid 
content in the investigated extracts was determined spec-
trophotometrically, using a method based on the formation 
of Al-flavonoid complex with the absorbance maximum at 
430 nm. The flavonoids content was expressed as l g of 
quercetin equivalents (QE) per g of dried extract (DE), by 
using a standard line. Antioxidant activity of extracts was 
determined using the DPPH method (Grujić et al., 2012). 
Absorbance was measured at 515 nm. The IC50 value, de-
fined as the concentration of the test sample leading to 50% 
reduction of the free radical concentration, was calculated 
graphically and expressed as μg of the extract/mL of the fi-
nal solution in measuring cell. Testing of the neutralization 
of peroxide and hydroxide radical were carried out. RSC 
value represents the percentage of neutralization of perox-
ide or hydroxide radical. The IC50 value which defined as 
the concentration of the test sample leading to 50% reduc-
tion of the radical was tested. Absorbance was measured 
at 515 and 562 nm. Lipid peroxidation intensity was also 
tested and absorbance was measured at 532 nm. The IC50 
values represented the concentration of the tested extract 
are responsible for 50% inhibition of lipid peroxidation. 
Chemical characterization of basil extracts was performed 
by high performance liquid chromatography (HPLC) using 
UV/Vis and fluorescence detectors. 
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Results and discussion
Basil extracts contained chlorogenic, p-hydroxyben-
zoic, caffeic, ferulic, vanillic, rosmarinic and cinnamic 
acid, rutin, quercetin, naringenin i epicatechin. From phe-
nolic acids, the most common in the extracts are rosmarin-
ic and ferulic acid which is in agreement with similar re-
search (Lee and Scael, 2009). Using a fluorescent (FAD) 
detector, epicatechin was identified. Based on these re-
sults, it can be concluded that the FAD is sensitive for the 
determination of certain flavonoids (epicatechin) com-
pared to UV/Vis detector which is in accordance with the 
literature (Donovan et al., 1999). Total phenolic content 
ranged from 0.53-118.19 mg GAE/g DE, and the highest 
yield was determined in extract obtained as infusion af-
ter 10 minutes. Flavonoid content ranged from 0.42-2.84 
mg KE/g, with peak in microwave extract after 4 minutes. 
IC50 values (concentration of analyzed sample that is re-
quired for 50% inhibition) varied from 11.72-210.39 μg/
mL for DPPH radical. The highest antioxidant capacity 
showed a sample obtained with 30% ethanol after 30 min-
utes. Testing the neutralization of the hydroxyl radicals, re-
sults showed that the IC50 values ranged from 11.44-57.86 
μg/mL. The highest scavenging activity showed a sample 
obtained by ultrasound by extraction after 10 minutes. Ex-
amination of antioxidant activity by neutralization hydro-
gen peroxide indicates that the samples obtained by dif-
ferent extraction methods have shown IC50 values ranging 
from 0.41-52.45 μg/mL. The highest antioxidant activity, 
showed sample obtained by extraction with 30% ethanol 
for 30 minutes. Results of examination of antioxidant ac-
tivity by the ability of inhibition of lipid peroxidase are 
summarized and IC50 values ranged from 1.41-46.99 μg/
mL. Lowest IC50 (the highest antioxidant potential) corre-
sponded to the sample obtained by the extraction with wa-
ter for 30 minutes. 
Conclusion
Basil extracts showed significant antioxidant activity. 
Sweet basil is a rich source of antioxidants that could con-
tribute to its disease-fighting potential. Extracts with the 
strongest antioxidant capacity were obtained by ethanol 
(30%, v/v) maceration during 30 minutes and infusion dur-
ing 10 minutes. Fluorescence detector of HPLC showed 
higher sensitivity for epicatechin determination than UV/
Vis detector.
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Introduction
Many plants have been traditionally used in folk med-
icine for cancer prevention or treatment. They may be-
long to food or medicinal plants. The research in last 10 
years has concentrated efforts to identify molecular targets 
for these natural components. Several major cell-signal-
ing pathways have been identified by which plant derived 
components influence carcinogenesis. 
Carcinogenesis may affect: transcription factors (nu-
clear factor-kapa B (NF-kB), activator protein-1 (AP-
1) and signal transducer and activator of transcription 
(STAT3), anti-apoptotic proteins (Bcl-2, Bcl-X1), pro-
apoptotic proteins (caspases), protein kinases (mitogen-
activated protein kinases (MAP)), cell cycle proteins (cy-
clins), cell adhesion molecules, cyclooxigenase-2 (COX-
2), lipoxygenase (LOX) and growth factor pathway. A big 
variety of plants employs modulation of NF-kB activity as 
the main pathway for anticancer effect. NF-kB can be acti-
vated by free radicals, inflammatory stimuli, cytokines, en-
dotoxins, radiation etc. This paper presents natural occur-
ring components for which evidence-based research identi-
fied some molecular targets in cancer prevention and ther-
apy (anethole capsaicin, curcumin, diosgenin, gambog-
ic acid, gingerol, resveratrol, thymoquinone, ursolic acid, 
zerumbone) (Aggarwal and Shishodia, 2006; Aggarwal et 
al., 2008; Nobili, 2009; Rajput and Mandal, 2012).
Selected plants
Anethole and derivatives (dithiolethione, eugenol, 
isoeugenol) present in fennel, anise, and camphor increase 
intracellular level of glutathione and glutathione S-trans-
ferase. Eugenol and isoeugenol are antioxidants, affect 
lipid peroxidation and inhibit arachidonic acid - induced 
tromboxane B2, due to which these components are used 
in adenocarcinomas (Aggarwal and Shishodia, 2006). Ane-
thole blocks NF-kB activation and affects inhibitory kappa 
B alpha kinase (IkBα). The suppression of carcinogenesis 
by anethole and derivatives is proposed to be by mediation 
of tumor necrosis factor (TNF) induced cellular respons-
es (Aggarwal and Shishodia, 2006; Aggarwal et al., 2008).
Capsaicin presents anticancer effects in culture cells 
(human tumor cells) and in animal models (skin, colon, 
lung, tongue and prostate cancer). Capsaicin lead to accu-
mulation of cells in G1 phase induced apoptosis and in-
hibited proliferation. The molecular mechanism included 
blocking TNF-mediated activation of NF-kB. In human 
multiple myeloma cells it also blocked the STAT3 activa-
tion pathway (Aggarwal and Shishodia, 2006; Aggarwal et 
al., 2008). 
Active compound of curcumin is polyphenol diferu-
loylmethane. It down regulates COX-2 and LOX expres-
sion, inducible nitric oxide synthase (iNOS), tumor necro-
sis factor (TNF), chemokines, cell surface adhesion mole-
cules, growth factor receptors (epidermal growth factor re-
ceptor - EGFR and human epidermal growth factor recep-
tor – HER2) and inhibits protein kinases (Aggarwal and 
Shishodia, 2006; Aggarwal et al., 2008).
Diosgenin, as a steroid saponin, is common for many 
different plants. It inhibits proliferation and straightens 
apoptosis in cell cultures (human colon cancer, osteosar-
coma, leukemia, rheumatoid arthritis). The proposed mo-
lecular mechanisms are disruption of Ca2+ homeostasis, 
release of apoptosis-inducing factors, modulation of cas-
pase-3, COX-2 and LOX activity, binding to chemokine 
receptor. It can suppress osteoclastogenesis through inhi-
bition of TNF-mediated activation of NF-kB (Aggarwal et 
al., 2008).
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Gambogic acid derived from resin of Garcinia indi-
ca inhibited gastric, hepatic breast and lung cancer. Some 
of the specific molecular mechanisms include inhibition of 
telomerase and telomerase reverse transcriptase mRNA ex-
pression and interaction with transferrin receptor. Since it 
inhibited the expression of gene products in apoptosis, pro-
liferation and angiogenesis, which are all regulated by NF-
kB it modulates on general level NF-kB pathway (Aggar-
wal et al., 2008). 
Gingerol has been tested mostly in prostate, gastric 
and breast cancer. Topically applied it inhibited COX-2 ex-
pression by suppression of NF-kB (Aggarwal and Shisho-
dia, 2006).
Resveratrol from grapes uses many different general 
molecular targets in apoptosis among which modulates ac-
tivity of NF-kB and MAP kinases (Aggarwal and Shisho-
dia, 2006).
Thymoquinone, a quinone from black cumin, sup-
presses proliferation of colorectal, ovarian, pancreatic and 
breast cancer, osteosarcoma, myeloblastic leukemia. It 
down regulates COX-2 and 5-LOX activity, iNOS, TNF 
and cyclin D1 which are all known to be regulated by NF-
kB. Thymoquinone prevented tumor angiogenesis both in 
vitro and in vivo (Aggarwal et al., 2008).
Ursolic acid is a triterpenoid present in many plants 
in different amounts, but considerably in rosemary. It sup-
presses expression of genes regulated by NF-kB, COX-2, 
LOX, iNOS, matrix metaloproteinase. It induces apoptosis 
by inhibition of DNA replication, inhibition of protein ty-
rosine kinases, activation of caspases and induction of Ca2+ 
release (Aggarwal et al., 2008).
Zerumbone, isolated from essential oil of wild ginger, 
has been effective in colon, breast and skin cancer. It inhib-
its activation of NF-kB and NF-kB-regulated gene expres-
sion. It also suppresses superoxide and nitric oxide gener-
ation and down-regulates COX-2, interleukin (IL-1) and 
TNF (Aggarwal et al., 2008).
Conclusion 
Plants known as spices, general food or medicinal 
plants have been investigated for anticancer activity. It was 
found that they target different molecules in carcinogene-
sis. Therefore, the contribution to antitumor effect of a sin-
gle plant may be due to synergic action of all active signal-
ing pathways that the plant exert. 
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Introduction 
Nowadays, food industry has a dual role: to provide re-
quired nutrients and to have favorable impact on humans’ 
health, protecting them from many chronic diseases. In the 
lights of that, biological active compounds deriving from 
plants are attracting more and more attention. Fruits from 
Sorbus genus are commonly consumed fresh or as tradi-
tionally prepared preservatives, such as jam, juice, jelly or 
wine. The same are also widely used as remedy in a treat-
ment of anemia, dyspepsia rheumatism and many digestive 
disorders. In spite of the widespread use in diet, preserva-
tives preparation, beverage manufacture and the traditional 
medicine, there are still very few reports concerning their 
detailed phenolic profile and biological activities. Name-
ly, within Sorbus genus, the most renowned species are S. 
aucuparia and S. domestica which are the most utilized as 
food. On the other hand, other species from Sorbus genus, 
such as S. intermedia (Swedish Whitebeam) are quite un-
explored and the literature data are also very limited. Over-
all, plant phenolics are recognized as phytonutrients with 
significant biological activities which are generally based 
on their ability to prevent oxidative stress and minimize 
oxidative cell injury. Thus, the aim of this study was a de-
tailed examination of 44 plant phenolics using LC-MS/MS 
technique and antioxidant potential of S. intermedia.
Materials and methods
Plant material was collected in November 2013, in 
Novi Sad, Republic of Serbia. Five extracts of fruits were 
prepared: water extract of fresh (WF) and air-dried sample 
(WD), methanol extract of fresh (MF) and air-dried sample 
(MD) as well as extract of traditionally prepared jam (J). 
For preparation of methanol extracts, 30 g fresh or air-dried 
fruits were grinded and extracted by maceration with 80% 
aqueous methanol (1 mL of solvent/ 0.1 g of plant materi-
al), constantly shaken at 120 rpm/min during 72 h at room 
temperature. For preparation of water extracts, 30 g fresh 
or air-dried fruits were grinded and extracted by maceration 
with boiling, distilled water (1 mL of solvent/ 0.1 g of plant 
material), constantly shaken at 120 rpm/min during 1 h at 
room temperature. After filtration, the solvents were evapo-
rated in vacuum at 40 °C. Crude residues were dissolved in 
hot, distilled water (10 mL/g). In order to remove the non-
polar compounds, the extracts were washed exhaustively 
with petroleum ether (fraction 40−60 °C) and concentrated 
to dryness under vacuum, yielding 9.84%, 26.87%, 6.84% 
and 31.59% for MF, MD, WF and WD extracts of S. inter-
media fruits, respectively. Jam was prepared according to 
Serbian traditional recipe by cooking fruits in boiled wa-
ter and crushing them during stirring. Afterwards, cooked 
fruits were sieved in order to remove seeds. The obtained 
product corresponds to definition of fruit purée. Further, in 
order to prepare jam the purée was boiled and 350 g of sug-
ar per 1 L of purée was added. The mixture was stirred un-
til appropriate consistency of jam. In order to prepare jam 
extracts, jam of S. intermedia, was weighed out (10 g) and 
evaporated in vacuum at 40 °C. Crude residues of jam ex-
tract were dissolved in hot, distilled water (10 mL of water/ 
1g of crude residue). Extract was then filtered and evapo-
rated in vacuum at 40 °C yielding 33.08%. Dried extracts 
of methanol, water and jam were dissolved in distilled wa-
ter to obtain 300 mg/mL stock solutions for evaluation of 
the total phenolic and flavonoid content, as well as antioxi-
dant activity. Additionally, dried extracts were dissolved in 
distilled water for LC-MS/MS analysis to obtain 20 mg/mL 
stock solutions. Determination of selected phenolics in ex-
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tracts of S. intermedia, was performed according to previ-
ously reported procedure (Orčić et al., 2014). For estima-
tion of total phenolic and total flavonoid content method 
reported by Beara et al., (2014) was conducted. In order to 
examine antioxidant activity of S. intermedia several dif-
ferent in vitro assays were performed. The scavenging ef-
fect on 2,2-diphenyl-1-picrylhydrazyl (DPPH), super oxide 
anion (O2
•-), nitric oxide (NO) and hydroxyl (HO•) radical, 
reducing power (FRAP assay) were tested according Beara 
et al. (2014).
Results and discussion
Presence of seven phenolics was confirmed using LC-
MS/MS analysis, with chlorogenic acid being the most 
abundant compound particularly in MF extracts. Further-
more, we detected presence of selected flavonols such as, 
amentoflavone, epicatechin and quercetin-3-O-glucoside 
in S. intermedia fruit extracts, while there was no prior 
study which specifically identified mentioned compounds. 
The total phenolic content in extracts of S. intermedia 
fruits ranged from 0.10-5.28 mg GAE/g of dw. It could be 
generally concluded that the highest content of total phe-
nolics were detected in air-dried extracts. Concerning the 
overall flavonoid content, similar amounts were found in 
all extracts. Having in mind that this is the first comprehen-
sive study of phenolic compounds in S. intermedia fruits, 
the obtained results are significant for further research and 
could support their usage as food supplement with heath 
benefits. 
Generally, the methanol extracts, especially fresh 
fruits showed the highest antiradical activity in all tests 
performed. Testing the neutralization of the hydroxyl radi-
cals, results showed that the IC50 values ranged from 0.18-
0.88 mg/mL. Methanol extract of fresh and air-dried fruits 
demonstrated a significant, same as standard antioxidant 
BHT, HO• scavenger activity. These facts are particular-
ly important because O2
•- react fast with other free radicals, 
such as NO•, and can cause biological damage occurring in 
many human diseases. Interestingly, jam extract was good 
as methanol extract of fresh fruit in neutralisation of DPPH 
radical, had a higher reducing power of extracts and was 
more active in neutralisation of NO• radical than water ex-
tracts.
Conclusion
Overall, according to the results presented it could be 
noted that extracts exhibited some antioxidant activity and 
jam showed to be rich source of antioxidants in everyday 
diet. Also, presented results firmly support everyday con-
sumption of Sorbus intermedia fruits as food with valuable 
health benefits.
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Introduction
Mountain tea (Sideritis scardica) is endemic to the 
Balkan Peninsula and is distributed in R. Macedonia, Bul-
garia, Turkey, Albania and Greece (Obon de Сastro, 1994). 
Flowering parts of S. scardica are widely utilized in Med-
iterranean folk medicine in the form of a decoction or in-
fusion. Various extracts of S. scardica are rich with flavo-
noids, phenolic acids, terpenes, phenylpropanoids (Kara-
pandzova et al., 2013; Petreska et al., 2011) and show com-
plex mineral composition (Karapandzova et al., 2013). 
However, the specific and particular aroma is maybe the 
most important reason for the wide use of the plant (Qa-
zimi et al., 2014a). Rosette leaves of mountain tea tradi-
tionally are not used (Qazimi et al., 2014b), although char-
acterized by specific aroma. There are no data about the 
volatile aroma compounds in the rosette leaves. To ana-
lyze these compounds a refined method of headspace sam-
pling hyphenated with GС/FID/MS analysis can be uti-
lized (Watson, 2005).
Therefore, the aim of this work was the determina-
tion of the volatile aroma compounds in the fresh and dried 
spontaneous and cultivated rosette leaves of S. scardica us-
ing a headspace (HS) method with GС/FID/MS.
Materials and methods
Plant material: The rosette leaves of S. scardica were 
collected in three different localities in R. Macedonia dur-
ing the summer of 2012. The spontaneous samples were 
collected from Ljuboten (Shara Mountain) and Gurgur-
nica (Suva Gora). One cultivated sample was collected 
from Dren (near Prilep). The plant material was air dried, 
packed in paper bags and kept in a dark and cold place un-
til analysis. 
Analyses of aroma compounds
GC and GC-MS analyses: 0.3 g of fresh or dried ro-
sette leaves was put in sealed vials, warmed for 5 min. 
and the gas phase (highly volatile compounds) was inves-
tigated on Agilent 7890А Gas Chromatography system 
equipped with flame ionization detector (FID) and Agile-
nt 5975C Mass Quadrupole detector as well as capillary 
flow technology which enable simultaneous analysis of 
the sample on both detectors. HP-5ms (30 m x 0.25 mm, 
film thickness 0.25 μm) capillary column was used. Oper-
ating conditions were as follows: oven temperature 60 °C, 
20 °C/min to 280 °C; helium as carrier gas at a flow rate of 
1 mL/min; injector temperature 260 °C and FID temperature 
270 °C. 1000 μL of gas phase was injected at split ratio 1:1. 
The mass spectrometry conditions were: ionization volt-
age 70 eV, ion source temperature 230 °C, transfer line 
temperature 280 °C and mass range from 50-500 Da. The 
MS was operated in scan mode. 
Headspace method: Incubation temperature 80 °C; in-
cubation time 5 min; syringe temperature 85 °C; agitator 
speed 500 rpm.
Identification of components: Identification of the 
components was made by comparing the mass spectra of 
components with those from NIST, Wiley and Adams mass 
libraries, by AMDIS (Automated Mass Spectral Deconvo-
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lution and Identification System) and by comparing litera-
ture and estimated Kovat’s (retention) indices that were de-
termined using a mixture of a homologous series of normal 
alkanes from С9 to С25 in n-hexane, under the same condi-
tions. The percentage ratio of the components was comput-
ed by the normalization method of the GС/FID peak areas 
and average values were taken.
Results and discussion
Total of 21 and 24 individual components were iden-
tified in the fresh spontaneous (f-Ss) and in the fresh cul-
tivated (f-Sc) rosette leaves of S. scardica, representing 
96.62-100% and 98.05% of the total content, respective-
ly. Data analysis of the chemical composition revealed five 
different classes of components: monoterpene hydrocar-
bons (MH) 40.51-41.97% and 48.49%, oxygen contain-
ing monoterpenes (OM) 3.65-4.17% and 4.46%, sesqui-
terpene hydrocarbons (SH) 42.07-47.66% and 30.31%, 
oxygen containing sesquiterpenes (OS) 0.57-3.12% and 
0.18%, alcohols (AL) 4.54-8.36% and 14.21%, respec-
tively. The prevailing components in f-Ss and f-Sc sam-
ples were: β-pinene (21.15-24.79% and 27.63%), α-pinene 
(11.42-12.69% and 14.09%) and limonene (3.40-7.49% 
and 6.53%) from the MH fraction; followed by the SH: 
germacrene D (21.05-21.82% and 14.53%) and trans- 
caryophyllene (10.86-13.00% and 9.76%), and the alco-
hol, 1-octen-3-ol (4.54-8.36% and 14.21%). The represen-
tatives from the OM and OS fractions were considered as 
minor constituents (< 2%). 
Total of 14 and 16 individual components were iden-
tified in the dried spontaneous (d-Ss) and in the dried cul-
tivated (d-Sc) rosette leaves of S. scardica, representing 
89.36-96.81% and 98.37% of the total content, respec-
tively. MH formed 40.32-55.43% and 92.43%, OM 2.99-
26.16% and 1.72%, SH 17.6-23.59% and 4.22%, respec-
tively. The OS fraction was found only in the d-Ss sam-
ples, 10.35-12.73%. The most abundant components in 
d-Ss and d-Sc samples were monoterpene hydrocarbons: 
β-pinene (21.25-23.12% and 38.89%), α-pinene (19.07-
19.81% and 33.05%) and limonene (up to 6.68% and 
13.01%). The higher abundance of OM: trans-pinocarveol 
(2.99-10.03%), myrtenal (up to 6.37%), pinocarvone (up to 
5.09%), SH: germacrene D (4.91-9.29%), trans-caryoph-
yllene (4.34-5.90%), δ-cadinene (3.03-5.93%), α-copaene 
(2.47-5.32%) and OS: caryophyllene oxide (6.76-9.35%) 
was specific only for the dried spontaneous samples of ro-
sette leaves. The number of components found in d-Sc was 
larger than in d-Ss. Also, the share of the classes of compo-
nents in d-Sc (MH > SH > OM) differed from d-Ss (MH > 
OM > SH > OS). 
Conclusion
Generally, f-Sc and d-Sc contain larger amount of 
monoterpenes, but smaller amount of sesquiterpenes than 
f-Ss and d-Ss. Only minor differences were revealed in the 
qualitative composition of the aroma volatiles between 
spontaneous and cultivated rosette leaves of S. scardica. 
Furthermore, there was almost no difference in the chem-
ical profiles of the aroma components between fresh and 
dried rosette leaves, except 1-octen-3-ol, that was present 
only in fresh rosette leaves of S. scardica. 
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Introduction
Sideritis scardica Griseb. is wild, hardy flowering pe-
rennials, known as mountain tea and is often used for pre-
paring teas to cure common cold, to alleviate sinus con-
gestion, aches, pains and viruses, including flu (Karapan-
dzova et al., 2013). The important role of S. scardica as 
traditional remedies tea and its conservation status has re-
quired its cultivation as market production (Kostadinova 
et al., 2008). Methanol and boiling water extracts (by do-
mestic infusion procedure) of S. scardica showed that ex-
tracts were rich in bound forms of phenolics such as hy-
droxycinnamic acids, phenylethanoid glycosides and fla-
vonoid glycosides, and showed very high antioxidant ca-
pacity (Petreska et al., 2011a). Phenolic compounds have 
several roles in the plants physiological processes and have 
demonstrated significant health beneficial effects (Petres-
ka et al., 2011b).
Therefore, the aim of this work was the determination 
of the phenolic compounds in the methanolic extracts of 
spontaneous and cultivated flowering stems of S. scardica 
using LC/DAD/ESI-MSn.
Materials and methods
Plant material: The flowering stems of S. scardica 
were collected in four different localities in R. Macedonia 
during the summer of 2013. The spontaneous samples (Ss) 
were collected from Ljuboten (Shara Mountain), Gurgur-
nica (Suva Gora) and Lazaropole (Bistra Mountain). One 
cultivated sample (Sc) was collected from Dren (near to 
Prilep). The plant material was air dried, packed in paper 
bags and kept in a dark and cold place until analysis. 
Extraction of phenolic compounds: 0.2 g of powder 
plant material (homogenized samples from flower, leaf and 
stem) was extracted with 25 mL of 70% methanol, 30 min 
using US bath. The supernatant was filtered through 0.45 
μm pore-size polyethersulfone filter before analysis.
LC/DAD/ESI-MSn analysis: Chromatographic separa-
tions were carried out on 250 mm x 4.6 mm, 5 µm C18 
Luna column (Phenomenix). The mobile phase consist-
ed of two solvents: water - formic acid (1% v/v) (A) and 
methanol (B). A linear gradient starting with 25% B was 
installed to reach 30% B at 7 min, 45% B at 30 min, 50% 
B at 50 min and 100% B at from 55 to 60 min. The flow 
rate was 0.5 mL/min to 50 min and 0.8 mL/min from 50 
min to 65 min, the injection volume 10 µL. The HPLC sys-
tem was equipped with an Agilent 1100 series diode array 
and mass detector in series (Agilent Technologies, Wald-
bronn, Germany). 
Spectral data from all peaks were accumulated in 
range 190-600 nm and chromatograms were recorded at 
290 and 300 nm from glycosides and acylated derivatives 
and at 330 nm for phenylethanoid glycosides and hydroxy-
cinnamic acid. The mass detector was a G2449A Ion-Trap 
Mass Spectrometar equipped with an electrospray ionisa-
tion (ESI) system and controlled by LCMSD software (Ag-
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ilent, v.6.1.). Nitrogen was used as nebulising gas at pres-
sure of 65 psi and the flow was adjusted to 12 L/min. The 
heated capillary and the voltage were maintained at 325 ºC 
and 4 kV, respectively. MS data were acquired in the nega-
tive ionization mode. The full scan covered the mass range 
at m/z 100-1200. Collision–induced fragmentation experi-
ments were performed in the ion trap using helium as col-
lision gas, with voltage ramping cycle from 0.3 up to 2 V. 
Maximum accumulation time of ion trap and the number of 
MS repetitions to obtain the MS average spectra were set at 
300 ms and 5, respectively.
The identification and peak assigmentation of all phe-
nolic compounds was based on comparison of their reten-
tion times and mass spectral data with those of standards 
and published dates. Hydroxycinnamic acids were quanti-
fied using 5-caffeoylquinic acid external standard at 330 
nm, phenylethanoid glycosides were quantified and ex-
pressed as verbascoside equivalent at 330 nm, hypolae-
tin glucosides were quantified with 4’-O-methylhypolae-
tin 7-O-[6′′′-O-acetyl]-allosyl(1→2)glucoside at 290 nm, 
whereas isoscutellarein glucosides were quantified and ex-
pressed as isoscutellarein 7-O-[6′′′-O-acetyl]-allosyl(1→2)
glucoside equivalent at 300 nm. The stock solutions of phe-
nolic standards were made up in 70% methanol to a con-
centration of 1000 µg/mL. The corresponding calibration 
curves were constructed with five dilutions of the stock so-
lutions.
Results and discussion
Phenolic compounds in the Sideritis extracts were 
identified by their UV spectra, their deprotonated molec-
ular ions and their corresponding ion fragments, by using 
LC/DAD/ESI-MSn. Total of 30 and 19 individual compo-
nents were identified in the methanolic extracts of sponta-
neous (Ss) and in the cultivated (Sc) flowering stems of S. 
scardica, representing 45.71-100.97 mg/g DW and 49.46 
mg/g DW of the total content, respectively. Phenolic com-
pounds in Ss and Sc were classified into four groups: hy-
droxycinnamic acids derivatives (4 and 3), phenylethanoid 
glycosides (8 and 5), flavonoid 7-O-diglucosides (5 and 4) 
and flavonoid acetylglucosides aglycones (13 and 7).
The total amount of hydroxycinnamic acid deriva-
tives in Ss and Sc extracts ranged from 2.80-5.31 mg/g and 
2.28 mg/g, respectively. 5-Caffeoylquinic acid was found 
in all samples and it was dominant hydroxycinnamic acid. 
Phenylethanoid glycosides (PHEG) were the abundant 
group of polyphenols in the studied samples with the con-
tent ranging from 17.92-59.39 mg/g in Ss and 11.68 mg/g 
in Sc. Verbascoside (7.07-24.00 mg/g), lavandulfolioside 
(4.77-14.92 mg/g), jonaside A (0.75-6.54 mg/g), allysono-
side (1.23-6.40 mg/g), forsythoside A (1.03-4.01 mg/g) and 
leucoseptoside A (1.32-3.00 mg/g) were the most abundant 
compounds in Ss samples and represent around 90% of to-
tal PHEG content. Verbascoside (6.77 mg/g) and lavan-
dulfolioside (2.47 mg/g) were the major compounds in Sc 
sample. Total content of flavonoid glycosides (non acet-
ylated and acetylated) in Ss and Sc ranged from 24.75- 
42.00 mg/g and 35.49 mg/g, respectively. The prevail-
ing components in Ss and Sc samples were  isoscutella-
rein 7-O-[6′′′-O-acetyl]-allosyl(1→2)glucoside (2.00-5.47 
mg/g and 12.89 mg/g), 3’-O-methylhypolaetin 7-O-[6′′′-
O-acetyl]-allosyl(1→2)glucoside (2.89-10.76 mg/g and 
10.34 mg/g), hypolaetin 7-O-[6′′′-O-acetyl]-allosyl(1→2)
glucoside (2.44-3.79 mg/g and 1.13 mg/g) and apigen-
in 7-(6”-p-coumaroylglucoside) (1.72-2.52 mg/g and 2.61 
mg/g), respectively. 4’-O-Methylhypolaetin 7-O-[6′′′-O-
acetyl]-allosyl-(1→2)-[6′′-O-acetyl]-glucoside (3.34-8.78 
mg/g) was the major component only in Ss samples.
Conclusion
Generally, the number of phenolic components found 
in Ss was larger than in Sc. The differences in total phe-
nolic content between spontaneous and cultivated samples 
are directly correlated with differences in phenylethanoid 
content. 
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Introduction
Pepper is an excellent source of proteins, vitamins, 
minerals, fats and oils, phenolic compounds, aromatic sub-
stances and other biologically active compounds (Campos 
et al., 2013). The importance of the red hot pepper varieties 
and their oleoresin extracts in the food and pharmaceutical 
industry is caused by the characteristic compounds, capsa-
icinoids and carotenoids (Guzman et al., 2011). Mainly, for 
determination of the compounds in the sweet or hot pepper 
varieties, the chromatographic methods (TLC, HPLC and 
GC) and UV-VIS spectrometric method were used (Davis 
et al., 2008; Othman et al., 2011). On the other hand, 1H 
NMR spectroscopy has been extensively used to provide 
information about the composition and relative content of 
fatty acid units in triglycerides (Barison et al., 2010). For 
analysis of the capsaicinoids and carotenoids, NMR spec-
troscopy is one of the most informative methods applied 
(Gómez-Calvario et al., 2015). The degree of unsaturation 
of vegetable oils can be effectively studied by IR spectros-
copy based on the changes observed in the frequency data 
of some bands and in the ratios of absorbances of the IR 
spectra (Vlachos et al., 2006). Therefore, the aim of this 
study is to evaluate the possibility of applying spectroscop-
ic techniques (NMR and IR) in the characterization of ex-
tracts obtained from red hot pepper.
Materials and methods
Extracts from the pericarp, placenta, seeds, and stalk 
of red hot pepper (Capsicum annuum L., ssp. microcarpum 
longum conoides, convar. Horgoshka) obtained by extrac-
tion with n-hexane using Soxhlet method and supercriti-
cal carbon dioxide were analyzed using NMR and ATR-
IR spectroscopy. The NMR spectra were run on a Bruk-
er AVANCE II+ 600 spectrometer at ambient temperature. 
About 15 mg of each sample were dissolved in CDCl3. 
TMS was used as an internal standard. The ATR-IR spec-
tra were measured in the middle IR region 600-4000 cm–1 
on a Brucker Tensor 27 FT spectrometer. The samples were 
directly deposed on diamond crystal ATR accessory and 
spectra were recorded by accumulating 64 scans at resolu-
tion of 2 cm–1.
Results and discussion
NMR Spectra. It was shown that the samples of ex-
tracts from the seeds contain exclusively triglycerides 
(TG). The calculated percent of unsaturated fatty acids was 
estimated about 80%. The estimated linoleic:oleic acid ra-
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tio was 2:1. N-polyunsaturated fatty acids (linolenic acid) 
were not observed. In this way the composition of TG in 
the seeds was shown to be similar to the corn and soybean 
oil. Traces of capsaicinoids were detected, while quantita-
tive determination was not possible. Carotenoids were not 
detected. The spectra of the samples from pericarp showed 
similar composition as these from the seeds. Additionally, 
the presence of about 25% of n-polyunsaturated fatty acids 
was detected. In the samples from the placenta a substan-
tial amount of capsaicinoids was presented. The proportion 
of TG:capsaicinoids was 1:2. In the region delta about 1.2-
1.4 ppm intense signals appear for long CH2 chains, prob-
ably waxes. In the stalk samples intensive signals were 
obtained due to presence of waxes. The proportion of the 
TG:capsaicinoids was approximately 1:0.15. 
ATR-IR Spectra. The oil composition affects the ex-
act position of the band for the C-H stretching of the cis-
double bond, and yields higher-frequency shift when the 
oil has higher content of polyunsaturated acyl groups (Vla-
chos et al., 2006). Furthermore, the ratio of the absorbance 
of the bands responsible for the C-H stretching of the cis-
double bonds and the asymmetric C-H stretching the meth-
ylene bonds could be used for quantitative estimation of 
the degree of unsaturation (Vlachos et al., 2006). In the 
ATR-IR spectra of the extracts of Capsicum annuum the 
band for the C-H stretching of the cis-double bond typical 
for vegetable oils rich in linoleic acid, such as soybean and 
corn oil, was found at 3009 cm–1. According to the ratio of 
the absorbance at 3009 and 2923 cm–1, the highest degree 
of unsaturation was found for the seed extracts. Also, the 
ATR-IR technique provides a fast and reliable identifica-
tion of capsaicinoids in Capsicum annuum extracts. The 
typical frequencies of the amide C=O stretching and am-
ide N-H bending vibration of capsaicin do not overlap with 
the IR bands of triglycerides, and therefore allow identifi-
cation of capsaicinoids even at low concentrations. Among 
the studied extracts, those obtained from placenta had the 
highest content of capsaicinoids. However, for exact deter-
mination of the capsaicinoids content a calibration curve 
based on a series of standard mixtures with known amount 
of triglycerides and capsaicin is required.
Conclusion
Extracts from the pericarp, placenta, seeds, and stalk 
of red hot pepper (Capsicum annuum L., ssp. microcar-
pum longum conoides, convar. Horgoshka) were studied 
by NMR and IR spectroscopy. It was shown that both spec-
tral techniques provide useful information on the triglycer-
ide content and degree of unsaturation of the red hot pep-
per extracts. The IR spectroscopy could serve as a fast tool 
for identification of capsaicinoids in the extracts, while the 
NMR analysis could be successfully applied for determi-
nation of the proportion tryglycerides:capsaicinoids.
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Introduction
In the last few decades, capsaicin has exerted potent 
anti-cancer properties by enouncing anti-proliferative, 
apoptotic and anti-metastatic activity. To the best of our 
knowledge, the specific cell targets and successive mech-
anism of cytotoxic activity of capsaicin in different type 
of malignant cells, still remains unclear and contradictory. 
Therefore, this mini review, explains some of the most sig-
nificant chemopreventive mechanisms of the action of cap-
saicin at a cellular level, reported in the recent literature.    
The specific cytotoxic activity of capsaicin is usually 
a result of targeting of capsaicin toward two aims: TRPV1 
(transient receptor potential cation channel subfamily V 
member 1) and tumor associated NADPH-oxidase. Some 
researchers reported that capsaicin provokes its anticancer 
activity through the interaction with TRPV1 receptor (Kim 
et al., 2006). Amantini et al., (2007) reported that capsaicin 
elicits apoptosis in U373 glioma cells, because the TRPV1 
receptor was highly expressed and oppositely the cytotox-
ic effect in U87 cell line in which the TRPV1 receptor was 
very low expressed, capsaicin did not show cytotoxic ef-
fects (Amantini et al., 2007). Hu et al., (2008) have shown 
that TRPV1 receptor is included in capsaicin induced Ca2+ 
influx, generation of reactive oxygen species (ROS), depo-
larization of the mitochondrial membrane, and ultimately 
cell death on the synovial fibroblasts in rats. On the other 
side, capsaicin is one of the molecules which could inhib-
it the activity of tumor associated NADPH-oxidase, which 
is related to the inhibition of proliferation of cancer cells 
(Hedges et al., 2003).  
The ability of capsaicin to inhibit the growth of differ-
ent cancer cells is primary mediated by its ability to induce 
apoptosis. Apoptosis represents a type of programmed cell 
death, which is one of the physiological mechanisms for 
maintaining the homeostasis in the organism. It has been 
reported that two different pathways are mainly mediating 
the process of activation of apoptosis. First one is extrinsic 
pathway which is accomplished by activating of the “death 
receptor”, and the other is intrinsic pathway which is fol-
lowed by activation of cascade of caspase enzymes (Chou 
et al., 2007).      
Extrinsic pathway
The extrinsic mechanism of apoptosis is characterized 
by activation of the external cell surface receptors, name-
ly TRAIL (Tumor necrosis factor (TNF)-related apoptosis-
inducing ligand) and DR (death receptor, Fas/CD95), lead-
ing to downstream caspase-mediated apoptosis (Codesido 
et al., 2014). These receptors can be activated by a signal 
that activates the enzymes procaspase 8 and 3, and there-
fore consequently triggers the apoptosis of cells. The num-
ber of studies, which included the extrinsic pathway into 
the mechanism of capsaicin mediated apoptosis, is much 
lower than numbers of reported studies which indicated the 
intrinsic pathway as the main mechanism of apoptosis. 
Moon et al., 2012 notified that capsaicin induced the 
surface expression of TRAIL-receptor D5 through the acti-
vation of SP1 due to a calcium influx-dependent SP1 (spe-
cific protein 1) in kidney cancer cells. In multiple malig-
nant glioma cells, subtoxic concentrations of capsaicin 
sensitized TRAIL-induced apoptosis mediated through ER 
Stress proteins CHOP/GADD153. DR5 and surviving con-
tribute to amplification of the caspase cascade, thus restor-
ing TRAIL sensitivity (Kim et al., 2010). 
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Intrinsic pathway
 The mechanism of intrinsic pathway of apoptosis 
is distinguished by intracellular activation of apoptosis 
through intracellular stressors, in which the most common 
are reactive oxygen species (ROS) and excess intracellu-
lar calcium. Disruption of the mitochondrial membrane 
and alterations in bcl-2, Bax, bcl-xL, and bad proteins, can 
cause a release of cytochrome C in cell cytosol and subse-
quent activation of the caspase cascade. These processes 
are the initial triggers that are eventually leading to apop-
tosis (Zhang et al., 2008). Cytochrom C together with some 
other factors can induce activation of caspase-9. Activated 
capsasa-9 can lead to activation of caspasa 3 and 7, which 
cleaves the inhibitor of caspasa activated DNAase and re-
sults in DNA fragmentation. Many studies examining the 
cytotoxic effects of capsaicin on prostate and other malig-
nant cell lines, have reported that capsaicin induced apop-
tosis is linked to intrinsic mechanisms.
Pramanik et al., (2011) have evaluated the mechanism 
of capsaicin-mediated ROS generation in pancreatic can-
cer cells and they suggested that mitochondrial complex-
I and III are involved in capsaicin mediated ROS gener-
ation. They demonstrated that capsaicin inhibited the en-
zymatic activity of antioxidant enzymes superoxide dis-
mutase (SOD), catalase and glutathione reductase, which 
resulted in oxidative stress. 
According to Kryston et al., (2011), the agonistic ef-
fect of capsaicin on TRPV1, can evoke intracellular in-
flux of calcium, which leads to further intracellular stress, 
activating apoptosis in various cell lines, namely prostate 
cancer. They found that the generation of ROS induced by 
capsaicin correlated with the dissipation of the inner mito-
chondrial transmembrane potential and the release of cy-
tochrome-c into the cytosol. Activation of the caspase-3 
cascade resulted in the cleavage of poly(ADP-ribose)poly-
merase (PARP) and resultant apoptosis. 
Conclusion 
A large number of investigators clearly demonstrated 
that capsaicin inhibits the growth of cancer cells by induc-
ing apoptosis and cell cycle arrest, but its molecular mech-
anisms in some types of cancers are not well understood. 
Therefore, additional studies are required to elucidate and 
to supplement the missing part of this data.
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Introduction
Dietary supplements containing red clover (Trifolium 
pratense) extract are used to reduce the symptoms of 
menopause, due to high isoflavone content with estrogenic 
effect: daidzein, genistein, formononetin and biochanin A 
(Boothet et al., 2006).
A large number of manufacturers and suppliers 
are present in the market, offering extracts of different 
quality. This paper presents the results obtained by Quality 
Control division of Pharmanova, during the qualification 
and selection process of raw material suppliers. The 
requirement specified for the quality of the extract used in 
Oestrofact E capsules is: at least 40% of total isoflavones, 
calculated on a dried basis. After reviewing the official 
scientific literature, the testing of samples, sent by the 
manufacturers/suppliers was performed. Monographs for 
the herbal drug (Powdered Red Clover), herbal extract 
(Powdered Red Clover Extract) and final product (Red 
Clover Tablets), that were consulted, have been published 
by the U.S. Pharmacopoeia (USP36/NF31, 2013). The 
monograph for Powdered Red Clover Extract states the 
isoflavone content should be not less than 90% and not 
more than 110% of the declared amount, calculated on the 
dried basis as the sum of daidzein, genistein, formononetin 
and biochanin A content.
Materials and methods
Test samples of red clover dry extracts with appropri-
ate documentation (specifications, certificates, production 
flow charts) were collected from three manufacturers. The 
samples were tested for the individual content of each iso-
flavone (daidzein, genistein, formononetin and biochanin 
A) as well as the total isoflavone content. One of the sam-
ples was also tested for homogeneity dependant on the 
sampling position (bottom, top, middle, centre, left, and 
right).
The method used for the identification and determination 
of isoflavones in red clover extract was developed in 
physico-chemical laboratory of Quality Control (QC) 
Pharmanova, and validated according to ICH guidelines. 
The technique used is HPLC with UV-VIS detector (254 
nm). Separation is achieved using a Phenomenex® Luna 
C18 (2), 250 x 4.6 mm, 5 μm particle column, at isocratic 
elution at 1 mL/min, using the following mobile phase: 
acetonitrile: 0.5% phosphoric acid (40:60, V/V).
Results and discussion
Individual and total isoflavone content was determined 
in three test samples. The results presented in percentage 
(%, m/m) represent the average of two consecutive results 
of the same sample:
1. Test sample I: daidzein 0.52%, genistein 0.51%, 
formononetin: 19.99%, biochianin A 11.31%, 
total isoflavones 32.33%
2. Test sample II: daidzein 9.26%, genistein 
11.29%, formononetin: 17.80%, biochianin A 
3.66%, total isoflavones 42.01%
3. Test sample III: daidzein 3.38%, genistein 
8.72%, formononetin: 15.53%, biochianin A 
18.25%, total isoflavones 45.80%
In order to get information on the homogeneity, one 
of the extract was sampled from different positions of the 
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bulk package. The total isoflavone content was determined 
from each of the samples and the results were as follows, 
top: 43.38%; bottom: 44.21%; middle center: 43.36%; 
middle left: 42.77%; middle right: 43.87%. When the 
results were statistically processed, the relative standard 
deviation (RSD) was found to be 0.54%, while the 
recovery percentage in relation to the declared value was 
in the range from 98.25% to 101.65%.
The estrogenic activity of red clover extract originates 
from its isoflavones: genistein and diadzein (called soy 
isoflavons, due to high contents in soy products), and 
two structurally similar, methylated isoflavons, biochanin 
A and formononetin. In fact, Biochanin A is methylated 
genistein, and formononetin methylated daidzein, so after 
oral application and demethylation in the digestive tract, 
only genistein and daidzein are found as active metabolites 
in the organism (Toleson et al., 2002). What remains the 
question is whether demethylation can occur during one of 
the dry extract production phases, as well as later during 
storage and sample manipulation. Thus, during the quality 
assessment of the extract, the ratio between individual 
isoflavones should be considered. The U.S. Pharmacopoeia, 
within HPLC identification, sets requirements for 
quantitative ratio between two 5,7-dihydroxyisoflavones 
(biochanin A and genistein) and two 7-hydroxyisoflavones, 
to be between 0.1 and 10.0.
The information collected, concerning the quality of 
world renowned brands used in clinical research and available 
in electronic databases indicate that in these products more 
than 75% of total isoflavone content comes from biochanin 
A and formononetin, while soy isoflavons (genistein and 
daidzein) represent a significantly smaller percentage:
•	 Promensil® capsule, 43.5 mg: biochanin A 
26 mg (60%), formononetin 16 mg (37%), 
genistein 1 mg (2%) and daidzein 0.5 mg (1%) 
(Knight et al., 1999)
•	 Rimostil® capsule, 28.6 mg: formononetin 27 
mg (87%), biochanin A 2 mg (7%), genistein 
and daidzein in trace amounts (Schult et al., 
2004)
When all is considered, the ratio of peaks from the 
chromatogram could indicate a possible attempt to falsi-
fy the extract. It is preferable for the peaks of formonone-
tin and biochanin A to stand out in relation to ones coming 
from genistein and daidzein.
Conclusion
Test sample I contains satisfactory levels of 
formononetin and biochanin, but low total isoflavone 
content (< 40%).
Test samples II and III comply with requirements 
for total isoflavone content (> 40%), but high levels of 
genistein and daidzein can indicate that the extracts were 
not pure red clover.
Requirements for the ratio between pairs of related 
isoflavones (B + G / D + F) were met by all of the extract 
samples, in accordance with USP/NF31 (0.1 to 10.0).
The total isoflavone content results in samples taken 
from different positions of the bulk package show no 
statistically significant difference (RSD < 2 and recovery 
< ± 3%), which confirms the homogeneity of the tested 
extract. The sampling principles in accordance with 
Ph.Eur.8.0, chapter 2.8.20. Herbal Drugs: Sampling and 
Sample Preparation should be applied whenever possible.
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Introduction
The genus Chenopodium (Amaranthaceae) comprises 
numerous species of perennial and annual plants known as 
goosefoots, which occur anywhere in the world. Only few 
species produce essential oil (glandular goosefoots) usu-
ally with characteristic chemical composition. In Europe, 
glandular goosefoot is Chenopodium botrys L. (syn. Dys-
phania botrys (L.) Mosyakin and Clemants) known as Je-
rusalem Oak Goosefoot, native to the Mediterranean re-
gion. The plant has been used for treatment of catarrh and 
humoral asthma and is known as a good substitute for the 
traditionally known medicinal plant Chenopodium ambro-
sioides (Yadav et al., 2007). 
C. botrys contains flavonoids, alkaloids and terpe-
noids. The characteristic odor of the plant is due to some 
monoterpenes and sesquiterpenes which were found to be 
responsible for the specific aromatic and fetid scent. The 
presence of some oxygen-containing sesquiterpenes was 
correlated with pronounced antibacterial and antifungal 
activity (Kokanova-Nedialkova et al., 2009). Studies on 
the flavonoids revealed presence of flavonols: chrysoeriol, 
quercetin, kaempferol and herbacetin and flavones: hispid-
ulin, salvigenin, 5-methylsalvigenin, 7-methyleupatulin, 
sinensetin and jaceosidin (Morteza-Semnani, 2015). 
Dried herbal part of C. botrys is used from local peo-
ple in Republic of Macedonia (RM) for preparing infusions 
or liquid extracts with diuretic, antispasmodic, carminative 
and antidiarrheal properties. The aim of this study was de-
termination of the chemical composition of Macedonian C. 
botrys and evaluation of its antimicrobial capacity.
Materials and methods
The aerial flowering parts (herba) of C. botrys, were 
collected in the period from July to September in 2012, 
2013 and 2014 from five localities in RM: 1. Kozuf, 2. 
Pretor, 3. Strumica, 4. Zletovo and 5. Radovish. Collect-
ed plant material was air-dried and preserved in paper bags 
until analysis, when it was minced and homogenised ap-
propriately.
The essential oil was isolated with steam distillation 
using all-glass Clevenger type apparatus according to the 
method listed in the monograph in the European pharma-
copoeia. 
Essential oil samples were analysed on Agilent 7890А 
Gas Chromatography system equipped with FID detector 
and Agilent 5975C Mass Quadrupole detector using previ-
ously published method (Adji Andov et al., 2014). 
Hydrolyzed extract of C. botrys herba was prepared 
according to the method listed in the monograph in the Eu-
ropean pharmacopoeia and were analyzed using an Agile-
nt 1200 series HPLC system equipped with a G1315D pho-
to-diode array detector, controlled by ChemStation LC 3D 
software. Chromatographic separations were carried out on 
a XDB-C18 Eclipse column (150 mm x 4.6 mm, 5 μm, Ag-
ilent Technologies, USA). Spectral data for all peaks were 
accumulated in the range of 190-400 nm and chromato-
grams were recorded at 260, 280, 330 and 370 nm. 
Antimicrobial activity. Microbial strains: Staphylococ-
cus aureus ATCC 25923, Escherichia coli ATCC 25922, 
Staphylococcus epidermidis ATCC 12228, Pseudomonas 
aeruginosa ATCC 9027, Candida albicans ATCC 10259 
and clinical isolates from patients (Enterococcus, Strepto-
coccus pyogenes, Proteus mirabilis, Salmonella enteriti-
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dis) were used. Method: Disc diffusion method was used 
in order to determine the growth inhibition zones of the mi-
croorganisms. The results were compared to the antimicro-
bial activity of several antibiotic drugs. Preparation of ex-
tracts: methanol extracts (1 g/mL) were prepared using ul-
trasonic assisted extraction procedure.    
Results and discussion
The results of the GC/FID/MS analysis showed that 
the main compounds of the essential oil of C. botrys herba 
were the sesquiterpenes: elemol acetate, saline-11-en-4α-
ol, selina-3,11-diene-6α-ol and elemol, followed by low-
er content of α-eudesmol acetate, α-henopodiol, botrydiol 
and α-chenopodiol-6-acetate. These compounds represent-
ed 62.74-81.21% of the oil. Additionally more than 50 oth-
er compounds were identified in very low quantities or in 
traces. The monoterpene ascaridol was absent. 
In hydrolyzed extract of C. botrys herba, hydroxycin-
namic acid, chlorogenic acid and caffeic acid and its de-
rivate were identified together with quercetin and isorh-
amnetin. Tentatively apigenin and luteolin were identified, 
based on comparison of the Rt and UV-DAD spectra with 
those of the authentic substances of apigenin and luteolin, 
used as referent flavonoids. The component that appeared 
in the HPLC chromatogram on Rt 24.7 min has UV-DAD 
spectra with UVmax on 348 nm and was assume to be her-
bacetin.
Methanol extracts of C. botrys herba showed promis-
ing antimicrobial activity against Staphylococcus aureus, 
Staphylococcus epidermidis and Streptococcus pyogenes, 
and no activity against Escherichia coli, Salmonella en-
teritidis, Pseudomonas aeruginosa and Proteus mirabilis. 
Additionally the extract showed promising antifungal ac-
tivity against Candida albicans. Obtained results are in ac-
cordance with the literature data. 
The essential oil isolated from C. botrys from differ-
ent regions in the world contains varying chemical compo-
sition where dominant components are the sesquiterpenes, 
mainly α- and β-chenopodiol, eudesma-3,11-dien-6α-ol, 
botrydiol, elemol, elemol acetate, α- β- and γ-eudesmol and 
new identified compound guaia-3,9-dien-11-ol, that was 
also identified in our oil. Some authors point out on higher 
presence of other sesquiterpenes such as α-cadinol, epi-α-
muurolol, cubenol and E-caryophyllene, while some other 
identified higher percentages of monoterpenes γ-terpineol, 
β-myrcene, p-cymene, α-terpinene, limonene, and espe-
cially ascaridole which were reported in essential oils of C. 
botrys from Spain and Slovakia (Morteza-Semnani, 2015). 
According Kokanova-Nedialkova et al. (2009) Cheno-
podium species contain phenol derivatives such as alco-
hols, aldexydes and glycosides (vanillic alcohol and vanil-
lic acid, phenolic glycoside named chenoalbuside, cinnam-
ic, sinapic and ferulic acid and their derivatives, hydroxy-
cinnamic acylglycosides and many other phenolic com-
pounds. In the group of flavonoids, quercetin, isorhamne-
tin, kaempferol and herbacetin and their glycosides were 
the only flavonols isolated from Chenopodium species, in-
cluding C. botrys, besides highly metylated flavons: salvi-
genin, sinensetin, hispidulin and their derivatives. 
Up to now, antimicrobial activity was tested only on 
the essential oil of C. botrys, which expressed signifi-
cant bactericidal activity against selected strains of Gram 
(+) and Gram (-) bacteria, comparable to that of the ref-
erence antibiotics amicacin and cephotaxim (Kokanova-
Nedialkova et al. 2009) and significant fungicidal activi-
ty against selected strains of Aspergillus niger and Candi-
da albicans, comparable to that of the reference antibiotics 
nystatine and amphotericin (Tzakou et al., 2007).
Conclusion
In the essential oil chemical composition of Macedo-
nian Chenopodium botrys as predominant compounds were 
determinate the oxygen-containing sesquiterpenes: elemol, 
eudesmol, chenopodiol and seline alcohols and their esters. 
The hydrolysed extract contained few phenolic acids, pre-
dominantly, cinnamic and caffeic acid and their derivates 
and quercetin, isorhamnetin, apigenin, luteolin and proba-
bly herbacetin. Methanol extracts show promising antimi-
crobial and antifungal activity. Further investigations are 
required for complete chemical identification of phenolic 
and flavonoid compounds as well as to reveal the antimi-
crobial and antifungal capacity of the plant extract, for fur-
ther medicinal or commercial use.
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Introduction
The chemical compounds present in the living organ-
isms are composed of chemical elements. In these days al-
most 120 chemical elements are known and 30 of them 
create the living matter, therefore are known as biogenic 
elements. Plants provide themselves with elements from 
air, soil and water. They are present within the compounds 
or in the form of ions and in some special cases they are 
unbound (e.g. oxygen). According to their representation 
in organisms, the biogenic elements are divided into three 
groups: macro-biogenic, micro-biogenic and trace ele-
ments. Macro-biogenic elements (C, O, H, N, S, P, Na, K, 
Ca, Mg, Cl, Fe) have a building function, micro-biogen-
ic elements (Cu, I, Mo, Mn, Zn, Co) are parts of enzymes 
and their function is catalytic, while trace elements (Al, 
As, B, Br, F, Li, Ni, Se, Si, Ti, V) are presented less than 
0.001% and their biological role still remain undiscovered. 
The content of these elements vary a lot depending on 
many factors. Nevertheless, edible plant represent biologi-
cal source of these elements for other living organisms in-
cluding humans. Thus, Chenopodium spp. (Amaranthace-
ae) is being used as a leafy vegetable and subsidiary grain 
crop in different parts of the world due to its rich nutrition-
al quality and its ability to grow in stress conditions.  
The Chenopodium genus comprises numerous species 
of perennial and annual plants that grow as herbaceous 
plant or as shrubs and small trees. In the flora of the Re-
public of Macedonia (RM), 15 species of this genus oc-
cur including C. botrys and C. album. Dried herbal parts 
of C. botrys are used from local people for preparing infu-
sions or liquid extracts with diuretic, antispasmodic, car-
minative and antidiarrheal properties while fresh leaves of 
C. album are known as substitute of some green leafy veg-
etables such as spinach. These two plant species have not 
been issue of chemical characterisation so far. Therefore, 
the aim of this study was determination of the content of 
selected biogenic elements of wild samples of C. botrys 
and C. album, collected from different localities of the Re-
public of Macedonia.
Materials and methods
Plant material (25 specimens), consisting of aerial 
flowering part (herba) and dried roots (radix) of two Che-
nopodium species (C. album and C. botrys), was collect-
ed from wild specimens on different localities in R. Mace-
donia, during 2012 and 2013. Collected plant material was 
air-dried and preserved in paper bags until analysis, when 
it was minced and homogenised appropriately.
For mineralization purposes 0.5 g of plant material 
were placed in a Teflon digestion vessels (OMNI/xp 1500), 
7 mL (69%, m/V) HNO3 and 2 mL H2O2 (30%, m/V) were 
added, the vessels were capped closed, and after 24 hours 
were placed in the rotor of the Mars microwave digestion 
(CEM, USA). The digestion was carried out on 180 °C in 
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two steps, first 25 min and then additional 15 min. The 
digests were filtered on filter paper (Munktell, Sweden), 
quantitatively transferred to 25 mL calibrated flasks, dilut-
ed with demineralised water and analyzed for the select-
ed elements.
All analyzed elements (Ca, K, Mg, P, Na, Cu, Fe, Mn 
and Zn) were determined by the application of inductively 
coupled plasma atomic emission spectrometer (ICP-AES) 
(Varian, 715-ES) applying an ultrasonic nebulizer CETAC 
(ICP/U-5000AT+) for better sensitivity. The optimal in-
strumental parameters for this technique were published 
previously (Balabanova et al., 2010). All results were cal-
culated on a dry mass basis (mg/kg d.m.). Samples were 
made in triplicates. Each data represents the mean ± 2 stan-
dard deviation of three samples.
Results and discussion
The two analyzed species of Chenopodium contained 
large amounts of potassium (K), calcium (Ca), magnesium 
(Mg) and phosphorus (P), which ranged from 961 mg/kg 
for P to 40907 mg/kg for K, in dried aerial flowering part 
(herba) of C. botrys and C. album. The most abundant 
macro-biogenic element in all analysed samples of herba 
was K (14136-40907 mg/kg), followed by Ca (7405-14146 
mg/kg), Mg (1082-5913 mg/kg) and P (961-2752 mg/kg). 
The content of micro-biogenic elements in herba of C. al-
bum and C. botrys was much lower, ranging from 4.0 mg/
kg for Cu to 863.1 mg/kg for Fe. The most abundant mi-
cro-biogenic element in the investigated samples of herba 
was Fe (33.3-863.1 mg/kg), followed by Na (14.6-606.0 
mg/kg), Mn (9.4-177.8 mg/kg), Zn (11.8-27.9 mg/kg) and 
Cu (4.0-15.6 mg/kg). 
The content of macro-biogenic elements in roots (ra-
dix) of C. album and C. botrys was lower when compared 
with the herba of both species, ranging from 589 mg/kg 
for P to 15839 mg/kg for K. The most abundant macro-bio-
genic element in all analysed samples from radix was K 
(14136-40907 mg/kg), followed by Ca (7405-14146 mg/
kg), Mg (1082-5913 mg/kg) and P (961-2752 mg/kg). The 
content of micro-biogenic elements in radix of C. album 
and C. botrys was lower than in herba, ranging from 4.0 
mg/kg for Cu to 863.1 mg/kg for Fe. Fe was also the most 
abundant micro-biogenic element in all investigated spec-
imens of radix (33.3-863.1 mg/kg), followed by Na (14.6-
606.0 mg/kg), Mn (9.4-177.8 mg/kg), Zn (11.8-27.9 mg/
kg) and Cu (4.0-15.6 mg/kg).    
According to literature data Bomkazi et al. (2013) 
found very high amount of K in young shoots and mature 
plant-leaves of C. album, (45799.3 mg/kg and 49028.6 mg/
kg, respectively), while the contents of Ca and Mg were 
lower. Comparing to our results, the content of K, Ca and 
Mg was higher than in our Macedonian samples from herba 
of C. album. Smaller amounts of Fe (218.1 and 120.4 mg/
kg), Zn (26.2 and 23.0 mg/kg) and Cu (14.0 and 9.1 mg/kg) 
were found also in young shoots and mature plant-leaves, 
respectively. In leaves of Indian C. album 452 mg/100 g 
K was found, followed by 150 mg/100 g Ca, and smaller 
amounts of Na, Mg, Zn, and Fe (43.0, 34.0, 24.0 and 4.2 
mg/100 g, respectively) (Dey et al., 2013). Obtained results 
for Macedonian C. album were in accordance with litera-
ture data. According to literature, C. botrys was found to 
be very good bio-accumulator of heavy metals, especially 
for Fe, Mn, Zn and Cu, which content rich up to 4145, 175, 
276 and 56 mg/kg, respectively (Malayeri et al., 2008).   
Conclusion
The content of biogenic elements in investigated Che-
nopodium species (C. album and C. botrys) from Macedo-
nian flora, showed that in both species the most abundant 
macro-biogenic element was K, in the dried aerial flower-
ing part (herba) as well as in the dried roots (radix), fol-
lowed by high amounts of Ca, Mg and P. Fe was predom-
inant micro-biogenic element, present in higher amounts 
in the herba of C. botrys. Both species represent biologi-
cal source of Mn, Zn and Cu. Differences in the contents of 
biogenic elements were high, depending on the harvesting 
locations. Further investigations are needed for analyzing 
the environmental influence on the contents of biogenic el-
ements in Chenopodium species. 
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Introduction
Zizyphus lotus L. is a medicinal plant which is found 
in many geographic areas, including the Mediterranean 
region, e.g. Tunisia. The different parts of this plant are 
frequently used in traditional medicine in order to treat 
several diseases such as skin infections, urinary troubles, 
insomnia and anxiety, digestive disorders, obesity, urinary 
troubles, diabetes, etc. (Bakhtaoui et al., 2014). Recent 
studies stipulate onto the anti-inflammatory, analgesic 
and anti-ulcerogenic activities of aqueous extracts of 
some parts of this plant on rodents, as well as on the 
immunomodulatory properties on human T-cell activation, 
and on IL-2 mRNA expression (Benammar et al., 2014). 
In order to investigate more thoroughly onto the 
properties of Zizyphus lotus L., a study dealing with the 
qualitative evaluation of different methanolic extracts of 
this plant (originating from roots, stems, leaves and seeds), 
as well as of their antioxidant properties was carried on. 
Materials and methods
All reagents were purchased from Merck and Sigma–
Aldrich and were of analytical grade. Different parts 
(leaves, roots, stems and seeds) of Zizyphus lotus L. were 
collected from north-western Tunisia (Bousalem region) 
at different times of the year (March, September and 
October), in 2014. The vegetal materials were grounded 
into powder and were packed in polythene bags for further 
use. 
The methanol extracts of different parts of the plant 
were prepared in a similar manner. An amount of ten 
grams (10 g) of ground samples (leaves, stems, root and 
seeds respectively) were extracted with 100 mL methanol 
in a Soxhlet extractor. Several extraction processes were 
carried on. The obtained extracts were filtered and then 
concentrated to dryness under vacuum. The residues were 
stored in a refrigerator at 4 °C until the time of extract use. 
The qualitative evaluation of the different extracts of 
Zizyphus lotus was carried on by means of phytochemical 
screening (for alkaloids, saponnins, terpenes, tannins, 
quinones, and flavonoids) and thin layer chromatography, 
using a series of specific standards (catechin, rutine, 
quercitine, gallic and tannic acids). Determinations were 
carried out in accordance with procedures described in 
literature. In order to quantify the total phenol content, the 
Folin-Ciocalteu reagent was used. The antiradical activities 
of the methanolic extracts of Zizyphus lotus was estimated 
using the stable free radical 2,2-diphenyl-1-pycrylhydrazyl 
(DPPH), according to the method of Brand-Williams et al. 
(1995). Rutine and butyl hydroxyl toluene were used as 
positive controls.
Results and discussion
The phytochemical analysis of the methanol extracts 
of the different parts (leaves, stems, root and seeds respec-
tively) of Zizyphus lotus revealed that all of these contain 
(in different amounts) saponnins, terpens, tannins and fla-
vonoids. The roots, stems and seeds also contain sterols. 
Excepting the leaves, coumarins and alkaloids were de-
tected only in traces. The obtained results showed that the 
fruit seeds should be considered a source of fatty acids, be-
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ing by far richer in saturated and poly saturated fatty acids 
than any other parts of the plant. In the case of the roots of 
Zizyphus lotus, the phytochemical results revealed a rich 
content in flavonoids, tannins and saponnins, compounds 
known for their anti-inflammatory and analgesic activity. 
The same active compounds (flavonoids, saponins, tannins 
and alkaloids) detected in the Zizyphus lotus leaves, could 
explain the analgesic effects of this plant and its use in folk 
medicine. The analysis of the thin layer chromatographic 
plates revealed the presence of polyphenols, catechin, ru-
tine, quercitin, tannic and gallic acids in the different parts 
of Zizyphus lotus.
Regarding the antioxidant activity of the methanolic 
extracts originating from the different parts of Zizyphus lo-
tus, it was found that the obtained efficient concentration 
values (IC50) ranged from 4.713 to 6.704 μg/mL, being sig-
nificantly lower as compared to the positive controls: butyl 
hydroxyl toluene (21.441 μg/mL) and rutine (13.762 μg/
mL). So, one could notice that the studied extracts show an 
important antioxidant activity. Among all, the seeds metha-
nol extract showed an antioxidant activity five times great-
er than butyl hydroxyl toluene’s one, and three times great-
er that the rutine’s one. 
Conclusion
The phytochemical screening of the methanolic ex-
tracts originating from different parts of Zizyphus lotus 
L. revealed the presence of some active compounds such 
as saponnins, terpenes, tannins, quinones and flavonoids. 
This content in active compounds confirms the importance 
of Zizyphus lotus L. in folk medicine, which could be con-
sidered as a natural alternative to some synthetic products. 
The methanol extracts of different parts of Zizyphus lo-
tus L. showed an important antioxidant activity. According 
to the obtained efficient concentration values, one could 
conclude that the seed’s methanolic extract has the highest 
antioxidant activity as compared to the leaves, stems and 
roots extracts, as well as to the positive controls (rutine and 
butyl hydroxyl toluene) used in this study.
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Introduction
Pines are among the most important and widespread 
forest trees as they occur in a different range of environ-
mental and climate conditions (Naydenov et al., 2006). 
Pinus nigra Arnold or black pine is a moderately variable 
species which grows widely throughout Mediterranean and 
is attributed to Balkan Peninsula as well as Republic of 
Macedonia where this conifer could be found on several 
localities (Karadzica, Kozuf, Shara Mountain etc.).
Essential oils isolated from different pine species are 
widely used as fragrances in cosmetic industry, as fla-
voring additives for food and beverages and as scenting 
agents in a variety of household products and intermediates 
in the synthesis of perfume chemicals (Sezik et al., 2010). 
Since antiquity, they have been known to possess biologi-
cal activity, most notably antibacterial, antifungal and an-
tioxidant properties therefore are used in the ethno medi-
cal practice and in the folk medicine throughout the world. 
Moreover, pine oils are used for medical purposes in aro-
matherapy as carminative, rubefacient, emmenagogue and 
even as abortifacient agents. Additionally, the systematic 
and potential usefulness of essential oil studies has become 
increasingly important because of their growing interest in 
use in both the food and pharmaceutical industries (Kil-
ic and Kocak, 2014). In this way, the chemistry and the bi-
ological activity of the essential oils isolated from differ-
ent pine species have been intensively studied, particularly 
needles essential oils. 
However, despite the abundant literature on this topic, 
there are no evident data about the chemistry and biolog-
ical activity of Macedonian black pine, thus the main ob-
jective of the present study was to investigate the chemical 
composition of the essential oils isolated from needles and 
to access their antimicrobial activity against certain types 
of microorganisms in order to define possible application 
and therapeutic uses of these essential oils as antimicrobi-
al agents.
Materials and methods
Plant material (terminal branches) was collected from 
two different localities in R. Macedonia (Kozuf and Nidze) 
and was dried at room temperature, for two weeks. Just be-
fore isolation, the needles were separated from the branch-
es and were properly minced. 
Essential oil isolation was made by steam distillation 
in all-glass Clevenger apparatus (Ph.Eur. 8, 2.8.12.). For 
that purpose, 20 g of minced needles were distilled for 4 
hours. For purification purpose, anhydrous sodium sulfate 
was added to the isolated essential oil to remove residu-
al water. 
For GC/FID/MS analysis, the essential oil was dis-
solved in xylene to obtain 1 μl/ml oil solution.
Essential oil samples were analyzed on Agilent 7890А 
Gas Chromatography system equipped with FID detector 
and Agilent 5975C Mass Quadrupole detector according 
to previously published method by Karapandzova et al. 
(Karapandzova, 2014).
Antimicrobial activity of essential oils was studied 
against 14 different microorganisms, including 13 bacterial 
isolates representing both Gram-positive (Staphylococcus 
aureus ATCC 29213, Staphylococcus epidermidis, Strepto-
coccus pneumoniae, Streptococcus agalactiae, Streptococ-
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cus pyogenes and Enterococcus) and Gram-negative bacte-
ria (Acinetobacter spp., Escherichia coli ATCC 25927, Sal-
monella enteritidis, Klebsiella pneumoniae ATCC 700603, 
Pseudomonas aeruginosa ATCC 27853, Haemophilus in-
fluenzae and Proteus mirabilis) and one strain of Candida 
albicans ATCC 10231. Antimicrobial screening of all test-
ed essential oils was made by disc diffusion and broth di-
lution method previously described by Karapandzova et al. 
(2014).
Results and discussion
The total needle essential oil content of Macedonian 
black pine calculated on anhydrous dried mass yielded 
from 8.03 to 8.34 ml/kg.    
Data analysis of the chemical composition of exam-
ined essential oil samples revealed six different class-
es of components: monoterpene hydrocarbons, oxygenat-
ed monoterpenes, sesquiterpene hydrocarbons, oxygenat-
ed sesquiterpenes, diterpenes and other non-terpene com-
ponents. The most abundant fraction in the essential oil 
isolated from needles of Pinus nigra collected from Ko-
zuf were monoterpene hydrocarbons (39.96%), while ses-
quiterpenes were declared as dominant (46.45%) in the oil 
samples isolated from Pinus nigra from Nidze. This vari-
ability in chemical composition of Macedonian black pines 
is probably due to the influence of environmental condi-
tions on the biosynthesis of terpene compounds.
Total of eighty nine components were identified in 
the investigated essential oil samples which represent-
ed 87.63% of total oil. Predominant components were 
monoterpenes: α-pinene (29.23-30.51%), β-pinene (1.44-
5.30%) and limonene + β-phellandrene (1.34-1.85%) and 
sesquiterpenes: trans-(E)-caryophyllene (8.56-11.38%), 
γ-murrolene (0.98-2.11%) and germacrene D (17.32-
21.21%).
Previously established differences in the essential oil 
composition presumably affect their antimicrobial activity. 
In this regard, essential oil isolated from needles of black 
pine collected from Nidze has showed antimicrobial activ-
ity towards Staphylococcus epidermidis and Streptococcus 
agalactiae. Additionally, essential oil isolated from black 
pine needles from Kozuf revealed good antimicrobial ac-
tivity against to another three microorganisms as they have 
showed strong antimicrobial effects toward Streptococcus 
pneumonia, Staphylococcus aureus and Candida albicans. 
Minimal inhibitory concentration (MIC) values for tested 
essential oil samples ranged from 15.25 to 62.25 μl/ml de-
pending on the microorganism. 
According to literature data, essential oils isolated 
from needles of Macedonian black pine have showed the 
greatest similarity to the chemical composition of oils ob-
tained from needles of black pines originating from Croatia 
and Greece with the exception of two components, 13-epi-
manool oxide (2.25%) which was identified in the oil of 
Croatian black pine (Idzojtic et al., 2005) and 3-methyl-
2-phenyl ester of butyric acid (2.10%) found in essential 
oils isolated from black pine from Greece (Roussis et al., 
1994). Data concerning the antimicrobial activity of Pinus 
nigra essential oils indicated that there are no available 
published studies regarding this species. In terms of anti-
microbial activity of the essential oils isolated from other 
pines, it is evident that it’s in a direct correlation with the 
chemical composition and largely depends on the domi-
nant components present in the oil.
Conclusion
Macedonian black pines contain essential oil with pre-
dominant components α- and β-pinene and have showed 
good antimicrobial activity against selected Gram (+) bac-
teria as well as Candida albicans. Nevertheless, further 
studies will be aimed in order to obtain more data about 
their antimicrobial potential as well as data about their 
safety usage until their final recommendation as antimicro-
bial agents.
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Introduction
Juniperus communis L. (Cupressaceae) (juniper) is 
coniferous evergreen tree or shrub, with needle-like leaves 
and berry-like cones, usually incorrectly consider as berry 
fruit. Actually, the plant grows as male and female plant 
and produce male and female cones, but only female 
cones are used as medicinal source for isolation of juniper 
oil (Juniperi aetherolem), valuable natural product for 
many purposes. The medicinal use of the juniper essential 
oil comprises: diuretic, antiseptic, digestive, stomachic 
and antireumathic activity, while commercial purposes 
include uses in food industry, in production of alcohol 
beverages, as well as, cosmetics and perfume production. 
The oil possesses specific chemical composition where as 
predominant components are considered the monoterpene 
hydrocarbons (α-pinene, β-pinene, β-myrcene, sabinene 
and limonene), followed by the fraction of oxygen-
containing monoterepenes (EMA/HMPC/12401/2010), 
where terpinene-4-ol is considered to be responsible for 
the diuretic effect of the juniper oil (Chatzapoulou and 
Kastsiotis, 1993; Orav et al., 2010). The oil composition is 
highly variable, and depends on genetic and environmental 
factors (source, geographical origin, maturity of the 
berries, age of the plant, environmental factors) (Jo and 
Kim, 2005; Tasic et al., 1993). Furthermore, the differences 
in the essential oil chemical composition usually trigger 
variations in its activity.    
Over the years, the juniper berries and the juniper 
berry essential oil are natural drugs that are commercially 
exploited and exported from Republic of Macedonia 
(RM). Regarding this, the aim of the present work was 
determination of the chemical composition and possible 
chemical variability of the isolated juniper oils from wild 
growing plants in RM.
Materials and methods
Samples of juniper berries were collected in late au-
tumn in 2010, 2011 and 2012 from six regions in RM 
(North-West Mountain - Mtn.: Bistra Mtn., and Shara Mtn.; 
Central Mtn.: Karadzica, Jakupica, and Dautica; Porechie: 
Kichevo, Makedonski Brod, and Samokov; Pelagonija re-
gion: Bitola, Pelister, Prilep, and Resen; Black Drim re-
gion: Debar, Karaorman, and Velestovo, and Maleshevija: 
Berovo). The collected plant material was air dried, stored 
at cool, and dark place, until analysis.   
The essential oils were isolated by steam-distillation in 
the Clevenger-type apparatus according to the method de-
scribed in the Ph.Eur.8.0 (2014). The oils were dried over 
anhydrous sodium sulfate and stored in vials in refrigera-
tor until analysis.
Essential oil samples were analyzed with Agilent 
7890А Gas Chromatography system equipped with flame 
ionization detector (FID), and Agilent 5975C Mass Quad-
ripole detector. For this purpose, an HP-5ms (30 m x 0.25 
mm, film thickness 0.25 μm) capillary column was used. 
Operating conditions and identification of the components 
were previously published (Sela et al., 2011). 
Microsoft Excel® (Microsoft Corp. Redmond, WA, 
USA) was used for obtained data tabulation, while multi-
variate statistical analysis software SIMCA 14 (Unimetrics 
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AB, Sweden) was used for depth analysis. Values of p less 
than 0.05 were considered significant.
Results and discussion
With GC/FID/MS, 93 components were determinate 
in the essential oil isolated from juniper berries from all 
geographic regions in RM. The juniper oil was composed 
mainly from monoterpene hydrocarbons: α-pinene 
(15.59-43.68%), β-myrcene (2.89-26.50%), sabinene 
(1.65-16.34%), and β-pinene (0.00-6.34%). The oxygen-
containing monoterpene, terpinen-4-ol was presented from 
0.02-4.35%. In addition, some sesquiterpene compounds 
were also important constituents of the oil and were 
present in larger percentages (germacrene D 1.25-12.89%; 
trans-E-caryophyllene 1.61-4.05% and α-humulene 1.61-
4.60%). The analysed essential oils showed differences 
in the chemical composition. According literature data, 
differences and variability in the composition of juniper oil 
originated from different regions in Europe and America 
were already reported. α-Pinene was declared as main 
constituent present from 27.00% in the Greek samples, 
over 28.60-38.20% in samples from Montenegro, and up 
to 46.63% in the Iranian samples (Rezvani, 2010). Other 
important components such as sabinene, germacrene D, 
myrcene, β-pinene and limonene were found in different 
amounts. 
Having in mind that chemical composition in vari-
ous samples of the essential oil mostly differs due to the 
influence of temperature, and/or geographic region (Jo 
and Kim, 2005), in depth statistical analyses using prin-
cipal component analysis (PCA), followed by Hierarchi-
cal Cluster Analysis (HCA) (calculated with Ward`s crite-
rion and sorted by size), partial least square - discriminant 
analysis (PLS-DA) and partial least square (PLS) analysis 
were carried out. 
PCA applied on data related to all 93 identified con-
stituents of the oil resulted with mathematical model with 
six principal components that explained 99.5% of the total 
variations, with no identified outliers in the model. Den-
drogram created by subsequent HCA pointed that analyzed 
samples could be clustered in two groups.
The samples in the first cluster were correlated with 
α-pinene and β-myrcene, while the second cluster was 
linked to germacrene D, β-elemene, trans-E-caryophyllene, 
α-humulene, γ-elemene, β-cadinene, γ-cadinene. PLS-DA 
preceded PLS analysis with a rationale for discriminatory 
variables identification. Nine components (germacrene D, 
α-pinene, β-myrcene, sabinene, α-humulene, β-elemene, 
trans-E-caryophyllene, γ-elemene and γ-cadinene) showed 
statistical significance and hence were identified as 
discriminatory variables.  
Conducted PLS analysis pointed to the relation of 
discriminatory variables with the year and  geographical 
region of harvesting, as well as the mean maximal, mean 
average and mean minimal temperature in the month of 
collection (October). The PLS analysis suggested a model 
with four components that explained 94% (R2Y) of the 
variables with prediction (Q2) of 90.2%. Statistical analysis 
of the results enabled determination of significant variables 
and establishment of correlation between the oil chemical 
compositions and/or the harvesting year, geographical 
region and mean temperature values. 
Conclusion
The GC/MS analyses of the chemical composition of 
the essential oils isolated from the berries of Macedonian 
juniper revealed presence of 93 components in total. HCA 
resulted with dendrogram where the samples were grouped 
in two clusters, one correlated with two monoterpene hy-
drocarbons, and second with the sesquiterpene hydrocar-
bons fraction. With PLS-DA, nine discriminatory variables 
were identified with statistical significance. Generally, the 
chemical composition of the juniper oil from RM is affect-
ed by the temperature and/or the year of harvesting.
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Introduction
Salvia species, commonly known as sage, have been 
used since ancient times for treatment of many different 
ailments, aches, epilepsy, colds, bronchitis, tuberculo-
sis, hemorrhage, and menstrual disorders. Although there 
are around 1000 species of Salvia, only the pharmacopoe-
ial herbs (Salvia officinalis L. and Salvia fruticosa Mill-
er) have significant commercial importance (Dincer et al., 
2013).
Essential oil, polyphenols and terpenes are considered 
as main chemical compounds responsible for the pharma-
cological activity of these species (Kintzios, 2000; Ramos 
et al., 2010).
S. fruticosa (Greek sage) is an endemic species of the 
Eastern Mediterranean basin and is the most widespread 
sage species in Greece (Kintzios, 2000; Ramos et al., 
2010). The leaves of this herb have been used for treat-
ment of various skin, blood, and infectious ailments (Ali-
Shtayeh et al., 2000) while the essential oil is effective 
against different microorganisms. Greek sage posses hy-
poglycemic effect and can be used against inflammations, 
hepatitis, and tuberculosis (Pitarokili et al., 2003). 
However, the most studies have focused on the essen-
tial oil, while there are few reports regarding the phenolic 
composition (Kintzios, 2000). 
Therefore, the aim of the present study was to examine 
the polyphenolic profile of 15 different wild growing pop-
ulations of S. fruticosa from Greece and Albania. 
Materials and methods
Plant material (Salvia fruticosa Mill., Lamiaceae), was 
collected from 15 different indigenous populations from 
nine different locations from Greece (Kavoussi - 2, Rhi-
zoscaro - 2, and Vrysses - 2) and Albania (Porto Palermo-
Qeparo - 4, Llogora -1 , Dhermi - 1, Borsh - 1, Ilias Vuno - 
1, and Palase - 1). The leaves were air dried, packed in pa-
per bags and kept in a dark and cold place until analysis. 
Plant identity was verified and voucher specimens were de-
posited at the Institute of Pharmacognosy, Faculty of Phar-
macy, Skopje, R. Macedonia.
The 70% methanolic extracts were prepared in ultra-
sonic bath by the method described by Cvetkovikj et al. 
(2013).
Qualitative analysis was carried out using an HPLC 
system from the Agilent 1100 series with photo-diode ar-
ray and mass detector (G2445A Ion-Trap Mass Spectrom-
eter) equipped with an electrospray ionization (ESI) (Ag-
ilent Technologies, Waldbronn, Germany), controlled by 
LCMSD software (Agilent, v.4.1). MS data were acquired 
in the negative ionization mode. The eluents were: formic 
acid (1%, V/V) (A) and acetonitrile (B) and the separations 
were achieved using the method established by Cvetkovikj 
et al. (2013), on a Zorbax Eclipse XDB RP C-18 column 
(150 mm × 4.6 mm, 5 μm, Agilent, Germany), protected 
with a guard column (4 mm × 4.6 mm, RP-18, 5 μm, Ag-
ilent, Germany). The phenolic compounds were identified 
using their UV and mass spectral data (deprotonated mo-
lecular ions and their corresponding fragments and losses). 
S5 PP 242
508
Maced. pharm. bull., 62 (suppl) 507 - 508 (2016)
Medicinal and aromatic plants
Po
st
er
 p
re
se
nt
at
io
ns
Results and discussion
With HPLC–DAD–ESI-MSn, qualitative character-
ization of 15 different extracts from Greek sage was per-
formed and a total of 37 different compounds were detect-
ed. The detected compounds were classified in five groups: 
12 derivates of hydroxycinnamic acid were the predom-
inant group, followed by the group of 12 flavone glyco-
sides of luteolin or apigenin, six phenolic diterpenes, five 
flavones and only one flavanone glycosides of hispidulin. 
Rosmarinic acid together with the flavone, nepetin 
(6-hydroxyluteolin 6-methyl ether), and the phenolic di-
terpene (rosmanol isomer) were detected in all 15 exam-
ined S. fruticosa samples. Thirteen compounds (luteo-
lin diglucoronide, luteolin 7-O-glucuronide, luteolin 7-O-
glucoside, hydroxyluteolin 7-gucuronide, apigenin 7-O-
rutinoside, hispidulin7-O-rutinoside, apigenin 7-O-glu-
coside, apigenin glucoronide, salvianolic acid K, rosma-
rinic acid, rosmanol isomer, carnosol isomer and eupato-
rin) were found in amounts higher than 5.00% in at least 
one population and were considered as principal compo-
nents of the methanolic extracts. Rosmarinic acid was pre-
dominant constituent (32.72-59.88%), followed by luteolin 
7-O-glucuronide (6.18-19.35%), salvianolic acid K (5.73-
21.62%) and rosmanol isomer (1.48-12.56%). 
Statistical analysis of variance (ANOVA) of the 13 
polyphenolic compounds detected in the extracts from S. 
fruticosa from nine different localities from two Balkan 
countries (Greece and Albania) revealed that there wasn’t a 
statistically significant difference in the polyphenolic com-
position of the S. fruticosa populations, regardless its ori-
gin.
The obtained results for the polyphenolic characteriza-
tion of the methanolic extracts were in accordance with the 
available literature. Ecarschou et al. (2002) identified ros-
marinic acid as major constituent in the ethanolic extracts 
while hispidulin, savigenin, cirsimaritin and the diterpenes 
casrnosic acid, carnosol and 12-methoxycarnosic acid were 
predominant compounds of the ethyl acetate extracts that 
showed antifungal activity (Exarchou et al., 2015). In eth-
yl-acetate and n-butanolic extracts from S. fruticosa from 
Crete, Greece, rosmarinic acid was not detected but deri-
vates of ferulic acid and flavone glycosides as well as de-
rivates of luteolin were identified and were considered as 
dominant components (Atwi et al., 2016).
Conclusion
With LC/DAD/ESI-MSn analysis of 15 specimens 
of S. fruticosa from Greece and Albania, 37 polypheno-
lic compounds were detected, where as predominant group 
were considered the hydroxycinnamic acid derivates, with 
rosmarinic acid present with more than 30% in all anal-
ysed populations. The flavone glycosides of luteolin and 
apigenin were second dominant group. Qualitative anal-
ysis showed no statistically significant difference in the 
polyphenolic composition indicating that the polypheno-
lic profile of S. fruticosa is more species allied rather than 
locality related.
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Introduction
The value of medicinal plants to the mankind is very 
well proven. It is estimated that 70 to 80% of the people 
worldwide rely chiefly on traditional health care system 
and largely on herbal medicines (Farnsworth and Soejarto, 
1991; Shanley and Luz, 2003; Shengji, 2002).
Natural medicinal raw material of plant origin has ap-
plication in therapy of the all pharmacological indication. 
More and more, they are taking integral part of the official 
pharmacy and because of their use in official therapy, they 
rising to a higher level continually.
However, the application of the medicinal plant raw 
material in dentistry is much smaller. 
Although, stomatology can be classified as medical or 
health community, still it has own specifications. For this 
reason, it can be induced the possibility for using plant ma-
terial in treatment of caries, dental plaque, gingivitis, peri-
odontal disease. The application is possible for different 
oral inflammations as they represent anti-inflammatory, an-
timicotic and antiviral agent. 
Furthermore, it is important the possibility for applica-
tion, different plant material and their products in prepara-
tion for oral hygiene. Permanent progress of stomatology 
as scientific area results with introduction of a new tech-
nology and new synthetic drugs but these impose also the 
use of potential natural medical raw material.
The carriers of pharmacological effects in plant mate-
rial are different chemical substances: tannins, flavonoids, 
saponins, anthraquinones and their products: essential oil, 
mucus, balsams etc. (Samuelsson, 2004).
Accordingly, the aim of this study was assessment of 
the plant material and the extracted chemical substances 
capacity in stomatology practice.
Material and methods
In this study 25 different medical plants were presented 
and additionally was estimated their potential application 
in stomatology due to their content of chemical defined and 
pharmacological active substances. 
Results and discussion
For the purpose of the study, 25 different medical plants 
were discussed: Ononidis radix is used for rinsing the 
mouth with toothache due to the triterpenes and flavonoids; 
Plantaginis radix, used against toothache (iridoids and 
aucubine); Tormentillae rhizome, for toothache and 
for oral inflammations, while ground herbal powder is 
effective for teeth due to tannins; Rubi fruticosi folium, 
to strengthen the right (flavon glycosides, phenolic acids, 
galotannines); Solidaginis virgaureae herba is used for 
inflammation of the oral mucosa as it contains flavonoids 
(rutin, quercetin); Benzoe tinkinensis, as addition to 
preparation for mouthwash (benzoic acid); Symphyti radix 
- mouthwash (tannines, alkaloids, alantoin); Caryophylli 
flos for toothache for inflammation of the oral mucosa, 
to reduce local pain and in dentistry (due to the presence 
of the essential oil components: eugenol, aceteugenol, 
β-caryophyllene); Verbasci flos as mouthwash, while the 
root is used for toothache (iridoid glycosides: aucubin, 
saponins, flavonoids); Zingiberis rhizome is used as 
toothpaste and for mouthwash and gargle (gingerol, 
essential oil components: zingiberen, citral); Caricae 
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fructus for ulcers treatment; Aloe capensis to treat diseases 
of the oral cavity (anthracene derivatives); Anisi fructus 
removes the bad odor from the mouth due to anethole and 
anisaldehyde; Frangulae cortex can be used against the 
purulent processes teeth (anthraquinones); Millefolii herba 
for toothache (essential oil, azulene); Althaeae radix as 
mouthwash; Capsici fructus, for garglingin inflammation 
of the mouth and pharynx (capsaicinoids, essential oil, 
carotenoids); Myrrha for halitosis and also has the potential 
to strengthen the teeth (essential oil: eugenol, m-cresol, 
alcohols); Melissae folium against deposits in the mouth 
and as toothache (essential oil: citronellal, citronellol, 
nerol, geraniol, citral); Menthae piperitae folium is used as 
toothpaste (essential oil: menthol, menthone, menthofuran); 
Chamomillae flos as toothpaste (essential oil: chamazulene, 
bisabolol, farnesene, flavonoids); Iridis rhizome as tooth 
powder, (essential oil); Basilici herba as toothpaste 
(essential oil: 1,8-cineole, linalol, methyl chavicol); 
Salviae folium as gargling agent and for disinfection of the 
mouth (essential oil: thujones, 1,8-cineole, borneol) and 
Aetheroleum Melaleucae for inflammatory processes due 
to the presence of 1,8-cineole (Heinrich, 2004).
Plant products have long been used in dentistry as part 
of various dental materials right from impression materials 
to eugenol, which forms an integral part of the dental 
clinic. The use of herbs in dental practice is not limited 
to only material sciences. A single herb shows a variety 
of effects like anti-inflammatory, antibacterial, antifungal 
activity and many more. Hence the incorporation of these 
herbs in dental practice will prove to be a valuable adjunct 
in dental treatment.
Conclusion
The use of natural medicinal raw materials is 
constantly increasing. The use in dentistry is not monitored 
enough. However, the above example of uses of medicinal 
plant material gives a broad possibility. Phytotherapeutic 
treatment in dentistry may include all of the most common 
toothache to the incorporation of the implant.
This paper is only an introduction for future clinical 
and laboratory investigation as a momentum for return to 
herbal medication in the treatment of different infective 
diseases in stomatology.
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Introduction 
Essential oils are natural products or complex 
mixtures of hundreds of chemical compounds isolated 
from aromatic plants. Most of these compounds can be 
grouped into four major groups: aliphatic compounds, 
terpenes and terpene derivatives, benzene derivatives and 
miscellaneous compounds (Oyen and Dung, 1999). They 
represent the base in the perfume production. However, in 
the analysis of certain types of perfume, it can be examined 
from which plant species are used essential oils for their 
product (Kovac-Besovic, 2001). 
Essential oil and plant materials containing such oils 
are natural products of great economic importance. Their 
main use is in perfumery, cosmetics, flavoring food and 
drink, for scenting incense and cleaning product (Sarac, 
2009). All the world’s leading brands of the highest quality 
perfumes use not one, but several different essential oils. 
With their combination, are achieved a number of so-
called “fragrance notes” by which they are famous and 
required. In pharmaceutics, essential oils are used to give 
drugs an agreeable smell or taste. A few essential oils or 
pure compounds isolated such oils are used directly as 
medicines due to their antimicrobial, antifungal or anti-
inflammatory activity (Samuelsson, 2004).
Thin layer chromatography (TLC) within a short 
period of time has become most important technique for 
the identification, characterization and determination 
of chemical compounds as well as complex mixtures 
(Nigam et al., 1965). With this technique can be analyzed 
the chemical substances of natural and synthetic origin 
(Kovac-Besovic, 2001).
Therefore the aim of the present study was to determine 
and confirm the essential oil components used for perfume 
production with thin layer chromatography.
Materials and methods
In this study were analysed five different commercial 
perfumes taken randomly, marked as sample 1, 2, 3, 4 and 
5. The contents written of the label (declaration) of each of 
the perfume gives the presence of chemical substances that 
are integral components of different essential oils derived 
from various plant materials.
The label given for perfume No. 1 declared the 
following components: linalool, geraniol, isoeugenol, 
limonen, citral, citronelal.
The label given for perfume No. 2 declared the 
following components: linalool, geraniol, citral, citronelal. 
The label given for perfume No. 3 declared the 
following components: linalool, geraniol, eugenol, 
limonen, citral, citronelal.
The label given for perfume No. 4 declared the 
following components: linalool, geraniol, isoeugenol, 
limonen, citral, citronelal, farnesol.
The label given for perfume No. 5 declared the 
following components: linalool, geraniol, limonen, citral, 
citronelal.
Components of the essential oils and extracts of 
plant material used as base for perfume production and 
chromatographic analysis were: Aetheroleum Rosae 
(geraniol, citronelol), Aetheroleum Lavanulae (linalool), 
Aetheroleum Citri (citral), Aetheroleum Melissae (citral 
and citronelal), Aetheroleum Caryophylli (eugenol), 
Aetheroleum Aurantii floris (farnesol).
One mL of different essential oils was diluted with 
toluene and 5 μL were used for TLC. 
Commercial perfumes were prepared in toluene in 
ratio 1:30 (Wagner and Bladt, 1996).
As TLC adsorbent, silica gel GF254 was used, while 
toluene-ethyl acetate in ratio 93:7 was used as mobile 
phase for separation of the components from the essential 
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oils as well as the perfumes. The detected components were 
visualized under UV lamb on 254 nm and 366 nm, while 
p-anisaldehyde-sulfuric acid was used as spray reagent.
The mobile phase is suitable for the analysis and 
comparison of all important essential oils, but the 
plates obtained with chloroform (Melissae folium) and 
dichlormethane (Caryophylli aetheroleum, Lavandulae 
aetheroleum), can be used as solvents systems for the drugs 
and their essential oils.
Results and discussion
Preliminary experiments were done on five randomly 
provided perfumes to determine and confirm the nature 
of constituents present (declared on the label), using a 
mixture of toluene-ethyl acetate (93:7) as developing 
solvent. Additionally, essential oils (Aetheroleum 
Rosae, Aetheroleum Lavandulae, Aetheroleum Citri, 
Aetheroleum Melissae, Aetheroleum Caryophylli, 
Aetheroleum Chamomillae) and plant material that 
naturally contain the target components were used. 
Performing TLC, visualized with p-anisaldehyde sulfuric 
acid and seen under UV lamp at 254 nm and 366 nm, in 
all investigated samples were detected: linalool, geraniol, 
citral and citronellal. In four samples was detected lemon, 
in two samples farnesol and isoeugenol, eugenol in one 
sample, while in three samples was identified coumarin. 
Conclusion 
The examples described above show that TLC has the 
ability to separate mixtures of substances of similar structure 
as are the perfumes and essential oils. Additionally it is 
important to mention that using TLC different perfumes 
were evaluated for their content declared on the labels 
provided from the manufacturer. Finally this was done 
with cheap and easy to perform technique.
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Introduction
Among the aromatic plants belonging to the Lamiace-
ae family, numerous of species and varieties of wild-grow-
ing plants of the genus Thymus are very important. Thy-
mus species are well known as medical plants that con-
tain tannins and flavonoids and are considered as aromat-
ic due to their essential oil content. Several studies empha-
sized the existence of marked chemical differences among 
essential oils extracted from different species or varieties. 
This chemical diversity is generally a function of three fac-
tors: genetical and physiological factors as well as the en-
vironmental conditions, that can affected the biological ac-
tivity of the oils (Mustafa et al., 2012).
Production of essential oils by plants is believed to 
be predominantly a defense mechanism against pathogens 
and pests as essential oils have been shown to possess an-
timicrobial and antifungal properties. Nowadays, essen-
tial oils and theirs components are gaining increasing in-
terest because of their relatively safe status, their wide ac-
ceptance by consumers and their exploitation for potential 
multi-purpose functional use (Mohammadi et al., 2013).
Beside this, the representatives of genus Thymus from 
Kosovo were poorly investigated in the past thus the aim 
of this study was essential oil chemical analysis of several 
wild-growing Thymus species collected from different lo-
cations in Kosovo.
Material and methods
Total of 20 samples of eight wild-growing Thymus 
species were analyzed. The samples of Thymus tosevii 
(Ošljak and Zapluže), Thymus jankae (Zapluže), Тhymus 
longicaulis (Belobrod), Thymus pulegioides (Vata), Thy-
mus moesiacus (Brezovica and Prevalla), and Thymus to-
sevii ssp. substriatus (Glloboçica) were collected from lo-
calities in South Kosovo. The samples of Thymus balcanus 
were collected on Ljumbard Mtn., West Kosovo while the 
sample of Thymus pannonicus from Gërmia, East Kosovo.
Plant material was harvested in full flowering stage 
during summer, 2013. The material was put on the paper 
sheets in a shade and left to air dry. Essential oils were iso-
lated by steam distillation in a Clevenger-type apparatus 
for 3 hours. 
The essential oil composition was analyzed by GC/
FID/MS on Agilent 7890А Gas Chromatography system 
equipped with flame ionization detector (FID) and Agile-
nt 5975C Mass Quadripole detector. Operating conditions 
were as follows: oven temperature 60 °C (5 min), 1 °C/min 
to 80 °C (2 min) and 5 °C/min to 280 °C (5 min); flow rate 
of 1 mL/min (He); injector T=260 °C; FID T= 270 °C; 1 
µL injection volume at split ratio 1:1.
The MS was operated in scan mode. Identification of 
the components present in essential oils was made by com-
paring mass spectra of components in essential oils with 
those from NIST, Wiley and Adams mass spectra libraries, 
by AMDIS (Automated Mass Spectral Deconvolution and 
Identification System) and by comparing literature and es-
timated Kovat′s (retention) indices that were determined 
using mixture of homologous series of normal alkanes 
from C9 to C25 in hexane, under the same above mentioned 
conditions. The percentage ratio of essential oils compo-
nents was computed by the normalization method of the 
GC/FID peak areas and average values were taken into fur-
ther consideration.
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Results and discussion
With gas chromatography, 140 compounds were iden-
tified in essential oil samples of T. balcanus (South Koso-
vo), representing 76.23-98.62% of the oil. Sesquiterpens 
were found as predominant components, with E-caryoph-
yllene (26.96%) as the most abundant compound. One oil 
sample has showed extremely deferent composition with 
monoterpene linalool (59.51%) as major constituent. Com-
pared with literature, similarities were found with the es-
sential oil isolated from T. balcanus from R. Macedo-
nia, which contains E-caryophyllene (22.42%), β-pinene 
(12.48%) and α-pinene (5.64%) as main constituents (Ku-
levanova et al., 1998).
On the other hand, 78 compounds were identified in 
the essential oil samples of T. jankae (South Kosovo), rep-
resenting 97.62% of the total oil. Monoterpenes were iden-
tified as main compounds (83.27%) with linalool acetate 
(19.89%), carvacrol (13.84%) and linalool (10.33%) as 
predominat constituents. Large amounts of linalool (28.1-
35.5%) were also found in essential oils of the Macedo-
nian T. jankae (Baba mountain) (Kulevanova et al., 1998).
Oxygenated monoterpens (75.01%) were dominated 
fraction in the essential oil of T. longicaulis. As main com-
pounds were detected alcohols linalool (37.69%) and ge-
raniol (17.73%) followed by other monoterpenes such as: 
β-myrcene (5.87%), terpinen-4-ol (4.79%) and cis-sabi-
nene hydrate (4.18%). 
The chemical profile of two samples of T. moesia-
cus (Brezovica and Prvale) was characterised with gerani-
ol (13.82% and 13.12%, respectively) and linalool (6.86% 
and 10.61%, respectively). The phenolic compound thy-
mol was determined in higher percent (13.97-19.02%) in 
the oil sample from Brezovica whereas carvacrol (22.33%) 
was dominated in the sample from Prevale. These four 
compounds represented 52.32-53.47% of total oils.
Sesquiterpens were predominant in the essential oil 
of T. pannonicus (72.25%) with germacrene D (17.98%) 
as main constituent. Larger amount of germacrene D 
(12.12%) was found in the oil samples of T. pannonicus 
from Romania, but the most abundant component in this 
oil was α-terpinyl acetate (48.83%) (Boz et al., 2011).
47 compounds were identified in one essential oil sam-
ple from T. pulegioides from Vata (South Kosovo), repre-
senting 99.29% of the oil. The oxygenated monoterpenes 
thymol (33.48%) and geraniol (23.36%) were the main 
constituents. Large amounts of γ-terpinene (10.49%) were 
also found. These three constituents represented 67.33% of 
the total oil. 
The quantitative variability of linalool (2.23-30.79%) 
was also noticed in three samples of T. tosevii followed by 
different percentages of thymol (1.23-5.41%) and carvacrol 
(2.29-40.34%), as well as linalool acetate (0.48-22.33%). 
Variability in the essential oil composition of T. tosevii was 
previously reported by Kulevanova et al. (1996) for the 
samples from Macedonia. The content of some important 
constituents of the oil varied in broad ranges such as 7.88-
20.92%, 0.24-21.79%, 0.58-30.08% and 0.05-26.87% for 
linalool, geraniol, thymol and carvacrol, respectively (Ku-
levanova et al., 1996).
The alcohol linalool (30.78%) was determine as main 
constituent in the oil of Thymus tosevii ssp. substriatus fol-
lowed by high quantities of linalool acetate (21.77%) and 
thymol (13.21%).
Conclusion
Chemical composition of essential oils of eight Thy-
mus species from Kosovo had showed great variability. As 
the essential oils of Thymus are valuable because of some 
monoterpene phenols and alcohols (thymol, linalool, gera-
niol), the most of the species (T. pulegioides, T. tosevii, T. 
tosevii ssp. substriatus, T. moesiacus, T. jankae and T. lon-
gicaulis) from Kosovo represent biological source of es-
sential oil that could be use for exploitation and further uti-
lization. On the other hand T. balcanus and T. pannonicus 
can be exploited for isolation of the sesquiterpene com-
pounds, germacrene D and E-caryophyllene, which were 
predominant constituents in the oils of these species. 
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Introduction
Nowadays, the use of cannabis and its legalization 
for medical use has become a worldwide trend, due to his 
significant pharmacological effects. Due to the legal con-
straints on the possession and use of C. sativa, relatively 
little research on the medicinal qualities of this plant has 
been conducted. Ben Amar (2006) has recently shown that, 
the therapeutic applications of cannabis and its derivatives 
have been studied by various world bodies, including the 
Scientific Committee of the House of Lords in Great Brit-
ain, the Institute of Medicine in the United States and the 
Senate Special Committee on Illegal Drugs in Canada. 
Since there is a lack of valuable and reliable information 
about the routes of cannabis administration and dosage, in 
this review, we have done overview of six different ways of 
medical cannabis administration, their risks and benefits. 
Smoking
Smoking cannabis produces the most immediate relief 
and permits the most refined control of the dosage. When 
cannabis is smoked, the active ingredients are deposited di-
rectly into the blood stream, after being absorbed through 
the mucus membrane of the lung. Whereas the central ner-
vous system and physiological effects occur within min-
utes by the smoking route or by vaporization, these effects 
proceed on a time scale of hours in the case of oral inges-
tion. 
Determining correct dosage is easier with smoked can-
nabis, since the effects are usually felt within 30-60 sec. 
and develop fully within 5-15 min. The effects may last 
from 30 min. to 3 h. 
Using natural-based chemical free rolling papers, such 
as those derived from hemp or rice is recommended for 
health reasons and to avoid using tree products. Although 
medical marijuana is nontoxic, smoking it can be hazard-
ous over the long term, because toxic compounds are cre-
ated in the combustion process. The World Health Organi-
zation (WHO) suggests that a typical marijuana cigarette 
(joint) contains between 0.5 g and 1.0 g of cannabis (av-
erage 0.75 g). Commercially available strains of cannabis 
can contain up to 30% THC. An average joint of a 10% 
THC cannabis strain would contain 75 mg of THC (0.75 g 
x 10% THC content).
Vaporizing 
Vaporizers can be used as a smokeless alternative. 
Cannabis vaporizers are designed to let users inhale ac-
tive cannabinoids while avoiding smoke. Vaporizers work 
by heating the cannabis just below the point of combus-
tion, the point at which smoke is produced. When the can-
nabis is properly heated, THC and other cannabinoids are 
emitted in the form of a vapor. This markedly reduces the 
amount of irritating particulate materials that get inhaled, 
resulting in much less inflammation and damage to the lin-
ing of the lungs. Many patients who find smoked cannabis 
highly irritating, report effective relief inhaling through va-
porizers. Dose is through self titration (gradually adjusting 
the dose of medicine, until the desired effect is achieved).
Using vaporizers, typically between 50 mg and 500 
mg of dried marijuana is used at once. Using a 10% THC 
strain would mean that between 5 mg and 50 mg of THC 
would be contained in this dose.
Sublingual delivery
The sublingual (under the tongue) or oro-mucosal (in 
the oral cavity) delivery method of an oil or tincture pro-
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vides another rapid onset of action as the medication is 
readily absorbed into the blood system. Tinctures are usual-
ly prepared in a base of alcohol, oil or glycerol. Many con-
centrated tinctures are taken by dropper under the tongue, 
and within a few minutes the patient will feel the effects. Ef-
fects of tinctures are usually felt within 5 min. up to 1 h and 
last about 4 h. It is recommended to start with about 3 drops 
of tincture, and wait an hour before increasing the dosage 
incrementally and as necessary. Other tinctures may be in 
a spray container and sprayed in the mouth to be absorbed 
in the oral cavity and thence into the bloodstream. The sub-
lingual spray is a compromise between the inhaled and oral 
routes: compared to the oral administration, it reduces the 
first-pass metabolism, thus increasing the bioavailability of 
the drug and allowing a greater dose-titration.
Oral ingestion
Oral administration results in a slower onset of action, 
lower peak blood levels of cannabinoids and a longer du-
ration of pharmacodynamic effects, compared to smoking. 
Taking cannabis by mouth in pill form or swallowed as a 
liquid, have both benefits and drawbacks. Since the canna-
binoids are fat-soluble, their absorption through the gut is 
slower and less predictable, being dependent upon the indi-
vidual’s metabolism as well as the contents of the stomach. 
The onset of action may take as long as 30 min. to an hour, 
making it more difficult to determine an effective dose, 
especially for the novice patient. In addition, when taken 
orally, the medication gets metabolized through the liver 
before getting into the bloodstream. The liver converts the 
THC to another chemical, called 11-hydroxy-THC which 
is more psychoactive than THC, and so the effects will be 
different than if inhaled or taken sublingually. The advan-
tage of the oral route is that it will last much longer, so a 
patient does not have to medicate as frequently. This can be 
helpful for glaucoma patients who are trying to maintain a 
lower intraocular pressure (Mathre, 2015).
Topical application
Cannabis can be applied externally as a topical oint-
ment, lotion, or poultice, and may be used in the treatment 
of skin inflammations, arthritis or muscle pains. The goal 
is for the medication to be absorbed at the specific location 
being treated. Although it is unclear how well the cannabi-
noids are absorbed through the skin, the more soluble ter-
penoids and flavonoids also have anti-inflammatory prop-
erties that can be effective.
Rectal administration
Rectal administration of marijuana has many advan-
tages. In addition to be a viable option for patients who 
can’t ingest or inhale cannabis, cannabis suppositories are 
the best choice. Cannabis suppositories are made either 
cannabis-infused coconut oil or cocoa butter infused with 
FECO oil (full infused cannabis oil). Avoiding the gastro-
intestinal tract, prevents metabolism by the stomach and 
liver, which breaks down the many different cannabinoids 
into their constituent parts (including THC), and allows the 
active constituents to reach the blood in much higher con-
centrations.
50% of THC is usually transformed into its more 
psychoactive form, 11-Hydroxy-delta-9-tetrahydrocan-
nabinol, when taken orally. Rectal administration avoids 
these effects, whilst allowing a higher proportion of THC 
to reach the bloodstream. While Δ9-THC itself is not ab-
sorbed through the rectal route, the pro-drug Δ9-THC-
hemisuccinate is absorbed; this fact, combined with de-
creased first-pass metabolism through the rectal route, re-
sults in a higher bioavailability of Δ9-THC by the rectal 
route (52-61%) than by the oral route. In humans, rec-
tal doses of 2.5-5.0 mg of the hemisuccinate ester of Δ9-
THC were associated with peak plasma levels of Δ9-THC 
ranging between 1.1 and 4.1 ng/mL within 2-8 h, and peak 
plasma levels of carboxy-Δ9-THC ranging between 6.1-
42.0 ng/mL within 1-8 h after administration (Abramov-
ici, 2013).
Conclusion
It is important to remember that in addition to dif-
ferences in the amount of cannabis used with the various 
routes of administration, each on is different with respect 
to the percentage of THC/ other cannabinoids that it deliv-
ers to the system and the timing of that delivery. For each 
pathology, it remains to be determined what type of canna-
binoid and what route of administration are the most suit-
able to maximize the beneficial effects of each preparation 
and minimize the incidence of undesirable reactions. To 
maximize the benefits (efficacy) and reduce the undesir-
able effects (toxicity), new formulations for administering 
and delivering cannabinoids are currently under investiga-
tion.
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Clinical pharmacy services –impact on health care 
Current clinical pharmacists play a critical role in thera-
peutic management and medication safety by applying their 
pharmacotherapeutic expertise to ensure rational and effec-
tive medication use and optimal patient outcomes (ACCP, 
2008). Close collaboration with physicians, nurses and oth-
er healthcare providers in interdisciplinary teams is vital.
Many studies have evaluated the role of a clinical 
pharmacist and the impact of clinical pharmacy services 
in different patient groups in both outpatient environments 
(community pharmacies and ambulatory clinics) and in-
patient facilities (teaching hospitals and nursing homes), 
(Anderson and Schumock, 2009; Gallagher et al., 2014; 
Rotta et al., 2015) and in various specialty settings (e.g. 
emergency department) (Davis et al., 2016; Lada and Del-
gado, 2007). 
Clinical pharmacy interventions – clinical and 
economic benefits
One of the main activities of clinical pharmacists are 
clinical interventions and they are described in several 
ways (Alderman and Farmer, 2001; Kjeldsen et al., 2014; 
Westerlund and Marklund, 2009). Most literature reviews 
conclude that clinical pharmacy interventions contribute 
to improve patient outcomes and cost savings focusing 
on specific clinical benefits (e.g. reduced adverse drug ef-
fects and medication errors, enhanced medication adher-
ence, appropriate use of medications and prescriptions) 
and economic benefits (e.g. cost-effectiveness) (Anderson 
and Schumock, 2009; Gallagher et al., 2014; Touchette et 
al., 2014). However, studies differ regarding their method-
ology and outcomes measures, and the description of phar-
macist interventions and their implementation are incon-
sistent (De Rijdt, 2008; Rotta et al., 2015).
Pharmacy students - clinical contributions
Academia shapes the culture of clinical pharmacy by 
training future professionals, e.g. in experiential practice 
rotations (Rathbun et al., 2012). Previous studies examin-
ing pharmacy students’ interventions in a variety of prac-
tice settings have documented their clinical and econom-
ic benefits; however, there are differences regarding study 
scope, design, and level of detail (Divall et al., 2010; Mers-
felder and Bouthillier, 2012; Shepler, 2014; Shogbon and 
Lundquist, 2014; Woolley et al., 2013). Although studies 
quantify and categorize student interventions, few provide 
specific details or discuss trends and the impact of clinical 
pharmacy preceptors on pharmacy students’ clinical con-
tributions (Divall et al., 2010; Mersfelder and Bouthilli-
er, 2012; Woolley et al., 2013).
Clinical preceptor - impact on pharmacy student 
interventions
This presentation focuses on the daily practice of a 
clinical pharmacy preceptor and academician in a large 
teaching institution in educating future pharmacists to pro-
vide clinical pharmacy services, specifically through iden-
tifying and communicating pharmacotherapeutic interven-
tions and consults and documenting their outcomes. 
It includes the results of a recent study assessing the 
quantity, characteristics, and acceptance rate of 1172 inter-
ventions performed by 30 pharmacy students at an inpa-
tient institution under the guidance of this preceptor (Tal-
bot et al., 2015).
S6 OP 247
* dorothea.rudolf@mephs.edu
520
Maced. pharm. bull., 62 (suppl) 519 - 520 (2016)
O
ra
l p
re
se
nt
at
io
ns
Clinical Pharmacy / Pharmaceutical chemistry / Biomolecular Sciences
Study methods
During their mandatory 6-week inpatient advanced 
practice experiential rotations, pharmacy students accom-
panied medical teams on daily rounds, seeing patients on 
one of three general medicine floors. Under the direct su-
pervision of the same preceptor, the students suggested 
drug therapy-related interventions, modifications of phar-
macotherapy to enhance patient care and safety. Students 
documented their interventions in a detailed log, including 
date, brief summary of the clinical situation, description of 
suggested intervention with evidence-based justification, 
and medical team’s acceptance or rejection.  Each inter-
vention was reviewed for appropriateness by the preceptor. 
Intervention data was categorized by acceptance/rejection, 
stratified into specific intervention types, and qualified by 
therapeutic classes and specific medications involved. De-
scriptive statistics were used in the analysis.  
Study results
The mean number of interventions/student/rotation 
was 39 (range: 8-83). Overall, the medical team accept-
ed 84% of suggested interventions; 4% were partially ac-
cepted. Most common intervention types were: adjusting 
dose/frequency/duration to match indication (17%), initi-
ating indicated medication (12%), renally adjusting dose/
frequency/duration (10%), changing administration sched-
ules to prevent interactions (6%), and discontinuing non-
indicated medications (6%). Therapeutic classes most fre-
quently involved were: antibiotics (24%), gastrointestinal 
agents (22%), cardiovascular drugs (13%), supplements 
(10%), and CNS medications (9%). Overall, 214 unique 
medications were associated with interventions, most com-
monly omeprazole (12%), vancomycin (7%), warfarin 
(3%), ciprofloxacin (3%), and cefepime (2.3%). Students’ 
weekly intervention rate increased as rotations progressed. 
Study conclusion
It was concluded that the high number of clinical inter-
ventions cataloged by this study emphasizes the significant 
impact that Pharmacy students can have on educating pro-
viders and enhancing patient care.  The increasing weekly 
intervention suggestion rate is likely related to students de-
veloping familiarity with the medical team, gaining aware-
ness of therapeutic problems, and building confidence in 
initiating and substantiating interventions. The high accep-
tance rate may be indicative of the medical teams’ past pos-
itive experiences with the students’ valuable clinical phar-
macy contributions. The quality of these beneficial inter-
ventions was likely augmented by consistent preceptorship. 
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Introduction and objective
Clinical pharmacy in Slovenia includes all services 
performed by pharmacists practising in clinics and hospi-
tals, community pharmacies, community health centres, 
nursing homes and other settings where medicines are pre-
scribed and used. Its main mission is to move the focus of 
attention from the drug to the single patient or population 
receiving drugs.
Clinical pharmacists in Slovenia are following the 
overall goal of clinical pharmacy activities, i.e., to promote 
the correct and appropriate use of medicinal products and 
devices. These activities aim to:
• maximize the clinical effect of medicines, i.e., us-
ing the most effective treatment for each individual patient,
• minimize the risk of treatment-induced adverse 
events, i.e., monitoring the therapy course and the patient’s 
compliance with therapy, and
• minimize the expenditures for drug treatments, i.e., 
trying to provide the best treatment alternative accompa-
nied by the cost-effective use of drugs for the greatest num-
ber of patients.
The aim of this contribution is to present recent 
achievements and perspectives of clinical pharmacy in 
Slovenia in terms of professional, educational and research 
activities.
Methods
Clinical pharmacists in Slovenia have carried into ef-
fect all well established methodological approches to im-
plement clinical pharmacy activities at primary, secondary 
and tertiary level of the healthcare system. The term “clini-
cal” describes the type of activities which are related to the 
health of the patient(s) in general and as such does not nec-
essarily imply an activity implemented only in a hospital 
setting but also in the community care. 
Results
Professional activities at primary level
There are two types of services that are devoloping 
currently in community care: first, offering medication re-
view in community pharmacies and second, establishing 
the practice of pharmacist-consultant on ambulatory (out-
patient) basis in community health centres and in nurs-
ing homes. Medication review, performed in community 
pharmacies, evaluates patient’s medicines with the aim of 
managing the risk and optimizing the outcome of medi-
cine therapy by detecting, solving and preventing drug-re-
lated problems. It helps patients use their medicine more 
effectively by improving knowledge, concordance and 
use of medicines.  It is offered as Medication use review 
which includes medication history and patient information, 
and Advanced medication review which is based on med-
ication history, patient information and clinical informa-
tion. Clinical information is obtained from patient’s medi-
cal records and direct contact between dispensing pharma-
cist and attending physician. Medication use review is per-
formed by pharmacist with competences, while Advanced 
medication review should be carried out only by specialist 
clinical or community pharmacist with appropriate com-
petences. 
The practice of pharmacist-consultant, performed on 
ambulatory (outpatient) basis has been introduced at the 
end of 2012 as a project run by Health Insurance Institute 
of Slovenia. The main purpose of the project is to bring to-
gether general practitioners and pharmacists to work close-
ly in order to ensure proper use of drugs in clinical prac-
tice. Multistep procedure is started by general practitio-
ner who identifies either patients with potential drug ad-
verse reactions or patients with potential drug-drug inter-
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actions in the case of polypharmacotherapy. These patients 
and their medical records are referred to the pharmacist 
who works on the basis of Advanced medication review. 
The pharmacist’s report is sent back to the general practi-
tioner who optimizes the pharmacotherapy in accordance 
with the patients. The acceptance rate of pharmacist’s pro-
posals is approximately 70%. As the 3 year project clearly 
showed significant decline of drug-related problems, Min-
istry of Health of Slovenia has decided in 2016 to intro-
duce the practice of pharmacist-consultant in the regular 
health program financed by the Health Insurance Institute 
of Slovenia.
Professional activities at secondary and tertiary level
A full scale model of clinical pharmacy activities in 
Slovenian hospitals has been introduced in 2007. They are 
performed in the wards at the patients’ bedside and in the 
hospital management system. Clinical pharmacists partic-
ipate in medical rounds, perform Advanced medication re-
views, implement medication reconciliation process, per-
form therapeutic drug monitoring activities and prepare 
drug formularies. Additionally, they participate in hospital 
committees for drugs, antibiotics and hospital infections, 
take an active role in creating pharmacotherapeutic guide-
lines and start setting up clinical pharmacy departments.
Three cases of good clinical pharmacy practice in Slo-
venian hospitals are presented. Clinical pharmacists in 
General hospital Murska Sobota participate at healthcare 
meetings and ward rounds, they run medication reconcil-
iation at hospital admissions and discharges and perform 
Advanced medication reviews in appointed patients. Clin-
ical pharmacists at the University clinic Golnic are inte-
grated in the treatment of patients at higher risks for ad-
verse drug reactions (those with decreased renal function, 
prescribed with strong inhibitors or inducers of drug en-
zymes and drug transporters, prescribed with strong opi-
oids, prescribed with drugs where TDM is performed and 
prescribed medicines with a feeding tube), oncology pa-
tients, patients with tuberculosis and patients with hered-
itary angioedema. Additionally, clinical pharmacists suc-
cessfully implemented on a full scale a medication recon-
ciliation model for all oncological patients admitted to the 
clinic and introduced TDM service for theopylline (Ru-
gelj et al., 2015). Moreover, recently, a randomized, dou-
ble-blind, controlled trial on clinical pharmacist’s inter-
vention reducing clinically relevant drug-drug interactions 
in patients with heart failure, was completed at the Uni-
versity clinic Golnik and published (Roblek et al., 2016). 
And finnaly, clinical pharmacists at the University Medi-
cal Centre Maribor successfully introduced on a full scale 
TDM for vankomycin, gentamicin, methyldigoxin and val-
proic acid. All patients receiving above-mentioned narrow 
therapeutic index drugs are entitled to TDM service.
Education activities
Slovene Chamber of Pharmacies runs specialistic 
courses on clinical pharmacy and community pharmacy. 
Currently, in Slovenia there are 60 specialists all together, 
by 2020 additional 90 specialists with competences will be 
available to perform clinical pharmacy activities in Slove-
nian healthcare system.
Faculty of Pharmacy, University of Ljubljana runs 
PhD course on clinical pharmacy. By 2020 we expect 20 
graduates able to design and conduct research activities in 
the area of clinical pharmacy.
Additionally, clinical pharmacists collaborate in under 
and postgraduate pharmacy courses and courses for physi-
cians and nurses,and finnally, clinical pharmacists organize 
pharmacokinetic courses in the hospital wards for physi-
cians and nurses.
Research activities
Clinical pharmacists perform clinical studies and run 
outcomes research in terms of examine closely clinical, hu-
manistic and economic outcomes, and publish original and 
review research articles in peer-reviewed journals.
Conclusion
Clinical pharmacy is implemented successfuly in ma-
jority of Slovenian clinics, hospitals, pharmacies and com-
munity health centres, it is incorporated in international co-
operation on many levels, and finnally, it is on a good way 
to grow up as an essential part of the Slovenian healthcare 
system. It is our aim to create a strong team of academ-
ic and professional clinical pharmacists with specializa-
tions and doctorates in clinical pharmacy, able to run qual-
ificative routine clinical practice and advanced clinical re-
search, both in favour of the patients. 
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Introduction
Therapeutic drug monitoring (TDM) is a clinical spe-
cialty that aims at improving patient care by dose individ-
ualization of drugs for which clinical experience or clini-
cal trials have shown an improved outcome in the gener-
al or special populations. TDM can be especially beneficial 
for dose adjustments for drugs with dose-dependent phar-
macokinetics, as an aid in the diagnosis of clinical toxicity, 
for evaluation of drug-drug interactions and drug compli-
ance (Milosheska et al., 2015). 
Clinical pharmacokinetics in practice is applied to 
TDM for drugs that are characterized by a narrow thera-
peutic range and a large variability in pharmacokinetics. 
Moreover, population modeling is a powerful tool to quan-
titatively evaluate the influence of various clinical, bio-
chemical, demographic factors and other sources of vari-
ability on the dose-concentration relationship. TDM in 
clinical practice is initiated for a number of antiepileptic 
drugs (AEDs) particularly due to the episodic nature of the 
condition and difficulties to assess the clinical efficacy of 
AEDs. Initially TDM was employed for the old generation 
of AEDs such as carbamazepine, valproic acid, phenytoin, 
and primidone, which are characterized by complex and 
variable pharmacokinetics. On the other hand, benefit of 
TDM for the new generation of AEDs including lamotrig-
ine, oxcarbazepine, topiramate, stiripentol, tiagabine, le-
vetiracetam, and zonisamide, is often questioned as they 
have more favourable pharmacokinetics, wider therapeutic 
range and better tolerability in terms of interaction and ad-
verse effects profile (Patsalos et al., 2008). Therefore, sub-
stantial research is needed to better document the value of 
TDM of the new AEDs in clinical practice. The aim of the 
present report was to provide evidence of the usage of pop-
ulation pharmacokinetic models as extensions of the ther-
apeutic drug monitoring in patients with epilepsy treated 
with lamotrigine (LTG) or oxcarbazepine (OXC). 
Materials and methods
Two prospective clinical studies were conducted on 
patients with confirmed epilepsy on stable OXC or LTG 
therapy at the University Medical Centre Ljubljana, Slo-
venia. Both studies were approved by the National Medi-
cal Ethics Committee of the Republic of Slovenia and were 
carried out according to the Declaration of Helsinki. At 
least two blood samples per patient were drawn, approx-
imating trough and peak steady-state concentrations. Plas-
ma concentrations of OXC and its main metabolite were 
determined by liquid chromatography tandem mass spec-
trometry method, developed and validated for the study 
purposes. For LTG plasma concentration measurements an 
adapted HPLC method with UV detection was used. Pa-
tients enrolled in LTG study were genotyped for metabo-
lizing enzymes (UGT1A4 and UGT2B7) by real-time PCR 
genotyping using TaqMan Allelic Discrimination Assays 
on the ABI 7500 instrument (Applied Biosystems, Foster 
City, California, USA) and for transporters (ABCB1 and 
SLC22A1) using a fluorescence-based competitive allele-
specific (KASPar) assays according to the manufactur-
er’s instructions (KBiosciences, Herts, UK). The popula-
tion pharmacokinetic analysis was performed employing 
a nonlinear mixed effects modeling approach using NON-
MEM software (ver. 7.3, Icon Development Solutions, Ell-
icott City, MD, USA.) (Bauer, 2011).
Results and discussion
A total of 100 pharmacokinetic profiles from adult pa-
tients on stable LTG therapy were available for pharma-
cokinetic analysis. The structural model used was a one-
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compartment model with first order absorption and elimi-
nation. With a base model, absorption rate (inter-individu-
al variability) was estimated at 1.96 h-1 (72.8%), oral clear-
ance at 2.32 L/h (41.4%) and distribution volume at 77.6 
L (30.2%). Residual variability was most adequately de-
scribed using a proportional error model and was estimat-
ed at 19.8%. LTG clearance was associated with UGT2B7 
genetic polymorphism, patient’s weight, renal function, 
smoking and co-treatment with enzyme inducing or inhib-
iting drugs. This study showed that there is a significant 
variability in LTG pharmacokinetics and therefore TDM 
can be useful in various clinical settings for therapy indi-
vidualization.
A total of 84 plasma concentration measurements of 
OXC and its active metabolite 10-monohydroxyoxcar-
bazepine (MHD) from 18 pediatric patients (age 6 months-
3years) with epilepsy on stable OXC therapy were includ-
ed into the study. The structural model was comprised of 
two-compartment model for the parent drug and one com-
partment model for the disposition of the active metabo-
lite. The estimated parameters were absorption rate con-
stant (Ka), volume of the central and peripheral compart-
ment of the parent drug (V1OXC and V2OXC), elimination 
and distribution clearance of the parent drug (CLOXC and 
QOXC), and clearance and distribution volume of the me-
tabolite (CLMHD and V1MHD). Estimated parameters (inter-
individual variability) of the base model were Ka 0.581 h-1 
(90.9%); CLOXC 33.7 L/h (41.4%); V1OXC 21.3 L (152%); 
V2OXC 3299 L; QOXC 26.4 L; CLMHD 0.128 L/h (26.4%); 
V1MHD 3.13 L. Model that include allometric scaling of the 
clearance and distribution volume parameters and matura-
tion function on OXC and MHD clearance was adopted as 
the final model. Developed model provided new insights 
into the developmental aspects of OXC and MHD disposi-
tion in pediatric patients. Future studies are needed to con-
firm those findings and to evaluate the developed pharma-
cokinetic model as a tool for therapy optimization.
Conclusion
Performed clinical studies demonstrated that there is 
a considerable variability in LTG and OXC pharmacoki-
netics and the application of therapeutic drug monitoring 
can be useful for therapy optimization in patients with ep-
ilepsy. Identification and quantification of the sources of 
variability among patients is essential for individualization 
of drug therapy, and it can be accomplished by employing 
population pharmacokinetic approach. Therefore, pharma-
cokinetic modeling can serve as valuable extension of ther-
apeutic drug monitoring and can be used for therapy opti-
mization and individualization in routine clinical practice 
significantly contributing to more rational pharmacothera-
py of antiepileptic drugs.
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Introduction
Individual differences in drug response, both benefi-
cial and adverse,  has long been recognized as complex and 
common problem in clinical practice (Ramamoorthy et al., 
2015).  Pharmacogenetics (PGx) aims at identifying genes 
and genetic variants that affect the clinical outcome of ther-
apy, i.e. determination of inherited genetic differences and 
genetic mechanisms that condition or disposition efficacy 
and toxicity of drugs (Jones 2013). PGx prediction of the 
therapeutic outcome in each patient individually, is a chal-
lenge and it’s usage in clinical practice is still far from re-
ality. The extensive research efforts undertaken over the 
past decade have identified several genetic markers that are 
strongly associated with outcomes of interest. Appraising 
the drug related function of CYP450 (CYP2D6, CYP2C9, 
CYP2C19, CYP3A5 and AKR1D1) genetic variants is the 
core for efficient modeling of population specific, cost-ef-
fective, PGx platform for individualization of drug thera-
py (Cabaleiro et al., 2015; Holmes et al., 2011; Jiang et al., 
2015; Kapedanovska Nestorovska et al., 2014; López-Ro-
dríguez  et al., 2008; Patel et al., 2014; Rejon-Parrilla et 
al., 2014) . 
The objective of this study is to determine the differen-
tial expression of polymorphic CYP450 genes and the cor-
relation of mRNA levels in the liver and peripheral blood, 
to evaluate the clinical validity of the CYP450 phenotype 
in prediction of pharmacokinetic properties and therapeu-
tic outcome of substrate drugs (CYP2D6 for risperidone, 
CYP2C19 for clopidogrel and CYP2C9 for ibuprofen) and 
to assess cost-effectiveness of PGx platform for individ-
ualized treatment with risperidone and clopidogrel in our 
country. 
Materials and methods
The studies included a total of 482 subjects, of which 
230 healthy volunteers and 252 patients. The presence of 
single nucleotide polymorphisms is determined by using 
the Real-Time Polymerase Chain Reaction while the rel-
ative mRNA level of the CYP2D6, CYP2C19, CYP2C9, 
CYP3A5 and AKR1D1 genes, in the liver and peripheral 
blood, was determined by the method of qRT-PCR. Plas-
ma and urinary concentrations of risperidone and 9-OH ris-
peridon as well as of ibuprofen in healthy volunteers and 
patients with psychiatric disorders are determined using a 
validated HPLC-MS / MS and HPLC.  Decision tree mod-
el, including only direct drug related costs was used to 
evaluate the economic viability of the PGx application in 
individualization of Rispiridone and Clopidrogel therapy 
in our country. 
Results and discussion
According to the results, the relative CYP450 mRNA 
levels and the degree of their mutual correlation in liver 
and peripheral blood indicate tissue specific, sexually di-
morphic, cis /trans regulated gene expression and activi-
ty. The CYP3A5 gene expression in blood can be used as a 
biomarker to study the physiological and pathological vari-
ations of CYP2D6, CYP2C9, CYP2C19 and AKR1D1 en-
zymes. Association of CYP450 allele variants with drug 
pharmacokinetics and treatment outcome, (CYP2D6 for 
risperidone, CYP2C9 for ibuprofen and CYP2C19 for 
clopidogrel), confirm the genetic basis of variability in 
drug response in patients from R. Macedonia. Risperidone 
metabolic ratio is a useful therapeutic biomarker to rec-
ommend CYP2D6 genetic testing to guide the present or 
future treatment of patients.The PGx defined Risperidone 
dose strategy (assuming 99% test accuracy) was associ-
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ated with €7.6 /month/patient increase in total treatment 
cost and health gain of 0,11 QALY, yielding an ICER of 
€69.32/ QALY, compared to the traditional approach. Re-
duced PGx test accuracy (95% and 50%) augmented the 
ICER (€610.73/QALY and €2300.22/QALY, respectively), 
due to the €30.53/ month increase in the treatment for each 
incorrect genotyped patient. Total accumulated cost per pa-
tient for the PGx guided clopidogrel therapy was €99.049 
versus € 107.62 for the traditional treatment strategy while 
the mean drug-associated cost was e €21.09 and €9.68, re-
spectively. The cost associated with and due to side events 
hospitalization was 1.5-fold less in PGx compared to the 
traditional treatment. Economic assessment of genetic 
screening testing for mutations that affect the level of ex-
pression and functional activity of CYP2D6 and CYP2C19 
genes justifies the application of PGx individualized treat-
ment with risperidone and clopidogrel in our country. 
Conclusion
The established association between the examined ge-
netic variations, drug pharmacokinetics, clinically signifi-
cant patient outcomes as well as the obtained pharmaco-
economic evidence, highlighte the opportunities of imple-
menting PGx guided drug treatment in R. Macedonia. 
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Introduction
Synonymous polymorphic variants of АВСВ1gene 
C1236T (rs1128503), C3435T (rs1045642) and non-syn-
onymous variant G2677T/A (rs2032582) thet results in ca-
hange of the aminoacid 893Ala with Ser/Thr are common-
ly associated with P-glycoprotein expression and function. 
P-gp has been linked with predisposition to psychiatric dis-
orders such as schizophrenia, bipolar disorders and depres-
sion. The P-gp expression and functional activity plays im-
portant role in pharmacotherapy resistance and unpredict-
able therapeutic response to antipsychotics (Bruhn et al., 
2014). Establishing the association between concentrations 
of risperidone and its active metabolite 9-OH risperidone 
in the body (plasma and urine) with the genetic profile of 
the metabolic and transporter proteins will enable better 
therapeutic approach and achievement of desired therapeu-
tic outcome (Zhu et al., 2007).
Objective
The aim of this research is to determine the association 
of polymorphic variability of ABCB1 gene with the relative 
mRNA expression of the transport protein in the body, to 
determine the relationship of P-glycoprotein with the pre-
disposition to schizophrenia and bipolar disorder, as well 
as to evaluate the inadequate response and the occurrence 
of side effects in patients treated with risperidone.
Materials and methods
The total of 222 subjects, of which 124 healthy sub-
jects (107 healthy volunteers and 45 postmortem individ-
uals) and 54 patients (bipolar disorder and schizophrenia) 
from Republic of Macedonia were included in the study. 
The presence of single nucleotide polymorphisms for the 
ABCB1 for three polymorphisms C1236T [rs1128503], 
G2677A/T [rs2032582] and C3435T [rs1045642] were an-
alyzed by Real-Time PCR while the relative expression of 
ABCB1 gene in different tissues (blood, brain, liver, kid-
ney, duodenum, jejunum, ileum colon) from the same indi-
viduals. Plasma and urinary concentrations of risperidone 
and 9-OH risperidon in healthy volunteers and patients 
with psychiatric disorders are determined using a validated 
HPLC-MS / MS and HPLC.  
Results and discussion
Our result confirmed the influence of АВСВ1gene po-
limorhosms, gender and age on P-gp mRNA relative ex-
pression. Determination of relative expression of ABCB1 
gene in different tissues (blood, brain, liver, kidney, duode-
num, jejunum, ileum colon) from the same individuals al-
lows interpretation of the tissue distribution of the trans-
port protein in the body. The homogeneity of the data en-
abled building of a predictive model for determining the 
relative expression of mRNA of the transporter protein 
in different tissues with an acceptable error (4-11%). The 
model is based on the obtained results for the influence of 
C1236T, G2677T/A and C3435T polymorphisms and hap-
lotypes, gender, age relative expression of ABCB1 in blood 
and their mutual interactions on the relative mRNA expres-
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sion of P-glycoprotein (Marzolini et al., 2004).
Due to the active role of P-glycoprotein in the trans-
port through the blood brain barrier (BBB), ABCB1 has a 
possible role in the predisposition for occurrence of cen-
tral nervous system diseases. The results of this study have 
confirmed the role of the ABCB1 gene in predisposition 
to psychiatric disorders and increased risk of developing 
bipolar disorder in carriers of the heterozygotes and mu-
tant homozygotes for polymorphic variations in 1236 and 
2677 in comparison to the normal genotype carriers (Ab-
bott, 2013).
HPLС-UV method for determination of the concentra-
tions of risperidone and 9-OH risperidone in plasma and 
urine, that can be used in clinical practice for therapeutic 
drug monitoring (TDM) was optimized and validated (Jo-
vanovic et al., 2010).
Pharmacogenetic analyzes confirmed the influence of 
polymorphic variability of the transporter to the pharma-
cokinetic properties of risperidone in healthy individuals 
from the study of bioequivalence and patient population. It 
gives an opportunity for clinical application of this analy-
sis in order to avoid side effects and to improve the thera-
peutic activity.
Our findings suggest that the allele frequencies in 
Macedonians are similar to those reported for Caucasians 
of European descendant and have shown statistically sig-
nificant differences in comparison with the Asians and Af-
rican population. We have identified eight different haplo-
types in our population but, three haplotypes CGC, TTT 
and CGT represent almost 90% of ethnical Macedonians. 
This study may contribute to population specific data on 
ABCB1 gene and has to be taken into account in order to 
for future establishment of the association and function-
al impact of ABCB1 polymorphisms with various drug re-
sponses and disease predispositions in R. Macedonia (Nau-
movska et al., 2014).
This study suggested influence of ABCB1 genetic 
variation on P-gp activity or expression and predisposition 
to mood disorders, but not to schizophrenia. One of the fu-
tures prospective of our work might be the evaluation of 
the influences of polymorphic variants in the promoter re-
gion on ABCB1 expression and estimation of its influence 
of predisposition for certain psychiatric disorders. One of 
the most important limiting factors in the study was the re-
stricted number of the patients, but obtained results are in 
agreement with most of the findings from other relevant 
studies.
Conclusion
Obtained results confirm the role of pharmacogenetics 
as a modern tool for rational pharmacotherapy, which is ec-
onomically justified.
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Myeloma multiplex still remains incurable disease. In 
the recent years there is a huge improvement in treatment 
of patients with multiple myeloma, particularly in younger 
patients with less than 65 years, mainly based on the intro-
duction of novel agents, such as bortezomib, thalidomide 
and lenalidomide. Doubling survival in myeloma patients 
as compared to the 1990s when only chemotherapy was 
used is based on introducing of autologous stem cell trans-
plantation and novel agents such as bortezomib, thalido-
mide and lenalidomide. So the main question is what do we 
learn nowadays from these improvement?
First of all today, we are facing the redefinition the 
therapeutic goal: “cure“or “disease control”, that means 
to convert the disease in a chronic condition which en-
ables the patient to survive more than 20 years with a good 
quality of life. Conventional chemotherapy did not ful-
fill these expectations and in the era of conservative ap-
proach with conservative chemotherapy younger patients 
lost 18 years of life, and most of them suffered the emo-
tional burden of several relapses until disease become re-
fractory. But the mainstay of these is based in the tests that 
are currently used to define complete remission. It become 
clear that previous evaluation have not enough strength to 
predict disease outcome. Low relative sensitivity is land-
mark of the criteria that have been recently used to define 
treatment response such as less than 5% plasma cells in the 
bone marrow, the disappearance of the M-protein by im-
munofixation, and the complete disappearance of any ex-
tra-osseus plasmocytoma (Palumbo et al., 2011). Today we 
have more sensitive tools which are required and enable us 
to improve the assessment of treatment efficacy in the pa-
tients with multiple myeloma.
Today, physicians are able to offer wider variety of 
treatment options for both young and elderly patients with 
multiple myeloma. Therapeutic options should be tailored 
and personalized according to patient’s characteristics by 
balancing efficacy and toxicity of each drug. Effective 
treatment should be concentrated at the early phase of dis-
ease, when clones are more drug sensitive, long – lasting 
remission are more frequent, and serious adverse events 
are less prominent. This approach significantly improves 
quality of life and may ultimately prolong overall survival 
(Genadieva Stavric et al., 2014; Moreau et al., 2015).
Initial therapy for multiple myeloma depends to a cer-
tain extent on patients characteristics such as: eligibility 
for autologous stem cell transplantation per se; age and co-
morbidities. The role of induction therapy is to induce re-
mission, but patient’s characteristics have a significant role 
in the initial treatment approach. Goals of treatment are: 
to eradicate the tumor clone, including cancer stem cell, 
to search for an appropriate balance between efficacy and 
toxicity with three different but complementary aims: qual-
ity of life, survival prolongation and eventually the dream 
of cure. This can be achieved if we use appropriate tools to 
evaluate treatment efficacy (Rajkumar et al., 2014; Ria et 
al., 2014). Achieving the lowest level of minimal residual 
disease can be an important goal of therapy, a step in the 
path to cure (Bianchi et al., 2015; Paiva et al., 2015).
When autologous stem cell transplantation is a thera-
peutic option for a newly diagnosed young, fit patient, the 
patient must be treated with agents that do not compro-
mise hematopoetic stem/progenitor cell collection, so af-
ter a few cycles of induction therapy progenitor stem cells 
should be collected. Nowadays initial treatment options for 
a young newly diagnosed patient with multiple myeloma 
should be based by a risk adopted approach conforming to 
the maxim of optimizing the therapeutic index by balanc-
ing efficacy with potential side effect (Paiva et al., 2015; 
Rajkumar et al., 2014; Ria et al., 2014).
If an hematologist would search for cured patients with 
multiple myeloma, he would stop in the registry of trans-
planted patients who underwent allogeneic transplantation. 
Unfortunately there is only a small number of these pa-
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tients. The main reasons for that are: high transplant related 
mortality, donor limitations, advanced age. In the field of 
autologous transplantation there is operationally “cure” for 
only 3-10% of multiple myeloma patients which will re-
main in complete remission after high-dose chemotherapy 
and autologous stem cell transplant. The main advantages 
of autologous transplantation are: achieving complete re-
mission in 15-30%, the possibility of long treatment-free 
period with excellent quality of life; prolongation of sur-
vival by one year. There is still a role of autologous stem 
cell transplantation in the era of novel agents. With autolo-
gous transplantation after induction therapy there is a pos-
sibility for further decrease of the tumor mass. Incorporat-
ing the novel agents in the induction protocols improved 
the complete remission rates and this is the first step to-
wards higher complete remission rate after transplantation. 
Today, complete remission is considered as “condition sine 
qua non” for an improved survival (Paiva et al., 2015). The 
efficacy of treatment is mainly related to the achievement 
of a durable response. We already know that mechanism of 
action of high-dose melphalan and novel agent are differ-
ent, so they are acting complementary. There are at least 
five active classes of treatment: alkylators, corticosteroids, 
proteasome inhibitors, immunomodulatory drugs, and an-
tracyclines. All these drugs have significant activity against 
multiple myeloma when are used alone, but having in mind 
that they may have complementary mechanism of action, 
their activity is increased further when they are combined 
between each-other. So, today we are facing numerous 
doublet, triplet and quadruplet combinations which have 
been tested through the use of these drugs. 
Therapeutic options should be tailored and personal-
ized according to patient’s characteristics by balancing ef-
ficacy and toxicity of each drug which is especially impor-
tant for elderly patients. In the mode of sequencing treat-
ment for elderly patients with multiple myeloma, our goal 
is to achieve and maintain maximal response while limit-
ing treatment-related toxicities as much as possible. Sec-
ond-generation novel agents, such as carfilzomib, pomalid-
omide, elotuzumab, bendamustine are currently being 
evaluated as an option to improve treatment outcome in 
myeloma patients (Bianchi et al., 2015).
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Introduction
Although mu opioid (MOP) analgesics, such as mor-
phine, are the preferred analgesics, they possess well char-
acterised, unwanted effects such as respiratory depression 
and abuse potential.
When a NOP (nociceptin receptor) agonist is co-ad-
ministered with a MOP agonist, the combination produc-
es a synergistic effect, resulting in enhanced analgesia (Ko 
and Husbands, 2013). This suggests the possibility of ob-
taining strong analgesia with only low efficacy partial ago-
nism at both MOP and NOP receptors. Buprenorphine pos-
sesses partial MOP agonist activity and, importantly, low 
efficacy, modest potency NOP partial agonism. Howev-
er, one study has detected no NOP receptor involvement 
in buprenorphine-induced physiological responses in pri-
mates (Cremeans et al., 2012) and so an improved anal-
gesic might have a buprenorphine-like profile but with en-
hanced NOP activity. Structure-activity relationship stud-
ies suggested that the region of space occupied by the tert-
butyl group in buprenorphine was key to good NOP recep-
tor activity (Cami-Kobeci et al., 2011a, 2011b; Khroyan et 
al., 2011).
To this end we have synthesized novel buprenorphine-
like analogs with increased NOP affinity and efficacy. 
Materials and methods
Access to analogues of buprenorphine in which the t-
butyl group is replaced by alternative bulky groups was by 
the standard procedure of Grignard addition to ketone.
Binding affinities of the new compounds, plus various 
standards, were determined in CHO cells transfected with 
human receptor cDNA, as previously described (Spagno-
lo et al., 2008); the displaced selective radioligands were 
[3H]DAMGO, [3H]Cl-DPDPE, [3H]U69593 and [3H]N/
OFQ for binding to MOP, delta opioid (DOP), kappa opi-
oid (KOP) and NOP receptors respectively.  
The ligands were assessed for functional activity in the 
[35S]GTPγS-binding assay in human receptor transfected 
CHO cells (Spagnolo et al., 2008).
BU08028 has been evaluated in vivo for attenuation of 
acute pain, using the tail flick assay and these results will 
be presented. To characterize the pharmacological profile 
of BU08028 as an analgesic in rhesus monkeys, acute ther-
mal nociception and capsaicin-induced thermal allodynia 
assays were conducted.
Results and discussion
Of the analogues of buprenorphine with variation in 
the C20 substituents BU08028 having t-pentylgroup,has a 
Ki of less than 10 nM at each receptor in the opioid recep-
tor family, making it the first universally high affinity opi-
oid ligand.  More importantly, even though the structure is 
very similar to that of buprenorphine, its affinity at NOP re-
ceptor is almost 10 fold higher than that of buprenorphine 
itself.
In vitro functional activity, as determined by [35S]
GTPγS binding, indicated that BU08028 has virtually no 
efficacy at delta and kappa receptors.  At mu receptors, the 
functional activity is very similar to buprenorphine, with 
only 21% stimulation relative to DAMGO. At NOP recep-
tors, the EC50 is 43.5 nM, approximately 6 times more po-
tent than buprenorphine, and has significantly higher ef-
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ficacy showing but it is far more efficacious, having 44% 
stimulationrelative to N/OFQ, ascompared to buprenor-
phine which has stimulation in the range of 15%.In the tail 
flick assay BU08028produced a dose-dependent increase 
in antinociception through MOP receptor activation.
Systemic administration of BU08028 (0.001-0.01 mg/
kg) in rhesus monkeys, dose-dependently produced antino-
ciception against acute thermal nociception and capsaicin-
induced thermal allodynia. Compared to buprenorphine 
(0.01-0.1 mg/kg), the antinociceptive effect of BU08028 
was more potent and much longer-lasting (i.e., more than 
24 hours). BU08028-induced antinociception was attenu-
ated equally by both mu opioid (MOP) receptor antagonist 
naltrexone (0.03 mg/kg) and NOP antagonist J-113397 (0.1 
mg/kg), indicating that BU08028 is a bifunctional MOP/
NOP agonist in primates. When administered alone in dos-
es up to 0.01 mg/kg, BU08028 did not induce itch scratch-
ing, a standard side-effect of opioids such as buprenor-
phine.
More importantly, BU08028 at antinociceptive dos-
es did not compromise physiological functions including 
respiration and cardiovascular activities measured by the 
radio-telemetric probes. Compared to MOP agonists, bu-
prenorphine and remifentanil, BU08028 did not produce 
reinforcing effects in monkeys under the progressive-ratio 
schedule of drug self-administration.
Conclusion
We have discovered BU08028, and other compounds, 
having binding affinity at MOP receptors similar to that of 
buprenorphine and, as desired, higher affinity and consid-
erably higher efficacy than buprenorphine at NOP recep-
tors.  In measures of hyperalgesia, both in rodents (rats) 
and non-human primates (rhesus monkey) BU08028was a 
potent, long-acting anti-hyperalgesic with both MOP and 
NOP components to its activityin the absence of common 
side effects associated with MOP agonists in primates.This 
study strongly supports the therapeutic potential of ligands 
with mixed MOP/NOP actions as innovative analgesics in 
humans.BU08028 therefore represents a potential analge-
sic agent, with low side effect profile.
This work was supported by NIDA grants DA020469 
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grants DA-035359 and DA-032568 (M-ChKo) and 
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Introduction
The Latvian Institute of Organic Synthesis is a target 
driven research institution that combines the findings from 
novel academic research practices with applied research in 
collaboration with pharmaceutical industry. The core com-
petences of the Latvian Institute of Organic Synthesis are 
medicinal chemistry and innovative drug discovery with 
outstanding expertise in molecular modelling, organic syn-
thesis, medicinal chemistry and preclinical drug develop-
ment for the treatment of infections, cancer, cardiovascu-
lar diseases, and neuronal disorders. During the last decade 
several new drug candidate molecules have been discov-
ered in the Latvian Institute of Organic Synthesis. 
From meldonium to new cardioprotective drug 
methyl-GBB 
Meldonium (mildronate; 3-(2,2,2-trimethylhydrazini-
um) propionate) is a clinically used cardiometabolic drug. 
The mechanism of action of the drug includes lowering 
the L-carnitine and its metabolite contents in body tissues 
through inhibition of enzyme γ-butyrobetaine hydroxy-
lase and organic cation/carnitine transporter type 2 protein 
(Dambrova et al, 2002; Dambrova et al., 2016). 
After investigation of molecular mechanisms of mel-
donium, we started screening program which resulted in 
the discovery of a novel compound, 4-[ethyl(dimethyl)am-
monio]butanoate (methyl-GBB) (Tars et al., 2014). Meth-
yl-GBB treatment decreased the acylcarnitine contents and 
lead to cardioprotective effects by limiting long-chain fatty 
acid oxidation and facilitating glucose metabolism. In vivo 
pretreatment with methyl-GBB attenuated the infarct size 
and significantly improved 24 h survival of rats (Liepinsh 
et al., 2015). In apolipoprotein E knockout mice, methyl-
GBB treatment reduced the size of atherosclerotic plaques 
(Vilskersts et al., 2015). In the experimental models of di-
abetes methyl-GBB administration improved insulin sen-
sitivity and reduced blood glucose levels (Liepinsh et al, 
2016). These results provide evidence that the pharmaco-
logical decreasing of the acylcarnitine content may repre-
sent a novel treatment strategy for cardiovascular diseases.
Conclusion
The Latvian Institute of Organic Synthesis hosts the 
innovative synergy of academic achievements in organic 
chemistry and pharmacology with competent applied re-
search in medicinal chemistry to drive smart drug discov-
ery projects.
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Introduction
DNA topoisomerases (Topo) are enzymes that isomer-
ise the tertiary structure of DNA without changing its pri-
mary structure. The high degree of conservation of these 
enzymes among prokaryotes and eukaryotes indicates an 
essential role in cell biology. Because its structure is a dou-
ble helix, DNA is under tortional stress that results in mul-
tiplex twisting of the molecule. To be processed for repli-
cation or gene expression, the supercoiled DNA must be-
come accessible to nucleic acid polymerases or compo-
nents of the transcription machinery. This change requires 
relaxation and untangling of the intertwined DNA strands, 
which are the typical tasks of Topo (Hande, 2003). 
In humans, two classes of Topo are well characterized, 
type I and type II. Topo type II (Topo II) are useful as drug 
target, since they have an indispensable function in cell bi-
ology and they lack biological redundancy. Inhibitors of 
these enzymes have become central parts of both prima-
ry and adjuvant chemotherapy regimens in neoplastic dis-
eases, and they probably will remain so for the foresee-
able future.
Classical Topo II inhibiting agents such as epipodo-
phyllotoxins or anthracyclines interfere with the break-
age-reunion reaction of Topo II by stabilizing this cleav-
able complex. The stabilization of the cleavable complex 
and not the inhibition of the Topo II activity is supposed to 
play the decisive role in the cytotoxic effect of the classical 
Topo II interacting agents. Accordingly, resistance against 
classical Topo II-inhibiting agents can result from any pro-
cess that leads to an altered binding of Topo II to drugs or 
DNA and a reduced formation of cleavable complexes. In-
deed, it was demonstrated that decreased Topo II catalytic 
activity can mediate drug resistance to cancer cells (Beck 
et al., 2001). 
Because of Topo II is the target for some of the most 
active anticancer drugs such as etoposide, teniposide, and 
doxorubicin used in the treatment of human malignancies, 
detailed investigations of bi- and ter-benzimidazole deriva-
tives revealed that these compounds constitute a new class 
of Topo I and II inhibitors. Work on such compounds indi-
cates that a fused ring system in the structure is critical for 
the activity.
In the past years, we synthesized several derivatives 
of benzazoles, such as benzoxazoles, benzimidazoles, ben-
zothiazoles, and oxazolo(4,5-b)pyridines as isosteric fused 
heterocyclic compounds to investigate their eukaryotic 
DNA Topo II inhibitory activity (Pinar et al. 2004) and re-
alized their three dimentional quantitative structure activi-
ty relationships (3D-QSAR) analysis by using comparative 
molecular similarity indices analysis (COMSIA) method 
(Tekiner-Gulbas et al., 2006).
A training set of 37 compounds of benzazoles, which 
are possessing benzoxazole, benzimidazole, benzothia-
zole, and oxazolo(4,5-b)pyridine fused heterocylic nucle-
us at their structure, were tested for their eukaryotic DNA 
Topo II inhibitor activity in cell-free system by using relax-
ation assay. The relaxation assay utilises supercoiled plas-
mid as substrate and has been used by many investigators 
to study the catalytic activity of Topo I and II types. In-
hibitory activities were presented as micromolar concen-
trations of the compounds that cause 50% inhibition per 
unit of enzyme (IC50), under the assay conditions. From 
the plots obtained with three different concentrations of the 
drugs, IC50 values were obtained and the results are the 
averages of two to three estimations. If no inhibition was 
obtained at 100 µM, the drug was assumed to have no in-
hibitory activity on eukaryotic DNA Topo II (Pinar et al., 
2004).
For the 3D-QSAR studies performed by using CoM-
SIA methods running the SYBYL program package with 
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the IRIX 6.5 operating system of a training set of benzox-
azole, benzimidazole, and oxazolo(4,5-b)pyridine deriva-
tives, which were their eukaryotic Topo II inhibitory activ-
ities observed in cell-free system by using relaxation assay, 
to assume the predictions for their structure activity rela-
tionships (Tekiner-Gulbas et al., 2006).
From among the training set of 37 compounds, 28 ben-
zazole derivatives were found to be able to inhibit the eu-
karyotic DNA Topo II in cell-free system at an initial con-
centration of 100 µg/ml. These 28 compounds were fur-
ther tested at a lower range of concentrations to define 
their inhibitory activity and etoposide was used as the stan-
dard drug in order to compare their activity. Of these 28 
compounds, 12 derivatives had IC50 values between 11.4 
and 46.8 µM range and they were considered as positive 
Topo II inhibitors. Among these compounds, 2-phenoxy-
methylbenzothiazole, 6-nitro- 2-(2-methoxyphenyl)ben-
zoxazole, 5-methylcarboxylate-2-phenylthiomethylbenz-
imidazole, and 6-methyl-2-(2-nitrophenyl)-benzoxazole 
were found as more active than the reference drug etopo-
side. Moreover, 5-nitro-2-(4-ethoxyphenyl)benzoxazole, 
5-(4-fluorophenyl-carboxyamide)-2-phenylbenzoxazole), 
5-methyl-2-phenylthiomethylbenzimidazole, and 5-nitro-
2-phenoxymethylbenzimidazole had Topo II inhibitory ac-
tivities comparable to etoposide. 
The results indicate that either having sterically bulky 
substituents such as phenylacetamide or phenoxyacet-
amide groups at position 5 or holding a non-aromatic moi-
ety as cyclohexyl or cyclopentyl rings and/or a pyridine 
ring at position 2 of the fused heterocyclic nucleus causes 
a severely reduced or lack of activity. On the other hand, 
different fused heterocyclic nuclei in the structures of the 
most potent Topo II inhibitors are indicating bioisosteric 
properties for the enzyme inhibitory activity (Pinar et al., 
2004).
For the 3D-QSAR studies, the best performed CoM-
SIA model was obtained from the combination of two 
fields (i.e., steric and hydrophobic). The LOO cross-vali-
dated PLS analysis of the best model gave rise to a cross-
validated value (q2) of 0.562, suggesting that the model 
is a useful tool for predicting Topo II inhibitory activity. 
The correlation coefficient between the calculated and ex-
perimental activities non crossvalidated value (r2) of 0.968 
with standard error 0.073 indicates that the fitness of ana-
lyzed results is 96.8% compared to experimental results. 
The respective relative contributions of steric and hydro-
phobic fields are 35% and 65%, indicating that hydropho-
bic field is more predominant. The established model was 
validated using a test set of compounds, which were not in-
cluded in the development of the model (Tekiner-Gulbas 
et al., 2006). 
There are two significant contours representing the fa-
vored steric area to increase the inhibition against the Topo 
II enzyme. If a bulky substituent, such as methoxy group, 
is attached on ortho position of 2-phenyl-5-nitro-benzox-
azole, it will occupy into favorable for steric contour and 
will enhance the activity. According to the 5-methylcar-
boxylate-2-phenylthiomethylbenzimidazole, both meta 
and para positions of the phenyl group, which are attached 
to the 2nd position of benzimidazole ring system, fit into 
the favorable for steric contour and improve the activity. 
In CoMSIA study, hydrophobic similarity index fields 
are also constructed and an area found, which is placed on 
phenyl ring of the most active compound 5-methylcarbox-
ylate-2-phenylthiomethylbenzimidazole, means favorable 
for hydrophobic. The phenyl group of another the most ac-
tive compound 2-phenyl-5-nitro-benzoxazole also fits into 
the same favorable area. On the other side, nitro group of 
2-phenyl-5-nitro-benzoxazole and carbonyl group of ester 
moiety of 5-methylcarboxylate-2-phenylthiomethylbenz-
imidazole play a very important role for increasing Topo 
II inhibitory activity. We could say that hydrophilic area is 
more significant than hydrophobic area to enhance the ac-
tivity. Because all phenyl rings attached at the 2nd position 
of benzazole ring system fit into one of the favorable hy-
drophobic contours.
In conclusion, the results point out that benzimidazole, 
benzoxazole, benzothiazole, and/or oxazolopyridine de-
rivatives also exhibit significant Topo II inhibitory activ-
ity and may provide advanced opportunities to design and 
develop new chemotherapeutic agents.Furthermore, the 
observed COMSIA contour plots provide many useful in-
sights into relationships between structural features and in-
hibitory activity for these benzazole derivatives.
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Introduction 
Our work was focused on the investigation for a ready 
to use prepared freeze dried rituximab immunoconjugates as 
potential radiopharmaceuticals for labeling with Lu-177 and 
Y-90 in order to increase the stability and higher efficiency 
and lower toxicity. We tested three bifunctional chelating 
agents (BFCA’s), p-SCN-Bn-DOTA, p-SCN-Bn-DTPA 
and 1B4M-DTPA conjugated to the same antibody using 
previously established protocol for conjugation (Gjorgieva 
Ackova, 2014, 2015; Smilkov, 2014).
The main goal was to investigate chemical character-
ization of the immunoconjugates, labeled with “cold” non-
radioactive isotopes of Lutetium and Yttrium in the same 
conditions as with radioactive Lutetium 177 and to show the 
chemical behavior and toxicological properties.
Material and method
The conjugation of antibody with three different bifunc-
tional cleating agents was performed using using previous-
ly established protocol for conjugation. The concentrations 
were adjusted to 1 mg/mL and the solutions were then ly-
ophilized. 
The purified immunoconjugates were formulated in ab-
sence of any cryoprotectant at the concentration of 10 mg/
mL, and subsequently lyophilized according to selected pro-
tocols.
The process of freeze drying was completed using Lab-
conco Free Zone Stoppering Tray Dryer, (USA), using pro-
tocol described by Park in 2013, modified to our experience.
Concentration of the antibody/immunoconjugate was 
determinate before and after freeze drying and reconstitu-
tion using UV spectrophotometer (Jenway UV/VIS spectro-
photometer 6715), and semi-micro UV polypropylene tubes 
with 0.1M PBS pH=8.0, at 280 nm in triplicate. 
After freeze drying both characterization of the conju-
gates and determination of the average number of BFCA at-
tached to each antibody molecule is performed by MALDI-
TOF mass spectrometry and integrity of the antibody was 
evaluated using SDS-PAGE electrophoresis, on 12% bis-tris 
acrylamide gel. 
The spectroscopic characterization of all three freeze 
dried immunoconjugates, in terms of monitoring the sec-
ondary protein structure (and its preservation), was achieved 
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by FT-IR and Raman spectroscopy.
The freeze dying immunoconjugates after reconsti-
tution were labeling with Lu-177 (555 MBq/mg in 0,5 M 
NH4OAc) and radiochemical purity was determined by in-
stant thin-layer chromatography on silica plates with a mo-
bile phase of ammonium acetate : methanol (1 : 1) using Cy-
clone Plus Phosphore Imager (Perkin Elmer). 
The obtained radioimmunoconjugates were characterized 
by SE-HPLC, using a Zorbax Bio Series GF-250 column and 
the elution process was monitored on UV detector at 280 nm 
and radiodetector (Wojdowska, 2014).
Toxicological studies were performed in Wistar rats af-
ter injection of rituximab labeled with cold Lutetium and 
Yttrium. Biodistribution studies were performed in 5-6 
week old nude mice grafted with Raji cells (2x106 cells in 
0.5 mL medium solution) after injection of radioactive Lu-
177-Rituximab.
Results and discussion
The 3 day protocol of freeze drying without the 
presence of mannitol, showed the greatest similarity in the 
elution profiles of the immunoconjugate prior lyophilization 
(Gholipour, 2014). 
After freeze drying, the pellets obtained corresponded to 
the composition and the time until complete reconstitution 
after addition of saline showed no significant difference in 
the time of complete dissolution of the lyophilisates, i.e. all 
tested samples were completely reconstituted in 2 min.
The average number of BFCA attached to each anti-
body molecule performed by MALDI-TOF mass spectrom-
etry shows presence of two main peaks corresponding to 
MW of 146491 Da (unconjugated antibody) and 149873 Da 
(conjugated antibody) which corresponds to an average of 
6.1 groups of p-SCN-Bn-DOTA (M = 551.61 g·mol-1), two 
peaks also, corresponding to MW of 146477 Da (unconju-
gated antibody) and 151246 Da (conjugated antibody) corre-
sponds to an average of 8.8 groups of p-SCN-Bn-DTPA (M 
= 540.54 g·mol-1) attached to a molecule of rituximab and 
two peaks corresponding to MW of 146848 Da (unconjugat-
ed antibody) and 151506 Da (conjugated antibody) corre-
sponding to average of 8.3 groups 1B4M-DTPA (M = 555.58 
g·mol-1) attached to a molecule of rituximab.
All immunoconjugates (both before and after lyophili-
zation) were separated in two distinct Mw species which mi-
grated in two bands (upper at ~50 kDa and lower at ~25 kDa) 
confirming the migration behavior typical for IgG antibod-
ies which are composed of twoidentical subunits each com-
posed by two polypeptide chains: two heavy and two light 
chains, linked via 4 disulfide bonds. The obtained fragments 
correspond to molecular masses of rituximab heavy and light 
chain given at the literature (Bil, 2007;)
In the experimental IR (in the region 2000-500 cm-
1) and Raman spectra (2000–400 cm-1 region) we observed 
retaining of native structure of the antibody and no obvious 
aggregation.
The radiochemical purity and determination of 
radioimmunoconjugates by SE-HPLC,  obtained after 
radiolabeling the with Lu-177 was higher than 5%. These 
conjugates were stable for 48h in 0.9% NaCl, however, 
progressive aggregation was observed.
Animal studies showed no toxicity and SPECT images 
in mice showed good localization of the tumor, as confirmed 
by ex-vivo organ counting. 
Conclusion
After evaluation of all the obtained results obtained we 
can conclude:
- Three immunoconjugates were synthesized, using 
p-SCN-Bn-DOTA, p-SCN-Bn-DTPA and 1B4M-
DTPA using the a selected ratio, 1:20
- Protocol for lyophilization was established, yielding 
lyophilisates with favorable physicochemical 
properties.
- The non-radioactive labeling with Y and Lu showed 
preserved secondary structure in all three types of 
immunoconjugate, confirming their stability in 
conditions of freeze-drying and labeling
- During labeling with Lu-177 all three types 
of radioimmunoconjugates showed high 
radiochemical purity, over 95%, which was 
confirmed both in ITLC and SE-HPLC.
The selection of the most appropriate immunoconjugate 
kit suitable for labeling with Lu-177 or with Y-90 can 
be made after stability study of the formulation and 
completition of cell culture studies.
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Introduction
The Guillain-Barre Syndrome (GBS), is an acute in-
flammatory disorder inducing arms and legs muscle weak-
ness (tetraplegia), as well as the loss of deep tendon reflex-
es (areflexia).
The development of GBS is mainly associated with an 
antecedent infection caused by Campylobacter jejuni (C. 
jejuni). These infections are not uniquely associated with 
any clinical subtype, but severe axonal degeneration is 
more common following C. jejuni (Hughes et al., 1999). 
Experimental evidence implicates concomitant production 
of specific serum antibodies against several types of gan-
gliosides that was thought to play an important role in the 
development of the disease (Willison and Yuki, 2002). On 
the other hand, proteins belonging to the family of heat 
shock proteins (HSP) are also believed to be etiological 
factors in many autoimmune diseases whose pathophysiol-
ogies are thought to stem from immune responses against 
HSP (Yonekura et al., 2004).
Hence, to shed further light on the mechanisms that 
trigger the immune responses in post infectious autoim-
mune diseases such as GBS, the aim of this study was to 
investigate the profiles and immunoreactivity of proteins 
from human peripheral nerve (HPN) tissue, the main path-
ological target of the disease, and from C. Jejuni (O:19), as 
the most often causative agent for GBS. 
Materials and methods
In the first part of the study, proteins were isolated 
from HPN and C. Jejuni (serotype O:19, ATCC 43446). 
Human peripheral nerve was obtained at autopsy within 
8 hr after death from patients who died from non-neuro-
logical disease (Department of Forensic Medicine, Faculty 
of Medicine, Ss. Cyril and Methodius University, Skopje, 
Macedonia). Afterward proteins were extracted, separated 
by 1D SDS-PAGE using a Protean IIxi electrophoresis cell 
(Protean IIxi, BioRad), and their potential cross reactivity 
identified by Western blotting. The electrophoretic bands 
containing the proteins of interest were isolated, subject-
ed to trypsin digestion, the resulting peptides submitted 
to nHPLC-nESI-MS and MS/MS (Dionex UltiMate3000 
nanoflow LC system connected to an LTQ-Orbitrap XL) 
analysis and the results elaborated using SEQUEST algo-
rithm (Proteome Discoverer 1.3, Thermo Fisher Scientific, 
Rodano, MI, Italy) for proteins identification and evalua-
tion of their similarities.
Results and discussion
Western blot analysis of the immunoreactivity of iso-
lated proteins to sera from patients with GBS, revealed sig-
nals for at least 8 immunoreactive bands for HPN and 8 
for C. jejuni O:19 – GBS. Bands corresponding to proteins 
associated to the strongest immunogenic response (60-70 
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kDa) and bands that revealed positive but weaker signal 
(45 kDa), were subjected to proteomic analysis.
For C. jejuni, no proteins were identifiable with suffi-
cient confidence level in the band corresponding to Mw~45 
kDa, while at Mw~60-70 kDa, 11 proteins were identified. 
Among them, 2 out of 3 and 7 out of 11 proteins respective-
ly, were proteins previously identified in microorganisms 
from the genre Campylobacter, while the remaining pro-
teins were in the overall from other microorganisms. All 
these proteins were from the family of chaperone/co-chap-
erone proteins (GroEL, DnaK and HtpG). 
By contrast, the main proteins identified in the corre-
sponding 45 kDa HPN band were enzymes and structur-
al proteins. In HPN, proteins identified in the mass range 
around 70 kDa (the SDS-PAGE band associated to the 
strongest immunogenic response) were human serum al-
bumin (HSA) neurofilament light peptide and different 
forms of cytoskeletal keratin. Three proteins from the HSP 
70 family (heat shock 70 kDa protein 1A/1B mw=70KDa, 
heat shock cognate 71 kDa protein mw=70.9 KDa, and 
heat shock-related 70 kDa protein 2 mw=70 KDa) were 
found, as well as HSP 60 (mw=60 KDa). Cross verification 
of these proteins in UniProt bacterial proteins database ren-
dered as reliable matching proteins (similarity score above 
45%) those belonging to bacterial chaperone DnaK pro-
teins.
In a recent study, de Jong and colleague reported the 
identification of seven epitopes present at different posi-
tions along the in constitutive self HSP 70 (De Jong et al., 
2014). 
Alignment of these peptides with the corresponding 
sequences in the above selected chaperones from different 
Campylobacter species (Mw~70 kDa) and human HSP 70, 
showed that two of those epitopes showed ~100% of se-
quence homology.
In analogy to what done for HSP 70, the presence of 
the HSP 60 consensus sequence L256xxLxxNxLxxxxxxx-
AVKAPGFGDxRKxx reported by Elfaitouri et al. (2013) 
was verified after alignment of mitochondrial 60 kDa heat 
shock protein identified in HPN with GroEL chaperone 
and with 60 kDa chaperonin (both proteins share around 
50% of similarity with HSP 60). In the cases of GroEL 
chaperone there was total coincidence of all key amino ac-
ids, while for 60 kDa chaperonin only lys264 was replaced 
by an isoleucine residue.
Therefore, the microbial chaperone proteins DnaK 
(~70 kDa) and the different forms of HSP 70 in HPN iden-
tified in this study, as well as bacterial GroEL an human 
HSP 60, reciprocally share high primary sequence homol-
ogy and conservation of their known epitopes. 
C. jejuni chaperone proteins (~70 kDa) can be suggest-
ed as possible antigens determining the induction of auto-
immune disorders such as GBS or, at least, to play a rel-
evant role in these diseases, possibly through a molecular 
mimicry mechanism (Elfaitouri et al., 2013).
In particular, in our case, it can be speculated that the 
HSP neuroprotective effect (after activation of the heat 
shock response in consequence of infection) may be inhib-
ited due to the interference of specific anti-HSP antibodies, 
eliciting the neurodegenerative effect of anti-GM1 autoan-
tibodies on the peripheral nervous system.
Conclusion
To the best of our knowledge, this is the first study in-
vestigating the molecular identity of cross reacting, immu-
nogenic proteins involved in GBS. The high resolution and 
mass accuracy provided by the Orbitrap analyzer, allowed 
to obtain an extensive, although presumably incomplete, 
identification of candidate proteins such as human and bac-
terial HSP. The results of this study confirmed that C. jejuni 
DnaK (~70 kDa) and human peripheral nerve HSP 70, and 
bacterial GroEL and human HSP 60 share high sequence 
homology, in good accordance with the massive amount of 
work showing that HSP are highly conserved in evolution, 
leading to magnificent similarities in structure and com-
position between mammalian HSPs and their homologues 
in microorganisms. Taken altogether, these results strong-
ly suggest a potential involvement of chaperone molecules 
in the development of the autoimmune response associat-
ed to GBS.
Hence, further studies that could help identify new 
molecular targets in inflammatory and autoimmune condi-
tions such as GBS should be focused on the better under-
standing of the multifaceted contribution of HSPs in im-
mune response and inflammation, thus to allow the devel-
opment of new diagnostic, therapeutical and pharmaceuti-
cal tools for the treatment of these harmful diseases.
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Introduction
Colorectal cancer (CRC) is a common, heterogeneous 
disease that arises through the aggregate effects of multi-
ple genetic mutations and epigenetic alterations involving 
genes that regulate cell growth and differentiation (Croce, 
2008). In addition, CRC tumors are often comprised of 
cytogenetically different clones that arise from the initial 
transformed cell through different secondary or tertiary ge-
netic alterations. This significant molecular heterogeneity 
of CRC leads to differences in the clinical presentation and 
response to the therapy, and therefore affects the clinical 
management of the patients.
The vast majority of the CRC cases (~75%) is described 
as sporadic CRC and has no apparent predisposing etiology. 
However, in recent years, a couple of particular morpholog-
ical subtypes of sporadic CRC have been recognized (Jass, 
2007). All of these subtypes present rather different clini-
cal features and molecular signatures and potentially have 
different underlying molecular origins. Sporadic microsat-
ellite stable (MSS) tumors usually arise through the clas-
sical adenoma-carcinoma pathway and demonstrate a high 
level of chromosomal instability (CIN) and mutations in 
genes as APC, KRAS, TP53, TGFBR2, PI3KCA etc. Muta-
tions in KRAS (predominantly point mutations in codon 12 
and 13) lead to a constitutively active GTP-bound protein 
and subsequent downstream activation of the MAPK sig-
naling cascade rising to unregulated proliferation and dif-
ferentiation of the cancer cells. Moreover, somatic chang-
es in KRAS are thought to be an early event in colon carci-
nogenesis and appear concordant between primary tumor 
and metastatic sites (Artale et al., 2008). Their role as neg-
ative predictive biomarkers for anti-EGFR targeted therapy 
(cetuximab, panitumumab) is well established (Javle and 
Hsueh 2009). However, the data from the studies explor-
ing the potential role of the KRAS mutations as prognostic 
biomarkers or as predictive biomarkers for standard 5-flu-
orouracil based adjuvant therapy are less consistent, which 
in part can be due to the significant heterogeneity of the as-
say methodology and the datasets that are analyzed. Hav-
ing that in mind, we conducted a prospective study in order 
to evaluate the possible prognostic effect of the KRAS mu-
tations in patients treated with capecitabine adjuvant mono-
therapy and to better understand the relationship between 
KRAS-mutation status and survival after CRC diagnosis.
Materials and methods
Study population
 A total of 97 patients with histologically proven stage III 
or high-risk stage II colon cancer were included in the study. 
All recruited patients underwent a surgical resection of the 
tumors and were submitted to capecitabine adjuvant therapy 
according to standard protocol. After the completion of the 
therapy, follow-up visits were scheduled for a total of 5 years. 
MSI analysis
 Microsatellite instability in tumor samples was ana-
lyzed with multiplex fluorescent polymerase chain reaction 
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followed by capillary electrophoresis on 3500 Automat-
ed Genetic Analyzer (Life Technologies, USA). MSI sta-
tus was determined using 9 STR markers: BAT25, BAT26, 
D2S123, D5S107, D5S346, D17S250, D18S58, D18S61 
and D18S535 derived from the panel of microsatellite loci 
defined by the NCI (Boland et al., 1998). The tumor sam-
ples were classified as MSI if instability was present at 
more of 30% of the loci screened.
KRAS mutation analysis
 KRAS mutations were analyzed in tumor samples us-
ing custom designed assay. Exon 2 of the KRAS gene was 
amplified using the following primers: AAGGCCTGCT-
GAAAATGACTG and AGAATGGTCCTGCACCAG-
TAA.  Bi-directional sequencing was performed using Big-
Dye Terminator v3.1 Cycle Sequencing Kit. Sequencing 
products were purified using BigDye XTerminator® Pu-
rification Kit (Life Technologies, USA) and analyzed by a 
capillary electrophoresis on a 3500 Genetic Analyzer (Life 
Technologies, USA).
Statistical analysis
 Differences in the demographic and clinical character-
istics of the patients were tested using unpaired Student t-
test (continuous variables) or Fisher’s exact test (categori-
cal variables). The primary end-point of the study was dis-
ease-free survival (DFS), defined as the time from end of 
the adjuvant therapy to the first recurrence diagnosis. Sur-
vival curves were generated according to the Kaplan and 
Meier method and survival distributions were compared 
with the use of the log-rank test. Hazard ratios and 95 per-
cent confidence intervals were computed with the use of 
Cox proportional-hazards regression model.
Results and discussion
A mutation in exon 2 of the KRAS gene was observed 
in a total of 26 (26.8%) patients, of which 21 (21.6%) in co-
don 12 and 5 (5.2%) in codon 13. The most common muta-
tion was Gly12Asp which accounted for 38.5% of all KRAS 
mutations. There was no statistically significant association 
between the KRAS mutations and the clinical features of pa-
tients, although there was a trend towards higher incidence 
of KRAS mutations in patients with stage III CRC (p=0.07). 
The survival analyses showed an association of the KRAS 
mutations with a shorter DFS; the five-year survival of pa-
tients carriers of KRAS mutation was 42.3% versus 73.2% 
in patients with wild-type KRAS (p=0.004). The multivari-
ate analysis adjusted for the gender, stage and tumor localiza-
tion, showed that the presence of KRAS mutation is an inde-
pendent predictor for poor prognosis in patients treated with 
adjuvant capecitabine monotherapy (HR 2.48; 95% CI 1,23-
5,01; p=0.011). This leads to a conclusion that only wild-type 
KRAS CRC patients could benefit from adjuvant capecitabine 
monotherapy. The association of KRAS mutations with poor 
DFS was even more evident in patients with microsatellite 
stable tumors. The 5-year survival of patients with MSS tu-
mors harboring KRAS mutation in codon 12 or 13 was 31.8% 
versus patients with wild-type KRAS, where the survival is 
71.9% (p=0.001). The hazard ratio of 2.64 (CI 1.22 – 5.70; 
p=0.014) indicate an increase in the risk of relapse in patients 
with MSS tumors compared to unselected group of patients. 
In models stratified according to clinicopathologic character-
istics, no difference in DFS was observed in patients with 
stage II and III, i.e. the presence of KRAS mutation was asso-
ciated with poor outcome of treatment with capecitabine re-
gardless of stage. However, different patterns in survival were 
observed according to gender of the patients, where the pres-
ence of the KRAS mutation remained a strong negative pre-
dictive factor for DFS only in male patients (HR 4.87; 95% 
CI 1.94 – 12.20; p< 0,001), where the average five-year sur-
vival of carriers of KRAS mutation was 29 months compared 
to 83.5 months in patients with wild-type KRAS (p<0.001). In 
contrast, in the female subgroup of patients, the presence of 
KRAS mutations had no significant effect on survival (58 vs. 
79.7 months, p=0.93). Since there is no significant difference 
in the frequency of KRAS mutations according to the gender 
(p=0.71), these differences in survival are probably not due a 
statistical error, and represent the possible protective effect of 
the estrogen hormones.
Conclusion
The mutations in the KRAS gene are a strong negative 
predictive factor for survival after adjuvant capecitabine 
monotherapy, especially in male patients. Routine KRAS 
testing can give significant contribution towards decision 
making regarding the treatment strategies in CRC by identi-
fying patients with a highly aggressive disease and poor sur-
vival irrespective of the capecitabine adjuvant monotherapy.
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Introduction
The resistance-nodulation-cell division family (RND) 
efflux pumps exemplify a unique phenomenon with drug 
resistance in different gram negative bacterial strains as a 
single mechanism causing resistance against several differ-
ent classes of antibiotics. In Escherichia coli AG102 and 
Acinetobacter baumannii SBMox2 strains the well char-
acterized RND efflux pumps are AcrAB-TolC and the Ad-
eABC respectively. Most of the antibiotics were found to 
be substrates for these pumps by increasing the expression 
of the efflux pump genes, leading to multidrug resistance 
(MDR) and the treatment failure and death caused by these 
gram negative bacterial infections or underlying diseases 
are common (Sun et al., 2014). Consequently, the need of 
searching new therapeutic solutions that suppress the ac-
tivity of efflux pumps and restore the sensitivity of com-
monly used antibiotic is essential.
RND efflux pumps, which are only found in Gram-neg-
ative bacteria, have a tripartite composition. RND type ef-
flux pumps contain an inner membrane transporter protein 
(RND pump), an outer membrane protein (OMP) channel, 
and a periplasmic membrane fusion protein (MFP). They 
are allowed direct extrusion of various antibiotics from the 
cytosol or periplasmic space to the outside of the bacteri-
al cell, and have been found to be associated extensive-
ly with clinically significant antibiotic resistance (Sun et 
al., 2014).
Recent studies reported that RND type efflux pumps, 
which are named AcrAB-TolC in E. coli and AdeABC in 
A. baumannii, comprise a transporter protein (RND pump) 
AcrB in E. coli or AdeB in A. baumannii acting as a pro-
ton/drug antiporter, an outer membrane channel protein 
TolC in E. coli or AdeC in A. baumannii, and a periplasmic 
membrane fusion protein AcrA, which serves as a linker 
between TolC and AcrB in E. coli or AdeB, which serves 
as a linker between AdelC and AdeB in A. baumannii (Sun 
et al., 2014). 
The emergence of MDR strains of Gram-negative bac-
teria pathogens is a problem of ever increasing significance 
(Sun et al. 2014). Interestingly, these RND efflux pumps 
decrease the antibacterial activity of dissimilar antibiotic 
structures, which can be considered a MDR mechanism. 
Because of bacteria become insensitive to different classes 
of antibiotic therapy, new therapeutic approaches must be 
looked for, searching for new molecules to block efflux, to 
restore drug susceptibility to resistant clinical strains.
The goal of this study is (i) to define the potential RND 
efflux pump inhibitor (EPI) activity of our previously syn-
thesized BSN coded 2-substituted benzothiazoles by ob-
serving the reversal antibacterial activity of antibiotics 
particularly to chloramphenicol (CHL) and/or ciprofloxa-
cin (CIP) in the AdeABC efflux pump overexpressor Aci-
netobacter baumannii SbMox2 and/or AcrAB-TolC ef-
flux pump overexpressor E. coli AG102 clinical isolates, 
and (ii) to examine the structure activity relationships by 
describing the binding site features of these tested com-
pounds and to analyze the active site protein-ligand inter-
actions of RND efflux pump AdeABC in A. baumannii by 
generating pharmacophore hypothesis.
Materials and methods
A well-known standard microdilution assay was used 
to determine the minimum inhibitory concentration (MIC) 
of our previously synthesized BSN coded 2-substituted 
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benzothiazoles derivatives (Yilmaz et al. 2013), CHL and 
CIP and MICs of CHL and CIP were determined in the 
presence and absence of the BSN coded compounds. 
A common feature pharmacophore hypothesis, Hi-
pHop method, was generated by using the Accelrys Dis-
covery Studio 2.1 software to explain the specification of 
the structure activity relationships of pharmacophoric sites 
of the tested BSN coded 2-substituted benzothiazoles in 
the targeted AdeABC efflux pump. This tool builds phar-
macophore hypotheses (overlaying common features) for 
which the fit of individual molecules to a hypothesis could 
be correlated with activity of the molecule. 
A set of potential AdeABC efflux pump inhibitors of 
BSN coded 2-substituted benzothiazoles, which exhibited 
16-folds or greater reduction in the MIC value of CHL af-
ter used in combination in A. baumannii SbMox-2, was se-
lected as the EPI active training set to use in the HipHop 
pharmacophore generation method. Among the tested 
BSN coded compounds, the most active molecules, BSN4, 
BSN6, and BSN23, were used to derive common fea-
ture-based alignments and considered as “reference com-
pounds” specifying a principal value of 2 and a maximum 
omitting features value of 0.
Results and discussion
For the antibacterial activity test against A. bauman-
nii SbMox-2 and/or E. coli AG102 clinical isolates, BSN 
coded 2-substituted benzothiazoles were first tested alone 
to observe their intrinsic antibacterial affinity. Howev-
er, when they were tested alone they did not exhibit any 
significant intrinsic antibacterial activity. But, when they 
were tested in combinations with CHL or CIP against the 
AdeABC overexpressor A. baumannii SbMox-2 mutant, 
a reversal in the antibacterial activity of 22, 20 fold dou-
ble dilution better MIC values were observed respectively 
for CHL and CIP. Moreover, the combinations of the test-
ed compounds with CHL or CIP against the AcrAB-TolC 
overexpressor E. coli AG102 strain were exhibited a rever-
sal antibacterial activity of 6, 10 fold double dilution better 
MIC values respectively for CHL and CIP. Among the test-
ed BSN coded benzothiazoles, BSN4, BSN6, and BSN23 
reversal the antibacterial activity of CHL revealing a MIC 
values of 0.125 µg/ml against the AdeABC overexpressor 
A. baumannii SbMox-2 strain.
The generated 3D-common feature pharmacophore 
hypothesis containing two Hydrogen Bond Acceptors 
(HBA) and three Hydrophobic Aromatics (HpAr) was an-
ticipated as the common-feature functions to explain the 
pharmacophoric site specifications of the EPI activity of 
BSN coded 2-substituted benzothiazole compounds. The 
generated pharmacophore model reveals that the two HBA 
and three HpAr features are found significant for binding 
to the active site of the target protein. Three HpAr features 
demonstrate the appropriate active shape of the molecule, 
displaying the required place of bulky aromatic moieties. 
Two HBA atoms or groups at the given positions are neces-
sary in the molecule to bind to the target protein.
Conclusion
The generated pharmacophore model revealed that 
when the tested compounds substituted by a benzyl group 
instead of phenyl ring attached to the benzothiazole nu-
cleus then, they could not be able to show any match with 
the hydrogen bond acceptor feature of nitrogen atom in 
the thiazole ring at the fused ring system. Therefore, these 
compounds showed lower fit value and were not able to 
match with all the mapped pharmacophore common-fea-
tures in the anticipated model. This observation explains 
why 2-phenylbenzotiazole structure is more favourable 
than 2-benzylbenzotiazole for increasing potency in this 
set of compounds.
In conclusion, the generated 3D-common feature 
pharmacophore hypothesis reveals that the conformation-
al properties of the compounds are significant for the Ade-
ABC efflux pump inhibitor activity against the multi-drug 
resistant A. baumannii SbMox-2 strain and compounds 
possessing 2-[4-(4-substituted-2-phenyl-acetamido)phe-
nyl]benzothiazole and/or 2-[4-(4-substituted-3-phenylpro-
pionamido)phenyl]benzothiazole structures are important 
for improving the AdeABC efflux pump inhibitor potency.
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Allergic rhinitis definition and treatment
Allergic rhinitis is clinically defined as an inflammation 
of the nose with characteristic symptoms such as 
rhinorrhoea, nasal obstruction, sneezing, and/or itching of 
the nose. The symptomatic disorder of the nasal mucosa 
and tissue is associated with an IgE-mediated immune 
response to allergens and is characterized by two phases: 
an immediate response after allergen exposure (early 
phase) and a late phase occurring up to 12 hours later, 
which predominantly causes nasal congestion (Calderon 
Moises et al., 2010). If a concurrent respiratory infection 
is present, a patient’s probability of developing bronchial 
asthma as comorbidity increases. Likewise, the risk of 
developing further allergies with more severe symptoms 
rises over the time of the disease (http://www.bitop.de).
The optimal treatment of allergic rhinitis depends on 
several individual factors. A stepwise therapeutic approach, 
however, is generally recommended. Current guidelines 
favour second-generation oral or topical H1 antihistamines 
for treating allergic rhinitis (Angier et al., 2010). More-
over, intranasal glucocorticosteroids and intranasal decon-
gestants are highly recommended as effective treatments 
for nasal blockage (Bousquet et al., 2008).
Azelastine is a new-generation antihistamine applied 
topically as nasal spray or eye drops. It is used as treatment 
of allergic rhinitis, hay fever, and allergic conjunctivitis. 
Although azelastine is regarded as effective possible first-
line treatment for allergic rhinitis, common side effects, 
such as bitter taste of the drug and local irritation reactions 
and rare side effects such as fatigue or headache, can occur.
Ectoine (2-methyl-1,4,5,6-tetrahydropyrimidine-
4-carboxyclic acid) is a compatible solute which is natural-
ly produced by bacteria, conferring resistance to external 
stress factors such as extreme temperatures, high salt con-
centrations, and ultraviolet radiation. It acts via a mecha-
nism called “preferential exclusion” and “preferential hy-
dration (DEGAM, 2008). Ectoine is expelled from proteins 
or lipid membranes, resulting in the modulation of the sol-
vent characteristic of surrounding water. Thus, ectoine 
is able to form a protective and stabilizing hydrate cap-
sule around the protein and therefore helps to protect bio-
molecules and proteins from irreversible structural mod-
ifications by inhibiting dehydration. This indirect effect 
leads to a more compact and more stable folding of pro-
teins and increases the stability of lipid membranes by in-
creasing their fluidity (Dirschka, 2008). The effect derives 
from the mechanism of halophilic bacteria which stabilis-
es the osmotic balance in the microorganic cell, where ex-
tremolytes such as ectoine are accumulated in the cytosol 
to equal out the varying salt concentration in the outer area 
(Lentzen and Schwarz, 2012). Stabilization of membranes 
such as those lining the airways or eyes might reduce the 
potential water loss of such membranes and protect them 
against invading allergens, thereby limiting the inflamma-
tory cascade induced by stress mediators at the membrane 
level, as has been shown for lung epithelia and skin cells 
(Lentzen and Schwarz, 2012). In vitro experiments have 
further shown that ectoine inhibits apoptosis, triggered by 
nanoparticles (Smiatek et al., 2012), and likewise blocks 
the activity of ceramides, which are regarded as central 
molecules in the sphingolipid metabolism as well as in the 
induction of apoptosis (Sydlik et al. (a), 2009). Current-
ly, ectoine is used in dermatological products for success-
fully treating skin diseases such as atopic dermatitis (Syd-
lik et al. (b), 2013). Still widely unknown is the use of ec-
toine in nasal sprays or eye drops. In such medical devic-
es, ectoine may strengthen the hydroprotection of the nasal 
membrane and may alleviate the infection of the inflamed 
tissue (Vestweber, 2009).
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Toxicological studies and results of human studies re-
flect the excellent safety profile of products containing ec-
toine, therewith making them promising candidates for the 
treatment of allergic rhinoconjunctivitis (Vestweber, 2009).
Review from clinical studies
In order to investigate the efficacy of treatment with 
ectoine, data from published as well as unpublished clinical 
studies were reviewed.
The current noninterventional, open-label study inves-
tigated treatment of allergic rhinitis comparing the intra-
nasal glucocorticoid beclomethasone with that of ectoine 
containing nasal spray. Within the study, different mode of 
action, on the one hand the glucocorticoid, was compared 
to a physical, membrane stabilizing molecule. Important-
ly, it was shown that nasal symptom scores of both treat-
ment groups improved significantly over the study period 
of 14 days. Although advantages of the beclomethasone 
spray in comparison with the ectoine spray were shown, re-
sults of the ectoine group showed its potential clinical effi-
cacy. Glucocorticoids bind to specific glucocorticoid recep-
tors which are present on almost all cells of the body. Fol-
lowing binding, transcription of a number of inflammato-
ry cytokines and chemokines can be modulated, which in 
turn results in decreased recruitment and activation of in-
flammatory cells. In allergic rhinitis, this results in a quick 
improvement of inflammatory symptoms which was con-
firmed in the results of the beclomethasone group. Oppo-
sitely, ectoine acts physically via a mechanism called “pref-
erential exclusion.” In the presence of ectoine, membranes 
and lipids are protected indirectly. As ectoine is expelled 
from the surface of proteins and lipids, those are protect-
ed by a water shell, thereby increasing the fluidity of mem-
branes and resulting in the preferential formation of the na-
tive conformation of proteins. This might stabilize mucous 
membranes such as lining epithelia of the nose, thereby 
protecting those from invading allergens and reducing al-
lergen-induced inflammations as shown in different model 
systems and as reported in congress report. It is understood 
that many allergens which cause allergic rhinitis symptoms 
have protease activities which act by impairing epithelial 
barrier function. This in turn results in increased penetra-
tion of allergens into nasal mucosa. The barrier stabilizing 
properties of ectoine may counteract this scenario by im-
proving the epithelial barrier and stabilizing membranes. In 
allergic rhinitis, this might protect the nasal mucosae from 
invading allergens, resulting in improvement of symptoms.
A recent placebo-controlled study in an environmental 
challenge chamber showed that 3 hours after application of 
the ectoine nasal spray and eye drops the symptoms were 
decreased by ~20%.
Conclusion
Taken together, this meta-analysis demonstrated 
that the application of ectoine-based nasal spray and 
eye drops improves symptoms of allergic rhinitis and 
rhinoconjunctivitis. This easy-to-apply, well-tolerated, 
naturally-based nasal and ocular treatment, which has no 
unpleasant taste and virtually no side effects, effectively 
reduces allergic rhinitis symptoms and represents an 
exciting alternative for rhinoconjunctivitis sufferers.
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Introduction
In clinical practice, the most often investigated 
enzyme and routinely determined in patients treated 
with azathioprine (AZA) is thiopurine methultransferase 
enzyme (TPMT). Inherited variations in the TPMT 
enzyme activity are especially important in determination 
of individual differences between patients regarding the 
therapeutic response as well as the toxic effects of AZA 
treatment (Al Hadithy et al., 2005; Ansari et al., 2002). 
Additionally, inherited variations in TPMT enzyme activity 
have an impact on production of active 6-thioguanine 
nucleotide metabolite (6-TGN) after administration of 
AZA or 6-mercaptopurine (Wright et al., 2004). Regarding 
this, higher concentration of 6-TGN metabolite (235-
450 pmol/8x108 Er) means better outcome of the disease 
activity, and therapeutic response as well (Cuffari et al., 
2011; Dubinsky et al., 2000).The aims of this study were 
to assess the relationship between TPMT enzyme activity 
and concentration of 6-TGN metabolite and to determine 
the impact of concentration of 6-TGN metabolite on 
the disease activity in patients with inflammatory bowel 
disease (IBD), both Crohn’s disease and ulcerative colitis, 
treated with AZA.
Materials and methods
Thirty-nine (39) patients with IBD from the Gastro-
enterohepatology clinic, Skopje were included in this 
study. All of them had used AZA in a period of more than 
3 months. Determination of TPMT enzyme activity was 
performed using the ELISA method (Bradford and Shih, 
2011). 3-5mL of blood volume was taken in a tube with 
EDTA or heparin as an anticoagulant. In a period of 30 
minutes after the blood draw, samples were centrifuged 
(1000g, 15 min.). Plasma was taken out and freezed on 
-20  or  -80°С until analysed. The technique of determi-
nation of the TPMT enzyme activity using ELISA meth-
od was performed in accordance with the reference manu-
al of the manufacturer of the ELISA kit, “HumanThiopu-
rineMethyltransferase (TPMT) ELISA Kit, My BioSource, 
USA. In order to establish a control group, blood samples 
were taken from healthy volunteers as well. Eritrocytes 
were than isolated from the blood sample and concentra-
tion of the 6-TGN was determined using the HPLC meth-
od. The bioanalytical method was validated according to 
the EMA Guideline on validation of bioanalytical method 
(EMA, 2011). The disease activity was assessed using the 
well known, Crohn’s disease activity index (CDAI) (Gas-
che et al., 2000) and the Ulcerative colitis activity index 
(UCAI) (Walmsey et al., 1998). According to the concen-
tration of 6-TGN metabolite, patients were divided in three 
groups: subtherapeutic group (<200 pmol/8x108 Er); ther-
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apeutic (200-400 pmol/8x108 Er) and overdosed (>400 
pmol/8x108 Er) (Smith et al., 2013). Results assessment 
of 6-TGN metabolite concentration in patients was estab-
lished for the first time in Macedonia in a collaboration be-
tween two institutions, Department of Preclinical and Clin-
ical Pharmacology and Toxicology, Medical Faculty, Sko-
pje and the Faculty of Pharmacy, Skopje.
Results and discussion
The average value of TPMT enzyme activity in all pa-
tients was 18,49 U/mL  Еr ± 8.27 U/mL  Еr (min. 1.9 U/
mL  Еr, max. 35.8 U/mL  Еr). The average value of 6-TGN 
metabolite concentration was 437,46 pmol/8x108 Er ± 
198.82 pmol/8x108 (min. 64.8 pmol/8x108 , max. 905.5 
pmol/8x108). 
The results of this study have shown linear indirect 
moderate correlation between the TPMT enzyme activ-
ity and 6-TGN metabolite concentration in patients with 
IBD treated with AZA (Spearman Rank Order Corellation: 
R=-0,3632). As the TPMT enzyme activity was increasing, 
6-TGN concentration was decreasing (p>0,05). 
Adittionaly, and increased concentration of 6-TGN 
correlated with increased probability of remission.
Conclusion
Monitoring of 6-TGN metabolite concentration in 
combination with determination of the TPMT enzyme 
activity may predict the therapeutic response in patients 
with IBD treated with AZA. As well, the result suggests 
that the method could be useful for detection of patients 
who do not respond to this therapy in order to identify new 
alternative treatments.
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Introduction
Fungal infections are widely spread in the global pop-
ulation today. Antifungal drugs are therapeutic agents ex-
tensively used to treat these infections. They can be classi-
fied in two groups: first, the natural antifungal antibiotics 
and second, synthetic drugs. According to the way of ad-
ministration antifungal drugs can be topical and systemic 
agents. For the systemic, drug’s properties such as absorp-
tion, distribution, plasma protein binding, metabolism or 
route of elimination considerably influence their therapeu-
tic success (Lemke and Williams, 2013). The drug’s in vivo 
efficiency is significantly influenced by its plasma protein 
binding (PPB). In vivo the drug molecules can be bound to 
proteins and lipids in plasma, to proteins and lipids in tis-
sues, or can be free (unbound) and diffuse among the aque-
ous environment of the blood and tissues. Depending on a 
specific affinity for plasma protein, a portion of the bound 
and unbound drug may differ. In most cases, only free drug 
molecules interact with the therapeutic target, a receptor, to 
produce effective therapy results and free drug’s fraction is 
the one that can be metabolized and excreted. One of the 
advantages of drug modeling is the ability to find an opti-
mal drug PPB range (Lemke and Williams, 2013). 
A number of drug’s molecular physicochemical prop-
erties notably influence its ADME properties. Lipophilici-
ty, molecular weight, molecular volume, polar surface area 
and solubility play important roles in drug absorption, pen-
etration into tissues, distribution as well as the degree of 
plasma protein binding and route of elimination. In our 
previous papers we studied the relationship between An-
giotensin-converting enzyme inhibitor’s lipophilicity and 
protein binding data (Odovic and Trbojevic-Stankovic, 
2012). Furthermore, the aim of this study was to investi-
gate the relationship between computed molecular proper-
ties of seven selected systemic antifungal drugs and their 
plasma protein binding (PPB) data available in literature. 
Materials and methods
Seven selected systemic antifungal drugs, amphotericin 
B, fluconazole, itraconazole, ketoconazole, posaconazole, 
terbinafine and voriconazole were investigated in this 
study.
The PPB degree data for selected antifungal agents 
was obtained from relevant literature (Lemke and Wil-
liams, 2013;  www.drugbank.ca). The values of antifun-
gal drugs’ molecular descriptors, aqueous solubility (logS), 
electronic descriptor - polar surface area (PSA), constitu-
tional parameter - molecular weight (Mw), geometric de-
scriptor - volume value (Vol) and seven different lipophi-
licity parameters, logP values (AlogPs, AClogP, milogP, 
AlogP, MlogP, XlogP2 and XlogP3) were calculated us-
ing two different software packages (www.molinspira-
tion.com; www.vcclab.org).  The selection of most suitable 
logP value was evaluated on the basis its best agreement 
with values of PPB obtained from literature. 
Microsoft Excel 2003 and Origin 7.0 PRO (Origin Lab 
Corporation, USA) were used for statistical analysis.
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Results and discussion
According to the data obtained from literature, 
antifungal drugs mostly have relatively similar and high 
values of plasma protein binding. These values range 
from 90% for amphotericin B to 99.8% for itraconazole. 
Ketoconazole, posaconazole and terbinafine have also 
high and almost equal values of PPB (99%, 98%, 99%, 
respectively) while fluconazole and voriconazole represent 
exceptions with their lower values of plasma protein 
binding (12% and 58% , respectively) (www.drugbank.ca). 
The five molecular descriptors, logP, PSA, Mw, Vol 
and logS, for all studied systemic antifungal drugs were 
calculated using software packages, Virtual Computational 
Chemistry Laboratory and Molinspiration Depiction 
Software (www.molinspiration.com; www.vcclab.org).
The methods used for logP calculation can be divided 
into property-based and substructure-based methods 
and there are two groups of substructure-based methods: 
fragmental and atom-based. The differences between 
calculation methods led to distinctions between absolute 
logP values. It is generally accepted that molecules with 
high lipophilicity show higher values of plasma protein 
binding in comparison to the less lipophilic ones with 
similar properties. Considering all this, in the first stage of 
the study the relationships between numbered calculated 
lipophilicity descriptors, logP values, and plasma 
protein binding data obtained from relevant literature for 
selected antifungal drugs were investigated using simple 
linear regression. The best correlation was obtained 
for the relationship between antifungal drugs’ plasma 
protein binding data and AClogP lipophilicity descriptor. 
Consequently, lipophilicity descriptor AClogP was chosen 
for further correlations. Following, the correlations between 
plasma protein binding data and other calculated molecular 
descriptors, PSA, Mw, Vol, logS were investigated 
providing relatively poor correlation (R2 < 0.35). 
In continuation, the relationships between antifungal 
drugs’ plasma protein binding data and two different 
molecular descriptors were investigated using multiple 
linear regression analysis (MLR). The relationship 
between antifungal drugs’ protein binding data and their 
lipophilicity with application of additional molecular 
descriptors, Mw, Vol, PSA, logS as additional independent 
variables provided significantly higher correlations (with 
R2 varying from 0.81 to 0.85). The obtained relations are 
presented with following Equations (1)-(4).
PPB predicted(%) = 12.699(±3.213)AClogP + 
0.046(±0.027)Mw + 17.105(±16.654) (1)
With n = 7; R2 = 0.851; S.D. = 15.714; F = 11.451;
PPBpredicted(%) = 12.406(±3.306)AClogP + 
0.049(±0.030)Vol + 19.185(±16.114) (2)
With n = 7; R2 = 0.847; S.D. = 15.922; F = 11.101.
PPBpredicted(%) = 14.921(±3.477)AClogP + 
0.097(±0.072)PSA + 25.055(±15.557) (3)
With n = 7; R2 = 0.823; S.D. = 17.136; F = 9.312;
PPBpredicted(%) = 15.144(±3.618)AClogP – 
2.207(±1.806)logS + 28.532(±14.628) (4)
With n = 7; R2 = 0.814; S.D. = 17.566; F = 8.764.
As can be seen the best correlation was obtained 
using MLR analysis with application of two molecular 
descriptors, AClogP and Mw or AClogP and Vol data, as 
independent variables ((Equation (1) and (2)). However, 
all established correlations can be considered as good with 
R2 higher than 0.80.
Conclusion
The discovery of new pharmacologically active 
substances and modeling of drugs with antifungal 
activity led to necessity of predicting drugs properties 
and their ADME data. The correlations that were found 
between antifungal drugs’ plasma protein binding data 
and their calculated molecular descriptors, confirmed that 
lipophilicity accompanied with other molecular properties, 
such as molecular weight, volume value, polar surface area 
and aqueous solubility are essential for drugs plasma protein 
binding. The presented computational technique could 
be regarded as additional, in vitro approach appropriate 
for evaluation of plasma protein binding of investigated 
drugs especially important in design of new synthesized 
antifungal drugs, since only free drug molecules can 
interact with the receptor to produce effective therapy 
results. 
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Introduction
Research of the leukotrienes originates from the clas-
sic pharmacologic studies in 1940 from Kellaway and 
Trethewie (Kellaway and Trethewie,1940). While studying 
albumin, they discovered a slow reacting substance, which 
stimulated smooth muscle. They named it as a slow react-
ing substance – SRS and based on the pharmacologic ac-
tivity they managed to conclude that it was a unique sub-
stance, found only in immunologically sensitized tissues 
by an antigen. Decades later, SRS was called anaphylaxis 
slow reacting substance (SRS-A).
Zileuton is absorbed immediately after oral admin-
istration and extensively metabolized by CYP and UDP 
glucuronosyltransferase. Even in this case, initial medi-
cine is responsible for the therapeutic effect. Zileuton is a 
medicine with short effect and a half-life of approximately 
2.5 hours and also very much bound to the proteins (93%). 
Pharmacologic effects of cys-LTs’ occur not only as a con-
sequence of the activation of cys-LT1 receptor; for exam-
ple, cys-LTs’ which trigger the vascular smooth muscle 
contraction (Gorenne et al., 1995). and stimulate expres-
sion of the P-selectin generated by endothelial cells via re-
ceptor LT2 (Pedersen et al., 1994).  
Work studied the effect of antileukotriene –Zileuton 
in the treatment of patients with bronchial asthma and in-
creased bronchial reactivity, comparing it with control 
group treated with salbutamol (beta2 adrenergic receptor 
agonist) applied via inhalation. 
Materials and methods
Formation of leukotrienes depends on the lypoxygen-
ation of the arachidonic acid by 5-lypoxygenase. Zileuton 
is an active and powerful inhibitor of the activity of 5-ly-
poxygenase and as such inhibits generation of its products. 
Consequently, besides inhibition of cys-LTs’, zileuton also 
inhibits the formation of leukotriene B4 (LTB4), which is a 
powerful chemotactic of other eicosanoids too, which de-
pend on the synthesis of leukotriene A4 (LTA4). Theoreti-
cally, therapeutic effects of 5-lipoxygenase should include 
all those seen at the antagonist cys-LT1, but also other ef-
fects which include inhibition of the LTB4 and other prod-
ucts of 5-lipoxygenase. 
Pharmacologic effects of cys-LTs’ occur not only as a 
consequence of the activation of cys-LT1 receptor; for ex-
ample, cys-LTs’ which trigger the vascular smooth muscle 
contraction (Gorenne et al., 1995) and stimulate expression 
of the P-selectin generated by endothelial cells via receptor 
LT2 (Pedersen et al., 1994). 
Work studied the effect of antileukotriene –Zileuton 
in the treatment of patients with bronchial asthma and in-
creased bronchial reactivity, comparing it with control 
group treated with salbutamol (beta2 adrenergic receptor 
agonist) applied via inhalation. 
SRaw = Raw x ITGV
Raw and the SRaw were taken for analyses. 
Parameters of the lung function are determined with 
Body plethysmography. Raw and ITGV were registered 
and specific resistance (SRaw) was calculated. 
In persons with bronchial asthma and increased bron-
chial reactivity (n=21), Zileuton applied in a dose of 600 
mg first day (oral route administration, 4 x 1 tabl.). After 
measurement of initial values, 1 capsule 600 mg of zileu-
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ton applied and measured Raw and ITGV after 60, 90 and 
120 min. In the end, in terms of control, applied salbuta-
mol (beta2-adrenergic agonist) in the form of aerosol and 
in a dose of (2 inh. x 0,2 mg); Raw and ITGV values were 
measured again and SRaw was calculated.  
 Zileuton, as antagonist of leukotriene receptor (600 
mg, tablet) administered orally 2 days in row at home (4 x 
600 mg) and after 1 day, respectively 2 days reported at the 
ambulance and measured initial values, tablet administered 
orally at the ambulance, and measured Raw and ITGV af-
ter 60, 90 and 120 min. At the end, as control, administered 
salbutamol (beta2-adrenergic agonist) in the form of aero-
sol and in a dose of (2 inh. x 0,2 mg), and Raw and ITGV 
values were measured again and SRaw was calculated.  
Gained results grouped and analysed. Statistic data 
processing included determination of the average values 
(X), standard deviation (SD), standard mistake (SEM), and 
testing of significance of changes in between groups of pa-
tient treated with antileukotriene substances. 
Gained results tested with a t-test in order to ascertain 
significant changes in between examined groups. In order 
to compare groups, utilized was statistic test ANOVA. This 
test is used in cases when necessary to evaluate more than 
two groups. Potential mistakes with t – test avoided with 
ANOVA used as a method of statistic test. 
Results and discussion
Results of this research, in patients with bronchial 
asthma, indicate that Zileuton administered in a dose of 
600 mg first day (oral route administration, 4 x 1 tabl.) has 
not caused significant decrease of the specific resistance 
(SRaw) of airways (p value 0.1 > Apha 0.05). 
Zileuton, administered 2 days in a row in a dose of 600 
mg (4 x 1 tabl. per day), has caused significant decrease of 
the specific resistance (SRaw) of airways (p value 0.03 < 
Alpha 0.05). Treatment of the control group with salbuta-
mol (agonist of beta2-adrenergic receptor) is also efficient 
in removal of the increased bronchomotor tonus, causing 
significant decrease of the resistance (Raw), respectively of 
the specific resistance (SRaw), (p value 0.05 = Alpha 0.05). 
Antagonists of leukotriene in doses administered 1 and 2 
days after administration of Zileuton at home in the same pa-
tient, does not significantly cause decrease of the arterial sys-
tolic and diastolic pressure (AP) (p value 0.1 > Alpha 0.05). 
Clinical trials with antileukotriene medicines were 
quite heterogeneous in response to the therapy, with pa-
tients that can be classified in two groups, those “respond-
ing” on the treatment and those “not responding” on it. 
For patients responding to the treatment with antileukotri-
ene, heart, lungs, and blood treatment clinics have recog-
nized these medicines as alternative to inhaled steroids, in 
small doses, in order to maintain slight chronic asthma un-
der the control. More studies are needed to define the role 
of these medicines in moderate and severe asthma. (Barnes 
and Miller, 2000). Some clinical trials indicated that an-
tagonists of leukotriene have an affinity in reduction of the 
dose of inhaled steroids necessary to control asthma exac-
erbations (Jarvis and Markham, 2000). 
Side effects of the patients administering zileuton are 
similar to those of patients administering placebo. In esti-
mated 4 to 5% of the patients administering zileuton there 
is an increase of liver enzymes responsibly within 2 first 
months of treatment. Hepatic enzymes should be moni-
tored in patients that have just entered the treatment with 
zileuton, in order to be protected from a potential toxici-
ty of the liver. 
Conclusion
Results of this research indicate that Zileuton, ad-
ministered in a dose of 600 mg (oral route administration, 
first day 4 x 1 tabl.) in patients with bronchial asthma has 
not caused significant decrease of the specific resistance 
(SRaw) of airways, (p value 0.1 > Alpha 0.05).   
Antileukotriene - Zileuton administered 2 days in a 
row, in a dose of 600 mg (4 x a day 1 tabl.), has caused sig-
nificant decrease of the specific resistance (SRaw) of air-
ways (p value 0.03 < Alpha 0.05). Treatment of the control 
group with salbutamol (agonist of beta2-adrenergic recep-
tor) is effective in removal of the increased bronchomo-
tor tonus, by causing significant decrease of the resistance 
(Raw), namely specific resistance (SRaw), (p value 0.05 = 
Alpha 0.05).  
This suggests that Zileuton is a powerful selective in-
hibitor of the activity of 5-lypoxygenase and as such inhibits 
generation of its products. Consequently, besides inhibition 
of cys-LTs’ formation, Zileuton also inhibits the formation 
of leukotriene B4 (LTB4), which is a powerful chemotactic 
of other eicosanoids too, which depend on the synthesis of 
lekotriene A4 (LTA4). According to gained results, the ef-
fect of antileukotriene (Zileuton) is not immediate after oral 
administration, but the powerful effect of the Zileuton seen 
only after two days of inhibition of cys-LTs’, and inhibition 
of leukotriene B4 (LTB4) and A4 (LTA4) based on the re-
cordings made of the specific resistance of airways (SRaw).
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Introduction
Over the last two decades, research regarding Neuro-
kinin-1 (NK1) receptor has been pursued aggressively to 
develop drugs that might be useful for a branch of phar-
macologic purposes including; anticancer, antiviral and an-
tiemetic and dozens of molecules have been entered into 
various phases of clinical trials. The endogenous ligand 
neuropeptide Substance P (SP) selectively binds to NK1 
receptor at the plasma membrane (Munoz et al. 2011). SP 
is an undecapeptide that belongs to the tachykinin peptide 
family and widely distributed in both the central and the 
peripheral nervous system of mammals. Activation of NK1 
receptor by SP stimulates G-protein mediated signaling 
pathways that are crucial for regulating cellular excitabil-
ity and function such as cAMP accumulation, arachidon-
ic acid mobilization and phosphatidylinositol turnover. It 
has been shown that activation of Akt suppresses apoptosis 
and stimulation of NK1 receptor by SP induces phosphory-
lation on Akt or Protein Kinase B (PKB) activity in human 
glioblastoma cells. After binding to the NK1 receptor in tu-
mor cells, SP induces mitogenesis and inhibits apoptosis. 
Hence NK1 receptor antagonists can lead to apoptosis and 
inhibit tumor cell proliferation. Antagonists of these recep-
tors inhibit the development of metastasis by blocking the 
activation of NK1 receptor by SP. It is shown that NK1 re-
ceptors are overexpressed in tumor cells and their antago-
nists such as aprepitant, L-733,060, and L-732,138 have 
antitumor activity against several human cancer cell lines 
such as melanoma, neuroblastoma, glioma, retinoblasto-
ma, pancreatic, larynx, gastric and colon carcinomas (Mu-
noz et al. 2011). 
It has been demonstrated that binding sites of pep-
tide antagonists and non-peptide antagonists of NK1recep-
tor are different than each other. SP and peptide NK1 re-
ceptor antagonists bind to the extracellular terminal region 
of the receptor, but non-peptide NK1 receptor antagonists 
bind to intracellular part of the enzyme between transmem-
brane helices (Munoz et al. 2011). Ligand binding pock-
et of an NK1 receptor is a hydrophobic core between the 
loops of transmembrane TM III-VII. Several residues, such 
as Gln165 (TM IV), His197 (TM V), His265 (TM VI) and 
Tyr287 (TM VII) are involved in the binding of many non-
peptide antagonists of the NK1 receptor. The other resi-
dues that are contributed in non-peptide antagonist binding 
are Ser169, Glu193, Lys194, Phe264, Phe267, Pro271 and 
Tyr272 (Almeida et al. 2004).
Over the last decade our group have been designed, 
synthesized, and working on the new anticancer active 
compounds. Some of our previously synthesized benzoxa-
zole and benzamide compounds showed significant inhib-
itory activity for human DNA Topoisomerases and Gluta-
thione S-transferases and also anticancer effects observed 
on various cell cultures (Pinar et al. 2004). 
In this research, we aimed to search the activity of our 
previously synthesized compound, 2-[4-(4-ethylbenzami-
do)phenyl]benzothiazole (BSN009), to the new anticancer 
target NK1 receptor and to identify the binding site fea-
tures and modes of NK1 receptor and the non-peptide an-
tagonists including our synthesized compound using mo-
lecular docking study.
Materials and methods
The cytotoxic activity of tested compounds (BSN009, 
CP-96345, L-733,060, L-732,138, and aprepitant) were as-
sayed using the MTT colorimetric protocol. MTT is cleaved 
to formazan by the “succinate-tetrazolium reductase” sys-
tem (EC 1.3.99.1) which belongs to the mitochondrial re-
spiratory chain and is active only in viable cells. Human 
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colon carcinoma cell line HT-29 (ATCC, HTB-38), breast 
cancer cell line MCF-7 (ATCC, HTB-38), human cervi-
cal carcinoma cell line HeLa (ATCC, CCL-2) and mouse 
embryonic fibroblast cell line NIH3T3 (ATCC, CRL-1658) 
were used in this study for cytotoxicity experiments.
To analyze the binding site features of the tested com-
pounds the molecular docking studies were performed by 
using CDocker working with Accelrys Discovery Studio 
(DS) 3.5 software.
The homology model of the NK1 receptor with CP-
96345 was developed by Evers and Klebe. For prepara-
tion of protein and ligands the target protein was taken, hy-
drogens were added and their positions were optimized us-
ing all atom CHARMm forcefield and the Powell method 
available in DS 3.5 protocol. The minimized protein was 
defined as the receptor using the binding site module. The 
binding site was defined from the cavity finding method 
which was modified to accommodate all the important in-
teracting residues in non-peptide antagonist binding site of 
the NK1 receptor. The protein was held rigid while the li-
gands were allowed to be flexible during refinement. The 
docking and scoring methodology was first validated by 
docking of ligand CP-96345. The docked position of CP-
96345 overlaps well with the homology model position,
Results and discussion
Our previously synthesized compound, 2-[4-(4-ethyl-
benzamido)phenyl]benzothiazole (BSN009) was found as 
an active compound at a concentration of 50 μM as a result 
of MTT assay and inhibited colon cancer cell lines growth 
about by 57.53%. On the other hand, it has also been found 
that  BSN-009 had no toxic effect on the normal cell line. 
As a result of the molecular docking studies; BSN-009 
was shown similar binding modes with NK1 receptor as 
known antagonists L-733,060, aprepitant, and L-732,138. 
The tested 2-substituted benzothiazole, BSN009, has hy-
drogen bonds with Gln165 (2,39 Angstrom) and His197 
(1,83 Angstrom) like other non-peptide antagonists of 
NK1 receptor Oxygen atom of carbonyl group of BSN009 
makes an H bond with His197. The phenyl ring of the ben-
zamide group of BSN009 has a pi-cation interactions with 
His187. Binding energy values (kcal/mol-1) of BSN009 
and aprepitant, which is a well-known NK1 receptor an-
tagonist, is close to each other.
Conclusion
In conclusion, the performed molecular docking study 
elucidated that Gln165, His197, His265 and Tyr287 are 
crucial amino acids in the non-peptide binding site of 
the NK1 receptor. As a result of the molecular docking 
study and cytotoxic experiments, it can be concluded that 
BSN009 may be a good anticancer drug candidate as an 
NK1 receptor antagonist and is worthy to carry on the an-
ticancer in vivo studies. This study also provide a model to 
design novel and more potent antitumor agents as NK1 re-
ceptor antagonists.
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Introduction
Drug-like property optimization offers significant op-
portunities for enhancing drug discovery. Development of 
a new drug is connected with quantitative structure-activ-
ity (properties) relationship, QSA(P)R, research. Lipohi-
licity is the key physicochemical property of a molecule 
which depends on its structure and determines its phar-
macokinetic behavior and biological activity. Due to its 
high cost-effectiveness and fair reproducibility, thin-lay-
er chromatography (TLC) is one of important alternatives 
for quantifying lipophilicity of drug candidates. The aim of 
this study was to calculate hydrophobicity index C0 with 
reversed phase (RP) TLC methods of 14 compounds with 
assumed antiepileptic activity and to examine whether C0 
values can be applied in QSA(P)R studies.
Materials and methods
RP TLC was used for study of the retention behav-
ior of N-(3- or 4- substituted phenyl)-2,2,-diphenyl-succin-
imide derivatives. Substance number 1 (s1) is not substi-
tuted, s2-s11 have attached in para position: -CH3, -OCH3, 
-OH, -NO2, -CN, -F, -Cl, -Br, -I, -COCH3, while s12-s14 
have in position meta -CN, -OH and -Cl, respectively. Pre-
coated RP-18W/UV254 10×10 cm plates (Macherey-Na-
gel GmbH and Co., Düren, Germany) were used as sta-
tionary phase and binary solutions of water with acetoni-
trile with a varying volume fraction, φ (0.45-0.65) of or-
ganic solvent, were the mobile phase. Each analyzed com-
pound was dissolved in acetone (c=2mg/ml) and 0.2 µl al-
iquots with a micropipette were spotted on the chromato-
graphic plates. Ascending technique with previous satu-
ration of the chambers was used. After development, the 
spots were detected at 254 nm with UV lamp and Rf val-
ues were measured. For each compound analyzed in this 
paper, logP values (logarithm of the partition coefficient 
of the compound) and logD values (log of the distribution 
coefficient of the compound at pH=7.4) were determined 
by the usage of different algorithms (www.alogps.com and 
www.acdlabs.com). Physicochemical parameters as num-
ber of rotatable bonds (RB), numbers of hydrogen bond 
donors (HBD), hydrogen bond acceptors (HBA), polar sur-
face area (PSA) and molar weight (MW) were obtained, as 
well. Finally, for each compound ka (constant of absorp-
tion in min-1) and logBB (logarithm of blood-brain barri-
er, BBB permeability) were predicted (www.acdlabs.com). 
All calculations and statistical analysis were done by use of 
software package Origin 8.0.
Results and discussion
Retardation factor, RM was calculated for each com-
pound according to the equation: RM=log(1/Rf-1). Further-
more, in the linear correlation of the RM values versus φ, 
the chromatographic retention constant RM0, was obtained 
as extrapolated value to 0% point: RM=RM0+S×φ. The iso-
cratic chromatographic hydrophobicity index, C0, is calcu-
lated as RM0/S and it is defined as point when the amount of 
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the analyte in the mobile and the stationary phase is equal. 
Since, C0 is usually applied for quantifying lipophilicity 
of the compound; it has been compared to the computer 
calculated logP values. Highly significant linear correla-
tion with good correlation coefficients has been observed 
between the C0 values and in silico logP/logD values 
(r2=0.78, r2=0.94 and r2=0.77 for MlogP, ClogP and logD, 
respectvely) in which substance with OH group in posi-
tion meta (s13) was an outlier. It has been assumed that s13 
forms an intramolecular hydrogen bond since OH group as 
HBD is close to dione group which is HBA. Probably due 
to this kind of interactions, s13 has reduced affinity to form 
hydrogen bonds with water and to be eluted with the mo-
bile phase when compared to its isomer, s4 which does not 
have possibility to form an intramolecular hydrogen bond.
Regarding the physicochemical characteristics and re-
lationship with “druglikness” properties of the compounds 
investigated, according to Lipinski’s rule of 5, poor absorp-
tion or permeation are more likely for compounds which 
have >5 HBD, MW>500, logP>5 and >10 HBA. As previ-
ously reported, none of the compounds violates even sin-
gle rule. Moreover, additional rules for good oral bioavail-
ability were proposed by Veber: ≤10 RB, ≤140Å2 PSA, or 
≤12 HBD+HBA. Analyzed compounds do not violate Ve-
ber rules hence good oral absorption can be expected. Ac-
cording to in silico data absorption rate is practically iden-
tical for all the examined compounds (ka between 0.051 
to 0.053 min-1). The main assumption is that the effect of 
the core consisted of three phenyl groups attached to suc-
cinimide ring may overwhelm that of the substituent and 
slight changes in lipophilicity determined by C0 practi-
cally do not affect their absorption rate. Physicochemical 
properties influence the passive BBB permeation of com-
pounds. Set of BBB rules was compiled by Clark: N+O<6, 
PSA<60–70Å2, MW<450, logD=1–3, ClogP–(N+O)>0 
in order for the compound to permeate through BBB. All 
compounds violate one or two rules (high logD and/or 
PSA), while s5 violate four rules. Nitro group has defined 
positive and negative poles and it is partially ionized in-
hibits BBB permeation of s5. Since BBB permeability de-
pends on lipophilicity (Di et al., 2003), logBB was present-
ed as function of C0 and square equation with good statis-
tical quality (r2=0.658, p<0.001) was obtained.
Conclusion
For the analyzed succinimide derivates, experimental-
ly obtained C0 values are comparable to the in silico deter-
mined logP/logD values with s13 excused from the com-
parison. Retention parameter, C0 can be proposed for ex-
pressing lipophilicity of the analytes examined in this pa-
per and it can be applied in QSA(P)R studies. 
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Chronic kidney disease (CKD) is a common, 
progressive condition that affects over 13% adult 
population in US only and the number of patients with end-
stage renal disease progressively increases every year. The 
National Kidney Foundation Kidney Disease Outcomes 
Quality Initiative (NKF KDOQI) classifies CKD into 
five stages according to estimated glomerular filtration 
rate. Glomerular filtration rate (GFR) has been usually 
estimated based on equation that incorporates serum 
creatinine concentration (SCR) along with demographic 
data and it is measured in ml/min per 1,73m2: the first 
stage has GFR >90 ml/min per 1.73 m2 and the second 
one between 60-89 ml/min/1.73m2, while stages 3, 4 and 5 
are being characterized with GFR 30-59, 15-29 or <15 ml/
min/1.73m2, respectively.
Based on CKD stage disease individualization of 
therapy is required especially for drugs which are mainly 
eliminated through urine and/or have narrow therapeutic 
index. Other conditions which may required individual 
dosage regimen are also: application of nefrotoxic drugs, 
conditions which may lead to development of chronic renal 
disease as hypertension, diabetes mellitus etc. Furthermore, 
severe hepatic dysfunction is usually accompanied by 
some renal impairment (hepato-renal syndrome). Reduced 
renal excretion has been reported in patients with severe 
cirrhosis (Child–Pugh class C) for a number of drugs 
mainly eliminated by renal excretion in unchanged form. 
Calculated creatinine clearance (CLCR) based on serum 
creatinine concentration is the most convenient method to 
estimate GFR as it requires only a single blood sample. 
As serum creatinine is so highly dependent on age, gender, 
and body size, a number of formulas and corrections have 
been developed to estimate the muscle mass and assumed 
creatinine production (Verbeeck and Musuamba, 2009).
One of the oldest method for GFR estimation in adults 
is Cockcroft-Gault formula: GFR(ml/min/1.73m2)=[140-
age(y)×body weight(kg)]/SCR(mg/dL)×72] multiplied 
with 0.85 if the patient is women. Estimated creatinine 
clearance may be calculated also based on Modification of 
Diet in Renal Disease (MDRD) formulas. MDRD1 formula 
beside the concentration of creatinine in serum requires 
additional information as urea concentration in serum, Cu 
in mg/dL and albumin concentration in serum, alb in g/
dL and it is given as: GFR=170×SCR exp(-0.999) × age 
exp(-0.176) × (0.762 for women) × (1.180 for black) × Cu 
exp(-0.170) × alb exp(0.318). However, MRDR2 formula 
requires only serum concentration level i.e.: GFR=186×SCR 
exp(-1.154)×age exp(-0.203)×(0.742 for women)×(1.212 
for black). Moreover, for patients whose GFR is over 60 
ml/min/1.73m2 it may be calculated by Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equation 
which is considered to give more precise estimation: 
GFR=a×[SCR(mg/dL))exp(c)/b]×[0.993 exp(age)] where 
a is for white race 141 for male and 144 for female, and 
in the black race 163 for male and 166 for female, b is 
0.9 for male and 0.7 for female and while c is -0.411 if 
serum creatinine levels is <0.9 mg/dL and -1.209 if serum 
creatinine levels is >0.9 mg/dL in male or -0.329 if SCR 
is <0.7 mg/dL and -1.209 if SCR levels is >0.7 mg/dL in 
female. If the patient is overweight/obese (BMI >25 kg/m2 
according to WHO), Salazar-Corcoran method should be 
used: GFR is estimated as GFR=[(137-age)×(0.285×body 
weight(kg)]+12.1×height(m)×height(m)]/[51×SCR(mg/
dL)] in male while in female patients the estimation is 
given as GFR=[(146-age)×(0.287×body weight(kg)]+9.74
×height(m)×height(m)]/[60×SCR(mg/dL)]. 
In children, Schwartz adjusted method is used 
for estimation of renal impairment degree i.e.: 
GFR=[k×height(cm)]/SCR(mg/dL) where k=0.33 for pre-
term newborns age under 1 year, k=0.45 for full term in-
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fants age<1, k=0.55 for children age 1-12 and girls in pu-
berty and 0.7 for boys in puberty (age >12). If the children 
are obese, Léger (Léger et al., 2002) formula is being ap-
plied: GFR=[56.7×body weight(kg)+0.142×height(cm)×h
eight(cm)]/[88.4×SCR(mg/dL)]. 
GFR can alternatively be calculated based on the 
serum concentration of cystatin C. Cystatin C, is a small, 
nonglycosylated basic protein, produced at a constant rate 
which renal elimination occurs only by glomerular filtration 
with no tubular secretion, and only minimal extrarenal 
elimination. The blood concentration of cystatin C depends 
almost entirely on the GFR and is not substantially affected 
by diet, nutritional status, or inflammatory or malignant 
diseases. If cystatin C is being determined by PENIA 
method GFR can be estimated as: GFR=80.35×cystatin 
C(mg/L)-4.32, while if it is determined by PETIA method 
GFR should be calculated as GFR=86.49×cystatine 
C(mg/L)-1.68(×1.384 for children <14) (Chew et al., 
2008). 
Once the GFR is determined, individual dosage regimen 
in patient with chronic kidney disease can be applied 
based on the following formula: D*=D×Q where D is the 
maintenance dose for patient with normal renal function, 
D* is maintenance dose for patient with renal impairment 
and Q is being calculated as Q= fnonr + fr×(CLCR*/
CLCR) i.e. Q=(1-fr) + fr×(CLCR*/CLCR) where CLCR is 
clearance creatinine in patient with normal renal function 
and CLCR* is the calculated clearance creatinine for the 
patient who requires individual dosage regimen, fr is the 
fraction of drug eliminated by urine and fnonr is the drug 
fraction eliminated extrarenal. The normal range of GFR, 
adjusted for body surface area, is 100-130 ml/min/1.73m2 
in men and 90-120 ml/min/1.73m2 in women younger 
than the age of 40 and in pharmacokinetic calculations 
for CLCR it is usually used 100 ml/min/1.73m2. In 
children, GFR is 110 ml/min/1.73m2 until 2 years of age 
in both sexes, and then it progressively decreases. Hence 
when new dose is being calculated in patient with renal 
impairment and in comparison with ones who have normal 
renal function CLCR=110 ml/min/1.73m2 is being used 
for children under the age of 2 and 100 ml/min/1.73m2 for 
older (Doogue and Polasek, 2011).
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Introduction
It has been known for many years that coumarins have 
versatile structure, significant therapeutic potential and 
are present in many natural therapeutic products (Riveiro 
et al., 2010). They have multiple biological activities, 
including anticoagulant (Mousa, 2002), anti-inflammatory 
(Hadjipavlou-Litina et al., 2007), antimicrobial (Nimavat 
et al., 2009) and anticancer activities (Belluti et al, 2010). 
In search for new chemotherapeutics against based on 
coumarin we have synthesized eight compounds that 
combine coumarin core and izoxazoles or thiazoles in 
hydrazinyldiene-chroman-2,4-diones (Jashari et al., 2014; 
Ballazhi et al., 2014; 2015). Three of the eight compounds, 
3-[2-(1,3-thiazol-2-yl)hydrazinylidene]chroman-2,4-dione 
(1), 3-[2-(4-methyl-1,3-thiazol-2-yl)hydrazinylidene]
chroman-2,4-dione (2) and 3-[2-(4,5-dimethyl-1,3-thiazol-
2-yl)hydrazinylidene]chroman-2,4-dione (3), have been 
shown to have most potent antiproliferative effects and 
induced apoptosis in breast cancer cells (Jashari et al., 
2014) and bone and lung metastatic cell lines from breast 
cancer (Ballazhi et al., 2015). In addition, synergistic 
effects of tamoxifen (Ballazhi et al., 2014) and doxorubicin 
(Ballazhi et al., 2016, submitted for publication) with 
these compounds were evaluated and apoptotic effect 
was confirmed. These compounds were further subjected 
to physicochemical characterization. In this study their 
distribution coefficients (logD) in three pH environments 
were evaluated and compared with the anticipated ones 
from different software packages. 
Materials and methods
4-Hydroxycoumarine (4-HC, reference), n-octanol and 
the compounds for preparation of phosphate buffer saline 
(PBS), NaH2PO4, NaOH and KH2PO4, were purchased 
from Merck KgaA (Germany). The tested compounds were 
synthesized by the procedure previously described (Jashari 
et al., 2014; Ballazhi et al., 2015). The experimentally 
obtained distribution coefficients (logDexp) between 
n-octanol and phosphate buffers (pH 7.4, NaH2PO4-NaOH, 
0.15 M, I = 0.397 M; pH 6.8, NaH2PO4-NaOH, 0.15 M, 
I = 0.397 M; and pH 5.8, Na2HPO4-KH2PO4-NaOH, 0.15 
M, I = 0.6, temp. coef. -0.0028/oC) were determined by 
shake-flask method (Ballazhi et al., 2016, submitted for 
publication). The experiments were performed in the 
systems n-octanol : PBS = 2:1; 1:1; 1:2 (vol), in triplicate. 
The mixtures of the organic and aqueous phase containing 
the compounds were shaken on a mechanical shaker for 2 h 
(shake-water bath, Haake, 25±0.1 oC). After equilibration, 
they were centrifuged for 10 min at 5000 rpm, the n-octanol 
phase was removed and in both phases the concentrations 
of the compounds were assayed spectrophotometrically 
(UV/VIS Perkin-Elmer System, USA) at λmax 290 nm 
for 4-HC and 410-420 nm for the tested compounds. 
The logDexp were calculated as the ratio between molar 
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concentration in n-octanol and aqueous phase. All 
experiments were made in triplicate. The logD7.4exp values 
were compared with the calculated ones (logDcalc) obtained 
by ChemAxon’s software (www.chemicalize.org/), Vega 
NIC (www.vegaNIC.com), ChemDraw (www.cemistry-
software.com), vcclab (www.vcclab.org)-ALOGPS 2.1 
and molinspiration (www.molinspiration.com). 
Results and discussion
The logD7.4exp, logD6.8exp and logD5.8exp values de-
termined for monobasic acid 4-HC were in accordance 
with the literature data as well as the partition coefficient 
of the un-dissociated 4-HC in pH 7.4, logP 2.66, which 
is similar to the value 2.37 determined by van der Gies-
sen and Janssen (1982). When n-octanol/PBS ratio was 
1:1, the logD7.4exp ranged between -0.065±0.003 (1) and 
0.957±0.038 (3), logD6.8 between 0.153±0.001 (1) and 
0.996±0.008 (3) and logD5.8 between 0.894±0.011 (1) and 
1.886±0.018 (3). Small differences and the same tenden-
cy were observed between the corresponding logDexp when 
determined in systems with different n-octanol/PBS ra-
tios. Large discrepancy was noted between logD7.4exp and 
logD7.4calc values. However, when a simple regression was 
performed, there was found a strong correlation between 
the logD7.4exp and logD7.4calc (0.986≤R≤0.999). Depend-
ing on the software used, predictions are composed of the 
molecules’ atomic increments, selected atom types to ac-
commodate electron delocalization and addition of con-
tributions of ionic forms. logD of zwitterions is calcu-
lated from the logD at the pI. Also, the effect of hydro-
gen bonds on logD is considered if the formation of a six 
membered ring between suitable donor and acceptor at-
oms can take place. As the logD values are pH-dependent, 
the logD calculation relies on the pKa prediction process. 
Considering data determined in the study, the smallest 
difference was observed when software package VegaN-
ic was applied (1.189≤Δ(logD7.4calc-logD7.4exp)≤1.527 for 4-HC; 
0.682≤Δ(logD7.4calc-logD7.4exp)≤1.096 for 1; 0.814≤Δ(logD7.4calc-
logD7.4exp)≤1.393 for 2; 1.075≤Δ(logD7.4calc-logD7.4exp)≤1.488 for 3), 
which is based on two well-known molecular descriptors: 
ALogP (hydrophobicity contribution of 120 atom types) 
and MlogP (13 structural parameters). The large discrep-
ancy between the predicted and experimentally determined 
values suggests that the structures of the coumarin deriva-
tives in the aqueous phase and/or in the organic phase are 
significantly different from the assuming structures. One 
of the reasons could be the tautomeric behavior of these 
compounds.
Conclusion
Distribution coefficients of novel coumarin derivatives 
in different pH mediums were determined.  The derivative 
having thiazole moiety with additional methyl groups 
attached to the carbons at the positions 4 and 5 (3) showed 
the highest lipophylicity. Further studies are needed for 
complete physico-chemical and PK/PD characterization of 
the synthesized compounds. 
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Introduction
Systematic lupus erithematosus (SLE) is multi siste-
matic autoimmune disease with wide range of clinical 
symptoms on almost every organ and tissue, with a high 
level of morbidity and mortality as a result. There is no 
clear cause for SLE and is hard to be cured (Bertsias et al., 
2012).
In recent years, with increasing levels of health care, 
there are new drugs to treat SLE. Although the survival rate 
from 1990 till today has increased by 68% (Urowitz and 
Gladman, 2000) due to the use of glucocorticoids and cy-
totoxic drugs, excessive use of these drugs leads to many 
side effects and death cases. Also, significant concerns re-
lated to opportunistic infections and secondary malignancy 
due to immunosuppressive treatments emerge the need for 
safer and more effective therapy. In recent decades, stem 
cell transplantation has emerged as a new treatment mo-
dality for refractory and severe SLE, mainly hematopoietic 
stem cell transplantation (HSCT) and mesenchymal stem 
cell transplantation (MSCT). The study of Liang and Sun 
(2015) is related to the rationale and current status of the 
MSCT in the treatment of SLE.
SLE therapy 
If the HSC defects are from aquired response, auto-
logus HSCT can be a treatable method after removing the 
cause of risk, and making reconstruction of the immune 
system with deleting the auto-reactive lymphocyte clone 
of hematopoietic origin. No matter of any of this, if genet-
ics is a dominant factor, allogenetic HSCT will be more ef-
fective and logically applicative approach (Liang and Sun, 
2015). 
In the most cases, patients are treated with an alloge-
netic HSCT for SLE and concominant hematological dis-
eases, and will have complete remission from the first and 
second conditions. But, beside the encouraging result, 
there might be some problems with HSCT treatment in 
SLE (Kushida et al., 2001). 
Allogenetic HSCT seems to have a huge curative po-
tential, but also, comes with enormous risk of GVHD 
(graft versus host disease) that have high occurrence and 
hold responsibility for worst results of allogenetic trans-
plantation in hematologic disease, with limitation of wider 
consideration of in autoimmune disease. GVHD are linked 
with some symptoms, like acute organ toxicity, delayed re-
constitution of immune system, increase TRM (transplan-
tation-related mortality), longer remaining of autoreactive 
lymphocytes, and high rate of opportunistic infections. As 
a conclusion of above written, autologus and allogenetic 
HSCT can’t be considered as best stem cell therapy (Bert-
sias et al., 2012).
In recent days, MSCT is new, hopeful stem cell thera-
py for SLE. Mesenchymal stem cells are multipotent, non-
hematopoietic cells that are being considered as a promis-
ing new treatment for tissue regeneration. It has demon-
strated that mesenchymal stem cells can differentiate into 
bone and cartilage, and have immunomodulatory effects on 
T-cells and B-cells. They also can’t be detected by the im-
mune system because they lack co-stimulatory molecules.
Combination of anti-proliferative and immunomod-
ulatory characteristics of MSCs and their immunological 
privilege will make a new approach in treatment of variety 
of autoimmune inflammatory diseases. By today, MSCs 
are used in cases with multiple sclerosis, neuromyelitis op-
tica, chronic and acute GVHD.
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Combinations of MSC deficiency and SLE began with 
making some experiments. Transplantation of allogeneic 
HSCs with bones to get MSCs is a path for prevention of 
the recurrence of autoimmune diseases in MRL/lpr mice, a 
murine model of lupus, in cases of easy relapse if HSCs are 
infused alone. Also, a positive response is found in trans-
plantation with allogeneic HSCs and MSCs namely it in-
creased survival level of MRL/lpr mice, but also with bone 
marrow transplantation (Ishida et al., 1994).
The named above results stress deficiency in lupus 
MSC populations and gave a strong impact for greater use 
of MSCT in lupus treatment, it is hard to see abnormality 
is from genetic or acquired factors is alike. This problem is 
very important in HSCT also, because it will determine the 
best and appropriate source for MSCT, or it would be au-
tologous or allogeneic.
The first study of MSC infusions in humans is the one 
from 1995, which demonstrates the appropriance of ex vivo 
expansion and subsequent infusion of autologous MSCs in 
15 patient volunteers. From that point, MSCT was consid-
ered as a great tool in the usage of engraftment, manage-
ment graft failure, prevention or treatment of GVHD after 
HSCT, and treatment of several other autoimmune diseas-
es (Liang et al., 2010).
The most important result of human MSC therapy is 
arising from clinical trials which have an aim of severe and 
refractory SLE patient, even with mechanisms with which 
MSCs conduct their functions of immune modulation and 
are still not completely understood, but will involve vari-
ety of paths. Affiliated Drum Tower Hospital (ADTH) of 
Nanjing University Medical School is the very first sec-
tion involved in in MSCT for treatment of autoimmune 
disease. More than 300 patients with active and persistent 
SLE, refractory to standard treatment, was under treatment 
with allogeneic MSCT. The treatment was due from March 
2007 through December 2013. 
Four patients had a great improvement in creatinine 
levels in serum. Anti-dsDNA titers decreased after 1 month 
post-MSCT in all cases. All patients could lower the doses 
of steroids and CTX, and also there were two cases where 
patients weren’t taking CTX anymore after 6 months re-
sults. There was no GVHD and TRM after allogenetic 
MSCT (Liang et al., 2010). 
Results clearly show that MSCs have large therapeu-
tic potential but also have many problems that have to be 
solved for making way for MSCT to treatment of lupus. 
One of the problems is getting standard cell production 
without considering heterogeneity, potential, influence of 
expansion media on the phenotype, and suitability of the 
source. Some factors possible change capability of expan-
sion, potency and phenotype, like age of donor and condi-
tion of growth, for even the surface makers of MSCs (Li-
ang and Sun, 2015). 
Lupus is a mesenchymal stem cell disease, not only 
hematopoietic, in light of defects in HSCs and also MSCs 
in SLE patients. At recent days risks of GVHD are limited 
in great range for the clinical use of allogenetic. Howev-
er, allogenetic MSCT will be better and more attractive to 
use then the allogenetic HSCT in treatment of lupus, with 
preliminary results in efficacy and safety. This will make a 
new platform in treatment of SLE patients with refractory 
and severe disease (Liang and Sun, 2015).
Conclusion
The number of patients with SLE in our country is 
higher to date and unfortunately in Macedonia, doctors 
use conventional therapy in treatment of SLE. That arise a 
need for implementation of the latest method in treatment 
of SLE with aim to improve the quality of life. Also, the 
number of hospital days will be lower, as well as the need 
of cure in countries abroad, and costs for medicines. The 
most important result will be improved quality of patinets` 
life, where people will have longer life and lower rate of 
mortality. For that cause, we should promote implementing 
conditions where this treatment will be in use, with simpli-
fying and making life better for SLE patinets. 
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Introduction
Bile acids, a main product of cholesterol catabolism, 
have traditionally been considered as intestinal emulsifiers 
of lipophilic xenobiotics. Due to an amphiphathic structure, 
bile acids have been recognized to facilitate a transport 
of various substances across biological membranes, 
influencing their physiological and pharmacological 
activity (Stojančević et al., 2013). During the past fifteen 
years bile acids were endowed with a hormone function 
since these steroid molecule species regulate numerous 
metabolic processes, determine metabolism and cell fate 
not only in enterohepatic tissues, but also on a systemic 
level (Stanimirov et al., 2015). In addition, bile acids 
and bile acid-activated receptors play a profound role 
in the process of carcinogenesis; however, this function 
has not been clearly elucidated jet. All of these peculiar 
functions are mediated by the interaction of bile acids with 
several proteins including nuclear and G-protein-coupled 
receptors as well as cell kinase pathways (Stanimirov et al., 
2012). This raises the complexity of bile acid functions on 
a novel level, emphasizing their role not only as a passive 
carrier that promotes transport of pharmacological agents 
across biological membranes, but also as the agents with 
potential pharmacodynamic function. Doxorubicin is one 
of the most potent and most commonly used antineoplastic 
agents for the treatment of both solid and hematological 
malignancies. Doxorubicin induces the programmed 
cell death in malignant cell through several pathways, 
including the DNA strand breaks by topoisomerase 2α 
inhibition, DNA alkylation, oxidative stress and oxidative 
damage of nucleic acids, proteins and lipid membranes, 
ATP depletion etc. However, cumulative, dose-dependent 
toxicity of this agent may result in hepatotoxic and 
cardiotoxic events which cast shadow on the quality of life 
of oncological survivors. Therefore, the enhancement of 
doxorubicin function along with reducing dose-dependent 
undesirable effects is one of the main challenges in 
developing novel doxorubicin formulations. The aim of 
this study was to determine an effect of secondary bile 
acid, ursodeoxycholic acid, on the cytotoxic activity and 
proapoptotic potential of doxorubicin in vitro, in a model 
of human breast adenocarcinoma.
Materials and methods
Human breast adenocarcinoma MCF-7 cells were 
treated with increasing concentrations of doxorubicin 
and ursodeoxycholic acid, and the cytotoxic activity was 
assessed using colorimetric MTT test. Cells were also 
simultaneously treated with selected concentration of 
doxorubicin and the concentration of ursodeoxycholic acid 
within the range of physiological level. The quantitative 
analysis of expression of genes involved in apoptosis, 
Bax and Bcl-2, was assessed using real-time quantitative 
PCR method. Gene expression was calculated using 
ΔΔCt method for relative quantification and normalized 
to β-actin as a housekeeping gene. The statistical analysis 
was performed using one-way analysis of variance with 
SPSS statistical software and if the p ≤ 0.05the results were 
considered as significant.
Results and discussion
Both doxorubicin and ursodeoxycholic acid expressed 
dose-dependent cytotoxic activity with half inhibitory 
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concentration (IC50) values of 0.64 μM and 320.5 
μM, respectively. When the cells were co-treated with 
0.25 μM of doxorubicin and non toxic concentration of 
ursodeoxycholic acid, the cytotoxicity increased up to 
39.6% (p ≤ 0.05), compared to doxorubicin alone which 
inhibited 33% of cell growth. This result indicates that 
the addition of ursodeoxycholic acid may significantly 
increase doxorubicin-induced cytotoxicity in MCF-7 
cell line. In the following step we wanted to dissect the 
effects of ursodeoxycholic acid on doxorubicin-induced 
apoptosis by determining the expression of apoptosis-
related genes Bax and Bcl-2. The expression of a pro-
apoptotic gene Bax in cells treated with doxorubicin alone 
was 3.22 fold higher (p < 0.01), and in the group of cells 
co-treated with doxorubicin and ursodeoxycholic acid 
was 2.28 fold higher in comparison with control group 
(p < 0.01). The expression of anti-apoptotic gene Bcl-2 
in the doxorubicin treated cells was 1.42 fold higher (p < 
0.01), whereas in co-treated cells was 1.25 fold decreased 
compared to the control (p < 0.01). These results indicate 
that co-treatment with ursodeoxycholic acid reduced the 
expression of both apoptosis-related genes compared to 
cells treated with doxorubicin alone, which is in agreement 
with well known antioxidant and apoptosis-reducing 
function of ursodeoxycholic acid (Perez and Briz, 2009). 
When we assessed the ratio of Bax to Bcl-2, a parameter 
that determines the susceptibility of cells to the apoptosis, 
the values of this ratio in doxorubicin treated cells was 
highly significantly increased in both doxorubicin-treated 
and ursodeoxycholic acid-co-treated cells, 6.26 ± 0.7 (p < 
0.01) and 7.89 ± 1.1 (p < 0.01), respectively, compared to 
control group of cells 2.9 ± 0.9. Even though the value of 
Bax/Bcl-2 ratio in the group of co-treated cells was higher 
compared to doxorubicin treated cells, the difference was 
not statistically significant. However, the results were in 
accordance with the results of MTT test indicating that the 
co-treatment with ursodeoxycholic acid had driven MCF-
7 cells into apoptosis in greater extent than treatment with 
doxorubicin alone.
Conclusion
The simultaneous treatment with ursodeoxycholic acid 
in non-toxic concentrations and doxorubicin significantly 
increased the cytotoxicity towards MCF-7 cell line, by 
promoting the programmed cell death, apoptosis, at least 
on the transcriptomic level. Therefore, ursodeoxycholic 
acid may be exploited as useful agent in developing novel 
pharmaceutical formulations or antineoplastic strategies 
relying on doxorubicin protocol.
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Introduction
Bile acids are endogenous amphiphatic steroid 
molecules able to modulate transport of drugs and other 
xenobiotics across various membranes through both, 
paracellular transcellular routes (Djanic et al., 2016a; 
Golocorbin-Kon et al., 2009, Lalić-Popović et al., 2013, 
Mikov and Fawcett 2006, Stojancevic et al., 2013). The 
effect of bile acids on drug transporters is currently 
a challenging topic due to consequences on efficacy 
and safety profiles of drugs. Research on this topic has 
been mostly restricted to the impact of bile acids on the 
eukaryotic drug transporters what is confirmed by several 
studies (Yang et al., 2011). Up to date there has been no 
study on bile acids interactions with multidrug transporters 
in probiotic bacteria. Given that bile acids interact with 
intestinal microbiota as significant drug-metabolizing 
system that may be the cause of inter- and intra- individual 
differences in drug metabolism (Stojancevic et al., 2014) 
the purpose of this study was to use computational servers 
and softwares to assess the binding affinities of different 
bile acids towards bacterial multidrug transporters and to 
propose the mechanism of their influence on drug transport 
through bacterial membrane (Djanic et al., 2016b). 
Materials and methods
As a representative of gut microflora, Lactobacillus 
acidophilus NCFM (LA) is chosen, as the most commonly 
commercially used probiotic bacterial strains and also 
abundant part of gut microflora. Docking study was carried 
out to estimate the binding affinities of three different 
bile acids: cholic acid (CA), 12-monoketocholic acid 
(MKC) and deoxycholic acid (DCA) to drug membrane 
transporters in LA. Docking step was performed using 
molecular docking program SwissDock web service which 
uses calculations performed in the CHARMM force field 
with EADock DSS. The lower estimated free energy of 
binding indicates the higher binding affinity. The list of 
multidrug transporters for LA was obtained from relational 
database – TransportDB, The amino acid sequence of 
all studied transport proteins were obtained from NCBI 
database in FASTA format. The 3D structures of proteins 
were predicted by I-TASSER server (Iterative Threading 
ASSEmbly Refinement). The obtained 3D structures 
are given a confidence score (c-score) which was in the 
range of [-5, 2] where a higher value indicates a model 
with a more reliable structure and vice-versa. Proteins with 
c-score below -1.5 were not taken into further consideration 
and were not analyzed in docking studies. 3D structures 
of CA and DCA in mol2 format were obtained from 
ZINC database. Structure of MKC was drawn in ACD/
ChemSketch, a freeware for chemical structure drawing 
and subsequent optimization from ACD Labs.
Results and discussion
According to data available at TransportDB database, 
the total number of multidrug transport proteins in LA was 
30, 14 from ATP-binding cassette (ABC) superfamily and 
16 from secondary transporters. The majority of predicted 
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3D structures had a high confidence score reflecting the 
reliability of the obtained structures. Four proteins did 
not fulfill these criteria and were not further analyzed 
in docking studies. In other words, 26 transporters were 
included in docking studies. 
The molecular docking results revealed that studied 
bile acids exhibit different binding affinities towards 
multidrug transporters in LA. The lowest binding energy 
for the majority of examined transporters was estimated for 
MKC. Namely, from all 26 examined transport proteins, 13 
(50%) gave the lowest binding energy in combination with 
MKC. The most prominent effect of MKC was observed 
in the cases of LBA1821 from ATP family and LBA0753 
from the family of secondary transporters. 
Analyzing docking results, the second ranked bile 
acid was CA that gave the lowest docking result with 7 
of 26 (26.9%) transporters. The most notable differences 
in docking score, regarding the CA was estimated for 
LBA0575, ABC transporter in LB. For only 6 transporters 
(23.0%), DCA was estimated to have the highest affinity 
compared to other examined bile acids. This is the most 
expressed in the case of LBA0552, secondary transporter. 
The correlation between hydrogen bond interactions 
and estimated free binding energies for all studied transport 
proteins revealed weak inverse relationship between the 
variables. Based on the calculated Pearson’s coefficient, it 
may be concluded that, in addition to the hydrogen-bond 
interactions, the hydrophobic interactions also contribute 
to the stability of analyzed complexes. 
Conclusion
The molecular docking results presented in this study 
revealed that studied bile acids exhibit different binding 
affinities towards multidrug transporters in LA that may 
be the consequence of different chemical structures. 
The greatest effect of MKC for the majority of studied 
transport proteins suggests that keto group at the position 
12 has a significant influence on the properties of MKC 
and consequently, on the interactions with membrane 
transporters. These findings might have a role in the 
prediction of bile acids and probiotics influence on drug 
pharmacokinetics. Computational techniques are expected 
to increase its contribution to structural pharmacology 
investigation of membrane transporters and their 
implication in drug metabolism. However, in order to 
confirm the predictive strength of these computationally 
obtained results, further in vitro and in vivo experimental 
validation is highly recommended.
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Introduction
The principles of therapeutic drug monitoring (TDM) 
were first discussed after the year1960 and since then, this 
concept has evolved and is implemented in different mo-
dalities in different countries (Hallworth, 1993). The ob-
jective of TDM is to evaluate the drug concentration in or-
der to maximize the pharmacotherapeutic effects and min-
imize the toxic effects (Gross, 2001). Several countries 
developed a specific service dealing with the therapeutic 
monitoring of drugs. In other countries this service is pro-
vided by the pharmaceutic department, clinical pharmacy 
department, or the clinical biochemistry department (Mur-
phy et al., 2007).
The Therapeutic Monitoring of drugs is considered as 
a helpful instrument in case of drugs with a narrow ther-
apeutic index, drugs highly bound to the proteins, drugs 
with high potential of interactions ecc. There are many fac-
tors influencing the therapeutic drug monitoring such as 
diseases, non-compliance, habits, sampling time ecc. How-
ever it is possible to retroactively evaluate the appropriate-
ness of the interventions undertaken through the results ob-
tained from monitoring of the serum drug levels (Burton et 
al., 2006).
Carbamazepine is an antiepileptic drug presenting a 
narrow therapeutic range and a complicated pharmacoki-
netics, thus representing a candidate drug to undergo ther-
apeutic monitoring (Levy et al., 2002; Neels et al., 2004).
The objective of this study was to evaluate the appro-
priateness of the interventions through the therapeutic car-
bamazepine monitoring in the neurology service in the 
University Hospital Mother Teresa in Tirana.
Materials and methods
The medical records regarding the monitoring of the 
serum levels for carbamazepine over 6 years (2008-2010 
and 2013-2015) were evaluated. Data analyses were per-
formed using Chi square test. Information was received 
from the Clinical Biochemical Laboratory and the Neurol-
ogy Service in the University Hospital Mother Teresa in 
Tirana. 
Results and discussion
We analyzed all medical records for patients who un-
derwent the measurement of the serum level of carbamaze-
pine for two separated periods: 2008-2010 and 2013-2015. 
All these requests for the measurement of carbamazepine 
serum level were performed by neurologists in order to 
identify whether the missing therapeutic effect or the pres-
ence of toxicity was dedicated to the abnormal serum lev-
el of the drug. The overall number of carbamazepine mea-
surements in the Clinical Biochemical Laboratory was for 
the years 2008-2010 respectively 286, 249 and 227; and for 
the years 2013-2015 the measurements were 34, 49 and 51 
respectively. All measurements were performed through 
immunoassay methods. Standard dose regimens for car-
bamazepine resulted in insufficient serum concentration in 
37% of the cases for the measurements performed in the 
years 2008-2010 and in 23% of the cases for the measure-
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ments performed in the years 2013-2015.  Standard dose 
regimens for carbamazepine resulted in overdose concen-
trations in 34% of the cases for the measurements per-
formed in the years 2008-2010 and in 21% of the cases for 
the measurements performed in the years 2013-2015. Cli-
nicians’ response to the abnormal concentrations of carba-
mazepine were appropriate in 65% of the interventions in 
the first 3 years and this appropriateness raised to 98% in 
the second three years of evaluation (p<0.01).
A limitation of our study consists in the evaluation of 
restricted information. It would be helpful if we could an-
alyze also the factors leading to the abnormal serum lev-
els of carbamazepine, the concomitant therapies which pa-
tients were taking at the time of serum level measurement.
Our study demonstrated better therapeutic outcomes 
after evaluation of the first period of TDM application on 
carbamazepine levels. This finding is in accordance with 
similar studies where better results were obtained after crit-
ical evaluation of the experience gathered (Patsalos et al., 
2008; Shakya et al., 2008).
The evaluation of the therapeutic interventions through 
the therapeutic monitoring of carbamazepine showed that 
the experience gained over the first three years’ experi-
ence with this evaluation brought to the better understand-
ing of the real need to perform the therapeutic monitoring 
of carbamazepine. This led to a significant cost contain-
ment in performing this evaluation. The cost of the thera-
peutic monitoring procedures has been a continuous con-
cern of the TDM service worldwide. Several studies have 
shown the benefits both in terms of therapeutic benefit for 
the patient and of economic benefit due to the implementa-
tion of the therapeutic drug monitoring for different drugs. 
By the other hand there are other groups of drugs which do 
not need to undergo continuous therapeutic drug monitor-
ing (Eadie, 1995). 
The therapeutic drug monitoring is applied in Albania 
through the Clinical Biochemical Laboratory within the 
University Hospital, since there is not yet in place e specif-
ic service dealing with therapeutic monitoring of drugs. A 
future challenge for the therapeutic drug monitoring in Al-
bania represents the inclusion of the clinical pharmacists 
in this process. It has been demonstrated through several 
studies that the pharmacists can play a critical role as part 
of the multidisciplinary team driving the TDM process as 
they have the skills and knowledge to resolve drug therapy 
problems (Ratanajamit et al., 2009; Steinman et al., 2011). 
The combination of different health professionals involved 
in the therapeutic drug monitoring process, together with 
the recent technology developments, facilitates new appli-
cations in this field (Eliason, 2013).
Conclusion
The service of therapeutic drug monitoring can pro-
vide important information about the appropriateness of 
the clinical prescriptions and can therefore influence the 
outcomes of the drug therapy. The continuous evaluation 
of the medical interventions through the therapeutic drug 
monitoring interventions can improve the drug therapy re-
sulting in better outcomes for the patient and in cost con-
tainment. The involvement of the clinical pharmacist in the 
multidisciplinary team can improve the performance of the 
therapeutic drug monitoring service.
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Introduction
Atorvastatin is a potent inhibitor of the 3-hydroxy-
3-methylglutaryl-coenzyme A reductase and it is wide-
ly used in the treatment of hypercholesterolemia and hy-
pertriglyceridemia (Fu et al., 2013). However, despite its 
clinical efficacy, great variability in clinical response ex-
ists. Much attention is paid to the genetic factors affecting 
inter-individual differences in clinical response and sever-
al studies in this area point to single nucleotide polymor-
phisms (SNPs) in the gene SLCO1B1 encoding multiple 
organic anion-transporting polypeptide 1B1 (OATP1B1). 
As a membrane influx transporter, OATP1B1 regulates the 
cellular/hepatic uptake of a number of endogenous com-
pounds and drugs, incl. atorvastatin (Giannakopoulou et 
al., 2014; Rodrigues et al., 2010; Chen et al., 2011). Hence, 
SLCO1B1 SNPs are attractive targets for analyzing their 
influence on statin differential response (Giannakopoulou 
et al., 2014). SNPs 521T>C (*5, rs4149056) and 388A>G 
(*1b, rs2306283) that encode alanine substitution of valine 
at amino acid 174 (p.Val174Ala) and amino acid change at 
position 130 (p.Asn130Asp), respectively, are considered 
as the most prevalent SLCO1B1 variants relevant for the 
variability of drug response. c.388A>G variant has been 
associated with increased OATP1B1 transport activity of 
several substrate drugs in vitro (He et al., 2011), unlike 
c.521T>C variant for which reduced transport activity in 
vitro and increased plasma concentrations of several sub-
strate drugs in the human body were observed (Kalliokos-
ki et al., 2010). The aim of this study was to investigate the 
influence of SLCO1B1 c.521T>C and c.388A>G variants 
on the lipid lowering effect of atorvastatin in a sample of 
Albanian population.
Materials and methods
Subjects and study design 
Briefly, 64 adults (53% males, av. age 58 yrs. and BMI 
28) with primary hypercholesterolemia, all of Albanian or-
igin participated in the study. All the participants used ator-
vastatin once daily in a dose range of 10-80 mg. The study 
was conducted in accordance with the ethical principles of 
the Declaration of Helsinki and the ICH Note for Guidance 
on GCP (CPMP/ICH/135/95). The final clinical trial proto-
col as well as the informed consent and other information 
that required pre-approval were reviewed and approved by 
the Independent Ethics Committee according to the appli-
cable regulations.
Methods
The genotyping of SLCO1B1 521T>C and 388A>G 
was performed at the UKIM-Center for biomolecular phar-
maceutical analyses, using TaqMan allelic discrimination 
assay (ТаqMan® Drug Metabolizing Assay; Applied Bio-
systems, Foster City, California, USA). Polymerase chain 
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reaction was performed on the Real-Time PCR system 
Mx3005P (Stratagene, La Jolla, CA, USA) using TaqMan 
genotyping protocols (TaqMan®Drug Metabolizing assay; 
Applied Biosystems Foster City, Ca, USA) in total volume 
of 12.5 μL under the following conditions: one cycle of 2 
min at 50 ºC, one cycle of 10 min at 95 ºC, and 50 cycles of 
15 sec at 92 ºC and 1 min at 60 ºC. Total cholesterol (TC), 
low-density lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol (HDL-C), triglycerides (TG), apo-
lipoprotein A (ApoA) and apolipoprotein B (ApoB) were 
measured at beginning and after 3 months of treatment by 
standard accredited methods. All data were statistically an-
alyzed using different statistical methods (independent t-
test, Mann-Whitney and Kruskall-Wallis tests and Bonfer-
roni correction, with 95%CI, IBM SPSS 19.0). Chi-square 
test was used to deduce deviations from Hardy-Weinberg 
equilibrium. The results were considered statistically sig-
nificant at p<0.05.
Results and discussion
The frequencies of the SLCO1B1 521T>C and 
388A>G variant alleles were found to be 11% and 41%, 
respectively. However, no carrier of c.521CC was identi-
fied. These frequencies were found to be similar to those 
observed in Macedonians (14.1% and 40%) (Daka et al., 
2015) and Caucasians (15% and 37%) (Mwinyi et al., 
2004). The observed frequency distributions did not show 
significant deviations from the Hardy-Weinberg equilibri-
um. Three-month treatment with atorvastatin significantly 
decreased the plasma levels of TC, LDL-C, TG and ApoB 
and increased the average values of HDL-C and ApoAI to 
the referent values. However, no statistically significant 
change in the levels of Lp(a) was observed and this pa-
rameter remained out of referent range (≥30 mg/dL; per-
cent change -8.23±15.16%). In the carriers of c.521TC 
(n=14), higher decrease in the levels of TC, TG and Lp(a) 
(11%, 15% and 26%, accordingly) was observed in com-
parison with the c.521TT carriers (n=50), pointing to low-
er activity of OATP1B1 in the carriers of variant c.521-
allel. This could be confirmed by the percent changes in 
the levels of HDL-C and ApoAI in different c.521 geno-
types of this ethnic group. Namely, after 3-month treat-
ment, the average percent change of HDL-C was lower in 
c.521TC carriers (7.46±9.66%) vs. higher average percent 
change of 15.96±93.68% in c.521TT carrier (53% low-
er increase). Similarly, the highest increase in the average 
percent change of ApoAI was observed in the carriers of 
c.521TT, 12.13±12.27% vs. 4.32±17.09% in the carriers 
of c.521TC (181% higher increase). No effect on the mean 
percentage changes of all these parameters after 3-month 
treatment with atorvastatin was observed among carriers 
of different SLCO1B1 c388A>G genotypes. These results 
are consistent with the findings from several studies con-
ducted in the European (Giannakopoulou et al. 2014), Bra-
zilian (Rodrigues et al., 2010) and Chinese population (Fu 
et al., 2013; Yang et al., 2010), where atorvastatin, simvas-
tatin and pitavastatin as drugs were administered.
Conclusion
No significant association between different SL-
CO1B1 c.388A> G genotypes and atorvastatin response 
was observed in the studied Albanian population. Visible 
differences were observed between c.521TC and c.521TT 
carries, suggesting association between the c.521T>C SNP 
and atorvastatin response. Additional studies, with a large 
sample size, are needed to confirm statistical significance 
of this finding.
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Introduction
Glutathione-S-transferases (GSTs) are a family of di-
meric multifunctional enzymes that play an important role 
in metabolism and detoxification of numerous xenobiot-
ics, electrophilic chemicals (including drugs), environmen-
tal carcinogens, and products of oxidative stress in living 
organisms. GSTs are found in almost all organisms from 
mammals to plants and even in some prokaryotes. Human 
GSTs consist of three families: cytosolic GSTs, mitochon-
drial GSTs, and microsomal GSTs. In mammalian cells 
cytosolic GSTs are further categorized into seven major 
classes according to their amino acid sequence: alpha, mu, 
pi, theta, zeta, omega, and sigma subfamilies, which have 
been identified in dimeric forms (Mathew et al., 2006).
For the GST-mediated detoxification reactions, a sub-
strate/GSH conjugation (complex formation) is required. 
GSTs are a family of Phase II detoxification enzymes that 
catalyze the conjugation of the GSH to a wide variety of 
electrophilic compounds. GSTs catalyze the conjugation 
of the reduced form of glutathione (GSH) to electrophilic 
centers of endogenous and exogenous hydrophobic com-
pounds. For GST-mediated catalytic reactions, the activa-
tion of the sulfur atom of the G site bound GSH to the thio-
late anion, which is a strong nucleophile, is required in or-
der to perform a GS-substrate conjugate by attacking to the 
electrophilic center of substrates bound to the H site. Fur-
thermore, the GS-conjugated compounds may be actively 
extruded from the cell through specialized pumps; princi-
pally, the multidrug resistance proteins MRP-1 and MRP-2 
(Wu and Dong, 2012).
Human glutathione-S-transferase pi1-1 (hGST P1-1) 
is a member of the pi class subfamily of cytosolic GST 
and composed of two homodimer GST P1 subunits. The 
structural analysis indicates that the hGST P1-1 is a sol-
uble protein comprised of 209 amino acid residues. The 
crystal structures show that each GST subunit of the pro-
tein dimer contains an independent catalytic site composed 
of two components. The first is a binding site specific for 
GSH or a closely related homolog (the G site) formed from 
a conserved group of amino-acid residues in the amino-ter-
minal domain of the polypeptide. The second component 
is a site that binds the hydrophobic substrate (the H site), 
which is structurally variable. Amino acid variations of the 
H-site, among the different GST classes, determine sub-
strate specificity (Wu and Dong, 2012).
It is known that hGST P1-1 participates in a particular 
role in one of the mechanisms of the development of resis-
tance in cancer cells towards the administration of antican-
cer agents in chemotherapy. Human GST P1-1 is overex-
pressed in many cancers and contributes to multidrug resis-
tance by directly conjugating to chemotherapeutic agents 
including cisplatin, adriamycin, etoposide, thiotepa, and 
chlorambucil. It is suggested that this resistance is related 
to high expression of hGST P1-1 in cancers such as breast, 
lung, colon, pancreas and cervix, thereby contributing to 
resistance to chemotherapy. Studies have shown that hGST 
P1-1 levels correlate with resistance to standard chemo-
therapy and are elevated in biopsies of tumour tissues that 
have become resistant to therapy after administration of 
anticancer agents (Wu and Dong, 2012). Consequently, in-
hibitors of human GST P1-1 catalytic activity remain a po-
tential therapeutic tool in cancer cell resistance to drugs. In 
order to overcome this resistance specific hGST P1-1 in-
hibitors are in demand.
Furthermore, a variety of sulfonamido-containing 
compounds are apparently accommodated by the H-site of 
GST and found to be the substrates for GSTs. Data given in 
the literature are clearly shown that GSTs can mediate the 
enzymatic cleavage of the sulfonamide bond displaying a 
sulfonamidase activity by catalyzing the GSH-mediated 
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hydrolysis of sulfonamide bonds. Groups capable of with-
drawing sufficient electron density from the alpha carbon 
atom to the sulfonyl group are an absolute requirement in 
this enzymatic process. GST-mediated sulfonamide cleav-
age results in the formation of the GS-conjugate, the corre-
sponding amine, and sulfur dioxide. The released GS-con-
jugate may provide a strong inhibitor against intracellular 
GSTs, thus facilitating cancer chemotherapy (Mathew et 
al., 2006).
The benzoxazoles have been the aim of many re-
searches for many years because they constitute an impor-
tant class of heterocyclic compounds exhibiting substantial 
chemotherapeutic activities.The newly synthesized 2-sub-
stituted-5-(4-nitrophenylsulfonamido)benzoxazole de-
rivatives, which were screened for the in vitro inhibition 
of hGST P1-1, exhibited significant inhibitor activities. 
Among the tested compounds, 2-(4-chlorobenzyl)-5-(4-
nitrophenyl-sulfonamido)benzoxazole displayed the most 
potent inhibitory activity for hGST P1-1 with an IC50 val-
ue of 10,2 µM, showing a similar potency with the used 
reference drug ethacrynic acid (Ertan-Bolelli et al., 2014).
The molecular docking studies performed by us-
ing CDocker method is revealed that the new synthesized 
2-substituted-5-(4-nitrophenyl-sulfonamido)benzoxazoles 
are acting as catalytic inhibitors of hGST P1-1 by binding 
to the H-site and performing conjugates with GSH forming 
S-(4-nitrophenyl)-GS complex via nucleophilic aromatic 
substitution reaction (Ertan-Bolelli et al., 2014). 
It is reported that the active site residues Tyr7 and 
Tyr108 play important roles for the activity of hGST P1-
1. Different models have been proposed for the activation 
of GST, all highlighting the key role of active site resi-
dues Tyr7 and Tyr108 (Wu and Bong, 2012). In the mech-
anism for activation of GSH, Tyr7 acts as a general base, 
promotes proton abstraction from the GSH thiol, and cre-
ates a thiolate anion with high nucleophilic reactivity. Ad-
ditionally, the hydroxyl group of Tyr108 appears to con-
tribute to the catalytic mechanism in the conjugation reac-
tion of GSH with the docked sulfonamide-substituted ben-
zoxazoles (Ertan-Bolelli et al., 2014,).
Moreover, it was found that groups capable of with-
drawing sufficient electron density from the alpha carbon 
atom to the sulfonyl group are an absolute requirement. 
The electrophilic substructure of the sulfonyl group is sole-
ly responsible for activation of the sulfonamide bond to-
ward cleavage. On the other hand, the amine portion has 
little or no impact on the cleavability of sulfonamide sub-
strates (Ertan-Bolelli et al., 2014).
In conclusion, the newly developed hGSTP1-1 in-
hibitory active 2-substituted-5-(4-nitrophenylsulfonami-
do)benzoxazoles are promising lead compound for further 
in vivo studies to develop a new chemotherapeutic agent 
for the treatment in MDR cancers. It is accepted that the 
hGST P1-1 contributes directly to drug resistance in some 
cell types via their catalytic activity. The development of 
chemotherapy resistant tumour cells is a significant prob-
lem encountered in cancer treatment. The finding of over 
expression of hGST P1-1 in many cancer tissues as well 
as in drug resistant cell line, suggests that elevated hGST 
P1-1 expression may be of direct relevance not only to ac-
quired resistance, but also in natural resistance. hGST P1-1 
has been shown to catalyse the conjugation of GSH with 
the alkylating agents chlorambucil and thiotepa, suggest-
ing that overexpression of hGST P1-1 in cells exposed to 
these drugs would confer resistance. Elevated cellular lev-
els of hGST P1-1 have been shown to accompany resis-
tance to various common anticancer drugs, and the addi-
tion of the GST inhibitors will be restored sensitivity to al-
kylating agents in drug-resistant cells. Therefore inhibitors 
of hGST P1-1 catalytic activity remain as a potential ther-
apeutic tool in MDR cancer chemotherapy. 
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Introduction
A major advance in the quinolones field came in 1980, 
when chemists at the Kyorin company reported the prep-
aration of norfloxacin, in which the cyclic diamine piper-
azine found in pipemidic acid was combined with 6-flou-
rine found in flumequine (Andriole, 2000). Later studies 
revealed that introduction of this atom serves both to in-
crease quinolone activity against the enzyme target DNA 
gyrase and to facilitate penetration into the bacterial cell. 
Norfloxacin is a broad-spectrum antibiotic that is active 
against both Gram-positive and Gram-negative bacte-
ria. The fluorine atom at the position 6 increases poten-
cy against Gram-negative organisms, while the piperazine 
moiety at the position 7 is responsible for anti-pseudo-
monal activity. As it is known, fluoroquinolones are fairly 
insoluble in water. Due to presence of basic amine and car-
boxylic acid they possess zwitter ionic character, which is 
reflected on their solubility, lipophilicity and acidity/basic-
ity. At acidic pH, both amine and acidic group are protonat-
ed providing the molecule positive charge. At high pH val-
ues, amine group is in the free base form, while the carbox-
yl group exists as a carboxylate anion, providing the over-
all molecule negative charge. Therefore, the fluoroquino-
lones tend to be more soluble in water at acidic and/or ba-
sic pH (Andriole, 2000; Riley et al. 1989), which signifi-
cantly affects their permeability. It has been well explained 
that solubility, dissolution and gastrointestinal permeabili-
ty are fundamental parameters that control rate and extent 
of drug absorption and its bioavailability. In order to devel-
op novel compounds based on quinolone core with favor-
able physico-chemical properties i.e. higher permeability, 
we have synthesized different derivatives of norfloxacin 
by incorporating (benzoylamino)methyl functions (BAM 
salts) on the free nitrogen of the 7-piperazinyl group. The 
aim of this study was to evaluate their solubility in wa-
ter (logSw) and phosphate buffer solution (PBS) pH 7.4 
(logS7.4) and pKa values as well.
Materials and methods
Norfloxacin was purchased from Fluka (Sigma-Al-
drich ChemieGmbh Munich, Germany), while the com-
pounds for preparation of phosphate buffer saline (PBS), 
NaH2PO4, NaOH and KH2PO4, were purchased from Mer-
ck KgaA (Germany). 
Methods
The BAM salts and norfloxacin derivatives were syn-
thesized by the methods already described (Breznica-Sel-
mani et al., 2015). Five different derivatives of norfloxacin 
were synthesized: 1-ethyl-6-fluoro-7-{4[(benzoylamino)
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methyl]piperazin-1-yl}-4-oxo-1,4-dihydroquinoline-
3-carboxylic acid (1a), 1-ethyl-6-fluoro-7-{4-[(4-meth-
ylbenzoylamino)methyl]piperazin-1-yl}-4-oxo-1,4-di-
hydroquinoline-3-carboxylic acid (1b), 1-ethyl-6-fluoro-
7-{4-[(3-methylbenzoylamino)methyl]piperazin-1-yl}-
4-oxo-1,4-dihydroquinoline-3-carboxylic acid (1c), 1-eth-
yl-6-fluoro-7-{4-[(2-chlorobenzoylamino)methyl] piper-
azin-1-yl}-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
(1d) and 1-ethyl-6-fluoro-7-{4-[(3-chlorobenzoylami-
no)methyl]piperazin-1-yl}-4-oxo-1,4-dihydroquinoline-
3-carboxylic acid (1e). Solubility of the newly synthesized 
(benzoylamino)methyl derivatives of norfloxacin and nor-
floxacin as a reference was determined in water and in PBS 
(pH 7.4) using a static equilibrium method (Zhang and 
Wang, 2008). An excess of the compounds was exposed to 
the solvents, accordingly, the mixtures were allowed to be 
stirred in a thermostatic water bath at 37 ± 1 oC (Haake, 
SWB 20, Waltham, MA, USA) and the samples were as-
sayed once every 4 h until the analyzing results were repli-
cated three consecutive times. Afterwards, the supernatant 
solutions, obtained by ultracentrifugation at 12 000 rpm for 
15 minutes, were filtered to ensure that they were free of 
particulate matter before sampling. The concentration of 
the synthesized compounds and norfloxacin was quanti-
fied by UV absorption at λmax 271-275 nm (Shimadzu UV 
– 1800, Japan). The whole procedure was light-protect-
ed. Sodium thiosulphate was added to the medium when 
PBS pH 7.4 was used to prevent oxidation. All the solubil-
ity experiments were repeated at least three times, and the 
mean values were considered as the measured results. The 
logScalc was calculated by online ChemAxon’s software 
for fast and accurate predictions of basic physicochem-
ical properties such as logP, logD, pKa and logS (www.
chemicalize.org). ChemAxon’saqueous solubility predic-
tor is based on the topology of the molecules. To determine 
the pKa’s of all synthesized compounds and norfloxacin, a 
potentiometric titration was applied and for data analysis, 
second-derivative method was used. As it was reported by 
Qiang and Adams (2004), the second-derivative method, 
widely used to determine the pKa’s of most drugs, is the 
most convenient for determination of pKa value among the 
three most applicable (Gran’s plot, second-derivative and 
the least-square non-linear regression), because it is inde-
pendent of titrate and titrant concentrations.
Results and discussion
The experimentally determined solubility data for the 
leading compound norfloxacin were in agreement with the 
pharmacopeia and literature data that point to very slight 
water solubility (0.1-1 mg/mL) and sharp increase in sol-
ubility at pH below 4 and above 10 due to the amphoteric 
nature (Dua et al., 2007). The water solubility of the syn-
thesized derivatives, experimentally determined, was low-
er than the one of the leading compound norfloxacin, rang-
ing from 0.005 (1b) to 0.030 mg/mL (1d). Considering the 
solubility in PBS (pH 7.4), similar values for norfloxacin 
derivatives were observed, ranging from 0.011 mg/mL (1e) 
to 0,036 mg/mL (1d), all being lower than the solubility of 
norfloxacin (0.447 mg/mL). However, it must be empha-
sized that the solubility of norfloxacin as hydrochloride salt 
was used as a reference. Lower solubility of these newly 
synthesized compounds can be explained by the lipophilic 
and inductive character of the (benzoylamino)methyl moi-
ety that disfavors ionization. There was no agreement be-
tween the predicted and experimentally determined data 
for solubility both in water and PBS (pH 7.4) for all the 
compounds. 
pKa values were readily determined by inspection of 
the second-derivative plot. The experimental values ob-
tained for norfloxacin as well as calculated ones did not 
differ significantly from those reported in the literature 
(Qiang and Adams, 2004). For all the synthesized com-
pounds, three pKa values were determined (around 4, 5 
and 14), suggesting preservation of the zwitter ionic char-
acter of the synthesized compounds.
Conclusion
Five derivatives of norfloxacin were synthesized. All 
the synthesized compounds have lower water solubility 
and potentially higher lipophylicity than the leading com-
pound norfloxacin. The experimental pKa values obtained 
for the leading compound as well as calculated ones did 
not differ significantly from those reported in the literature 
for norfloxacin.
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Introduction
N-Mannich bases are of particular interest in drug 
chemistry because of their potential to be used as prodrugs 
of NH-acidic drugs containing amide, imide, ureide and 
amine moieties (Bala et al., 2014; Stella et al., 2007). With 
respect to the amines, N-Mannich bases are useful when an 
increase in their lipophilicity is required. Lipophilicity is 
one of the most important determinants of the pharmaco-
kinetic characteristics of a drug since it is related to its ab-
sorption as well as distribution to the target site. Lipophi-
licity of the quinolones as an important factor in the qui-
nolones intestinal absorption is considered responsible for 
the poor relationship between their in vivo and in vitro ac-
tivity (Cabrera Perez et al., 2002). Therefore, in these com-
pounds, formation of N-Mannich base could suppress the 
pKa, which means that an important proportion could re-
main unionized at the pH of intestine. 
With an aim to increase lipophylicity of norfloxacin, 
we have synthesized five different derivatives of norflox-
acin [1-ethyl-6-fluoro-7-{4[(benzoylamino)methyl]pi-
perazin-1-yl}-4-oxo-1,4-dihydroquinoline-3-carboxyl-
ic acid (1a), 1-ethyl-6-fluoro-7-{4-[(4-methylbenzoylami-
no)methyl]piperazin-1-yl}-4-oxo-1,4-dihydroquinoline-
3-carboxylic acid (1b), 1-ethyl-6-fluoro-7-{4-[(3-meth-
ylbenzoylamino)methyl] piperazin-1-yl}-4-oxo-1,4-di-
hydroquinoline-3-carboxylic acid (1c), 1-ethyl-6-fluoro-
7-{4-[(2-chloro-benzoylamino)methyl] piperazin-1-yl}-
4-oxo-1,4-dihydroquinoline-3-carboxylic acid (1d) and 
1-ethyl-6-fluoro-7-{4-[(3-chlorobenzoylamino)methyl]pi-
perazin-1-yl}-4-oxo-1,4-dihydroquinoline-3-carboxylic 
acid (1e)], by incorporating (benzoylamino)methyl func-
tions on the free nitrogen of the 7-piperazinyl group. In ad-
dition to the structural characterization of these novel com-
pounds as potential N-Mannich base prodrugs of norfloxa-
cin, distribution behavior of these compounds between n-
octanol and buffer solution (pH 7.4) was mater of inter-
est. In addition, logD7.4 values, experimentally obtained, 
were compared with the predicted ones by computation-
al method developed by ChemAxon (http://www.chemi-
calize.org//).
Materials and methods
Norfloxacin and 1-octanol were purchased from Flu-
ka (Sigma-Aldrich Chemie Gmbh Munich, Germany). 
The compounds for preparation of phosphate buffer saline 
(PBS), NaH2PO4, NaOH and KH2PO4, were purchased 
from Merck KgaA (Germany). 
The experimental partition coefficient (D) between n-
octanol and PBS (pH 7.4) was determined by shaking flask 
method described by Abuo-Rahma et al. (2009). Stock so-
lutions of (benzoylamino)methyl derivatives of norfloxa-
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cin in PBS (pH 7.4) were prepared in concentration of app. 
0.2 mg/mL for all tested compounds, respectively. After-
wards, equal volumes of each solution and n-octanol were 
mixed, vortexed for 3 min and agitated for 12 h in a shak-
ing water bath at 25 ± 0.1 oC. The test tubes were protected 
from light by wrapping in aluminum foil. Before a partition 
coefficient was determined, the organic and aqueous phase 
was mutually saturated by shaking for 24 h at the temper-
ature of the experiment. After equilibration, the octanol 
phase was removed with a Pasteur pipette and both phases 
were assayed spectrophotometrically at λmax 270-280 nm. 
The experimental partition coefficient D was determined 
from equation: D = Ci- Cw/Cw* Vw/ V0, where Ci rep-
resents the total concentration of solute in both phases af-
ter distribution, Cw the solute concentration in the aqueous 
phase after distribution; Vw represents the volume of the 
aqueous and Vo the volume of the organic phase. All par-
tition coefficient determinations were made in triplicate. 
The logDcalc was calculated by online ChemAxon’s soft-
ware (www.chemicalize.org/), where both logP and logD 
predictions are based on a modified version of the meth-
od of Viswanadhan et al. (1989). The predicted partition 
coefficients are composed of the molecules’ atomic incre-
ments and the applied modifications include the redefini-
tion of selected atom types to accommodate electron delo-
calization and the addition of contributions of ionic forms. 
The logP value of zwitterions is calculated from the logD 
at the isoelectric point. Also, the effect of hydrogen bonds 
on logP is considered if the formation of a six membered 
ring between suitable donor and acceptor atoms can take 
place. As the logD values are pH-dependent, the logD cal-
culation relies on the pKa prediction process.
Results and discussion
Generally, the experimentally obtained distribution 
coefficients of norfloxacin derivatives were higher than 
the one of the corresponding leading compound, with the 
logD7.4exp ranging from -0.91 to 0.58 (vs. logD7.4exp 
-0.89 for norfloxacin). To reveal a correlation between the 
experimental and calculated values, a linear regression was 
performed. Weak correlation R2=0.046 between the calcu-
lated and the experimental values for all synthesized com-
pounds was observed. Similar data were reported from oth-
er researchers as well (Abuo-Rahma et al., 2009). One of 
the reasons for this weak correlation may be zwitterion-
ic nature of the fluoroquinolones at physiological pH. It is 
clear that at pH corresponding to the isoelectric point, zwit-
terions and neutral molecules are present at their highest 
concentrations. Therefore, this ratio is remarkably impor-
tant feature to describe the lipophilicity of fluoroquinolones 
(Bakhotmah et al., 2011). Our results revealed that the iso-
electric points of the synthesized compounds are around 
pH 5-7. According to Kujawaski et al. (Kujawski et al., 
2012), predicted logD is calculated only for neutral com-
pounds. Programs for calculating logD are based on break-
ing molecules into fragments and summing these constant 
fragment values plus certain correction factors. Consider-
ing that, polyprotic equation becomes more complicated 
and potentially accumulates errors due to the logD and pKa 
predictions (Kujawski and Popielarska, 2012). This may be 
a reason for flimsy correlation between the predicted and 
experimental values of logD7.4 for the synthesized com-
pounds in our study.
Conclusion
Novel (benzoylamino)methyl derivatives of fluoroqui-
nolones were synthesized in one step and in high yields, 
starting from the leading compound norfloxacin. Addi-
tion of (benzoylamino)methyl functions in the piperazinyl 
ring of the leading compounds by substitution of hydrogen 
atom at position 4 resulted in formation of potentially use-
ful antimicrobial compounds. The structures of the synthe-
sized derivatives were confirmed by different spectroscop-
ic techniques. The lipophilicity of the synthesized deriva-
tives was higher than the ones of the leading compound, in-
dicating possibility for improved bioavailability and pene-
tration into bacterial cells.
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Introduction
Methotrexate (MTX), also known as amethopterin is 
an antifolate and an antimetabolite drug, a chemical ana-
logue of folic acid developed by Yellapragada Subbarao of 
Lederle (Rossi, 2013). MTX was first administered to chil-
dren with acute lymphoblastic leukemia (ALL) in 1948. 
MTX became the first drug that induced remission. Remis-
sions were short, but the principle was clear, antifolates 
could suppress proliferation of malignant cells, and could 
thereby re-establish normal bone-marrow function. MTX 
received FDA approval in 1953. Since that time it has been 
used worldwide for a variety of medical interventions.
Firstly, MTX has been used as a parenteral formula-
tion for cancer treatment. The use of MTX in the treatment 
of psoriasis and rheumatoid arthritis dates from the 1960s. 
From the late 1970s to the early 1980s, many rheumatol-
ogists were reporting their experiences with MTX use in 
rheumatoid arthritis treatment (Ward, 1985). MTX can be 
given orally or by intravenous, intramuscular or subcuta-
neous injection (Jundt et al, 1993). Intramuscular, intrave-
nous or subcutaneous administration is usually reserved 
for patients with poor oral bioavailability of the drug or 
poor adherence to oral therapy, or when the cost is an is-
sue. Weekly dosing of MTX is recommended. More fre-
quent administration than weekly increases the risk of tox-
icity. The entire dose can be administered at once or divid-
ed into three doses taken over a 24-hour period (i.e., every 
eight hours). MTX should never be given in daily doses. 
During the 1980’s and 1990’s many studies were done with 
MTX to determine if it could suppress the growth of a tub-
al or ectopic pregnancy. Researchers discovered that MTX 
could be given as a safe treatment for the ectopic pregnan-
cy treatment cured without surgery. Further research found 
that MTX could also be used to induce a chemical abor-
tion. A small percentage of the cases required surgical in-
tervention. The benefit of a MTX-induced abortion is that 
if there is an unknown tubal pregnancy it will be treated. 
MTX has also been found efficacious in the treatment of 
other diseases, including psoriasis, asthma, systemic lupus 
erythematosus, Crohn’s disease, myositis and vasculitis. 
Many physicians use MTX for its steroid-sparing proper-
ties in patients with asthma and others who may have side 
effects related to corticosteroid use. The key of the success 
of MTX in the treatment any of these diseases (with the 
exception of ALL) is the recognition that low-dose thera-
py achieves efficacy while minimizing side effects (Moss, 
1995).
MTX is a toxic medication, but if it is dosed correctly 
and monitored appropriately, its toxic effects can be min-
imized. These effects are categorized as minor or major. 
Minor toxic effects such as stomatitis, malaise, nausea, 
vomiting, diarrhea, headaches and mild alopecia are not 
life threatening but occur in 20 to 30 percents of patients. 
Other effects in this category include fatigue, mood alter-
ation, dizziness, fever, myalgia and polyarthralgia. Most 
minor toxic effects are associated with depletion of fo-
late. Folate supplementation with 1 mg daily or 7 mg once 
weekly should be considered for all patients. Studies show 
that low-dose folate does not interfere with the efficacy of 
MTX (ACRM, 1996). Most rheumatologists advise pa-
tients to avoid taking the folate dose on the same day as 
the MTX dose. Often, minor toxic effects respond to a re-
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duction in the MTX dose or an adjustment in the dosing 
schedule. Major toxic effects of MTX, such as hepatic, re-
nal, pulmonary and bone marrow disorders, occur less fre-
quently than the minor effects but may be life threatening.
In order to improve therapeutic efficacy and the com-
fort of the application of MTX, new pharmaceutical for-
mulation is ongoing. Controlled release of MTX has been 
achieved by several techniques, but mostly in in vitro and 
preclinical animal models. Formulations of MTX that have 
been recently developed in order to improve cancer treat-
ment include injectable thermosensitive hydrogels con-
taining MTX-loaded chitosan-based microspheres, folic 
acid-chitosan-MTX core-shell nanoparticles, thermosensi-
tive systems prepared on biocompatible polymer Pluron-
ic F-127 as a vehicle, MTX-loaded alpha-lactalbumin mi-
croparticles, MTX-monoclonal antibody conjugates, MTX 
intercalated in a nanoceramic vehicle magnesium alumin-
ium layered double hydroxide, coated with poly(D,L-lac-
tide-co-glycolide) (PLGA). Most of these pharmaceutical 
formulations have demonstrated superiority when com-
pared to conventional formulations of MTX in terms of 
localized drug delivery, long-term sustained drug release, 
and good biocompatibility (Beidokhti et al., 2016). Nov-
el topical formulations of MTX have been also evaluated 
for the potential use in the treatment of psoriasis. Some of 
these formulations with enhanced skin penetration of MTX 
include microemulsions, nanogels, niosomes, liposomal 
hydrogels, deformable liposomes and solid lipid nanopar-
ticles (SLN) (Avasatthi et al., 2015). The latest topical 
formulations of MTX for the treatment of psoriasis pre-
pared as nano-vesicles use mostly bioadhesive surfactant 
systems containing polysorbate 60 or 80 as surfactants. 
NLC-based smart gel of MTX composed of lipids, surfac-
tant Tween 80 and co-surfactant PEG 400, was formulated 
for intra-articular administration that could give site-spe-
cific delivery of a drug to the rheumatic joints (Shinde et 
al., 2016). MTX was also formulated in transdermal patch-
es with different ratios of ethyl-cellulose and hydroxypro-
pylmethyl-cellulose, and permeation enhancers Tween-80, 
Span-80, dimethyl sulphoxide (DMSO), and isopropyl my-
ristate. These transdermal patches were evaluated for in vi-
tro release, ex vivo permeation and pharmacokinetics in 
vivo, and all formulations exerted improved bioavailabili-
ty in comparison to MTX without enhancers (Rama et al., 
2012).
In summary, MTX plays a significant role in the treat-
ment of various diseases, but toxicity remains the main is-
sue of the use of MTX. Therefore, novel pharmaceutical 
formulations, which have reduced toxicity, better pharma-
cokinetic properties and targeted delivery, have emerged. 
Promising results have been obtained, but mostly in in vi-
tro and in vivo animal studies. Therefore, these new formu-
lations and drug delivery systems of MTX need to be fur-
ther evaluated, especially in clinical settings.
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Introduction
The endoplasmic reticulum (ER) represents a mem-
branous labyrinth of branching interlinked tubules and flat-
tened sacs extending from the perinuclear space through-
out the cytoplasm, being responsible for an assortment of 
critical cellular housekeeping functions. The rough ER, as-
sembled with ribosomes, plays a key role in protein syn-
thesis, folding, posttranslational modification, and trans-
port. The smooth ER has a central role in the biosynthesis 
of lipids and steroids, assembly of lipid bilayers, metabo-
lism of carbohydrates, metabolism of drugs and xenobi-
otics and regulation of calcium intracellular homeostasis. 
Quality control mechanisms of the cell ensure that new-
ly synthesized proteins are folded into their correct config-
uration according to their function and destination in the 
cell. Therefore, protein folding in particular represents an 
exquisitely orchestrated aspect of protein synthesis in the 
ER that involves pathways for folding, assembly, modifi-
cation, quality control, and recycling. In addition to an ox-
idizing environment, protein folding requires the participa-
tion of chaperone proteins, glycosylating enzymes and ad-
equately high calcium levels. Appropriate folding of the 
nascent polypeptide chain is achieved through the actions 
of a series of molecular chaperones and foldases, which 
keep the polypeptide in soluble form and facilitate folding 
into a thermodynamically favored structure. Since the ER 
provides high fidelity quality control in protein synthesis, 
maturation and transport, it is a highly dynamic organelle, 
whose complex function can be significantly influenced by 
various factors both inside the cell and in its microenviron-
ment. Failures in control mechanisms lead to accumulation 
of unfolded, misfolded, insoluble or otherwise damaged 
proteins in the lumen of the ER resulting in a state known 
as ER stress (Stankov et al, 2013). Continued accumulation 
of incorrectly folded proteins can irreversibly and irrepara-
bly damage cellular functions leading to cell death. There-
fore, several cellular sensors and pathways have evolved to 
respond to this threat and to reduce the risk. Prime among 
these is the unfolded protein response (UPR), a signaling 
pathway primarily aiming at protecting cellular integrity 
by restoring proper ER folding capacity and overall pro-
tein processing. However, terminally misfolded proteins 
that cannot be repaired may be removed from the cell by 
one of two separate processes. One process is ER-associat-
ed degradation (ERAD), which involves the retro-translo-
cation of irreparably misfolded proteins from the ER back 
into the cytosol, where they are ubiquitinated and subse-
quently subjected to degradation via the proteasome. Fur-
thermore, insoluble misfolded proteins may be assembled 
together with other cellular debris into aggresomes (jux-
tanuclear complexes that occur as a cell culture phenom-
enon, for sequestration of toxic, aggregated proteins) and 
then recycled via autophagy.
Material and methods
Detailed and comprehensive search of PubMed and 
Scopus databases was carried out for original and review 
articles using the key words: endoplasmic reticulum stress, 
unfolded protein response, diabetes mellitus, in order to 
determine patophysiological implications of ER stress in 
type 2 diabetes (T2D) and to identify potential ER stress-
targeting antidiabetic agent.
Results and discussion
An imbalance in energy intake and expenditure leads 
to obesity, a major health threat that increases the risk of 
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T2D, cardiovascular disease and cancer. Obese subjects 
show activation of UPR in metabolic tissues including ad-
ipose tissue, liver, and the pancreas. Obesity is also asso-
ciated with both hepatic and peripheral insulin resistance, 
along with elevated levels of proinflammatory cytokines. 
Studies with genetically obese or diet-induced obese mice 
revealed elevated levels of ER stress-associated markers: 
RNA (PKR)-like ER kinase (PERK) and eukaryotic trans-
lation initiation factor-2 alpha phosphorylation, inositol-
requiring enzyme-1 (IRE1)-mediated JNK activation, and 
higher amounts of ER chaperone protein, glucose-regulat-
ed protein 78 (GRP78) in the liver and adipose tissue. ER 
stress in obesity is thought to be induced by an augment-
ed demand for protein synthesis under nutrient excess and 
by elevated levels of saturated free fatty acids (FFA). Ex-
cess in saturated FFA, especially palmitate has been shown 
to cause ER stress and to activate the UPR in pancreat-
ic β-cells and hepatocytes by altering the integrity of ER 
membrane. It is well-recognized that hyperglycemia, high 
plasma levels of saturated FFAs and obesity in general are 
key risk factors for the development of T2D. The same 
conditions are identified as triggers of ER stress, particu-
larly in organs such as the liver and pancreas. In addition, 
leptin resistance, a condition that has been documented in 
the majority of the obese population, has been shown to 
contribute to obesity-linked disorders via ER stress. Obe-
sity induces T2D, a metabolic disorder characterized by 
a combination of insulin resistance, dysregulated hepat-
ic glucose production, and inadequate insulin secretion by 
pancreatic β-cells. At the molecular level, it involves per-
turbations in insulin signaling, such as reduced insulin re-
ceptor function and reduced post–insulin receptor phos-
phorylation steps. ER stress parameters such as phosphor-
ylation of PERK and IRE1, ER-associated protein kinas-
es that determine cell fate during UPR, are increased in the 
liver and adipose tissues of T2D animals (Stankov, 2010). 
The three branches of the UPR: IRE1, PERK, and activat-
ing transcription factor 6 (ATF6), have been implicated in 
the cellular inflammatory processes. Increased activation 
of IRE1, X-box binding protein-1 (XBP1) and JNK results 
in decreased insulin receptor signaling and insulin resis-
tance. Moreover, ER stress parameters including Grp78, 
XBP1s, phospho-eIF2α, and phospho-JNK, are increased 
in the liver and adipose tissues of obese insulin-resistant 
non-diabetic humans and these parameters are significant-
ly reduced after weight loss. Interestingly, ursodeoxycholic 
acid (UDCA), a naturally occurring hydrophilic bile acid 
that has long been used to treat chronic cholestatic liver 
disease is emerged as the agent that mitigates ER stress at 
the cellular level (Stanimirov et al, 2015). The administra-
tion of UDCA resulted in normalization of hyperglycemia 
and restoration of hepatic and muscle insulin sensitivity in 
obese humans. Additionally, UDCA has been shown to act 
as leptin-sensitizing agent. Therefore, UDCA represents 
an ER stress-modifying agent with therapeutic potential in 
ER stress-induced complications of obesity. In accordance, 
UDCA has been shown to exert an anti-atherogenic activ-
ity in diabetic atherosclerosis by targeting ER stress. Ad-
ditionally, by ameliorating ER stress-associated detrimen-
tal signaling, UDCA improves function of dysfunctional 
endothelial cells and prevents formation of atherosclerot-
ic plaque. However, the detailed molecular mechanisms of 
UDCA-mediated alleviation of ER stress are still to be elu-
cidated.
Conclusions
More detailed insight in ER stress mechanisms will 
provide opportunity to develop UPR-manipulating anti-di-
abetic therapeutic strategies. Therapeutic agents aimed at 
ameliorating ER stress by promoting proper protein pro-
cessing and generally supporting proper ER maintenance 
may have useful effects in the therapy of obesity, T2D, and 
cardiovascular disease. Ursodeoxycholic acid administra-
tion showed some promising results so far; however, fur-
ther studies are highly recommendable in order to decipher 
beneficial effects of its administration on ER stress signal-
ing in diabetic patients.
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Introduction
Detection of chromosomal abnormalities in myelodys-
plastic syndromes (MDS) enables classification according 
to WHO and risk stratification according to IPSS and R-IP-
SS, providing physicians with data regarding personal ther-
apy approach. Multiplex ligation-dependent probe ampli-
fication (MLPA) is a technique for targeted copy number 
variation (CNV) identification in many human genes simul-
taneously. MLPA is a multiplex polymerase chain reaction 
(PCR)-based technique that can quantify up to 50 differ-
ent genomic targets simultaneously in a single experiment 
through amplification of specific hybridizing probes (Fab-
ris et al., 2011). As the sequence recognized by an MLPA 
probe is only 50-70 nucleotides long, this assay is very use-
ful for detection of deletions or amplifications of single ex-
ons (Schouten et al., 2002). The high specificity of MLPA 
is due to the ability of this method to distinguish sequenc-
es differing in length by only one nucleotide. Another ad-
vantage of this method is also the low amount of input DNA 
(minimum of 20-50 ng) required for a successful MLPA re-
action (Schouten et al., 2002). Up to 40-50 small specific 
probes are directed at DNA regions of interest and to ref-
erence regions not associated with the disease, providing a 
resolution greater than FISH or BAC – based aCGH (Do-
nahue et al., 2011). Each probe consists of two oligonu-
cleotides (5´and 3´end-probes), that hybridize to adjacent 
sites of the target sequence. The short oligonucleotide con-
tains a target-specific sequence and a universal PCR primer 
X. The long probe consists of a target-specific sequence, a 
universal PCR primer Y and a stuffer sequence of variable 
length in between (19-370 nucleotides) to generate the size 
differences necessary for electrophoretic resolution (Dona-
hue et al., 2011; Sellener and Taylor, 2004). The MLPA re-
action comprises five steps and requires a thermocycler and 
automated genetic analyzer for fragment analysis by capil-
lary electrophoresis. A crucial step of the MLPA assay, es-
pecially when used in the diagnostic setting (i.e. gene dele-
tion or when used in the diagnostic setting (i.e. gene dele-
tion or and interpretation of results. The most widely used 
is the Coffalyser software, an Excel-based program able to 
perform data normalization steps and necessary corrections 
(Coffa et al., 2008; Jankowski et al. 2008). The results in-
terpretation is based on the mathematical comparison be-
tween relative quantities of target DNA amplified from a 
tested (patient) sample vs. those of a normal (control) sam-
ple (Abdool et al., 2010). In general, signals are interpret-
ed as aberrant at cut-off values below 0.7 (deletion) and 
above 1.3 (duplication/ amplification) (Eijk-Van Os et al., 
2011). The utility of MLPA assay in the testing of acute leu-
kemias and myelodysplastic syndromes has been analyzed, 
confirming excellent accuracy and specificity of MLPA as 
compared to FISH (Stippia et al., 2012). 
Materials and methods
Our cohort consisted of 70 patients (pts) with ‘de-no-
vo’ and therapy-related MDS (t- MDS), diagnosed at the 
University Clinic of Hematology, “Ss Cyril and Methodi-
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us” University, Skopje, Republic of Macedonia in the pe-
riod of 52 months. Patients signed informed consent for 
entrance in the study. From each patient was collected 1 
mL of material, obtained by bone marrow biopsy (BMB) 
and put in the test tube with an anticoagulant - K3ED-
TA. Deoxyribonucleic acid (DNA) was isolated with stan-
dard phenol chloroform extraction in the Faculty of Phar-
macy, Department of biomolecular sciences, Skopje, Re-
public of Macedonia. The material from BMB was cen-
trifuged at 3000 rpm, 4°C, 5 min. The watery upper layer 
was decanted, and the precipitated cells were washed with 
0.9%NaCl, and later washed with lysed solution (1.55M 
NH4Cl, 0.1M NH4HCO3 and 1mM EDTA Ph 7.4, final 
concentration), centrifuged at 3000 rpm, 4°C, 5 min, in or-
der to lyse the rest of red cells. The rest of the other cells 
were digested over night at 37°C with 0.1M NaCl, 0.05 
M Tris, 1mM EDTA in final concentration. The next day 
was performed fluid-fluid extraction with saturated phenol 
(pH=8) and Chloroform : Isoamyl alcohol 24:1, after cen-
trifugation at 3000 rpm, 4°C, 5 min. and removal of the up-
per watery layer, the precipitation of the DNA with cold 
100% ethanol was performed and dissolved with TE puffer 
(Tris 10mM и EDTA 1 mM, final concentration). The iso-
lated DNA was incubated overnight on 37°C for homoge-
neous dissolution in the puffer. The intactness of the isolat-
ed DNA was examined on gel electrophoresis. With Nano-
Drop 2000 spectrophotometer (Thermo Scientific) was de-
termined the concentration of the isolated DNAs. 
The SALSA MLPA MDS kits (P144 and P145, MRC 
Holland) were used to detect chromosomal abnormalities 
commonly associated with MDS. The probe mix contained 
probes for chromosomes 5, 7, 8, 11, 12 (ETV6), 17 (TP53), 
20 and 21 (RUNX1). Analyses were performed with the 
application of P414-A1 MDS MLPA kits of MRC Holland, 
according to their protocol. The analysis of the results was 
performed by software - Coffalyser.
Results and discussion
Of 70 patients (pts), 33 women (47.1%) and 37 men 
(52.9%) participated in the study, aged 64.3 years (range 
22-86 years). With primary MDS were 66 pts and with 4 
pts with t- MDS. Chromosomal abnormalities were de-
tected in 32.9% pts (5p+, 5q-, 7p-, 7q-, 8p+, 8q+, 11p-, 
12p-, 17p-, 17q+, 19p+, 19p-, 20q-  in different combina-
tions), while 67.1% pts had normal findings. According to 
the WHO patients were classified as follows: RCMD – 34, 
RCED - 5, 5q syndrome - 1, RARS -1, RAEB 1- 6, RAEB 
-2 - 6, CMML-1 - 2, CMML-2 - 3, t-MDS - 4,  MDS-u - 
2, AML- 6 pts. According to IPSS, distribution was as fol-
lows: with low risk - 16 pts (22.9%), with intermediate 1 
- 37 (52.9%), with intermediate 2 – 8 (11.3%), with high 
risk - 9 (12.9). According to R-IPSS, distribution was as 
follows: with very low risk - 5 (7.1%), with low risk 22 
(31.4%), with intermediate risk - 24 (34.3%), with high risk 
- 10 (14.3%), with very high risk - 9 (12.9%) pts. Patients 
were treated based on IPSS and R-IPSS. Transformation 
in AML was registered in 24.3%, after 9.2 months. Over-
all survival (OS) was 30.2 months. In pts with chromosom-
al abnormalities OS was 25.7 months and in those without 
chromosomal abnormalities OS 34.2 months, but the dif-
ference was not statistically significant (p =0 .13101). 22 
patients died.
Conclusion
MDS MLPA assay is sufficiently specific and repro-
ducible to be used in routine diagnostic settings as the first-
line genetic screening tool. Data concerning chromosomal 
abnormalities in MDS enable physicians to make treatment 
strategy at diagnosis. There are different treatment options 
for different risk groups including allogeneic transplanta-
tion for high and very high risk patients.
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Introduction
In order to obtain accurate, reliable and traceable re-
sults from the interventional biomedical studies, including 
clinical trials, and to come up with effective and safe me-
dicinal products, and in the same time, to protect the confi-
dentiality of personal health data, it is necessary to have a 
regulated access to the health information of the individu-
als. Data protection and privacy requirements are given in 
the Declaration of Helsinki (1964-2013) which states: “It 
is the duty of physicians who are involved in medical re-
search to protect the life, health, dignity, integrity, right to 
self-determination, privacy, and confidentiality of personal 
information of research subjects.” All precautions should 
be taken to protect the privacy of the subjects participat-
ing in biomedical research and to minimize the impact of 
study on their mental, physical and social integrity. Article 
24 states: “Every precaution must be taken to protect the 
privacy of research subjects and the confidentiality of their 
personal information”. One of the basic principles in the 
Guideline for Good Clinical Practice E6 (R1) (1996), sec-
tion 2:11 states: “The confidentiality of records that could 
identify subjects should be protected, respecting the priva-
cy and confidentiality rules in accordance with the appli-
cable regulatory requirement(s).” To this end, each subject 
that has been enrolled in a clinical trial is assigned a unique 
identification number in order to protect his/her identity. 
This identification number is used instead of the name of 
the entity when the investigator submits reports of adverse 
events and/or other information related to the clinical tri-
al. Personal data protection is a mandatory part of the In-
formed Consent, introduced as a compulsory element by 
the Nuremberg code. In the Informed Consent it is clearly 
stated that all medical records which contain personal pa-
tient data will be kept confidential within the limits of ap-
plicable laws and regulations and will not be available to 
the public. If the study results are published, the identity of 
the subjects will remain protected. 
Data protection in EU
In the EU, personal data may be collected only under 
strictly controlled conditions and for legitimate purposes. 
Harmonized legislation is established among EU Member 
States regarding the protection of personal data. In addi-
tion, the European Commission keeps constant dialogue 
with non-EU countries to achieve high level of protection 
of personal data. Personal data protection in the EU is cur-
rently regulated by Directive 95/46/EC on the protection 
of personal data (1995) and Directive 2002/58/EC on the 
processing of personal data and the protection of privacy 
in the electronic communication (2002). Directive 95/46/
EC provides the legal framework which strives to find the 
balance between the high level of protection of personal 
data and the free movement of personal data within the EU. 
The Directive sets strict limits on the collection and use 
of personal data and requires each Member State to ap-
point an independent national body responsible for the pro-
tection of personal data. Directive does not deal explicitly 
with biomedical research, but it is the basis for principles 
of protection of personal data in biomedical research. Di-
rective 2002/58/EC provides an equivalent level of protec-
tion of fundamental rights and freedoms and especially of 
the right to privacy with regard to the processing of person-
al data in the electronic communications sector and the free 
movement of such data and the equipment for electronic 
communications and services in EU.
Rapid technological development and related regula-
tory challenges of privacy protection caused the Europe-
an Commission to propose a new regulation on the pro-
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tection of individuals with regard of the processing of per-
sonal data and their free movement - Data Protection Reg-
ulation (“DPR”) (2015). After intense lobbying, the final 
text of DPR has been agreed on 17th of December 2015. 
It is expected to come into force in 2018. DPR will re-
place the current legislation and the various inconsistent 
national laws on data protection, with a transitional peri-
od of two years. Considering that the collection, process-
ing and transfer of personal data, particularly the records 
of individual subjects/patients in accordance with applica-
ble laws are critical to the success of biomedical research, 
the adoption of this regulation will affect sponsors, inves-
tigators and other participants in biomedical research/clin-
ical trial. DPR mainly refers to: the unification/qualifica-
tion of key-coded data of the subject/patient with which 
the subject/patient can be identified, clearer definition of 
the roles and responsibilities of the sponsor and the con-
tract research organizations as responsible for the process-
ing and control of data, clarification of the guidelines on 
existing restrictions on the transfer of data from the EU to 
parties outside the EU, the introduction of legal sanctions 
for violating laws on data protection, as well as adminis-
trative penalties.
Data protection in USA
In the USA, the medical information is regulated by 
the Health Insurance Portability and Accountability Act 
(HIPAA). HIPAA applies to health workers dealing with 
the processing of medical data and all other entities that 
come into contact with medical information. Standards 
for privacy of individually identified health information 
are given inthe HIPAA Privacy Rule and reffer to the col-
lection, use and protection of health information or medi-
cal records. However, HIPPA-rules are related to defined 
entities only, they protect electronic data only and many 
of the entities are not or cannot be harmonized with the 
HIPPA safety requirements. Additionally, there are many 
guidelines that have been developed by government agen-
cies and industry associations, which are not legally bind-
ing, used only for self-regulation and are considered “good 
practices”.
Data protection in the Republic of Macedonia
In Macedonia, the Law on Personal Data Protection 
(2008) regulates the protection of personal data as funda-
mental rights and freedoms of individuals. The principles 
of this law are implemented in biomedical research. Arti-
cle 2 defines special categories of personal data “data con-
cerning health, including genetic data”.  Article 8 prohib-
its the processing of special categories of personal data, but 
an exception is made if “it is necessary for the purposes of 
medical diagnosis, treatment or management of a health in-
stitution and if it is carried by a person whose profession is 
to provide medical care under oath of secrecy of the infor-
mation revealed to him in the course of his profession and 
if an appropriate safeguards are established in order to per-
form activities of public interest determined by law or by 
decision of the Directorate”. In addition, according to the 
Article 31, the personal data shall be transferred in another 
state only if the second one provides the same level of pro-
tection. With this being stated it is safe to conclude that if 
biomedical research is performed in accordance with this 
Law, the code of ethics of health workers and an appropri-
ate level of protection is provided and there is no barrier for 
scientific research.
Conclusion
It is clear that different countries have different ap-
proaches to personal data protection in clinical studies. In 
the USA there is no comprehensive national law regulat-
ing the collection and use of personal data. The novel DPR 
in EU is expected to be directly applicable to all Mem-
ber States, to provide comprehensive and consistent lev-
el of protection, to be unique regimen for protection and in 
the same time simple but stronger executive framework in 
all Member States. When entering into force it is expected 
to affect national regulations, including the one in Mace-
donia. 
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Introduction
The goal of the epidemiological research is to explain 
the natural causes of various diseases and conditions, their 
prevalence and the burden that they represent for society. 
Pharmacoepidemiology as a science evaluates the risks 
and benefits of drug use in large numbers of patients in 
everyday practice. Although (pharmaco)epidemiological 
studies are non-interventional there is still a risk of dis-
closure of sensitive medical information. The Internation-
al Pharmacoepidemiological Society (ISPE) recognizes the 
need for balance between the protection of personal and 
medical data of patients and the necessity of relevant sci-
entific and medical information to be used to solve medical 
and other problems related to public health. ISPE recom-
mendations are based on existing laws on data protection 
and ethical guidelines, including inspection and approval 
by ethics committees. In accordance with these recommen-
dations: (a) the studies should be designed in a way to pro-
tect the personal and medical information and confidenti-
ality of medical records; (b) ISPE and other professional 
societies should continue to develop codes of conduct and 
“good practices” for epidemiological research and should 
encourage the researchers to follow them; (c) all pharma-
coepidemiological studies that use personal data should 
be approved by ethics committees before commencing the 
study; (d) ethics committees may waive a requirement for 
written informed consent in cases where the direct harm 
to individuals is unlikely and individually identifiable data 
are not published; (e) the use of sophisticated informa-
tion technology should be encouraged to ensure, where ap-
propriate, that no identifying information remains on re-
search datasets; (f) secondary research and statistical anal-
ysis of data already collected for other purposes should be 
approved, provided that the secondary research serves the 
public health and appropriate measures are implemented to 
protect personal data; (g) ISPE supports the notion that re-
search using completely anonymize databases should not 
require IRB approval or specific patient authorization for 
each use of the data; (h) ISPE supports the development of 
guidelines and techniques for the anonymization of datas-
ets; (i) the international transfer of data should be permit-
ted under the condition that either a comparable legal lev-
el of data protection exists in the recipient country or spe-
cial provisions are made by the person responsible for the 
data to ensure the same level of data protection exists in the 
country from which the data are transferred; and (j) unau-
thorized access to or distribution of personal and medical 
data should be subject to legal penalties sufficient to act as 
an obstacle (http://www.pharmacoepi.org/).
Data protection in EU
In January 2012, the European Commission present-
ed the draft of a new General Data Protection Regula-
tion (GDPR) to the European Parliament and the Coun-
cil of the EU. The GDPR is planned to replace the Direc-
tive 95/46/EC (1995), which constitutes the present Euro-
pean legal framework for processing of personal data. The 
first Articles with specific relevance for scientific research 
are concerned with general principles (Article 5) and law-
fulness (Article 6) of personal data processing. Article 5b 
lays down that personal data shall be collected for speci-
fied, explicit and legitimate purposes and may not be fur-
ther processed in a way incompatible with those purpos-
es. This corresponds to the same principle in the current 
Directive 95/46/EC. However, in the Directive 95/46/EC 
there is an exemption for research i.e. that further process-
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ing of data for historical, statistical or scientific purposes is 
not to be considered as incompatible with the original pur-
pose as long as Member States provide appropriate safe-
guards. This exemption was omitted in DPR, significant-
ly reducing the scope for data sharing between research 
groups and severely restraining the use of retrospective 
study designs. If taken literally, the omission of the exemp-
tion threatens the (pharmaco)epidemiological research. In 
the final version of the DPR that has been agreed upon on 
17th of December 2015 Article 5b has been extended: “fur-
ther processing of personal data for archiving purposes in 
the public interest, or scientific and historical research pur-
poses or statistical purposes shall, in accordance with Ar-
ticle 83(1), not be considered incompatible with the initial 
purpose”. Introducing this exemption gives a legal basis 
for the (pharmaco)epidemiological research, especially the 
retrospective study designs. 
Data protection in USA
Department of Health and Human Services (HHS) 
have realized that it is not always possible to get an au-
thorization to use protected health information for research 
purposes, especially in research relating to public health 
and (pharmaco)epidemiological research.The HIPAA Pri-
vacy Rule (2004) acknowledges the possibility of selection 
bias if an authorization is sought. Due to these reasons, the 
Department of HHS decided that there are certain circum-
stances under which protected health information for re-
search purposes can be used without an authorization, but 
certain criteria must be met and strict safeguards should be 
established. For the authorization waiver to be granted by 
the Ethics committee the following criteria should be met: 
(a) the research cannot be conducted without the waiver; 
(b) the research cannot be conducted without access to the 
protected health information; (c) use and disclosure of pro-
tected health information has minimal risk of disclosure of 
the privacy of the subject; (d) there is an appropriate plan 
to protect data from misuse and disclosure; (e) there is an 
appropriate plan for the destruction of all identifiers con-
tained in the protected health information as soon as pos-
sible and in accordance with the research; (f) there is an 
adequate written assurance that the protected health infor-
mation shall not be used or disclosed again to another in-
dividual or legal entity, unless required by law, in cases of 
authorized oversight of the research or for other research 
which has a license to use and disclose the protected health 
information.
Data protection in the Republic of Macedonia
In Macedonia, the Law on Protection of Personal Data 
(“Official Gazette of the Republic of Macedonia” No.7/05, 
103/08) regulates the protection of personal data as funda-
mental rights and freedoms of individuals. Article 5 states: 
“secondary data processing for historic, scientific or sta-
tistical research shall be deemed in compliance with the 
primary purposes for collecting data, provided that appro-
priate safeguards are established which are in accordance 
with the law”. This clearly shows that the use of person-
al medical data for purposes of (pharmaco)epidemiolog-
ical research is justified and by this law allowed. Article 
11 states: „Notwithstanding paragraph 1 of this Article, 
the controller has no obligation to inform the data subject 
about the processing of personal data for historical, scien-
tific or statistical purposes, if it is impossible or requires 
a disproportionate effort or expense”. This allows for the 
personal data to be used without Informed Consent if ap-
propriate safeguard of the personal data is in place. The ob-
jectives of the (pharmaco)epidemiological research are by 
all means scientific and the methods of data processing are 
mostly statistical and the research itself serves the public 
health which deems (pharmaco)epidemiological research 
in compliance with this Law.
Conclusion
Non-interventional studies represent a significant por-
tion of the combined (pharmaco)epidemiological litera-
ture and are of great public health significance. Restric-
tive interpretation of regulation could have devastating 
consequences for large (pharmaco)epidemiological stud-
ies where obtaining Informed Consent is not possible, or 
where non-participation in the study is a threat to impar-
tiality and accuracy of the results.
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Introduction
Cyclooxygenase (COX) is an enzyme responsible for 
the initial step of arachidonic acid metabolism and pros-
taglandin production. There are two isoforms of COX: 
COX-1 which is considered to be physiological and con-
stitutively expressed in many tissues and COX-2 which is 
considered to be inducible and pathological due to the fact 
that this isoform catalyzes production of prostaglandins 
which are mediators of pain and inflammation (Kiefer and 
Dannhardt, 2004; Goodsell, 2000). While the inhibition 
of COX-2 isoform is beneficial, the inhibition of COX-1 
is considered to be associated with many side effects, but 
especially with gastric side effects. Conventional Nonste-
roidal Anti-inflammatory Drugs (NSAIDs), like ibuprofen 
are non-selective and they inhibit both COX isoforms, thus 
producing gastric side effects which may vary from mild, 
like gastrointestinal irritation to very serious, like ulcer-
ation and bleeding (Radi and Khan, 2006). Ibuprofen is of-
ten an inspirational drug for developing novel compounds 
with anti-inflammatory activity, and often is used as a ref-
erence drug for comparison of anti-inflammatory activity.
We have previously reported that simple derivatives 
of β-aryl-β-hydroxyalkanoic acids exhibit good anti-in-
flammatory activity and good gastric tolerability (Savić 
et al., 2011). These compounds are interesting because 
their structure deviate from the usual structure of selec-
tive COX-2 inhibitor: their structure is simple, they con-
tain carboxylic acid moiety and they lack sulphonamide or 
sulphone group. It is expected that these agents have com-
parable efficiency to ibuprofen, but a better safety profile.
Gastric tolerability can be assessed by method of Ad-
ami et al. (1963). Macroscopic observations can be sup-
ported by biochemical parameters which are oxidative 
stress markers: malondialdehyde (MDA) and glutathione 
(GSH).
It has been reported in literature that compounds show-
ing less ulcerogenic activity also showed reduced MDA 
content, a byproduct of lipid peroxidation (Pohle et al., 
2001). Therefore, MDA levels were determined in stom-
ach tissues of animals which were treated with the highest 
dose of investigated compounds and obtained results were 
compared with result for ibuprofen. GSH is a tripeptide, a 
superoxide radical scavenger and it protects thiol protein 
groups required for maintaining the integrity of cell against 
oxidation. GSH is present in the stomach at high concen-
trations and plays an important role in maintaining the in-
tegrity of gastric mucosa (Hirota et al., 1989), so it is im-
portant to determine levels of this parameter in rat stom-
ach. Quotient of GSH and MDA (in arbitrary units, AU) is 
referred as oxidative stress index (OSI) and can efficiently 
point out the compound exhibiting the best gastric tolera-
bility (Petrovic et al., 2014). It is very convenient to intro-
duce this index in order to precisely understand the results 
regarding compounds influence at oxidative stress mech-
anisms. 
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Materials and methods
In order to assess the anti-inflammatory activity carra-
geenan-induced rat paw edema test was performed on adult 
male Wistar rats. After the animals were sacrificed, their 
stomach was removed, opened along the greater curvature 
and washed out with saline. Lesions were examined using 
illuminated magnifier (3X) in order to assess gastric dam-
age according to a modified scoring system of Adami et 
al (1963). These stomachs were immediately frozen and 
stored at −80°C until determination of total protein con-
tent, MDA and GSH. To prepare the tissue homogenates, 
unfrozen stomach tissues were roughly chopped with liq-
uid nitrogen using a pestle and mortar. The fragmented tis-
sues (0.5 g each) were mixed with 4.5 ml of homogeni-
zation tris-buffer (10 mM, pH 7.4), homogenized on ice 
using an Ultra-Turrax homogenizer, filtered and centri-
fuged at 1000 g at 4 °C for 20 min. The supernatants were 
then used to determine the enzymatic activities (Mei et al., 
2012). Both MDA and GSH are determined according to 
methods used by Uskoković-Marković et al. (2007).
Results and discussion
Seven acids [3-hydroxy-3-(4-nitrophenyl)-3-phenyl-
propanoic acid (1); 3-(4-(trifluoromethyl)phenyl)-3-hy-
droxy-3-phenylpropanoic acid (2); 3-(4-chlorophenyl)-
3-hydroxy-3-phenylpropanoic acid (3); 3-hydroxy-3-(4-
methylphenyl)-3-phenylpropanoic acid (4); 3-(3-(trifluo-
romethyl)phenyl)-3-hydroxy-3-phenyl-propanoic acid (5); 
3-(3-chlorophenyl)-3-hydroxy-3-phenylpropanoic acid (6); 
3-(3-methylphenyl)-3-hydroxy-3-phenylpropanoic acid 
(7)] were synthesized using already reported modification 
of Reformatsky reaction additionally optimized by increas-
ing temperature of reaction to 65-69°C (Savić et al., 2011). 
None of the synthesized substances produced any sig-
nificant gastric lesions. The changes observed were in range 
of 0–1 according to the Adami’s scoring scale. MDA val-
ues for all compounds except for compound 2 were lower 
than for ibuprofen. GSH level is increased in groups treat-
ed with ibuprofen, compounds 1, 2 and 6 compared to the 
control group. The level of GSH in groups treated with oth-
er compounds is similar to the control group. OSI was very 
high In gastric mucosa of animals received compounds 1 
(186.45), 3 (132.6), 6 (137.4) and 7 (114.8) which means 
that these compounds produce good protection against ox-
idative stress in gastric tissue. In this respect compounds 2 
(61.0) and 5 (48.0) produced more oxidative stress in gas-
tric tissue than ibuprofen, while compound 4 (89.3) was on 
a pair with ibuprofen (79.9). 
Conclusion
Although macroscopic examination of rat stomach 
showed that none of tested compounds produced any sig-
nificant gastric lesions, biochemical parameters differen-
tiated these compounds according to oxidative stress they 
produced. The obtained biochemical results indicated that 
ibuprofen produced significantly more oxidative stress 
in gastric tissue than four out of seven synthetized com-
pounds. The results impose the conclusion that this four 
compounds exhibit better gastric tolerability than ibupro-
fen. Using OSI to describe results is much more concise 
way to perceive oxidative stress than using MDA and GSH 
values separately.
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Introduction
Lung carcinoma is known as a malignancy with a high 
incidence and an increased mortality rate worldwide (Li et 
al., 2014). The discovery of a prophylactic and a curative 
treatment for this disease still represents a challenge for the 
researchers. 
Another subject of scientific interest is the discovery of 
antitumoral agents of natural origin with potent anticancer 
activity and low/no toxic effects against normal cells. 
Betulin is a natural compound, member of the 
pentacyclic triterpene family, obtained in high yields from 
the bark of the birch tree (Krol et al., 2015). Betulin is 
known for its multiple pharmacological effects, including: 
anti-inflammatory, hepatoprotective, anticancer and 
antiangiogenic effects (Dehelean et al., 2013; Krol et al., 
2015). The use of betulin as an anticancer agent presents 
multiple advantages (potent anticancer effects and no 
toxicity in vitro against healthy cells and in vivo even at 
high doses), but one of its major disadvantages is its low 
water solubility, which limits its administration in vivo. A 
goal of the researchers was to find a proper formulation to 
increase betulin solubility in aqueous solutions what leads 
to increased bioavailability and higher antitumor activity. 
The aim of our study was to obtain a silver nanoformu-
lation of betulin and to verify its pharmacological effects in 
vitro on a human lung carcinoma cell line - A549. 
Materials and methods
In this study we used A549 human lung carcinoma 
cells. The cell line was purchased from ECACC (European 
Collection of Cell Cultures) at passage no. 39. A549 cells 
were kept in liquid nitrogen and one week before the ex-
periment started, we cultured in specific medium culture.
The cells were cultured in high glucose (4.5 g/l) Dul-
becco’s modified Eagle Medium (DMEM – Sigma Aldrich, 
Germany) supplemented with 15 mM Hepes, 2 mM L-glu-
tamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and 
10% foetal bovine serum (FBS). Cells were kept in a hu-
midified atmosphere with 5% CO2 at 37 °C and were pas-
saged every two days. Cells number was assessed by using 
Neubauer chamber in the presence of Trypan Blue.
For the cell viability assay, the cells(10000 cells/ well) 
were cultured in 96-well plates and left for 24h to adhere. 
The cells were stimulated for 24 h with different concen-
trations (10 and 50 uM) and were divided in the following 
groups: 1 - cells stimulated with DMSO (dimethylsulfox-
ide), 2 - cells stimulated with betulin dissolved in DMSO, 
3 - cells stimulated with silver nanoformulation blank and 
4 - cells stimulated with betulin silver nanoformulation. 
The cells viability was assessed by Alamar blue and MTT 
methods. It was also tested the effect of the new formula-
tion against the migration capacity of the cells by scratch 
assay and pictures were taken at different time points: 0h, 
3h, 8h and 24h.
Results and discussion
Stimulation of the A549 cells with different concen-
trations of betulin silver nanoformulation (10 and 50 uM) 
for 24h induced cytotoxicity of the cells in a dose-depen-
dent manner. These results were compared with the results 
obtained after the stimulation with betulin dissolved in di-
methylsulfoxide (DMSO), the solvent in which betulin has 
an increased solubility and the cytotoxic effect was higher 
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in the case of the nanoformulation.
It was also tested the effect of these formulations 
against the capacity of migration of the A549 cells by the 
means of scratch assay and it was observed that at the 
smallest concentration used in the study, the nanoformula-
tion was able to inhibit the migration of the cells. 
Other studies developed on human lung carcinoma 
showed that betulin solved in DMSO had cytotoxic and 
anti-migratory effects (Rzeski et al., 2009). The anticancer 
mechanism of action of betulin is still unknown and sev-
eral studies proposed as mechanism of action induction of 
apoptosis via the intrinsic mitochondrial pathway (Pyo et 
al., 2009). Another mechanism of action of betulin was the 
inhibition of tumor cells proliferation through activation of 
AMPK signaling (Li et al., 2014).
Conclusion
Our results showed that betulin formulated as a sil-
ver nanoformulation had a potent antiproliferative effect 
against human lung carcinoma cell line - A549 after 24h 
stimulation. Further studies will be realized in order to elu-
cidate the anticancer mechanism of action of betulin and 
for the evaluation of the in vivo effects in animal models 
with human lung carcinoma.
This research was supported by the PN-II-RU-
TE-2014-4-2842 grant, no. 180/2015. 
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Introduction
Pericarditis is inflammation of the pericardium, the 
serous membrane enclosing the heart and the roots of the 
great blood vessels. Richard Bright first described the as-
sociation of pericarditis with renal failure in his land-
mark observation of 100 cases of patients with ‘albumin-
ous urine’, which appeared in the Guys Hospital Report 
of 1836 (Bright, 1836). Autopsy studies demonstrated 
pericarditis or pericardial effusion in 37 of these patients. 
,,Uremic pericarditis” is a term used to describe patients 
who develop clinical manifestations of pericarditis before 
renal replacement therapy or within 8 weeks of its initia-
tion. ,,Dialysis pericarditis” is used for patients who de-
velop clinical features of pericarditis after being stabilized 
on dialysis usually after 8 weeks of its initiation (Barach, 
1922).Though several therapeutic modalities have been 
used to treat uremic and dialysis pericarditis and pericar-
dial effusion, initial treatment of pericarditis is usually de-
termined by the hemodynamic stability of the patient. In 
azotemic patients pericarditis is due to number of causes 
including infection, diseases like systemic lupus erythro-
matosis (SLE), or to uremic toxins itself. The incidence 
of acute pericardial disease punctuating chronic renal fail-
ure is decreasing because of effective dialysis and renal 
transplantation; approximately 20% of uremic patients re-
quiring chronic dialysis develop pericarditis.It is surpris-
ing that even though pericardial involvement remains an 
important cause of morbidity and mortality in patientswith 
end stage renal disease (ESRD), the academic interest and 
the literature regarding the same has reduced over the past 
few years. During 1995 and 1998, less than 1% of the 650 
authors discussing pericarditis were specifically related to 
uremic pericarditis uremia one of main complications in 
patients with terminal chronic kidney insufficiency is ure-
mic pericarditis which usually is presented as acute uremic 
pericarditis but sometimes it can be chronic constrictive 
pericarditis with pericardial effusions.
Uremic pericarditis is caused from renal insufficien-
cy either acute or chronic as result of inflammation of vis-
ceral and parietal layers by uremic toxin and disorders of 
urea and creatinine metabolism which are highly elevated 
in uremic patients.  Uremic patients treated with hemodi-
alysis can develop chonstrictive uremic pericarditis. Defin-
itive cause of uremic pericarditis is still unknown. Many 
studies have documented that the onset of uremic pericar-
ditis in uremic patients treated with HD is result of termi-
nal renal disease and inadequate Hemodialysis(HD) ses-
sions where enough amounts of fluid are not eliminated, 
volemic overload with secondary hyper-tension and over-
weight between HD intervals. Some authors suggest that 
uremic pericarditis can be result of retention of uremic tox-
ins in organism.
Symptoms are pain pericarditis uremic presented with 
different intensity, which is alleviated when the patient is 
sitting or leaning forward. Clinical signs of pericarditis 
in patients with renal disease terminals (ESRD treat my 
chronic hemodialysis are similar to signs observed from 
other causes. Most patients complain of fever and pain 
pleural chest, the intensity of which is very different. the 
pain is localized in the region pericardial and may resemble 
the pain of angina pectoris. When developing effusionmas-
sivepericardial may also appear dyspnea and heart failure. 
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Often pericarditis uremic accompanied with fever and high 
temperature. of particular importance is examination aus-
cultation in the region of the heart after the notes sound of 
friction pericardial that are superficial. These is nonsystolic 
and diastolic and performances and typically three compo-
nents of their appearance. When added effusion pericardi-
al (the liquid) noise friction pericardial often disappear.Ef-
fusion pericarditis jugular veins cause strain (Kussmaul’s 
sign-t) and can develop a paradoxical pulse (decrease of 
systolic pressure in inspiration). However, although there 
are documented facts that all patients with terminal renal 
disease treated me with recurrent pericarditis chronic he-
modialysis may not manifest symptoms. In suspected cas-
es of pericarditis, echocardiography should be done first so 
that Chiara’s effusion pericardial highlights.
Aim of this paper is to verify and document the im-
pact of terminal chronic kidney insufficiency and the im-
pact from HD on the onset of pericarditis and its complica-
tions. Etiology of different types of pericarditis in patients 
with different diseases (cardiovascular, respiratory, infec-
tious etc.) have been studied thoroughly except for man-
ifestations and etiology of pericarditis in uremic patients 
treated with HD where not enough studies have been made 
therefore its etiology is still not definitely known. There-
fore more and larger studies need to be made with more 
patients so the exact cause of this phenomenon with le-
thal consequences in uremic patients treated with HD can 
be found. 
Materials and methods
In this clinical prospective observational study 
were analyzed 90 patients with terminal chronic kid-
ney insufficiency treated with HD in Clinical Hospital 
of Tetovo on Department of Nephrology with mean age 
62.40±5.20 identical for both genders. Initial evaluation in-
cludes a clinical history and physical examination, ECG, 
echocardiography(3D color Doppler) chest radiography, 
and lab studies.ECG can be diagnostic in acute pericardi-
tis and typically shows ST elevation in all leads. The ratio 
of the amplitude of ST segment to the amplitude of the T 
wave in leads I, V4, V5, and V6 on electrocardiogram can 
be used to differentiate acute pericarditis (AP) from ear-
ly repolarization (ER) and early repolarization of left ven-
tricular hypertrophy (ERLVH), according to a recent study. 
Statistical elaboration
The basic statistical methods used in this study were: 
arithmetical average value, standard deviation X±SD, Stu-
dent “t” test, Mann Whitney U test, Wilcoxon test. The sta-
tistical significance of the differences between subjects of 
the experimented group and control group for the gained 
parameters  was analyzed with “Anova Two Factor ” with 
statistical value for ,,p” smallearthen 1% ( p<0.0001).
Results and discussion
From 90 patients treated with HD, 30 patients (10 
females, 20 males) showed symptoms of chest pain and 
tightening similar to pectoral angina (in small number of 
patients persistent temperature accompanied with fever 
was found). All patients who presented with symptoms of 
uremic pericarditis had fluid overload (between HD inter-
vals) of 4000-6000ml.
Conclusion
In our work we verified that in 30% of examined pa-
tients predominate symptoms of uremic pericarditis, from 
those: in 25% pericarditis was caused as inadequate HD 
treatment, fluid overload between HD intervals, dietetic-
hygienic disrespect of HD, termination of HD séance be-
fore required, disuse of antihypertensive and diuretic ther-
apy (in 10% of patients with two weekly sessions of HD 
from 4 to 5 hours per séance), while in 5% of patients peri-
carditis was consequence of various infections. The hemo-
dialysis patients also used the supp. Indomethacin, aspirin, 
corticotherapy and broad spectrum antibiotic. 
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Introduction
Cardiovascular diseases still count among the main 
causes of mortality in patients with chronic renal insuffi-
ciency (CRI). One of the risk indicators of cardiovascu-
lar factors considering this group of patients is Arterial hy-
pertension (AH). Angiotensin Converting Enzyme inhibi-
tors (ACE) are the most effective group of drugs used for 
the treatment of hypertension in patients with CRI (Brown 
et al., 1998)  and cardiovascular diseases (CVD), based 
on the prevention of renal and CVD damages. ACE in-
hibitors are used primarily for the aforementioned diseas-
es due to their effectiveness in slowing down the pace of 
progress and reducing the rate of morbidity and mortali-
ty in patients with these diseases. A large number of stud-
ies have been published where they show the positive ef-
fects of ACE inhibitors. These drugs remain further as the 
most preferred drugs in the treatment of patients with CRI 
and AH. AH and lipid abnormalities are among the most 
important causes that accelerate the progression of chron-
ic renal disease (CRD) and the risk of CVD. The etiology 
of arterial hypertension is a multifactorial (near 20-25% of 
cases with AH the etiology is known, while other cases are 
due to many other disorders: hormonal, renal, cardiac, in-
fectious, congenital diseases or inherited, different urop-
struksionet, RVU (Reflux Vesico Uretral) etc. 
AH remains one most important and common factor 
of diseases throughout the world. Between normotension 
and hypetension pressure not any precise definition per-
sists, but based on the preferences and the World Health 
Organization all the values of systolic pressure higher than 
140 mmHg and diastolic higher than 90 mmHg are treated 
as arterial hypertension. Recent years, a number of studies 
have verified and documented that between AH and lipid 
abnormalities and progress of CKD (Chronic Kidney Dis-
ease) there is a high positive correlation. There are facts 
documented that patients with CKD and other consequenc-
es besides AH, a large number of them suffer from a hip-
ertregliceridemia and dyslipidemia, so it is very necessary 
examination, treatment, determination and correlation of 
lipids with AH, that in the initial stages of CRD with the 
sole purpose of preventing rapid pace of progress towards 
CRD uremia. Many contemporary studies testify a close 
connection between pressure and uremic dyslipidemia ver-
ifying that the AH with its oscillations significantly af-
fect lipid disorder helping their stratification on the wall 
of blood vessels, thus increasing the risk of aterogenesis of 
coronary arteries, cerbrale with frequent manifestations of 
acute myocardial infarction. 
Materials and methods
In the study 240 subjects were included (of which 140 
male and 100 female respectively. The average age was 
56.80 ± 12.50 years.  The first group of 120 patients (50 fe-
male and 70 male) were treated over 12 months with the 
ACE inhibitor and the second group (50 female and 70 
male) were treated with Angiotensin II AT1 receptor block-
ers and renin-angiotensin-aldosterone system. The patients 
were examined before and after the study. The examina-
tion was carried out for the analysis of proteinuria, serum 
urea, serum creatinine, uric acid electrolytes, profile of lip-
id and determination of the level of glomerular filtration 
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rate (GFR glomerular filtration Rate by Cockroft & Gault 
formula) before and after the therapy. The method used is 
standard deviation ± SD, two factor ANOVA.
Results and discussion
From the results obtained the blood pressure of the pa-
tients was lower in both treated groups, though statistical-
ly not significant. When comparing the groups treated with 
ACE inhibitors and the group treated with different group 
of medicines respectively there was statistically signifi-
cant difference <0.005 for the concentrations of urea, cre-
atinine, uric acid and with a stagnation of GFR in favor of 
the group that was treated with ACE inhibitors for over 12 
months.
Conclusion
Many contemporary studies testify a close connection 
between pressure and uremic dyslipidemia verifying that 
the AH with its oscillations significantly affect lipid dis-
order helping their stratification on the wall of blood ves-
sels, thus increasing the risk of aterogenesis of coronary 
arteries,  cerebral with frequent manifestations of acute 
myocardial infarction, left ventricular hypertrophy, angi-
na pectoris, heart failure congestive and cerebrovascular 
brain stroke (Antony et al., 1996). Common effects of AH 
and hyperlipidemia manifestly affect modification and re-
duce in renal functions causing nefroangiosklerosis with 
glomerulosclerosis. It is estimated that 10-13% of elderly 
patients in the US suffer from CKD and AH without taking 
to account the degree of CRD. AH during CRF is volumic 
type (with manifestations of cardiovascular complications 
with hypertensive cardiomyopathy etc. and despite that 
sometimes it may be as a result of other mechanisms like 
hipernatremia etc. Although more research needs to be car-
ried out, our results suggest that ACE inhibitors, regardless 
of their antihypertensive effects, can reduce and slow down 
significantly the rate of chronic renal failure and cardiovas-
cular diseases (Weiner et al., 2007). Inadequate treatment 
of HTA in patients with CRI symptoms will lead to risk of 
CVD and an increase in renal diseases. 
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Introduction
Disorders of lipoprotein metabolism in patients with 
rheumatoid arthritis (RA) even in early stages can be cause 
for the increased incidence of cardiovascular diseases, 
cerebrovascular events, perpheric artherial diseases and 
premature atherosclerosis (atherosclerosis praecox). In this 
study we wanted to display the apolipoproteinic abnor-
malities in patients with RA, their correlation and how RA 
causes changes of apolipoproteinic profile.  RA is system-
ic disease of connective tissue (Boers et al., 2003; Dessein 
et al., 2006; Park et al., 1999; Gonzalez-Gay et al., 2005) 
with unknown ethiology, subacute or chronic with exacer-
bations and remissions, most commonly found in peryphe-
rial joints, symetrically, which with time can cause destruc-
tion, deformities and at the end ankylosis of joints. It is 
known fact that patients with RA are more prone to differ-
ent inflamations which is confirmed from the fact that these 
patients have higher concentrations of C-Reactive Prote-
ine, a biomarker who suggest the presence of inflamma-
tion who when is combined with apolipoproteinic abnor-
malities is count as additional factor on the onset of athero-
sclerotic changes of coronary and cerebrovascular arteries, 
with early onset of atherosclerosis in patients with RA. 
Aim of study
Primary aim of this study is to show apolipoprotein-
ic abnormalities and the concentrations of CPR in patients 
with RA, and their role on the progress of RA and their ath-
erogenic effect on coronary, cerebrovacular and peripheri-
al artheries. 
Matherial and methods
  In this cross-section study a total of 40 patients were 
included, from whom 24 were females with mean age of 
48.0±18.6 and 16 males with mean age of 49.5±12.8, with 
verified diagnosis of RA according to criteria of Ameri-
can Association for Rheumatoid Arthritis of 1987. Control 
group was composed from 40 healthy individuals (voulen-
tary blood donors)   from whom 24 females and 16 males. 
In all patients (examined group and control group) beside 
routine analysis for lipid profile other analysis were made 
as well: total lipids (TL), total cholesterol (TCh), triglyc-
erides (TG), HDL-ch,LDL-ch,ApolipoproteinA-1,Apo-
B100, Apo-E, Lp(a)CRO and lipoprotein lipase (LPL) lev-
els too.
Results and discussion
Our study confirmed that patients with RA are 
prone to have increased levels of: TL=8.20±2.70mmol/
l;TCh=6.8±2.70mmol/l;TG=3.46±0.65 mmol/l; and LDL-
ch=4.48±0.90 mmol/l whereas HDL levels were de-
creaed HDL-ch= 0.94 ± 0.60 mmol/l. From analysis of 
apolipoproteins we found low concentrations of Apo-
A1=0.94±0.12 g/l  and high concentrations of  ApoB100= 
2.98±1.85 g/l; Apo-E=6.50±1.70 g/l , Lp(a)=48.0±18.60, 
and CRP=18.0± 6.80 mg/l  in contranst from the control 
group results: TL= 6.20±0.50 mmol/l; TCh =4,30±0.60 
mmol/l; TG=1.24±0.70 mmol/l; HDL-ch= 1.28±0.40 and 
LDL-ch=2.90±0.90 mmol/l, and CRP= 4  mg/l. Lipopro-
tein lipase levels in patients with RA in our study showed 
low levels:LPL-12.80±4.20 u/L comparing with the control 
group LPL- 24.80±12.00 u/L. Decreased activity of LPL is 
believed to be result of increased concentrations of cyto-
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cines: Interleukin 1, Interleukin 1β, Interleukin 1α, Inter-
leukin 2,Interleukin 6, Interleukin 8, Interleukin 10, Inter-
leukin 12 and Tumor Necrosis Factor. Disturbed apolipo-
proteinic profile, proinflamatory cytokines and increased 
levels of CRP are fact that patients with RA are prone to 
increased risk for atherosclerotic changes in blood ves-
sels, with increased risk for cardiovascular diseases, cere-
brovascular events, peripheric artherial disease and onset 
of early (premature) atheros-clerosis (atherosclerosis prae-
cox). 
Conclusion
It can be concluded that measuring lipidic and apoli-
poproteinic abnormalities in RA patients can help to take 
hygienic-dietetic measures as well as treatment methods 
which significantly would decrease prevalence of dyslip-
idemia and would also slow down the atherogenesis which 
would reduce in minimum the onset of cardiovascular, 
cerebrovascular, atherosclerotic macroarteriopathy and 
early atherosclerosis in patients with RA. Management of 
lipid abnormalities in patients with RA aims to normalize 
the atherogenic index (TCh/HDLch) with statines, fibrates, 
nyacine, cholestipol, cholestyramine or combined therapy, 
also prevention of inflamatory processes.
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Introduction
One of chronic disorders of terminal renal failure is 
also a metabolic disorder of L-Carnitines. L-carnitine in 
the body acts as an antioxidant fighting the harmful par-
ticles in the body known as free radicals, which dam-
age the DNA and excite it. The lower concentration of L-
carnitine(L-c) in patients treated with hemodialysis (HD) 
is a consequence of the loss of it through dialisant (Clut-
terbuck at al., 2002; Fornasini et al., 2007) digestion and 
reduce endogenous synthesis as a result of absence of the 
precursor (predecessor) amino acid Lisine. In the kidney, 
osmolytes including carnitine are crucial since hyperto-
nicity is usual and the kidney must cope with fluctuations 
of diuresis (increased production of urine) and antidirue-
sis. Extracellular osmolarity of medullary cells may be-
come more than four-fold that of isotonicity. In healthy in-
dividuals, carnitine is freely filtered and tubular resorption 
of free carnitine (FC) is almost complete. What is excret-
ed in urine is carnitine ester, or acylcarnitine (AC).   In 
healthy people, the renal clearance of AC is four to eight 
times that of FC.Impairment of excretion of AC occurs 
with deteriorating renal function leading to decreased car-
nitine clearance and resulting in elevated plasma levels of 
carnitine.Uremic patients have elevated levels of AC that 
occur as both elevated FC and total carnitine before (Ar-
duini et al., 2006). Due to accumulation of metabolic in-
termediates, impaired carnitine biosynthesis, reduced pro-
tein intake, and increased removal of carnitine through he-
modialysis (HD), patients who undergo routine HD usu-
ally present with plasma carnitine. (Cibulka et al., 2005) 
There are documented facts that the plasma levels of L-C 
at the end of each dialysis session slimmed down to about 
70-80% on average.  This reduction in plasma levels of 
L-carnitine  affter HD is a consequence of epoetin-resis-
tant anemia, intradyalitic hypotension,cardiomyopathy, fa-
ti-gue,muscle weakness, of various inflammation, reduced 
endogenous synthesis of cofactors of L-Carnitines and 
malnutrition. L-Carnitines affects remodeling of phospho-
lipidic membrane of red blood cells, stimulates erythropoi-
esis in high concentrations>200 μmol/L, increases surviv-
al time of red blood cells, redu-ces oxidative stress through 
the hem oxygenasis-1, and It reduces inflammation, and re-
duces the value of C-reactive protein (PCR) and lipids. A 
large number of observers have documented studies of an 
inverse correlation between the dose of rHuEPO and car-
nitine level. 
Randomized and controlled studies in a meta-analysis 
suggest that supplementation with L-Carnitines  has shown 
positive effects in response to therapy with Erythropoie-
tin in chronic uremic patients treated with HD. Uremic pa-
tients treated with HD due to low values of L-C often man-
ifest anemia resistant to therapy with human Eritropoet-
in Recombinant (rHuEpo) with substitution with L-Carni-
tines significantly reduces the resis-tence to therapy with 
rHuEpo, with K/DOQI association recent years suggests 
that patients treated with chronic HD and resistant to ther-
apy by the end of the session with HD must necessarily be 
treated with L-Carnitine (KDOQI Clinical Practice guide-
lines 2008-2009). Aim of this paper was to show the effects 
of L-Carnitine in uremic patients treated with HD.
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Materials and methods
In total 100 patients treated with chronic HD were 
studied. Of the 100 patients treated with HD-46 (45%) 
were female- 54 (55%) were male, with an average iden-
tical age of 58.70±12.60, treated over 8 years in Tetovo 
Clinical Hospital and Clinic Skopje. Patients were divid-
ed into two groups: The first group comprised of 65 pa-
tients  had a sensitive reaction to therapy with rHuEpo dose 
of 2000-4000 IU after  HD  subcutaneous and the second 
group consisted of 11 women and 12 men who after  HD 
had the highest value carnitine clearence on even after in-
creasing the dose showed a  resistance to therapy after 6-8 
weeks and we decided that this patients to be trea-ted with 
L-C ampoules of 1 g after each session of HD and 2x500 
mg L-C in the form tablets days that have not HD. With-
in 8 months of this dose, we have seen a rapid increase in 
the level of carnitines, reaching levels two to three times 
higher than the concentration of physiological L-C and 
high impact to eritropoesis and stimulation of erythroblasts 
(11,12) as well as positive effects on therapy with rHuEpo 
which was manifested with adjustment of blood (Er, Hb, 
Htc) and improvement of symptoms of renal anemia . Our 
study confirms the elimination of L-C of 16.80 ± 28.40% 
over a period of 8-12 months of treatment with HD.
Results and discussion
Before starting the Epo therapy mean values of Hb in-
female patients were 5.20±1.15 mmol / l, while in males 
were=5.60±1.10 mmol/l, the number of Er in female 
was:2.90± 0.86 x 10 12 / l, while in males were=3.20± 0.90 
x 10 12/l. Values of HTC in female were=0:24 ± 0:04 while 
the men-12:28±12:06. After treatment with EPO therapy 
and amp. L-Carnitine a 1.0 g intravenously at the end of 
the session that the HD the desired target Hb was > 6.80 
mmol / l and after 16 weeks the women target was Hb> 
6:40 mmol/l, while the male target Hb>6.85 mmol/l, the Er 
number of female reached: 3.60±0.80x10 12 / l, while in 
the male were 3.85±0.80x1012 /l. The values of Htc in the 
female came up-0.32± 0.03 while the men-0.04± 0.35. The 
comparison of values of patients before treatment with L-
carnitine and Epo therapy and after treatment showed a sig-
nificant statistical difference of p <0.0001. Statistical pro-
cessing: statistical methods that were used are: arithmetic 
mean value, standard deviation: X ± SD, Studentov,,t”test, 
Mann-Withney U test,Annova Two-Factor. The results ob-
tained from the examination of Hb, Er, Htc are processed 
and presented in the form of charts, tables and diagrams.
.
Conclusion
We can conclude that patients undernourished, anemic 
and resistent to therapy with rHuEpo and lower values of 
the concentrations of L-C after the session with HD, sup-
ple-mentation with carnitine (per os or ampular) can im-
prove reanale anemia significantl resistant to Epo therapy. 
Our findings confirm that elimination of L-carnitines after 
application of L-C in HD decrease from 16.80 ±28.40% 
.But are necessary further studies with larger number of pa-
tients with longer duration so that can be documented and 
verified the effects of L-carnitine to uremic patients and re-
sistant to Epo therapy. 
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Introduction
In order to  estimate central nervous delivery of nov-
el compounds a lot of useful in vitro models have been 
developed including Parallel Artificial Membrane Perme-
ability Assay (PAMPA) (Avdeef, 2005), Biopartitioning 
Micellar Chromatography (BMC) (Molero-Monfort et al., 
2000), Immobilized Chromatographic Techniques (IAM), 
and cell based assays. BMC is a mode of micellar liq-
uid chromatography that uses micellar mobile phases of 
Brij35 under adequate experimental conditions. It can be 
useful in mimicking the drug partitioning process into bi-
ological systems, because the characteristics of BMC sys-
tem are similar to biological barriers and extracellular flu-
ids (Molero-Monfort et al., 2000). On the other hand clas-
sical reversed phased HPLC system is recognized as the 
well-established system for estimation of compounds lipo-
philicity. The important role of lipophilicity and its use in 
prediction of blood-brain permeability of drugs have been 
demonstrated in several studies (Kaliszan, 2007). Reten-
tion data obtained by this method can be further used in 
correlation studies with some physicochemical and bio-
logical properties of tested compounds (Liu et al., 2011). 
The compounds examined in this study were imidazoline 
receptor ligands (IRs) (Ernsberger, 2000). IRs have been 
tested as novel centrally acting antihypertensives and drug 
candidates for treatment of various neurological disorders 
(Fenton et al., 2006; Finn et al., 2003). Since these ligands 
exhibit additional CNS effects, several structurally relat-
ed CNS drugs were also included in this research. In this 
work, the retention data of 16 imidazoline/α-adrenergic re-
ceptor ligands and 15 CNS drugs, were examined using 
BMC and RP-HPLC systems and correlated with permea-
bility coefficients (Pe) previously obtained in our laborato-
ry using PAMPA (Vucicevic et al., 2015). 
Materials and methods
Chromatographic conditions
Chromatographic analysis was carried out on an Agi-
lent Technologies 1200 Series system   (Santa Clara, CA, 
USA). BMC analyses were performed on a Zorbax Ex-
tend-C18 column (150 mm × 4.6 mm, particle size 5 μm), 
with a flow rate of 1 ml/min and a temperature of 36.5 °C. 
Micellar mobile phase was prepared by dissolving poly-
oxyethylene (23) lauryl ether Brij 35 (Sigma–Aldrich Che-
mie Gmbh, Steinheim, Germany) in buffered solution at 
pH 7.40 (which corresponds to blood pH of humans) to get 
a final surfactant concentration of 0.04 M. RP-HPLC mea-
surements were performed using a XTerra® RP18 column 
(100 mm × 4.6 mm, particle size 3.5 μm). The flow rate 
was 0.8 ml/min, column temperature was set to 25 °C. Mo-
bile phase was consisted of different ratios of methanol and 
sodium dihydrogen phosphate buffer (pH 7.40).
Computational method
The Quantitative Structure-Permeability Relationship 
(QSPR) models were developed using retention data from 
BMC system. PLS regression analysis was performed us-
ing the Soft Independent Modeling of Class Analogy SIM-
CA P+ 12.0 program (Umetrics AB, 2008), while STATIS-
TICA 5.0 (StatSoft Inc., 1998) was used for the stepwise 
MLR and ANN analysis. The dominant molecules/cations 
species at pH = 7.4 of examined compounds have been ob-
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tained using the MarvinSketch 6.1.0 (ChemAxon, 2013). 
The geometry of all compounds have been minimized us-
ing B3LYP/6-31G(d,p) level of the Density Functional 
Theory (DFT) (Becke, 1993; Lee et al., 1988) included in 
ChemBio3D Ultra 13.0 program (CambridgeSoft Corpora-
tion, 2013). Constitutional, geometrical, physicochemical 
and electronical parameters of optimized molecular struc-
tures were calculated using following software: ChemBi-
o3D Ultra 13.0, Dragon 6.0 (Talete srl, 2010) and ADMET 
Predictor 6.5. Additionally, HOMO and LUMO energies 
obtained using ChemBio3D Ultra 13.0 were used to cal-
culate some quantum chemically based reactivity molecu-
lar parameters, such as chemical potential (l), electronega-
tivity (v), hardness (g), global softness (S) and electrophi-
licity index (x) (Iczkowski and Margrave, 1961; Parr and 
Yang, 1989). 
Results and discussion
Using ADMET predictor 6.5 (Simulation Plus, Inc., 
2013) and ACD/i-Lab software (http://www.acdlabs.com/
resources/ilab/) it was shown that those compounds are not 
substrates Pgp and their BBB-permeability could be ac-
curately predicted by using non-cellular in vitro methods. 
Significant correlation was obtained between logarithm of 
BMC retention factor (logkBMC) and effective permeabil-
ity (Pe) (R2=0.69), while for RP-HPLC system the corre-
lation was lower (R2 logkwRP-HPLC / Pe = 0.49). There-
fore it can be concluded that logkBMC parameter could 
be used as more reliable than logkwRP-HPLC to assess 
the BBB penetration of IRs/α-ARs ligands and CNS drugs 
in more time efficient manner. Further, retention factors 
(logkBMC) of α-adrenergic/imidazoline receptor ligands 
and CNS drugs were used as dependent (Y) variable in 
this QSPR studies, while their calculated molecular de-
scriptors were selected as independent (X) variables. Par-
tial Least Square (PLS) regression, stepwise Multiple Lin-
ear Regression (stepwise MLR), and Artificial Neural Net-
works (ANN) techniques were applied in order to create 
new mathematical models. Stepwise MLR analysis have 
been resulted in statisticaly better performance than PLS 
and ANN, and therefore MLR/QSPR-logkBMC model 
was selected as an optimal. The P_VSA_s_5, VE1_RG, P_
VSA_p_2 and GATS1e were selected descriptors with the 
most significant influence on logkBMC and consequent-
ly on Pe, indicating on possible structural modifications 
which could enhance BBB penetration. 
Conclusion
Formed models could be used as time and cost effi-
cient screening tool for evaluation of blood-brain barrier 
permeation of novel α-adrenergic/imidazoline receptor li-
gands, as promising drug candidates for treatment of hy-
pertension or neurological diseases. 
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Introduction
Pharmaceutical care is the responsible pharmacists 
practice, which provide safe and best available therapy for 
the patient. It is the professional activity in which the phar-
macist, using his knowledge and experience, revealing pa-
tients’ needs, set priorities in the treatment process, and 
takes responsibility for a positive outcome of drug thera-
py (Hepler and Strand, 1989). That responsibility is shared 
with the doctor who determined the diagnosis and pre-
scribed therapy, and with patients, encouraging them to the 
compliance, frequent check and counseling about respon-
sible treatment. Today, many countries are trying to incor-
porate this new concept in its health care system, and al-
though such attempts are of great interest to national and 
international pharmacy organizations, many challenges of-
ten appear in the implementation of this concept. Some of 
the difficulties may include: attitudes and opinions of other 
health professionals, lack of cooperation, and inadequate 
communication between them, an insufficient number of 
pharmacists, space or equipment for the provision of phar-
maceutical care, including the structure and organization 
of health care (EDQM, 2012). 
Pharmaceutical care derives from the principles and 
postulates of clinical pharmacy, which pharmacists recog-
nize as the scientific basis for intervention in the treatment 
of patients (RPSGB, 2007). The concept of clinical phar-
macy clarifies the role of the pharmacist in the process of 
providing health care. It involves different ways of cooper-
ation of health professionals in which science and practice 
can be linked to patient care. But to make this impact had 
the biggest impact possible, it is necessary to develop clin-
ical knowledge, but also communication skills, judgment 
and decision- making. Clinical practice should occupy an 
increasing role in the daily work of a pharmacist, instead 
of being just one of the possible options or specialty phar-
macist. Clinical pharmacy practice means and includes the 
philosophy of pharmaceutical care that is focused on spe-
cialized knowledge and experience in the treatment. As a 
scientific discipline, clinical pharmacy includes the task of 
collecting and contributing to the creation of new knowl-
edge that can improve the health and quality of life (Mc-
Givney et al., 2007).
Indicators of quality of pharmaceutical care are equal-
ly appropriate for in-patient and community settings, for 
hospital and community pharmacists, and other health-
care professionals, as applicable, in low-, middle-income 
and industrialized countries in Europe and other regions 
of the world. The indicators provide information about the 
range; quantity and quality of pharmaceutical care inter-
ventions/services delivered. The indicators also provide an 
opportunity to gather in-depth knowledge on pharmaceu-
tical care practices regionally, nationally, and internation-
ally that will permit the sharing and follow-up of experi-
ences over time by professional disciplines and the health 
sector in general, regionally, nationally and international-
ly. These indicators are rather broad, and can be further de-
veloped and refined over time, but they are easily under-
stood and will help pharmacists, other healthcare provid-
ers, and professional regulators to formalize and develop 
the pharmaceutical care philosophy and its working meth-
ods (EDQM, 2012).
Some of the terms, which are used in Indicators of 
quality, are:
1. Adverse drug reaction (ADR) means a response 
to a medicinal product which is noxious and 
unintended and which occurs at doses normal-
ly used in man for the prophylaxis, diagnosis or 
therapy of disease or for the restoration, correc-
tion or modification of physiological function
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2. Documentation – the detailed description of a 
patient-provider or provider-provider interac-
tion. Documentation serves as a record for stat-
ing relevant participants, evidence, assumption, 
rationale, and analytical methods used in eval-
uating patient progress and quality of care or 
outcomes for individuals. Also functions as a 
means of communication among providers and 
analysis for billing purposes. 
3. Customer loyalty - expresses an intended be-
havior related to the product or service. This in-
cludes the likelihood of future purchases or re-
newal of service contracts or, conversely, how 
likely it is that the customer will switch to an-
other brand or service provider.
4. Follow up is maintenance of contact with or re-
examination of a person (as a patient) at usu-
ally prescribed intervals following diagnosis or 
treatment 
5. Medication review is an evaluation of patient‘s 
medicines with the aim of optimizing the out-
come of medicine therapy by detecting, solving 
and preventing drug-related problems 
6. Interprofessional collaboration – working to-
gether with one or more health care profession-
als who each make a unique contribution to ob-
tain optimal patient medication outcomes, con-
sidering patient needs, expectations, and quali-
ty of life 
7. Patient Medication Profile – is a comprehensive 
summary of all regular medicines taken by the 
patient. 
Professional assessment of prescription is the assess-
ment of whether the prescription includes an appropri-
ate dosage form and appropriate route of administration; 
appropriateness according to patient’s condition; dosage 
within therapeutic range; duration of treatment; appropri-
ateness according to patient’s parameters (age, weight, etc.) 
and previous medication; compatibility with other medica-
tion; consistency with formularies, clinical guidelines and 
protocols; possible side effects; risk of adverse drug reac-
tions; potential for non-concordance, inappropriate use and 
misuse by patient; contraindications (RPSGB, 2007).
Pharmaceutical care is the responsible provision of 
drug therapy for the purpose of achieving definite out-
comes that improve a patient’s quality of life. These out-
comes are:
•	 Cure of a disease
•	 Elimination or reduction of a patients’ symp-
tomatology
•	 Arresting or slowing of a disease process
•	 Preventing a disease or symptomatology
Pharmaceutical care involves the process that a phar-
macist co-operates with the patient and healthcare pro-
fessionals in designing, implementing, and monitoring a 
therapeutic plan that will produce specific therapeutic out-
comes for the patient. This in turn involves three major 
functions:
•	 Identifying potential and actual drug-related 
problems
•	 Resolving actual drug-related problems and 
•	 Preventing drug-related problems.
Pharmaceutical care is a necessary element of health 
care, and should be integrated with other elements (Mc-
Givney et al., 2007).
Pharmaceutical care is, however, provided for the di-
rect benefit to the patient, and the pharmacist is responsible 
directly to the patient for the quality of that care. The fun-
damental relationship in pharmaceutical care is a mutually 
beneficial exchange in which the patient grants authority to 
the provider and the provider gives competence and com-
mitment (accept responsibility) to the patient. These funda-
mental goals, processes, and relationships of pharmaceuti-
cal care exist regardless of practice setting and of profes-
sional background (Hepler and Strand, 1989).
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Legal framework
Pharmaceutical Chamber of Macedonia (Chamber) as 
a professional association of pharmacists with high educa-
tion, beside public authorizations for issuing, continuing, 
renewing and revoking of working licenses and keeping 
registers, with the adoption of the Law on Health Care Pro-
tection in 2012 has obtained one more public authorization 
– professional supervision (LHP, 2012). According to this 
Law, supervision of the professional work of the health-
care institutions and other institutions that perform health-
care activities and of the healthcare workers and co-work-
ers is being performed for the purpose of control of the 
professional work, the implementation of the professional 
guidelines, assessment of the professional work, as well as 
assessment of the conditions and the manner of provided 
healthcare (LHP, 2012). The final goal of the profession-
al supervision is evaluation of the quality of the healthcare 
services provided by the healthcare workers, in this case 
pharmacists, and undertaking measures for their improve-
ment. The quality of provided services by the pharmacists, 
as well as the conditions under they are provided have in-
valuable significance for the provision of pharmaceutical 
activities as a part of the whole health care protection, care 
for the patients, prevention of the diseases and obtainment 
health for the population. The Chamber has fully recog-
nized the aims and the goals of the professional supervi-
sion, the need for determining the provision, quantity and 
sustainability of the quality of the healthcare services re-
spectively, as well as determining the conditions for per-
forming the supervision and their maintenance at the re-
quired level according to the current legal provisions.
Creating basis for implementation and 
developing acts and tools
The implementation of the professional supervision 
as a new public authorization in the Chamber started with 
forming a Commission for organizing the professional su-
pervision with duties: to make proposed list of pharmacists 
– providers of the supervision, to develop criteria for per-
forming professional supervision, to propose annual plan 
for conducting professional supervision, to keep evidence 
of performed supervisions and suggested and taken mea-
sures for improvement, to write annual reports, to give re-
ports of performed supervisions to the Ministry of Health, 
to make orders for performing the supervision, to deter-
mine performers for supervision, all according to the Law, 
the Statute of the Chamber and the Code of Ethics (Rule-
book, 2014). 
During the 2013, the Commission for professional su-
pervision created a Rulebook on the performing the profes-
sional supervision, which later was adopted by the Cham-
ber’s Assembly and published in the Official Gazette of 
R. Macedonia (Rulebook, 2014).  In the Rulebook are de-
termined the way of organizing the professional supervi-
sion and the procedures for performing according to the 
legal provisions. The conducted supervision can be reg-
ular supervision or professional supervision when neces-
sary – extraordinary professional supervision (LHP, 2012). 
Regular supervision is conducted according to the annu-
al plan, set by the Commission and adopted by the Execu-
tive Board of the Chamber (LHP, 2012). The extraordinary 
supervision is carried out in the case of a request for ex-
amination the operation of the health care facility and the 
work of the pharmacists during the provision of the phar-
maceutical services (LHP, 2012). The request can be sub-
mitted by patient, member of the patient’s family and gov-
ernmental body (LHP, 2012). The professional supervision 
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is conducted by the performers, who fulfill certain crite-
ria such as (1) having specialization in the certain field of 
pharmacy or master degree, at least 5 years working ex-
perience in appropriate health care institution and valid li-
cense to work, or (2) having at least 10 years working ex-
perience in appropriate healthcare institution and valid li-
cense to work (Rulebook, 2014). During the profession-
al supervision performers examine, evaluated and control 
the organization and the management of the work in the 
healthcare institution, the manner of work of the healthcare 
institution, professional qualifications of the pharmacists, 
the rights and the obligations of the pharmacists, profes-
sional work of the pharmacists, their continuing education, 
keeping official books and registers and provision of the 
legal requirements and professional guidelines (Rulebook, 
2014). After completing the professional supervision, per-
formers prepare minutes, which is submitted to the Com-
mission. Commission further submits report to the Minis-
try of Health (LHP, 2012). If the performers determine ir-
regularity in the work, they are obliged to give directions 
for eliminating the irregularity (Rulebook, 2014). They are 
also obliged to give instructions for improvement if need-
ed. If pharmacists and the pharmacy don’t carry out the in-
structions within the period laid down by the performers, 
then the Commission shall notify the competent authorities 
and bodies of the Chamber (Rulebook, 2014).
Furthermore, the Chamber announced call for selec-
tion of providers of professional supervision. After the per-
formers’ selections was completed, lists of providers of the 
professional supervisions for community pharmacy, hos-
pital and clinical pharmacy, laboratories and other health 
care providers where pharmacists work were formed.
It was also decided professional supervision to start to 
be conducted in community pharmacies, and then to cover 
other healthcare institutions. 
Because of fair, efficient and quality delivery of pro-
fessional supervision the Commission has prepared List of 
indicators for the implementation of professional supervi-
sion over the work of community pharmacies and pharma-
cists who work in them. The List is a helpful tool to facil-
itate the conduction of the professional supervision with-
out subjective influence on performers. The List is struc-
tured form of statements that determine certain obligation, 
criteria, condition or process needed to establish the quali-
ty of the provided healthcare services by the pharmacists as 
well as the conditions in which those services are provided.
Performing and initial results
Professional supervision began to be implemented in 
the second half of 2014. At the beginning was conducted 
on 8 pharmacists employed in 6 pharmacies on the territory 
of Skopje. The next year, were conducted 28 supervisions 
on pharmacists employed in 19 pharmacies in 9 communi-
ties in Skopje. In all performed supervisions it was found 
that the healthcare workers – pharmacists work profession-
ally, respect legal requirements, educate continuously, re-
spect patients’ rights and confidentiality of the data, com-
municate with other healthcare workers, take care of the 
environment where they work, equipment and inventory. It 
was also determined that there were not irregularities in the 
overall work of the pharmacies as healthcare institutions. 
The condition settled in performed professional supervi-
sions indicates several facts. Most of the pharmacies don’t 
produce magistral preparations. They order them from oth-
er legal entities – galenic laboratories. Most of them have 
contract with Health Insurance Fund, and only for the med-
icines that are reimbursed they obligatory keep electronic 
record for the patients. Only 2 pharmacies have Standard 
Operating Procedures (SOPs) for the most of the processes 
performed in the pharmacy. In the supervised pharmacies, 
no one from the pharmacists has reported adverse reaction 
in the National center for reporting adverse reactions. No 
one at the pharmacies keeps evidence for shortages of the 
medicines. The performers of the supervision in individu-
al cases have given instructions and guidelines, for exam-
ple, haw to improve area for dissolving syrups, which data 
to be put in the electronic records, development and imple-
mentation of SOPs for individual processes in pharmacy, 
conflict management and else. 
Professional supervision is being performed in 2016 
according to the Plan for the current year.
Future developments and expectations
In the future, the Chamber regarding the public autho-
rization – professional supervision aims: to increase the 
number of the performers to be able to carry out more su-
pervisions simultaneously on the territory of Macedonia, 
to develop lists of indicators for other healthcare institu-
tions where pharmacists work and to begin to conduct pro-
fessional supervision
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Background
The drug licensing regulatory system ensures that mar-
keted drugs to be used, meet the high standards and re-
quirements for quality, efficacy and safety. Unfortunately, 
in practice, prescribers are often obliged to deviate from 
granted medicine marketing authorisation, due to the lack 
of availability of appropriate medicines for patient’s thera-
peutic needs and progress. This concept of medicines use 
not mentioned in the approved labelling (FDA Modern-
ization Act) or outside of the terms of Summary of Prod-
uct Characteristics regarding indication, age, dosage, phar-
maceutical form and route of administration (British NHS 
Guideline) is defined as off-label use of licensed medicines.
On the global level, many supportive  evidence and 
health care needs confirm that off-label medicines use 
occurs in every country and each level or specialty area 
of  healthcare (Conroy, 2003). Moreover, it is an integral 
part of  Good Medical Practice and may provide the best 
available option or even the standard of care in a particu-
lar health condition (Dresser and Frader, 2009). In general, 
this concept is legal and may be appropriate, but it can be 
associated with safety, clinical and ethical concerns, em-
phasizing the increased incidence of adverse events associ-
ated with off-label medicines uses in particularly vulnera-
ble patient groups (Gazarian and Kelly, 2006). 
A concerning issue is that the majority of all off-la-
bel uses have limited to no scientific support (Radley et al., 
2006) and a considerable number of prescribers have no or 
limited knowledge about off-label medicine use or do not 
meet regulations regarding off-label use, if they exist. (Pi-
ñeiro Pérez et al., 2014). 
Experience shows that to ensure the quality of off-la-
bel use of medicines, there should be a formal mechanism 
to assess the feasibility, monitoring the safety and efficien-
cy of medication used based on this concept.Thus, in con-
tinuum, the off-label use of medicines has been an essen-
tial part of the ethical and legal considerations as well as, 
many regulatory initiatives. 
The overall objective is to present a model regulatory 
framework setting out guidelines and recommendations for 
quality use of off-label medicines within the national pro-
file of health care policy. 
A literature search was undertaken to identify the is-
sues and challenges related to off-label medicines use in-
cluding clinical, safety and ethical concerns. 
Recommendations for model framework 
Principles of good practice for off-label use of med-
icines should include the following elements: identifying 
the medical needs; compilation of a consensus list of ac-
cepted, scientific based off-label uses; creating an official 
expert group for the evaluation and approval of specific off-
label uses; and, providing a safe and effective supply. The 
main guiding principles and developed activities to sup-
port a responsible decision-making with regard to off-la-
bel medicines include: 1) the medical need- the best avail-
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able treatment in cases of specific characteristics when au-
thorized medicines cannot meet the patients’ need; 2) suf-
ficient scientific basis and/or clinical practice experience 
to justify their action. Distinguish the routine off-label use, 
which is the use of these medicines based on “high qual-
ity” evidence and the use in specific exceptional circum-
stances; 3) information duty and a high degree of respect 
for patient rights, involving the patient/carer in decision-
making process; 4) monitoring and reporting the outcomes, 
efficiency and adverse reactions; 5) considering self-mon-
itoring of prescribing practices, liability and accountabili-
ty. An additional special responsibility which among others 
falls on pharmacists should be to ensure that the prescrib-
er is conscious for off-label prescribing and the reasons for 
that 6) production of compendia of certain medicines, en-
listing those off-label uses judged to be legitimate.7) fi-
nancial sustainability of an off-label use in medical prac-
tice. Before deciding to compound a patient-specific prep-
aration, a step by step evaluation of alternatives should be 
made. These alternatives include a therapeutic alternative, 
dose rounding or manipulation of licensed dosage forms 
(splitting tablets, crushing tablets/opening capsules, dis-
persing their content in water or food, splitting supposito-
ries, the use of a preparation designed for another route of 
administration). 
Conclusion
Prescription, compounding, dispensing and adminis-
tration of off label use of medicines should be regulated 
within the national profile of health care policy.
The regulation regarding the practice of off-label med-
icine use differs between countries. Some countries have 
this practice regulated by law, while in others it is cov-
ered by good practice regulations or general profession-
al recommendations and ethical standards. Assuming that 
there is no any general rule to regulate the “accurate” off-
label use of medicines it is of paramount importance for 
the countries to find a national solution to fulfil the ethical 
and legal demand, especially in the areas of pharmaceuti-
cal law and health insurance law. The common elements of 
these regulatory frameworks are the physicians’ freedom to 
prescribe off-label medicines if the scientific evidence ex-
ists and the need to inform patients when making this deci-
sion. Making policy efforts, by adopting appropriate guide-
lines for off-label medicines use, based on scientific evi-
dence, with specifications of healthcare professionals’ re-
sponsibilities and a registry of off-label drug use in every 
day practice, would make possible a valuable approach to-
wards ensuring a quality use of these medicines. Recom-
mended solutions, as practiced in some countries, would 
support prescribes in more direct and  active approach to 
handle the ethical and legal phenomenon  associated with 
the off-label use of medicines
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Background 
With the independence of the Republic of Macedonia 
(RM) in 1991, in parallel with the transition from planned 
to market economy, the Health System has also under-
gone through phases of transition from centrally planned 
towards market-guided. In 2005 with the amendments of 
the Law on Healthcare (LH), the Primary Healthcare Re-
form started to be intensively implemented, by primary 
health system transformation from Public to Private Sector. 
With this process which is almost entirely completed, all 
community pharmacies in RM have been privatized in the 
course of 2007, hence today, there are a total of 846 orga-
nizational units out of which 714 have concluded contract 
with the Health Insurance Fund of Macedonia (HIFM). 
The Community Pharmacy is the basic unit in the phar-
maceutical sector and it poses a primary level of pharma-
ceutical care. The contemporary community pharmacy prac-
tice in RM is clearly positioned in the Health Care System 
(LMMD, 2007) it acts in accordance with the principles of 
Good Pharmacy Practice (GPP), and it is organized in ac-
cordance with the requirements of the International Quality 
Management Standards ISO 9001:2000, as well as the Envi-
ronment protection standards ISO 14001:2004.  The activi-
ties for implementation of GPP in Community Pharmacy are 
also based on the established standards by the World Health 
Organization (WHO), in regards to the definition of health, 
illness, as well as the role of the pharmacist in the Healthcare 
system (WHO, 2006). In line with all these improvements in 
01.07.2013 the system of e-prescription has been introduced. 
Turnover of medicines in the Private Health 
Institution (PHI) community pharmacy 
The pharmaceutical sector in RM has been regulated, 
in accordance with the Laws on:  1) medicines and medi-
cal devices; 2) Health care; 3) Health Insurance, further on, 
the Decree for Health Institutions Network, a series of  rule-
books and other bylaws (LHP, 2004; LHI, 2010; LMMD, 
2007). The work in the community pharmacies with the 
HIFM is regulated with a special Rulebook referring to the 
way of prescription and dispensing medicines and narcot-
ic drugs (RB, 2010). In regards to the turnover of medi-
cines, the medicines from “the list of medicines for prima-
ry healthcare” which are issued on prescription are provid-
ed through the PHI Community Pharmacies which have con-
cluded contracts with the HIFM. The rulebook for determin-
ing the monthly funds that the PHI Community Pharmacies 
receive from the HIFM for the dispensed medicines on pre-
scription from the abovementioned list funded by the HIFM, 
is in force. With the latest contracts and technical instruc-
tions of HIFM from 2014, electronic communication has 
been established between HIFM and the pharmacies by in-
troducing a system of electronic way of invoicing of the per-
formed healthcare services. The pharmacies which have con-
cluded contracts with the HIFM, submit monthly invoices 
for the dispensed medicines on prescription which are fund-
ed by the HIFM in written and electronic form, together with 
the relevant supporting documentation. From the HIFM data 
on dispensed medicines on prescription, for the period 2013-
2015 the trend of continuous growth in usage of medicines 
in the past years has been evident and this trend continues on 
in the first half of 2015 (HIFM, 2015a). Namely, most of the 
funds (27,5% from the total amount of HIFM) are foreseen 
for the ATC Group C – medicines for the cardiovascular sys-
tem, while on the second place with about 15%, are the med-
icines for the R group i.e., for treatment of illnesses of the re-
spiratory system. The medicines that affect the CNS (ATC 
Group N) are on the third place with a share of 14, 5%. The 
most dispensed medicine according to the number of pre-
scriptions in the first half of 2015 is the medicine enalapril 
with a total of 971.540 dispensed prescriptions.    
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Medicines pricing policy  
Another important aspect from the work of the Com-
munity Pharmacy is the medicines pricing policy. Namely, 
there is a national medicines pricing policy in RM for the 
medicines from the essential medicines list and the medi-
cines from the list of medicines funded by HIFM (positive 
list). In addition, a rulebook has been adopted which deter-
mines the criteria and the procedure for determination of 
the reference prices of the medicines. In 2014, HIFM made 
the fifth in a row annual revision of all the reference prices 
from the positive list and determined new reference pric-
es harmonized with the prices of medicines in the region 
and the new marketing approved process of the medicines 
from the National Agency of medicines and medical devic-
es. The reference prices of medicines are guaranteed for all 
the insured persons.   
As a result of the entire process, the latest data confirm 
that out of the total of 426 registered generic medicines 
from the Primary positive list, around 75% are without 
additional participation from the patients. The total num-
ber of the medicines without participation per nonpropri-
etary name of medicines is still the highest until now and 
in 2014 it was 42% of the total number of dispensed med-
icines on prescription funded by the HIFM. Regarding the 
medicines per INN which are with participation, the larg-
est part (82%) are with minimum participation or without 
participation. From the remaining medicines, 14% are with 
minimum participation and 4% are with maximum one. In 
the first half of 2015 the total increase of the number of 
dispensed prescriptions was around 10% compared to the 
same period of 2014 (HIFM, 2015b). 
 PHI community pharmacy inspection and most 
frequent irregularities detected in the work
The inspection of the PHI Community Pharmacy is 
performed on the bases of: 1) Law on Health Insurance, 2) 
bylaws, and 3) contracts concluded between HIFM and the 
PHI Pharmacies. The inspection is performed in the prem-
ises of the PHI Pharmacies and with a person authorized 
for the finances. Defined representative control sample is at 
least 15 randomly selected medicines. The licensed inspec-
tors from the HIFM and the inspectors from the Pharma-
ceutical Sector have conducted a total number of 852 con-
trols; 98% of the total number of pharmacies which have 
a contract with the HIFM have been controlled in 2014 
(HIFM, 2015b). 
Regarding the noncompliance in the work of a certain 
PHI Pharmacy – working unit according to the Legal reg-
ulations and the Contractual provisions, contractual penal-
ties are foreseen from a measure reprimand to a measure 
one-sided termination of the contract. From the conduct-
ed inspections of the PHI Pharmacies most frequent deter-
mined irregularities in their work are the following: 1) the 
pharmacy does not have one or more medicines on pre-
scription from the generic medicines for which it is obliged 
to have at all times; 2) irregularities for which a measure 
reprimand is issued (if these irregularities are not elimi-
nated within 8 days the pharmacy is subject to contractu-
al penalty); 3) problems with the documentation related to 
the pharmacy or the pharmaceutical staff; 4) irregularities 
in the way the medicines are dispensed; 5) the pharmacy 
does not have internet connection and 6) “other”. Upon the 
concluded noncompliance in the work of the pharmacies 
determined through the inspections, HIFM undertakes ad-
equate measures.  
Pharmaceutical care in community pharmacy  
In order for the pharmacist to successfully perform 
all the duties in the pharmaceutical practice, he/she must 
possess specific knowledge, competencies and skills and 
to continually upgrade them. The findings confirm that the 
pharmacist in a community pharmacy about 80% of his/her 
time devotes only to the process of medicines dispensing, 
while the remaining of the time is focused on giving infor-
mation about the medicines. This data impose the need for 
significant changes in the profile of community pharmacist 
work. In regards to the pharmaceutical services, offered by 
the PHI Pharmacies which have significant importance and 
direct influence on the health state of the patients, as one of 
the strategic goal,  is the continuous increase of the num-
ber of services and their modernization through monitor-
ing of the impressions of the users related to the provid-
ed services. Namely, the community pharmacists active-
ly participate in: promotion of the healthy lifestyle, pro-
viding advice to the patients and consumers and stimulate 
them to look after their health, they organize presentations, 
run health campaigns, etc. From the services offered by the 
PHI community pharmacies one can emphasize: measure-
ment of bodyweight, blood pressure, taking pregnancy test, 
further on, running programs for quitting of smoking, for 
reducing of bodyweight etc. 
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Introduction
Omnes, omnia, omnio. 
(To teach everything, in-depth to everyone)
John Amos Komensky 
Education is the basis for social transformation of hu-
man society. It represents a motivator, in its own right, to-
wards democratization and the development of human so-
ciety. Its effects on economic growth are indisputable, also 
on workforce mobility, as well as on the ability of integrat-
ing into international economic trends.
Current perspective shows that EU countries, and the 
whole world as well, are faced with challenges brought 
on by globalization, issues in demographic trends, and the 
enormous changes in labor market, based on technological 
development. The last challenge underlines the need for a 
society firmly grounded on learning (knowledge-based-so-
ciety), where training and education must come first. “The 
purpose of lifelong learning is to maintain and preserve a 
positive and active approach towards learning at all ages, 
in the course of a lifetime” (MES, 2004).
Education and learning has enabled mankind an ‘easi-
er and more successful placement, not only concerning labor 
market, but also in knowledge in general, in a world of con-
stant engagements’ thereby, irrefutably imposing the neces-
sity of an ‘intervention’ for improving the educational sys-
tem in each country. Knowledge, skills, and attitudes, ac-
quired and developed in surroundings varying from family to 
academia, are not permanent. A firm integration and learning 
in the life of an adult is a very important aspect of lifelong 
learning. From the viewpoint of lifelong learning (LLL), 
learning is defined as an ‘endless continuum’ alongside the 
building of a positive attitude towards learning in general. 
From the standpoint of pharmacy, as a regulated pro-
fession, LLL is of great importance. LLL in pharmacy is 
self-directed and practitioner centered, and it emphasizes 
the importance of practice-based learning. Pharmacists, as 
health professionals, in order to perform their healthcare 
activities with patients, need a license to work, thus they 
are obliged to continuous education. The purpose is to en-
sure that pharmacists maintain and/or enhance their knowl-
edge, skills, and competencies to practice throughout their 
careers in their specific area of practice.
The Republic of Macedonia, as one of the countries 
that signed the Declaration of Bologna, an in the same 
time, a candidate for EU membership, tends to follow ev-
ery European trend, including education. As in other Euro-
pean countries ‘the purpose of educational policy, of each 
one, is to provide the opportunity for a suitable education-
al level for everyone and for all’ (MES, 2004) age groups, 
ensuring that they are in possession of knowledge, skills 
and attitudes, in accordance with the demands of society 
and the labor market, which is at the same time integrated 
into the concept of lifelong learning. The pharmacist of the 
21st century should be in possession of a large amount of 
knowledge, but also personal skills, such as communica-
tion, critical thinking, problem-solving, the ability to work 
in teams and perceive lifelong learning. 
In the time period between 2007 until the end of 2013, 
the leading EU program in the domain of education and 
training is the program called “Lifelong learning|, imple-
mented by the European commission. On national level, 
the national agencies, formed in participant countries, have 
been granted the implementation and running of the pro-
gram. Provided the main goals of strategic documents for 
education and training in R. M. have been analyzed, it is 
noted that their definitions are to a great extent, compati-
ble with the goals of European policies, but also with the 
“Lifelong learning” program 2007 – 2013. 
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The Copenhagen protocol and the initiatives in the 
context of the Bologna protocol have been responsible for 
the beginning and significant progress in support of nation-
al reforms of lifelong learning, higher education modern-
ization, and the development of communal European in-
struments, promoting quality, transparency and mobility 
(European Union, 2009).
The new strategic framework of European collabo-
ration in education and training |Education and training 
2020” has a particular focus on four strategic goals:
1. Making lifelong learning and mobility a reality;
2. Improvement of quality and efficiency of education 
and training;
3. Promoting equality, social cohesion and active cit-
izenship;
4. Strengthening creativity and innovation, including 
entrepreneurship on all levels of education and training  
Making lifelong learning and mobility a reality
Even though in the domain of lifelong learning, there 
can be new initiatives that will develop, reflecting future 
challenges, there is still a need of further improvement, 
particularly in the implementation of ubiquitous lifelong 
learning strategies (European Union, 2009). The need of 
“action” s stressed, through which the development of na-
tional frameworks for qualifications based on relevant edu-
cational gateways will ensure their development, and their 
connection to the European qualification framework, the 
creation of more flexible learning pathways, including bet-
ter passages between different sectors of education and 
training, a more open approach to non-formal and informal 
learning and improved transparency and acknowledgement 
of educational gateways. Further efforts are at the same 
time the need of promoting learning among adults, the 
improvement of quality of guiding systems and learning, 
to make it generally more attractive, and including new 
forms of learning and implementation of new technologies 
of teaching and learning. As an indispensable element of 
lifelong learning, and also an important means raising em-
ployability and adaptability of people is the enlargement of 
mobility of all those learning, and the time periods spent in 
learning abroad, making them more of a rule than an ex-
ception. While at the same time, already established prin-
ciples in the European protocol for quality and mobility 
should be implemented.
European programs for education and training have 
the tendency of promoting education that will strengthen 
the sustainability of economic growth. The ultimate gain is 
effectuating of the process of creating more and better po-
sitions and a better social cohesion, thus leading to a soci-
ety based on knowledge.
At this very point we find the source of the claim that 
strengthening of educational capacities of the Republic of 
Macedonia, is largely conditioned by the use of Europe-
an programs of education and training “Lifelong learning” 
and consequently the new program for education and train-
ing of youth and sports “Erasmus plus 2014 – 2020”. 
Useful links
Competences supporting lifelong learning and the “new skills for 
new jobs” initiative 
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2
010:135:0008:0011:EN:PDF
Towards more knowledge-based policy and practice in education 
and training 
http://ec.europa.eu/education/lifelong-learning-policy/doc/
policy/sec1098_en.pdf
Better integrating lifelong guidance into lifelong learning 
strategies 
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2
008:319:0004:0007:EN:PDF
European Qualifications Framework for lifelong learning
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2
008:111:0001:0007:EN:PDF
Key competences for lifelong learning 
http://europa.eu/eur-lex/lex/LexUriServ/LexUriServ.do?uri=OJ:
L:2006:394:0010:0018:EN:PDF
European Qualifications Framework for lifelong learning - 
Implementing the Community Lisbon Programme
h t t p : / / e u r - l e x . e u r o p a . e u / L e x U r i S e r v / L e x U r i S e r v.
do?uri=COM:2006:0479:FIN:EN:PDF
A new impetus for European cooperation in Vocational Education 
and Training to support the Europe 2020
 http://eur-lex.europa.eu/LexUriServ/LexUriServ.
do?uri=COM:2010:0296:FIN:EN:PDF
Establishment of a European Quality Assurance Reference 
Framework for Vocational Education and Training
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2
009:155:0001:0010:EN:PDF
Establishment of the European Credit system for Vocational 
Education and Training 
h t t p : / / e u r - l e x . e u r o p a . e u / L e x U r i S e r v / L e x U r i S e r v.
do?uri=COM:2008:0180:FIN:EN:PDF
Copenhagen Declaration
http://ec.europa.eu/education/lifelong-learning-policy/doc/
policy/copenhagen_en.pdf
Action programme in the field of lifelong learning (2007-2013)
http://eur-lex.europa.eu/lex/LexUriServ/LexUriServ.do?uri=OJ:
L:2006:327:0045:0068:EN:PDF
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Pharmacists in all practice settings (including com-
munity pharmacy, hospital pharmacy, academia, public 
health pharmacy, managed care pharmacy, clinical labo-
ratory pharmacy, and industrial pharmacy) are confront-
ed with ethical challenges, and those challenges are like-
ly to increase in the future (IPF, 2013). There is not a con-
sistent approach among countries in seeking compliance 
with pharmacist codes of ethics, and the level of pharma-
cists’ professional autonomy, which varies greatly around 
the world, is influenced by many factors, including a coun-
try’s history, social structures, social systems (e.g., eco-
nomic, legal, political, and cultural systems), method of 
health care delivery and financing, and system of pharma-
cy education (FIP, 2002).
Issues of ethical behavior and autonomy are especially 
important to pharmacy practice because the profession is in 
transition, moving from largely a supply function to a pa-
tient-care function. This transition will be impeded if prac-
titioners do not have sufficient autonomy to act in support 
of patients’ best interests. If pharmacy practice were to lim-
it itself strictly to a supply function, various forces - eco-
nomic, technologic, social, and political - would likely co-
alesce over time to replace the pharmacist with other less 
expensive means of safely supplying medicines to patients. 
On the other hand, if pharmacists move toward assuming 
responsibility for helping patients and health profession-
als make the best use of medicines, they will be providing 
a higher value service than a mere supply function - a vi-
tal and complex service that is generally lacking in health 
care today. As pharmacist associations attempt to stimulate 
pharmacy’s professional transition, they should help their 
members understand and address the ethical and moral di-
mensions of this transition. In countries in which the ed-
ucation of pharmacists has prepared them to enlarge their 
role in fostering responsible use of medicines, pharmacy 
practitioners have a moral obligation to put that education 
to its fullest use (FIP, 2002). In countries in which laws re-
quire pharmacists to own community pharmacies, the case 
for preserving those laws will be stronger if pharmacists are 
engaged in professional activities beyond the supply func-
tion and have demonstrated that they are a vital force in im-
proving outcomes from the use of medicines.
The FIP identified the following four categories (with 
specific examples) of ethical issues experienced by phar-
macists in all areas of practice (IPF, 2013):
1. Ethical challenges originating from individual and per-
sonal considerations. 
- Lack of a sense of professional responsibility. 
- Lack of competence. 
- Personal values in conflict with professional val-
ues, including conflicts  that lead to refusal to 
provide service. 
- Stigma (e.g., denying service due to stigma [or in-
convenience] towards illicit drug users or persons 
with disabilities). 
- Lack of awareness of principles of ethics in phar-
macy. 
- Lack of care to apply ethical principles in prac-
tice. 
- Cultural, religious, or national interests in conflict 
with professional ethics. 
- Personal characteristics and traits (e.g., lack of 
moral courage). 
2. Ethical challenges originating from economic consider-
ations, either by limiting costs or by increasing revenues. 
- Managing resources – allocating limited resources. 
- Profitability and viability of business (greed vs. 
reasonable profit). 
- Advertising to promote inappropriate consump-
tion. 
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- Insurance company policies that conflict with pa-
tients’ best interests. 
- Financial incentives offered by industry to sell 
certain products. 
- Workload pressures. 
- Products selected for sale in the pharmacy (e.g., 
tobacco, complementary medicines of unproven 
efficacy or quality, slimming products that don’t 
work). 
- Counterfeit drugs. 
- Conflict of interest in continuing education pre-
sentations. 
- Conflict of interest in publishing research find-
ings. 
3. Ethical challenges originating from human interactions 
(employer-employee or between colleagues). 
- Inter professional conflict. 
- Policy of the owner/employer. 
- Conflicts between the employer and the practitio-
ner’s commitments to engagement with profes-
sional organizations. 
- Reporting colleagues (“whistle-blowing”). 
- Power imbalance and bullying/harassment (and 
subsequent job insecurity). 
- Lack of respect for colleagues. 
- Lack of good role modeling and initiative to teach 
younger practitioners. 
- Patient rights (e.g., privacy/confidentiality) (FIP, 
2004). 
4. Ethical challenges arising from the system or framework 
of practice.
- Barriers imposed by institutional authorities. 
- Restrictions/challenges in adopting new technol-
ogies. 
- Lack of revision (updating) of codes of ethics. 
- Varying interpretations of codes of ethics. 
- Perceptions that codes of ethics are nonbinding. 
- Legislative or regulatory constraints. 
- Paradigm shifts; new scientific knowledge (e.g., 
pharmacogenomics). 
Professional autonomy is the right and privilege grant-
ed by a governmental authority to a class of professionals, 
and to each licensed individual within that profession, to 
exercise independent, expert judgment within a legally de-
fined scope of practice, to provide services in the best in-
terests of the client.
Professional autonomy helps pharmacists fulfill their 
societal mission. That mission, as expressed in FIP’s Cen-
tennial Declaration, is to help patients make responsible 
use of medicines.
Throughout its history, the profession of pharmacy has 
served humanity well around the globe. Although pharma-
cy has great potential for extending its record of service, it 
faces many obstacles in attempting to do so, not the least 
of which are challenges related to professional ethics and 
autonomy. Pharmacy cannot achieve its full potential, and 
patients will not benefit from that potential, unless pharma-
cists are committed to the highest standards of profession-
al conduct and have sufficient autonomy to serve patients’ 
best interests (The Tokyo Declaration, 1997).
In every country, the appropriate association of phar-
macists should produce a Code of Ethics for pharmacists 
setting out their professional obligations and take steps to 
ensure that pharmacists comply with the provisions of that 
Code. The obligations of pharmacists set out in these codes 
should include to act with fairness and equity in the alloca-
tion of any health resources made available to them, to en-
sure that their priorities are the safety, well being and best 
interests of those to whom they provide professional ser-
vices and that they act at all times with integrity in their 
dealings with them, to collaborate with other health pro-
fessionals to ensure that the best possible quality of health-
care is provided both to individuals and the community at 
large (IPF, 2013). 
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In the recent world all human activities are subjected to 
the ethical evaluation. The values of Good and Evil consist 
part of thinking as well as the behaviour of the people, af-
firming and seeking the goodness, criticizing and escaping 
from bad purposes and actions. So is in all kinds of living, in 
the professions (which are almost 20.000) and in the scienc-
es (more then 400), as everyday and special appearances of 
human acts. Professional and scientific ethics are very im-
portant moral issues and visions of the modern civilisation.
Pharmacy is one of the most important and the most 
interest contemporary activity and science. For this, its 
philosophy and ethics are instructive for understanding the 
world and the human orientations (on pharmacy and its 
ethics I wrote in 2008-th in text “Bioethics, the Good Phar-
maceutical Practice, and Protection of Moral Principles”, 
in my book Professional Ethics, 2011, pp. 68-83). Basic 
for the pharmacy is that it (although one of the oldest occu-
pation and one of the very first science) is not one-dimen-
sional, but one of the most complex new science with in-
ter-disciplinary, even more correct with poly-disciplinary 
approach. It is part of medicine, as the most important and 
the most developed recent science and practice for saving 
and improving the human health, but part of biology too, as 
well as of the chemistry, of the economy and the others dif-
ferent kinds of human thought and interests. The pharmacy 
is also defining by its relation to the bioethics, as modern 
and in the same time the most pompous orientation in the 
people’s spiritual and social life, with whom moral aims 
and purposes are treating as model for almighty and par-
ticular human practice in every region and act. So pharma-
cy present oneself as exceptional instructive type of activi-
ty to-day which can to show us on problems and necessery 
values in many districts of human services which reflect to 
the human condition. With that ethics of pharmacy is one 
of the most eminent and the most influential for the new 
(bio)ethical sights and axiological principles.
For understanding the ethics of pharmacy is very con-
siderable its complexity of activities-from definition the 
most difficult tasks before mind and the scientific inquir-
ers, from numberless and capable laboratory examinations 
and improvings of medicines worldwide, from highqual-
ified (offen industrial) performance of medicines, from 
its rigorous (the most frequently international) control for 
employment approval, from very advance organization 
of trade as well as the daily distribution for medical prac-
tice and for individual necessary. Every of this steps of the 
large pharmaceutics activity are not only structure part of 
the medical practice as well as of the medical ethics also, 
they have special meaning and particular professional eth-
ical norms, which compose general ethics of health. Phar-
maceutics stores are indispensable portion for connection 
and realizing of medical treatment with personal aims of 
patients, but also centers for high higienical purposes, dis-
tributors of healthy food, vitamins, and minerals, necessary 
services for small healthy aids etc. 
Every pharmaceutics levels have its very severe ethi-
cal sense and values. Biotechnology and practical pharma-
cy are expanded worldwide. But forfrom the pharmacy are 
not important only its simple and pointed norms. It helps to 
rethink the problems of human existence but also the ethics 
which concern us with the universal visions of human uni-
ty with nature. In this case, in modern pharmacy we sense 
the tracks of classical alchemy, which is not lost for the 
humankind. As was said in Renaissance, we stand on the 
shoulders of countless people who worked of this fields–
and this can not be forget and wipe out. To the ethics of 
pharmacy that give new and very interesting dimensions.
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Introduction
Professions, as one of key sectors of social systems, 
bear a leading role in the existing social work organization. 
Free professions take up a special place and significance, 
all the way from Roman artes liberales to our times.
Pharmaceutical profession, as one of the oldest, led by 
ethical principles, is regulated by postulates accepted by 
the profession members, and in modern times established 
through legislations. Typical determinants of the regulat-
ed professions, which also refer to pharmacists, as cham-
ber members, are as follows: following ethical principles, 
specific skills and knowledge, professional development, 
autonomy at work, continuing improvement, competen-
cies development, professional associations, licensing. Up-
dated legislations in Europe recognize chambers as most 
widespread professional organizations of pharmacists as 
healthcare professionals. Specificities of the field, as well 
as responsibilities in providing healthcare, ask of the phar-
macists to possess optimum level of knowledge, skills, at-
titude, and competency. The need for continuing profes-
sional development is recognized by professional author-
ity, employers, practices, as well as professional associa-
tions, which, through their activities and projects, repre-
sent support to pharmacists’ professional development. 
Tools that allow development and competencies assess-
ment of the pharmacists, are accepted by international as-
sociations (WHO, FIP) and are applied in the South-East 
Europe (Stojkov et al., 2014). 
By analyzing legislations of the countries in the region 
– Serbia, Federation of Bosnia and Herzegovina and Mace-
donia, a mutual platform can be noticed, which emphasiz-
es pharmacists’ professional identity, profession protection 
and care for patients’ interests. It was confirmed through 
the Memorandum on cooperation, signed in Sarajevo in 
2015.
Goals of the paper are to perceive difficulties and pos-
sible solutions when renewing the license for the first time 
and to collect data on pharmacists’ continuing education 
and professional development, their attitudes and prefer-
ences of the fields and types of education, form of organi-
zation, limiting and facilitating factors.
Materials and methods
Data that were used are the ones on the number of 
pharmacists who need to renew their license with Pharma-
ceutical Chamber of Serbia (FKS) in accordance with al-
ready existing legislations, and the number of pharmacist 
who do not fulfill set conditions. The causes and possibility 
of overcoming this problem were also discussed.
A research was conducted on pharmacists’ continu-
ing education and professional development, attitudes and 
preferences of the fields and types of education, form of 
organization, limiting and facilitating factors, structured in 
electronic questionnaire, put up on the FKS website during 
2015. Electronic questionnaire was voluntarily filled in by 
490 pharmacists.
The results were presented in percentages, depend-
ing on the total amount of participants, discussed and com-
pared to relevant literature data on similar conducted re-
search.
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Results and discussion
During 2015, FKS has initiated preparations for phar-
macists’ license renewal. According to the available data, 
from the total of 5500 Chamber members, 2500 pharma-
cists needed to renew their license, after the expiration of 
the first seven-year period. The key condition for work per-
mit -license renewal is the number of points gathered dur-
ing licensed period, acquired through participation in ac-
credited education. Preliminary analysis, which included 
data on pharmacists’ education, pointed out that a signifi-
cant number does not fulfill the required conditions (over 
70%). In order to prevent the difficulties in the unobstruct-
ed professional improvement and work permit renewal, the 
Chamber has launched a legislation modification.
Pharmacists who participated in the poll, primarily 
employed in community pharmacies (93.9%), recognised 
professional competencies as the most needed profession-
al improvement (55.7%), whereas expressed needs for per-
sonal competencies and organization, as well as manage-
ment competencies are significantly lower (26.4%; 17.4%). 
Pharmacists’ familiarity with competencies and compe-
tencies framework, is the result of a project, which last-
ed for several years, on assessment and competencies de-
velopment of pharmacists in Serbia (Stojkov et al., 2014), 
as well as the National document (www.farmkom.rs/index.
php?) enacted by the FKS Assembly. The Chamber, as a 
professional organization, provides continuing education 
of pharmacists, and their areas of interest, so the poll in-
cluded a question on the fields that are of interest to phar-
macists, and the preference was given to safety and effi-
ciency of nutrients in polytherapy (28.7%), as well as spe-
cial populations (children and elderly) and medicine safety 
(27.2%). The participants in the poll have shown high pref-
erence towards the following forms of learning: showcase 
and workshops; and when it comes to study models, the 
internet and interactive workshops were the first choice. 
Day of the week that suits most participants was Saturday 
(49.5%), and the limiting factors were expenses and time 
(34.9%; 51%). The research conducted in Australia (Mari-
ot et al., 2007), stated availability and relevance of the con-
tent as the limiting factors, next to time. Also, more flex-
ible education programmes of education were suggested, 
and they are becoming more significant in Serbia as well 
– digital formats available on the internet are dominant as 
first choice of learning (48.6%). Access to the internet and 
foreign language knowledge were not recognized as rele-
vant limiting factors among the participating pharmacists: 
48.6% and 32.6% of participants respectfully marked these 
factors as least relevant in the sense of limitation. From 
the answers to the question: ”How many continuing ed-
ucations did you participate in last year”, it can be deter-
mined that pharmacists took an active part in their profes-
sional improvement: over 40% took part in 2-5, and 45.3% 
in more than 5 continuing educations. Only 5.1% stated 
that they did not participate.
Conclusion
The road that leads professions of the modern times to-
wards modern formatting is drafted through several stages 
of professionalism: modification of legislation and protec-
tion of professions by means of law, improvement in prac-
tice through professional development, establishing spe-
cial trust relationship between free professions representa-
tives and beneficiaries, providing professional associations 
with wider authorization, and finally cooperation on a re-
gional level. The chambers, as most widespread pharma-
ceutical organizations should provide support to continu-
ing professional development, protection of profession’s 
interests, as well as be important factors in improvement of 
pharmaceutical healthcare.
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Background
Compounding in a hospital pharmacy (HP) setting is a 
comprehensive essential function of the pharmacy practice 
and, also important core element of the provision of health-
care tailored to the needs of an individual patient. In gener-
al, for the purpose of compounding, many unit operations 
and decision making processes are required that, on the one 
hand, more fully define this activity in several ways;  one 
of the simpler definitions is as follows:“The act of prepa-
ration, mixing, assembling, altering, packaging, and label-
ing of a drug, drug-delivery device or device in accordance 
with a licensed practitioner’s prescription, medication or-
der, or initiative based on the practitioner–patient–phar-
macist–compounder relationship in the course of profes-
sional practice (GSP, 2016). As acknowledged, compound-
ed medicines, medicinal products and devices in HP are 
not approved by competent regulatory body thus, the reg-
ulatory approval process for medicines do not verify their 
quality, safety or effectiveness. All these underlining rea-
sons can serve as further evidence of the paramount impor-
tance for establishing contemporary compounding practice 
in HPto comprise not only the art, current scientific princi-
ples, good pharmacy practice, facility, equipment, person-
nel and etc., but also provisions for pharmacists to comply 
with policy, regulations and guidelines in this filed. Addi-
tionally, it is required to put the focus on issues and chal-
lenges related to the implementation of the official stan-
dards for Good Compounding Practice (GCP), if they ex-
ist. In continuum, with the development of the sciences re-
lated to the dosage form formulation and advanced thera-
pies, the position and responsibilities of hospital pharma-
cists (HPs) requires enhancing their knowledge and skills 
in the field of patient centered pharmaceutical care.
Recommendations for implementation of 
standards
It is known that compounding of medicines in HP is 
followed by clinical and technical risks. Therefore, for the 
purpose of risk reduction, guideline or algorithm adopt-
ed on national level to facilitate decision making process 
within this function is strongly recommended.  For exam-
ple, in many cases the HPs should have to verify wheth-
er an equivalent medicine is available on the national mar-
ket or not, and consequently, to consider certain alternative 
therapies including risk evaluation concept. In line with 
this, the HPt, for instance, can suggest usage of a less po-
tent steroid molecule or dosage form instead of dilution 
of certain formulation or in other case, to advice differ-
ent route of drug administration for patient (GMC, 2013). 
When all solutions are exhausted, HPs have to compound 
a dosage form compliant with the best health care needs 
of patient. Additionally, the basic principles of good prac-
tices in compounding demand HPs to comply with nation-
al regulations and with all relevant international standards 
were developed by the World Health Organization (Good 
Manufacturing Practices-GMP Guide), EudraLex and the 
Pharmaceutical Inspection Convention and Pharmaceuti-
cal Inspection Co-operation Scheme (PIC/S-Good Prepa-
ration Practices-GPP Guide) including requirements in rel-
evant Pharmacopeias. To start with, an appropriate quali-
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ty assurance system has to be established with the aim to 
reduce the risks linked with compounding medicinal prod-
ucts- whether it is sterile or non-sterile. Therefore, a risk 
assessment for compounded medical products should al-
ways be carried out in order to define their quality assur-
ance level. According to the references presented in the 
Resolution CM/Res (2011)1 on quality and safety assur-
ance requirements for medicinal products compounded in 
pharmacies for the special needs of patients (Council of 
Europe, 2011), there is a need of establishing a “risk evalu-
ation system” for the  assessment of  “high- risk” and “low- 
risk”  compounded  medicinal products. In this context, it 
is recommended that the GMP guideline has to be used as 
a reference for an appropriate quality assurance for “high 
risk preparations”, while the PIC/S GPP Guide can be used 
for so called, “low-risk preparations”. However, the appli-
cation of other guidelines with an equivalent quality level 
is possible, depending on the national legislation or guid-
ance. According to GMP and GPP guides, there are integral 
elements needed for reducing risk linked with compound-
ing, including: standard operation procedures affirmed by 
quality assurance unit, calibrated equipment, quality con-
trol of starting materials, evaluation of starting materials 
and compounding  process by means of health hazards, 
documented independent check of pharmaceutical calcu-
lations, trained personnel involved etc. To underline as an 
example, the organization of services for total parenteral 
nutrition in many cases is a real challenge for HPs due to 
the unavailability of commercially prepared products. As 
it is known, this service of HP may be followed by risk in 
calculation errors, stability and incompatibility connected 
with product compounding. However, since the aforemen-
tioned GCP guidelines are more general they cannot cover 
in detail all aspects thus, some countries developed addi-
tional national guidelines on compounding adopted by cer-
tain professional bodies (PB, 2015).These guidelines in-
clude both, steps in compounding process and competenc-
es required. Another important compounding aspects relat-
ed to algorithm for decision making process when there is 
a need to choose suitable dosage form for the patient need. 
For example, firstly, it is looking for standardized, validat-
ed dosage form; secondly, if it is not available, then com-
pounding according to scientific principles and practice is 
recommended and thirdly, whenever suitable and possi-
ble, to consider compounding of the simplest pharmaceu-
tical formula (Glass and Haywood, 2006). The next step 
is the process of dosage form evaluation which includes 
several GCP related aspects that must be considered such 
as: ingredients quality, palatability, irritability, toxicity and 
stability; possibility of extensive API metabolism by first 
pass, therapeutic index data and bioavailability; packaging, 
storage, and labeling, assessment for possible interactions 
development between API-excipients-containers, quality 
control, stability, expiration, and beyond-use dating stabil-
ity testing date etc. Additional important steps tailored to 
compounding process in HP environment include: evalua-
tion of toxicity and safety of compounded dosage form and 
monitoring of the clinical effect ad and adverse drug re-
actions etc. When medicines with marketing authorization 
have to be modified to facilitate administration there is a 
benefit for compounding pharmacists to acquire informa-
tion from the manufacturer about: physical and chemical 
data about API, excipients,  critical functional character-
istics of dosage form, possibility for manipulation in order 
to change the dosage form, possibility to obtain API from 
manufacture to compound quality dosage form, relevant 
information about testing and analyzing API on request by 
pharmacist (EMA/CHMP/PEG/194810/2005). 
Conclusion
HPs should maintain at least four sets of records for 
compounding. An existing development requires reference 
library and other sources of information relevant to com-
pounding to be included in the guidelines for GCP. 
As a provider of pharmaceutical care, the HPs have to 
be well educated and trained in the field of art and science 
of pharmacy compounding for creating personalized medi-
cines solutions. In addition to the policy and good practic-
es, further guidelines supporting the creation of safe and 
effective medicines have to be put in place.
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Introduction
Chronic diseases are increasing in global prevalence 
and seriously threaten developing countries. They become 
dominant health burden, with 70-80% of health-care costs 
spent on their management. Chronic diseases are interrelat-
ed, have common risk factors and are largely preventable. 
However, in their prevention, only 3% of health expenses 
are presently invested (Commission of the European Com-
munities, 2007; The Economist Intelligence Unit, 2012). 
Management of chronic diseases has been also pointed as a 
serious concern, with WHO’s statement that approximate-
ly 50% of chronic patients do not adhere to therapy and re-
ports on the economic magnitude of this problem (WHO, 
2003), 194,500 deaths and estimated costs of €125bn annu-
ally in the EU due to miss-dose and non-adherence to pre-
scribed medication (PGEU, 2008). Therefore, a successful 
and sustainable chronic disease management program re-
quires a collaborative approach at the system level, both 
professional-directed and patient-oriented (NEHI, 2009).
The current primary care models implicate that the 
strong physician-patient-pharmacist relationships are not 
promoted; training for chronic disease management is rare-
ly sufficient and there is insufficient continuity and coordi-
nation among health-care providers. Among the healthcare 
professionals, community pharmacists are the most acces-
sible and are in an ideal position to assist the management 
of patients with chronic diseases. However, despite the re-
cent developments in pharmacy practice there still appears 
to be an overall unawareness of their potential within this 
area of health-care system, with “the potential for pharma-
cy being untapped” (Petrushevska-Tozi and Mladenovska, 
2012; WHO, 2011). Therefore, WHO has been called phar-
macies upon to engage further in health promotion, chron-
ic disease prevention and rational use of medicines, specif-
ically by supporting people with chronic conditions, im-
proving their quality of life and self-management, support-
ing better knowledge about pharmacotherapy, etc (WHO, 
2011). However, in order to take up the challenge, it would 
be necessary to examine what have already been done in 
chronic disease management by community pharmacists in 
the Republic of Macedonia, from both patients and health-
care providers perspectives, which was the aim of this 
study. 
Materials and methods
For the patients and health-care providers, two sepa-
rate cross-sectional descriptive questionnaires were de-
signed, where combined pre-coded open ended and mul-
tiple choice closed questions were used with type of re-
sponse format A-agree, B-partly agree, C- disagree, cov-
ering two essential components: need of providing patient 
education by a pharmacist to prevent chronic diseases and 
disability by promoting healthy life-style and need of ex-
panding pharmacy services and interventions in chronic 
disease management. The questionnaires were pre-tested 
by involving the target groups in the design (10 commu-
nity pharmacists (PHs) from different pharmacies, 10 gen-
eral practitioners (GPs), 10 specialists in internal medicine 
(SPs) and 10 patients (PTs), to evaluate the apparent (log-
ical) validity of the questionnaires (instructions, coverage 
of the issue of research, format and questions sequences, 
legibility and readability, too much/little offered answers, 
measurability of the questions, time for completing, etc.). 
The average age (±SD) of the health-care professionals 
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was 47.3 ±10.5 yrs, of which 76.7% were females. Related 
to the profile of patient group, the average age (±SD) was 
67±9 yrs, with most of them females (80%) and 60% hav-
ing university degree diploma. 
The responses were collected face-to-face in the GPs’ 
and SPs’offices and community pharmacies, from Janu-
ary 3rd to February 28th, 2016, with the surveyors being 
pharmacists. Only 10% of the respondents stated that some 
of the questions were unclear and these items will be fur-
ther reconsidered when generating direct anonymous final 
questionnaire. 
Obtained data were tabulated using Microsoft Excel® 
(Microsoft Corp. Redmond, WA, USA), computed and 
consequently evaluated using statistical software STAT-
GRAPHICS Centurion XVI evaluation (Stat Point tech-
nologies Inc., USA). 
Results and discussion
Unlike GPs, who think that patients are either well- or 
partly educated about the chronic diseases, their preven-
tion and management (30% and 70%, respectively), 20% 
and 40% of the PTs, 20% and 70% of the SPs, and 50% and 
50% of the PHs believe that patients are not properly or 
partly educated, respectively, pointing to the necessity of 
pharmacists to use their competences and skills in educat-
ing patients about prevention and management of chronic 
disease. This necessity was approved by 60% of the PHs 
and SPs, while 40% of them it partly approved. Interest-
ingly, 30% of GPs were not agreed with this statement, un-
like 100% of PTs, who expect best pharmacy practice and 
care in this area. In this respect, 100% of PHs and 90% of 
PTs are agreed that engagement of pharmacists in chronic 
disease management would improve patients’ use of med-
icines and adherence and their understanding about the 
chronic diseases they have. However, only 20% of the GPs 
and 40% of the SPs think that CPs can improve patients’ 
use of medicines, pointing that the pharmacists cannot im-
prove patients’ understanding about their chronic disease. 
Within the chronic diseases management, engage-
ment of pharmacists in education of chronic patients for 
using medical devices for drug administration or therapeu-
tic monitoring was also evaluated. The most of responders 
were agreed that this activity contributes to efficacious dis-
eases management by a patient itself and improve outcome 
of the treatment. Only 20% of the PHs and 30% of the GPs 
were not agreed with one or both of these statements, un-
like PTs, who were all agreed. Considering engagement of 
the community pharmacists in disease/therapeutic moni-
toring, 70% of PHs, 60% of GPs, 50% of SPs and 100% of 
PTs acknowledge the need of these additional services. In-
terestingly, 20% of PHs are not interested and 10% of GPs 
and SPs think the same. 
Interest and willingness of pharmacists to be engaged 
in education, care and control of patients with chronic dis-
eases were also a matter of interest. For 90% of PHs, 60% 
of GPs and 100% of SPs, pharmacy structure was identi-
fied as a key factor/barrier. All health care responders were 
consent that it is necessary to determine the resources and 
content for education and training of pharmacists in man-
aging chronic diseases and to implement and develop mu-
tual cooperation between pharmacists and physicians for a 
better control of chronic diseases. 
Conclusion
From the processed answers one can conclude that the 
role of community pharmacists in chronic disease manage-
ment is indisputable. Further thorough research is needed 
to identify the key areas for intervention for medication 
adherence to be improved, pharmacy services to be intro-
duced or their scope expanded, interprofessional collabora-
tion to be strengthened, and education and training of phar-
macists in managing chronic diseases to be implemented. 
In addition, a strategy for all stakeholders should be de-
veloped, in order awareness and understanding of the role 
of pharmacists in providing pharmaceutical care and addi-
tional services in patients with chronic diseases to be in-
creased.
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Introduction
Responsible self-medication with over-the counter 
(OTC) drugs assumes that individuals treat minor ailments 
and conditions with medicines approved by national regu-
latory agencies and are available without prescription, safe 
and effective when used as directed (Bakic-Miric, 2009; 
Cavaco and Pereira, 2012). Literature data indicate that 
self medication is prevalent form of medical care in the 
world, with estimation that 80% of all medical symptoms 
are self-recognized and self-treated without professional 
care where more than 92% of all consumers used at least 
one OTC drug in the past year, and 55% of which have 
used more than one (Wertheimer and Serradell, 2008). 
Community pharmacists working on the frontline 
of health-care system are primary and easiest accessible 
source of professional information for OTC drugs as most 
commonly they are supplied in community pharmacies, al-
though in some countries there are OTC drugs that can be 
sold elsewhere. Community pharmacists - OTC consum-
ers interface is of substantial importance for ensuring prop-
er and safe OTC drug use as community pharmacists have 
more experience with self-care products than any other 
health care professional (Gazibara et al., 2013).
The aim of the present study was to investigate com-
munity pharmacists’ attitudes, perceptions, practice and 
perceived barriers/obstacles in ensuring the proper phar-
maceutical care with OTC medicines in the community 
pharmacies in Republic of Macedonia (RM).
Materials and methods
Educational course entitled “The role of pharmacist in 
self-care and self medication” was conducted by pharma-
ceutical company Alkaloid AD, Skopje in a two months 
period, February to March, 2014. Participant of this course 
were mainly community pharmacists and minority of phar-
macy technicians, from different regions in RM. Survey 
was completed by 465 participants of the course.
For the purpose of this survey, a structured anonymous 
questionary was used. The questionnaire included 26 items 
related to the community pharmacists` attitudes and per-
ceptions in everyday practice with OTC drugs as well as 
obstacles in ensuring the proper pharmaceutical care. 
The anonymous questionnaire covers data related to: 
i) socio-demographic factors (city, age, gender, work ex-
perience in the pharmacy), location and workforce in the 
community pharmacy and average number of patients and 
prescriptions per week; ii) attitudes (job satisfaction, im-
portance of OTC counseling in everyday practice, willing-
ness to provide OTC recommendations) and iii) probable 
barriers (lack of time, lack of trainings, continuing educa-
tion courses, etc.) 
Obtained data were tabulated using Microsoft Excel® 
(Microsoft Corp. Redmond, WA, USA) and were comput-
ed and consequently evaluated using statistical software 
STATGRAPHICS Centurion XVI evaluation (StatPoint 
technologies Inc., USA).
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Results and discussion
A vast majority of the surveyed participants were grad-
uated pharmacists (89.2%) while pharmacy technicians with 
5.4% were significant minority. The rest 5.4% did not pro-
vide information about educational attainment. All regions 
in RM were represented, with prevalence of the capital, 
Skopje, with 28.9% followed by Pelagonija Region (Bitola, 
Prilep, Resen) with 16.1%, South-Eastern Region (Gevgeli-
ja, Bodanci, Dojran, Radovis, Strumica, Valdandovo) with 
12.3%, South-Western Region (Debar, Kicevo, Ohrid, Stru-
ga, Vevcani) with 10.6%, Polog Region (Gostivar, Tetovo) 
with 9.7%, Eastern Region (Stip, Kocani, Berovo, Delce-
vo, M.Kamenica, Vinica) with 9%, Vardar Region (Veles, 
Kavadarci, Sv. Nikole, Negotino) with 7.3% and North-
Eastern Region (Kratovo, Kumanovo) with 5.9%. Female 
gender was represented with 90.5%. The dominant cohort 
(52.3%) was in age group of 23 – 35 years. The average 
community pharmacy experience was 11.88±9.28 years. 
Nearly 42% were community pharmacy owners. Most of 
the surveyed pharmacists (53.12%) reported that communi-
ty pharmacy they work in, has more than 2000 prescriptions 
and 29.03% reported 1000-2000 prescriptions dispensed per 
month. Overall job satisfaction was rated on a scale of 1 to 
5 where 1 refers to highest and 5 to lowest satisfaction. The 
determined average satisfaction was 2.24±1.2 with mode of 
1 in 30.32% and only 4.1% were not satisfied by their job as 
community pharmacists. The highest percentage of respon-
dents (28.8%) reported counseling patients on OTC medi-
cations 16-20% of their working time, which equates to the 
approximately 75 to 90 minutes during an eight hour shift. 
Slightly over 50% of the respondents reported that they 
were educated for OTC drugs during their undergraduated 
studies, however still high percentage - 46.67% were not. 
Approximately one third of the surveyed community phar-
macists always advice patients for OTC drugs use while the 
majority (60.43%) frequently does that.
Solely, continuing education courses were source of 
OTC drugs knowledge for 29.89% of surveyed partici-
pants, working experience (practice) for 26.67%, under-
graduated studies for 5.81% and pharmaceutical compa-
nies for 4.73%. Combined, continuing education cours-
es/practice was reported by 17.85% and undergraduated 
studies/practice by 7.96% of the respondents as OTC drug 
knowledge source. More than a half (57.2%) of the sur-
veyed pharmacist agreed that OTC drug counseling is im-
portant component of community pharmacy practice, while 
42.6% strongly agreed with this statement. Nearly equal 
percent responded that they have enough time for OTC 
drugs counseling (41.94%) and opposite (not enough time 
- 42.79%). A majority (80%) agreed that patients accept 
their advices in respect to OTC drugs selection. Almost 
equally either agree or strongly agree (app. 50% each) that 
they are willing to provide OTC recommendations when 
given the opportunity. Confidence in own competentiali-
ty (knowledge) related to adequate OTC drugs selection 
was expressed by 65.6% of the respondents. Participants 
were asked to rank their knowledge about certain OTC 
drugs classes, where 1 referred to highest and 7 to low-
est rank. The highest scores were determined for cough/
cold OTC drugs 1.89±1.31 and pain/analgesics OTC drugs 
1.96±1.34, while the lowest scores were related to eye/ear 
and first aid OTC drugs, 5.16±2 and 4.82±2.24 according-
ly. The results were comparable with the ranking related 
to the patients’ demands for classes of OTC drugs coun-
seling (rank of 1 indicated most frequently and 7 - least 
frequently). Advices for cough/cold OTC drugs were re-
quested in average of 1.71±1.12 and pain/analgesics OTC 
drugs, in average of 1.95±1.35 with a mode of 1, 52.9% 
and 39.35% respectively. Patients` demands for first aid 
and eye/ear OTC drugs counseling were lowest with aver-
age of 5.45±1.96 and 5.35±1.8 consequently.
Respondents agreed (52.7%) and strongly agreed 
(44.52%) that patient counseling positively influence com-
munity pharmacy practice. Most frequently (63.87%) ques-
tions and advices for OTC drugs are initiated by the commu-
nity pharmacists, while 27.3% are instigated by the patients. 
Majority of the surveyed participants, 61.94%, were 
interested for input into OTC drug counseling while 
33.98% articulated high interest.
Participants were asked to rank six quoted barriers/
obstacles that might influence proper pharmaceutical care 
with OTC medicines in the community pharmacies. Rank 
of 1 referred to the most significant and 6 to least signif-
icant barrier/obstacle.  Lack of time and personal scarci-
ty with average of 1.55±1.22 and 2.78±1.57 respectively, 
were identified as the most significant barriers/obstacles. 
Conclusion
Outcomes from the conducted survey provided an in-
sight to the main attitudes, willingness, barriers/obstacles 
and educational requirements of pharmacists in Republic 
of Macedonia related to self-medication with OTC drugs. 
The results obtained are valuable for the pharmaceutical 
community and can be used in order to improve and ad-
vance community pharmacy practice by further promoting 
the pharmacist’s role in self-care.
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Introduction
Providing optimum public health care are the main 
goals of a health system that requires integration of hu-
man resources at all levels. Therefore, any low esteem or 
dissatisfaction conceived by any of the key components of 
the service chain may relatively threaten the comprehen-
sive health care. Pharmacists as the key players in this mul-
tidisciplinary sector are no exception to this rule. In Ban-
gladesh a study was conducted to identify the factors af-
fecting employee job satisfaction of pharmaceutical sec-
tor (Parvin and Kabir, 2011). Given the noticeable lack of 
studies involving management styles with the job satisfac-
tion of pharmacists this study attempts to address the gap 
in the literature. In 2007 Jovic-Vranes A. et al. found that 
job satisfaction was associated with good interpersonal re-
lationships, working environments and a feeling of being 
able to provide good quality care. Other studies opine that 
there is a strong association between low levels of job sat-
isfaction and organizational factors (Piko et al., 2006). A 
study by Krogstad U. et al. 2006, reflected that support and 
feedback from one’s immediate supervisor was the main 
explanatory variable for job satisfaction among nurses. Bu-
ciuniene et al. 2003, concluded that low salaries result in 
low job satisfaction among Lithuanian primary health care 
doctors. Rad, Yarmohammadian, 2006 and De Stefano et 
al. 2005, exerted that the greater the chances for develop-
ment within the organization, the greater the likelihood of a 
higher level of job satisfaction. The results of Bodur, 2001, 
study showed low levels of job satisfaction mainly due to 
working conditions and salary. A significant relationship 
between job satisfaction and management style was exhib-
ited in a master’s’ thesis by Nakata, 1992. 
The research questions of the present study are: 
1. What are the management styles (MS) of first-
line managers as perceived by staff pharma-
cists (SP) in the marketing strategy depart-
ments in selected pharmaceutical companies? 
2. What are the management styles (MS) of first-
line managers desired by staff pharmacists (SP) 
in the marketing strategy departments in select-
ed pharmaceutical companies? 
3. Is there a relationship between the perceived 
management style (MS) of first-line managers 
and the job satisfaction (JS) of staff pharma-
cists (SP)?  
The purpose of this study is to determine the SP’s per-
ception on MS and its relationship to their JS working in 
MSDs in reputed pharmaceutical companies of Bangla-
desh. This study also investigates the MS that SPs desire in 
their organizations. The broader purpose of the study is to 
provide information that might assist pharmaceutical com-
panies in providing the best working environment for phar-
macists’ job satisfaction, efficiency and retention.
Materials and methods
The conceptual framework for this cross-sectional 
study design is based on Likert management theory which 
describes a continuum of four types of management styles 
and the adaptations of Maslow’s hierarchy of needs. Per-
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ceived and desired management styles (independent vari-
ables) were measured by the Profile of Organizational 
Characteristics, Form SLM-1978 by Rensis Likert Asso-
ciates, Inc. with response choices from l to 4. Each ques-
tion requires two responses, one that describes the manage-
ment style on the participant’s working unit at the present 
time and one that describes how the subject would like the 
management style on the working unit to operate. Job sat-
isfaction (dependent variable) was measured by a job sat-
isfaction tool based on a tool developed by Munson and 
Heda (1974) which is based on the conceptualization of 
Maslow’s hierarchy of needs. The subscales measure: au-
thoritative satisfaction, interpersonal satisfaction (belong-
ing), involvement needs (ego needs), training/other facili-
ties satisfaction, workload satisfaction and satisfaction re-
garding payment/promotion. Additionally, demographic 
data, such as educational level, age range were collected. 
So, there were three types of interview questionnaires used 
for this study: Questionnaire A- written in English, con-
sisting of 19 questions regarding job satisfaction among 
the pharmacists, Questionnaire B- written in English, con-
sisting of 10 questions, each of them having 2 parts, one 
was for the perceived management style and the other for 
desired management style, Questionnaire C-7 items elicit-
ed socio-demographic data including the respondents’ age, 
gender, level of education.  A sample of 384 individuals 
was randomly selected from 10 pre-selected pharmaceu-
tical companies which belong to top 20 companies of the 
country. Data was gathered through face-to face interviews 
with individual respondents between July and October, 
2015 and it was analyzed with the program SPSS v22.0.
Results and discussion
Among the respondents 63.6% were male and 36.4% 
female. The data indicated that the SP currently perceive 
an overall benevolent-authoritative style of management 
on their units represented by an overall mean score of 4.66 
which reflects less fear and punishment than in the exploit-
ative-authoritative style but does not use staff involvement. 
The SP desired an MS approaching the participative group 
style with an overall mean score of 7.2 which expresses 
the necessity of a style that uses ideas solicited from the 
staff and asks for the staff’s opinions on matters that af-
fect their work.
The JS subscale with the highest mean score was in-
terpersonal satisfaction (4.27) which is associated with the 
concept of belonging and warmth in relationships at their 
workplace. The JS subscale score having the lowest mean 
was payment (3.42, where 3=Disagree slightly) which con-
veys that SP were in general less satisfied with the income 
and opportunities and scope for promotion in their jobs.
Null hypothesis H0: There is no relationship between 
perceived management style and job satisfaction. Alter-
nate hypothesis Ha: There is significant relationship be-
tween perceived management style and job satisfaction. 
The Pearson Product-Moment Correlation score for these 
two variables was r=0.436 (p=0.00000000000876) which 
convincingly rejects the null hypothesis and is further in-
tensified by Spearman rank correlation and Kendall rank 
correlation coefficient ρ = 0.317 (P = 0.0000000156) and τ 
= 0.239 (P = 0.0000000159) respectively.
Conclusion
The strong correlation between management style and 
job satisfaction emphasizes the need to intervene with an 
appropriate organization-specific MS (i.e. participative 
group style) to promote JS among pharmacists.
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Introduction
Acne vulgaris is a common chronic skin disease affect-
ing ∼85% of adolescents and young adults, although all age 
groups could be affected. Active pharmaceutical ingredi-
ents (API) and commercial dosage forms that are common-
ly used for acne treatment are characterized by lack of effi-
cacy and number of side and adverse effects mainly relat-
ed to the inability for targeted and controlled drug delivery. 
Currently, there is extensive ongoing research for finding 
alternative approaches for acne treatment.  Topical appli-
cation of propolis (natural bioactive compound) has shown 
notable efficacy against microorganisms etiologically con-
nected with acne. However, often propolis extracts due to 
distinctive color, strong and aromatic odor and stickiness 
fail to ensure patient compliance. One approach that might 
be used for improvement of acne treatment efficacy and 
patient compliance is to incorporate API into drug delivery 
carriers (micro/nanoparticulated) thus enabling controlled 
drug release at the site of action. Having in mind previ-
ous, our group is working on development of porous mic-
roparticulated systems (microsponges) for topical delivery 
of propolis with certain physico-chemical and biopharma-
ceutical properties favoring prolonged release, enhanced 
efficacy and patient compliance in acne treatment. In the 
previous work of Dodov et al. (2016) microsponges load-
ed with 20% propolis ethanolic propylene glycolic extract 
were formulated. The current work is addressed to formu-
lation and characterization of microsponges prepared with 
25% propolis ethanolic extract using two different hydro-
philic surfactants.  
Materials and methods
Materials
Ethylcellulose (EC) and Chitosan (CTS) (high vis-
cous) were purchased from Sigma- Aldrich, USA. Tween 
80 (T80), Tween 20 (T20), Span 80 (S80), Aceton (ACT), 
and Dichlormethane (DM) were obtained from Merck, 
Germany. Propolis ethanolic extract (PE) (25%) was sup-
plied from Apimel, Macedonia. All other chemicals and re-
agents were of analytical grade and used without any mod-
ifications.
Preparation of microsponges loaded with propolis extract 
The PE loaded microsponges (MPL) were prepared 
using previously optimized double emulsion solvent dif-
fusion technique (Crcarevska et al., 2015; Dodov et al., 
2016). This method involves preparation of a primary W/O 
emulsion, and a subsequent second emulsification result-
ing in a W/O/W multiple emulsion. The primary W/O sys-
tem was prepared by continuous dropwise addition of in-
ternal water phase (CTS (0.8% (m/v) in 3% acetic acid 
(v/v)), water (W1) and ACT) to oil phase (EC, S80, DHM 
and PE) during a period of 4 min under continuous ro-
tor–stator homogenization (Ultra-Turrax1 T-25, Dispers-
ing element S25N-10G, IKA, Germany, 24000 rpm, ambi-
ent conditions). After the addition of internal water phase 
was completed, mixing was continued for additional 1 min. 
Multiple W/O/W emulsion was prepared by dropwise ad-
dition of primary W/O emulsion to outer water phase (wa-
ter (W2) and T80 or T20 as surfactant), for time period 
of 10 minutes at the same conditions as for W/O prima-
ry emulsion.
The removal of ACT, DHM, ethanol and the solidifica-
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tion of MPLs was finalized under continuous mixing (24000 
rpm, 40 °C, 30 min). The resulting MPL dispersion was 
cooled down to room temperature under magnetic stirring 
(200 rpm, 20 min, Variomag, Multipoint HP 15, Germany). 
Composition of the prepared formulations was as fol-
lows: CTS (0.8%):W1:ACT (ml) = 1:0.67:5, S80/EC=0.33, 
T20/W2 or T80/W2 = 0.015. S80/DHM:PE/EC was 
0.0039:0.5 (MPL1), 0.004:1 (MPL2), 0.0043:2 (MPL3) 
and 0.005:4 (MPL4). A total of 8 formulations were pre-
pared. 4 formulations were prepared with T20 (MPL-T20) 
and 4 with T80 (MPL-T80) as hydrophilic surfactant.
Nonencapsulated PE was separated and prepared 
MPLs were freeze dried (Freeze-dryer, Labconco, USA, 
0,05 mBar, - 49 °C, 24h) in presence of  cryoprotecting 
agent (20% trehalose/g EC)
MPLs characterization
Characterisation of particle size and particle size 
distribution of MPLs was done by laser diffractometry 
(Crcarevska et al., 2015). Particle size was expressed in 
micrometers (µm) by volume diameter Dv50±SD, while 
particle size distribution was expressed in term of SPAN 
factor±SD.
The non-encapsulated fraction of PE was separated 
from the MPLs, and the propolis content (PC) was deter-
mined according to procedure described by Dodov et al. 
(2016). PC was expressed as dry PE (g)/EC (g)±SD.
MPL`s in vitro release studies were performed by non-
membranic dissolution model (Dodov et al., 2016). In brief, 
accurately weighted amounts of freeze-dried MPLs with 
known and equal content of PE (0.002 g dry PE/ ml) were 
placed in closed glass tubes on thermostat water-bath hor-
izontal shaker (4h, 32 °C, 40 rpm, (Unitronic OR, Selecta, 
Barcelona, Spain)). In appropriate time intervals the sam-
ples were centrifuged (4000 rpm, 5 min) (Tehtnika Centric 
322B, Slovenia) and 8 ml of the total volume of superna-
tants were collected. This volume was replaced with 8 ml 
of distilled water (32 °C) and dissolution studies continued.
Drug release data were fitted into zero order, Higuchi, 
Korsmeyer-Peppas and Peppas and Sahlin model (DD-
Solver 1.0 - Microsoft Excel menu-driven add-in program).
Results and discussion
Dv50 for formulations prepared with T20 as hy-
drophilic surfactant was 26.67±2.15 µm (MPL1-T20), 
34.79±6.46 µm (MPL2-T20), 89.72±5.64 µm (MPL3-T20) 
and 157.05±31.86 µm (MPL4-T20), while for those pre-
pared with T80, Dv50 was 31.56±1.19 µm (MPL1-T80), 
75.56±1.02 µm (MPL2-T80), 96.15±4.01 µm (MPL3-
T80) and 475.47±17.24 µm (MPL4-T80). Particle size 
for freeze dried MPLs was 9.14±0.27 µm (MPL1-T20), 
20.41±0.87 µm (MPL2-T20), 36.25±1.89 µm (MPL3-
T20), 117.68±4.19 µm (MPL4-T20), 25.26±0.0.66 µm 
(MPL1-T80), 22.87±1.35 µm (MPL2-T80), 33.50±3.32 µm 
(MPL3-T80) and 117.09±11.51 µm (MPL4-T80). Obtained 
results pointed that particle size increased with increment 
of PE/EC. When particle size of freeze dried MPLs was 
compared significant difference was determined in MPL1-
T20/MPL1-T80 (one way ANOVA, Fischer LSD, p<0.05).
PC expressed as dry PE (g)/EC (g) was 0.37±0.07 in 
MPL1-T20, 0.74±0.02 in MPL2-T20, 1.47±0.04 in MPL3-
T20 and 2.93±0.1 at MPL4-T20, while in MPLs prepared 
with T80 as hydrophilic surfactant it was 0.33±0.05 in 
MPL1-T80, 0.73±0.12 in MPL2-T80, 1.41±0.22 in MPL3-
T80 and 3.35±0.23 in MPL4-T80. It can be concluded that 
increment of PE/EC resulted with increased PC most likely 
due to the higher amount of PE available for encapsulation 
into MPLs. Significant difference was observed among 
all samples except MPL1-T20/MPL1-T80, MPL2-T20/
MPL2-T80 and MPL3-T20/MPL3-T80 (one way ANOVA, 
Fisher’s LSD, p<0.05). 
Dissolution studies pointed that release of PE from 
MPLs was continued for 3-4 hours, indicating prolonged 
release compared to PE alone (immediately dissolved). 
Dissolution profile comparison using pairwise procedure - 
f2 similarity factor, resulted with f2 values >50 in all tested 
formulations except MPL1-T20/MPL1-T80. It can be an-
ticipated that lack of similarity is most likely related to the 
difference in their particle size.
Drug release data best fitted to model of Peppas and 
Sahlin, a model accounted for the coupled effects of Ficki-
an diffusion and case II transport. However, a negative K1 
value indicated insignificant effect of Fickian diffusion on 
drug release.
Conclusion
MPLs loaded with 25% PE were prepared by dou-
ble emulsion solvent diffusion technique. Influence of the 
amount of used propolis (PE/EC= 0.5, 1, 2 and 4) and type 
of hydrophilic surfactants (T20 and T80) on MPLs prop-
erties was evaluated. By subsequent incorporation of pre-
pared MPLs into gel system additional prolongation of PE 
release could be achieved, thus resulting with a topical dos-
age form with appropriate controlled released properties in 
favor of efficient acne treatment. 
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Introduction
St. John’s Wort Oil (Hyperici Oleum) is a traditional 
herbal preparation which is prepared by fatty oil macera-
tion of the flowering aerial parts of Hypericum perforatum 
Linn. (fam.Hypericaceae) in sunlight for several weeks 
(EMEA/HMPC/101303/2008). It is used mainly external-
ly for the treatment of wounds, especially burn wounds, 
bruises and swellings. Internally, it is used to treat dyspep-
sia (Kovar and Maisenbacher, 1992). 
In the Ph. Eur. official are St John’s Wort (Hyperici 
herba) and St. John’s Wort dry extract, quantified (Hyperici 
herba extractum siccum), but not St. John’s Wort Oil (Hy-
perici oleum) (Anyżewska et al., 2010). St. John’s Wort 
Oil (Hyperici Oleum) is official according to the German 
Commission E and Swiss Pharmacopoeia. These pharma-
copoeias suggest spectrophotometric determination where 
hypericin content is expressed as sum of all derivatives 
of hypericin like hypericin, pseudohypericin, protohyper-
icin and isohypericin (Anyżewska et al., 2010, EMEA/
HMPC/101303/2008).
Hypericin which is naphtodiantrone, has specific pro-
tonation and deprotonation behavior. The protonation be-
havior of carbonyl groups is assigned to the pKa= -6, depro-
tonation of OH groups in position 3 and 4 to the pKa= 2 and 
second deprotonation assigned to the pKa= 9, which gener-
ates diphenolate ion by ionization of one of the OH groups 
in position 1, 6, 8 or 13. This indicates that hypericin is pres-
ent as an anion under most circumstances due to its rather 
low pKa value of 2 (Wirz, 2000). Specific conditioning of 
Solid Phase Extraction (SPE) cartridges is crucial since it 
positively charges the stationary surface with which bond-
ing of hypericin is enabled and separation from the vegeta-
ble oil is possible, which is one of the main challenges. 
The aim of this study is to develop HPLC method for 
quantitative determination of hypericin in St John’s Wort 
oil using solid phase extraction as sample preparation 
method and compare it to the official spectrophotometric 
pharmacopoeial method. 
Materials and methods
Plant material: Aerial flowering parts of wild H. per-
foratum populations were collected from locality Stracin, 
R. Macedonia. 
Preparation of Hyperici Oleum: Herbal drug (crushed, 
fresh flowers and dry upper aerial part) and vegetable oil 
(sunflower oil) ratio was 1:4. The transparent glass jars 
containing the herbal drug and vegetable oil were left at 
sunny place for 6 weeks. Afterwards the herbal drug was 
pressed out and oil extracts were collected in dark, cylin-
drical flasks (EMEA/HMPC/101303/2008). 
Primary reference standard hypericin was purchased 
from HWi Analytik GmbH, Rülzheim, Germany with 
89.73% purity. Methanolic solution of the standard (0.006 
mg/mL) was prepared (Hm). Solution of hypericin stan-
dard in sunflower oil (0.006 mg/mL) was prepared (Ho). 
For SPE, n-hexane dilution of Ho was done (H1=0.006 
mg/mL and H2=0.003 mg/mL). 
2 mL of each, commercial St. John’s Wort oil (B1) or 
St. John’s Wort oil (crushed fresh flowers in sunflower oil) 
(B2) were diluted to 10 mL with n-hexane. For the spiked 
sample (B3), 1 ml Ho and 1 ml B1 were diluted to 5 mL 
with n-hexane. 
Sample preparation was done using solid-phase ami-
nopropylsilica extraction cartridges (Sep-Pak®, 6cc, 500 
mg sorbent), which were conditioned sequentially with 10 
mL each of 0.01 N NaOH, methanol, acetone and n-hex-
ane (Kovar and Maisenbacher, 1992). Samples were load-
ed on SPE-NH2 cartridges using vacuum manifold and 
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then the cartridge bed was rinsed with 12 mL of n-hex-
ane. Elution was done with 4 mL 5 % (m/V) oxalic acid 
in acetone:methanol (1:1 V/V) (Eoa) or with mobile phase 
(Emp). For HPLC analysis the following eluates were ob-
tained: EmpH1, EmpH2, EmpB1, EoaB1, EmpB2, EoaB2, 
EmpB3 and EoaB3.
The chromatographic analyses were carried out using 
Agilent 1200 HPLC equipped with DAD G1315D, quater-
nary pump G1311A, column thermostat G1316A and ther-
mostatted autosampler G1329A. Separation was achieved 
using Agilent ZORBAX SB-C18 column (4.6 x 250 mm, 
5 μm). The isocratic mobile phase at a flow 1 mL/min con-
sisted of 78 mL ethyl acetate, 82 mL sodium dihydrogen 
phosphate solution adjusted to pH 2 with phosphoric acid 
and 360 mL methanol. Injection volume was 20 μL and the 
wavelength of detection was 590 nm. The separation was 
performed at 40˚C (Monograph of St. John’s Wort dry ex-
tract; Ph. Eur.8).
For spectrophotometric measurements a Perkin- Elmer 
UV/ VIS spectrophotometer Lambda 16 was used. 
Results and discussion
With SPE procedure, the vegetable oil was successful-
ly separated and the phytocomponents were clearly eluated 
into the eluates, with characteristic red colour.
With HPLC analysis of EmpH1, EmpH2, EmpB3 and 
EoaB3 eluates a peak of hypericin was identified, with Rt 
and UV/ VIS spectrum corresponding to the results ob-
tained by HPLC analysis of the methanolic solution of the 
hypericin standard (Hm). Relative peak intensity of the tar-
get component- hypericin was higher in Emp eluates com-
pared to Eoa eluates. By analysis of EmpH1, EmpH2, 
EmpB3 and EoaB3 satisfactory selectivity of the SPE pro-
cedure and HPLC method for hypericin were proven. 
HPLC analysis of EmpB1, EoaB1, EmpB2, EoaB2 did 
not reveal any peak corresponding to hypericin, suggesting 
that target component may not be present in form of hyper-
icin in St. John’s Wort Oil. 
Possible reason for missing peak from hypericin in the 
HPLC analyses might be due to photolysis when exposed 
to sunlight several weeks during preparation of Hyperici 
oleum. This thesis is also suggested from Maisenbacher et 
al. (1992) who had examined a solution of hypericin in ac-
etone after irradiation with a daylight lamp for 40 h and by 
UV/ VIS, IR and 1H NMR spectroscopy have given as-
sumption of the basic structure of lipophilic hypericin- de-
rivatives generated by photolysis of hypericin. It was sug-
gested that St. John’s Wort Oil red colour comes from the 
lipophilic breakdown products of hypericin (Kovar and 
Maisenbacher, 1992).
On the other hand, with spectrophotometry method 
proposed in Ph. Helv. 11.0 the obtained results complied 
with the pharmacopoeial criteria and indicated presence of 
hypericin in the samples H2, B1 and B2. 
Presence of unidentified compounds detected in the 
HPLC chromatogram of St. John’s Wort Oil indicated that 
further research should be done in order to explain the pos-
sible chemical modification of hypericin like derivatives.
Conclusion
Within this research, SPE procedure was successful-
ly applied for separating hypericin and other phytocompo-
nents from vegetable oil solution. Hypericin was not de-
tected in St. John’s Wort Oil by the proposed HPLC meth-
od, although the content of hypericin derivatives, deter-
mined by spectrophotometric method, was in compliance 
with the Ph. Helv 11.0. Analysis of the obtained results 
suggests possibility that the target component hypericin 
may undergo chemical modification as unidentified peaks 
were detected in the chromatogram of St. John’s Wort Oil. 
Further analysis of different preparation methods for St. 
John’s Wort Oil and their affection to hypericin content, 
stability testing of hypericin in vegetable oil, as well as 
quantitative and qualitative determination of the possible 
degradation products of hypericin are required
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Introduction
А new core-shell silica particles were developed as a 
material for chromatographic stationary phases that can 
separate small and large molecules and complex samples, 
providing fast and high efficiency separations at pressures 
compatible with conventional HPLC equipment (Guiochon 
and Gritti, 2011). Core shell particles (also called fused-
core™ particles, shell particles or controlled-surface-po-
rosity particles) consist of a non porous silica core and a 
narrow shell of porous silica. Compared with convention-
al columns with fully porous particles, core shell particles 
provide shorter diffusion paths of the analytes into the sta-
tionary phase which significantly influence the separation 
parameters (Berger, 2011; Destefano et al., 2008; Wu et 
al., 2013). Core-shell columns have been mostly used for 
reversed-phase HPLC, as well as in hydrophilic interac-
tion liquid chromatography (HILIC), chiral separation, two 
dimensional liquid chromatography and capillary electro-
chromatography separation (Kirkland et al., 2013; Ruta et 
al., 2012). Transfer of the HPLC methods from columns 
packed with fully porous silica particles to core-shell col-
umns provide significant time and cost savings, while 
maintaining column performance and minimizing operat-
ing difficulties (Hayes et al., 2014).
The aim of our work was to transfer the method for 
determination of related substances of metamizole sodi-
um using the method described in the Ph.Eur. monograph 
(01/2008:1346) from conventional to core-shell column 
and to optimize the method for determination of related 
substances of metamizole in tablets.
Materials and methods
Chemicals and standards 
Metamizole sodium and metamizole impurity A, cer-
tified reference standards, were purchased from EDQM 
(Strasbourg, France). Sodium dihydrogen phosphate, (Ph.
Eur., grade for analysis) and triethylamine were purchased 
from Merck, Germany. Methanol (HPLC grade) was pur-
chased from Carlo Erba Reagents, France. Water R, was 
obtained with a TKA-LAB Reinstwasser system (Nie-
derelbert, Germany). 
Chromatographic Conditions 
HPLC separation was performed on Agilent 1200 LC 
Systems, using ChemStation software, Version B.04.03 for 
data acquisition and instrument control. The column used 
for the separation was Kinetex XB-C18, 50 mm x 2.1 mm, 
5 μm (Phenomenex, Inc). Mixture of 28 volumes of meth-
anol R and 72 volumes of a buffer solution containing 1000 
volumes of a 6.0 g/L solution of sodium dyhidrogen phos-
phate R and 1 volume of triethylamine R, pH 7.0, was used 
as a mobile phase. The column temperature was 25°C. 
Flow rate was 0.2 mL/min. Injection volume was 0.5 μL. 
UV detection was performed at 254 nm.
Preparation of solutions
Reference solution e, containing metamizole sodium 
(0.3 mg/mL) and metamizole impurity A (0.4 mg/mL) pre-
pared as described in Ph.Eur. monograph (01/2008:1346) 
was used as system suitability solution.
Test solution was prepared by dissolving a quantity of 
powdered tablets containing 500 mg metamizole and dilu-
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tion to 100, 0 ml of methanol. 
Reference solutions used for calculations were pre-
pared according to the method for related substances de-
scribed in Ph.Eur. monograph 01/2008:1346.
Validation of the method
Validation of the method was performed according to 
International Conference on Harmonization (ICH) Guide-
line on Validation of Analytical Procedures: Text and 
Methodology (ICH, 2005).
Results and discussion
The method for simultaneous determination of met-
amizole sodium and its two impurities (A and C) described 
in Ph.Eur. monograph (01/2008:1346) was transferred 
from conventional fully porous column (base deactivated 
octadecylsilyl silica gel for chromatography R, 0.25 m x 
4.6 mm; 5 μm) to column based on core-shell technology 
(XB-C18, 50 mm x 2.1 mm, 5 μm) and optimized for de-
termination of  related substances of metamizole in tablets. 
Satisfactory system suitability requirements were ob-
tained in total analysis time of 9 minutes (4.5 times of the 
retention time of metamizole, Rt = 2.15) and the value for 
resolution (Rs) between metamizole and impurity A (Rs = 
3.11) fulfills the requirement of the Ph.Eur monograph (Rs 
≥ 2.5). The purity ratio was within the calculated thresh-
old limit (1.000) for both impurity A (0.128) and impuri-
ty C (0.0197), confirming the purity of the peaks and spec-
ificity of the method. The obtained values for number of 
theoretical plates (N=10187), retention factor (k’=1.88), 
symmetry factor (As=1.28) and relative standard deviation 
(RSD(Rt)=0.16%; RSD(peak area)=0.53%; n=6) for the 
peak of metamizole impurity A, indicate on a satisfactory 
column efficiency and adequate performance of the chro-
matographic system. 
The results obtained from the regression analysis of 
the peak area (y) versus concentration (x), confirmed the 
linearity of the method (y = 6,476x + 2,417; R2 = 0.9999) 
in concentration range from 5 μg /mL to 50 μg /mL of met-
amisole impurity A (5, 10, 20, 25, 30, and 50 μg/mL). The 
values for limit of detection (DL=0.33 µg/mL) and limit 
of quantification (QL= 0.99 µg/mL), determined from the 
residual standard deviation of the regression line and the 
slope are below the disregard limit (1.25 µg/mL) given in 
the Ph.Eur. monograph, indicating on satisfactory sensitiv-
ity of the method. 
The repeatability of the method was confirmed from 
the values for the relative standard deviation (RSD), ob-
tained from determination of the test solution (RSD = 2.26 
%, n=6). Recovery values obtained from the determination 
of metamizole impurity A (81.3 % - 90.4 %) in the test so-
lution (spiked with metamizole impurity A, at three differ-
ent concentrations) confirmed that the method was accu-
rate in the range of 80-120% of the working concentration. 
The results from the determination of the robustness of 
the method indicated that small but deliberate changes in 
the analytical conditions did not affect the system suitabil-
ity parameters and that the method can be applied in rou-
tine work.
Conclusion
The results have shown that the optimized method us-
ing core-shell column is suitable for determination of re-
lated substances of metamizole in tablets containing met-
amizole sodium, providing fast and highly efficient sepa-
ration on conventional HPLC equipment, available in al-
most any laboratory.
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Introduction
The pharmacy profession is facing continuous evolve-
ment toward patient (PT) oriented health care services in or-
der to ensure the safe, effective and rational use of medi-
cines. The areas of pharmacist practice are versatile - from 
activities concerned with PT care and public health to drug 
design and development, supply and dispensing (Traulsen 
and Almarsdottir, 2005). Currently 2413 pharmacists are li-
censed at the pharmaceutical chamber of R. Macedonia, 
where 1107 are employed in CPs across the country (data 
obtained from Pharmaceutical chamber of Macedonia on 
22.02.2016).  Having in mind that a major area of licensed 
pharmacist (LP) settlements in R. Macedonia are CPs (~46% 
of all LPs), we conducted a survey (20.10.2014-20.01.2015) 
in order to establish a baseline in respect of CP activity, staff-
ing, infrastructure etc. We hope that the results of the con-
ducted survey will help for further development of CP sector.
Materials and methods
Focus-methodology group approach was applied in 
the process of design and structuring of the questionnaire. 
It was conducted between 1-10 October, 2014 on 10 LP 
employed at CPs across the country in order to explore the 
level of understanding, acceptability (questions wording, 
complexity and ambiguity of proposed answers) as well 
as the time required to complete the questionnaire. After-
wards the final questionnaire with 29 items was structured.
The anonymous questionnaire covers data related to 
socio-demographic factors (city, age, gender and length of 
time registered as a LP), average number of PTs and pre-
scriptions (Px) in the CP per week, location and workforce 
in the CP, services offered, continuing education and expe-
riences and opinions related to e- Px. 
The questionnaire was distributed to 150 CPs across 
the country and 124 were returned. Only one questionnaire 
was in a group with more than 20% missing values and 
therefore 123 questionnaires were analyzed.
Obtained data were tabulated using Microsoft Excel® 
(Microsoft Corp. Redmond, WA, USA) and were comput-
ed and consequently evaluated using statistical software 
STATGRAPHICS Centurion XVI evaluation (StatPoint 
technologies Inc., USA)
Results and discussion
According to the data found on the web site of Mace-
donian Agency for Drugs and Medicinal Products (http://
malmed.gov.mk) there are 1019 registered pharmacies in 
R. Macedonia of which 846 (83%) are CPs (web site ac-
cessed at 24.02.2016). The analyzed sample of 123 CPs 
covers 14.54% of all CPs in R. Macedonia pointing to sat-
isfactory margin over target of necessary 10% to have re-
liable results.
Related to the profile of LP employed in CPs the av-
erage age was 36.24 ± 9.89 years of which 96.7% were 
females. The average length of time registered as a LP 
was 10 ± 8.9 years. Only 2.4% have degree of postgradu-
ate health-care specialist, and 1.6% were enrolled in such 
study at the time of survey.
Most of the surveyed CPs (48.4%) were visited by up 
to 1000 PTs per week followed by those with 1000-2499 
PTs (41.8%). The average number of dispensed Px items 
per week 500-999 (47.5%) preceded the ones with low-
er than 500 (40.8%). Majority of the respondents (45.4%) 
stated that the number of dispensed Px per week issued by 
general practitioners was 500-900 while the specialists in 
55.4% cases issued in average 100-499.  Most of the CPs 
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(60%) were visited by medium number of PTs from all age 
groups (56.9%). The average working time per day (Mon. 
to Sat.) was 13.22±1.35 hours, where 30% have open-
ing hours from 8:00-21:00 h, 15.83% from 8:00-22:00 h 
and 10% from 7:30-21:00 h. Sunday was working day in 
35.83% of surveyed CPs with 7.15±2.03 working hours on 
average with only 3.33% working 12 or more hours.  Only 
8.1% of the respondents worked within small chain (up 
to 3 CP), where majority (69.7%) worked in large chain 
and the rest of 22.1% worked in single CPs. CP location in 
46.3% of the cases was in central city region and in 21.1% 
near the general practitioner and/or hospital (15.4%). 
The findings related to workforce indicated that aver-
age number of total staff per CP was 4±1.52 persons.  On 
average, there were 2.34 ± 1.04 LPs reported as working in 
each CP with the most common response (mode) being 2 
(39.2%) while the maximum reported number of LPs was 
5. In 21.7% of cases only one LP was employed. Isolat-
ed consultation/counseling area for PTs was not available 
in 86.3% of the CPs.  Only 7.4% CPs dispensed in-house 
compounded medications. 
Related to medication (MED) therapy management, 
61.7% of the LPs would like to have information about 
previous use of the certain MED, 37.4% if the PT knows 
how to use the MED, 34.6% were there any allergies or in-
tolerances noted, 33.6% about other used MEDs and only 
4.7% were asking the PT if he/she was familiar with pos-
sible side/adverse effects of the drug dispensed. Preferenc-
es about the drug manufacturer were asked in 19.6%. LPs 
in 93.5% of the cases audited possible physicians’ errors, 
71.5% check out drug interactions, 74% allergy to the pre-
scribed drug or its excipients,  51.2% other allergies pres-
ent  and something else in 14.6%. MED therapy errors 
were solved and evidenced in 64.4%, while in 32.2% were 
solved but not evidenced. Only 9.4% of the respondents re-
ported adverse drug reactions. 
More than 90% of the respondents advised PTs for eye 
drops and inhaler use, ∼82% for pregnancy testing, ∼40% for 
insulin pen and ∼28% for other matters. Drug use instruc-
tions were written on MED package by ∼97% of the LPs. 
Respondents’ opinion about the availability of infor-
mation needed for efficient MED therapy management was 
as follows: 
- all of them would like to know if there is history of drug 
related allergies and ~80% about other allergies pres-
ent,  where more than 56% appreciated to obtain the in-
formation both from the PT and medical dossier,
- diagnosis was stated to be valuable by ~87% while med-
ical history (past 6 months) was valued by 58.5%. Med-
ical dossier as source was selected by more than 50%,
- adverse drug reactions was found to be valuable for 97.3%, 
and both medical dossier and PT as source by 39.1%,
- discharge summary and results from screening and lab-
oratory tests were valued by ~41%, 29% and 52% re-
spectively and medical dossier as source by ~64%, 
60% and 71% of the respondents accordingly. 
PT adherence to chronic therapy was followed via di-
rect PT questioning by 70% of the respondents.
Blood glucose could be monitored in 18.7%, while 
blood pressure in 35.8% of surveyed CPs. Health promo-
tions (eg. colon cancer, nutrition dietetic regimens) and 
pregnancy advices were practiced in 18.7% and 36.6% of 
the cases respectively. 
Nearly 84% responded that PTs were seeking advic-
es for smoking cessation and nutrition, ~65% for vaccines, 
and ~55% were asked regarding alcohol drinking as well 
as physical activity. More than 95% of the respondents 
stated that PTs sought an advice concerning drugs cur-
rently used, side/adverse drug reaction, change of therapy/
treatment, health related issues in general and herbal drugs. 
Urgent contraception, dietetic regimen in time of ongoing 
therapy, MED storage conditions and need of physician 
visit were issues of PTs` interest in more than 80% of the 
cases. Nearly 60% of the respondents stated that they were 
asked about therapy monitoring and ~66% about new ap-
proved drugs. 
Only 26.2% responded that unwanted medicines were 
returned to CP for disposal.
Survey for PTs` experience from CP work and activi-
ties in the past year was conducted in 16.1%, but howev-
er 51.3% stated that they were planning to conduct such a 
survey in the future.  PTs ` compliant procedure was estab-
lished in 26.5% of the surveyed CPs. 
Continuing education preferences were expressed by 
75% of the respondents, but however when it comes to the 
type and topic, response rate from the surveyed LPs was 
relatively low, 52.8% and 37.4% respectively. From those 
responded 84.6% preferred conventional lectures, semi-
nars, symposia, congresses, and only 10.8% e-education. 
Topics related to new approved drugs and CP practice & 
communication were preferred by 21.7% and 19.6% from 
the respondents, accordingly.  
The vast majority of the respondents were satisfied by 
introduction and use of e- Px. 
Only 25% of the surveyed LPs provided their opinion 
in relation to CP work improvement where 29% of the re-
spondents suggested less administrative tasks, e- Px only 
and PTs` part in the e- Px to be automatically filled by data 
already present in the system and 22.6% suggested to make 
clear distinction between duties of LPs and pharmaceutical 
technicians working in CPs, as well as different person re-
sponsible for Px and OTC drugs.
Conclusion
This study enabled baseline establishment for the cur-
rent situation in CP practice in R. Macedonia. The results 
could be used for further development and improvement of 
CPs sector in our country.
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Introduction
Background and Aims:  Antibiotics have always been 
considered one of the wonder discoveries of the 20th cen-
tury. This is true, but the real wonder is the rise of antimi-
crobial resistance in hospitals, communities, and the en-
vironment concomitant with their use. The extraordinary 
genetic capacities of microbes have benefited from man’s 
overuse of antibiotics to exploit every source of resistance 
genes and every means of horizontal gene transmission to 
develop multiple mechanisms of resistance for each and 
every antibiotic introduced into practice clinically or oth-
erwise (Davies and Davies, 2010). Resistance mechanisms 
have been identified and described for all known antimi-
crobials. Acquired bacterial antibiotic resistance can result 
from the mutation of normal cellular genes, the acquisition 
of foreign resistance genes, or a combination. The most 
common resistance mechanisms employed by bacteria in-
clude enzymatic degradation or alteration of the antimicro-
bial, mutation in the antimicrobial target site, decreased 
cell wall permeability to the antimicrobial, and active ef-
flux of the antimicrobial (Harbottle et al., 2006).  With re-
spect to the pediatric population, respiratory tract infec-
tions (RTIs) are a common reason for health care provider 
visits and the primary reason for antimicrobials prescrib-
ing in this population. The overuse of antibiotics in chil-
dren is becoming a major public health problem. Although 
most of the common childhood infections, such as the up-
per respiratory tract infections, are caused by viruses, large 
volumes of antibiotics are prescribed for these infections 
in children in the primary care setting. It is estimated that 
90% of upper respiratory tract infections are self-limiting 
viral illnesses and even bacterial infections like acute otitis 
media often run a self-limiting course. Clinical trials have 
shown that antibiotic use to treat common upper respirato-
ry tract infection like sore throat, nasopharyngitis and oti-
tis media has no or minimal benefit on the clinical outcome 
(Kutty, 2011). Given the proven relationship between the 
resistance rate of a specific pathogen and the rate of antibi-
otic usage (community setting and nosocomial), the aim of 
this study was to evaluate the resistance rate to specific an-
tibiotics in common respiratory tract pathogens in pediat-
ric population in R. Macedonia. 
Materials and methods
Retrospective analysis of medical data from 7079 pa-
tients was done in the period July 2013 – January 2014. 
The analyzed isolates were taken from: nose (2141), throat, 
epipharynx, pharynx, deep swab from pharynx, tonsils 
(2752); drainage secretions (2186). The testing was per-
formed by the Cabinet for microbiological analysis, Insti-
tute for respiratory diseases in children - „Kozle” (Skopje). 
Data from sensitivity tests (antibiograms) were analyzed 
for 6 RTIs pathogens - Moraxella catarrhalis, Streptococ-
cus pneumoniae, Haemophilus influenzae type b, Staphy-
lococcus aureus, Streptococcus pyogenes and Escherich-
ia coli. The isolates were obtained using standard microbi-
ological procedures and screened using disc-diffusion test. 
Sensitivity was tested to penicillins (Amoxicillin, Oxacil-
lin), cephalosporins (Cefadroxil, Cefuroxime, Cefixime, 
Ceftriaxone) and macrolides (Azithromycin, Clarithromy-
cin, Erythromycin). The antibiotics were selected based on 
the institute’s prescription practices for RTIs. The patho-
gen sensitivity to a specific antibiotic in the antibiogram 
reports was numerically labeled - 3 (sensitive), 2 (moder-
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ately sensitive), 0 (resistant). Data from oxacillin test (3/0) 
were analyzed for Streptococcus pneumoniae. A basic sta-
tistical analysis was performed to calculate the resistance 
rate (percentage value) of every individual pathogen to ev-
ery specific antibiotic. The resistance rate (lack of suscep-
tibility) was calculated by dividing the number of isolates 
with an identified resistant pathogen (numerically labeled 
as 0 in the antibiogram reports) and the total number of iso-
lates of that given pathogen.    
Results and discussion
Moraxella catarrhalis demonstrated 9.5% resistance 
rate to Cefixime, and an average resistance to macro-
lides - 10-12%. Streptococcus pneumoniae had a sizeable 
(30.9%) resistance rate to Cefixime, 38-43% to macrolides, 
and a dramatically high (70.1%) resistance rate on the Ox-
acillin test. The oxacillin test for S.pneumoniae is consid-
ered a test for penicillin susceptibility in the first place, 
but unsusceptible isolates are also considered unsuscep-
tible to extended-spectrum cephalosporins (e.g. Ceftriax-
one or Cefotaxime). Haemophilus influenzae demonstrat-
ed significant resistance to Cefixime (10.6%). There were 
no cases of resistance to Amoxicillin. Staphylococcus au-
reus showed a substantial (14-23%) resistance rate to the 
macrolides. Streptococcus pyogenes showed no resistance 
to any of the tested antibacterial agents. Escherichia coli 
showed a very high resistance rate to the class of chepal-
osporins: Cefadroxil - 77.8%, Cefuroxime - 61.5%, Cefix-
ime - 71.3%, and Ceftriaxone - 67.3%. The study revealed 
a 28-35% resistance rate of Klebsiella pneumoniae to the 
group of cephalosporins. K. pneumoniae is considered in-
trinsically resistant to amoxicillin. 
If on the other hand, we take into account the data for 
antimicrobials consumption in Europe for the aforemen-
tioned period - a causative relationship between the antimi-
crobials use and the rate of antimicrobial resistance could 
clearly be established. For example, in 2011, Greece was 
on the first place with antimicrobials consumption in Eu-
rope (35 DDD/1000/day), and at the same time the data 
for antimicrobials resistance rates in Greece demonstrat-
ed very high values for various isolates. The same could 
be concluded for Cyprus and other countries that are po-
sitioned on the top of the list for antimicrobials consump-
tion. Contrary to this, Netherlands, Estonia, Latvia and the 
Scandinavian countries, which are positioned on the bot-
tom of the same list, are also the countries in Europe with 
the least percentage of antimicrobial resistance (EARS-Net 
Annual Report, 2013). 
The situation in Macedonia was much like that in 
Greece and Cyprus. The consumption of antimicrobials for 
the period 2008-2012 was approximately 32 DDD/1000/
day. For that period, the most commonly utilized antibi-
otics were the beta-lactams. During this time, the con-
sumption of antimicrobials dropped compared to the pre-
vious period for all groups of antibiotics, except for the 
penicillins, where an increase was noticed. The most com-
monly prescribed anti-infective agent for systemic use 
was Amoxicillin + clavulanic acid. Amoxicillin followed 
on the second place, whereas Cefuroxime and Cefixime 
placed fourth and fifth. Ciprofloxacin was positioned on 
the third place (Annual report 2012, Health Insurance Fund 
of Macedonia). Furthermore, also to be considered is the 
fact that in the time of conduction of this research, Cefix-
ime was the only oral third-generation cephalosporin reg-
istered in Macedonia, and even more, available as a pedi-
atric oral suspension. To this, could partially be attributed 
the observed great percentage of resistance to Cefixime.  
If we take into consideration the data obtained in this 
research, we can clearly postulate that the high consump-
tion of antimicrobials in Macedonia could be in a great 
manner responsible for the substantial percentage of an-
timicrobial resistance, by constantly increasing the ever-
growing positive pressure on microorganisms to continu-
ously acquire new means of resistance.
Conclusion
The results from the susceptibility tests on one side, 
and the total antibiotics use (32 DDD/1000/day) in the 
Macedonian population on the other, proved the previous-
ly stated proportional relationship between the population 
antibiotics consumption level and pathogen resistance rate. 
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Introduction
Risperidone (RPD) is an antipsychoticdrug commonly 
used for the treatment of schizophrenia. The treatment for 
this disease is generally life-long, so the oral route is the 
most convenient and non-invasive way of drug administra-
tion. However, RPD is a poorly water-soluble BCS class 
II drug that undergoes extensive first-pass hepatic metab-
olism and has poor oral bioavailability. Moreover, it binds 
about 90% to plasma proteins, which renders its delivery 
across the blood-brain barrier (Kumar et al., 2009).
Literature data suggests that nanoparticles could avoid 
the first-pass effect and provide prolonged release, thus 
enabling significant reduction of the RPD dose and min-
imising its undesired side-effects (Patel et al., 2011). Lip-
id nanoparticles are a promising strategy for drug deliv-
ery to the brain due to their rapid uptake, bio-acceptabili-
ty, biodegradability and lower toxicity compared to poly-
meric nanoparticles. Nanostructured lipid carriers (NLCs) 
are an improved generation of lipid carriers that are pre-
ferred over conventional lipid formulations and solid lip-
id nanoparticles due to their enhanced properties for drug 
loading, modulation of the drug release profile and im-
proved physical stability (Alam et al., 2015). Additional-
ly, the small size, unique drug incorporation abilities, ste-
ric propertiesand possibilities for surface modification of 
NLCs favour brain targeting and delivery.
The presented study focuses on the formulation opti-
misation of surface stabilised RPD loaded NLCs and their 
characterisation in terms of particle size, particle size dis-
tribution and drug encapsulation efficiency.
Materials and methods
Materials
Cutina® GMS V PH (GMS) was kindly donated by 
Cognis, Germany. Miglyol 812 and Phospholipon 90G (Ph 
90G) were purchased from Sasol, Germany and Lipoid, 
Germany, respectively. Sodium glycocholate (SGH) and 
Tween 80 were obtained from NutriScience Innovations, 
LLC, USA and Merck, Germany, respectively. Poloxam-
er 407, Poloxamer 188 and PEG 6000 were a generous gift 
from BASF, Germany. Bovine serum albumin (BSA) was 
obtained from Sigma (St. Louis, MO, USA). Risperidone 
(RPD) was purchased from Teva-Tech, Israel. All the oth-
er chemicals and reagents were of the highest purity grade 
commercially available and used as received.
Preparation of NLCs
Different formulations of blank NLCs were prepared 
using melt emulsification and rotor-stator homogenisation 
technique. Optimised formulation (sample 1) (central com-
posite design: blocked cube star) composed of 2.5% GMS, 
2.5% Miglyol812, 0.75% Ph 90G and 0.2% SGH was se-
lected by minimising both responses, mean particle diame-
ter (D50) and particle size distribution expressed in terms of 
SPAN factor. Briefly, the lipid phase was melted by heat-
ing to ~80 °C and dispersed in an aqueous phase containing 
SGH, preheated at the same temperature, under high shear 
homogenisation (7 min, 24.000 rpm) using Ultra-Turrax® 
T25 (Ika-Werke, Germany). Subsequently, the dispersion 
was allowed to recrystallize at 5 °C for 1 h. 
In order to turn the hydrophobic NLC surface into a 
more hydrophilic one, sample 1 was further modified by 
incorporating different concentrations (4.0, 4.5, 5.0 and 
S8 OP 305
640
Maced. pharm. bull., 62 (suppl) 639 - 640 (2016)
O
ra
l p
re
se
nt
at
io
ns
Student session
5.5% w/w) of Tween 80 (samples 1A1-4), Poloxamer 407 
(sample 1B1-4), Poloxamer 188 (sample 1C1-4) or PEG 
6000 (sample 1D1-4) in the aqueous phase, prior to the 
high-shear homogenisation. Sample 1A4, prepared with 
5.5% Tween 80 was selected for preparation of RPD load-
ed NLCs, based on the results obtained from in vitro pro-
tein adsorption studies. Drug loaded NLCs were prepared 
using the same procedure as described above, by adding 
different concentrations of RPD (drug/lipid mass ratio 1, 
10 and 20%; samples R1, R10 and R20, respectively) to the 
melted lipid phase prior to the high-shear homogenisation.
Characterisation of NLCs
The objective of the protein adsorption studies was to 
determine the amount of adsorbed BSA on the surface of 
NLCs prepared with different types and concentrations of 
stabilisers. Briefly, 100 µl aliquots of the prepared sam-
pleswere incubated with 2mg of BSA in 2 ml of phosphate-
buffered saline (pH=7.4) for 1 h on shaking water bath (37 
°C, 75 rpm). After adsorption, the unbound protein was sepa-
rated by centrifugal ultrafiltration through three washing cy-
cles using Vivaspin 20, 1000 KDa (15 min, 4000 rpm; Het-
tich, Rotofix 32, Germany). Afterwards, the volume of sam-
ples was condensed to the initial volume of NLC dispersions. 
The adsorbed amount of BSA/mg lipid was calculated indi-
rectly by determining the total amount of protein remaining 
in the filtrate by UV spectroscopy (595 nm; Bio-Rad’s Mod-
el 3550-UV Microplate Reader) after reaction with Bio-Rad 
protein assay (Bio-Rad, USA), based on the method of Brad-
ford (microtiter plate protocol) and subsequent subtraction 
from the initial BSA amount. The particle size (D50) and par-
ticle size distribution (SPAN) of the prepared NLCs were de-
termined by laser diffractometry (Mastersizer 2000, Hydro 
2000S, Malvern Instruments Ltd., UK). 
In order to determine the drug content (mg RPD/g lipid) 
and encapsulation efficiency (EE%) of RPD in the NLCs, 
the particles in the suspension were separated by centrifugal 
ultrafiltration through three washing cycles using Vivaspin 
20, 1000 KDa (15 min, 4000 rpm; Hettich, Rotofix 32, Ger-
many) and brake-opened using methanol. The solution was 
then passed through a 0.45 µm filter and analysed by re-
verse-phased HPLC method (Agilent HPLC system, 1200 
Series; column: Waters Spherisorb ODS-2; 150 mm x 4.6 
mm, 5 µm). The used mobile phase was consisted of meth-
anol, acetate buffer (0.05M, pH=4.6) and triethanolamine 
(60:40:0.02, v/v/v) with flow rate of 1 ml/min at 25.0±0.5 °C. 
The injection volume was 50 µl and the detection was car-
ried out at 280 nm. The EE% was calculated from the total 
amount of drug in the nanoparticle suspension and the quan-
tity of RPD added initially during the preparation.
Results and discussion
In the development of site-specific drug delivery sys-
tems it is a prerequisite to identify the factors determining 
the carriers’ in vivo behaviour and disposition. For effective 
brain targeting, NLCs should have a hydrophilic surface, 
reduced protein adsorption pattern and prolonged blood cir-
culatory time in order to permit efficient and satisfied inter-
actions and penetration in the brain endothelial cells.
Considerable differences in BSA adsorption onto 
NLCs surface were detected for different stabilizers in a 
concentration-dependent manner and in all cases the to-
tal protein adsorption was lower compared to unmodified 
NLCs (sample 1). NLCs prepared with Tween 80 (samples 
1A1-4) resulted with lowest amount of adsorbed BSA (sur-
factant concentrations: 4.0, 4.5, 5.0 and 5.5%; unbound 
BSA: 46.5, 65.4, 68.2 and 94.9%, respectively). The ob-
tained results are in accordance with the literature data 
pointing that the presence of Tween 80 could minimise the 
interaction of the nanoparticles with serum albumin and 
prolong their half-life in the blood circulation (Göppert and 
Rainer, 2005), potentially giving NLCs best stealth charac-
teristics compared to other formulations. Therefore, sam-
ple 1A4, prepared with 5.5% of Tween 80 was selected for 
preparation of RPD loaded NLCs.
The obtained unmodified NLCs (sample 1) had D50 of 
107 nm and SPAN factor of 0.804 with unimodal narrow 
size distribution. There were no significant differences in 
D50 between unmodified and surface-modified particles. 
The D50 and SPAN of RPD loaded NLCs were 116 nm and 
0.832 (sample R1), 127 nm and 0.959 (sample R10) and 123 
nm and 1.012 (sample R20), respectively.
The determined drug content in the prepared formula-
tions was 8.8, 99.9 and 227.5 mg RPD/g lipid and the EE 
was 87.2, 89.9 and 91% for R1, R10 and R20, respectively. It 
is obvious that higher drug concentration used for prepar-
ing the samples resulted with increased drug content, thus 
pointing that the drug/lipid ratio was a critical parameter 
for efficient RPD loading into the NLCs.
Conclusion
In an attempt to realise the ‘magic bullet’ concept 
postulated by Ehrlich, the presented study indicates that 
Tween 80 stabilised NLCs could be suitable risperidone 
carriers with prolonged blood circulation time and site-
specific brain delivery.
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Introduction
Human brain is one of the most intricate organs 
because of its hundreds of billions of neurons continuously 
transmitting electrochemical signals to each other. With 
the aging of the world population, brain-based disorders, 
especially neurodegenerative diseases like Alzheimer’s and 
Parkinson’s are becoming one of the major health problems. 
However, brain is the most difficult organ for drug delivery 
and poses unique challenges. Specific anatomic and 
physiological features of the cerebrovasculature and cerebral 
tissue fluids result in barriers, i.e. blood–brain barrier (BBB), 
which limits the penetration of many molecules/substances 
including drugs to the central nervous system. Molecular 
characteristics, which are known to reduce the ability for 
partition/penetrance into the lipids of the cell membranes 
(through the BBB) are, a significant polarity, high potential 
for hydrogen bond formation, molecular weight of more 
than 500 kDa, as well as molecular structures which contain 
rotatable bonds and those that are highly branched (Haque 
et al., 2012; Mutlu et al., 2011). 
Accordingly, the development of brain drug-delivery 
systems is imperative. Among different particulate carri-
er systems, liposomes have gained much attention because 
of their biocompatibility and structural similarity to that of 
cells. Liposomes can fuse with cells, facilitating the trans-
port of drugs across biomembranes. Also, liposomes pos-
sess excellent criteria as drug carriers, because they are 
closed vesicles composed of an internal aqueous compart-
ment and an external lipophilic bilayer of phospholipids 
molecules. External surface of liposomes can be modified 
by polyethylene glycol (PEG) to produce stealth properties. 
Stealth liposomes are characterized by long circulation time 
in vivo and could be easily coupled to different targeting 
moieties in order to improve the site-specific drug delivery.
Having in mind the limitations of currently available 
drugs for treatment of neurodegenerative diseases, devel-
opment of phytopharmaceutical based liposomes could be 
considered as an attractive alternative approach for effica-
cious treatment of brain disorders. Natural polyphenols are 
well known organic compounds with antioxidative, free 
radical scavenging and anti-inflammatory characteristics. 
In this connection, polyphenols are thought to be potential 
candidates in prevention and treatment of diseases caused 
by oxidative damage, such as neurodegenerative disorders 
(Mignet et al., 2013). However, they exhibit low bioavail-
ability and poor solubility, which limits their use. 
Therefore, the aim of this study was design and 
formulation of PEGylated liposomes containing rosmarinic 
extract in order to enhance the bioavailability and efficacy 
of polyphenols in treatment of neurodegenerative disorders.
Materials and methods
Materials 
Soybean lecithin (SL) was purchased from Vitalia, 
Macedonia. LIPOID PE 18:0/18:0-PEG 2000 (PEG) was 
kindly donated from Lipoid, Germany. Cholesterol (CH) was 
obtained from Sigma Aldrich (St. Louis, USA). Rosmarin-
ic extract (RA-E) was a generous gift from the Institute of 
Pharmacognosy, Faculty of Pharmacy, Skopje, Macedonia. 
All the other chemicals and reagents were of the highest pu-
rity grade commercially available and used as received.
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Preparation of liposomes
During the preliminary studies, different formulations 
of liposomes were prepared in order to obtain vesicles with 
mean size of ~200 nm suitable for brain delivery (Gelden-
huys et al., 2015). Optimized process parameters’ were fur-
ther used for formulation modification. Samples were pre-
pared by the modified lipid film hydration technique. Brief-
ly, required amounts of SL and CH (mass ratio=5:1, 10:1 
and 20:1; samples 1, 2 and 3) were dissolved in chloroform/
methanol mixture 4:1 (v/v). Afterwards, the organic sol-
vents were removed by evaporation under vacuum using a 
rotavapor (25 °C, 50 rpm; Buchi 215, Switzerland). Thus 
obtained dried lipid film was hydrated with aqueous phase, 
phosphate buffer pH 7.4, under three hydration steps: ul-
trasonication (50/60 Hz), vortexing and gentle shaking. Ev-
ery step lasted 5 min and four cycles of hydration were per-
formed. Obtained liposomes were submitted to high shear 
homogenization (24 000 rpm, 5 min; Ultra-Turrax T25, Ika-
Werke, Germany) and were allowed to stand for 24 h at 4 oC. 
For preparation of RA-E loaded liposomes (200 mg initially 
added) two different approaches were performed, i). RA-E 
was dissolved in organic solvents mixture required for lip-
id phase formation (samples 1a, 2a and 3a) and ii). RA-HE 
was dissolved in an aqueous phase (sample 1b, 2b and 3b).
From results obtained from particle size analysis and 
drug encapsulation efficiency (EE%), sample 2a was se-
lected for preparation of PEGylated liposomes (sample 
P2a), where PEG was incorporated into the lipid phase 
(SL:CH:PEG mass ratio=10:1:0.5).
Liposome characterization
Prepared liposomes were characterized in terms of mean 
particle size (D50) and particle size distribution (SPAN fac-
tor) by laser diffractometry (Mastersizer 2000, Hydro 2000S, 
Malvern Instr. Ltd., UK). EE% was calculated on a basis of 
non-encapsulated portion of RA-E by HPLC.  Analyses were 
performed on Merck Hitachi HPLC system (Darmstadt, Ger-
many), equipped with Ellite LaChrom L-2200 autosampler, 
L-2130 pump and L-2450 diode array detector. The column 
used was Zorbax Eclipse XDB RP C-18 column (150 mm × 
4.6 mm, 5 μm, Agilent, Germany). The used mobile phase 
was: A - 1% formic acid (pH 3.0) and B - acetonitrile (90:10 
v/v). Chromatographic conditions were set according to the 
method described by Cvetkovikj et al. (2013) with small 
modifications. Quantification of rosmarinic acid was per-
formed using UV/VIS DAD at 330 nm.
Results and discussion
Obtained blank liposomes had D50 of 134, 129 and 130 
nm (sample 1, 2 and 3, respectively) with unimodal nar-
row size distribution (SPAN factor 1.905, 1.743 and 1.782, 
respectively). By incorporation of RA-E into the aqueous 
phase, no significant differences in particle size of the pre-
pared samples were observed and drug EE was found to 
quiet low (~ 17%). On the other hand, incorporation of 
RA-E into the lipid film resulted with increase in lipo-
somes size (D50 168, 136 and 161 nm for sample 1a, 2a and 
3a, respectively), the particle distribution became broad-
er and EE was 39.4-54.2%. From obtained data, it is possi-
ble to come to a conclusion that procedure of RA-E load-
ing into liposomes seemed to have a significant effect on 
D50 and EE. Also, the differences in drug EE between the 
two different approaches could be related to the nature and 
physicochemical properties of the used herbal extract.
Therefore, sample 2a with D50 136 nm and EE 
of 54.2% was selected for preparation of PEGylated 
liposomes. Blank PEGylated liposomes had a mean size 
of 141 nm (SPAN 3.845) The steric stabilization afforded 
by PEG incorporation into the lipid bilayer of RA-HE 
loaded liposomes affected the mean size of the vesicles. 
Namely, sample P2a had D50 of 163 nm (SPAN 2.06), 
which is known to be suitable for intravenous application 
achieving long plasma circulation time (Tanaka et al., 
2004), and no significant difference in EE was observed. 
Further studies related to the influence of PEG quantity on 
the physicochemical and biopharmaceutical properties of 
liposomes should reveal the potential of designed system 
for efficient brain delivery of RA-E. 
Conclusion
In this study, RA-E loaded conventional and PEGylat-
ed liposomes were successfully prepared. Considering the 
characteristics of the liposomes such as particle size, dis-
tribution and encapsulation efficiency, the delivery system 
seems suitable to overcome the drawbacks and to improve 
brain drug therapy after parenteral application.
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Introduction
Arctostaphylos uva-ursi (L.) Spreng. fam. Ericace-
ae, also known as bearberry or bear’s ear, is a small pro-
cumbent woody groundcover shrub, widely distributed 
on a global level. The flowers are small, urn-shaped and 
grouped in terminal clusters that bloom in summer and the 
fruits are a red berries. The leaves are small, shiny and ev-
ergreen, remaining green for 1-3 years before falling. 
The use of bearberry leaves for the first time was lit-
erally documented in the middle Ages in the Welsh “Phy-
sicians of Nyddfai” from the 13th century. From the begin-
ning of 19th century, bearberry is in official use. It was used 
for treatment of different diseases such as hydrops, lithia-
sis, in diabetes, for the therapy of gonorrhoea, etc. Now-
adays only the use as urinary tract antiseptic and diuret-
ic remains due to the presence of arbutin and hydroqui-
none (Beaux et al., 1999; Jurica et al., 2015). Additional-
ly, the herb contains tannins that have astringent effect and 
protect from early stage of infections (Dykes et al., 2003; 
Head, 2008; Pegg et al., 2008). 
According to Ph.Eur.8.0 (2014), commercial forms 
that are used consist of whole or cut, dried leaf of Arcto-
staphylos uva-ursi that contains not less than 7.00% of an-
hydrous arbutin (Ph.Eur.8.0., 2014). The content of arbu-
tin can be determined in plant extracts by many methods 
including: sprectrophotometry, capillary zone electropho-
resis, and HPCL method, that was found to be the most 
suitable for arbutin separation and is prescribed within the 
Ph.Eur.8.0. (Amarowizh et al., 2009; Parejo et al., 2001; 
Ph.Eur.8.0, 2014). 
In the Republic of Macedonia the natural populations 
of bearberry represent a unique source of leaves which are 
distributed in the following areas: Skopje Valley, moun-
tains of Yakupitsa, Karadzitsa, Dautitsa, Shar Mountain, 
Osogovo Mountains and Mariovo. Bear’s ear thrives on 
rocky ground in the light woods of black and white pine 
and in subalpic plant communities on limestone and dolo-
mite ground. Although it is an indigenous species for this 
region there are no literature data for the content of the ar-
butin in bearberry populations.
Therefore, the aim of the present study was to quantify 
the amount of arbutin from seven different populations of 
Arctostaphylos uva-ursi from Korab Mountain with high 
performance liquid chromatography (HPLC).
Materials and methods
Plant Material
Leaves were collected from seven different natural 
populations of A. uva-ursi from seven different mountain 
areas of Korab, from R. Macedonia. Every area shows dif-
ferent geographical characteristics. Plant identity was veri-
fied and voucher specimens were deposited at the Institute 
of Pharmacognosy, Faculty of Pharmacy, Skopje, Macedo-
nia. Leaves were air dried, packed in paper bags, and kept 
in the dark and cold until analysis.
Extraction: The water extracts were isolated from 
dried leaves from bearberry, according to the method de-
scribed in the European Pharmacopeia (Ph.Eur.8.0., 2014).
HPLC method
Chromatographic analyses were carried out using 
an HPLC system from the Agilent 1200 series, apply-
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ing the method described in the Ph.Eur.8.0 monograph 
(01/2008:1054), using a Zorbax Eclipse XDB RP C-18 col-
umn (150 mm × 4.6 mm, 5 μm, Agilent, Germany), pro-
tected with a guard column (4 mm × 4.6 mm, RP-18, 5 μm, 
Agilent, Germany). The eluents were: methanol R and wa-
ter R, 10:90 (v/v). The flow rate was 1.2 mL/min and the 
injection volume was 20 μL. The column temperature was 
maintained at room temperature, and detection was carried 
out at 280 nm. 
Quantification of the samples for arbutin was per-
formed immediately after extraction to avoid possible 
chemical alterations using a 1 mg/mL stock of arbutin stan-
dard.
Results and discussion
The content of arbutin expressed as % of anhydrous 
arbutin, was determinate by high performance liquid chro-
matography from seven different populations of A. uva 
ursi from Macedonia and ranged from 7.41% to 10.46%. 
Among the analysed samples the highest content of arbutin 
was found in population 06 (P06) = 10.46% and the lowest 
was in the population 11 (P11) = 7.84%.
All seven sampled indigenous populations of bearber-
ry leaf had arbutin content above 7.00%, which comply 
with the Ph.Eur.8.0 requirements. 
Conclusion
Seven population of Arctostaphylos uva-ursi from Ko-
rab Mountain were evaluated regarding arbutin content ac-
cording to the Ph.Eur.8.0 method. The content was deter-
mined by high performance liquid chromatography and 
the results were ranged from 7.84% to 10.46%. All pop-
ulations complied with the requirements of the Ph.Eur.8.0 
(not less than 7%).
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Introduction
Antiplatelet therapy is standard treatment in patients 
with acute coronary syndromes (ACS) and/or undergo-
ing percutaneous coronary interventions (PCI). Clopido-
grel, an adenosine diphosphate receptor (P2Y12) block-
er, has been used as a gold standard (alone orinassocia-
tion with aspirin) to prevent vascular complications in ath-
erothrombotic patients undergoing PCI, and as a long-term 
prevention of cardiovascular events (Campo et al., 2011). 
Clopidogrel is subject to efflux via P-glycoprotein (encod-
ed by the ABCB1 gen, also known as MDR1). The clini-
cal outcome of Clopidogrel may be influenced by both ge-
netic and non-genetic factors. Among genetic factors, the 
ABCB1 polymorphisms, particularly C3435T, may be as-
sociated with altered drug metabolism, efficacy and clini-
cal outcome (Mega et al., 2010). The aim of this study is 
to evaluate the influence of ABCB1 C3435T genetic poly-
morphism on clinical cardiovascular outcomes in coronary 
artery disease patients on Clopidogrel treatment.
Materials and methods
The study included a total of 227 subjects, of which 
107 healthy volunteers (76 men and 31 women) and 120 
patients diagnosed with coronary artery disease on treat-
ment with Clopidogrel from the Special Hospital for Sur-
gical Diseases “Filip II”. The genotyping of both the con-
trol group and the patient group was performed with Real-
Time PCR based on the allelic discrimination method using 
TaqMan SNP genotyping assay for C3435T (rs1045642 as-
say ID C_7586657_20) according to the guidelines of the 
manufacturer (Life Technologies, USA). Statistical analy-
sis was performed using SPSS software (v. 22). The gen-
otype distributions were assessed for the Hardy-Weinberg 
equilibrium (HWE) with χ2 test using an online calculator 
(http://ihg.gsf.de/cgi-bin/hw/hwa1.pl).Odds ratios (OR) 
were calculated with 95% confidence interval limits (95% 
CI). The level of statistical significance was defined as p 
≤ 0.05.
Results and discussion
The distributions of the ABCB1 allele, genotype and 
haplotype frequencies of C1236T, G2677T/Aand C3435T 
genetic variations in ABCB1 gene for the Macedonian 
healthy population (control group) have been determined. 
According to our results, the frequency of the wild-type al-
lele for C3435T (51%) in our study is similar to the gener-
al frequency reported for Caucasians of European descen-
dant, but differs from that of Asian and African population. 
Allelic frequencies in exon 26 were 51.4% for C allele and 
48.6% for mutant T allele, whereas the observed genotype 
frequencies were 25.2% for 3435CC, 52.3% for 3435CT 
and 22.5% for 3435TT (Naumovska et al., 2014). The de-
termination of distribution of the ABCB1 allele, genotype 
and haplotype frequency of the C3435T genetic variation 
in ABCB1 gene in the patient group is in progress.
In recent years, there are vast numbers of published 
data that report on evidence for the influence of SNPs in 
the ABCB1 gene on P-gp function. These polymorphic 
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variants are potential determinants of inter-individual vari-
ability in drug response and potential for a negative clinical 
outcome. A meta-analysis of twelve studies (four involved 
platelet activity and ten involved clinical outcomes) indi-
cated that the ABCB1 C3435T polymorphism might be a 
risk factor for early major adverse cardiovascular events 
(MACE) in patients on clopidogrel, and that TT homozy-
gotes decreased the outcome of bleeding compared with 
CC homozygotes. The four platelet activity studies result-
ed in an association between high platelet activity and the 
ABCB1 C3435T polymorphism that was not statistically 
significant. The long-term MACE had no significant asso-
ciation with ABCB1 C3435T polymorphism. Three studies 
demonstrated that significant elevated risk of early MACE 
was associated with T allele, TT homozygote and CT + TT 
dominant genetic model. The ABCB1 C3435T polymor-
phism was unrelated to the rate of myocardial infarction, 
ischemic stroke and all-cause mortality. Seven cohort stud-
ies reported that stent thrombosis was not associated with 
ABCB1 C3435T polymorphism in all genotype models. 
The comparison of TT vs. CC was associated with a sig-
nificant reduction in the outcome of bleeding in five cohort 
studies (Su et al., 2012). Another meta-analysis of six stud-
ies with 10.153 subjects failed to show an association be-
tween the ABCB1 C3435T polymorphism and the risk of 
long-term adverse clinical events in clopidogrel treated pa-
tients. The association of the C3435T polymorphism with 
risk of overall recurrent ischemic events and stent throm-
bosis in clopidogrel treated patients was not statistically 
significant for all genetic models. However, a significant 
association was identified between the TT homozygotes 
and risk of short-term recurrent ischemic events (Luo et 
al., 2012).Another study found no association of ABCB1 
C3435T genotype with clopidogrel response or risk of 
stent thrombosis in patients undergoing coronary stenting. 
DNA samples from 1524 clopidogrel-treated patients un-
dergoing PCI were genotyped, ADP – induced platelet ag-
gregation was assessed and the clinical impact of the ge-
netic variant was investigated by comparison of genotype 
frequencies in a registry of 66 cases with definite drug – 
eluting stent thrombosis versus an ST-free control cohort 
(n = 1408). The aggregation did not differ across geno-
type groups, and platelet aggregation values were simi-
lar and numerically lower in homozygous T-allele carri-
ers compared to the remaining patients. The genotype dis-
tribution did not differ between case subjects and control 
subjects. Among the 66 ST case subjects, 19 were carri-
ers of the ABCB1 3435TT genotype, which was not sig-
nificantly different from the rate of TT carriers in the con-
trol group (Jaitner et al., 2012). In contrast to the previ-
ous, the Genetic Variants in ABCB1, CYP2C19 and Car-
diovascular Outcomes Following Treatment with Clopido-
grel and Prasugrel study showed that the C3435T genotype 
was significantly associated with risk of adverse cardio-
vascular events. 2932 patients with an acute coronary syn-
drome (ACS) in the TRITON-TIMI 38 treated with clopi-
dogrel were genotyped. Among the ACS patients, ABCB1 
C3435T genotype was significantly associated with risk of 
the primary endpoint of cardiovascular death, MI or stroke. 
TT homozygotes showed a 72% increased risk of the pri-
mary endpoint as compared with CT/CC individuals when 
evaluated through 15 months. The rates of stent thrombo-
sis did not differ between the TT homozygotes and CT/CC 
patients (Mega et al., 2010).
Conclusion
ABCB1 C3435T SNP has been associated with an in-
creased P-glycoprotein expression, which theoretically 
should lead to decreased absorption, lower platelet inhi-
bition and an increased rate of ischemic event occurrence 
in patients treated with clopidogrel. However, controver-
sy exists regarding whether the C3435T variant influenc-
es clopidogrel associated clinical outcomes. The ongoing 
ABCB1 C3435T genotyping study of patients with coro-
nary artery disease is expected to determine the influence 
of this variant on clopidogrel associated clinical outcome 
in R. Macedonia.
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Introduction
Atorvastatin (ATS) is an important and efficacious 
member of the statins drug class in treating dyslipidemia 
and coronary heart disease. It works by inhibiting 3-hy-
droxy-3-methylglutaryl coenzyme-A (HMG-CoA) reduc-
tase that reduces hepatocyte cholesterol levels which in 
turn causes up-regulation of low-density lipoprotein (LDL) 
receptors and increased clearance of LDL-cholesterol from 
the plasma. ATS is a poorly water-soluble BCS class II 
drug, which is highly lipophilic (partition coefficient [log 
P (octanol/water)] of 6.36) in nature (Oliveira et al., 2013). 
Its low oral bioavailability (~12%) is attributed to its poor 
aqueous solubility, pre-systemic metabolism in GI mucosa 
and efflux by P-gp (Khan et al., 2016). 
To overcome these problems, various solubilization 
strategies have been proposed in the literature (Ali et al., 
2013). One such more successful technique is formulation 
of spontaneous or self-emulsifying drug delivery system. 
Self-emulsifying drug delivery systems have been catego-
rized as, self-microemulsifying (SMEDDS) and self-nano-
emulsifying drug delivery systems (SNEDDS) depending 
upon the droplet size produced after dispersion. 
The SMEDDS are preconcentrates of microemulsion, 
which form a microemulsion upon contacting water. These 
are anhydrous homogeneous mixtures of oil, surfactant 
and/or cosurfactant, and drug which when come in contact 
with aqueous medium (GI fluids) form a o/w (oil-in-wa-
ter) microemulsion with little agitation (provided by peri-
staltic movement of GIT). This spontaneous formation of a 
fine emulsion in the GIT presents the drug in a solubilized 
form, and the small droplet size provides a large interfa-
cial surface area for drug absorption (Kishore et al., 2015).
In light of above said facts, the aim of the present study 
was to establish the solubility of ATS in aqueous systems 
using self-microemulsification technique. ATS containing 
SMEDDS were developed using olive oil as oil phase, PEG 
400 as surfactant and Tween 20 as co-surfactant screened 
from the solubility studies. Mixture simplex lattice design 
was applied for determination of the optimal formulation 
where mean droplet size, size distribution and optical clar-
ity were followed as responses. 
Materials and methods
Materials
Olive oil was supplied from Fluka Analytical, Spain. 
Tween 20 (polysorbate 20) was purchased from Merck, 
Germany. PEG 400 (polyethylene glycol 400) was ob-
tained from Merck, Germany. Atorvastatin calcium (ATS; 
Form VII, D50 1.4 µm) was kindly donated by Alkaloid, 
Macedonia. All the other chemicals and reagents were of 
the highest purity grade commercially available and used 
as received. 
Solubility studies
The solubility determination of ATS in various liquid 
lipids (olive oil, mineral oil, peanut oil, sesame oil, oleic 
acid, castor oil), surfactants (Tween 20, Tween 60, Tween 
80, Span 20, Span 80) and co-surfactants (PEG 200, PEG 
400, propylene glycol, ethanol, isopropanol) was per-
formed by the test tube method. Excess ATS (250 mg) was 
added into 1 g of each vehicle followed by vortex mixing 
for 30 s. Mixtures were equilibrated for 72 h at 37 °C on 
a controlled shaker water bath (Haake SWB 20, Germa-
ny). Afterwards, mixtures were centrifuged (4000 rpm, 45 
min; Tehtnica, Centric 322B, Slovenia). Solubility of ATS 
in different vehicles was determined visually. Only sam-
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ples where ATS was completely dissolved were used for 
preparation of SMEDDS. The experiments were conduct-
ed in triplicate.
Preparation of SMEDDS
Based on the results obtained from solubility stud-
ies, olive oil, Tween 20 and PEG 400 were selected for 
preparation of ATS-SMEDDS (ATS 20 mg). Mixture sim-
plex lattice design (Design-Expert V8 trial, Stat-Ease, Inc., 
Minneapolis, USA) was applied for determination of their 
optimal quantities. Mixture components in total of 100% 
(Smix = 0.5 g) were varied. Low and high levels of studied 
variables were: variable A, olive oil - 10 and 50%; variable 
B, Tween 20 – 10 and 50% and variable C, PEG 400 - 40 
and 80%. A total of 13 experiments were carried out. Mean 
droplet size, size distribution and optical clarity were fol-
lowed as responses. Optimization was carried out in terms 
of minimal values of followed responses. In brief, designed 
Smix`s with ATS were prepared in test tubes and stirred for 
24 h (200 rpm, 37 °C; Variomag, USA). Afterwards, the 
prepared mixtures were added into 300 mL of 0.1 M HCl in 
a glass beakers maintained at 37 °C and stirred at 300 rpm 
until a transparent solution was formed.
Characterization of SMEDDS
Mean droplet size (D50) and size distribution (ex-
pressed as SPAN factor value) of the obtained SMEDDS 
were assessed by laser diffractometry using Mastersizer 
2000, Hydro 2000S, Malvern Instruments Ltd., UK.
Samples of freshly prepared SMEDD formulations 
were investigated for optical clarity spectrophotometri-
cally (400 nm; UV/vis spectrophotometer, Perkin Elmer, 
Lambda 16, USA). The lower absorbance indicated higher 
optical clarity of the systems. 
The ATS content present in prepared formulations was 
assessed by dissolving 1ml of the liquid SMEDD formu-
lation in methanol. After suitable dilutions with methanol, 
drug content was assayed at 246 nm (UV/vis spectropho-
tometer, Perkin Elmer, Lambda 16, USA).
Results and discussion
Solubility studies were carried out in order to identify 
the suitable vehicles for the formulation of SMEDDS. Ol-
ive oil, Tween 20 and PEG 400 were selected as oil phase, 
surfactant and co-surfactant based on their highest solubil-
ity towards ATS.
Results from experimental design studies pointed that 
D50 was in range of 0.61 µm to 1.212 µm and SPAN factor 
from 1.072 to 2.958, with unimodal particle size distribu-
tion.  The absorbance related to optical clarity of the pre-
pared formulations was in range of 0.119 to 0.455.
A special cubic model for D50 and reduced cubic mod-
el for SPAN factor and optical clarity was applied. Math-
ematical models for influence of selected variables upon 
followed responses were created and significant variables 
were identified. Variables BC, AC, AB and ABC were sig-
nificant for D50. For SPAN factor value and optical clarity, 
variables BC, AC, AB and AC*(A-C) and BC*(B-C) and 
AC*(A-C) were significant factors, respectively.
Results from experimental design studies were used 
for determination of optimal formulation; sample prepared 
with 15.44% olive oil, 19.48% Tween 20 and 65.08% PEG 
400 with predicted responses of 0.78 for D50, 1.14 for 
SPAN factor and 0.18 for absorbance with the desirabili-
ty value of 0.831. Cross validation of the model was car-
ried out and satisfactory results for percent of relative er-
ror (less than 10%) of the predicted and experimental val-
ues were obtained.
The ATS content in prepared SMEDDS was found to 
be in the range of 94–99%. The data inferred good drug-
loading with low standard deviation indicating the unifor-
mity of drug content. 
Optimized liquid formulation of ATS was further 
spray-dried in order to obtain solid SMEDDS.
Conclusion
Liquid SMEDDS of ATS were composed according to 
the solubility of drug in mixtures of oil phase, surfactant 
and co-surfactant systems. Optimal formulation was se-
lected based on results from the experimental design stud-
ies. Further investigations will be focused on characteriza-
tion of solid SMEDDS in order to confirm the potential of 
the designed system for solving the problem of formulat-
ing drugs with low aqueous solubility and poor systemic 
bioavailability. 
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Introduction
Multiple emulsions are complex polydispersed sys-
tems where both oil in water (o/w) and water in oil (w/o) 
emulsion exists simultaneously in a single system, stabi-
lized by lipophillic and hydrophilic surfactants, respective-
ly. The ratio of these surfactants is critical factor for achiev-
ing stable vesicular system (Kumar et al., 2012).  Multiple 
emulsions have been formulated for controlled/sustained 
or targeted drug delivery, taste masking, enzyme immobili-
zation, as well as cosmetic vehicles for skin care products. 
Water/oil/water (w/o/w) multiple emulsions consist of 
dispersed oil globules containing smaller aqueous droplets; 
each inner aqueous droplet is separated from the outer aque-
ous phase by an oil phase layer which acts as a liquid mem-
brane. Therefore,  w/o/w multiple emulsions have many 
advantages over conventional emulsions such as: relative-
ly high entrapment capacity for water-soluble agents, pro-
tection of substances that may undergo degradation, abil-
ity to introduce incompatible substances in two aqueous 
compartments of the same system and prolonged release 
rate of incorporated active agent (Mahmood and Akhtar, 
2013). The release properties and stability of w/o/w mul-
tiple emulsions are influenced by different factors, such as 
surfactants type and concentration, method of preparation, 
and some physical properties of the designed vesicular sys-
tem (globule size, viscosity, conductivity, phase volume ra-
tio, etc) (Vasiljevic et al., 2009).
In our preliminary studies, different factors (surfac-
tants concentration, phase volume ratio, preparation pro-
cedure) were investigated, and optimized formulation and 
process parameters were selected for further development 
of w/o/w multiple emulsion system suitable for topical de-
livery of resveratrol (RSV). RSV, an antioxidant polyphe-
nol from red wine, has been the subject of intense interest 
in recent years due to a range of unique anti-aging proper-
ties (Baxter, 2008). Therefore, the purposes of this research 
were to develop w/o/w multiple emulsion formulation us-
ing Brij® 93 and Tween® 20 as surfactants with resvera-
trol as active agent and to evaluate the characteristic prop-
erties and stability of the designed system. 
Materials and methods
Materials
Resveratrol (RSV) 2% aqueous solution was kindly 
donated from ACTIChem., France. Polyoxyethilene oleyl 
ether (Brij® 93) and polyoxyethilene sorbitan monolaurate 
(Tween® 20) were obtained from ICI, USA. Liquid par-
affin was supplied from Merck KGaA, Germany. All oth-
er chemicals and reagent were of analytical grade and used 
as received.
Preparation of multiple emulsions
Multiple emulsions were prepared by a two-step emul-
sification process. Briefly, for primary emulsification, 3 g 
of aqueous phase and 1 g of oil phase (liquid paraffin and 
Brij 93, mass ratio = 1:0.25) were preheated at 38 °C. Af-
terwards, the aqueous phase was gradually added to the 
oil phase using high-shear rotor-stator homogenizer (2.5 
min, 9500 rpm; Ultra-Turrax® T25, Ika-Werke, Germany). 
Homogenization was continued for additional 7.5 min. 
For secondary emulsification, prepared w/o emulsion was 
emulsified with 6 g of external aqueous phase containing 
1% of Tween 20 under the same conditions. Three differ-
ent formulations of RSV loaded (1.5%) w/o/w emulsions 
were prepared (sample 1 - RSV was incorporated into the 
inner aqueous phase (100%), sample 2 – 75% of RSV was 
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incorporated into the inner vs. 25% in outer aqueous phase) 
and sample 3 – RSV was equally divided into two aqueous 
compartments (50:50%)).  Blank sample was prepared for 
comparison.
Characterization of multiple emulsions with resveratrol
Microscopic analysis was conducted in order to gain 
information about the multiple structure of the prepared 
emulsions.  An optical microscope (OPTIKA® B-352A, 
OPTIKA SRL, Italy) with camera (AIPTEK™ 1080p HD, 
Aiptek International GmbH, Germany) was used through-
out the study. The droplet size was measured using Mas-
tersizer 2000 (Malvern instruments, UK) equipped with 
Hydro 2000S, Malvern Instruments Ltd., UK. 
In vitro RSV release studies were carried out using 
simple dissolution cells with semipermeable membrane 
(Visking tube from regenerated cellulose, thickness 0.9 
nm, pores size 1.52-2 nm; Serva Feinbiochemica GmbH, 
Germany). Briefly, 2 g of each formulation was added to 
donor compartment and membrane was tied on the bottom 
end of the tube. The tube was dipped into vessel contain-
ing 40 ml of water and was stirred at 100 rpm on a mag-
netic stirrer and maintained at 32 °C. Aliquots of 5 ml were 
collected from receiving chamber at predetermined time 
intervals and the RSV content was determined UV spec-
tophotometrically (UV/VIS Spectrophotometer, Perkin El-
mer Lambda 16, USA) at 324 nm.
Stability studies
The emulsions were monitored for consistency, color, 
homogeneity, phase separation and particle size during the 
storage period of three months at 5 ± 3 °C. Conductometric 
analysis was performed after the preparation of the sam-
ples and after three months stability period. Conductivity 
of the emulsions was measured directly using conductivi-
ty meter SevenCompact™ Conductivity S230 (METTLER 
TOLEDO, Switzerland) at 25 °C ± 2 °C.
Results and discussion
Immediately after preparation, the w/o/w emulsions 
were apparently brownish and homogenous viscous liq-
uids. The samples do not show any changes in appearance 
and homogeneity during the first 2 months of stability stud-
ied period. However, physical destabilization/flocculation 
was observed at the end of third month.
Microscopic analysis revealed the multiple character 
of the prepared samples with droplets containing a large 
number of small internal droplets (type A multiple emul-
sions) (Okushima et al., 2004). Blank sample had a mean 
size of 1.82 µm and SPAN factor of 1.45, with unimodal 
narrow size distribution. Mean droplet size of RSV load-
ed emulsions was 2.35, 1.76 and 2.38 µm and SPAN fac-
tor 1.45, 1.77 and 1.37 for samples 1, 2 and 3, respective-
ly. No significant differences in particle size were observed 
during the first two months of stability studied period. Af-
ter three months, mean droplet size was 0.21, 0.69 and 0.46 
µm for sample 1, 2 and 3, respectively, with bimodal par-
ticle size distribution indicating physical destabilization of 
the prepared systems probably due to the osmotic flow of 
water from internal to the external phase thus leading to 
shrinkage of the internal water droplets. Electrical conduc-
tivity of the freshly prepared samples was 48.8 – 54.2 µS/
cm. At the end of stability studied period only slight in-
crease in the conductivity values was observed most like-
ly due to coalescence of the internal and aqueous phases 
(Mahmood and Akhtar, 2013), but however no significant 
differences in conductivity were determined. 
RSV release from the prepared samples was 50.13, 
51.86 and 85.42% during the investigated period of 24 h 
for samples 1, 2 and 3, respectively. The rate of RSV re-
lease followed non-zero order kinetics (R > 0.997) with the 
release exponent ranging between 0.1 and 0.5.
Conclusion
Resveratrol (1.5%) loaded w/o/w multiple emulsions 
containing low concentration of surfactants were prepared 
and characterized with respect to their size, release prop-
erties and stability. Obtained results suggested that formu-
lation prepared with equally divided amount of resvera-
trol into the two aqueous compartments could be explored 
as a skin rejuvenating candidate. Further studies will be 
focused on formulation modification in order to achieve 
long-term stability.
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Introduction
Probiotics are defined as live microorganisms that 
have positive health effects on the host. There are many 
strains of probiotics that can confer health benefits, but the 
most prominent species are Lactobacillus and Bifidobacte-
rium. Numerous evidences indicate that selected probiotic 
strains can provide health benefits to the human host. Up to 
date, many clinical trials investigated the medical effects of 
these bacteria, particularly the positive effects to the gas-
trointestinal (GI) system. Moreover, studies have shown 
that probiotics exert beneficial effects to the immune sys-
tem, the urogenital system, in diabetes, oral health etc. 
(Charalampopoulos and Rastall, 2009).
The immune system, being highly adaptable defense 
system, functions in preserving the integrity of the organ-
ism by eliminating all elements perceived as foreign. Sev-
eral in vitro and in vivo studies have shown that specific 
strains of probiotics are able to modulate the functioning of 
the immune system, stimulate the immune function to pro-
tect against infectious diseases and different types of can-
cer and regulate over expressed immune responses asso-
ciated with immune inflammatory disorders such as aller-
gy (Gill and Guarner, 2004). In addition, studies presented 
beneficial effects in atopic diseases, including atopic ecze-
ma, allergic rhinitis and asthma.
The purpose of this review was to explore among the 
reported effects of different probiotic strains to the immune 
system, specifically in allergy.
Effects of probiotics in asthma and rhinitis
In one of the study with 41 asthmatic children (age 
6-12 years) a decrease of the inflammatory cytokine, 
TNF-α and Th2 cytokine IL-10 and IL-13 was shown. Pe-
ripheral blood mononuclear cells (PBMCs) were collected 
from the patients assigned to the probiotic-treated groups 
prior to and following the treatment and were then incubat-
ed with phytohemagglutinin, Dermatophagoides pteron-
yssinus, supplemented with Lactobacillus gasseri for 72h. 
Production of the cytokines in the culture supernatants was 
assayed using enzyme-linked immune-sorbent assay (ELI-
SA). The results of the study showed that the patients who 
took L. gasseri capsules for 8 weeks showed significant de-
crease in the cytokine level compared to the control group 
(Chen, et al., 2010).
Another study examined the effect of Lactobacillus 
casei in the treatment of asthma and allergic rhinitis. A 
group of 187 asthmatic children between the age 2 and 5 
years were tested for period of 12 months. This study pre-
sented that the milk, fermented with Lactobacillus casei 
didn’t show significant difference in the health status of 
asthmatic children compared to the control group. How-
ever, consumption of Lactobacillus casei fermented milk 
resulted in improvement in children with allergic rhinitis, 
i.e the number of rhinitis episodes was lower in the chil-
dren treated with probiotics compared to the control group 
(Giovannini et al., 2007).
Effects of probiotics in allergy animal models
Animal studies concerning effects of probiotics in al-
lergy also emerge, presenting a deeper understanding of 
the effects of probiotics. For example, one study exam-
ined the potential of 28 strains of probiotics in prophylax-
is of peanut-induced allergy in mouse model. Groups of 8 
mice were orally exposed to PBS (control) or peanut ex-
tract (PE) plus cholera toxin (CT). Oral exposure was per-
formed on days 0, 1, 2, 10, 17 and 24.  After a 6-week pro-
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biotic treatment with each strain and a 4-week oral expo-
sure regimen to PBS or PE with CT, the IgE specific for PE 
was measured. The results showed that Lactobacillus plan-
tarum increases the IgE in the serum, but Lactobacillus sal-
ivarius decreases the IgE for PE. In addition Lactobacillus 
casei Shirota didn’t show any effect to the IgE for PE, but 
the measured IL-4 and IL-5 levels were lowered by just us-
ing these strains. Again, L. plantarum increases the IL-4 
level but didn’t show any effect on IL-5 and L. salivari-
us showed slightly decreased level of the both cytokines 
(Meijerink et al., 2012).
Another study in mouse model of asthma studied the 
effect of Lactobacillus rhamnosus, using clinical evalua-
tions in vivo, bronchoalveolar lavage fluid analysis, serum 
IgG analysis, cytokine and lymphocyte proliferation as-
says.  The mice were sensitized by intra peritoneal admin-
istration of 10 µg ovalbumin with alum mixture. Treg cells, 
isolated from the spleen were analyzed for CD4+ CD25+ 
Foxp3+ expression using flow citometry. This study pre-
sented that Lactobacillus rhamnosus treatment led to a sig-
nificant increase in CD4+CD25+Foxp3+ Treg cells, com-
pared to the percentage in positive control mice, suggest-
ing that Lactobacillus rhamnosus induced attenuation of 
allergic responses in the mouse model of asthma is associ-
ated with an increased CD4+CD25+Foxp3+ Treg cell popu-
lation (Jang et al., 2012).
Conclusion
Many studies are trying to unveil the mechanisms of 
probiotic involvement and their beneficial effects to the 
health. Animal studies and clinical trials in different popu-
lations regarding different medical conditions, present ef-
fects that are somewhat controversial. In this context, as 
our literature research resulted, many of the evidences re-
garding immunological (allergic) diseases present weak or 
minimal effects.
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Introduction
The sialic acid is involved in many biological process-
es, related to the non-reducing terminal end of glycolip-
ides, glycoproteins and other glycoconjugates. Most fre-
quently, in glycoconjugate complexes, the sialic acid is 
found in a monomeric form. 
Sialic acid is often found as a polymerized structure. 
Sialic monomers possess the ability to bond with one an-
other and form dimers, oligomers and polysialic acids. In 
particular, polysialic acids are found to be involved in neu-
ral adhesion, more precisely, they regulate the activity of 
the molecules that control neural adhesion. 
The group of sialic acids contains about 50 derivates 
of N-acetylneuraminic acid, N-glycolylneuraminic acid 
and deaminoneuraminic acid. Methylation, sulfation, acet-
ylation and interactions between monomers of these three 
substances form the large group of sialic acids. 
Polysialic acids are mainly involved in changes of 
many functions of the nervous system. Neural cell adhe-
sion molecule is the most studied polysialated protein in 
which the polysialic acid contains α2-8 bonded N-acetyl-
neuraminic acid. This protein is connected to the cell mem-
brane with glycosyl phosphatidylinositol or it can be pres-
ent as a transmembrane protein involved in cell signaliza-
tion. Polysialic acids are present in the adult brain in the 
hypocampus, thalamus, amygdale, subventricular zone 
and prefrontal cortex, to be precise, in the parts where neu-
ral plasticity, neural generation and remodeling of neural 
connections are ongoing. It is more abundant in embryon-
ic brain tissue. 
The processes that polysialic acids are involved in-
clude neural cell migration, axonal guidance, myelina-
tion, fasciculation and plasticity of the nervous system. 
The mechanism of these actions is the anti-adhesive effect 
of polysialic acids in cell-cell and cell-matrix interactions. 
The anti-adhesive effect on is a results of the polyanion-
ic nature of these molecules, that generate a large negative 
electric field (Sato and Kijatima, 2013). 
Clinical implication
Schizophrenia is a psychiatric disorder with multiple 
factors contributing to its pathogenesis. Some reports sug-
gest that polysialic acids are involved in schizophrenia and 
other related psychiatric disorders. The background of this 
thesis lays in the gene that codes for an enzyme called al-
pha-2,8-sialyltransferase. Biochemical analysis suggests 
that the activity of this gene is decreased in schizophrenic 
patients, thus resulting with impairment of the quality and 
quantity of polysialic acids in the brain (Sato and Kijatima, 
2013). The level of sialylation of the neural cell adhesion 
molecule is decreased as well. 
Many cancer cells express polysialic acids on their cell 
surfaces. This results in attack to these cells by many mol-
ecules including anti-sialic antibodies (Sato and Kijatima, 
2013). Furthermore, because of its anti-adhesive effect, 
polysialic acids stimulate metastasis of the disease. 
Mono/di/oligosialic acids are considered as parts of 
other pathological changes in the human organism. Many 
bacterial toxins such as toxins from cholera, tetanus and 
pertussis, as well as various virus types bind to sialylated 
glycoconjugates. An example of this is the binding of influ-
enza virus with sialic acid containing glycans. The mecha-
nism of action is based on the activity of influenza’s most 
important glycoproteins: hemagglutinine and neuramini-
dase. Both glycoproteins recognize and bind to the the si-
alylated glycans of the cell membrane. First, the virus rep-
lication occurs, and then the activity of neuraminidase be-
gins stimulating dissociation of the sialic acids from the 
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glycan and subsequent increased permeability of  the cell 
membrane for the virus (Gamblin and Skehel, 2010). 
Sialic acids are also found to be involved in nonalcho-
holic fatty liver diease (Zhenya et al., 2016). The concen-
tration of the sialic acids in the serum increases when non-
alcoholic fatty liver disease occurs in non obese patients. 
Three possible mechanisms might underline the associa-
tion between sialic acids and the disease. Firstly, nonalco-
holic fatty liver disease patients are insulin resistant. The 
mechanisms that cause insulin resistance also causes ele-
vated sialation of the glycolipides and glycoproteins in the 
human serum and secondly, the reason for a higher concen-
tration of sialic acids in the serum of these patients can be 
the oxidative stress. Oxidative stress is an inevitable part 
of this disease, damaging the liver, and producing reactive 
oxygen species that interact with the terminal nonreducing 
parts of the serum glycoconjugates. This results with dis-
sociation of the sialic acids in the human serum. Finally, si-
alic acids can be part of proteins produced by the liver as a 
response to the disease, called acute phase proteins. Sialic 
acids are involved in other inflammatory processes such as 
cardiovascular diseases. 
Sialic acids are bioindicators of diabetes mellitus. 
Their presence is greater in type 2 diabetes patients suf-
fering from diabetic nephropathy. Some of the sialylated 
glycoproteins in the human serum are called acute phase 
reactants, because their concentration increases during in-
flammation. In type two diabetes mellitus, there is a stage 
of cytokine induced-acute phase response which leads to 
elevated sialic acid concentration in the serum. In diabet-
ic nephropathy, there is damage to the vascular endotheli-
al cells of the kidney, which is accompanied with inflam-
mation, resulting with elevated concentration of sialic ac-
ids in the serum. It is important to note that the concentra-
tion of these substances is greater when diabetic nephropa-
thy occurs, in comparison to cases with uncomplicated di-
abetes (Varma et al., 2016). 
Conclusion
Sialic acids play a great roll in the ethiopathology and 
the diagnosing of many pathological changes in the hu-
man organism. They are considered one of the indicators 
in diagnosing diabetic nephropathy in patients suffering 
from type 2 diabetes mellitus. Elevated levels of sialic ac-
ids in the human serum are associated with non obese fat-
ty liver disease and indicate a potential risk for its develop-
ment. This means that sialic acids play a role in the meta-
bolic changes that result with this disease, and as such are 
used in its diagnosis. In infections on the other hand, sial-
ic acids are used indirectly in therapy. Identification of the 
mechanisms of binding of the viruses to the cells, enables 
creation of antiviral medications for treatment of many in-
fections caused by resistant viruses and bacteria. Various 
types of cancer show elevated concentration of polysialic 
acids, making the diagnosis of the disease easier. Finally, 
in vivo and in vitro analyses show that enzymatic activity 
of alpha 2,8-sialyltransferase is decreased in patients with 
schizophrenia, resulting with impairment of the quality and 
quantity of the polisyalic acids.
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Introduction
Biologic medicines are mainly protein-based medi-
cines derived from living organisms or cells cultured in a 
laboratory. Those medicinal products are larger and more 
complex than conventional (non-biological) drugs. Biolog-
icals can be hormones (growth hormones, insulin, erythro-
poietin), enzymes, monoclonal antibodies, blood products, 
immunological medicinal products (sera and vaccines) or 
advanced technology products such as gene and cell ther-
apy (Consensus Information Paper, 2013). The structure–
function relationships of biologicals are very sensitive, be-
cause modifications of tertiary or quaternary configuration 
may affect safety, purity and potency. They have a complex 
mechanism of action by targeting more selective to the cell 
or molecule that is responsible for the development of cer-
tain diseases.
The paradigm for biologicals “the process is the prod-
uct” still is viable today.  Their manufacturing is challeng-
ing process, where critical culturing and purification steps 
is required to produce a consistent, high quality active in-
gredient. Gene manipulation, fermentation and purification 
are used with high level of expertise in order to guaran-
tee the safety and efficacy of the final product. Biologicals 
are usually more difficult to characterize than chemical-
ly derived medicinal products. Moreover, post-translation-
al modifications such as glycosylation, oxidation and de-
amination can be significantly altered by changes (Geigert, 
2013). Even minor changes in manufacturing process can 
cause significant changes in efficacy or immunogenicity.
The use of modern technologies like biotechnology, 
DNA recombinant techniques etc. results with the first re-
combinant biological medicine, human insulin (Humulin), 
approved for therapeutic use in 1982 from FDA. The era of 
recombinant monoclonal antibodies started in 1995.  Since 
then, the number of biologicals approved for human use, 
including monoclonal antibodies (mAbs), has increased 
considerably.
These medicines have advanced the treatment of many 
chronic and life-threatening diseases. Even though bio-
logicals are much more expensive than chemical entities, 
health care providers and payers considered that they are 
worth their cost - as long as the appropriate patients re-
ceive them and achieve the desired clinical outcomes. Pa-
tients for whom biologicals are a good choice include those 
who have failed on conventional therapies or for whom no 
other options exist. The predictions are that by 2017 glob-
al biological pharmaceutical market will amounts to about 
$220 billion (Dolinar and Reilly, 2013). 
On the other hand, after the first biological medicines 
were launched, exclusivity rights on these drugs have be-
gun to expire, and thus present an opportunity for pharma-
ceutical companies to consider developing biosimilar med-
icines of these products. In general, this means that the bi-
ological reference medicine must have been authorized for 
at least 10 years before a biosimilar can be made available 
by another company.
What are biosimilars?
Biosimilars are not generic versions of biologics. “A 
biosimilar is a biological medicinal product that contains 
a version of the active substance of an already authorized 
original biological medicinal product (called reference 
medicinal product). Similarity to the reference medicinal 
product in terms of quality characteristics, biological ac-
tivity, safety and efficacy based on a comprehensive com-
parability exercise needs to be established.” This includes 
physicochemical and biological characterization and re-
quires knowledge on how to interpret   any differences be-
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tween a biosimilar and its reference medicinal product (Eu-
ropean Medicines Agency, 2014). Actually, the changing 
outlook for biosimilars comes at a time when the global 
pharmaceutical market is feeling the combined impact of 
two key events: a period of unprecedented patent expira-
tions on many of the world’s largest pharmaceutical prod-
ucts, and a financial crisis that has required healthcare sys-
tems to make significant and sustained cost reductions. Bi-
osimilars may have the potential to increase patient ac-
cess to potentially valuable therapies at a lower cost (IMS 
Health, 2011). 
Approval and licensing pathways of 
biosimilars  
In 2005, the EMA/ European Commission were the 
first to implement a well documented legal and regulato-
ry pathway for the approval of biosimilar products that is 
distinct from the generic pathway. The approval of the first 
biosimilar product, somatropin (Omnitrope), following the 
EMA’s new approach, was in 2006, followed by erythro-
poietin (2007) and filgrastim (2008). Five years later, in 
2013 the first mAb biosimilar, infliximab, was approved in 
Europe. Market authorization for biosimilars is issued on 
“step by step, case by case” basis to demonstrate similarity 
with respect to structural and functional characterization, 
in vitro biological assays and pharmacokinetic and phar-
macodynamics evaluation, as well as safety, efficacy and 
immunogenicity studies. 
Substitution and interchangeability
Substitution of generic drugs for reference drugs is un-
controversial because the two will be identical if they have 
demonstrated bioequivalence. Since biological drugs can 
never be exact copies, the question whether they can be 
substitutes of original biologics remains unclear (Ebbers 
and Chamberlain, 2014). These medicinal products are not 
directly interchangeable. In EU these terms, interchange-
ability and substitution, are not used as synonyms. (Espin 
et al., 2011). Interchangeability refers to the prescription 
of biosimilar in place of the reference product by prescrib-
ers, while substitution means that pharmacists are allowed 
to dispense a biosimilar. EMA does not guarantee inter-
changeability and established that these aspects are beyond 
its competence. The decisions on the interchangeability 
of biosimilars and innovator products rest with the Mem-
ber States in the EU. The European Generic Association 
(EGA) reported that more than 12 countries across the EU 
have introduced rules to avert automatic substitution of in-
novator biological with biosimilars. 
The increased use of this medicine have arisen many 
questions and there remains an need to continued guidance 
for substitution from regulatory agencies with regards to 
safety issues, as well as those for pharmacovigilance and 
risk- mitigation activities. This is anticipated and will be 
critical to the further therapeutic use of biosimilars.  
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Introduction
The aflatoxins are toxic substances produced as sec-
ondary metabolites by the fungus Aspergillus flavus and 
Aspergillus parasiticus. Foods in which aflatoxins are 
commonly found include rice, corn, peanuts, tree nuts, co-
coa beans. The aflatoxins are potent toxic, carcinogenic, 
mutagenic and immunosuppressive agents. Today, there 
are approximately 16 known types of aflatoxins including: 
aflatoxin B1, aflatoxin B2, aflatoxin B3, aflatoxin G1, af-
latoxin G2, aflatoxin G2a, aflatoxin M1, aflatoxin M2, af-
latoxin P and aflatoxin T2. The four major aflatoxins that 
cause illness in humans and can be found in food are: afla-
toxin B1, aflatoxin B2, aflatoxin G1 and aflatoxin G2. The 
International Agency for Research on Cancer has classified 
aflatoxin B1 as a group 1 carcinogen (carcinogenic to hu-
mans) and aflatoxin M1 as a group 2b carcinogen (carcino-
genic to laboratory animals and possibly carcinogenic to 
humans, respectively). The exposure to aflatoxins and the 
resulting aflatoxicosis can vary from acute to chronic, and 
the illness can range from mild to severe. Acute exposure 
to high doses of aflatoxins can result in aflatoxicosis, hav-
ing the liver as a target organ, which can lead to serious liv-
er damage. Chronic exposure to sublethal doses of aflatox-
ins can result in liver cancer, impaired protein formation, 
impaired blood coagulation and toxic hepatitis.
People who have aflatoxicosis might exhibit the fol-
lowing characteristics:
- Liver damage may be confirmed by jaundice and 
characteristic yellowing of tissues
- Gall bladder may become swollen
- Immunosuppression may provide an opportunity for 
secondary infections
- Vitamin K functions may decrease
- High level of aflatoxin B1 – albumin adducts may be 
present in plasma. 
Clinical implication
The most commonly used human samples for aflatox-
in analysis are blood and urine. Aflatoxin exposure can be 
monitored by using biomarkers that detect the presence of 
aflatoxin metabolites, excreted DNA adducts and blood 
protein adducts. Aflatoxin - albumin adducts are found in 
peripheral blood after exposure to aflatoxin B1. Aflatoxin 
M1 and aflatoxin B1 – DNA adduct (aflatoxin B1 – gua-
nine adduct) can be detected in the urine of people consum-
ing sufficient amounts of aflatoxin B1. Increased levels of 
serum alkaline phosphatase are a biochemical indicator for 
aflatoxins toxicity. 
Detection methods for aflatoxins in human body sam-
ples are radioimmunoassay (RIA), enzyme – linked immu-
nosorbent assay (ELISA), high – performance liquid chro-
matographic fluorescence detection (HPLCf).  
Albumin samples are digested with proteinase K in 
a phosphate - buffered saline (PBS, pH 7.4) for 15 h at 
37oC. Following hydrolysis, bovine serum albumin (BSA) 
is added to improve precipitation, followed by cold etha-
nol addition. Samples are kept at -20oC for 2 h, centrifuged 
at 1500xg for 15 min and the supernatant is diluted with 
6% ethanol in PBS. The samples are then loaded into an 
activated Sep – pak CIS cartridge (Waters, Milford, MA), 
washed with water, 5% methanol, and the aflatoxins are 
eluted with 80% methanol. Eluates are dried, reconstituted 
in PBS containing 1% fetal calf serum (to saturate residu-
al proteinase K activity), and tested with ELISA using afla-
toxin – lysine standard (Wild et al., 1990). 
A study conducted in sub – Saharan Africa proved 
that chronic hepatomegaly is common among school – age 
children in sub – Saharan Africa. This study examined the 
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role of aflatoxin in chronic hepatomegaly. Plasma sam-
ples were collected in 2002 and 2004 from 218 children 
attending two schools in neighboring villages (Mantagini 
and Yumbuni). Plasma samples were assayed for aflatoxin 
exposure using the aflatoxin – albumin adduct biomarker 
(AF – alb). The blood AF – alb levels were determined us-
ing ELISA. One negative and three positive controls were 
analyzed alongside each batch of samples. The limit de-
tection for AF – alb was 3 pg/mg albumin. AF – alb levels 
were high in children from both schools, but the geometric 
mean value (95 % confidence interval) in 2002 was signif-
icantly higher in Matangini (206.5 pg/mg albumin) than in 
Yumbuni (73.2 pg/mg). AF – alb levels were also higher in 
children with firm hepatomegaly (176.6 pg/mg) compared 
to the control group (79.9 pg/mg). In 2004, AF – alb lev-
els were higher than in 2002 (539.7 vs. 114.5pg/mg), but 
with no significant difference between the villages or be-
tween hepatomegaly and control groups (539.7 vs. 512.6 
pg/mg). Exposure to aflatoxin was associated with child-
hood chronic hepatomegaly in 2002 (Gong et al., 2012).
Aflatoxin is known to cross the placental barrier and 
exposures in utero could influence genomic programming, 
fetal growth and development. In a study, pregnant Gam-
bian women were examined for aflatoxin exposure at two 
stages of their pregnancy (early - < 16 weeks; and later - 
16 weeks onward), during the rainy (June to October 2009) 
or dry (November to May 2010) season, using aflatoxin 
albumin adducts (AF – alb). Plasma samples were ana-
lyzed for AF – alb using a competitive ELISA. One neg-
ative and three positive controls were analyzed alongside 
each batch of samples. The limit of detection for AF –alb 
was 0.6 pg/mg albumin. Mean AF – alb was higher dur-
ing the dry season than in the rainy season, in both early 
and later pregnancy, although the difference was strongest 
in later pregnancy. There was a modest increase in AF – 
alb in later compared to early pregnancy (geometric mean 
41.8 vs. 34.5 pg/mg), but this was restricted to the dry sea-
son when exposures were generally higher. The study con-
firmed that Gambian pregnant women were exposed to af-
latoxin throughout the pregnancy, with higher levels in the 
dry season. Overall, the stage of pregnancy was not signif-
icantly associated with AF-alb but season was (Castelino 
et al., 2014).
Prevention
Considering the danger of human contamination with 
aflatoxins, prevention is an imperative, as the safest and 
most economical protection method. The most promis-
ing strategy currently being used to reduce contamination 
of crops with aflatoxin is to introduce non – aflatoxin (bi-
ological control) A. flavus. The method involves spread-
ing non – aflatoxigenic spores onto the field. It is assumed 
that addition of the non – aflatoxin producing strain would 
then allow it to out – compete the wild – type populations 
and thereby displace the wild – type fungus. This strategy 
is called a “displacement” strategy. Assuming this is effi-
cient, the resulting treated fields should never have to be 
treated again, because, then, only the non – aflatoxigenic 
population of fungi would be present in the fields. Wheth-
er or not introduction of biological control strains into the 
fields is enough to reduce aflatoxin contamination to level 
required for acceptance of the contaminated food as fit for 
consumption is still unknown. There is no doubt that bio-
logical control strains are able to reduce the size of the pop-
ulations of aflatoxin – producing strains, but the available 
data suggest that at most only a four – to five – fold reduc-
tion in aflatoxin contamination is achieved (Ehrlich, 2014).
Conclusion
Aflatoxins are mycotoxins contaminating large pro-
portion of the food all around the world. Knowing that 
aflatoxins are carcinogenic, teratogenic and mutagenic 
agents and cause different forms of toxicosis (aflatoxico-
sis), emphasizes the fact that serious efforts are needed to-
wards researching and discovering appropriate strategies 
for prevention and treatment. The prevention and treatment 
should be directed towards finding strategies to protect the 
grains and discovering agents which will be used to protect 
the human body from the toxic effect of aflatoxins. Aware-
ness should be raised in governments to assemble groups 
of healthcare workers which will contribute to lowering the 
aflatoxins exposure, and hopefully their elimination.
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Introduction 
Advertising and promotion of medicines are among 
key regulatory functions of the medicines chain.  The 
World Health Organization (WHO) defines promotion as: 
“all informational and persuasive activities by manufactur-
ers and distributors, the effect of which is to induce the pre-
scription, supply, purchase and/or use of medicinal drugs”. 
In 1989, WHO established ethical criteria for medicines 
promotion that are still relevant today (WHO, 1988). Ac-
cording to the principles of good practice for promoting 
medicines to the general public, this function is permit-
ted for pharmaceuticals classified as nonprescription med-
icines (over-the-counter, OTC), but should not be direct-
ed at children as target audience. However, the manufac-
turers of prescription only medicines are in restrictive po-
sition in providing information to patients since the adver-
tising of prescription only medicines to the general pub-
lic is prohibited. As acknowledge, OTC medicines as part 
of health coverage are medicines which are approved for 
use without a medical prescription. These medicines and 
health-related products from general sale list can be pur-
chased by patients and consumers through pharmacies, and 
in many countries (including our country), from non-phar-
macy retail outlets. In this context, as no healthcare pro-
fessional is necessarily involved in OTC medicines use it 
is evident that the nature of their promotion to the gener-
al public have a special importance for supporting their ap-
propriate and responsible use by patients and consumers. 
From all these underlying reasons associated with adver-
tising and promotion of medicines, it is generally accept-
ed that this pharmaceutical function in each country must 
comply with national health policies and regulations, as 
well as with standards, guiding principles and ethical crite-
ria. Different mechanisms can be used for regulation of ad-
vertising of OTC medicines. 
The aim of our study is to present the elements of ef-
ficient and ethical promotion of OTC medicines accord-
ing to the WHO standards, and to demonstrate the special 
role and benefit of OTC medicines promotion in the public 
health context. Moreover, the preliminary results of con-
ducted analysis in the domain of OTC medicines promo-
tion on domestic market are also discussed in this context. 
Materials and methods 
The varieties of OTC medicines promotional materials 
available on the domestic market for the provision of pa-
tient and consumer information are also analyzed. In fact, 
approximately 30 OTC medicines from retail environment 
for pain relievers, laxatives, cough and cold from different 
manufacturer has been included in the study.  
Results and discussion
In general, advertising and promotional materials in-
tended to patient and consumer can be available in a va-
riety of forms, including: 1) printed material for example 
leaflets, posters then, materials in newspapers and maga-
zines or direct mail materials etc.; 2) electronic media ad-
vertising form such as websites and on-line material, 3) au-
dio and audiovisual advertising forms (e.g. television, vid-
eos or radio commercials); 4) ‘‘other’’ forms (e.g. outdoor 
advertising, promotional text messages, and so on). 
WHO describes the purpose of advertising as: “Attract 
attention, offer choices, and provide limited general infor-
mation to mass audiences of consumers. It must stimulate 
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the interest of prospective buyers in a… product; inform 
them of what it may do for them… Therefore, advertis-
ing should not be overloaded with information to the point 
that the individual prospective buyer may fail to compre-
hend it or may even ignore it”. Overall, the OTC medi-
cines promotional materials aimed to raise patient and con-
sumer awareness about their condition and, in particular 
about the possibility for suitable self-medication and self-
care. Moreover, these materials should also advice patients 
and consumer about new products and/or attract their at-
tention on the new indications for use of old one OTC med-
icines. Another positive benefit of OTC medicines promo-
tional material, but not less important, is that they can lead 
to reinforce of other forms of communication for exam-
ple, with health professionals and as a consequence, they 
should promote and facilitate the rational use of OTC med-
icines. The obvious example is the warning information 
on the promotional material stating: “if symptoms persist, 
consult a health care professional”. It is well known that 
the OTC medicines promotional materials play also impor-
tant role in patients and consumers decision making pro-
cess towards selection of medicines, where there is a mul-
tiplicity of choice and also direct them to medicines label-
ing important for safe and appropriate use. From the prac-
tical point of view, OTC medicines promotional material 
may also have a positive effect on patient’s compliance. 
The OTC medicines manufacturers are competing with 
each other to encourage patients and consumers to use their 
products.
Basic ethical standards for OTC promotion have to en-
sure that the information conveyed to patients and consum-
ers is truthful and not misleading. The concept of promo-
tion is not to force people to buy and use an OTC medi-
cine they do not want or need. General ethical criteria for 
OTC medicine advertising are highlighted in WHO assess-
ment document (WHO, 2000): 1)“While advertisements 
to the general public should take account of people’s le-
gitimate desire for information regarding their health, they 
should not take undue advantage of people’s concern for 
their health”; 2)“While health education aimed at children 
is highly desirable, drug advertisements should not be di-
rected at children”; 3)“Advertisements may claim that a 
drug can cure, prevent, or relieve an ailment only if this 
can be substantiated”; 4)“They should also indicate, where 
applicable, appropriate limitations to the use of drugs”; 5) 
“When lay language is used, the information should be 
consistent with the approved scientific data sheet or other 
legally determined scientific basis for approval. Language 
which brings about fear or distress should not be used”.
These criteria constitute general principles for ethical 
standards which could be adapted by governments to na-
tional circumstances as appropriate to their political, eco-
nomic, cultural, social, educational, scientific and techni-
cal situation, laws and regulations, and the level of their 
health system development. It is worthy to mention that in 
our country these criteria are being fully met.
Other important dimension of OTC medicines promo-
tion is the mechanism for its regulation. In line with this, 
it is highly recommended that two systems should be put 
in place, such as pre-marketing release and post-marketing 
surveillance system. Actually, the first system formally ap-
proved promotional material while, the second one would 
secure enforcement mechanism.    
Patients have a legitimate right to get good quality in-
formation, in a well-regulated way, from the reliable source 
for each OTC medicines.      
Conclusion
Patients have a legitimate right to get good quality in-
formation, in a well-regulated way, from the reliable source 
for each OTC medicines. In continuum, they are being con-
veyed with increasing amounts of OTC medicines promo-
tional materials from different parties and through multi-
ple channels. It is obvious, that some information might be 
of varying quality and accuracy. The high standards should 
be applied in OTC medicines promotion. Apart from eth-
ical and effective promotion standards of OTC medicines 
this regulatory function, alone is not providing detailed and 
comprehensive information on OTC medicines, but it can 
convey needed information for responsible self-medication 
by patients.
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Introduction
During the harvest of the chamomile, which can be 
done as monophase, or as dual phase, that in other words 
means picking up only the flower that has its own purpose 
or to harvesting completely the stem and the flower togeth-
er? In the Republic of Macedonia the right conditions are 
in the second half of May and beginning of June, depend-
ing on soil-climate conditions and on larger parcels it is 
done by machines with special constructed combine har-
vester or it is done manually.
After the harvest, the chamomile is being dried in spe-
cial driers which are various, with different capacities for 
drying and are mainly divided into:
1. Driers on solar energy
2. Driers on solid fuel
3. Driers on oil derivates
4. Driers on electric current
5. Combined driers
1. Principle of work and driers’ role in the chamomile 
drying process
The chamomile as culture is very specific in the dry-
ing process and the harvest depends on the drying process 
itself. It is harvested the whole and is haymaking, or the 
flower is collected by combine harvester, depending on the 
market demands it is intended to. The chamomile contains 
active and hidden moisture, mainly in the harvest phase. 
When the flower is collected, it contains about 65% mois-
ture that is active and should be lowered to 12% during 
the drying process, percentage of moisture that allows the 
chamomile to be stored in various packages, where the dry-
ing process continues, and does not harm while is stored, 
kept, transported or used.
2. Techniques and technologies for chamomile drying
Chamomile can be dried as flower or as whole plant 
with the stem and the flower together. From thermal as-
pect, and mechanical laws, especially thermodynamics, the 
drying is done by thermal energy along with cold and hot 
air circulation. That is the essence of chamomile drying as 
a culture, because chamomile contains active and hidden 
moisture and needs strictly defined principle of regulation 
by temperature amplitudes and air circulation amplitudes, 
depending on that, time duration of the drying and the con-
sumed energy we get the price of cost of this working pro-
cess, and the quality as general (Dimov, 2014).
The driers are placed in Ltd. “Koro Company” in Sko-
pje which is a company main activity that deals with cul-
tivation and processing of medical and aromatic plants. 
The first drier was with smaller dimensions, 5.8 meters in 
length, 1.55 meters width and 2 m height, 18 m3 cover 12 
000 m3 air. The heaters’ energy (capacity) was 60 calories. 
The second drier was with the following dimensions: 5.8 
meters in length, 3.4 meters width and 2 m height. The fan 
was with 26000 m3 capacity and the heaters had maximum 
capacity of 160 kg calories.
There is proportion of the dimensions of the drier with 
thermodynamic laws and there was quality drying neces-
sary for balance of the inflow, entrance air circulation for 
time unit and entrance energy which are 2 essential factors 
for drying, and if the driers have different dimensions, also 
it is necessary to modify the values of the heaters and the 
fan that are basic parameters.
Materials and methods
Methods - Machines with special constructed combine 
harvester or it is done manually. 
Materials - The term Chamomile actually refers to a 
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range of different daisy-like plants, which are a member of 
the Asteraceae family. There are many different species of 
chamomile, the two most commonly being German chamo-
mile (Marticaria recutita) and Roman chamomile (Chamae-
melum nobile). They have been used since Ancient times 
for their calming and anti-inflammatory properties and each 
offer their own additional health benefits (Dimov, 2014).
The chamomile stem is procumbent, and the leaves 
are alternate, bipinnate, finely dissected, and downy to gla-
brous. The chamomile flowers are held in solitary, terminal 
flowerheads, rising 8-12 inches above the ground. Chamo-
mile flowers consist of prominent yellow disk flowers and 
silver-white ray flowers. The flowers are arranged in con-
ical centre (having 18 white rays), receptacle, on which 
the yellow, tubular florets are placed. Chamomile flowers 
bloom during the months of June and July. The Chamomile 
is from from Northeastern Region of Macedonia in Munic-
ipality of Rankovce. 
Results and discussion
From the obtained results, it can be noticed that dif-
ferent volume of the driers 1 and 2, receive different green 
mass, which in our case is in the center of attention, the 
factor of height green mass (layer thickness) that are aver-
age 45 centimeters.
During the measurements it was noticed that chamo-
mile layer of 40 cm with three switches had duration for 
drying of about 24 hours with constantly turned on heaters, 
and in the case with layer bigger than 45 cm, drier of 2 me-
ters height, the process of drying shall be prolonged to 30 
hours, with 4 or 5 switches.
Only the flower was dried which has structure like this: 
flower is 70% green mass, and 30% flower lattices. We no-
ticed that by each switching, the green mass was damaged 
and quality lowered. While measuring in both driers, we 
came to a conclusion that the layer of spread mass should 
not exceed 40 cm spread on the floor, without any shelves. 
That conclusion is due to the fact that each harvest has to 
be done in appropriate weather conditions on temperature 
above 20 °C with average air humidity of 40%, which are 
ideal climate conditions for chamomile harvesting.
That was the reason for such measurements and mon-
itoring of this issue and we gained wide knowledge for 
quality of chamomile production and regime of drying and 
that the quality itself and economy of the final product de-
pends on it.
Conclusion
Our results are contribution in understanding of this 
medical plant and its process of drying. Obtained results 
have a contribution in the pharmaceutical industry and give 
opportunity for future research. It will be worthwhile to 
perform further studies in order to confirm these results. 
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Introduction
Quality by design (QbD) principles are implemented 
into the design and development of microsponges as drug 
delivery carriers (MDDC) with potential to be incorporat-
ed into gel as semi-solid dosage form for topical applica-
tion. As a stand for identification and optimization of crit-
ical material attributes (CMA) and critical process param-
eters (CPP), MDDC particle size was used as it is criti-
cal for their encapsulation efficiency, drug loading capaci-
ty and drug release profile (properties related to drug prod-
uct efficacy and safety). In the previous work of Crcarevs-
ka et al. (2015) CMA and CPP were identified using Qual-
ity Risk Management (QRM) analysis and hence CPP 
were further optimized using design of experiments stud-
ies. Optimal process conditions for minimal particle size 
(D10, D50, D90) and minimal distribution (Span factor) 
were determined to be rotation speed of 24000 rpm and ro-
tor–stator homogenizer as type of stirrer used for evapo-
ration of organic phase for MDDC preparation by double 
emulsion-solvent-diffusion technique. Amount of chitosan 
(CTS), ethylcelulose (EC), span 80 (S80), tween 80 (T80), 
acetone (ACT), dichlormethane (DHM) and internal water 
phase (W1) were identified as potentially significant CMA. 
In this work factorial design of experiments (DoE) was ap-
plied for rationalization of previously identified potential-
ly significant formulation variables. Afterwards formula-
tion optimization of MDDC loaded with clindamycin hy-
drochloride was carried out using Central Composite (CC) 
Response Surface Method (RSM) DoE.
Materials and methods
Materials
EC was purchased from Sigma, USA. CTS (high vis-
cous) was supplied from Aldrich, Island. T80, S80 and 
DHM were obtained from Merck, Germany; while ACT 
was purchased from Alkaloid, Macedonia. Clindamycin 
hydrochloride (CM-HCl) was kindly donated by Higija 
Farm, Bitola, Macedonia. All other used chemicals and re-
agents were with analytical grade and were used without 
any modifications.
Methods 
Determination of statistical significant influence of 
previously identified CMA (Crcarevska et al., 2015) on 
particle size (D50) and particle size distribution (Span fac-
tor) was carried out using 2 IV
7-3 factorial DoE (Design-
Expert V8 trial, Stat-Ease, Inc., Minneapolis, USA). All 
formulation variables were varied on two levels, with 8 
central points. The total of 24 experiments was carried out. 
Low and high levels of actual values for studied variables 
were as follows: for factor A: CTS (0.8%) - 0.1 to 0.5 ml, 
factor B: W1 - 1.5 to 3.5 ml, factor C: ACT - 0.2 to 1 ml, 
factor D: S80 - 0.03 to 0.13 g, factor E: EC - 0.03 to 0.13 
g, factor F: DHM - 6 to 12.5 ml and factor G: T80 - 0.15 
to 0.45 g.
In order to optimize formulation variables for prepa-
ration of MDDC with desired particle size and distribu-
tion, as well as drug content and encapsulation efficien-
cy, formulation factors identified with factorial DoE, were 
varied in the relevant design space. For this purpose a to-
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tal of 40 experiments were created using face centered CC 
type Min Run Res V - RSM DoE (Design-Expert V8 tri-
al, Stat-Ease, Inc., Minneapolis, USA). The design ma-
trix was constructed in one block where each studied fac-
tor was varied at 5 levels (low and high level of factorial 
and axial points and center point). Used low and high ac-
tual values of studied factors were as follows: factor A1 
(W1) - 1.5 to 3.5 ml, factor B1 (ACT) - 0.2 to 1 ml, factor 
C1 (S80) - 0.03 to 0.13 g, factor D1 (DHM) - 6 to 12.5 ml 
and factor F1 (CM-HCl) - 0.03 to 0.13 g. CTS (0.8%) and 
T80 amounts were fixed at 0.1 ml and 0.45 g respectively. 
MDDC were prepared using previously optimized 
double emulsion-solvent diffusion technique and charac-
terized in means of particle size (D10, D50, D90) and parti-
cle size distribution (Span factor) (Crcarevska et al., 2015). 
Results and discussion
MDDC were prepared by double emulsion solvent dif-
fusion technique using rotor–stator homogenization tech-
nique. In the previous work of Crcarevska et al. (2015) for-
mulation and process variables that might have critical in-
fluence upon drug product quality were identified. Having 
in mind number of variables identified a sequential strat-
egy in the further development of MDDC was selected. 
Process variables were optimized, and hence the current 
work is related to detailed characterization of influence of 
formulation variables on MDDC properties. Results from 
factorial design studies enabled identification of variables 
with statically significant influence on D50 and Span fac-
tor. D50 of prepared MDDC was in a range of 15.255 ± 
0.37 µm to 220.816 ± 5.23 µm, while Span factor ranged 
from 2.612 ± 0.28 to 16.092 ± 0.45. Mathematical mod-
els of inverse function of D50 square root and inverse 
function of Span factor and studied variables were estab-
lished. One way ANOVA pointed that factors B (W1), C 
(ACT), D (S80), E (EC), F (DHM) and factors interaction 
AF (W1*DHM) and AG (CTS*T80) are significant model 
terms in case of D50. W1 was determined to be statistical-
ly significant in case of Span factor.
Based on the obtained results for further studies re-
lated to optimization of formulation of MDDC CM-HCl 
loaded, variables W1, ACT, S80, EC and DHM were se-
lected. Also, amount of CM-HCl was considered as for-
mulation variable that might influence MDDC properties. 
Results from CC-RSM studies permitted detailed charac-
terization of influence of studied variables on particle size 
(D10, D50, D90) and particle size distribution (Span fac-
tor). D10 of MDDC CM-HCl loaded was in range of 1.375 
± 0. 64 to 64.538 ± 3.22 µm. Mathematical modeling of 
log10 (D10) resulted with linear model. One way ANOVA 
pointed that S80 and EC are statistically significant mod-
el terms. D50 for MDDC CM-HCl loaded was in range 
of 6.582 ± 0.85 µm to 338.146 ± 8.72 µm. Reduced qua-
dratic model for square root of D50 was established. Vari-
ables W1, S80, EC, S80*EC, (EC)2 and (CM-HCl)2 were 
found to be statistically significant in case of D50. D90 
was in a range of 53.104 ± 2.35 µm to 1235.82 ± 15.46 
µm. Influence of investigated variables on D90 of MDDC 
CM-HCl loaded could be described by reduced quadrat-
ic model. Statically significant model terms were DHM, 
W1*ACT, W1*DHM, ACT*EC, ACT*CM-HCl, S80*EC, 
S80*DHM and (ACT)2. Span factor ranged from 1.546 ± 
0.37 to 13.841 ± 2.62. Inverse function of square root of 
Span factor was also modeled by reduced quadratic mod-
el. Variables ACT, EC, CM-HCl and interaction terms 
W1*S0, EC*DHM, DHM*CM-HCl as well as (S80)2 were 
determined as statistically significant model terms in case 
of Span factor.
Conclusion
A sequential experimental strategy was applied in 
the development of MDDC-CM-HCl loaded. Screening 
DoE (2 IV
7-3 factorial design) was employed for identifi-
cation and rationalization of significant formulation vari-
ables. Detailed characterization of variable influence upon 
parameters of interest was performed using Central Com-
posite (type Min Run Res V) - Response Surface Meth-
od DoE. In the current study results related to particle size 
and particle size distribution were presented. MDDC-CM-
HCl loaded will be further characterized in means of drug 
content (DC) (mg CM-HCl/g EC  ± SD, and encapsulation 
efficiency (EE%) (percentages of mass of entrapped CM-
HCl compared to used CM-HCl for preparation of MDDC 
(%) ± SD). Obtained results will be used for formulation 
optimization.
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Introduction
Pharmacovigilance is the science that allows systemat-
ic detecting, gathering, monitoring and evaluation of new 
data on drug safety and risk/benefit ratio in their use. It is in 
continuous upswing and it is represented as a control tool 
which is vital for providing safe, effective and high qual-
ity drugs for human use. The specific targets for pharma-
covigilance include better patient care and increased safe-
ty in the use of drugs, better public health, giving its con-
tribution in the assessment of the benefit, hazard, risk and 
the effectiveness of the use of medicines, encouraging their 
safe, rational and efficient use and providing education and 
clinical practice for pharmacovigilance for the public.
The new pharmacovigilance legislation came into ef-
fect in July 2012 and it was the biggest change to the reg-
ulation of human medicines in the European Union since 
1995. This new legislative had significant implications for 
applicants, as well as for patients, healthcare professionals 
and regulators.
The National center for pharmacovigilance in Repub-
lic of Macedonia is founded in 1997 in the Institute for 
preclinical and clinical pharmacology, Medicinal Facul-
ty, Skopje. Since 2015 National PV center is transferred 
in Macedonian agency for Drugs and Medical Devices 
(MALMED). This center works in accordance with the Na-
tional regulative for pharmacovigilance, which has adopt-
ed main recommendations from European Union legisla-
tion. Since 2002 Macedonia is full member in the Uppsala 
monitoring center. Although the National center for phar-
macovigilance exists for almost twenty years, the aware-
ness for reporting adverse drug reactions (ADR) by the 
healthcare professionals, especially the community phar-
macists is on a minimal level. This problem is even big-
ger with respect to biosimilars because they are relatively 
new drugs and very different from the non – biosimilars in 
terms of generics.
For these reasons we are established a questionnaire 
that evaluates the main PV questions and accesses the 
awareness, the knowledge and the methods of application 
of pharmacovigilance among pharmacists in the communi-
ty pharmacies (Meher et al., 2015).
Materials and methods
Study design
This is a questionnaire based study.
The study setting
This study is conducted in over 20 community phar-
macies in Skopje, Republic of Macedonia.
The study population
This is a non – interventional, but required and useful 
study which is done among the post graduated pharmacists 
who work in the community pharmacies. Those who are 
not willing to participate and those who will not return the 
questionnaires, are going to be excluded from this study. 
The study instrument
The study instrument is validated and predesigned 
questionnaire which is structured by following other ques-
tionnaires from similar studies. This study questionnaire 
is designed to evaluate the awareness, knowledge and the 
methods of application of pharmacovigilance in the com-
munity pharmacies. 
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- The term ‘awareness’ mean the perception of a 
situation or a fact.
- ‘Knowledge’ mean the theoretical or practical 
application of pharmacovigilance.
- ‘Method of application’ is the practical applica-
tion of pharmacovigilance.
This questionnaire is comprised of 20 questions 
(awareness – 7, knowledge – 7, methods of application – 
6) (Hema et al., 2012)
Discussion
The main aims of pharmacovigilance are the early de-
tection of the adverse reactions and interactions, monitor-
ing their frequency and identification of the risk factors for 
the adverse reactions of the drugs and especially of the bi-
osimilars. Because of this, active involvement by the com-
munity pharmacists is needed in coordination with other 
healthcare professionals and medical institutions (Hema et 
al., 2012).
With this study we access the awareness, knowledge 
and the methods of application of pharmacovigilance 
among the postgraduate pharmacists and pharmacy tech-
nicians who work in community pharmacies. We consider 
that with this study we can provide information which will 
be significant for the proper education and training for the 
pharmacists in the future, as well we will gather informa-
tion about the real gap between the knowledge and the real 
experience for reporting adverse drug reactions, especially 
for biosimilars (Gupta et al., 2015). Also we will determine 
the factors responsible for under reporting the adverse drug 
reactions, although we think that a proper education is the 
most essential factor. For this, the most appropriate time to 
do so is during the undergraduate and postgraduate train-
ing of the pharmacists.
To facilitate the activity of phamacovigilance, a cul-
ture of learning about it should start early in the profes-
sional training of the pharmacy students and postgraduat-
ed pharmacists. This will enable the pharmacists to realize 
that all medicines, including biosimilars can cause adverse 
drug reactions and learn about the procedures for proper 
reporting (Hema et al., 2012).
Conclusion
Nowadays, in the well developed countries the need 
for an efficient pharmacovigilance system has been real-
ized more than ever to ensure the safe use of medicines, but 
that is not the case with the non – developed countries like 
ours. For that, after this study there will be an education-
al intervention with lectures and workshops on pharmaco-
vigilance to understand the importance of pharmacovigi-
lance and the necessity of reporting adverse drug reactions.
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Background
According to ISO/IEC 17025:2005 any analytical 
equipment used in a testing laboratory should comply to 
required specifications and perform suitably for its intend-
ed purpose to be capable of achieving the required accu-
racy for the tests performed, including volumetric glass-
ware if it’s use has significant influence on the test result, 
or the volumetric accuracy is critical to the performance of 
the method.
Volumetric glassware used in analytical laborato-
ry may either deliver volume (burettes and bulb burettes, 
single volume pipettes, one-mark pipettes, bulb burettes, 
graduated pipettes, including blow-out pipettes) or con-
tain a stated volume (one-mark volumetric flasks, graduat-
ed measuring cylinders). Most items of volumetric glass-
ware are available commercially in two classes, Class A or 
AS and Class B. The distinction between the two Classes is 
based principally on the tolerance limits of the nominal vol-
ume of the glassware as specified in the relevant Standards. 
Normally, for a given volume, the tolerance for Class B is 
twice that for Class A. When the laboratory acquires class 
A and AS volumetric glassware, it is supplied with a batch 
calibration certificate, where the tolerance and the error of 
the material is traceable to an international standard. If the 
item has been calibrated in-house, the laboratory shall have 
a documented record of the calibration data showing trace-
ability to national standards (UKAS, 2009). 
The laboratory should identify the needs for calibra-
tion and/or verification and develop a policy for manage-
ment of the appropriate volumetric glassware. Before be-
ing placed in use, laboratory glassware should be calibrat-
ed or checked to establish that it meets the laboratory’s re-
quirements and complies with the relevant standard spec-
ification. Intermediate checks may be needed to maintain 
the confidence in the calibration status of the glassware, 
which should be carried out according to a defined proce-
dure (ISO/IEC 17025:2005).
Marking of volumetric glassware
Commercially available volumetric glassware may be 
manufactured either from sodalime glass or borosilicate 
glass and should be marked in accordance with the nation-
al/international standard to which it is purchased, with re-
gards to the tolerance (Class A or B), capacity in volume 
unit, reference temperature (i.e. calibration temperature), 
time of flow/delivery time (for verification or certification 
purposes for legal metrology) and identification number 
(Class A). The volumetric glassware should bear also co-
lour code (pipettes complying with BS 700 and BS 1583 
may be colour coded, in which case the coding shall com-
ply with BS 3996), manufacturers and/or vendor’s name or 
mark (UKAS, 2009).
Cleaning of volumetric glassware
The volume contained in or delivered from volumet-
ric glassware depends on cleanliness of the entire internal 
surface to ensure uniform wetting and performing a well 
shaped meniscus Cleaning procedures, storage and segre-
gation of volumetric equipment may be critical, particular-
ly for trace analyses where leaching and adsorption can be 
significant. The laboratory should establish procedures for 
the cleaning of the glassware (for hand washing or washing 
with the washing machine), including cleaning validation 
protocol considering the possibility of the poor/deficient 
washing or the cross contamination with cleaning agents, 
like detergents (ISO 4787, 2010).
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According to ISO 4787 it is recommended that vol-
umetric instruments should not be heated to a tempera-
ture considerably above 180 °C. Washing and drying the 
glass material for volumetric purposes should be made to 
a temperature below 90°C; above 150°C may be signifi-
cant changes in borosilicate glass volumetric capacity of 
the material and above 90°C for the soda-lime glass.
Qualification of volumetric glassware
Qualification of equipment refers to actions of prov-
ing and documenting that any analytical equipment com-
plies with the required specifications and performs suitably 
for its intended purpose. The performance of volumetric 
equipment should be verified at appropriate intervals ac-
cording to a plan and procedures established by the labo-
ratory, taking into account the type of equipment, the ex-
tent of use and supplier’s recommendations (WHO, 2010). 
The initial level of the qualification of the volumetric 
glassware should include selection of the volumetric glass-
ware that is manufactured according to the requirements of 
the corresponding ISO standard (ISO 385, ISO 648, ISO 
1042 and ISO 4787). 
The second level of the qualification of the volumetric 
glassware should include establishment that it meets the 
laboratory’s requirements and complies with the relevant 
standard specification, by performing visual inspection of 
the glassware (compliance with marking requirements), 
checking the batch calibration certificate of the supplied 
equipment, or in the cases where certificate is not avail-
able, calibration of the volumetric glassware should be per-
formed prior use. 
The need for the calibration of the laboratory glass-
ware before first use depends of the volumetric accuracy 
that is critical to the performance of the method, for which 
the glassware is intended to be used. The criteria for per-
forming the calibration of the volumetric glassware, re-
garding the maximum permissible overall error in the test-
ing method and maximum specified tolerance for the vol-
umetric glassware should be established by each laborato-
ry in accordance to the requirements of the corresponding 
ISO standard (ISO 385, ISO 648, ISO 1042 and ISO 4787).
Calibration of the laboratory glassware may be per-
formed internally by the authorized (experienced and 
trained) personnel, according to the suitably documented 
procedure, developed by the laboratory, or externally by 
the accredited institution.
According to ISO 4787, the general procedure for cali-
bration of laboratory glassware is based upon a gravimetric 
method, for determination of volume of water, either con-
tained in or delivered by the volumetric instrument. This 
volume of water is based upon knowledge of its mass un-
der consideration of buoyancy and its tabulated density. 
The third level of the qualification of the volumetric 
glassware should include verification of the calibration sta-
tus, by performing calibration on the glassware, at regular 
intervals, depending on the extent and the nature of usage. 
The initial calibration intervals should be at least once a 
year. If justified, these intervals may be extended. 
The fourth level of the qualification of the volumet-
ric glassware should include visual inspection of the glass-
ware before each use (glass surface shall be free from ob-
vious damage, the graduations and inscriptions shall be 
clearly readable and especially with instruments adjusted 
to deliver the jet shall be free from damage and allow an 
unrestricted outflow of liquid). Careful visual inspection of 
the material in use is made to check for signs of deteriora-
tion or attack, such as, scratches, blur glass, broken glass, 
chipped glass, scale or calibration mark not visible; the de-
teriorated material must be rejected (if it would compro-
mise the safety of personnel or the purposes for which it 
intended), or segregated and used for qualitative work or 
tasks which are compatible with their status. In the case of 
aggressive uses of this material, such as the use of hydro-
fluoric acid or other corrosive substances, thermal shock, 
mechanical shock, visual inspection should be performed 
after cleaning and before storing the glassware.
Conclusion
Analytical laboratories should confirm the traceabili-
ty of volumetric measurements used in support of testing 
and calibration activities, by establishing procedures for 
calibration and check of the laboratory glassware used in 
volumetric measurements. Different national accreditation 
bodies (NAB) establish different minimum requirements 
for the volumetric glassware used in a laboratory, with re-
gards to the validity of the calibration and the frequency of 
the verification of the suitability of the volumetric glass-
ware. The intervals, methods and the specification criteria 
for qualification of volumetric glassware are established by 
each laboratory, taking into account the type of equipment 
in accordance with the relevant standard requirements.
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Background
Dietary supplements are complex products intended 
to supplement human diet with nutrients such as vitamins, 
minerals, herbs, amino acids, extracts or combination of 
the mentioned ingredients (Sander et al., 2006). The min-
erals are inorganic nutrients which are divided in two cate-
gories: macro-elements (Na, K, Ca, Mg, P and Cl) and mi-
croelements which are also classified as “trace elements” 
because of their essentiality at low quantities in humans 
(Cu, Fe, Ni, Zn, Mn, Se, Co, Cr, Mo, V, F and I) (Gupta 
and Gupta, 2012). Since the human body cannot synthe-
size them, macro and microelements must be    supplied 
by food or dietary supplements (Lesniewiecz et al., 2006).
One of the most important characteristics of a di-
etary supplement, from a nutritional point of view, is “how 
much” macro and microelements are present in the prod-
uct. They can be regarded as essential or harmful depend-
ing on the concentration, speciation (the distribution among 
the different chemical compounds) and the presence or ab-
sence of other elements (Korfali et al., 2013). Additional-
ly, dietary supplements are regulated as food and in many 
countries they are not subjected to quality control in the 
same manner as pharmaceutical dosage forms, which is a 
potential threat to public health (Tumir et al., 2010; Marer-
ro et al., 2013). The increased consumption of these prod-
ucts, especially in developed countries requires monitor-
ing of elemental concentration with emphasis on harmful 
or potentially harmful elements for human health. There-
fore, a multi-element analysis method applicable to vari-
ous types of dietary supplements should be used for deter-
mination of element content. This review covers the appli-
cation of atomic absorption (AA) techniques vs. ICP-OES 
for determination of macro and microelements in dietary 
supplements. 
Comparative assessment of the application of AAS vs. 
ICP-OES in the analysis of macro and microelements in di-
etary supplements 
The determination of macro and microelements in di-
etary supplements has been made utilizing different meth-
ods such as X-ray fluorescence, capillary zone electro-
phoresis, flame atomic absorption spectrometry (FAAS), 
graphite furnace atomic absorption spectrometry (GFAAS), 
inductively coupled plasma-optical emission spectrome-
try (ICP-OES) and inductively coupled plasma-mass spec-
trometry (ICP-MS). The choice of the method mainly de-
pends on the type of dietary supplement and the compo-
nents in the matrix. However, the applied methods must 
have sufficient selectivity and sensitivity, therefore ana-
lysts may find that GFAAS, ICP-OES or ICP-MS are the 
most suitable (Abernety et al., 2010).   
GFAAS is a frequently used technique for determina-
tion of macro and microelements as well as trace metals in 
biological, clinical, food, environmental or geological ma-
trices. It is capable of detecting low concentrations (parts 
per billion, ppb, w/w) in microliter quantities of the sam-
ple (Lewen, 2011). Although this technique is relatively in-
expensive, it can be used only for single-element analy-
sis. Also, non-metals cannot be determined because their 
atomic absorption wavelengths are in far UV range which 
is not suitable for analysis due to absorption of air compo-
nents (Baysal et al., 2013).  
Plasma-based techniques have gradually gained im-
portance in verifying whether food specimens, dietary sup-
plements and pharmaceutical products comply with health 
requirements and/or national or international regulations. 
These techniques can be applied to all possible matrices 
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and analytes. They are characterized by extended dynam-
ic concentration range (several orders of magnitude) and 
are multi-elemental in nature, thus they possess high sensi-
tivity and suitable detection power (Marrero et al., 2013). 
Inductively coupled plasma-optical emission spec-
trometry (ICP-OES) is a multi-element technique that al-
lows the determination of major, minor and trace elements 
in complex samples. This technique offers high sample 
through output enabling analysis of large batches, simul-
taneous determination of many elements in a single sam-
ple, large dynamic liner range and low chemical and ma-
trix interferences (Gupta and Gupta, 2012). For the major-
ity of analyses for ICP-OES it is necessary to convert solid 
samples into liquid solution by acid digestion. For this pur-
pose, the closed –vessel microwave oven has been used, 
due to short heating times, reduced risk of contamination 
and low volume reagent requirements. The utilization of 
closed-vessel microwave oven improves limits of detec-
tion of ICP-OES at the same time reducing reagent quanti-
ties and cost of analysis. Given all the advantages of ICP-
OES as well as the characteristics of the dietary supple-
ments (complex matrix, presence of various elements in 
wide range of concentrations), it is slowly but surely be-
coming the method of choice for determination of mac-
ro and microelements in different types of dietary supple-
ments (Barbosa et al., 2015; Castro et al., 2009; Marrero et 
al., 2013; Pytlakovska et al., 2012).     
Conclusion 
The data clearly demonstrates the effectiveness and 
productivity of ICP-OES as compared to more traditional 
methods such as atomic absorption spectrometry. The ICP-
OES can make measurements across a wide range of con-
centrations, thus allowing the analysis of a single solution 
per sample for all the elements of interest. In future, it seems 
more likely that sensitive methods such as ICP-OES will be-
gin to play even greater role in the analysis of macro and mi-
croelements in different types of dietary supplements. The 
performances of modern ICP-OES instruments make it pos-
sible to meet the challenges of the complicated dietary sup-
plement matrix and low limits of detection in order to ad-
dress both product safety as well as product quality.  
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Introduction
Arctostaphylos uva-ursi (L.) Spreng. fam. Ericaceae, 
also known as red bearberry, bearberry or bear’s ear,  is a 
trailing, evergreen woody ground cover shrub with pad-
dle-shaped leaves on flexible branches. It has thick, leath-
ery leaves, rolled under the edges, which are yellow-green 
in spring, dark green in summer and reddish-purple in the 
fall, remaining on the bearberry for 1-3 years before fall-
ing. The flowers are small, white or pink, bell-shaped and 
grouped in nodding clusters that bloom in summer. The 
fruits are white-red berries and they persist into winter. The 
bearberry is widely distributed on a global level.
The use of bearberry leaves for the first time was lit-
erally documented in the middle Ages in the Welsh “Phy-
sicians of Nyddfai” from the 13th century. From the be-
ginning of 19th century, bearberry is in official use. It was 
used for treatment of different diseases such as hydrops, 
lithiasis, in diabetes, for the therapy of gonorrhoea, etc. 
Nowadays only the use as urinary tract antiseptic and di-
uretic remains due to the presence of arbutin and hydroqui-
none (Jurica et. al., 2015). The herb also contains tannins 
that have a powerful astringent effect and protect from ear-
ly stage of infections (Head, 2008). The usual form of ad-
ministration is as infusion and it is of great value in diseas-
es of the bladder and kidneys, it strengthens and tones the 
urinary passages. 
In Republic of Macedonia the natural populations of 
bearberry represent a unique source of leaves which are 
distributed in the following areas: Skopje Valley, moun-
tains of Jakupica, Karadzica, Dautica, Shar Mountain, Os-
ogovo Mountains and Mariovo. The knowledge of the tex-
ture of these soils has a great importance, since these soils 
are formed only on certain substrates (pure and compact 
limestones and dolomites), where all physical, physical – 
mechanical, chemical and biological properties greatly de-
pend on the parent material.  The mechanical composition 
of these soils varies extensively and depends on the me-
chanical composition of the residuum from which the min-
eral part of the soil is composed, on the character of the 
limestone and the dolomite (the degree of weathering and 
silicification), on the deposition of nearby materials (from 
the higher fields) and on the degree of erosion (Filipovs-
ki, 1997).
 Bearberry thrives on rocky ground in the light woods 
of black and white pine and in subalpic plant communities 
on limestone and dolomite ground. The content of bear-
berry is tightly connected to the environmental conditions. 
Basic precondition for normal growth are the soils which 
is important to be rich in CaCO3. According to the field 
surveys the bearberry mostly grows on two soil types: cal-
comelanosol, regosol (WRB, 2006). Here in Republic of 
Macedonia there are soils formed upon lime stones and do-
lomites (Markoski et. al., 2013). Also important conditions 
for this plant are the climate conditions and sea level. Bear-
berry usually lives at sea level over 1500 m on soils with 
high humidity, it cannot be seen in urban areas. Although 
it is an indigenous species for this region there is no liter-
ature data for the composition of the soils that bearberry 
thrives on.
Therefore the aim of this study was to analyze the min-
eral composition of the soils that bearberry grows on.
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Materials and methods
Soil samples S2, S3, S4 and S6 collected from four lo-
cations on Mountain Korab, where bearberry populations 
are growing.
Soil samples were collected from 10cm, 20cm and 
30cm depth and used in ruined condition for the laboratory 
analyzes. The mean values are given in the results.
The following methods were used for the analyses of 
the soils:
- pH (reaction) of the soil solution was deter-
mined electrometrically with a glass electrode 
in a water suspension and a suspension of 1M 
HCl (Mitrikeski andMitkova, 2006),
- Content of CaCO3 determineted by Schebler 
calcimetar (Mitrikeski and Mitkova, 2006),
- Content of organic matter was determined ac-
cording to total Carbon (Orlov et. al.. 1981),
- Total N was determined by calculation (Fili-
povski, 1974),
- Easily available forms of  Phosphorus and 
Potassium were determined by Al-method 
(Pelivanovska, 2011),
- Determination of cations (Al, Fe, Mg, Mn, Cr, 
Cu, Ni, Pb, Zn) was done on Agilent Technolo-
gies 700 Series ICP – OES.
Results and discussion
Common chemical characteristics of the soil (pH, 
CaCO3, organic matter, total N, P2O5, K2O) were evaluat-
ed. The obtained data showed pH=7.7 for S2, pH=8 for S3, 
pH=7.9 for S4 and pH=7.6 for S6 in a water soil suspen-
sion. The values of the pH reaction of the soil solution were 
closely correlated with the content of CaCO3. Highest val-
ue for CaCO3 was found in S3 (60.81%) and lowest in S2 
(44.16%). Regarding the content of easily accessible forms 
of Phosphorus and Potassium, these soils are poor in P2O5 
and little to middle supplied with K2O.
The presence of target elements (CaO, Al, Fe, Mg, Mn, 
Cr, Cu, Ni, Pb, Zn) was analyzed with ICP OES. CaO was 
most present in S3 and least in S6, Al was most present in 
S2 and least in S3, Fe was most present in S2 and least in 
S3, Mg was most present in S6 and least in S3, Mn was 
most present in S6 and least in S3, Cr was most present in 
S2 and least in S4, Cu was most present in S2 and least in 
S3, Ni was most present in S2 and least in S4, Pb was most 
present in S4 and least in S3, Zn was most present in S4 
and least in S3.
Conclusion
Bearberry population viability and the content of bio-
active compounds in bearberry are tightly connected to the 
environmental conditions. pH value of analyzed samples 
varied from 7.6 to 7.9. Precondition for normal growth 
of this plant that lives on limestone and dolomite ground 
are the soils which is important to be rich in CaCO3 and 
highest value of CaCO3 (60.81%) found in S3 and lowest 
(44.16%) found in S2 confirms that. CaO was most present 
in S3 and least in S6. These soils are poor in P2O5 and lit-
tle to middle supplied with K2O. Regarding cations, when 
the analyzed soil samples were compared between them 
self, S2 was richest in Fe, Cr, Ni and Cu and S6 in Mg and 
Mn; S3 was poorest with Al, Fe, Mg, Mn, Cu, Pb and Zn.
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Introduction
Amygdalin (D-mandelonitrile-β-Dgentiobioside) is 
a cyanogenic glycoside derived from the aromatic amino 
acid phenylalanine. Amygdalin is hydrolysed in the pres-
ence of the enzyme amygdalase and water, involving a 
two-stage process to produce glucose along with an agly-
cone made up of benzaldehyde and odourless hydrocyanic 
acid. Natural amygdalin has a dextrorotatory (R) configu-
ration that is considered to be the active form. Neo-amyg-
dalin is its inactive (S) isomer and does not occur in nature. 
Isoamygdalin is the name of the mixture of the epimers R-
amygdalin and S-amygdalin. The term ‘laetrile’ (D-man-
delonitrile-ß-glucuronide) is an acronym from laevorotato-
ry and mandelonitrile, used to describe a purified form of 
amygdalin (Fenselau et al., 1977). The occurrence of cya-
nogenic glycosides is widespread. Amygdalin is very com-
mon among plants of the Rosaceae, particularly the Prunus 
genus. This includes not only the bitter almond but also the 
kernels of apricots, peaches and plums (Pengelly, 2004). 
Hydrocyanic acid, which is the product of the hydrolysis 
of amygdalin reflexively stimulates the respiratory center 
and produces antitussive and antiasthmatic effects (Lv et 
al., 2005).
Amygdalin is supposed to be useful in tretman of can-
cer, but still there is no reliable clinical evidence for this in-
dication (Blahata et al., 2016). Many hypotheses have been 
proposed to explain the anticancer effects of amygdalin, 
among them, amygdalin enhances the functions of pancre-
atic enzymes, which may prevent transformation of can-
cer primordial germ cells or has the capacity to restores the 
vitamin deficiency that could lead to metabolic disorders 
in cancer patients (Chang et al., 2006). Moreover, treat-
ment with high concentrations of amygdalin on the human 
DU145 and LNCaP prostate cancer cells can induce apop-
totic cell death (Chang et al., 2006). On the other hand, 
Chang et al. (2005) reported that Armeniacae semen con-
taining abundant amygdalin exhibits analgesic and anti-in-
flammatory effects, showing that low doses of amygdalin 
may relieve pain.
Amygdalin is water and methanol soluble. Traditional-
ly, the extraction method of the chemical ingredients in the 
plant materials is decoction in boiling water. Other meth-
ods used are soxhlet extraction and reflux extraction (Lv 
et al., 2005). Ultrasonic extraction with boiling methanol 
can be also applied to extract amygdalin from plant ker-
nels. The last method is promising, because some amyg-
dalin is decomposed into benzaldehyde, HCN, and glu-
cose by emulsion (a hydrolysis enzyme present in kernels), 
and some are converted into its epimers, neoamygdalin (L- 
mandelonitrile-β-D-gentiobioside) during the process of 
decoction in water. Other way for inhibiting the conver-
sion of amygdalin to neoamygdalin is by changing the pH 
(adding citric acid in the medium for extraction).
The determination and quantification of amygdalin 
was performed mainly by high-performance liquid chro-
matography (HPLC) (Wasserkrug et al., 1997). 
Therefore, the aim of this study was to determine the 
amygdalin content in kernels of Prunus cerasifera, Prunus 
armeniaca and Prunus domestica, as well as in commercial 
available food supplement using HPLC method.
Materials and methods
Plant material
Kernels of Prunus armeniaca, Prunus cerasifera and 
Prunus domestica were purchased from a green market, 
while the food supplement containing extract of Prunus ar-
meniaca kernels was purchased from pharmacy store. 
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Extraction
The seeds from the kernels were pulverized by means 
of a blender. 0.5 g of each sample (including the content 
from the capsule) was extracted with 25 mL boiling meth-
anol with ultrasonic bath under reflux for 30 min. The tem-
perature of system was the boiling point of methanol. Af-
ter extraction, the extracts were filtered through a filter pa-
per in 25 cm3 flask. Furthermore, 1.5 mL of the extracts 
were additionally filtered through disposable Econofilter 
25/0.45 μm RC pore size and injected in the HPLC sys-
tem for analysis.
Quantification of amygdalin was performed using UV/
VIS DAD at 215 nm with calibration standard of amygda-
lin prepared as 0.1 mg/mL stock in methanol. 
HPLC method
Chromatographic analyses were performed on an Ag-
ilent 1200 HPLC/DAD system equipped with quaternary 
pump G1311A, column thermostat G1316A TCC, thermo-
statted autosampler G1329A TCC, and controlled by LC 
3D software (Wilmington DE). Separation was achieved 
using a Zorbax Eclipse XDB C-18 column (150 mm × 4.6 
mm, 5 μm, Agilent, Germany), protected with a guard col-
umn (4 mm × 4.6 mm, RP-18, 5 μm, Agilent, Germany). 
The mobile phase consisted of acetonitrile and water of 
HPLC grade in ratio 15:85 (v/v). The flow rate was 1 mL/
min and the injection volume was 20 μL.
Results and discussion
With HPLC analysis amygdalin was identified in the 
extracts of the kernels from the samples of Prunus arme-
niaca, Prunus cerasifera and according to Rt and UV/VIS 
spectra corresponding to the Rt and UV/VIS spectra of the 
peak in the HPLC chromatogram of amygdalin standard. 
We were unable to identify amygdalin in the sample of 
Prunus domestica. In the Prunus armeniaca kernels 4.89% 
of amygdalin was determined, while in Prunus cerasifera 
kernels amygdalin content was 2.64%. On the other hand, 
in the commercial food supplement preparation 17.86% of 
amygdalin was quantified that complied with the declared 
amount of amygdalin. 
Conclusion
An extraction procedure and high performance liquid 
chromatography method were successfully developed and 
applied for determination of amygdalin in plant material as 
well in pharmaceutical preparation/extract that can be fur-
ther utilized for amygdalin content determination in var-
ious natural and pharmaceutical samples. Using, HPLC 
the amygdalin was quantified in kernels of Prunus cera-
sifera (26.4 mg/g DW), and Prunus armeniaca (48.9 mg/g 
DW) and these data can serve as a starting point for fur-
ther investigations and assessment of other natural sourc-
es of amygdalin. 
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Introduction
Pimpinella anisum (Fam. Apiaceae) - aniseed and Foe-
niculum vulgare (Fam. Apiaceae) - sweet fennel are tradi-
tionally and commercially used in preparing of alcoholic 
beverages like OUZO, MASTIKA and YENI RAKI which 
are usually consumed at the Balkan’s countries. These 
kinds of drinks contain an extracts of Foeniculum vulgare 
or seldom Pimpinella anisum. Sometimes estrogenic ef-
fects can be observed when they are consumed by female 
human population. These estrogenic effects are manifest-
ed with stimulation of the lactic secretion, stimulation of 
menstruation or facilitate birth. In man population can re-
lieves the symptoms of climacterium (Albert-Puleo, 1980). 
One of the components which are responsible for estro-
genic activity is dianethol, which is formed after the fu-
sion of two molecules of cis-anethole, but there is infor-
mation that trans-anethole has also estrogenic effects (Ku-
levanova, 2004).
There are also some studies on laboratory animals as-
sessing the bioactivity of trans-anethole. When adminis-
tered orally to immature female rats at 80 mg/kg b.w. for 3 
days significantly increased uterine weight to 2 g/kg com-
pared to 0.5 g/kg in controls and 3 g/kg in animals giv-
en estradiol valerate subcutaneously at 0.1 µg/rat/day (p < 
0.001). The results confirmed that trans-anethole has estro-
genic activity. On the other hand, some other experiments 
showed that it has no anti-estrogenic, progestational, anti-
progestational, androgenic or anti-androgenic activity. Es-
trogenic activity of trans-anethole at high concentrations 
has been determined by a sensitive and specific bioassay 
using recombinant yeast cells expressing the human estro-
gen receptor (Howes et al., 2002).
The aim of the research was to analyze potential estro-
genic components like trans-anethole and cis-anethole in 
alcoholic beverages OUZO, MASTIKA and YENI RAKI 
using GC-FID-MS technique.
Materials and methods
Samples: Alcoholic beverages: commercially pur-
chased alcoholic spirit – OUZO; commercially purchased 
alcoholic spirit – YENI RAKI; commercially purchased 
alcoholic spirit – MASTIKA and traditionally homemade 
MASTIKA.
Sample preparation: 100 μL of each beverage were di-
luted to 1000 μL with methanol and analyzed on GC/FID/
MS.
GC/FID/MS analysis: Samples were analysed with 
an Agilent 7890А Gas Chromatography system equipped 
with FID detector and Agilent 5975C mass spectrometer. 
For this purpose, an HP-5ms capillary column (30 m x 0.25 
mm, film thickness 0.25 μm) was used. Adams’ analytical 
conditions were as follows: oven temperature at 60 °C (0 
min), 3 °C/min to 240 °C (1 min) and at the end increased 
to 280 °C at a rate of 10 °C/min (1 min) (Adams, 2007); he-
lium, as carrier gas, at a flow rate of 1 mL/min (at the end 
of analysis we eluted 10 more minutes with helium with 
aim to separate some of the components in extract enough 
well); injector temperature 220 °C and that of the FID de-
tector 270 °C. One μL of each EO was injected at split ra-
tio 1:1. The mass spectrometry conditions were: ionisation 
voltage 70 eV, ion source temperature 230 °C, transfer line 
temperature 280 °C and mass range from 50 - 550 Da. The 
MS was operated in scan mode.
Identification of the components: The components 
were identified according to the literature (Adams, 2007), 
and Kovat′s (retention) indices determined using a homol-
ogous mixture of normal alkanes (C9-C25) analysed un-
der Automated Mass Spectral Deconvolution and Identi-
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fication System (AMDIS) conditions (AMDIS ver.2.1.). 
Confirmation was by comparing the mass spectra of com-
ponents present in the extracts with reference spectra ob-
tained from NIST, Wiley and Adams’ mass spectra librar-
ies. Quantification of extracts components was performed 
using the normalisation method of the GC/FID peak areas 
with no correction factors (Adams, 2007).
Results and discussion
Using GS/FID/MS analysis five different compo-
nents were identified in OUZO sample (2-butanol (5.92%), 
1-buten-3-ol (7.65%), anis aldehyde (9.50%), trans-ane-
thole (23.98%), 1(1’-azetinidyl)-2,6-dimetil-1-cyclohex-
an (8.06%) and 4-metoxyphenyl ((2-methylenecyclohex-
yl)methanol), four different components in a sample of 
homemade MASTIKA (estragol – 7.42%), cis-anethole 
(42.38%), trans-anethole (35.09%), 3-metoxy-2meth-
yl-2H-pyrazolo[4,3,3-E][1,2,4]triazin – 8.52%) and a sin-
gle component of trans-anethole in the YENI RAKI and 
commercial purchase MASTIKA (100% trans-anethole). 
This indicates that in traditionally homemade MASTIKA 
and commercial OUZO an extract of aniseed or sweet fen-
nel seed was added or plant seeds were used in the pro-
cess of production or distillation. On the other hand sin-
gle peak of trans-anethole in the YENI RAKI and the com-
mercial available MASTIKA indicates that probably a pure 
compound of trans-anethole was added into the produc-
tion process. The amount of trans-anethole was highest in 
the sample of YENI RAKI, almost twice higher compared 
with the OUZO sample, two and half times higher than 
commercial MASTIKA and approximately 5x higher than 
in the sample of traditionally homemade MASTIKA. cis-
Anethole was identified only in the sample of traditional-
ly homemade MASTIKA and was present in amount even 
higher than trans-anethole. This can be explained with the 
fact that trans-anethole has been converted into cis-ane-
thole during the four years period of storage, consequent-
ly possessing probably higher estrogenic potency than the 
other analyzed samples.
Conclusion
For the purposes of this research, a method of GC/MS/
FID was applied for determination of the target compo-
nents, particularly cis- and trans- isomers of anethole, in 
alcoholic beverages. YENI RAKI has highest content of 
trans-anethole, followed by OUZO and MASTIKA, com-
mercial and homemade. Further research is needed in order 
to evaluate the relationship between the content of these 
compounds and their respective estrogenic potential.
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Introduction
The genus Hypericum consists of about 470 species 
of flowering plants that occur in all temperate parts of the 
world (Robson, 2003). Well known medicinally valuable 
species Hypericum perforatum (common St. John’s Wort) 
is native to parts of Europe and Asia but has been spread 
worldwide as a cosmopolitan invasive weed including tem-
perate regions of Canada, United States and Africa, as well. 
Chemical investigations of Hypericum perforatum 
have detected several groups of medicinally active com-
pounds. The most common classes include naphthodian-
thrones (hypericin, pseudohypericin, hyperforin, adhy-
perforin), phloroglucinols, catechins and proanthocyani-
dins, flavonoids and biflavonoids (hyperoside, querci-
trin, isoquercitrin, rutin, biapigenin, amentoflavone), xan-
tones (noratbyrol), phenolic acids and other phenolic com-
pounds, antraquinone derivatives, as well as essential oils. 
The phytochemical investigation of Hypericum perforatum 
essential oil mainly began with the determination of the es-
sential oil content. According to some authors, it is a highly 
variable value and ranges from 0.1% to 1% (Klemow et al., 
2011; Robson, 2003) hence this species is considered as es-
sential oil poor plant. Concerning the literature data, there 
have been numerous investigations of the chemical com-
position of Hypericum perforatum essential oil. The ma-
jor constituents were found to be monoterpenes (α-pinene, 
β-pinene, limonene, myrcene, geraniol and α-terpineol), 
sesquiterpenes (β-caryophyllene and caryophyllene oxide) 
as well as aliphatic (2-methyloctan, n-nonan, n-undecan, 
n-octanal and n-decanal) and saturated hydrocarbons (do-
decanole, 3-methylnonane, isoundecane and undecane) 
that could be present in appreciable concentrations (Bertoli 
et al., 2011; Crockett, 2010; Robson, 2003). 
The widespread popularity of Hypericum perforatum 
usage as an herbal remedy results from its efficacy in a 
treatment of a variety of diseases. This plant has been used 
over thousands of years to treat cuts, abrasions, bruises, 
sunburns and other wounds as well as to treat anxiety, de-
pression and rheumatic pain. Also, this plant is thought to 
possess antiseptic, antiviral, anti-inflammatory and gastro-
protective effects (Crockett, 2010).   
Despite the numerous literature data about the chemi-
cal composition of the Hypericum perforatum essential oil, 
still there is no officially available data about the chemistry 
of essential oil isolated from Macedonian species, there-
fore the principal aim of our further research study will be 
assessment of the chemical composition of essential oil ob-
tained from the aerial parts of this plant harvested from its 
natural habitats in R. Macedonia.
Materials and methods
The plant material of investigated Hypericum perfo-
ratum populations is generally consisted of air-dried aeri-
al parts collected during the flowering stage, packed in pa-
per bags and kept in a dark and cold place until analysis. 
The essential oil isolation is usually made from dried 
and properly minced plant material by steam distillation in 
all-glass Clevenger apparatus according to standard meth-
od described in European Pharmacopeia. 
The common method of choice for the investigation 
of chemical composition of the essential oil is gas chroma-
tography tandem mass spectrometry (Bardhi et al., 2015).
Results and discussion
Data analysis of the chemical composition of Hyper-
icum perforatum essential oil isolated from species origi-
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nating from southern Albania revealed six different classes 
of components: monoterpene hydrocarbons, oxygen-con-
taining monoterpenes, sesquiterpene hydrocarbons, oxy-
gen-containing sesquiterpenes, diterpenes and non-terpene 
components. Generally, monoterpene (1.94-47.21%) and 
sesquiterpene (6.67-50.88%) hydrocarbons were dominant 
fractions in all tested samples. Beside terpene compounds, 
these essential oils contain high levels of other non-terpene 
components (11.68-29.25%) mainly consisted of aliphatic 
chains. GC/FID/MS analyses of the examed essential oils 
revealed a total of 126 compounds from which seven com-
pounds were found in amounts higher than 3.00%: α-pinene 
(2.03–36.74%), β-pinene (0.36–6.89%), 2-methyl-decane 
(0.82–3.14%), carvacrol (0.14–5.60%), trans-(E)-caryoph-
yllene (0.5–19.27%), β-selinene (1.34–13.86%) and caryo-
phyllene oxide (1.15–12.35%) (Bardhi et al., 2015). The 
main fraction of compounds in Hypericum perforatum es-
sential oils obtained from plant material collected in south-
eastern Serbia were found to be sesquiterpenes (57.7%), 
followed by monoterpenes (22.4%), both mostly consisted 
of hydrocarbons. Other components present in this oil were 
non-terpene compounds (18.1%); alkanes, isoalkanes, n-
alkanes, anteiso-alkanes and fatty acids and their deriva-
tives. The main components were found to be germacrene 
D (18.6%), (E)-caryophyllene (11.2%), 2-methyloctane 
(9.5%), α-pinene (6.5%), bicyclogermacrene (5.0%) and 
(E)-β-ocimene (4.6%) (Ðorđević, 2015). The essential oil 
of Hypericum perforatum collected from different localities 
in Lithuania was rich in β-caryophyllene (5.1-19.1%) and 
caryophyllene oxide (6.1-35.8%), followed by germacrene 
D (4.5-31.5%), spathulenol (3.9-8.5%), β-farnezene (0.6-
8.2%), α-muurolene-14-ol (1.6-9.1%) and α-cadinol (2.2-
6.2%). In this study, all tested samples, the amount of the 
most abundant fractions, sesquiterpene hydrocarbons and 
oxygenated sesquiterpenes, comprised 62.0-81.8% of the 
essential oils (Mockutė et al., 2003). Chemical investiga-
tion of the essential oil composition of Hypericum perfo-
ratum was also made on plant material collected from Tur-
key. GC/MS analysis has shown that the main constituents 
were monoterpenes: α-pinene, β-pinene and β-myrcene, 
followed by sesquiterpenes: α-copaene, (E)-caryophyllene 
and α-selinene. Hydrocarbons (nonane, decane, 2, 6-di-
methyl decane and undecane) and aldehydes (hexanal) 
were also identified in the essential oil (Derun et al., 2013).
Conclusion
Concerning the literature data, some similarity in the 
chemical composition of essential oil obtained from the 
aerial parts of Hypericum perforatum collected from Al-
bania and Serbia could be found, probably due to the influ-
ence of appropriate environmental conditions. In our fur-
ther research study, we can expect similar chemistry in es-
sential oil isolated from Hypericum perforatum harvested 
from its natural habitats in R. Macedonia which can help 
to assess the potential of this plant for its further sustain-
able exploitation.
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Introduction
Organic solvents are widely used in the manufactur-
ing process of pharmaceutical products. Their application 
in the synthesis of active pharmaceutical ingredients is of 
exceptional importance since the use of specific solvents 
can determine the physicochemical characteristics, influ-
ence the yield of the synthetic reaction and purity of the 
product. Organic solvents are also routinely applied in the 
manufacturing of excipients and during the drug product 
formulation. Using standard manufacturing processes or-
ganic solvents are generally removed to the extent possible 
from the final product. Small amounts that remain in the 
final drug product are commonly referred as residual sol-
vents (RS). Their presence, even at low levels, may influ-
ence the efficacy, safety and stability of the pharmaceutical 
products (Grodowska and Parczewski, 2010). 
Regulation on residual solvents testing
ICH regulation 
The International Conference on Harmonization (ICH) 
of Technical Requirements for Registration of Pharmaceu-
ticals for Human Use, under ICH Topic Q3C (published in 
December 1997), require for “testing to be performed for 
residual solvents when production or purification process-
es are known to result in the presence of such solvents”. 
ICH categorizes commonly used RS into three differ-
ent classes based on their toxicity: Class 1 (solvents to be 
avoided), Class 2 (solvents to be limited), Class 3 (solvents 
with low toxic potential). The European Pharmacopoe-
ia (Ph. Eur.) and The United states Pharmacopoeia (USP) 
limit the amount of RS in pharmaceuticals, considering the 
ICH guidelines for RS. The control limits for RS are for-
mulated based on the potential risks when the drug is ad-
ministered orally. Class 1 contains known solvent that are 
human carcinogens, compounds strongly suspected of be-
ing human carcinogens, and environmental hazard. The 
limits for Class 1 solvents are between 2-8 ppm except for 
1,1,1-trichloroethane 1500 ppm, due to its environmental 
hazard.  Class 2 solvents are non-genotoxic animal carcin-
ogens or possible causative agents of irreversible toxicity 
and their concentration limits vary between 50 and 3880 
ppm. Class 3 solvents have low toxic potential and have 
been found less toxic in acute or short-term studies and 
negative in genotoxicity studies. Their limit of 5000 ppm is 
acceptable without justification. A higher amount may also 
be acceptable with proper justification. 
ICH Q3C (R5) guideline for residual solvents also sets 
criteria for analytical methods used to identify and quanti-
fy these residual solvents as well provide acceptable con-
centration limits. Ph. Eur (3rd edition) and USP (USP 28,) 
have adopted this guideline and have revised their general 
methods to reflect it.
European Pharmacopoeia
In general chapter of Ph. Eur, Identification and con-
trol of residual solvents, two different methods for quali-
tative and quantitative analysis of RS: System-A and Sys-
tem-B are described. Gas chromatography (GC) with head-
space (HS) injection is proposed in two systems (A and B). 
System A utilize fused-silica capillary wide-bore column 
(30m x 0.32mm or 0.53mm i.d) coated with cross-linked 6 
% polycyanopropylphenylsiloxane and 94 % polydimeth-
ylsiloxane while  System B uses  fused-silica capillary 
wide-bore column (30 m x 0.32 mm or 0.53 mm i.d.) coat-
ed with macrogol 20000R. System A is preferred whilst 
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System B is employed for confirmation of identity. 
Three different sample preparation procedures are pro-
posed based on the sample solubility—I: water for the wa-
ter soluble samples; II: DMF (N,N-dimethylformamide) 
for the water insoluble samples; III: DMI (1,3-dimeth-
yl-2-imidazolidinone) for the control of DMF and DMA 
(N,N-dimethylacetamide) in water insoluble samples. In 
the case of water soluble samples where water insoluble 
RS are present, the reference RS solutions in water are pre-
pared using DMSO (dimethylsulfoxide) as bridging sol-
vent. Moreover, the Ph. Eur. takes into account the possi-
bility of using, apart from FID, a mass spectrometer (MS) 
or electron capture detector (ECD). MS and ECD detectors 
are proposed as alternatives for FID in the analysis of chlo-
rinated RS of Class-1 due to the poor sensitivity of FID to-
wards chlorinated solvents.
United States Pharmacopoeia
Current official methods for residual solvent determi-
nation are described in chapter Organic Volatile Impurities. 
USP chapter <467> suggests analysis of residual solvents 
using a gas chromatograph (GC) equipped with a flame ion-
ization detector (FID) and an automated headspace sampler 
(HS). The three testing procedures are used to screen and 
identify (Procedure A), confirm (Procedure B) and quan-
titatively determine (Procedure C) the residual solvents in 
the sample. When the user has information about the spe-
cific solvents utilized during the manufacturing of the arti-
cle, only Procedure C needs to be performed. If the solvents 
used are unknown, all three procedures are needed for iden-
tification and quantization. These three procedures (A, B, 
C) differ among themselves in column type (film-coatings 
G43 A or G16 and dimensions) and in chromatographic 
conditions. Procedure A in the USP <467> General Chapter 
has the same chromatographic and headspace conditions as 
in System A. Similarly, Procedure B finds its equivalent in 
Ph. Eur. in the system configuration of System B.
Sample preparation is different for water-soluble and 
water-insoluble articles. 
Three different headspace conditions are available al-
though USP does not specify which HS conditions should 
be chosen. These are dependent on the solvent that was 
chosen for preparation of the sample (water or N,N-di-
methylformamide), residual solvents under analysis (high 
or low boiling) and analyzed material (thermally stable or 
unstable).
According to USP, determination of class 3 RS can be 
also done by loss on drying (USP <731> Chapter), as long 
as the total loss on drying is less than the maximum accept-
able limit for class 3 residual solvents (5000 ppm).
USP general procedures do not relate to specific sol-
vents, but they try to compromise chromatographic and 
headspace conditions, in order to analyze all or the majori-
ty of organic solvents mentioned in chapter <467>. 
Conclusion 
Methods for analysis of residual solvents described in 
pharmacopoeias are gas chromatographic methods that dif-
fer in procedures for sample preparation and headspace pa-
rameters. Proposed stationary phases for chromatographic 
columns and their intended used are the same. In Ph. Eur. 
mass spectrometer or electron capture detectors have been 
additionally taken into account (apart from FID). General-
ly, all methods for quantitative determination of residual 
solvents taken from pharmacopoeias need validation. 
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Background
Falsification of medicines is a global problem that 
should be addressed with deep attention and interest. This 
problem represents a threat to the well-being, health and 
even the life of the patients, and cause a great damage on 
the economy and society. 
A medicine can be falsified regarding its identity, in-
cluding its packaging and everything that is visible on it: 
the marking, the ingredients, the quantity of ingredients; 
its source (the manufacturer, the land of origin, the coun-
try where it is manufactured, the marketing authorization 
holder) and the documents regarding the channels of dis-
tribution. Falsified medicines may contain different quan-
tity of the active ingredient, wrong active ingredient or no 
active ingredient, wrong excipients and are produced in 
sub-standard manufacturing conditions. Therefore the use 
of falsified medicine may result in no therapeutic effect or 
even negative effect on patient’s health. Additionally, falsi-
fied medicines undermine the credibility of the health care 
systems, leading to a reduction in patient trust in the le-
gal supply chain of medicines and spend valuable human 
and financial resources. Innovative pharmaceutical com-
panies invest in pharmaceutical development to assure the 
quality, safety, efficacy of their respective products order 
to provide maximal therapeutic effect with minimum side 
effects. In contrary, the main goal of the manufacturers of 
falsified medicines is easy money. Falsified medicines may 
also cause loss of the credibility and reputation of the phar-
maceutical companies (Council of Europe, 2013a; WHO, 
2008).
The “life-cycle” of falsified product involves unau-
thorized manufacturers, brokers, illegal/unregulated sup-
plier, wholesalers, and unregulated internet. Patients re-
ceive falsified medicines easily without them knowing that 
the product is not what it is declared to be, not being aware 
of the consequences, the effect of these products, the in-
ternet, and the manufacturers are encouraged to enter this 
business because it is extremely profitable and in many 
countries unregulated (MHRA, 2012).
Taking into the account the threat and the extent of the 
phenomenon with the falsified medicines, a serious multi-
lateral approach is necessary which includes taking mea-
sures to combat the falsification of medicines at both the 
national and global level. 
Legislation in EU
The European Union (EU) has a strong legal frame-
work for the licensing, manufacturing and distribution of 
medicines, centered around the Directive on falsified med-
icines for human use (21. 07. 2011 - EU Directive 2011/62 
of the European Parliament and of the Council amending 
Directive 2001/83/EC) as regards the prevention of the en-
try into the legal supply chain of medicinal products which 
are falsified in relation to their identity, history or source, 
so that only licensed pharmacies and approved retailers 
are allowed to offer medicines for sale, including legiti-
mate sale via the internet (Council of Europe, 2011).  Ac-
cording to EU Directive 2011/62, falsified medicine is de-
fined as any medicinal product with a false representation 
of: its identity, including its packaging and labeling, its 
name or its composition as regards any of the ingredients 
including excipients and the strength of those ingredients; 
its source, including its manufacturer, its country of manu-
facturing, its country of origin or its marketing authoriza-
tion holder; or its history, including the records and docu-
ments relating to the distribution channels used. This def-
inition does not include unintentional quality defects and 
is without prejudice to infringements of intellectual prop-
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erty rights. According to EMA and the Directive, there are 
going to be different penalties and allegations for falsify-
ing and counterfeiting medicines. This Directive aims to 
prevent falsified medicines entering the legal supply chain 
and reaching patients. It introduces harmonized safety and 
strengthened control measures across Europe by applying 
new measures, which can be grouped into four main pil-
lars: safety features of medicines, supply chain and good 
distribution practice, active substances and excipients and 
internet sales.
The Medicrime convention is the tool which EMA 
uses to criminalize the falsification of medicines. It gives 
directions on strategic approach for development the le-
gal framework in the field of medicinal products, both na-
tionally and internationally in order to better protect pub-
lic health and national healthcare systems, through coop-
eration between sectors in public administration, measures 
for national control, preventative measures etc. (Council of 
Europe, 2013b). 
Legislation in USA
EMAs equivalent in the USA is the FDA. It is a fed-
eral agency and is a part of the U.S. Department of Health 
and Human Services. It is responsible for taking care of 
the general health, among other things, and therefore pro-
vides legislation about falsified medicines. What the DI-
RECTIVE 2011/62 is for EU, FDASIA is for USA, Con-
gress of USA (Title VII of the Food and Drug Administra-
tion Safety and Innovation Act (FDASIA, 2012). In this act 
through so called “sections” are described the ways to pro-
tect the distributive chain and criminalize the falsification 
of medicines.
Legislation in the Republic of Macedonia
In R. Macedonia there is no specific law concerning 
falsification of medicines. The problem with falsification 
of medicines is covered partially by the Criminal Code of 
R.M., the Law of Medicines and Medical Devices and the 
Law of Customs measures and Intellectual Property Rights.
Conclusion
Falsification of medicinal products is a crime carried 
out using deception and other techniques typical of orga-
nized crime and represents a public health problem and a 
problem of the trade competition as an intellectual prop-
erty right infringement. An essential starting point in the 
fight against falsified medicines in R. Macedonia is the es-
tablishment of an adequate national legal framework and 
regulatory system, based on the EU and USA legislation 
concerning this issue. Additionally, development of mech-
anisms for effective collaboration and communication be-
tween health authorities, police, customs, the judiciary, 
manufacturers, wholesalers, retailers, health profession-
als and patients on national and international level is nec-
essary aspect that should be considered for the success in 
this fight.
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